assay_id,cell_id,assay_category,tissue_id,confidence_score,assay_tissue,assay_test_type,chembl_id,src_assay_id,curated_by,assay_type,variant_id,src_id,assay_subcellular_fraction,relationship_type,description,assay_strain,assay_cell_type,tid,bao_format
1,,,,8,,,CHEMBL615117,,Autocuration,B,,1,,H,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,12052,BAO_0000019
2,,,,0,,,CHEMBL615118,,Autocuration,F,,1,,U,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,22226,BAO_0000219
3,,,,0,,,CHEMBL615119,,Autocuration,B,,1,,U,,,,22226,BAO_0000019
4,,,,4,,,CHEMBL615120,,Autocuration,B,,1,,H,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,,104729,BAO_0000249
5,163.0,,,1,,,CHEMBL615121,,Intermediate,F,,1,,N,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,143B,80001,BAO_0000219
6,163.0,,,1,,,CHEMBL615122,,Intermediate,F,,1,,N,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,143B,80001,BAO_0000219
7,163.0,,,1,,,CHEMBL615123,,Intermediate,F,,1,,N,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,143B,80001,BAO_0000219
8,163.0,,,1,,,CHEMBL615124,,Expert,F,,1,,N,In vitro cell cytotoxicity was determined against 143B cell line,,143B,80001,BAO_0000219
9,163.0,,,1,,,CHEMBL615125,,Intermediate,F,,1,,N,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,143B,80001,BAO_0000219
10,163.0,,,1,,,CHEMBL615126,,Intermediate,F,,1,,N,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,143B,80001,BAO_0000219
11,163.0,,,1,,,CHEMBL615127,,Intermediate,F,,1,,N,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,143B,80001,BAO_0000219
12,163.0,,,1,,,CHEMBL615128,,Expert,F,,1,,N,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,143B,80001,BAO_0000219
13,,,,1,,,CHEMBL857900,,Intermediate,F,,1,,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185,BAO_0000218
14,,,,1,,,CHEMBL615129,,Intermediate,F,,1,,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185,BAO_0000218
15,,,,1,,,CHEMBL615130,,Intermediate,F,,1,,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185,BAO_0000218
16,,,,1,,,CHEMBL615131,,Intermediate,F,,1,,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185,BAO_0000218
17,,,,9,,,CHEMBL884521,,Expert,A,,1,,D,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,,100122,BAO_0000357
18,,,,8,,,CHEMBL615132,,Autocuration,B,,1,,H,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,12054,BAO_0000357
19,,,,8,,,CHEMBL615133,,Autocuration,B,,1,,H,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,12054,BAO_0000019
20,,,,8,,,CHEMBL615134,,Autocuration,B,,1,,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,12054,BAO_0000357
21,,,,8,,,CHEMBL615135,,Autocuration,B,,1,,H,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,12054,BAO_0000357
22,,,,8,,,CHEMBL615136,,Autocuration,B,,1,,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,12054,BAO_0000357
23,,,,8,,,CHEMBL615137,,Autocuration,B,,1,,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,12054,BAO_0000357
24,,,,8,,,CHEMBL615138,,Autocuration,B,,1,,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,12054,BAO_0000357
25,,,,0,,,CHEMBL836324,,Autocuration,B,,1,,U,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,22226,BAO_0000219
26,,,,8,,,CHEMBL615139,,Autocuration,B,,1,,H,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,,12054,BAO_0000357
27,,,,8,,,CHEMBL615140,,Autocuration,B,,1,,H,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,,12054,BAO_0000357
28,,,,8,,,CHEMBL615141,,Autocuration,B,,1,,H,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,12426,BAO_0000219
29,,,,8,,,CHEMBL615142,,Autocuration,B,,1,,H,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,,12054,BAO_0000357
30,,,,8,,,CHEMBL615143,,Autocuration,B,,1,,H,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,,12054,BAO_0000357
31,,,,8,,,CHEMBL615144,,Autocuration,B,,1,,H,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,,12054,BAO_0000357
32,,,,8,,,CHEMBL872867,,Autocuration,B,,1,,H,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,,12054,BAO_0000357
33,,,,8,,,CHEMBL615145,,Autocuration,B,,1,,H,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,,12054,BAO_0000357
34,,,,8,,,CHEMBL615146,,Autocuration,B,,1,,H,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,,12054,BAO_0000357
35,,,,8,,,CHEMBL615147,,Autocuration,B,,1,,H,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,,12054,BAO_0000357
36,,,,0,,,CHEMBL615148,,Autocuration,A,,1,,U,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,,22226,BAO_0000019
37,,,,0,,,CHEMBL615149,,Autocuration,B,,1,,U,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,,22226,BAO_0000019
38,,,,0,,,CHEMBL615150,,Autocuration,B,,1,,U,Dissociation constant with dimeric 16S rRNA RNA construct B,,,22226,BAO_0000019
39,,,,3,,,CHEMBL615151,,Intermediate,B,,1,,M,Dissociation constant towards 16S rRNA construct A,,,22222,BAO_0000225
40,,,,3,,,CHEMBL615152,,Intermediate,B,,1,,M,Dissociation constant towards 16S rRNA construct B,,,22222,BAO_0000225
41,,,,3,,,CHEMBL615153,,Expert,B,,1,,M,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,,100263,BAO_0000225
42,,,,3,,,CHEMBL615154,,Expert,B,,1,,M,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,,100263,BAO_0000225
43,,,,8,,,CHEMBL615155,,Autocuration,B,,1,,H,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,13053,BAO_0000019
44,,,,8,,,CHEMBL615156,,Autocuration,B,,1,,H,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,13053,BAO_0000019
45,,,,8,,,CHEMBL615157,,Autocuration,B,,1,,H,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,20001,BAO_0000019
46,,,,8,,,CHEMBL615158,,Autocuration,B,,1,,H,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,20001,BAO_0000019
47,,,,9,,,CHEMBL615159,,Expert,B,,1,,D,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,12971,BAO_0000019
48,,,,9,,,CHEMBL615172,,Expert,B,,1,,D,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,12971,BAO_0000019
49,,,,9,,,CHEMBL615173,,Expert,B,,1,,D,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,12971,BAO_0000019
50,,,,9,,,CHEMBL615174,,Expert,B,,1,,D,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,12971,BAO_0000019
51,,,,8,,,CHEMBL884518,,Autocuration,B,,1,,H,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,13053,BAO_0000019
52,,,,8,,,CHEMBL615175,,Autocuration,B,,1,,H,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,11512,BAO_0000357
53,,,,8,,,CHEMBL615176,,Autocuration,B,,1,,H,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,11512,BAO_0000357
54,,,,8,,,CHEMBL615177,,Autocuration,B,,1,,H,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,11512,BAO_0000357
55,,,,5,,,CHEMBL615178,,Autocuration,B,,1,Membranes,D,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,,104740,BAO_0000249
56,506.0,,,1,,,CHEMBL615179,,Intermediate,F,,1,,N,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,1A9,80002,BAO_0000219
57,,,,7,,,CHEMBL615180,,Autocuration,F,,1,,D,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,Oocytes,104835,BAO_0000219
58,,,,7,,,CHEMBL615181,,Autocuration,F,,1,,D,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,Oocytes,104821,BAO_0000219
59,,,,7,,,CHEMBL615182,,Autocuration,F,,1,,D,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,Oocytes,104848,BAO_0000219
60,506.0,,,1,,,CHEMBL615183,,Expert,F,,1,,N,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,1A9,80002,BAO_0000219
61,506.0,,,1,,,CHEMBL615184,,Intermediate,F,,1,,N,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,1A9,80002,BAO_0000219
62,506.0,,,1,,,CHEMBL615185,,Intermediate,F,,1,,N,Cytotoxic activity against human ovarian cancer (1A9) cell line,,1A9,80002,BAO_0000219
63,506.0,,,1,,,CHEMBL615186,,Intermediate,F,,1,,N,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,1A9,80002,BAO_0000219
64,506.0,,,1,,,CHEMBL615187,,Intermediate,F,,1,,N,Effective dose of compound against replication of 1A9 cell line was evaluated,,1A9,80002,BAO_0000219
65,506.0,,,1,,,CHEMBL885343,,Expert,F,,1,,N,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,1A9,80002,BAO_0000219
66,506.0,,,1,,,CHEMBL615188,,Intermediate,F,,1,,N,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,1A9,80002,BAO_0000219
67,506.0,,,1,,,CHEMBL615189,,Intermediate,F,,1,,N,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,1A9,80002,BAO_0000219
68,506.0,,,1,,,CHEMBL615190,,Intermediate,F,,1,,N,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,1A9,80002,BAO_0000219
69,506.0,,,1,,,CHEMBL615191,,Intermediate,F,,1,,N,Inhibitory activity against Taxol resistant 1A9 cell lines,,1A9,80002,BAO_0000219
70,506.0,,,1,,,CHEMBL615192,,Expert,F,,1,,N,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,1A9,80002,BAO_0000219
71,506.0,,,1,,,CHEMBL827083,,Expert,F,,1,,N,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,1A9,80002,BAO_0000219
72,506.0,,,1,,,CHEMBL615193,,Expert,F,,1,,N,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,1A9,80002,BAO_0000219
73,506.0,,,1,,,CHEMBL615194,,Intermediate,F,,1,,N,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,1A9,80002,BAO_0000219
74,506.0,,,1,,,CHEMBL615195,,Intermediate,F,,1,,N,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,1A9,80002,BAO_0000219
75,506.0,,,1,,,CHEMBL615196,,Intermediate,F,,1,,N,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,1A9,80002,BAO_0000219
76,503.0,,,1,,,CHEMBL615197,,Intermediate,F,,1,,N,Inhibitory concentration against Jurkat cells,,Jurkat,81072,BAO_0000219
77,,,,0,,,CHEMBL615198,,Intermediate,F,,1,,U,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,22226,BAO_0000019
78,,,,9,,,CHEMBL615199,,Expert,A,,1,,D,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,,100121,BAO_0000357
79,,,,8,,,CHEMBL615200,,Expert,B,,1,,H,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,11231,BAO_0000357
80,,,,8,,,CHEMBL615201,,Expert,B,,1,,H,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,11231,BAO_0000357
81,,,,8,,,CHEMBL615202,,Expert,B,,1,,H,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,11231,BAO_0000357
82,,,,8,,,CHEMBL615203,,Autocuration,B,,1,Microsomes,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,,11231,BAO_0000251
83,,,,8,,,CHEMBL615204,,Autocuration,B,,1,Microsomes,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,,11231,BAO_0000251
84,,,,8,,,CHEMBL615205,,Autocuration,B,,1,Microsomes,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,,11231,BAO_0000251
85,,,,8,,,CHEMBL615206,,Autocuration,B,,1,Microsomes,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,,11231,BAO_0000251
86,,,2107.0,8,Liver,,CHEMBL615207,,Autocuration,B,,1,Microsomes,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,,12083,BAO_0000251
87,,,,8,,,CHEMBL827084,,Autocuration,B,,1,,H,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,,11231,BAO_0000019
88,,,,8,,,CHEMBL615208,,Autocuration,B,,1,,H,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,,11231,BAO_0000019
89,,,,8,,,CHEMBL615209,,Autocuration,B,,1,,H,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,,11231,BAO_0000019
90,,,2107.0,9,Liver,,CHEMBL615210,,Autocuration,B,,1,Microsomes,D,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,,12083,BAO_0000251
91,,,2107.0,9,Liver,,CHEMBL615211,,Autocuration,B,,1,Microsomes,D,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,12083,BAO_0000251
92,,,2107.0,9,Liver,,CHEMBL615212,,Autocuration,B,,1,Microsomes,D,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,12083,BAO_0000251
93,,,,8,,,CHEMBL615213,,Expert,B,,1,,H,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,11377,BAO_0000357
94,,,,8,,,CHEMBL615273,,Expert,B,,1,,H,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,11377,BAO_0000357
95,726.0,,,1,,,CHEMBL615274,,Expert,F,,1,,N,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,HepG2,81020,BAO_0000219
96,726.0,,,1,,,CHEMBL615275,,Intermediate,F,,1,,N,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,HepG2,81020,BAO_0000219
97,726.0,,,1,,,CHEMBL615276,,Intermediate,F,,1,,N,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,HepG2,81020,BAO_0000219
98,726.0,,,1,,,CHEMBL615277,,Intermediate,F,,1,,N,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,HepG2,81020,BAO_0000219
99,726.0,,,1,,,CHEMBL615326,,Intermediate,F,,1,,N,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,HepG2,81020,BAO_0000219
100,,,,1,,,CHEMBL883130,,Expert,F,,1,,N,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,50606,BAO_0000218
101,726.0,,,1,,,CHEMBL884519,,Intermediate,F,,1,,N,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,HepG2,81020,BAO_0000219
102,726.0,,,1,,,CHEMBL615327,,Intermediate,F,,1,,N,Concentration required to inhibit 50% of 2.2.15 cell line,,HepG2,81020,BAO_0000219
103,726.0,,,1,,,CHEMBL615328,,Intermediate,A,,1,,N,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,HepG2,81020,BAO_0000219
104,,,,1,,,CHEMBL615329,,Intermediate,F,,1,,N,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,2.2.15,50587,BAO_0000218
105,,,,1,,,CHEMBL615330,,Intermediate,F,,1,,N,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,2.2.15,50587,BAO_0000218
106,,,,1,,,CHEMBL615331,,Expert,F,,1,,N,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,2.2.15,50606,BAO_0000218
107,,,,1,,,CHEMBL615332,,Intermediate,F,,1,,N,In vitro anti-HBV activity in 2.2.15 cells,,2.2.15,50587,BAO_0000218
108,,,,1,,,CHEMBL615333,,Intermediate,F,,1,,N,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,2.2.15,50587,BAO_0000218
109,,,,1,,,CHEMBL615334,,Intermediate,F,,1,,N,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,2.2.15,50587,BAO_0000218
110,,,,1,,,CHEMBL615335,,Intermediate,F,,1,,N,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,2.2.15,50587,BAO_0000218
111,,,,1,,,CHEMBL615336,,Intermediate,F,,1,,N,Cytotoxicity in 2.2.15 cells,,2.2.15,50587,BAO_0000218
112,,,,1,,,CHEMBL615337,,Intermediate,F,,1,,N,Cytotoxicity in 2.2.15 cells; Not determined,,2.2.15,50587,BAO_0000218
113,,,,1,,,CHEMBL615338,,Intermediate,F,,1,,N,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,2.2.15,50587,BAO_0000218
114,,,,1,,,CHEMBL615339,,Intermediate,F,,1,,N,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,2.2.15,50587,BAO_0000218
115,,,,1,,,CHEMBL615340,,Intermediate,F,,1,,N,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,2.2.15,50587,BAO_0000218
116,726.0,,,1,,,CHEMBL615341,,Intermediate,F,,1,,N,Antiviral activity against HBV was determined in 2.215 cell line,,HepG2,81020,BAO_0000219
117,,,,0,,,CHEMBL615342,,Autocuration,B,,1,Microsomes,U,Inhibition of 20-HETE synthesis in human renal microsomes,,,22226,BAO_0000251
118,,,,0,,,CHEMBL615343,,Autocuration,B,,1,,U,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,22226,BAO_0000019
119,388.0,,,1,,,CHEMBL615344,,Intermediate,F,,1,,N,Inhibitory concentration against 2008 (ovarian) cells,,2008,80612,BAO_0000219
120,388.0,,,1,,,CHEMBL615345,,Intermediate,F,,1,,N,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,2008,80612,BAO_0000219
121,388.0,,,1,,,CHEMBL615346,,Intermediate,F,,1,,N,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,2008,80612,BAO_0000219
122,388.0,,,1,,,CHEMBL615347,,Intermediate,F,,1,,N,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,2008,80612,BAO_0000219
123,388.0,,,1,,,CHEMBL615348,,Intermediate,F,,1,,N,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,2008,80612,BAO_0000219
124,561.0,,,1,,,CHEMBL827085,,Intermediate,F,,1,,N,In vitro inhibition of 2008/R ovarian cancer cell line,,2008/R,80613,BAO_0000219
125,561.0,,,1,,,CHEMBL615349,,Intermediate,F,,1,,N,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,2008/R,80613,BAO_0000219
126,389.0,,,1,,,CHEMBL615350,,Intermediate,F,,1,,N,In vitro inhibition of 2008/S ovarian cancer cell line,,2008/S,80614,BAO_0000219
127,389.0,,,1,,,CHEMBL615351,,Intermediate,F,,1,,N,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,2008/S,80614,BAO_0000219
128,,,,2,,,CHEMBL615352,,Expert,B,,1,,S,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,,100256,BAO_0000220
129,,,,2,,,CHEMBL615353,,Intermediate,B,,1,,S,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,,100256,BAO_0000220
130,,,,2,,,CHEMBL615354,,Expert,B,,1,,S,Inhibition of chymotrypsin-like activity of 20S proteasome,,,100256,BAO_0000220
131,,,,2,,,CHEMBL615355,,Expert,B,,1,,S,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,100256,BAO_0000220
132,,,,2,,,CHEMBL615356,,Intermediate,B,,1,,S,Inhibitory activity against 20S proteosome,,,100256,BAO_0000220
133,,,,0,,,CHEMBL615357,,Autocuration,B,,1,,U,Compound was tested for inhibitory activity against tryptase,,,22226,BAO_0000019
134,726.0,,,1,,,CHEMBL615358,,Intermediate,F,,1,,N,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,HepG2,81020,BAO_0000219
135,726.0,,,1,,,CHEMBL827086,,Intermediate,F,,1,,N,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,HepG2,81020,BAO_0000219
136,,,,0,,,CHEMBL615359,,Autocuration,B,,1,,U,Compound was tested for the inhibition of Alpha-glucosidase,,,22226,BAO_0000019
137,,,,8,,,CHEMBL615360,,Autocuration,B,,1,,H,Inhibitory concentration against human neutrophil elastase (HNE),,,235,BAO_0000357
138,,,948.0,0,Heart,,CHEMBL615361,,Autocuration,F,,1,,U,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,,22226,BAO_0000218
139,,,,8,,,CHEMBL615362,,Autocuration,F,,1,,H,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640,BAO_0000019
140,,,,8,,,CHEMBL615363,,Expert,F,,1,,H,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640,BAO_0000019
141,,,,8,,,CHEMBL615364,,Autocuration,B,,1,,H,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640,BAO_0000357
142,,,,8,,,CHEMBL615365,,Expert,F,,1,,H,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640,BAO_0000019
143,524.0,,,1,,,CHEMBL615366,,Intermediate,F,,1,,N,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,P338,80360,BAO_0000219
144,524.0,,,1,,,CHEMBL615367,,Intermediate,F,,1,,N,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,P338,80360,BAO_0000219
145,554.0,,,1,,,CHEMBL615368,,Intermediate,F,,1,,N,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,PBL,80384,BAO_0000219
146,,,,0,,,CHEMBL615369,,Autocuration,F,,1,,U,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,,22226,BAO_0000019
147,,,,0,,,CHEMBL615370,,Autocuration,F,,1,,U,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,,22226,BAO_0000019
148,,,,8,,,CHEMBL615673,,Autocuration,B,,1,,H,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,191,BAO_0000357
149,,,,0,,,CHEMBL615674,,Autocuration,F,,1,,U,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,,22226,BAO_0000019
150,,,,0,,,CHEMBL615675,,Autocuration,F,,1,,U,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,,22226,BAO_0000019
151,635.0,,,0,,,CHEMBL615676,,Autocuration,F,,1,,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,CCRF-CEM,22226,BAO_0000219
152,635.0,,,0,,,CHEMBL615677,,Autocuration,F,,1,,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,CCRF-CEM,22226,BAO_0000219
153,635.0,,,0,,,CHEMBL615678,,Autocuration,F,,1,,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,CCRF-CEM,22226,BAO_0000219
154,635.0,,,0,,,CHEMBL615679,,Autocuration,F,,1,,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,CCRF-CEM,22226,BAO_0000219
155,,,,0,,,CHEMBL615680,,Autocuration,F,,1,,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,,22226,BAO_0000019
156,,,,0,,,CHEMBL615681,,Autocuration,F,,1,,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,,22226,BAO_0000019
157,,,,6,,,CHEMBL857972,,Autocuration,B,,1,,H,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,104290,BAO_0000249
158,,,,1,,,CHEMBL857899,,Intermediate,F,,1,,N,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,,50264,BAO_0000218
159,,,,1,,,CHEMBL615371,,Intermediate,F,,1,,N,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,,50527,BAO_0000218
160,468.0,,,1,,,CHEMBL615372,,Expert,F,,1,,N,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,HEL,50527,BAO_0000218
161,,,,1,,,CHEMBL615373,,Intermediate,F,,1,,N,Antiviral activity against 07/1 strain of VZV; ND: No data,,,50527,BAO_0000218
162,,,,1,,,CHEMBL615374,,Intermediate,F,,1,,N,Antiviral activity against 07/1 strain of VZV; ND=No data,,,50527,BAO_0000218
163,,,,1,,,CHEMBL615375,,Intermediate,F,,1,,N,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,,50145,BAO_0000218
164,,,,0,,,CHEMBL615376,,Autocuration,B,,1,,U,Ratio of Ki at A2 to Ki at A1 receptors,,,22226,BAO_0000019
165,,,,8,,,CHEMBL615377,,Expert,B,,1,,H,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,,11143,BAO_0000249
166,,,,8,,,CHEMBL615378,,Expert,B,,1,,H,"Inhibition of 1,3-beta-glucan synthase",,,18077,BAO_0000357
167,832.0,,,1,,,CHEMBL615379,,Intermediate,F,,1,,N,Inhibition of growth of 1-87 human tumor cell line,,1-87 tumor cell line,80609,BAO_0000219
168,,,,9,,,CHEMBL615380,,Expert,B,,1,,D,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,,12166,BAO_0000219
169,,,,9,,,CHEMBL615381,,Autocuration,B,,1,,D,Inhibitory activity against soybean 1-lipoxygenase (SLO),,,100171,BAO_0000357
170,,,,9,,,CHEMBL615382,,Autocuration,B,,1,,D,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,,100171,BAO_0000357
171,,,,9,,,CHEMBL615383,,Autocuration,B,,1,,D,% inhibition against soybean 1-lipoxygenase (SLO),,,100171,BAO_0000357
172,,,,9,,,CHEMBL615384,,Autocuration,B,,1,,D,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,,100171,BAO_0000357
173,,,,9,,,CHEMBL615385,,Autocuration,B,,1,,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,,100171,BAO_0000357
174,,,,9,,,CHEMBL615386,,Autocuration,B,,1,,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,,100171,BAO_0000357
175,,,,9,,,CHEMBL615387,,Autocuration,B,,1,,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,,100171,BAO_0000357
176,,,,9,,,CHEMBL615388,,Autocuration,B,,1,,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,,100171,BAO_0000357
177,,,,9,,,CHEMBL615214,,Autocuration,B,,1,,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,,100171,BAO_0000357
178,,,,9,,,CHEMBL827087,,Autocuration,B,,1,,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,,100171,BAO_0000357
179,,,,9,,,CHEMBL615215,,Autocuration,B,,1,,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,,100171,BAO_0000357
180,,,,9,,,CHEMBL615216,,Autocuration,B,,1,,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,,100171,BAO_0000357
181,,,,9,,,CHEMBL615217,,Autocuration,B,,1,,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,,100171,BAO_0000357
182,,,,9,,,CHEMBL615218,,Autocuration,B,,1,,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,,100171,BAO_0000357
183,,,,9,,,CHEMBL615219,,Autocuration,B,,1,,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,,100171,BAO_0000357
184,,,,0,,,CHEMBL615220,,Autocuration,B,,1,,U,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,,22226,BAO_0000019
185,294.0,,,1,,,CHEMBL615221,,Intermediate,F,,1,,N,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,C3H 10T1/2,80049,BAO_0000219
186,,,,0,,,CHEMBL615222,,Intermediate,F,,1,,U,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,22226,BAO_0000019
187,,,,8,,,CHEMBL615223,,Autocuration,B,,1,,H,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,11489,BAO_0000357
188,,,,8,,,CHEMBL615224,,Autocuration,B,,1,,H,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,11862,BAO_0000357
189,,,,8,,,CHEMBL615225,,Autocuration,B,,1,,H,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,11862,BAO_0000357
190,,,,8,,,CHEMBL615226,,Autocuration,B,,1,,H,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,11489,BAO_0000357
191,,,,8,,,CHEMBL615227,,Autocuration,B,,1,,H,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,11862,BAO_0000357
192,,,,9,,,CHEMBL615228,,Expert,F,,1,,D,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,,12347,BAO_0000019
193,,,,9,,,CHEMBL615229,,Expert,B,,1,,D,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,,100120,BAO_0000357
194,,,2369.0,9,Adrenal gland,,CHEMBL615230,,Expert,B,,1,,D,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,,100120,BAO_0000357
195,,,,9,,,CHEMBL615231,,Expert,B,,1,,D,Inhibition of rat adrenal 11-beta-hydroxylase,,,100120,BAO_0000357
196,,,,9,,,CHEMBL884520,,Expert,B,,1,,D,Inhibition of rat adrenal 11-beta-hydroxylase,,,100120,BAO_0000357
197,,,,9,,,CHEMBL615232,,Expert,B,,1,,D,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,,100120,BAO_0000357
198,,,,8,,,CHEMBL615233,,Autocuration,B,,1,,H,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,10328,BAO_0000019
199,,,,8,,,CHEMBL827088,,Autocuration,B,,1,,H,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,11490,BAO_0000357
200,,,,8,,,CHEMBL615234,,Autocuration,B,,1,,H,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,11490,BAO_0000357
201,,,,8,,,CHEMBL615235,,Autocuration,F,,1,,H,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,11134,BAO_0000019
202,,,,8,,,CHEMBL615236,,Autocuration,B,,1,,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,12052,BAO_0000019
203,,,,8,,,CHEMBL615237,,Autocuration,B,,1,,H,Compound was tested in vitro for inhibition of 12-LO human platelet,,,11134,BAO_0000019
204,,,,8,,,CHEMBL615238,,Autocuration,F,,1,,H,Inhibitory concentration against human platelet 12-lipoxygenase,,,11134,BAO_0000019
205,,,,8,,,CHEMBL615239,,Autocuration,B,,1,,H,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,11134,BAO_0000019
206,,,,9,,,CHEMBL615240,,Autocuration,F,,1,,D,Inhibitory concentration against human platelet 12-lipoxygenase,,,11134,BAO_0000019
207,,,,8,,,CHEMBL615241,,Expert,B,,1,,H,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,11835,BAO_0000019
208,,,,8,,,CHEMBL615242,,Expert,B,,1,,H,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,11601,BAO_0000357
209,,,,8,,,CHEMBL615243,,Autocuration,B,,1,,H,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,11134,BAO_0000019
210,,,,8,,,CHEMBL615244,,Autocuration,B,,1,,H,Inhibitory activity against human platelet 12-lipoxygenase,,,11134,BAO_0000019
211,,,,8,,,CHEMBL615245,,Autocuration,B,,1,,H,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,11134,BAO_0000019
212,,,,8,,,CHEMBL615246,,Autocuration,B,,1,,H,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,11134,BAO_0000019
213,,,,8,,,CHEMBL615247,,Autocuration,B,,1,,H,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,11134,BAO_0000019
214,,,,8,,,CHEMBL615248,,Autocuration,B,,1,,H,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,11134,BAO_0000019
215,,,,8,,,CHEMBL615249,,Autocuration,B,,1,,H,Inhibitory activity towards porcine 12-lipoxygenase,,,11601,BAO_0000357
216,,,,8,,,CHEMBL615250,,Autocuration,B,,1,,H,Tested for inhibition against porcine 12-LO,,,11601,BAO_0000357
217,,,,8,,,CHEMBL615251,,Autocuration,B,,1,,H,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,12052,BAO_0000019
218,,,,8,,,CHEMBL615252,,Autocuration,B,,1,,H,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,12052,BAO_0000019
219,,,,8,,,CHEMBL828340,,Expert,B,,1,,H,In vitro inhibition of rat platelet 12-lipoxygenase,,,12052,BAO_0000019
220,,,,8,,,CHEMBL615253,,Autocuration,B,,1,,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,12052,BAO_0000019
221,,,,8,,,CHEMBL615254,,Autocuration,B,,1,,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,12052,BAO_0000019
222,,,,8,,,CHEMBL615255,,Autocuration,B,,1,,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,12052,BAO_0000019
223,,,,8,,,CHEMBL615256,,Autocuration,B,,1,,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,12052,BAO_0000019
224,,,,8,,,CHEMBL615257,,Autocuration,B,,1,,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,12052,BAO_0000019
225,,,,8,,,CHEMBL615258,,Autocuration,B,,1,,H,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,12052,BAO_0000019
226,621.0,,,1,,,CHEMBL615259,,Intermediate,F,,1,,N,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,41M,80007,BAO_0000219
227,621.0,,,1,,,CHEMBL615260,,Expert,F,,1,,N,In vitro antitumor activity against 41M cell line.,,41M,80007,BAO_0000219
228,621.0,,,1,,,CHEMBL615261,,Intermediate,F,,1,,N,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,41M,80007,BAO_0000219
229,621.0,,,1,,,CHEMBL615262,,Intermediate,F,,1,,N,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,41M,80007,BAO_0000219
230,621.0,,,1,,,CHEMBL615263,,Expert,F,,1,,N,In vitro antitumor activity against 41McisR cell line.,,41M,80007,BAO_0000219
231,621.0,,,1,,,CHEMBL838393,,Expert,F,,1,,N,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,41M,80007,BAO_0000219
232,621.0,,,1,,,CHEMBL615264,,Intermediate,F,,1,,N,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,41M,80007,BAO_0000219
233,,,,9,,,CHEMBL615265,,Expert,B,,1,,D,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,,84,BAO_0000357
234,,,,9,,,CHEMBL615266,,Expert,B,,1,,D,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,68,BAO_0000357
235,,,,8,,,CHEMBL615267,,Expert,B,,1,,H,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,68,BAO_0000357
236,,,,8,,,CHEMBL615268,,Expert,B,,1,,H,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,10201,BAO_0000357
237,,,,8,,,CHEMBL615269,,Expert,B,,1,,H,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,10201,BAO_0000357
238,,,,8,,,CHEMBL615270,,Expert,B,,1,,H,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,10201,BAO_0000357
239,,,,8,,,CHEMBL615271,,Autocuration,B,,1,,H,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,12220,BAO_0000357
240,,,,8,,,CHEMBL615272,,Autocuration,B,,1,,H,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,11303,BAO_0000357
241,,,,8,,,CHEMBL615103,,Autocuration,B,,1,,H,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,11303,BAO_0000357
242,,,,8,,,CHEMBL615104,,Autocuration,B,,1,,H,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,,11303,BAO_0000357
243,,,,8,,,CHEMBL615105,,Autocuration,B,,1,,H,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,12220,BAO_0000357
244,,,,8,,,CHEMBL872866,,Autocuration,B,,1,,H,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,12220,BAO_0000357
245,,,,8,,,CHEMBL615106,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,11303,BAO_0000357
246,,,,8,,,CHEMBL615107,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,,11303,BAO_0000019
247,,,,8,,,CHEMBL615108,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,,11303,BAO_0000357
248,,,,8,,,CHEMBL615109,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,,11303,BAO_0000357
249,,,,8,,,CHEMBL615110,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,11303,BAO_0000357
250,,,,8,,,CHEMBL840105,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,11303,BAO_0000019
251,,,,8,,,CHEMBL615111,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,,11303,BAO_0000019
252,,,,8,,,CHEMBL615112,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,,11303,BAO_0000019
253,,,,8,,,CHEMBL615113,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,,11303,BAO_0000019
254,,,,8,,,CHEMBL615114,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,,11303,BAO_0000019
255,,,,8,,,CHEMBL615115,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,11303,BAO_0000357
256,,,,8,,,CHEMBL615116,,Autocuration,B,,1,,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,11303,BAO_0000019
257,,,,8,,,CHEMBL615698,,Autocuration,B,,1,,H,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,11303,BAO_0000357
258,,,,0,,,CHEMBL615699,,Autocuration,B,,1,,U,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,,22226,BAO_0000019
259,,,,0,,,CHEMBL615700,,Autocuration,B,,1,,U,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,,22226,BAO_0000019
260,,,,8,,,CHEMBL615701,,Expert,B,,1,,H,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,,100249,BAO_0000357
261,,,,0,,,CHEMBL615702,,Autocuration,B,,1,,U,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,22226,BAO_0000019
262,,,,0,,,CHEMBL615703,,Autocuration,B,,1,,U,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,22226,BAO_0000019
263,,,,0,,,CHEMBL615704,,Autocuration,B,,1,,U,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,,22226,BAO_0000019
264,,,,6,,,CHEMBL615705,,Autocuration,F,,1,,H,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,104698,BAO_0000019
265,,,,6,,,CHEMBL615706,,Autocuration,F,,1,,H,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,104698,BAO_0000019
266,,,2116.0,9,Ileum,,CHEMBL615707,,Intermediate,F,,1,,D,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,,20033,BAO_0000221
267,,,,8,,,CHEMBL615708,,Expert,F,,1,,H,Stimulatory activity of intragastric pressure was tested in the rat,,,10623,BAO_0000019
268,,,,8,,,CHEMBL615709,,Autocuration,B,,1,,H,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,121,BAO_0000357
269,,,,0,,,CHEMBL615710,,Autocuration,F,,1,,U,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,,22226,BAO_0000218
270,,,,8,,,CHEMBL615711,,Autocuration,F,,1,,H,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,12688,BAO_0000019
271,,,,9,,,CHEMBL615712,,Expert,B,,1,,D,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,,121,BAO_0000357
272,,,,9,,,CHEMBL836325,,Expert,B,,1,,D,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,,121,BAO_0000357
273,,,,8,,,CHEMBL615713,,Autocuration,F,,1,,H,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,12198,BAO_0000019
274,,,,8,,,CHEMBL615714,,Autocuration,B,,1,,H,Inhibition constant of high-affinity 5-HT uptake,,,12198,BAO_0000357
275,,,,8,,,CHEMBL615715,,Autocuration,F,,1,,H,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,12198,BAO_0000019
276,,,,8,,,CHEMBL615716,,Autocuration,F,,1,,H,Maximum rate was determined for high affinity transport of 5-HT,,,12198,BAO_0000019
277,,,,4,,,CHEMBL615717,,Autocuration,F,,1,,H,Compound was tested for agonistic activity against 5-HT uptake,,,104714,BAO_0000019
278,,,,8,,,CHEMBL881818,,Expert,B,,1,,H,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,10577,BAO_0000019
279,,,,8,,,CHEMBL884540,,Expert,B,,1,,H,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,,105,BAO_0000357
280,,,,5,,,CHEMBL615718,,Autocuration,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,104744,BAO_0000224
281,,,,4,,,CHEMBL615719,,Autocuration,B,,1,,H,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,104744,BAO_0000224
282,,,,4,,,CHEMBL615720,,Autocuration,B,,1,Membranes,H,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,104744,BAO_0000249
283,,,,4,,,CHEMBL615721,,Autocuration,B,,1,Membranes,H,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,104744,BAO_0000249
284,,,,4,,,CHEMBL615722,,Autocuration,B,,1,,H,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744,BAO_0000019
285,,,,8,,,CHEMBL615723,,Autocuration,F,,1,,H,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,51,BAO_0000019
286,,,10000000.0,8,Hippocampus,,CHEMBL615724,,Autocuration,B,,1,,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51,BAO_0000221
287,,,10000000.0,8,Hippocampus,,CHEMBL615725,,Autocuration,B,,1,,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51,BAO_0000221
288,,,10000000.0,8,Hippocampus,,CHEMBL615726,,Autocuration,B,,1,,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51,BAO_0000221
289,,,,8,,In vivo,CHEMBL615727,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,,10576,BAO_0000218
290,,,,9,,,CHEMBL615728,,Intermediate,F,,1,,D,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,,105570,BAO_0000019
291,449.0,,,8,,,CHEMBL857971,,Autocuration,B,,1,,H,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHO,279,BAO_0000219
292,,,,8,,,CHEMBL615729,,Autocuration,B,,1,,H,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
293,,,,9,,,CHEMBL615730,,Expert,F,,1,,D,Efficacy against 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000019
294,,,,8,,,CHEMBL615731,,Expert,F,,1,,H,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,12687,BAO_0000019
295,,,,8,,,CHEMBL615732,,Expert,F,,1,,H,Relative potency towards 5-HT2A receptor of rat tail artery,,,12687,BAO_0000019
296,,,,8,,,CHEMBL615733,,Expert,F,,1,,H,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,12687,BAO_0000019
297,,,,8,,,CHEMBL615734,,Expert,F,,1,,H,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,12687,BAO_0000019
298,,,,8,,,CHEMBL615735,,Autocuration,F,,1,,H,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,12687,BAO_0000019
299,,,,8,,,CHEMBL615736,,Expert,F,,1,,H,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,12687,BAO_0000019
300,,,2116.0,9,Ileum,,CHEMBL615737,,Intermediate,F,,1,,D,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,20033,BAO_0000221
301,,,2116.0,9,Ileum,,CHEMBL615738,,Intermediate,F,,1,,D,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,,20033,BAO_0000221
302,,,2116.0,9,Ileum,,CHEMBL615739,,Intermediate,F,,1,,D,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,20033,BAO_0000221
303,,,,8,,,CHEMBL615278,,Autocuration,B,,1,,H,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,10623,BAO_0000357
304,,,,9,,,CHEMBL615279,,Expert,F,,1,,D,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,10623,BAO_0000019
305,,,,8,,,CHEMBL615280,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 4 receptor,,,168,BAO_0000357
306,,,,0,,,CHEMBL615281,,Autocuration,B,,1,,U,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,,22226,BAO_0000019
307,,,,0,,,CHEMBL615282,,Autocuration,F,,1,,U,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,,22226,BAO_0000019
308,,,,0,,,CHEMBL615283,,Autocuration,F,,1,,U,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,22226,BAO_0000019
309,649.0,,,1,,,CHEMBL615284,,Autocuration,B,,1,,N,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,HL-60,80156,BAO_0000219
310,,,,0,,,CHEMBL615285,,Autocuration,B,,1,,U,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,,22226,BAO_0000019
311,,,,0,,,CHEMBL615286,,Autocuration,B,,1,,U,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,22226,BAO_0000019
312,,,,7,,,CHEMBL615287,,Autocuration,B,,1,,D,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,Oocytes,104703,BAO_0000219
313,,,,2,,,CHEMBL615288,,Intermediate,F,,1,,S,Chymotryptic inhibitory activity against 26S proteasome,,,100256,BAO_0000220
314,,,,2,,,CHEMBL615289,,Intermediate,B,,1,,S,Inhibitory activity against 26S proteasome degradation of IkB,,,100256,BAO_0000220
315,478.0,,,1,,,CHEMBL615290,,Intermediate,F,,1,,N,In vitro inhibition of 2780/DOX ovarian cancer cell line,,A2780,81034,BAO_0000219
316,478.0,,,1,,,CHEMBL884522,,Intermediate,F,,1,,N,In vitro inhibition of 2780/S ovarian cancer cell line,,A2780,81034,BAO_0000219
317,,,,0,,,CHEMBL615291,,Autocuration,F,,1,,U,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,,22226,BAO_0000019
318,,,,3,,,CHEMBL615292,,Intermediate,B,,1,,M,Association constant for binding to AATT 28-mer AATT hairpin,,,22222,BAO_0000225
319,,,,3,,,CHEMBL615293,,Intermediate,B,,1,,M,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,22222,BAO_0000225
320,,,,3,,,CHEMBL615294,,Intermediate,B,,1,,M,Reaction Rate Parameter for 28-mer AATT hairpin,,,22222,BAO_0000225
321,,,,3,,,CHEMBL615295,,Intermediate,B,,1,,M,Reaction Rate Parameter for 28-mer AATT hairpin,,,22222,BAO_0000225
322,,,,0,,,CHEMBL825021,,Autocuration,F,,1,,U,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,,22226,BAO_0000019
323,,,,0,,,CHEMBL615296,,Autocuration,F,,1,,U,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,,22226,BAO_0000019
324,,,,0,,,CHEMBL615297,,Autocuration,F,,1,,U,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,,22226,BAO_0000019
325,,,,0,,,CHEMBL615298,,Autocuration,F,,1,,U,Cytotoxicity against cell line 2SC/20 determined by MTT test,,,22226,BAO_0000019
326,,,,0,,,CHEMBL615299,,Autocuration,F,,1,,U,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,,22226,BAO_0000019
327,,,,0,,,CHEMBL615300,,Autocuration,F,,1,,U,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,,22226,BAO_0000019
328,,,,8,,,CHEMBL615301,,Autocuration,B,,1,,H,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,241,BAO_0000357
329,,,,9,,,CHEMBL615302,,Expert,B,,1,,D,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,,241,BAO_0000357
330,,,,0,,,CHEMBL615303,,Autocuration,B,,1,,U,Selectivity ratio of ID50 in liver and heart,,,22226,BAO_0000019
331,,,,8,,,CHEMBL615304,,Autocuration,B,,1,,H,"Selectivity, ratio of relative ID50 in liver and heart",,,12132,BAO_0000019
332,,,,8,,,CHEMBL615305,,Autocuration,B,,1,,H,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,12132,BAO_0000019
333,,,,8,,,CHEMBL615306,,Autocuration,B,,1,,H,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132,BAO_0000218
334,,,,8,,,CHEMBL615307,,Autocuration,B,,1,,H,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132,BAO_0000218
335,,,,8,,In vivo,CHEMBL615308,,Autocuration,B,,1,,H,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132,BAO_0000218
336,,,,8,,In vivo,CHEMBL615309,,Autocuration,F,,1,,H,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132,BAO_0000218
337,,,,0,,,CHEMBL615310,,Autocuration,B,,1,,U,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,22226,BAO_0000019
338,,,,8,,,CHEMBL615311,,Autocuration,B,,1,,H,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,12132,BAO_0000019
339,,,,0,,,CHEMBL615312,,Autocuration,B,,1,,U,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,,22226,BAO_0000019
340,,,,8,,,CHEMBL615313,,Autocuration,B,,1,,H,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,12132,BAO_0000019
341,,,,8,,,CHEMBL615314,,Autocuration,F,,1,,H,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,12132,BAO_0000019
342,,,,8,,,CHEMBL615315,,Autocuration,B,,1,,H,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,12132,BAO_0000019
343,,,,0,,,CHEMBL615316,,Autocuration,B,,1,,U,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,,22226,BAO_0000218
344,,,,8,,In vivo,CHEMBL615317,,Autocuration,B,,1,,H,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,,12132,BAO_0000218
345,,,,8,,,CHEMBL615318,,Autocuration,B,,1,,H,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132,BAO_0000218
346,,,,0,,,CHEMBL615319,,Autocuration,B,,1,,U,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,,22226,BAO_0000218
347,,,,8,,,CHEMBL615320,,Autocuration,B,,1,,H,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,12132,BAO_0000019
348,,,,8,,,CHEMBL615321,,Autocuration,F,,1,,H,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,12132,BAO_0000019
349,,,,0,,,CHEMBL615322,,Autocuration,B,,1,,U,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,,22226,BAO_0000019
350,,,,8,,,CHEMBL615323,,Autocuration,B,,1,,H,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,19690,BAO_0000357
351,,,,8,,,CHEMBL615407,,Autocuration,B,,1,,H,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,19690,BAO_0000357
352,,,,8,,,CHEMBL857267,,Autocuration,B,,1,,H,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,19690,BAO_0000357
353,,,,8,,,CHEMBL615408,,Autocuration,B,,1,,H,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,19690,BAO_0000357
354,,,,8,,,CHEMBL615409,,Autocuration,B,,1,,H,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,19690,BAO_0000357
355,,,,8,,,CHEMBL615410,,Autocuration,B,,1,,H,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,19690,BAO_0000357
356,,,,8,,,CHEMBL615411,,Autocuration,B,,1,,H,Inhibition constant against 3-dehydroquinate synthase,,,19690,BAO_0000357
357,,,,8,,,CHEMBL615412,,Autocuration,B,,1,,H,Association rate constant against 3-dehydroquinate synthase,,,19690,BAO_0000357
358,,,,8,,,CHEMBL615413,,Autocuration,B,,1,,H,Rate constant against 3-dehydroquinate synthase,,,19690,BAO_0000357
359,,,,0,,,CHEMBL615414,,Autocuration,B,,1,,U,Inhibitory activity against fuc-TVII,,,22226,BAO_0000019
360,,,2107.0,9,Liver,,CHEMBL615415,,Autocuration,B,,1,Microsomes,D,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,12236,BAO_0000251
361,,,2107.0,9,Liver,,CHEMBL615416,,Autocuration,B,,1,Microsomes,D,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,12236,BAO_0000251
362,,,2107.0,9,Liver,,CHEMBL615417,,Autocuration,B,,1,Microsomes,D,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,12236,BAO_0000251
363,,,2107.0,9,Liver,,CHEMBL615418,,Autocuration,B,,1,Microsomes,D,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,12236,BAO_0000251
364,,,2107.0,9,Liver,,CHEMBL615419,,Autocuration,B,,1,Microsomes,D,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,12236,BAO_0000251
365,,,2107.0,9,Liver,,CHEMBL615420,,Autocuration,B,,1,Microsomes,D,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,,12236,BAO_0000251
366,,,2107.0,9,Liver,,CHEMBL615421,,Autocuration,B,,1,Microsomes,D,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,,12236,BAO_0000251
367,,,2107.0,9,Liver,,CHEMBL615422,,Autocuration,B,,1,Microsomes,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,,12236,BAO_0000251
368,,,2107.0,9,Liver,,CHEMBL615423,,Autocuration,B,,1,Microsomes,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,,12236,BAO_0000251
369,,,2107.0,9,Liver,,CHEMBL872868,,Autocuration,B,,1,Microsomes,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,,12236,BAO_0000251
370,,,2107.0,9,Liver,,CHEMBL615424,,Autocuration,B,,1,Microsomes,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,,12236,BAO_0000251
371,,,,4,,,CHEMBL825022,,Autocuration,B,,1,,H,Inhibitory activity against 3-phosphoglycerate kinase.,,,104832,BAO_0000224
372,,,,4,,,CHEMBL615425,,Autocuration,B,,1,,H,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,104832,BAO_0000224
373,,,,4,,,CHEMBL615426,,Autocuration,B,,1,,H,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,104832,BAO_0000224
374,,,,9,,,CHEMBL615427,,Expert,B,,1,,D,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,,10612,BAO_0000357
375,844.0,,,1,,,CHEMBL615428,,Intermediate,F,,1,,N,Cytotoxicity on 3677 melanoma cells,,3677 melanoma cell line,80616,BAO_0000219
376,844.0,,,1,,,CHEMBL615429,,Intermediate,F,,1,,N,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,3677 melanoma cell line,80616,BAO_0000219
377,700.0,,,1,,,CHEMBL615430,,Intermediate,F,,1,,N,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,MC-38,80617,BAO_0000219
378,,,,0,,,CHEMBL615431,,Intermediate,F,,1,,U,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,,22226,BAO_0000019
379,798.0,,,0,,,CHEMBL615432,,Autocuration,F,,1,,U,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,B16,22226,BAO_0000218
380,798.0,,,0,,,CHEMBL615433,,Autocuration,F,,1,,U,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,B16,22226,BAO_0000218
381,,,,9,,,CHEMBL615434,,Expert,F,,1,,D,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,,12464,BAO_0000019
382,,,,1,,,CHEMBL615435,,Intermediate,F,,1,,N,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,,50085,BAO_0000218
383,,,,1,,,CHEMBL615436,,Intermediate,F,,1,,N,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,,50679,BAO_0000218
384,,,,1,,,CHEMBL615437,,Intermediate,F,,1,,N,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,,50679,BAO_0000218
385,,,,9,,,CHEMBL615438,,Expert,F,,1,,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,12464,BAO_0000019
386,,,,9,,,CHEMBL615439,,Expert,F,,1,,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,12464,BAO_0000019
387,,,,9,,,CHEMBL615440,,Expert,F,,1,,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,12464,BAO_0000019
388,,,,9,,,CHEMBL615441,,Expert,F,,1,,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,,12464,BAO_0000019
389,,,,1,,,CHEMBL615641,,Intermediate,F,,1,,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,,50665,BAO_0000218
390,,,,1,,,CHEMBL872065,,Intermediate,F,,1,,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,,50665,BAO_0000218
391,,,,1,,,CHEMBL825023,,Intermediate,F,,1,,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,,50665,BAO_0000218
392,,,,1,,,CHEMBL615642,,Intermediate,F,,1,,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,,50665,BAO_0000218
393,,,,8,,,CHEMBL615643,,Expert,B,,1,,H,Inhibition of human rhinovirus 3C protease,,,12464,BAO_0000357
394,,,,0,,,CHEMBL615644,,Autocuration,B,,1,,U,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,,22226,BAO_0000019
395,833.0,,,1,,,CHEMBL615645,,Intermediate,F,,1,,N,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,3EM 37,80619,BAO_0000218
396,833.0,,,1,,,CHEMBL615646,,Intermediate,F,,1,,N,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,3EM 37,80619,BAO_0000218
397,833.0,,,1,,,CHEMBL615647,,Intermediate,F,,1,,N,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,3EM 37,80619,BAO_0000218
398,833.0,,,1,,,CHEMBL615648,,Intermediate,F,,1,,N,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,3EM 37,80619,BAO_0000218
399,833.0,,,1,,,CHEMBL615649,,Intermediate,F,,1,,N,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,3EM 37,80619,BAO_0000218
400,833.0,,,1,,,CHEMBL615650,,Intermediate,F,,1,,N,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,3EM 37,80619,BAO_0000218
401,847.0,,,1,,,CHEMBL615651,,Intermediate,F,,1,,N,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,3LL cell line,80620,BAO_0000218
402,847.0,,,1,,,CHEMBL615652,,Intermediate,F,,1,,N,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,3LL cell line,80620,BAO_0000218
403,847.0,,,1,,,CHEMBL615653,,Expert,F,,1,,N,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,3LL cell line,80620,BAO_0000218
404,847.0,,,1,,,CHEMBL615654,,Intermediate,F,,1,,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,3LL cell line,80620,BAO_0000219
405,847.0,,,1,,,CHEMBL615655,,Intermediate,F,,1,,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,3LL cell line,80620,BAO_0000219
406,847.0,,,1,,,CHEMBL825024,,Intermediate,F,,1,,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,3LL cell line,80620,BAO_0000219
407,847.0,,,1,,,CHEMBL615656,,Intermediate,F,,1,,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,3LL cell line,80620,BAO_0000219
408,847.0,,,1,,,CHEMBL615657,,Intermediate,F,,1,,N,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,3LL cell line,80620,BAO_0000219
409,847.0,,,1,,,CHEMBL615658,,Intermediate,F,,1,,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,3LL cell line,80620,BAO_0000219
410,847.0,,,1,,,CHEMBL615659,,Intermediate,F,,1,,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,3LL cell line,80620,BAO_0000219
411,847.0,,,1,,,CHEMBL615660,,Intermediate,F,,1,,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,3LL cell line,80620,BAO_0000219
412,847.0,,,1,,,CHEMBL615661,,Intermediate,F,,1,,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,3LL cell line,80620,BAO_0000219
413,847.0,,,1,,,CHEMBL615662,,Intermediate,F,,1,,N,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,3LL cell line,80620,BAO_0000219
414,847.0,,,1,,,CHEMBL615663,,Intermediate,F,,1,,N,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,3LL cell line,80620,BAO_0000219
415,847.0,,,1,,,CHEMBL615664,,Intermediate,F,,1,,N,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,3LL cell line,80620,BAO_0000219
416,847.0,,,1,,,CHEMBL615665,,Intermediate,F,,1,,N,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,3LL cell line,80620,BAO_0000219
417,847.0,,,1,,,CHEMBL615666,,Intermediate,F,,1,,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,3LL cell line,80620,BAO_0000219
418,847.0,,,1,,,CHEMBL615667,,Intermediate,F,,1,,N,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,3LL cell line,80620,BAO_0000219
419,847.0,,,1,,,CHEMBL615668,,Intermediate,F,,1,,N,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,3LL cell line,80620,BAO_0000219
420,847.0,,,1,,,CHEMBL615669,,Intermediate,F,,1,,N,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,3LL cell line,80620,BAO_0000219
421,847.0,,,1,,,CHEMBL615670,,Intermediate,F,,1,,N,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,3LL cell line,80620,BAO_0000219
422,847.0,,,1,,,CHEMBL836739,,Intermediate,F,,1,,N,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,3LL cell line,80620,BAO_0000219
423,847.0,,,1,,,CHEMBL615671,,Intermediate,F,,1,,N,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,3LL cell line,80620,BAO_0000219
424,847.0,,,1,,,CHEMBL615672,,Intermediate,F,,1,,N,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,3LL cell line,80620,BAO_0000219
425,847.0,,,1,,,CHEMBL615791,,Intermediate,F,,1,,N,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,3LL cell line,80620,BAO_0000219
426,847.0,,,1,,,CHEMBL615792,,Intermediate,F,,1,,N,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,3LL cell line,80620,BAO_0000219
427,847.0,,,1,,,CHEMBL615793,,Intermediate,F,,1,,N,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,3LL cell line,80620,BAO_0000219
428,847.0,,,1,,,CHEMBL615794,,Intermediate,F,,1,,N,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,3LL cell line,80620,BAO_0000219
429,847.0,,,1,,,CHEMBL615795,,Intermediate,F,,1,,N,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,3LL cell line,80620,BAO_0000219
430,971.0,,,1,,,CHEMBL615590,,Intermediate,F,,1,,N,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,3LLD122,80621,BAO_0000219
431,,,,0,,,CHEMBL615591,,Autocuration,F,,1,,U,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,22226,BAO_0000218
432,,,,0,,,CHEMBL615592,,Autocuration,F,,1,,U,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,22226,BAO_0000218
433,,,,0,,,CHEMBL615593,,Autocuration,F,,1,,U,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,22226,BAO_0000218
434,,,,0,,,CHEMBL615594,,Autocuration,F,,1,,U,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,22226,BAO_0000218
435,723.0,,,1,,,CHEMBL615595,,Intermediate,F,,1,,N,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,NIH3T3,80951,BAO_0000219
436,723.0,,,1,,,CHEMBL615596,,Intermediate,F,,1,,N,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,NIH3T3,80951,BAO_0000219
437,723.0,,,8,,,CHEMBL615597,,Expert,F,,1,,H,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,NIH3T3,11169,BAO_0000219
438,723.0,,,1,,,CHEMBL615598,,Intermediate,F,,1,,N,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,NIH3T3,80951,BAO_0000219
439,723.0,,,1,,,CHEMBL615599,,Intermediate,F,,1,,N,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,NIH3T3,80951,BAO_0000219
440,723.0,,,1,,,CHEMBL615600,,Expert,F,,1,,N,Effective dose against murine 3T3 fibroblasts cells,,NIH3T3,80951,BAO_0000219
441,723.0,,,1,,,CHEMBL615601,,Expert,F,,1,,N,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,NIH3T3,80951,BAO_0000219
442,723.0,,,1,,,CHEMBL615602,,Expert,F,,1,,N,Cytotoxic effect on 3T3 cells,,NIH3T3,80951,BAO_0000219
443,723.0,,,1,,,CHEMBL615603,,Expert,F,,1,,N,Cytotoxic effect on 3T3 cells,,NIH3T3,80951,BAO_0000219
444,723.0,,,1,,,CHEMBL615604,,Intermediate,F,,1,,N,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,NIH3T3,80951,BAO_0000219
445,723.0,,,1,,,CHEMBL615605,,Intermediate,F,,1,,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,NIH3T3,80951,BAO_0000219
446,723.0,,,1,,,CHEMBL615606,,Intermediate,F,,1,,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,NIH3T3,80951,BAO_0000219
447,723.0,,,1,,,CHEMBL884526,,Expert,F,,1,,N,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,NIH3T3,80951,BAO_0000219
448,723.0,,,1,,,CHEMBL615607,,Expert,F,,1,,N,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,NIH3T3,80951,BAO_0000219
449,723.0,,,1,,,CHEMBL615608,,Intermediate,F,,1,,N,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,NIH3T3,80951,BAO_0000219
450,723.0,,,1,,,CHEMBL615609,,Expert,F,,1,,N,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,NIH3T3,80951,BAO_0000219
451,723.0,,,1,,,CHEMBL615682,,Expert,F,,1,,N,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,NIH3T3,80951,BAO_0000219
452,723.0,,,1,,,CHEMBL615683,,Intermediate,F,,1,,N,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,NIH3T3,80951,BAO_0000219
453,723.0,,,1,,,CHEMBL615684,,Expert,F,,1,,N,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,NIH3T3,80951,BAO_0000218
454,,,,7,,,CHEMBL615685,,Autocuration,F,,1,,D,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,,104860,BAO_0000219
455,723.0,,,1,,,CHEMBL615686,,Expert,F,,1,,N,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,NIH3T3,80951,BAO_0000219
456,723.0,,,1,,,CHEMBL615687,,Intermediate,F,,1,,N,Inhibitory activity against 3T3 cell line,,NIH3T3,80951,BAO_0000219
457,723.0,,,1,,,CHEMBL884523,,Intermediate,F,,1,,N,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,NIH3T3,80951,BAO_0000219
458,,,,8,,,CHEMBL615688,,Expert,F,,1,,H,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,11169,BAO_0000019
459,723.0,,,1,,,CHEMBL615689,,Intermediate,F,,1,,N,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,NIH3T3,80951,BAO_0000219
460,723.0,,,1,,,CHEMBL615690,,Intermediate,F,,1,,N,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,NIH3T3,80951,BAO_0000219
461,,,,8,,,CHEMBL615691,,Expert,F,,1,,H,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,11169,BAO_0000019
462,,,,8,,,CHEMBL615692,,Expert,F,,1,,H,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,11169,BAO_0000019
463,723.0,,,1,,,CHEMBL615693,,Intermediate,F,,1,,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,NIH3T3,80951,BAO_0000219
464,723.0,,,1,,,CHEMBL615324,,Expert,F,,1,,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,NIH3T3,80951,BAO_0000219
465,723.0,,,9,,,CHEMBL615325,,Expert,F,,1,,D,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,NIH3T3,9,BAO_0000219
466,723.0,,,9,,,CHEMBL615490,,Expert,F,,1,,D,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,NIH3T3,9,BAO_0000219
467,723.0,,,9,,,CHEMBL615491,,Expert,F,,1,,D,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,NIH3T3,188,BAO_0000219
468,723.0,,,9,,,CHEMBL615492,,Expert,F,,1,,D,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,NIH3T3,188,BAO_0000219
469,723.0,,,1,,,CHEMBL615493,,Intermediate,F,,1,,N,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,NIH3T3,80951,BAO_0000219
470,723.0,,,1,,,CHEMBL615494,,Intermediate,F,,1,,N,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,NIH3T3,80951,BAO_0000219
471,723.0,,,1,,,CHEMBL615495,,Intermediate,F,,1,,N,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,NIH3T3,80951,BAO_0000219
472,723.0,,,1,,,CHEMBL615496,,Intermediate,F,,1,,N,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,NIH3T3,80951,BAO_0000219
473,723.0,,,1,,,CHEMBL615497,,Intermediate,F,,1,,N,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,NIH3T3,80951,BAO_0000219
474,723.0,,,1,,,CHEMBL615498,,Expert,F,,1,,N,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,NIH3T3,80951,BAO_0000219
475,723.0,,,1,,,CHEMBL615499,,Intermediate,A,,1,,N,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,NIH3T3,80951,BAO_0000219
476,723.0,,,1,,,CHEMBL835522,,Expert,F,,1,,N,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,NIH3T3,80951,BAO_0000219
477,723.0,,,1,,,CHEMBL615500,,Intermediate,F,,1,,N,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,NIH3T3,80951,BAO_0000219
478,723.0,,,1,,,CHEMBL615501,,Intermediate,F,,1,,N,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,NIH3T3,80951,BAO_0000219
479,723.0,,,1,,,CHEMBL615502,,Intermediate,F,,1,,N,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,NIH3T3,80951,BAO_0000219
480,723.0,,,1,,,CHEMBL615503,,Intermediate,F,,1,,N,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,NIH3T3,80951,BAO_0000219
481,723.0,,,1,,,CHEMBL615504,,Intermediate,F,,1,,N,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,NIH3T3,80951,BAO_0000219
482,723.0,,,1,,,CHEMBL615505,,Intermediate,F,,1,,N,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,NIH3T3,80951,BAO_0000219
483,723.0,,,1,,,CHEMBL615506,,Expert,F,,1,,N,Inhibition of swiss 3T3 mouse fibroblast proliferation,,NIH3T3,80951,BAO_0000219
484,723.0,,,1,,,CHEMBL615507,,Intermediate,F,,1,,N,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,NIH3T3,80951,BAO_0000219
485,620.0,,,1,,,CHEMBL615508,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,3T3-L1,80006,BAO_0000218
486,620.0,,,1,,,CHEMBL615509,,Intermediate,F,,1,,N,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,3T3-L1,80006,BAO_0000219
487,620.0,,,1,,,CHEMBL615510,,Intermediate,F,,1,,N,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,3T3-L1,80006,BAO_0000219
488,620.0,,,1,,,CHEMBL615511,,Intermediate,F,,1,,N,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,3T3-L1,80006,BAO_0000219
489,620.0,,,1,,,CHEMBL615512,,Intermediate,F,,1,,N,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,3T3-L1,80006,BAO_0000219
490,620.0,,,1,,,CHEMBL615513,,Intermediate,F,,1,,N,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,3T3-L1,80006,BAO_0000218
491,620.0,,,1,,,CHEMBL615514,,Intermediate,F,,1,,N,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,3T3-L1,80006,BAO_0000218
492,620.0,,,1,,,CHEMBL615515,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,3T3-L1,80006,BAO_0000219
493,620.0,,,1,,,CHEMBL615516,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,3T3-L1,80006,BAO_0000219
494,620.0,,,1,,,CHEMBL615517,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,3T3-L1,80006,BAO_0000219
495,620.0,,,1,,,CHEMBL615518,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,3T3-L1,80006,BAO_0000219
496,620.0,,,1,,,CHEMBL615519,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,3T3-L1,80006,BAO_0000219
497,620.0,,,1,,,CHEMBL615520,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,3T3-L1,80006,BAO_0000218
498,620.0,,,1,,,CHEMBL615521,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,3T3-L1,80006,BAO_0000218
499,620.0,,,1,,,CHEMBL615522,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,3T3-L1,80006,BAO_0000218
500,620.0,,,1,,,CHEMBL615523,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,3T3-L1,80006,BAO_0000218
501,620.0,,,1,,,CHEMBL615524,,Expert,F,,1,,N,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,3T3-L1,80006,BAO_0000218
502,620.0,,,1,,,CHEMBL615525,,Expert,F,,1,,N,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,3T3-L1,80006,BAO_0000218
503,620.0,,,1,,,CHEMBL615526,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,3T3-L1,80006,BAO_0000218
504,620.0,,,1,,,CHEMBL615527,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,3T3-L1,80006,BAO_0000218
505,620.0,,,1,,,CHEMBL615528,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,3T3-L1,80006,BAO_0000218
506,620.0,,,1,,,CHEMBL615529,,Expert,F,,1,,N,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,3T3-L1,80006,BAO_0000218
507,620.0,,,1,,,CHEMBL615530,,Expert,F,,1,,N,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,3T3-L1,80006,BAO_0000218
508,620.0,,,1,,,CHEMBL615531,,Expert,F,,1,,N,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,3T3-L1,80006,BAO_0000218
509,620.0,,,1,,,CHEMBL615532,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,3T3-L1,80006,BAO_0000219
510,620.0,,,1,,,CHEMBL615533,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,3T3-L1,80006,BAO_0000219
511,620.0,,,1,,,CHEMBL615534,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,3T3-L1,80006,BAO_0000219
512,620.0,,,1,,,CHEMBL615535,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,3T3-L1,80006,BAO_0000218
513,620.0,,,1,,,CHEMBL615536,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,3T3-L1,80006,BAO_0000218
514,620.0,,,1,,,CHEMBL615537,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,3T3-L1,80006,BAO_0000218
515,620.0,,,1,,,CHEMBL615538,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,3T3-L1,80006,BAO_0000218
516,620.0,,,1,,,CHEMBL836166,,Intermediate,F,,1,,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,3T3-L1,80006,BAO_0000218
517,620.0,,,8,,,CHEMBL615539,,Expert,F,,1,,H,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,3T3-L1,11214,BAO_0000219
518,620.0,,,1,,,CHEMBL615540,,Intermediate,F,,1,,N,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,3T3-L1,80006,BAO_0000219
519,620.0,,,8,,,CHEMBL615541,,Expert,F,,1,,H,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,3T3-L1,11214,BAO_0000219
520,620.0,,,1,,,CHEMBL615542,,Expert,F,,1,,N,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,3T3-L1,80006,BAO_0000219
521,620.0,,,1,,,CHEMBL615543,,Intermediate,F,,1,,N,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,3T3-L1,80006,BAO_0000219
522,620.0,,,1,,,CHEMBL615544,,Expert,F,,1,,N,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,3T3-L1,80006,BAO_0000219
523,620.0,,,1,,,CHEMBL615545,,Expert,F,,1,,N,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,3T3-L1,80006,BAO_0000219
524,620.0,,,1,,,CHEMBL615546,,Expert,F,,1,,N,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,3T3-L1,80006,BAO_0000219
525,620.0,,,1,,,CHEMBL615547,,Expert,F,,1,,N,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,3T3-L1,80006,BAO_0000219
526,620.0,,,1,,,CHEMBL615548,,Expert,F,,1,,N,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,3T3-L1,80006,BAO_0000219
527,620.0,,,1,,,CHEMBL615549,,Expert,F,,1,,N,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,3T3-L1,80006,BAO_0000219
528,620.0,,,1,,,CHEMBL615550,,Expert,F,,1,,N,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,3T3-L1,80006,BAO_0000219
529,1118.0,,,1,,,CHEMBL615551,,Intermediate,F,,1,,N,Inhibitory activity against rat fibroblast (3Y1) cell line,,3Y1 cell line,80622,BAO_0000219
530,1118.0,,,1,,,CHEMBL615552,,Expert,F,,1,,N,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,3Y1 cell line,80622,BAO_0000219
531,1118.0,,,1,,,CHEMBL615553,,Expert,F,,1,,N,Cytotoxicity in 3Y1 cells.,,3Y1 cell line,80622,BAO_0000219
532,1118.0,,,1,,,CHEMBL615554,,Expert,F,,1,,N,Cytostatic effect in 3Y1 cells.,,3Y1 cell line,80622,BAO_0000219
533,1118.0,,,1,,,CHEMBL615555,,Intermediate,F,,1,,N,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,3Y1 cell line,80622,BAO_0000219
534,1118.0,,,1,,,CHEMBL615556,,Expert,F,,1,,N,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,3Y1 cell line,80622,BAO_0000219
535,,,,0,,,CHEMBL615557,,Autocuration,B,,1,,U,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,22226,BAO_0000019
536,,,,0,,,CHEMBL615558,,Autocuration,B,,1,,U,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,22226,BAO_0000019
537,,,,0,,,CHEMBL872066,,Autocuration,B,,1,,U,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,22226,BAO_0000019
538,,,,9,,,CHEMBL615559,,Expert,B,,1,,D,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,,11607,BAO_0000019
539,,,,8,,,CHEMBL615560,,Autocuration,B,,1,,H,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,11607,BAO_0000019
540,,,,8,,,CHEMBL615561,,Autocuration,B,,1,,H,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,11607,BAO_0000019
541,,,,8,,,CHEMBL857062,,Expert,B,,1,,H,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,11607,BAO_0000019
542,,,,8,,,CHEMBL615562,,Expert,B,,1,,H,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,11607,BAO_0000019
543,,,,8,,,CHEMBL615563,,Autocuration,B,,1,,H,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,11607,BAO_0000019
544,,,,8,,,CHEMBL615564,,Autocuration,B,,1,,H,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,11607,BAO_0000357
545,,,,8,,,CHEMBL615565,,Autocuration,B,,1,,H,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,11607,BAO_0000019
546,,,,8,,,CHEMBL615566,,Autocuration,B,,1,,H,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,11607,BAO_0000019
547,,,,9,,,CHEMBL615567,,Expert,B,,1,,D,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,,11607,BAO_0000019
548,,,,8,,,CHEMBL615568,,Autocuration,B,,1,,H,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,11607,BAO_0000019
549,,,,8,,,CHEMBL615569,,Autocuration,B,,1,,H,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,11607,BAO_0000357
550,,,,8,,,CHEMBL615570,,Autocuration,B,,1,,H,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,11607,BAO_0000019
551,,,,8,,,CHEMBL615571,,Autocuration,B,,1,,H,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,11607,BAO_0000019
552,,,,4,,,CHEMBL615572,,Autocuration,B,,1,,H,Binding affinity against melatonin (MT1) receptor (pC1),,,104733,BAO_0000224
553,,,,0,,,CHEMBL615573,,Autocuration,B,,1,,U,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,22226,BAO_0000019
554,,,,0,,,CHEMBL615574,,Autocuration,B,,1,,U,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,22226,BAO_0000019
555,,,,0,,,CHEMBL615575,,Autocuration,B,,1,,U,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,22226,BAO_0000019
556,,,,8,,,CHEMBL615576,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,10619,BAO_0000357
557,,,,8,,,CHEMBL615577,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,10619,BAO_0000357
558,,,10000000.0,8,Hippocampus,,CHEMBL615578,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,51,BAO_0000221
559,,,,8,,,CHEMBL615579,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
560,,,,8,,,CHEMBL615580,,Expert,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
561,,,,8,,,CHEMBL615581,,Expert,B,,1,,H,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,51,BAO_0000019
562,,,10000000.0,8,Hippocampus,,CHEMBL615582,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,51,BAO_0000221
563,,,10000000.0,8,Hippocampus,,CHEMBL615583,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,51,BAO_0000221
564,,,10000000.0,8,Hippocampus,,CHEMBL615584,,Autocuration,B,,1,,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51,BAO_0000221
565,,,10000000.0,8,Hippocampus,,CHEMBL833691,,Autocuration,B,,1,,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51,BAO_0000221
566,,,10000000.0,8,Hippocampus,,CHEMBL615585,,Autocuration,B,,1,,H,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51,BAO_0000221
567,,,10000000.0,8,Hippocampus,,CHEMBL615586,,Autocuration,B,,1,,H,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51,BAO_0000221
568,,,10000000.0,8,Hippocampus,,CHEMBL884524,,Autocuration,B,,1,,H,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51,BAO_0000221
569,,,10000000.0,8,Hippocampus,,CHEMBL615587,,Autocuration,B,,1,,H,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,51,BAO_0000221
570,,,10000000.0,8,Hippocampus,,CHEMBL615588,,Autocuration,B,,1,,H,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,51,BAO_0000221
571,,,,9,,,CHEMBL615589,,Expert,B,,1,Membranes,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,,10576,BAO_0000249
572,,,10000000.0,8,Hippocampus,,CHEMBL615442,,Expert,B,,1,,H,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,,51,BAO_0000221
573,,,10000000.0,8,Hippocampus,,CHEMBL615443,,Autocuration,B,,1,,H,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,51,BAO_0000221
574,,,10000000.0,8,Hippocampus,,CHEMBL615444,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,51,BAO_0000221
575,,,10000000.0,8,Hippocampus,,CHEMBL615445,,Expert,B,,1,,H,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,51,BAO_0000221
576,,,10000000.0,8,Hippocampus,,CHEMBL615446,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,51,BAO_0000221
577,449.0,,,8,,,CHEMBL615447,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,CHO,51,BAO_0000219
578,,,10000000.0,8,Hippocampus,,CHEMBL615448,,Expert,B,,1,,H,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,51,BAO_0000221
579,,,10000000.0,8,Hippocampus,,CHEMBL615449,,Expert,B,,1,,H,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,51,BAO_0000221
580,449.0,,,8,,,CHEMBL615450,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHO,51,BAO_0000219
581,,,10000000.0,8,Hippocampus,,CHEMBL615451,,Expert,B,,1,,H,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,51,BAO_0000221
582,,,,8,,,CHEMBL615452,,Autocuration,B,,1,,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,51,BAO_0000357
583,,,10000000.0,8,Hippocampus,,CHEMBL615453,,Autocuration,B,,1,,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51,BAO_0000221
584,,,10000000.0,8,Hippocampus,,CHEMBL615454,,Autocuration,B,,1,,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51,BAO_0000221
585,,,10000000.0,8,Hippocampus,,CHEMBL615455,,Autocuration,B,,1,,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51,BAO_0000221
586,,,10000000.0,8,Hippocampus,,CHEMBL615456,,Autocuration,B,,1,,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51,BAO_0000221
587,,,10000000.0,8,Hippocampus,,CHEMBL615457,,Autocuration,B,,1,,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51,BAO_0000221
588,,,10000000.0,8,Hippocampus,,CHEMBL615458,,Expert,B,,1,,H,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,51,BAO_0000218
589,,,10000000.0,8,Hippocampus,,CHEMBL615459,,Expert,B,,1,,H,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51,BAO_0000221
590,449.0,,,9,,,CHEMBL615460,,Expert,B,,1,,D,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,CHO,51,BAO_0000219
591,,,,8,,,CHEMBL615461,,Autocuration,F,,1,,H,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,,51,BAO_0000019
592,,,,8,,,CHEMBL615462,,Autocuration,F,,1,,H,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,,51,BAO_0000019
593,,,10000000.0,8,Hippocampus,,CHEMBL615463,,Autocuration,F,,1,,H,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,,51,BAO_0000221
594,,,2116.0,8,Ileum,,CHEMBL615464,,Autocuration,B,,1,,H,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,51,BAO_0000221
595,,,2116.0,8,Ileum,,CHEMBL615465,,Autocuration,B,,1,,H,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,51,BAO_0000221
596,,,2116.0,8,Ileum,,CHEMBL615466,,Autocuration,B,,1,,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,51,BAO_0000221
597,,,2116.0,8,Ileum,,CHEMBL615467,,Autocuration,B,,1,,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,51,BAO_0000221
598,,,2116.0,8,Ileum,,CHEMBL615468,,Autocuration,B,,1,,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,51,BAO_0000221
599,,,2116.0,8,Ileum,,CHEMBL615469,,Autocuration,B,,1,,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,,51,BAO_0000221
600,,,,8,,,CHEMBL615470,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
601,,,,8,,,CHEMBL615471,,Autocuration,B,,1,,H,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
602,,,,8,,,CHEMBL615472,,Autocuration,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
603,,,10000000.0,8,Hippocampus,,CHEMBL883242,,Autocuration,B,,1,,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,106,BAO_0000221
604,,,10000000.0,8,Hippocampus,,CHEMBL615473,,Autocuration,F,,1,,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,106,BAO_0000221
605,449.0,,,8,,,CHEMBL615474,,Autocuration,B,,1,,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,CHO,11863,BAO_0000218
606,,,,8,,,CHEMBL615475,,Autocuration,B,,1,,H,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
607,308.0,,,8,,,CHEMBL615476,,Autocuration,F,,1,,H,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,HeLa,51,BAO_0000219
608,308.0,,,8,,,CHEMBL615477,,Autocuration,F,,1,,H,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,HeLa,51,BAO_0000219
609,,,,8,,,CHEMBL615478,,Autocuration,F,,1,,H,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,51,BAO_0000019
610,449.0,,,8,,,CHEMBL615160,,Autocuration,F,,1,,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,CHO,51,BAO_0000219
611,449.0,,,8,,,CHEMBL615161,,Expert,F,,1,,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,CHO,51,BAO_0000219
612,449.0,,,8,,,CHEMBL615162,,Autocuration,F,,1,,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,CHO,51,BAO_0000219
613,449.0,,,8,,,CHEMBL615163,,Autocuration,F,,1,,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,CHO,51,BAO_0000219
614,449.0,,,8,,,CHEMBL615164,,Expert,B,,1,,H,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHO,51,BAO_0000219
615,449.0,,,8,,,CHEMBL615165,,Expert,B,,1,,H,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHO,51,BAO_0000219
616,449.0,,,8,,,CHEMBL615166,,Autocuration,B,,1,,H,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,CHO,51,BAO_0000219
617,,,,8,,,CHEMBL615167,,Autocuration,F,,1,,H,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,51,BAO_0000219
618,308.0,,,9,,,CHEMBL615168,,Expert,B,,1,,D,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,HeLa,51,BAO_0000219
619,308.0,,,9,,,CHEMBL615169,,Expert,B,,1,,D,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,HeLa,51,BAO_0000219
620,449.0,,,9,,,CHEMBL615170,,Expert,B,,1,,D,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,CHO,51,BAO_0000219
621,449.0,,,9,,,CHEMBL615171,,Expert,B,,1,,D,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,CHO,51,BAO_0000219
622,,,,8,,,CHEMBL615694,,Autocuration,F,,1,,H,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,51,BAO_0000019
623,,,,8,,,CHEMBL615695,,Autocuration,F,,1,,H,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,51,BAO_0000019
624,,,,8,,,CHEMBL615696,,Autocuration,F,,1,,H,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,51,BAO_0000019
625,449.0,,,8,,,CHEMBL615697,,Autocuration,F,,1,,H,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHO,51,BAO_0000219
626,449.0,,,9,,,CHEMBL859410,,Expert,F,,1,,D,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,CHO,51,BAO_0000219
627,449.0,,,8,,,CHEMBL615841,,Autocuration,F,,1,,H,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,CHO,51,BAO_0000219
628,449.0,,,9,,,CHEMBL615842,,Expert,F,,1,,D,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,CHO,51,BAO_0000219
629,449.0,,,8,,,CHEMBL835003,,Autocuration,F,,1,,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHO,51,BAO_0000219
630,449.0,,,8,,,CHEMBL615843,,Autocuration,F,,1,,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,CHO,51,BAO_0000219
631,449.0,,,9,,,CHEMBL615979,,Expert,F,,1,,D,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,CHO,51,BAO_0000219
632,449.0,,,8,,,CHEMBL615980,,Autocuration,F,,1,,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,CHO,51,BAO_0000219
633,449.0,,,9,,,CHEMBL615981,,Expert,F,,1,,D,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,CHO,51,BAO_0000219
634,,,,9,,,CHEMBL615982,,Expert,F,,1,,D,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,,51,BAO_0000019
635,,,,9,,,CHEMBL615983,,Expert,F,,1,,D,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,51,BAO_0000019
636,,,,9,,,CHEMBL615984,,Expert,F,,1,,D,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,,51,BAO_0000019
637,,,,9,,,CHEMBL615985,,Expert,F,,1,,D,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,,51,BAO_0000019
638,449.0,,,8,,,CHEMBL615986,,Autocuration,F,,1,,H,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHO,51,BAO_0000219
639,449.0,,,8,,,CHEMBL615987,,Autocuration,F,,1,,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHO,51,BAO_0000219
640,449.0,,,8,,,CHEMBL615988,,Autocuration,F,,1,,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,CHO,51,BAO_0000219
641,449.0,,,8,,,CHEMBL615989,,Expert,F,,1,,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHO,51,BAO_0000219
642,449.0,,,8,,,CHEMBL615990,,Autocuration,F,,1,,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,CHO,51,BAO_0000219
643,449.0,,,8,,,CHEMBL615991,,Autocuration,F,,1,,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,CHO,51,BAO_0000219
644,449.0,,,8,,,CHEMBL615992,,Autocuration,F,,1,,H,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHO,51,BAO_0000219
645,449.0,,,8,,,CHEMBL615993,,Autocuration,F,,1,,H,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,CHO,51,BAO_0000219
646,449.0,,,8,,,CHEMBL615994,,Expert,F,,1,,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHO,51,BAO_0000219
647,449.0,,,8,,,CHEMBL615995,,Autocuration,F,,1,,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,CHO,51,BAO_0000219
648,449.0,,,8,,,CHEMBL615996,,Autocuration,F,,1,,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHO,51,BAO_0000219
649,449.0,,,8,,,CHEMBL615997,,Autocuration,F,,1,,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,CHO,51,BAO_0000219
650,,,,8,,,CHEMBL615998,,Autocuration,F,,1,,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51,BAO_0000019
651,,,,8,,,CHEMBL615999,,Autocuration,F,,1,,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51,BAO_0000019
652,,,,8,,,CHEMBL616000,,Autocuration,F,,1,,H,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,51,BAO_0000019
653,722.0,,,8,,,CHEMBL616001,,Autocuration,F,,1,,H,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,HEK293,51,BAO_0000219
654,,,,9,,,CHEMBL616002,,Expert,F,,1,,D,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,,51,BAO_0000019
655,,,,8,,,CHEMBL616003,,Expert,F,,1,,H,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,51,BAO_0000019
656,,,,9,,,CHEMBL616004,,Expert,F,,1,,D,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,,51,BAO_0000019
657,,,,9,,,CHEMBL616005,,Expert,F,,1,,D,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,,51,BAO_0000019
658,,,,8,,,CHEMBL616006,,Autocuration,F,,1,,H,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,51,BAO_0000019
659,,,,8,,,CHEMBL616007,,Expert,F,,1,,H,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,51,BAO_0000019
660,,,,8,,,CHEMBL616008,,Autocuration,F,,1,,H,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,51,BAO_0000019
661,,,,8,,,CHEMBL616009,,Autocuration,F,,1,,H,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,51,BAO_0000019
662,,,,8,,,CHEMBL616010,,Expert,F,,1,,H,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,51,BAO_0000019
663,,,,9,,,CHEMBL616011,,Expert,F,,1,,D,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,,51,BAO_0000019
664,,,,9,,,CHEMBL615740,,Expert,F,,1,,D,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,,51,BAO_0000019
665,,,,8,,,CHEMBL615741,,Autocuration,F,,1,,H,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,51,BAO_0000019
666,,,,8,,,CHEMBL615742,,Expert,F,,1,,H,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,51,BAO_0000019
667,,,,8,,,CHEMBL615743,,Autocuration,F,,1,,H,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,51,BAO_0000019
668,449.0,,,8,,,CHEMBL615744,,Autocuration,F,,1,,H,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,CHO,51,BAO_0000219
669,449.0,,,8,,,CHEMBL615745,,Expert,F,,1,,H,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,CHO,51,BAO_0000219
670,,,,8,,,CHEMBL615746,,Autocuration,B,,1,,H,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,51,BAO_0000357
671,,,,8,,,CHEMBL615747,,Autocuration,B,,1,,H,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,51,BAO_0000357
672,,,,8,,,CHEMBL615748,,Autocuration,F,,1,,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51,BAO_0000019
673,,,,8,,,CHEMBL615749,,Autocuration,F,,1,,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,51,BAO_0000019
674,,,,8,,,CHEMBL615750,,Autocuration,F,,1,,H,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,51,BAO_0000019
675,,,,9,,,CHEMBL616259,,Expert,F,,1,,D,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,,51,BAO_0000019
676,,,,8,,,CHEMBL616260,,Autocuration,F,,1,,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51,BAO_0000019
677,,,,9,,,CHEMBL616261,,Expert,F,,1,,D,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,,51,BAO_0000019
678,,,,9,,,CHEMBL616262,,Expert,F,,1,,D,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,51,BAO_0000019
679,,,,9,,,CHEMBL616263,,Expert,F,,1,,D,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,51,BAO_0000019
680,,,,9,,,CHEMBL616264,,Expert,F,,1,,D,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,,51,BAO_0000019
681,,,,9,,,CHEMBL616265,,Expert,F,,1,,D,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,,51,BAO_0000019
682,,,,9,,,CHEMBL616266,,Expert,F,,1,,D,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,51,BAO_0000019
683,,,,9,,,CHEMBL616267,,Expert,F,,1,,D,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,51,BAO_0000019
684,,,,9,,,CHEMBL616268,,Expert,F,,1,,D,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,,51,BAO_0000019
685,,,,9,,,CHEMBL616269,,Expert,B,,1,,D,Inhibition of human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
686,449.0,,,8,,,CHEMBL884528,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHO,51,BAO_0000219
687,722.0,,,9,,,CHEMBL616270,,Expert,B,,1,,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,HEK293,105,BAO_0000219
688,449.0,,,8,,,CHEMBL616271,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,CHO,51,BAO_0000219
689,449.0,,,8,,,CHEMBL616272,,Autocuration,F,,1,,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHO,51,BAO_0000219
690,,,,8,,,CHEMBL616273,,Expert,B,,1,,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,51,BAO_0000357
691,,,,9,,,CHEMBL616274,,Expert,B,,1,,D,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
692,449.0,,,8,,,CHEMBL616275,,Autocuration,B,,1,,H,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,CHO,51,BAO_0000219
693,449.0,,,8,,,CHEMBL616276,,Autocuration,B,,1,,H,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHO,51,BAO_0000219
694,,,,0,,In vivo,CHEMBL616277,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,22226,BAO_0000218
695,,,,0,,In vivo,CHEMBL616278,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,,22226,BAO_0000218
696,,,,0,,In vivo,CHEMBL616279,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,,22226,BAO_0000218
697,,,,0,,In vivo,CHEMBL616280,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,22226,BAO_0000218
698,,,,0,,In vivo,CHEMBL616281,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,,22226,BAO_0000218
699,,,,0,,In vivo,CHEMBL616282,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,22226,BAO_0000218
700,,,,0,,In vivo,CHEMBL616283,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,,22226,BAO_0000218
701,,,,0,,In vivo,CHEMBL616284,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,,22226,BAO_0000218
702,,,,0,,In vivo,CHEMBL616285,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,,22226,BAO_0000218
703,,,,0,,In vivo,CHEMBL616286,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,,22226,BAO_0000218
704,,,,0,,In vivo,CHEMBL616287,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,,22226,BAO_0000218
705,,,,0,,In vivo,CHEMBL616288,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,,22226,BAO_0000218
706,,,,0,,In vivo,CHEMBL616289,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,,22226,BAO_0000218
707,,,,0,,In vivo,CHEMBL615610,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,,22226,BAO_0000218
708,,,,0,,In vivo,CHEMBL615611,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,,22226,BAO_0000218
709,,,,0,,In vivo,CHEMBL615612,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,,22226,BAO_0000218
710,,,,0,,In vivo,CHEMBL615613,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,,22226,BAO_0000218
711,,,,0,,In vivo,CHEMBL615614,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,,22226,BAO_0000218
712,,,,0,,In vivo,CHEMBL615615,,Autocuration,F,,1,,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,22226,BAO_0000218
713,,,,4,,,CHEMBL615616,,Autocuration,B,,1,,H,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,105093,BAO_0000019
714,,,1898.0,8,Hypothalamus,,CHEMBL615617,,Autocuration,B,,1,,H,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,11923,BAO_0000249
715,,,,8,,,CHEMBL615618,,Autocuration,B,,1,,H,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,10577,BAO_0000019
716,,,,8,,,CHEMBL615619,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,10577,BAO_0000019
717,,,,8,,,CHEMBL615620,,Expert,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,10577,BAO_0000019
718,,,,8,,,CHEMBL615621,,Autocuration,B,,1,,H,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,55,BAO_0000357
719,,,,8,,,CHEMBL615622,,Autocuration,B,,1,,H,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,55,BAO_0000357
720,,,,8,,,CHEMBL615623,,Autocuration,F,,1,,H,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,12166,BAO_0000019
721,,,,8,,,CHEMBL615624,,Autocuration,F,,1,,H,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,12166,BAO_0000019
722,,,,8,,,CHEMBL615625,,Autocuration,F,,1,,H,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,12166,BAO_0000019
723,,,,8,,,CHEMBL767045,,Autocuration,F,,1,,H,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,12166,BAO_0000019
724,,,,8,,,CHEMBL615626,,Autocuration,F,,1,,H,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,,55,BAO_0000019
725,,,,8,,,CHEMBL615627,,Autocuration,F,,1,,H,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,,55,BAO_0000019
726,,,,8,,,CHEMBL615628,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,,55,BAO_0000019
727,,,,8,,,CHEMBL615629,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,55,BAO_0000357
728,,,,9,,,CHEMBL615630,,Expert,B,,1,,D,Inhibitory concentration against 5-lipoxygenase from human whole blood,,,55,BAO_0000357
729,,,,8,,,CHEMBL615631,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,55,BAO_0000219
730,,,,8,,,CHEMBL615632,,Autocuration,F,,1,,H,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,17087,BAO_0000218
731,,,,8,,,CHEMBL615633,,Autocuration,B,,1,,H,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,17087,BAO_0000357
732,,,,8,,,CHEMBL615634,,Autocuration,F,,1,,H,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,17087,BAO_0000218
733,,,,8,,,CHEMBL615635,,Expert,B,,1,,H,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,55,BAO_0000019
734,,,,8,,,CHEMBL615636,,Expert,B,,1,,H,In vitro inhibition of rat 5-Lipoxygenase,,,12166,BAO_0000357
735,,,,9,,,CHEMBL615637,,Expert,B,,1,,D,Inhibitory activity against 5-Lipoxygenase,,,12166,BAO_0000357
736,702.0,,,8,,,CHEMBL615638,,Expert,B,,1,,H,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,RBL-1,12166,BAO_0000219
737,702.0,,,8,,,CHEMBL615639,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,RBL-1,12166,BAO_0000219
738,702.0,,,8,,,CHEMBL615640,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,RBL-1,12166,BAO_0000219
739,,,,8,,,CHEMBL615796,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,12166,BAO_0000019
740,,,,8,,,CHEMBL615845,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,12166,BAO_0000219
741,,,,8,,,CHEMBL615846,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,12166,BAO_0000357
742,702.0,,,8,,,CHEMBL615847,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,RBL-1,12166,BAO_0000219
743,,,,8,,,CHEMBL615848,,Autocuration,B,,1,,H,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,12166,BAO_0000357
744,,,,0,,,CHEMBL615849,,Autocuration,B,,1,,U,Ratio of IC50 against 5-LO and COX,,,22226,BAO_0000019
745,,,,8,,,CHEMBL615850,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,12166,BAO_0000357
746,,,,8,,,CHEMBL615851,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,12166,BAO_0000357
747,,,,8,,,CHEMBL615852,,Autocuration,B,,1,,H,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,12166,BAO_0000219
748,,,,8,,,CHEMBL615853,,Autocuration,F,,1,,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,12166,BAO_0000019
749,,,2367.0,8,Prostate gland,,CHEMBL884527,,Autocuration,B,,1,,H,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,120,BAO_0000357
750,,,,0,,,CHEMBL872871,,Autocuration,B,,1,,U,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,,22226,BAO_0000019
751,,,,0,,,CHEMBL615854,,Autocuration,B,,1,,U,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,,22226,BAO_0000019
752,,,,0,,,CHEMBL767046,,Autocuration,B,,1,,U,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,,22226,BAO_0000019
753,,,,8,,,CHEMBL615855,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,10732,BAO_0000357
754,,,,9,,,CHEMBL615856,,Expert,F,,1,,D,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,,12198,BAO_0000019
755,,,,9,,,CHEMBL615857,,Expert,F,,1,,D,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,12198,BAO_0000019
756,,,,9,,,CHEMBL615858,,Expert,F,,1,,D,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,12198,BAO_0000019
757,,,10000000.0,8,Hippocampus,,CHEMBL615859,,Expert,B,,1,,H,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,10576,BAO_0000221
758,,,,8,,,CHEMBL615860,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,51,BAO_0000357
759,,,,0,,,CHEMBL615861,,Autocuration,B,,1,,U,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,22226,BAO_0000019
760,,,,0,,,CHEMBL615862,,Autocuration,B,,1,,U,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,22226,BAO_0000019
761,,,,0,,,CHEMBL615863,,Autocuration,B,,1,,U,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,,22226,BAO_0000019
762,,,,0,,,CHEMBL615864,,Autocuration,B,,1,,U,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,22226,BAO_0000019
763,,,10000000.0,4,Hippocampus,,CHEMBL615865,,Autocuration,B,,1,,H,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,104744,BAO_0000221
764,,,10000000.0,4,Hippocampus,,CHEMBL615866,,Autocuration,B,,1,,H,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,104744,BAO_0000221
765,,,10000000.0,4,Hippocampus,,CHEMBL615867,,Autocuration,B,,1,,H,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,104744,BAO_0000221
766,,,,4,,,CHEMBL615868,,Autocuration,B,,1,Membranes,H,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,104744,BAO_0000249
767,,,,5,,,CHEMBL615869,,Autocuration,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,,104744,BAO_0000249
768,,,,5,,,CHEMBL615870,,Autocuration,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,,104744,BAO_0000019
769,,,,5,,,CHEMBL615871,,Autocuration,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,,104744,BAO_0000019
770,,,,4,,,CHEMBL615872,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,104744,BAO_0000224
771,,,10000000.0,4,Hippocampus,,CHEMBL833492,,Autocuration,B,,1,,H,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,104744,BAO_0000221
772,,,10000000.0,4,Hippocampus,,CHEMBL615873,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,104744,BAO_0000221
773,,,,4,,,CHEMBL615479,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,104744,BAO_0000224
774,,,,4,,,CHEMBL615480,,Autocuration,B,,1,,H,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,104744,BAO_0000019
775,,,,5,,,CHEMBL615481,,Autocuration,B,,1,,D,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,,104744,BAO_0000249
776,,,,4,,,CHEMBL872869,,Autocuration,B,,1,,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744,BAO_0000019
777,,,,4,,,CHEMBL615482,,Autocuration,B,,1,,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744,BAO_0000019
778,,,955.0,4,Brain,,CHEMBL615483,,Autocuration,B,,1,,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,104744,BAO_0000221
779,,,955.0,4,Brain,,CHEMBL615484,,Autocuration,B,,1,,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,104744,BAO_0000221
780,,,,4,,,CHEMBL615485,,Autocuration,B,,1,,H,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,104744,BAO_0000019
781,,,,5,,,CHEMBL615486,,Autocuration,B,,1,,D,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,,104744,BAO_0000224
782,,,,4,,,CHEMBL615487,,Autocuration,B,,1,,H,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,104744,BAO_0000224
783,,,,4,,,CHEMBL615488,,Autocuration,B,,1,,H,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,104744,BAO_0000224
784,,,,4,,,CHEMBL615489,,Autocuration,B,,1,,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,104744,BAO_0000224
785,,,,4,,,CHEMBL615389,,Autocuration,B,,1,,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,104744,BAO_0000224
786,,,,4,,,CHEMBL615390,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,104744,BAO_0000019
787,,,,4,,,CHEMBL615391,,Autocuration,B,,1,,H,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,104744,BAO_0000019
788,,,,4,,,CHEMBL615392,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,104744,BAO_0000224
789,,,,0,,,CHEMBL615393,,Autocuration,B,,1,,U,Affinity for 5-hydroxytryptamine 1 receptor,,,22226,BAO_0000019
790,,,955.0,4,Brain,,CHEMBL615394,,Autocuration,B,,1,,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,104744,BAO_0000221
791,,,955.0,4,Brain,,CHEMBL615395,,Autocuration,B,,1,,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,104744,BAO_0000221
792,,,,4,,,CHEMBL615396,,Autocuration,B,,1,,H,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,104744,BAO_0000224
793,,,955.0,4,Brain,,CHEMBL615397,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,104744,BAO_0000221
794,,,,4,,,CHEMBL615398,,Autocuration,B,,1,,H,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744,BAO_0000019
795,,,,0,,,CHEMBL615399,,Autocuration,B,,1,,U,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,,22226,BAO_0000019
796,,,,4,,,CHEMBL615400,,Autocuration,B,,1,,H,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,104744,BAO_0000019
797,,,,5,,,CHEMBL615401,,Autocuration,B,,1,,D,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,,104744,BAO_0000019
798,,,,0,,,CHEMBL615402,,Autocuration,B,,1,,U,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,,22226,BAO_0000019
799,,,,4,,,CHEMBL615403,,Autocuration,B,,1,,H,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,104744,BAO_0000019
800,,,955.0,4,Brain,,CHEMBL615404,,Autocuration,B,,1,,H,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,104744,BAO_0000221
801,,,,4,,,CHEMBL615781,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,104744,BAO_0000019
802,,,955.0,4,Brain,,CHEMBL615782,,Autocuration,B,,1,,H,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,104744,BAO_0000220
803,,,955.0,4,Brain,,CHEMBL615783,,Autocuration,B,,1,,H,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,104744,BAO_0000221
804,,,,0,,,CHEMBL873481,,Autocuration,B,,1,,U,Compound was tested for binding affinity against 5-HT1 receptor,,,22226,BAO_0000019
805,,,,0,,,CHEMBL615784,,Autocuration,B,,1,,U,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,22226,BAO_0000019
806,,,,8,,,CHEMBL615785,,Expert,B,,1,,H,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,10576,BAO_0000357
807,,,,8,,,CHEMBL615786,,Autocuration,F,,1,,H,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,10576,BAO_0000249
808,,,,8,,In vivo,CHEMBL615787,,Autocuration,F,,1,,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,10576,BAO_0000218
809,,,,8,,In vivo,CHEMBL615788,,Autocuration,F,,1,,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,10576,BAO_0000218
810,,,,8,,,CHEMBL767044,,Autocuration,F,,1,,H,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000019
811,,,,8,,In vivo,CHEMBL615789,,Autocuration,F,,1,,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,10576,BAO_0000218
812,,,,8,,In vivo,CHEMBL615790,,Autocuration,F,,1,,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,10576,BAO_0000218
813,,,,8,,,CHEMBL615813,,Autocuration,F,,1,,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,10576,BAO_0000019
814,,,,8,,,CHEMBL615814,,Autocuration,F,,1,,H,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,10576,BAO_0000219
815,,,,8,,,CHEMBL615815,,Expert,F,,1,,H,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,51,BAO_0000219
816,,,,8,,,CHEMBL615816,,Autocuration,F,,1,,H,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,10576,BAO_0000219
817,,,,8,,,CHEMBL615817,,Expert,B,,1,,H,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,10576,BAO_0000249
818,,,10000000.0,8,Hippocampus,,CHEMBL615818,,Autocuration,B,,1,,H,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,10576,BAO_0000221
819,,,10000000.0,8,Hippocampus,,CHEMBL615819,,Autocuration,B,,1,,H,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,10576,BAO_0000221
820,,,,8,,,CHEMBL615820,,Expert,B,,1,Membranes,H,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,10576,BAO_0000249
821,,,10000000.0,9,Hippocampus,,CHEMBL615821,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,,10576,BAO_0000221
822,,,10000000.0,9,Hippocampus,,CHEMBL615822,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,10576,BAO_0000221
823,,,10000000.0,8,Hippocampus,,CHEMBL615823,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000221
824,,,10000000.0,9,Hippocampus,,CHEMBL615824,,Expert,B,,1,,D,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,,10576,BAO_0000221
825,,,10000000.0,9,Hippocampus,,CHEMBL615825,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,10576,BAO_0000221
826,,,,8,,,CHEMBL615826,,Expert,B,,1,,H,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000357
827,,,,8,,,CHEMBL615827,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000249
828,,,10000000.0,8,Hippocampus,,CHEMBL615828,,Expert,B,,1,,H,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000249
829,,,10000000.0,8,Hippocampus,,CHEMBL615829,,Expert,B,,1,,H,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576,BAO_0000221
830,,,10000000.0,8,Hippocampus,,CHEMBL615830,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000221
831,,,10000000.0,8,Hippocampus,,CHEMBL615831,,Expert,B,,1,,H,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,10576,BAO_0000221
832,,,,8,,,CHEMBL615832,,Autocuration,B,,1,,H,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
833,,,,8,,,CHEMBL615833,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,10576,BAO_0000019
834,,,10000000.0,8,Hippocampus,,CHEMBL615834,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,10576,BAO_0000221
835,,,,8,,,CHEMBL615835,,Intermediate,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,10576,BAO_0000249
836,,,10000000.0,8,Hippocampus,,CHEMBL615836,,Autocuration,B,,1,,H,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,10576,BAO_0000249
837,,,,9,,,CHEMBL615837,,Expert,B,,1,,D,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,,10576,BAO_0000019
838,,,,9,,,CHEMBL615838,,Expert,B,,1,,D,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,,10576,BAO_0000019
839,,,,8,,,CHEMBL615839,,Expert,B,,1,,H,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,10576,BAO_0000249
840,,,,8,,,CHEMBL884525,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,10576,BAO_0000019
841,,,,8,,,CHEMBL615840,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,10576,BAO_0000249
842,,,10000000.0,8,Hippocampus,,CHEMBL615405,,Expert,B,,1,,H,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576,BAO_0000221
843,,,,8,,,CHEMBL615406,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,10576,BAO_0000019
844,,,10000000.0,8,Hippocampus,,CHEMBL615900,,Expert,B,,1,,H,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,10576,BAO_0000221
845,,,10000000.0,8,Hippocampus,,CHEMBL615901,,Expert,B,,1,,H,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,10576,BAO_0000221
846,,,,8,,,CHEMBL615902,,Expert,B,,1,,H,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,10576,BAO_0000357
847,,,10000000.0,8,Hippocampus,,CHEMBL615903,,Autocuration,B,,1,,H,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,10576,BAO_0000221
848,,,,8,,,CHEMBL615904,,Autocuration,B,,1,,H,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,10576,BAO_0000357
849,,,,8,,,CHEMBL615905,,Expert,B,,1,,H,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,10576,BAO_0000357
850,,,,8,,,CHEMBL615906,,Autocuration,B,,1,,H,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,10576,BAO_0000019
851,,,,8,,,CHEMBL615907,,Autocuration,F,,1,,H,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,10576,BAO_0000019
852,,,,8,,,CHEMBL615908,,Expert,B,,1,,H,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,10576,BAO_0000019
853,,,10000000.0,8,Hippocampus,,CHEMBL615909,,Autocuration,B,,1,,H,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,10576,BAO_0000221
854,,,,8,,,CHEMBL615910,,Autocuration,B,,1,,H,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,10576,BAO_0000019
855,,,,8,,,CHEMBL615911,,Autocuration,B,,1,,H,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,10576,BAO_0000019
856,,,,8,,,CHEMBL615912,,Autocuration,B,,1,,H,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,10576,BAO_0000019
857,,,,8,,,CHEMBL615913,,Expert,B,,1,,H,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000019
858,,,,8,,,CHEMBL615914,,Expert,B,,1,,H,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,10576,BAO_0000357
859,,,10000000.0,8,Hippocampus,,CHEMBL615915,,Autocuration,B,,1,,H,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,10576,BAO_0000221
860,,,,8,,,CHEMBL615916,,Autocuration,B,,1,,H,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,10576,BAO_0000357
861,,,,8,,,CHEMBL615917,,Expert,B,,1,,H,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,10576,BAO_0000357
862,,,,8,,,CHEMBL615918,,Expert,B,,1,,H,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
863,,,10000000.0,8,Hippocampus,,CHEMBL615919,,Expert,B,,1,,H,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,10576,BAO_0000249
864,,,10000000.0,9,Hippocampus,,CHEMBL615920,,Expert,B,,1,,D,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,10576,BAO_0000221
865,,,,8,,,CHEMBL615921,,Autocuration,B,,1,,H,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
866,,,,8,,,CHEMBL615922,,Expert,B,,1,,H,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,10576,BAO_0000357
867,,,,9,,,CHEMBL881290,,Expert,F,,1,,D,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,10576,BAO_0000249
868,,,10000000.0,8,Hippocampus,,CHEMBL615923,,Autocuration,B,,1,,H,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,10576,BAO_0000221
869,,,10000000.0,8,Hippocampus,,CHEMBL615924,,Autocuration,F,,1,,H,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576,BAO_0000221
870,,,10000000.0,8,Hippocampus,,CHEMBL615925,,Autocuration,F,,1,,H,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576,BAO_0000221
871,,,,9,,,CHEMBL615926,,Expert,B,,1,,D,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
872,,,,9,,,CHEMBL615927,,Expert,B,,1,,D,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000019
873,,,10000000.0,8,Hippocampus,,CHEMBL615928,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10576,BAO_0000221
874,,,,9,,,CHEMBL615929,,Expert,B,,1,,D,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,,10576,BAO_0000357
875,,,10000000.0,8,Hippocampus,,CHEMBL615930,,Autocuration,B,,1,,H,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,10576,BAO_0000221
876,449.0,,,8,,,CHEMBL615931,,Autocuration,B,,1,,H,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHO,51,BAO_0000219
877,449.0,,,8,,,CHEMBL615932,,Autocuration,F,,1,,H,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHO,51,BAO_0000219
878,449.0,,,8,,,CHEMBL615933,,Autocuration,F,,1,,H,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHO,51,BAO_0000219
879,,,,8,,,CHEMBL615934,,Autocuration,B,,1,,H,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
880,,,,8,,,CHEMBL615935,,Autocuration,B,,1,,H,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,51,BAO_0000357
881,,,,8,,,CHEMBL615936,,Autocuration,F,,1,,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51,BAO_0000019
882,449.0,,,8,,,CHEMBL615937,,Autocuration,B,,1,,H,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,CHO,51,BAO_0000219
883,,,,8,,,CHEMBL615938,,Autocuration,B,,1,,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
884,,,,8,,,CHEMBL615797,,Autocuration,B,,1,,H,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,51,BAO_0000357
885,,,,8,,,CHEMBL615798,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
886,,,,8,,,CHEMBL872870,,Autocuration,B,,1,,H,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,51,BAO_0000357
887,,,,8,,,CHEMBL615799,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,51,BAO_0000357
888,,,,8,,,CHEMBL615800,,Autocuration,B,,1,,H,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
889,722.0,,,8,,,CHEMBL615801,,Autocuration,F,,1,,H,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,HEK293,51,BAO_0000219
890,,,,8,,,CHEMBL615802,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,51,BAO_0000019
891,,,,8,,,CHEMBL615803,,Autocuration,B,,1,,H,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,51,BAO_0000357
892,,,,8,,,CHEMBL835002,,Expert,F,,1,,H,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,51,BAO_0000019
893,,,,8,,,CHEMBL615804,,Autocuration,F,,1,,H,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,51,BAO_0000019
894,308.0,,,8,,,CHEMBL615805,,Expert,B,,1,,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,HeLa,51,BAO_0000219
895,449.0,,,8,,,CHEMBL615806,,Autocuration,B,,1,,H,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,CHO,51,BAO_0000219
896,,,,9,,,CHEMBL615807,,Expert,B,,1,,D,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,,51,BAO_0000357
897,,,,8,,,CHEMBL615808,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,51,BAO_0000357
898,,,,9,,,CHEMBL615809,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
899,308.0,,,8,,,CHEMBL615810,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,HeLa,51,BAO_0000219
900,,,,8,,,CHEMBL615811,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
901,449.0,,,8,,,CHEMBL615812,,Autocuration,B,,1,,H,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,CHO,51,BAO_0000219
902,449.0,,,8,,,CHEMBL615751,,Autocuration,B,,1,,H,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHO,51,BAO_0000219
903,,,,8,,,CHEMBL615752,,Autocuration,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
904,449.0,,,8,,,CHEMBL615753,,Expert,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,CHO,51,BAO_0000219
905,449.0,,,8,,,CHEMBL615754,,Autocuration,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,CHO,51,BAO_0000219
906,,,,8,,,CHEMBL615755,,Autocuration,B,,1,,H,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
907,449.0,,,9,,,CHEMBL615756,,Expert,B,,1,,D,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHO,51,BAO_0000219
908,,,,8,,,CHEMBL615757,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000019
909,,,,8,,,CHEMBL615758,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,51,BAO_0000357
910,,,,8,,,CHEMBL615759,,Expert,B,,1,,H,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,51,BAO_0000357
911,,,,8,,,CHEMBL615760,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
912,308.0,,,8,,,CHEMBL615761,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,HeLa,51,BAO_0000219
913,,,,8,,,CHEMBL872104,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,51,BAO_0000357
914,,,,8,,,CHEMBL615762,,Autocuration,B,,1,,H,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
915,,,,8,,,CHEMBL615763,,Autocuration,B,,1,,H,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
916,,,,8,,,CHEMBL615764,,Autocuration,B,,1,,H,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,51,BAO_0000357
917,1167.0,,,8,,,CHEMBL615765,,Autocuration,B,,1,,H,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,Cell line,51,BAO_0000219
918,,,,8,,,CHEMBL615766,,Autocuration,B,,1,,H,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,51,BAO_0000019
919,,,,8,,,CHEMBL615767,,Autocuration,B,,1,,H,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
920,,,,8,,,CHEMBL615768,,Expert,B,,1,,H,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
921,,,,8,,,CHEMBL615769,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
922,,,,8,,,CHEMBL615770,,Expert,B,,1,,H,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,51,BAO_0000357
923,,,,8,,,CHEMBL615771,,Autocuration,B,,1,,H,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
924,,,,8,,,CHEMBL615772,,Expert,B,,1,,H,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,51,BAO_0000357
925,,,,8,,,CHEMBL615773,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
926,,,,8,,,CHEMBL615774,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
927,,,,8,,,CHEMBL615775,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
928,,,,8,,,CHEMBL615776,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,51,BAO_0000357
929,,,,8,,,CHEMBL615777,,Expert,B,,1,,H,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
930,,,,8,,,CHEMBL615778,,Autocuration,B,,1,,H,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,51,BAO_0000219
931,,,,9,,,CHEMBL615779,,Expert,B,,1,,D,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,51,BAO_0000357
932,,,,8,,,CHEMBL615780,,Autocuration,B,,1,,H,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,51,BAO_0000357
933,,,,8,,,CHEMBL616298,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
934,,,,8,,,CHEMBL616299,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
935,485.0,,,8,,,CHEMBL616300,,Autocuration,B,,1,,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,CHO-K1,51,BAO_0000219
936,485.0,,,8,,,CHEMBL616301,,Expert,F,,1,,H,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,CHO-K1,51,BAO_0000219
937,,,,8,,,CHEMBL616302,,Autocuration,B,,1,,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000019
938,,,,8,,,CHEMBL616117,,Autocuration,B,,1,,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,51,BAO_0000019
939,,,,8,,,CHEMBL616118,,Autocuration,B,,1,,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,51,BAO_0000019
940,,,,8,,,CHEMBL616119,,Autocuration,B,,1,,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,51,BAO_0000019
941,308.0,,,9,,,CHEMBL616120,,Expert,B,,1,,D,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,HeLa,51,BAO_0000219
942,,,,8,,,CHEMBL616121,,Autocuration,B,,1,,H,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
943,,,,8,,,CHEMBL616122,,Autocuration,B,,1,,H,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,51,BAO_0000357
944,,,,8,,,CHEMBL616123,,Autocuration,B,,1,,H,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
945,,,,9,,,CHEMBL616124,,Expert,B,,1,,D,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
946,,,,8,,,CHEMBL616125,,Expert,B,,1,,H,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,51,BAO_0000357
947,,,,8,,,CHEMBL616126,,Expert,B,,1,,H,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,,51,BAO_0000357
948,449.0,,,8,,,CHEMBL616127,,Autocuration,B,,1,,H,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,CHO,51,BAO_0000219
949,,,,8,,,CHEMBL616128,,Expert,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000019
950,,,,8,,,CHEMBL616129,,Autocuration,B,,1,,H,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,51,BAO_0000357
951,,,,8,,,CHEMBL616130,,Expert,B,,1,,H,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
952,,,,8,,,CHEMBL616131,,Autocuration,B,,1,,H,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,51,BAO_0000357
953,308.0,,,8,,,CHEMBL616132,,Autocuration,B,,1,,H,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,HeLa,51,BAO_0000219
954,308.0,,,9,,,CHEMBL616133,,Expert,B,,1,,D,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,HeLa,51,BAO_0000219
955,,,,8,,,CHEMBL616134,,Autocuration,B,,1,,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
956,,,,8,,,CHEMBL616135,,Autocuration,B,,1,,H,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,51,BAO_0000357
957,,,,9,,,CHEMBL616136,,Expert,B,,1,,D,Affinity for 5-hydroxytryptamine 1A receptor subtype,,,51,BAO_0000357
958,,,,8,,,CHEMBL616137,,Autocuration,B,,1,,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,51,BAO_0000019
959,,,,8,,,CHEMBL872105,,Autocuration,B,,1,,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,51,BAO_0000019
960,,,,8,,,CHEMBL616138,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,51,BAO_0000357
961,,,,9,,,CHEMBL616139,,Expert,B,,1,,D,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
962,,,,8,,,CHEMBL616140,,Autocuration,F,,1,,H,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,51,BAO_0000019
963,,,,8,,,CHEMBL616141,,Expert,B,,1,,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,51,BAO_0000019
964,,,,8,,,CHEMBL616142,,Autocuration,B,,1,,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
965,,,,8,,,CHEMBL616143,,Autocuration,B,,1,,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,51,BAO_0000357
966,308.0,,,8,,,CHEMBL616144,,Autocuration,B,,1,,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,HeLa,51,BAO_0000219
967,308.0,,,8,,,CHEMBL616145,,Autocuration,B,,1,,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,HeLa,51,BAO_0000219
968,308.0,,,8,,,CHEMBL616012,,Autocuration,B,,1,,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,HeLa,51,BAO_0000219
969,308.0,,,8,,,CHEMBL616013,,Autocuration,B,,1,,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,HeLa,51,BAO_0000219
970,,,,8,,,CHEMBL616014,,Autocuration,F,,1,,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,51,BAO_0000019
971,,,,8,,,CHEMBL616015,,Autocuration,F,,1,,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,51,BAO_0000019
972,,,,8,,,CHEMBL616016,,Autocuration,F,,1,,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,51,BAO_0000019
973,,,,8,,In vivo,CHEMBL616017,,Autocuration,F,,1,,H,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,,51,BAO_0000218
974,,,,8,,,CHEMBL616018,,Autocuration,B,,1,,H,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,51,BAO_0000019
975,,,,8,,,CHEMBL616019,,Autocuration,F,,1,,H,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,51,BAO_0000019
976,,,,8,,,CHEMBL616020,,Autocuration,F,,1,,H,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,51,BAO_0000019
977,,,,8,,,CHEMBL858018,,Autocuration,B,,1,,H,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
978,722.0,,,8,,,CHEMBL616021,,Autocuration,F,,1,,H,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,HEK293,51,BAO_0000219
979,,,,8,,,CHEMBL616022,,Expert,F,,1,,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,51,BAO_0000019
980,,,,8,,,CHEMBL616023,,Autocuration,F,,1,,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,51,BAO_0000019
981,,,,8,,,CHEMBL616024,,Autocuration,F,,1,,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,51,BAO_0000019
982,,,,8,,,CHEMBL616025,,Autocuration,F,,1,,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,51,BAO_0000019
983,449.0,,,8,,,CHEMBL616026,,Autocuration,F,,1,,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHO,51,BAO_0000219
984,,,,8,,,CHEMBL616027,,Autocuration,F,,1,,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,51,BAO_0000019
985,,,,9,,,CHEMBL616028,,Expert,F,,1,,D,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,,51,BAO_0000019
986,,,,9,,,CHEMBL616029,,Expert,F,,1,,D,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,,51,BAO_0000019
987,449.0,,,8,,,CHEMBL616030,,Expert,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,CHO,51,BAO_0000219
988,,,,8,,,CHEMBL616031,,Expert,B,,1,,H,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,51,BAO_0000019
989,,,,9,,,CHEMBL616032,,Expert,F,,1,,D,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,51,BAO_0000019
990,,,,9,,,CHEMBL616033,,Expert,F,,1,,D,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,51,BAO_0000019
991,,,,8,,,CHEMBL616034,,Autocuration,F,,1,,H,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51,BAO_0000019
992,,,,8,,,CHEMBL616035,,Autocuration,F,,1,,H,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51,BAO_0000019
993,,,,8,,,CHEMBL616036,,Autocuration,F,,1,,H,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000019
994,,,,8,,,CHEMBL616037,,Autocuration,F,,1,,H,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51,BAO_0000019
995,,,,8,,,CHEMBL616038,,Autocuration,F,,1,,H,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51,BAO_0000019
996,,,,8,,,CHEMBL616039,,Autocuration,F,,1,,H,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51,BAO_0000019
997,,,,8,,,CHEMBL616040,,Autocuration,F,,1,,H,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000019
998,308.0,,,9,,,CHEMBL616041,,Expert,F,,1,,D,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,HeLa,51,BAO_0000219
999,308.0,,,9,,,CHEMBL616042,,Expert,F,,1,,D,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,HeLa,51,BAO_0000219
1000,308.0,,,9,,,CHEMBL616043,,Expert,F,,1,,D,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,HeLa,51,BAO_0000219
1001,,,,8,,,CHEMBL616044,,Autocuration,F,,1,,H,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,51,BAO_0000019
1002,,,,8,,,CHEMBL616045,,Autocuration,F,,1,,H,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,51,BAO_0000019
1003,722.0,,,8,,,CHEMBL616046,,Autocuration,F,,1,,H,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,HEK293,51,BAO_0000219
1004,449.0,,,8,,,CHEMBL616047,,Autocuration,F,,1,,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,CHO,51,BAO_0000219
1005,449.0,,,8,,,CHEMBL616048,,Autocuration,F,,1,,H,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHO,51,BAO_0000219
1006,449.0,,,9,,,CHEMBL616049,,Expert,F,,1,,D,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,CHO,51,BAO_0000219
1007,449.0,,,8,,,CHEMBL616050,,Autocuration,F,,1,,H,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,CHO,51,BAO_0000219
1008,,,,8,,,CHEMBL616051,,Expert,F,,1,,H,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,51,BAO_0000219
1009,,,,8,,,CHEMBL616212,,Autocuration,F,,1,,H,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,51,BAO_0000219
1010,,,,8,,,CHEMBL616213,,Autocuration,F,,1,,H,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,51,BAO_0000019
1011,,,,8,,In vitro,CHEMBL616214,,Expert,B,,1,,H,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,,51,BAO_0000219
1012,,,,8,,In vitro,CHEMBL616215,,Expert,B,,1,,H,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,,51,BAO_0000219
1013,,,,8,,,CHEMBL616216,,Autocuration,B,,1,,H,Binding activity radioligand.,,,51,BAO_0000357
1014,,,,8,,,CHEMBL616217,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,51,BAO_0000019
1015,,,,8,,,CHEMBL616218,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1016,,,,8,,,CHEMBL616219,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1017,,,,8,,,CHEMBL616220,,Autocuration,B,,1,,H,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1018,,,,9,,,CHEMBL833493,,Expert,B,,1,,D,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1019,,,,8,,,CHEMBL616221,,Autocuration,B,,1,,H,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1020,449.0,,,9,,,CHEMBL616222,,Expert,B,,1,,D,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,CHO,51,BAO_0000219
1021,,,,8,,,CHEMBL616223,,Autocuration,F,,1,,H,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000019
1022,,,,8,,,CHEMBL616224,,Autocuration,F,,1,,H,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,51,BAO_0000019
1023,,,,8,,,CHEMBL616225,,Expert,B,,1,,H,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,51,BAO_0000019
1024,722.0,,,9,,,CHEMBL616226,,Expert,B,,1,,D,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,HEK293,51,BAO_0000219
1025,722.0,,,8,,,CHEMBL616227,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,HEK293,51,BAO_0000219
1026,722.0,,,8,,,CHEMBL616228,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,HEK293,51,BAO_0000219
1027,722.0,,,8,,,CHEMBL616229,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,HEK293,51,BAO_0000219
1028,722.0,,,8,,,CHEMBL616230,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,HEK293,51,BAO_0000219
1029,722.0,,,8,,,CHEMBL616231,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,HEK293,51,BAO_0000219
1030,,,,8,,,CHEMBL616232,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
1031,722.0,,,8,,,CHEMBL616233,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,HEK293,51,BAO_0000219
1032,722.0,,,8,,,CHEMBL857973,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,HEK293,51,BAO_0000219
1033,,,,8,,,CHEMBL616234,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,51,BAO_0000219
1034,,,,8,,,CHEMBL616235,,Autocuration,B,,1,,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1035,308.0,,,8,,,CHEMBL616236,,Expert,B,,1,,H,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,HeLa,51,BAO_0000219
1036,,,,8,,,CHEMBL616237,,Expert,B,,1,,H,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,51,BAO_0000019
1037,722.0,,,8,,,CHEMBL616238,,Autocuration,B,,1,,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,HEK293,51,BAO_0000219
1038,722.0,,,8,,,CHEMBL616239,,Autocuration,B,,1,,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,HEK293,51,BAO_0000219
1039,,,,8,,,CHEMBL616240,,Autocuration,B,,1,,H,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,51,BAO_0000219
1040,308.0,,,9,,,CHEMBL616241,,Expert,B,,1,,D,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,HeLa,51,BAO_0000219
1041,722.0,,,8,,,CHEMBL616242,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,HEK293,51,BAO_0000219
1042,722.0,,,8,,,CHEMBL616243,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,HEK293,51,BAO_0000219
1043,,,,9,,,CHEMBL616244,,Expert,B,,1,,D,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1044,,,,9,,,CHEMBL616245,,Autocuration,B,,1,,D,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1045,,,,8,,,CHEMBL616246,,Autocuration,B,,1,,H,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,106,BAO_0000357
1046,,,,8,,,CHEMBL616247,,Autocuration,B,,1,,H,Binding affinity against 5-HT1D receptor,,,105,BAO_0000357
1047,,,,8,,,CHEMBL616248,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor,,,105,BAO_0000357
1048,,,,8,,,CHEMBL616249,,Autocuration,B,,1,,H,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,107,BAO_0000357
1049,,,,8,,,CHEMBL616250,,Autocuration,B,,1,,H,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,10576,BAO_0000357
1050,,,,8,,,CHEMBL616251,,Autocuration,B,,1,,H,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1051,,,,8,,In vivo,CHEMBL616252,,Autocuration,F,,1,,H,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,,11863,BAO_0000218
1052,,,,8,,In vivo,CHEMBL616253,,Autocuration,F,,1,,H,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,,11863,BAO_0000218
1053,,,,8,,In vivo,CHEMBL616254,,Autocuration,F,,1,,H,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,,11863,BAO_0000218
1054,,,,9,,,CHEMBL616255,,Expert,F,,1,,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,,11863,BAO_0000218
1055,,,,9,,,CHEMBL832872,,Expert,F,,1,,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,,11863,BAO_0000218
1056,,,,9,,,CHEMBL616256,,Expert,F,,1,,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,,11863,BAO_0000218
1057,,,,9,,,CHEMBL616257,,Expert,F,,1,,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,,11863,BAO_0000218
1058,,,,9,,,CHEMBL616258,,Expert,F,,1,,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,,11863,BAO_0000218
1059,,,,9,,,CHEMBL616384,,Expert,F,,1,,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,,11863,BAO_0000218
1060,,,10000000.0,8,Hippocampus,,CHEMBL616385,,Autocuration,B,,1,,H,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,11863,BAO_0000221
1061,,,,8,,,CHEMBL616386,,Expert,B,,1,,H,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,11863,BAO_0000357
1062,,,10000000.0,9,Hippocampus,,CHEMBL616387,,Expert,B,,1,,D,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,11863,BAO_0000221
1063,,,10000000.0,8,Hippocampus,,CHEMBL616388,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,11863,BAO_0000221
1064,,,10000000.0,9,Hippocampus,,CHEMBL616389,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,11863,BAO_0000221
1065,,,10000000.0,8,Hippocampus,,CHEMBL616390,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,11863,BAO_0000221
1066,,,,8,,,CHEMBL616391,,Autocuration,B,,1,,H,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,11863,BAO_0000357
1067,,,10000000.0,9,Hippocampus,,CHEMBL616392,,Expert,B,,1,,D,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,11863,BAO_0000221
1068,,,,8,,,CHEMBL616393,,Autocuration,B,,1,,H,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1069,,,,8,,,CHEMBL616394,,Autocuration,B,,1,,H,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,,51,BAO_0000357
1070,,,,8,,,CHEMBL616395,,Autocuration,B,,1,,H,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,,51,BAO_0000019
1071,,,,8,,,CHEMBL616396,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity at 5- HT1A receptor,,,51,BAO_0000357
1072,,,,8,,,CHEMBL872907,,Autocuration,B,,1,,H,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,51,BAO_0000019
1073,,,,8,,,CHEMBL616397,,Autocuration,B,,1,,H,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,51,BAO_0000019
1074,,,,8,,,CHEMBL616398,,Autocuration,B,,1,,H,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,,51,BAO_0000019
1075,,,,8,,,CHEMBL616399,,Expert,B,,1,,H,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1076,,,,8,,,CHEMBL857065,,Autocuration,B,,1,,H,Binding activity radioligand.,,,51,BAO_0000357
1077,,,,8,,,CHEMBL616400,,Expert,B,,1,,H,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,51,BAO_0000019
1078,,,,8,,,CHEMBL616401,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,51,BAO_0000019
1079,,,,8,,,CHEMBL616402,,Expert,B,,1,,H,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,10624,BAO_0000019
1080,,,,8,,,CHEMBL616403,,Expert,B,,1,,H,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,,51,BAO_0000019
1081,,,10000000.0,8,Hippocampus,,CHEMBL616404,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,,51,BAO_0000221
1082,,,,8,,,CHEMBL616405,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,,51,BAO_0000249
1083,,,,8,,,CHEMBL616406,,Autocuration,B,,1,,H,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,,51,BAO_0000019
1084,,,,8,,,CHEMBL616407,,Expert,F,,1,,H,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,,51,BAO_0000019
1085,,,,8,,,CHEMBL616408,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,,51,BAO_0000019
1086,,,,9,,,CHEMBL616409,,Expert,B,,1,,D,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,,10576,BAO_0000249
1087,,,10000000.0,9,Hippocampus,,CHEMBL616410,,Expert,B,,1,,D,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,,10576,BAO_0000221
1088,,,,8,,,CHEMBL616411,,Autocuration,B,,1,,H,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,10576,BAO_0000357
1089,,,,9,,,CHEMBL616412,,Expert,F,,1,Membranes,D,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,10576,BAO_0000249
1090,,,10000000.0,9,Hippocampus,,CHEMBL616413,,Expert,F,,1,Membranes,D,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,10576,BAO_0000249
1091,,,10000000.0,8,Hippocampus,,CHEMBL616414,,Autocuration,B,,1,,H,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10576,BAO_0000221
1092,,,10000000.0,9,Hippocampus,,CHEMBL616415,,Expert,B,,1,,D,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,,10576,BAO_0000221
1093,,,,8,,,CHEMBL616416,,Autocuration,B,,1,,H,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,10576,BAO_0000019
1094,,,,8,,,CHEMBL616417,,Expert,B,,1,,H,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,10576,BAO_0000357
1095,,,,8,,,CHEMBL616418,,Autocuration,B,,1,,H,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,10576,BAO_0000357
1096,,,,8,,In vitro,CHEMBL616419,,Autocuration,B,,1,,H,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,10576,BAO_0000219
1097,,,,8,,,CHEMBL616420,,Autocuration,B,,1,,H,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,10576,BAO_0000357
1098,,,,8,,,CHEMBL616421,,Autocuration,B,,1,Membranes,H,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,10576,BAO_0000249
1099,,,,8,,,CHEMBL616422,,Autocuration,B,,1,Membranes,H,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,10576,BAO_0000249
1100,,,,8,,,CHEMBL616423,,Expert,B,,1,Membranes,H,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,10576,BAO_0000249
1101,,,,9,,,CHEMBL616424,,Expert,B,,1,,D,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,,10576,BAO_0000357
1102,,,,8,,,CHEMBL616425,,Expert,B,,1,,H,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1103,,,,8,,,CHEMBL616426,,Expert,B,,1,,H,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,10576,BAO_0000357
1104,,,10000000.0,8,Hippocampus,,CHEMBL616427,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,10576,BAO_0000221
1105,,,10000000.0,8,Hippocampus,,CHEMBL616428,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,10576,BAO_0000221
1106,,,10000000.0,8,Hippocampus,,CHEMBL616290,,Autocuration,B,,1,,H,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576,BAO_0000221
1107,,,,9,,,CHEMBL616052,,Expert,B,,1,,D,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1108,,,,8,,,CHEMBL616053,,Autocuration,B,,1,,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1109,,,,8,,,CHEMBL616054,,Autocuration,B,,1,,H,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000249
1110,,,,8,,,CHEMBL616055,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1111,,,,8,,,CHEMBL616056,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,10576,BAO_0000357
1112,,,,8,,,CHEMBL616057,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,10576,BAO_0000019
1113,,,955.0,9,Brain,,CHEMBL616058,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,10576,BAO_0000221
1114,,,955.0,8,Brain,,CHEMBL616059,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,10576,BAO_0000221
1115,,,,8,,,CHEMBL616060,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000249
1116,,,10000000.0,9,Hippocampus,,CHEMBL616061,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,,10576,BAO_0000221
1117,,,10000000.0,8,Hippocampus,,CHEMBL616062,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,10576,BAO_0000221
1118,,,,8,,,CHEMBL616063,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000249
1119,,,2435.0,8,Striatum,,CHEMBL616064,,Autocuration,B,,1,,H,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,10576,BAO_0000249
1120,,,,9,,,CHEMBL616065,,Expert,B,,1,Membranes,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,,10576,BAO_0000249
1121,,,,9,,,CHEMBL616066,,Expert,B,,1,Membranes,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,,10576,BAO_0000249
1122,,,10000000.0,8,Hippocampus,,CHEMBL616067,,Autocuration,B,,1,,H,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000221
1123,,,10000000.0,8,Hippocampus,,CHEMBL616068,,Autocuration,B,,1,,H,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,10576,BAO_0000221
1124,,,10000000.0,8,Hippocampus,,CHEMBL616069,,Intermediate,B,,1,,H,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000221
1125,,,,8,,,CHEMBL616070,,Expert,B,,1,,H,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,10576,BAO_0000249
1126,,,10000000.0,8,Hippocampus,,CHEMBL616071,,Autocuration,B,,1,,H,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000221
1127,,,10000000.0,8,Hippocampus,,CHEMBL616072,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,10576,BAO_0000221
1128,,,10000000.0,8,Hippocampus,,CHEMBL616073,,Autocuration,B,,1,,H,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,10576,BAO_0000221
1129,,,10000000.0,8,Hippocampus,,CHEMBL616074,,Autocuration,B,,1,,H,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,10576,BAO_0000221
1130,,,,8,,,CHEMBL616075,,Expert,B,,1,,H,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,10576,BAO_0000019
1131,,,,8,,,CHEMBL616076,,Autocuration,B,,1,,H,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1132,,,,9,,,CHEMBL616077,,Expert,B,,1,,D,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,,10576,BAO_0000019
1133,,,,9,,,CHEMBL616078,,Expert,B,,1,,D,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,,10576,BAO_0000019
1134,,,,9,,,CHEMBL616079,,Expert,B,,1,,D,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,,10576,BAO_0000019
1135,485.0,,,9,,,CHEMBL616080,,Expert,B,,1,,D,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,CHO-K1,10576,BAO_0000219
1136,,,,8,,,CHEMBL616081,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1137,,,10000000.0,9,Hippocampus,,CHEMBL616082,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,,10576,BAO_0000221
1138,,,10000000.0,8,Hippocampus,,CHEMBL616083,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,10576,BAO_0000221
1139,,,,8,,,CHEMBL616084,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,10576,BAO_0000019
1140,,,,8,,,CHEMBL616085,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,10576,BAO_0000019
1141,,,,8,,,CHEMBL616086,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,10576,BAO_0000019
1142,,,10000000.0,8,Hippocampus,,CHEMBL616087,,Autocuration,B,,1,,H,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,10576,BAO_0000221
1143,,,,8,,,CHEMBL616088,,Expert,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,10576,BAO_0000357
1144,,,,8,,,CHEMBL616089,,Autocuration,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,10576,BAO_0000019
1145,,,,9,,,CHEMBL616090,,Expert,B,,1,,D,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,,10576,BAO_0000357
1146,,,,8,,,CHEMBL616091,,Autocuration,B,,1,,H,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,10576,BAO_0000357
1147,,,2435.0,8,Striatum,,CHEMBL616092,,Autocuration,B,,1,Membranes,H,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,10576,BAO_0000249
1148,,,,8,,,CHEMBL616093,,Autocuration,B,,1,,H,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,10576,BAO_0000357
1149,,,,8,,In vivo,CHEMBL616094,,Autocuration,B,,1,,H,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,,10576,BAO_0000218
1150,,,955.0,8,Brain,,CHEMBL616095,,Autocuration,B,,1,,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,10576,BAO_0000221
1151,,,,9,,,CHEMBL616096,,Expert,B,,1,,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1152,,,,8,,,CHEMBL616097,,Expert,B,,1,,H,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,10576,BAO_0000249
1153,,,,9,,,CHEMBL616098,,Expert,B,,1,Membranes,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,,10576,BAO_0000249
1154,,,10000000.0,8,Hippocampus,,CHEMBL616099,,Autocuration,B,,1,,H,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000221
1155,,,10000000.0,8,Hippocampus,,CHEMBL616100,,Autocuration,B,,1,,H,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000221
1156,,,,8,,,CHEMBL616101,,Expert,B,,1,,H,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1157,,,,8,,,CHEMBL616102,,Expert,B,,1,,H,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,10576,BAO_0000249
1158,,,,8,,,CHEMBL616103,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1159,,,,8,,,CHEMBL616104,,Expert,B,,1,,H,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,10576,BAO_0000019
1160,,,,8,,,CHEMBL616105,,Expert,B,,1,,H,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,10576,BAO_0000019
1161,,,,9,,,CHEMBL616106,,Expert,B,,1,,D,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000019
1162,,,,8,,,CHEMBL616107,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,10576,BAO_0000019
1163,,,,8,,,CHEMBL616108,,Expert,B,,1,,H,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,10576,BAO_0000357
1164,,,10000000.0,8,Hippocampus,,CHEMBL616109,,Expert,B,,1,,H,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,10576,BAO_0000221
1165,,,,8,,,CHEMBL616110,,Autocuration,B,,1,,H,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,10576,BAO_0000357
1166,449.0,,,8,,,CHEMBL616111,,Expert,B,,1,,H,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,CHO,10576,BAO_0000219
1167,,,,8,,,CHEMBL616112,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,10576,BAO_0000019
1168,,,10000000.0,8,Hippocampus,,CHEMBL616113,,Autocuration,B,,1,,H,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,10576,BAO_0000221
1169,,,,8,,,CHEMBL616114,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000019
1170,,,,8,,,CHEMBL616115,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000019
1171,,,,8,,,CHEMBL616116,,Autocuration,B,,1,,H,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1172,,,955.0,8,Brain,,CHEMBL615844,,Expert,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000221
1173,,,10000000.0,8,Hippocampus,,CHEMBL615939,,Expert,B,,1,,H,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000221
1174,,,,8,,,CHEMBL615940,,Expert,B,,1,,H,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,10576,BAO_0000019
1175,,,10000000.0,8,Hippocampus,,CHEMBL615941,,Expert,B,,1,,H,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,10576,BAO_0000221
1176,,,10000000.0,8,Hippocampus,,CHEMBL615942,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,10576,BAO_0000221
1177,,,10000000.0,8,Hippocampus,,CHEMBL615943,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,10576,BAO_0000221
1178,,,10000000.0,8,Hippocampus,,CHEMBL615944,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,10576,BAO_0000221
1179,,,10000000.0,8,Hippocampus,,CHEMBL615945,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,10576,BAO_0000221
1180,,,10000000.0,8,Hippocampus,,CHEMBL615946,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,10576,BAO_0000221
1181,,,10000000.0,8,Hippocampus,,CHEMBL615947,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,10576,BAO_0000221
1182,,,10000000.0,8,Hippocampus,,CHEMBL615948,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,10576,BAO_0000221
1183,,,10000000.0,8,Hippocampus,,CHEMBL615949,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,10576,BAO_0000221
1184,,,10000000.0,8,Hippocampus,,CHEMBL615950,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,10576,BAO_0000221
1185,,,10000000.0,8,Hippocampus,,CHEMBL615951,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,10576,BAO_0000221
1186,,,10000000.0,8,Hippocampus,,CHEMBL615952,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,10576,BAO_0000221
1187,,,10000000.0,8,Hippocampus,,CHEMBL615953,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,10576,BAO_0000221
1188,,,10000000.0,8,Hippocampus,,CHEMBL615954,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,10576,BAO_0000221
1189,,,10000000.0,9,Hippocampus,,CHEMBL615955,,Expert,B,,1,,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,10576,BAO_0000221
1190,,,10000000.0,8,Hippocampus,,CHEMBL615956,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,10576,BAO_0000221
1191,,,10000000.0,8,Hippocampus,,CHEMBL615957,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,10576,BAO_0000221
1192,,,,8,,,CHEMBL615958,,Expert,B,,1,,H,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,10576,BAO_0000019
1193,,,,8,,,CHEMBL615959,,Expert,B,,1,,H,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,10576,BAO_0000019
1194,,,,8,,,CHEMBL615960,,Autocuration,B,,1,,H,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,10576,BAO_0000019
1195,,,,8,,,CHEMBL615961,,Autocuration,B,,1,,H,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,10576,BAO_0000019
1196,,,955.0,8,Brain,,CHEMBL615962,,Expert,B,,1,,H,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,10576,BAO_0000221
1197,,,,8,,,CHEMBL615963,,Expert,B,,1,,H,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,10576,BAO_0000019
1198,,,,8,,,CHEMBL615964,,Autocuration,B,,1,,H,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,10576,BAO_0000019
1199,,,,8,,,CHEMBL615965,,Autocuration,B,,1,,H,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,10576,BAO_0000019
1200,449.0,,,8,,,CHEMBL615966,,Expert,B,,1,,H,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,CHO,10576,BAO_0000219
1201,,,,8,,,CHEMBL615967,,Expert,B,,1,,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,10576,BAO_0000249
1202,,,,8,,,CHEMBL615968,,Expert,B,,1,,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,10576,BAO_0000019
1203,449.0,,,8,,,CHEMBL615969,,Autocuration,B,,1,,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,CHO,10576,BAO_0000218
1204,,,,8,,,CHEMBL615970,,Autocuration,B,,1,,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,10576,BAO_0000218
1205,,,,9,,,CHEMBL615971,,Expert,B,,1,,D,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,,10576,BAO_0000357
1206,,,,8,,,CHEMBL615972,,Expert,B,,1,Membranes,H,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,10576,BAO_0000249
1207,,,,8,,,CHEMBL615973,,Autocuration,B,,1,,H,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,10576,BAO_0000249
1208,,,,8,,,CHEMBL615974,,Autocuration,B,,1,,H,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,10576,BAO_0000249
1209,449.0,,,9,,,CHEMBL615975,,Expert,B,,1,,D,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHO,51,BAO_0000219
1210,,,,8,,,CHEMBL615976,,Expert,B,,1,,H,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,10576,BAO_0000249
1211,,,10000000.0,9,Hippocampus,,CHEMBL872106,,Expert,B,,1,,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,,10576,BAO_0000221
1212,,,,8,,,CHEMBL615977,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000357
1213,,,,8,,,CHEMBL615978,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,10576,BAO_0000357
1214,,,,8,,,CHEMBL616166,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,10576,BAO_0000357
1215,,,,8,,,CHEMBL616167,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,10576,BAO_0000357
1216,,,,8,,,CHEMBL616168,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,10576,BAO_0000357
1217,,,,8,,,CHEMBL616169,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,10576,BAO_0000357
1218,,,,8,,,CHEMBL616170,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,10576,BAO_0000357
1219,,,,8,,,CHEMBL616171,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,10576,BAO_0000357
1220,,,,8,,,CHEMBL616172,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,10576,BAO_0000357
1221,,,,8,,,CHEMBL616173,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,10576,BAO_0000357
1222,,,,8,,,CHEMBL616174,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,10576,BAO_0000357
1223,,,,8,,,CHEMBL616175,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,10576,BAO_0000357
1224,,,,8,,,CHEMBL616176,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,10576,BAO_0000357
1225,,,,8,,,CHEMBL616177,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,10576,BAO_0000357
1226,,,,8,,,CHEMBL616178,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,10576,BAO_0000357
1227,,,,8,,,CHEMBL616179,,Autocuration,B,,1,,H,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,10576,BAO_0000019
1228,,,,8,,,CHEMBL616180,,Autocuration,B,,1,,H,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1229,,,,8,,,CHEMBL616181,,Autocuration,B,,1,,H,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,10576,BAO_0000357
1230,,,,8,,,CHEMBL616182,,Autocuration,B,,1,,H,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,10576,BAO_0000019
1231,,,10000000.0,8,Hippocampus,,CHEMBL616183,,Autocuration,B,,1,,H,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000221
1232,,,,8,,,CHEMBL615874,,Expert,B,,1,,H,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,10576,BAO_0000019
1233,485.0,,,9,,,CHEMBL615875,,Expert,B,,1,,D,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,CHO-K1,10576,BAO_0000219
1234,,,,8,,,CHEMBL615876,,Autocuration,B,,1,,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,10576,BAO_0000019
1235,,,,8,,,CHEMBL615877,,Autocuration,B,,1,,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,10576,BAO_0000019
1236,,,,8,,,CHEMBL615878,,Autocuration,B,,1,,H,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,10576,BAO_0000357
1237,,,,8,,,CHEMBL615879,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,10576,BAO_0000357
1238,,,,8,,,CHEMBL615880,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,10576,BAO_0000357
1239,,,,8,,,CHEMBL615881,,Autocuration,B,,1,,H,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,10576,BAO_0000019
1240,,,,9,,,CHEMBL615882,,Expert,B,,1,,D,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,10576,BAO_0000019
1241,,,,8,,In vivo,CHEMBL615883,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,,10576,BAO_0000218
1242,,,,8,,In vivo,CHEMBL615884,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,,10576,BAO_0000218
1243,,,,8,,In vivo,CHEMBL615885,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,,10576,BAO_0000218
1244,,,,8,,In vivo,CHEMBL615886,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,,10576,BAO_0000218
1245,,,,8,,In vivo,CHEMBL615887,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,,10576,BAO_0000218
1246,,,,8,,In vivo,CHEMBL615888,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,,10576,BAO_0000218
1247,,,,8,,In vivo,CHEMBL615889,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,,10576,BAO_0000218
1248,,,,8,,In vivo,CHEMBL615890,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,,10576,BAO_0000218
1249,,,,8,,In vivo,CHEMBL615891,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,,10576,BAO_0000218
1250,,,,8,,In vivo,CHEMBL615892,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,,10576,BAO_0000218
1251,,,,8,,In vivo,CHEMBL615893,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,,10576,BAO_0000218
1252,,,,8,,In vivo,CHEMBL615894,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,,10576,BAO_0000218
1253,,,,8,,In vivo,CHEMBL615895,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,,10576,BAO_0000218
1254,,,,8,,In vivo,CHEMBL615896,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,,10576,BAO_0000218
1255,,,,8,,In vivo,CHEMBL615897,,Autocuration,F,,1,,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,,10576,BAO_0000218
1256,,,,9,,,CHEMBL615898,,Expert,F,,1,Membranes,D,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,10576,BAO_0000249
1257,,,,8,,,CHEMBL615899,,Autocuration,B,,1,,H,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,10576,BAO_0000019
1258,,,,8,,,CHEMBL616291,,Autocuration,B,,1,,H,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,10576,BAO_0000019
1259,,,,8,,,CHEMBL616292,,Autocuration,B,,1,,H,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,10576,BAO_0000357
1260,,,,8,,,CHEMBL616293,,Autocuration,F,,1,,H,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,10576,BAO_0000249
1261,,,10000000.0,8,Hippocampus,,CHEMBL616294,,Expert,B,,1,,H,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576,BAO_0000221
1262,,,10000000.0,8,Hippocampus,,CHEMBL616295,,Autocuration,B,,1,,H,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,10576,BAO_0000249
1263,,,955.0,8,Brain,,CHEMBL616296,,Autocuration,B,,1,,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,10576,BAO_0000221
1264,,,,8,,,CHEMBL616297,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,10576,BAO_0000019
1265,,,,8,,,CHEMBL616605,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,10576,BAO_0000019
1266,,,,8,,,CHEMBL616606,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,10576,BAO_0000019
1267,,,,8,,,CHEMBL616607,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,10576,BAO_0000019
1268,,,,8,,,CHEMBL616608,,Expert,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,10576,BAO_0000019
1269,,,,8,,,CHEMBL616609,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,10576,BAO_0000019
1270,,,,9,,,CHEMBL616610,,Expert,F,,1,,D,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,,10576,BAO_0000019
1271,,,,8,,,CHEMBL616611,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,10576,BAO_0000019
1272,,,,8,,,CHEMBL616612,,Expert,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,10576,BAO_0000019
1273,,,,8,,,CHEMBL616613,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,10576,BAO_0000019
1274,,,,8,,,CHEMBL616614,,Expert,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,10576,BAO_0000019
1275,,,,8,,,CHEMBL616615,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,10576,BAO_0000019
1276,,,,8,,,CHEMBL616616,,Expert,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,10576,BAO_0000019
1277,,,,8,,,CHEMBL616617,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,10576,BAO_0000019
1278,,,,8,,,CHEMBL616618,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,10576,BAO_0000019
1279,,,,8,,,CHEMBL616619,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,10576,BAO_0000019
1280,,,,8,,,CHEMBL616620,,Expert,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,10576,BAO_0000019
1281,,,,8,,,CHEMBL616621,,Expert,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,10576,BAO_0000019
1282,,,,8,,,CHEMBL616622,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,10576,BAO_0000019
1283,,,,8,,,CHEMBL616146,,Expert,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,10576,BAO_0000019
1284,,,,8,,,CHEMBL832873,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,10576,BAO_0000019
1285,,,,8,,,CHEMBL616147,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,10576,BAO_0000019
1286,,,,8,,,CHEMBL872872,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,10576,BAO_0000019
1287,,,,8,,,CHEMBL616148,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,10576,BAO_0000019
1288,,,10000000.0,8,Hippocampus,,CHEMBL616149,,Autocuration,B,,1,,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,10576,BAO_0000221
1289,,,10000000.0,8,Hippocampus,,CHEMBL616150,,Expert,B,,1,,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,10576,BAO_0000221
1290,,,,9,,,CHEMBL616151,,Expert,B,,1,Membranes,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,,10576,BAO_0000249
1291,,,10000000.0,8,Hippocampus,,CHEMBL872873,,Expert,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,10576,BAO_0000221
1292,,,10000000.0,8,Hippocampus,,CHEMBL616670,,Autocuration,B,,1,,H,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,10576,BAO_0000221
1293,,,10000000.0,8,Hippocampus,,CHEMBL616671,,Autocuration,B,,1,,H,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,10576,BAO_0000221
1294,,,,9,,,CHEMBL884861,,Expert,F,,1,,D,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,10576,BAO_0000249
1295,,,,8,,,CHEMBL616672,,Autocuration,B,,1,,H,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,10576,BAO_0000357
1296,,,,8,,,CHEMBL616673,,Autocuration,B,,1,,H,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,10576,BAO_0000019
1297,,,,8,,,CHEMBL616674,,Expert,F,,1,,H,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,10576,BAO_0000019
1298,,,,8,,,CHEMBL616675,,Autocuration,B,,1,,H,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,10576,BAO_0000357
1299,,,10000000.0,8,Hippocampus,,CHEMBL616676,,Autocuration,B,,1,,H,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,10576,BAO_0000221
1300,,,10000000.0,8,Hippocampus,,CHEMBL616677,,Autocuration,B,,1,,H,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10576,BAO_0000221
1301,,,10000000.0,8,Hippocampus,,CHEMBL616678,,Autocuration,B,,1,,H,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10576,BAO_0000221
1302,,,,9,,,CHEMBL616679,,Expert,B,,1,,D,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1303,,,10000000.0,8,Hippocampus,,CHEMBL616680,,Expert,B,,1,,H,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,10576,BAO_0000221
1304,,,10000000.0,8,Hippocampus,,CHEMBL616681,,Autocuration,B,,1,,H,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576,BAO_0000221
1305,,,10000000.0,8,Hippocampus,,CHEMBL616682,,Autocuration,B,,1,,H,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576,BAO_0000221
1306,,,10000000.0,8,Hippocampus,,CHEMBL616683,,Autocuration,B,,1,,H,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000221
1307,,,10000000.0,8,Hippocampus,,CHEMBL616684,,Autocuration,B,,1,,H,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000221
1308,,,10000000.0,8,Hippocampus,,CHEMBL616685,,Autocuration,B,,1,,H,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,10576,BAO_0000221
1309,,,955.0,8,Brain,,CHEMBL616686,,Autocuration,B,,1,,H,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,10576,BAO_0000221
1310,,,,8,,,CHEMBL616687,,Autocuration,B,,1,,H,Affinity for 5-hydroxytryptamine 1A receptor site,,,10576,BAO_0000357
1311,,,,8,,,CHEMBL616688,,Autocuration,B,,1,,H,Affinity for 5-hydroxytryptamine 1A receptor site,,,10576,BAO_0000357
1312,,,10000000.0,8,Hippocampus,,CHEMBL616689,,Autocuration,B,,1,,H,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,10576,BAO_0000221
1313,,,,8,,,CHEMBL616690,,Autocuration,B,,1,,H,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,10576,BAO_0000357
1314,,,,8,,,CHEMBL616691,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,10576,BAO_0000357
1315,,,10000000.0,9,Hippocampus,,CHEMBL616692,,Expert,B,,1,,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,,10576,BAO_0000221
1316,,,,8,,,CHEMBL616693,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,10576,BAO_0000249
1317,,,,9,,,CHEMBL616694,,Expert,B,,1,,D,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,10576,BAO_0000019
1318,,,10000000.0,8,Hippocampus,,CHEMBL616695,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,10576,BAO_0000221
1319,,,,8,,,CHEMBL616696,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,10576,BAO_0000357
1320,,,,8,,,CHEMBL616697,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,10576,BAO_0000357
1321,,,,8,,,CHEMBL616698,,Autocuration,B,,1,,H,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1322,,,,9,,,CHEMBL616949,,Expert,B,,1,,D,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000019
1323,,,10000000.0,8,Hippocampus,,CHEMBL616950,,Autocuration,B,,1,,H,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,10576,BAO_0000221
1324,,,,8,,,CHEMBL832875,,Autocuration,B,,1,,H,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,10576,BAO_0000357
1325,,,955.0,8,Brain,,CHEMBL616951,,Expert,B,,1,,H,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,10576,BAO_0000221
1326,,,955.0,8,Brain,,CHEMBL616952,,Expert,B,,1,,H,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,10576,BAO_0000221
1327,,,,8,,,CHEMBL616953,,Expert,B,,1,,H,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,10576,BAO_0000357
1328,,,,8,,,CHEMBL616954,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,10576,BAO_0000357
1329,,,,8,,,CHEMBL616955,,Autocuration,B,,1,,H,GTPgammaS radioligand binding assay,,,106,BAO_0000357
1330,,,,8,,,CHEMBL616956,,Autocuration,B,,1,,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,106,BAO_0000357
1331,,,,8,,,CHEMBL616957,,Autocuration,F,,1,,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,106,BAO_0000019
1332,,,,8,,,CHEMBL616958,,Autocuration,F,,1,,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,106,BAO_0000019
1333,,,,8,,,CHEMBL616959,,Autocuration,B,,1,,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1334,,,,8,,,CHEMBL616960,,Autocuration,B,,1,,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,106,BAO_0000357
1335,,,,8,,,CHEMBL616961,,Autocuration,F,,1,,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,106,BAO_0000019
1336,308.0,,,8,,,CHEMBL616962,,Expert,B,,1,,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,HeLa,106,BAO_0000219
1337,308.0,,,8,,,CHEMBL616963,,Autocuration,B,,1,,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,HeLa,106,BAO_0000219
1338,,,,9,,,CHEMBL616524,,Expert,B,,1,,D,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,,106,BAO_0000357
1339,449.0,,,8,,,CHEMBL616525,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,CHO,106,BAO_0000219
1340,,,,8,,,CHEMBL872908,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,106,BAO_0000019
1341,,,,8,,,CHEMBL616526,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,106,BAO_0000019
1342,,,,9,,,CHEMBL616527,,Expert,B,,1,,D,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1343,,,,8,,,CHEMBL616528,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,106,BAO_0000219
1344,,,,8,,,CHEMBL616529,,Autocuration,B,,1,,H,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,106,BAO_0000357
1345,,,,8,,,CHEMBL616530,,Autocuration,B,,1,,H,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,106,BAO_0000357
1346,,,,8,,,CHEMBL616531,,Expert,B,,1,,H,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1347,,,,8,,,CHEMBL616532,,Autocuration,B,,1,,H,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1348,,,,8,,,CHEMBL616533,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1349,,,,8,,,CHEMBL616534,,Expert,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1350,,,,8,,,CHEMBL616535,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,106,BAO_0000357
1351,,,,8,,,CHEMBL616536,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,106,BAO_0000357
1352,,,,8,,,CHEMBL616537,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1353,485.0,,,8,,,CHEMBL616538,,Expert,F,,1,,H,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,CHO-K1,106,BAO_0000219
1354,,,,8,,,CHEMBL616539,,Expert,F,,1,,H,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,106,BAO_0000019
1355,,,,8,,,CHEMBL616540,,Expert,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000019
1356,,,,8,,,CHEMBL616429,,Autocuration,B,,1,,H,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,106,BAO_0000357
1357,,,,8,,,CHEMBL616430,,Expert,B,,1,,H,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1358,,,,9,,,CHEMBL616431,,Expert,B,,1,,D,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,,106,BAO_0000219
1359,,,,9,,,CHEMBL616432,,Expert,B,,1,,D,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1360,,,,9,,,CHEMBL616433,,Expert,B,,1,,D,Affinity for 5-hydroxytryptamine 1B receptor subtype,,,106,BAO_0000357
1361,,,,9,,,CHEMBL616434,,Expert,B,,1,,D,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1362,449.0,,,8,,,CHEMBL616435,,Autocuration,B,,1,,H,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,CHO,106,BAO_0000219
1363,,,,8,,,CHEMBL616436,,Expert,B,,1,,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,106,BAO_0000019
1364,308.0,,,8,,,CHEMBL616437,,Autocuration,B,,1,,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,HeLa,106,BAO_0000219
1365,308.0,,,8,,,CHEMBL616438,,Autocuration,B,,1,,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,HeLa,106,BAO_0000219
1366,308.0,,,8,,,CHEMBL616439,,Autocuration,B,,1,,H,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,HeLa,106,BAO_0000219
1367,,,,9,,,CHEMBL616440,,Expert,B,,1,,D,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,,106,BAO_0000357
1368,485.0,,,8,,,CHEMBL616441,,Autocuration,B,,1,,H,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,CHO-K1,106,BAO_0000219
1369,,,,8,,,CHEMBL616442,,Expert,B,,1,,H,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,106,BAO_0000357
1370,,,,8,,,CHEMBL616443,,Autocuration,B,,1,,H,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,106,BAO_0000357
1371,485.0,,,8,,,CHEMBL616444,,Expert,B,,1,,H,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,CHO-K1,106,BAO_0000219
1372,,,,9,,,CHEMBL616445,,Expert,B,,1,,D,Binding activity against human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1373,,,,9,,,CHEMBL616446,,Expert,B,,1,,D,Binding activity against human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1374,449.0,,,9,,,CHEMBL616447,,Expert,B,,1,,D,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,CHO,106,BAO_0000219
1375,,,,8,,,CHEMBL616448,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,106,BAO_0000357
1376,449.0,,,8,,,CHEMBL616449,,Autocuration,B,,1,,H,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,CHO,106,BAO_0000219
1377,449.0,,,8,,,CHEMBL616450,,Autocuration,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,CHO,106,BAO_0000219
1378,449.0,,,8,,,CHEMBL857974,,Autocuration,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,CHO,106,BAO_0000219
1379,449.0,,,8,,,CHEMBL616451,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHO,106,BAO_0000219
1380,449.0,,,8,,,CHEMBL616452,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHO,106,BAO_0000219
1381,449.0,,,8,,,CHEMBL616453,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,CHO,106,BAO_0000219
1382,449.0,,,8,,,CHEMBL616454,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,CHO,106,BAO_0000219
1383,,,,9,,,CHEMBL616455,,Expert,B,,1,,D,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1384,449.0,,,8,,,CHEMBL616456,,Autocuration,B,,1,,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,CHO,106,BAO_0000219
1385,,,,8,,,CHEMBL616457,,Autocuration,B,,1,,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,106,BAO_0000357
1386,449.0,,,8,,,CHEMBL616458,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,CHO,106,BAO_0000219
1387,449.0,,,8,,,CHEMBL616459,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,CHO,106,BAO_0000219
1388,,,,8,,,CHEMBL616460,,Expert,F,,1,,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,106,BAO_0000019
1389,,,,8,,,CHEMBL616461,,Expert,F,,1,,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,106,BAO_0000019
1390,449.0,,,8,,,CHEMBL616462,,Autocuration,F,,1,,H,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,CHO,106,BAO_0000219
1391,449.0,,,8,,,CHEMBL616463,,Autocuration,F,,1,,H,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,CHO,106,BAO_0000219
1392,,,,8,,,CHEMBL616464,,Autocuration,F,,1,,H,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,105,BAO_0000019
1393,449.0,,,8,,,CHEMBL616465,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,CHO,105,BAO_0000219
1394,,,,8,,,CHEMBL832874,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,17105,BAO_0000357
1395,,,,8,,,CHEMBL616184,,Autocuration,F,,1,,H,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,,106,BAO_0000019
1396,,,,8,,,CHEMBL616185,,Autocuration,B,,1,,H,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,,106,BAO_0000019
1397,,,,8,,,CHEMBL616186,,Intermediate,B,,1,,H,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,,106,BAO_0000019
1398,,,,8,,,CHEMBL616187,,Autocuration,B,,1,,H,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,,106,BAO_0000019
1399,,,,8,,,CHEMBL616188,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,10577,BAO_0000357
1400,,,,9,,,CHEMBL873475,,Intermediate,B,,1,,D,Binding affinity for 5-hydroxytryptamine 1B receptor,,,10577,BAO_0000357
1401,,,2435.0,9,Striatum,,CHEMBL616189,,Expert,B,,1,,D,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,,10577,BAO_0000019
1402,,,,8,,,CHEMBL616190,,Expert,B,,1,,H,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,10577,BAO_0000357
1403,,,,8,,,CHEMBL616191,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,10576,BAO_0000357
1404,,,,8,,,CHEMBL616192,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,10576,BAO_0000357
1405,,,,8,,,CHEMBL616193,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,10576,BAO_0000357
1406,,,,8,,,CHEMBL616194,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,10576,BAO_0000357
1407,,,,8,,,CHEMBL616195,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,10576,BAO_0000357
1408,,,,8,,,CHEMBL616196,,Autocuration,B,,1,,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,10576,BAO_0000357
1409,,,10000000.0,8,Hippocampus,,CHEMBL616197,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,10576,BAO_0000249
1410,,,,8,,,CHEMBL616198,,Intermediate,B,,1,,H,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000019
1411,,,10000000.0,8,Hippocampus,,CHEMBL616199,,Autocuration,B,,1,,H,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,10576,BAO_0000221
1412,,,10000000.0,8,Hippocampus,,CHEMBL616200,,Expert,B,,1,,H,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,10576,BAO_0000221
1413,,,10000000.0,8,Hippocampus,,CHEMBL616201,,Expert,B,,1,,H,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000221
1414,,,10000000.0,8,Hippocampus,,CHEMBL616202,,Expert,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,10576,BAO_0000221
1415,,,10000000.0,8,Hippocampus,,CHEMBL616203,,Expert,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,10576,BAO_0000221
1416,,,10000000.0,8,Hippocampus,,CHEMBL616204,,Expert,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,10576,BAO_0000221
1417,,,10000000.0,8,Hippocampus,,CHEMBL616205,,Expert,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,10576,BAO_0000221
1418,,,10000000.0,8,Hippocampus,,CHEMBL616206,,Expert,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,10576,BAO_0000221
1419,,,,8,,,CHEMBL616207,,Expert,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,10576,BAO_0000249
1420,,,,8,,,CHEMBL616208,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,10576,BAO_0000249
1421,,,,8,,,CHEMBL616209,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,10576,BAO_0000249
1422,,,,8,,,CHEMBL616210,,Expert,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,10576,BAO_0000357
1423,,,10000000.0,8,Hippocampus,,CHEMBL616211,,Expert,B,,1,,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,10576,BAO_0000221
1424,,,10000000.0,8,Hippocampus,,CHEMBL616504,,Autocuration,B,,1,,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,10576,BAO_0000221
1425,,,10000000.0,9,Hippocampus,,CHEMBL616505,,Expert,B,,1,,D,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000221
1426,,,,8,,,CHEMBL616506,,Autocuration,F,,1,,H,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000019
1427,,,10000000.0,8,Hippocampus,,CHEMBL872107,,Autocuration,B,,1,,H,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10576,BAO_0000221
1428,,,10000000.0,9,Hippocampus,,CHEMBL616507,,Expert,B,,1,,D,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,,10576,BAO_0000221
1429,,,,8,,,CHEMBL616303,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,10576,BAO_0000249
1430,,,10000000.0,8,Hippocampus,,CHEMBL616304,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,10576,BAO_0000221
1431,,,10000000.0,8,Hippocampus,,CHEMBL616305,,Expert,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,10576,BAO_0000221
1432,,,10000000.0,8,Hippocampus,,CHEMBL616306,,Intermediate,F,,1,,H,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000221
1433,,,,8,,,CHEMBL616307,,Autocuration,B,,1,,H,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1434,,,10000000.0,9,Hippocampus,,CHEMBL881829,,Expert,B,,1,,D,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,,10576,BAO_0000221
1435,,,,8,,,CHEMBL616308,,Expert,B,,1,,H,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,10576,BAO_0000357
1436,,,,8,,,CHEMBL616309,,Autocuration,B,,1,,H,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,10576,BAO_0000019
1437,,,,8,,,CHEMBL616310,,Expert,B,,1,,H,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,10576,BAO_0000019
1438,449.0,,,8,,,CHEMBL616311,,Autocuration,B,,1,,H,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,CHO,10576,BAO_0000219
1439,,,,8,,,CHEMBL616312,,Expert,B,,1,,H,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000357
1440,,,,8,,,CHEMBL616313,,Autocuration,B,,1,,H,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,10576,BAO_0000357
1441,,,10000000.0,9,Hippocampus,,CHEMBL616314,,Expert,B,,1,,D,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000221
1442,,,10000000.0,8,Hippocampus,,CHEMBL616315,,Autocuration,B,,1,,H,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576,BAO_0000221
1443,,,10000000.0,8,Hippocampus,,CHEMBL616567,,Autocuration,B,,1,,H,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,10576,BAO_0000221
1444,,,10000000.0,8,Hippocampus,,CHEMBL616568,,Autocuration,B,,1,,H,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,10576,BAO_0000221
1445,,,,8,,,CHEMBL616569,,Intermediate,B,,1,,H,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,10576,BAO_0000019
1446,,,,8,,,CHEMBL616570,,Expert,B,,1,,H,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,10576,BAO_0000357
1447,,,,8,,,CHEMBL616571,,Autocuration,B,,1,,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,10576,BAO_0000357
1448,,,10000000.0,8,Hippocampus,,CHEMBL616572,,Autocuration,B,,1,,H,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,10576,BAO_0000221
1449,,,,8,,,CHEMBL616573,,Expert,B,,1,,H,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,10576,BAO_0000249
1450,,,,9,,,CHEMBL616574,,Expert,B,,1,,D,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,,10576,BAO_0000357
1451,,,10000000.0,8,Hippocampus,,CHEMBL616575,,Expert,B,,1,,H,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,10576,BAO_0000221
1452,,,10000000.0,8,Hippocampus,,CHEMBL872108,,Autocuration,B,,1,,H,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,10576,BAO_0000221
1453,,,,8,,,CHEMBL616576,,Autocuration,B,,1,,H,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,10576,BAO_0000357
1454,,,,8,,,CHEMBL616577,,Autocuration,B,,1,,H,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,10576,BAO_0000249
1455,,,,8,,,CHEMBL616578,,Autocuration,B,,1,,H,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,10576,BAO_0000249
1456,,,,8,,,CHEMBL616579,,Expert,B,,1,,H,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,10576,BAO_0000357
1457,,,,9,,,CHEMBL616580,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,,10576,BAO_0000019
1458,,,,8,,,CHEMBL616581,,Autocuration,B,,1,,H,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,10576,BAO_0000019
1459,,,10000000.0,8,Hippocampus,,CHEMBL616582,,Autocuration,B,,1,,H,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576,BAO_0000221
1460,,,10000000.0,8,Hippocampus,,CHEMBL616583,,Expert,B,,1,,H,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576,BAO_0000221
1461,,,10000000.0,9,Hippocampus,,CHEMBL616584,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,,10576,BAO_0000221
1462,,,,8,,,CHEMBL616585,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1463,,,10000000.0,9,Hippocampus,,CHEMBL616586,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,,10576,BAO_0000221
1464,,,10000000.0,8,Hippocampus,,CHEMBL616587,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,10576,BAO_0000221
1465,,,10000000.0,8,Hippocampus,,CHEMBL616588,,Autocuration,B,,1,,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,10576,BAO_0000221
1466,,,10000000.0,8,Hippocampus,,CHEMBL616589,,Autocuration,B,,1,,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,10576,BAO_0000221
1467,,,10000000.0,8,Hippocampus,,CHEMBL616590,,Expert,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10576,BAO_0000221
1468,449.0,,,8,,,CHEMBL616591,,Expert,B,,1,,H,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,CHO,10576,BAO_0000219
1469,,,,8,,,CHEMBL616592,,Expert,B,,1,,H,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1470,,,,8,,,CHEMBL616593,,Autocuration,B,,1,,H,The inhibition activity of 5-HT1A at 1 uM,,,10576,BAO_0000357
1471,485.0,,,8,,,CHEMBL616594,,Expert,B,,1,,H,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,CHO-K1,10576,BAO_0000219
1472,,,,8,,,CHEMBL616595,,Expert,B,,1,,H,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,10576,BAO_0000249
1473,,,,8,,,CHEMBL616596,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,10576,BAO_0000357
1474,,,10000000.0,8,Hippocampus,,CHEMBL616597,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,10576,BAO_0000221
1475,,,10000000.0,8,Hippocampus,,CHEMBL616598,,Expert,B,,1,,H,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,10576,BAO_0000221
1476,,,,9,,,CHEMBL616599,,Expert,F,,1,Membranes,D,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,,10576,BAO_0000249
1477,,,10000000.0,9,Hippocampus,,CHEMBL616600,,Expert,F,,1,Membranes,D,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,10576,BAO_0000249
1478,,,,8,,,CHEMBL616601,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,10576,BAO_0000019
1479,,,,8,,,CHEMBL616602,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,10576,BAO_0000019
1480,,,,8,,,CHEMBL616603,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,10576,BAO_0000019
1481,,,,8,,,CHEMBL616604,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,10576,BAO_0000019
1482,,,,8,,,CHEMBL616316,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,10576,BAO_0000249
1483,,,,8,,,CHEMBL616317,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,10576,BAO_0000249
1484,,,,9,,,CHEMBL616318,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,,10576,BAO_0000019
1485,,,10000000.0,8,Hippocampus,,CHEMBL616319,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,10576,BAO_0000221
1486,,,10000000.0,8,Hippocampus,,CHEMBL616320,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,10576,BAO_0000221
1487,,,10000000.0,9,Hippocampus,,CHEMBL616321,,Expert,B,,1,,D,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,,10576,BAO_0000221
1488,,,,8,,,CHEMBL616322,,Autocuration,F,,1,,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,10576,BAO_0000019
1489,,,,8,,,CHEMBL616323,,Autocuration,F,,1,,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,10576,BAO_0000019
1490,,,,8,,,CHEMBL616324,,Autocuration,B,,1,,H,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,10576,BAO_0000357
1491,,,10000000.0,8,Hippocampus,,CHEMBL616325,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,10576,BAO_0000221
1492,,,10000000.0,8,Hippocampus,,CHEMBL616326,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,10576,BAO_0000221
1493,,,10000000.0,8,Hippocampus,,CHEMBL616327,,Autocuration,B,,1,,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,10576,BAO_0000221
1494,,,,8,,,CHEMBL616328,,Autocuration,B,,1,,H,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1495,,,,8,,,CHEMBL858110,,Autocuration,B,,1,,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,10576,BAO_0000249
1496,,,,8,,,CHEMBL616329,,Autocuration,F,,1,,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,10576,BAO_0000249
1497,,,,8,,,CHEMBL616330,,Autocuration,B,,1,,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,10576,BAO_0000249
1498,,,,8,,,CHEMBL616331,,Autocuration,F,,1,,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,10576,BAO_0000249
1499,,,,8,,,CHEMBL616332,,Autocuration,F,,1,,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,10576,BAO_0000249
1500,,,955.0,8,Brain,,CHEMBL857063,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,10576,BAO_0000249
1501,,,,8,,,CHEMBL616333,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,10576,BAO_0000019
1502,,,,8,,,CHEMBL616334,,Expert,F,,1,,H,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,10576,BAO_0000019
1503,,,10000000.0,8,Hippocampus,,CHEMBL616335,,Autocuration,B,,1,,H,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,10576,BAO_0000221
1504,,,,8,,,CHEMBL616336,,Autocuration,B,,1,,H,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,10576,BAO_0000019
1505,,,,8,,,CHEMBL616337,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,10576,BAO_0000249
1506,,,,8,,,CHEMBL616338,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,10576,BAO_0000019
1507,,,10000000.0,8,Hippocampus,,CHEMBL616339,,Autocuration,B,,1,,H,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,10576,BAO_0000221
1508,,,10000000.0,8,Hippocampus,,CHEMBL616340,,Autocuration,B,,1,,H,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,10576,BAO_0000221
1509,,,,8,,,CHEMBL616341,,Autocuration,B,,1,,H,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,10576,BAO_0000357
1510,,,,9,,,CHEMBL616342,,Expert,B,,1,,D,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1511,,,,9,,,CHEMBL616343,,Expert,B,,1,,D,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,,10576,BAO_0000019
1512,,,,8,,,CHEMBL616344,,Expert,B,,1,,H,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,10576,BAO_0000019
1513,,,,8,,,CHEMBL616345,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,10576,BAO_0000357
1514,,,,8,,,CHEMBL616346,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,10576,BAO_0000019
1515,,,10000000.0,8,Hippocampus,,CHEMBL616347,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,10576,BAO_0000221
1516,,,,8,,,CHEMBL616348,,Expert,B,,1,,H,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,10576,BAO_0000019
1517,,,,8,,,CHEMBL616349,,Expert,B,,1,,H,Binding affinity at 5-hydroxytryptamine 1A receptor,,,10576,BAO_0000357
1518,,,,9,,,CHEMBL616152,,Expert,B,,1,Membranes,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,,10576,BAO_0000249
1519,,,,8,,,CHEMBL616153,,Autocuration,B,,1,,H,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,10576,BAO_0000249
1520,,,,8,,,CHEMBL616154,,Expert,B,,1,,H,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,10576,BAO_0000019
1521,,,,8,,,CHEMBL616155,,Autocuration,B,,1,,H,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,10576,BAO_0000019
1522,,,10000000.0,9,Hippocampus,,CHEMBL616156,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,,10576,BAO_0000221
1523,,,10000000.0,9,Hippocampus,,CHEMBL616157,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,,10576,BAO_0000221
1524,,,10000000.0,8,Hippocampus,,CHEMBL616158,,Autocuration,B,,1,,H,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,10576,BAO_0000221
1525,,,,8,,,CHEMBL616159,,Autocuration,B,,1,,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,10576,BAO_0000357
1526,,,,8,,,CHEMBL616160,,Expert,B,,1,,H,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,10576,BAO_0000357
1527,,,,8,,,CHEMBL616161,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,10576,BAO_0000019
1528,,,,8,,,CHEMBL616162,,Autocuration,F,,1,,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,10576,BAO_0000019
1529,,,,9,,,CHEMBL616163,,Expert,B,,1,,D,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,12687,BAO_0000357
1530,,,,8,,,CHEMBL616164,,Expert,B,,1,Membranes,H,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,10626,BAO_0000249
1531,,,955.0,8,Brain,,CHEMBL616165,,Autocuration,B,,1,,H,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,10576,BAO_0000221
1532,,,,8,,,CHEMBL616355,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,,51,BAO_0000019
1533,,,,8,,,CHEMBL616356,,Autocuration,F,,1,,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,10576,BAO_0000019
1534,,,955.0,8,Brain,,CHEMBL616357,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,10576,BAO_0000221
1535,,,,8,,,CHEMBL616358,,Autocuration,B,,1,,H,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,10576,BAO_0000019
1536,,,,8,,,CHEMBL616359,,Autocuration,B,,1,,H,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1537,,,,8,,,CHEMBL616360,,Expert,B,,1,,H,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,51,BAO_0000357
1538,,,,8,,,CHEMBL616361,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1539,,,,8,,,CHEMBL616362,,Autocuration,B,,1,,H,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1540,,,,8,,,CHEMBL616363,,Autocuration,B,,1,Brain membranes,H,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,51,BAO_0000249
1541,,,,8,,,CHEMBL616364,,Autocuration,B,,1,,H,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,51,BAO_0000357
1542,,,,8,,,CHEMBL616365,,Autocuration,B,,1,,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1543,,,,8,,,CHEMBL616366,,Expert,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000357
1544,,,,8,,,CHEMBL872906,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1545,,,,8,,,CHEMBL616367,,Autocuration,B,,1,,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,51,BAO_0000357
1546,,,,8,,,CHEMBL616368,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1547,,,,8,,,CHEMBL616369,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,51,BAO_0000357
1548,,,,9,,,CHEMBL616370,,Expert,B,,1,,D,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,,51,BAO_0000357
1549,,,,9,,,CHEMBL616371,,Expert,B,,1,,D,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,,51,BAO_0000357
1550,449.0,,,8,,,CHEMBL616372,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHO,51,BAO_0000219
1551,,,,8,,,CHEMBL616373,,Expert,B,,1,,H,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,51,BAO_0000219
1552,,,,8,,In vivo,CHEMBL616374,,Autocuration,B,,1,,H,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51,BAO_0000218
1553,,,10000000.0,8,Hippocampus,,CHEMBL616375,,Autocuration,B,,1,,H,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51,BAO_0000221
1554,,,,8,,,CHEMBL616376,,Autocuration,B,,1,,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,51,BAO_0000357
1555,,,,8,,,CHEMBL857064,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,51,BAO_0000357
1556,,,,8,,,CHEMBL616377,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,51,BAO_0000357
1557,,,,8,,,CHEMBL616378,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,51,BAO_0000357
1558,,,,8,,,CHEMBL616379,,Autocuration,B,,1,,H,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,51,BAO_0000357
1559,,,,8,,,CHEMBL616380,,Autocuration,B,,1,,H,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000357
1560,,,,8,,,CHEMBL616381,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,11863,BAO_0000357
1561,,,,8,,,CHEMBL616382,,Autocuration,B,,1,,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000357
1562,,,,8,,,CHEMBL616383,,Autocuration,B,,1,,H,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,11863,BAO_0000357
1563,449.0,,,9,,,CHEMBL616350,,Expert,B,,1,,D,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,CHO,11863,BAO_0000219
1564,,,,8,,,CHEMBL616351,,Autocuration,B,,1,,H,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000357
1565,,,,8,,,CHEMBL616352,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,11863,BAO_0000357
1566,,,,8,,,CHEMBL616353,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000357
1567,,,,8,,,CHEMBL616354,,Autocuration,B,,1,,H,Binding affinity against serotonergic 5-HT1a receptor,,,11863,BAO_0000357
1568,,,,8,,,CHEMBL616508,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,11863,BAO_0000357
1569,,,,9,,,CHEMBL616559,,Expert,B,,1,,D,Binding affinity for 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000357
1570,,,,8,,,CHEMBL616560,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000357
1571,,,,8,,,CHEMBL616561,,Autocuration,B,,1,,H,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,11863,BAO_0000357
1572,449.0,,,8,,,CHEMBL616562,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHO,11863,BAO_0000219
1573,449.0,,,8,,,CHEMBL616563,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHO,11863,BAO_0000219
1574,,,,8,,,CHEMBL616564,,Autocuration,B,,1,,H,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000357
1575,,,,8,,,CHEMBL616565,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,11863,BAO_0000357
1576,,,,8,,,CHEMBL616566,,Autocuration,B,,1,,H,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000218
1577,,,,8,,,CHEMBL616989,,Autocuration,B,,1,,H,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,11863,BAO_0000357
1578,,,,8,,,CHEMBL857975,,Autocuration,B,,1,,H,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000357
1579,,,,9,,,CHEMBL616990,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000357
1580,,,,8,,,CHEMBL616991,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,11863,BAO_0000357
1581,,,,8,,,CHEMBL616992,,Autocuration,B,,1,,H,Tested against 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000357
1582,,,,8,,,CHEMBL616993,,Autocuration,B,,1,,H,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,11863,BAO_0000357
1583,,,,8,,,CHEMBL616994,,Expert,B,,1,,H,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,,106,BAO_0000019
1584,,,,8,,,CHEMBL616995,,Autocuration,B,,1,,H,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,,106,BAO_0000019
1585,722.0,,,9,,,CHEMBL616996,,Intermediate,B,,1,,D,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,HEK293,105571,BAO_0000219
1586,,,,8,,In vivo,CHEMBL616997,,Autocuration,F,,1,,H,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,106,BAO_0000218
1587,,,,8,,In vivo,CHEMBL616998,,Autocuration,F,,1,,H,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,106,BAO_0000218
1588,,,,8,,,CHEMBL616999,,Autocuration,F,,1,,H,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,,106,BAO_0000019
1589,,,,8,,,CHEMBL617000,,Autocuration,F,,1,,H,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,,106,BAO_0000019
1590,,,,8,,,CHEMBL617001,,Autocuration,F,,1,,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,,106,BAO_0000019
1591,,,,8,,,CHEMBL858111,,Autocuration,F,,1,,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,,106,BAO_0000019
1592,,,,8,,,CHEMBL617002,,Autocuration,F,,1,,H,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,106,BAO_0000019
1593,,,,8,,,CHEMBL617003,,Autocuration,F,,1,,H,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,106,BAO_0000019
1594,,,,8,,,CHEMBL617004,,Autocuration,F,,1,,H,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,106,BAO_0000019
1595,,,,9,,,CHEMBL617005,,Expert,F,,1,,D,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,,106,BAO_0000019
1596,485.0,,,9,,,CHEMBL616623,,Expert,F,,1,,D,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,CHO-K1,106,BAO_0000219
1597,449.0,,,8,,,CHEMBL616624,,Autocuration,F,,1,,H,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,CHO,106,BAO_0000219
1598,,,,8,,,CHEMBL883243,,Autocuration,B,,1,,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1599,,,,8,,,CHEMBL616625,,Autocuration,F,,1,,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,106,BAO_0000019
1600,449.0,,,8,,,CHEMBL616626,,Expert,F,,1,,H,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,CHO,106,BAO_0000219
1601,449.0,,,8,,,CHEMBL616627,,Autocuration,F,,1,,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,CHO,106,BAO_0000219
1602,449.0,,,8,,,CHEMBL616628,,Autocuration,F,,1,,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,CHO,106,BAO_0000219
1603,449.0,,,8,,,CHEMBL616629,,Autocuration,F,,1,,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,CHO,106,BAO_0000219
1604,449.0,,,8,,,CHEMBL616630,,Autocuration,F,,1,,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,CHO,106,BAO_0000219
1605,,,,8,,,CHEMBL616631,,Expert,F,,1,,H,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,106,BAO_0000019
1606,,,,8,,,CHEMBL616632,,Autocuration,F,,1,,H,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,106,BAO_0000019
1607,,,,9,,,CHEMBL616633,,Expert,B,,1,,D,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1608,449.0,,,8,,,CHEMBL616634,,Expert,B,,1,,H,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,CHO,106,BAO_0000219
1609,,,,8,,,CHEMBL616635,,Autocuration,B,,1,,H,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,106,BAO_0000357
1610,,,,9,,,CHEMBL885358,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1611,449.0,,,9,,,CHEMBL616636,,Expert,B,,1,,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,CHO,106,BAO_0000219
1612,449.0,,,8,,,CHEMBL616637,,Expert,B,,1,,H,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,CHO,106,BAO_0000219
1613,,,,8,,,CHEMBL616638,,Autocuration,B,,1,,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1614,449.0,,,8,,,CHEMBL616639,,Expert,B,,1,,H,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,CHO,106,BAO_0000219
1615,449.0,,,8,,,CHEMBL616640,,Expert,B,,1,,H,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,CHO,106,BAO_0000219
1616,449.0,,,8,,,CHEMBL616641,,Expert,B,,1,,H,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,CHO,106,BAO_0000219
1617,449.0,,,8,,,CHEMBL616642,,Expert,B,,1,,H,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,CHO,106,BAO_0000219
1618,449.0,,,8,,,CHEMBL616643,,Expert,B,,1,,H,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,CHO,106,BAO_0000219
1619,,,,8,,,CHEMBL616644,,Autocuration,B,,1,,H,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,106,BAO_0000357
1620,,,,8,,,CHEMBL616645,,Autocuration,B,,1,,H,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,106,BAO_0000357
1621,,,,8,,,CHEMBL616646,,Autocuration,F,,1,,H,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,105,BAO_0000019
1622,,,,8,,,CHEMBL616647,,Expert,F,,1,,H,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,105,BAO_0000019
1623,,,,8,,,CHEMBL616509,,Autocuration,B,,1,,H,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,105,BAO_0000357
1624,,,,8,,,CHEMBL616510,,Autocuration,B,,1,,H,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,105,BAO_0000357
1625,,,,8,,,CHEMBL616511,,Autocuration,B,,1,,H,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1626,,,,8,,,CHEMBL616512,,Expert,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,,105,BAO_0000357
1627,,,,8,,,CHEMBL616513,,Autocuration,B,,1,,H,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,,105,BAO_0000357
1628,,,2435.0,8,Striatum,,CHEMBL616514,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,105,BAO_0000019
1629,,,,8,,,CHEMBL616515,,Expert,B,,1,,H,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,,105,BAO_0000357
1630,,,,8,,,CHEMBL616516,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,,105,BAO_0000019
1631,,,,8,,,CHEMBL616517,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,105,BAO_0000357
1632,,,,8,,,CHEMBL616518,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,105,BAO_0000357
1633,,,,8,,,CHEMBL616519,,Autocuration,B,,1,,H,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,105,BAO_0000357
1634,,,,8,,,CHEMBL616520,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,105,BAO_0000357
1635,,,,8,,,CHEMBL616521,,Autocuration,B,,1,,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,,105,BAO_0000357
1636,,,,8,,,CHEMBL616522,,Autocuration,B,,1,,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,,105,BAO_0000357
1637,,,,8,,,CHEMBL884531,,Autocuration,B,,1,,H,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,105,BAO_0000357
1638,,,,8,,,CHEMBL616523,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,,105,BAO_0000357
1639,,,2435.0,8,Striatum,,CHEMBL616731,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,105,BAO_0000019
1640,,,,8,,,CHEMBL616732,,Autocuration,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,,105,BAO_0000019
1641,,,,8,,,CHEMBL616733,,Autocuration,B,,1,,H,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,,105,BAO_0000357
1642,,,,8,,,CHEMBL616734,,Autocuration,B,,1,,H,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,105,BAO_0000357
1643,,,,8,,,CHEMBL616735,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,,105,BAO_0000249
1644,,,,8,,,CHEMBL616736,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,,105,BAO_0000249
1645,,,,8,,,CHEMBL616737,,Expert,F,,1,,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105,BAO_0000019
1646,,,,8,,,CHEMBL616738,,Autocuration,B,,1,,H,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,,105,BAO_0000019
1647,,,,8,,,CHEMBL616739,,Expert,F,,1,,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105,BAO_0000019
1648,,,,8,,,CHEMBL616740,,Expert,F,,1,,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105,BAO_0000019
1649,,,,8,,,CHEMBL616741,,Expert,F,,1,,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105,BAO_0000019
1650,722.0,,,8,,,CHEMBL616742,,Autocuration,B,,1,,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,HEK293,105,BAO_0000219
1651,,,,9,,,CHEMBL616743,,Intermediate,B,,1,,D,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,,105570,BAO_0000019
1652,,,,9,,,CHEMBL616744,,Intermediate,B,,1,,D,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,,105570,BAO_0000019
1653,,,,9,,,CHEMBL616745,,Intermediate,F,,1,,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,,105570,BAO_0000019
1654,,,,9,,,CHEMBL616746,,Intermediate,F,,1,,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570,BAO_0000019
1655,,,,9,,,CHEMBL616747,,Intermediate,F,,1,,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,,105570,BAO_0000019
1656,,,,9,,,CHEMBL616748,,Intermediate,F,,1,,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,,105570,BAO_0000019
1657,,,,9,,,CHEMBL616648,,Intermediate,F,,1,,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,,105570,BAO_0000019
1658,,,,9,,,CHEMBL616649,,Intermediate,B,,1,,D,Binding affinity against 5-hydroxytryptamine 1D receptor,,,105570,BAO_0000357
1659,,,,9,,,CHEMBL616650,,Intermediate,B,,1,,D,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,,105570,BAO_0000357
1660,,,,9,,,CHEMBL616651,,Intermediate,F,,1,,D,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570,BAO_0000218
1661,,,,9,,,CHEMBL616652,,Intermediate,F,,1,,D,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570,BAO_0000218
1662,,,,9,,,CHEMBL616653,,Intermediate,F,,1,,D,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570,BAO_0000218
1663,,,,9,,,CHEMBL616654,,Intermediate,F,,1,,D,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,,105570,BAO_0000218
1664,,,,9,,,CHEMBL616655,,Intermediate,B,,1,,D,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,,105570,BAO_0000019
1665,,,,9,,,CHEMBL616656,,Intermediate,B,,1,,D,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,,105570,BAO_0000357
1666,,,,8,,,CHEMBL616657,,Autocuration,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,,105,BAO_0000019
1667,,,2435.0,9,Striatum,,CHEMBL616658,,Intermediate,B,,1,,D,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,,105570,BAO_0000357
1668,,,,9,,,CHEMBL616659,,Intermediate,B,,1,,D,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,,105570,BAO_0000357
1669,,,,8,,,CHEMBL616660,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor,,,51,BAO_0000357
1670,,,,8,,,CHEMBL616661,,Autocuration,B,,1,,H,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,106,BAO_0000357
1671,,,,8,,,CHEMBL616662,,Expert,F,,1,,H,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,105,BAO_0000019
1672,,,,8,,,CHEMBL616663,,Autocuration,F,,1,,H,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000019
1673,,,,8,,,CHEMBL616664,,Autocuration,F,,1,,H,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000019
1674,449.0,,,9,,,CHEMBL881820,,Expert,F,,1,,D,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,CHO,105,BAO_0000219
1675,449.0,,,8,,,CHEMBL616665,,Autocuration,F,,1,,H,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,CHO,105,BAO_0000219
1676,449.0,,,8,,,CHEMBL616666,,Expert,B,,1,,H,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,CHO,105,BAO_0000219
1677,449.0,,,8,,,CHEMBL616667,,Autocuration,B,,1,,H,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,CHO,105,BAO_0000219
1678,449.0,,,8,,,CHEMBL616668,,Expert,F,,1,,H,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,CHO,105,BAO_0000219
1679,449.0,,,9,,,CHEMBL616669,,Expert,F,,1,,D,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,CHO,105,BAO_0000219
1680,449.0,,,8,,,CHEMBL617040,,Expert,F,,1,,H,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,CHO,105,BAO_0000219
1681,449.0,,,8,,,CHEMBL617041,,Autocuration,F,,1,,H,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,CHO,105,BAO_0000219
1682,449.0,,,8,,,CHEMBL617042,,Expert,F,,1,,H,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,CHO,105,BAO_0000219
1683,449.0,,,8,,,CHEMBL617043,,Expert,F,,1,,H,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,CHO,105,BAO_0000219
1684,,,,8,,,CHEMBL617044,,Autocuration,F,,1,,H,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,105,BAO_0000019
1685,449.0,,,8,,,CHEMBL617045,,Expert,F,,1,,H,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,CHO,105,BAO_0000219
1686,449.0,,,9,,,CHEMBL617046,,Expert,F,,1,,D,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,CHO,105,BAO_0000219
1687,449.0,,,9,,,CHEMBL617047,,Expert,F,,1,,D,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,CHO,105,BAO_0000219
1688,,,,8,,,CHEMBL617048,,Expert,F,,1,,H,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,105,BAO_0000019
1689,,,,8,,,CHEMBL616897,,Autocuration,F,,1,,H,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,105,BAO_0000019
1690,,,,9,,,CHEMBL616898,,Expert,F,,1,,D,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,,105,BAO_0000019
1691,449.0,,,9,,,CHEMBL858201,,Expert,F,,1,,D,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,CHO,105,BAO_0000219
1692,,,,8,,,CHEMBL616899,,Autocuration,F,,1,,H,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,105,BAO_0000019
1693,,,,8,,In vitro,CHEMBL616900,,Autocuration,B,,1,,H,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,,105,BAO_0000219
1694,449.0,,,8,,,CHEMBL616901,,Expert,B,,1,,H,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,CHO,105,BAO_0000219
1695,,,,8,,,CHEMBL616902,,Autocuration,B,,1,,H,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,105,BAO_0000357
1696,449.0,,,9,,,CHEMBL616903,,Expert,B,,1,,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHO,105,BAO_0000219
1697,449.0,,,8,,,CHEMBL616904,,Expert,B,,1,,H,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,CHO,105,BAO_0000219
1698,,,,8,,,CHEMBL616905,,Autocuration,B,,1,,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1699,449.0,,,8,,,CHEMBL616906,,Expert,B,,1,,H,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,CHO,105,BAO_0000219
1700,449.0,,,8,,,CHEMBL616907,,Expert,B,,1,,H,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHO,105,BAO_0000219
1701,449.0,,,8,,,CHEMBL616908,,Expert,B,,1,,H,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHO,105,BAO_0000219
1702,449.0,,,9,,,CHEMBL616909,,Expert,B,,1,,D,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHO,105,BAO_0000219
1703,449.0,,,9,,,CHEMBL616910,,Expert,B,,1,,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHO,105,BAO_0000219
1704,449.0,,,8,,,CHEMBL616911,,Expert,B,,1,,H,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHO,105,BAO_0000219
1705,449.0,,,8,,,CHEMBL616912,,Expert,B,,1,,H,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHO,105,BAO_0000219
1706,,,,8,,,CHEMBL616913,,Autocuration,B,,1,,H,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,105,BAO_0000357
1707,449.0,,,9,,,CHEMBL616914,,Expert,B,,1,,D,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,CHO,105,BAO_0000219
1708,449.0,,,8,,,CHEMBL616915,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,CHO,105,BAO_0000219
1709,,,,8,,,CHEMBL616916,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,105,BAO_0000019
1710,,,,9,,,CHEMBL616917,,Expert,B,,1,,D,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1711,,,,8,,,CHEMBL616918,,Autocuration,B,,1,,H,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,105,BAO_0000357
1712,,,,8,,,CHEMBL616919,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,105,BAO_0000219
1713,,,,8,,,CHEMBL616920,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,105,BAO_0000357
1714,,,,8,,,CHEMBL872914,,Autocuration,B,,1,,H,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,105,BAO_0000357
1715,,,,8,,,CHEMBL616921,,Autocuration,B,,1,,H,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,105,BAO_0000357
1716,,,,8,,,CHEMBL616922,,Expert,B,,1,,H,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1717,,,,8,,,CHEMBL616923,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1718,,,,8,,,CHEMBL616924,,Expert,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1719,,,,8,,,CHEMBL875909,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,105,BAO_0000357
1720,,,,8,,,CHEMBL616925,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,105,BAO_0000357
1721,,,,8,,,CHEMBL616926,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,105,BAO_0000357
1722,,,,8,,,CHEMBL616927,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1723,485.0,,,8,,,CHEMBL616928,,Expert,F,,1,,H,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,CHO-K1,105,BAO_0000219
1724,,,,9,,In vitro,CHEMBL616929,,Expert,B,,1,,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,,105,BAO_0000219
1725,,,,9,,,CHEMBL616930,,Expert,B,,1,,D,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1726,,,,8,,,CHEMBL616931,,Expert,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000019
1727,,,,8,,,CHEMBL616932,,Autocuration,B,,1,,H,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,105,BAO_0000357
1728,,,,8,,,CHEMBL616933,,Expert,B,,1,,H,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1729,,,,9,,,CHEMBL616934,,Expert,B,,1,,D,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,,105,BAO_0000219
1730,,,,9,,,CHEMBL616935,,Expert,B,,1,,D,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1731,,,,8,,,CHEMBL616936,,Autocuration,B,,1,,H,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,105,BAO_0000357
1732,,,,9,,,CHEMBL616937,,Expert,B,,1,,D,Affinity for 5-hydroxytryptamine 1D receptor subtype,,,105,BAO_0000357
1733,,,,9,,,CHEMBL616938,,Expert,B,,1,,D,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1734,,,,8,,,CHEMBL616939,,Autocuration,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000019
1735,,,,8,,,CHEMBL616940,,Expert,B,,1,,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,105,BAO_0000019
1736,,,,9,,,CHEMBL616941,,Expert,B,,1,,D,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,,105,BAO_0000357
1737,485.0,,,8,,,CHEMBL616942,,Autocuration,B,,1,,H,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,CHO-K1,105,BAO_0000219
1738,485.0,,,8,,,CHEMBL616943,,Autocuration,B,,1,,H,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,CHO-K1,105,BAO_0000219
1739,449.0,,,4,,,CHEMBL616944,,Autocuration,B,,1,,H,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,CHO,104802,BAO_0000219
1740,,,,8,,,CHEMBL616945,,Autocuration,F,,1,,H,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,105,BAO_0000019
1741,,,,8,,,CHEMBL616946,,Autocuration,B,,1,,H,Binding activity radioligand.,,,105,BAO_0000357
1742,,,,8,,,CHEMBL616947,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,105,BAO_0000019
1743,485.0,,,8,,,CHEMBL616948,,Expert,B,,1,,H,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,CHO-K1,105,BAO_0000219
1744,,,,8,,,CHEMBL616851,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1745,,,,8,,,CHEMBL616852,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1746,,,,8,,,CHEMBL616853,,Autocuration,B,,1,,H,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1747,,,,9,,,CHEMBL616854,,Expert,B,,1,,D,Binding activity against human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1748,449.0,,,9,,,CHEMBL616855,,Expert,B,,1,,D,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,CHO,105,BAO_0000219
1749,449.0,,,8,,,CHEMBL616856,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,CHO,105,BAO_0000219
1750,449.0,,,8,,,CHEMBL616857,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHO,105,BAO_0000219
1751,,,,8,,,CHEMBL616858,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1752,449.0,,,8,,,CHEMBL616859,,Autocuration,B,,1,,H,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,CHO,105,BAO_0000219
1753,449.0,,,8,,,CHEMBL616860,,Autocuration,B,,1,,H,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,CHO,105,BAO_0000219
1754,722.0,,,8,,,CHEMBL616861,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,HEK293,105,BAO_0000219
1755,722.0,,,8,,,CHEMBL616541,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,HEK293,105,BAO_0000219
1756,722.0,,,8,,,CHEMBL616542,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,HEK293,105,BAO_0000219
1757,449.0,,,8,,,CHEMBL616543,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,CHO,105,BAO_0000219
1758,,,,9,,,CHEMBL616544,,Expert,B,,1,,D,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1759,449.0,,,8,,,CHEMBL616545,,Autocuration,B,,1,,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,CHO,105,BAO_0000219
1760,,,,8,,,CHEMBL616546,,Autocuration,B,,1,,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,105,BAO_0000357
1761,449.0,,,8,,,CHEMBL616547,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,CHO,105,BAO_0000219
1762,449.0,,,8,,,CHEMBL616548,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,CHO,105,BAO_0000219
1763,,,,8,,,CHEMBL616549,,Expert,F,,1,,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,105,BAO_0000019
1764,,,,8,,,CHEMBL616550,,Expert,F,,1,,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,105,BAO_0000019
1765,,,,8,,,CHEMBL857066,,Autocuration,B,,1,,H,Binding affinity against 5-HT2C receptor,,,108,BAO_0000357
1766,,,,8,,,CHEMBL616551,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor,,,108,BAO_0000357
1767,,,,8,,,CHEMBL616552,,Autocuration,B,,1,,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,10577,BAO_0000357
1768,,,,8,,,CHEMBL832876,,Autocuration,F,,1,,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,10577,BAO_0000019
1769,,,,8,,,CHEMBL616553,,Expert,B,,1,,H,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,10577,BAO_0000019
1770,,,,8,,,CHEMBL616554,,Autocuration,B,,1,,H,Binding affinity towards 5-HT1B was determined,,,10577,BAO_0000357
1771,,,,8,,,CHEMBL616555,,Expert,B,,1,,H,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,10577,BAO_0000019
1772,,,,8,,,CHEMBL616556,,Expert,B,,1,,H,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,10577,BAO_0000019
1773,,,,8,,,CHEMBL616557,,Autocuration,B,,1,,H,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,10577,BAO_0000019
1774,,,,8,,,CHEMBL616558,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,10577,BAO_0000019
1775,,,,9,,,CHEMBL616749,,Expert,B,,1,,D,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,,10577,BAO_0000019
1776,,,,8,,,CHEMBL616750,,Autocuration,B,,1,,H,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,10577,BAO_0000357
1777,,,,8,,,CHEMBL616751,,Autocuration,B,,1,,H,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,10577,BAO_0000357
1778,,,,8,,,CHEMBL616752,,Autocuration,B,,1,,H,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,10577,BAO_0000249
1779,,,2435.0,8,Striatum,,CHEMBL616753,,Autocuration,B,,1,,H,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,10577,BAO_0000019
1780,,,,9,,,CHEMBL616754,,Expert,B,,1,,D,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,,10577,BAO_0000357
1781,,,,8,,,CHEMBL616755,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,10577,BAO_0000019
1782,,,2435.0,8,Striatum,,CHEMBL616756,,Autocuration,B,,1,,H,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,10577,BAO_0000019
1783,,,2435.0,8,Striatum,,CHEMBL616757,,Autocuration,B,,1,,H,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,10577,BAO_0000019
1784,,,2435.0,8,Striatum,,CHEMBL616758,,Autocuration,B,,1,,H,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,10577,BAO_0000357
1785,,,,8,,,CHEMBL616759,,Autocuration,B,,1,,H,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,10577,BAO_0000249
1786,,,,8,,,CHEMBL616760,,Autocuration,B,,1,,H,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,10577,BAO_0000357
1787,,,2435.0,8,Striatum,,CHEMBL616761,,Autocuration,B,,1,,H,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,10577,BAO_0000019
1788,,,2435.0,8,Striatum,,CHEMBL616762,,Autocuration,B,,1,,H,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,10577,BAO_0000019
1789,,,,8,,,CHEMBL616763,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,10577,BAO_0000019
1790,,,,8,,,CHEMBL872909,,Expert,B,,1,,H,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,10577,BAO_0000357
1791,,,,8,,,CHEMBL616764,,Autocuration,B,,1,,H,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,10577,BAO_0000357
1792,,,,9,,,CHEMBL616765,,Expert,B,,1,,D,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,,10577,BAO_0000357
1793,,,2435.0,8,Striatum,,CHEMBL616766,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,10577,BAO_0000357
1794,,,2435.0,8,Striatum,,CHEMBL616767,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,10577,BAO_0000357
1795,,,,8,,,CHEMBL616768,,Autocuration,B,,1,,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,10577,BAO_0000357
1796,,,,8,,,CHEMBL616769,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,10577,BAO_0000357
1797,,,,8,,,CHEMBL616770,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,10577,BAO_0000019
1798,,,,8,,,CHEMBL616771,,Autocuration,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,10577,BAO_0000019
1799,,,2435.0,8,Striatum,,CHEMBL616772,,Autocuration,B,,1,,H,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,10577,BAO_0000019
1800,,,,8,,,CHEMBL616773,,Expert,B,,1,,H,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,10577,BAO_0000019
1801,,,,8,,,CHEMBL616774,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,10577,BAO_0000019
1802,,,,8,,,CHEMBL616775,,Autocuration,B,,1,,H,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,10577,BAO_0000357
1803,,,,8,,,CHEMBL616776,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,10577,BAO_0000249
1804,,,,8,,,CHEMBL616777,,Autocuration,B,,1,,H,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,10577,BAO_0000357
1805,,,,8,,,CHEMBL616778,,Autocuration,B,,1,,H,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,10577,BAO_0000357
1806,,,,9,,,CHEMBL616779,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,,10577,BAO_0000249
1807,,,,9,,,CHEMBL616780,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,10577,BAO_0000357
1808,,,,8,,,CHEMBL616781,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,10577,BAO_0000019
1809,,,,8,,,CHEMBL616782,,Autocuration,B,,1,,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,10577,BAO_0000357
1810,,,,8,,,CHEMBL616783,,Autocuration,B,,1,,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,10577,BAO_0000357
1811,,,2435.0,8,Striatum,,CHEMBL616784,,Expert,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,10577,BAO_0000019
1812,,,,8,,,CHEMBL616785,,Autocuration,B,,1,,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,10577,BAO_0000357
1813,,,955.0,8,Brain,,CHEMBL857067,,Autocuration,B,,1,,H,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,10577,BAO_0000249
1814,,,,8,,,CHEMBL616786,,Autocuration,B,,1,,H,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,10577,BAO_0000019
1815,,,955.0,8,Brain,,CHEMBL616787,,Autocuration,B,,1,,H,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,10577,BAO_0000249
1816,,,,8,,,CHEMBL616788,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,10577,BAO_0000357
1817,,,,8,,,CHEMBL616789,,Autocuration,B,,1,,H,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,10577,BAO_0000357
1818,,,,9,,,CHEMBL616790,,Expert,B,,1,,D,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,,10577,BAO_0000019
1819,,,,8,,,CHEMBL616791,,Expert,B,,1,,H,Binding affinity at 5-hydroxytryptamine 1B receptor,,,10577,BAO_0000357
1820,,,,8,,,CHEMBL616792,,Autocuration,B,,1,,H,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,10577,BAO_0000019
1821,,,,9,,,CHEMBL616793,,Expert,B,,1,,D,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,,10577,BAO_0000249
1822,,,,8,,,CHEMBL616794,,Autocuration,B,,1,,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,10577,BAO_0000357
1823,,,,8,,,CHEMBL616795,,Autocuration,B,,1,,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,10577,BAO_0000357
1824,,,,4,,,CHEMBL616796,,Autocuration,B,,1,,H,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,104686,BAO_0000019
1825,,,,8,,,CHEMBL616797,,Autocuration,B,,1,,H,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1826,,,,8,,,CHEMBL616798,,Autocuration,B,,1,Brain membranes,H,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,106,BAO_0000249
1827,,,,8,,,CHEMBL616799,,Autocuration,B,,1,,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,106,BAO_0000357
1828,,,,8,,,CHEMBL616800,,Autocuration,B,,1,,H,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,106,BAO_0000357
1829,,,,8,,,CHEMBL616801,,Autocuration,B,,1,,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1830,,,,8,,,CHEMBL616802,,Autocuration,B,,1,,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,106,BAO_0000357
1831,,,,8,,,CHEMBL616803,,Autocuration,B,,1,,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,106,BAO_0000357
1832,,,,8,,,CHEMBL857068,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,106,BAO_0000357
1833,,,,8,,,CHEMBL616804,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,106,BAO_0000357
1834,,,,8,,,CHEMBL616805,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,106,BAO_0000357
1835,,,,8,,,CHEMBL616806,,Autocuration,B,,1,,H,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1836,,,,8,,,CHEMBL616807,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1B receptor,,,106,BAO_0000357
1837,,,,8,,,CHEMBL616808,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,106,BAO_0000357
1838,,,,8,,,CHEMBL616809,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,106,BAO_0000357
1839,,,,8,,,CHEMBL616810,,Autocuration,B,,1,,H,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,106,BAO_0000357
1840,,,,4,,,CHEMBL616811,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,104802,BAO_0000224
1841,,,,8,,,CHEMBL616812,,Autocuration,B,,1,,H,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,,108,BAO_0000357
1842,,,,8,,,CHEMBL616813,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,108,BAO_0000357
1843,,,,8,,,CHEMBL616814,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,,108,BAO_0000357
1844,,,,8,,,CHEMBL616815,,Autocuration,B,,1,,H,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,108,BAO_0000357
1845,,,,8,,,CHEMBL616816,,Autocuration,B,,1,,H,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,108,BAO_0000357
1846,,,,8,,,CHEMBL616817,,Autocuration,B,,1,,H,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,,108,BAO_0000357
1847,,,,8,,,CHEMBL616818,,Autocuration,B,,1,,H,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,,108,BAO_0000357
1848,,,,8,,,CHEMBL616819,,Expert,B,,1,,H,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,,108,BAO_0000357
1849,,,,8,,,CHEMBL616820,,Expert,B,,1,,H,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,,108,BAO_0000357
1850,,,,8,,,CHEMBL616821,,Expert,B,,1,,H,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,,108,BAO_0000019
1851,,,,8,,,CHEMBL616822,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,,108,BAO_0000357
1852,,,,8,,,CHEMBL616823,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,108,BAO_0000019
1853,,,,9,,,CHEMBL616824,,Autocuration,B,,1,,D,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,,12689,BAO_0000357
1854,,,,9,,,CHEMBL616825,,Autocuration,B,,1,,D,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,12689,BAO_0000357
1855,,,,9,,,CHEMBL616826,,Autocuration,B,,1,,D,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,12689,BAO_0000357
1856,,,,9,,,CHEMBL616827,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,,12689,BAO_0000019
1857,,,,9,,,CHEMBL616828,,Autocuration,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,,12689,BAO_0000357
1858,,,,9,,,CHEMBL616829,,Autocuration,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,12689,BAO_0000357
1859,,,,9,,,CHEMBL616830,,Autocuration,B,,1,,D,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,,12689,BAO_0000019
1860,,,,9,,,CHEMBL616831,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 1C receptor,,,12689,BAO_0000357
1861,,,,9,,,CHEMBL616832,,Autocuration,B,,1,,D,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689,BAO_0000019
1862,,,,9,,,CHEMBL616833,,Autocuration,B,,1,,D,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689,BAO_0000019
1863,,,,9,,,CHEMBL616834,,Expert,B,,1,,D,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689,BAO_0000019
1864,,,,9,,,CHEMBL829595,,Autocuration,B,,1,,D,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689,BAO_0000019
1865,,,,9,,,CHEMBL616835,,Autocuration,B,,1,,D,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,,12689,BAO_0000357
1866,,,,9,,,CHEMBL872910,,Autocuration,B,,1,,D,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,,12689,BAO_0000249
1867,,,,8,,,CHEMBL616836,,Expert,B,,1,,H,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,12689,BAO_0000357
1868,,,,9,,,CHEMBL616837,,Autocuration,B,,1,,D,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,,12689,BAO_0000357
1869,,,,9,,,CHEMBL616466,,Autocuration,B,,1,,D,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,,12689,BAO_0000019
1870,722.0,,,9,,,CHEMBL616467,,Autocuration,B,,1,,D,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,HEK293,12689,BAO_0000219
1871,,,,8,,,CHEMBL616468,,Autocuration,B,,1,,H,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,108,BAO_0000357
1872,,,,8,,,CHEMBL616469,,Autocuration,B,,1,,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,108,BAO_0000357
1873,,,,8,,,CHEMBL616470,,Autocuration,B,,1,,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,108,BAO_0000357
1874,,,,8,,,CHEMBL616471,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1C receptor,,,12689,BAO_0000357
1875,,,,8,,,CHEMBL616472,,Autocuration,B,,1,,H,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,12689,BAO_0000357
1876,,,,8,,,CHEMBL616473,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1C receptor,,,12689,BAO_0000357
1877,,,,8,,,CHEMBL616474,,Autocuration,B,,1,,H,Binding affinity against serotonergic 5-HT1c receptor,,,12689,BAO_0000357
1878,,,,8,,,CHEMBL616475,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,12689,BAO_0000357
1879,,,,8,,,CHEMBL616476,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,12689,BAO_0000357
1880,,,,8,,,CHEMBL616477,,Autocuration,B,,1,,H,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,105,BAO_0000019
1881,,,,4,,,CHEMBL616478,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,104686,BAO_0000224
1882,,,,4,,,CHEMBL616479,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,104686,BAO_0000224
1883,,,,4,,,CHEMBL616480,,Autocuration,B,,1,,H,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,104686,BAO_0000019
1884,,,,5,,,CHEMBL616481,,Autocuration,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,,104686,BAO_0000019
1885,,,,5,,,CHEMBL616482,,Autocuration,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,,104686,BAO_0000249
1886,,,955.0,5,Brain,,CHEMBL884713,,Autocuration,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,,104686,BAO_0000221
1887,,,,4,,,CHEMBL616483,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,104686,BAO_0000224
1888,,,,4,,,CHEMBL616484,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,104686,BAO_0000224
1889,,,,4,,,CHEMBL616485,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,104686,BAO_0000019
1890,,,,4,,,CHEMBL616486,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,104686,BAO_0000224
1891,,,,4,,,CHEMBL616487,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,104686,BAO_0000224
1892,,,,4,,,CHEMBL616488,,Autocuration,B,,1,,H,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,104686,BAO_0000224
1893,,,,4,,,CHEMBL616489,,Autocuration,B,,1,,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686,BAO_0000019
1894,,,,4,,,CHEMBL616490,,Autocuration,B,,1,,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686,BAO_0000019
1895,,,,4,,,CHEMBL616491,,Autocuration,B,,1,,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,104686,BAO_0000019
1896,,,,4,,,CHEMBL616492,,Autocuration,B,,1,,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,104686,BAO_0000019
1897,,,,4,,,CHEMBL616493,,Autocuration,B,,1,,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686,BAO_0000019
1898,,,,4,,,CHEMBL616494,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,104686,BAO_0000019
1899,,,,4,,,CHEMBL616495,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,104686,BAO_0000019
1900,,,,4,,,CHEMBL616496,,Autocuration,B,,1,,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,104686,BAO_0000019
1901,,,,4,,,CHEMBL616497,,Autocuration,B,,1,,H,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686,BAO_0000019
1902,,,,4,,,CHEMBL616498,,Autocuration,B,,1,,H,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686,BAO_0000019
1903,,,,4,,,CHEMBL616499,,Autocuration,B,,1,,H,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,104686,BAO_0000019
1904,,,,4,,,CHEMBL616500,,Autocuration,B,,1,,H,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,104686,BAO_0000019
1905,,,955.0,5,Brain,,CHEMBL616501,,Autocuration,B,,1,,D,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,104686,BAO_0000221
1906,,,955.0,4,Brain,,CHEMBL616502,,Autocuration,B,,1,,H,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,104686,BAO_0000221
1907,,,,4,,,CHEMBL884529,,Autocuration,B,,1,Membranes,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,104686,BAO_0000249
1908,,,,4,,,CHEMBL616503,,Autocuration,B,,1,Membranes,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,104686,BAO_0000249
1909,,,,4,,,CHEMBL616964,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
1910,,,,4,,,CHEMBL616965,,Autocuration,B,,1,Membranes,H,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,104686,BAO_0000249
1911,,,,4,,,CHEMBL616966,,Autocuration,B,,1,,H,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,104686,BAO_0000224
1912,,,,4,,,CHEMBL616967,,Autocuration,B,,1,,H,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,104686,BAO_0000224
1913,,,,5,,,CHEMBL616968,,Autocuration,B,,1,,D,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
1914,,,,4,,,CHEMBL616969,,Autocuration,B,,1,,H,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,104686,BAO_0000224
1915,,,,4,,,CHEMBL884530,,Autocuration,B,,1,,H,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,104686,BAO_0000019
1916,,,,4,,,CHEMBL616970,,Autocuration,B,,1,,H,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
1917,,,,4,,,CHEMBL616971,,Autocuration,B,,1,,H,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,104686,BAO_0000224
1918,,,,4,,,CHEMBL616972,,Autocuration,B,,1,,H,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,104686,BAO_0000224
1919,,,,4,,,CHEMBL616973,,Autocuration,B,,1,,H,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,104686,BAO_0000224
1920,,,,4,,,CHEMBL616974,,Autocuration,B,,1,,H,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,104686,BAO_0000224
1921,,,,4,,,CHEMBL616975,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,104686,BAO_0000019
1922,,,,4,,,CHEMBL616976,,Autocuration,B,,1,,H,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,104686,BAO_0000019
1923,,,,4,,,CHEMBL616977,,Autocuration,B,,1,,H,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,104686,BAO_0000224
1924,,,,4,,,CHEMBL616978,,Autocuration,B,,1,,H,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,104686,BAO_0000224
1925,,,,4,,,CHEMBL616979,,Autocuration,B,,1,,H,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,104686,BAO_0000224
1926,,,,4,,,CHEMBL616980,,Autocuration,B,,1,,H,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
1927,,,,4,,,CHEMBL616981,,Autocuration,B,,1,Membranes,H,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,104686,BAO_0000249
1928,,,,4,,,CHEMBL616982,,Autocuration,B,,1,Membranes,H,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,104686,BAO_0000249
1929,,,,4,,,CHEMBL616983,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,104686,BAO_0000224
1930,,,,4,,,CHEMBL616984,,Autocuration,B,,1,,H,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,104686,BAO_0000019
1931,,,,5,,,CHEMBL616985,,Autocuration,B,,1,,D,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
1932,,,,4,,,CHEMBL616986,,Autocuration,B,,1,,H,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,104686,BAO_0000224
1933,,,,4,,,CHEMBL616987,,Autocuration,B,,1,,H,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,104686,BAO_0000224
1934,,,,4,,,CHEMBL616988,,Autocuration,B,,1,,H,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,104686,BAO_0000019
1935,,,,4,,,CHEMBL617243,,Autocuration,B,,1,,H,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,104686,BAO_0000019
1936,,,,4,,,CHEMBL617244,,Autocuration,B,,1,,H,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,104686,BAO_0000019
1937,485.0,,,5,,,CHEMBL617245,,Autocuration,B,,1,,D,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHO-K1,104686,BAO_0000219
1938,,,,4,,,CHEMBL617246,,Autocuration,B,,1,Membranes,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,104686,BAO_0000249
1939,,,,4,,,CHEMBL617546,,Autocuration,B,,1,,H,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,104686,BAO_0000224
1940,,,,4,,,CHEMBL617547,,Autocuration,B,,1,Brain membranes,H,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,104686,BAO_0000249
1941,,,,4,,In vitro,CHEMBL617548,,Autocuration,B,,1,,H,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,104686,BAO_0000219
1942,,,,4,,,CHEMBL617549,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
1943,,,,4,,,CHEMBL617550,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,104686,BAO_0000224
1944,,,,4,,,CHEMBL617551,,Autocuration,B,,1,,H,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,104686,BAO_0000224
1945,,,,4,,,CHEMBL617552,,Autocuration,B,,1,Membranes,H,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,104686,BAO_0000249
1946,,,,4,,,CHEMBL617553,,Autocuration,B,,1,Membranes,H,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,104686,BAO_0000249
1947,,,1515.0,4,Thoracic aorta,,CHEMBL617554,,Autocuration,F,,1,,H,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,104686,BAO_0000019
1948,,,,4,,,CHEMBL617555,,Autocuration,B,,1,,H,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000019
1949,,,,4,,,CHEMBL617556,,Autocuration,B,,1,,H,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,104686,BAO_0000224
1950,,,,8,,,CHEMBL617557,,Autocuration,B,,1,,H,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,10624,BAO_0000357
1951,,,,8,,,CHEMBL617558,,Autocuration,B,,1,,H,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,10624,BAO_0000357
1952,,,,8,,,CHEMBL617559,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,17106,BAO_0000357
1953,,,,9,,,CHEMBL617560,,Expert,B,,1,,D,Binding affinity for 5-hydroxytryptamine 1D receptor,,,17106,BAO_0000357
1954,,,,8,,,CHEMBL617561,,Autocuration,B,,1,,H,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,17106,BAO_0000249
1955,,,,8,,,CHEMBL617562,,Autocuration,B,,1,,H,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,17106,BAO_0000249
1956,,,2435.0,8,Striatum,,CHEMBL617563,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,17106,BAO_0000357
1957,,,,8,,,CHEMBL617564,,Autocuration,F,,1,,H,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,17106,BAO_0000019
1958,,,,8,,,CHEMBL617565,,Expert,B,,1,,H,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,17106,BAO_0000019
1959,,,,8,,,CHEMBL856076,,Autocuration,B,,1,,H,Binding activity radioligand.,,,17106,BAO_0000357
1960,,,,8,,,CHEMBL617566,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,17106,BAO_0000019
1961,,,,8,,,CHEMBL875911,,Expert,B,,1,,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,17106,BAO_0000019
1962,,,,8,,,CHEMBL617567,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,17106,BAO_0000019
1963,,,,8,,,CHEMBL617568,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,17106,BAO_0000249
1964,,,,8,,,CHEMBL617569,,Expert,B,,1,,H,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,17106,BAO_0000019
1965,,,,8,,,CHEMBL617570,,Expert,B,,1,,H,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,17106,BAO_0000249
1966,,,,8,,,CHEMBL617571,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,17106,BAO_0000357
1967,,,,8,,,CHEMBL617572,,Autocuration,B,,1,,H,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,,105,BAO_0000357
1968,,,,8,,,CHEMBL617573,,Expert,B,,1,,H,The compound was tested for intrinsic activity against 5-HT1D receptor,,,105,BAO_0000357
1969,,,,8,,,CHEMBL617574,,Autocuration,B,,1,,H,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,105,BAO_0000019
1970,,,,8,,,CHEMBL617575,,Expert,B,,1,,H,The compound was tested for binding affinity against 5-HT1D receptor,,,105,BAO_0000357
1971,,,,8,,,CHEMBL617576,,Autocuration,B,,1,,H,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,10578,BAO_0000357
1972,,,,8,,,CHEMBL617577,,Autocuration,F,,1,,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,10578,BAO_0000019
1973,,,,8,,,CHEMBL617578,,Autocuration,F,,1,,H,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,10578,BAO_0000019
1974,,,,8,,,CHEMBL617579,,Autocuration,B,,1,,H,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,10578,BAO_0000357
1975,,,,8,,,CHEMBL617580,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,10578,BAO_0000019
1976,,,,8,,,CHEMBL617581,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,10578,BAO_0000249
1977,,,,8,,,CHEMBL617582,,Autocuration,B,,1,,H,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,10578,BAO_0000357
1978,,,,8,,,CHEMBL617583,,Expert,B,,1,,H,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,10578,BAO_0000019
1979,,,,8,,,CHEMBL617584,,Autocuration,B,,1,,H,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,105,BAO_0000357
1980,,,,8,,,CHEMBL617585,,Autocuration,B,,1,,H,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1981,,,,8,,,CHEMBL875912,,Autocuration,B,,1,,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,105,BAO_0000357
1982,,,,8,,,CHEMBL617586,,Autocuration,B,,1,,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1983,,,,8,,,CHEMBL617587,,Autocuration,B,,1,,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,105,BAO_0000357
1984,,,,8,,,CHEMBL617588,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,105,BAO_0000357
1985,,,,8,,,CHEMBL857980,,Autocuration,B,,1,,H,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1986,,,,8,,,CHEMBL617589,,Autocuration,B,,1,,H,Tested against 5-hydroxytryptamine 1D receptor,,,105,BAO_0000357
1987,,,,8,,,CHEMBL617590,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,105,BAO_0000357
1988,722.0,,,8,,,CHEMBL617591,,Autocuration,B,,1,,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,HEK293,105,BAO_0000219
1989,,,,9,,,CHEMBL617592,,Expert,B,,1,,D,Binding affinity against 5-Hydroxytryptamine 1D receptor,,,105,BAO_0000357
1990,,,,8,,,CHEMBL617593,,Autocuration,B,,1,,H,,,,105,BAO_0000357
1991,485.0,,,8,,,CHEMBL617594,,Autocuration,B,,1,,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHO-K1,106,BAO_0000219
1992,485.0,,,8,,,CHEMBL617595,,Autocuration,B,,1,,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHO-K1,105,BAO_0000219
1993,722.0,,,8,,,CHEMBL617596,,Autocuration,B,,1,,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,HEK293,105,BAO_0000219
1994,722.0,,,8,,,CHEMBL617597,,Autocuration,B,,1,,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,HEK293,105,BAO_0000219
1995,,,,8,,,CHEMBL617598,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,105,BAO_0000019
1996,,,,8,,,CHEMBL872916,,Autocuration,B,,1,,H,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,105,BAO_0000357
1997,,,,8,,,CHEMBL617599,,Expert,B,,1,,H,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,105,BAO_0000357
1998,,,,8,,,CHEMBL617091,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,105,BAO_0000357
1999,485.0,,,8,,,CHEMBL617092,,Expert,B,,1,,H,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,CHO-K1,105,BAO_0000219
2000,485.0,,,8,,,CHEMBL617093,,Autocuration,B,,1,,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHO-K1,105,BAO_0000219
2001,,,,8,,,CHEMBL617094,,Autocuration,F,,1,,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,105,BAO_0000019
2002,,,,8,,,CHEMBL617095,,Autocuration,F,,1,,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,105,BAO_0000019
2003,,,,8,,,CHEMBL617096,,Autocuration,F,,1,,H,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,105,BAO_0000019
2004,,,,8,,,CHEMBL617097,,Autocuration,F,,1,,H,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,105,BAO_0000019
2005,,,,8,,,CHEMBL617098,,Autocuration,F,,1,,H,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,105,BAO_0000019
2006,,,,8,,,CHEMBL617301,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,105,BAO_0000357
2007,,,,8,,,CHEMBL617302,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,105,BAO_0000357
2008,,,,8,,,CHEMBL617303,,Autocuration,B,,1,,H,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,105,BAO_0000357
2009,,,,8,,,CHEMBL617304,,Expert,B,,1,,H,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,105,BAO_0000357
2010,449.0,,,8,,,CHEMBL617305,,Expert,B,,1,,H,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,CHO,105,BAO_0000219
2011,,,,9,,,CHEMBL617306,,Autocuration,B,,1,,D,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,,105,BAO_0000219
2012,,,,8,,,CHEMBL617307,,Autocuration,B,,1,,H,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,17106,BAO_0000357
2013,,,,8,,,CHEMBL617308,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,105,BAO_0000019
2014,,,,8,,,CHEMBL617309,,Autocuration,B,,1,,H,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,105,BAO_0000357
2015,,,,8,,,CHEMBL617310,,Autocuration,B,,1,,H,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,105,BAO_0000357
2016,,,,8,,,CHEMBL617311,,Autocuration,B,,1,,H,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,105,BAO_0000357
2017,,,,8,,,CHEMBL617312,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,105,BAO_0000357
2018,,,,8,,,CHEMBL617313,,Autocuration,B,,1,,H,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,105,BAO_0000357
2019,,,,8,,,CHEMBL617314,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,105,BAO_0000357
2020,,,,8,,,CHEMBL617315,,Autocuration,F,,1,,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,106,BAO_0000019
2021,722.0,,,8,,,CHEMBL617316,,Autocuration,B,,1,,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,HEK293,106,BAO_0000219
2022,722.0,,,8,,,CHEMBL617317,,Autocuration,B,,1,,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,HEK293,106,BAO_0000219
2023,449.0,,,8,,,CHEMBL617318,,Autocuration,B,,1,,H,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,CHO,106,BAO_0000219
2024,,,,8,,,CHEMBL617319,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,106,BAO_0000019
2025,,,,9,,,CHEMBL617320,,Expert,B,,1,,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,106,BAO_0000357
2026,,,,9,,,CHEMBL617321,,Expert,B,,1,,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,106,BAO_0000357
2027,,,,9,,,CHEMBL617322,,Expert,B,,1,,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,106,BAO_0000357
2028,,,,8,,,CHEMBL616862,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,106,BAO_0000357
2029,,,,8,,,CHEMBL616863,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,106,BAO_0000357
2030,449.0,,,8,,,CHEMBL616864,,Autocuration,B,,1,,H,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,CHO,106,BAO_0000219
2031,485.0,,,8,,,CHEMBL616865,,Autocuration,B,,1,,H,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,CHO-K1,106,BAO_0000219
2032,485.0,,,8,,,CHEMBL616866,,Autocuration,B,,1,,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,CHO-K1,106,BAO_0000219
2033,,,,8,,,CHEMBL616867,,Autocuration,F,,1,,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,106,BAO_0000019
2034,485.0,,,8,,,CHEMBL616868,,Expert,B,,1,,H,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,CHO-K1,106,BAO_0000219
2035,,,,8,,,CHEMBL616869,,Expert,B,,1,,H,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,105,BAO_0000357
2036,449.0,,,8,,,CHEMBL616870,,Expert,B,,1,,H,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,CHO,106,BAO_0000219
2037,485.0,,,8,,,CHEMBL616871,,Autocuration,F,,1,,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,CHO-K1,105,BAO_0000219
2038,485.0,,,8,,,CHEMBL616872,,Autocuration,F,,1,,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,CHO-K1,105,BAO_0000219
2039,485.0,,,8,,,CHEMBL616873,,Autocuration,F,,1,,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,CHO-K1,105,BAO_0000219
2040,485.0,,,8,,,CHEMBL616838,,Autocuration,F,,1,,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,CHO-K1,105,BAO_0000219
2041,,,,8,,,CHEMBL616839,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,105,BAO_0000357
2042,,,,8,,,CHEMBL616840,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,,106,BAO_0000019
2043,,,,8,,,CHEMBL616841,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,105,BAO_0000357
2044,,,,8,,,CHEMBL616842,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,105,BAO_0000357
2045,,,,8,,,CHEMBL857976,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,105,BAO_0000357
2046,449.0,,,8,,,CHEMBL616843,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,CHO,10618,BAO_0000219
2047,,,,9,,,CHEMBL616844,,Expert,B,,1,,D,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,,10618,BAO_0000357
2048,,,,8,,,CHEMBL616845,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,10618,BAO_0000357
2049,,,,9,,,CHEMBL616846,,Expert,B,,1,,D,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,,10618,BAO_0000357
2050,,,,8,,,CHEMBL616847,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,10618,BAO_0000357
2051,,,,8,,,CHEMBL616848,,Autocuration,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,10618,BAO_0000019
2052,,,,8,,,CHEMBL616849,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,10618,BAO_0000357
2053,,,,8,,,CHEMBL872911,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,10618,BAO_0000357
2054,,,,8,,,CHEMBL616850,,Autocuration,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,10618,BAO_0000019
2055,449.0,,,9,,,CHEMBL616699,,Expert,B,,1,,D,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,CHO,10618,BAO_0000219
2056,,,,8,,,CHEMBL616700,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,10618,BAO_0000357
2057,449.0,,,8,,,CHEMBL616701,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHO,10618,BAO_0000219
2058,449.0,,,8,,,CHEMBL616702,,Autocuration,B,,1,,H,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,CHO,10618,BAO_0000219
2059,449.0,,,8,,,CHEMBL616703,,Autocuration,B,,1,,H,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,CHO,10618,BAO_0000219
2060,,,,8,,,CHEMBL616704,,Autocuration,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,10618,BAO_0000357
2061,449.0,,,8,,,CHEMBL616705,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,CHO,10618,BAO_0000219
2062,,,,8,,,CHEMBL616706,,Autocuration,B,,1,,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,10618,BAO_0000357
2063,449.0,,,8,,,CHEMBL616707,,Autocuration,B,,1,,H,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,CHO,10618,BAO_0000219
2064,,,,8,,,CHEMBL616708,,Autocuration,B,,1,,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,10618,BAO_0000357
2065,,,,8,,,CHEMBL616709,,Autocuration,B,,1,,H,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,10618,BAO_0000357
2066,449.0,,,8,,,CHEMBL616710,,Autocuration,B,,1,,H,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,CHO,10618,BAO_0000219
2067,449.0,,,8,,,CHEMBL616711,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,CHO,10618,BAO_0000219
2068,449.0,,,8,,,CHEMBL616712,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,CHO,10618,BAO_0000219
2069,,,,8,,,CHEMBL616713,,Autocuration,B,,1,,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,10618,BAO_0000357
2070,,,,8,,,CHEMBL616714,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,10618,BAO_0000357
2071,,,,8,,,CHEMBL616715,,Autocuration,B,,1,,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,10618,BAO_0000357
2072,,,,8,,,CHEMBL616716,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,10618,BAO_0000357
2073,,,,8,,,CHEMBL616717,,Autocuration,F,,1,,H,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,279,BAO_0000019
2074,,,,8,,,CHEMBL616718,,Expert,F,,1,,H,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,279,BAO_0000019
2075,,,,8,,,CHEMBL875905,,Autocuration,F,,1,,H,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,279,BAO_0000019
2076,,,,8,,,CHEMBL616719,,Autocuration,F,,1,,H,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,279,BAO_0000019
2077,,,,8,,,CHEMBL616720,,Expert,F,,1,,H,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,279,BAO_0000019
2078,,,,8,,,CHEMBL616721,,Autocuration,B,,1,,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,279,BAO_0000357
2079,449.0,,,8,,,CHEMBL616722,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,CHO,279,BAO_0000219
2080,,,,8,,,CHEMBL616723,,Autocuration,B,,1,,H,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,279,BAO_0000357
2081,449.0,,,8,,,CHEMBL616724,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,CHO,279,BAO_0000219
2082,,,,8,,,CHEMBL616725,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,279,BAO_0000357
2083,,,,8,,,CHEMBL616726,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,279,BAO_0000357
2084,,,,8,,,CHEMBL616727,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,279,BAO_0000357
2085,,,,8,,,CHEMBL616728,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,279,BAO_0000357
2086,,,,8,,,CHEMBL616729,,Autocuration,B,,1,,H,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,279,BAO_0000357
2087,,,,8,,,CHEMBL616730,,Expert,B,,1,,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,279,BAO_0000019
2088,,,,8,,,CHEMBL617125,,Autocuration,B,,1,,H,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,279,BAO_0000357
2089,,,,8,,,CHEMBL857977,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,279,BAO_0000357
2090,449.0,,,8,,,CHEMBL617126,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHO,279,BAO_0000219
2091,449.0,,,8,,,CHEMBL617127,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,CHO,279,BAO_0000219
2092,,,,8,,,CHEMBL617128,,Autocuration,B,,1,,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,279,BAO_0000357
2093,449.0,,,8,,,CHEMBL617129,,Autocuration,B,,1,,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,CHO,279,BAO_0000219
2094,,,,8,,,CHEMBL617130,,Autocuration,B,,1,,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,279,BAO_0000357
2095,449.0,,,8,,,CHEMBL617131,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,CHO,279,BAO_0000219
2096,449.0,,,8,,,CHEMBL617132,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,CHO,279,BAO_0000219
2097,449.0,,,8,,,CHEMBL617133,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,CHO,279,BAO_0000219
2098,,,,8,,,CHEMBL617134,,Autocuration,B,,1,,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,279,BAO_0000357
2099,,,,8,,,CHEMBL617135,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,279,BAO_0000357
2100,,,,8,,,CHEMBL617136,,Autocuration,B,,1,,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,279,BAO_0000357
2101,,,,4,,,CHEMBL617137,,Autocuration,B,,1,,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,104686,BAO_0000019
2102,,,,4,,,CHEMBL617138,,Autocuration,B,,1,,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,104686,BAO_0000019
2103,,,,4,,,CHEMBL617139,,Autocuration,B,,1,,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,104686,BAO_0000019
2104,,,,8,,,CHEMBL617140,,Autocuration,B,,1,,H,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000019
2105,,,,4,,In vivo,CHEMBL617141,,Autocuration,F,,1,,H,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,,104686,BAO_0000218
2106,,,,4,,,CHEMBL858112,,Autocuration,F,,1,,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686,BAO_0000019
2107,,,,8,,,CHEMBL617142,,Intermediate,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,17005,BAO_0000019
2108,,,,0,,,CHEMBL617143,,Autocuration,B,,1,,U,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,,22226,BAO_0000019
2109,,,,0,,,CHEMBL617144,,Autocuration,B,,1,,U,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,,22226,BAO_0000019
2110,,,,0,,,CHEMBL617145,,Autocuration,B,,1,,U,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,,22226,BAO_0000019
2111,,,,0,,,CHEMBL617146,,Autocuration,B,,1,,U,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,22226,BAO_0000019
2112,,,,4,,,CHEMBL617147,,Autocuration,B,,1,,H,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,,104784,BAO_0000019
2113,,,,4,,,CHEMBL617148,,Autocuration,B,,1,,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,,104784,BAO_0000019
2114,,,,4,,,CHEMBL617149,,Autocuration,B,,1,,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,,104784,BAO_0000019
2115,,,,4,,,CHEMBL617150,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,104784,BAO_0000224
2116,,,,4,,,CHEMBL617151,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,104784,BAO_0000224
2117,,,,4,,,CHEMBL617201,,Autocuration,B,,1,,H,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,104784,BAO_0000224
2118,,,,8,,,CHEMBL617202,,Autocuration,B,,1,,H,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,10209,BAO_0000357
2119,,,,4,,In vivo,CHEMBL617203,,Autocuration,B,,1,,H,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,104826,BAO_0000218
2120,,,,4,,,CHEMBL617204,,Autocuration,B,,1,,H,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,104826,BAO_0000019
2121,,,,4,,,CHEMBL617205,,Autocuration,B,,1,,H,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,104826,BAO_0000224
2122,,,,5,,,CHEMBL617206,,Autocuration,B,,1,,D,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,,104826,BAO_0000019
2123,,,,4,,In vivo,CHEMBL617207,,Autocuration,B,,1,,H,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,104826,BAO_0000218
2124,,,,5,,,CHEMBL617208,,Autocuration,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,,104826,BAO_0000019
2125,,,,4,,,CHEMBL617209,,Autocuration,B,,1,,H,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,104826,BAO_0000224
2126,,,,4,,,CHEMBL617210,,Autocuration,B,,1,,H,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,104826,BAO_0000224
2127,,,,4,,,CHEMBL617211,,Autocuration,B,,1,,H,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,104826,BAO_0000224
2128,,,,5,,,CHEMBL617212,,Autocuration,B,,1,,D,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,104826,BAO_0000019
2129,,,,4,,,CHEMBL617213,,Autocuration,B,,1,,H,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,,104784,BAO_0000224
2130,,,,4,,,CHEMBL617214,,Autocuration,B,,1,,H,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,,104784,BAO_0000224
2131,,,,0,,,CHEMBL617215,,Autocuration,B,,1,,U,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,22226,BAO_0000221
2132,,,,0,,,CHEMBL617216,,Autocuration,B,,1,,U,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,22226,BAO_0000221
2133,,,,8,,,CHEMBL617217,,Autocuration,B,,1,,H,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,,17005,BAO_0000357
2134,,,,4,,,CHEMBL617218,,Autocuration,B,,1,,H,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000019
2135,,,,4,,,CHEMBL872913,,Autocuration,B,,1,,H,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000019
2136,,,,4,,,CHEMBL617219,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,104826,BAO_0000019
2137,,,,4,,,CHEMBL873482,,Autocuration,B,,1,,H,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2138,,,,5,,,CHEMBL617220,,Autocuration,B,,1,,D,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,,104686,BAO_0000019
2139,,,,4,,,CHEMBL617221,,Autocuration,B,,1,,H,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,104686,BAO_0000019
2140,,,,4,,,CHEMBL617222,,Autocuration,B,,1,,H,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,104686,BAO_0000019
2141,,,,4,,,CHEMBL875906,,Autocuration,F,,1,,H,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,104686,BAO_0000019
2142,,,,4,,,CHEMBL617223,,Autocuration,B,,1,,H,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,104686,BAO_0000019
2143,,,,4,,,CHEMBL617224,,Autocuration,B,,1,,H,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2144,,,,5,,,CHEMBL617225,,Autocuration,B,,1,,D,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,104686,BAO_0000224
2145,,,,4,,,CHEMBL617226,,Autocuration,B,,1,,H,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,104686,BAO_0000224
2146,,,,4,,,CHEMBL617227,,Autocuration,B,,1,,H,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,104686,BAO_0000224
2147,,,,4,,,CHEMBL617228,,Autocuration,B,,1,,H,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,104686,BAO_0000224
2148,,,,4,,,CHEMBL617229,,Autocuration,B,,1,,H,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,104686,BAO_0000224
2149,,,,4,,,CHEMBL617230,,Autocuration,B,,1,,H,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,104686,BAO_0000224
2150,,,,4,,,CHEMBL617231,,Autocuration,B,,1,,H,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,104686,BAO_0000224
2151,,,,4,,,CHEMBL617232,,Autocuration,B,,1,,H,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,104686,BAO_0000224
2152,,,,4,,,CHEMBL617233,,Autocuration,B,,1,,H,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2153,,,,4,,,CHEMBL617234,,Autocuration,B,,1,,H,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,104686,BAO_0000224
2154,,,,4,,,CHEMBL617235,,Autocuration,F,,1,,H,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,104686,BAO_0000019
2155,,,,4,,,CHEMBL617236,,Autocuration,F,,1,,H,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,104686,BAO_0000019
2156,,,10000000.0,4,Hippocampus,,CHEMBL617237,,Autocuration,B,,1,,H,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,104686,BAO_0000221
2157,,,10000000.0,4,Hippocampus,,CHEMBL617238,,Autocuration,B,,1,,H,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,104686,BAO_0000221
2158,,,955.0,5,Brain,,CHEMBL617239,,Autocuration,B,,1,,D,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,,104686,BAO_0000221
2159,,,,4,,,CHEMBL617240,,Autocuration,B,,1,,H,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,104686,BAO_0000019
2160,,,,4,,,CHEMBL617241,,Autocuration,B,,1,Membranes,H,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,104686,BAO_0000249
2161,,,,4,,,CHEMBL875907,,Autocuration,B,,1,Membranes,H,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,104686,BAO_0000249
2162,,,,4,,,CHEMBL617242,,Autocuration,B,,1,,H,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,104686,BAO_0000019
2163,,,,4,,,CHEMBL617152,,Autocuration,F,,1,,H,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,104686,BAO_0000019
2164,,,955.0,5,Brain,,CHEMBL617153,,Autocuration,B,,1,,D,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,104686,BAO_0000221
2165,,,,5,,,CHEMBL617154,,Autocuration,B,,1,Membranes,D,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,,104686,BAO_0000249
2166,,,955.0,4,Brain,,CHEMBL617155,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,104686,BAO_0000221
2167,,,,4,,,CHEMBL617156,,Autocuration,F,,1,,H,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,104686,BAO_0000019
2168,,,,4,,,CHEMBL617157,,Autocuration,F,,1,,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,104686,BAO_0000019
2169,,,,4,,,CHEMBL617158,,Autocuration,F,,1,,H,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686,BAO_0000019
2170,,,,4,,,CHEMBL617159,,Autocuration,F,,1,,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,104686,BAO_0000019
2171,,,,4,,,CHEMBL617160,,Autocuration,F,,1,,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,104686,BAO_0000019
2172,,,,4,,,CHEMBL858113,,Autocuration,F,,1,,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686,BAO_0000019
2173,,,955.0,4,Brain,,CHEMBL617247,,Autocuration,B,,1,,H,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,104686,BAO_0000220
2174,,,,4,,,CHEMBL617248,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,104686,BAO_0000019
2175,,,955.0,4,Brain,,CHEMBL617249,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,104686,BAO_0000249
2176,,,,4,,,CHEMBL617250,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,104686,BAO_0000019
2177,,,,4,,,CHEMBL617251,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,104686,BAO_0000019
2178,,,,5,,,CHEMBL617252,,Autocuration,B,,1,,D,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000019
2179,,,,4,,,CHEMBL617006,,Autocuration,B,,1,,H,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,104686,BAO_0000019
2180,,,,4,,,CHEMBL617007,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,104686,BAO_0000019
2181,,,,4,,,CHEMBL617008,,Autocuration,F,,1,,H,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,104686,BAO_0000019
2182,,,,4,,,CHEMBL617009,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,104686,BAO_0000019
2183,,,,5,,,CHEMBL617010,,Autocuration,B,,1,,D,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,,104686,BAO_0000224
2184,,,,5,,,CHEMBL857978,,Autocuration,B,,1,,D,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000019
2185,,,,5,,,CHEMBL617011,,Autocuration,B,,1,,D,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000019
2186,,,,5,,,CHEMBL617012,,Autocuration,B,,1,,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,,104686,BAO_0000019
2187,,,,4,,,CHEMBL617013,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,104686,BAO_0000224
2188,,,,4,,,CHEMBL617014,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,104686,BAO_0000249
2189,,,,4,,,CHEMBL617015,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000019
2190,,,,4,,,CHEMBL617016,,Autocuration,B,,1,,H,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,104686,BAO_0000019
2191,,,,4,,,CHEMBL617017,,Autocuration,B,,1,,H,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,104686,BAO_0000224
2192,,,955.0,4,Brain,,CHEMBL617018,,Autocuration,B,,1,,H,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,104686,BAO_0000221
2193,,,,4,,,CHEMBL617019,,Autocuration,F,,1,,H,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,104686,BAO_0000019
2194,,,,4,,,CHEMBL617020,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,BAO_0000019
2195,,,,4,,,CHEMBL617021,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,BAO_0000019
2196,,,,4,,,CHEMBL617022,,Autocuration,B,,1,,H,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,BAO_0000019
2197,,,,4,,,CHEMBL617023,,Autocuration,B,,1,,H,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,BAO_0000019
2198,,,,4,,,CHEMBL617024,,Autocuration,B,,1,,H,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,BAO_0000019
2199,,,,4,,,CHEMBL617025,,Autocuration,B,,1,,H,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075,BAO_0000019
2200,,,,4,,,CHEMBL617026,,Autocuration,B,,1,,H,Hill coefficient of compound was determined,,,105075,BAO_0000224
2201,,,,0,,,CHEMBL617027,,Autocuration,B,,1,,U,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,22226,BAO_0000019
2202,,,,5,,,CHEMBL617028,,Autocuration,B,,1,,D,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,,104686,BAO_0000019
2203,,,,8,,,CHEMBL617029,,Expert,B,,1,,H,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,12687,BAO_0000019
2204,,,,8,,,CHEMBL875908,,Expert,B,,1,,H,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,12687,BAO_0000019
2205,,,,8,,,CHEMBL617030,,Autocuration,B,,1,,H,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,12687,BAO_0000357
2206,,,,8,,,CHEMBL617031,,Autocuration,B,,1,,H,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,12687,BAO_0000019
2207,,,,8,,,CHEMBL617032,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,12687,BAO_0000019
2208,,,,5,,,CHEMBL617033,,Autocuration,B,,1,,D,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,,104686,BAO_0000224
2209,,,,4,,,CHEMBL617034,,Autocuration,B,,1,,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,104686,BAO_0000224
2210,,,,4,,,CHEMBL617035,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,104686,BAO_0000224
2211,,,,4,,,CHEMBL617036,,Autocuration,B,,1,,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,104686,BAO_0000019
2212,,,,4,,,CHEMBL617037,,Autocuration,B,,1,,H,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,104784,BAO_0000224
2213,,,,0,,,CHEMBL617038,,Autocuration,B,,1,,U,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,22226,BAO_0000219
2214,,,,4,,,CHEMBL617039,,Autocuration,B,,1,,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,104784,BAO_0000219
2215,,,,4,,,CHEMBL617161,,Autocuration,B,,1,,H,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,104784,BAO_0000224
2216,,,,4,,,CHEMBL617162,,Autocuration,B,,1,,H,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,104784,BAO_0000224
2217,,,,4,,,CHEMBL617163,,Autocuration,B,,1,,H,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,104784,BAO_0000224
2218,,,,4,,,CHEMBL617164,,Autocuration,B,,1,,H,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,104784,BAO_0000224
2219,,,,4,,,CHEMBL617165,,Autocuration,B,,1,Brain membranes,H,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,104784,BAO_0000249
2220,,,,4,,,CHEMBL617166,,Autocuration,B,,1,,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,104784,BAO_0000224
2221,,,,4,,,CHEMBL617167,,Autocuration,B,,1,,H,Binding affinity towards 5-HT2 receptor,,,104784,BAO_0000224
2222,,,,4,,,CHEMBL872912,,Autocuration,B,,1,,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,104784,BAO_0000224
2223,,,,4,,,CHEMBL617168,,Autocuration,B,,1,,H,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,104784,BAO_0000224
2224,,,,4,,,CHEMBL617169,,Autocuration,B,,1,,H,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,104686,BAO_0000224
2225,,,,4,,,CHEMBL617170,,Autocuration,B,,1,,H,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,104784,BAO_0000224
2226,,,,4,,,CHEMBL617171,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,104784,BAO_0000224
2227,,,,4,,,CHEMBL617172,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,104784,BAO_0000224
2228,,,,4,,,CHEMBL617173,,Autocuration,B,,1,,H,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,104784,BAO_0000224
2229,,,,0,,,CHEMBL617174,,Autocuration,B,,1,,U,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,22226,BAO_0000019
2230,,,,4,,,CHEMBL617175,,Autocuration,B,,1,,H,5-hydroxytryptamine 2 receptor binding affinity,,,104784,BAO_0000224
2231,,,,8,,,CHEMBL617176,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,17005,BAO_0000357
2232,,,,8,,,CHEMBL617177,,Autocuration,B,,1,,H,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,17005,BAO_0000357
2233,,,,4,,,CHEMBL617178,,Autocuration,B,,1,,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,104784,BAO_0000224
2234,,,,4,,,CHEMBL617179,,Autocuration,B,,1,,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,104784,BAO_0000224
2235,,,,4,,,CHEMBL617180,,Autocuration,B,,1,,H,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,104784,BAO_0000224
2236,,,,8,,,CHEMBL617181,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,17005,BAO_0000357
2237,,,,8,,,CHEMBL617182,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor,,,17005,BAO_0000357
2238,,,,8,,,CHEMBL617183,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor,,,17005,BAO_0000357
2239,,,,8,,,CHEMBL617184,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,17005,BAO_0000357
2240,,,,8,,,CHEMBL617185,,Autocuration,B,,1,,H,Binding affinity against serotonergic 5-HT2 receptor,,,17005,BAO_0000357
2241,,,,8,,,CHEMBL617186,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,17005,BAO_0000357
2242,,,,8,,,CHEMBL617187,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,17005,BAO_0000357
2243,,,,8,,,CHEMBL617188,,Autocuration,B,,1,,H,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,17005,BAO_0000357
2244,,,,8,,,CHEMBL617189,,Autocuration,B,,1,,H,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,17005,BAO_0000218
2245,,,,5,,,CHEMBL617190,,Autocuration,B,,1,,D,Inhibitory activity against cloned human 5-HT2 receptor,,,104784,BAO_0000224
2246,449.0,,,5,,,CHEMBL617191,,Autocuration,B,,1,,D,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,CHO,104784,BAO_0000219
2247,449.0,,,5,,,CHEMBL617192,,Autocuration,B,,1,,D,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,CHO,104784,BAO_0000219
2248,449.0,,,5,,,CHEMBL617193,,Autocuration,B,,1,,D,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,CHO,104784,BAO_0000219
2249,449.0,,,5,,,CHEMBL617194,,Autocuration,B,,1,,D,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,CHO,104784,BAO_0000219
2250,,,,4,,,CHEMBL617195,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104784,BAO_0000224
2251,,,,4,,,CHEMBL881830,,Autocuration,B,,1,,H,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,104784,BAO_0000224
2252,,,,8,,,CHEMBL617196,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,17005,BAO_0000357
2253,,,,4,,,CHEMBL617197,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,104686,BAO_0000224
2254,,,,8,,,CHEMBL617198,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,17005,BAO_0000357
2255,,,,8,,,CHEMBL873476,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,17005,BAO_0000357
2256,,,,8,,,CHEMBL617199,,Expert,B,,1,,H,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,17005,BAO_0000019
2257,,,,8,,,CHEMBL617200,,Autocuration,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2258,,,,8,,,CHEMBL617484,,Autocuration,B,,1,,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,51,BAO_0000357
2259,,,,8,,,CHEMBL617485,,Autocuration,B,,1,,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,107,BAO_0000357
2260,,,,8,,,CHEMBL617486,,Autocuration,B,,1,,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,51,BAO_0000357
2261,,,,8,,,CHEMBL858022,,Autocuration,B,,1,,H,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,107,BAO_0000357
2262,449.0,,,8,,,CHEMBL617049,,Autocuration,B,,1,,H,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,CHO,107,BAO_0000219
2263,449.0,,,9,,,CHEMBL617050,,Expert,F,,1,,D,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,CHO,107,BAO_0000219
2264,,,,8,,,CHEMBL617051,,Autocuration,F,,1,,H,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,107,BAO_0000219
2265,,,,8,,,CHEMBL617052,,Autocuration,F,,1,,H,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,107,BAO_0000219
2266,,,,8,,,CHEMBL617053,,Autocuration,F,,1,,H,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,107,BAO_0000219
2267,449.0,,,8,,,CHEMBL617054,,Autocuration,B,,1,,H,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,CHO,107,BAO_0000219
2268,449.0,,,8,,,CHEMBL617055,,Autocuration,B,,1,,H,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,CHO,107,BAO_0000219
2269,,,,8,,,CHEMBL882924,,Autocuration,B,,1,,H,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,107,BAO_0000357
2270,,,,9,,,CHEMBL617056,,Expert,B,,1,,D,Inhibition of human 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2271,449.0,,,8,,,CHEMBL617057,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHO,107,BAO_0000219
2272,,,,8,,,CHEMBL617058,,Expert,B,,1,,H,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,107,BAO_0000219
2273,,,,8,,,CHEMBL617059,,Autocuration,B,,1,,H,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,107,BAO_0000357
2274,449.0,,,8,,,CHEMBL617060,,Autocuration,B,,1,,H,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,CHO,107,BAO_0000219
2275,449.0,,,8,,,CHEMBL617061,,Expert,B,,1,,H,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,CHO,107,BAO_0000219
2276,307.0,,,8,,,CHEMBL617062,,Expert,B,,1,,H,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,L929,107,BAO_0000219
2277,449.0,,,8,,,CHEMBL617063,,Expert,B,,1,,H,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHO,107,BAO_0000219
2278,,,,8,,,CHEMBL617064,,Autocuration,F,,1,,H,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,107,BAO_0000019
2279,,,,8,,,CHEMBL617065,,Autocuration,F,,1,,H,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,107,BAO_0000019
2280,449.0,,,8,,,CHEMBL617066,,Autocuration,B,,1,,H,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,CHO,107,BAO_0000219
2281,449.0,,,8,,,CHEMBL617067,,Autocuration,B,,1,,H,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,CHO,107,BAO_0000219
2282,,,,8,,,CHEMBL617068,,Autocuration,F,,1,,H,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,107,BAO_0000019
2283,,,,8,,,CHEMBL617069,,Autocuration,F,,1,,H,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,107,BAO_0000019
2284,,,,8,,,CHEMBL617070,,Autocuration,F,,1,,H,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,107,BAO_0000019
2285,,,,8,,,CHEMBL617071,,Autocuration,B,,1,,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,107,BAO_0000357
2286,,,,8,,,CHEMBL872915,,Autocuration,B,,1,,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,107,BAO_0000357
2287,,,,8,,,CHEMBL617072,,Autocuration,B,,1,,H,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,107,BAO_0000357
2288,,,,8,,,CHEMBL617073,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,107,BAO_0000357
2289,,,,8,,,CHEMBL617074,,Autocuration,B,,1,,H,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,107,BAO_0000357
2290,449.0,,,8,,,CHEMBL617075,,Expert,B,,1,,H,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHO,107,BAO_0000219
2291,,,,8,,,CHEMBL617076,,Autocuration,B,,1,,H,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2292,,,,9,,,CHEMBL617077,,Expert,B,,1,,D,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,,107,BAO_0000019
2293,,,,8,,,CHEMBL617078,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,107,BAO_0000357
2294,,,,9,,,CHEMBL617079,,Expert,B,,1,,D,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2295,,,,8,,,CHEMBL617080,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,107,BAO_0000357
2296,449.0,,,8,,,CHEMBL617081,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,CHO,107,BAO_0000219
2297,,,,8,,,CHEMBL617082,,Expert,B,,1,,H,Binding affinity towards human 5-HT2A receptor in BEK cells,,,107,BAO_0000219
2298,,,,8,,,CHEMBL617083,,Autocuration,B,,1,,H,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2299,,,,8,,,CHEMBL617084,,Autocuration,B,,1,,H,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,107,BAO_0000357
2300,,,,9,,,CHEMBL617085,,Expert,B,,1,,D,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2301,,,,8,,,CHEMBL617086,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,107,BAO_0000357
2302,,,,8,,,CHEMBL617087,,Autocuration,B,,1,,H,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,107,BAO_0000219
2303,,,,8,,,CHEMBL617088,,Autocuration,B,,1,,H,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2304,,,,8,,,CHEMBL617089,,Autocuration,B,,1,,H,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2305,,,,8,,,CHEMBL617090,,Expert,B,,1,,H,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,107,BAO_0000019
2306,,,,8,,,CHEMBL617513,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,107,BAO_0000357
2307,722.0,,,8,,,CHEMBL617514,,Autocuration,B,,1,,H,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,HEK293,107,BAO_0000219
2308,,,,8,,,CHEMBL617515,,Autocuration,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,107,BAO_0000019
2309,,,,8,,,CHEMBL617516,,Autocuration,B,,1,,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,107,BAO_0000357
2310,,,,9,,,CHEMBL617517,,Expert,B,,1,,D,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,107,BAO_0000357
2311,449.0,,,9,,,CHEMBL617518,,Expert,B,,1,,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,CHO,107,BAO_0000219
2312,,,,8,,,CHEMBL617519,,Autocuration,B,,1,,H,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2313,,,,9,,,CHEMBL617520,,Expert,B,,1,,D,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2314,,,,8,,,CHEMBL617521,,Autocuration,B,,1,,H,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,107,BAO_0000357
2315,,,,9,,,CHEMBL617522,,Expert,B,,1,,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2316,,,,8,,,CHEMBL617523,,Autocuration,B,,1,,H,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,107,BAO_0000357
2317,,,,8,,,CHEMBL617524,,Autocuration,B,,1,,H,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,107,BAO_0000357
2318,,,,4,,,CHEMBL617525,,Autocuration,B,,1,,H,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,104686,BAO_0000019
2319,,,,5,,,CHEMBL617526,,Autocuration,B,,1,,D,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,,104686,BAO_0000019
2320,,,,4,,,CHEMBL617527,,Autocuration,B,,1,,H,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,104686,BAO_0000224
2321,,,,4,,,CHEMBL617528,,Autocuration,B,,1,,H,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,104686,BAO_0000019
2322,,,,4,,,CHEMBL617529,,Autocuration,B,,1,,H,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,104686,BAO_0000019
2323,,,,4,,,CHEMBL617530,,Autocuration,B,,1,,H,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,104686,BAO_0000224
2324,,,,4,,,CHEMBL617531,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,104686,BAO_0000019
2325,,,,4,,,CHEMBL617532,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,104686,BAO_0000019
2326,,,,4,,,CHEMBL617533,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,104686,BAO_0000019
2327,,,,4,,,CHEMBL617534,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,104686,BAO_0000019
2328,,,,4,,,CHEMBL617535,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,104686,BAO_0000224
2329,,,,4,,,CHEMBL617536,,Autocuration,B,,1,,H,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,104686,BAO_0000224
2330,,,,4,,,CHEMBL617537,,Autocuration,B,,1,,H,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2331,,,,4,,,CHEMBL617538,,Autocuration,B,,1,,H,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2332,,,,4,,In vitro,CHEMBL617539,,Autocuration,B,,1,,H,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,104686,BAO_0000219
2333,,,,5,,,CHEMBL617540,,Autocuration,B,,1,,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2334,,,,5,,,CHEMBL617541,,Autocuration,B,,1,,D,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,,104686,BAO_0000224
2335,,,,4,,,CHEMBL617542,,Autocuration,B,,1,,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2336,,,,4,,,CHEMBL617543,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,104686,BAO_0000224
2337,485.0,,,5,,,CHEMBL617544,,Autocuration,B,,1,,D,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHO-K1,104686,BAO_0000219
2338,485.0,,,5,,,CHEMBL617545,,Autocuration,B,,1,,D,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHO-K1,104686,BAO_0000219
2339,,,,5,,,CHEMBL617413,,Autocuration,B,,1,,D,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,,104686,BAO_0000019
2340,,,,4,,,CHEMBL617414,,Autocuration,B,,1,,H,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,104686,BAO_0000019
2341,,,,5,,,CHEMBL617415,,Autocuration,B,,1,,D,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,,104686,BAO_0000019
2342,,,,4,,,CHEMBL617416,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2343,,,,4,,,CHEMBL617417,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,104686,BAO_0000224
2344,,,,4,,,CHEMBL617418,,Autocuration,B,,1,,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,104686,BAO_0000019
2345,,,,4,,,CHEMBL617419,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,104686,BAO_0000019
2346,,,,4,,,CHEMBL617420,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,104686,BAO_0000224
2347,,,,5,,,CHEMBL617421,,Autocuration,B,,1,,D,Affinity for 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2348,,,,4,,,CHEMBL617422,,Autocuration,B,,1,,H,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,104686,BAO_0000224
2349,,,,4,,,CHEMBL617423,,Autocuration,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,104686,BAO_0000019
2350,,,,4,,,CHEMBL617424,,Autocuration,B,,1,,H,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,104686,BAO_0000019
2351,,,,4,,,CHEMBL617425,,Autocuration,B,,1,,H,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,104686,BAO_0000019
2352,,,,4,,,CHEMBL617426,,Autocuration,B,,1,,H,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,104686,BAO_0000224
2353,,,,4,,In vivo,CHEMBL617427,,Autocuration,B,,1,,H,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,,104686,BAO_0000218
2354,,,955.0,4,Brain,,CHEMBL617428,,Autocuration,B,,1,,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,104686,BAO_0000221
2355,,,,4,,,CHEMBL617429,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,104686,BAO_0000224
2356,,,,4,,,CHEMBL617430,,Autocuration,B,,1,,H,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,104686,BAO_0000019
2357,,,,4,,,CHEMBL617431,,Autocuration,B,,1,,H,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,104686,BAO_0000019
2358,,,1870.0,4,Frontal cortex,,CHEMBL617432,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,104686,BAO_0000019
2359,,,,4,,,CHEMBL617433,,Autocuration,B,,1,,H,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2360,,,,4,,,CHEMBL617434,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2361,,,,5,,,CHEMBL617435,,Autocuration,B,,1,,D,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,,104686,BAO_0000224
2362,,,,4,,,CHEMBL617436,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,104686,BAO_0000019
2363,,,2435.0,5,Striatum,,CHEMBL617437,,Autocuration,B,,1,,D,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,,104686,BAO_0000019
2364,,,,4,,,CHEMBL617438,,Autocuration,B,,1,,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,104686,BAO_0000019
2365,,,,4,,,CHEMBL617439,,Autocuration,B,,1,,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,104686,BAO_0000019
2366,,,,4,,,CHEMBL617440,,Autocuration,B,,1,,H,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2367,,,,4,,,CHEMBL617441,,Autocuration,B,,1,,H,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2368,,,,5,,,CHEMBL872918,,Autocuration,B,,1,,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,,104686,BAO_0000019
2369,,,,5,,,CHEMBL617442,,Autocuration,B,,1,,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,,104686,BAO_0000019
2370,,,,4,,,CHEMBL617443,,Autocuration,B,,1,,H,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,104686,BAO_0000019
2371,,,,4,,,CHEMBL617444,,Autocuration,B,,1,,H,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,104686,BAO_0000019
2372,,,,4,,,CHEMBL617445,,Autocuration,B,,1,,H,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,104686,BAO_0000019
2373,,,,4,,,CHEMBL617446,,Autocuration,B,,1,,H,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,104686,BAO_0000019
2374,,,,4,,,CHEMBL617447,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,104686,BAO_0000249
2375,,,,4,,,CHEMBL617448,,Autocuration,B,,1,,H,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,104686,BAO_0000019
2376,,,,4,,,CHEMBL617449,,Autocuration,B,,1,,H,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,104686,BAO_0000019
2377,,,,4,,,CHEMBL617450,,Autocuration,B,,1,,H,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,104686,BAO_0000019
2378,,,,4,,,CHEMBL617451,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,104686,BAO_0000019
2379,,,,4,,,CHEMBL617452,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,104686,BAO_0000019
2380,,,,4,,,CHEMBL617453,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,104686,BAO_0000019
2381,,,,4,,,CHEMBL617660,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,104686,BAO_0000019
2382,,,,4,,,CHEMBL617661,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,104686,BAO_0000019
2383,,,,4,,,CHEMBL617662,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,104686,BAO_0000019
2384,,,,4,,,CHEMBL872919,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,104686,BAO_0000019
2385,,,,4,,,CHEMBL617663,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,104686,BAO_0000019
2386,,,,4,,,CHEMBL617664,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,104686,BAO_0000019
2387,,,,4,,,CHEMBL617665,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,104686,BAO_0000019
2388,,,,4,,,CHEMBL617666,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,104686,BAO_0000019
2389,,,,4,,,CHEMBL617667,,Autocuration,B,,1,,H,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,104686,BAO_0000019
2390,,,,4,,,CHEMBL617668,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,104686,BAO_0000249
2391,,,,4,,,CHEMBL617669,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,104686,BAO_0000249
2392,,,,4,,,CHEMBL617670,,Autocuration,B,,1,,H,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2393,,,,5,,,CHEMBL617671,,Autocuration,B,,1,,D,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2394,,,,4,,,CHEMBL617672,,Autocuration,B,,1,,H,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2395,,,,4,,,CHEMBL617673,,Autocuration,B,,1,,H,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,104686,BAO_0000019
2396,,,,4,,,CHEMBL617674,,Autocuration,B,,1,,H,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,104686,BAO_0000224
2397,,,,4,,,CHEMBL617675,,Autocuration,B,,1,,H,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,104686,BAO_0000019
2398,,,,4,,,CHEMBL617676,,Autocuration,B,,1,,H,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,104686,BAO_0000019
2399,,,,4,,,CHEMBL617677,,Autocuration,B,,1,,H,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,104686,BAO_0000019
2400,,,,5,,,CHEMBL617678,,Autocuration,B,,1,,D,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000019
2401,,,,4,,,CHEMBL617679,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,104686,BAO_0000224
2402,,,,4,,,CHEMBL617680,,Autocuration,B,,1,,H,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,104686,BAO_0000224
2403,,,,4,,,CHEMBL617681,,Autocuration,B,,1,,H,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,104686,BAO_0000019
2404,,,955.0,4,Brain,,CHEMBL617682,,Autocuration,B,,1,,H,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,104686,BAO_0000221
2405,,,,4,,,CHEMBL617683,,Autocuration,B,,1,,H,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,104686,BAO_0000224
2406,,,,4,,,CHEMBL617684,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,104686,BAO_0000224
2407,,,,5,,,CHEMBL617685,,Autocuration,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2408,,,,4,,,CHEMBL617686,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,104686,BAO_0000019
2409,,,,4,,,CHEMBL617687,,Autocuration,B,,1,,H,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,104686,BAO_0000224
2410,,,,4,,,CHEMBL617688,,Autocuration,B,,1,,H,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,104686,BAO_0000224
2411,,,,4,,,CHEMBL617689,,Autocuration,F,,1,,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686,BAO_0000019
2412,,,,4,,,CHEMBL617690,,Autocuration,F,,1,,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686,BAO_0000019
2413,,,,4,,In vivo,CHEMBL617691,,Autocuration,F,,1,,H,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,104686,BAO_0000218
2414,,,,4,,In vivo,CHEMBL617692,,Autocuration,F,,1,,H,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,104686,BAO_0000218
2415,,,,4,,In vivo,CHEMBL617693,,Autocuration,F,,1,,H,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,104686,BAO_0000218
2416,,,,4,,In vivo,CHEMBL617694,,Autocuration,F,,1,,H,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,104686,BAO_0000218
2417,,,955.0,8,Brain,,CHEMBL857985,,Expert,B,,1,,H,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,12687,BAO_0000221
2418,,,,9,,,CHEMBL617695,,Expert,B,,1,,D,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,12687,BAO_0000019
2419,,,,8,,,CHEMBL617696,,Autocuration,B,,1,,H,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,12687,BAO_0000019
2420,,,,8,,,CHEMBL617697,,Autocuration,B,,1,,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,12687,BAO_0000357
2421,,,,9,,,CHEMBL617257,,Expert,B,,1,,D,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,,12687,BAO_0000019
2422,,,,9,,,CHEMBL617258,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,12687,BAO_0000357
2423,,,,8,,,CHEMBL617259,,Expert,B,,1,,H,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,12687,BAO_0000019
2424,,,,8,,,CHEMBL617260,,Autocuration,B,,1,,H,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,12687,BAO_0000357
2425,,,,9,,,CHEMBL617261,,Expert,B,,1,,D,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2426,,,,8,,,CHEMBL617262,,Autocuration,B,,1,,H,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,12687,BAO_0000019
2427,,,,8,,,CHEMBL617263,,Expert,B,,1,,H,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,12687,BAO_0000019
2428,,,,8,,,CHEMBL617264,,Autocuration,B,,1,,H,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,12687,BAO_0000019
2429,,,,9,,,CHEMBL617265,,Expert,B,,1,,D,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000019
2430,,,,8,,,CHEMBL617266,,Autocuration,B,,1,Membranes,H,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000249
2431,,,,8,,,CHEMBL617267,,Autocuration,B,,1,,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,12687,BAO_0000019
2432,,,,8,,,CHEMBL617268,,Expert,B,,1,,H,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,12687,BAO_0000019
2433,449.0,,,8,,,CHEMBL617269,,Autocuration,B,,1,,H,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,CHO,12687,BAO_0000219
2434,,,,8,,,CHEMBL617323,,Expert,B,,1,,H,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,12687,BAO_0000357
2435,,,,8,,,CHEMBL617324,,Autocuration,B,,1,,H,Serotonergic activity of the compound.,,,12687,BAO_0000357
2436,,,,8,,,CHEMBL617325,,Autocuration,B,,1,,H,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,12687,BAO_0000249
2437,,,,9,,,CHEMBL617326,,Expert,B,,1,,D,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,,12687,BAO_0000019
2438,,,,8,,,CHEMBL617327,,Expert,B,,1,,H,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,12687,BAO_0000249
2439,,,,9,,,CHEMBL617328,,Expert,F,,1,,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687,BAO_0000019
2440,,,,9,,,CHEMBL617329,,Expert,F,,1,,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687,BAO_0000019
2441,,,,9,,,CHEMBL617330,,Expert,F,,1,,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687,BAO_0000019
2442,,,,8,,,CHEMBL617331,,Autocuration,B,,1,,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687,BAO_0000357
2443,,,,8,,,CHEMBL617332,,Autocuration,B,,1,,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,12687,BAO_0000357
2444,,,,8,,,CHEMBL617333,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2445,,,,8,,,CHEMBL617334,,Autocuration,B,,1,,H,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,107,BAO_0000357
2446,,,,8,,,CHEMBL617335,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,107,BAO_0000357
2447,,,,8,,,CHEMBL617336,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,107,BAO_0000357
2448,,,,8,,,CHEMBL617337,,Autocuration,B,,1,,H,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,107,BAO_0000357
2449,,,,9,,,CHEMBL617338,,Expert,B,,1,,D,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,,107,BAO_0000357
2450,,,,8,,,CHEMBL617339,,Autocuration,B,,1,,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2451,,,,8,,,CHEMBL617340,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2452,,,,8,,,CHEMBL617341,,Autocuration,B,,1,,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,107,BAO_0000357
2453,,,,8,,,CHEMBL617342,,Expert,B,,1,,H,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2454,,,,8,,,CHEMBL617343,,Expert,B,,1,,H,Affinity for 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2455,723.0,,,8,,,CHEMBL617344,,Expert,B,,1,,H,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,NIH3T3,107,BAO_0000219
2456,,,,8,,,CHEMBL617345,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,107,BAO_0000357
2457,,,,8,,,CHEMBL617346,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,107,BAO_0000357
2458,,,,8,,,CHEMBL617347,,Autocuration,B,,1,,H,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2459,,,,8,,,CHEMBL617348,,Autocuration,B,,1,,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,107,BAO_0000357
2460,,,,8,,,CHEMBL617349,,Autocuration,B,,1,,H,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,107,BAO_0000357
2461,,,,8,,,CHEMBL617350,,Autocuration,F,,1,,H,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,107,BAO_0000019
2462,,,,8,,,CHEMBL872339,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,107,BAO_0000357
2463,,,,8,,,CHEMBL617351,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,107,BAO_0000357
2464,,,,8,,,CHEMBL617352,,Expert,B,,1,,H,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2465,,,,8,,,CHEMBL617353,,Autocuration,B,,1,,H,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2466,,,,8,,,CHEMBL617354,,Autocuration,B,,1,,H,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2467,,,,8,,,CHEMBL617355,,Autocuration,B,,1,,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2468,449.0,,,8,,,CHEMBL617356,,Expert,B,,1,,H,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,CHO,107,BAO_0000219
2469,,,,8,,,CHEMBL617357,,Autocuration,B,,1,,H,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2470,,,,8,,,CHEMBL617358,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2471,,,,8,,,CHEMBL617359,,Expert,B,,1,,H,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2472,,,,8,,,CHEMBL617360,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,107,BAO_0000357
2473,,,,8,,,CHEMBL875913,,Autocuration,B,,1,,H,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,107,BAO_0000357
2474,,,,8,,,CHEMBL617361,,Autocuration,B,,1,,H,Affinity against 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2475,,,,9,,,CHEMBL617362,,Expert,B,,1,,D,Binding affinity against 5-Hydroxytryptamine 2A receptor,,,107,BAO_0000357
2476,,,,8,,,CHEMBL617363,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,107,BAO_0000357
2477,,,,8,,,CHEMBL617364,,Autocuration,B,,1,,H,Tested against 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2478,,,,4,,,CHEMBL617365,,Autocuration,B,,1,,H,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,105075,BAO_0000224
2479,,,,4,,,CHEMBL617366,,Autocuration,B,,1,,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,105075,BAO_0000224
2480,,,,4,,,CHEMBL617367,,Autocuration,B,,1,,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,105075,BAO_0000224
2481,,,,4,,,CHEMBL617368,,Autocuration,B,,1,,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,105075,BAO_0000224
2482,,,,8,,,CHEMBL617369,,Autocuration,B,,1,,H,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,107,BAO_0000357
2483,722.0,,,9,,,CHEMBL617370,,Expert,B,,1,,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,HEK293,227,BAO_0000219
2484,449.0,,,9,,,CHEMBL617371,,Expert,F,,1,,D,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,CHO,227,BAO_0000219
2485,,,,8,,,CHEMBL617372,,Autocuration,B,,1,,H,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,227,BAO_0000357
2486,,,,9,,,CHEMBL617373,,Expert,B,,1,,D,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,,227,BAO_0000357
2487,,,,8,,,CHEMBL617374,,Autocuration,F,,1,,H,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,227,BAO_0000019
2488,,,,8,,,CHEMBL617375,,Autocuration,F,,1,,H,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,227,BAO_0000019
2489,,,,8,,,CHEMBL617376,,Autocuration,F,,1,,H,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,227,BAO_0000019
2490,,,,8,,,CHEMBL617377,,Autocuration,F,,1,,H,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,227,BAO_0000019
2491,,,,8,,,CHEMBL617378,,Autocuration,F,,1,,H,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,227,BAO_0000019
2492,,,,8,,,CHEMBL617379,,Autocuration,F,,1,,H,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,227,BAO_0000019
2493,,,,8,,,CHEMBL617380,,Autocuration,B,,1,,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,227,BAO_0000357
2494,,,,8,,,CHEMBL617381,,Autocuration,B,,1,,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,227,BAO_0000357
2495,,,,8,,,CHEMBL617382,,Autocuration,B,,1,,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,227,BAO_0000357
2496,,,,8,,,CHEMBL617383,,Autocuration,B,,1,,H,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2497,,,,8,,,CHEMBL617384,,Expert,B,,1,,H,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,107,BAO_0000357
2498,,,,8,,,CHEMBL617385,,Expert,B,,1,,H,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,107,BAO_0000357
2499,,,,8,,,CHEMBL617386,,Autocuration,B,,1,,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,107,BAO_0000019
2500,,,,8,,,CHEMBL617387,,Autocuration,B,,1,,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,107,BAO_0000019
2501,723.0,,,8,,,CHEMBL617388,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,NIH3T3,107,BAO_0000219
2502,449.0,,,8,,,CHEMBL617389,,Autocuration,F,,1,,H,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHO,107,BAO_0000219
2503,449.0,,,9,,,CHEMBL617390,,Expert,F,,1,,D,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHO,107,BAO_0000219
2504,,,,4,,,CHEMBL617391,,Autocuration,B,,1,,H,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,104817,BAO_0000224
2505,,,,8,,,CHEMBL617392,,Autocuration,B,,1,,H,Binding activity radioligand.,,,107,BAO_0000357
2506,,,,8,,,CHEMBL617393,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,107,BAO_0000019
2507,307.0,,,8,,,CHEMBL617394,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,L929,107,BAO_0000219
2508,307.0,,,8,,,CHEMBL617395,,Expert,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,L929,107,BAO_0000219
2509,307.0,,,8,,,CHEMBL617396,,Expert,B,,1,,H,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,L929,107,BAO_0000219
2510,307.0,,,8,,,CHEMBL617397,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,L929,107,BAO_0000219
2511,,,,8,,,CHEMBL617398,,Autocuration,B,,1,,H,Binding affinity against 5-HT2A receptor,,,107,BAO_0000357
2512,,,,8,,,CHEMBL617399,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2513,722.0,,,8,,,CHEMBL617400,,Autocuration,B,,1,,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,HEK293,107,BAO_0000219
2514,722.0,,,8,,,CHEMBL617401,,Autocuration,B,,1,,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,HEK293,107,BAO_0000219
2515,722.0,,,9,,,CHEMBL617402,,Expert,B,,1,,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,HEK293,107,BAO_0000219
2516,722.0,,,9,,,CHEMBL617403,,Expert,B,,1,,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,HEK293,107,BAO_0000219
2517,,,,8,,,CHEMBL617404,,Expert,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,107,BAO_0000357
2518,722.0,,,9,,,CHEMBL857981,,Expert,B,,1,,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,HEK293,107,BAO_0000219
2519,722.0,,,9,,,CHEMBL617405,,Expert,B,,1,,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,HEK293,107,BAO_0000219
2520,722.0,,,9,,,CHEMBL617253,,Expert,B,,1,,D,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,HEK293,107,BAO_0000219
2521,,,,8,,,CHEMBL617254,,Expert,B,,1,,H,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,107,BAO_0000357
2522,722.0,,,8,,,CHEMBL617255,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,HEK293,107,BAO_0000219
2523,722.0,,,8,,,CHEMBL617256,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,HEK293,107,BAO_0000219
2524,722.0,,,8,,,CHEMBL616874,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,HEK293,107,BAO_0000219
2525,722.0,,,9,,,CHEMBL616875,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,HEK293,107,BAO_0000219
2526,722.0,,,8,,,CHEMBL616876,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,HEK293,107,BAO_0000219
2527,722.0,,,8,,,CHEMBL616877,,Expert,B,,1,,H,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,HEK293,107,BAO_0000219
2528,722.0,,,9,,,CHEMBL616878,,Expert,B,,1,,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,HEK293,107,BAO_0000219
2529,722.0,,,8,,,CHEMBL616879,,Expert,B,,1,,H,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,HEK293,107,BAO_0000219
2530,722.0,,,8,,,CHEMBL616880,,Expert,B,,1,,H,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,HEK293,107,BAO_0000219
2531,722.0,,,9,,,CHEMBL616881,,Expert,B,,1,,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,HEK293,107,BAO_0000219
2532,723.0,,,8,,,CHEMBL616882,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,NIH3T3,107,BAO_0000219
2533,723.0,,,8,,,CHEMBL616883,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,NIH3T3,107,BAO_0000219
2534,723.0,,,8,,,CHEMBL616884,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,NIH3T3,107,BAO_0000219
2535,722.0,,,8,,,CHEMBL616885,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,HEK293,107,BAO_0000219
2536,485.0,,,8,,,CHEMBL616886,,Autocuration,B,,1,,H,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,CHO-K1,107,BAO_0000219
2537,485.0,,,8,,,CHEMBL616887,,Expert,B,,1,,H,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,CHO-K1,107,BAO_0000219
2538,,,,9,,,CHEMBL616888,,Expert,B,,1,,D,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,107,BAO_0000357
2539,722.0,,,8,,,CHEMBL616889,,Autocuration,B,,1,,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,HEK293,107,BAO_0000219
2540,722.0,,,8,,,CHEMBL616890,,Autocuration,B,,1,,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,HEK293,107,BAO_0000219
2541,449.0,,,9,,,CHEMBL616891,,Expert,B,,1,,D,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,CHO,107,BAO_0000219
2542,722.0,,,8,,,CHEMBL616892,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,HEK293,107,BAO_0000219
2543,722.0,,,8,,,CHEMBL616893,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,HEK293,107,BAO_0000219
2544,723.0,,,8,,,CHEMBL616894,,Autocuration,F,,1,,H,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,NIH3T3,10620,BAO_0000219
2545,723.0,,,8,,,CHEMBL616895,,Expert,B,,1,,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,NIH3T3,107,BAO_0000219
2546,,,,8,,,CHEMBL616896,,Autocuration,F,,1,,H,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,10620,BAO_0000019
2547,,,,8,,,CHEMBL617099,,Autocuration,B,,1,,H,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,10621,BAO_0000357
2548,,,,8,,,CHEMBL617100,,Autocuration,B,,1,,H,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,10621,BAO_0000357
2549,,,,8,,,CHEMBL884532,,Autocuration,B,,1,,H,Binding affinity against rabbit aorta 5-HT2A receptor,,,107,BAO_0000357
2550,,,,8,,,CHEMBL617101,,Expert,B,,1,,H,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,,107,BAO_0000357
2551,,,,8,,,CHEMBL617102,,Expert,B,,1,,H,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,,107,BAO_0000357
2552,,,,8,,,CHEMBL617103,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,107,BAO_0000019
2553,,,,8,,,CHEMBL617104,,Expert,B,,1,,H,The compound was tested for binding affinity against 5-HT2A receptor,,,107,BAO_0000357
2554,485.0,,,8,,,CHEMBL857979,,Autocuration,B,,1,,H,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,CHO-K1,10576,BAO_0000219
2555,,,,8,,,CHEMBL857502,,Autocuration,B,,1,,H,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,12687,BAO_0000019
2556,,,,8,,,CHEMBL617105,,Autocuration,B,,1,,H,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,12687,BAO_0000019
2557,,,945.0,8,Stomach,,CHEMBL858021,,Autocuration,B,,1,,H,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,12687,BAO_0000019
2558,,,945.0,9,Stomach,,CHEMBL875910,,Expert,B,,1,,D,Binding affinity for 5-HT 2A in rat stomach fundus,,,12687,BAO_0000019
2559,,,,8,,,CHEMBL617106,,Autocuration,B,,1,,H,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,12687,BAO_0000019
2560,723.0,,,8,,,CHEMBL617107,,Expert,B,,1,,H,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,NIH3T3,12687,BAO_0000219
2561,,,,8,,,CHEMBL617108,,Autocuration,F,,1,,H,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000019
2562,,,,8,,,CHEMBL617109,,Autocuration,F,,1,,H,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000019
2563,,,,8,,,CHEMBL617110,,Autocuration,B,,1,,H,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2564,,,,8,,,CHEMBL617111,,Autocuration,B,,1,,H,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,12687,BAO_0000357
2565,,,,9,,,CHEMBL617112,,Expert,F,,1,,D,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,,12687,BAO_0000019
2566,,,,8,,,CHEMBL617113,,Autocuration,B,,1,,H,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2567,,,,8,,,CHEMBL617114,,Autocuration,B,,1,,H,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2568,,,,8,,,CHEMBL617115,,Autocuration,B,,1,,H,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2569,,,,8,,,CHEMBL617116,,Autocuration,F,,1,,H,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,12687,BAO_0000219
2570,,,,8,,,CHEMBL617117,,Autocuration,F,,1,,H,Efficacy at 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000019
2571,,,,8,,,CHEMBL617118,,Autocuration,B,,1,,H,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,12687,BAO_0000357
2572,,,,9,,,CHEMBL617119,,Expert,B,,1,,D,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,12687,BAO_0000357
2573,,,,9,,,CHEMBL617120,,Expert,B,,1,,D,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,,12687,BAO_0000357
2574,,,,9,,,CHEMBL617121,,Expert,F,,1,,D,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,12687,BAO_0000219
2575,,,,8,,,CHEMBL617122,,Autocuration,F,,1,,H,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,12687,BAO_0000219
2576,,,,8,,,CHEMBL617123,,Autocuration,B,,1,,H,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000019
2577,,,,8,,,CHEMBL617124,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,12687,BAO_0000019
2578,,,,8,,,CHEMBL617600,,Expert,B,,1,,H,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,12687,BAO_0000249
2579,,,,8,,,CHEMBL617601,,Expert,B,,1,,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,12687,BAO_0000357
2580,,,,8,,,CHEMBL882923,,Expert,B,,1,,H,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,12687,BAO_0000019
2581,,,,8,,,CHEMBL617602,,Autocuration,B,,1,,H,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2582,,,,8,,,CHEMBL617603,,Autocuration,B,,1,,H,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,12687,BAO_0000019
2583,,,,8,,,CHEMBL617604,,Autocuration,B,,1,,H,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2584,,,,8,,,CHEMBL617605,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,12687,BAO_0000019
2585,,,,8,,,CHEMBL617606,,Expert,B,,1,,H,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,12687,BAO_0000019
2586,,,,9,,,CHEMBL617607,,Expert,B,,1,,D,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000019
2587,,,,8,,,CHEMBL617455,,Autocuration,B,,1,,H,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,BAO_0000249
2588,,,,9,,,CHEMBL617456,,Expert,B,,1,,D,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,12687,BAO_0000019
2589,,,,8,,,CHEMBL617457,,Expert,B,,1,,H,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,12687,BAO_0000357
2590,,,,9,,,CHEMBL617458,,Expert,B,,1,,D,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2591,,,,9,,,CHEMBL617459,,Expert,B,,1,,D,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,,12687,BAO_0000019
2592,,,,8,,,CHEMBL617460,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,12687,BAO_0000357
2593,,,,8,,,CHEMBL617461,,Expert,B,,1,,H,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,12687,BAO_0000357
2594,,,,9,,,CHEMBL617462,,Expert,B,,1,,D,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,,12687,BAO_0000019
2595,,,,8,,,CHEMBL617463,,Autocuration,B,,1,,H,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,12687,BAO_0000357
2596,,,,8,,,CHEMBL617464,,Autocuration,B,,1,,H,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,12687,BAO_0000019
2597,,,,8,,,CHEMBL617465,,Autocuration,B,,1,,H,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,12687,BAO_0000019
2598,,,,8,,,CHEMBL617466,,Expert,B,,1,,H,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,12687,BAO_0000019
2599,,,,8,,,CHEMBL617467,,Autocuration,B,,1,,H,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,12687,BAO_0000019
2600,,,,8,,,CHEMBL617468,,Expert,B,,1,,H,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,12687,BAO_0000019
2601,,,,8,,,CHEMBL617469,,Autocuration,B,,1,,H,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,12687,BAO_0000019
2602,,,,8,,,CHEMBL617470,,Autocuration,B,,1,,H,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000019
2603,,,,8,,,CHEMBL617471,,Autocuration,B,,1,,H,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,12687,BAO_0000019
2604,723.0,,,8,,,CHEMBL617472,,Expert,B,,1,,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,NIH3T3,12687,BAO_0000219
2605,,,,8,,,CHEMBL617473,,Expert,B,,1,,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,12687,BAO_0000357
2606,,,,9,,,CHEMBL617474,,Expert,B,,1,,D,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,12687,BAO_0000019
2607,,,,9,,,CHEMBL617475,,Expert,B,,1,,D,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,12687,BAO_0000019
2608,,,955.0,8,Brain,,CHEMBL617476,,Autocuration,B,,1,,H,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,12687,BAO_0000221
2609,,,,8,,,CHEMBL617477,,Expert,B,,1,,H,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2610,723.0,,,8,,,CHEMBL617478,,Expert,B,,1,,H,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,NIH3T3,12687,BAO_0000219
2611,,,,8,,,CHEMBL617479,,Autocuration,F,,1,,H,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,12687,BAO_0000221
2612,,,,8,,,CHEMBL617480,,Autocuration,B,,1,,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,12687,BAO_0000357
2613,,,,8,,,CHEMBL617481,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2614,,,,8,,,CHEMBL617482,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,12687,BAO_0000019
2615,,,,8,,,CHEMBL617483,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,12687,BAO_0000019
2616,,,,8,,,CHEMBL621528,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,12687,BAO_0000357
2617,723.0,,,9,,,CHEMBL621529,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,NIH3T3,12687,BAO_0000219
2618,,,,8,,,CHEMBL621530,,Expert,B,,1,,H,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,12687,BAO_0000357
2619,,,,8,,,CHEMBL621531,,Expert,B,,1,,H,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687,BAO_0000357
2620,,,,9,,,CHEMBL621532,,Expert,B,,1,,D,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000019
2621,,,,8,,,CHEMBL621533,,Expert,B,,1,,H,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,12687,BAO_0000357
2622,449.0,,,8,,,CHEMBL621534,,Expert,B,,1,,H,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHO,12687,BAO_0000219
2623,,,,8,,,CHEMBL621535,,Autocuration,B,,1,,H,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,12687,BAO_0000019
2624,,,,8,,,CHEMBL621536,,Autocuration,B,,1,,H,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,12687,BAO_0000357
2625,,,,8,,,CHEMBL621537,,Autocuration,B,,1,,H,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2626,,,,9,,,CHEMBL621538,,Expert,B,,1,,D,Binding affinity for 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2627,,,,8,,,CHEMBL621539,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,12687,BAO_0000019
2628,,,,8,,,CHEMBL621540,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,12687,BAO_0000019
2629,,,,8,,,CHEMBL621541,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,12687,BAO_0000019
2630,,,,8,,,CHEMBL621542,,Autocuration,B,,1,,H,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,12687,BAO_0000019
2631,,,,8,,,CHEMBL621543,,Expert,B,,1,,H,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,12687,BAO_0000357
2632,,,,8,,,CHEMBL621544,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,12687,BAO_0000357
2633,,,,9,,,CHEMBL621545,,Expert,B,,1,,D,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,,12687,BAO_0000357
2634,,,,8,,,CHEMBL621546,,Autocuration,B,,1,,H,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687,BAO_0000357
2635,,,,8,,,CHEMBL621547,,Autocuration,B,,1,,H,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,12687,BAO_0000357
2636,723.0,,,8,,,CHEMBL618692,,Expert,B,,1,,H,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,NIH3T3,12687,BAO_0000219
2637,,,,8,,,CHEMBL618693,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2638,,,,8,,,CHEMBL872922,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,12687,BAO_0000357
2639,,,,8,,,CHEMBL618694,,Autocuration,B,,1,,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,12687,BAO_0000357
2640,,,,9,,,CHEMBL618695,,Expert,B,,1,,D,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,,12687,BAO_0000357
2641,,,,8,,,CHEMBL618696,,Autocuration,B,,1,,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,12687,BAO_0000357
2642,,,,8,,,CHEMBL618697,,Expert,B,,1,,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,12687,BAO_0000357
2643,,,,8,,,CHEMBL618892,,Autocuration,B,,1,,H,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,12687,BAO_0000357
2644,,,,8,,,CHEMBL618893,,Autocuration,B,,1,,H,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,12687,BAO_0000357
2645,,,,8,,,CHEMBL618894,,Autocuration,B,,1,,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2646,723.0,,,8,,,CHEMBL618895,,Expert,B,,1,,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,NIH3T3,12687,BAO_0000219
2647,,,,9,,,CHEMBL618896,,Expert,B,,1,,D,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,12687,BAO_0000357
2648,,,5383.0,8,Caudate-putamen,,CHEMBL618897,,Autocuration,B,,1,,H,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,12687,BAO_0000019
2649,,,,8,,,CHEMBL618898,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,12687,BAO_0000357
2650,,,,8,,,CHEMBL618899,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,12687,BAO_0000357
2651,,,,8,,,CHEMBL618900,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,12687,BAO_0000357
2652,,,,8,,,CHEMBL618901,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,12687,BAO_0000019
2653,,,,8,,,CHEMBL618902,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2654,,,10000000.0,9,Hippocampus,,CHEMBL618903,,Expert,B,,1,,D,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000221
2655,,,,8,,,CHEMBL618904,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2656,,,,8,,,CHEMBL618905,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,12687,BAO_0000357
2657,,,,8,,,CHEMBL618906,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,12687,BAO_0000357
2658,723.0,,,8,,,CHEMBL618907,,Expert,B,,1,,H,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,NIH3T3,12687,BAO_0000219
2659,,,,8,,,CHEMBL618908,,Autocuration,B,,1,,H,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,12687,BAO_0000019
2660,,,,8,,,CHEMBL617909,,Autocuration,B,,1,,H,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2661,,,,8,,,CHEMBL617910,,Expert,B,,1,,H,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,12687,BAO_0000019
2662,,,955.0,8,Brain,,CHEMBL617911,,Autocuration,B,,1,,H,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,12687,BAO_0000221
2663,,,,8,,,CHEMBL872923,,Autocuration,B,,1,,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,BAO_0000249
2664,,,,8,,,CHEMBL617912,,Autocuration,B,,1,,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,BAO_0000249
2665,,,,9,,,CHEMBL617913,,Expert,B,,1,,D,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,,12687,BAO_0000019
2666,,,,8,,,CHEMBL617914,,Expert,B,,1,,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,BAO_0000249
2667,,,,8,,,CHEMBL617915,,Autocuration,B,,1,,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,BAO_0000249
2668,,,,8,,,CHEMBL617916,,Autocuration,B,,1,,H,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687,BAO_0000249
2669,,,,9,,,CHEMBL617917,,Expert,B,,1,,D,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000019
2670,,,,8,,,CHEMBL617918,,Expert,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,12687,BAO_0000019
2671,,,,8,,,CHEMBL617919,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,12687,BAO_0000019
2672,,,,9,,,CHEMBL617920,,Expert,B,,1,,D,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,12687,BAO_0000019
2673,,,,9,,,CHEMBL617921,,Expert,B,,1,,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,,12687,BAO_0000019
2674,,,,5,,,CHEMBL617922,,Expert,B,,1,,D,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,,105102,BAO_0000224
2675,,,,8,,,CHEMBL617923,,Autocuration,B,,1,,H,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,12687,BAO_0000357
2676,,,,8,,,CHEMBL617924,,Autocuration,B,,1,,H,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687,BAO_0000357
2677,,,,8,,,CHEMBL617925,,Autocuration,B,,1,,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,12687,BAO_0000357
2678,,,,9,,,CHEMBL617926,,Expert,B,,1,,D,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,,12687,BAO_0000357
2679,,,,8,,,CHEMBL617927,,Autocuration,B,,1,,H,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,12687,BAO_0000357
2680,,,,8,,,CHEMBL617928,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,12687,BAO_0000357
2681,,,,9,,,CHEMBL617929,,Expert,B,,1,,D,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687,BAO_0000019
2682,,,,8,,,CHEMBL617930,,Expert,B,,1,,H,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,12687,BAO_0000019
2683,,,,8,,,CHEMBL617931,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,12687,BAO_0000019
2684,,,,8,,,CHEMBL617932,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,12687,BAO_0000019
2685,449.0,,,8,,,CHEMBL617933,,Autocuration,B,,1,,H,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,CHO,12687,BAO_0000219
2686,,,,8,,,CHEMBL617934,,Autocuration,B,,1,,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,12687,BAO_0000019
2687,,,,8,,,CHEMBL617935,,Autocuration,B,,1,,H,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,12687,BAO_0000019
2688,,,,8,,,CHEMBL617936,,Autocuration,B,,1,,H,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,12687,BAO_0000357
2689,,,,8,,,CHEMBL617937,,Autocuration,B,,1,,H,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,12687,BAO_0000019
2690,,,,8,,,CHEMBL617938,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,12687,BAO_0000019
2691,,,,8,,,CHEMBL617939,,Autocuration,B,,1,,H,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,12687,BAO_0000218
2692,,,,8,,,CHEMBL617940,,Autocuration,B,,1,,H,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,12687,BAO_0000218
2693,,,,8,,,CHEMBL617941,,Autocuration,B,,1,,H,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,12687,BAO_0000218
2694,,,,8,,,CHEMBL617942,,Expert,B,,1,,H,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,12687,BAO_0000357
2695,,,,8,,,CHEMBL617943,,Expert,B,,1,,H,Ratio of pKi of 5-HT2A to that of D2 receptor,,,12687,BAO_0000357
2696,,,,4,,,CHEMBL617944,,Expert,B,,1,,H,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,105093,BAO_0000224
2697,,,,4,,,CHEMBL617945,,Expert,B,,1,,H,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,105093,BAO_0000224
2698,,,,4,,,CHEMBL617946,,Expert,B,,1,,H,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,105075,BAO_0000224
2699,,,,8,,,CHEMBL617947,,Autocuration,B,,1,,H,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,12687,BAO_0000357
2700,,,,8,,,CHEMBL617948,,Expert,B,,1,,H,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,12687,BAO_0000357
2701,,,,8,,,CHEMBL858116,,Autocuration,F,,1,,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,12687,BAO_0000019
2702,,,,8,,,CHEMBL617949,,Autocuration,F,,1,,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,12687,BAO_0000019
2703,,,,8,,,CHEMBL617950,,Autocuration,F,,1,,H,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,12687,BAO_0000019
2704,,,1515.0,8,Thoracic aorta,,CHEMBL617951,,Expert,F,,1,,H,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,12687,BAO_0000019
2705,,,1515.0,8,Thoracic aorta,,CHEMBL617952,,Expert,F,,1,,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,12687,BAO_0000019
2706,,,1515.0,8,Thoracic aorta,,CHEMBL617953,,Autocuration,F,,1,,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,12687,BAO_0000019
2707,,,,8,,,CHEMBL617954,,Autocuration,B,,1,,H,Binding activity radioligand.,,,12687,BAO_0000357
2708,,,,8,,,CHEMBL617955,,Expert,B,,1,,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,12687,BAO_0000019
2709,,,,8,,,CHEMBL857071,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,12687,BAO_0000019
2710,,,,8,,,CHEMBL617270,,Expert,B,,1,,H,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,12687,BAO_0000019
2711,339.0,,,8,,,CHEMBL617271,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,N1E-115,12687,BAO_0000219
2712,339.0,,,8,,,CHEMBL617272,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,N1E-115,12687,BAO_0000219
2713,,,,8,,,CHEMBL617273,,Autocuration,B,,1,,H,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,12687,BAO_0000019
2714,,,,9,,,CHEMBL617274,,Expert,F,,1,,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,,12687,BAO_0000019
2715,,,,8,,,CHEMBL617275,,Autocuration,B,,1,,H,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2716,,,,8,,,CHEMBL617276,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2717,,,,8,,,CHEMBL617277,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2718,,,,8,,,CHEMBL617278,,Expert,B,,1,,H,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,108,BAO_0000019
2719,,,,8,,,CHEMBL617279,,Expert,B,,1,,H,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,108,BAO_0000019
2720,,,,8,,,CHEMBL617280,,Expert,B,,1,,H,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,108,BAO_0000019
2721,,,,8,,,CHEMBL617281,,Autocuration,B,,1,,H,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2722,,,,8,,,CHEMBL617282,,Autocuration,B,,1,,H,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2723,,,,8,,,CHEMBL617283,,Expert,B,,1,,H,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,108,BAO_0000019
2724,,,,8,,,CHEMBL617284,,Expert,B,,1,,H,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,108,BAO_0000019
2725,722.0,,,8,,,CHEMBL617285,,Autocuration,B,,1,,H,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,HEK293,108,BAO_0000219
2726,,,,8,,,CHEMBL617286,,Autocuration,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,108,BAO_0000019
2727,,,,9,,,CHEMBL617287,,Expert,B,,1,,D,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,,108,BAO_0000357
2728,,,,8,,,CHEMBL617288,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,108,BAO_0000357
2729,,,,8,,,CHEMBL617289,,Autocuration,B,,1,,H,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,108,BAO_0000357
2730,,,,8,,,CHEMBL872917,,Autocuration,B,,1,,H,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,108,BAO_0000357
2731,,,,8,,,CHEMBL617290,,Autocuration,B,,1,,H,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,108,BAO_0000357
2732,449.0,,,8,,,CHEMBL617291,,Autocuration,B,,1,,H,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHO,108,BAO_0000219
2733,449.0,,,8,,,CHEMBL617292,,Autocuration,B,,1,,H,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,CHO,108,BAO_0000219
2734,723.0,,,8,,,CHEMBL617293,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,NIH3T3,108,BAO_0000219
2735,449.0,,,9,,,CHEMBL617294,,Expert,F,,1,,D,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHO,108,BAO_0000219
2736,,,,8,,,CHEMBL617295,,Expert,B,,1,,H,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,108,BAO_0000019
2737,,,,8,,,CHEMBL617296,,Autocuration,B,,1,,H,Binding activity radioligand.,,,108,BAO_0000357
2738,,,,8,,,CHEMBL617297,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,108,BAO_0000019
2739,449.0,,,8,,,CHEMBL617298,,Expert,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,CHO,108,BAO_0000219
2740,449.0,,,8,,,CHEMBL617299,,Expert,B,,1,,H,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,CHO,108,BAO_0000219
2741,449.0,,,8,,,CHEMBL617300,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,CHO,108,BAO_0000219
2742,,,,8,,,CHEMBL617454,,Autocuration,B,,1,,H,Binding affinity against 5-HT2C receptor,,,108,BAO_0000357
2743,722.0,,,8,,,CHEMBL617505,,Autocuration,B,,1,,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,HEK293,108,BAO_0000219
2744,722.0,,,9,,,CHEMBL617506,,Expert,B,,1,,D,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,HEK293,108,BAO_0000219
2745,722.0,,,9,,,CHEMBL617507,,Expert,B,,1,,D,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,HEK293,108,BAO_0000219
2746,,,,8,,,CHEMBL617508,,Expert,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,108,BAO_0000357
2747,722.0,,,9,,,CHEMBL857982,,Expert,B,,1,,D,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,HEK293,108,BAO_0000219
2748,722.0,,,9,,,CHEMBL617509,,Expert,B,,1,,D,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,HEK293,108,BAO_0000219
2749,722.0,,,9,,,CHEMBL617510,,Expert,B,,1,,D,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,HEK293,108,BAO_0000219
2750,,,,8,,,CHEMBL617511,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,108,BAO_0000357
2751,722.0,,,8,,,CHEMBL617512,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,HEK293,108,BAO_0000219
2752,722.0,,,8,,,CHEMBL617749,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,HEK293,108,BAO_0000219
2753,722.0,,,8,,,CHEMBL617750,,Autocuration,B,,1,,H,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,HEK293,108,BAO_0000219
2754,722.0,,,8,,,CHEMBL617751,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,HEK293,108,BAO_0000219
2755,722.0,,,8,,,CHEMBL617752,,Expert,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,HEK293,108,BAO_0000219
2756,722.0,,,8,,,CHEMBL617753,,Autocuration,B,,1,,H,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,HEK293,108,BAO_0000219
2757,722.0,,,8,,,CHEMBL617754,,Expert,B,,1,,H,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,HEK293,108,BAO_0000219
2758,722.0,,,9,,,CHEMBL617755,,Expert,B,,1,,D,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,HEK293,108,BAO_0000219
2759,722.0,,,8,,,CHEMBL617756,,Autocuration,B,,1,,H,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,HEK293,108,BAO_0000219
2760,722.0,,,8,,,CHEMBL617757,,Expert,B,,1,,H,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,HEK293,108,BAO_0000219
2761,722.0,,,8,,,CHEMBL617758,,Expert,B,,1,,H,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,HEK293,108,BAO_0000219
2762,723.0,,,8,,,CHEMBL617759,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,NIH3T3,108,BAO_0000219
2763,722.0,,,8,,,CHEMBL617760,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,HEK293,108,BAO_0000219
2764,485.0,,,8,,,CHEMBL617761,,Expert,B,,1,,H,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,CHO-K1,108,BAO_0000219
2765,,,,9,,,CHEMBL617762,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2766,,,,8,,,CHEMBL617763,,Autocuration,B,,1,,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2767,722.0,,,8,,,CHEMBL857983,,Autocuration,B,,1,,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,HEK293,108,BAO_0000219
2768,722.0,,,8,,,CHEMBL617764,,Autocuration,B,,1,,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,HEK293,108,BAO_0000219
2769,308.0,,,8,,,CHEMBL617765,,Autocuration,B,,1,,H,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,HeLa,108,BAO_0000219
2770,,,,8,,,CHEMBL617766,,Autocuration,F,,1,,H,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,108,BAO_0000019
2771,,,10000000.0,8,Hippocampus,,CHEMBL617767,,Autocuration,F,,1,,H,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,108,BAO_0000221
2772,722.0,,,8,,,CHEMBL617768,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,HEK293,108,BAO_0000219
2773,722.0,,,8,,,CHEMBL617769,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,HEK293,108,BAO_0000219
2774,,,,8,,,CHEMBL858023,,Autocuration,B,,1,,H,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,11864,BAO_0000357
2775,,,945.0,8,Stomach,,CHEMBL617770,,Autocuration,B,,1,,H,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,11864,BAO_0000019
2776,,,945.0,8,Stomach,,CHEMBL617771,,Autocuration,B,,1,,H,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,11864,BAO_0000019
2777,625.0,,,8,,,CHEMBL617772,,Autocuration,F,,1,,H,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,A9,11864,BAO_0000219
2778,723.0,,,8,,,CHEMBL617773,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,NIH3T3,11864,BAO_0000219
2779,723.0,,,8,,,CHEMBL617850,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,NIH3T3,11864,BAO_0000219
2780,723.0,,,8,,,CHEMBL617851,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,NIH3T3,11864,BAO_0000219
2781,,,,8,,,CHEMBL617852,,Autocuration,F,,1,,H,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,11864,BAO_0000019
2782,,,945.0,8,Stomach,,CHEMBL858024,,Autocuration,B,,1,,H,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,,12689,BAO_0000019
2783,,,945.0,9,Stomach,,CHEMBL617853,,Expert,B,,1,,D,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,,12689,BAO_0000019
2784,,,,8,,,CHEMBL617854,,Expert,B,,1,,H,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,108,BAO_0000357
2785,,,,8,,,CHEMBL873477,,Expert,B,,1,,H,Binding affinity for 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2786,,,,8,,,CHEMBL617855,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2787,,,,8,,,CHEMBL617856,,Expert,B,,1,,H,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,108,BAO_0000019
2788,,,,8,,,CHEMBL617857,,Autocuration,B,,1,,H,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,108,BAO_0000019
2789,,,,8,,,CHEMBL617858,,Autocuration,B,,1,,H,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,108,BAO_0000249
2790,,,,8,,,CHEMBL617859,,Autocuration,B,,1,,H,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2791,,,,8,,,CHEMBL617860,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2792,,,,8,,,CHEMBL617861,,Autocuration,B,,1,,H,Binding activity radioligand.,,,108,BAO_0000357
2793,,,,8,,,CHEMBL617862,,Expert,B,,1,,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,108,BAO_0000019
2794,,,,8,,,CHEMBL617863,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,108,BAO_0000019
2795,,,,8,,,CHEMBL617864,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,108,BAO_0000249
2796,,,,8,,,CHEMBL617649,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,108,BAO_0000249
2797,,,,8,,,CHEMBL617650,,Expert,F,,1,,H,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,108,BAO_0000019
2798,,,,8,,,CHEMBL617651,,Expert,F,,1,,H,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,108,BAO_0000019
2799,,,,8,,,CHEMBL617652,,Autocuration,B,,1,,H,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,,108,BAO_0000357
2800,,,,8,,,CHEMBL857072,,Autocuration,B,,1,,H,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,,108,BAO_0000019
2801,,,,8,,,CHEMBL617653,,Autocuration,B,,1,,H,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2802,,,,8,,,CHEMBL617654,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,12687,BAO_0000019
2803,,,,8,,,CHEMBL617655,,Autocuration,F,,1,,H,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000019
2804,,,,8,,,CHEMBL617656,,Expert,B,,1,,H,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,12689,BAO_0000357
2805,,,,8,,,CHEMBL617657,,Autocuration,B,,1,,H,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,12689,BAO_0000357
2806,,,,8,,,CHEMBL617658,,Autocuration,B,,1,,H,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,12689,BAO_0000357
2807,,,,9,,,CHEMBL617659,,Expert,B,,1,,D,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000357
2808,,,,9,,,CHEMBL617838,,Expert,B,,1,,D,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000357
2809,,,,9,,,CHEMBL617839,,Expert,B,,1,Brain membranes,D,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,,12689,BAO_0000249
2810,,,,8,,,CHEMBL617840,,Autocuration,B,,1,,H,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,12689,BAO_0000357
2811,,,,8,,,CHEMBL617841,,Autocuration,B,,1,,H,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,12689,BAO_0000019
2812,,,,8,,,CHEMBL875915,,Autocuration,B,,1,,H,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,12689,BAO_0000019
2813,,,,8,,In vitro,CHEMBL617842,,Expert,B,,1,,H,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,,12689,BAO_0000219
2814,723.0,,,8,,,CHEMBL617843,,Expert,B,,1,,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,NIH3T3,12689,BAO_0000219
2815,,,,8,,,CHEMBL617844,,Expert,B,,1,,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,12689,BAO_0000357
2816,,,,8,,,CHEMBL617845,,Expert,B,,1,,H,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000357
2817,723.0,,,8,,,CHEMBL617846,,Expert,B,,1,,H,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,NIH3T3,12689,BAO_0000219
2818,,,,8,,,CHEMBL617847,,Autocuration,B,,1,,H,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,12689,BAO_0000357
2819,,,,8,,,CHEMBL617848,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000357
2820,,,,8,,,CHEMBL617849,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,12689,BAO_0000357
2821,,,,8,,,CHEMBL621507,,Expert,B,,1,,H,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,12689,BAO_0000357
2822,,,,8,,,CHEMBL621508,,Expert,B,,1,,H,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,12689,BAO_0000357
2823,,,,8,,,CHEMBL621509,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,12689,BAO_0000019
2824,,,,8,,,CHEMBL621510,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,12689,BAO_0000019
2825,,,,8,,,CHEMBL621511,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,12689,BAO_0000019
2826,625.0,,,8,,,CHEMBL621512,,Expert,B,,1,,H,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,A9,12689,BAO_0000219
2827,,,,8,,,CHEMBL621513,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,12689,BAO_0000357
2828,,,,8,,,CHEMBL621514,,Expert,B,,1,,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,12689,BAO_0000357
2829,,,,8,,In vitro,CHEMBL621515,,Expert,B,,1,,H,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,,12689,BAO_0000219
2830,,,,8,,,CHEMBL621516,,Autocuration,B,,1,,H,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,12689,BAO_0000219
2831,,,5383.0,8,Caudate-putamen,,CHEMBL621517,,Autocuration,B,,1,,H,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,12689,BAO_0000019
2832,,,,8,,,CHEMBL621518,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,12689,BAO_0000357
2833,,,,8,,,CHEMBL621519,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,12689,BAO_0000019
2834,,,,8,,,CHEMBL621520,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000357
2835,,,,8,,,CHEMBL621521,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000357
2836,,,,8,,,CHEMBL621522,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,12689,BAO_0000357
2837,,,,8,,,CHEMBL621523,,Expert,B,,1,,H,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,12689,BAO_0000219
2838,,,,8,,,CHEMBL621524,,Autocuration,B,,1,,H,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000357
2839,,,,9,,,CHEMBL621525,,Expert,B,,1,,D,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,,12689,BAO_0000357
2840,,,,8,,,CHEMBL872921,,Autocuration,B,,1,,H,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,12689,BAO_0000357
2841,,,,8,,,CHEMBL621526,,Autocuration,B,,1,,H,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000357
2842,,,,8,,,CHEMBL621527,,Expert,B,,1,,H,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,12689,BAO_0000219
2843,,,,9,,,CHEMBL617865,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,,12689,BAO_0000019
2844,,,,8,,,CHEMBL617866,,Autocuration,B,,1,,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000357
2845,,,,8,,,CHEMBL617867,,Autocuration,B,,1,,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,12689,BAO_0000019
2846,,,,8,,,CHEMBL617487,,Autocuration,B,,1,,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,12689,BAO_0000357
2847,,,,8,,,CHEMBL617488,,Expert,B,,1,,H,Binding affinity for 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000357
2848,,,,8,,,CHEMBL617489,,Autocuration,B,,1,,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,12689,BAO_0000357
2849,,,,8,,,CHEMBL617490,,Autocuration,B,,1,,H,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,12689,BAO_0000019
2850,,,,8,,,CHEMBL617491,,Autocuration,B,,1,,H,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,12689,BAO_0000019
2851,,,,8,,,CHEMBL617492,,Autocuration,B,,1,,H,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,12689,BAO_0000019
2852,,,,8,,,CHEMBL617493,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,12689,BAO_0000019
2853,,,,8,,,CHEMBL617494,,Autocuration,B,,1,,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,12689,BAO_0000357
2854,,,,9,,,CHEMBL617495,,Expert,B,,1,,D,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,,12689,BAO_0000019
2855,,,,8,,,CHEMBL617496,,Autocuration,B,,1,,H,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,12689,BAO_0000357
2856,485.0,,,8,,,CHEMBL617497,,Autocuration,B,,1,,H,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,CHO-K1,12689,BAO_0000219
2857,,,,8,,,CHEMBL617498,,Autocuration,B,,1,,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,12689,BAO_0000357
2858,,,,8,,,CHEMBL617499,,Autocuration,B,,1,,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,12689,BAO_0000357
2859,,,,8,,,CHEMBL617500,,Autocuration,F,,1,,H,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,12689,BAO_0000019
2860,,,,8,,,CHEMBL617501,,Autocuration,B,,1,,H,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2861,,,,8,,,CHEMBL617502,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2862,,,,8,,,CHEMBL617503,,Autocuration,B,,1,,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,227,BAO_0000357
2863,,,,8,,,CHEMBL617504,,Autocuration,B,,1,,H,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,227,BAO_0000357
2864,,,,8,,,CHEMBL617406,,Autocuration,B,,1,,H,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,227,BAO_0000357
2865,,,,9,,,CHEMBL617407,,Expert,B,,1,,D,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,,227,BAO_0000019
2866,,,,8,,,CHEMBL617408,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,227,BAO_0000357
2867,,,,8,,,CHEMBL617409,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,227,BAO_0000357
2868,,,,8,,,CHEMBL617410,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,227,BAO_0000357
2869,,,,8,,,CHEMBL617411,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,227,BAO_0000357
2870,,,,8,,,CHEMBL617412,,Autocuration,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,227,BAO_0000019
2871,,,,9,,,CHEMBL617774,,Expert,B,,1,,D,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,,227,BAO_0000357
2872,722.0,,,9,,,CHEMBL617775,,Expert,B,,1,,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,HEK293,227,BAO_0000219
2873,722.0,,,9,,,CHEMBL617776,,Expert,B,,1,,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,HEK293,227,BAO_0000219
2874,449.0,,,9,,,CHEMBL617777,,Expert,F,,1,,D,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHO,227,BAO_0000219
2875,449.0,,,9,,,CHEMBL617778,,Expert,F,,1,,D,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHO,227,BAO_0000219
2876,722.0,,,8,,,CHEMBL617779,,Autocuration,B,,1,,H,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,HEK293,227,BAO_0000219
2877,722.0,,,8,,,CHEMBL617780,,Expert,B,,1,,H,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,HEK293,227,BAO_0000219
2878,722.0,,,8,,,CHEMBL617781,,Autocuration,B,,1,,H,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,HEK293,227,BAO_0000219
2879,722.0,,,9,,,CHEMBL617782,,Expert,B,,1,,D,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,HEK293,227,BAO_0000219
2880,722.0,,,9,,,CHEMBL617783,,Expert,B,,1,,D,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,HEK293,227,BAO_0000219
2881,,,,8,,,CHEMBL617784,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,227,BAO_0000357
2882,722.0,,,8,,,CHEMBL617785,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,HEK293,227,BAO_0000219
2883,722.0,,,8,,,CHEMBL857984,,Expert,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,HEK293,227,BAO_0000219
2884,722.0,,,8,,,CHEMBL617786,,Expert,B,,1,,H,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,HEK293,227,BAO_0000219
2885,722.0,,,8,,,CHEMBL617787,,Expert,B,,1,,H,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,HEK293,227,BAO_0000219
2886,722.0,,,9,,,CHEMBL617788,,Expert,B,,1,,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,HEK293,227,BAO_0000219
2887,722.0,,,9,,,CHEMBL617789,,Expert,B,,1,,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,HEK293,227,BAO_0000219
2888,722.0,,,8,,,CHEMBL617790,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,HEK293,227,BAO_0000219
2889,485.0,,,8,,,CHEMBL617791,,Expert,B,,1,,H,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,CHO-K1,227,BAO_0000219
2890,,,,8,,,CHEMBL617608,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2B receptor,,,227,BAO_0000357
2891,722.0,,,8,,,CHEMBL617609,,Autocuration,B,,1,,H,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,HEK293,227,BAO_0000219
2892,722.0,,,8,,,CHEMBL617610,,Autocuration,B,,1,,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,HEK293,227,BAO_0000219
2893,722.0,,,8,,,CHEMBL617611,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,HEK293,227,BAO_0000219
2894,722.0,,,8,,,CHEMBL617612,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,HEK293,227,BAO_0000219
2895,722.0,,,8,,,CHEMBL617613,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,HEK293,227,BAO_0000219
2896,,,,8,,,CHEMBL617614,,Autocuration,B,,1,,H,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,,227,BAO_0000019
2897,,,945.0,8,Stomach,,CHEMBL617615,,Expert,B,,1,,H,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,12688,BAO_0000019
2898,,,945.0,8,Stomach,,CHEMBL858114,,Expert,B,,1,,H,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,12688,BAO_0000357
2899,,,945.0,8,Stomach,,CHEMBL617616,,Autocuration,B,,1,,H,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,12688,BAO_0000357
2900,,,945.0,9,Stomach,,CHEMBL617617,,Expert,F,,1,,D,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,,12688,BAO_0000019
2901,,,,9,,,CHEMBL875914,,Expert,F,,1,,D,Antagonistic against 5-hydroxytryptamine 2B receptor,,,12688,BAO_0000019
2902,,,945.0,8,Stomach,,CHEMBL617618,,Autocuration,F,,1,,H,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,12688,BAO_0000019
2903,,,945.0,9,Stomach,,CHEMBL617619,,Expert,B,,1,,D,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,,12688,BAO_0000357
2904,,,,8,,,CHEMBL617620,,Autocuration,F,,1,,H,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,12688,BAO_0000019
2905,,,,8,,,CHEMBL617621,,Autocuration,F,,1,,H,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,12688,BAO_0000019
2906,,,,8,,,CHEMBL617622,,Autocuration,F,,1,,H,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,12688,BAO_0000019
2907,,,945.0,9,Stomach,,CHEMBL617623,,Expert,B,,1,,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,12688,BAO_0000357
2908,,,945.0,9,Stomach,,CHEMBL617624,,Expert,B,,1,,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,12688,BAO_0000357
2909,,,945.0,9,Stomach,,CHEMBL617625,,Expert,B,,1,,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,12688,BAO_0000357
2910,,,945.0,9,Stomach,,CHEMBL617626,,Expert,B,,1,,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,12688,BAO_0000357
2911,,,945.0,8,Stomach,,CHEMBL617627,,Autocuration,F,,1,,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,12688,BAO_0000019
2912,,,945.0,8,Stomach,,CHEMBL617628,,Expert,F,,1,,H,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,12688,BAO_0000019
2913,,,945.0,8,Stomach,,CHEMBL617629,,Autocuration,F,,1,,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,12688,BAO_0000019
2914,,,945.0,8,Stomach,,CHEMBL858115,,Autocuration,F,,1,,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,12688,BAO_0000019
2915,,,945.0,9,Stomach,,CHEMBL617630,,Expert,F,,1,,D,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,,12688,BAO_0000019
2916,,,1515.0,8,Thoracic aorta,,CHEMBL617631,,Autocuration,F,,1,,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,12688,BAO_0000019
2917,,,,8,,,CHEMBL617632,,Autocuration,B,,1,,H,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,12688,BAO_0000357
2918,,,,8,,,CHEMBL617633,,Expert,B,,1,,H,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,12688,BAO_0000357
2919,,,,8,,,CHEMBL617634,,Autocuration,B,,1,,H,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,12688,BAO_0000357
2920,,,,8,,,CHEMBL617635,,Autocuration,B,,1,,H,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,12688,BAO_0000357
2922,,,945.0,9,Stomach,,CHEMBL617637,,Autocuration,F,,1,,D,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,12688,BAO_0000019
2923,,,,8,,,CHEMBL617638,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 1A receptor,,,227,BAO_0000357
2924,,,,8,,,CHEMBL617639,,Autocuration,B,,1,,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,227,BAO_0000357
2925,,,,8,,,CHEMBL617640,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,227,BAO_0000357
2926,,,,8,,,CHEMBL617641,,Autocuration,B,,1,,H,Evaluated for the binding affinity to 5-HT 2B receptor,,,227,BAO_0000357
2927,,,,8,,,CHEMBL617642,,Autocuration,B,,1,,H,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,227,BAO_0000357
2928,,,,8,,,CHEMBL617643,,Autocuration,B,,1,,H,Binding affinities against 5-hydroxytryptamine 2B receptor,,,227,BAO_0000357
2929,,,,8,,,CHEMBL617644,,Autocuration,B,,1,,H,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,227,BAO_0000357
2930,,,,8,,,CHEMBL617645,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,227,BAO_0000357
2931,,,,8,,,CHEMBL617646,,Expert,B,,1,,H,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,108,BAO_0000357
2932,,,,8,,,CHEMBL617647,,Autocuration,B,,1,,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,108,BAO_0000357
2933,,,,8,,,CHEMBL617648,,Autocuration,B,,1,,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,,108,BAO_0000357
2934,,,,8,,,CHEMBL617875,,Autocuration,B,,1,,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,,108,BAO_0000357
2935,,,,8,,,CHEMBL617876,,Autocuration,B,,1,,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,,108,BAO_0000357
2936,,,,8,,,CHEMBL617877,,Expert,B,,1,,H,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,,108,BAO_0000357
2937,,,,8,,,CHEMBL617878,,Expert,B,,1,,H,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,108,BAO_0000357
2938,,,,8,,,CHEMBL617879,,Autocuration,B,,1,,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,108,BAO_0000357
2939,,,,8,,,CHEMBL617880,,Autocuration,B,,1,,H,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,,108,BAO_0000019
2940,,,2435.0,9,Striatum,,CHEMBL617881,,Intermediate,B,,1,,D,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,,20033,BAO_0000357
2941,,,,8,,,CHEMBL857073,,Autocuration,B,,1,,H,Binding affinity against 5-HT1A receptor,,,51,BAO_0000357
2942,449.0,,,8,,,CHEMBL617882,,Expert,F,,1,,H,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,CHO,108,BAO_0000219
2943,449.0,,,9,,,CHEMBL617883,,Expert,F,,1,,D,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,CHO,108,BAO_0000219
2944,,,,8,,,CHEMBL617884,,Autocuration,F,,1,,H,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,108,BAO_0000219
2945,449.0,,,8,,,CHEMBL617885,,Autocuration,B,,1,,H,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,CHO,108,BAO_0000219
2946,449.0,,,8,,,CHEMBL617886,,Autocuration,B,,1,,H,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,CHO,108,BAO_0000219
2947,,,,9,,,CHEMBL617887,,Expert,B,,1,,D,Inhibition of human 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2948,,,,8,,,CHEMBL617888,,Autocuration,B,,1,,H,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,108,BAO_0000357
2949,,,,8,,,CHEMBL617889,,Autocuration,B,,1,,H,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,108,BAO_0000019
2950,,,,8,,,CHEMBL617890,,Autocuration,B,,1,,H,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2951,,,,8,,,CHEMBL617891,,Autocuration,B,,1,,H,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,108,BAO_0000357
2952,,,,8,,,CHEMBL617892,,Autocuration,B,,1,,H,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,108,BAO_0000357
2953,449.0,,,8,,,CHEMBL617893,,Expert,B,,1,,H,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,CHO,108,BAO_0000219
2954,449.0,,,8,,,CHEMBL617894,,Expert,B,,1,,H,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,CHO,108,BAO_0000219
2955,449.0,,,8,,,CHEMBL617895,,Expert,B,,1,,H,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHO,108,BAO_0000219
2956,449.0,,,8,,,CHEMBL617896,,Autocuration,B,,1,,H,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,CHO,108,BAO_0000219
2957,,,,9,,,CHEMBL617897,,Expert,B,,1,,D,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,,108,BAO_0000357
2958,,,,8,,,CHEMBL617898,,Autocuration,F,,1,,H,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,108,BAO_0000019
2959,,,,8,,,CHEMBL617899,,Autocuration,F,,1,,H,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,108,BAO_0000019
2960,449.0,,,8,,,CHEMBL617900,,Expert,B,,1,,H,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,CHO,108,BAO_0000219
2961,,,,8,,,CHEMBL617901,,Autocuration,F,,1,,H,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,108,BAO_0000019
2962,,,,8,,,CHEMBL617902,,Autocuration,F,,1,,H,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,108,BAO_0000019
2963,,,,8,,,CHEMBL617903,,Autocuration,F,,1,,H,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,108,BAO_0000019
2964,,,,8,,,CHEMBL617904,,Autocuration,B,,1,,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,108,BAO_0000357
2965,,,,8,,,CHEMBL617905,,Autocuration,B,,1,,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,108,BAO_0000357
2966,,,,8,,,CHEMBL617906,,Autocuration,B,,1,,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,108,BAO_0000357
2967,,,,8,,,CHEMBL617907,,Autocuration,B,,1,,H,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,108,BAO_0000357
2968,,,,8,,,CHEMBL617908,,Autocuration,B,,1,,H,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,108,BAO_0000357
2969,449.0,,,8,,,CHEMBL620617,,Expert,B,,1,,H,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHO,108,BAO_0000219
2970,,,,9,,,CHEMBL620618,,Expert,B,,1,,D,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,,108,BAO_0000019
2971,,,,8,,,CHEMBL620619,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,108,BAO_0000357
2972,,,,9,,,CHEMBL620620,,Expert,B,,1,,D,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
2973,,,,8,,,CHEMBL620621,,Autocuration,B,,1,,H,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,108,BAO_0000357
2974,,,,7,,,CHEMBL872920,,Autocuration,B,,1,Membranes,D,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,,104698,BAO_0000249
2975,,,,6,,,CHEMBL620622,,Autocuration,B,,1,,H,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,104698,BAO_0000223
2976,,,,7,,,CHEMBL620623,,Autocuration,B,,1,,D,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,,104698,BAO_0000019
2977,,,,6,,,CHEMBL620624,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,104698,BAO_0000019
2978,,,,6,,,CHEMBL620625,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,104698,BAO_0000019
2979,,,,6,,,CHEMBL620626,,Autocuration,B,,1,,H,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,104698,BAO_0000219
2980,,,,6,,,CHEMBL621307,,Autocuration,B,,1,,H,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,104698,BAO_0000019
2981,,,,6,,,CHEMBL621308,,Autocuration,B,,1,,H,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,104698,BAO_0000019
2982,,,,6,,,CHEMBL621309,,Autocuration,B,,1,,H,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,104698,BAO_0000223
2983,,,,6,,,CHEMBL621310,,Autocuration,B,,1,,H,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,104698,BAO_0000223
2984,,,,6,,,CHEMBL621311,,Autocuration,B,,1,,H,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,104698,BAO_0000223
2985,,,,6,,,CHEMBL621502,,Autocuration,B,,1,,H,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,104698,BAO_0000249
2986,,,,6,,,CHEMBL621503,,Autocuration,B,,1,,H,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,104698,BAO_0000249
2987,,,,6,,,CHEMBL621504,,Autocuration,B,,1,Membranes,H,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,104698,BAO_0000249
2988,,,,6,,,CHEMBL621505,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000223
2989,,,,6,,,CHEMBL621506,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,104698,BAO_0000019
2990,,,,6,,,CHEMBL619781,,Autocuration,B,,1,,H,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,104698,BAO_0000223
2991,,,,6,,,CHEMBL619782,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,104698,BAO_0000223
2992,,,,6,,,CHEMBL619783,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,104698,BAO_0000019
2993,,,,7,,,CHEMBL619784,,Autocuration,B,,1,,D,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,,104698,BAO_0000019
2994,,,,6,,,CHEMBL619785,,Autocuration,B,,1,,H,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,104698,BAO_0000249
2995,,,,6,,,CHEMBL619786,,Autocuration,B,,1,,H,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000223
2996,,,,6,,,CHEMBL619787,,Autocuration,B,,1,,H,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,104698,BAO_0000019
2997,,,,6,,,CHEMBL872925,,Autocuration,B,,1,,H,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,104698,BAO_0000019
2998,,,,6,,,CHEMBL619788,,Autocuration,B,,1,,H,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,104698,BAO_0000019
2999,,,,6,,,CHEMBL619789,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,104698,BAO_0000249
3000,,,,6,,,CHEMBL619790,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,104698,BAO_0000249
3001,,,,6,,,CHEMBL619791,,Autocuration,B,,1,,H,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,104698,BAO_0000019
3002,,,,6,,,CHEMBL619792,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,104698,BAO_0000019
3003,,,,6,,,CHEMBL619793,,Autocuration,B,,1,Membranes,H,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,104698,BAO_0000249
3004,,,,7,,,CHEMBL619794,,Autocuration,B,,1,,D,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000223
3005,,,955.0,6,Brain,,CHEMBL619795,,Autocuration,B,,1,,H,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,104698,BAO_0000221
3006,,,,6,,,CHEMBL619796,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,104698,BAO_0000019
3007,,,,6,,,CHEMBL620448,,Autocuration,B,,1,,H,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,104698,BAO_0000223
3008,,,,6,,,CHEMBL620449,,Autocuration,B,,1,,H,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,104698,BAO_0000223
3009,,,,6,,,CHEMBL620450,,Autocuration,B,,1,,H,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,104698,BAO_0000223
3010,,,,6,,,CHEMBL620451,,Autocuration,B,,1,,H,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,104698,BAO_0000223
3011,,,,6,,,CHEMBL620631,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,104698,BAO_0000223
3012,,,,6,,,CHEMBL620632,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,104698,BAO_0000019
3013,,,,6,,,CHEMBL620633,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,104698,BAO_0000019
3014,,,,6,,,CHEMBL620634,,Autocuration,B,,1,,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,104698,BAO_0000223
3015,,,,6,,,CHEMBL620635,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,104698,BAO_0000019
3016,,,,6,,In vivo,CHEMBL620636,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3017,,,,6,,In vivo,CHEMBL620637,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,,104698,BAO_0000218
3018,,,,6,,In vivo,CHEMBL620638,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3019,,,,6,,In vivo,CHEMBL620639,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3020,,,,6,,In vivo,CHEMBL620640,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3021,,,,6,,In vivo,CHEMBL620641,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,,104698,BAO_0000218
3022,,,,6,,In vivo,CHEMBL620642,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3023,,,,6,,In vivo,CHEMBL620643,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3024,,,,6,,In vivo,CHEMBL620644,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3025,,,,6,,In vivo,CHEMBL620645,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3026,,,,6,,In vivo,CHEMBL620646,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,,104698,BAO_0000218
3027,,,,6,,In vivo,CHEMBL620647,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3028,,,,6,,In vivo,CHEMBL620648,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3029,,,,6,,In vivo,CHEMBL620649,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3030,,,,6,,In vivo,CHEMBL620650,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3031,,,,6,,In vivo,CHEMBL620651,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,,104698,BAO_0000218
3032,,,,6,,In vivo,CHEMBL872875,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,,104698,BAO_0000218
3033,,,,6,,In vivo,CHEMBL620652,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,,104698,BAO_0000218
3034,,,,6,,,CHEMBL620653,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,104698,BAO_0000019
3035,,,,6,,,CHEMBL857076,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,104698,BAO_0000019
3036,,,,7,,,CHEMBL620654,,Autocuration,B,,1,,D,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000019
3037,,,,6,,,CHEMBL620655,,Autocuration,B,,1,,H,Binding activity radioligand.,,,104698,BAO_0000223
3038,,,,6,,,CHEMBL620656,,Autocuration,B,,1,Brain membranes,H,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,104698,BAO_0000249
3039,,,,6,,,CHEMBL620657,,Autocuration,B,,1,Brain membranes,H,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,104698,BAO_0000249
3040,,,,8,,,CHEMBL620658,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,108,BAO_0000357
3041,,,,8,,,CHEMBL620659,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,108,BAO_0000357
3042,,,,8,,,CHEMBL620660,,Autocuration,B,,1,,H,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,108,BAO_0000357
3043,,,,8,,,CHEMBL620661,,Autocuration,B,,1,,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
3044,,,,8,,,CHEMBL620662,,Autocuration,B,,1,,H,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
3045,,,,8,,,CHEMBL620663,,Expert,B,,1,,H,Affinity for 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
3046,,,,8,,,CHEMBL620664,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,108,BAO_0000357
3047,,,,8,,,CHEMBL620665,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,108,BAO_0000357
3048,,,,8,,,CHEMBL620666,,Autocuration,B,,1,,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,108,BAO_0000357
3049,,,,8,,,CHEMBL620667,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,108,BAO_0000357
3050,,,,8,,,CHEMBL620668,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,108,BAO_0000357
3051,,,,8,,,CHEMBL620669,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,108,BAO_0000357
3052,,,,8,,,CHEMBL620670,,Expert,B,,1,,H,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
3053,,,,8,,,CHEMBL620671,,Autocuration,B,,1,,H,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
3054,,,,8,,,CHEMBL620672,,Autocuration,B,,1,,H,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,108,BAO_0000357
3055,,,,8,,,CHEMBL620673,,Autocuration,B,,1,,H,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,108,BAO_0000357
3056,,,,8,,,CHEMBL620674,,Autocuration,B,,1,,H,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
3057,,,,8,,,CHEMBL620675,,Autocuration,B,,1,,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
3058,,,,8,,,CHEMBL620676,,Autocuration,B,,1,,H,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,108,BAO_0000357
3059,,,,8,,,CHEMBL621382,,Autocuration,B,,1,,H,Affinity against 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
3060,,,,9,,,CHEMBL621383,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
3061,,,,8,,,CHEMBL621384,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,108,BAO_0000357
3062,,,,8,,,CHEMBL621385,,Autocuration,B,,1,,H,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,,144,BAO_0000357
3063,,,,8,,,CHEMBL617989,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,,144,BAO_0000357
3064,,,,4,,,CHEMBL617990,,Expert,F,,1,,H,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,,104714,BAO_0000019
3065,,,2116.0,4,Ileum,,CHEMBL875085,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,104714,BAO_0000221
3066,,,,4,,,CHEMBL617991,,Autocuration,F,,1,,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,,104714,BAO_0000019
3067,,,,4,,,CHEMBL617992,,Autocuration,F,,1,,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,,104714,BAO_0000019
3068,,,2116.0,4,Ileum,,CHEMBL617993,,Autocuration,B,,1,,H,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,104714,BAO_0000221
3069,,,2116.0,4,Ileum,,CHEMBL617994,,Autocuration,B,,1,,H,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,,104714,BAO_0000221
3070,,,,4,,,CHEMBL617995,,Autocuration,F,,1,,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,,104714,BAO_0000019
3071,,,,4,,,CHEMBL617996,,Autocuration,F,,1,,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,,104714,BAO_0000019
3072,,,,4,,,CHEMBL617997,,Autocuration,F,,1,,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,,104714,BAO_0000019
3073,,,,4,,,CHEMBL617998,,Autocuration,F,,1,,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,,104714,BAO_0000019
3074,,,,4,,,CHEMBL617999,,Autocuration,F,,1,,H,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,,104714,BAO_0000019
3075,,,,4,,,CHEMBL618000,,Autocuration,F,,1,,H,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,,104714,BAO_0000019
3076,,,2116.0,4,Ileum,,CHEMBL617815,,Autocuration,F,,1,,H,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,,104714,BAO_0000221
3077,,,2116.0,4,Ileum,,CHEMBL617816,,Autocuration,F,,1,,H,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,,104714,BAO_0000221
3078,,,2116.0,4,Ileum,,CHEMBL617817,,Autocuration,F,,1,,H,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,,104714,BAO_0000221
3079,,,2116.0,4,Ileum,,CHEMBL617818,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,,104714,BAO_0000221
3080,,,2116.0,4,Ileum,,CHEMBL617819,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,,104714,BAO_0000221
3081,,,,4,,,CHEMBL617820,,Autocuration,B,,1,,H,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,,104714,BAO_0000223
3082,,,2116.0,4,Ileum,,CHEMBL617821,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,104714,BAO_0000221
3083,,,2116.0,4,Ileum,,CHEMBL617822,,Autocuration,F,,1,,H,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,104714,BAO_0000221
3084,,,2116.0,4,Ileum,,CHEMBL617823,,Autocuration,F,,1,,H,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,,104714,BAO_0000221
3085,,,2116.0,4,Ileum,,CHEMBL617824,,Autocuration,F,,1,,H,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,,104714,BAO_0000221
3086,,,2116.0,4,Ileum,,CHEMBL617825,,Autocuration,F,,1,,H,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,,104714,BAO_0000221
3087,,,2116.0,4,Ileum,,CHEMBL617826,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,,104714,BAO_0000221
3088,,,2116.0,4,Ileum,,CHEMBL617827,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,104714,BAO_0000221
3089,,,2116.0,4,Ileum,,CHEMBL617828,,Autocuration,F,,1,,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,104714,BAO_0000221
3090,,,2116.0,4,Ileum,,CHEMBL617829,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,104714,BAO_0000221
3091,,,2116.0,4,Ileum,,CHEMBL617830,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,,104714,BAO_0000221
3092,,,2116.0,4,Ileum,,CHEMBL617831,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,,104714,BAO_0000221
3093,,,2116.0,4,Ileum,,CHEMBL617832,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,,104714,BAO_0000221
3094,,,,0,,,CHEMBL617833,,Autocuration,B,,1,,U,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,22226,BAO_0000019
3095,,,,8,,,CHEMBL617834,,Autocuration,B,,1,,H,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,51,BAO_0000357
3096,,,,5,,,CHEMBL617835,,Expert,B,,1,,D,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,,104714,BAO_0000223
3097,,,,4,,,CHEMBL617836,,Autocuration,B,,1,,H,Binding affinity towards 5-HT3 receptor,,,104714,BAO_0000223
3098,,,,4,,,CHEMBL617837,,Autocuration,B,,1,,H,Binding activity radioligand.,,,104714,BAO_0000223
3099,,,,4,,,CHEMBL620392,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,104714,BAO_0000019
3100,,,,4,,,CHEMBL620393,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,104714,BAO_0000223
3101,,,,4,,,CHEMBL620394,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,104714,BAO_0000223
3102,,,,4,,,CHEMBL620395,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,104714,BAO_0000223
3103,,,,0,,,CHEMBL620396,,Autocuration,B,,1,,U,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,22226,BAO_0000019
3104,433.0,,,4,,,CHEMBL620582,,Expert,B,,1,,H,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,NG108-15,105030,BAO_0000219
3105,,,,4,,In vivo,CHEMBL620583,,Autocuration,B,,1,,H,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,,105030,BAO_0000218
3106,,,,4,,,CHEMBL620584,,Autocuration,B,,1,,H,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,105030,BAO_0000019
3107,,,,4,,,CHEMBL620585,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,105030,BAO_0000224
3108,,,,4,,,CHEMBL620586,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,105030,BAO_0000224
3109,,,,4,,,CHEMBL620587,,Autocuration,B,,1,,H,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,105030,BAO_0000019
3110,,,,4,,,CHEMBL620588,,Autocuration,B,,1,,H,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,105030,BAO_0000019
3111,,,,4,,,CHEMBL620589,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor agonism in mouse,,,105030,BAO_0000218
3112,,,,4,,,CHEMBL620590,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,105030,BAO_0000219
3113,,,,4,,,CHEMBL617956,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,105030,BAO_0000019
3114,,,,4,,,CHEMBL617957,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,105030,BAO_0000019
3115,,,,4,,,CHEMBL617958,,Autocuration,B,,1,,H,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,105030,BAO_0000224
3116,,,,4,,,CHEMBL617959,,Autocuration,B,,1,,H,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,105030,BAO_0000219
3117,,,,4,,,CHEMBL617960,,Autocuration,B,,1,,H,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,105030,BAO_0000219
3118,,,,4,,,CHEMBL617961,,Autocuration,B,,1,,H,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,105030,BAO_0000224
3119,,,,4,,In vitro,CHEMBL617962,,Autocuration,B,,1,,H,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,,105030,BAO_0000219
3120,339.0,,,4,,,CHEMBL617963,,Autocuration,B,,1,,H,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,N1E-115,105030,BAO_0000219
3121,,,,8,,,CHEMBL617964,,Autocuration,B,,1,,H,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,11765,BAO_0000019
3122,,,,8,,,CHEMBL617965,,Autocuration,B,,1,,H,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,11765,BAO_0000219
3123,,,,9,,,CHEMBL617966,,Autocuration,B,,1,,D,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,,10630,BAO_0000357
3124,,,,8,,,CHEMBL857074,,Autocuration,B,,1,,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,17106,BAO_0000019
3125,,,,8,,,CHEMBL617967,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,,144,BAO_0000357
3126,,,,8,,,CHEMBL617968,,Autocuration,B,,1,,H,Binding activity radioligand.,,,144,BAO_0000357
3127,,,,4,,,CHEMBL617969,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,,104714,BAO_0000223
3128,,,,4,,,CHEMBL617970,,Autocuration,B,,1,,H,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,104714,BAO_0000223
3129,,,,4,,,CHEMBL617971,,Autocuration,B,,1,,H,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,,104714,BAO_0000223
3130,,,,4,,,CHEMBL617972,,Autocuration,B,,1,,H,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,104714,BAO_0000019
3131,,,,4,,,CHEMBL617973,,Autocuration,F,,1,,H,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,104714,BAO_0000019
3132,,,,4,,,CHEMBL617974,,Autocuration,F,,1,,H,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,104714,BAO_0000019
3133,,,2116.0,4,Ileum,,CHEMBL617975,,Autocuration,F,,1,,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,104714,BAO_0000221
3134,,,,4,,,CHEMBL617976,,Autocuration,F,,1,,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,104714,BAO_0000019
3135,,,,4,,,CHEMBL617977,,Autocuration,F,,1,,H,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,104714,BAO_0000019
3136,,,,4,,,CHEMBL617978,,Autocuration,F,,1,,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,104714,BAO_0000019
3137,,,,4,,,CHEMBL617979,,Autocuration,F,,1,,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,104714,BAO_0000019
3138,449.0,,,4,,,CHEMBL617980,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,CHO,104714,BAO_0000219
3139,,,,7,,,CHEMBL617981,,Autocuration,B,,1,,D,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000019
3140,,,,8,,,CHEMBL617982,,Autocuration,B,,1,,H,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,12020,BAO_0000019
3141,,,,8,,,CHEMBL617983,,Autocuration,B,,1,,H,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,12020,BAO_0000357
3142,,,,7,,,CHEMBL617984,,Autocuration,B,,1,,D,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,,104698,BAO_0000019
3143,,,,6,,,CHEMBL617985,,Autocuration,B,,1,,H,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,104698,BAO_0000019
3144,,,948.0,6,Heart,In vivo,CHEMBL617986,,Autocuration,F,,1,,H,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,104698,BAO_0000218
3145,,,948.0,6,Heart,,CHEMBL617987,,Autocuration,F,,1,,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,104698,BAO_0000019
3146,,,948.0,6,Heart,,CHEMBL617988,,Autocuration,F,,1,,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,104698,BAO_0000019
3147,,,948.0,6,Heart,,CHEMBL617792,,Autocuration,F,,1,,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,104698,BAO_0000019
3148,,,948.0,6,Heart,,CHEMBL617793,,Autocuration,F,,1,,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,104698,BAO_0000019
3149,,,,6,,,CHEMBL617794,,Autocuration,F,,1,,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,104698,BAO_0000019
3150,,,,6,,,CHEMBL617795,,Autocuration,F,,1,,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,104698,BAO_0000019
3151,,,,6,,,CHEMBL617796,,Autocuration,F,,1,,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,104698,BAO_0000019
3152,,,,6,,,CHEMBL617797,,Autocuration,F,,1,,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,104698,BAO_0000019
3153,,,,7,,In vivo,CHEMBL617798,,Autocuration,F,,1,,D,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,,104698,BAO_0000218
3154,,,,6,,In vivo,CHEMBL617799,,Autocuration,F,,1,,H,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,,104698,BAO_0000218
3155,,,,7,,In vivo,CHEMBL617800,,Autocuration,F,,1,,D,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3156,,,,7,,,CHEMBL617801,,Autocuration,F,,1,,D,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,,104698,BAO_0000019
3157,,,,7,,In vivo,CHEMBL617802,,Autocuration,F,,1,,D,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,,104698,BAO_0000218
3158,,,,7,,,CHEMBL617803,,Autocuration,F,,1,,D,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,,104698,BAO_0000019
3159,,,,6,,,CHEMBL617804,,Autocuration,B,,1,,H,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,104698,BAO_0000019
3160,,,,7,,,CHEMBL617805,,Autocuration,B,,1,,D,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000019
3161,,,,6,,,CHEMBL617806,,Autocuration,B,,1,,H,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000223
3162,,,,6,,,CHEMBL617807,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,104698,BAO_0000019
3163,,,,6,,,CHEMBL617808,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,104698,BAO_0000019
3164,,,,6,,,CHEMBL617809,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,104698,BAO_0000249
3165,,,,6,,,CHEMBL617810,,Autocuration,B,,1,,H,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,104698,BAO_0000019
3166,,,955.0,6,Brain,,CHEMBL617811,,Autocuration,B,,1,,H,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,104698,BAO_0000249
3167,,,955.0,6,Brain,,CHEMBL617812,,Autocuration,B,,1,,H,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,104698,BAO_0000221
3168,,,,6,,,CHEMBL617813,,Autocuration,B,,1,,H,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,104698,BAO_0000249
3169,,,,6,,,CHEMBL617814,,Autocuration,B,,1,,H,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,104698,BAO_0000249
3170,,,,6,,,CHEMBL617698,,Autocuration,B,,1,,H,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,104698,BAO_0000019
3171,,,,7,,,CHEMBL617699,,Autocuration,B,,1,,D,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,,104698,BAO_0000019
3172,,,,7,,,CHEMBL617700,,Autocuration,B,,1,,D,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,,104698,BAO_0000019
3173,,,,7,,,CHEMBL617701,,Autocuration,B,,1,,D,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000223
3174,,,,6,,,CHEMBL617702,,Autocuration,B,,1,,H,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,104698,BAO_0000019
3175,,,,6,,,CHEMBL617703,,Autocuration,B,,1,Membranes,H,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,104698,BAO_0000249
3176,,,,7,,,CHEMBL617704,,Autocuration,B,,1,,D,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,,104698,BAO_0000019
3177,,,,6,,,CHEMBL617705,,Autocuration,B,,1,,H,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,104698,BAO_0000223
3178,,,,7,,,CHEMBL617706,,Autocuration,B,,1,,D,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000223
3179,433.0,,,6,,,CHEMBL617707,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,NG108-15,104698,BAO_0000219
3180,433.0,,,6,,,CHEMBL617708,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,NG108-15,104698,BAO_0000219
3181,,,,6,,,CHEMBL617709,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,104698,BAO_0000019
3182,,,,6,,,CHEMBL617710,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,104698,BAO_0000019
3183,,,,6,,,CHEMBL882925,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,104698,BAO_0000019
3184,,,,6,,,CHEMBL617711,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,104698,BAO_0000019
3185,,,,6,,,CHEMBL617712,,Autocuration,F,,1,,H,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,104698,BAO_0000019
3186,,,,7,,,CHEMBL617713,,Autocuration,F,,1,,D,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,,104698,BAO_0000019
3187,,,,6,,,CHEMBL617714,,Autocuration,F,,1,,H,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,104698,BAO_0000019
3188,,,,6,,,CHEMBL617715,,Autocuration,F,,1,,H,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,104698,BAO_0000218
3189,,,,6,,In vivo,CHEMBL617716,,Autocuration,F,,1,,H,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,,104698,BAO_0000218
3190,,,,6,,,CHEMBL617717,,Autocuration,F,,1,,H,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,104698,BAO_0000218
3191,,,,6,,In vivo,CHEMBL617718,,Autocuration,F,,1,,H,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3192,,,,6,,In vivo,CHEMBL617719,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3193,,,,6,,In vivo,CHEMBL617720,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,,104698,BAO_0000218
3194,,,,7,,In vivo,CHEMBL617721,,Autocuration,F,,1,,D,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3195,,,,6,,In vivo,CHEMBL617722,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3196,,,,6,,In vivo,CHEMBL617723,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,,104698,BAO_0000218
3197,,,,6,,In vivo,CHEMBL617724,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3198,,,,6,,In vivo,CHEMBL617725,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3199,,,,6,,In vivo,CHEMBL617726,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3200,,,,6,,In vivo,CHEMBL617727,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3201,,,,6,,In vivo,CHEMBL617728,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3202,,,,6,,In vivo,CHEMBL617729,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3203,,,,6,,In vivo,CHEMBL617730,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3204,,,,6,,In vivo,CHEMBL617731,,Autocuration,F,,1,,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3205,,,,6,,In vivo,CHEMBL617732,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3206,,,,6,,In vivo,CHEMBL617733,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3207,,,,6,,In vivo,CHEMBL617734,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3208,,,,6,,In vivo,CHEMBL872874,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,,104698,BAO_0000218
3209,,,,6,,In vivo,CHEMBL617735,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,,104698,BAO_0000218
3210,,,,6,,In vivo,CHEMBL617736,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,,104698,BAO_0000218
3211,,,,6,,In vivo,CHEMBL617737,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,,104698,BAO_0000218
3212,,,,6,,In vivo,CHEMBL617738,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,,104698,BAO_0000218
3213,,,,6,,In vivo,CHEMBL617739,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3214,,,,6,,In vivo,CHEMBL617740,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3215,,,,6,,In vivo,CHEMBL617741,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3216,,,,6,,In vivo,CHEMBL617742,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3217,,,,6,,In vivo,CHEMBL617743,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3218,,,,6,,In vivo,CHEMBL617744,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3219,,,,6,,In vivo,CHEMBL617745,,Autocuration,F,,1,,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,,104698,BAO_0000218
3220,,,,6,,,CHEMBL617746,,Autocuration,F,,1,,H,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,104698,BAO_0000218
3221,,,,6,,,CHEMBL617747,,Autocuration,F,,1,,H,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,104698,BAO_0000218
3222,,,,6,,In vivo,CHEMBL617748,,Autocuration,F,,1,,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,,104698,BAO_0000218
3223,,,,6,,In vivo,CHEMBL618909,,Autocuration,F,,1,,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,,104698,BAO_0000218
3224,,,,6,,In vivo,CHEMBL618910,,Autocuration,F,,1,,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,,104698,BAO_0000218
3225,,,,6,,In vivo,CHEMBL618911,,Autocuration,F,,1,,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,,104698,BAO_0000218
3226,,,,6,,In vivo,CHEMBL618912,,Autocuration,F,,1,,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,,104698,BAO_0000218
3227,,,,6,,In vivo,CHEMBL618913,,Autocuration,F,,1,,H,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,,104698,BAO_0000218
3228,,,,6,,,CHEMBL618914,,Autocuration,F,,1,,H,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,104698,BAO_0000019
3229,,,,6,,,CHEMBL618915,,Autocuration,F,,1,,H,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,104698,BAO_0000019
3230,,,,7,,,CHEMBL618916,,Autocuration,B,,1,,D,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000223
3231,,,,6,,,CHEMBL618917,,Autocuration,F,,1,,H,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,104698,BAO_0000019
3232,,,10000000.0,7,Hippocampus,,CHEMBL618918,,Intermediate,B,,1,,D,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,104698,BAO_0000221
3233,,,,7,,,CHEMBL618919,,Autocuration,B,,1,,D,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,,104698,BAO_0000019
3234,,,,7,,,CHEMBL618920,,Autocuration,B,,1,,D,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000019
3235,,,,6,,,CHEMBL618921,,Autocuration,B,,1,,H,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000223
3236,,,,6,,,CHEMBL618922,,Autocuration,B,,1,,H,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000019
3237,,,,6,,,CHEMBL618923,,Autocuration,B,,1,,H,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,104698,BAO_0000019
3238,,,,6,,,CHEMBL618924,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,104698,BAO_0000019
3239,,,,6,,,CHEMBL618925,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,104698,BAO_0000019
3240,,,,6,,,CHEMBL618926,,Autocuration,B,,1,,H,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,104698,BAO_0000019
3241,,,2116.0,9,Ileum,,CHEMBL618927,,Intermediate,F,,1,,D,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,,20033,BAO_0000221
3242,,,2116.0,9,Ileum,,CHEMBL618928,,Intermediate,F,,1,,D,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,,20033,BAO_0000221
3243,,,2116.0,9,Ileum,,CHEMBL618929,,Intermediate,F,,1,,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,,20033,BAO_0000221
3244,,,2116.0,9,Ileum,,CHEMBL618930,,Intermediate,F,,1,,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,,20033,BAO_0000221
3245,,,2116.0,9,Ileum,,CHEMBL618931,,Intermediate,F,,1,,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,20033,BAO_0000221
3246,,,2116.0,9,Ileum,,CHEMBL619594,,Intermediate,F,,1,,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,20033,BAO_0000221
3247,,,2116.0,9,Ileum,,CHEMBL619595,,Intermediate,F,,1,,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,,20033,BAO_0000221
3248,,,2116.0,9,Ileum,,CHEMBL619596,,Intermediate,F,,1,,D,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,,20033,BAO_0000221
3249,,,2116.0,9,Ileum,,CHEMBL619755,,Intermediate,F,,1,,D,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,,20033,BAO_0000221
3250,,,2116.0,9,Ileum,,CHEMBL619756,,Intermediate,F,,1,,D,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,,20033,BAO_0000221
3251,,,2116.0,9,Ileum,,CHEMBL619757,,Intermediate,F,,1,,D,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,,20033,BAO_0000221
3252,,,2116.0,9,Ileum,,CHEMBL619758,,Intermediate,F,,1,,D,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,,20033,BAO_0000221
3253,,,2116.0,9,Ileum,,CHEMBL619759,,Intermediate,F,,1,,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,,20033,BAO_0000221
3254,,,2116.0,9,Ileum,,CHEMBL619760,,Intermediate,F,,1,,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,,20033,BAO_0000221
3255,,,2116.0,9,Ileum,,CHEMBL619761,,Intermediate,F,,1,,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,,20033,BAO_0000221
3256,,,2116.0,9,Ileum,,CHEMBL619762,,Intermediate,F,,1,,D,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,,20033,BAO_0000221
3257,,,2116.0,9,Ileum,,CHEMBL619763,,Intermediate,F,,1,,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,20033,BAO_0000221
3258,,,2116.0,9,Ileum,,CHEMBL617868,,Intermediate,F,,1,,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,20033,BAO_0000221
3259,,,,9,,,CHEMBL617869,,Intermediate,B,,1,,D,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,20033,BAO_0000357
3260,,,2435.0,9,Striatum,,CHEMBL882926,,Intermediate,B,,1,,D,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,20033,BAO_0000249
3261,,,2435.0,9,Striatum,,CHEMBL617870,,Intermediate,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,20033,BAO_0000249
3262,,,2435.0,9,Striatum,,CHEMBL617871,,Intermediate,B,,1,,D,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,,20033,BAO_0000357
3263,,,2435.0,9,Striatum,,CHEMBL617872,,Intermediate,B,,1,,D,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,20033,BAO_0000357
3264,,,2435.0,9,Striatum,,CHEMBL617873,,Intermediate,B,,1,,D,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,20033,BAO_0000357
3265,,,2435.0,9,Striatum,,CHEMBL617874,,Intermediate,B,,1,,D,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,20033,BAO_0000357
3266,,,2116.0,9,Ileum,,CHEMBL619067,,Intermediate,F,,1,,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,,20033,BAO_0000221
3267,,,2116.0,9,Ileum,,CHEMBL619068,,Intermediate,F,,1,,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,,20033,BAO_0000221
3268,,,2116.0,9,Ileum,,CHEMBL619069,,Intermediate,F,,1,,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,20033,BAO_0000221
3269,,,,9,,,CHEMBL619070,,Intermediate,B,,1,,D,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,,20033,BAO_0000357
3270,,,,9,,,CHEMBL619071,,Intermediate,B,,1,,D,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,,20033,BAO_0000357
3271,,,,9,,,CHEMBL619072,,Intermediate,F,,1,,D,Agonistic activity against 5-hydroxytryptamine 4 receptor,,,20033,BAO_0000019
3272,,,,9,,,CHEMBL619073,,Intermediate,F,,1,,D,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,,20033,BAO_0000019
3273,,,,9,,,CHEMBL619074,,Intermediate,F,,1,,D,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,,20033,BAO_0000019
3274,,,,9,,,CHEMBL619075,,Intermediate,B,,1,,D,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,,20033,BAO_0000357
3275,,,2435.0,9,Striatum,,CHEMBL619076,,Intermediate,B,,1,,D,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,,20033,BAO_0000357
3276,,,2435.0,9,Striatum,,CHEMBL619077,,Intermediate,B,,1,,D,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,,20033,BAO_0000357
3277,,,2435.0,9,Striatum,,CHEMBL619078,,Intermediate,B,,1,,D,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,20033,BAO_0000249
3278,,,2435.0,9,Striatum,,CHEMBL619079,,Intermediate,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,20033,BAO_0000249
3279,,,2116.0,9,Ileum,,CHEMBL619080,,Intermediate,B,,1,,D,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,,20033,BAO_0000221
3280,,,,9,,,CHEMBL619081,,Expert,B,,1,,D,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,,20033,BAO_0000357
3281,,,,9,,,CHEMBL619082,,Intermediate,B,,1,,D,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,20033,BAO_0000357
3282,,,,9,,,CHEMBL619083,,Intermediate,B,,1,,D,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,,20033,BAO_0000357
3283,,,,9,,,CHEMBL619084,,Intermediate,B,,1,,D,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,20033,BAO_0000357
3284,,,2116.0,9,Ileum,,CHEMBL859397,,Intermediate,F,,1,,D,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,20033,BAO_0000221
3285,,,2116.0,9,Ileum,,CHEMBL619085,,Intermediate,F,,1,,D,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,,20033,BAO_0000221
3286,,,2116.0,9,Ileum,,CHEMBL619086,,Intermediate,F,,1,,D,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,,20033,BAO_0000221
3287,,,2116.0,9,Ileum,,CHEMBL619087,,Intermediate,F,,1,,D,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,,20033,BAO_0000221
3288,,,2116.0,9,Ileum,,CHEMBL619088,,Intermediate,F,,1,,D,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,20033,BAO_0000221
3289,,,,9,,,CHEMBL619089,,Intermediate,B,,1,,D,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,,20033,BAO_0000357
3290,,,,8,,,CHEMBL619090,,Autocuration,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,,168,BAO_0000357
3291,,,,9,,,CHEMBL619091,,Intermediate,F,,1,,D,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,,20033,BAO_0000019
3292,,,,9,,,CHEMBL619092,,Intermediate,B,,1,,D,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,,20033,BAO_0000357
3293,,,,9,,,CHEMBL619093,,Intermediate,B,,1,,D,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,,20033,BAO_0000019
3294,722.0,,,8,,,CHEMBL619094,,Autocuration,B,,1,,H,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,HEK293,168,BAO_0000219
3295,,,,9,,,CHEMBL619095,,Intermediate,B,,1,,D,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,,20033,BAO_0000019
3296,,,,9,,,CHEMBL857988,,Intermediate,B,,1,,D,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,,20033,BAO_0000357
3297,,,,9,,,CHEMBL619096,,Intermediate,B,,1,,D,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,,20033,BAO_0000357
3298,,,2435.0,9,Striatum,,CHEMBL619097,,Intermediate,B,,1,,D,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,,20033,BAO_0000357
3299,,,10000000.0,9,Hippocampus,,CHEMBL619098,,Intermediate,B,,1,,D,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,,20033,BAO_0000221
3300,,,,9,,,CHEMBL619751,,Intermediate,B,,1,,D,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,,20033,BAO_0000357
3301,,,,9,,,CHEMBL619752,,Intermediate,B,,1,,D,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,,20033,BAO_0000357
3302,,,2116.0,9,Ileum,,CHEMBL875096,,Intermediate,F,,1,,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,20033,BAO_0000221
3303,,,,8,,,CHEMBL619004,,Autocuration,B,,1,,H,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,108,BAO_0000357
3304,,,,8,,,CHEMBL619005,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,168,BAO_0000357
3305,,,,8,,,CHEMBL619006,,Autocuration,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,168,BAO_0000019
3306,308.0,,,8,,,CHEMBL619007,,Autocuration,B,,1,,H,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,HeLa,168,BAO_0000219
3307,,,,8,,,CHEMBL619008,,Autocuration,B,,1,,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,168,BAO_0000357
3308,,,,8,,,CHEMBL619009,,Autocuration,B,,1,,H,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,168,BAO_0000357
3309,308.0,,,8,,,CHEMBL619010,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,HeLa,168,BAO_0000219
3310,,,,8,,,CHEMBL619011,,Autocuration,B,,1,,H,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,10622,BAO_0000357
3311,,,,8,,,CHEMBL619012,,Autocuration,B,,1,,H,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,10622,BAO_0000357
3312,,,,8,,,CHEMBL619013,,Autocuration,B,,1,,H,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,10622,BAO_0000219
3313,,,,8,,,CHEMBL619014,,Autocuration,B,,1,,H,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,10622,BAO_0000357
3314,,,2081.0,8,Cardiac atrium,,CHEMBL857503,,Autocuration,F,,1,,H,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,11249,BAO_0000019
3315,,,2081.0,8,Cardiac atrium,,CHEMBL619015,,Autocuration,F,,1,,H,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,11249,BAO_0000019
3316,,,,8,,,CHEMBL619016,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,11249,BAO_0000357
3317,,,10000000.0,8,Hippocampus,,CHEMBL619017,,Autocuration,B,,1,,H,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,11249,BAO_0000221
3318,,,10000000.0,8,Hippocampus,,CHEMBL619018,,Autocuration,B,,1,,H,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,,168,BAO_0000221
3319,,,,8,,,CHEMBL619019,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,,168,BAO_0000019
3320,,,,9,,,CHEMBL619020,,Expert,B,,1,,D,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,,10623,BAO_0000357
3321,,,,8,,,CHEMBL619021,,Autocuration,F,,1,,H,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,10623,BAO_0000019
3322,,,,8,,,CHEMBL619022,,Autocuration,B,,1,,H,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,10623,BAO_0000357
3323,,,,8,,,CHEMBL619023,,Autocuration,B,,1,,H,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,10623,BAO_0000357
3324,,,,8,,,CHEMBL619024,,Autocuration,F,,1,,H,lntrinsic activity relative to 5-HT receptor,,,10623,BAO_0000019
3325,,,,8,,,CHEMBL619025,,Autocuration,F,,1,,H,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,10623,BAO_0000019
3326,,,,8,,,CHEMBL619026,,Expert,F,,1,,H,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,10623,BAO_0000019
3327,,,,8,,,CHEMBL619027,,Autocuration,F,,1,,H,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,10623,BAO_0000019
3328,,,,8,,,CHEMBL619028,,Autocuration,F,,1,,H,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,10623,BAO_0000019
3329,,,,8,,,CHEMBL619029,,Autocuration,F,,1,,H,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,10623,BAO_0000019
3330,,,,8,,,CHEMBL619030,,Autocuration,F,,1,,H,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,10623,BAO_0000019
3331,,,,8,,,CHEMBL619031,,Expert,B,,1,,H,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,10623,BAO_0000357
3332,,,,8,,,CHEMBL619032,,Autocuration,F,,1,,H,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,10623,BAO_0000019
3333,,,,9,,,CHEMBL619033,,Expert,B,,1,,D,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,,10623,BAO_0000357
3334,,,,8,,,CHEMBL619034,,Autocuration,B,,1,,H,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,10623,BAO_0000357
3335,,,,8,,,CHEMBL619035,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,10623,BAO_0000357
3336,,,,8,,,CHEMBL619036,,Autocuration,B,,1,,H,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,10623,BAO_0000357
3337,,,,9,,,CHEMBL619037,,Expert,B,,1,,D,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,,10623,BAO_0000019
3338,,,2435.0,8,Striatum,,CHEMBL619038,,Autocuration,B,,1,,H,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,10623,BAO_0000249
3339,,,,8,,,CHEMBL619039,,Autocuration,B,,1,,H,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,10623,BAO_0000249
3340,,,,8,,,CHEMBL619040,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,10623,BAO_0000249
3341,,,2435.0,9,Striatum,,CHEMBL619041,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,10623,BAO_0000019
3342,,,2435.0,8,Striatum,,CHEMBL619042,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,10623,BAO_0000019
3343,,,2435.0,8,Striatum,,CHEMBL619043,,Expert,B,,1,,H,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,10623,BAO_0000249
3344,,,2435.0,8,Striatum,,CHEMBL619044,,Expert,B,,1,,H,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,10623,BAO_0000019
3345,,,2435.0,8,Striatum,,CHEMBL619045,,Expert,B,,1,,H,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,10623,BAO_0000249
3346,,,2435.0,8,Striatum,,CHEMBL619046,,Expert,B,,1,,H,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,10623,BAO_0000249
3347,,,,8,,,CHEMBL619047,,Expert,B,,1,,H,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,10623,BAO_0000249
3348,,,955.0,8,Brain,,CHEMBL619048,,Autocuration,F,,1,,H,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,10623,BAO_0000221
3349,,,,8,,,CHEMBL859398,,Autocuration,F,,1,,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,10623,BAO_0000019
3350,,,,8,,,CHEMBL619049,,Autocuration,F,,1,,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,10623,BAO_0000019
3351,,,,8,,,CHEMBL857886,,Autocuration,F,,1,,H,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,10623,BAO_0000019
3352,,,,8,,,CHEMBL619050,,Autocuration,F,,1,,H,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,10623,BAO_0000019
3353,,,,8,,,CHEMBL620591,,Autocuration,F,,1,,H,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,10623,BAO_0000019
3354,,,,9,,,CHEMBL620592,,Expert,B,,1,,D,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,,10623,BAO_0000357
3355,,,2435.0,8,Striatum,,CHEMBL620593,,Expert,B,,1,,H,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,10623,BAO_0000249
3356,,,,9,,,CHEMBL620594,,Expert,F,,1,,D,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,,10623,BAO_0000019
3357,,,,8,,,CHEMBL875079,,Expert,F,,1,,H,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,10623,BAO_0000019
3358,,,,8,,,CHEMBL620595,,Expert,F,,1,,H,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,10623,BAO_0000019
3359,,,,9,,,CHEMBL620596,,Expert,F,,1,,D,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,,10623,BAO_0000019
3360,,,,8,,,CHEMBL620597,,Autocuration,F,,1,,H,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,10623,BAO_0000019
3361,,,,8,,,CHEMBL620598,,Expert,F,,1,,H,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,10623,BAO_0000019
3362,,,,8,,,CHEMBL620599,,Expert,F,,1,,H,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,10623,BAO_0000218
3363,,,,8,,,CHEMBL620600,,Autocuration,F,,1,,H,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,10623,BAO_0000019
3364,,,,8,,,CHEMBL620601,,Autocuration,F,,1,,H,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,,168,BAO_0000019
3365,,,,8,,,CHEMBL620602,,Autocuration,F,,1,,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,168,BAO_0000019
3366,,,,8,,,CHEMBL620603,,Autocuration,B,,1,,H,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,168,BAO_0000357
3367,,,,8,,,CHEMBL620604,,Autocuration,B,,1,,H,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,168,BAO_0000357
3368,,,,8,,,CHEMBL620605,,Autocuration,B,,1,,H,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,168,BAO_0000357
3369,,,,8,,,CHEMBL620606,,Autocuration,B,,1,,H,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,168,BAO_0000357
3370,,,,8,,,CHEMBL620607,,Autocuration,F,,1,,H,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,168,BAO_0000019
3371,,,,8,,,CHEMBL620608,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-HT4 receptor was determined,,,168,BAO_0000357
3372,,,,8,,,CHEMBL620609,,Autocuration,F,,1,,H,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,168,BAO_0000019
3373,,,,8,,,CHEMBL620610,,Autocuration,F,,1,,H,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,168,BAO_0000019
3374,,,,8,,,CHEMBL620611,,Autocuration,B,,1,,H,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,168,BAO_0000357
3375,,,,8,,,CHEMBL620612,,Autocuration,B,,1,,H,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,168,BAO_0000357
3376,,,,8,,,CHEMBL620613,,Autocuration,B,,1,,H,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,168,BAO_0000357
3377,,,,8,,,CHEMBL620614,,Autocuration,B,,1,,H,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,168,BAO_0000357
3378,,,,8,,,CHEMBL620615,,Expert,B,,1,,H,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,168,BAO_0000357
3379,,,,6,,,CHEMBL857075,,Autocuration,B,,1,Brain membranes,H,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,104698,BAO_0000249
3380,,,,6,,,CHEMBL620616,,Autocuration,B,,1,Brain membranes,H,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,104698,BAO_0000249
3381,,,,6,,,CHEMBL619411,,Autocuration,B,,1,Brain membranes,H,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,104698,BAO_0000249
3382,,,,6,,,CHEMBL619412,,Autocuration,B,,1,,H,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,104698,BAO_0000019
3383,,,,7,,,CHEMBL619413,,Autocuration,B,,1,,D,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000019
3384,,,10000000.0,6,Hippocampus,,CHEMBL619414,,Autocuration,B,,1,,H,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,104698,BAO_0000221
3385,,,,6,,,CHEMBL619415,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,104698,BAO_0000019
3386,,,,6,,,CHEMBL619416,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,104698,BAO_0000019
3387,,,,6,,,CHEMBL619417,,Autocuration,F,,1,,H,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,104698,BAO_0000019
3388,,,,7,,,CHEMBL619418,,Autocuration,B,,1,,D,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000223
3389,,,,7,,,CHEMBL619419,,Autocuration,B,,1,,D,Binding affinity against 5-Hydroxytryptamine 3 receptor,,,104698,BAO_0000223
3390,,,,6,,,CHEMBL619420,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,104698,BAO_0000019
3391,,,,6,,,CHEMBL619421,,Autocuration,B,,1,,H,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,104698,BAO_0000249
3392,,,,7,,,CHEMBL619422,,Autocuration,B,,1,,D,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,,104698,BAO_0000019
3393,,,,6,,,CHEMBL619423,,Autocuration,B,,1,,H,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,104698,BAO_0000019
3394,,,,6,,,CHEMBL875080,,Autocuration,B,,1,,H,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,104698,BAO_0000019
3395,,,,6,,,CHEMBL619424,,Autocuration,B,,1,,H,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,104698,BAO_0000019
3396,,,,6,,,CHEMBL619425,,Autocuration,B,,1,,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,104698,BAO_0000249
3397,,,,6,,,CHEMBL619426,,Autocuration,B,,1,,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,104698,BAO_0000223
3398,,,,6,,,CHEMBL619427,,Autocuration,B,,1,,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,104698,BAO_0000223
3399,,,,7,,,CHEMBL619645,,Autocuration,B,,1,,D,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000223
3400,,,,9,,,CHEMBL619646,,Expert,B,,1,,D,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,10576,BAO_0000249
3401,,,955.0,8,Brain,,CHEMBL619647,,Autocuration,F,,1,,H,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,12020,BAO_0000221
3402,,,,8,,,CHEMBL619648,,Autocuration,F,,1,,H,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,12020,BAO_0000019
3403,,,,8,,,CHEMBL619165,,Autocuration,F,,1,,H,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,12020,BAO_0000019
3404,,,,8,,In vivo,CHEMBL620719,,Autocuration,F,,1,,H,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,,12020,BAO_0000218
3405,,,,8,,,CHEMBL872924,,Autocuration,B,,1,,H,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,12020,BAO_0000019
3406,,,,8,,,CHEMBL620720,,Autocuration,B,,1,,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,12020,BAO_0000357
3407,,,,8,,,CHEMBL620721,,Autocuration,B,,1,,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,12020,BAO_0000019
3408,,,,8,,,CHEMBL620722,,Autocuration,B,,1,,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,12020,BAO_0000019
3409,,,,6,,,CHEMBL620723,,Autocuration,B,,1,,H,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,104698,BAO_0000019
3410,,,,8,,,CHEMBL620724,,Autocuration,B,,1,,H,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,12020,BAO_0000019
3411,,,,6,,,CHEMBL620725,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,104698,BAO_0000249
3412,,,,9,,,CHEMBL620726,,Autocuration,F,,1,,D,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,,12020,BAO_0000019
3413,,,,8,,,CHEMBL620727,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,144,BAO_0000357
3414,,,,4,,,CHEMBL620728,,Autocuration,B,,1,,H,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,104714,BAO_0000223
3415,,,,0,,,CHEMBL620729,,Autocuration,B,,1,,U,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,22226,BAO_0000019
3416,,,,4,,,CHEMBL858288,,Autocuration,F,,1,,H,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,104714,BAO_0000019
3417,,,,4,,,CHEMBL620730,,Autocuration,B,,1,,H,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714,BAO_0000223
3418,,,,4,,,CHEMBL620731,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714,BAO_0000223
3419,,,,4,,,CHEMBL620732,,Autocuration,F,,1,,H,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,,104714,BAO_0000019
3420,,,,4,,,CHEMBL618042,,Autocuration,F,,1,,H,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,104714,BAO_0000019
3421,,,,4,,,CHEMBL618043,,Autocuration,F,,1,,H,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,,104714,BAO_0000019
3422,,,,4,,,CHEMBL618044,,Autocuration,B,,1,,H,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,104714,BAO_0000223
3423,,,,4,,,CHEMBL618045,,Autocuration,F,,1,,H,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,104714,BAO_0000019
3424,,,,4,,,CHEMBL618046,,Autocuration,B,,1,,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,104714,BAO_0000223
3425,,,,4,,,CHEMBL618047,,Autocuration,F,,1,,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,104714,BAO_0000019
3426,,,,4,,,CHEMBL875084,,Autocuration,F,,1,,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,104714,BAO_0000019
3427,,,,4,,,CHEMBL618048,,Autocuration,F,,1,,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,104714,BAO_0000019
3428,,,,4,,,CHEMBL618049,,Autocuration,B,,1,,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,104714,BAO_0000223
3429,,,,4,,,CHEMBL619764,,Autocuration,F,,1,,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,104714,BAO_0000019
3430,,,,4,,,CHEMBL619765,,Autocuration,F,,1,,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,104714,BAO_0000019
3431,,,,4,,,CHEMBL619766,,Autocuration,F,,1,,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,104714,BAO_0000019
3432,,,,4,,,CHEMBL619767,,Autocuration,B,,1,,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,104714,BAO_0000223
3433,,,,4,,,CHEMBL619768,,Autocuration,B,,1,,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,104714,BAO_0000223
3434,,,,4,,,CHEMBL619769,,Autocuration,F,,1,,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,104714,BAO_0000019
3435,,,,4,,,CHEMBL619770,,Autocuration,B,,1,,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,104714,BAO_0000223
3436,,,,4,,,CHEMBL619771,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714,BAO_0000223
3437,,,,4,,,CHEMBL619772,,Autocuration,B,,1,,H,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,104714,BAO_0000219
3438,,,,4,,,CHEMBL619773,,Autocuration,B,,1,,H,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,104714,BAO_0000223
3439,433.0,,,4,,,CHEMBL619774,,Autocuration,B,,1,,H,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,NG108-15,104714,BAO_0000219
3440,,,,4,,,CHEMBL875083,,Autocuration,B,,1,,H,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,104714,BAO_0000019
3441,433.0,,,4,,,CHEMBL620718,,Autocuration,B,,1,,H,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,NG108-15,104714,BAO_0000219
3442,,,,4,,,CHEMBL618127,,Autocuration,B,,1,,H,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,104714,BAO_0000223
3443,,,,4,,,CHEMBL618128,,Autocuration,B,,1,,H,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,104714,BAO_0000223
3444,,,,4,,In vitro,CHEMBL618129,,Autocuration,B,,1,,H,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,,104714,BAO_0000219
3445,,,,4,,,CHEMBL618130,,Autocuration,B,,1,,H,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,104714,BAO_0000223
3446,,,,4,,,CHEMBL618131,,Autocuration,F,,1,,H,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,104714,BAO_0000019
3447,,,,4,,,CHEMBL618132,,Autocuration,F,,1,,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,,104714,BAO_0000019
3448,,,,4,,,CHEMBL618133,,Autocuration,F,,1,,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,,104714,BAO_0000019
3449,,,,4,,,CHEMBL618134,,Autocuration,F,,1,,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,,104714,BAO_0000019
3450,,,,4,,,CHEMBL618135,,Autocuration,F,,1,,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,104714,BAO_0000019
3451,,,,4,,,CHEMBL618136,,Autocuration,B,,1,,H,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,104714,BAO_0000223
3452,,,,4,,,CHEMBL618137,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714,BAO_0000223
3453,,,,4,,,CHEMBL618138,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,104714,BAO_0000223
3454,,,,4,,,CHEMBL618139,,Autocuration,B,,1,,H,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,104714,BAO_0000223
3455,,,,4,,,CHEMBL618140,,Autocuration,B,,1,,H,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,104714,BAO_0000223
3456,,,,4,,,CHEMBL618141,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,104714,BAO_0000223
3457,,,,8,,,CHEMBL873478,,Expert,B,,1,,H,Binding affinity for 5-hydroxytryptamine 2C receptor,,,108,BAO_0000357
3458,,,,6,,,CHEMBL618142,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104698,BAO_0000223
3459,,,,8,,,CHEMBL618143,,Autocuration,B,,1,,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,144,BAO_0000357
3460,,,,8,,,CHEMBL618144,,Autocuration,B,,1,,H,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,144,BAO_0000357
3461,,,,8,,,CHEMBL618145,,Autocuration,B,,1,,H,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,144,BAO_0000357
3462,,,,4,,,CHEMBL618146,,Autocuration,B,,1,,H,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,104714,BAO_0000223
3463,,,,4,,,CHEMBL618147,,Autocuration,B,,1,,H,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,104714,BAO_0000223
3464,,,,4,,,CHEMBL618148,,Autocuration,B,,1,,H,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,104714,BAO_0000223
3465,,,,8,,,CHEMBL618149,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,144,BAO_0000019
3466,,,,8,,,CHEMBL872927,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,144,BAO_0000357
3467,,,,8,,,CHEMBL618150,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,144,BAO_0000357
3468,,,,8,,,CHEMBL618151,,Autocuration,B,,1,,H,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,144,BAO_0000357
3469,,,,8,,,CHEMBL875094,,Autocuration,B,,1,,H,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,144,BAO_0000357
3470,,,,8,,,CHEMBL618152,,Autocuration,B,,1,,H,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,144,BAO_0000019
3471,,,,8,,,CHEMBL618153,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,144,BAO_0000357
3472,,,,8,,,CHEMBL618888,,Autocuration,B,,1,,H,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,144,BAO_0000357
3473,,,,8,,,CHEMBL618889,,Autocuration,F,,1,,H,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,144,BAO_0000019
3474,,,,8,,,CHEMBL618890,,Autocuration,B,,1,,H,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,144,BAO_0000357
3475,,,,8,,,CHEMBL618891,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,144,BAO_0000019
3476,,,,8,,,CHEMBL619054,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,144,BAO_0000019
3477,,,,4,,,CHEMBL619055,,Autocuration,B,,1,,H,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,104714,BAO_0000223
3478,,,,8,,,CHEMBL619056,,Autocuration,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,144,BAO_0000357
3479,,,,8,,,CHEMBL619057,,Autocuration,F,,1,,H,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,144,BAO_0000019
3480,,,,8,,,CHEMBL619058,,Autocuration,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,144,BAO_0000357
3481,,,,9,,,CHEMBL619059,,Expert,F,,1,,D,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,Oocytes,12020,BAO_0000219
3482,,,,9,,,CHEMBL619060,,Expert,F,,1,,D,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,Oocytes,12020,BAO_0000219
3483,,,,9,,,CHEMBL875095,,Expert,F,,1,,D,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,Oocytes,12020,BAO_0000219
3484,,,2116.0,9,Ileum,,CHEMBL619061,,Intermediate,F,,1,,D,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,,20033,BAO_0000221
3485,,,2116.0,9,Ileum,,CHEMBL619062,,Intermediate,F,,1,,D,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,,20033,BAO_0000221
3486,,,,9,,,CHEMBL619063,,Intermediate,F,,1,,D,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,,20033,BAO_0000019
3487,,,2116.0,9,Ileum,,CHEMBL619064,,Intermediate,B,,1,,D,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,,20033,BAO_0000221
3488,,,,9,,,CHEMBL619065,,Intermediate,B,,1,,D,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,,20033,BAO_0000357
3489,,,2116.0,9,Ileum,,CHEMBL619066,,Intermediate,B,,1,,D,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,,20033,BAO_0000221
3490,,,2116.0,8,Ileum,,CHEMBL619775,,Autocuration,B,,1,,H,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,10209,BAO_0000221
3491,,,,8,,,CHEMBL619776,,Autocuration,B,,1,,H,Affinity against 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3492,,,,4,,,CHEMBL619777,,Autocuration,B,,1,,H,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,104841,BAO_0000224
3493,,,,4,,,CHEMBL619778,,Autocuration,B,,1,,H,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,104841,BAO_0000224
3494,,,2116.0,4,Ileum,,CHEMBL619779,,Autocuration,B,,1,,H,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,,104841,BAO_0000221
3495,,,,4,,,CHEMBL619780,,Autocuration,B,,1,,H,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,104841,BAO_0000224
3496,,,,4,,,CHEMBL619166,,Autocuration,B,,1,,H,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,104841,BAO_0000224
3497,,,,4,,,CHEMBL619167,,Autocuration,F,,1,,H,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,104841,BAO_0000019
3498,,,,4,,,CHEMBL619168,,Autocuration,F,,1,,H,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,104841,BAO_0000019
3499,,,2081.0,9,Cardiac atrium,,CHEMBL619169,,Expert,B,,1,,D,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,,168,BAO_0000219
3500,,,2081.0,9,Cardiac atrium,,CHEMBL619170,,Expert,B,,1,,D,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,,168,BAO_0000219
3501,,,,5,,,CHEMBL619171,,Autocuration,F,,1,,D,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,,104841,BAO_0000019
3502,,,2081.0,9,Cardiac atrium,,CHEMBL619172,,Expert,F,,1,,D,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,,168,BAO_0000219
3503,,,,0,,,CHEMBL619173,,Autocuration,B,,1,,U,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,,22226,BAO_0000019
3504,,,,0,,,CHEMBL619174,,Autocuration,B,,1,,U,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,,22226,BAO_0000019
3505,,,,4,,,CHEMBL619175,,Autocuration,B,,1,,H,5-hydroxytryptamine receptor binding affinity was determined in rats,,,104705,BAO_0000019
3506,,,,4,,,CHEMBL619176,,Autocuration,B,,1,,H,Binding affinity at rat 5-hydroxytryptamine receptor.,,,104705,BAO_0000224
3507,,,,4,,,CHEMBL619177,,Autocuration,B,,1,,H,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,104705,BAO_0000019
3508,,,,4,,,CHEMBL619178,,Autocuration,B,,1,,H,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,104705,BAO_0000224
3509,,,,4,,,CHEMBL619179,,Autocuration,B,,1,,H,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,104705,BAO_0000224
3510,,,945.0,4,Stomach,,CHEMBL619180,,Autocuration,F,,1,,H,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,104705,BAO_0000019
3511,,,945.0,4,Stomach,,CHEMBL619181,,Autocuration,F,,1,,H,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,104705,BAO_0000019
3512,,,,4,,,CHEMBL619182,,Autocuration,F,,1,,H,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,104705,BAO_0000019
3513,,,,4,,,CHEMBL619183,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,104705,BAO_0000224
3514,,,,4,,,CHEMBL619184,,Autocuration,B,,1,,H,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,104705,BAO_0000224
3515,,,10000000.0,8,Hippocampus,,CHEMBL619185,,Autocuration,B,,1,,H,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,10576,BAO_0000221
3516,,,,8,,,CHEMBL619186,,Expert,B,,1,,H,Binding affinity for rat 5-hydroxytryptamine transporter.,,,12198,BAO_0000357
3517,,,,4,,,CHEMBL619187,,Autocuration,B,,1,,H,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,104705,BAO_0000019
3518,,,,5,,,CHEMBL619188,,Autocuration,B,,1,,D,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,,104705,BAO_0000019
3519,,,,5,,,CHEMBL619189,,Autocuration,B,,1,,D,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,,104705,BAO_0000224
3520,,,955.0,9,Brain,,CHEMBL619190,,Expert,F,,1,,D,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,,12198,BAO_0000019
3521,,,2037.0,9,Cerebellum,,CHEMBL619191,,Expert,F,,1,,D,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,,12198,BAO_0000221
3522,,,,5,,,CHEMBL619192,,Autocuration,B,,1,,D,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,,104705,BAO_0000019
3523,,,,5,,,CHEMBL619193,,Autocuration,B,,1,,D,Percent binding affinity against 5-hydroxytryptamine receptor,,,104705,BAO_0000224
3524,,,,0,,,CHEMBL619194,,Autocuration,B,,1,,U,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,22226,BAO_0000019
3525,,,,5,,,CHEMBL619195,,Autocuration,B,,1,,D,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,,104705,BAO_0000224
3526,,,,5,,,CHEMBL619196,,Autocuration,B,,1,,D,Affinity against 5-hydroxytryptamine receptor was determined,,,104705,BAO_0000224
3527,,,945.0,5,Stomach,,CHEMBL619197,,Autocuration,B,,1,,D,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,,104705,BAO_0000019
3528,,,,9,,In vitro,CHEMBL619198,,Expert,B,,1,,D,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,121,BAO_0000219
3529,,,,9,,In vitro,CHEMBL875081,,Expert,B,,1,,D,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,121,BAO_0000219
3530,,,,8,,,CHEMBL884712,,Autocuration,B,,1,,H,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,18065,BAO_0000357
3531,,,,8,,,CHEMBL884710,,Expert,B,,1,,H,Inhibition of 5-hydroxytryptamine reuptake,,,121,BAO_0000357
3532,,,,8,,,CHEMBL619199,,Autocuration,F,,1,,H,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,18065,BAO_0000019
3533,,,,8,,,CHEMBL619200,,Autocuration,F,,1,,H,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,18065,BAO_0000019
3534,,,,8,,,CHEMBL619201,,Autocuration,F,,1,,H,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,18065,BAO_0000019
3535,,,,8,,,CHEMBL619202,,Autocuration,F,,1,,H,Tested for 5-hydroxytryptamine receptor uptake,,,18065,BAO_0000019
3536,449.0,,,9,,,CHEMBL619203,,Expert,B,,1,,D,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,CHO,51,BAO_0000219
3537,,,,9,,,CHEMBL619204,,Expert,F,,1,,D,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,,51,BAO_0000019
3538,,,,8,,,CHEMBL619205,,Autocuration,B,,1,,H,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,,10576,BAO_0000249
3539,,,,8,,,CHEMBL619206,,Autocuration,B,,1,,H,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,10576,BAO_0000357
3540,,,,8,,,CHEMBL619207,,Expert,B,,1,,H,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,10576,BAO_0000249
3541,,,2435.0,8,Striatum,,CHEMBL619208,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,10825,BAO_0000019
3542,,,2435.0,8,Striatum,,CHEMBL619209,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,10825,BAO_0000019
3543,,,2435.0,8,Striatum,,CHEMBL619210,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,10825,BAO_0000019
3544,,,2435.0,8,Striatum,,CHEMBL619211,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,10825,BAO_0000019
3545,,,2435.0,8,Striatum,,CHEMBL619212,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,10825,BAO_0000019
3546,,,2435.0,8,Striatum,,CHEMBL620681,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,10825,BAO_0000019
3547,,,2435.0,8,Striatum,,CHEMBL620682,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,10825,BAO_0000019
3548,,,2435.0,8,Striatum,,CHEMBL620683,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,10825,BAO_0000019
3549,,,2435.0,8,Striatum,,CHEMBL620684,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,10825,BAO_0000019
3550,,,2435.0,8,Striatum,,CHEMBL620685,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,10825,BAO_0000019
3551,,,2435.0,8,Striatum,,CHEMBL620686,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,10825,BAO_0000019
3552,,,349.0,8,Limbic system,,CHEMBL620687,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,10825,BAO_0000019
3553,,,349.0,8,Limbic system,,CHEMBL620688,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,10825,BAO_0000019
3554,,,349.0,8,Limbic system,,CHEMBL620689,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,10825,BAO_0000019
3555,,,349.0,8,Limbic system,,CHEMBL620690,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,10825,BAO_0000019
3556,,,349.0,8,Limbic system,,CHEMBL620691,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,10825,BAO_0000019
3557,,,349.0,8,Limbic system,,CHEMBL620692,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,10825,BAO_0000019
3558,,,349.0,8,Limbic system,,CHEMBL620693,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,10825,BAO_0000019
3559,,,,8,,,CHEMBL620694,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 4 receptor,,,168,BAO_0000357
3560,,,,8,,,CHEMBL857986,,Autocuration,F,,1,,H,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,168,BAO_0000019
3561,,,,8,,,CHEMBL620695,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,168,BAO_0000357
3562,,,,8,,,CHEMBL620696,,Expert,B,,1,,H,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,168,BAO_0000357
3563,,,,8,,,CHEMBL620697,,Autocuration,B,,1,,H,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,168,BAO_0000357
3564,,,,8,,,CHEMBL620698,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,168,BAO_0000357
3565,,,,8,,,CHEMBL620699,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,168,BAO_0000357
3566,,,,8,,,CHEMBL620700,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,168,BAO_0000357
3567,643.0,,,8,,,CHEMBL620701,,Autocuration,B,,1,,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,COS-7,168,BAO_0000219
3568,643.0,,,8,,,CHEMBL875082,,Autocuration,B,,1,,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,COS-7,168,BAO_0000219
3569,643.0,,,8,,,CHEMBL620702,,Autocuration,B,,1,,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,COS-7,168,BAO_0000219
3570,643.0,,,8,,,CHEMBL620703,,Autocuration,B,,1,,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,COS-7,168,BAO_0000219
3571,673.0,,,8,,,CHEMBL620704,,Autocuration,B,,1,,H,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,C6,168,BAO_0000219
3572,673.0,,,8,,,CHEMBL620705,,Expert,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,C6,168,BAO_0000219
3573,673.0,,,8,,,CHEMBL620706,,Expert,B,,1,,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,C6,168,BAO_0000219
3574,673.0,,,8,,,CHEMBL620707,,Expert,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,C6,168,BAO_0000219
3575,,,,8,,,CHEMBL620708,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,10624,BAO_0000357
3576,,,,8,,,CHEMBL620709,,Autocuration,B,,1,,H,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,105,BAO_0000357
3577,,,,9,,,CHEMBL620710,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 5A receptor,,,10624,BAO_0000357
3578,449.0,,,8,,,CHEMBL620711,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,CHO,10624,BAO_0000219
3579,,,,9,,,CHEMBL620712,,Expert,B,,1,,D,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,,10624,BAO_0000357
3580,,,,9,,,CHEMBL620713,,Expert,B,,1,,D,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,,10624,BAO_0000357
3581,,,,9,,,CHEMBL620714,,Expert,B,,1,,D,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,,10624,BAO_0000357
3582,,,,9,,,CHEMBL620715,,Expert,B,,1,,D,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,,10624,BAO_0000357
3583,,,,8,,,CHEMBL620716,,Autocuration,B,,1,,H,Binding affinity towards 5-HT5A receptor,,,10624,BAO_0000357
3584,,,,8,,,CHEMBL620717,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,10624,BAO_0000357
3585,,,,8,,,CHEMBL618072,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,10624,BAO_0000357
3586,,,,8,,,CHEMBL857987,,Autocuration,B,,1,,H,Binding affinity towards cloned human 5-HT5A receptor was determined,,,10624,BAO_0000357
3587,722.0,,,8,,,CHEMBL618073,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,HEK293,10624,BAO_0000219
3588,722.0,,,8,,,CHEMBL618074,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,HEK293,10624,BAO_0000219
3589,722.0,,,8,,,CHEMBL618075,,Autocuration,B,,1,,H,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,HEK293,10624,BAO_0000219
3590,,,,9,,,CHEMBL618076,,Expert,B,,1,,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,,10625,BAO_0000357
3591,,,,9,,,CHEMBL618077,,Expert,B,,1,,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,10625,BAO_0000357
3592,,,,9,,,CHEMBL618078,,Expert,B,,1,,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,,10625,BAO_0000357
3593,,,,9,,,CHEMBL881821,,Expert,B,,1,,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,,10625,BAO_0000357
3594,,,,9,,,CHEMBL618079,,Expert,B,,1,,D,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,,10625,BAO_0000357
3595,,,,8,,,CHEMBL618080,,Expert,B,,1,,H,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,10625,BAO_0000357
3596,722.0,,,8,,,CHEMBL618081,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,HEK293,10576,BAO_0000219
3597,722.0,,,8,,,CHEMBL618082,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,HEK293,10626,BAO_0000219
3598,,,,8,,,CHEMBL618083,,Expert,B,,1,,H,Binding affinity towards 5-HT5a receptor,,,10624,BAO_0000357
3599,,,,9,,,CHEMBL618084,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 5A receptor,,,10624,BAO_0000357
3600,,,,8,,,CHEMBL618085,,Expert,B,,1,,H,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,10624,BAO_0000357
3601,,,,8,,,CHEMBL618086,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,10624,BAO_0000357
3602,,,,8,,,CHEMBL875092,,Autocuration,B,,1,,H,Binding affinities against 5-hydroxytryptamine 5A receptor,,,10624,BAO_0000357
3603,,,,8,,,CHEMBL618087,,Autocuration,B,,1,,H,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,10624,BAO_0000357
3604,,,,8,,,CHEMBL872926,,Autocuration,B,,1,,H,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,10624,BAO_0000357
3605,,,,4,,,CHEMBL618088,,Autocuration,F,,1,,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,,104714,BAO_0000019
3606,,,,4,,,CHEMBL618089,,Autocuration,B,,1,,H,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,104714,BAO_0000223
3607,,,,9,,,CHEMBL618090,,Expert,B,,1,,D,Inhibition of human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3608,,,,9,,,CHEMBL618091,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,,10627,BAO_0000357
3609,,,,8,,,CHEMBL618092,,Autocuration,B,,1,,H,Inhibition against human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3610,,,,9,,,CHEMBL618093,,Expert,B,,1,,D,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,,10627,BAO_0000357
3611,308.0,,,8,,,CHEMBL618094,,Expert,B,,1,,H,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,HeLa,10627,BAO_0000219
3612,,,,9,,,CHEMBL618095,,Expert,B,,1,,D,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3613,,,,9,,,CHEMBL875093,,Expert,B,,1,,D,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3614,,,,9,,,CHEMBL618096,,Expert,B,,1,,D,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,10627,BAO_0000357
3615,,,,9,,,CHEMBL618118,,Expert,B,,1,,D,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,,10627,BAO_0000357
3616,,,,9,,,CHEMBL618119,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3617,,,,8,,,CHEMBL618120,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3618,,,,8,,,CHEMBL618121,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3619,722.0,,,8,,,CHEMBL618122,,Expert,B,,1,,H,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,HEK293,10627,BAO_0000219
3620,,,,8,,,CHEMBL618123,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,10627,BAO_0000357
3621,722.0,,,8,,,CHEMBL618124,,Expert,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,HEK293,10627,BAO_0000219
3622,,,,8,,,CHEMBL618125,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3623,722.0,,,9,,,CHEMBL618126,,Expert,B,,1,,D,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,HEK293,10627,BAO_0000219
3624,,,,8,,,CHEMBL618236,,Expert,B,,1,,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,10627,BAO_0000019
3625,,,,8,,,CHEMBL618237,,Expert,B,,1,,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,10627,BAO_0000019
3626,643.0,,,8,,,CHEMBL618238,,Expert,B,,1,,H,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,COS-7,10627,BAO_0000219
3627,,,,9,,,CHEMBL618239,,Expert,B,,1,,D,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3628,,,,8,,,CHEMBL618240,,Autocuration,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000019
3629,,,,8,,,CHEMBL618241,,Autocuration,B,,1,,H,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,10627,BAO_0000357
3630,722.0,,,8,,,CHEMBL859399,,Autocuration,B,,1,,H,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,HEK293,10627,BAO_0000219
3631,,,,8,,,CHEMBL618242,,Autocuration,F,,1,,H,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,10627,BAO_0000019
3632,,,,8,,,CHEMBL857991,,Autocuration,B,,1,,H,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3633,,,,8,,,CHEMBL619951,,Expert,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3634,308.0,,,9,,,CHEMBL619952,,Expert,B,,1,,D,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,HeLa,10627,BAO_0000219
3635,308.0,,,9,,,CHEMBL619953,,Expert,B,,1,,D,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,HeLa,10627,BAO_0000219
3636,308.0,,,8,,,CHEMBL619954,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,HeLa,10627,BAO_0000219
3637,308.0,,,8,,,CHEMBL619955,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,HeLa,10627,BAO_0000219
3638,308.0,,,8,,,CHEMBL619956,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,HeLa,10627,BAO_0000219
3639,449.0,,,8,,,CHEMBL619957,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHO,10627,BAO_0000219
3640,722.0,,,8,,,CHEMBL619958,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,HEK293,10627,BAO_0000219
3641,722.0,,,8,,,CHEMBL620627,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,HEK293,10627,BAO_0000219
3642,722.0,,,8,,,CHEMBL620628,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,HEK293,10627,BAO_0000219
3643,308.0,,,8,,,CHEMBL620629,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,HeLa,10627,BAO_0000219
3644,,,,8,,,CHEMBL620630,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3645,308.0,,,8,,,CHEMBL620782,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,HeLa,10627,BAO_0000219
3646,,,,8,,,CHEMBL620783,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3647,,,,8,,,CHEMBL620784,,Expert,B,,1,,H,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3648,308.0,,,8,,,CHEMBL620785,,Expert,B,,1,,H,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,HeLa,10627,BAO_0000219
3649,,,,8,,,CHEMBL857992,,Autocuration,B,,1,,H,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,10627,BAO_0000357
3650,,,,8,,,CHEMBL620786,,Autocuration,B,,1,,H,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,10627,BAO_0000219
3651,308.0,,,8,,,CHEMBL620787,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,HeLa,10627,BAO_0000219
3652,308.0,,,8,,,CHEMBL620788,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,HeLa,10627,BAO_0000219
3653,308.0,,,8,,,CHEMBL620789,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,HeLa,10627,BAO_0000219
3654,308.0,,,8,,,CHEMBL620790,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,HeLa,10627,BAO_0000219
3655,449.0,,,8,,,CHEMBL620791,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,CHO,10628,BAO_0000219
3656,,,,8,,,CHEMBL620792,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,10628,BAO_0000019
3657,,,,8,,,CHEMBL620793,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,10628,BAO_0000357
3658,,,,8,,,CHEMBL620794,,Autocuration,B,,1,,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,10628,BAO_0000357
3659,308.0,,,9,,,CHEMBL620795,,Autocuration,B,,1,,D,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,HeLa,10627,BAO_0000219
3660,,,,8,,,CHEMBL620796,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3661,,,,8,,,CHEMBL620797,,Autocuration,B,,1,,H,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,10627,BAO_0000357
3662,,,,9,,,CHEMBL620798,,Expert,F,,1,,D,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,10627,BAO_0000019
3663,,,,8,,,CHEMBL620799,,Autocuration,B,,1,,H,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,10627,BAO_0000357
3664,,,,8,,,CHEMBL620800,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3665,,,,8,,,CHEMBL620801,,Autocuration,B,,1,,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,10627,BAO_0000357
3666,,,,8,,,CHEMBL875100,,Autocuration,B,,1,,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3667,,,,8,,,CHEMBL620802,,Autocuration,B,,1,,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,10627,BAO_0000357
3668,,,,8,,,CHEMBL620803,,Expert,F,,1,,H,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000019
3669,,,,8,,,CHEMBL620804,,Expert,F,,1,,H,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,10627,BAO_0000019
3670,,,,8,,,CHEMBL620805,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,10627,BAO_0000357
3671,,,,8,,,CHEMBL620806,,Autocuration,B,,1,,H,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3672,,,,8,,,CHEMBL620807,,Autocuration,B,,1,,H,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,10627,BAO_0000357
3673,,,,8,,,CHEMBL620808,,Autocuration,B,,1,,H,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,10627,BAO_0000357
3674,,,,8,,,CHEMBL620809,,Autocuration,B,,1,,H,Binding affinities against 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3675,,,,8,,,CHEMBL620810,,Autocuration,B,,1,,H,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3676,,,,9,,,CHEMBL620811,,Expert,B,,1,,D,Binding affinity towards 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3677,,,,8,,,CHEMBL620812,,Autocuration,B,,1,,H,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,10627,BAO_0000357
3678,,,,8,,,CHEMBL620813,,Autocuration,B,,1,,H,Affinity against 5-hydroxytryptamine 6 receptor,,,10627,BAO_0000357
3679,,,,8,,,CHEMBL620814,,Autocuration,B,,1,,H,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,10627,BAO_0000357
3680,,,,9,,,CHEMBL620815,,Expert,B,,1,,D,Inhibition of human 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3681,722.0,,,8,,,CHEMBL620816,,Autocuration,B,,1,,H,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,HEK293,10209,BAO_0000219
3682,,,,8,,,CHEMBL620817,,Autocuration,B,,1,,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3683,,,,8,,,CHEMBL620818,,Autocuration,B,,1,,H,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,10209,BAO_0000357
3684,722.0,,,8,,,CHEMBL620819,,Expert,B,,1,,H,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,HEK293,10209,BAO_0000219
3685,,,,9,,,CHEMBL620820,,Expert,B,,1,,D,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,,10209,BAO_0000357
3686,449.0,,,8,,,CHEMBL620821,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,CHO,10209,BAO_0000219
3687,,,,9,,,CHEMBL620822,,Expert,B,,1,,D,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3688,,,,9,,,CHEMBL620823,,Expert,B,,1,,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3689,,,,9,,,CHEMBL620824,,Expert,B,,1,,D,Binding affinity against 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3690,449.0,,,8,,,CHEMBL620825,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,CHO,10209,BAO_0000219
3691,,,,8,,,CHEMBL872930,,Autocuration,B,,1,,H,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,10209,BAO_0000357
3692,,,,8,,,CHEMBL620826,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3693,,,,8,,,CHEMBL620827,,Autocuration,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,10209,BAO_0000357
3694,,,,8,,,CHEMBL620828,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3695,,,,8,,,CHEMBL620829,,Autocuration,B,,1,,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3696,722.0,,,8,,,CHEMBL620830,,Expert,B,,1,,H,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,HEK293,10209,BAO_0000219
3697,,,,8,,,CHEMBL620831,,Expert,B,,1,,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,10209,BAO_0000019
3698,,,,8,,,CHEMBL620832,,Expert,B,,1,,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,10209,BAO_0000019
3699,,,,9,,,CHEMBL621548,,Expert,B,,1,,D,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3700,,,,8,,,CHEMBL621549,,Autocuration,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000019
3701,,,,8,,,CHEMBL621550,,Autocuration,B,,1,,H,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,10209,BAO_0000357
3702,449.0,,,8,,,CHEMBL621551,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,CHO,10209,BAO_0000219
3703,,,,8,,,CHEMBL621552,,Autocuration,B,,1,,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,10209,BAO_0000019
3704,,,,8,,,CHEMBL857077,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3705,,,,8,,,CHEMBL618158,,Autocuration,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,10209,BAO_0000357
3706,643.0,,,9,,,CHEMBL618159,,Expert,B,,1,,D,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,COS-7,10209,BAO_0000219
3707,643.0,,,8,,,CHEMBL875101,,Autocuration,B,,1,,H,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,COS-7,10209,BAO_0000219
3708,722.0,,,9,,,CHEMBL618160,,Expert,B,,1,,D,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,HEK293,10209,BAO_0000219
3709,,,,8,,,CHEMBL618161,,Expert,B,,1,,H,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,10209,BAO_0000357
3710,722.0,,,8,,,CHEMBL618162,,Expert,B,,1,,H,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,HEK293,10209,BAO_0000219
3711,,,,8,,,CHEMBL618163,,Expert,B,,1,,H,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,10209,BAO_0000357
3712,,,,8,,,CHEMBL618164,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,10209,BAO_0000357
3713,,,,8,,,CHEMBL618165,,Expert,B,,1,,H,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,10209,BAO_0000219
3714,722.0,,,8,,,CHEMBL618166,,Autocuration,B,,1,,H,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,HEK293,10209,BAO_0000219
3715,722.0,,,8,,,CHEMBL857989,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,HEK293,10209,BAO_0000219
3716,722.0,,,8,,,CHEMBL619888,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,HEK293,10209,BAO_0000219
3717,722.0,,,8,,,CHEMBL619889,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,HEK293,10209,BAO_0000219
3718,722.0,,,8,,,CHEMBL619890,,Autocuration,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,HEK293,10209,BAO_0000219
3719,449.0,,,8,,,CHEMBL619891,,Autocuration,B,,1,,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,CHO,10209,BAO_0000219
3720,722.0,,,8,,,CHEMBL619892,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,HEK293,10209,BAO_0000219
3721,722.0,,,9,,,CHEMBL619893,,Expert,B,,1,,D,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,HEK293,10209,BAO_0000219
3722,722.0,,,8,,,CHEMBL619894,,Autocuration,B,,1,,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,HEK293,10209,BAO_0000219
3723,722.0,,,9,,,CHEMBL619895,,Intermediate,B,,1,,D,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,HEK293,10209,BAO_0000219
3724,,,,9,,,CHEMBL619896,,Intermediate,B,,1,,D,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,10209,BAO_0000357
3725,643.0,,,8,,,CHEMBL619897,,Autocuration,B,,1,,H,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,COS-7,10209,BAO_0000219
3726,722.0,,,8,,,CHEMBL619898,,Autocuration,B,,1,,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,HEK293,10209,BAO_0000219
3727,722.0,,,8,,,CHEMBL619899,,Expert,B,,1,,H,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,HEK293,10209,BAO_0000219
3728,722.0,,,8,,,CHEMBL619900,,Autocuration,B,,1,,H,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,HEK293,10209,BAO_0000219
3729,722.0,,,9,,,CHEMBL619901,,Expert,B,,1,,D,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,HEK293,10209,BAO_0000219
3730,722.0,,,8,,,CHEMBL620580,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,HEK293,10209,BAO_0000219
3731,722.0,,,8,,,CHEMBL620581,,Autocuration,B,,1,,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,HEK293,10209,BAO_0000219
3732,722.0,,,8,,,CHEMBL620733,,Autocuration,B,,1,,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,HEK293,10209,BAO_0000219
3733,,,,9,,,CHEMBL620734,,Autocuration,B,,1,,D,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,,10209,BAO_0000357
3734,,,,9,,,CHEMBL620735,,Expert,B,,1,,D,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,10022,BAO_0000357
3735,,,,8,,,CHEMBL620736,,Autocuration,B,,1,,H,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,,10209,BAO_0000019
3736,449.0,,,8,,,CHEMBL620737,,Autocuration,B,,1,,H,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,CHO,11923,BAO_0000219
3737,449.0,,,8,,,CHEMBL620738,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,CHO,11923,BAO_0000219
3738,449.0,,,8,,,CHEMBL620739,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,CHO,11923,BAO_0000219
3739,449.0,,,8,,,CHEMBL620740,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,CHO,11923,BAO_0000219
3740,449.0,,,8,,,CHEMBL620741,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,CHO,11923,BAO_0000219
3741,449.0,,,8,,,CHEMBL620742,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,CHO,11923,BAO_0000219
3742,449.0,,,8,,,CHEMBL620743,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,CHO,11923,BAO_0000219
3743,449.0,,,8,,,CHEMBL620744,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,CHO,11923,BAO_0000219
3744,449.0,,,8,,,CHEMBL620745,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,CHO,11923,BAO_0000219
3745,449.0,,,8,,,CHEMBL620746,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,CHO,11923,BAO_0000219
3746,449.0,,,8,,,CHEMBL620747,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,CHO,11923,BAO_0000219
3747,449.0,,,8,,,CHEMBL620748,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,CHO,11923,BAO_0000219
3748,449.0,,,8,,,CHEMBL620749,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,CHO,11923,BAO_0000219
3749,,,,8,,,CHEMBL620750,,Expert,B,,1,,H,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,11923,BAO_0000357
3750,,,,9,,,CHEMBL620751,,Expert,B,,1,,D,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,11923,BAO_0000357
3751,,,,8,,,CHEMBL620752,,Expert,B,,1,,H,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,11923,BAO_0000357
3752,,,,8,,,CHEMBL872929,,Autocuration,B,,1,,H,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,,11923,BAO_0000019
3753,,,,9,,,CHEMBL620753,,Expert,B,,1,,D,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,,11923,BAO_0000357
3754,,,,9,,,CHEMBL620754,,Expert,B,,1,,D,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,,11923,BAO_0000357
3755,449.0,,,9,,,CHEMBL620755,,Expert,B,,1,,D,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,CHO,11923,BAO_0000219
3756,,,,8,,,CHEMBL620756,,Autocuration,B,,1,,H,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,11923,BAO_0000357
3757,,,,8,,,CHEMBL620757,,Autocuration,B,,1,,H,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,,11923,BAO_0000357
3758,449.0,,,8,,,CHEMBL620758,,Autocuration,B,,1,,H,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,CHO,11923,BAO_0000219
3759,449.0,,,8,,,CHEMBL620759,,Autocuration,B,,1,,H,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,CHO,11923,BAO_0000219
3760,449.0,,,8,,,CHEMBL620760,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,CHO,11923,BAO_0000219
3761,449.0,,,8,,,CHEMBL620761,,Autocuration,B,,1,,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,CHO,11923,BAO_0000219
3762,,,2116.0,8,Ileum,,CHEMBL620762,,Autocuration,F,,1,,H,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,11923,BAO_0000221
3763,,,2116.0,8,Ileum,,CHEMBL620763,,Autocuration,F,,1,,H,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,11923,BAO_0000221
3764,,,2116.0,8,Ileum,,CHEMBL620764,,Autocuration,F,,1,,H,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,,11923,BAO_0000221
3765,,,,9,,,CHEMBL857990,,Expert,B,,1,Membranes,D,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,,11923,BAO_0000249
3766,,,,8,,,CHEMBL620765,,Autocuration,B,,1,,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,,11923,BAO_0000357
3767,,,,8,,,CHEMBL620766,,Expert,B,,1,,H,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,,11923,BAO_0000357
3768,,,1898.0,8,Hypothalamus,,CHEMBL620767,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,,11923,BAO_0000019
3769,,,,8,,,CHEMBL620768,,Autocuration,B,,1,,H,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,,11923,BAO_0000357
3770,,,1898.0,8,Hypothalamus,,CHEMBL619051,,Expert,B,,1,,H,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,,11923,BAO_0000249
3771,,,,8,,,CHEMBL619052,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,11923,BAO_0000357
3772,722.0,,,9,,,CHEMBL619053,,Expert,F,,1,,D,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,HEK293,11923,BAO_0000219
3773,722.0,,,9,,,CHEMBL619703,,Expert,F,,1,,D,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,HEK293,11923,BAO_0000219
3774,722.0,,,9,,,CHEMBL619704,,Autocuration,F,,1,,D,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,HEK293,11923,BAO_0000219
3775,,,,8,,,CHEMBL619851,,Expert,B,,1,,H,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3776,,,,8,,,CHEMBL619852,,Autocuration,B,,1,,H,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,,10209,BAO_0000357
3777,,,,8,,,CHEMBL619853,,Autocuration,B,,1,,H,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,,10209,BAO_0000357
3778,,,,9,,,CHEMBL619854,,Expert,B,,1,,D,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3779,,,,8,,,CHEMBL619855,,Expert,B,,1,,H,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3780,,,,8,,,CHEMBL619856,,Autocuration,B,,1,,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,,10209,BAO_0000357
3781,,,,8,,,CHEMBL619857,,Autocuration,B,,1,,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,10209,BAO_0000357
3782,,,,8,,,CHEMBL619858,,Expert,F,,1,,H,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,,10209,BAO_0000019
3783,,,,8,,,CHEMBL619859,,Autocuration,B,,1,,H,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,,10209,BAO_0000357
3784,,,,8,,,CHEMBL619860,,Autocuration,B,,1,,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,10209,BAO_0000357
3785,,,,8,,,CHEMBL619861,,Autocuration,B,,1,,H,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3786,,,,8,,,CHEMBL619862,,Expert,B,,1,,H,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3787,,,,8,,,CHEMBL619863,,Autocuration,B,,1,,H,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,,10209,BAO_0000357
3788,,,,8,,,CHEMBL619864,,Autocuration,B,,1,,H,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,,10209,BAO_0000357
3789,,,,8,,,CHEMBL872928,,Autocuration,B,,1,,H,Binding affinities against 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3790,,,,8,,,CHEMBL619865,,Autocuration,B,,1,,H,Binding affinities towards 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3791,,,,8,,,CHEMBL619866,,Expert,B,,1,,H,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,,10209,BAO_0000357
3792,,,,8,,,CHEMBL619867,,Autocuration,B,,1,,H,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,,10209,BAO_0000357
3793,,,2116.0,8,Ileum,,CHEMBL619868,,Autocuration,B,,1,,H,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,10209,BAO_0000221
3794,,,,8,,,CHEMBL619869,,Autocuration,F,,1,,H,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,,55,BAO_0000019
3795,,,,9,,,CHEMBL619870,,Expert,F,,1,,D,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,,55,BAO_0000019
3796,,,,8,,,CHEMBL619871,,Autocuration,B,,1,,H,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,,55,BAO_0000357
3797,,,,8,,,CHEMBL619872,,Autocuration,B,,1,,H,In vitro inhibition of human recombinant lipoxygenase enzyme,,,55,BAO_0000357
3798,,,,8,,,CHEMBL619873,,Autocuration,B,,1,,H,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,,55,BAO_0000357
3799,,,178.0,8,Blood,,CHEMBL619874,,Expert,B,,1,,H,Inhibition of 5-lipoxygenase in human whole blood.,,,55,BAO_0000357
3800,,,178.0,8,Blood,,CHEMBL619875,,Expert,B,,1,,H,Inhibition of 5-lipoxygenase in human whole blood.,,,55,BAO_0000357
3801,,,,8,,,CHEMBL619876,,Autocuration,B,,1,,H,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,,55,BAO_0000357
3802,,,,8,,,CHEMBL619877,,Autocuration,B,,1,,H,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,,55,BAO_0000357
3803,,,,8,,,CHEMBL619878,,Expert,F,,1,,H,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,,55,BAO_0000219
3804,,,178.0,8,Blood,,CHEMBL619879,,Autocuration,F,,1,,H,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,,55,BAO_0000019
3805,,,,8,,,CHEMBL619880,,Autocuration,B,,1,,H,In vitro inhibition of 5-lipoxygenase from human polymorphs,,,55,BAO_0000357
3806,,,,8,,,CHEMBL619881,,Autocuration,B,,1,,H,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,,55,BAO_0000357
3807,,,,8,,,CHEMBL619882,,Expert,B,,1,,H,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,,55,BAO_0000357
3808,,,,8,,,CHEMBL619883,,Autocuration,B,,1,,H,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,,55,BAO_0000357
3809,,,178.0,9,Blood,,CHEMBL619884,,Expert,B,,1,,D,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,,55,BAO_0000357
3810,,,,8,,,CHEMBL619885,,Autocuration,B,,1,,H,In vitro potency against human 5-Lipoxygenase,,,55,BAO_0000357
3811,,,,9,,,CHEMBL619886,,Expert,F,,1,,D,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,,55,BAO_0000019
3812,,,178.0,8,Blood,,CHEMBL619887,,Autocuration,F,,1,,H,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,,55,BAO_0000019
3813,,,,8,,,CHEMBL875097,,Autocuration,F,,1,,H,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,55,BAO_0000019
3814,,,,8,,,CHEMBL618001,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,,55,BAO_0000219
3815,,,,8,,,CHEMBL618002,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,,55,BAO_0000219
3816,,,,8,,,CHEMBL618003,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,,55,BAO_0000219
3817,,,,8,,,CHEMBL618004,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,,55,BAO_0000219
3818,,,,8,,,CHEMBL618005,,Autocuration,B,,1,,H,Inhibition of human 5-lipoxygenase in human cells,,,55,BAO_0000219
3819,,,,8,,,CHEMBL618006,,Expert,B,,1,,H,Inhibition of human neutrophil 5-lipoxygenase,,,55,BAO_0000357
3820,,,,8,,,CHEMBL875086,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,,55,BAO_0000019
3821,,,178.0,8,Blood,,CHEMBL618007,,Expert,B,,1,,H,Inhibition of 5-lipoxygenase from human whole blood,,,55,BAO_0000357
3822,,,,8,,,CHEMBL618008,,Autocuration,B,,1,,H,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,55,BAO_0000357
3823,,,,8,,,CHEMBL618009,,Autocuration,B,,1,,H,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,,55,BAO_0000219
3824,,,,8,,,CHEMBL618010,,Expert,B,,1,,H,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,,55,BAO_0000357
3825,,,,8,,,CHEMBL618011,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,55,BAO_0000357
3826,,,,8,,,CHEMBL618012,,Expert,B,,1,,H,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,,55,BAO_0000357
3827,,,,8,,,CHEMBL882927,,Autocuration,B,,1,,H,Tested against 5-lipoxygenase,,,55,BAO_0000357
3828,,,,8,,,CHEMBL618013,,Autocuration,B,,1,,H,Tested for activity against 5-Lipoxygenase (5-LO),,,55,BAO_0000357
3829,,,,8,,,CHEMBL618014,,Autocuration,B,,1,,H,Tested for activity against 5-lipoxygenase,,,55,BAO_0000357
3830,,,,8,,,CHEMBL618015,,Autocuration,B,,1,,H,Tested for inhibition of 5-HPETE production by human 5-LO,,,55,BAO_0000357
3831,,,,8,,,CHEMBL618016,,Autocuration,F,,1,,H,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,55,BAO_0000019
3832,,,,8,,,CHEMBL618017,,Expert,B,,1,,H,Inhibition of Human 5-lipoxygenase,,,55,BAO_0000357
3833,,,,8,,,CHEMBL618018,,Autocuration,B,,1,,H,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,,55,BAO_0000019
3834,,,,8,,,CHEMBL875087,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,55,BAO_0000219
3835,,,,8,,,CHEMBL618019,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,,55,BAO_0000219
3836,,,,8,,,CHEMBL618020,,Autocuration,B,,1,,H,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,,55,BAO_0000019
3837,,,,8,,,CHEMBL618021,,Autocuration,B,,1,,H,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,,55,BAO_0000019
3838,,,178.0,8,Blood,,CHEMBL618022,,Autocuration,B,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,,55,BAO_0000357
3839,,,,8,,,CHEMBL618023,,Autocuration,B,,1,,H,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,,55,BAO_0000357
3840,,,,8,,,CHEMBL618024,,Autocuration,B,,1,,H,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,55,BAO_0000357
3841,,,,8,,,CHEMBL873950,,Expert,B,,1,,H,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,,55,BAO_0000019
3842,,,,8,,,CHEMBL618025,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,55,BAO_0000357
3843,,,,8,,,CHEMBL618026,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,,55,BAO_0000219
3844,,,,8,,,CHEMBL618027,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,,55,BAO_0000219
3845,,,,8,,,CHEMBL618028,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,,55,BAO_0000219
3846,,,,8,,,CHEMBL618029,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,,55,BAO_0000219
3847,,,,8,,,CHEMBL618030,,Expert,B,,1,,H,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,,55,BAO_0000357
3848,,,,8,,,CHEMBL618031,,Expert,B,,1,,H,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,,55,BAO_0000357
3849,,,,8,,,CHEMBL618032,,Autocuration,B,,1,,H,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,,55,BAO_0000357
3850,,,,8,,,CHEMBL618033,,Autocuration,B,,1,,H,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,55,BAO_0000357
3851,,,,8,,,CHEMBL618034,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,,55,BAO_0000357
3852,,,,8,,,CHEMBL875088,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,55,BAO_0000357
3853,,,,8,,,CHEMBL618035,,Autocuration,B,,1,,H,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,,55,BAO_0000019
3854,,,,8,,,CHEMBL618036,,Autocuration,B,,1,,H,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,,55,BAO_0000019
3855,,,,8,,,CHEMBL618037,,Expert,B,,1,,H,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,,55,BAO_0000357
3856,,,,8,,,CHEMBL618038,,Expert,B,,1,,H,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,55,BAO_0000357
3857,,,,8,,,CHEMBL618761,,Autocuration,F,,1,,H,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,55,BAO_0000019
3858,,,,8,,,CHEMBL618762,,Expert,B,,1,,H,Inhibition of lipoxygenase at the concentration of 0.1 uM,,,55,BAO_0000357
3859,,,,8,,,CHEMBL618763,,Expert,B,,1,,H,Inhibition of lipoxygenase at the concentration of 1 uM,,,55,BAO_0000357
3860,,,,8,,,CHEMBL618764,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,,55,BAO_0000357
3861,,,,9,,,CHEMBL618765,,Expert,B,,1,,D,Inhibition of 5-Lipoxygenase (5-LOX),,,55,BAO_0000357
3862,,,,8,,,CHEMBL618766,,Expert,B,,1,,H,Inhibition of 5-lipoxygenase in mouse macrophages.,,,17087,BAO_0000357
3863,,,,8,,,CHEMBL618767,,Expert,B,,1,,H,Inhibition of 5-lipoxygenase in mouse macrophages.,,,17087,BAO_0000357
3864,,,,8,,,CHEMBL619380,,Autocuration,B,,1,,H,Inhibitory activity against lipoxygenase-2 in mice,,,17087,BAO_0000357
3865,,,,8,,,CHEMBL619381,,Expert,B,,1,,H,Inhibitory activity against murine lipoxygenase-2.,,,17087,BAO_0000357
3866,,,,9,,,CHEMBL619382,,Expert,B,,1,,D,Inhibition of 5-lipoxygenase from mouse macrophage,,,17087,BAO_0000357
3867,,,,8,,,CHEMBL619383,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,,17087,BAO_0000357
3868,,,,8,,,CHEMBL619384,,Autocuration,B,,1,,H,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,55,BAO_0000019
3869,,,,8,,,CHEMBL619385,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,,55,BAO_0000019
3870,,,,8,,,CHEMBL882928,,Autocuration,B,,1,,H,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,,55,BAO_0000019
3871,,,,9,,,CHEMBL619386,,Expert,B,,1,,D,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,,12166,BAO_0000019
3872,,,,8,,,CHEMBL619387,,Autocuration,B,,1,,H,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,,12166,BAO_0000019
3873,,,,8,,,CHEMBL619388,,Autocuration,B,,1,,H,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,12166,BAO_0000019
3874,,,,8,,,CHEMBL619389,,Autocuration,B,,1,,H,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,,12166,BAO_0000019
3875,,,,8,,,CHEMBL619390,,Expert,B,,1,,H,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,,12166,BAO_0000019
3876,,,,8,,,CHEMBL619391,,Expert,B,,1,,H,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,,12166,BAO_0000019
3877,,,,8,,,CHEMBL619392,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,,12166,BAO_0000019
3878,,,,8,,,CHEMBL619393,,Autocuration,B,,1,,H,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,,12166,BAO_0000019
3879,,,,8,,,CHEMBL619394,,Autocuration,B,,1,,H,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,,12166,BAO_0000019
3880,702.0,,,8,,,CHEMBL619395,,Autocuration,B,,1,,H,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,RBL-1,12166,BAO_0000219
3881,702.0,,,8,,,CHEMBL619396,,Autocuration,B,,1,,H,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,RBL-1,12166,BAO_0000219
3882,,,,8,,,CHEMBL619397,,Autocuration,B,,1,,H,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,,12166,BAO_0000357
3883,,,,8,,,CHEMBL619398,,Autocuration,B,,1,,H,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,,12166,BAO_0000357
3884,,,,8,,,CHEMBL619399,,Autocuration,B,,1,,H,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,,12166,BAO_0000357
3885,,,,8,,,CHEMBL619400,,Autocuration,B,,1,,H,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,12166,BAO_0000357
3886,,,,8,,,CHEMBL619401,,Autocuration,B,,1,,H,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,12166,BAO_0000019
3887,,,,8,,,CHEMBL619402,,Autocuration,B,,1,,H,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,,12166,BAO_0000019
3888,663.0,,,9,,,CHEMBL619403,,Expert,B,,1,,D,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,RBL-2H3,12166,BAO_0000219
3889,,,,8,,,CHEMBL619404,,Autocuration,B,,1,,H,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,12166,BAO_0000357
3890,,,,8,,,CHEMBL619405,,Autocuration,B,,1,,H,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,,12166,BAO_0000357
3891,702.0,,,8,,,CHEMBL619406,,Expert,B,,1,,H,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,RBL-1,12166,BAO_0000219
3892,702.0,,,9,,,CHEMBL619407,,Expert,B,,1,,D,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,RBL-1,12166,BAO_0000219
3893,,,,8,,,CHEMBL619408,,Autocuration,B,,1,,H,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,,12166,BAO_0000357
3894,702.0,,,8,,,CHEMBL619409,,Autocuration,B,,1,,H,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,RBL-1,12166,BAO_0000219
3895,702.0,,,8,,,CHEMBL619410,,Expert,B,,1,,H,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,RBL-1,12166,BAO_0000219
3896,702.0,,,8,,,CHEMBL619753,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,RBL-1,12166,BAO_0000219
3897,702.0,,,8,,,CHEMBL619754,,Autocuration,B,,1,,H,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,RBL-1,12166,BAO_0000219
3898,,,,8,,,CHEMBL619903,,Expert,B,,1,,H,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,,12166,BAO_0000357
3899,,,,8,,,CHEMBL619904,,Expert,B,,1,,H,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,,12166,BAO_0000357
3900,,,,8,,,CHEMBL619905,,Expert,B,,1,,H,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,,12166,BAO_0000357
3901,,,,8,,,CHEMBL619906,,Autocuration,B,,1,,H,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,,12166,BAO_0000019
3902,,,,8,,,CHEMBL619907,,Autocuration,B,,1,,H,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,,12166,BAO_0000019
3903,,,,8,,,CHEMBL619908,,Autocuration,B,,1,,H,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,,12166,BAO_0000019
3904,,,,8,,,CHEMBL619909,,Autocuration,B,,1,,H,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,,12166,BAO_0000019
3905,702.0,,,8,,,CHEMBL619910,,Expert,F,,1,,H,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,RBL-1,12166,BAO_0000219
3906,702.0,,,8,,,CHEMBL882929,,Expert,B,,1,,H,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,RBL-1,12166,BAO_0000219
3907,702.0,,,8,,,CHEMBL619911,,Expert,B,,1,,H,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,RBL-1,12166,BAO_0000219
3908,,,,8,,,CHEMBL619912,,Autocuration,B,,1,,H,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,,12166,BAO_0000019
3909,,,,9,,,CHEMBL619913,,Expert,B,,1,,D,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,,12166,BAO_0000357
3910,702.0,,,8,,,CHEMBL619914,,Expert,B,,1,,H,In vitro inhibitory activity against RBL-1 5-LO,,RBL-1,12166,BAO_0000219
3911,702.0,,,8,,,CHEMBL619915,,Autocuration,B,,1,,H,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,RBL-1,12166,BAO_0000219
3912,702.0,,,8,,,CHEMBL619916,,Autocuration,B,,1,,H,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,RBL-1,12166,BAO_0000219
3913,,,,8,,,CHEMBL619917,,Autocuration,B,,1,,H,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,,12166,BAO_0000218
3914,,,,8,,,CHEMBL619918,,Autocuration,B,,1,,H,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,,12166,BAO_0000357
3915,,,,8,,,CHEMBL619919,,Autocuration,B,,1,,H,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,,12166,BAO_0000218
3916,702.0,,,8,,,CHEMBL883710,,Autocuration,B,,1,,H,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,RBL-1,12166,BAO_0000219
3917,,,178.0,8,Blood,,CHEMBL619920,,Autocuration,B,,1,,H,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,,12166,BAO_0000019
3918,,,,8,,,CHEMBL619921,,Expert,B,,1,,H,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,,12166,BAO_0000357
3919,,,,8,,,CHEMBL619922,,Autocuration,F,,1,,H,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,,12166,BAO_0000019
3920,,,,8,,,CHEMBL619923,,Autocuration,F,,1,,H,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,,12166,BAO_0000219
3921,702.0,,,8,,,CHEMBL619924,,Expert,B,,1,,H,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,RBL-1,12166,BAO_0000219
3922,,,,8,,,CHEMBL619925,,Expert,B,,1,,H,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,,12166,BAO_0000357
3923,702.0,,,8,,,CHEMBL619926,,Expert,B,,1,,H,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,RBL-1,12166,BAO_0000219
3924,702.0,,,8,,,CHEMBL619927,,Autocuration,B,,1,,H,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,RBL-1,12166,BAO_0000219
3925,702.0,,,8,,,CHEMBL619928,,Expert,B,,1,,H,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,RBL-1,12166,BAO_0000219
3926,702.0,,,8,,,CHEMBL619929,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase,,RBL-1,12166,BAO_0000219
3927,702.0,,,8,,,CHEMBL875089,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,RBL-1,12166,BAO_0000219
3928,702.0,,,8,,,CHEMBL619930,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,RBL-1,12166,BAO_0000219
3929,702.0,,,8,,,CHEMBL619931,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,RBL-1,12166,BAO_0000219
3930,702.0,,,8,,,CHEMBL619932,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,RBL-1,12166,BAO_0000219
3931,702.0,,,8,,,CHEMBL619933,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,RBL-1,12166,BAO_0000219
3932,702.0,,,8,,,CHEMBL619934,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,RBL-1,12166,BAO_0000219
3933,702.0,,,8,,,CHEMBL619935,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,RBL-1,12166,BAO_0000219
3934,702.0,,,8,,,CHEMBL619936,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,RBL-1,12166,BAO_0000219
3935,702.0,,,8,,,CHEMBL619937,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,RBL-1,12166,BAO_0000219
3936,702.0,,,8,,,CHEMBL619938,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,RBL-1,12166,BAO_0000219
3937,702.0,,,8,,,CHEMBL619939,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,RBL-1,12166,BAO_0000219
3938,702.0,,,8,,,CHEMBL619940,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,RBL-1,12166,BAO_0000219
3939,702.0,,,8,,,CHEMBL875090,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,RBL-1,12166,BAO_0000219
3940,702.0,,,8,,,CHEMBL619941,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,RBL-1,12166,BAO_0000219
3941,702.0,,,8,,,CHEMBL619942,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,RBL-1,12166,BAO_0000219
3942,702.0,,,8,,,CHEMBL883711,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,RBL-1,12166,BAO_0000219
3943,702.0,,,8,,,CHEMBL619943,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,RBL-1,12166,BAO_0000219
3944,702.0,,,8,,,CHEMBL619944,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,RBL-1,12166,BAO_0000219
3945,702.0,,,8,,,CHEMBL619945,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,RBL-1,12166,BAO_0000219
3946,702.0,,,8,,,CHEMBL619946,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,RBL-1,12166,BAO_0000219
3947,702.0,,,8,,,CHEMBL619947,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,RBL-1,12166,BAO_0000219
3948,702.0,,,8,,,CHEMBL619948,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,RBL-1,12166,BAO_0000219
3949,702.0,,,8,,,CHEMBL619949,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,RBL-1,12166,BAO_0000219
3950,,,,8,,,CHEMBL619950,,Expert,B,,1,,H,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,,12166,BAO_0000019
3951,,,,8,,,CHEMBL618050,,Autocuration,B,,1,,H,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,,12166,BAO_0000019
3952,663.0,,,8,,,CHEMBL875091,,Expert,F,,1,,H,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,RBL-2H3,12166,BAO_0000219
3953,663.0,,,8,,,CHEMBL618051,,Expert,F,,1,,H,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,RBL-2H3,12166,BAO_0000219
3954,702.0,,,9,,,CHEMBL618052,,Expert,B,,1,,D,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,RBL-1,12166,BAO_0000219
3955,,,,8,,,CHEMBL618053,,Autocuration,B,,1,,H,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,,12166,BAO_0000019
3956,,,,8,,,CHEMBL618054,,Expert,B,,1,,H,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,,12166,BAO_0000019
3957,702.0,,,9,,,CHEMBL618055,,Expert,B,,1,,D,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,RBL-1,12166,BAO_0000219
3958,702.0,,,8,,,CHEMBL618056,,Expert,B,,1,,H,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,RBL-1,12166,BAO_0000219
3959,,,,8,,,CHEMBL618057,,Autocuration,B,,1,,H,In vitro inhibitory activity against 5-lipoxygenase was determined,,,12166,BAO_0000357
3960,702.0,,,8,,,CHEMBL618058,,Autocuration,B,,1,,H,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,RBL-1,12166,BAO_0000219
3961,702.0,,,8,,,CHEMBL618059,,Expert,B,,1,,H,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,RBL-1,12166,BAO_0000219
3962,,,,9,,,CHEMBL618060,,Expert,F,,1,,D,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,,12166,BAO_0000019
3963,702.0,,,8,,,CHEMBL618061,,Autocuration,B,,1,,H,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,RBL-1,12166,BAO_0000219
3964,,,,8,,,CHEMBL618062,,Autocuration,B,,1,,H,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,,12166,BAO_0000019
3965,702.0,,,8,,,CHEMBL618063,,Expert,B,,1,,H,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,RBL-1,12166,BAO_0000219
3966,,,,8,,,CHEMBL618064,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,,12166,BAO_0000357
3967,702.0,,,9,,,CHEMBL618065,,Expert,B,,1,,D,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,RBL-1,12166,BAO_0000219
3968,702.0,,,9,,,CHEMBL618066,,Expert,B,,1,,D,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,RBL-1,12166,BAO_0000219
3969,702.0,,,8,,,CHEMBL618067,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,RBL-1,12166,BAO_0000219
3970,702.0,,,8,,,CHEMBL618068,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,RBL-1,12166,BAO_0000219
3971,702.0,,,9,,,CHEMBL618069,,Expert,B,,1,,D,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,RBL-1,12166,BAO_0000219
3972,702.0,,,8,,,CHEMBL618070,,Expert,B,,1,,H,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,RBL-1,12166,BAO_0000219
3973,,,349.0,8,Limbic system,,CHEMBL618071,,Autocuration,F,,1,,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,,10825,BAO_0000019
3974,,,349.0,8,Limbic system,,CHEMBL619247,,Autocuration,F,,1,,H,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,10825,BAO_0000019
3975,,,,8,,,CHEMBL619248,,Autocuration,F,,1,,H,Approximate dose levels for a half maximal reduction of 5-HTP levels,,,10825,BAO_0000019
3976,,,10000000.0,8,Hippocampus,,CHEMBL619249,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,10576,BAO_0000221
3977,,,10000000.0,8,Hippocampus,,CHEMBL619250,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,10576,BAO_0000221
3978,,,,8,,,CHEMBL619251,,Autocuration,B,,1,,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,10577,BAO_0000019
3979,,,178.0,8,Blood,,CHEMBL619252,,Autocuration,F,,1,,H,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,,55,BAO_0000019
3980,,,178.0,8,Blood,,CHEMBL619253,,Autocuration,F,,1,,H,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,,55,BAO_0000019
3981,,,,8,,,CHEMBL619254,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,12166,BAO_0000219
3982,,,,8,,,CHEMBL619255,,Expert,B,,1,,H,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,,17140,BAO_0000219
3983,,,,8,,,CHEMBL619256,,Expert,B,,1,,H,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,,17140,BAO_0000219
3984,,,,8,,,CHEMBL875418,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,,17140,BAO_0000219
3985,,,,8,,,CHEMBL619257,,Expert,B,,1,,H,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,17140,BAO_0000219
3986,,,,8,,,CHEMBL619258,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,17140,BAO_0000219
3987,,,,8,,,CHEMBL619259,,Expert,B,,1,,H,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,,17140,BAO_0000357
3988,,,,8,,,CHEMBL619260,,Expert,B,,1,,H,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,,17140,BAO_0000357
3989,,,178.0,8,Blood,In vivo,CHEMBL619261,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
3990,,,178.0,8,Blood,In vivo,CHEMBL619263,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
3991,,,178.0,8,Blood,In vivo,CHEMBL619264,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
3992,,,178.0,8,Blood,In vivo,CHEMBL619265,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
3993,,,178.0,8,Blood,In vivo,CHEMBL619266,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
3994,,,178.0,8,Blood,In vivo,CHEMBL619902,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
3995,,,178.0,8,Blood,In vivo,CHEMBL620058,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
3996,,,178.0,8,Blood,In vivo,CHEMBL620059,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
3997,,,178.0,8,Blood,In vivo,CHEMBL620060,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
3998,,,178.0,8,Blood,In vivo,CHEMBL620061,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
3999,,,178.0,8,Blood,In vivo,CHEMBL620062,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,,55,BAO_0000218
4000,,,178.0,8,Blood,In vivo,CHEMBL620063,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4001,,,178.0,8,Blood,In vivo,CHEMBL620064,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,,55,BAO_0000218
4002,,,178.0,8,Blood,In vivo,CHEMBL620065,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4003,,,178.0,8,Blood,In vivo,CHEMBL620066,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,,55,BAO_0000218
4004,,,178.0,8,Blood,In vivo,CHEMBL620067,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4005,,,178.0,8,Blood,In vivo,CHEMBL620068,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,,55,BAO_0000218
4006,,,178.0,8,Blood,In vivo,CHEMBL620069,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4007,,,178.0,8,Blood,In vivo,CHEMBL620070,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,,55,BAO_0000218
4008,,,178.0,8,Blood,In vivo,CHEMBL620071,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4009,,,178.0,8,Blood,In vivo,CHEMBL620072,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,,55,BAO_0000218
4010,,,178.0,8,Blood,In vivo,CHEMBL620036,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4011,,,178.0,8,Blood,In vivo,CHEMBL857702,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,,55,BAO_0000218
4012,,,178.0,8,Blood,In vivo,CHEMBL620037,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4013,,,178.0,8,Blood,In vivo,CHEMBL620038,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,,55,BAO_0000218
4014,,,178.0,8,Blood,In vivo,CHEMBL620039,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4015,,,178.0,8,Blood,In vivo,CHEMBL620040,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,,55,BAO_0000218
4016,,,178.0,8,Blood,In vivo,CHEMBL620041,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4017,,,178.0,8,Blood,In vivo,CHEMBL620042,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,,55,BAO_0000218
4018,,,178.0,8,Blood,In vivo,CHEMBL620043,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4019,,,178.0,8,Blood,In vivo,CHEMBL620044,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,,55,BAO_0000218
4020,,,178.0,8,Blood,In vivo,CHEMBL620045,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4021,,,178.0,8,Blood,In vivo,CHEMBL620046,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,,55,BAO_0000218
4022,,,178.0,8,Blood,In vivo,CHEMBL620047,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4023,,,178.0,8,Blood,In vivo,CHEMBL620048,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,,55,BAO_0000218
4024,,,178.0,8,Blood,In vivo,CHEMBL857703,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4025,,,178.0,8,Blood,In vivo,CHEMBL620049,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,,55,BAO_0000218
4026,,,178.0,8,Blood,In vivo,CHEMBL620050,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4027,,,178.0,8,Blood,In vivo,CHEMBL620051,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4028,,,178.0,8,Blood,In vivo,CHEMBL619213,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4029,,,178.0,8,Blood,In vivo,CHEMBL619214,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4030,,,178.0,8,Blood,In vivo,CHEMBL619804,,Autocuration,F,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4031,,,178.0,8,Blood,In vivo,CHEMBL619805,,Autocuration,F,,1,,H,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4032,,,178.0,8,Blood,In vivo,CHEMBL619806,,Autocuration,F,,1,,H,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4033,,,178.0,8,Blood,In vivo,CHEMBL619807,,Autocuration,F,,1,,H,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4034,,,178.0,8,Blood,In vivo,CHEMBL619808,,Autocuration,F,,1,,H,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4035,,,,8,,,CHEMBL619809,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,,55,BAO_0000218
4036,,,,8,,,CHEMBL619810,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,,55,BAO_0000218
4037,,,,8,,,CHEMBL619811,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,,55,BAO_0000218
4038,,,,8,,,CHEMBL620769,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,,55,BAO_0000218
4039,,,,8,,,CHEMBL620770,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,,55,BAO_0000218
4040,,,,8,,,CHEMBL620771,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,,55,BAO_0000218
4041,,,,8,,,CHEMBL620772,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,,55,BAO_0000218
4042,,,,8,,,CHEMBL620773,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,,55,BAO_0000218
4043,,,,8,,,CHEMBL620774,,Autocuration,B,,1,,H,Ability to inhibit 5-lipoxygenase in guinea pig,,,55,BAO_0000357
4044,,,,8,,,CHEMBL620775,,Expert,B,,1,,H,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,,55,BAO_0000357
4045,,,,8,,,CHEMBL620776,,Autocuration,B,,1,,H,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,,55,BAO_0000357
4046,,,178.0,8,Blood,,CHEMBL620777,,Autocuration,B,,1,,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,,55,BAO_0000218
4047,,,,8,,,CHEMBL620778,,Autocuration,B,,1,,H,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,,55,BAO_0000357
4048,,,,8,,,CHEMBL620779,,Autocuration,B,,1,,H,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,,55,BAO_0000357
4049,,,,8,,,CHEMBL621500,,Expert,B,,1,,H,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,,55,BAO_0000019
4050,,,,8,,,CHEMBL621501,,Expert,B,,1,,H,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,55,BAO_0000019
4051,,,,8,,,CHEMBL618098,,Autocuration,B,,1,,H,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,55,BAO_0000019
4052,,,,8,,,CHEMBL618099,,Autocuration,B,,1,,H,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,55,BAO_0000019
4053,,,,8,,,CHEMBL618100,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase,,,55,BAO_0000357
4054,,,,8,,,CHEMBL618101,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,,55,BAO_0000357
4055,,,,8,,,CHEMBL618102,,Autocuration,B,,1,,H,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,,55,BAO_0000357
4056,,,,8,,,CHEMBL618103,,Autocuration,B,,1,,H,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,,55,BAO_0000357
4057,,,,8,,,CHEMBL618104,,Autocuration,B,,1,,H,Inhibitory activity uM,,,55,BAO_0000357
4058,,,,8,,,CHEMBL883712,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,,55,BAO_0000219
4059,,,,8,,,CHEMBL618105,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase at 10 uM,,,55,BAO_0000357
4060,,,,8,,,CHEMBL618106,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,55,BAO_0000357
4061,,,,8,,,CHEMBL618107,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,,55,BAO_0000357
4062,,,,8,,,CHEMBL618108,,Autocuration,B,,1,,H,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,55,BAO_0000357
4063,,,,8,,,CHEMBL618109,,Autocuration,B,,1,,H,Inhibitory activity uM,,,55,BAO_0000357
4064,,,,8,,,CHEMBL618110,,Autocuration,B,,1,,H,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,,55,BAO_0000357
4065,,,,8,,,CHEMBL618111,,Expert,B,,1,,H,Inhibitory activity uM,,,55,BAO_0000357
4066,,,,8,,,CHEMBL618112,,Autocuration,F,,1,,H,Inhibitory activity uM,,,55,BAO_0000019
4067,,,,8,,,CHEMBL618113,,Autocuration,B,,1,,H,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,55,BAO_0000019
4068,,,,8,,,CHEMBL618114,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,55,BAO_0000357
4069,,,2116.0,8,Ileum,,CHEMBL620871,,Expert,F,,1,,H,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,,55,BAO_0000221
4070,,,,8,,,CHEMBL620872,,Autocuration,B,,1,,H,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,55,BAO_0000357
4071,,,,8,,,CHEMBL620873,,Autocuration,B,,1,,H,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,55,BAO_0000357
4072,,,,8,,,CHEMBL620874,,Autocuration,B,,1,,H,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,,55,BAO_0000357
4073,,,,8,,,CHEMBL620875,,Expert,B,,1,,H,In vitro inhibition of human 5-Lipoxygenase.,,,55,BAO_0000357
4074,,,2107.0,0,Liver,,CHEMBL620876,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,22226,BAO_0000251
4075,,,2107.0,0,Liver,,CHEMBL620877,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,22226,BAO_0000251
4076,,,2107.0,0,Liver,,CHEMBL857854,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,22226,BAO_0000251
4077,,,2107.0,0,Liver,,CHEMBL620878,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,,22226,BAO_0000251
4078,,,2107.0,0,Liver,,CHEMBL620879,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,22226,BAO_0000251
4079,,,2107.0,0,Liver,,CHEMBL620880,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,22226,BAO_0000251
4080,,,2107.0,0,Liver,,CHEMBL620881,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,22226,BAO_0000251
4081,,,2107.0,0,Liver,,CHEMBL620882,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,22226,BAO_0000251
4082,,,2107.0,0,Liver,,CHEMBL620883,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,22226,BAO_0000251
4083,,,2107.0,0,Liver,,CHEMBL620884,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,22226,BAO_0000251
4084,,,2107.0,0,Liver,,CHEMBL620885,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,22226,BAO_0000251
4085,,,2107.0,0,Liver,,CHEMBL620886,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,,22226,BAO_0000251
4086,,,2107.0,0,Liver,,CHEMBL620887,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,22226,BAO_0000251
4087,,,2107.0,0,Liver,,CHEMBL618039,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,22226,BAO_0000251
4088,,,2107.0,0,Liver,,CHEMBL618040,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,22226,BAO_0000251
4089,,,2107.0,0,Liver,,CHEMBL618041,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,,22226,BAO_0000251
4090,,,2107.0,0,Liver,,CHEMBL618216,,Autocuration,B,,1,Microsomes,U,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,22226,BAO_0000251
4091,,,2107.0,0,Liver,,CHEMBL618217,,Autocuration,B,,1,Microsomes,U,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,22226,BAO_0000251
4092,,,2107.0,0,Liver,,CHEMBL618218,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,,22226,BAO_0000251
4093,,,2107.0,0,Liver,,CHEMBL618219,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,,22226,BAO_0000251
4094,,,2107.0,0,Liver,,CHEMBL618220,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,,22226,BAO_0000251
4095,,,2107.0,0,Liver,,CHEMBL618221,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,,22226,BAO_0000251
4096,,,2107.0,0,Liver,,CHEMBL618222,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,,22226,BAO_0000251
4097,,,2107.0,0,Liver,,CHEMBL618223,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,22226,BAO_0000251
4098,,,2107.0,0,Liver,,CHEMBL618224,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,22226,BAO_0000251
4099,,,2107.0,0,Liver,,CHEMBL618225,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,,22226,BAO_0000251
4100,,,2107.0,0,Liver,,CHEMBL618226,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,,22226,BAO_0000251
4101,,,2107.0,0,Liver,,CHEMBL618227,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,22226,BAO_0000251
4102,,,2107.0,0,Liver,,CHEMBL618228,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,22226,BAO_0000251
4103,,,2107.0,0,Liver,,CHEMBL618229,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,22226,BAO_0000251
4104,,,2107.0,0,Liver,,CHEMBL618230,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,22226,BAO_0000251
4105,,,2107.0,0,Liver,,CHEMBL618231,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,22226,BAO_0000251
4106,,,2107.0,0,Liver,,CHEMBL618232,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,22226,BAO_0000251
4107,,,2107.0,0,Liver,,CHEMBL618233,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,22226,BAO_0000251
4108,,,2107.0,0,Liver,,CHEMBL618234,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,22226,BAO_0000251
4109,,,2107.0,0,Liver,,CHEMBL618235,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,22226,BAO_0000251
4110,,,2107.0,0,Liver,,CHEMBL618115,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,22226,BAO_0000251
4111,,,2107.0,0,Liver,,CHEMBL618116,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,22226,BAO_0000251
4112,,,2107.0,0,Liver,,CHEMBL618117,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,22226,BAO_0000251
4113,,,2107.0,0,Liver,,CHEMBL619968,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,22226,BAO_0000251
4114,,,2107.0,0,Liver,,CHEMBL619969,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,22226,BAO_0000251
4115,,,2107.0,0,Liver,,CHEMBL619970,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,22226,BAO_0000251
4116,,,2107.0,0,Liver,,CHEMBL619971,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,,22226,BAO_0000251
4117,,,2107.0,0,Liver,,CHEMBL619972,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,,22226,BAO_0000251
4118,,,2107.0,0,Liver,,CHEMBL619973,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,,22226,BAO_0000251
4119,,,2107.0,0,Liver,,CHEMBL619974,,Autocuration,B,,1,Microsomes,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,,22226,BAO_0000251
4120,,,2107.0,0,Liver,,CHEMBL619975,,Autocuration,B,,1,Microsomes,U,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,22226,BAO_0000251
4121,,,,0,,,CHEMBL619976,,Autocuration,B,,1,Microsomes,U,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,,22226,BAO_0000251
4122,,,2107.0,0,Liver,,CHEMBL619977,,Autocuration,B,,1,Microsomes,U,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,22226,BAO_0000251
4123,,,2107.0,0,Liver,,CHEMBL619978,,Autocuration,B,,1,Microsomes,U,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,22226,BAO_0000251
4124,,,2107.0,0,Liver,,CHEMBL619979,,Autocuration,B,,1,Microsomes,U,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,,22226,BAO_0000251
4125,,,2107.0,0,Liver,,CHEMBL619980,,Autocuration,B,,1,Microsomes,U,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,22226,BAO_0000251
4126,,,2107.0,0,Liver,,CHEMBL619981,,Autocuration,B,,1,Microsomes,U,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,22226,BAO_0000251
4127,741.0,,,1,,,CHEMBL619982,,Intermediate,F,,1,,N,In vitro inhibition of 7226/S myeloma cancer cell line,,RPMI-8226,80433,BAO_0000219
4128,993.0,,,1,,,CHEMBL619983,,Intermediate,F,,1,,N,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,BEL-7404 tumor cell line,80698,BAO_0000219
4129,391.0,,,1,,,CHEMBL620031,,Intermediate,F,,1,,N,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,786-0,80640,BAO_0000219
4130,391.0,,,1,,,CHEMBL620032,,Intermediate,F,,1,,N,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,786-0,80640,BAO_0000219
4131,505.0,,,1,,,CHEMBL620033,,Expert,F,,1,,N,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,V79,81264,BAO_0000219
4132,505.0,,,1,,,CHEMBL620034,,Expert,F,,1,,N,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,V79,81264,BAO_0000219
4133,1119.0,,,1,,,CHEMBL620035,,Intermediate,F,,1,,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,7800C1 cell line,80635,BAO_0000219
4134,1119.0,,,1,,,CHEMBL618318,,Intermediate,F,,1,,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,7800C1 cell line,80635,BAO_0000219
4135,1119.0,,,1,,,CHEMBL618319,,Intermediate,F,,1,,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,7800C1 cell line,80635,BAO_0000219
4136,1119.0,,,1,,,CHEMBL618320,,Intermediate,F,,1,,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,7800C1 cell line,80635,BAO_0000219
4137,1119.0,,,1,,,CHEMBL618321,,Intermediate,F,,1,,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,7800C1 cell line,80635,BAO_0000219
4138,1119.0,,,1,,,CHEMBL883118,,Intermediate,F,,1,,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,7800C1 cell line,80635,BAO_0000219
4139,391.0,,,1,,,CHEMBL883795,,Intermediate,F,,1,,N,In vitro antitumor activity against renal 786-0 tumor cell lines,,786-0,80640,BAO_0000219
4140,391.0,,,1,,,CHEMBL618322,,Intermediate,F,,1,,N,Cytotoxic activity against 786-0 Renal cancer cell line,,786-0,80640,BAO_0000219
4141,391.0,,,1,,,CHEMBL618323,,Intermediate,F,,1,,N,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,786-0,80640,BAO_0000219
4142,391.0,,,1,,,CHEMBL618324,,Intermediate,F,,1,,N,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,786-0,80640,BAO_0000219
4143,391.0,,,1,,,CHEMBL618325,,Intermediate,F,,1,,N,In vitro antitumor activity against human renal 786-0 cell line,,786-0,80640,BAO_0000219
4144,391.0,,,1,,,CHEMBL875416,,Intermediate,F,,1,,N,Inhibition of Renal cancer in 786-0 cancer cell lines,,786-0,80640,BAO_0000219
4145,391.0,,,1,,,CHEMBL618326,,Intermediate,F,,1,,N,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,786-0,80640,BAO_0000219
4146,391.0,,,1,,,CHEMBL618327,,Intermediate,F,,1,,N,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,786-0,80640,BAO_0000219
4147,391.0,,,1,,,CHEMBL619215,,Intermediate,F,,1,,N,inhibition of the growth of renal cancer(786-0) cell line,,786-0,80640,BAO_0000219
4148,391.0,,,1,,,CHEMBL619216,,Intermediate,F,,1,,N,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,786-0,80640,BAO_0000219
4149,391.0,,,1,,,CHEMBL619217,,Intermediate,F,,1,,N,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,786-0,80640,BAO_0000219
4150,391.0,,,1,,,CHEMBL619218,,Intermediate,F,,1,,N,The IC50 value was measured on 786-0 cell line in ovarian tumor,,786-0,80640,BAO_0000219
4151,391.0,,,1,,,CHEMBL619219,,Intermediate,F,,1,,N,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,786-0,80640,BAO_0000219
4152,391.0,,,1,,,CHEMBL619220,,Intermediate,F,,1,,N,The IC50 value was measured on 786-0 cell line in renal tumor type.,,786-0,80640,BAO_0000219
4153,391.0,,,1,,,CHEMBL619221,,Intermediate,F,,1,,N,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,786-0,80640,BAO_0000219
4154,391.0,,,1,,,CHEMBL619222,,Intermediate,F,,1,,N,Tested for cytotoxic activity against renal cancer 786-0 cell line,,786-0,80640,BAO_0000219
4155,391.0,,,1,,,CHEMBL857454,,Intermediate,F,,1,,N,Compound was tested for growth inhibitory activity against 786-0 cell line,,786-0,80640,BAO_0000219
4156,702.0,,,8,,,CHEMBL619223,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,RBL-1,12166,BAO_0000219
4157,702.0,,,8,,,CHEMBL619224,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,RBL-1,12166,BAO_0000219
4158,,,,8,,,CHEMBL619225,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,12166,BAO_0000019
4159,702.0,,,8,,,CHEMBL619226,,Expert,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,RBL-1,12166,BAO_0000219
4160,702.0,,,8,,,CHEMBL619227,,Expert,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,RBL-1,12166,BAO_0000219
4161,,,,8,,,CHEMBL619228,,Autocuration,B,,1,,H,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,,12166,BAO_0000357
4162,,,,8,,,CHEMBL619229,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,,12166,BAO_0000219
4163,702.0,,,8,,,CHEMBL619230,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,RBL-1,12166,BAO_0000219
4164,,,,8,,,CHEMBL619231,,Autocuration,B,,1,,H,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,,12166,BAO_0000357
4165,,,,8,,,CHEMBL619232,,Autocuration,B,,1,,H,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,,12166,BAO_0000357
4166,,,,8,,,CHEMBL619233,,Expert,B,,1,,H,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,,12166,BAO_0000357
4167,,,,8,,,CHEMBL619234,,Autocuration,B,,1,,H,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,,12166,BAO_0000357
4168,,,,8,,,CHEMBL619235,,Autocuration,B,,1,,H,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,,12166,BAO_0000357
4169,,,,9,,,CHEMBL619236,,Expert,B,,1,,D,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,,12166,BAO_0000019
4170,702.0,,,8,,,CHEMBL619237,,Autocuration,B,,1,,H,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,RBL-1,12166,BAO_0000219
4171,,,,8,,,CHEMBL619238,,Autocuration,B,,1,,H,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,,12166,BAO_0000357
4172,,,,8,,,CHEMBL619239,,Expert,B,,1,,H,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,,12166,BAO_0000357
4173,,,,8,,,CHEMBL619240,,Autocuration,B,,1,,H,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,,12166,BAO_0000357
4174,,,,8,,,CHEMBL875417,,Autocuration,B,,1,,H,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,12166,BAO_0000019
4175,702.0,,,8,,,CHEMBL619241,,Autocuration,B,,1,,H,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,RBL-1,12166,BAO_0000219
4176,,,,8,,,CHEMBL619242,,Expert,F,,1,,H,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,12166,BAO_0000019
4177,702.0,,,8,,,CHEMBL883796,,Autocuration,B,,1,,H,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,RBL-1,12166,BAO_0000219
4178,,,,8,,,CHEMBL619243,,Autocuration,B,,1,,H,Tested for its inhibitory activity against 5-lipoxygenase,,,12166,BAO_0000357
4179,,,,8,,,CHEMBL619244,,Autocuration,B,,1,,H,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,,12166,BAO_0000357
4180,,,,8,,,CHEMBL619245,,Expert,B,,1,,H,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,,12166,BAO_0000019
4181,,,,8,,,CHEMBL619246,,Expert,B,,1,,H,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,12166,BAO_0000019
4182,702.0,,,8,,,CHEMBL619984,,Expert,B,,1,,H,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,RBL-1,12166,BAO_0000219
4183,702.0,,,8,,,CHEMBL619985,,Autocuration,B,,1,,H,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,RBL-1,12166,BAO_0000219
4184,702.0,,,8,,,CHEMBL619986,,Autocuration,B,,1,,H,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,RBL-1,12166,BAO_0000219
4185,702.0,,,8,,,CHEMBL619987,,Expert,B,,1,,H,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,RBL-1,12166,BAO_0000219
4186,,,,8,,,CHEMBL619988,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,,12166,BAO_0000218
4187,702.0,,,8,,,CHEMBL619989,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,RBL-1,12166,BAO_0000219
4188,702.0,,,8,,,CHEMBL619990,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,RBL-1,12166,BAO_0000219
4189,,,,8,,,CHEMBL619991,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,12166,BAO_0000219
4190,,,,8,,,CHEMBL619992,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,,12166,BAO_0000219
4191,,,,8,,In vivo,CHEMBL619993,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,,12166,BAO_0000218
4192,663.0,,,8,,,CHEMBL619994,,Autocuration,F,,1,,H,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,RBL-2H3,12166,BAO_0000219
4193,663.0,,,8,,,CHEMBL619995,,Autocuration,F,,1,,H,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,RBL-2H3,12166,BAO_0000219
4194,,,,8,,,CHEMBL619996,,Autocuration,B,,1,,H,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,,12166,BAO_0000019
4195,,,,8,,,CHEMBL619997,,Autocuration,B,,1,,H,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,,12166,BAO_0000019
4196,,,,8,,,CHEMBL619998,,Expert,B,,1,,H,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,,12166,BAO_0000019
4197,,,,8,,,CHEMBL619999,,Expert,B,,1,,H,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,,12166,BAO_0000019
4198,,,,8,,,CHEMBL620000,,Autocuration,B,,1,,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,,12166,BAO_0000019
4199,702.0,,,8,,,CHEMBL620001,,Autocuration,B,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,RBL-1,12166,BAO_0000219
4200,,,,9,,,CHEMBL620002,,Expert,B,,1,,D,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,,12166,BAO_0000357
4201,702.0,,,8,,,CHEMBL620003,,Autocuration,B,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,RBL-1,12166,BAO_0000219
4202,702.0,,,8,,,CHEMBL620004,,Expert,F,,1,,H,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,RBL-1,12166,BAO_0000219
4203,,,,8,,,CHEMBL874063,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of 5-lipoxygenase,,,12166,BAO_0000357
4204,702.0,,,8,,,CHEMBL620005,,Autocuration,B,,1,,H,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,RBL-1,12166,BAO_0000219
4205,702.0,,,8,,,CHEMBL620006,,Autocuration,B,,1,,H,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,RBL-1,12166,BAO_0000219
4206,702.0,,,8,,,CHEMBL620007,,Autocuration,B,,1,,H,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,RBL-1,12166,BAO_0000219
4207,702.0,,,8,,,CHEMBL620008,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,RBL-1,12166,BAO_0000219
4208,702.0,,,9,,,CHEMBL620009,,Expert,B,,1,,D,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,RBL-1,12166,BAO_0000219
4209,702.0,,,8,,,CHEMBL620010,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,RBL-1,12166,BAO_0000219
4210,702.0,,,8,,,CHEMBL620011,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,RBL-1,12166,BAO_0000219
4211,702.0,,,8,,,CHEMBL620677,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,RBL-1,12166,BAO_0000219
4212,702.0,,,8,,,CHEMBL620678,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,RBL-1,12166,BAO_0000219
4213,702.0,,,8,,,CHEMBL620679,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,RBL-1,12166,BAO_0000219
4214,702.0,,,8,,,CHEMBL620680,,Autocuration,B,,1,,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,RBL-1,12166,BAO_0000219
4215,,,,9,,,CHEMBL620838,,Expert,B,,1,,D,Inhibitory activity against 5-lipoxygenase at 10 uM,,,12166,BAO_0000357
4216,,,,8,,,CHEMBL620839,,Autocuration,B,,1,,H,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,,12166,BAO_0000357
4217,,,,8,,,CHEMBL620840,,Expert,B,,1,,H,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,,12166,BAO_0000357
4218,702.0,,,8,,,CHEMBL620841,,Expert,B,,1,,H,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,RBL-1,12166,BAO_0000219
4219,702.0,,,8,,,CHEMBL620842,,Autocuration,B,,1,,H,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,RBL-1,12166,BAO_0000219
4220,702.0,,,8,,,CHEMBL620843,,Autocuration,B,,1,,H,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,RBL-1,12166,BAO_0000219
4221,702.0,,,8,,,CHEMBL620844,,Autocuration,B,,1,,H,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,RBL-1,12166,BAO_0000219
4222,702.0,,,8,,,CHEMBL620845,,Autocuration,B,,1,,H,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,RBL-1,12166,BAO_0000219
4223,,,,8,,,CHEMBL620846,,Autocuration,B,,1,,H,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,,12166,BAO_0000019
4224,,,,8,,,CHEMBL873951,,Autocuration,B,,1,,H,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,12166,BAO_0000357
4225,,,,8,,,CHEMBL620847,,Autocuration,B,,1,,H,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,12166,BAO_0000357
4226,702.0,,,8,,,CHEMBL620848,,Autocuration,B,,1,,H,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,RBL-1,12166,BAO_0000219
4227,702.0,,,8,,,CHEMBL620849,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,RBL-1,12166,BAO_0000219
4228,702.0,,,8,,,CHEMBL620850,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,RBL-1,12166,BAO_0000219
4229,702.0,,,8,,,CHEMBL620851,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,RBL-1,12166,BAO_0000219
4230,702.0,,,8,,,CHEMBL620852,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,RBL-1,12166,BAO_0000219
4231,702.0,,,8,,,CHEMBL875098,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,RBL-1,12166,BAO_0000219
4232,702.0,,,9,,,CHEMBL620853,,Expert,B,,1,,D,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,RBL-1,12166,BAO_0000219
4233,,,,8,,,CHEMBL620854,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,,12166,BAO_0000019
4234,702.0,,,8,,,CHEMBL620855,,Autocuration,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,RBL-1,12166,BAO_0000219
4235,702.0,,,8,,,CHEMBL839884,,Expert,B,,1,,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,RBL-1,12166,BAO_0000219
4236,702.0,,,8,,,CHEMBL620856,,Autocuration,B,,1,,H,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,RBL-1,12166,BAO_0000219
4237,702.0,,,8,,,CHEMBL620857,,Autocuration,B,,1,,H,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,RBL-1,12166,BAO_0000219
4238,,,,8,,,CHEMBL620858,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,12166,BAO_0000019
4239,,,,8,,,CHEMBL620859,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,12166,BAO_0000019
4240,,,,8,,,CHEMBL620860,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,12166,BAO_0000019
4241,,,,8,,,CHEMBL620861,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,,12166,BAO_0000019
4242,,,,8,,,CHEMBL620862,,Expert,B,,1,,H,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,,12166,BAO_0000357
4243,,,,8,,,CHEMBL620863,,Autocuration,B,,1,,H,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,,12166,BAO_0000357
4244,,,,8,,,CHEMBL620864,,Autocuration,B,,1,,H,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,12166,BAO_0000019
4245,702.0,,,8,,,CHEMBL620865,,Autocuration,B,,1,,H,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,RBL-1,12166,BAO_0000219
4246,702.0,,,8,,,CHEMBL620866,,Autocuration,B,,1,,H,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,RBL-1,12166,BAO_0000219
4247,663.0,,,8,,,CHEMBL620867,,Autocuration,B,,1,,H,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,RBL-2H3,12166,BAO_0000219
4248,663.0,,,8,,,CHEMBL620868,,Autocuration,B,,1,,H,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,RBL-2H3,12166,BAO_0000219
4249,663.0,,,8,,,CHEMBL620869,,Autocuration,F,,1,,H,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,RBL-2H3,12166,BAO_0000219
4250,,,,8,,,CHEMBL873952,,Autocuration,F,,1,,H,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,,12166,BAO_0000019
4251,,,,8,,,CHEMBL875099,,Autocuration,B,,1,,H,The compound was tested for inhibition of isolated 5-lipoxygenase,,,12166,BAO_0000357
4252,663.0,,,8,,,CHEMBL620870,,Autocuration,F,,1,,H,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,RBL-2H3,12166,BAO_0000219
4253,,,,8,,,CHEMBL618261,,Autocuration,B,,1,,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,,12166,BAO_0000019
4254,,,,8,,,CHEMBL618262,,Autocuration,B,,1,,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,,12166,BAO_0000019
4255,,,,8,,,CHEMBL619428,,Autocuration,B,,1,,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,,12166,BAO_0000019
4256,,,,8,,,CHEMBL619429,,Autocuration,B,,1,,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,12166,BAO_0000019
4257,,,,8,,,CHEMBL619430,,Autocuration,B,,1,,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,12166,BAO_0000019
4258,702.0,,,8,,,CHEMBL620017,,Autocuration,B,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,RBL-1,12166,BAO_0000219
4259,702.0,,,8,,,CHEMBL620018,,Autocuration,B,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,RBL-1,12166,BAO_0000219
4260,702.0,,,8,,,CHEMBL620019,,Autocuration,F,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,RBL-1,12166,BAO_0000219
4261,702.0,,,8,,,CHEMBL620020,,Autocuration,F,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,RBL-1,12166,BAO_0000219
4262,702.0,,,8,,,CHEMBL620021,,Autocuration,F,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,RBL-1,12166,BAO_0000219
4263,702.0,,,8,,,CHEMBL620022,,Autocuration,F,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,RBL-1,12166,BAO_0000219
4264,702.0,,,8,,,CHEMBL620023,,Autocuration,F,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,RBL-1,12166,BAO_0000219
4265,702.0,,,8,,,CHEMBL620024,,Autocuration,F,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,RBL-1,12166,BAO_0000219
4266,702.0,,,8,,,CHEMBL620025,,Autocuration,F,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,RBL-1,12166,BAO_0000219
4267,702.0,,,8,,,CHEMBL620026,,Autocuration,F,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,RBL-1,12166,BAO_0000219
4268,702.0,,,8,,,CHEMBL620027,,Autocuration,F,,1,,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,RBL-1,12166,BAO_0000219
4269,,,,9,,,CHEMBL620028,,Expert,F,,1,,D,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,,12166,BAO_0000019
4270,,,,8,,,CHEMBL620029,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,,12166,BAO_0000357
4271,,,,8,,,CHEMBL620030,,Autocuration,B,,1,,H,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,,12166,BAO_0000357
4272,702.0,,,8,,,CHEMBL875415,,Autocuration,B,,1,,H,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,RBL-1,12166,BAO_0000219
4273,702.0,,,8,,,CHEMBL618256,,Autocuration,B,,1,,H,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,RBL-1,12166,BAO_0000219
4274,702.0,,,8,,,CHEMBL618257,,Autocuration,B,,1,,H,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,RBL-1,12166,BAO_0000219
4275,702.0,,,8,,,CHEMBL618258,,Autocuration,B,,1,,H,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,RBL-1,12166,BAO_0000219
4276,702.0,,,8,,,CHEMBL618259,,Autocuration,B,,1,,H,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,RBL-1,12166,BAO_0000219
4277,,,,8,,,CHEMBL618260,,Autocuration,B,,1,,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,12166,BAO_0000019
4278,702.0,,,8,,,CHEMBL618215,,Autocuration,B,,1,,H,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,RBL-1,12166,BAO_0000219
4279,702.0,,,8,,,CHEMBL618390,,Autocuration,B,,1,,H,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,RBL-1,12166,BAO_0000219
4280,702.0,,,8,,,CHEMBL618391,,Autocuration,B,,1,,H,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,RBL-1,12166,BAO_0000219
4281,702.0,,,8,,,CHEMBL618392,,Autocuration,B,,1,,H,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,RBL-1,12166,BAO_0000219
4282,702.0,,,8,,,CHEMBL618393,,Autocuration,B,,1,,H,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,RBL-1,12166,BAO_0000219
4283,,,,8,,,CHEMBL618394,,Autocuration,B,,1,,H,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,,12166,BAO_0000219
4284,702.0,,,8,,,CHEMBL618395,,Expert,B,,1,,H,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,RBL-1,12166,BAO_0000219
4285,702.0,,,9,,,CHEMBL618396,,Expert,B,,1,,D,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,RBL-1,12166,BAO_0000219
4286,702.0,,,9,,,CHEMBL858253,,Expert,B,,1,,D,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,RBL-1,12166,BAO_0000219
4287,,,,9,,,CHEMBL618397,,Autocuration,B,,1,,D,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,12166,BAO_0000019
4288,,,,8,,,CHEMBL618398,,Autocuration,B,,1,,H,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,,12054,BAO_0000357
4289,,,,0,,,CHEMBL618399,,Autocuration,B,,1,,U,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,,22226,BAO_0000019
4290,,,,8,,,CHEMBL618400,,Expert,B,,1,,H,In vitro inhibition of 5-Lipoxygenase; Inactive.,,,55,BAO_0000357
4291,,,,8,,,CHEMBL618401,,Autocuration,B,,1,,H,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,,55,BAO_0000357
4292,,,,8,,,CHEMBL618402,,Autocuration,B,,1,,H,Inhibitory concentration against 5-lipoxygenase; No inhibition,,,55,BAO_0000357
4293,702.0,,,8,,,CHEMBL876400,,Autocuration,B,,1,,H,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,RBL-1,55,BAO_0000219
4294,,,,8,,,CHEMBL618403,,Expert,B,,1,,H,Inhibitory activity against 5-lipoxygenase.,,,55,BAO_0000357
4295,,,,8,,,CHEMBL618404,,Autocuration,B,,1,,H,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,,55,BAO_0000357
4296,,,,8,,,CHEMBL618405,,Autocuration,B,,1,,H,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,,55,BAO_0000357
4297,,,,8,,,CHEMBL618406,,Autocuration,B,,1,,H,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,,55,BAO_0000357
4298,,,,8,,,CHEMBL618407,,Expert,F,,1,,H,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,,55,BAO_0000019
4299,,,,8,,,CHEMBL618408,,Autocuration,B,,1,,H,Tested for the inhibitory activity against 5-lipoxygenase,,,55,BAO_0000357
4300,,,,8,,,CHEMBL618409,,Autocuration,B,,1,,H,Compound was tested for its inhibitory activity against 5-lipoxygenase,,,55,BAO_0000357
4301,,,,8,,,CHEMBL618410,,Autocuration,B,,1,,H,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,,55,BAO_0000357
4302,,,,8,,,CHEMBL618411,,Autocuration,B,,1,,H,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,,55,BAO_0000357
4303,,,,8,,,CHEMBL618412,,Autocuration,B,,1,,H,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,,55,BAO_0000357
4304,702.0,,,8,,,CHEMBL618413,,Autocuration,B,,1,,H,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,RBL-1,12166,BAO_0000219
4305,,,,8,,,CHEMBL618414,,Autocuration,B,,1,,H,,,,12166,BAO_0000357
4306,,,,8,,,CHEMBL618415,,Autocuration,B,,1,,H,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,,10102,BAO_0000357
4307,,,,8,,,CHEMBL618416,,Autocuration,B,,1,,H,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,,10102,BAO_0000019
4308,,,,8,,,CHEMBL876401,,Autocuration,B,,1,,H,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,,10102,BAO_0000357
4309,,,,8,,,CHEMBL618417,,Expert,B,,1,,H,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,,10102,BAO_0000357
4310,,,,8,,,CHEMBL618418,,Autocuration,B,,1,,H,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,,10102,BAO_0000357
4311,,,,8,,,CHEMBL618419,,Autocuration,B,,1,,H,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,,10102,BAO_0000357
4312,,,,8,,,CHEMBL618420,,Autocuration,B,,1,,H,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,,10102,BAO_0000357
4313,,,,8,,,CHEMBL618421,,Autocuration,B,,1,,H,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,,10102,BAO_0000357
4314,,,,8,,,CHEMBL618422,,Autocuration,B,,1,,H,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,,11238,BAO_0000019
4315,,,,8,,,CHEMBL618423,,Autocuration,B,,1,,H,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,,11238,BAO_0000019
4316,,,,8,,,CHEMBL618424,,Autocuration,B,,1,,H,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,,11238,BAO_0000019
4317,,,,2,,,CHEMBL618425,,Intermediate,B,,1,,S,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,,100284,BAO_0000220
4318,,,,0,,,CHEMBL618426,,Autocuration,F,,1,,U,The dark toxicity against 543 human galactophore carcinoma cells,,,22226,BAO_0000019
4319,390.0,,,1,,,CHEMBL618427,,Expert,F,,1,,N,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,Panel (56 tumour cell lines),80623,BAO_0000219
4320,345.0,,,1,,,CHEMBL618428,,Expert,F,,1,,N,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,5637,80008,BAO_0000219
4321,345.0,,,1,,,CHEMBL618429,,Intermediate,F,,1,,N,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,5637,80008,BAO_0000219
4322,345.0,,,1,,,CHEMBL618430,,Intermediate,F,,1,,N,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,5637,80008,BAO_0000219
4323,345.0,,,1,,,CHEMBL618431,,Expert,F,,1,,N,Growth inhibition against human 5637 cell lines,,5637,80008,BAO_0000219
4324,345.0,,,1,,,CHEMBL883799,,Expert,F,,1,,N,Antitumor activity against human bladder carcinoma 5637 cells.,,5637,80008,BAO_0000219
4325,345.0,,,1,,,CHEMBL618432,,Intermediate,F,,1,,N,Antitumor activity against human bladder carcinoma 5637 cells,,5637,80008,BAO_0000219
4326,345.0,,,1,,,CHEMBL618433,,Intermediate,F,,1,,N,Antitumor activity against human bladder carcinoma 5637 cells,,5637,80008,BAO_0000219
4327,,,,9,,,CHEMBL618434,,Expert,B,,1,,D,In vitro inhibition of bovine trypsin(Trp).,,,10443,BAO_0000357
4328,407.0,,,8,,,CHEMBL618435,,Expert,B,,1,,H,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,CV-1,240,BAO_0000219
4329,,,,8,,,CHEMBL876402,,Autocuration,B,,1,,H,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,,10577,BAO_0000357
4330,,,,6,,,CHEMBL618436,,Autocuration,F,,1,,H,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,,104698,BAO_0000019
4331,,,,0,,In vivo,CHEMBL618437,,Autocuration,F,,1,,U,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,,22226,BAO_0000218
4332,,,,9,,,CHEMBL618438,,Intermediate,B,,1,,D,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,,20033,BAO_0000357
4333,,,,8,,,CHEMBL883800,,Expert,A,,1,Microsomes,H,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,17045,BAO_0000251
4334,,,,8,,,CHEMBL618439,,Expert,A,,1,Microsomes,H,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,17045,BAO_0000251
4335,,,,0,,,CHEMBL618440,,Intermediate,F,,1,,U,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,22226,BAO_0000019
4336,,,,0,,,CHEMBL618441,,Intermediate,F,,1,,U,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,22226,BAO_0000019
4337,,,,8,,,CHEMBL618442,,Expert,B,,1,,H,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,,11938,BAO_0000019
4338,,,,8,,,CHEMBL618443,,Autocuration,B,,1,,H,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,,11938,BAO_0000019
4339,,,,8,,,CHEMBL619158,,Expert,B,,1,,H,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,,11938,BAO_0000019
4340,,,,8,,,CHEMBL620974,,Autocuration,B,,1,,H,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,,11938,BAO_0000019
4341,,,,8,,,CHEMBL620975,,Autocuration,B,,1,,H,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,,11938,BAO_0000357
4342,,,,0,,,CHEMBL620976,,Intermediate,F,,1,,U,Average inhibitory concentration against 60 human cell lines was reported,,,22226,BAO_0000019
4343,,,,0,,,CHEMBL620977,,Expert,F,,1,,U,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,,22226,BAO_0000019
4344,542.0,,,1,,,CHEMBL620978,,Intermediate,F,,1,,N,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,Panel NCI-60 (60 carcinoma cell lines),80315,BAO_0000219
4345,542.0,,,1,,,CHEMBL620979,,Intermediate,F,,1,,N,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,Panel NCI-60 (60 carcinoma cell lines),80315,BAO_0000219
4346,542.0,,,1,,,CHEMBL620980,,Expert,F,,1,,N,In vitro mean growth inhibitory activity against 60-cell panel,,Panel NCI-60 (60 carcinoma cell lines),80315,BAO_0000219
4347,542.0,,,1,,,CHEMBL620981,,Expert,F,,1,,N,In vitro mean growth lethal concentration against 60-cell panel,,Panel NCI-60 (60 carcinoma cell lines),80315,BAO_0000219
4348,542.0,,,1,,,CHEMBL620982,,Expert,F,,1,,N,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,Panel NCI-60 (60 carcinoma cell lines),80315,BAO_0000219
4349,542.0,,,1,,,CHEMBL620983,,Expert,F,,1,,N,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,Panel NCI-60 (60 carcinoma cell lines),80315,BAO_0000219
4350,,,,4,,,CHEMBL620984,,Autocuration,F,,1,,H,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,104775,BAO_0000019
4351,,,,4,,,CHEMBL620985,,Autocuration,F,,1,,H,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,104775,BAO_0000019
4352,,,,8,,,CHEMBL620986,,Expert,B,,1,,H,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,,275,BAO_0000357
4353,,,,1,,,CHEMBL620987,,Expert,F,,1,,N,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,,50425,BAO_0000218
4354,,,,1,,,CHEMBL620988,,Expert,F,,1,,N,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,,50425,BAO_0000218
4355,,,,1,,,CHEMBL620989,,Expert,F,,1,,N,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,,50425,BAO_0000218
4356,,,,1,,,CHEMBL620990,,Expert,F,,1,,N,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,,50425,BAO_0000218
4357,,,,1,,,CHEMBL620991,,Intermediate,F,,1,,N,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,,50425,BAO_0000218
4358,850.0,,,1,,,CHEMBL620992,,Intermediate,F,,1,,N,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,6C3HED,80628,BAO_0000218
4359,850.0,,,1,,,CHEMBL620993,,Intermediate,F,,1,,N,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,6C3HED,80628,BAO_0000218
4360,850.0,,,1,,,CHEMBL620994,,Intermediate,F,,1,,N,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,6C3HED,80628,BAO_0000218
4361,850.0,,,1,,,CHEMBL620995,,Intermediate,F,,1,,N,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,6C3HED,80628,BAO_0000218
4362,850.0,,,1,,,CHEMBL620996,,Intermediate,F,,1,,N,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,6C3HED,80628,BAO_0000218
4363,850.0,,,1,,,CHEMBL875581,,Intermediate,F,,1,,N,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,6C3HED,80628,BAO_0000218
4364,,,,0,,In vivo,CHEMBL620997,,Autocuration,F,,1,,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,,22224,BAO_0000218
4365,,,,0,,In vivo,CHEMBL620998,,Autocuration,F,,1,,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,,22224,BAO_0000218
4366,,,,0,,In vivo,CHEMBL620999,,Autocuration,F,,1,,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,,22224,BAO_0000218
4367,,,,0,,In vivo,CHEMBL621000,,Autocuration,F,,1,,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,,22224,BAO_0000218
4368,,,,0,,In vivo,CHEMBL621001,,Autocuration,F,,1,,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,,22224,BAO_0000218
4369,,,,0,,In vivo,CHEMBL621002,,Autocuration,F,,1,,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,,22224,BAO_0000218
4370,,,,0,,In vivo,CHEMBL621003,,Autocuration,F,,1,,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,,22224,BAO_0000218
4371,,,,0,,In vivo,CHEMBL621004,,Autocuration,F,,1,,U,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,,22224,BAO_0000218
4372,,,,0,,In vivo,CHEMBL621005,,Autocuration,F,,1,,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,,22224,BAO_0000218
4373,,,,0,,In vivo,CHEMBL621006,,Autocuration,F,,1,,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,,22224,BAO_0000218
4374,,,,0,,In vivo,CHEMBL621007,,Autocuration,F,,1,,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,,22224,BAO_0000218
4375,,,,0,,,CHEMBL621008,,Autocuration,F,,1,,U,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,22224,BAO_0000218
4376,,,,0,,,CHEMBL621009,,Autocuration,F,,1,,U,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,22224,BAO_0000218
4377,,,,0,,,CHEMBL857705,,Autocuration,F,,1,,U,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,22224,BAO_0000218
4378,,,,0,,,CHEMBL619828,,Autocuration,F,,1,,U,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,22224,BAO_0000218
4379,,,,0,,,CHEMBL619829,,Autocuration,F,,1,,U,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,,22224,BAO_0000218
4380,,,,0,,,CHEMBL619830,,Autocuration,F,,1,,U,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,,22224,BAO_0000218
4381,,,,0,,,CHEMBL619831,,Autocuration,F,,1,,U,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,,22224,BAO_0000218
4382,,,,0,,,CHEMBL619832,,Autocuration,F,,1,,U,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,,22224,BAO_0000218
4383,,,,0,,,CHEMBL619833,,Autocuration,A,,1,,U,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,,22224,BAO_0000218
4384,,,,0,,,CHEMBL619834,,Autocuration,A,,1,,U,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,,22224,BAO_0000218
4385,,,,0,,,CHEMBL619835,,Autocuration,A,,1,,U,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,,22224,BAO_0000218
4386,,,,0,,,CHEMBL619836,,Autocuration,A,,1,,U,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,,22224,BAO_0000218
4387,850.0,,,1,,,CHEMBL619837,,Intermediate,F,,1,,N,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,6C3HED,80628,BAO_0000218
4388,,,,0,,In vivo,CHEMBL619838,,Autocuration,F,,1,,U,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,,22224,BAO_0000218
4389,,,,1,,,CHEMBL619839,,Intermediate,A,,1,,N,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,,50594,BAO_0000218
4390,850.0,,,1,,In vivo,CHEMBL619840,,Intermediate,F,,1,,N,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,6C3HED,80628,BAO_0000218
4391,850.0,,,1,,In vivo,CHEMBL619841,,Intermediate,F,,1,,N,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,6C3HED,80628,BAO_0000218
4392,850.0,,,1,,,CHEMBL857704,,Expert,F,,1,,N,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,6C3HED,80628,BAO_0000218
4393,850.0,,,1,,,CHEMBL619842,,Intermediate,F,,1,,N,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,6C3HED,80628,BAO_0000218
4394,850.0,,,1,,,CHEMBL619843,,Expert,F,,1,,N,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,6C3HED,80628,BAO_0000218
4395,,,,0,,,CHEMBL619844,,Autocuration,B,,1,,U,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,,22226,BAO_0000019
4396,,,2107.0,0,Liver,,CHEMBL857855,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,,22226,BAO_0000251
4397,,,2107.0,0,Liver,,CHEMBL619845,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,22226,BAO_0000251
4398,,,2107.0,0,Liver,,CHEMBL619846,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,,22226,BAO_0000251
4399,,,2107.0,0,Liver,,CHEMBL619847,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,,22226,BAO_0000251
4400,,,2107.0,0,Liver,,CHEMBL619848,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,,22226,BAO_0000251
4401,,,2107.0,0,Liver,,CHEMBL620893,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,,22226,BAO_0000251
4402,,,2107.0,0,Liver,,CHEMBL620894,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,,22226,BAO_0000251
4403,,,2107.0,0,Liver,,CHEMBL620895,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,,22226,BAO_0000251
4404,,,2107.0,0,Liver,,CHEMBL620896,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,22226,BAO_0000251
4405,,,2107.0,0,Liver,,CHEMBL620897,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,22226,BAO_0000251
4406,,,2107.0,0,Liver,,CHEMBL620898,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,22226,BAO_0000251
4407,,,2107.0,0,Liver,,CHEMBL620899,,Autocuration,B,,1,Microsomes,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,22226,BAO_0000251
4408,,,1969.0,0,Plasma,In vivo,CHEMBL620900,,Autocuration,A,,1,,U,The apparent total plasma clearance in monkey,,,22224,BAO_0000218
4409,,,,0,,In vivo,CHEMBL620901,,Autocuration,A,,1,,U,Compound was evaluated for Hepatic clearance in monkey,,,22224,BAO_0000218
4410,,,,0,,In vivo,CHEMBL620902,,Autocuration,A,,1,,U,Lower clearance in monkey (i.v.) at 0.5 mpk,,,22224,BAO_0000218
4411,,,,0,,In vivo,CHEMBL620903,,Autocuration,A,,1,,U,Plasma clearance in rhesus monkey,,,22224,BAO_0000218
4412,,,,0,,In vivo,CHEMBL620904,,Autocuration,A,,1,,U,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,,22224,BAO_0000218
4413,,,,0,,In vivo,CHEMBL620905,,Autocuration,A,,1,,U,Plasma clearance of compound was determined in monkey,,,22224,BAO_0000218
4414,,,,0,,In vivo,CHEMBL620906,,Autocuration,A,,1,,U,Plasma clearance was calculated in rhesus monkey,,,22224,BAO_0000218
4415,,,,0,,In vivo,CHEMBL875420,,Autocuration,A,,1,,U,Plasma clearance in rhesus monkey,,,22224,BAO_0000218
4416,,,,0,,In vivo,CHEMBL620907,,Autocuration,A,,1,,U,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,22224,BAO_0000218
4417,,,,0,,In vivo,CHEMBL620908,,Autocuration,A,,1,,U,Plasma clearance was evaluated in rhesus,,,22224,BAO_0000218
4418,,,,0,,In vivo,CHEMBL620909,,Autocuration,A,,1,,U,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,,22224,BAO_0000218
4419,,,,0,,In vivo,CHEMBL620910,,Autocuration,A,,1,,U,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,22224,BAO_0000218
4420,,,,0,,In vivo,CHEMBL620911,,Autocuration,A,,1,,U,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,22224,BAO_0000218
4421,,,,0,,In vivo,CHEMBL620912,,Autocuration,A,,1,,U,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,22224,BAO_0000218
4422,,,,0,,In vivo,CHEMBL620913,,Autocuration,A,,1,,U,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,,22224,BAO_0000218
4423,,,,0,,In vivo,CHEMBL620914,,Autocuration,A,,1,,U,Cmax in monkey after administration of 1 mg/kg iv,,,22224,BAO_0000218
4424,,,,0,,In vivo,CHEMBL620915,,Autocuration,A,,1,,U,Cmax was determine after peroral administration at 10 mpk in Rhesus,,,22224,BAO_0000218
4425,,,,0,,In vivo,CHEMBL620916,,Autocuration,A,,1,,U,Cmax in cynomolgus monkey by iv administration,,,22224,BAO_0000218
4426,,,,0,,In vivo,CHEMBL620917,,Autocuration,A,,1,,U,Cmax in cynomolgus monkey by po administration,,,22224,BAO_0000218
4427,,,,0,,In vivo,CHEMBL620918,,Autocuration,A,,1,,U,Cmax value evaluated in monkey,,,22224,BAO_0000218
4428,,,,0,,In vivo,CHEMBL620919,,Autocuration,A,,1,,U,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,22224,BAO_0000218
4429,,,1969.0,0,Plasma,In vivo,CHEMBL620920,,Autocuration,A,,1,,U,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,,22224,BAO_0000218
4430,,,1969.0,0,Plasma,In vivo,CHEMBL620921,,Autocuration,A,,1,,U,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,,22224,BAO_0000218
4431,,,1969.0,0,Plasma,In vivo,CHEMBL620922,,Autocuration,A,,1,,U,Maximal plasma concentration in squirrel monkeys,,,22224,BAO_0000218
4432,,,,0,,In vivo,CHEMBL620923,,Autocuration,A,,1,,U,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,22224,BAO_0000218
4433,,,1969.0,0,Plasma,In vivo,CHEMBL620924,,Autocuration,A,,1,,U,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,,22224,BAO_0000218
4434,,,,0,,In vivo,CHEMBL620925,,Autocuration,A,,1,,U,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,22224,BAO_0000218
4435,,,,0,,In vivo,CHEMBL620926,,Autocuration,A,,1,,U,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,22224,BAO_0000218
4436,,,,0,,In vivo,CHEMBL620927,,Autocuration,A,,1,,U,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,22224,BAO_0000218
4437,,,,0,,In vivo,CHEMBL620928,,Autocuration,A,,1,,U,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,,22224,BAO_0000218
4438,,,,0,,In vivo,CHEMBL620929,,Autocuration,A,,1,,U,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,,22224,BAO_0000218
4439,,,1969.0,0,Plasma,In vivo,CHEMBL620930,,Autocuration,A,,1,,U,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,,22224,BAO_0000218
4440,,,,0,,,CHEMBL620931,,Autocuration,A,,1,,U,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,,22224,BAO_0000218
4441,,,,0,,,CHEMBL620932,,Autocuration,A,,1,,U,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,,22224,BAO_0000218
4442,,,,0,,In vivo,CHEMBL620933,,Autocuration,A,,1,,U,Absolute bioavailability was evaluated in monkey,,,22224,BAO_0000218
4443,,,,0,,In vivo,CHEMBL620934,,Autocuration,A,,1,,U,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,,22224,BAO_0000218
4444,,,,0,,In vivo,CHEMBL620935,,Autocuration,A,,1,,U,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,,22224,BAO_0000218
4445,,,,0,,In vivo,CHEMBL620936,,Autocuration,A,,1,,U,Bioavailability of compound was determined in rhesus monkey,,,22224,BAO_0000218
4446,,,,0,,In vivo,CHEMBL620937,,Autocuration,A,,1,,U,Bioavailability determined after oral administration in marmoset,,,22224,BAO_0000218
4447,,,,0,,In vivo,CHEMBL620938,,Autocuration,A,,1,,U,Oral bioavailability in cynomolgus monkey,,,22224,BAO_0000218
4448,,,,0,,In vivo,CHEMBL620939,,Autocuration,A,,1,,U,Bioavailability in monkey (p.o.) at 2.0 mpk,,,22224,BAO_0000218
4449,,,,0,,In vivo,CHEMBL620940,,Autocuration,A,,1,,U,Bioavailability was evaluated after oral administration in monkey,,,22224,BAO_0000218
4450,,,,0,,In vivo,CHEMBL620941,,Autocuration,A,,1,,U,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,22224,BAO_0000218
4451,,,,0,,In vivo,CHEMBL620942,,Autocuration,A,,1,,U,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,22224,BAO_0000218
4452,,,,0,,In vivo,CHEMBL620943,,Autocuration,A,,1,,U,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,22224,BAO_0000218
4453,,,,0,,In vivo,CHEMBL620944,,Autocuration,A,,1,,U,Bioavailability of the compound was determined in monkey,,,22224,BAO_0000218
4454,,,,0,,In vivo,CHEMBL620945,,Autocuration,A,,1,,U,Bioavailability in squirrel monkey (dose 5 mg/kg),,,22224,BAO_0000218
4455,,,,0,,In vivo,CHEMBL620946,,Autocuration,A,,1,,U,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,22224,BAO_0000218
4456,,,,0,,In vivo,CHEMBL620947,,Autocuration,A,,1,,U,Oral bioavailability in monkey,,,22224,BAO_0000218
4457,,,,0,,In vivo,CHEMBL620948,,Autocuration,A,,1,,U,Compound was tested for bioavailability in squirrel monkey,,,22224,BAO_0000218
4458,,,,0,,In vivo,CHEMBL620949,,Autocuration,A,,1,,U,Oral bioavailability in Rhesus monkey,,,22224,BAO_0000218
4459,,,,0,,In vivo,CHEMBL620950,,Autocuration,A,,1,,U,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,,22224,BAO_0000218
4460,,,,0,,In vivo,CHEMBL620951,,Autocuration,A,,1,,U,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,,22224,BAO_0000218
4461,,,,0,,In vivo,CHEMBL620952,,Autocuration,A,,1,,U,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,,22224,BAO_0000218
4462,,,,0,,In vivo,CHEMBL875421,,Autocuration,A,,1,,U,Oral bioavailability in monkey (dose 5 mg/kg),,,22224,BAO_0000218
4463,,,,0,,In vivo,CHEMBL620953,,Autocuration,A,,1,,U,Oral bioavailability of compound at 5 mg/kg in monkey,,,22224,BAO_0000218
4464,,,,1,,In vivo,CHEMBL873491,,Intermediate,A,,1,,N,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,50588,BAO_0000218
4465,,,,1,,In vivo,CHEMBL620954,,Intermediate,A,,1,,N,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,,50588,BAO_0000218
4466,,,1969.0,1,Plasma,,CHEMBL620955,,Intermediate,A,,1,,N,Plasma half life determined,,,50588,BAO_0000218
4467,,,1969.0,1,Plasma,,CHEMBL618097,,Intermediate,A,,1,,N,Plasma half life in dog,,,50588,BAO_0000218
4468,,,1969.0,1,Plasma,,CHEMBL618268,,Intermediate,A,,1,,N,Plasma half-life in Beagle dogs,,,50588,BAO_0000218
4469,,,1969.0,1,Plasma,In vivo,CHEMBL618269,,Intermediate,A,,1,,N,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,50588,BAO_0000218
4470,,,1969.0,1,Plasma,In vivo,CHEMBL618270,,Intermediate,A,,1,,N,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,,50588,BAO_0000218
4471,,,,1,,In vivo,CHEMBL618271,,Intermediate,A,,1,,N,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,,50588,BAO_0000218
4472,,,,1,,In vivo,CHEMBL873493,,Intermediate,A,,1,,N,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,,50588,BAO_0000218
4473,,,,1,,,CHEMBL621031,,Intermediate,A,,1,,N,Tested for the half life period in dog,,,50588,BAO_0000218
4474,,,,1,,In vivo,CHEMBL621032,,Intermediate,A,,1,,N,Tested for the half life period in dog at dosage of 10 mpk,,,50588,BAO_0000218
4475,,,,1,,,CHEMBL621033,,Intermediate,A,,1,,N,The compound was tested for half life in dog,,,50588,BAO_0000218
4476,,,1969.0,1,Plasma,,CHEMBL621034,,Intermediate,A,,1,,N,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,,50588,BAO_0000218
4477,,,,1,,,CHEMBL621035,,Intermediate,A,,1,,N,The half life was determined,,,50588,BAO_0000218
4478,,,1969.0,1,Plasma,,CHEMBL621036,,Intermediate,A,,1,,N,The plasma half-life in dogs,,,50588,BAO_0000218
4479,,,1969.0,1,Plasma,,CHEMBL621037,,Intermediate,A,,1,,N,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,,50588,BAO_0000218
4480,,,,1,,,CHEMBL619812,,Intermediate,A,,1,,N,Half life in dog,,,50588,BAO_0000218
4481,,,,1,,In vivo,CHEMBL619813,,Intermediate,A,,1,,N,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,,50588,BAO_0000218
4482,,,,1,,In vivo,CHEMBL873335,,Intermediate,A,,1,,N,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,,50588,BAO_0000218
4483,,,,1,,In vivo,CHEMBL619814,,Intermediate,A,,1,,N,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,50588,BAO_0000218
4484,,,,1,,In vivo,CHEMBL619815,,Expert,A,,1,,N,Cmax in ferrets after 30 mg/kg oral dose,,,50506,BAO_0000218
4485,,,,1,,In vivo,CHEMBL619816,,Expert,F,,1,,N,Emesis in ferrets at 30 mg/kg oral dose,,,50506,BAO_0000218
4486,,,,0,,In vivo,CHEMBL619817,,Autocuration,A,,1,,U,Bioavailability in cynomolgus monkey,,,22224,BAO_0000218
4487,,,,1,,In vivo,CHEMBL619818,,Intermediate,A,,1,,N,Volume of distribution in cynomolgus,,,100710,BAO_0000218
4488,,,1969.0,0,Plasma,,CHEMBL619819,,Autocuration,A,,1,,U,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,,22224,BAO_0000218
4489,,,,0,,,CHEMBL619820,,Autocuration,A,,1,,U,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,22224,BAO_0000218
4490,,,,0,,,CHEMBL875419,,Autocuration,A,,1,,U,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,,22224,BAO_0000218
4491,,,1969.0,0,Plasma,In vivo,CHEMBL619821,,Autocuration,A,,1,,U,AUC in guinea pig after 3mg/kg oral dose,,,22224,BAO_0000218
4492,,,,0,,In vivo,CHEMBL619822,,Autocuration,A,,1,,U,Bioavailability in guinea pig was tested,,,22224,BAO_0000218
4493,,,,0,,In vivo,CHEMBL619823,,Autocuration,A,,1,,U,Tested for oral bioavailability in guinea pig at 5 mg/kg,,,22224,BAO_0000218
4494,,,,0,,In vivo,CHEMBL619824,,Autocuration,A,,1,,U,Tested for the oral bioavailability of the compound,,,22224,BAO_0000218
4495,,,,0,,In vivo,CHEMBL619825,,Autocuration,A,,1,,U,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,,22224,BAO_0000218
4496,,,,0,,In vivo,CHEMBL619826,,Autocuration,A,,1,,U,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,,22224,BAO_0000218
4497,,,2048.0,0,Lung,In vivo,CHEMBL619827,,Autocuration,A,,1,,U,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,22224,BAO_0000218
4498,,,,0,,In vivo,CHEMBL618167,,Autocuration,A,,1,,U,Cmax in guinea pig after 3mg/kg oral dose,,,22224,BAO_0000218
4499,,,178.0,0,Blood,,CHEMBL618168,,Autocuration,A,,1,,U,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,,22224,BAO_0000019
4500,,,955.0,0,Brain,,CHEMBL618169,,Autocuration,A,,1,,U,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,,22224,BAO_0000019
4501,,,,0,,,CHEMBL618170,,Autocuration,A,,1,,U,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,,22224,BAO_0000019
4502,,,160.0,0,Intestine,,CHEMBL618171,,Autocuration,A,,1,,U,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,,22224,BAO_0000019
4503,,,2113.0,0,Kidney,,CHEMBL618172,,Autocuration,A,,1,,U,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,,22224,BAO_0000019
4504,,,2107.0,0,Liver,,CHEMBL618173,,Autocuration,A,,1,,U,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,,22224,BAO_0000019
4505,,,,0,,,CHEMBL618174,,Autocuration,A,,1,,U,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,,22224,BAO_0000019
4506,,,2106.0,0,Spleen,,CHEMBL875408,,Autocuration,A,,1,,U,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,,22224,BAO_0000019
4507,,,,0,,In vivo,CHEMBL839827,,Autocuration,A,,1,,U,Elimination T1/2 in Guinea pig (PO dose),,,22224,BAO_0000218
4508,,,,0,,,CHEMBL618175,,Autocuration,A,,1,,U,Partition coefficient was measured as -log (counts per min ),,,22224,BAO_0000019
4509,,,,0,,In vivo,CHEMBL618176,,Autocuration,A,,1,,U,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,22224,BAO_0000218
4510,,,,0,,In vivo,CHEMBL618177,,Autocuration,A,,1,,U,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,22224,BAO_0000218
4511,,,,0,,In vivo,CHEMBL618178,,Autocuration,A,,1,,U,Elimination T1/2 in Guinea pig (PO dose),,,22224,BAO_0000218
4512,,,,0,,In vivo,CHEMBL618179,,Autocuration,A,,1,,U,"Tested for the half life period of the compound, intravenously",,,22224,BAO_0000218
4513,,,,0,,,CHEMBL873489,,Autocuration,A,,1,,U,Half-life was measured,,,22224,BAO_0000019
4514,,,,0,,,CHEMBL618180,,Autocuration,A,,1,,U,The time required for onset of inotropy after addition of a single dose of delta F75,,,22224,BAO_0000019
4515,,,,0,,In vivo,CHEMBL618181,,Autocuration,A,,1,,U,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,,22224,BAO_0000218
4516,,,,0,,In vivo,CHEMBL618182,,Autocuration,A,,1,,U,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,,22224,BAO_0000218
4517,,,,0,,In vivo,CHEMBL618183,,Autocuration,A,,1,,U,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,22224,BAO_0000218
4518,,,,1,,In vivo,CHEMBL618184,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
4519,,,,1,,In vivo,CHEMBL618185,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594,BAO_0000218
4520,,,,1,,In vivo,CHEMBL618186,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
4521,,,,1,,In vivo,CHEMBL618187,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
4522,,,,1,,In vivo,CHEMBL618188,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,,50594,BAO_0000218
4523,,,,1,,In vivo,CHEMBL875409,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
4524,,,,1,,In vivo,CHEMBL618189,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
4525,,,178.0,1,Blood,In vivo,CHEMBL618190,,Intermediate,A,,1,,N,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,,50594,BAO_0000218
4526,,,178.0,1,Blood,In vivo,CHEMBL618191,,Intermediate,A,,1,,N,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,,50594,BAO_0000218
4527,,,178.0,1,Blood,In vivo,CHEMBL618192,,Intermediate,A,,1,,N,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,,50594,BAO_0000218
4528,,,10000001.0,1,Bone,In vivo,CHEMBL618193,,Intermediate,A,,1,,N,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,,50594,BAO_0000218
4529,,,10000001.0,1,Bone,In vivo,CHEMBL618194,,Intermediate,A,,1,,N,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,,50594,BAO_0000218
4530,,,10000001.0,1,Bone,In vivo,CHEMBL618195,,Intermediate,A,,1,,N,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,,50594,BAO_0000218
4531,,,955.0,1,Brain,In vivo,CHEMBL618196,,Intermediate,A,,1,,N,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,,50594,BAO_0000218
4532,,,955.0,1,Brain,In vivo,CHEMBL618197,,Intermediate,A,,1,,N,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,,50594,BAO_0000218
4533,,,955.0,1,Brain,In vivo,CHEMBL618198,,Intermediate,A,,1,,N,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,,50594,BAO_0000218
4534,,,948.0,1,Heart,In vivo,CHEMBL618199,,Intermediate,A,,1,,N,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,,50594,BAO_0000218
4535,,,948.0,1,Heart,In vivo,CHEMBL618200,,Intermediate,A,,1,,N,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,,50594,BAO_0000218
4536,,,948.0,1,Heart,In vivo,CHEMBL618201,,Intermediate,A,,1,,N,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,,50594,BAO_0000218
4537,,,160.0,1,Intestine,In vivo,CHEMBL618202,,Intermediate,A,,1,,N,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,,50594,BAO_0000218
4538,,,160.0,1,Intestine,In vivo,CHEMBL618203,,Intermediate,A,,1,,N,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,,50594,BAO_0000218
4539,,,160.0,1,Intestine,In vivo,CHEMBL618204,,Intermediate,A,,1,,N,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,,50594,BAO_0000218
4540,,,2113.0,1,Kidney,In vivo,CHEMBL618205,,Intermediate,A,,1,,N,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,,50594,BAO_0000218
4541,,,2113.0,1,Kidney,In vivo,CHEMBL618206,,Intermediate,A,,1,,N,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,,50594,BAO_0000218
4542,,,2113.0,1,Kidney,In vivo,CHEMBL618207,,Intermediate,A,,1,,N,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,,50594,BAO_0000218
4543,,,2107.0,1,Liver,In vivo,CHEMBL618208,,Intermediate,A,,1,,N,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,,50594,BAO_0000218
4544,,,2107.0,1,Liver,In vivo,CHEMBL618932,,Intermediate,A,,1,,N,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,,50594,BAO_0000218
4545,,,2107.0,1,Liver,In vivo,CHEMBL618933,,Intermediate,A,,1,,N,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,,50594,BAO_0000218
4546,,,2048.0,1,Lung,In vivo,CHEMBL618934,,Intermediate,A,,1,,N,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,,50594,BAO_0000218
4547,,,2048.0,1,Lung,In vivo,CHEMBL618935,,Intermediate,A,,1,,N,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,,50594,BAO_0000218
4548,,,2048.0,1,Lung,In vivo,CHEMBL618936,,Intermediate,A,,1,,N,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,,50594,BAO_0000218
4549,,,2385.0,1,Muscle tissue,In vivo,CHEMBL618937,,Intermediate,A,,1,,N,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,,50594,BAO_0000218
4550,,,2385.0,1,Muscle tissue,In vivo,CHEMBL618938,,Intermediate,A,,1,,N,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,,50594,BAO_0000218
4551,,,2385.0,1,Muscle tissue,In vivo,CHEMBL619104,,Intermediate,A,,1,,N,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,,50594,BAO_0000218
4552,,,2106.0,1,Spleen,In vivo,CHEMBL619105,,Intermediate,A,,1,,N,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,,50594,BAO_0000218
4553,,,2106.0,1,Spleen,In vivo,CHEMBL619106,,Intermediate,A,,1,,N,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,,50594,BAO_0000218
4554,,,2106.0,1,Spleen,In vivo,CHEMBL619107,,Intermediate,A,,1,,N,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,,50594,BAO_0000218
4555,,,945.0,1,Stomach,In vivo,CHEMBL875410,,Intermediate,A,,1,,N,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,,50594,BAO_0000218
4556,,,945.0,1,Stomach,In vivo,CHEMBL619108,,Intermediate,A,,1,,N,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,,50594,BAO_0000218
4557,,,945.0,1,Stomach,In vivo,CHEMBL619109,,Intermediate,A,,1,,N,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,,50594,BAO_0000218
4558,,,,1,,In vivo,CHEMBL619110,,Intermediate,A,,1,,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,50594,BAO_0000218
4559,,,,1,,In vivo,CHEMBL619111,,Intermediate,F,,1,,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,50594,BAO_0000218
4560,,,,1,,In vivo,CHEMBL619112,,Intermediate,A,,1,,N,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,,50594,BAO_0000218
4561,,,,1,,In vivo,CHEMBL619113,,Intermediate,A,,1,,N,MRT value at a dose of 10 mg/kg peroral administration in mice.,,,50594,BAO_0000218
4562,,,,1,,In vivo,CHEMBL619114,,Intermediate,A,,1,,N,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,,50594,BAO_0000218
4563,,,,1,,In vivo,CHEMBL619115,,Intermediate,F,,1,,N,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,50594,BAO_0000218
4564,478.0,,,1,,,CHEMBL619116,,Intermediate,F,,1,,N,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,A2780,81034,BAO_0000219
4565,478.0,,,1,,,CHEMBL619117,,Intermediate,F,,1,,N,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,A2780,81034,BAO_0000219
4566,478.0,,,1,,,CHEMBL619118,,Intermediate,F,,1,,N,Compound was evaluated for cytotoxicity against A2780 cell lines.,,A2780,81034,BAO_0000219
4567,478.0,,,1,,,CHEMBL619119,,Intermediate,F,,1,,N,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,A2780,81034,BAO_0000219
4568,478.0,,,1,,,CHEMBL619120,,Intermediate,F,,1,,N,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,A2780,81034,BAO_0000219
4569,478.0,,,1,,,CHEMBL619121,,Intermediate,F,,1,,N,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,A2780,81034,BAO_0000219
4570,478.0,,,1,,,CHEMBL619122,,Intermediate,F,,1,,N,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,A2780,81034,BAO_0000219
4571,478.0,,,1,,,CHEMBL619123,,Intermediate,F,,1,,N,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,A2780,81034,BAO_0000219
4572,478.0,,,1,,,CHEMBL619124,,Intermediate,F,,1,,N,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,A2780,81034,BAO_0000219
4573,478.0,,,1,,,CHEMBL619125,,Intermediate,F,,1,,N,Compound was evaluated for cytotoxicity against A2780 cell line,,A2780,81034,BAO_0000219
4574,478.0,,,1,,,CHEMBL875411,,Intermediate,F,,1,,N,In vitro inhibitory activity against human tumor cell line A2780,,A2780,81034,BAO_0000219
4575,478.0,,,1,,,CHEMBL619126,,Intermediate,F,,1,,N,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,A2780,81034,BAO_0000219
4576,478.0,,,1,,,CHEMBL619127,,Intermediate,F,,1,,N,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,A2780,81034,BAO_0000219
4577,478.0,,,1,,,CHEMBL619128,,Intermediate,F,,1,,N,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,A2780,81034,BAO_0000219
4578,478.0,,,1,,,CHEMBL619129,,Intermediate,F,,1,,N,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,A2780,81034,BAO_0000219
4579,478.0,,,1,,,CHEMBL619130,,Intermediate,F,,1,,N,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,A2780,81034,BAO_0000219
4580,478.0,,,1,,,CHEMBL619131,,Intermediate,F,,1,,N,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,A2780,81034,BAO_0000219
4581,478.0,,,1,,,CHEMBL619132,,Intermediate,F,,1,,N,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,A2780,81034,BAO_0000219
4582,478.0,,,1,,,CHEMBL619133,,Expert,F,,1,,N,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,A2780,81034,BAO_0000218
4583,478.0,,,1,,,CHEMBL619134,,Intermediate,F,,1,,N,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,A2780,81034,BAO_0000219
4584,478.0,,,1,,,CHEMBL619135,,Intermediate,F,,1,,N,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,A2780,81034,BAO_0000219
4585,478.0,,,1,,,CHEMBL619136,,Intermediate,F,,1,,N,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,A2780,81034,BAO_0000219
4586,478.0,,,1,,,CHEMBL619137,,Intermediate,F,,1,,N,Relative resistance factor in A2780 cisplatin-resistant line,,A2780,81034,BAO_0000219
4587,478.0,,,1,,,CHEMBL883713,,Intermediate,F,,1,,N,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,A2780,81034,BAO_0000219
4588,478.0,,,1,,,CHEMBL875412,,Intermediate,F,,1,,N,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,A2780,81034,BAO_0000219
4589,478.0,,,1,,,CHEMBL619138,,Expert,F,,1,,N,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,A2780,81034,BAO_0000218
4590,478.0,,,1,,,CHEMBL619262,,Expert,F,,1,,N,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,A2780,81034,BAO_0000218
4591,478.0,,,1,,,CHEMBL619139,,Intermediate,F,,1,,N,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,A2780,81034,BAO_0000219
4592,478.0,,,1,,,CHEMBL619140,,Intermediate,F,,1,,N,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,A2780,81034,BAO_0000219
4593,478.0,,,1,,,CHEMBL619141,,Intermediate,F,,1,,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,A2780,81034,BAO_0000219
4594,478.0,,,1,,,CHEMBL619142,,Intermediate,F,,1,,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,A2780,81034,BAO_0000219
4595,478.0,,,1,,,CHEMBL619143,,Intermediate,F,,1,,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,A2780,81034,BAO_0000219
4596,478.0,,,1,,,CHEMBL619144,,Intermediate,F,,1,,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,A2780,81034,BAO_0000219
4597,478.0,,,1,,,CHEMBL619145,,Intermediate,F,,1,,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,A2780,81034,BAO_0000219
4598,478.0,,,1,,,CHEMBL619146,,Intermediate,F,,1,,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,A2780,81034,BAO_0000219
4599,478.0,,,1,,,CHEMBL619147,,Intermediate,F,,1,,N,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,A2780,81034,BAO_0000219
4600,478.0,,,1,,,CHEMBL619148,,Intermediate,F,,1,,N,Antiproliferative effect of compound on A2780/DX cell line,,A2780,81034,BAO_0000219
4601,478.0,,,1,,,CHEMBL619149,,Intermediate,F,,1,,N,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,A2780,81034,BAO_0000219
4602,478.0,,,1,,,CHEMBL619150,,Intermediate,F,,1,,N,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,A2780,81034,BAO_0000219
4603,478.0,,,1,,,CHEMBL619151,,Intermediate,F,,1,,N,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,A2780,81034,BAO_0000219
4604,478.0,,,1,,,CHEMBL883794,,Intermediate,F,,1,,N,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,A2780,81034,BAO_0000219
4605,478.0,,,1,,,CHEMBL619152,,Intermediate,F,,1,,N,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,A2780,81034,BAO_0000219
4606,478.0,,,1,,,CHEMBL619153,,Intermediate,F,,1,,N,In vitro cytotoxicity against A2780ADR cell line,,A2780,81034,BAO_0000219
4607,478.0,,,1,,,CHEMBL619154,,Intermediate,F,,1,,N,In vitro cytotoxicity against A2780CIS cell line,,A2780,81034,BAO_0000219
4608,478.0,,,1,,,CHEMBL619155,,Intermediate,F,,1,,N,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,A2780,81034,BAO_0000219
4609,478.0,,,1,,,CHEMBL619156,,Intermediate,F,,1,,N,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,A2780,81034,BAO_0000219
4610,478.0,,,1,,,CHEMBL619157,,Intermediate,F,,1,,N,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,A2780,81034,BAO_0000219
4611,478.0,,,1,,,CHEMBL619797,,Intermediate,F,,1,,N,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,A2780,81034,BAO_0000219
4612,,,,0,,In vivo,CHEMBL619798,,Autocuration,A,,1,,U,Oral bioavailability of compound in rhesus macaques,,,22224,BAO_0000218
4613,,,,0,,In vivo,CHEMBL619799,,Autocuration,A,,1,,U,Oral bioavailability in monkey,,,22224,BAO_0000218
4614,,,,0,,In vivo,CHEMBL619800,,Autocuration,A,,1,,U,Oral bioavailability evaluated in monkey,,,22224,BAO_0000218
4615,,,,0,,In vivo,CHEMBL619801,,Autocuration,A,,1,,U,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,,22224,BAO_0000218
4616,,,,0,,In vivo,CHEMBL619802,,Autocuration,A,,1,,U,Oral bioavailability in Rhesus monkey,,,22224,BAO_0000218
4617,,,,0,,In vivo,CHEMBL619803,,Autocuration,A,,1,,U,Oral bioavailability was calculated in rhesus monkey,,,22224,BAO_0000218
4618,,,,0,,In vivo,CHEMBL619965,,Autocuration,A,,1,,U,Oral bioavailability in cynomolgus monkey,,,22224,BAO_0000218
4619,,,,0,,In vivo,CHEMBL619966,,Autocuration,A,,1,,U,Oral bioavailability in monkey,,,22224,BAO_0000218
4620,,,,0,,In vivo,CHEMBL619967,,Autocuration,A,,1,,U,Oral bioavailability in monkey,,,22224,BAO_0000218
4621,,,,0,,In vivo,CHEMBL620073,,Autocuration,A,,1,,U,Oral bioavailability in monkey (dose 1 mg/kg),,,22224,BAO_0000218
4622,,,,0,,In vivo,CHEMBL620074,,Autocuration,A,,1,,U,Oral bioavailability in monkey (dose 5 mg/kg),,,22224,BAO_0000218
4623,,,,0,,In vivo,CHEMBL620075,,Autocuration,A,,1,,U,Oral bioavailability in monkey,,,22224,BAO_0000218
4624,,,,0,,In vivo,CHEMBL620076,,Autocuration,A,,1,,U,Oral bioavailability in monkey,,,22224,BAO_0000218
4625,,,,0,,In vivo,CHEMBL620077,,Autocuration,A,,1,,U,Oral bioavailability in rhesus monkey,,,22224,BAO_0000218
4626,,,,0,,In vivo,CHEMBL620078,,Autocuration,A,,1,,U,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,,22224,BAO_0000218
4627,,,,0,,In vivo,CHEMBL620079,,Autocuration,A,,1,,U,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,,22224,BAO_0000218
4628,,,,0,,In vivo,CHEMBL620080,,Autocuration,A,,1,,U,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,22224,BAO_0000218
4629,,,,0,,In vivo,CHEMBL620081,,Autocuration,A,,1,,U,Oral bioavailability in Rhesus monkey,,,22224,BAO_0000218
4630,,,,0,,In vivo,CHEMBL620082,,Autocuration,A,,1,,U,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,,22224,BAO_0000218
4631,,,,0,,In vivo,CHEMBL620083,,Autocuration,A,,1,,U,Oral bioavailability in monkey at 10 mg/kg of the compound,,,22224,BAO_0000218
4632,,,,0,,In vivo,CHEMBL620084,,Autocuration,A,,1,,U,Bioavailability in Rhesus monkey,,,22224,BAO_0000218
4633,,,,0,,,CHEMBL620085,,Autocuration,A,,1,,U,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
4634,,,,0,,,CHEMBL874595,,Autocuration,A,,1,,U,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
4635,,,,0,,In vivo,CHEMBL873352,,Autocuration,A,,1,,U,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,,22224,BAO_0000218
4636,,,,0,,In vivo,CHEMBL620086,,Autocuration,A,,1,,U,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,,22224,BAO_0000218
4637,,,,0,,In vivo,CHEMBL620087,,Autocuration,A,,1,,U,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,,22224,BAO_0000218
4638,,,,0,,In vivo,CHEMBL620088,,Autocuration,A,,1,,U,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,22224,BAO_0000218
4639,,,,0,,In vivo,CHEMBL620089,,Autocuration,A,,1,,U,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,22224,BAO_0000218
4640,,,,0,,In vivo,CHEMBL620090,,Autocuration,A,,1,,U,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,22224,BAO_0000218
4641,,,,0,,In vivo,CHEMBL620091,,Autocuration,A,,1,,U,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,22224,BAO_0000218
4642,,,,0,,,CHEMBL620092,,Autocuration,A,,1,Microsomes,U,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,,22224,BAO_0000251
4643,,,,0,,,CHEMBL620093,,Autocuration,A,,1,Microsomes,U,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,,22224,BAO_0000251
4644,,,,0,,,CHEMBL620094,,Autocuration,A,,1,Microsomes,U,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,,22224,BAO_0000251
4645,,,,0,,,CHEMBL620095,,Autocuration,A,,1,Microsomes,U,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,,22224,BAO_0000251
4646,,,,0,,In vivo,CHEMBL620096,,Autocuration,A,,1,,U,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
4647,,,,0,,In vivo,CHEMBL620097,,Autocuration,A,,1,,U,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
4648,,,,0,,,CHEMBL620098,,Autocuration,A,,1,,U,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,,22224,BAO_0000019
4649,,,,0,,,CHEMBL620099,,Autocuration,A,,1,,U,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
4650,,,,0,,,CHEMBL620100,,Autocuration,A,,1,,U,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
4651,,,,0,,,CHEMBL620101,,Autocuration,A,,1,,U,Elimination Half-life of compound was determined in monkey,,,22224,BAO_0000019
4652,,,,0,,,CHEMBL620102,,Autocuration,A,,1,,U,Half life of compound was determined in rhesus monkey,,,22224,BAO_0000019
4653,,,1969.0,0,Plasma,,CHEMBL620103,,Autocuration,A,,1,,U,Half life in monkey plasma,,,22224,BAO_0000366
4654,,,1969.0,0,Plasma,,CHEMBL620104,,Autocuration,A,,1,,U,Half life in monkey plasma; Not detected,,,22224,BAO_0000366
4655,,,,0,,In vivo,CHEMBL874596,,Autocuration,A,,1,,U,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,22224,BAO_0000218
4656,,,,0,,In vivo,CHEMBL873490,,Autocuration,A,,1,,U,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,,22224,BAO_0000218
4657,,,,0,,,CHEMBL620105,,Autocuration,A,,1,,U,Terminal half life of the compound.,,,22224,BAO_0000019
4658,,,,0,,In vivo,CHEMBL620780,,Autocuration,A,,1,,U,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,22224,BAO_0000218
4659,,,,0,,In vivo,CHEMBL620781,,Autocuration,A,,1,,U,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,22224,BAO_0000218
4660,,,,0,,,CHEMBL620956,,Autocuration,A,,1,,U,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,22224,BAO_0000218
4661,,,1088.0,0,Urine,,CHEMBL620957,,Autocuration,A,,1,,U,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
4662,,,1088.0,0,Urine,,CHEMBL620958,,Autocuration,A,,1,,U,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
4663,,,,0,,In vivo,CHEMBL620959,,Autocuration,A,,1,,U,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,,22224,BAO_0000218
4664,,,,0,,In vivo,CHEMBL620960,,Autocuration,A,,1,,U,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,,22224,BAO_0000218
4665,,,,0,,In vivo,CHEMBL620961,,Autocuration,A,,1,,U,Volume of distribution was evaluated in rhesus,,,22224,BAO_0000218
4666,,,,0,,In vivo,CHEMBL620962,,Autocuration,A,,1,,U,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,22224,BAO_0000218
4667,,,,0,,In vivo,CHEMBL620963,,Autocuration,A,,1,,U,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,,22224,BAO_0000218
4668,,,,0,,In vivo,CHEMBL620964,,Autocuration,A,,1,,U,Bioavailability in hamster was determined,,,22224,BAO_0000218
4669,,,,0,,In vivo,CHEMBL620965,,Autocuration,A,,1,,U,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,,22224,BAO_0000218
4670,,,,0,,In vivo,CHEMBL620966,,Autocuration,A,,1,,U,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,,22224,BAO_0000218
4671,,,178.0,0,Blood,,CHEMBL620967,,Autocuration,A,,1,,U,Half life of compound was determined in hamster blood,,,22224,BAO_0000221
4672,,,,0,,,CHEMBL620968,,Autocuration,A,,1,,U,Michaelis-Menten constant of the compound.,,,22224,BAO_0000019
4673,,,,0,,,CHEMBL874597,,Autocuration,A,,1,,U,Vmax value was measured at 0 uM concentration of silyl ether.,,,22224,BAO_0000019
4674,,,,0,,,CHEMBL620969,,Autocuration,A,,1,,U,Vmax value was measured at 10 uM concentration of silyl ether.,,,22224,BAO_0000019
4675,,,,0,,,CHEMBL620970,,Autocuration,A,,1,,U,Vmax value was measured at 5 uM concentration of silyl ether.,,,22224,BAO_0000019
4676,,,,9,,,CHEMBL620971,,Expert,B,,1,,D,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,,235,BAO_0000357
4677,,,,0,,,CHEMBL620972,,Autocuration,A,,1,,U,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,,22224,BAO_0000218
4678,,,,0,,,CHEMBL620973,,Autocuration,A,,1,,U,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,22224,BAO_0000019
4679,,,,0,,,CHEMBL618243,,Autocuration,A,,1,,U,Active metabolite of ifosfamide determined in humans; A-Active,,,22224,BAO_0000019
4680,,,,0,,,CHEMBL618244,,Autocuration,A,,1,,U,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,,22224,BAO_0000019
4681,,,,0,,,CHEMBL618245,,Autocuration,A,,1,,U,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,,22224,BAO_0000019
4682,,,,0,,,CHEMBL618246,,Autocuration,A,,1,,U,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,,22224,BAO_0000019
4683,,,,0,,,CHEMBL618247,,Autocuration,A,,1,,U,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,,22224,BAO_0000019
4684,,,,0,,,CHEMBL618248,,Autocuration,A,,1,,U,Compound was evaluated for oral bioavailability in human,,,22224,BAO_0000218
4685,,,1088.0,0,Urine,,CHEMBL618249,,Autocuration,A,,1,,U,Metabolite of ifosfamide determined in urine; NF-Not found,,,22224,BAO_0000019
4686,,,,0,,,CHEMBL618250,,Autocuration,A,,1,,U,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,,22224,BAO_0000019
4687,,,,0,,,CHEMBL874598,,Autocuration,A,,1,,U,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,,22224,BAO_0000019
4688,,,,0,,,CHEMBL618251,,Autocuration,A,,1,,U,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,,22224,BAO_0000019
4689,,,,0,,,CHEMBL618252,,Autocuration,A,,1,,U,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,,22224,BAO_0000019
4690,,,,0,,,CHEMBL618253,,Autocuration,A,,1,,U,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,,22224,BAO_0000019
4691,,,,0,,,CHEMBL618254,,Autocuration,A,,1,,U,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,,22224,BAO_0000019
4692,,,,0,,,CHEMBL618255,,Autocuration,A,,1,,U,Percent of compound in healthy individuals (Group D),,,22224,BAO_0000019
4693,,,2107.0,0,Liver,,CHEMBL618983,,Autocuration,A,,1,Microsomes,U,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,22224,BAO_0000251
4694,,,,0,,,CHEMBL618984,,Autocuration,A,,1,,U,Binding towards human plasma protein at 10 uM,,,22224,BAO_0000019
4695,,,,0,,,CHEMBL618985,,Autocuration,A,,1,,U,Binding towards human plasma protein at 100 uM,,,22224,BAO_0000019
4696,,,,0,,,CHEMBL618986,,Autocuration,A,,1,,U,Human plasma protein binding activity was determined,,,22224,BAO_0000019
4697,,,,0,,,CHEMBL618987,,Autocuration,A,,1,,U,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,22224,BAO_0000019
4698,,,,0,,,CHEMBL618988,,Autocuration,A,,1,,U,Percent binding of compound towards human plasma protein was determined,,,22224,BAO_0000019
4699,,,2107.0,0,Liver,In vitro,CHEMBL618989,,Autocuration,A,,1,Microsomes,U,Plasma clearance in human liver microsomes,,,22224,BAO_0000251
4700,,,2107.0,0,Liver,In vitro,CHEMBL618990,,Autocuration,A,,1,Microsomes,U,In vitro intrinsic clearance in human liver microsome,,,22224,BAO_0000251
4701,,,2107.0,0,Liver,In vitro,CHEMBL618991,,Autocuration,A,,1,Microsomes,U,In vitro intrinsic clearance in human liver microsome,,,22224,BAO_0000251
4702,,,,0,,In vitro,CHEMBL876725,,Autocuration,A,,1,Microsomes,U,In vitro microsome metabolism clearance in human was determined,,,22224,BAO_0000251
4703,,,,0,,In vitro,CHEMBL618992,,Autocuration,A,,1,Microsomes,U,In vitro microsome metabolism clearance in human was determined; High,,,22224,BAO_0000251
4704,,,,0,,In vitro,CHEMBL618993,,Autocuration,A,,1,Microsomes,U,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,,22224,BAO_0000251
4705,,,2107.0,0,Liver,In vitro,CHEMBL618994,,Autocuration,A,,1,Microsomes,U,Pharmacokinetic property (clearance) in human liver microsome,,,22224,BAO_0000251
4706,,,2107.0,0,Liver,In vitro,CHEMBL618995,,Autocuration,A,,1,Microsomes,U,Plasma clearance in human liver microsomes,,,22224,BAO_0000251
4707,,,2107.0,0,Liver,In vitro,CHEMBL618996,,Autocuration,A,,1,Microsomes,U,In vitro clearance in human liver microsomes,,,22224,BAO_0000251
4708,,,2107.0,0,Liver,In vitro,CHEMBL618997,,Autocuration,A,,1,Microsomes,U,Intrinsic clearance in human liver microsomes was determined,,,22224,BAO_0000251
4709,,,2107.0,0,Liver,In vitro,CHEMBL618998,,Autocuration,A,,1,Microsomes,U,Intrinsic clearance in human liver microsomes was determined,,,22224,BAO_0000251
4710,,,,0,,In vivo,CHEMBL618999,,Autocuration,A,,1,,U,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,,22224,BAO_0000218
4711,,,,0,,In vivo,CHEMBL620223,,Autocuration,A,,1,,U,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,,22224,BAO_0000218
4712,,,,0,,,CHEMBL620224,,Autocuration,A,,1,,U,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,,22224,BAO_0000218
4713,,,,0,,,CHEMBL620225,,Autocuration,A,,1,,U,Stability in human plasma 2 hr after incubation expressed as percent concentration,,,22224,BAO_0000019
4714,,,,0,,,CHEMBL620226,,Autocuration,A,,1,,U,Stability in human plasma 4 hr after incubation expressed as percent concentration,,,22224,BAO_0000019
4715,,,1088.0,0,Urine,,CHEMBL620227,,Autocuration,A,,1,,U,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224,BAO_0000019
4716,,,1088.0,0,Urine,,CHEMBL876726,,Autocuration,A,,1,,U,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224,BAO_0000019
4717,,,1088.0,0,Urine,,CHEMBL620228,,Autocuration,A,,1,,U,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224,BAO_0000019
4718,,,1088.0,0,Urine,,CHEMBL620229,,Autocuration,A,,1,,U,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224,BAO_0000019
4719,,,,1,,In vivo,CHEMBL620230,,Intermediate,F,,1,,N,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,50594,BAO_0000218
4720,,,,1,,In vivo,CHEMBL620231,,Intermediate,F,,1,,N,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,50594,BAO_0000218
4721,,,,1,,In vivo,CHEMBL620232,,Intermediate,F,,1,,N,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,50594,BAO_0000218
4722,,,,1,,In vivo,CHEMBL620233,,Intermediate,F,,1,,N,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,,50594,BAO_0000218
4723,,,,1,,,CHEMBL620234,,Intermediate,A,,1,,N,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,,50594,BAO_0000218
4724,,,,1,,,CHEMBL620235,,Intermediate,A,,1,,N,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,,50594,BAO_0000218
4725,,,,1,,,CHEMBL620236,,Intermediate,A,,1,,N,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,,50594,BAO_0000218
4726,,,2107.0,1,Liver,,CHEMBL620237,,Intermediate,A,,1,,N,In vitro metabolic potential in mouse liver microsomes,,,50594,BAO_0000218
4727,,,,1,,,CHEMBL620238,,Intermediate,A,,1,,N,Ability of compound to bind to plasma protein was evaluated in HSA cells,,,50594,BAO_0000218
4728,,,2369.0,1,Adrenal gland,,CHEMBL620239,,Intermediate,A,,1,,N,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,,50594,BAO_0000218
4729,,,955.0,1,Brain,,CHEMBL620240,,Intermediate,A,,1,,N,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,,50594,BAO_0000218
4730,,,955.0,1,Brain,,CHEMBL620241,,Intermediate,A,,1,,N,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,,50594,BAO_0000218
4731,,,,1,,,CHEMBL876727,,Intermediate,A,,1,,N,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,,50594,BAO_0000218
4732,,,2113.0,1,Kidney,,CHEMBL620242,,Intermediate,A,,1,,N,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,,50594,BAO_0000218
4733,,,,1,,,CHEMBL620243,,Intermediate,A,,1,,N,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,,50594,BAO_0000218
4734,,,,1,,,CHEMBL620244,,Intermediate,A,,1,,N,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,,50594,BAO_0000218
4735,,,1977.0,1,Serum,,CHEMBL620245,,Intermediate,A,,1,,N,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,,50594,BAO_0000218
4736,,,1977.0,1,Serum,,CHEMBL620246,,Intermediate,A,,1,,N,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,,50594,BAO_0000218
4737,,,1977.0,1,Serum,,CHEMBL620247,,Intermediate,A,,1,,N,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,,50594,BAO_0000218
4738,,,1969.0,1,Plasma,In vivo,CHEMBL620248,,Intermediate,A,,1,,N,Half life of compound was determined in plasma of mice at 24 mg/Kg,,,50594,BAO_0000218
4739,,,1969.0,1,Plasma,In vivo,CHEMBL873497,,Intermediate,A,,1,,N,Half life of compound was determined in plasma of mice at 40 mg/Kg,,,50594,BAO_0000218
4740,,,1969.0,1,Plasma,In vivo,CHEMBL620249,,Intermediate,A,,1,,N,Half life of compound was determined in plasma of mice at 5 mg/Kg,,,50594,BAO_0000218
4741,,,,1,,In vivo,CHEMBL620250,,Intermediate,F,,1,,N,Half life after intraperitoneal administration in mice at 18 uM/kg,,,50594,BAO_0000218
4742,,,,1,,In vivo,CHEMBL620251,,Intermediate,F,,1,,N,Half life after intraperitoneal administration in mice at 23 uM/kg,,,50594,BAO_0000218
4743,,,,1,,In vivo,CHEMBL620252,,Intermediate,F,,1,,N,Half life after intraperitoneal administration in mice at 25 uM/kg,,,50594,BAO_0000218
4744,,,,1,,In vivo,CHEMBL620253,,Intermediate,F,,1,,N,Half life after intraperitoneal administration in mice at 26 uM/kg,,,50594,BAO_0000218
4745,,,,1,,In vivo,CHEMBL620254,,Intermediate,F,,1,,N,Half life after intravenous administration in mice at 23 uM/kg,,,50594,BAO_0000218
4746,,,,1,,In vivo,CHEMBL620255,,Intermediate,A,,1,,N,Half life after intravenous administration in mice at 24 uM/kg,,,50594,BAO_0000218
4747,,,,1,,In vivo,CHEMBL620256,,Intermediate,A,,1,,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,50594,BAO_0000218
4748,,,,1,,In vivo,CHEMBL876728,,Intermediate,A,,1,,N,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,,50594,BAO_0000218
4749,,,,1,,In vivo,CHEMBL620257,,Intermediate,A,,1,,N,Maximum time required to reach Cp max was evaluated in mice after oral administration,,,50594,BAO_0000218
4750,,,,1,,In vivo,CHEMBL620258,,Intermediate,A,,1,,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,,50594,BAO_0000218
4751,,,,1,,In vivo,CHEMBL620259,,Intermediate,A,,1,,N,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,,50594,BAO_0000218
4752,,,,1,,In vivo,CHEMBL620260,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,,50594,BAO_0000218
4753,,,178.0,1,Blood,In vivo,CHEMBL620261,,Intermediate,A,,1,,N,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,,50594,BAO_0000218
4754,,,,1,,In vivo,CHEMBL620262,,Intermediate,A,,1,,N,Half life at a dose of 10 mg/kg intravenous administration in mice.,,,50594,BAO_0000218
4755,,,,1,,In vivo,CHEMBL620263,,Intermediate,A,,1,,N,Half life at a dose of 10 mg/kg peroral administration in mice.,,,50594,BAO_0000218
4756,,,,1,,,CHEMBL620264,,Intermediate,A,,1,,N,Half life in ob/ob mice,,,50594,BAO_0000218
4757,,,,1,,In vivo,CHEMBL620265,,Intermediate,A,,1,,N,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,,50594,BAO_0000218
4758,,,,1,,,CHEMBL620266,,Intermediate,A,,1,,N,Half-life was measured in mouse,,,50594,BAO_0000218
4759,,,,1,,In vivo,CHEMBL620267,,Intermediate,A,,1,,N,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,,50594,BAO_0000218
4760,,,,1,,,CHEMBL619364,,Intermediate,A,,1,,N,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,,50594,BAO_0000218
4761,,,,1,,,CHEMBL619365,,Intermediate,A,,1,,N,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,,50594,BAO_0000218
4762,,,955.0,1,Brain,,CHEMBL619366,,Intermediate,A,,1,,N,T2 in brain of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
4763,,,2113.0,1,Kidney,,CHEMBL619367,,Intermediate,A,,1,,N,T2 in kidney of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
4764,,,2107.0,1,Liver,,CHEMBL619368,,Intermediate,A,,1,,N,T2 in liver of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
4765,,,2048.0,1,Lung,,CHEMBL619369,,Intermediate,A,,1,,N,T2 in lungs of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
4766,,,2106.0,1,Spleen,,CHEMBL876729,,Intermediate,A,,1,,N,T2 in spleen of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
4767,,,,1,,In vivo,CHEMBL619370,,Intermediate,A,,1,,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,50594,BAO_0000218
4768,,,,1,,In vivo,CHEMBL619371,,Intermediate,A,,1,,N,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,,50594,BAO_0000218
4769,,,,1,,In vivo,CHEMBL619372,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,,50594,BAO_0000218
4770,,,,1,,In vivo,CHEMBL620012,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,,50594,BAO_0000218
4771,,,,1,,In vivo,CHEMBL620013,,Intermediate,A,,1,,N,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,,50594,BAO_0000218
4772,478.0,,,1,,,CHEMBL620014,,Intermediate,F,,1,,N,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,A2780,81034,BAO_0000219
4773,478.0,,,1,,,CHEMBL620015,,Intermediate,F,,1,,N,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,A2780,81034,BAO_0000219
4774,478.0,,,1,,,CHEMBL621010,,Intermediate,F,,1,,N,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,A2780,81034,BAO_0000219
4775,478.0,,,1,,,CHEMBL621011,,Intermediate,F,,1,,N,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,A2780,81034,BAO_0000219
4776,478.0,,,1,,,CHEMBL621012,,Intermediate,F,,1,,N,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,A2780,81034,BAO_0000219
4777,478.0,,,1,,,CHEMBL621013,,Intermediate,F,,1,,N,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,A2780,81034,BAO_0000219
4778,478.0,,,1,,,CHEMBL621014,,Intermediate,F,,1,,N,In vitro cytotoxicity against A2780TAX cell line,,A2780,81034,BAO_0000219
4779,481.0,,,1,,,CHEMBL618154,,Intermediate,F,,1,,N,In vitro inhibitory activity against human tumor cell line A2780cis,,A2780cisR,80017,BAO_0000219
4780,478.0,,,1,,,CHEMBL618155,,Expert,F,,1,,N,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,A2780,81034,BAO_0000219
4781,481.0,,,1,,,CHEMBL618156,,Intermediate,F,,1,,N,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,A2780cisR,80017,BAO_0000219
4782,481.0,,,1,,,CHEMBL618157,,Intermediate,F,,1,,N,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,A2780cisR,80017,BAO_0000219
4783,478.0,,,1,,,CHEMBL618328,,Intermediate,F,,1,,N,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,A2780,81034,BAO_0000219
4784,478.0,,,1,,,CHEMBL618329,,Intermediate,F,,1,,N,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,A2780,81034,BAO_0000219
4785,478.0,,,1,,,CHEMBL618330,,Intermediate,F,,1,,N,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,A2780,81034,BAO_0000219
4786,478.0,,,1,,,CHEMBL618331,,Expert,F,,1,,N,In vitro antitumor activity against A2780cisR cell line.,,A2780,81034,BAO_0000219
4787,478.0,,,1,,,CHEMBL618332,,Intermediate,F,,1,,N,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,A2780,81034,BAO_0000219
4788,478.0,,,1,,,CHEMBL618333,,Expert,F,,1,,N,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,A2780,81034,BAO_0000219
4789,481.0,,,1,,,CHEMBL618334,,Intermediate,F,,1,,N,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,A2780cisR,80017,BAO_0000219
4790,478.0,,,1,,,CHEMBL618335,,Expert,F,,1,,N,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,A2780,81034,BAO_0000219
4791,,,,9,,,CHEMBL618336,,Expert,B,,1,,D,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,,11736,BAO_0000019
4792,,,,8,,,CHEMBL618337,,Expert,F,,1,,H,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,11736,BAO_0000019
4793,,,,9,,,CHEMBL618338,,Expert,F,,1,,D,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,11736,BAO_0000019
4794,722.0,,,9,,,CHEMBL618339,,Expert,F,,1,,D,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,HEK293,278,BAO_0000219
4795,722.0,,,9,,,CHEMBL618340,,Expert,F,,1,,D,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,HEK293,278,BAO_0000219
4796,,,,9,,,CHEMBL618341,,Expert,B,,1,,D,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,,11831,BAO_0000019
4797,,,,8,,,CHEMBL618342,,Expert,F,,1,,H,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,11831,BAO_0000019
4798,,,,9,,,CHEMBL618343,,Expert,F,,1,,D,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,11831,BAO_0000019
4799,,,,8,,,CHEMBL621038,,Expert,B,,1,,H,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,,280,BAO_0000357
4800,574.0,,,0,,,CHEMBL621039,,Autocuration,F,,1,,U,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,T-cells,22226,BAO_0000219
4801,574.0,,,0,,,CHEMBL621040,,Autocuration,F,,1,,U,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,T-cells,22226,BAO_0000219
4802,455.0,,,1,,,CHEMBL621041,,Intermediate,F,,1,,N,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,A-375,80018,BAO_0000219
4803,455.0,,,1,,,CHEMBL621042,,Intermediate,F,,1,,N,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,A-375,80018,BAO_0000219
4804,455.0,,,1,,,CHEMBL621043,,Intermediate,F,,1,,N,In vitro antitumor activity against A375cell line extracted form melanoma,,A-375,80018,BAO_0000219
4805,455.0,,,1,,,CHEMBL621044,,Expert,F,,1,,N,Inhibition of cell growth in (A375) melan cell line,,A-375,80018,BAO_0000219
4806,455.0,,,1,,,CHEMBL621045,,Intermediate,F,,1,,N,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,A-375,80018,BAO_0000219
4807,455.0,,,1,,,CHEMBL621046,,Intermediate,F,,1,,N,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,A-375,80018,BAO_0000219
4808,455.0,,,1,,,CHEMBL621047,,Intermediate,F,,1,,N,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,A-375,80018,BAO_0000219
4809,797.0,,,1,,,CHEMBL621048,,Intermediate,F,,1,,N,Antiproliferative activity measured against A427 human lung carcinoma,,A-427,80019,BAO_0000219
4810,797.0,,,1,,,CHEMBL883798,,Intermediate,F,,1,,N,Antiproliferative activity measured against A427 human lung carcinoma,,A-427,80019,BAO_0000219
4811,797.0,,,1,,,CHEMBL621049,,Intermediate,F,,1,,N,Cytotoxicity against lung carcinoma A427 tumor cell lines,,A-427,80019,BAO_0000219
4812,797.0,,,1,,,CHEMBL621050,,Intermediate,F,,1,,N,Inhibition of large cell lung carcinoma (A427),,A-427,80019,BAO_0000219
4813,797.0,,,1,,,CHEMBL621051,,Intermediate,F,,1,,N,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,A-427,80019,BAO_0000219
4814,797.0,,,1,,,CHEMBL621052,,Intermediate,F,,1,,N,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,A-427,80019,BAO_0000219
4815,797.0,,,1,,,CHEMBL621053,,Intermediate,F,,1,,N,Inhibitory concentration in human lung carcinoma A427 cell line,,A-427,80019,BAO_0000219
4816,797.0,,,1,,,CHEMBL621054,,Intermediate,F,,1,,N,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,A-427,80019,BAO_0000219
4817,,,,0,,In vivo,CHEMBL621055,,Autocuration,A,,1,,U,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,22224,BAO_0000218
4818,,,,0,,In vivo,CHEMBL876398,,Autocuration,A,,1,,U,Tested for volume of distribution upon iv administration to african green monkey,,,22224,BAO_0000218
4819,,,,0,,In vivo,CHEMBL621056,,Autocuration,A,,1,,U,Volume of distribution in monkey,,,22224,BAO_0000218
4820,,,,0,,In vivo,CHEMBL621057,,Autocuration,A,,1,,U,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,22224,BAO_0000218
4821,,,,0,,In vivo,CHEMBL621058,,Autocuration,A,,1,,U,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,,22224,BAO_0000218
4822,,,,0,,In vivo,CHEMBL621059,,Autocuration,A,,1,,U,Pharmacokinetic property(Vdss) in cynomolgus monkey,,,22224,BAO_0000218
4823,,,,0,,In vivo,CHEMBL621060,,Autocuration,A,,1,,U,The distribution volume after intravenous administration in cynomolgus monkeys,,,22224,BAO_0000218
4824,,,,0,,In vivo,CHEMBL621061,,Autocuration,A,,1,,U,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,,22224,BAO_0000218
4825,,,,0,,In vivo,CHEMBL621062,,Autocuration,A,,1,,U,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,,22224,BAO_0000218
4826,,,,0,,In vivo,CHEMBL621063,,Autocuration,A,,1,,U,Volume displacement was calculated in rhesus monkey,,,22224,BAO_0000218
4827,,,,0,,In vivo,CHEMBL621064,,Autocuration,A,,1,,U,Volume of distribution in steady state was determined in rhesus monkey,,,22224,BAO_0000218
4828,,,,0,,In vivo,CHEMBL621065,,Autocuration,A,,1,,U,Volume of distribution of compound was determined in monkey,,,22224,BAO_0000218
4829,,,,0,,In vivo,CHEMBL621066,,Autocuration,A,,1,,U,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,22224,BAO_0000218
4830,,,,0,,In vivo,CHEMBL621067,,Autocuration,A,,1,,U,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,22224,BAO_0000218
4831,,,,0,,In vivo,CHEMBL621068,,Autocuration,A,,1,,U,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,22224,BAO_0000218
4832,,,,0,,In vivo,CHEMBL876399,,Autocuration,A,,1,,U,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,22224,BAO_0000218
4833,,,,0,,In vivo,CHEMBL621069,,Autocuration,A,,1,,U,Volume distribution in monkey after administration of 1 mg/kg iv,,,22224,BAO_0000218
4834,,,,0,,In vivo,CHEMBL621070,,Autocuration,A,,1,,U,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,22224,BAO_0000218
4835,,,,0,,In vivo,CHEMBL621071,,Autocuration,A,,1,,U,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,22224,BAO_0000218
4836,,,,0,,In vivo,CHEMBL621072,,Autocuration,A,,1,,U,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
4837,,,,0,,In vivo,CHEMBL618209,,Autocuration,A,,1,,U,Oral systemic bioavailability upon iv administration to african green monkey,,,22224,BAO_0000218
4838,,,,0,,In vivo,CHEMBL618210,,Autocuration,A,,1,,U,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,22224,BAO_0000218
4839,,,,0,,,CHEMBL618211,,Autocuration,A,,1,,U,Baboon plasma free fraction. ,,,22224,BAO_0000019
4840,,,,0,,,CHEMBL618212,,Autocuration,A,,1,,U,Area under the curve was calculated in rhesus monkey after iv administration,,,22224,BAO_0000218
4841,,,,0,,,CHEMBL618213,,Autocuration,A,,1,,U,Area under the curve was calculated in rhesus monkey after peroral administration,,,22224,BAO_0000019
4842,,,,0,,,CHEMBL618214,,Autocuration,A,,1,,U,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,,22224,BAO_0000019
4843,,,,0,,In vivo,CHEMBL873492,,Autocuration,A,,1,,U,Half life period in monkey after 5 mg/kg dose,,,22224,BAO_0000218
4844,,,,0,,In vivo,CHEMBL618272,,Autocuration,A,,1,,U,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,,22224,BAO_0000218
4845,,,,0,,In vivo,CHEMBL618273,,Autocuration,A,,1,,U,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,,22224,BAO_0000218
4846,,,1969.0,0,Plasma,In vivo,CHEMBL618274,,Autocuration,A,,1,,U,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,22224,BAO_0000218
4847,,,,0,,In vivo,CHEMBL618275,,Autocuration,A,,1,,U,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,,22224,BAO_0000218
4848,,,,0,,In vivo,CHEMBL618276,,Autocuration,A,,1,,U,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,22224,BAO_0000218
4849,,,,0,,,CHEMBL618277,,Autocuration,A,,1,,U,Compound was evaluated for terminal half life in monkey,,,22224,BAO_0000019
4850,,,,0,,In vivo,CHEMBL618278,,Autocuration,A,,1,,U,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,,22224,BAO_0000218
4851,,,1969.0,0,Plasma,In vivo,CHEMBL618279,,Autocuration,A,,1,,U,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,22224,BAO_0000218
4852,,,,0,,,CHEMBL618280,,Autocuration,A,,1,,U,Half life of compound was determined in squirrel monkey,,,22224,BAO_0000019
4853,,,,0,,In vivo,CHEMBL618281,,Autocuration,A,,1,,U,Half life after iv administration in cynomolgus monkey,,,22224,BAO_0000218
4854,,,1969.0,0,Plasma,In vivo,CHEMBL618282,,Autocuration,A,,1,,U,Half life in monkey plasma after administration of 1 mg/kg iv,,,22224,BAO_0000218
4855,,,,0,,,CHEMBL618283,,Autocuration,A,,1,,U,Half life was calculated in rhesus monkey,,,22224,BAO_0000019
4856,,,,0,,,CHEMBL618284,,Autocuration,A,,1,,U,Half life in monkey,,,22224,BAO_0000019
4857,,,,0,,In vivo,CHEMBL618285,,Autocuration,A,,1,,U,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,22224,BAO_0000218
4858,,,,0,,,CHEMBL618286,,Autocuration,A,,1,,U,Half life was evaluated in rhesus,,,22224,BAO_0000019
4859,,,,0,,In vivo,CHEMBL618287,,Autocuration,A,,1,,U,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,,22224,BAO_0000218
4860,,,,0,,In vivo,CHEMBL618288,,Autocuration,A,,1,,U,Half life period was determine after peroral administration at 10 mpk in Rhesus,,,22224,BAO_0000218
4861,,,,0,,In vivo,CHEMBL876393,,Autocuration,A,,1,,U,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,22224,BAO_0000218
4862,,,,0,,In vivo,CHEMBL618289,,Autocuration,A,,1,,U,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,22224,BAO_0000218
4863,,,,0,,In vivo,CHEMBL618290,,Autocuration,A,,1,,U,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,,22224,BAO_0000218
4864,,,,0,,,CHEMBL618291,,Autocuration,A,,1,,U,Half-life was calculated in monkey,,,22224,BAO_0000019
4865,,,,0,,,CHEMBL618292,,Autocuration,A,,1,,U,Half-life in Squirrel monkey,,,22224,BAO_0000019
4866,,,,0,,,CHEMBL618293,,Autocuration,A,,1,,U,Half-life in rhesus monkey,,,22224,BAO_0000019
4867,,,,0,,In vivo,CHEMBL618294,,Autocuration,A,,1,,U,Half-life was measured in monkey after an iv dose of 1 mg/kg,,,22224,BAO_0000218
4868,,,,0,,In vivo,CHEMBL618295,,Autocuration,A,,1,,U,Half-life period after intravenous administration in cynomolgus monkeys,,,22224,BAO_0000218
4869,,,,0,,In vivo,CHEMBL618296,,Autocuration,A,,1,,U,Half-life period after oral administration in cynomolgus monkeys,,,22224,BAO_0000218
4870,,,,0,,In vivo,CHEMBL618297,,Autocuration,A,,1,,U,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,,22224,BAO_0000218
4871,,,1088.0,0,Urine,,CHEMBL618298,,Autocuration,A,,1,,U,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224,BAO_0000019
4872,,,1088.0,0,Urine,,CHEMBL618299,,Autocuration,A,,1,,U,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224,BAO_0000019
4873,,,1088.0,0,Urine,,CHEMBL618300,,Autocuration,A,,1,,U,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224,BAO_0000019
4874,,,1088.0,0,Urine,,CHEMBL618301,,Autocuration,A,,1,,U,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224,BAO_0000019
4875,,,1088.0,0,Urine,,CHEMBL618302,,Autocuration,A,,1,,U,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,22224,BAO_0000019
4876,,,1088.0,0,Urine,,CHEMBL876394,,Autocuration,A,,1,,U,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,22224,BAO_0000019
4877,,,1088.0,0,Urine,,CHEMBL618303,,Autocuration,A,,1,,U,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,22224,BAO_0000019
4878,,,1088.0,0,Urine,,CHEMBL618304,,Autocuration,A,,1,,U,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,22224,BAO_0000019
4879,,,,0,,In vivo,CHEMBL618305,,Autocuration,A,,1,,U,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,,22224,BAO_0000218
4880,,,,0,,In vivo,CHEMBL618306,,Autocuration,A,,1,,U,Oral bioavailability in human,,,22224,BAO_0000218
4881,,,,0,,,CHEMBL618307,,Autocuration,A,,1,,U,Compound was tested for human plasma protein binding,,,22224,BAO_0000019
4882,,,,0,,,CHEMBL618308,,Autocuration,A,,1,,U,Compound was tested for human plasma protein binding; Not determined,,,22224,BAO_0000019
4883,,,,0,,,CHEMBL618309,,Autocuration,A,,1,,U,Protein binding activity of compound in human plasma; % Free,,,22224,BAO_0000019
4884,,,,0,,,CHEMBL618310,,Autocuration,A,,1,,U,Unbound fraction (plasma),,,22224,BAO_0000019
4885,,,1969.0,0,Plasma,,CHEMBL873353,,Autocuration,A,,1,,U,Half life for the hydrolysis of compound in human blood serum,,,22224,BAO_0000366
4886,,,1969.0,0,Plasma,,CHEMBL618311,,Autocuration,A,,1,,U,Half life period in human plasma using phosphate buffer (0.08 M),,,22224,BAO_0000366
4887,,,1969.0,0,Plasma,,CHEMBL618312,,Autocuration,A,,1,,U,Half life period in human plasma using phosphate buffer (0.1 M),,,22224,BAO_0000366
4888,,,1969.0,0,Plasma,,CHEMBL618313,,Autocuration,A,,1,,U,Half-life in human plasma was determined,,,22224,BAO_0000366
4889,,,,0,,,CHEMBL618314,,Autocuration,A,,1,,U,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,,22224,BAO_0000019
4890,,,,0,,,CHEMBL618315,,Autocuration,A,,1,,U,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,,22224,BAO_0000019
4891,,,,0,,,CHEMBL618316,,Autocuration,A,,1,,U,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,22224,BAO_0000019
4892,,,,0,,,CHEMBL618317,,Autocuration,A,,1,,U,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,22224,BAO_0000019
4893,,,,0,,,CHEMBL620138,,Autocuration,A,,1,,U,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,22224,BAO_0000019
4894,,,,0,,,CHEMBL858280,,Autocuration,A,,1,,U,Partition coefficient (logP),,,22224,BAO_0000019
4895,,,,0,,,CHEMBL620139,,Autocuration,A,,1,,U,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,,22224,BAO_0000019
4896,,,,0,,,CHEMBL620140,,Autocuration,A,,1,Microsomes,U,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,,22224,BAO_0000251
4897,,,,0,,,CHEMBL620141,,Autocuration,A,,1,,U,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,,22224,BAO_0000019
4898,,,,0,,,CHEMBL620142,,Autocuration,A,,1,,U,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,,22224,BAO_0000019
4899,,,,0,,,CHEMBL620143,,Autocuration,A,,1,,U,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,,22224,BAO_0000019
4900,,,,0,,,CHEMBL620144,,Autocuration,A,,1,Microsomes,U,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,,22224,BAO_0000251
4901,,,,0,,,CHEMBL620145,,Autocuration,A,,1,Microsomes,U,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,,22224,BAO_0000251
4902,,,,0,,,CHEMBL620146,,Autocuration,A,,1,Microsomes,U,Metabolism of compound in human microsomes; Trace,,,22224,BAO_0000251
4903,,,2107.0,0,Liver,,CHEMBL620147,,Autocuration,A,,1,Microsomes,U,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,,22224,BAO_0000251
4904,,,,0,,,CHEMBL620148,,Autocuration,A,,1,Microsomes,U,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,,22224,BAO_0000251
4905,,,2107.0,0,Liver,,CHEMBL620149,,Autocuration,A,,1,Microsomes,U,In vitro metabolic potential in human liver microsomes,,,22224,BAO_0000251
4906,,,,0,,,CHEMBL876412,,Autocuration,A,,1,,U,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,,22224,BAO_0000019
4907,,,,0,,,CHEMBL619352,,Autocuration,A,,1,,U,Tested for human plasma protein binding of the compound; Not tested,,,22224,BAO_0000019
4908,,,,0,,,CHEMBL619353,,Autocuration,A,,1,,U,Compound was tested for percent protein binding (PB) in human,,,22224,BAO_0000019
4909,,,1969.0,0,Plasma,,CHEMBL619354,,Autocuration,A,,1,,U,Protein binding in human plasma,,,22224,BAO_0000019
4910,,,,0,,,CHEMBL619355,,Autocuration,A,,1,,U,Permeability coefficient (B to A) in Caco-2 cell,,,22224,BAO_0000019
4911,,,,0,,,CHEMBL619356,,Autocuration,A,,1,,U,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,,22224,BAO_0000019
4912,,,,0,,,CHEMBL619357,,Autocuration,A,,1,,U,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,,22224,BAO_0000019
4913,,,,0,,,CHEMBL619358,,Autocuration,A,,1,,U,In vitro rate of absorption observed as Caco-2 permeability in humans,,,22224,BAO_0000019
4914,495.0,,,0,,,CHEMBL619359,,Autocuration,A,,1,,U,Cellular permeability of compound was determined in Caco-2 cells; High,,Caco-2,22224,BAO_0000219
4915,495.0,,,0,,,CHEMBL619360,,Autocuration,A,,1,,U,Permeability in Caco-2 cells of compound,,Caco-2,22224,BAO_0000219
4916,,,,0,,,CHEMBL619361,,Autocuration,A,,1,,U,Permeability coefficient (A to B) in Caco-2 cell,,,22224,BAO_0000019
4917,,,,0,,,CHEMBL619362,,Autocuration,A,,1,,U,Permeability coefficient (B to A) in Caco-2 cell,,,22224,BAO_0000019
4918,,,,0,,,CHEMBL619363,,Autocuration,A,,1,,U,Permeability coefficient (Papp) (Caco-2 cell monolayer),,,22224,BAO_0000019
4919,,,,0,,,CHEMBL618942,,Autocuration,A,,1,,U,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,,22224,BAO_0000019
4920,,,,0,,,CHEMBL618943,,Autocuration,A,,1,,U,Compound was tested for protein binding in human plasma,,,22224,BAO_0000019
4921,,,,0,,,CHEMBL618944,,Autocuration,A,,1,,U,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,,22224,BAO_0000019
4922,,,1088.0,0,Urine,,CHEMBL618945,,Autocuration,A,,1,,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,,22224,BAO_0000019
4923,,,,1,,In vivo,CHEMBL618946,,Intermediate,A,,1,,N,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,,50594,BAO_0000218
4924,,,,1,,In vivo,CHEMBL876413,,Intermediate,A,,1,,N,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,50594,BAO_0000218
4925,,,,1,,In vivo,CHEMBL618947,,Intermediate,A,,1,,N,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,,50594,BAO_0000218
4926,,,1969.0,1,Plasma,In vivo,CHEMBL618948,,Intermediate,A,,1,,N,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,,50594,BAO_0000218
4927,,,1969.0,1,Plasma,In vivo,CHEMBL618949,,Intermediate,A,,1,,N,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594,BAO_0000218
4928,,,,1,,In vivo,CHEMBL618950,,Intermediate,F,,1,,N,Tmax after intraperitoneal administration in mice at 23 uM/kg,,,50594,BAO_0000218
4929,,,,1,,In vivo,CHEMBL618951,,Intermediate,A,,1,,N,Tmax after oral administration at 30 mg/kg in ICR mouse,,,50594,BAO_0000218
4930,,,,1,,In vivo,CHEMBL618952,,Intermediate,A,,1,,N,Tmax after peroral administration in mice at 2.4 uM/kg,,,50594,BAO_0000218
4931,,,,1,,In vivo,CHEMBL618953,,Intermediate,A,,1,,N,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,,50594,BAO_0000218
4932,,,955.0,1,Brain,In vivo,CHEMBL618954,,Intermediate,A,,1,,N,Tmax in brain of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
4933,,,2113.0,1,Kidney,In vivo,CHEMBL618955,,Intermediate,A,,1,,N,Tmax in kidney of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
4934,,,2107.0,1,Liver,In vivo,CHEMBL618956,,Intermediate,A,,1,,N,Tmax in liver of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
4935,,,2048.0,1,Lung,In vivo,CHEMBL618957,,Intermediate,A,,1,,N,Tmax in lungs of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
4936,,,,1,,In vivo,CHEMBL618958,,Intermediate,F,,1,,N,Tmax in mice at 18 uM/kg i.p. administration,,,50594,BAO_0000218
4937,,,,1,,In vivo,CHEMBL618959,,Intermediate,F,,1,,N,Tmax in mice at 23 uM/kg i.v. administration,,,50594,BAO_0000218
4938,,,,1,,In vivo,CHEMBL618960,,Intermediate,F,,1,,N,Tmax in mice at 25 uM/kg i.p. administration,,,50594,BAO_0000218
4939,,,,1,,In vivo,CHEMBL876723,,Intermediate,F,,1,,N,Tmax in mice at 26 uM/kg i.p. administration,,,50594,BAO_0000218
4940,,,2106.0,1,Spleen,In vivo,CHEMBL618961,,Intermediate,A,,1,,N,Tmax in spleen of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
4941,,,,1,,In vivo,CHEMBL618962,,Intermediate,A,,1,,N,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,,50594,BAO_0000218
4942,,,,1,,In vivo,CHEMBL618963,,Intermediate,A,,1,,N,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,,50594,BAO_0000218
4943,,,,1,,,CHEMBL618964,,Intermediate,A,,1,,N,Tmax value in IRC mice,,,50594,BAO_0000218
4944,,,,1,,In vivo,CHEMBL618965,,Intermediate,A,,1,,N,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,50594,BAO_0000218
4945,,,,1,,In vivo,CHEMBL618966,,Intermediate,A,,1,,N,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,50594,BAO_0000218
4946,,,1088.0,1,Urine,,CHEMBL618967,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,,50594,BAO_0000218
4947,,,1088.0,1,Urine,,CHEMBL618968,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,,50594,BAO_0000218
4948,,,1088.0,1,Urine,,CHEMBL618969,,Intermediate,A,,1,,N,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,,50594,BAO_0000218
4949,,,,1,,,CHEMBL618970,,Intermediate,A,,1,,N,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,50594,BAO_0000218
4950,,,,1,,,CHEMBL618971,,Intermediate,A,,1,,N,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,50594,BAO_0000218
4951,,,,1,,In vivo,CHEMBL618972,,Intermediate,A,,1,,N,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,50594,BAO_0000218
4952,,,,1,,In vivo,CHEMBL618973,,Intermediate,A,,1,,N,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,,50594,BAO_0000218
4953,,,,1,,In vivo,CHEMBL618974,,Intermediate,A,,1,,N,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,,50594,BAO_0000218
4954,,,,1,,In vivo,CHEMBL618975,,Intermediate,A,,1,,N,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,50594,BAO_0000218
4955,,,,1,,In vivo,CHEMBL618976,,Intermediate,A,,1,,N,Vd in mice,,,50594,BAO_0000218
4956,,,,1,,In vivo,CHEMBL618977,,Intermediate,A,,1,,N,Volume of distribution in mouse,,,50594,BAO_0000218
4957,,,,1,,In vivo,CHEMBL876724,,Intermediate,A,,1,,N,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594,BAO_0000218
4958,,,,1,,In vivo,CHEMBL618978,,Intermediate,A,,1,,N,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,,50594,BAO_0000218
4959,,,,1,,In vivo,CHEMBL618979,,Intermediate,A,,1,,N,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,,50594,BAO_0000218
4960,,,,1,,In vivo,CHEMBL618980,,Intermediate,A,,1,,N,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,,50594,BAO_0000218
4961,,,,1,,In vivo,CHEMBL618981,,Intermediate,A,,1,,N,Pharmacokinetic property (vdss) was measured in mouse,,,50594,BAO_0000218
4962,,,,1,,In vivo,CHEMBL618982,,Intermediate,A,,1,,N,Value distribution upon iv administration in mouse,,,50594,BAO_0000218
4963,,,,1,,In vivo,CHEMBL620150,,Intermediate,A,,1,,N,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,50594,BAO_0000218
4964,,,,1,,In vivo,CHEMBL620151,,Intermediate,A,,1,,N,Volume of distribution was evaluated in mice after intravenous administration,,,50594,BAO_0000218
4965,,,,1,,In vivo,CHEMBL620152,,Intermediate,A,,1,,N,Volume of distribution was evaluated in mice after oral administration,,,50594,BAO_0000218
4966,,,,1,,In vivo,CHEMBL620153,,Intermediate,A,,1,,N,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,,50594,BAO_0000218
4967,,,,1,,In vivo,CHEMBL876395,,Intermediate,A,,1,,N,Steady state volume of distribution was determined in mice,,,50594,BAO_0000218
4968,,,,1,,In vivo,CHEMBL620154,,Intermediate,A,,1,,N,Volume distribution (steady state) of compound was determined in mouse,,,50594,BAO_0000218
4969,,,,1,,In vivo,CHEMBL620155,,Intermediate,A,,1,,N,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,,50594,BAO_0000218
4970,,,,1,,In vivo,CHEMBL620156,,Intermediate,A,,1,,N,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,,50594,BAO_0000218
4971,,,,1,,In vivo,CHEMBL620157,,Intermediate,A,,1,,N,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,50594,BAO_0000218
4972,,,2113.0,1,Kidney,In vivo,CHEMBL620158,,Intermediate,A,,1,,N,Biodistribution of compound (oxidized form) in in kidney tissue,,,50594,BAO_0000218
4973,,,178.0,1,Blood,In vivo,CHEMBL620159,,Intermediate,A,,1,,N,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,50594,BAO_0000218
4974,,,178.0,1,Blood,In vivo,CHEMBL620160,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,50594,BAO_0000218
4975,,,178.0,1,Blood,In vivo,CHEMBL620161,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
4976,797.0,,,1,,,CHEMBL620162,,Intermediate,F,,1,,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,A-427,80019,BAO_0000219
4977,500.0,,,1,,,CHEMBL620163,,Expert,F,,1,,N,Inhibition of A431 human squamous cell carcinoma cell proliferation,,A-431,80852,BAO_0000219
4978,500.0,,,1,,,CHEMBL620833,,Expert,F,,1,,N,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,A-431,80852,BAO_0000219
4979,500.0,,,1,,,CHEMBL876396,,Expert,F,,1,,N,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,A-431,80852,BAO_0000219
4980,500.0,,,1,,,CHEMBL620834,,Expert,F,,1,,N,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,A-431,80852,BAO_0000219
4981,500.0,,,1,,,CHEMBL620835,,Expert,F,,1,,N,Inhibition of A431 human carcinoma cell proliferation,,A-431,80852,BAO_0000219
4982,500.0,,,1,,,CHEMBL620836,,Expert,F,,1,,N,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,A-431,80852,BAO_0000219
4983,500.0,,,1,,,CHEMBL620837,,Intermediate,F,,1,,N,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,A-431,80852,BAO_0000219
4984,500.0,,,1,,,CHEMBL621017,,Intermediate,F,,1,,N,In vitro cytotoxicity against epidermoid carcinoma cell line,,A-431,80852,BAO_0000219
4985,500.0,,,9,,,CHEMBL621018,,Expert,F,,1,,D,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,A-431,9,BAO_0000218
4986,500.0,,,1,,,CHEMBL621019,,Intermediate,F,,1,,N,Antiproliferative activity of compound was measured on human tumor cell line A431.,,A-431,80852,BAO_0000219
4987,500.0,,,1,,,CHEMBL621020,,Intermediate,F,,1,,N,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,A-431,80852,BAO_0000219
4988,500.0,,,1,,,CHEMBL621021,,Intermediate,F,,1,,N,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,A-431,80852,BAO_0000219
4989,500.0,,,8,,,CHEMBL621022,,Expert,F,,1,,H,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,A-431,9,BAO_0000219
4990,500.0,,,1,,,CHEMBL621023,,Expert,F,,1,,N,Tested for antiproliferative activity against human A431 cells,,A-431,80852,BAO_0000219
4991,500.0,,,9,,,CHEMBL621024,,Expert,F,,1,,D,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,A-431,9,BAO_0000219
4992,500.0,,,1,,,CHEMBL621025,,Expert,F,,1,,N,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,A-431,80852,BAO_0000219
4993,500.0,,,1,,,CHEMBL621026,,Expert,F,,1,,N,Inhibition of A431 cell proliferation,,A-431,80852,BAO_0000219
4994,500.0,,,1,,,CHEMBL621027,,Expert,F,,1,,N,Cytotoxic effect on A431 human epidermoid carcinoma cells,,A-431,80852,BAO_0000219
4995,500.0,,,1,,,CHEMBL876397,,Expert,F,,1,,N,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,A-431,80852,BAO_0000219
4996,500.0,,,1,,,CHEMBL883797,,Intermediate,F,,1,,N,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,A-431,80852,BAO_0000219
4997,500.0,,,1,,,CHEMBL621028,,Intermediate,F,,1,,N,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,A-431,80852,BAO_0000219
4998,500.0,,,1,,,CHEMBL621029,,Intermediate,F,,1,,N,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,A-431,80852,BAO_0000219
4999,500.0,,,1,,,CHEMBL621030,,Intermediate,F,,1,,N,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,A-431,80852,BAO_0000219
5000,500.0,,,8,,,CHEMBL621147,,Expert,F,,1,,H,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,A-431,9,BAO_0000219
5001,500.0,,,1,,,CHEMBL621148,,Intermediate,F,,1,,N,In vivo antiproliferative activity against A431 cell line,,A-431,80852,BAO_0000218
5002,500.0,,,9,,,CHEMBL621149,,Expert,F,,1,,D,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,A-431,9,BAO_0000219
5003,500.0,,,1,,,CHEMBL621150,,Expert,F,,1,,N,Inhibition of A431 human epidermoid carcinoma cell proliferation,,A-431,80852,BAO_0000219
5004,500.0,,,9,,,CHEMBL621151,,Expert,F,,1,,D,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,A-431,9,BAO_0000219
5005,500.0,,,1,,,CHEMBL621152,,Intermediate,F,,1,,N,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,A-431,80852,BAO_0000219
5006,500.0,,,1,,,CHEMBL621153,,Intermediate,F,,1,,N,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,A-431,80852,BAO_0000219
5007,500.0,,,1,,,CHEMBL884000,,Intermediate,F,,1,,N,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,A-431,80852,BAO_0000219
5008,,,,9,,,CHEMBL621154,,Expert,F,,1,,D,Inhibition of EGFR overexpressing A431 cell proliferation,,,9,BAO_0000019
5009,500.0,,,1,,,CHEMBL621155,,Expert,F,,1,,N,Inhibition of A431 cell proliferation,,A-431,80852,BAO_0000219
5010,500.0,,,9,,,CHEMBL621156,,Expert,F,,1,,D,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,A-431,9,BAO_0000219
5011,500.0,,,9,,,CHEMBL621157,,Expert,F,,1,,D,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,A-431,9,BAO_0000219
5012,500.0,,,8,,,CHEMBL621158,,Expert,F,,1,,H,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,A-431,9,BAO_0000219
5013,500.0,,,1,,,CHEMBL621159,,Intermediate,F,,1,,N,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,A-431,80852,BAO_0000219
5014,500.0,,,1,,,CHEMBL621160,,Intermediate,F,,1,,N,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,A-431,80852,BAO_0000219
5015,500.0,,,1,,,CHEMBL621161,,Intermediate,F,,1,,N,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,A-431,80852,BAO_0000219
5016,500.0,,,1,,,CHEMBL621162,,Intermediate,F,,1,,N,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,A-431,80852,BAO_0000219
5017,500.0,,,1,,,CHEMBL621163,,Intermediate,F,,1,,N,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,A-431,80852,BAO_0000219
5018,500.0,,,1,,,CHEMBL621164,,Intermediate,F,,1,,N,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,A-431,80852,BAO_0000219
5019,500.0,,,1,,,CHEMBL621165,,Intermediate,F,,1,,N,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,A-431,80852,BAO_0000219
5020,,,,0,,,CHEMBL619159,,Autocuration,A,,1,,U,Half-life period in cynomolgus monkey,,,22224,BAO_0000019
5021,,,1969.0,0,Plasma,In vitro,CHEMBL619160,,Autocuration,A,,1,,U,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,,22224,BAO_0000366
5022,,,,0,,In vivo,CHEMBL619161,,Autocuration,A,,1,,U,Longer half-life in monkey (i.v.) at 0.5 mpk,,,22224,BAO_0000218
5023,,,1969.0,0,Plasma,,CHEMBL619162,,Autocuration,A,,1,,U,Plasma half life in monkey,,,22224,BAO_0000366
5024,,,1969.0,0,Plasma,,CHEMBL619163,,Autocuration,A,,1,,U,Plasma half-life in rhesus monkey,,,22224,BAO_0000366
5025,,,1969.0,0,Plasma,In vivo,CHEMBL619164,,Autocuration,A,,1,,U,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,22224,BAO_0000218
5026,,,1969.0,0,Plasma,In vivo,CHEMBL619320,,Autocuration,A,,1,,U,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,22224,BAO_0000218
5027,,,,0,,In vivo,CHEMBL619321,,Autocuration,A,,1,,U,Tested for half life upon iv administration to african green monkey,,,22224,BAO_0000218
5028,,,,0,,In vivo,CHEMBL873336,,Autocuration,A,,1,,U,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,22224,BAO_0000218
5029,,,,0,,In vivo,CHEMBL619322,,Autocuration,A,,1,,U,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,22224,BAO_0000218
5030,,,,0,,In vivo,CHEMBL619323,,Autocuration,A,,1,,U,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,22224,BAO_0000218
5031,,,,0,,In vivo,CHEMBL619324,,Autocuration,A,,1,,U,The time for peak concentration value after oral administration in cynomolgus monkeys,,,22224,BAO_0000218
5032,,,,0,,,CHEMBL619325,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,,22224,BAO_0000019
5033,,,,0,,,CHEMBL876411,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,,22224,BAO_0000019
5034,,,,0,,,CHEMBL619326,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,,22224,BAO_0000019
5035,,,,0,,,CHEMBL619327,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,,22224,BAO_0000019
5036,,,,0,,,CHEMBL619328,,Autocuration,A,,1,,U,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,,22224,BAO_0000019
5037,,,,0,,,CHEMBL619329,,Autocuration,A,,1,,U,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,,22224,BAO_0000019
5038,,,,0,,,CHEMBL619330,,Autocuration,A,,1,,U,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,,22224,BAO_0000019
5039,,,,0,,,CHEMBL619331,,Autocuration,A,,1,,U,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,,22224,BAO_0000019
5040,,,,0,,,CHEMBL619332,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,,22224,BAO_0000019
5041,,,,0,,,CHEMBL619333,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,,22224,BAO_0000019
5042,,,,0,,,CHEMBL619334,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,,22224,BAO_0000019
5043,,,,0,,,CHEMBL619335,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,,22224,BAO_0000019
5044,,,,0,,,CHEMBL619336,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,,22224,BAO_0000019
5045,,,,0,,,CHEMBL619337,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,,22224,BAO_0000019
5046,,,,0,,,CHEMBL619338,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,,22224,BAO_0000019
5047,,,,0,,,CHEMBL619339,,Autocuration,A,,1,,U,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,,22224,BAO_0000019
5048,,,,1,,In vivo,CHEMBL619340,,Intermediate,A,,1,,N,Bioavailability in rat (cannulated) (dose 2 mg/kg),,,50597,BAO_0000218
5049,,,1969.0,1,Plasma,In vivo,CHEMBL873496,,Intermediate,A,,1,,N,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,,50597,BAO_0000218
5050,,,1969.0,1,Plasma,,CHEMBL619341,,Intermediate,A,,1,,N,AUC value in rat after IV administration at a dose of 10 mg/kg,,,50597,BAO_0000218
5051,,,1969.0,1,Plasma,,CHEMBL619342,,Intermediate,A,,1,,N,AUC value in rat after oral administration at a dose of 10 mg/kg,,,50597,BAO_0000218
5052,,,,1,,In vivo,CHEMBL619343,,Intermediate,A,,1,,N,Cmax value in rat after oral administration at a dose of 10 mg/kg,,,50597,BAO_0000218
5053,,,,1,,In vivo,CHEMBL619344,,Intermediate,A,,1,,N,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,,50597,BAO_0000218
5054,,,,1,,In vivo,CHEMBL619345,,Intermediate,A,,1,,N,Tmax value in rat after oral administration at a dose of 10 mg/kg,,,50597,BAO_0000218
5055,,,,1,,,CHEMBL619346,,Intermediate,A,,1,,N,Vc value in rat after IV administration at a dose of 10 mg/kg,,,50597,BAO_0000218
5056,,,,1,,In vivo,CHEMBL619347,,Intermediate,A,,1,,N,Half life period in rat after IV administration at a dose of 10 mg/kg,,,50597,BAO_0000218
5057,,,,0,,,CHEMBL619348,,Autocuration,A,,1,,U,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,22224,BAO_0000019
5058,,,,0,,,CHEMBL619349,,Autocuration,A,,1,,U,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,,22224,BAO_0000019
5059,,,,0,,,CHEMBL619350,,Autocuration,A,,1,,U,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,,22224,BAO_0000019
5060,,,,0,,,CHEMBL619351,,Autocuration,A,,1,,U,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,,22224,BAO_0000019
5061,,,,0,,,CHEMBL875953,,Autocuration,A,,1,,U,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,,22224,BAO_0000019
5062,,,,0,,,CHEMBL621716,,Autocuration,A,,1,,U,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,,22224,BAO_0000019
5063,,,,0,,,CHEMBL621717,,Autocuration,A,,1,,U,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,,22224,BAO_0000019
5064,,,,0,,,CHEMBL621718,,Autocuration,A,,1,,U,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,22224,BAO_0000019
5065,,,,0,,,CHEMBL621719,,Autocuration,A,,1,,U,Area under curve after 1 mpk peroral administration to beagles,,,22224,BAO_0000019
5066,,,,0,,,CHEMBL621720,,Autocuration,A,,1,,U,Area under curve after 2 mpk peroral administration to beagles,,,22224,BAO_0000019
5067,,,,0,,In vivo,CHEMBL621721,,Autocuration,A,,1,,U,Cmax value after 1 mpk peroral administration to beagles,,,22224,BAO_0000218
5068,,,1088.0,0,Urine,,CHEMBL621722,,Autocuration,A,,1,,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,,22224,BAO_0000019
5069,,,1088.0,0,Urine,,CHEMBL621723,,Autocuration,A,,1,,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,,22224,BAO_0000019
5070,,,1088.0,0,Urine,,CHEMBL621724,,Autocuration,A,,1,,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,,22224,BAO_0000019
5071,,,1088.0,0,Urine,,CHEMBL623443,,Autocuration,A,,1,,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,,22224,BAO_0000019
5072,,,1088.0,0,Urine,,CHEMBL623444,,Autocuration,A,,1,,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,,22224,BAO_0000019
5073,,,1088.0,0,Urine,,CHEMBL623445,,Autocuration,A,,1,,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,,22224,BAO_0000019
5074,,,1088.0,0,Urine,,CHEMBL623446,,Autocuration,A,,1,,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,,22224,BAO_0000019
5075,,,2107.0,0,Liver,,CHEMBL623447,,Autocuration,A,,1,Microsomes,U,Metabolic stability observed at 30 min after administration in human liver microsomes,,,22224,BAO_0000251
5076,,,,0,,,CHEMBL623448,,Autocuration,A,,1,,U,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,,22224,BAO_0000019
5077,,,,0,,,CHEMBL623449,,Autocuration,A,,1,,U,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,,22224,BAO_0000019
5078,,,,0,,,CHEMBL623450,,Autocuration,A,,1,,U,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,,22224,BAO_0000019
5079,,,2107.0,0,Liver,,CHEMBL623451,,Autocuration,A,,1,Microsomes,U,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,,22224,BAO_0000251
5080,,,,0,,,CHEMBL623452,,Autocuration,A,,1,,U,Metabolic stability (% remaining at 30 mins) in human S9.,,,22224,BAO_0000019
5081,,,,0,,,CHEMBL623453,,Autocuration,A,,1,,U,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,,22224,BAO_0000019
5082,,,2107.0,0,Liver,,CHEMBL623454,,Autocuration,A,,1,Microsomes,U,Percent parent compound remaining after 20 min incubation with human liver microsomes,,,22224,BAO_0000251
5083,,,2107.0,0,Liver,,CHEMBL623455,,Autocuration,A,,1,Microsomes,U,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,,22224,BAO_0000251
5084,,,2107.0,0,Liver,,CHEMBL624371,,Autocuration,A,,1,Microsomes,U,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,,22224,BAO_0000251
5085,,,,0,,,CHEMBL624372,,Autocuration,A,,1,,U,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,,22224,BAO_0000218
5086,,,,0,,,CHEMBL624373,,Autocuration,A,,1,,U,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,,22224,BAO_0000019
5087,,,,0,,,CHEMBL624374,,Autocuration,A,,1,,U,Percent remaining in human plasma after incubation for 60 min at 37 C.,,,22224,BAO_0000019
5088,,,,0,,,CHEMBL624556,,Autocuration,A,,1,,U,The percent remaining in human plasma after 30 min was determined,,,22224,BAO_0000019
5089,,,1969.0,0,Plasma,,CHEMBL624557,,Autocuration,A,,1,,U,Conversion rate of the prodrug in human plasma,,,22224,BAO_0000366
5090,,,1969.0,0,Plasma,,CHEMBL624558,,Autocuration,A,,1,,U,Conversion rate of the prodrug in human plasma; ND means no data,,,22224,BAO_0000366
5091,,,178.0,0,Blood,,CHEMBL624559,,Autocuration,A,,1,,U,Half life of compound was determined in human blood,,,22224,BAO_0000221
5092,,,,0,,,CHEMBL624560,,Autocuration,A,,1,,U,Half life of compound was determined in man with once daily dosing,,,22224,BAO_0000019
5093,,,,0,,In vitro,CHEMBL624561,,Autocuration,A,,1,Microsomes,U,Half life in human microsomes,,,22224,BAO_0000251
5094,,,1969.0,0,Plasma,,CHEMBL624562,,Autocuration,A,,1,,U,Half life in human plasma,,,22224,BAO_0000366
5095,,,1969.0,0,Plasma,,CHEMBL624563,,Autocuration,A,,1,,U,Half life in human plasma; Not detected,,,22224,BAO_0000366
5096,,,,0,,In vivo,CHEMBL624564,,Autocuration,A,,1,,U,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,,22224,BAO_0000218
5097,,,2107.0,0,Liver,In vitro,CHEMBL624565,,Autocuration,A,,1,Microsomes,U,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,,22224,BAO_0000251
5098,,,1969.0,0,Plasma,,CHEMBL875152,,Autocuration,A,,1,,U,Half-life in human plasma,,,22224,BAO_0000366
5099,,,1969.0,0,Plasma,,CHEMBL624566,,Autocuration,A,,1,,U,Half-life of the parent prodrug in plasma,,,22224,BAO_0000366
5100,,,1969.0,0,Plasma,In vitro,CHEMBL873805,,Autocuration,A,,1,,U,In vitro half life in human plasma was determined,,,22224,BAO_0000366
5101,,,2107.0,0,Liver,In vitro,CHEMBL624567,,Autocuration,A,,1,Microsomes,U,The compound was tested In Vitro for half life in human liver microsomes.,,,22224,BAO_0000251
5102,,,,0,,In vivo,CHEMBL624568,,Autocuration,A,,1,,U,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,,22224,BAO_0000218
5103,,,,0,,In vivo,CHEMBL624569,,Autocuration,A,,1,,U,Observed volume of distribution,,,22224,BAO_0000218
5104,,,,0,,In vivo,CHEMBL624570,,Autocuration,A,,1,,U,Oral bioavailability in human,,,22224,BAO_0000218
5105,,,,0,,,CHEMBL624571,,Autocuration,A,,1,,U,Tested for human plasma protein binding of the compound,,,22224,BAO_0000019
5106,,,,0,,,CHEMBL624572,,Autocuration,A,,1,,U,"First order rate constant, k was determined in human plasma",,,22224,BAO_0000019
5107,,,,0,,,CHEMBL624573,,Autocuration,A,,1,,U,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,22224,BAO_0000019
5108,,,,0,,,CHEMBL875153,,Autocuration,A,,1,,U,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,22224,BAO_0000019
5109,,,2107.0,0,Liver,,CHEMBL624574,,Autocuration,A,,1,Microsomes,U,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,22224,BAO_0000251
5110,,,,0,,,CHEMBL624575,,Autocuration,A,,1,,U,The compound was tested for the plasma binding in human,,,22224,BAO_0000019
5111,,,,0,,,CHEMBL624576,,Autocuration,A,,1,,U,Plasma protein binding (human),,,22224,BAO_0000019
5112,,,2107.0,0,Liver,In vitro,CHEMBL624577,,Autocuration,A,,1,Microsomes,U,Compound was evaluated for half-life in human liver microsomes,,,22224,BAO_0000251
5113,,,178.0,0,Blood,In vitro,CHEMBL624578,,Autocuration,A,,1,,U,Half life measured in vitro for its stability in human blood,,,22224,BAO_0000221
5114,,,1977.0,0,Serum,,CHEMBL622796,,Autocuration,A,,1,,U,Half life in human serum,,,22224,BAO_0000019
5115,,,1977.0,0,Serum,,CHEMBL622797,,Autocuration,A,,1,,U,Half life in human serum; ND=not determined,,,22224,BAO_0000019
5116,,,,0,,,CHEMBL622798,,Autocuration,A,,1,,U,Half life were determined in CEM-SS cell extract in decomposition step 1,,,22224,BAO_0000019
5117,,,,0,,,CHEMBL622799,,Autocuration,A,,1,,U,Half life were determined in CEM-SS cell extract in decomposition step 2,,,22224,BAO_0000019
5118,,,1969.0,0,Plasma,,CHEMBL622800,,Autocuration,A,,1,,U,Half life of the in human plasma,,,22224,BAO_0000366
5119,,,,0,,In vitro,CHEMBL622801,,Autocuration,A,,1,S9,U,Half life period in human hepatic S9 fraction was determined,,,22224,BAO_0000220
5120,,,2107.0,0,Liver,In vitro,CHEMBL622802,,Autocuration,A,,1,Microsomes,U,Half life period in human liver microsome was determined,,,22224,BAO_0000251
5121,,,,0,,,CHEMBL622803,,Autocuration,A,,1,,U,Half life period was determined; 6-7,,,22224,BAO_0000019
5122,,,,0,,,CHEMBL875154,,Autocuration,A,,1,,U,Half life period was evaluated in human,,,22224,BAO_0000019
5123,,,1969.0,0,Plasma,,CHEMBL622804,,Autocuration,A,,1,,U,Half life time in human plasma,,,22224,BAO_0000366
5124,,,955.0,1,Brain,In vivo,CHEMBL622805,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5125,,,948.0,1,Heart,In vivo,CHEMBL622611,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5126,,,948.0,1,Heart,In vivo,CHEMBL622612,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5127,,,2113.0,1,Kidney,In vivo,CHEMBL875160,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5128,,,2113.0,1,Kidney,In vivo,CHEMBL622613,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,50594,BAO_0000218
5129,,,2113.0,1,Kidney,In vivo,CHEMBL622614,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5130,,,2107.0,1,Liver,In vivo,CHEMBL622615,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5131,,,2107.0,1,Liver,In vivo,CHEMBL622616,,Intermediate,A,,1,,N,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,50594,BAO_0000218
5132,,,2107.0,1,Liver,In vivo,CHEMBL622617,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5133,,,2106.0,1,Spleen,In vivo,CHEMBL622618,,Intermediate,A,,1,,N,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,50594,BAO_0000218
5134,,,2106.0,1,Spleen,In vivo,CHEMBL622619,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,50594,BAO_0000218
5135,,,2106.0,1,Spleen,In vivo,CHEMBL622620,,Intermediate,A,,1,,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5136,,,955.0,1,Brain,In vivo,CHEMBL622621,,Intermediate,A,,1,,N,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
5137,,,178.0,1,Blood,In vivo,CHEMBL622622,,Intermediate,A,,1,,N,Biodistribution of compound (oxidized form) in blood tissue,,,50594,BAO_0000218
5138,,,178.0,1,Blood,In vivo,CHEMBL622623,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5139,,,178.0,1,Blood,In vivo,CHEMBL622624,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,50594,BAO_0000218
5140,,,178.0,1,Blood,In vivo,CHEMBL622625,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
5141,,,178.0,1,Blood,In vivo,CHEMBL622626,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5142,,,178.0,1,Blood,In vivo,CHEMBL622627,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,50594,BAO_0000218
5143,,,955.0,1,Brain,In vivo,CHEMBL622628,,Intermediate,A,,1,,N,Biodistribution of compound (oxidized form) in brain tissue of mice,,,50594,BAO_0000218
5144,,,955.0,1,Brain,In vivo,CHEMBL622629,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5145,,,955.0,1,Brain,In vivo,CHEMBL622630,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
5146,,,955.0,1,Brain,In vivo,CHEMBL622631,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5147,,,955.0,1,Brain,In vivo,CHEMBL622632,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,50594,BAO_0000218
5148,,,955.0,1,Brain,In vivo,CHEMBL622633,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,50594,BAO_0000218
5149,,,948.0,1,Heart,In vivo,CHEMBL622634,,Intermediate,A,,1,,N,Biodistribution of compound (oxidized form) in heart tissue of mice,,,50594,BAO_0000218
5150,,,948.0,1,Heart,In vivo,CHEMBL622635,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5151,,,948.0,1,Heart,In vivo,CHEMBL875161,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5152,,,948.0,1,Heart,In vivo,CHEMBL622636,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
5153,,,948.0,1,Heart,In vivo,CHEMBL623335,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5154,,,948.0,1,Heart,In vivo,CHEMBL623336,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,50594,BAO_0000218
5155,,,2113.0,1,Kidney,In vivo,CHEMBL623337,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5156,,,2113.0,1,Kidney,In vivo,CHEMBL623338,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,50594,BAO_0000218
5157,,,2113.0,1,Kidney,In vivo,CHEMBL623339,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
5158,,,2113.0,1,Kidney,In vivo,CHEMBL623524,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5159,,,2113.0,1,Kidney,In vivo,CHEMBL623525,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,50594,BAO_0000218
5160,,,2107.0,1,Liver,In vivo,CHEMBL623526,,Intermediate,A,,1,,N,Biodistribution of compound (oxidized form) in liver tissue,,,50594,BAO_0000218
5161,,,2107.0,1,Liver,In vivo,CHEMBL623527,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
5162,,,2107.0,1,Liver,In vivo,CHEMBL623528,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
5163,500.0,,,1,,,CHEMBL624615,,Intermediate,F,,1,,N,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,A-431,80852,BAO_0000219
5164,500.0,,,1,,,CHEMBL621672,,Intermediate,F,,1,,N,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,A-431,80852,BAO_0000219
5165,500.0,,,1,,,CHEMBL621673,,Expert,F,,1,,N,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,A-431,80852,BAO_0000218
5166,500.0,,,1,,,CHEMBL621674,,Expert,F,,1,,N,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,A-431,80852,BAO_0000218
5167,500.0,,,9,,,CHEMBL884002,,Expert,F,,1,,D,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,A-431,9,BAO_0000219
5168,500.0,,,1,,,CHEMBL621850,,Intermediate,F,,1,,N,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,A-431,80852,BAO_0000219
5169,500.0,,,1,,,CHEMBL621851,,Intermediate,F,,1,,N,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,A-431,80852,BAO_0000219
5170,500.0,,,9,,,CHEMBL621852,,Expert,F,,1,,D,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,A-431,9,BAO_0000219
5171,500.0,,,9,,,CHEMBL621853,,Expert,F,,1,,D,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,A-431,9,BAO_0000219
5172,500.0,,,1,,,CHEMBL621854,,Expert,F,,1,,N,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,A-431,80852,BAO_0000218
5173,500.0,,,1,,,CHEMBL621855,,Expert,F,,1,,N,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,A-431,80852,BAO_0000218
5174,500.0,,,1,,,CHEMBL623724,,Expert,F,,1,,N,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,A-431,80852,BAO_0000218
5175,500.0,,,1,,,CHEMBL623725,,Expert,F,,1,,N,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,A-431,80852,BAO_0000218
5176,500.0,,,1,,,CHEMBL623726,,Expert,F,,1,,N,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,A-431,80852,BAO_0000218
5177,500.0,,,9,,,CHEMBL623727,,Expert,F,,1,,D,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,A-431,9,BAO_0000219
5178,500.0,,,8,,,CHEMBL623728,,Expert,F,,1,,H,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,A-431,9,BAO_0000219
5179,500.0,,,1,,,CHEMBL623729,,Expert,F,,1,,N,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,A-431,80852,BAO_0000218
5180,500.0,,,1,,,CHEMBL623730,,Expert,F,,1,,N,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,A-431,80852,BAO_0000218
5181,500.0,,,1,,,CHEMBL623731,,Expert,F,,1,,N,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,A-431,80852,BAO_0000218
5182,500.0,,,1,,,CHEMBL623732,,Expert,F,,1,,N,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,A-431,80852,BAO_0000218
5183,500.0,,,1,,,CHEMBL623733,,Expert,F,,1,,N,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,A-431,80852,BAO_0000218
5184,500.0,,,1,,,CHEMBL623734,,Expert,F,,1,,N,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,A-431,80852,BAO_0000218
5185,500.0,,,1,,,CHEMBL623735,,Expert,F,,1,,N,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,A-431,80852,BAO_0000218
5186,500.0,,,1,,,CHEMBL623736,,Expert,F,,1,,N,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,A-431,80852,BAO_0000219
5187,500.0,,,1,,,CHEMBL623737,,Intermediate,F,,1,,N,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,A-431,80852,BAO_0000219
5188,500.0,,,1,,,CHEMBL623738,,Intermediate,F,,1,,N,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,A-431,80852,BAO_0000219
5189,500.0,,,1,,,CHEMBL875168,,Intermediate,F,,1,,N,Dose giving a 50% decrease in the living cell number (A437 cells),,A-431,80852,BAO_0000219
5190,646.0,,,1,,,CHEMBL623739,,Expert,F,,1,,N,In vitro inhibitory concentration against proliferation of A459 cell line.,,A549,80682,BAO_0000219
5191,646.0,,,1,,,CHEMBL623740,,Intermediate,F,,1,,N,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,A549,80682,BAO_0000219
5192,646.0,,,1,,,CHEMBL624424,,Intermediate,F,,1,,N,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,A549,80682,BAO_0000219
5193,624.0,,,1,,,CHEMBL624425,,Intermediate,F,,1,,N,In vitro antitumor activity against renal A498 tumor cell lines,,A498,80021,BAO_0000219
5194,624.0,,,1,,,CHEMBL624426,,Intermediate,F,,1,,N,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,A498,80021,BAO_0000219
5195,624.0,,,1,,,CHEMBL624427,,Intermediate,F,,1,,N,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,A498,80021,BAO_0000219
5196,624.0,,,1,,,CHEMBL624428,,Intermediate,F,,1,,N,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,A498,80021,BAO_0000219
5197,624.0,,,1,,,CHEMBL624429,,Intermediate,F,,1,,N,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,A498,80021,BAO_0000219
5198,624.0,,,1,,,CHEMBL624620,,Intermediate,F,,1,,N,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,A498,80021,BAO_0000219
5199,624.0,,,1,,,CHEMBL624621,,Intermediate,F,,1,,N,Cytotoxicity on kidney carcinoma (A-498) cell line,,A498,80021,BAO_0000219
5200,624.0,,,1,,,CHEMBL624622,,Intermediate,F,,1,,N,Compound was evaluated against Human cell line renal A498,,A498,80021,BAO_0000219
5201,624.0,,,1,,,CHEMBL624623,,Intermediate,F,,1,,N,Compound was tested for inhibition of A498 human renal cancer cell line,,A498,80021,BAO_0000219
5202,624.0,,,1,,,CHEMBL874365,,Intermediate,F,,1,,N,Growth inhibitory activity against A498 human cancer cell line,,A498,80021,BAO_0000219
5203,624.0,,,1,,,CHEMBL624624,,Intermediate,F,,1,,N,In vitro antitumor activity against human renal A498 cell line,,A498,80021,BAO_0000219
5204,624.0,,,1,,,CHEMBL624625,,Intermediate,F,,1,,N,In vitro cytotoxic activity against renal (A498) cell line,,A498,80021,BAO_0000219
5205,624.0,,,1,,,CHEMBL624626,,Intermediate,F,,1,,N,In vitro cytotoxic activity against human renal cancer (A498) cell line,,A498,80021,BAO_0000219
5206,624.0,,,1,,,CHEMBL624627,,Intermediate,F,,1,,N,Tested for cytostatic activity against renal A498 cell line,,A498,80021,BAO_0000219
5207,624.0,,,1,,,CHEMBL883157,,Intermediate,F,,1,,N,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,A498,80021,BAO_0000219
5208,624.0,,,1,,,CHEMBL624628,,Expert,F,,1,,N,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,A498,80021,BAO_0000219
5209,,,,0,,In vivo,CHEMBL624629,,Autocuration,A,,1,,U,Cmax value after 2 mpk peroral administration to beagles,,,22224,BAO_0000218
5210,,,,0,,In vivo,CHEMBL623551,,Autocuration,A,,1,,U,Bioavailability,beagle,,22224,BAO_0000218
5211,,,,0,,In vivo,CHEMBL623552,,Autocuration,A,,1,,U,Bioavailability after 1 mpk peroral administration to beagles,beagle,,22224,BAO_0000218
5212,,,,0,,In vivo,CHEMBL623553,,Autocuration,A,,1,,U,Bioavailability after 2 mpk peroral administration to beagles,beagle,,22224,BAO_0000218
5213,,,,0,,,CHEMBL623554,,Autocuration,A,,1,,U,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,,22224,BAO_0000019
5214,,,,0,,,CHEMBL623555,,Autocuration,A,,1,,U,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,,22224,BAO_0000019
5215,,,,0,,,CHEMBL623556,,Autocuration,A,,1,,U,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,,22224,BAO_0000019
5216,,,,0,,,CHEMBL623557,,Autocuration,A,,1,,U,Solubility against bovine alpha-chymotrypsin,,,22224,BAO_0000019
5217,,,,0,,,CHEMBL623558,,Autocuration,A,,1,,U,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,22224,BAO_0000019
5218,,,,0,,,CHEMBL623559,,Autocuration,A,,1,,U,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,22224,BAO_0000019
5219,,,2106.0,0,Spleen,,CHEMBL623560,,Autocuration,A,,1,,U,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,,22224,BAO_0000221
5220,,,,0,,,CHEMBL623561,,Autocuration,A,,1,,U,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,,22224,BAO_0000019
5221,,,,0,,,CHEMBL623562,,Autocuration,A,,1,,U,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,,22224,BAO_0000019
5222,,,,0,,,CHEMBL623563,,Autocuration,A,,1,,U,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,,22224,BAO_0000019
5223,,,2106.0,0,Spleen,,CHEMBL623564,,Autocuration,A,,1,,U,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,,22224,BAO_0000221
5224,,,,0,,,CHEMBL873806,,Autocuration,A,,1,,U,Half life in presence of 2 mg/mL BSA at pH 8.8,,,22224,BAO_0000019
5225,,,,0,,,CHEMBL623565,,Autocuration,A,,1,,U,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,,22224,BAO_0000019
5226,,,,0,,,CHEMBL623566,,Autocuration,A,,1,,U,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,,22224,BAO_0000019
5227,,,,0,,,CHEMBL623567,,Autocuration,A,,1,,U,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,,22224,BAO_0000019
5228,,,,0,,,CHEMBL623568,,Autocuration,A,,1,,U,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,,22224,BAO_0000019
5229,,,1969.0,1,Plasma,,CHEMBL623569,,Intermediate,A,,1,,N,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,,50588,BAO_0000218
5230,,,1969.0,1,Plasma,,CHEMBL623570,,Intermediate,A,,1,,N,AUC after administration at 100 mg/kg/day in dogs,,,50588,BAO_0000218
5231,,,1969.0,1,Plasma,,CHEMBL624254,,Intermediate,A,,1,,N,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,,50588,BAO_0000218
5232,,,1969.0,1,Plasma,,CHEMBL624255,,Intermediate,A,,1,,N,AUC value after 15 mg/kg iv dose in Dogs,,,50588,BAO_0000218
5233,,,1969.0,1,Plasma,,CHEMBL624256,,Intermediate,A,,1,,N,AUC value after 30 mg/kg po dose in Dogs,,,50588,BAO_0000218
5234,,,1969.0,1,Plasma,,CHEMBL624257,,Intermediate,A,,1,,N,AUC value after administration of 4 mg/Kg oral dose in dog,,,50588,BAO_0000218
5235,,,1969.0,1,Plasma,,CHEMBL624258,,Intermediate,A,,1,,N,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,,50588,BAO_0000218
5236,,,,1,,,CHEMBL875277,,Intermediate,A,,1,,N,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,,50588,BAO_0000218
5237,,,,1,,,CHEMBL622667,,Intermediate,A,,1,,N,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,,50588,BAO_0000218
5238,,,,1,,,CHEMBL622668,,Intermediate,A,,1,,N,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,,50588,BAO_0000218
5239,,,,1,,,CHEMBL622669,,Intermediate,A,,1,,N,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,,50588,BAO_0000218
5240,,,,1,,,CHEMBL622670,,Intermediate,A,,1,,N,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,,50588,BAO_0000218
5241,,,,1,,,CHEMBL622671,,Intermediate,A,,1,,N,Area under curve determined in dogs after oral administration of 10 mg/kg,,,50588,BAO_0000218
5242,,,,1,,,CHEMBL622672,,Intermediate,A,,1,,N,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,50588,BAO_0000218
5243,,,,1,,,CHEMBL622673,,Expert,A,,1,,N,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,,50588,BAO_0000218
5244,,,,1,,,CHEMBL622674,,Expert,A,,1,,N,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,,50588,BAO_0000218
5245,,,,1,,,CHEMBL622675,,Intermediate,A,,1,,N,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,50588,BAO_0000218
5246,,,,1,,,CHEMBL622676,,Intermediate,A,,1,,N,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,,50588,BAO_0000218
5247,,,,1,,,CHEMBL622677,,Intermediate,A,,1,,N,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,50588,BAO_0000218
5248,,,,1,,,CHEMBL622678,,Intermediate,A,,1,,N,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,,50588,BAO_0000218
5249,,,,1,,,CHEMBL622679,,Intermediate,A,,1,,N,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,,50588,BAO_0000218
5250,,,,1,,,CHEMBL622680,,Intermediate,A,,1,,N,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,50588,BAO_0000218
5251,,,,1,,,CHEMBL622681,,Intermediate,A,,1,,N,Area under curve was determine after peroral administration at 10 mpk in dog,,,50588,BAO_0000218
5252,,,,1,,,CHEMBL875278,,Intermediate,A,,1,,N,Area under curve was determine after peroral administration at 5 mpk in dog,,,50588,BAO_0000218
5253,,,,1,,,CHEMBL622682,,Intermediate,A,,1,,N,Area under curve was determined,,,50588,BAO_0000218
5254,,,,1,,,CHEMBL622683,,Intermediate,A,,1,,N,Area under curve in dogs,,,50588,BAO_0000218
5255,,,,1,,,CHEMBL622684,,Intermediate,A,,1,,N,Area under curve in dogs at 10 mg/kg dose fo oral administration,,,50588,BAO_0000218
5256,,,,1,,,CHEMBL622685,,Intermediate,A,,1,,N,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,,50588,BAO_0000218
5257,,,,1,,,CHEMBL622686,,Intermediate,A,,1,,N,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,,50588,BAO_0000218
5258,,,,1,,,CHEMBL618344,,Intermediate,A,,1,,N,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,50588,BAO_0000218
5259,,,,1,,,CHEMBL875582,,Intermediate,A,,1,,N,Area under curve value in dog at a dose of 5 mg/kg,,,50588,BAO_0000218
5260,,,,1,,,CHEMBL618345,,Intermediate,A,,1,,N,Area under curve was determined after 0.1 mg/kg iv administration in dog,,,50588,BAO_0000218
5261,,,,1,,,CHEMBL618346,,Intermediate,A,,1,,N,Area under curve was determined after 0.3 mg/kg po administration in dog,,,50588,BAO_0000218
5262,,,,1,,,CHEMBL618347,,Intermediate,A,,1,,N,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,,50588,BAO_0000218
5263,,,,1,,,CHEMBL618348,,Intermediate,A,,1,,N,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,,50588,BAO_0000218
5264,,,,0,,,CHEMBL618349,,Autocuration,A,,1,,U,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,,22224,BAO_0000019
5265,,,,0,,,CHEMBL618350,,Autocuration,A,,1,,U,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,22224,BAO_0000019
5266,,,,0,,,CHEMBL618351,,Autocuration,A,,1,,U,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,,22224,BAO_0000019
5267,,,,0,,,CHEMBL618352,,Autocuration,A,,1,,U,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,,22224,BAO_0000019
5268,,,178.0,0,Blood,,CHEMBL873494,,Autocuration,A,,1,,U,Time taken to reduce 50% of the concentration of compound in blood plasma,,,22224,BAO_0000221
5269,,,1969.0,0,Plasma,,CHEMBL618353,,Autocuration,A,,1,,U,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,22224,BAO_0000366
5270,,,1969.0,0,Plasma,,CHEMBL618354,,Autocuration,A,,1,,U,Half life in human plasma,,,22224,BAO_0000366
5271,,,1969.0,0,Plasma,,CHEMBL875583,,Autocuration,A,,1,,U,Half life in human plasma was reported,,,22224,BAO_0000366
5272,,,1977.0,0,Serum,,CHEMBL618355,,Autocuration,A,,1,,U,Half life in human serum,,,22224,BAO_0000019
5273,,,1969.0,0,Plasma,,CHEMBL618356,,Autocuration,A,,1,,U,Half life upon exposure to human plasma,,,22224,BAO_0000366
5274,,,,0,,In vitro,CHEMBL618357,,Autocuration,A,,1,Microsomes,U,t1/2 in human microsomes,,,22224,BAO_0000251
5275,,,1969.0,0,Plasma,,CHEMBL618358,,Autocuration,A,,1,,U,Half life period in 80% human plasma at 37 degree Centigrade,,,22224,BAO_0000366
5276,,,14.0,0,Zone of skin,,CHEMBL618359,,Autocuration,A,,1,,U,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,,22224,BAO_0000221
5277,,,1969.0,0,Plasma,In vitro,CHEMBL618360,,Autocuration,A,,1,,U,Half-life measured in in vitro Cathepsin B assay in human plasma,,,22224,BAO_0000366
5278,,,,0,,,CHEMBL618361,,Autocuration,A,,1,,U,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,,22224,BAO_0000019
5279,,,2107.0,0,Liver,In vitro,CHEMBL618362,,Autocuration,A,,1,Microsomes,U,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,,22224,BAO_0000251
5280,,,1969.0,0,Plasma,,CHEMBL618363,,Autocuration,A,,1,,U,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,22224,BAO_0000366
5281,,,1969.0,0,Plasma,,CHEMBL618364,,Autocuration,A,,1,,U,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,22224,BAO_0000366
5282,,,1969.0,0,Plasma,,CHEMBL875584,,Autocuration,A,,1,,U,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,22224,BAO_0000366
5283,,,,0,,,CHEMBL618365,,Autocuration,A,,1,,U,Half-life in the CEM cell extracts,,,22224,BAO_0000019
5284,,,1969.0,0,Plasma,,CHEMBL873495,,Autocuration,A,,1,,U,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,,22224,BAO_0000366
5285,,,1969.0,0,Plasma,,CHEMBL618366,,Autocuration,A,,1,,U,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,,22224,BAO_0000366
5286,,,,0,,,CHEMBL618367,,Autocuration,A,,1,,U,Half-life was determined,,,22224,BAO_0000019
5287,,,178.0,0,Blood,,CHEMBL618368,,Autocuration,A,,1,,U,Half-life (human blood stability),,,22224,BAO_0000221
5288,,,178.0,0,Blood,,CHEMBL618369,,Autocuration,A,,1,,U,Half-life (human blood stability); no data,,,22224,BAO_0000221
5289,,,1969.0,0,Plasma,,CHEMBL618370,,Autocuration,A,,1,,U,Half-life in human plasma,,,22224,BAO_0000366
5290,,,,0,,,CHEMBL618371,,Autocuration,A,,1,,U,CYP3A4 metabolism half-life (t1/2),,,22224,BAO_0000019
5291,,,178.0,0,Blood,,CHEMBL618372,,Autocuration,A,,1,,U,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,,22224,BAO_0000221
5292,,,1969.0,0,Plasma,In vitro,CHEMBL618373,,Autocuration,A,,1,,U,In vitro half life in human plasma,,,22224,BAO_0000366
5293,,,1969.0,0,Plasma,In vitro,CHEMBL618374,,Autocuration,A,,1,,U,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,,22224,BAO_0000366
5294,,,1969.0,0,Plasma,In vitro,CHEMBL618375,,Autocuration,A,,1,,U,In vitro hydrolysis in human plasma,,,22224,BAO_0000366
5295,,,1969.0,0,Plasma,In vitro,CHEMBL618376,,Autocuration,A,,1,,U,In vitro hydrolysis in human plasma; no data,,,22224,BAO_0000366
5296,,,2107.0,0,Liver,In vitro,CHEMBL618377,,Autocuration,A,,1,Microsomes,U,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,,22224,BAO_0000251
5297,,,1969.0,0,Plasma,,CHEMBL618378,,Autocuration,A,,1,,U,Plasma half life in human,,,22224,BAO_0000366
5298,,,1969.0,0,Plasma,,CHEMBL618379,,Autocuration,A,,1,,U,Stability after incubation with human plasma (at 37 degree C),,,22224,BAO_0000366
5299,,,1969.0,0,Plasma,,CHEMBL618380,,Autocuration,A,,1,,U,T1/2 was evaluated in human plasma,,,22224,BAO_0000366
5300,,,1969.0,0,Plasma,,CHEMBL618381,,Autocuration,A,,1,,U,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,22224,BAO_0000366
5301,,,1969.0,0,Plasma,,CHEMBL618382,,Autocuration,A,,1,,U,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,,22224,BAO_0000366
5302,,,,0,,,CHEMBL618383,,Autocuration,A,,1,,U,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,22224,BAO_0000019
5303,,,,0,,In vitro,CHEMBL618384,,Autocuration,A,,1,,U,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,,22224,BAO_0000019
5304,,,,0,,In vitro,CHEMBL618385,,Autocuration,A,,1,,U,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,,22224,BAO_0000019
5305,,,1969.0,0,Plasma,,CHEMBL619099,,Autocuration,A,,1,,U,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,,22224,BAO_0000366
5306,,,1969.0,0,Plasma,,CHEMBL619100,,Autocuration,A,,1,,U,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,,22224,BAO_0000366
5307,,,,0,,,CHEMBL619101,,Autocuration,A,,1,,U,Time taken for 50% to be consumed by serum PON1 was determined,,,22224,BAO_0000019
5308,,,,0,,,CHEMBL619102,,Autocuration,A,,1,,U,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,,22224,BAO_0000019
5309,,,2107.0,0,Liver,,CHEMBL619103,,Autocuration,A,,1,Microsomes,U,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,22224,BAO_0000251
5310,,,,0,,,CHEMBL619268,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224,BAO_0000218
5311,,,,0,,,CHEMBL619269,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224,BAO_0000218
5312,,,,0,,,CHEMBL619270,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224,BAO_0000218
5313,,,,0,,,CHEMBL619271,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224,BAO_0000218
5314,,,,0,,,CHEMBL875585,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224,BAO_0000218
5315,,,,0,,,CHEMBL619272,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,22224,BAO_0000218
5316,391.0,,,1,,,CHEMBL619273,,Intermediate,F,,1,,N,Compound tested for growth inhibition of renal cancer cell line 786-0,,786-0,80640,BAO_0000219
5317,391.0,,,1,,,CHEMBL619274,,Intermediate,F,,1,,N,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,786-0,80640,BAO_0000219
5318,391.0,,,1,,,CHEMBL619275,,Expert,F,,1,,N,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,786-0,80640,BAO_0000219
5319,391.0,,,1,,,CHEMBL619276,,Intermediate,F,,1,,N,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,786-0,80640,BAO_0000219
5320,391.0,,,1,,,CHEMBL619277,,Intermediate,F,,1,,N,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,786-0,80640,BAO_0000219
5321,391.0,,,1,,,CHEMBL619278,,Intermediate,F,,1,,N,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,786-0,80640,BAO_0000219
5322,391.0,,,1,,,CHEMBL619279,,Intermediate,F,,1,,N,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,786-0,80640,BAO_0000219
5323,391.0,,,1,,,CHEMBL858458,,Intermediate,F,,1,,N,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,786-0,80640,BAO_0000219
5324,391.0,,,1,,,CHEMBL619280,,Expert,F,,1,,N,Cytotoxic effect on renal cancer line 786-0,,786-0,80640,BAO_0000219
5325,391.0,,,1,,,CHEMBL619281,,Intermediate,F,,1,,N,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,786-0,80640,BAO_0000219
5326,391.0,,,1,,,CHEMBL619282,,Intermediate,F,,1,,N,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,786-0,80640,BAO_0000219
5327,391.0,,,1,,,CHEMBL619283,,Intermediate,F,,1,,N,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,786-0,80640,BAO_0000219
5328,391.0,,,1,,,CHEMBL619284,,Intermediate,F,,1,,N,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,786-0,80640,BAO_0000219
5329,391.0,,,1,,,CHEMBL619285,,Intermediate,F,,1,,N,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,786-0,80640,BAO_0000219
5330,391.0,,,1,,,CHEMBL619286,,Intermediate,F,,1,,N,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,786-0,80640,BAO_0000219
5331,391.0,,,1,,,CHEMBL619287,,Intermediate,F,,1,,N,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,786-0,80640,BAO_0000219
5332,391.0,,,1,,,CHEMBL857455,,Intermediate,F,,1,,N,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,786-0,80640,BAO_0000219
5333,391.0,,,1,,,CHEMBL883801,,Intermediate,F,,1,,N,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,786-0,80640,BAO_0000219
5334,972.0,,,1,,,CHEMBL619288,,Intermediate,F,,1,,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,791T cell line,80641,BAO_0000219
5335,972.0,,,1,,,CHEMBL619289,,Intermediate,F,,1,,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,791T cell line,80641,BAO_0000219
5336,972.0,,,1,,,CHEMBL619290,,Intermediate,F,,1,,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,791T cell line,80641,BAO_0000219
5337,972.0,,,1,,,CHEMBL619291,,Intermediate,F,,1,,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,791T cell line,80641,BAO_0000219
5338,972.0,,,1,,,CHEMBL619292,,Intermediate,F,,1,,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,791T cell line,80641,BAO_0000219
5339,972.0,,,1,,,CHEMBL619293,,Intermediate,F,,1,,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,791T cell line,80641,BAO_0000219
5340,972.0,,,1,,,CHEMBL619294,,Intermediate,F,,1,,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,791T cell line,80641,BAO_0000219
5341,972.0,,,1,,,CHEMBL619295,,Intermediate,F,,1,,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,791T cell line,80641,BAO_0000219
5342,972.0,,,1,,,CHEMBL619296,,Intermediate,F,,1,,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,791T cell line,80641,BAO_0000219
5343,972.0,,,1,,,CHEMBL619297,,Intermediate,F,,1,,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,791T cell line,80641,BAO_0000219
5344,391.0,,,1,,,CHEMBL619298,,Intermediate,F,,1,,N,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,786-0,80640,BAO_0000219
5345,,,,0,,,CHEMBL619299,,Intermediate,F,,1,,U,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,,22226,BAO_0000019
5346,741.0,,,1,,,CHEMBL619300,,Expert,F,,1,,N,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,RPMI-8226,80433,BAO_0000219
5347,741.0,,,1,,,CHEMBL619301,,Expert,F,,1,,N,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,RPMI-8226,80433,BAO_0000219
5348,741.0,,,1,,,CHEMBL619302,,Intermediate,F,,1,,N,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,RPMI-8226,80433,BAO_0000219
5349,741.0,,,1,,,CHEMBL619303,,Intermediate,F,,1,,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,RPMI-8226,80433,BAO_0000219
5350,741.0,,,1,,,CHEMBL619304,,Intermediate,F,,1,,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,RPMI-8226,80433,BAO_0000219
5351,741.0,,,1,,,CHEMBL857706,,Intermediate,F,,1,,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,RPMI-8226,80433,BAO_0000219
5352,741.0,,,1,,,CHEMBL619305,,Intermediate,F,,1,,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,RPMI-8226,80433,BAO_0000219
5353,741.0,,,1,,,CHEMBL619306,,Intermediate,F,,1,,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433,BAO_0000219
5354,741.0,,,1,,,CHEMBL619307,,Intermediate,F,,1,,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,RPMI-8226,80433,BAO_0000219
5355,741.0,,,1,,,CHEMBL619308,,Intermediate,F,,1,,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,RPMI-8226,80433,BAO_0000219
5356,741.0,,,1,,,CHEMBL619309,,Intermediate,F,,1,,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,RPMI-8226,80433,BAO_0000219
5357,741.0,,,1,,,CHEMBL619310,,Intermediate,F,,1,,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433,BAO_0000219
5358,624.0,,,1,,,CHEMBL619311,,Intermediate,F,,1,,N,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,A498,80021,BAO_0000219
5359,624.0,,,1,,,CHEMBL619312,,Intermediate,F,,1,,N,Compound was tested for the growth inhibition of A498 renal tumor cell line,,A498,80021,BAO_0000219
5360,624.0,,,1,,,CHEMBL619313,,Intermediate,F,,1,,N,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,A498,80021,BAO_0000219
5361,624.0,,,1,,,CHEMBL619314,,Intermediate,F,,1,,N,In vitro inhibitory concentration against renal cancer cell line A498,,A498,80021,BAO_0000219
5362,624.0,,,1,,,CHEMBL619959,,Intermediate,F,,1,,N,Cytotoxicity against A 498 tumor cell line,,A498,80021,BAO_0000219
5363,624.0,,,1,,,CHEMBL619960,,Intermediate,F,,1,,N,In vitro antitumor activity against A498 human cancer cell line,,A498,80021,BAO_0000219
5364,624.0,,,1,,,CHEMBL619961,,Intermediate,F,,1,,N,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,A498,80021,BAO_0000219
5365,624.0,,,1,,,CHEMBL619962,,Intermediate,F,,1,,N,Inhibitory dose required against A498 human tumor cell lines,,A498,80021,BAO_0000219
5366,624.0,,,1,,,CHEMBL875586,,Intermediate,F,,1,,N,Anticancer activity against one renal cancer (A498 cell line),,A498,80021,BAO_0000219
5367,624.0,,,1,,,CHEMBL619963,,Intermediate,F,,1,,N,In vitro cytotoxicity against melanoma A498 cell line,,A498,80021,BAO_0000219
5368,624.0,,,1,,,CHEMBL619964,,Intermediate,F,,1,,N,Compound was tested for growth inhibitory activity against A498 cell line,,A498,80021,BAO_0000219
5369,624.0,,,1,,,CHEMBL620108,,Intermediate,F,,1,,N,Compound tested for growth inhibition of renal cancer cell line A498,,A498,80021,BAO_0000219
5370,624.0,,,1,,,CHEMBL620109,,Intermediate,F,,1,,N,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,A498,80021,BAO_0000219
5371,624.0,,,1,,,CHEMBL620110,,Intermediate,F,,1,,N,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,A498,80021,BAO_0000219
5372,624.0,,,1,,,CHEMBL620111,,Intermediate,F,,1,,N,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,A498,80021,BAO_0000219
5373,624.0,,,1,,,CHEMBL620112,,Intermediate,F,,1,,N,Tested for cytotoxicity against A498 cell lines in renal cancer,,A498,80021,BAO_0000219
5374,624.0,,,1,,,CHEMBL620113,,Intermediate,F,,1,,N,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,A498,80021,BAO_0000219
5375,624.0,,,1,,,CHEMBL620114,,Expert,F,,1,,N,Cytotoxic effect on renal cancer lines A498,,A498,80021,BAO_0000219
5376,624.0,,,1,,,CHEMBL620115,,Intermediate,F,,1,,N,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,A498,80021,BAO_0000219
5377,624.0,,,1,,,CHEMBL620116,,Intermediate,F,,1,,N,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,A498,80021,BAO_0000219
5378,624.0,,,1,,,CHEMBL620117,,Intermediate,F,,1,,N,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,A498,80021,BAO_0000219
5379,624.0,,,1,,,CHEMBL620118,,Intermediate,F,,1,,N,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,A498,80021,BAO_0000219
5380,624.0,,,1,,,CHEMBL620119,,Intermediate,F,,1,,N,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,A498,80021,BAO_0000219
5381,624.0,,,1,,,CHEMBL620120,,Intermediate,F,,1,,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,A498,80021,BAO_0000219
5382,646.0,,,1,,,CHEMBL620121,,Expert,F,,1,,N,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,A549,80682,BAO_0000219
5383,646.0,,,1,,,CHEMBL620122,,Intermediate,F,,1,,N,Antitumor activity against A549 human lung carcinoma cell line,,A549,80682,BAO_0000219
5384,646.0,,,1,,,CHEMBL620123,,Intermediate,F,,1,,N,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,A549,80682,BAO_0000219
5385,646.0,,,1,,,CHEMBL620124,,Intermediate,F,,1,,N,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,A549,80682,BAO_0000219
5386,646.0,,,1,,,CHEMBL620125,,Intermediate,F,,1,,N,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,A549,80682,BAO_0000219
5387,646.0,,,1,,,CHEMBL620126,,Expert,F,,1,,N,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,A549,80682,BAO_0000219
5388,646.0,,,1,,,CHEMBL883027,,Intermediate,F,,1,,N,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A549,80682,BAO_0000219
5389,646.0,,,1,,,CHEMBL620127,,Expert,F,,1,,N,In vitro cytotoxic activity against human lung A549 cell line,,A549,80682,BAO_0000219
5390,646.0,,,1,,,CHEMBL620128,,Intermediate,F,,1,,N,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,A549,80682,BAO_0000219
5391,646.0,,,1,,,CHEMBL620129,,Intermediate,F,,1,,N,In vitro cytotoxic activity against human lung A549 cell line),,A549,80682,BAO_0000219
5392,646.0,,,1,,,CHEMBL620130,,Intermediate,F,,1,,N,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,A549,80682,BAO_0000219
5393,646.0,,,1,,,CHEMBL620131,,Expert,F,,1,,N,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,A549,80682,BAO_0000219
5394,646.0,,,1,,,CHEMBL620132,,Intermediate,F,,1,,N,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,A549,80682,BAO_0000219
5395,646.0,,,1,,,CHEMBL620133,,Intermediate,F,,1,,N,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,A549,80682,BAO_0000219
5396,646.0,,,1,,,CHEMBL620134,,Expert,F,,1,,N,Inhibition of A549 human lung carcinoma cell proliferation,,A549,80682,BAO_0000219
5397,646.0,,,1,,,CHEMBL620135,,Intermediate,F,,1,,N,Inhibitory activity against A549 lung adenocarcinoma cell line,,A549,80682,BAO_0000219
5398,646.0,,,1,,,CHEMBL620136,,Intermediate,F,,1,,N,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,A549,80682,BAO_0000219
5399,646.0,,,1,,,CHEMBL620137,,Intermediate,F,,1,,N,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,A549,80682,BAO_0000219
5400,646.0,,,1,,,CHEMBL620268,,Intermediate,F,,1,,N,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,A549,80682,BAO_0000219
5401,646.0,,,1,,,CHEMBL620269,,Intermediate,F,,1,,N,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A549,80682,BAO_0000219
5402,646.0,,,1,,,CHEMBL620270,,Intermediate,F,,1,,N,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,A549,80682,BAO_0000219
5403,646.0,,,1,,,CHEMBL620271,,Intermediate,F,,1,,N,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,A549,80682,BAO_0000219
5404,646.0,,,1,,,CHEMBL620272,,Expert,F,,1,,N,Inhibition of A549 cancer cell proliferation,,A549,80682,BAO_0000219
5405,646.0,,,1,,,CHEMBL620273,,Expert,F,,1,,N,Inhibition of A549 cancer cell proliferation (Not tested),,A549,80682,BAO_0000219
5406,646.0,,,1,,,CHEMBL620274,,Intermediate,F,,1,,N,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,A549,80682,BAO_0000219
5407,646.0,,,1,,,CHEMBL620275,,Intermediate,F,,1,,N,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,A549,80682,BAO_0000219
5408,646.0,,,1,,,CHEMBL620276,,Intermediate,F,,1,,N,Antiproliferative potency determined as inhibitory concentration against A549 cells,,A549,80682,BAO_0000219
5409,646.0,,,1,,,CHEMBL620277,,Intermediate,F,,1,,N,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,A549,80682,BAO_0000219
5410,646.0,,,1,,,CHEMBL620278,,Intermediate,F,,1,,N,Cytotoxicity against Renal cell lines A549 was determined,,A549,80682,BAO_0000219
5411,,,,1,,,CHEMBL620279,,Intermediate,A,,1,,N,Area under curve was determined in dog after a 3 mg/kg of oral dose,,,50588,BAO_0000218
5412,,,,1,,,CHEMBL620280,,Intermediate,A,,1,,N,Area under curve was determined in dog after oral administration at 1 mg/kg,,,50588,BAO_0000218
5413,,,,1,,,CHEMBL620281,,Intermediate,A,,1,,N,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,50588,BAO_0000218
5414,,,,1,,,CHEMBL620282,,Intermediate,A,,1,,N,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,50588,BAO_0000218
5415,,,,1,,,CHEMBL621134,,Intermediate,A,,1,,N,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,,50588,BAO_0000218
5416,,,,1,,,CHEMBL621135,,Intermediate,A,,1,,N,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,,50588,BAO_0000218
5417,,,,1,,,CHEMBL621136,,Intermediate,A,,1,,N,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,,50588,BAO_0000218
5418,,,,1,,,CHEMBL621137,,Intermediate,A,,1,,N,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,,50588,BAO_0000218
5419,,,1969.0,1,Plasma,,CHEMBL621138,,Intermediate,A,,1,,N,Area under plasma concentration time curve in dog upon oral administration,,,50588,BAO_0000218
5420,,,1969.0,1,Plasma,,CHEMBL875587,,Intermediate,A,,1,,N,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,,50588,BAO_0000218
5421,,,,1,,,CHEMBL621139,,Intermediate,A,,1,,N,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,,50588,BAO_0000218
5422,,,,1,,,CHEMBL621140,,Intermediate,A,,1,,N,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,,50588,BAO_0000218
5423,,,,1,,,CHEMBL621141,,Intermediate,A,,1,,N,Area under the curve for the compound was obtained when tested in dog,,,50588,BAO_0000218
5424,,,,1,,,CHEMBL621142,,Intermediate,A,,1,,N,Area under the curve at a dose of 1 mg/kg,,,50588,BAO_0000218
5425,,,,1,,,CHEMBL621143,,Intermediate,A,,1,,N,Area under the curve at a dose of 1 mg/kg (oral),,,50588,BAO_0000218
5426,,,,1,,,CHEMBL621144,,Intermediate,A,,1,,N,Area under the curve at i.v. dose of 0.2 mg/kg,,,50588,BAO_0000218
5427,,,,1,,,CHEMBL621145,,Intermediate,A,,1,,N,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,,50588,BAO_0000218
5428,,,,1,,,CHEMBL621146,,Intermediate,A,,1,,N,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,,50588,BAO_0000218
5429,,,,1,,,CHEMBL622567,,Intermediate,A,,1,,N,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,,50588,BAO_0000218
5430,,,,1,,,CHEMBL622568,,Intermediate,A,,1,,N,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,,50588,BAO_0000218
5431,,,,1,,,CHEMBL622569,,Intermediate,A,,1,,N,Compound was evaluated for area under the curve in dog blood.,,,50588,BAO_0000218
5432,,,,1,,,CHEMBL622570,,Intermediate,A,,1,,N,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,,50588,BAO_0000218
5433,,,1969.0,1,Plasma,,CHEMBL622571,,Intermediate,A,,1,,N,AUC in dog after oral dose (1 mg/kg),,,50588,BAO_0000218
5434,,,,1,,,CHEMBL622572,,Intermediate,A,,1,,N,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,,50588,BAO_0000218
5435,,,,1,,,CHEMBL622573,,Intermediate,A,,1,,N,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,,50588,BAO_0000218
5436,,,,1,,,CHEMBL622574,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC after intravenous administration to dogs,,,50588,BAO_0000218
5437,,,,1,,,CHEMBL622575,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC after oral administration to dogs,,,50588,BAO_0000218
5438,,,,1,,,CHEMBL622576,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,,50588,BAO_0000218
5439,,,,1,,,CHEMBL622577,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,,50588,BAO_0000218
5440,,,,1,,,CHEMBL622578,,Intermediate,A,,1,,N,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,,50588,BAO_0000218
5441,,,,1,,,CHEMBL622579,,Intermediate,A,,1,,N,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,,50588,BAO_0000218
5442,,,,1,,,CHEMBL622580,,Intermediate,A,,1,,N,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,,50588,BAO_0000218
5443,,,,1,,,CHEMBL622581,,Intermediate,A,,1,,N,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,,50588,BAO_0000218
5444,,,,1,,,CHEMBL622582,,Intermediate,A,,1,,N,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,50588,BAO_0000218
5445,,,,1,,,CHEMBL622583,,Intermediate,A,,1,,N,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,50588,BAO_0000218
5446,,,,1,,,CHEMBL622584,,Intermediate,A,,1,,N,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,50588,BAO_0000218
5447,,,,1,,,CHEMBL622585,,Intermediate,A,,1,,N,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,50588,BAO_0000218
5448,,,,1,,,CHEMBL622586,,Intermediate,A,,1,,N,Compound was evaluated for oral bioavailability in dog; 90-100,,,50588,BAO_0000218
5449,,,,1,,,CHEMBL623281,,Intermediate,A,,1,,N,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,,50588,BAO_0000218
5450,,,,1,,,CHEMBL623282,,Intermediate,A,,1,,N,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,,50588,BAO_0000218
5451,,,,1,,,CHEMBL623283,,Intermediate,A,,1,,N,PAPP (membrane permeability) in dog kidney cell monolayer assay,,,50588,BAO_0000218
5452,,,,1,,,CHEMBL623284,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
5453,,,,1,,,CHEMBL623285,,Intermediate,A,,1,,N,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,,50588,BAO_0000218
5454,,,1969.0,1,Plasma,,CHEMBL623463,,Intermediate,A,,1,,N,Plasma protein binding towards dog plasma at 10 uM,,,50588,BAO_0000218
5455,,,1969.0,1,Plasma,,CHEMBL875952,,Intermediate,A,,1,,N,Plasma protein binding towards dog plasma at 100 uM,,,50588,BAO_0000218
5456,,,,1,,In vivo,CHEMBL621705,,Intermediate,A,,1,,N,Bioavailability in dog (dose 4 mg/kg p.o.),,,50588,BAO_0000218
5457,,,,1,,In vivo,CHEMBL621706,,Intermediate,A,,1,,N,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,,50588,BAO_0000218
5458,,,,1,,In vivo,CHEMBL621707,,Intermediate,A,,1,,N,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,,50588,BAO_0000218
5459,,,,1,,In vivo,CHEMBL621708,,Intermediate,A,,1,,N,Bioavailability in dogs,,,50588,BAO_0000218
5460,,,,1,,In vivo,CHEMBL621709,,Intermediate,A,,1,,N,Bioavailability,,,50588,BAO_0000218
5461,,,,1,,In vivo,CHEMBL621710,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 10 mg/kg),,,50588,BAO_0000218
5462,,,,1,,In vivo,CHEMBL621711,,Intermediate,A,,1,,N,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,,50588,BAO_0000218
5463,,,,1,,In vivo,CHEMBL621712,,Intermediate,A,,1,,N,Bioavailability in dog (dose 10.0 mg/kg p.o.),,,50588,BAO_0000218
5464,,,,1,,In vivo,CHEMBL621713,,Intermediate,A,,1,,N,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,,50588,BAO_0000218
5465,,,,1,,In vivo,CHEMBL621714,,Intermediate,A,,1,,N,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,,50588,BAO_0000218
5466,,,,0,,,CHEMBL621715,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224,BAO_0000218
5467,,,2107.0,0,Liver,,CHEMBL623717,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224,BAO_0000218
5468,,,2107.0,0,Liver,,CHEMBL623718,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,22224,BAO_0000218
5469,,,2107.0,0,Liver,,CHEMBL623719,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224,BAO_0000218
5470,,,,0,,,CHEMBL623720,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224,BAO_0000218
5471,,,,0,,,CHEMBL623721,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224,BAO_0000218
5472,,,2385.0,0,Muscle tissue,,CHEMBL623722,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224,BAO_0000218
5473,,,2385.0,0,Muscle tissue,,CHEMBL623723,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,22224,BAO_0000218
5474,,,2385.0,0,Muscle tissue,,CHEMBL618543,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224,BAO_0000218
5475,,,2106.0,0,Spleen,,CHEMBL618544,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224,BAO_0000218
5476,,,2106.0,0,Spleen,,CHEMBL875155,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224,BAO_0000218
5477,,,,0,,,CHEMBL618545,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224,BAO_0000218
5478,,,,0,,,CHEMBL618546,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,22224,BAO_0000218
5479,,,,0,,,CHEMBL623529,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224,BAO_0000218
5480,,,,0,,,CHEMBL623530,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,22224,BAO_0000218
5481,,,,0,,,CHEMBL621764,,Autocuration,A,,1,,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224,BAO_0000218
5482,,,,0,,,CHEMBL621765,,Autocuration,A,,1,,U,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,22224,BAO_0000019
5483,,,2037.0,0,Cerebellum,,CHEMBL621766,,Autocuration,A,,1,,U,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,22224,BAO_0000019
5484,,,1870.0,0,Frontal cortex,,CHEMBL621767,,Autocuration,A,,1,,U,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,22224,BAO_0000019
5485,,,,0,,,CHEMBL621768,,Autocuration,A,,1,,U,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,,22224,BAO_0000019
5486,,,2435.0,0,Striatum,,CHEMBL621769,,Autocuration,A,,1,,U,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,,22224,BAO_0000019
5487,,,,0,,,CHEMBL621770,,Autocuration,A,,1,,U,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,22224,BAO_0000019
5488,,,2037.0,0,Cerebellum,,CHEMBL621771,,Autocuration,A,,1,,U,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,22224,BAO_0000019
5489,,,1870.0,0,Frontal cortex,,CHEMBL621772,,Autocuration,A,,1,,U,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,22224,BAO_0000019
5490,,,,0,,,CHEMBL621773,,Autocuration,A,,1,,U,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,,22224,BAO_0000019
5491,,,2435.0,0,Striatum,,CHEMBL621774,,Autocuration,A,,1,,U,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,,22224,BAO_0000019
5492,,,,0,,,CHEMBL621775,,Autocuration,A,,1,,U,Compound was evaluated for oral bioavailability in rats,,,22224,BAO_0000218
5493,,,1969.0,0,Plasma,In vivo,CHEMBL621776,,Autocuration,A,,1,,U,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,,22224,BAO_0000218
5494,,,,0,,,CHEMBL621777,,Autocuration,A,,1,,U,Half life period was evaluated in monkey,,,22224,BAO_0000019
5495,,,,0,,In vivo,CHEMBL875162,,Autocuration,A,,1,,U,Half-life in rhesus monkeys by intravenous administration of dose,,,22224,BAO_0000218
5496,,,1969.0,1,Plasma,,CHEMBL621778,,Intermediate,A,,1,,N,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,,50594,BAO_0000218
5497,,,1969.0,1,Plasma,,CHEMBL621779,,Intermediate,A,,1,,N,AUC after intraperitoneal administration of 100 mg/kg in mice,,,50594,BAO_0000218
5498,,,1969.0,1,Plasma,,CHEMBL622479,,Intermediate,A,,1,,N,AUC value was determined after oral administration,,,50594,BAO_0000218
5499,,,,1,,,CHEMBL622480,,Intermediate,A,,1,,N,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,50594,BAO_0000218
5500,,,,1,,,CHEMBL622481,,Intermediate,A,,1,,N,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,50594,BAO_0000218
5501,,,,1,,,CHEMBL622482,,Intermediate,A,,1,,N,Area under curve by ioral administration in mouse,,,50594,BAO_0000218
5502,,,,1,,,CHEMBL622483,,Intermediate,A,,1,,N,Area under curve by iv administration in mouse,,,50594,BAO_0000218
5503,,,,1,,,CHEMBL622484,,Intermediate,A,,1,,N,Area under curve at 0-8 hr in IRC mice after peroral administration,,,50594,BAO_0000218
5504,,,,1,,,CHEMBL622641,,Intermediate,A,,1,,N,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,,50594,BAO_0000218
5505,,,,1,,,CHEMBL622642,,Intermediate,A,,1,,N,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,,50594,BAO_0000218
5506,,,,1,,,CHEMBL622643,,Intermediate,A,,1,,N,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,,50594,BAO_0000218
5507,,,,1,,,CHEMBL622644,,Intermediate,A,,1,,N,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,,50594,BAO_0000218
5508,741.0,,,1,,,CHEMBL622645,,Intermediate,F,,1,,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,RPMI-8226,80433,BAO_0000219
5509,741.0,,,1,,,CHEMBL622646,,Intermediate,F,,1,,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,RPMI-8226,80433,BAO_0000219
5510,741.0,,,1,,,CHEMBL621238,,Intermediate,F,,1,,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,RPMI-8226,80433,BAO_0000219
5511,741.0,,,1,,,CHEMBL621239,,Intermediate,F,,1,,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,RPMI-8226,80433,BAO_0000219
5512,741.0,,,1,,,CHEMBL621240,,Intermediate,F,,1,,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433,BAO_0000219
5513,741.0,,,1,,,CHEMBL621241,,Intermediate,F,,1,,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,RPMI-8226,80433,BAO_0000219
5514,741.0,,,1,,,CHEMBL621242,,Intermediate,F,,1,,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,RPMI-8226,80433,BAO_0000219
5515,741.0,,,1,,,CHEMBL620350,,Intermediate,F,,1,,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433,BAO_0000219
5516,741.0,,,1,,,CHEMBL620351,,Intermediate,F,,1,,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,RPMI-8226,80433,BAO_0000219
5517,741.0,,,1,,,CHEMBL620352,,Intermediate,F,,1,,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,RPMI-8226,80433,BAO_0000219
5518,741.0,,,1,,,CHEMBL620353,,Intermediate,F,,1,,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,RPMI-8226,80433,BAO_0000219
5519,741.0,,,1,,,CHEMBL620354,,Intermediate,F,,1,,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,RPMI-8226,80433,BAO_0000219
5520,741.0,,,1,,,CHEMBL620355,,Intermediate,F,,1,,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433,BAO_0000219
5521,741.0,,,1,,,CHEMBL620356,,Intermediate,F,,1,,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,RPMI-8226,80433,BAO_0000219
5522,741.0,,,1,,,CHEMBL620357,,Intermediate,F,,1,,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,RPMI-8226,80433,BAO_0000219
5523,741.0,,,1,,,CHEMBL620358,,Intermediate,F,,1,,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433,BAO_0000219
5524,741.0,,,1,,,CHEMBL620359,,Expert,F,,1,,N,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,RPMI-8226,80433,BAO_0000219
5525,741.0,,,1,,,CHEMBL620360,,Intermediate,F,,1,,N,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,RPMI-8226,80433,BAO_0000219
5526,741.0,,,1,,,CHEMBL620361,,Intermediate,F,,1,,N,Cytotoxicity of compound against 8226/DOX1V cells,,RPMI-8226,80433,BAO_0000219
5527,741.0,,,1,,,CHEMBL620362,,Intermediate,F,,1,,N,Cytotoxicity of compound against 8226/S cells,,RPMI-8226,80433,BAO_0000219
5528,741.0,,,1,,,CHEMBL620363,,Intermediate,F,,1,,N,Inhibitory concentration against 8226 myeloma cancer cell line,,RPMI-8226,80433,BAO_0000219
5529,741.0,,,1,,,CHEMBL620364,,Intermediate,F,,1,,N,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,RPMI-8226,80433,BAO_0000219
5530,854.0,,,1,,,CHEMBL620365,,Intermediate,F,,1,,N,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,833K,80647,BAO_0000219
5531,854.0,,,1,,,CHEMBL620366,,Intermediate,F,,1,,N,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,833K,80647,BAO_0000219
5532,854.0,,,1,,,CHEMBL620367,,Expert,F,,1,,N,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,833K,80647,BAO_0000219
5533,854.0,,,1,,,CHEMBL620368,,Intermediate,F,,1,,N,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,833K,80647,BAO_0000219
5534,,,,0,,,CHEMBL620369,,Autocuration,B,,1,,U,Inhibitory activity against caspase-1,,,22226,BAO_0000019
5535,,,,8,,,CHEMBL620370,,Autocuration,B,,1,,H,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,,45,BAO_0000357
5536,705.0,,,1,,,CHEMBL620371,,Intermediate,F,,1,,N,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,8701-BC,80648,BAO_0000219
5537,705.0,,,1,,,CHEMBL620372,,Intermediate,F,,1,,N,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,8701-BC,80648,BAO_0000219
5538,,,,0,,,CHEMBL876492,,Intermediate,F,,1,,U,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,,22226,BAO_0000019
5539,,,,0,,,CHEMBL620373,,Intermediate,F,,1,,U,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,,22226,BAO_0000019
5540,,,,0,,,CHEMBL620374,,Intermediate,F,,1,,U,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,,22226,BAO_0000019
5541,,,,0,,,CHEMBL620375,,Autocuration,B,,1,,U,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,,22226,BAO_0000019
5542,,,,0,,,CHEMBL857902,,Autocuration,F,,1,,U,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,22226,BAO_0000019
5543,,,,0,,,CHEMBL620376,,Autocuration,F,,1,,U,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,22226,BAO_0000019
5544,,,,8,,,CHEMBL620377,,Autocuration,B,,1,,H,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,,11922,BAO_0000357
5545,324.0,,,1,,,CHEMBL620378,,Intermediate,F,,1,,N,Tested for in vitro cytotoxic potency of compound in 9KB assay,,KB ,81115,BAO_0000219
5546,324.0,,,1,,,CHEMBL620379,,Intermediate,A,,1,,N,Tested for in vitro cytotoxic potency of compound in 9KB assay,,KB ,81115,BAO_0000219
5547,,,,0,,,CHEMBL620380,,Autocuration,F,,1,,U,In vitro cytotoxicity of compound was tested against 9KB cells.,,,22226,BAO_0000219
5548,392.0,,,1,,,CHEMBL884006,,Intermediate,F,,1,,N,Cytotoxic concentration against 9L cells was determined on day 3,,9L,80653,BAO_0000219
5549,392.0,,,1,,,CHEMBL620381,,Expert,F,,1,,N,Tested in vitro for anticancer activity against 9L cells,,9L,80653,BAO_0000219
5550,392.0,,,1,,,CHEMBL620382,,Expert,F,,1,,N,Tested in vitro for anticancer activity against 9L cells; Not determined,,9L,80653,BAO_0000219
5551,646.0,,,1,,,CHEMBL620383,,Intermediate,F,,1,,N,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,A549,80682,BAO_0000219
5552,646.0,,,1,,,CHEMBL876493,,Intermediate,F,,1,,N,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,A549,80682,BAO_0000219
5553,646.0,,,1,,,CHEMBL620384,,Intermediate,F,,1,,N,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,A549,80682,BAO_0000219
5554,646.0,,,1,,,CHEMBL620385,,Intermediate,F,,1,,N,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,A549,80682,BAO_0000219
5555,646.0,,,1,,,CHEMBL620386,,Expert,F,,1,,N,Cytotoxicity against human lung carcinoma A549 cell line,,A549,80682,BAO_0000219
5556,646.0,,,9,,,CHEMBL620387,,Expert,F,,1,,D,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,A549,25,BAO_0000219
5557,646.0,,,9,,,CHEMBL621404,,Expert,F,,1,,D,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,A549,25,BAO_0000219
5558,646.0,,,1,,,CHEMBL621405,,Intermediate,F,,1,,N,"In vitro growth inhibition of A549, lung carcinoma",,A549,80682,BAO_0000219
5559,646.0,,,1,,,CHEMBL621406,,Intermediate,F,,1,,N,"In vitro growth inhibition of A549, lung carcinoma.",,A549,80682,BAO_0000219
5560,646.0,,,1,,,CHEMBL621407,,Expert,F,,1,,N,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,A549,80682,BAO_0000219
5561,646.0,,,1,,,CHEMBL621408,,Intermediate,F,,1,,N,Cytotoxic activity against human lung cancer A549 cell line was determined,,A549,80682,BAO_0000219
5562,646.0,,,1,,,CHEMBL885345,,Expert,F,,1,,N,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,A549,80682,BAO_0000219
5563,646.0,,,1,,,CHEMBL621409,,Intermediate,F,,1,,N,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,A549,80682,BAO_0000219
5564,646.0,,,1,,,CHEMBL876034,,Expert,F,,1,,N,Cytotoxicity in A549 (human carcinoma) cell line.,,A549,80682,BAO_0000219
5565,646.0,,,1,,,CHEMBL621410,,Intermediate,F,,1,,N,Cytotoxicity on lung carcinoma (A-549) cell line,,A549,80682,BAO_0000219
5566,646.0,,,1,,,CHEMBL621411,,Expert,F,,1,,N,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,A549,80682,BAO_0000219
5567,646.0,,,1,,,CHEMBL621412,,Intermediate,F,,1,,N,Effective dose of compound against replication of A549 cell line was evaluated,,A549,80682,BAO_0000219
5568,646.0,,,1,,,CHEMBL621413,,Expert,F,,1,,N,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,A549,80682,BAO_0000219
5569,646.0,,,1,,,CHEMBL621414,,Intermediate,F,,1,,N,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,A549,80682,BAO_0000219
5570,646.0,,,1,,,CHEMBL621415,,Intermediate,F,,1,,N,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,A549,80682,BAO_0000219
5571,646.0,,,1,,,CHEMBL621416,,Intermediate,F,,1,,N,The compound was evaluated for antiproliferative activity against A549 cell line,,A549,80682,BAO_0000219
5572,646.0,,,1,,,CHEMBL621417,,Intermediate,F,,1,,N,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,A549,80682,BAO_0000219
5573,646.0,,,1,,,CHEMBL621418,,Intermediate,F,,1,,N,Concentration required for growth inhibition of human lung carcinoma cell line A549,,A549,80682,BAO_0000219
5574,646.0,,,1,,,CHEMBL621419,,Intermediate,F,,1,,N,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,A549,80682,BAO_0000219
5575,646.0,,,1,,,CHEMBL621420,,Intermediate,F,,1,,N,Growth inhibition against A549 cell line was evaluated,,A549,80682,BAO_0000219
5576,646.0,,,1,,,CHEMBL875823,,Intermediate,F,,1,,N,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,A549,80682,BAO_0000219
5577,646.0,,,1,,,CHEMBL621421,,Expert,F,,1,,N,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,A549,80682,BAO_0000219
5578,646.0,,,1,,,CHEMBL621422,,Intermediate,F,,1,,N,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,A549,80682,BAO_0000219
5579,646.0,,,1,,,CHEMBL884014,,Expert,F,,1,,N,Chemosensitivity against DT-diaphorase rich A549 cell lines,,A549,80682,BAO_0000219
5580,646.0,,,1,,,CHEMBL621423,,Intermediate,F,,1,,N,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,A549,80682,BAO_0000219
5581,646.0,,,1,,,CHEMBL621424,,Expert,F,,1,,N,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,A549,80682,BAO_0000219
5582,646.0,,,1,,,CHEMBL621425,,Intermediate,F,,1,,N,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,A549,80682,BAO_0000219
5583,646.0,,,1,,,CHEMBL621426,,Expert,F,,1,,N,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,A549,80682,BAO_0000219
5584,646.0,,,1,,,CHEMBL621427,,Intermediate,F,,1,,N,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,A549,80682,BAO_0000219
5585,646.0,,,1,,,CHEMBL621428,,Intermediate,F,,1,,N,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,A549,80682,BAO_0000219
5586,646.0,,,1,,,CHEMBL621429,,Expert,F,,1,,N,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,A549,80682,BAO_0000219
5587,646.0,,,1,,,CHEMBL621430,,Intermediate,F,,1,,N,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,A549,80682,BAO_0000219
5588,646.0,,,1,,,CHEMBL621431,,Intermediate,F,,1,,N,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,A549,80682,BAO_0000219
5589,646.0,,,1,,,CHEMBL621432,,Intermediate,F,,1,,N,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,A549,80682,BAO_0000219
5590,646.0,,,1,,,CHEMBL621433,,Expert,F,,1,,N,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,A549,80682,BAO_0000219
5591,646.0,,,1,,,CHEMBL875824,,Intermediate,F,,1,,N,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,A549,80682,BAO_0000219
5592,646.0,,,1,,,CHEMBL621434,,Intermediate,F,,1,,N,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,A549,80682,BAO_0000219
5593,646.0,,,1,,,CHEMBL621435,,Intermediate,F,,1,,N,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,A549,80682,BAO_0000219
5594,646.0,,,1,,,CHEMBL621436,,Intermediate,F,,1,,N,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,A549,80682,BAO_0000219
5595,646.0,,,1,,,CHEMBL621437,,Intermediate,F,,1,,N,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,A549,80682,BAO_0000219
5596,646.0,,,1,,,CHEMBL621438,,Intermediate,F,,1,,N,Compound was tested for the growth inhibition of A549 lung tumor cell line,,A549,80682,BAO_0000219
5597,646.0,,,1,,,CHEMBL621439,,Expert,F,,1,,N,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,A549,80682,BAO_0000219
5598,646.0,,,1,,,CHEMBL621440,,Intermediate,F,,1,,N,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,A549,80682,BAO_0000219
5599,,,,1,,In vivo,CHEMBL621441,,Intermediate,A,,1,,N,Oral bioavailability in dog (conscious),,,50588,BAO_0000218
5600,,,,1,,In vivo,CHEMBL621442,,Intermediate,A,,1,,N,Compound was evaluated for the oral bioavailability after oral administration in dog.,,,50588,BAO_0000218
5601,,,,1,,In vivo,CHEMBL621443,,Intermediate,A,,1,,N,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,,50588,BAO_0000218
5602,,,,1,,In vivo,CHEMBL621444,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
5603,,,,1,,In vivo,CHEMBL625133,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
5604,,,,1,,In vivo,CHEMBL625134,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
5605,,,,1,,In vivo,CHEMBL625135,,Intermediate,A,,1,,N,Oral bioavailability in dog (fasted),,,50588,BAO_0000218
5606,,,,1,,In vivo,CHEMBL625136,,Intermediate,A,,1,,N,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,,50588,BAO_0000218
5607,,,,1,,In vivo,CHEMBL625137,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
5608,,,,1,,In vivo,CHEMBL625138,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
5609,,,,1,,In vivo,CHEMBL625139,,Intermediate,A,,1,,N,Percent bioavailability in dog,,,50588,BAO_0000218
5610,,,,1,,In vivo,CHEMBL872264,,Intermediate,A,,1,,N,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,,50588,BAO_0000218
5611,,,,1,,In vivo,CHEMBL625140,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
5612,,,,1,,In vivo,CHEMBL624436,,Intermediate,A,,1,,N,The compound was evaluated for bioavailability in dogs; 34-44,,,50588,BAO_0000218
5613,,,,1,,In vivo,CHEMBL624437,,Intermediate,A,,1,,N,Bioavailability in dog (dose 4 mg/kg p.o.),,,50588,BAO_0000218
5614,,,,1,,In vivo,CHEMBL872261,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
5615,,,,1,,,CHEMBL624438,,Intermediate,A,,1,,N,8 hour trough Blood level in dog was measured after administration of compound,,,50588,BAO_0000218
5616,,,1969.0,1,Plasma,In vivo,CHEMBL624439,,Intermediate,A,,1,,N,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,,50588,BAO_0000218
5617,,,,1,,,CHEMBL624440,,Intermediate,A,,1,,N,C24 after oral administration at 5 mg/kg,,,50588,BAO_0000218
5618,,,,1,,,CHEMBL624441,,Intermediate,A,,1,,N,Clearance after oral and iv dosing in dogs,,,50588,BAO_0000218
5619,,,1969.0,1,Plasma,,CHEMBL624442,,Intermediate,A,,1,,N,Clearance of the drug was measured in the plasma of dog,,,50588,BAO_0000218
5620,,,,1,,,CHEMBL624443,,Intermediate,A,,1,,N,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,,50588,BAO_0000218
5621,,,,1,,In vivo,CHEMBL624444,,Intermediate,A,,1,,N,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,50588,BAO_0000218
5622,,,,1,,In vivo,CHEMBL624445,,Intermediate,A,,1,,N,Clearance of compound was determined in dogs,,,50588,BAO_0000218
5623,,,,1,,In vivo,CHEMBL624446,,Intermediate,A,,1,,N,Clearance on i.v. administration of 2 mg/kg was measured in dog,,,50588,BAO_0000218
5624,,,,1,,In vivo,CHEMBL624447,,Intermediate,A,,1,,N,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,50588,BAO_0000218
5625,,,,1,,In vivo,CHEMBL624448,,Intermediate,A,,1,,N,Plasma clearance in dog was determined,,,50588,BAO_0000218
5626,,,,1,,In vivo,CHEMBL624449,,Intermediate,A,,1,,N,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,50588,BAO_0000218
5627,,,,1,,In vivo,CHEMBL624450,,Intermediate,A,,1,,N,Plasma clearance in dog after administration of 0.25 mg/kg iv,,,50588,BAO_0000218
5628,,,,1,,In vivo,CHEMBL875942,,Intermediate,A,,1,,N,Plasma clearance in dog after administration of 1 mg/kg iv,,,50588,BAO_0000218
5629,,,,1,,In vivo,CHEMBL624451,,Intermediate,A,,1,,N,Plasma clearance in dogs,,,50588,BAO_0000218
5630,,,,1,,In vivo,CHEMBL624452,,Intermediate,A,,1,,N,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,,50588,BAO_0000218
5631,,,,1,,In vivo,CHEMBL624453,,Intermediate,A,,1,,N,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,50588,BAO_0000218
5632,,,,1,,In vivo,CHEMBL624454,,Intermediate,A,,1,,N,Plasma clearance after 15 mg/kg iv dose in Dogs,,,50588,BAO_0000218
5633,,,,1,,In vivo,CHEMBL624455,,Intermediate,A,,1,,N,Plasma clearance after 30 mg/kg po dose in Dogs,,,50588,BAO_0000218
5634,,,,1,,In vivo,CHEMBL624456,,Intermediate,A,,1,,N,Plasma administration to dogs,,,50588,BAO_0000218
5635,,,,1,,In vivo,CHEMBL624457,,Intermediate,A,,1,,N,Plasma clearance was determined,,,50588,BAO_0000218
5636,,,,1,,In vivo,CHEMBL624458,,Intermediate,A,,1,,N,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,,50588,BAO_0000218
5637,,,,1,,In vivo,CHEMBL624459,,Intermediate,A,,1,,N,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,,50588,BAO_0000218
5638,,,2107.0,2,Liver,In vitro,CHEMBL624460,,Intermediate,A,,1,Microsomes,S,Intrinsic clearance in human liver microsomes,,,102164,BAO_0000251
5639,,,2107.0,2,Liver,In vitro,CHEMBL624461,,Intermediate,A,,1,Microsomes,S,Intrinsic clearance in human liver microsomes,,,102164,BAO_0000251
5640,,,,1,,In vivo,CHEMBL875943,,Intermediate,A,,1,,N,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,50588,BAO_0000218
5641,,,,1,,In vivo,CHEMBL624462,,Intermediate,A,,1,,N,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,50588,BAO_0000218
5642,,,,1,,In vivo,CHEMBL624463,,Intermediate,A,,1,,N,Clearance in dog (dose 1 mg/kg i.v.),,,50588,BAO_0000218
5643,,,,1,,In vivo,CHEMBL624464,,Intermediate,A,,1,,N,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,,50588,BAO_0000218
5644,,,,1,,In vivo,CHEMBL624465,,Intermediate,A,,1,,N,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,50588,BAO_0000218
5645,,,,1,,In vivo,CHEMBL624466,,Intermediate,A,,1,,N,Plasma clearance after peroral administration at 10 mpk in dog,,,50588,BAO_0000218
5646,,,,1,,In vivo,CHEMBL624467,,Intermediate,A,,1,,N,Plasma clearance after peroral administration at 5 mpk in dog,,,50588,BAO_0000218
5647,,,,1,,In vivo,CHEMBL624468,,Intermediate,A,,1,,N,Plasma clearance after peroral administration at 5 mg/kg in dog,,,50588,BAO_0000218
5648,,,,1,,In vivo,CHEMBL624469,,Intermediate,A,,1,,N,Plasma clearance was measured in dog,,,50588,BAO_0000218
5649,,,,1,,In vivo,CHEMBL624470,,Intermediate,A,,1,,N,Plasma clearance was measured in dog,,,50588,BAO_0000218
5650,,,,1,,In vivo,CHEMBL624471,,Intermediate,A,,1,,N,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,,50588,BAO_0000218
5651,,,,1,,In vivo,CHEMBL624472,,Intermediate,A,,1,,N,Total clearance was determined after 0.1 mg/kg iv administration in dog,,,50588,BAO_0000218
5652,,,,1,,In vivo,CHEMBL622775,,Intermediate,A,,1,,N,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,,50588,BAO_0000218
5653,,,,1,,In vivo,CHEMBL622776,,Intermediate,A,,1,,N,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,,50588,BAO_0000218
5654,,,,1,,In vivo,CHEMBL622777,,Intermediate,A,,1,,N,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,,50588,BAO_0000218
5655,,,,1,,In vivo,CHEMBL622778,,Intermediate,A,,1,,N,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,,50588,BAO_0000218
5656,,,,1,,In vivo,CHEMBL622779,,Intermediate,A,,1,,N,Clearance by intravenous administration of 1.2 mg/kg in dog,,,50588,BAO_0000218
5657,,,,1,,In vivo,CHEMBL622780,,Intermediate,A,,1,,N,Clearance by iv administration in dogs at a dose of 1 mg/kg,,,50588,BAO_0000218
5658,,,1969.0,1,Plasma,In vivo,CHEMBL622781,,Intermediate,A,,1,,N,Clearance value was evaluated in dog plasma,,,50588,BAO_0000218
5659,,,,1,,In vivo,CHEMBL622782,,Intermediate,A,,1,,N,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,50588,BAO_0000218
5660,,,1969.0,1,Plasma,In vivo,CHEMBL622783,,Intermediate,A,,1,,N,Compound was tested for plasma clearance in dog,,,50588,BAO_0000218
5661,,,,1,,In vivo,CHEMBL622784,,Intermediate,A,,1,,N,Pharmacokinetic property (Plasma clearance) was measured in dog,,,50588,BAO_0000218
5662,,,,1,,,CHEMBL622785,,Intermediate,A,,1,,N,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,,50594,BAO_0000218
5663,,,,1,,,CHEMBL622786,,Intermediate,A,,1,,N,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,,50594,BAO_0000218
5664,,,,1,,,CHEMBL622787,,Intermediate,A,,1,,N,Area under curve value in mouse at a dose of 10 mg/kg,,,50594,BAO_0000218
5665,,,,1,,,CHEMBL875949,,Intermediate,A,,1,,N,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,,50594,BAO_0000218
5666,,,,1,,,CHEMBL622788,,Intermediate,A,,1,,N,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,,50594,BAO_0000218
5667,,,,1,,,CHEMBL622789,,Intermediate,F,,1,,N,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,50594,BAO_0000218
5668,,,,1,,,CHEMBL622790,,Intermediate,F,,1,,N,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,50594,BAO_0000218
5669,,,,1,,,CHEMBL622791,,Intermediate,F,,1,,N,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,50594,BAO_0000218
5670,,,,1,,,CHEMBL622792,,Intermediate,F,,1,,N,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,50594,BAO_0000218
5671,,,,1,,,CHEMBL622793,,Intermediate,A,,1,,N,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,,50594,BAO_0000218
5672,,,,1,,,CHEMBL622794,,Intermediate,A,,1,,N,Area under curve was determined for the compound at 24 mg/Kg,,,50594,BAO_0000218
5673,,,,1,,,CHEMBL622795,,Intermediate,A,,1,,N,Area under curve was determined for the compound at 40 mg/Kg,,,50594,BAO_0000218
5674,,,,1,,,CHEMBL621803,,Intermediate,A,,1,,N,Area under curve was determined for the compound at 5 mg/Kg,,,50594,BAO_0000218
5675,,,,1,,,CHEMBL621804,,Intermediate,A,,1,,N,Area under the curve for the compound is obtained at dose 25 mg/kg,,,50594,BAO_0000218
5676,,,,1,,,CHEMBL621805,,Intermediate,A,,1,,N,Area under the curve for the compound was obtained when tested in mouse,,,50594,BAO_0000218
5677,,,,1,,,CHEMBL621806,,Intermediate,A,,1,,N,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,,50594,BAO_0000218
5678,,,,1,,,CHEMBL621807,,Intermediate,A,,1,,N,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,,50594,BAO_0000218
5679,,,,1,,,CHEMBL621808,,Intermediate,A,,1,,N,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,,50594,BAO_0000218
5680,,,,1,,,CHEMBL621809,,Intermediate,A,,1,,N,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,,50594,BAO_0000218
5681,,,,1,,,CHEMBL621810,,Intermediate,A,,1,,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,50594,BAO_0000218
5682,,,,1,,,CHEMBL875164,,Intermediate,A,,1,,N,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,50594,BAO_0000218
5683,,,,1,,,CHEMBL621811,,Intermediate,A,,1,,N,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,50594,BAO_0000218
5684,,,,1,,,CHEMBL621812,,Intermediate,A,,1,,N,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,,50594,BAO_0000218
5685,,,,1,,,CHEMBL621813,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,,50594,BAO_0000218
5686,,,,1,,,CHEMBL621814,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,,50594,BAO_0000218
5687,,,,1,,,CHEMBL621815,,Intermediate,A,,1,,N,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,,50594,BAO_0000218
5688,,,,1,,,CHEMBL621816,,Intermediate,A,,1,,N,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,,50594,BAO_0000218
5689,,,,1,,,CHEMBL621817,,Intermediate,A,,1,,N,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,50594,BAO_0000218
5690,,,,1,,,CHEMBL621818,,Intermediate,A,,1,,N,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,,50594,BAO_0000218
5691,,,,1,,,CHEMBL621819,,Intermediate,A,,1,,N,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,,50594,BAO_0000218
5692,,,,1,,,CHEMBL621820,,Intermediate,A,,1,,N,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,,50594,BAO_0000218
5693,,,,1,,,CHEMBL621821,,Intermediate,A,,1,,N,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,,50594,BAO_0000218
5694,,,,1,,,CHEMBL621822,,Intermediate,A,,1,,N,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,,50594,BAO_0000218
5695,,,,1,,,CHEMBL619474,,Intermediate,A,,1,,N,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,,50594,BAO_0000218
5696,,,,1,,,CHEMBL619475,,Intermediate,A,,1,,N,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,50594,BAO_0000218
5697,,,,1,,,CHEMBL619476,,Intermediate,A,,1,,N,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,50594,BAO_0000218
5698,,,,1,,,CHEMBL619477,,Intermediate,A,,1,,N,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,,50594,BAO_0000218
5699,,,,1,,,CHEMBL619478,,Intermediate,A,,1,,N,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,,50594,BAO_0000218
5700,,,,1,,,CHEMBL619479,,Intermediate,A,,1,,N,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,,50594,BAO_0000218
5701,,,,1,,,CHEMBL619480,,Intermediate,A,,1,,N,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,,50594,BAO_0000218
5702,,,,1,,,CHEMBL619481,,Intermediate,A,,1,,N,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,,50594,BAO_0000218
5703,,,,1,,,CHEMBL619482,,Intermediate,A,,1,,N,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,,50594,BAO_0000218
5704,,,,1,,,CHEMBL619483,,Intermediate,A,,1,,N,Area under the curve was evaluated in mice after intravenous administration,,,50594,BAO_0000218
5705,,,,1,,,CHEMBL619484,,Intermediate,A,,1,,N,Area under the curve was evaluated in mice after oral administration,,,50594,BAO_0000218
5706,,,1969.0,1,Plasma,,CHEMBL619485,,Intermediate,A,,1,,N,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,,50594,BAO_0000218
5707,,,1969.0,1,Plasma,,CHEMBL619486,,Intermediate,A,,1,,N,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,,50594,BAO_0000218
5708,,,,1,,,CHEMBL619487,,Intermediate,A,,1,,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,50594,BAO_0000218
5709,,,,1,,,CHEMBL619488,,Intermediate,A,,1,,N,AUMC after intraperitoneal administration of 100 mg/kg in mice,,,50594,BAO_0000218
5710,,,178.0,1,Blood,In vivo,CHEMBL620106,,Intermediate,A,,1,,N,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5711,392.0,,,1,,,CHEMBL620107,,Intermediate,F,,1,,N,The compound was tested in vitro for anticancer activity against 9L cells,,9L,80653,BAO_0000219
5712,,,,0,,,CHEMBL620283,,Autocuration,F,,1,,U,Anti proliferation activity determined; Weak effect,,,22226,BAO_0000019
5713,,,,0,,,CHEMBL875176,,Autocuration,F,,1,,U,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,,22226,BAO_0000219
5714,,,,0,,,CHEMBL620284,,Autocuration,F,,1,,U,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,,22226,BAO_0000219
5715,,,,0,,,CHEMBL623515,,Autocuration,F,,1,,U,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,,22226,BAO_0000219
5716,,,,0,,,CHEMBL623516,,Autocuration,F,,1,,U,The cytotoxic activity was in vitro tested by 9PS assay method,,,22226,BAO_0000019
5717,,,,0,,,CHEMBL623517,,Autocuration,F,,1,,U,The cytotoxic activity was in vitro tested by 9PS assay method.,,,22226,BAO_0000019
5718,,,,0,,,CHEMBL857878,,Autocuration,A,,1,,U,Partition coefficient (logD6.5),,,22224,BAO_0000019
5719,478.0,,,1,,,CHEMBL623518,,Expert,F,,1,,N,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,A2780,81034,BAO_0000219
5720,455.0,,,1,,,CHEMBL624195,,Intermediate,F,,1,,N,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,A-375,80018,BAO_0000219
5721,500.0,,,1,,,CHEMBL624196,,Expert,F,,1,,N,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,A-431,80852,BAO_0000219
5722,500.0,,,9,,,CHEMBL624197,,Expert,F,,1,,D,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,A-431,9,BAO_0000219
5723,624.0,,,1,,,CHEMBL624198,,Intermediate,F,,1,,N,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,A498,80021,BAO_0000219
5724,624.0,,,1,,,CHEMBL621287,,Intermediate,F,,1,,N,in vitro cytotoxicity against A 498 cancer cell line,,A498,80021,BAO_0000219
5725,624.0,,,1,,,CHEMBL621288,,Intermediate,F,,1,,N,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,A498,80021,BAO_0000219
5726,624.0,,,1,,,CHEMBL876496,,Intermediate,F,,1,,N,Cytotoxic activity against A 498 renal cancer cell lines.,,A498,80021,BAO_0000219
5727,624.0,,,1,,,CHEMBL621289,,Intermediate,F,,1,,N,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,A498,80021,BAO_0000219
5728,,,,0,,,CHEMBL621290,,Autocuration,F,,1,,U,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,22226,BAO_0000019
5729,,,,0,,,CHEMBL621291,,Autocuration,F,,1,,U,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,22226,BAO_0000019
5730,,,,0,,,CHEMBL621292,,Autocuration,F,,1,,U,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,22226,BAO_0000019
5731,,,,0,,,CHEMBL621293,,Autocuration,F,,1,,U,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,22226,BAO_0000019
5732,646.0,,,1,,,CHEMBL621294,,Intermediate,F,,1,,N,Inhibitory concentration required against A 549 lung cancer cell line,,A549,80682,BAO_0000219
5733,646.0,,,1,,,CHEMBL621295,,Intermediate,F,,1,,N,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,A549,80682,BAO_0000219
5734,646.0,,,1,,,CHEMBL884007,,Intermediate,F,,1,,N,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,A549,80682,BAO_0000219
5735,646.0,,,1,,,CHEMBL621296,,Intermediate,F,,1,,N,In vitro cytotoxicity against lung cancer A 549 cell lines,,A549,80682,BAO_0000219
5736,646.0,,,1,,,CHEMBL621297,,Intermediate,F,,1,,N,Compound was tested for its cytotoxicity against A 549 cell line,,A549,80682,BAO_0000219
5737,646.0,,,1,,,CHEMBL839828,,Expert,F,,1,,N,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,A549,80682,BAO_0000219
5738,646.0,,,1,,,CHEMBL620397,,Intermediate,F,,1,,N,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,A549,80682,BAO_0000219
5739,646.0,,,1,,,CHEMBL620398,,Expert,F,,1,,N,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,A549,80682,BAO_0000219
5740,646.0,,,1,,,CHEMBL620399,,Intermediate,F,,1,,N,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,A549,80682,BAO_0000219
5741,646.0,,,1,,,CHEMBL620400,,Expert,F,,1,,N,In vitro inhibition of A549 (human lung cancer) cell growth.,,A549,80682,BAO_0000219
5742,646.0,,,1,,,CHEMBL620401,,Intermediate,F,,1,,N,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,A549,80682,BAO_0000219
5743,646.0,,,1,,,CHEMBL620402,,Expert,F,,1,,N,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,A549,80682,BAO_0000219
5744,646.0,,,1,,,CHEMBL620403,,Expert,F,,1,,N,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,A549,80682,BAO_0000219
5745,,,,0,,,CHEMBL620404,,Autocuration,F,,1,,U,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,,22226,BAO_0000218
5746,,,,4,,In vivo,CHEMBL620405,,Autocuration,F,,1,,H,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,,104694,BAO_0000218
5747,,,,4,,In vivo,CHEMBL620406,,Autocuration,F,,1,,H,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,,104694,BAO_0000218
5748,,,,4,,In vivo,CHEMBL620407,,Autocuration,F,,1,,H,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,,104694,BAO_0000218
5749,,,,4,,In vivo,CHEMBL620408,,Autocuration,F,,1,,H,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,,104694,BAO_0000218
5750,,,,4,,In vivo,CHEMBL620409,,Autocuration,F,,1,,H,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,,104694,BAO_0000218
5751,624.0,,,1,,,CHEMBL620410,,Expert,F,,1,,N,Inhibition of A-498 human Renal cell proliferation,,A498,80021,BAO_0000219
5752,,,,0,,,CHEMBL620411,,Autocuration,F,,1,,U,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,,22226,BAO_0000019
5753,,,,0,,,CHEMBL620412,,Autocuration,F,,1,,U,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,,22226,BAO_0000019
5754,,,,0,,,CHEMBL876596,,Autocuration,F,,1,,U,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,,22226,BAO_0000019
5755,622.0,,,1,,,CHEMBL620413,,Expert,F,,1,,N,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,A 172,80012,BAO_0000219
5756,622.0,,,1,,,CHEMBL620414,,Intermediate,F,,1,,N,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A 172,80012,BAO_0000219
5757,622.0,,,1,,,CHEMBL620415,,Intermediate,F,,1,,N,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A 172,80012,BAO_0000219
5758,646.0,,,1,,,CHEMBL620416,,Expert,F,,1,,N,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,A549,80682,BAO_0000219
5759,646.0,,,1,,,CHEMBL620417,,Intermediate,F,,1,,N,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,A549,80682,BAO_0000219
5760,646.0,,,1,,,CHEMBL620418,,Expert,F,,1,,N,Cytotoxic activity evaluated against A549 tumor cells,,A549,80682,BAO_0000219
5761,646.0,,,1,,,CHEMBL620419,,Intermediate,F,,1,,N,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,A549,80682,BAO_0000219
5762,646.0,,,1,,,CHEMBL620420,,Intermediate,F,,1,,N,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,A549,80682,BAO_0000219
5763,646.0,,,1,,,CHEMBL620421,,Intermediate,F,,1,,N,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,A549,80682,BAO_0000219
5764,646.0,,,1,,,CHEMBL620422,,Intermediate,F,,1,,N,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,A549,80682,BAO_0000219
5765,646.0,,,1,,,CHEMBL620423,,Intermediate,F,,1,,N,Cytotoxicity of compound against A549 cell line,,A549,80682,BAO_0000219
5766,646.0,,,1,,,CHEMBL620424,,Expert,F,,1,,N,Cytotoxicity against human lung cell carcinoma A549 cell line,,A549,80682,BAO_0000219
5767,646.0,,,1,,,CHEMBL620425,,Intermediate,F,,1,,N,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,A549,80682,BAO_0000219
5768,646.0,,,1,,,CHEMBL620426,,Intermediate,F,,1,,N,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,A549,80682,BAO_0000219
5769,646.0,,,1,,,CHEMBL620427,,Intermediate,F,,1,,N,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,A549,80682,BAO_0000219
5770,646.0,,,1,,,CHEMBL620428,,Intermediate,F,,1,,N,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,A549,80682,BAO_0000219
5771,646.0,,,1,,,CHEMBL620429,,Intermediate,F,,1,,N,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,A549,80682,BAO_0000219
5772,646.0,,,1,,,CHEMBL620430,,Expert,F,,1,,N,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,A549,80682,BAO_0000219
5773,646.0,,,1,,,CHEMBL839887,,Expert,F,,1,,N,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,A549,80682,BAO_0000219
5774,646.0,,,1,,,CHEMBL620431,,Intermediate,F,,1,,N,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,A549,80682,BAO_0000219
5775,646.0,,,1,,,CHEMBL884010,,Intermediate,F,,1,,N,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,A549,80682,BAO_0000219
5776,646.0,,,1,,,CHEMBL620538,,Intermediate,F,,1,,N,In vitro cytotoxicity against A549 (human lung cancer),,A549,80682,BAO_0000219
5777,646.0,,,1,,,CHEMBL620539,,Expert,F,,1,,N,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,A549,80682,BAO_0000219
5778,646.0,,,1,,,CHEMBL623373,,Intermediate,F,,1,,N,In vivo antiproliferative activity against A549 cell line,,A549,80682,BAO_0000218
5779,646.0,,,1,,,CHEMBL623374,,Intermediate,F,,1,,N,Inhibition of non-small-cell lung adenocarcinoma (A549),,A549,80682,BAO_0000219
5780,646.0,,,1,,,CHEMBL623375,,Intermediate,F,,1,,N,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,A549,80682,BAO_0000219
5781,646.0,,,1,,,CHEMBL623376,,Intermediate,F,,1,,N,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,A549,80682,BAO_0000219
5782,646.0,,,1,,,CHEMBL623377,,Intermediate,F,,1,,N,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,A549,80682,BAO_0000219
5783,646.0,,,1,,,CHEMBL623378,,Intermediate,F,,1,,N,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,A549,80682,BAO_0000219
5784,646.0,,,1,,,CHEMBL623379,,Intermediate,F,,1,,N,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,A549,80682,BAO_0000219
5785,646.0,,,1,,,CHEMBL623380,,Intermediate,F,,1,,N,Inhibitory activity against A549 lung cancer cell line,,A549,80682,BAO_0000219
5786,646.0,,,1,,,CHEMBL623381,,Intermediate,F,,1,,N,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,A549,80682,BAO_0000219
5787,646.0,,,1,,,CHEMBL623382,,Intermediate,F,,1,,N,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,A549,80682,BAO_0000219
5788,646.0,,,1,,,CHEMBL623383,,Intermediate,F,,1,,N,Inhibitory concentration against A549 (lung cancer) cell line,,A549,80682,BAO_0000219
5789,646.0,,,1,,,CHEMBL623384,,Expert,F,,1,,N,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,A549,80682,BAO_0000219
5790,646.0,,,1,,,CHEMBL623385,,Intermediate,F,,1,,N,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,A549,80682,BAO_0000219
5791,646.0,,,1,,,CHEMBL623386,,Expert,F,,1,,N,Activity against A549 cancer cell line.,,A549,80682,BAO_0000219
5792,646.0,,,1,,,CHEMBL884105,,Intermediate,F,,1,,N,The compound was evaluated for cytotoxicity against A549 cell line,,A549,80682,BAO_0000219
5793,646.0,,,1,,,CHEMBL623387,,Intermediate,F,,1,,N,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,A549,80682,BAO_0000219
5794,646.0,,,1,,,CHEMBL621568,,Intermediate,F,,1,,N,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,A549,80682,BAO_0000219
5795,646.0,,,1,,,CHEMBL621569,,Intermediate,F,,1,,N,Growth inhibitory activity was measured for human A549 tumor cell line.,,A549,80682,BAO_0000219
5796,646.0,,,1,,,CHEMBL621570,,Intermediate,F,,1,,N,Inhibitory activity against A549 lung cancer cell line,,A549,80682,BAO_0000219
5797,646.0,,,1,,,CHEMBL621571,,Intermediate,F,,1,,N,Inhibitory activity against A549 cell line; inactive,,A549,80682,BAO_0000219
5798,646.0,,,1,,,CHEMBL621572,,Expert,F,,1,,N,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,A549,80682,BAO_0000219
5799,646.0,,,1,,,CHEMBL621573,,Expert,F,,1,,N,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,A549,80682,BAO_0000219
5800,646.0,,,1,,,CHEMBL621574,,Intermediate,F,,1,,N,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,A549,80682,BAO_0000219
5801,646.0,,,1,,,CHEMBL621575,,Intermediate,F,,1,,N,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,A549,80682,BAO_0000219
5802,646.0,,,1,,,CHEMBL621576,,Intermediate,F,,1,,N,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,A549,80682,BAO_0000219
5803,646.0,,,1,,,CHEMBL621577,,Intermediate,F,,1,,N,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,A549,80682,BAO_0000219
5804,646.0,,,1,,,CHEMBL621578,,Intermediate,F,,1,,N,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,A549,80682,BAO_0000219
5805,646.0,,,1,,,CHEMBL621579,,Intermediate,F,,1,,N,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,A549,80682,BAO_0000219
5806,646.0,,,1,,,CHEMBL621580,,Intermediate,F,,1,,N,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,A549,80682,BAO_0000219
5807,,,,1,,In vivo,CHEMBL621581,,Intermediate,A,,1,,N,Plasma clearance (in vivo) in mongrel dogs was determined,,,50588,BAO_0000218
5808,,,,1,,In vivo,CHEMBL621582,,Intermediate,A,,1,,N,Plasma clearance was measured in dog,,,50588,BAO_0000218
5809,,,,1,,In vivo,CHEMBL621583,,Intermediate,A,,1,,N,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,50588,BAO_0000218
5810,,,,1,,In vivo,CHEMBL621584,,Intermediate,A,,1,,N,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,50588,BAO_0000218
5811,,,1969.0,1,Plasma,In vivo,CHEMBL621585,,Intermediate,A,,1,,N,Tested for plasma clearance in dog,,,50588,BAO_0000218
5812,,,,1,,In vivo,CHEMBL621586,,Intermediate,A,,1,,N,The compound was tested for clearance in dog plasma.,,,50588,BAO_0000218
5813,,,,1,,In vivo,CHEMBL875835,,Intermediate,A,,1,,N,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,,50588,BAO_0000218
5814,,,,1,,In vivo,CHEMBL621587,,Intermediate,A,,1,,N,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,,50588,BAO_0000218
5815,,,1969.0,1,Plasma,In vivo,CHEMBL621588,,Intermediate,A,,1,,N,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,50588,BAO_0000218
5816,,,2107.0,1,Liver,In vitro,CHEMBL621589,,Intermediate,A,,1,Microsomes,N,In vitro clearance in dog liver microsomes,,,50588,BAO_0000218
5817,,,,1,,In vivo,CHEMBL621590,,Intermediate,A,,1,,N,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,50588,BAO_0000218
5818,,,,1,,In vivo,CHEMBL621591,,Intermediate,A,,1,,N,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,,50588,BAO_0000218
5819,,,,1,,In vivo,CHEMBL621592,,Intermediate,A,,1,,N,Plasma clearance in dog,,,50588,BAO_0000218
5820,,,,1,,In vivo,CHEMBL621593,,Intermediate,A,,1,,N,Clearance rate in dog,,,50588,BAO_0000218
5821,,,1969.0,1,Plasma,In vivo,CHEMBL621594,,Intermediate,A,,1,,N,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,,50588,BAO_0000218
5822,,,,1,,In vivo,CHEMBL621595,,Intermediate,A,,1,,N,Clearance in dogs,,,50588,BAO_0000218
5823,,,,1,,In vivo,CHEMBL621596,,Intermediate,A,,1,,N,Plasma clearance in dogs,,,50588,BAO_0000218
5824,,,,1,,In vivo,CHEMBL621597,,Intermediate,A,,1,,N,Plasma clearance was determined,,,50588,BAO_0000218
5825,,,,1,,In vivo,CHEMBL621598,,Intermediate,A,,1,,N,Lower clearance in dog (i.v.) at 0.5 mpk,,,50588,BAO_0000218
5826,,,,1,,In vivo,CHEMBL621599,,Intermediate,A,,1,,N,Plasma clearance in Beagle dogs,,,50588,BAO_0000218
5827,,,,1,,In vivo,CHEMBL875836,,Intermediate,A,,1,,N,Plasma clearance (Clp) in dog,,,50588,BAO_0000218
5828,,,,1,,In vivo,CHEMBL621600,,Intermediate,A,,1,,N,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,,50588,BAO_0000218
5829,,,,1,,In vivo,CHEMBL621601,,Intermediate,A,,1,,N,Plasma clearance (pharmacokinetic parameter) in dog was determined,,,50588,BAO_0000218
5830,,,,1,,In vivo,CHEMBL618474,,Intermediate,A,,1,,N,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,,50588,BAO_0000218
5831,,,,1,,In vivo,CHEMBL618475,,Intermediate,A,,1,,N,Plasma clearance of compound was determined in dog,,,50588,BAO_0000218
5832,,,,1,,In vivo,CHEMBL624524,,Intermediate,A,,1,,N,Plasma clearance after intravenous administration of 1 mg/kg in dog,,,50588,BAO_0000218
5833,,,,1,,In vivo,CHEMBL624525,,Intermediate,A,,1,,N,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,50588,BAO_0000218
5834,,,,1,,In vivo,CHEMBL624526,,Intermediate,A,,1,,N,Plasma clearance in dog was determined,,,50588,BAO_0000218
5835,,,,1,,In vivo,CHEMBL624527,,Intermediate,A,,1,,N,Plasma clearance was calculated in dog,,,50588,BAO_0000218
5836,,,,1,,In vivo,CHEMBL624528,,Intermediate,A,,1,,N,Plasma clearance at the dose of 2 mg/kg in dog,,,50588,BAO_0000218
5837,,,,1,,In vivo,CHEMBL624529,,Intermediate,A,,1,,N,Plasma clearance in dog,,,50588,BAO_0000218
5838,,,,1,,In vivo,CHEMBL624530,,Intermediate,A,,1,,N,Plasma clearance in dog,,,50588,BAO_0000218
5839,,,,1,,In vivo,CHEMBL624531,,Intermediate,A,,1,,N,Plasma clearance in dog; Unable to calculate,,,50588,BAO_0000218
5840,,,,1,,In vivo,CHEMBL624532,,Intermediate,A,,1,,N,Plasma clearance in rhesus monkey,,,50588,BAO_0000218
5841,,,,1,,In vivo,CHEMBL624533,,Intermediate,A,,1,,N,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,50588,BAO_0000218
5842,,,,1,,In vivo,CHEMBL624534,,Intermediate,A,,1,,N,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588,BAO_0000218
5843,,,,1,,In vivo,CHEMBL624535,,Intermediate,A,,1,,N,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588,BAO_0000218
5844,,,,1,,In vivo,CHEMBL624536,,Intermediate,A,,1,,N,Plasma clearance was evaluated in dog,,,50588,BAO_0000218
5845,,,,1,,In vivo,CHEMBL624537,,Intermediate,A,,1,,N,Plasma clearance was evaluated in dog; Not tested,,,50588,BAO_0000218
5846,,,,1,,In vivo,CHEMBL624538,,Intermediate,A,,1,,N,Plasma clearance was evaluated in rhesus,,,50588,BAO_0000218
5847,,,,1,,In vivo,CHEMBL624539,,Intermediate,A,,1,,N,Plasma clearance was evaluated in rhesus; Not tested,,,50588,BAO_0000218
5848,,,,1,,In vivo,CHEMBL624540,,Intermediate,A,,1,,N,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,,50588,BAO_0000218
5849,,,,1,,In vivo,CHEMBL624541,,Intermediate,A,,1,,N,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50588,BAO_0000218
5850,,,,1,,In vivo,CHEMBL624542,,Intermediate,A,,1,,N,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,50588,BAO_0000218
5851,,,,1,,In vivo,CHEMBL624543,,Intermediate,A,,1,,N,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588,BAO_0000218
5852,,,,1,,In vivo,CHEMBL624544,,Intermediate,A,,1,,N,Clearance value at a dose of 0.2 mg/kg i.v.,,,50588,BAO_0000218
5853,,,1969.0,1,Plasma,In vivo,CHEMBL624545,,Intermediate,A,,1,,N,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,,50588,BAO_0000218
5854,,,,1,,In vivo,CHEMBL624546,,Intermediate,A,,1,,N,Cmax after oral dose of compound at 3 mg/kg in dogs,,,50588,BAO_0000218
5855,,,,1,,In vivo,CHEMBL875957,,Intermediate,A,,1,,N,Cmax after single intravenous bolus of 1 mg/kg in dogs,,,50588,BAO_0000218
5856,,,,1,,In vivo,CHEMBL624547,,Intermediate,A,,1,,N,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,50588,BAO_0000218
5857,,,,1,,In vivo,CHEMBL624548,,Intermediate,A,,1,,N,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,,50588,BAO_0000218
5858,,,,1,,In vivo,CHEMBL624549,,Intermediate,A,,1,,N,Cmax in dog after administration of 1 mg/kg iv,,,50588,BAO_0000218
5859,,,1969.0,1,Plasma,In vivo,CHEMBL624550,,Intermediate,A,,1,,N,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,,50588,BAO_0000218
5860,,,,1,,In vivo,CHEMBL621613,,Intermediate,A,,1,,N,Cmax on p.o. administration of 10 mg/kg was measured in dog,,,50588,BAO_0000218
5861,,,,1,,In vivo,CHEMBL621614,,Intermediate,A,,1,,N,Cmax was determine after peroral administration at 10 mpk in dog,,,50588,BAO_0000218
5862,,,,1,,In vivo,CHEMBL623431,,Intermediate,A,,1,,N,Cmax was determine after peroral administration at 5 mpk in dog,,,50588,BAO_0000218
5863,,,,1,,In vivo,CHEMBL623432,,Intermediate,A,,1,,N,Cmax was determine after peroral administration at 5 mg/kg in dog,,,50588,BAO_0000218
5864,,,,1,,In vivo,CHEMBL623433,,Intermediate,A,,1,,N,Cmax after 0.3 mg/kg po administration in dog,,,50588,BAO_0000218
5865,,,,1,,In vivo,CHEMBL623434,,Intermediate,A,,1,,N,Cmax after peroral administration in dogs at 2.4 uM/kg,,,50588,BAO_0000218
5866,,,,1,,In vivo,CHEMBL623435,,Intermediate,A,,1,,N,Cmax in dog after oral administration at 1 mg/kg,,,50588,BAO_0000218
5867,,,,1,,In vivo,CHEMBL623436,,Intermediate,A,,1,,N,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,,50588,BAO_0000218
5868,,,,1,,In vivo,CHEMBL875958,,Intermediate,A,,1,,N,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,,50588,BAO_0000218
5869,,,,1,,In vivo,CHEMBL623437,,Intermediate,A,,1,,N,Cmax value after 15 mg/kg iv dose in Dogs,,,50588,BAO_0000218
5870,,,178.0,1,Blood,In vivo,CHEMBL623438,,Intermediate,A,,1,,N,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5871,,,178.0,1,Blood,In vivo,CHEMBL623439,,Intermediate,A,,1,,N,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5872,,,10000001.0,1,Bone,In vivo,CHEMBL623440,,Intermediate,A,,1,,N,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5873,,,10000001.0,1,Bone,In vivo,CHEMBL623441,,Intermediate,A,,1,,N,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5874,,,10000001.0,1,Bone,In vivo,CHEMBL623442,,Intermediate,A,,1,,N,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5875,,,,1,,In vivo,CHEMBL623469,,Intermediate,A,,1,,N,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5876,,,,1,,In vivo,CHEMBL623470,,Intermediate,A,,1,,N,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5877,,,,1,,In vivo,CHEMBL623471,,Intermediate,A,,1,,N,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5878,,,948.0,1,Heart,In vivo,CHEMBL623472,,Intermediate,A,,1,,N,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5879,,,948.0,1,Heart,In vivo,CHEMBL623473,,Intermediate,A,,1,,N,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5880,,,948.0,1,Heart,In vivo,CHEMBL623474,,Intermediate,A,,1,,N,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5881,,,2113.0,1,Kidney,In vivo,CHEMBL623475,,Intermediate,A,,1,,N,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5882,,,2113.0,1,Kidney,In vivo,CHEMBL623476,,Intermediate,A,,1,,N,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5883,,,2113.0,1,Kidney,In vivo,CHEMBL623477,,Intermediate,A,,1,,N,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5884,,,160.0,1,Intestine,In vivo,CHEMBL621896,,Intermediate,A,,1,,N,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5885,,,160.0,1,Intestine,In vivo,CHEMBL621897,,Intermediate,A,,1,,N,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5886,,,160.0,1,Intestine,In vivo,CHEMBL621898,,Intermediate,A,,1,,N,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5887,,,2107.0,1,Liver,In vivo,CHEMBL621899,,Intermediate,A,,1,,N,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5888,,,2107.0,1,Liver,In vivo,CHEMBL621900,,Intermediate,A,,1,,N,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5889,,,2107.0,1,Liver,In vivo,CHEMBL621901,,Intermediate,A,,1,,N,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5890,,,2048.0,1,Lung,In vivo,CHEMBL621902,,Intermediate,A,,1,,N,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5891,,,2048.0,1,Lung,In vivo,CHEMBL621903,,Intermediate,A,,1,,N,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5892,,,2048.0,1,Lung,In vivo,CHEMBL622587,,Intermediate,A,,1,,N,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5893,,,2385.0,1,Muscle tissue,In vivo,CHEMBL620285,,Intermediate,A,,1,,N,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5894,,,2385.0,1,Muscle tissue,In vivo,CHEMBL875285,,Intermediate,A,,1,,N,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5895,,,2385.0,1,Muscle tissue,In vivo,CHEMBL620286,,Intermediate,A,,1,,N,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5896,,,,1,,In vivo,CHEMBL620287,,Intermediate,A,,1,,N,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5897,,,,1,,In vivo,CHEMBL620288,,Intermediate,A,,1,,N,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5898,,,,1,,In vivo,CHEMBL620289,,Intermediate,A,,1,,N,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5899,,,160.0,1,Intestine,In vivo,CHEMBL620290,,Intermediate,A,,1,,N,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5900,,,160.0,1,Intestine,In vivo,CHEMBL620291,,Intermediate,A,,1,,N,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5901,,,160.0,1,Intestine,In vivo,CHEMBL620292,,Intermediate,A,,1,,N,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5902,,,2106.0,1,Spleen,In vivo,CHEMBL620293,,Intermediate,A,,1,,N,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5903,,,2106.0,1,Spleen,In vivo,CHEMBL620294,,Intermediate,A,,1,,N,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5904,,,2106.0,1,Spleen,In vivo,CHEMBL618614,,Intermediate,A,,1,,N,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5905,,,945.0,1,Stomach,In vivo,CHEMBL618615,,Intermediate,A,,1,,N,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5906,,,945.0,1,Stomach,In vivo,CHEMBL618616,,Intermediate,A,,1,,N,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
5907,622.0,,,1,,,CHEMBL618617,,Expert,F,,1,,N,Cytotoxicity against A-172 human tumor cell lines,,A 172,80012,BAO_0000219
5908,622.0,,,1,,,CHEMBL618618,,Intermediate,F,,1,,N,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,A 172,80012,BAO_0000219
5909,623.0,,,1,,,CHEMBL618619,,Intermediate,F,,1,,N,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,A204,80014,BAO_0000219
5910,478.0,,,1,,,CHEMBL618620,,Intermediate,F,,1,,N,Tested for antiproliferative activity against A-2780 tumoral cell line,,A2780,81034,BAO_0000219
5911,455.0,,,1,,,CHEMBL618621,,Intermediate,F,,1,,N,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,A-375,80018,BAO_0000219
5912,455.0,,,1,,,CHEMBL618622,,Intermediate,F,,1,,N,Tested in vitro against A-375 cell line human melanoma,,A-375,80018,BAO_0000219
5913,797.0,,,1,,,CHEMBL618623,,Expert,F,,1,,N,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,A-427,80019,BAO_0000219
5914,797.0,,,1,,,CHEMBL618624,,Intermediate,F,,1,,N,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A-427,80019,BAO_0000219
5915,797.0,,,1,,,CHEMBL618625,,Expert,F,,1,,N,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,A-427,80019,BAO_0000219
5916,797.0,,,1,,,CHEMBL618626,,Intermediate,F,,1,,N,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A-427,80019,BAO_0000219
5917,797.0,,,1,,,CHEMBL618627,,Intermediate,F,,1,,N,Antitumor activity on A-427 lung carcinoma cell lines,,A-427,80019,BAO_0000219
5918,797.0,,,1,,,CHEMBL618628,,Intermediate,F,,1,,N,Cytotoxic activity against human A-427 lung tumor cell line,,A-427,80019,BAO_0000219
5919,797.0,,,1,,,CHEMBL618629,,Expert,F,,1,,N,In vitro antitumor effects against human A-427 cell lines.,,A-427,80019,BAO_0000219
5920,797.0,,,1,,,CHEMBL618630,,Expert,F,,1,,N,In vitro inhibition of A-427 (human lung cancer) cell growth.,,A-427,80019,BAO_0000219
5921,797.0,,,1,,,CHEMBL618631,,Intermediate,F,,1,,N,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,A-427,80019,BAO_0000219
5922,797.0,,,1,,,CHEMBL618632,,Intermediate,F,,1,,N,Cytotoxic activity of compound against A-427 lung human tumor cell line,,A-427,80019,BAO_0000219
5923,500.0,,,1,,,CHEMBL618633,,Expert,F,,1,,N,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,A-431,80852,BAO_0000219
5924,624.0,,,1,,,CHEMBL619315,,Intermediate,F,,1,,N,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,A498,80021,BAO_0000219
5925,624.0,,,1,,,CHEMBL619316,,Expert,F,,1,,N,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,A498,80021,BAO_0000219
5926,624.0,,,1,,,CHEMBL619317,,Intermediate,F,,1,,N,Cytotoxicity against human kidney carcinoma A-498cell lines,,A498,80021,BAO_0000219
5927,624.0,,,1,,,CHEMBL619318,,Intermediate,F,,1,,N,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,A498,80021,BAO_0000219
5928,624.0,,,1,,,CHEMBL619319,,Intermediate,F,,1,,N,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,A498,80021,BAO_0000219
5929,624.0,,,1,,,CHEMBL619739,,Intermediate,F,,1,,N,Antitumor cytotoxic activity against A-498 cell line was determined,,A498,80021,BAO_0000219
5930,624.0,,,1,,,CHEMBL619740,,Intermediate,F,,1,,N,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,A498,80021,BAO_0000219
5931,624.0,,,1,,,CHEMBL883158,,Intermediate,F,,1,,N,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,A498,80021,BAO_0000219
5932,624.0,,,1,,,CHEMBL884012,,Intermediate,F,,1,,N,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,A498,80021,BAO_0000219
5933,624.0,,,1,,,CHEMBL619741,,Intermediate,F,,1,,N,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,A498,80021,BAO_0000219
5934,624.0,,,1,,,CHEMBL619742,,Intermediate,F,,1,,N,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,A498,80021,BAO_0000219
5935,646.0,,,1,,,CHEMBL876610,,Intermediate,F,,1,,N,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,A549,80682,BAO_0000219
5936,646.0,,,1,,,CHEMBL619743,,Intermediate,F,,1,,N,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,A549,80682,BAO_0000219
5937,646.0,,,1,,,CHEMBL619744,,Intermediate,F,,1,,N,In vitro antiproliferative activity against human A-549 NSCL cell line,,A549,80682,BAO_0000219
5938,646.0,,,1,,,CHEMBL619745,,Intermediate,F,,1,,N,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,A549,80682,BAO_0000219
5939,646.0,,,1,,,CHEMBL619746,,Intermediate,F,,1,,N,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,A549,80682,BAO_0000219
5940,646.0,,,1,,,CHEMBL619747,,Intermediate,F,,1,,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,A549,80682,BAO_0000219
5941,646.0,,,1,,,CHEMBL619748,,Intermediate,F,,1,,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,A549,80682,BAO_0000219
5942,646.0,,,1,,,CHEMBL619749,,Intermediate,F,,1,,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,A549,80682,BAO_0000219
5943,646.0,,,1,,,CHEMBL619750,,Intermediate,F,,1,,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,A549,80682,BAO_0000219
5944,646.0,,,1,,,CHEMBL624014,,Intermediate,F,,1,,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,A549,80682,BAO_0000219
5945,646.0,,,1,,,CHEMBL624015,,Intermediate,F,,1,,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,A549,80682,BAO_0000219
5946,646.0,,,1,,,CHEMBL885344,,Expert,F,,1,,N,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,A549,80682,BAO_0000219
5947,646.0,,,1,,,CHEMBL623224,,Intermediate,F,,1,,N,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,A549,80682,BAO_0000219
5948,646.0,,,1,,,CHEMBL623225,,Intermediate,F,,1,,N,Cytotoxic activity against A-549 cell line,,A549,80682,BAO_0000219
5949,646.0,,,1,,,CHEMBL622698,,Intermediate,F,,1,,N,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,A549,80682,BAO_0000219
5950,646.0,,,1,,,CHEMBL622699,,Intermediate,F,,1,,N,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,A549,80682,BAO_0000219
5951,646.0,,,1,,,CHEMBL622700,,Expert,F,,1,,N,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,A549,80682,BAO_0000219
5952,646.0,,,1,,,CHEMBL622701,,Intermediate,F,,1,,N,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,A549,80682,BAO_0000219
5953,646.0,,,1,,,CHEMBL622702,,Intermediate,F,,1,,N,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,A549,80682,BAO_0000219
5954,646.0,,,1,,,CHEMBL622703,,Intermediate,F,,1,,N,Cytotoxic activity against human lung carcinoma (A-549) cell line,,A549,80682,BAO_0000219
5955,646.0,,,1,,,CHEMBL622704,,Expert,F,,1,,N,Cytotoxic activity towards A-549 cells,,A549,80682,BAO_0000219
5956,646.0,,,1,,,CHEMBL622705,,Intermediate,F,,1,,N,"In vitro percent inhibition of A549, lung carcinoma.",,A549,80682,BAO_0000219
5957,646.0,,,1,,,CHEMBL622706,,Intermediate,F,,1,,N,"In vitro percent inhibition of A549, lung carcinoma",,A549,80682,BAO_0000219
5958,646.0,,,1,,,CHEMBL622707,,Intermediate,F,,1,,N,"In vitro percent inhibition of A549, lung carcinoma.",,A549,80682,BAO_0000219
5959,646.0,,,1,,,CHEMBL622708,,Intermediate,F,,1,,N,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,A549,80682,BAO_0000219
5960,646.0,,,1,,,CHEMBL622709,,Intermediate,F,,1,,N,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,A549,80682,BAO_0000219
5961,646.0,,,1,,,CHEMBL622710,,Intermediate,F,,1,,N,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,A549,80682,BAO_0000219
5962,646.0,,,1,,,CHEMBL622711,,Intermediate,F,,1,,N,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,A549,80682,BAO_0000219
5963,646.0,,,1,,,CHEMBL622712,,Intermediate,F,,1,,N,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,A549,80682,BAO_0000218
5964,646.0,,,1,,,CHEMBL622713,,Intermediate,F,,1,,N,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,A549,80682,BAO_0000218
5965,646.0,,,1,,,CHEMBL622714,,Intermediate,F,,1,,N,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,A549,80682,BAO_0000218
5966,646.0,,,1,,,CHEMBL622715,,Intermediate,F,,1,,N,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,A549,80682,BAO_0000218
5967,646.0,,,1,,,CHEMBL622716,,Intermediate,F,,1,,N,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,A549,80682,BAO_0000218
5968,646.0,,,1,,,CHEMBL622717,,Intermediate,F,,1,,N,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,A549,80682,BAO_0000219
5969,646.0,,,1,,,CHEMBL622718,,Intermediate,F,,1,,N,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,A549,80682,BAO_0000218
5970,646.0,,,1,,,CHEMBL622719,,Expert,F,,1,,N,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,A549,80682,BAO_0000219
5971,646.0,,,1,,,CHEMBL622720,,Intermediate,F,,1,,N,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,A549,80682,BAO_0000219
5972,646.0,,,1,,,CHEMBL622721,,Intermediate,F,,1,,N,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,A549,80682,BAO_0000219
5973,646.0,,,1,,,CHEMBL622722,,Intermediate,F,,1,,N,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,A549,80682,BAO_0000219
5974,646.0,,,1,,,CHEMBL876030,,Intermediate,F,,1,,N,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,A549,80682,BAO_0000219
5975,646.0,,,1,,,CHEMBL620206,,Intermediate,F,,1,,N,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,A549,80682,BAO_0000219
5976,646.0,,,1,,,CHEMBL620207,,Expert,F,,1,,N,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,A549,80682,BAO_0000219
5977,646.0,,,1,,,CHEMBL620208,,Expert,F,,1,,N,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,A549,80682,BAO_0000219
5978,646.0,,,1,,,CHEMBL620209,,Expert,F,,1,,N,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,A549,80682,BAO_0000219
5979,646.0,,,1,,,CHEMBL620210,,Expert,F,,1,,N,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,A549,80682,BAO_0000219
5980,646.0,,,1,,,CHEMBL621639,,Expert,F,,1,,N,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,A549,80682,BAO_0000219
5981,646.0,,,1,,,CHEMBL621640,,Intermediate,F,,1,,N,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,A549,80682,BAO_0000219
5982,646.0,,,1,,,CHEMBL621641,,Expert,F,,1,,N,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,A549,80682,BAO_0000219
5983,646.0,,,1,,,CHEMBL621642,,Expert,F,,1,,N,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,A549,80682,BAO_0000219
5984,646.0,,,1,,,CHEMBL621643,,Intermediate,F,,1,,N,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,A549,80682,BAO_0000219
5985,646.0,,,1,,,CHEMBL621644,,Intermediate,F,,1,,N,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,A549,80682,BAO_0000219
5986,646.0,,,1,,,CHEMBL621645,,Intermediate,F,,1,,N,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,A549,80682,BAO_0000219
5987,646.0,,,1,,,CHEMBL621646,,Intermediate,F,,1,,N,In vitro antiproliferative activity against A549 cell line,,A549,80682,BAO_0000219
5988,646.0,,,1,,,CHEMBL621647,,Intermediate,F,,1,,N,Synergism with indomethacin in A549 cells,,A549,80682,BAO_0000219
5989,646.0,,,1,,,CHEMBL621648,,Intermediate,F,,1,,N,Synergism with tolmetin in A549 cells,,A549,80682,BAO_0000219
5990,646.0,,,1,,,CHEMBL621649,,Intermediate,F,,1,,N,Synergism with sulindac in A549 cells,,A549,80682,BAO_0000219
5991,646.0,,,1,,,CHEMBL621650,,Intermediate,F,,1,,N,Antagonism of indomethacin in A549 cells,,A549,80682,BAO_0000219
5992,646.0,,,1,,,CHEMBL621651,,Intermediate,F,,1,,N,Antagonism of sulindac in A549 cells,,A549,80682,BAO_0000219
5993,646.0,,,1,,,CHEMBL621652,,Intermediate,F,,1,,N,Antagonism of tolmetin in A549 cells,,A549,80682,BAO_0000219
5994,646.0,,,1,,,CHEMBL621653,,Intermediate,F,,1,,N,Synergism with indomethacin in A549 cells,,A549,80682,BAO_0000219
5995,646.0,,,1,,,CHEMBL621654,,Intermediate,F,,1,,N,Synergism with sulindac in A549 cells,,A549,80682,BAO_0000219
5996,646.0,,,1,,,CHEMBL621655,,Intermediate,F,,1,,N,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,A549,80682,BAO_0000219
5997,,,,1,,In vivo,CHEMBL621656,,Intermediate,A,,1,,N,Cmax value after 30 mg/kg po dose in Dogs,,,50588,BAO_0000218
5998,,,,1,,In vivo,CHEMBL621657,,Intermediate,A,,1,,N,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,50588,BAO_0000218
5999,,,,1,,In vivo,CHEMBL621658,,Intermediate,A,,1,,N,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,,50588,BAO_0000218
6000,,,,1,,In vivo,CHEMBL621659,,Intermediate,A,,1,,N,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,50588,BAO_0000218
6001,,,,1,,In vivo,CHEMBL621660,,Intermediate,A,,1,,N,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,,50588,BAO_0000218
6002,,,,1,,In vivo,CHEMBL621661,,Intermediate,A,,1,,N,Cmax value after administration of 4 mg/Kg oral dose in dog,,,50588,BAO_0000218
6003,,,,1,,In vivo,CHEMBL621662,,Intermediate,A,,1,,N,Cmax value in dog,,,50588,BAO_0000218
6004,,,,1,,In vivo,CHEMBL621663,,Intermediate,A,,1,,N,Cmax value in dogs after oral administration at 1 mg/kg,,,50588,BAO_0000218
6005,,,,1,,In vivo,CHEMBL621664,,Intermediate,A,,1,,N,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,,50588,BAO_0000218
6006,,,1969.0,1,Plasma,In vivo,CHEMBL621665,,Intermediate,A,,1,,N,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,,50588,BAO_0000218
6007,,,1969.0,1,Plasma,In vivo,CHEMBL621666,,Intermediate,A,,1,,N,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,,50588,BAO_0000218
6008,,,,1,,In vivo,CHEMBL621667,,Intermediate,A,,1,,N,Concentration maxima after oral dosing in dogs,,,50588,BAO_0000218
6009,,,,1,,In vivo,CHEMBL876738,,Intermediate,A,,1,,N,Concentration maxima after oral dosing in dogs; not available,,,50588,BAO_0000218
6010,,,,1,,In vivo,CHEMBL621668,,Intermediate,A,,1,,N,Concentration maxima after oral dosing in dogs; not available,,,50588,BAO_0000218
6011,,,,1,,In vivo,CHEMBL621669,,Intermediate,A,,1,,N,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,,50588,BAO_0000218
6012,,,,1,,In vivo,CHEMBL621670,,Intermediate,A,,1,,N,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,,50588,BAO_0000218
6013,,,,1,,In vivo,CHEMBL621671,,Intermediate,A,,1,,N,In vivo maximal concentration was calculated at 1 mg/kg in dog,,,50588,BAO_0000218
6014,,,,1,,In vivo,CHEMBL622360,,Intermediate,A,,1,,N,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,,50588,BAO_0000218
6015,,,,1,,In vivo,CHEMBL622361,,Intermediate,A,,1,,N,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,,50588,BAO_0000218
6016,,,1969.0,1,Plasma,In vivo,CHEMBL622362,,Intermediate,A,,1,,N,Cmax in dog plasma after oral dose (1 mg/kg),,,50588,BAO_0000218
6017,,,1969.0,1,Plasma,In vivo,CHEMBL622363,,Intermediate,A,,1,,N,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,,50588,BAO_0000218
6018,,,1969.0,1,Plasma,In vivo,CHEMBL622364,,Intermediate,A,,1,,N,Maximal plasma concentration at a dose of 1 mg/kg,,,50588,BAO_0000218
6019,,,1969.0,1,Plasma,In vivo,CHEMBL622365,,Intermediate,A,,1,,N,Maximal plasma concentration at a dose of 1 mg/kg (oral),,,50588,BAO_0000218
6020,,,1969.0,1,Plasma,In vivo,CHEMBL622533,,Intermediate,A,,1,,N,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,,50588,BAO_0000218
6021,,,,1,,In vivo,CHEMBL622534,,Intermediate,A,,1,,N,Maximum concentration of compound in dog was evaluated.,,,50588,BAO_0000218
6022,,,,1,,In vivo,CHEMBL622535,,Intermediate,A,,1,,N,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,,50588,BAO_0000218
6023,,,,1,,In vivo,CHEMBL876739,,Intermediate,A,,1,,N,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,,50588,BAO_0000218
6024,,,,1,,In vivo,CHEMBL622536,,Intermediate,A,,1,,N,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,50588,BAO_0000218
6025,,,1969.0,1,Plasma,In vivo,CHEMBL622537,,Intermediate,A,,1,,N,Maximum concentration obtained in dog plasma was determined,,,50588,BAO_0000218
6026,,,,1,,In vivo,CHEMBL622538,,Intermediate,A,,1,,N,Maximum concentration was determined,,,50588,BAO_0000218
6027,,,,1,,In vivo,CHEMBL627867,,Intermediate,A,,1,,N,Maximum concentration at the dose of 2 mg/kg in dog,,,50588,BAO_0000218
6028,,,,1,,In vivo,CHEMBL627868,,Intermediate,A,,1,,N,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,50588,BAO_0000218
6029,,,1969.0,1,Plasma,In vivo,CHEMBL627869,,Intermediate,A,,1,,N,Maximum concentration was evaluated in dog plasma,,,50588,BAO_0000218
6030,,,,1,,In vivo,CHEMBL627870,,Intermediate,A,,1,,N,Maximum concentration was evaluated after 75 min after administration in dog,,,50588,BAO_0000218
6031,,,1969.0,1,Plasma,In vivo,CHEMBL627871,,Intermediate,A,,1,,N,Maximum plasma concentration determined in dog after oral administration of 17b,,,50588,BAO_0000218
6032,,,1969.0,1,Plasma,In vivo,CHEMBL627872,,Intermediate,A,,1,,N,Maximum plasma concentration determined in dog after oral administration of 2b,,,50588,BAO_0000218
6033,,,1969.0,1,Plasma,In vivo,CHEMBL627873,,Intermediate,A,,1,,N,Maximum plasma concentration in dog,,,50588,BAO_0000218
6034,,,1969.0,1,Plasma,In vivo,CHEMBL627874,,Intermediate,A,,1,,N,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,,50588,BAO_0000218
6035,,,1969.0,1,Plasma,In vivo,CHEMBL627875,,Intermediate,A,,1,,N,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,,50588,BAO_0000218
6036,,,1969.0,1,Plasma,In vivo,CHEMBL627876,,Intermediate,A,,1,,N,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,,50588,BAO_0000218
6037,,,1969.0,1,Plasma,In vivo,CHEMBL627877,,Intermediate,A,,1,,N,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,,50588,BAO_0000218
6038,,,1969.0,1,Plasma,In vivo,CHEMBL627878,,Intermediate,A,,1,,N,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588,BAO_0000218
6039,,,1969.0,1,Plasma,In vivo,CHEMBL627879,,Intermediate,A,,1,,N,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,,50588,BAO_0000218
6040,,,1969.0,1,Plasma,In vivo,CHEMBL875355,,Intermediate,A,,1,,N,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,50588,BAO_0000218
6041,,,1969.0,1,Plasma,In vivo,CHEMBL627880,,Intermediate,A,,1,,N,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,50588,BAO_0000218
6042,,,1969.0,1,Plasma,In vivo,CHEMBL627881,,Intermediate,A,,1,,N,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,50588,BAO_0000218
6043,,,1969.0,1,Plasma,In vivo,CHEMBL627882,,Intermediate,A,,1,,N,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,50588,BAO_0000218
6044,,,1969.0,1,Plasma,In vivo,CHEMBL627883,,Intermediate,A,,1,,N,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,,50588,BAO_0000218
6045,,,1969.0,1,Plasma,In vivo,CHEMBL628526,,Intermediate,A,,1,,N,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,,50588,BAO_0000218
6046,,,1969.0,1,Plasma,In vivo,CHEMBL628527,,Intermediate,A,,1,,N,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,,50588,BAO_0000218
6047,,,1969.0,1,Plasma,In vivo,CHEMBL628528,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,,50588,BAO_0000218
6048,,,1969.0,1,Plasma,In vivo,CHEMBL628529,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,,50588,BAO_0000218
6049,,,1969.0,1,Plasma,In vivo,CHEMBL628530,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,,50588,BAO_0000218
6050,,,1969.0,1,Plasma,In vivo,CHEMBL625243,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,,50588,BAO_0000218
6051,,,1969.0,1,Plasma,In vivo,CHEMBL625244,,Expert,A,,1,,N,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,,50588,BAO_0000218
6052,,,,1,,In vivo,CHEMBL625245,,Intermediate,A,,1,,N,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,,50588,BAO_0000218
6053,,,,1,,In vivo,CHEMBL625246,,Intermediate,A,,1,,N,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,,50588,BAO_0000218
6054,,,945.0,1,Stomach,In vivo,CHEMBL625247,,Intermediate,A,,1,,N,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
6055,,,1088.0,1,Urine,In vivo,CHEMBL625248,,Intermediate,A,,1,,N,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594,BAO_0000218
6056,,,1088.0,1,Urine,In vivo,CHEMBL625249,,Intermediate,A,,1,,N,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,,50594,BAO_0000218
6057,,,1088.0,1,Urine,In vivo,CHEMBL625250,,Intermediate,A,,1,,N,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,,50594,BAO_0000218
6058,,,,1,,,CHEMBL625251,,Intermediate,A,,1,,N,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,,50594,BAO_0000218
6059,,,,1,,,CHEMBL875356,,Intermediate,A,,1,,N,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,,50594,BAO_0000218
6060,,,,1,,,CHEMBL625252,,Intermediate,A,,1,,N,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,,50594,BAO_0000218
6061,,,178.0,1,Blood,,CHEMBL625253,,Intermediate,A,,1,,N,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,50594,BAO_0000218
6062,,,,1,,,CHEMBL625254,,Intermediate,A,,1,,N,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,,50594,BAO_0000218
6063,,,,1,,,CHEMBL625255,,Intermediate,A,,1,,N,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,,50594,BAO_0000218
6064,,,,1,,,CHEMBL625256,,Intermediate,A,,1,,N,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,,50594,BAO_0000218
6065,,,178.0,1,Blood,,CHEMBL625257,,Intermediate,A,,1,,N,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,50594,BAO_0000218
6066,,,178.0,1,Blood,,CHEMBL625258,,Intermediate,A,,1,,N,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,,50594,BAO_0000218
6067,,,,1,,,CHEMBL625259,,Intermediate,A,,1,,N,Compound was evaluated for washout rate in mice (Radiolabeled compound),,,50594,BAO_0000218
6068,,,,1,,,CHEMBL625260,,Intermediate,A,,1,,N,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,,50594,BAO_0000218
6069,,,,1,,,CHEMBL625261,,Intermediate,A,,1,,N,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,50594,BAO_0000218
6070,,,,1,,,CHEMBL625262,,Intermediate,A,,1,,N,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,50594,BAO_0000218
6071,,,,1,,,CHEMBL622639,,Intermediate,A,,1,,N,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,50594,BAO_0000218
6072,,,,1,,,CHEMBL622640,,Intermediate,A,,1,,N,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,,50594,BAO_0000218
6073,,,,1,,,CHEMBL622812,,Intermediate,A,,1,,N,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,,50594,BAO_0000218
6074,,,,1,,,CHEMBL622813,,Intermediate,A,,1,,N,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,,50594,BAO_0000218
6075,,,,1,,,CHEMBL622814,,Intermediate,A,,1,,N,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,,50594,BAO_0000218
6076,,,,1,,,CHEMBL622815,,Intermediate,A,,1,,N,Time at maximum activity in mice (Radiolabeled compound),,,50594,BAO_0000218
6077,,,,1,,,CHEMBL625342,,Intermediate,A,,1,,N,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,,50594,BAO_0000218
6078,,,,1,,,CHEMBL625343,,Intermediate,A,,1,,N,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,,50594,BAO_0000218
6079,,,,1,,,CHEMBL877591,,Intermediate,A,,1,,N,Binding towards mouse plasma protein at 10 uM,,,50594,BAO_0000218
6080,,,,1,,,CHEMBL625344,,Intermediate,A,,1,,N,Binding towards mouse plasma protein at 100 uM,,,50594,BAO_0000218
6081,,,,1,,In vivo,CHEMBL625345,,Intermediate,A,,1,,N,Bioavailability was evaluated in mice after intravenous administration,,,50594,BAO_0000218
6082,,,,1,,In vivo,CHEMBL625346,,Intermediate,A,,1,,N,Bioavailability was evaluated in mice after oral administration,,,50594,BAO_0000218
6083,,,,1,,In vivo,CHEMBL625347,,Intermediate,A,,1,,N,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,,50594,BAO_0000218
6084,,,,1,,In vivo,CHEMBL625348,,Intermediate,A,,1,,N,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,,50594,BAO_0000218
6085,,,,1,,In vivo,CHEMBL625349,,Intermediate,A,,1,,N,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,,50594,BAO_0000218
6086,,,,1,,In vivo,CHEMBL625350,,Intermediate,A,,1,,N,Oral bioavailability in mouse,,,50594,BAO_0000218
6087,,,,1,,In vivo,CHEMBL882952,,Intermediate,A,,1,,N,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,,50594,BAO_0000218
6088,,,955.0,1,Brain,In vivo,CHEMBL625351,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6089,,,955.0,1,Brain,In vivo,CHEMBL625352,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6090,,,955.0,1,Brain,In vivo,CHEMBL877592,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6091,,,955.0,1,Brain,In vivo,CHEMBL625353,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6092,,,955.0,1,Brain,In vivo,CHEMBL625354,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6093,,,955.0,1,Brain,In vivo,CHEMBL626019,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6094,,,948.0,1,Heart,In vivo,CHEMBL626020,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6095,,,948.0,1,Heart,In vivo,CHEMBL626021,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6096,,,948.0,1,Heart,In vivo,CHEMBL626022,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6097,,,948.0,1,Heart,In vivo,CHEMBL626192,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6098,646.0,,,1,,,CHEMBL626193,,Intermediate,F,,1,,N,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,A549,80682,BAO_0000219
6099,646.0,,,1,,,CHEMBL626194,,Expert,F,,1,,N,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,A549,80682,BAO_0000219
6100,646.0,,,1,,,CHEMBL626195,,Intermediate,F,,1,,N,Cytotoxicity against human lung carcinoma A-549 cell lines,,A549,80682,BAO_0000219
6101,646.0,,,1,,,CHEMBL626196,,Intermediate,F,,1,,N,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,A549,80682,BAO_0000219
6102,646.0,,,1,,,CHEMBL626197,,Intermediate,F,,1,,N,In vitro cytotoxicity against human lung carcinoma cell line A-549,,A549,80682,BAO_0000219
6103,646.0,,,1,,,CHEMBL626198,,Intermediate,F,,1,,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,A549,80682,BAO_0000219
6104,646.0,,,1,,,CHEMBL626199,,Intermediate,F,,1,,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,A549,80682,BAO_0000219
6105,646.0,,,1,,,CHEMBL626200,,Intermediate,F,,1,,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,A549,80682,BAO_0000219
6106,646.0,,,1,,,CHEMBL626201,,Intermediate,F,,1,,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,A549,80682,BAO_0000219
6107,646.0,,,1,,,CHEMBL626202,,Intermediate,F,,1,,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,A549,80682,BAO_0000219
6108,646.0,,,1,,,CHEMBL626203,,Intermediate,F,,1,,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,A549,80682,BAO_0000219
6109,646.0,,,1,,,CHEMBL626204,,Intermediate,F,,1,,N,In vitro cytotoxicity against A-549 human lung cancer cells,,A549,80682,BAO_0000219
6110,646.0,,,1,,,CHEMBL624701,,Intermediate,F,,1,,N,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,A549,80682,BAO_0000219
6111,646.0,,,1,,,CHEMBL624702,,Intermediate,F,,1,,N,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,A549,80682,BAO_0000219
6112,646.0,,,1,,,CHEMBL624703,,Expert,F,,1,,N,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,A549,80682,BAO_0000219
6113,646.0,,,1,,,CHEMBL624704,,Intermediate,F,,1,,N,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,A549,80682,BAO_0000219
6114,646.0,,,1,,,CHEMBL624705,,Intermediate,F,,1,,N,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,A549,80682,BAO_0000219
6115,646.0,,,1,,,CHEMBL624706,,Expert,F,,1,,N,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,A549,80682,BAO_0000219
6116,646.0,,,1,,,CHEMBL624707,,Intermediate,F,,1,,N,Antitumor cytotoxic activity against A-549 cell line was determined,,A549,80682,BAO_0000219
6117,646.0,,,1,,,CHEMBL624708,,Intermediate,F,,1,,N,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,A549,80682,BAO_0000219
6118,646.0,,,1,,,CHEMBL624709,,Intermediate,F,,1,,N,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,A549,80682,BAO_0000219
6119,646.0,,,1,,,CHEMBL884107,,Expert,F,,1,,N,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,A549,80682,BAO_0000219
6120,646.0,,,1,,,CHEMBL624710,,Intermediate,F,,1,,N,Antitumoral activity was assayed against A-549 cell line,,A549,80682,BAO_0000219
6121,646.0,,,1,,,CHEMBL624711,,Intermediate,F,,1,,N,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,A549,80682,BAO_0000219
6122,646.0,,,1,,,CHEMBL624712,,Intermediate,F,,1,,N,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,A549,80682,BAO_0000219
6123,646.0,,,1,,,CHEMBL624713,,Expert,F,,1,,N,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,A549,80682,BAO_0000219
6124,646.0,,,1,,,CHEMBL624714,,Intermediate,F,,1,,N,Compound was tested for inhibition of cell growth of A-549 cells,,A549,80682,BAO_0000219
6125,646.0,,,1,,,CHEMBL624715,,Intermediate,F,,1,,N,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,A549,80682,BAO_0000219
6126,646.0,,,1,,,CHEMBL624716,,Intermediate,F,,1,,N,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,A549,80682,BAO_0000219
6127,646.0,,,1,,,CHEMBL619505,,Expert,F,,1,,N,In vitro cytotoxicity against A549-human lung carcinoma cells.,,A549,80682,BAO_0000219
6128,646.0,,,1,,,CHEMBL619506,,Expert,F,,1,,N,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,A549,80682,BAO_0000219
6129,646.0,,,1,,,CHEMBL619507,,Intermediate,F,,1,,N,Cytotoxic activity against A-549 cell lines.,,A549,80682,BAO_0000219
6130,646.0,,,1,,,CHEMBL619508,,Expert,F,,1,,N,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,A549,80682,BAO_0000219
6131,646.0,,,1,,,CHEMBL619509,,Intermediate,F,,1,,N,Cytotoxicity against human A549 non small cell lung cell lines,,A549,80682,BAO_0000219
6132,646.0,,,1,,,CHEMBL619510,,Expert,F,,1,,N,Inhibition of cell growth in (A-549) lung cell line,,A549,80682,BAO_0000219
6133,646.0,,,1,,,CHEMBL619511,,Intermediate,F,,1,,N,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,A549,80682,BAO_0000219
6134,646.0,,,1,,,CHEMBL619512,,Intermediate,F,,1,,N,In vitro antitumor activity against A-549 tumor cells.,,A549,80682,BAO_0000219
6135,646.0,,,1,,,CHEMBL619513,,Expert,F,,1,,N,In vitro antitumor effects against human A-549 cell lines.,,A549,80682,BAO_0000219
6136,646.0,,,1,,,CHEMBL619514,,Intermediate,F,,1,,N,In vitro cytotoxic activity of compound against A-549 cell line,,A549,80682,BAO_0000219
6137,646.0,,,1,,,CHEMBL619515,,Intermediate,F,,1,,N,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,A549,80682,BAO_0000219
6138,646.0,,,1,,,CHEMBL619516,,Intermediate,F,,1,,N,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,A549,80682,BAO_0000219
6139,646.0,,,1,,,CHEMBL884005,,Intermediate,F,,1,,N,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,A549,80682,BAO_0000219
6140,646.0,,,1,,,CHEMBL619517,,Expert,F,,1,,N,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,A549,80682,BAO_0000219
6141,646.0,,,1,,,CHEMBL619518,,Intermediate,F,,1,,N,Inhibitory concentration of compound against A-549 cell line,,A549,80682,BAO_0000219
6142,646.0,,,1,,,CHEMBL619519,,Intermediate,F,,1,,N,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,A549,80682,BAO_0000219
6143,646.0,,,1,,,CHEMBL876489,,Intermediate,F,,1,,N,cytotoxic activity against leukemia (A-549) cancer cell line,,A549,80682,BAO_0000219
6144,646.0,,,1,,,CHEMBL619520,,Expert,F,,1,,N,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,A549,80682,BAO_0000219
6145,646.0,,,1,,,CHEMBL619521,,Intermediate,F,,1,,N,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,A549,80682,BAO_0000219
6146,646.0,,,1,,,CHEMBL619522,,Intermediate,F,,1,,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,A549,80682,BAO_0000219
6147,646.0,,,1,,,CHEMBL619523,,Intermediate,F,,1,,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,A549,80682,BAO_0000219
6148,646.0,,,1,,,CHEMBL619524,,Intermediate,F,,1,,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,A549,80682,BAO_0000219
6149,646.0,,,1,,,CHEMBL619525,,Intermediate,F,,1,,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,A549,80682,BAO_0000219
6150,646.0,,,1,,,CHEMBL619526,,Intermediate,F,,1,,N,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,A549,80682,BAO_0000219
6151,646.0,,,1,,,CHEMBL619527,,Intermediate,F,,1,,N,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,A549,80682,BAO_0000219
6152,646.0,,,1,,,CHEMBL619528,,Intermediate,F,,1,,N,Cytotoxicity against A549 cells; No cytotoxicity,,A549,80682,BAO_0000219
6153,646.0,,,1,,,CHEMBL619529,,Expert,F,,1,,N,Cytotoxicity against human lung carcinoma (A549) cell lines,,A549,80682,BAO_0000219
6154,646.0,,,1,,,CHEMBL619530,,Expert,F,,1,,N,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,A549,80682,BAO_0000219
6155,646.0,,,1,,,CHEMBL876490,,Intermediate,F,,1,,N,In vitro anticancer activity against human lung (A549) cell line,,A549,80682,BAO_0000219
6156,646.0,,,1,,,CHEMBL619531,,Intermediate,F,,1,,N,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,A549,80682,BAO_0000219
6157,646.0,,,1,,,CHEMBL619532,,Intermediate,F,,1,,N,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6158,646.0,,,1,,,CHEMBL619533,,Intermediate,F,,1,,N,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6159,646.0,,,1,,,CHEMBL619534,,Intermediate,F,,1,,N,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6160,646.0,,,1,,,CHEMBL620164,,Intermediate,F,,1,,N,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6161,646.0,,,1,,,CHEMBL620165,,Intermediate,F,,1,,N,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6162,646.0,,,1,,,CHEMBL620166,,Expert,F,,1,,N,Inhibition of A549 human lung tumor cell proliferation,,A549,80682,BAO_0000219
6163,646.0,,,1,,,CHEMBL620167,,Intermediate,F,,1,,N,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,A549,80682,BAO_0000219
6164,646.0,,,1,,,CHEMBL620168,,Expert,F,,1,,N,In vitro cytotoxicity against human tumor cell line A549,,A549,80682,BAO_0000219
6165,646.0,,,1,,,CHEMBL620338,,Intermediate,F,,1,,N,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,A549,80682,BAO_0000219
6166,646.0,,,1,,,CHEMBL620339,,Intermediate,F,,1,,N,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,A549,80682,BAO_0000219
6167,646.0,,,1,,,CHEMBL620340,,Intermediate,F,,1,,N,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,A549,80682,BAO_0000219
6168,646.0,,,1,,,CHEMBL620341,,Intermediate,F,,1,,N,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,A549,80682,BAO_0000219
6169,646.0,,,1,,,CHEMBL876491,,Intermediate,F,,1,,N,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,A549,80682,BAO_0000219
6170,646.0,,,1,,,CHEMBL620342,,Intermediate,F,,1,,N,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,A549,80682,BAO_0000219
6171,646.0,,,1,,,CHEMBL620343,,Intermediate,F,,1,,N,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,A549,80682,BAO_0000219
6172,646.0,,,1,,,CHEMBL620344,,Intermediate,F,,1,,N,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,A549,80682,BAO_0000219
6173,646.0,,,1,,,CHEMBL620345,,Intermediate,F,,1,,N,In vitro anticancer activity against human lung (A549) cell line,,A549,80682,BAO_0000219
6174,646.0,,,1,,,CHEMBL620346,,Intermediate,F,,1,,N,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,A549,80682,BAO_0000219
6175,646.0,,,1,,,CHEMBL620347,,Intermediate,F,,1,,N,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,A549,80682,BAO_0000219
6176,646.0,,,1,,,CHEMBL620348,,Intermediate,F,,1,,N,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,A549,80682,BAO_0000219
6177,646.0,,,1,,,CHEMBL620349,,Intermediate,F,,1,,N,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,A549,80682,BAO_0000219
6178,646.0,,,1,,,CHEMBL618667,,Intermediate,F,,1,,N,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,A549,80682,BAO_0000219
6179,646.0,,,1,,,CHEMBL618668,,Expert,F,,1,,N,Percentage inhibition of human lung carcinoma (A549) cell lines,,A549,80682,BAO_0000219
6180,646.0,,,1,,,CHEMBL876031,,Intermediate,F,,1,,N,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,A549,80682,BAO_0000219
6181,646.0,,,1,,,CHEMBL618759,,Intermediate,F,,1,,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,A549,80682,BAO_0000219
6182,646.0,,,1,,,CHEMBL618760,,Intermediate,F,,1,,N,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,A549,80682,BAO_0000219
6183,646.0,,,1,,,CHEMBL619000,,Intermediate,F,,1,,N,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,A549,80682,BAO_0000219
6184,646.0,,,1,,,CHEMBL619001,,Intermediate,F,,1,,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,A549,80682,BAO_0000219
6185,646.0,,,1,,,CHEMBL619002,,Intermediate,F,,1,,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,A549,80682,BAO_0000219
6186,646.0,,,1,,,CHEMBL619003,,Intermediate,F,,1,,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,A549,80682,BAO_0000219
6187,646.0,,,1,,,CHEMBL619597,,Intermediate,F,,1,,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,A549,80682,BAO_0000219
6188,646.0,,,1,,,CHEMBL619598,,Intermediate,F,,1,,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,A549,80682,BAO_0000219
6189,646.0,,,1,,,CHEMBL619599,,Intermediate,F,,1,,N,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,A549,80682,BAO_0000219
6190,646.0,,,1,,,CHEMBL619600,,Intermediate,F,,1,,N,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,A549,80682,BAO_0000219
6191,646.0,,,1,,,CHEMBL619601,,Intermediate,F,,1,,N,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,A549,80682,BAO_0000219
6192,646.0,,,1,,,CHEMBL619602,,Intermediate,F,,1,,N,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6193,646.0,,,1,,,CHEMBL619603,,Intermediate,F,,1,,N,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6194,646.0,,,1,,,CHEMBL619604,,Intermediate,F,,1,,N,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6195,646.0,,,1,,,CHEMBL619605,,Intermediate,F,,1,,N,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6196,,,,1,,In vivo,CHEMBL619606,,Intermediate,A,,1,,N,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,,50588,BAO_0000218
6197,,,,1,,In vivo,CHEMBL876032,,Intermediate,A,,1,,N,Pharmacokinetic activity (Cmax) in dog,,,50588,BAO_0000218
6198,,,,1,,In vivo,CHEMBL619607,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,50588,BAO_0000218
6199,,,,1,,In vivo,CHEMBL619608,,Intermediate,A,,1,,N,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,,50588,BAO_0000218
6200,,,,1,,In vivo,CHEMBL619609,,Intermediate,A,,1,,N,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,,50588,BAO_0000218
6201,,,1969.0,1,Plasma,In vivo,CHEMBL619610,,Intermediate,A,,1,,N,Cmax in dog plasma after 30mg/kg oral dose,,,50588,BAO_0000218
6202,,,178.0,1,Blood,In vivo,CHEMBL619611,,Intermediate,A,,1,,N,Tested for the peak blood level in dog,,,50588,BAO_0000218
6203,,,,1,,In vivo,CHEMBL619612,,Intermediate,A,,1,,N,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,,50588,BAO_0000218
6204,,,,1,,In vivo,CHEMBL619613,,Intermediate,A,,1,,N,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,,50588,BAO_0000218
6205,,,178.0,1,Blood,In vivo,CHEMBL619614,,Intermediate,A,,1,,N,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,,50588,BAO_0000218
6206,,,,1,,,CHEMBL619615,,Intermediate,A,,1,,N,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,,50588,BAO_0000218
6207,,,,1,,,CHEMBL619616,,Intermediate,A,,1,,N,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,,50588,BAO_0000218
6208,,,1969.0,1,Plasma,,CHEMBL619617,,Intermediate,A,,1,,N,Final plasma concentration in dogs after oral administration at 1 mg/kg,,,50588,BAO_0000218
6209,,,,1,,,CHEMBL619618,,Intermediate,A,,1,,N,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,,50588,BAO_0000218
6210,,,,1,,,CHEMBL876033,,Intermediate,A,,1,,N,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,,50588,BAO_0000218
6211,,,,1,,,CHEMBL619619,,Intermediate,A,,1,,N,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,,50588,BAO_0000218
6212,,,,1,,,CHEMBL619620,,Intermediate,A,,1,,N,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,,50588,BAO_0000218
6213,,,1088.0,1,Urine,,CHEMBL619621,,Intermediate,A,,1,,N,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,,50588,BAO_0000218
6214,,,1088.0,1,Urine,,CHEMBL619622,,Intermediate,A,,1,,N,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,,50588,BAO_0000218
6215,,,1088.0,1,Urine,,CHEMBL618874,,Intermediate,A,,1,,N,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,,50588,BAO_0000218
6216,,,,1,,In vivo,CHEMBL618875,,Intermediate,A,,1,,N,Absolute bioavailability was evaluated in dog,,,50588,BAO_0000218
6217,,,,1,,In vivo,CHEMBL618876,,Intermediate,A,,1,,N,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,,50588,BAO_0000218
6218,,,,1,,In vivo,CHEMBL618877,,Intermediate,A,,1,,N,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,,50588,BAO_0000218
6219,,,,1,,In vivo,CHEMBL618878,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6220,,,,1,,In vivo,CHEMBL618879,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6221,,,,1,,In vivo,CHEMBL618880,,Intermediate,A,,1,,N,Bioavailability after intravenous administration in dogs,,,50588,BAO_0000218
6222,,,,1,,In vivo,CHEMBL618881,,Intermediate,A,,1,,N,Bioavailability after peroral administration in dogs,,,50588,BAO_0000218
6223,,,,1,,In vivo,CHEMBL618882,,Intermediate,A,,1,,N,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,50588,BAO_0000218
6224,,,,1,,In vivo,CHEMBL624226,,Intermediate,A,,1,,N,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,,50588,BAO_0000218
6225,,,1969.0,1,Plasma,In vivo,CHEMBL624227,,Intermediate,A,,1,,N,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,,50588,BAO_0000218
6226,,,,1,,In vivo,CHEMBL624228,,Intermediate,A,,1,,N,Bioavailability,,,50588,BAO_0000218
6227,,,,1,,In vivo,CHEMBL624229,,Intermediate,A,,1,,N,Bioavailability,,,50588,BAO_0000218
6228,,,,1,,In vivo,CHEMBL624230,,Intermediate,A,,1,,N,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,,50588,BAO_0000218
6229,,,,1,,In vivo,CHEMBL624231,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6230,,,,1,,In vivo,CHEMBL624232,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6231,,,,1,,In vivo,CHEMBL625127,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6232,,,,1,,In vivo,CHEMBL625128,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6233,,,,1,,In vivo,CHEMBL621675,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6234,,,,1,,In vivo,CHEMBL621676,,Intermediate,A,,1,,N,Bioavailability in dog (p.o.) at 2.0 mpk,,,50588,BAO_0000218
6235,,,,1,,In vivo,CHEMBL621677,,Intermediate,A,,1,,N,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,,50588,BAO_0000218
6236,,,,1,,In vivo,CHEMBL621678,,Intermediate,A,,1,,N,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,50588,BAO_0000218
6237,,,,1,,In vivo,CHEMBL621679,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6238,,,,1,,In vivo,CHEMBL621680,,Intermediate,A,,1,,N,Bioavailability was evaluated after oral administration in dog,,,50588,BAO_0000218
6239,,,,1,,In vivo,CHEMBL621681,,Intermediate,A,,1,,N,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,50588,BAO_0000218
6240,,,,1,,In vivo,CHEMBL876740,,Intermediate,A,,1,,N,Bioavailability was evaluated in dog,,,50588,BAO_0000218
6241,,,,1,,In vivo,CHEMBL621682,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6242,,,,1,,In vivo,CHEMBL621683,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6243,,,,1,,In vivo,CHEMBL621684,,Intermediate,A,,1,,N,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,50588,BAO_0000218
6244,,,,1,,In vivo,CHEMBL621685,,Intermediate,A,,1,,N,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,50588,BAO_0000218
6245,,,,1,,In vivo,CHEMBL621686,,Intermediate,A,,1,,N,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,50588,BAO_0000218
6246,,,,1,,In vivo,CHEMBL621687,,Intermediate,A,,1,,N,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588,BAO_0000218
6247,,,,1,,In vivo,CHEMBL621688,,Intermediate,A,,1,,N,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,,50588,BAO_0000218
6248,,,,1,,In vivo,CHEMBL621689,,Intermediate,A,,1,,N,Bioavailability of compound in dog was determined after peroral administration,,,50588,BAO_0000218
6249,,,,1,,In vivo,CHEMBL621690,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6250,,,,1,,In vivo,CHEMBL621691,,Intermediate,A,,1,,N,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,,50588,BAO_0000218
6251,,,,1,,In vivo,CHEMBL875941,,Intermediate,A,,1,,N,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,,50588,BAO_0000218
6252,,,,1,,In vivo,CHEMBL621692,,Intermediate,A,,1,,N,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,,50588,BAO_0000218
6253,,,,1,,In vivo,CHEMBL621693,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6254,,,,1,,In vivo,CHEMBL621694,,Intermediate,A,,1,,N,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,,50588,BAO_0000218
6255,,,948.0,1,Heart,In vivo,CHEMBL621695,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6256,,,948.0,1,Heart,In vivo,CHEMBL621696,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6257,,,2113.0,1,Kidney,In vivo,CHEMBL621697,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6258,,,2113.0,1,Kidney,In vivo,CHEMBL621698,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6259,,,2113.0,1,Kidney,In vivo,CHEMBL623420,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6260,,,2113.0,1,Kidney,In vivo,CHEMBL623421,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6261,,,2113.0,1,Kidney,In vivo,CHEMBL623422,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6262,,,2113.0,1,Kidney,In vivo,CHEMBL623423,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6263,,,2107.0,1,Liver,In vivo,CHEMBL623424,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6264,,,2107.0,1,Liver,In vivo,CHEMBL623425,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6265,,,2107.0,1,Liver,In vivo,CHEMBL623426,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6266,,,2107.0,1,Liver,In vivo,CHEMBL623427,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6267,,,2107.0,1,Liver,In vivo,CHEMBL623428,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6268,,,2107.0,1,Liver,In vivo,CHEMBL875947,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6269,,,2048.0,1,Lung,In vivo,CHEMBL623429,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6270,,,2048.0,1,Lung,In vivo,CHEMBL623430,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6271,,,2048.0,1,Lung,In vivo,CHEMBL622588,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6272,,,2048.0,1,Lung,In vivo,CHEMBL622589,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6273,,,2048.0,1,Lung,In vivo,CHEMBL622751,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6274,,,2048.0,1,Lung,In vivo,CHEMBL622752,,Intermediate,A,,1,,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,50594,BAO_0000218
6275,42.0,,,1,,,CHEMBL622753,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6276,42.0,,,1,,,CHEMBL622647,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6277,42.0,,,1,,,CHEMBL875163,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6278,42.0,,,1,,,CHEMBL622648,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6279,42.0,,,1,,,CHEMBL622649,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6280,42.0,,955.0,1,Brain,,CHEMBL622650,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6281,42.0,,955.0,1,Brain,,CHEMBL622651,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6282,42.0,,955.0,1,Brain,,CHEMBL622652,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6283,42.0,,955.0,1,Brain,,CHEMBL622653,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6284,42.0,,955.0,1,Brain,,CHEMBL622654,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6285,42.0,,948.0,1,Heart,,CHEMBL622655,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6286,42.0,,948.0,1,Heart,,CHEMBL622656,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6287,42.0,,948.0,1,Heart,,CHEMBL622657,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6288,42.0,,948.0,1,Heart,,CHEMBL622658,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6289,42.0,,948.0,1,Heart,,CHEMBL622659,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6290,42.0,,2113.0,1,Kidney,,CHEMBL624630,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6291,42.0,,2113.0,1,Kidney,,CHEMBL624631,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6292,42.0,,2113.0,1,Kidney,,CHEMBL624632,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6293,646.0,,,1,,,CHEMBL624633,,Intermediate,F,,1,,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,A549,80682,BAO_0000219
6294,646.0,,,1,,,CHEMBL624634,,Intermediate,F,,1,,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,A549,80682,BAO_0000219
6295,646.0,,,1,,,CHEMBL624635,,Intermediate,F,,1,,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,A549,80682,BAO_0000219
6296,646.0,,,1,,,CHEMBL624636,,Intermediate,F,,1,,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,A549,80682,BAO_0000219
6297,646.0,,,1,,,CHEMBL857055,,Expert,F,,1,,N,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,A549,80682,BAO_0000219
6298,646.0,,,1,,,CHEMBL624637,,Expert,F,,1,,N,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,A549,80682,BAO_0000219
6299,646.0,,,1,,,CHEMBL624638,,Expert,F,,1,,N,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,A549,80682,BAO_0000219
6300,646.0,,,1,,,CHEMBL874366,,Expert,F,,1,,N,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,A549,80682,BAO_0000219
6301,646.0,,,1,,,CHEMBL624639,,Expert,F,,1,,N,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,A549,80682,BAO_0000219
6302,646.0,,,1,,,CHEMBL624640,,Expert,F,,1,,N,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,A549,80682,BAO_0000219
6303,646.0,,,1,,,CHEMBL624641,,Intermediate,F,,1,,N,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,A549,80682,BAO_0000219
6304,646.0,,,1,,,CHEMBL624642,,Intermediate,F,,1,,N,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,A549,80682,BAO_0000219
6305,646.0,,,1,,,CHEMBL624643,,Intermediate,F,,1,,N,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,A549,80682,BAO_0000219
6306,646.0,,,1,,,CHEMBL624644,,Intermediate,F,,1,,N,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,A549,80682,BAO_0000219
6307,646.0,,,1,,,CHEMBL624645,,Intermediate,F,,1,,N,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,A549,80682,BAO_0000219
6308,646.0,,,1,,,CHEMBL619445,,Intermediate,F,,1,,N,The compound was evaluated for its cytotoxic potency against A-549 cell line,,A549,80682,BAO_0000219
6309,646.0,,,1,,,CHEMBL839886,,Expert,F,,1,,N,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,A549,80682,BAO_0000219
6310,646.0,,,1,,,CHEMBL619446,,Intermediate,F,,1,,N,Cytotoxic activity of compound against A-549 tumor cell line.,,A549,80682,BAO_0000219
6311,646.0,,,1,,,CHEMBL619447,,Intermediate,F,,1,,N,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,A549,80682,BAO_0000219
6312,646.0,,,1,,,CHEMBL619448,,Intermediate,F,,1,,N,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,A549,80682,BAO_0000219
6313,646.0,,,1,,,CHEMBL619449,,Intermediate,F,,1,,N,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,A549,80682,BAO_0000219
6314,646.0,,,1,,,CHEMBL619450,,Intermediate,F,,1,,N,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,A549,80682,BAO_0000219
6315,646.0,,,1,,,CHEMBL619451,,Intermediate,F,,1,,N,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,A549,80682,BAO_0000219
6316,646.0,,,1,,,CHEMBL619452,,Expert,F,,1,,N,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,A549,80682,BAO_0000219
6317,646.0,,,1,,,CHEMBL619453,,Intermediate,F,,1,,N,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,A549,80682,BAO_0000219
6318,646.0,,,1,,,CHEMBL874367,,Intermediate,F,,1,,N,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,A549,80682,BAO_0000219
6319,646.0,,,1,,,CHEMBL619454,,Intermediate,F,,1,,N,Cytotoxic concentration against A-549 tumor cells.,,A549,80682,BAO_0000219
6320,646.0,,,1,,,CHEMBL619455,,Intermediate,F,,1,,N,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,A549,80682,BAO_0000219
6321,646.0,,,1,,,CHEMBL619456,,Intermediate,F,,1,,N,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,A549,80682,BAO_0000219
6322,,,,1,,,CHEMBL619457,,Expert,F,,1,,N,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,,50191,BAO_0000218
6323,,,,1,,,CHEMBL619458,,Intermediate,F,,1,,N,Activity against Acinetobacter calcoaceticus (AC54),,,50192,BAO_0000218
6324,,,,1,,,CHEMBL619459,,Expert,F,,1,,N,In vitro antifungal activity against Aspergillus flavus CM74,,,50274,BAO_0000218
6325,,,,1,,,CHEMBL619460,,Expert,F,,1,,N,In vitro antifungal activity against Aspergillus flavus CM74,,,50274,BAO_0000218
6326,,,,1,,,CHEMBL619461,,Intermediate,F,,1,,N,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,,50416,BAO_0000218
6327,,,,1,,,CHEMBL619462,,Intermediate,F,,1,,N,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,,50416,BAO_0000218
6328,,,,1,,,CHEMBL620388,,Intermediate,F,,1,,N,Antimicrobial activity against Aspergillus fumigatus (MIC),,,50416,BAO_0000218
6329,,,,1,,,CHEMBL620389,,Intermediate,F,,1,,N,Antimicrobial activity against Aspergillus fumigatus (MIC),,,50416,BAO_0000218
6330,,,,1,,,CHEMBL620390,,Intermediate,F,,1,,N,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,,50416,BAO_0000218
6331,,,,1,,,CHEMBL620391,,Expert,F,,1,,N,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,50416,BAO_0000218
6332,,,,1,,,CHEMBL621073,,Expert,F,,1,,N,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,50416,BAO_0000218
6333,,,,1,,,CHEMBL621074,,Intermediate,F,,1,,N,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,,50296,BAO_0000218
6334,,,,1,,,CHEMBL621075,,Intermediate,F,,1,,N,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,,50366,BAO_0000218
6335,,,,1,,,CHEMBL619554,,Intermediate,F,,1,,N,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,50535,BAO_0000218
6336,,,,1,,,CHEMBL619555,,Intermediate,F,,1,,N,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,50535,BAO_0000218
6337,,,,1,,,CHEMBL619556,,Intermediate,F,,1,,N,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,,50169,BAO_0000218
6338,,,,1,,,CHEMBL619557,,Intermediate,F,,1,,N,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,,50169,BAO_0000218
6339,,,,1,,,CHEMBL619558,,Intermediate,F,,1,,N,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,,50169,BAO_0000218
6340,646.0,,,1,,,CHEMBL619559,,Intermediate,F,,1,,N,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6341,646.0,,,1,,,CHEMBL619560,,Intermediate,F,,1,,N,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6342,646.0,,,1,,,CHEMBL619561,,Intermediate,F,,1,,N,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,A549,80682,BAO_0000219
6343,646.0,,,1,,,CHEMBL619562,,Intermediate,F,,1,,N,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,A549,80682,BAO_0000219
6344,646.0,,,1,,,CHEMBL619563,,Intermediate,F,,1,,N,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,A549,80682,BAO_0000219
6345,646.0,,,1,,,CHEMBL857457,,Intermediate,F,,1,,N,GI values against A549 cells (lung cancer),,A549,80682,BAO_0000219
6346,646.0,,,1,,,CHEMBL619564,,Intermediate,F,,1,,N,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,A549,80682,BAO_0000219
6347,646.0,,,1,,,CHEMBL619565,,Intermediate,F,,1,,N,Inhibitory activity against A549 human adenocarcinoma,,A549,80682,BAO_0000219
6348,646.0,,,1,,,CHEMBL619566,,Intermediate,F,,1,,N,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,A549,80682,BAO_0000218
6349,646.0,,,1,,,CHEMBL619567,,Intermediate,F,,1,,N,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,A549,80682,BAO_0000218
6350,646.0,,,1,,,CHEMBL619568,,Intermediate,F,,1,,N,Inhibitory activity against A549 lung adenocarcinoma cell line,,A549,80682,BAO_0000219
6351,646.0,,,1,,,CHEMBL619569,,Intermediate,F,,1,,N,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,A549,80682,BAO_0000219
6352,646.0,,,1,,,CHEMBL619570,,Intermediate,F,,1,,N,Cytotoxicity against human A549 lung cells,,A549,80682,BAO_0000219
6353,646.0,,,1,,,CHEMBL619571,,Intermediate,F,,1,,N,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,A549,80682,BAO_0000218
6354,646.0,,,1,,,CHEMBL619572,,Expert,F,,1,,N,Growth inhibition of A549 (human lung carcinoma) cell line.,,A549,80682,BAO_0000219
6355,646.0,,,1,,,CHEMBL619573,,Expert,F,,1,,N,Effective dose required for inhibitory activity against A549 human tumor cell line.,,A549,80682,BAO_0000219
6356,646.0,,,1,,,CHEMBL619574,,Intermediate,F,,1,,N,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,A549,80682,BAO_0000219
6357,646.0,,,1,,,CHEMBL619575,,Intermediate,F,,1,,N,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,A549,80682,BAO_0000219
6358,646.0,,,1,,,CHEMBL619576,,Expert,F,,1,,N,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,A549,80682,BAO_0000219
6359,646.0,,,1,,,CHEMBL619577,,Intermediate,F,,1,,N,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,A549,80682,BAO_0000219
6360,646.0,,,1,,,CHEMBL619578,,Intermediate,F,,1,,N,In vitro inhibitory activity against A549 tumor cell culture,,A549,80682,BAO_0000219
6361,646.0,,,1,,,CHEMBL884009,,Intermediate,F,,1,,N,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,A549,80682,BAO_0000219
6362,646.0,,,1,,,CHEMBL619579,,Intermediate,F,,1,,N,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,A549,80682,BAO_0000219
6363,646.0,,,1,,,CHEMBL619580,,Intermediate,F,,1,,N,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,A549,80682,BAO_0000219
6364,646.0,,,1,,,CHEMBL619581,,Intermediate,F,,1,,N,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,A549,80682,BAO_0000219
6365,646.0,,,1,,,CHEMBL619582,,Intermediate,F,,1,,N,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,A549,80682,BAO_0000219
6366,646.0,,,1,,,CHEMBL619583,,Intermediate,F,,1,,N,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,A549,80682,BAO_0000219
6367,646.0,,,1,,,CHEMBL876502,,Intermediate,F,,1,,N,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,A549,80682,BAO_0000219
6368,646.0,,,1,,,CHEMBL619584,,Intermediate,F,,1,,N,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,A549,80682,BAO_0000219
6369,646.0,,,1,,,CHEMBL619585,,Intermediate,F,,1,,N,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,A549,80682,BAO_0000219
6370,646.0,,,1,,,CHEMBL619586,,Intermediate,F,,1,,N,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,A549,80682,BAO_0000219
6371,646.0,,,1,,,CHEMBL619587,,Intermediate,F,,1,,N,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,A549,80682,BAO_0000219
6372,646.0,,,1,,,CHEMBL619588,,Intermediate,F,,1,,N,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,A549,80682,BAO_0000219
6373,646.0,,,1,,,CHEMBL619589,,Intermediate,F,,1,,N,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,A549,80682,BAO_0000219
6374,646.0,,,1,,,CHEMBL619590,,Intermediate,F,,1,,N,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,A549,80682,BAO_0000219
6375,646.0,,,1,,,CHEMBL619591,,Intermediate,F,,1,,N,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,A549,80682,BAO_0000219
6376,646.0,,,1,,,CHEMBL619592,,Intermediate,F,,1,,N,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,A549,80682,BAO_0000219
6377,646.0,,,1,,,CHEMBL619593,,Intermediate,F,,1,,N,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,A549,80682,BAO_0000219
6378,646.0,,,1,,,CHEMBL620217,,Intermediate,F,,1,,N,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,A549,80682,BAO_0000219
6379,646.0,,,1,,,CHEMBL620218,,Intermediate,F,,1,,N,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,A549,80682,BAO_0000219
6380,646.0,,,1,,,CHEMBL620219,,Intermediate,F,,1,,N,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,A549,80682,BAO_0000219
6381,646.0,,,1,,,CHEMBL620220,,Intermediate,F,,1,,N,Antitumor activity against A549/ATCC cell line,,A549,80682,BAO_0000219
6382,646.0,,,1,,,CHEMBL625141,,Intermediate,F,,1,,N,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,A549,80682,BAO_0000219
6383,646.0,,,1,,,CHEMBL625142,,Expert,F,,1,,N,In vitro cytotoxicity against A549/ATCC cell line.,,A549,80682,BAO_0000219
6384,646.0,,,1,,,CHEMBL625143,,Intermediate,F,,1,,N,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,A549,80682,BAO_0000219
6385,646.0,,,1,,,CHEMBL625144,,Intermediate,F,,1,,N,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,A549,80682,BAO_0000219
6386,646.0,,,1,,,CHEMBL622474,,Intermediate,F,,1,,N,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,A549,80682,BAO_0000219
6387,646.0,,,1,,,CHEMBL884104,,Intermediate,F,,1,,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,A549,80682,BAO_0000219
6388,,,,0,,,CHEMBL622475,,Autocuration,F,,1,,U,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,,22226,BAO_0000219
6389,,,,0,,In vivo,CHEMBL622476,,Intermediate,A,,1,,U,Compound was tested for oral bioavailability in dogs,,,22224,BAO_0000218
6390,,,,1,,In vivo,CHEMBL875831,,Intermediate,A,,1,,N,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,,50588,BAO_0000218
6391,,,,1,,In vivo,CHEMBL622477,,Intermediate,A,,1,,N,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,,50588,BAO_0000218
6392,,,,1,,In vivo,CHEMBL622478,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6393,,,,1,,In vivo,CHEMBL623172,,Intermediate,A,,1,,N,Compound was tested for the oral bioavailability in dog; No availability,,,50588,BAO_0000218
6394,,,,1,,In vivo,CHEMBL623173,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 5 mg/kg),,,50588,BAO_0000218
6395,,,,1,,In vivo,CHEMBL623174,,Intermediate,A,,1,,N,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,50588,BAO_0000218
6396,,,,1,,In vivo,CHEMBL623175,,Intermediate,A,,1,,N,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,50588,BAO_0000218
6397,,,,1,,In vivo,CHEMBL623340,,Intermediate,A,,1,,N,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,,50588,BAO_0000218
6398,,,,1,,In vivo,CHEMBL623341,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 5 mg/kg),,,50588,BAO_0000218
6399,,,,1,,In vivo,CHEMBL623342,,Intermediate,A,,1,,N,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,,50588,BAO_0000218
6400,,,,1,,In vivo,CHEMBL623343,,Intermediate,A,,1,,N,Oral bioavailability of active FTIs in dogs,,,50588,BAO_0000218
6401,,,,1,,In vivo,CHEMBL623344,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,50588,BAO_0000218
6402,,,,1,,In vivo,CHEMBL623345,,Expert,A,,1,,N,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,,50588,BAO_0000218
6403,,,,1,,In vivo,CHEMBL875832,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6404,,,,1,,In vivo,CHEMBL623346,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6405,,,,1,,In vivo,CHEMBL623347,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6406,,,,1,,In vivo,CHEMBL623348,,Intermediate,A,,1,,N,Oral bioavailability of compound was determined in dog; Not tested,,,50588,BAO_0000218
6407,,,,1,,In vivo,CHEMBL623349,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6408,,,,1,,In vivo,CHEMBL623350,,Intermediate,A,,1,,N,Oral bioavailability (10 mg/kg) was determined in dog,,,50588,BAO_0000218
6409,,,,1,,In vivo,CHEMBL623351,,Intermediate,A,,1,,N,Oral bioavailability,,,50588,BAO_0000218
6410,,,,1,,In vivo,CHEMBL623352,,Intermediate,A,,1,,N,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,,50588,BAO_0000218
6411,,,,1,,In vivo,CHEMBL623353,,Intermediate,A,,1,,N,Oral bioavailability administered in solution in rats,,,50588,BAO_0000218
6412,,,,1,,In vivo,CHEMBL875833,,Intermediate,A,,1,,N,Oral bioavailability after 30 mg/kg po dose in Dogs,,,50588,BAO_0000218
6413,,,,1,,In vivo,CHEMBL623354,,Intermediate,A,,1,,N,Oral bioavailability at a dose of 1 mg/kg in dogs,,,50588,BAO_0000218
6414,,,,1,,In vivo,CHEMBL623355,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 1 mg/kg p.o.),,,50588,BAO_0000218
6415,,,,1,,In vivo,CHEMBL623356,,Intermediate,A,,1,,N,Oral bioavailability in Dog; ND = not determined,,,50588,BAO_0000218
6416,,,,1,,In vivo,CHEMBL623357,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6417,,,,1,,In vivo,CHEMBL623358,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6418,,,,1,,In vivo,CHEMBL623359,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6419,,,,1,,In vivo,CHEMBL623360,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6420,,,,1,,In vivo,CHEMBL623361,,Intermediate,A,,1,,N,Oral bioavailability in dogs; No data,,,50588,BAO_0000218
6421,,,,1,,In vivo,CHEMBL623362,,Intermediate,A,,1,,N,Oral bioavailability measured in dogs,,,50588,BAO_0000218
6422,,,,1,,In vivo,CHEMBL623363,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6423,,,,1,,In vivo,CHEMBL623364,,Intermediate,A,,1,,N,Oral bioavailability was calculated in dog,,,50588,BAO_0000218
6424,,,,1,,In vivo,CHEMBL875834,,Intermediate,A,,1,,N,Oral bioavailability after 0.3 mg/kg po administration in dog,,,50588,BAO_0000218
6425,,,,1,,In vivo,CHEMBL623365,,Intermediate,A,,1,,N,Oral bioavailability in dog (i.v. dosing),,,50588,BAO_0000218
6426,,,,1,,In vivo,CHEMBL623366,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6427,,,,1,,In vivo,CHEMBL623367,,Intermediate,A,,1,,N,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,,50588,BAO_0000218
6428,,,,1,,In vivo,CHEMBL623368,,Intermediate,A,,1,,N,Oral bioavailability in Beagle dogs,,,50588,BAO_0000218
6429,,,,1,,In vivo,CHEMBL623369,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6430,,,,1,,In vivo,CHEMBL623370,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6431,,,,1,,In vivo,CHEMBL623371,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6432,,,,1,,In vivo,CHEMBL623372,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6433,,,,1,,In vivo,CHEMBL621351,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6434,,,,1,,In vivo,CHEMBL621352,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6435,,,,1,,In vivo,CHEMBL621353,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6436,,,,1,,In vivo,CHEMBL621354,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6437,,,,1,,In vivo,CHEMBL621355,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6438,,,,1,,In vivo,CHEMBL621356,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6439,,,,1,,In vivo,CHEMBL621357,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6440,,,,1,,In vivo,CHEMBL621358,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6441,,,,1,,In vivo,CHEMBL621359,,Intermediate,A,,1,,N,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,,50588,BAO_0000218
6442,,,,1,,In vivo,CHEMBL621360,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,50588,BAO_0000218
6443,,,,1,,In vivo,CHEMBL621361,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,50588,BAO_0000218
6444,,,,1,,In vivo,CHEMBL621362,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6445,,,,1,,In vivo,CHEMBL621363,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6446,,,,1,,In vivo,CHEMBL621364,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6447,,,,1,,In vivo,CHEMBL621166,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,,50588,BAO_0000218
6448,,,,1,,In vivo,CHEMBL621167,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 1 mg/kg i.v.),,,50588,BAO_0000218
6449,,,,1,,In vivo,CHEMBL621168,,Intermediate,A,,1,,N,Oral bioavailability (F) in dogs,,,50588,BAO_0000218
6450,,,,1,,In vivo,CHEMBL621169,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6451,,,,1,,In vivo,CHEMBL875950,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6452,,,,1,,In vivo,CHEMBL621170,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 10 mg/kg),,,50588,BAO_0000218
6453,,,,1,,In vivo,CHEMBL621171,,Intermediate,A,,1,,N,Oral bioavailability after peroral administration at 5 mpk in Dog,,,50588,BAO_0000218
6454,,,,1,,In vivo,CHEMBL621172,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 5 mg/kg),,,50588,BAO_0000218
6455,,,,1,,In vivo,CHEMBL621173,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 10 mg/kg),,,50588,BAO_0000218
6456,42.0,,2113.0,1,Kidney,,CHEMBL621174,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6457,42.0,,2113.0,1,Kidney,,CHEMBL621175,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6458,42.0,,2107.0,1,Liver,,CHEMBL621176,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6459,42.0,,2107.0,1,Liver,,CHEMBL621177,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6460,42.0,,2107.0,1,Liver,,CHEMBL621178,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6461,42.0,,2107.0,1,Liver,,CHEMBL621179,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6462,42.0,,2107.0,1,Liver,,CHEMBL621180,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6463,42.0,,2048.0,1,Lung,,CHEMBL875951,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6464,42.0,,2048.0,1,Lung,,CHEMBL621181,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6465,42.0,,2048.0,1,Lung,,CHEMBL621182,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6466,42.0,,2048.0,1,Lung,,CHEMBL621183,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6467,42.0,,2048.0,1,Lung,,CHEMBL621184,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6468,42.0,,,1,,,CHEMBL621185,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6469,42.0,,,1,,,CHEMBL621186,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6470,42.0,,,1,,,CHEMBL621187,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6471,42.0,,,1,,,CHEMBL621188,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6472,42.0,,,1,,,CHEMBL621189,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6473,42.0,,2106.0,1,Spleen,,CHEMBL621190,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6474,42.0,,2106.0,1,Spleen,,CHEMBL618520,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6475,42.0,,2106.0,1,Spleen,,CHEMBL621739,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6476,42.0,,2106.0,1,Spleen,,CHEMBL621740,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6477,42.0,,2106.0,1,Spleen,,CHEMBL621741,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6478,42.0,,,1,,,CHEMBL621742,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6479,42.0,,,1,,,CHEMBL621743,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6480,42.0,,,1,,,CHEMBL621744,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6481,42.0,,,1,,,CHEMBL621745,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6482,42.0,,,1,,,CHEMBL621746,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6483,42.0,,,1,,,CHEMBL621747,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6484,42.0,,,1,,,CHEMBL621748,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6485,42.0,,,1,,,CHEMBL621749,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6486,42.0,,,1,,,CHEMBL621750,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6487,42.0,,,1,,,CHEMBL621751,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6488,42.0,,948.0,1,Heart,,CHEMBL621752,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6489,42.0,,948.0,1,Heart,,CHEMBL621753,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6490,42.0,,948.0,1,Heart,,CHEMBL875955,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6491,42.0,,948.0,1,Heart,,CHEMBL621754,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6492,42.0,,948.0,1,Heart,,CHEMBL621755,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6493,42.0,,2107.0,1,Liver,,CHEMBL621756,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6494,42.0,,2107.0,1,Liver,,CHEMBL624199,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6495,42.0,,2107.0,1,Liver,,CHEMBL624200,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6496,42.0,,2107.0,1,Liver,,CHEMBL624375,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6497,42.0,,2107.0,1,Liver,,CHEMBL624376,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6498,42.0,,2048.0,1,Lung,,CHEMBL624377,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6499,42.0,,2048.0,1,Lung,,CHEMBL624378,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6500,,,,1,,,CHEMBL857901,,Intermediate,F,,1,,N,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,50067,BAO_0000218
6501,,,,1,,,CHEMBL875274,,Intermediate,F,,1,,N,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,50067,BAO_0000218
6502,,,,1,,,CHEMBL624379,,Intermediate,F,,1,,N,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,50067,BAO_0000218
6503,,,,1,,,CHEMBL624380,,Intermediate,F,,1,,N,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,50067,BAO_0000218
6504,,,,1,,,CHEMBL624381,,Intermediate,F,,1,,N,Activity against Acinetobacter calcoaceticus (AC54),,,50192,BAO_0000218
6505,,,,1,,,CHEMBL624382,,Intermediate,F,,1,,N,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,,50714,BAO_0000218
6506,,,,1,,,CHEMBL624383,,Intermediate,F,,1,,N,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,,50714,BAO_0000218
6507,,,,1,,,CHEMBL624384,,Intermediate,F,,1,,N,Chlorohexidine coefficient for Actinomyces naeslundii 631,,,50296,BAO_0000218
6508,,,,1,,,CHEMBL624385,,Intermediate,F,,1,,N,Chlorohexidine coefficient for Actinomyces naeslundii B74,,,50296,BAO_0000218
6509,,,,1,,,CHEMBL624386,,Intermediate,F,,1,,N,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,,50296,BAO_0000218
6510,,,,1,,,CHEMBL624387,,Intermediate,F,,1,,N,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,,50296,BAO_0000218
6511,,,,1,,,CHEMBL624388,,Intermediate,F,,1,,N,Plaque bactericidal index against Actinomyces naeslundii 631,,,50296,BAO_0000218
6512,,,,1,,,CHEMBL624389,,Intermediate,F,,1,,N,Plaque bactericidal index against Actinomyces naeslundii N/9,,,50296,BAO_0000218
6513,,,,1,,,CHEMBL624390,,Intermediate,F,,1,,N,Plaque bactericidal index against Actinomyces naeslundii B74,,,50296,BAO_0000218
6514,,,,1,,,CHEMBL875275,,Intermediate,F,,1,,N,Plaque bactericidal index against Actinomyces naeslundii N/3,,,50296,BAO_0000218
6515,,,,1,,,CHEMBL624391,,Intermediate,F,,1,,N,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,,50056,BAO_0000218
6516,,,,1,,,CHEMBL623636,,Intermediate,F,,1,,N,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,,50056,BAO_0000218
6517,,,,1,,,CHEMBL623637,,Intermediate,F,,1,,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,50532,BAO_0000218
6518,,,,1,,,CHEMBL623638,,Intermediate,F,,1,,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,50532,BAO_0000218
6519,,,,1,,,CHEMBL623639,,Intermediate,F,,1,,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,50532,BAO_0000218
6520,,,,1,,,CHEMBL623640,,Intermediate,F,,1,,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,50532,BAO_0000218
6521,,,,1,,,CHEMBL623641,,Intermediate,F,,1,,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,50532,BAO_0000218
6522,,,,1,,,CHEMBL623642,,Intermediate,F,,1,,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,,50532,BAO_0000218
6523,,,,1,,,CHEMBL623643,,Intermediate,F,,1,,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,50532,BAO_0000218
6524,,,,1,,,CHEMBL623644,,Intermediate,F,,1,,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,50532,BAO_0000218
6525,,,,1,,,CHEMBL623645,,Intermediate,F,,1,,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,50532,BAO_0000218
6526,,,,1,,,CHEMBL623646,,Intermediate,F,,1,,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,50532,BAO_0000218
6527,,,,1,,,CHEMBL623647,,Intermediate,F,,1,,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,50532,BAO_0000218
6528,,,,1,,,CHEMBL623648,,Intermediate,F,,1,,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,,50532,BAO_0000218
6529,,,,1,,,CHEMBL623649,,Intermediate,F,,1,,N,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,50366,BAO_0000218
6530,,,,1,,,CHEMBL623650,,Intermediate,F,,1,,N,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,50366,BAO_0000218
6531,,,,1,,,CHEMBL623651,,Intermediate,F,,1,,N,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,,50366,BAO_0000218
6532,,,,1,,,CHEMBL623652,,Expert,F,,1,,N,Chlorohexidine coefficient for Actinomyces viscosus M-100,,,50366,BAO_0000218
6533,,,,1,,,CHEMBL623653,,Intermediate,F,,1,,N,Chlorohexidine coefficient for Actinomyces viscosus M-626,,,50366,BAO_0000218
6534,,,,1,,,CHEMBL623654,,Intermediate,F,,1,,N,Chlorohexidine coefficient for Actinomyces viscosus T14V,,,50366,BAO_0000218
6535,,,,1,,,CHEMBL623655,,Intermediate,F,,1,,N,Plaque bactericidal index against Actinomyces viscosus 8A06,,,50366,BAO_0000218
6536,,,,1,,,CHEMBL623656,,Intermediate,F,,1,,N,Plaque bactericidal index against Actinomyces viscosus M-100,,,50366,BAO_0000218
6537,,,,1,,,CHEMBL623657,,Expert,F,,1,,N,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,,50366,BAO_0000218
6538,,,,1,,,CHEMBL623658,,Intermediate,F,,1,,N,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,50366,BAO_0000218
6539,,,,1,,,CHEMBL623659,,Intermediate,F,,1,,N,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,50366,BAO_0000218
6540,,,,1,,,CHEMBL623660,,Intermediate,F,,1,,N,Plaque bactericidal index against Actinomyces viscosus 626,,,50366,BAO_0000218
6541,,,,1,,,CHEMBL623661,,Intermediate,F,,1,,N,Plaque bactericidal index against Actinomyces viscosus T14V,,,50366,BAO_0000218
6542,,,,1,,,CHEMBL875281,,Intermediate,F,,1,,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,,50535,BAO_0000218
6543,,,,1,,,CHEMBL623662,,Intermediate,F,,1,,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,,50535,BAO_0000218
6544,,,,1,,,CHEMBL623663,,Intermediate,F,,1,,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,,50535,BAO_0000218
6545,,,,1,,,CHEMBL623664,,Intermediate,F,,1,,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,,50535,BAO_0000218
6546,,,,1,,,CHEMBL623665,,Intermediate,F,,1,,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,,50535,BAO_0000218
6547,165.0,,,1,,,CHEMBL621856,,Intermediate,F,,1,,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,A673,80023,BAO_0000219
6548,645.0,,,1,,,CHEMBL620432,,Intermediate,F,,1,,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,A704,80661,BAO_0000219
6549,,,,0,,,CHEMBL620433,,Autocuration,F,,1,,U,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,,22226,BAO_0000219
6550,625.0,,,1,,,CHEMBL620434,,Intermediate,F,,1,,N,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,A9,80024,BAO_0000219
6551,625.0,,,1,,,CHEMBL620435,,Intermediate,F,,1,,N,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,A9,80024,BAO_0000219
6552,625.0,,,1,,,CHEMBL620436,,Intermediate,F,,1,,N,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,A9,80024,BAO_0000219
6553,625.0,,,1,,,CHEMBL876597,,Intermediate,F,,1,,N,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,A9,80024,BAO_0000219
6554,874.0,,,1,,,CHEMBL620437,,Expert,F,,1,,N,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,Human ovarian carcinoma cell line,81037,BAO_0000219
6555,625.0,,,1,,,CHEMBL620438,,Expert,F,,1,,N,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,A9,80024,BAO_0000219
6556,625.0,,,1,,,CHEMBL620439,,Expert,F,,1,,N,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,A9,80024,BAO_0000219
6557,625.0,,,1,,,CHEMBL619657,,Expert,F,,1,,N,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,A9,80024,BAO_0000219
6558,625.0,,,1,,,CHEMBL619658,,Intermediate,F,,1,,N,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,A9,80024,BAO_0000219
6559,625.0,,,1,,,CHEMBL619659,,Intermediate,F,,1,,N,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,A9,80024,BAO_0000219
6560,,,,8,,,CHEMBL619660,,Expert,F,,1,,H,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,,10649,BAO_0000019
6561,625.0,,,1,,,CHEMBL619661,,Intermediate,F,,1,,N,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,A9,80024,BAO_0000219
6562,625.0,,,1,,,CHEMBL619662,,Intermediate,F,,1,,N,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,A9,80024,BAO_0000219
6563,975.0,,,1,,,CHEMBL619663,,Intermediate,F,,1,,N,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,AA6,80663,BAO_0000219
6564,,,,0,,,CHEMBL619664,,Autocuration,F,,1,,U,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,,22226,BAO_0000219
6565,,,,0,,,CHEMBL619665,,Autocuration,F,,1,,U,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,,22226,BAO_0000219
6566,974.0,,,1,,,CHEMBL883244,,Intermediate,F,,1,,N,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,AA5,80662,BAO_0000219
6567,974.0,,,1,,,CHEMBL884011,,Intermediate,F,,1,,N,Cytotoxicity was measured against AA5/HIV-1(IIIB),,AA5,80662,BAO_0000219
6568,974.0,,,1,,,CHEMBL619666,,Intermediate,F,,1,,N,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,AA5,80662,BAO_0000219
6569,379.0,,,1,,,CHEMBL619667,,Intermediate,F,,1,,N,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,U-937,80566,BAO_0000219
6570,274.0,,,1,,,CHEMBL619668,,Intermediate,F,,1,,N,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,UV4,80578,BAO_0000219
6571,185.0,,,1,,,CHEMBL619669,,Expert,F,,1,,N,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,CHO-AA8,80089,BAO_0000219
6572,185.0,,,1,,,CHEMBL876608,,Intermediate,F,,1,,N,Average intracellular compound concentration when the hypoxic SER=1.6,,CHO-AA8,80089,BAO_0000219
6573,185.0,,,1,,,CHEMBL619670,,Intermediate,F,,1,,N,Average intracellular compound concentration when the hypoxic SER=1.6.,,CHO-AA8,80089,BAO_0000219
6574,185.0,,,1,,,CHEMBL619671,,Intermediate,F,,1,,N,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,CHO-AA8,80089,BAO_0000219
6575,185.0,,,1,,,CHEMBL619672,,Intermediate,F,,1,,N,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,CHO-AA8,80089,BAO_0000219
6576,185.0,,,1,,,CHEMBL619673,,Intermediate,F,,1,,N,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,CHO-AA8,80089,BAO_0000219
6577,185.0,,,1,,,CHEMBL619674,,Intermediate,F,,1,,N,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,CHO-AA8,80089,BAO_0000219
6578,185.0,,,1,,,CHEMBL619675,,Intermediate,F,,1,,N,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,CHO-AA8,80089,BAO_0000219
6579,185.0,,,1,,,CHEMBL619676,,Intermediate,F,,1,,N,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,CHO-AA8,80089,BAO_0000219
6580,185.0,,,1,,,CHEMBL619677,,Intermediate,F,,1,,N,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,CHO-AA8,80089,BAO_0000219
6581,185.0,,,1,,,CHEMBL619678,,Intermediate,A,,1,,N,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,CHO-AA8,80089,BAO_0000219
6582,185.0,,,1,,,CHEMBL619679,,Intermediate,A,,1,,N,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,CHO-AA8,80089,BAO_0000219
6583,185.0,,,1,,,CHEMBL619680,,Expert,A,,1,,N,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,CHO-AA8,80089,BAO_0000219
6584,185.0,,,1,,,CHEMBL621457,,Intermediate,A,,1,,N,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,CHO-AA8,80089,BAO_0000219
6585,185.0,,,1,,,CHEMBL876609,,Expert,F,,1,,N,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,CHO-AA8,80089,BAO_0000219
6586,185.0,,,1,,,CHEMBL621458,,Intermediate,F,,1,,N,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,CHO-AA8,80089,BAO_0000219
6587,185.0,,,1,,,CHEMBL621459,,Expert,F,,1,,N,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,CHO-AA8,80089,BAO_0000219
6588,185.0,,,1,,,CHEMBL621460,,Expert,F,,1,,N,Aerobic growth inhibition in Chinese hamster cell line AA8,,CHO-AA8,80089,BAO_0000219
6589,185.0,,,1,,,CHEMBL621461,,Expert,F,,1,,N,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,CHO-AA8,80089,BAO_0000219
6590,185.0,,,1,,,CHEMBL621462,,Expert,F,,1,,N,Inhibition of growth under aerobic conditions in AA8 cells,,CHO-AA8,80089,BAO_0000219
6591,,,,1,,In vivo,CHEMBL621463,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 10 mg/kg),,,50588,BAO_0000218
6592,,,,1,,In vivo,CHEMBL621464,,Intermediate,A,,1,,N,Oral bioavailability in dog at 10 mg/kg of the compound,,,50588,BAO_0000218
6593,,,,1,,In vivo,CHEMBL621465,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 5 uM/kg),,,50588,BAO_0000218
6594,,,,1,,In vivo,CHEMBL621466,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 5 uM/kg),,,50588,BAO_0000218
6595,,,,1,,In vivo,CHEMBL621467,,Intermediate,A,,1,,N,Oral bioavailability in dog (mongrel),,,50588,BAO_0000218
6596,,,,1,,In vivo,CHEMBL621468,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 10 mg/kg),,,50588,BAO_0000218
6597,,,,1,,In vivo,CHEMBL876734,,Intermediate,F,,1,,N,Oral bioavailability in dog (dose 10 mg/kg),,,50588,BAO_0000218
6598,,,,1,,In vivo,CHEMBL618476,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6599,,,,1,,In vivo,CHEMBL618477,,Intermediate,A,,1,,N,Bioavailability in dog (dose 1 mg/kg i.v.),,,50588,BAO_0000218
6600,,,,1,,In vivo,CHEMBL618478,,Intermediate,A,,1,,N,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,,50588,BAO_0000218
6601,,,,1,,In vivo,CHEMBL618479,,Intermediate,A,,1,,N,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,,50588,BAO_0000218
6602,,,,1,,In vivo,CHEMBL618480,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6603,,,,1,,In vivo,CHEMBL618481,,Intermediate,A,,1,,N,Bioavailability in dog (dose 3-10 mg/kg),,,50588,BAO_0000218
6604,,,1969.0,1,Plasma,In vivo,CHEMBL618482,,Intermediate,A,,1,,N,The compound was tested for bioavailability of compound in plasma of dog; Complete,,,50588,BAO_0000218
6605,,,,1,,In vivo,CHEMBL618483,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6606,,,,1,,In vivo,CHEMBL618484,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6607,,,,1,,In vivo,CHEMBL618485,,Intermediate,A,,1,,N,Bioavailability in dog,,,50588,BAO_0000218
6608,,,,1,,In vivo,CHEMBL618486,,Intermediate,A,,1,,N,oral bioavailability was measured in dogs,,,50588,BAO_0000218
6609,,,,1,,,CHEMBL618487,,Intermediate,A,,1,,N,Compound was tested for plasma protein binding in dog; Not determined,,,50588,BAO_0000218
6610,,,,1,,,CHEMBL618488,,Intermediate,A,,1,,N,Compound was tested for plasma protein binding of dog,,,50588,BAO_0000218
6611,,,,1,,,CHEMBL876735,,Intermediate,A,,1,,N,Compound was tested for plasma protein binding of dog; Not determined,,,50588,BAO_0000218
6612,,,,1,,,CHEMBL618489,,Intermediate,A,,1,,N,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,,50588,BAO_0000218
6613,,,,1,,In vivo,CHEMBL618490,,Intermediate,A,,1,,N,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,,50588,BAO_0000218
6614,,,,1,,,CHEMBL618491,,Intermediate,A,,1,,N,Half life was determined,,,50588,BAO_0000218
6615,,,,1,,In vivo,CHEMBL618492,,Intermediate,A,,1,,N,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,,50588,BAO_0000218
6616,,,,1,,,CHEMBL873354,,Intermediate,A,,1,,N,Half life was evaluated in dog,,,50588,BAO_0000218
6617,,,,1,,,CHEMBL618493,,Intermediate,A,,1,,N,Half life was determined,,,50588,BAO_0000218
6618,,,,1,,In vivo,CHEMBL618494,,Intermediate,A,,1,,N,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588,BAO_0000218
6619,,,948.0,1,Heart,In vivo,CHEMBL618495,,Intermediate,A,,1,,N,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588,BAO_0000218
6620,,,2113.0,1,Kidney,In vivo,CHEMBL618496,,Intermediate,A,,1,,N,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588,BAO_0000218
6621,,,2107.0,1,Liver,In vivo,CHEMBL618497,,Intermediate,A,,1,,N,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588,BAO_0000218
6622,,,2048.0,1,Lung,In vivo,CHEMBL618498,,Intermediate,A,,1,,N,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588,BAO_0000218
6623,,,2106.0,1,Spleen,In vivo,CHEMBL618499,,Intermediate,A,,1,,N,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588,BAO_0000218
6624,,,,1,,,CHEMBL876736,,Intermediate,A,,1,,N,LogP in dog,,,50588,BAO_0000218
6625,,,,1,,,CHEMBL618500,,Intermediate,A,,1,,N,Partition coefficient (logP),,,50588,BAO_0000218
6626,,,,1,,,CHEMBL857831,,Intermediate,A,,1,,N,Partition coefficient in dog,,,50588,BAO_0000218
6627,,,,1,,In vivo,CHEMBL618501,,Intermediate,A,,1,,N,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,,50588,BAO_0000218
6628,,,,1,,In vivo,CHEMBL618502,,Intermediate,A,,1,,N,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,,50588,BAO_0000218
6629,,,,1,,,CHEMBL618503,,Intermediate,A,,1,,N,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,,50588,BAO_0000218
6630,,,,1,,,CHEMBL618504,,Intermediate,A,,1,,N,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,,50588,BAO_0000218
6631,,,,1,,,CHEMBL618505,,Intermediate,A,,1,,N,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,,50588,BAO_0000218
6632,,,,1,,,CHEMBL618506,,Intermediate,A,,1,,N,Metabolism of compound in dog S9 microsomes; Trace,,,50588,BAO_0000218
6633,,,2107.0,1,Liver,,CHEMBL618507,,Intermediate,A,,1,,N,In vitro metabolic potential in dog liver microsomes,,,50588,BAO_0000218
6634,,,,1,,In vivo,CHEMBL876737,,Intermediate,A,,1,,N,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,,50588,BAO_0000218
6635,,,,1,,In vivo,CHEMBL618508,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6636,,,,1,,In vivo,CHEMBL618509,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6637,,,,1,,In vivo,CHEMBL618510,,Intermediate,A,,1,,N,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50588,BAO_0000218
6638,,,,1,,In vivo,CHEMBL618511,,Intermediate,A,,1,,N,The compound was tested for bioavailability in dogs,,,50588,BAO_0000218
6639,,,,1,,In vivo,CHEMBL618512,,Intermediate,A,,1,,N,The compound was tested for oral bioavailability in dogs,,,50588,BAO_0000218
6640,,,,1,,In vivo,CHEMBL618513,,Intermediate,A,,1,,N,Oral bioavailability in dog,,,50588,BAO_0000218
6641,,,,1,,,CHEMBL618514,,Intermediate,A,,1,,N,Compound was tested for percent protein binding (PB) in dog,,,50588,BAO_0000218
6642,,,,1,,,CHEMBL620052,,Intermediate,A,,1,,N,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,,50588,BAO_0000218
6643,,,1969.0,1,Plasma,In vivo,CHEMBL620053,,Intermediate,A,,1,,N,Compound was evaluated for plasma clearance.,,,50588,BAO_0000218
6644,,,1969.0,1,Plasma,In vivo,CHEMBL620054,,Intermediate,A,,1,,N,The compound was tested for plasma clearance in dog,,,50588,BAO_0000218
6645,,,1969.0,1,Plasma,In vivo,CHEMBL620055,,Intermediate,A,,1,,N,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,,50588,BAO_0000218
6646,,,,1,,,CHEMBL620056,,Intermediate,A,,1,,N,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,,50588,BAO_0000218
6647,,,2107.0,1,Liver,,CHEMBL620057,,Intermediate,A,,1,,N,In vitro relative rate of metabolism was determined in dog liver microsomes,,,50588,BAO_0000218
6648,,,,1,,In vivo,CHEMBL618939,,Intermediate,A,,1,,N,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,,50588,BAO_0000218
6649,,,,1,,In vivo,CHEMBL618940,,Intermediate,A,,1,,N,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,50588,BAO_0000218
6650,,,,1,,In vivo,CHEMBL618941,,Intermediate,A,,1,,N,Half life after intravenous administration in dogs at 1.2 uM/kg,,,50588,BAO_0000218
6651,42.0,,2048.0,1,Lung,,CHEMBL624473,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6652,42.0,,2048.0,1,Lung,,CHEMBL624474,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6653,42.0,,2048.0,1,Lung,,CHEMBL624475,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6654,42.0,,,1,,,CHEMBL624476,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594,BAO_0000218
6655,42.0,,,1,,,CHEMBL623478,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594,BAO_0000218
6656,42.0,,,1,,,CHEMBL623479,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594,BAO_0000218
6657,42.0,,,1,,,CHEMBL623480,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594,BAO_0000218
6658,42.0,,,1,,,CHEMBL623481,,Intermediate,A,,1,,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594,BAO_0000218
6659,,,955.0,1,Brain,,CHEMBL623482,,Intermediate,A,,1,,N,C2 in brain of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
6660,,,2113.0,1,Kidney,,CHEMBL623483,,Intermediate,A,,1,,N,C2 in kidney of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
6661,,,2107.0,1,Liver,,CHEMBL623484,,Intermediate,A,,1,,N,C2 in liver of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
6662,,,2048.0,1,Lung,,CHEMBL623485,,Intermediate,A,,1,,N,C2 in lungs of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
6663,,,2106.0,1,Spleen,,CHEMBL623486,,Intermediate,A,,1,,N,C2 in spleen of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
6664,,,,1,,In vivo,CHEMBL623487,,Intermediate,A,,1,,N,Plasma clearance in mouse,,,50594,BAO_0000218
6665,,,,1,,In vivo,CHEMBL623488,,Intermediate,A,,1,,N,Clearance of compound after intravenous administration in mice at 24 uM/kg,,,50594,BAO_0000218
6666,,,,1,,In vivo,CHEMBL623489,,Intermediate,A,,1,,N,Clearance from mouse blood following i.v. administration of 10 mg/kg,,,50594,BAO_0000218
6667,,,,1,,In vivo,CHEMBL875157,,Intermediate,A,,1,,N,Clearance was evaluated in mice after intravenous administration,,,50594,BAO_0000218
6668,,,,1,,In vivo,CHEMBL623490,,Intermediate,A,,1,,N,Clearance was evaluated in mice after oral administration,,,50594,BAO_0000218
6669,,,,1,,In vivo,CHEMBL623491,,Intermediate,A,,1,,N,Pharmacokinetic property (Plasma clearance) was measured in mouse,,,50594,BAO_0000218
6670,,,,1,,In vivo,CHEMBL623492,,Intermediate,A,,1,,N,Plasma clearance of compound was determined at 40 mg/Kg,,,50594,BAO_0000218
6671,,,,1,,In vivo,CHEMBL623493,,Intermediate,A,,1,,N,Plasma clearance of at 24 mg/Kg,,,50594,BAO_0000218
6672,,,,1,,In vivo,CHEMBL623494,,Intermediate,A,,1,,N,Plasma clearance at 24 mg/Kg,,,50594,BAO_0000218
6673,,,,1,,In vivo,CHEMBL623495,,Intermediate,A,,1,,N,Plasma clearance at 5 mg/Kg,,,50594,BAO_0000218
6674,,,,1,,In vivo,CHEMBL623496,,Intermediate,A,,1,,N,Plasma clearance in mice,,,50594,BAO_0000218
6675,,,,1,,In vivo,CHEMBL623497,,Intermediate,A,,1,,N,Plasma clearance value upon iv administration in mouse,,,50594,BAO_0000218
6676,,,1969.0,1,Plasma,In vivo,CHEMBL623498,,Intermediate,A,,1,,N,Total plasma clearance in mice,,,50594,BAO_0000218
6677,,,,1,,In vivo,CHEMBL623499,,Intermediate,A,,1,,N,Clearance in mouse,,,50594,BAO_0000218
6678,,,,1,,In vivo,CHEMBL623500,,Intermediate,A,,1,,N,Clearance value was determined,,,50594,BAO_0000218
6679,,,,1,,In vivo,CHEMBL623501,,Intermediate,A,,1,,N,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,,50594,BAO_0000218
6680,,,,0,,,CHEMBL875158,,Intermediate,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
6681,,,,1,,In vivo,CHEMBL623502,,Intermediate,A,,1,,N,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,,50594,BAO_0000218
6682,,,,1,,In vivo,CHEMBL623503,,Intermediate,A,,1,,N,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,,50594,BAO_0000218
6683,,,,1,,In vivo,CHEMBL623504,,Intermediate,A,,1,,N,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594,BAO_0000218
6684,,,,1,,In vivo,CHEMBL623505,,Intermediate,A,,1,,N,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,,50594,BAO_0000218
6685,,,,1,,In vivo,CHEMBL623506,,Intermediate,A,,1,,N,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,,50594,BAO_0000218
6686,,,,1,,In vivo,CHEMBL623507,,Intermediate,A,,1,,N,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,50594,BAO_0000218
6687,,,,1,,In vivo,CHEMBL623508,,Intermediate,A,,1,,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,,50594,BAO_0000218
6688,,,,1,,In vivo,CHEMBL623509,,Intermediate,A,,1,,N,Cmax after oral administration at 30 mg/kg in ICR mouse,,,50594,BAO_0000218
6689,,,,1,,In vivo,CHEMBL875159,,Intermediate,A,,1,,N,Cmax after peroral administration in mice at 2.4 uM/kg,,,50594,BAO_0000218
6690,,,955.0,1,Brain,In vivo,CHEMBL623510,,Intermediate,A,,1,,N,Cmax in brain of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
6691,,,2113.0,1,Kidney,In vivo,CHEMBL623511,,Intermediate,A,,1,,N,Cmax in kidney of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
6692,,,2107.0,1,Liver,In vivo,CHEMBL623512,,Intermediate,A,,1,,N,Cmax in liver of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
6693,,,2048.0,1,Lung,In vivo,CHEMBL623513,,Intermediate,A,,1,,N,Cmax in lungs of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
6694,,,,1,,In vivo,CHEMBL623514,,Intermediate,F,,1,,N,Cmax in mice at 18 uM/kg i.p. administration,,,50594,BAO_0000218
6695,,,,1,,In vivo,CHEMBL622609,,Intermediate,F,,1,,N,Cmax in mice at 23 uM/kg i.v. administration,,,50594,BAO_0000218
6696,,,,1,,In vivo,CHEMBL622610,,Intermediate,F,,1,,N,Cmax in mice at 24 uM/kg i.p. administration,,,50594,BAO_0000218
6697,,,,1,,In vivo,CHEMBL621823,,Intermediate,F,,1,,N,Cmax in mice at 25 uM/kg i.p. administration,,,50594,BAO_0000218
6698,,,,1,,In vivo,CHEMBL621824,,Intermediate,F,,1,,N,Cmax in mice at 26 uM/kg i.p. administration,,,50594,BAO_0000218
6699,,,2106.0,1,Spleen,In vivo,CHEMBL621825,,Intermediate,A,,1,,N,Cmax in spleen of mice at the oral dose of 50 mg/kg,,,50594,BAO_0000218
6700,,,,1,,In vivo,CHEMBL621826,,Intermediate,A,,1,,N,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,,50594,BAO_0000218
6701,,,,1,,In vivo,CHEMBL621827,,Intermediate,A,,1,,N,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,,50594,BAO_0000218
6702,,,,1,,In vivo,CHEMBL621828,,Intermediate,A,,1,,N,Cmax value was determined,,,50594,BAO_0000218
6703,,,,1,,In vivo,CHEMBL621829,,Intermediate,A,,1,,N,Cmax value in IRC mice,,,50594,BAO_0000218
6704,,,,1,,In vivo,CHEMBL621830,,Intermediate,A,,1,,N,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,50594,BAO_0000218
6705,,,,1,,In vivo,CHEMBL621831,,Intermediate,A,,1,,N,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,50594,BAO_0000218
6706,,,1969.0,1,Plasma,In vivo,CHEMBL621832,,Intermediate,A,,1,,N,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,,50594,BAO_0000218
6707,,,1969.0,1,Plasma,In vivo,CHEMBL624579,,Intermediate,A,,1,,N,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,,50594,BAO_0000218
6708,,,,1,,In vivo,CHEMBL624580,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,,50594,BAO_0000218
6709,,,,1,,,CHEMBL624581,,Intermediate,F,,1,,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,,50535,BAO_0000218
6710,,,,1,,,CHEMBL624582,,Intermediate,F,,1,,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,,50535,BAO_0000218
6711,,,,1,,,CHEMBL624583,,Intermediate,F,,1,,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,,50535,BAO_0000218
6712,455.0,,,1,,,CHEMBL624584,,Intermediate,F,,1,,N,Inhibitory activity against human tumor cell line A0375 melanoma.,,A-375,80018,BAO_0000219
6713,,,,9,,,CHEMBL624585,,Expert,B,,1,Brain membranes,D,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,,12512,BAO_0000249
6714,,,,9,,,CHEMBL875165,,Expert,F,,1,,D,Forskolin-induced cAMP production at human A1 adenosine receptor,,,114,BAO_0000019
6715,449.0,,,8,,,CHEMBL619490,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,CHO,114,BAO_0000219
6716,449.0,,,8,,,CHEMBL619491,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,CHO,114,BAO_0000219
6717,449.0,,,8,,,CHEMBL619492,,Expert,F,,1,,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,CHO,114,BAO_0000219
6718,449.0,,,8,,,CHEMBL619493,,Expert,F,,1,,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,CHO,114,BAO_0000219
6719,449.0,,,8,,,CHEMBL619494,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,CHO,114,BAO_0000219
6720,449.0,,,8,,,CHEMBL619495,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,CHO,114,BAO_0000219
6721,449.0,,,8,,,CHEMBL619496,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,CHO,114,BAO_0000219
6722,449.0,,,9,,,CHEMBL619497,,Expert,F,,1,,D,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,CHO,114,BAO_0000219
6723,449.0,,,8,,,CHEMBL619498,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,CHO,114,BAO_0000219
6724,449.0,,,8,,,CHEMBL619499,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,CHO,114,BAO_0000219
6725,449.0,,,8,,,CHEMBL619500,,Expert,F,,1,,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,CHO,114,BAO_0000219
6726,449.0,,,8,,,CHEMBL619501,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,CHO,114,BAO_0000219
6727,449.0,,,8,,,CHEMBL619502,,Expert,F,,1,,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,CHO,114,BAO_0000219
6728,449.0,,,8,,,CHEMBL619503,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,CHO,114,BAO_0000219
6729,449.0,,,8,,,CHEMBL619504,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,CHO,114,BAO_0000219
6730,449.0,,,8,,,CHEMBL621298,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,CHO,114,BAO_0000219
6731,449.0,,,8,,,CHEMBL621299,,Expert,F,,1,,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,CHO,114,BAO_0000219
6732,449.0,,,8,,,CHEMBL621300,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,CHO,114,BAO_0000219
6733,449.0,,,8,,,CHEMBL621301,,Autocuration,F,,1,,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,CHO,114,BAO_0000219
6734,449.0,,,8,,,CHEMBL621302,,Expert,F,,1,,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,CHO,114,BAO_0000219
6735,164.0,,,1,,,CHEMBL621303,,Intermediate,F,,1,,N,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,A10,80013,BAO_0000219
6736,164.0,,,0,,,CHEMBL621304,,Autocuration,F,,1,,U,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,A10,22226,BAO_0000219
6737,164.0,,,0,,,CHEMBL621305,,Autocuration,F,,1,,U,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,A10,22226,BAO_0000219
6738,164.0,,,1,,,CHEMBL621306,,Intermediate,F,,1,,N,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,A10,80013,BAO_0000219
6739,164.0,,,1,,,CHEMBL618444,,Intermediate,F,,1,,N,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,A10,80013,BAO_0000219
6740,164.0,,,1,,,CHEMBL618445,,Intermediate,F,,1,,N,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,A10,80013,BAO_0000219
6741,185.0,,,1,,,CHEMBL618446,,Intermediate,F,,1,,N,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,CHO-AA8,80089,BAO_0000219
6742,185.0,,,1,,,CHEMBL618447,,Intermediate,F,,1,,N,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,CHO-AA8,80089,BAO_0000219
6743,185.0,,,1,,,CHEMBL618448,,Intermediate,F,,1,,N,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,CHO-AA8,80089,BAO_0000219
6744,185.0,,,1,,,CHEMBL618449,,Intermediate,F,,1,,N,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,CHO-AA8,80089,BAO_0000219
6745,185.0,,,1,,,CHEMBL618637,,Intermediate,F,,1,,N,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,CHO-AA8,80089,BAO_0000219
6746,185.0,,,1,,,CHEMBL618638,,Intermediate,F,,1,,N,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,CHO-AA8,80089,BAO_0000219
6747,185.0,,,1,,,CHEMBL618639,,Intermediate,F,,1,,N,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,CHO-AA8,80089,BAO_0000219
6748,185.0,,,1,,,CHEMBL618640,,Expert,F,,1,,N,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,CHO-AA8,80089,BAO_0000219
6749,185.0,,,1,,,CHEMBL618641,,Expert,F,,1,,N,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,CHO-AA8,80089,BAO_0000219
6750,185.0,,,1,,,CHEMBL618642,,Intermediate,F,,1,,N,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,CHO-AA8,80089,BAO_0000219
6751,185.0,,,1,,,CHEMBL618643,,Intermediate,F,,1,,N,Inhibitory activity against aerobic growth of AA8 cells.,,CHO-AA8,80089,BAO_0000219
6752,185.0,,,1,,,CHEMBL884013,,Intermediate,A,,1,,N,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHO-AA8,80089,BAO_0000219
6753,185.0,,,1,,,CHEMBL622723,,Expert,F,,1,,N,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHO-AA8,80089,BAO_0000219
6754,185.0,,,1,,,CHEMBL622724,,Intermediate,F,,1,,N,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHO-AA8,80089,BAO_0000219
6755,185.0,,,1,,,CHEMBL622725,,Expert,F,,1,,N,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,CHO-AA8,80089,BAO_0000219
6756,185.0,,,1,,,CHEMBL622726,,Expert,F,,1,,N,Cytotoxicity against AA8 cell line,,CHO-AA8,80089,BAO_0000219
6757,185.0,,,1,,,CHEMBL622727,,Intermediate,F,,1,,N,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,CHO-AA8,80089,BAO_0000219
6758,185.0,,,1,,,CHEMBL622728,,Intermediate,A,,1,,N,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHO-AA8,80089,BAO_0000219
6759,185.0,,,1,,,CHEMBL622729,,Intermediate,F,,1,,N,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHO-AA8,80089,BAO_0000219
6760,185.0,,,1,,,CHEMBL622730,,Intermediate,A,,1,,N,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHO-AA8,80089,BAO_0000219
6761,185.0,,,1,,,CHEMBL622731,,Intermediate,F,,1,,N,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,CHO-AA8,80089,BAO_0000219
6762,185.0,,,1,,,CHEMBL622732,,Intermediate,F,,1,,N,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,CHO-AA8,80089,BAO_0000219
6763,185.0,,,1,,,CHEMBL622733,,Intermediate,F,,1,,N,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,CHO-AA8,80089,BAO_0000219
6764,,,,0,,,CHEMBL622734,,Autocuration,F,,1,,U,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,,22224,BAO_0000218
6765,185.0,,,1,,,CHEMBL622735,,Expert,F,,1,,N,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,CHO-AA8,80089,BAO_0000219
6766,185.0,,,0,,,CHEMBL618746,,Autocuration,F,,1,,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,CHO-AA8,22224,BAO_0000219
6767,185.0,,,0,,,CHEMBL618747,,Autocuration,F,,1,,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,CHO-AA8,22224,BAO_0000219
6768,185.0,,,0,,,CHEMBL620540,,Autocuration,F,,1,,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,CHO-AA8,22224,BAO_0000219
6769,185.0,,,0,,,CHEMBL620541,,Autocuration,F,,1,,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,CHO-AA8,22224,BAO_0000219
6770,185.0,,,0,,,CHEMBL620542,,Autocuration,F,,1,,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,CHO-AA8,22224,BAO_0000219
6771,185.0,,,0,,,CHEMBL620543,,Autocuration,F,,1,,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,CHO-AA8,22224,BAO_0000219
6772,185.0,,,0,,,CHEMBL618832,,Autocuration,F,,1,,U,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,CHO-AA8,22224,BAO_0000219
6773,185.0,,,1,,,CHEMBL618833,,Expert,F,,1,,N,Concentration required to reduce AA8 cell survival by 10%,,CHO-AA8,80089,BAO_0000219
6774,185.0,,,0,,,CHEMBL618834,,Autocuration,F,,1,,U,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,CHO-AA8,22224,BAO_0000219
6775,185.0,,,0,,,CHEMBL618835,,Autocuration,F,,1,,U,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,CHO-AA8,22224,BAO_0000219
6776,185.0,,,0,,,CHEMBL618836,,Autocuration,F,,1,,U,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,CHO-AA8,22224,BAO_0000219
6777,185.0,,,0,,,CHEMBL618837,,Autocuration,F,,1,,U,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,CHO-AA8,22224,BAO_0000219
6778,185.0,,,0,,,CHEMBL618838,,Autocuration,F,,1,,U,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,CHO-AA8,22224,BAO_0000219
6779,185.0,,,0,,,CHEMBL618839,,Autocuration,F,,1,,U,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,CHO-AA8,22224,BAO_0000219
6780,185.0,,,0,,,CHEMBL618840,,Autocuration,F,,1,,U,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,CHO-AA8,22224,BAO_0000219
6781,,,,0,,,CHEMBL618841,,Autocuration,F,,1,,U,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,22224,BAO_0000019
6782,185.0,,,0,,,CHEMBL618842,,Autocuration,F,,1,,U,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,CHO-AA8,22224,BAO_0000219
6783,185.0,,,0,,,CHEMBL618843,,Autocuration,F,,1,,U,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,CHO-AA8,22224,BAO_0000219
6784,,,,1,,In vivo,CHEMBL618844,,Intermediate,A,,1,,N,Half life period after 15 mg/kg iv dose in Dogs,,,50588,BAO_0000218
6785,,,,1,,In vivo,CHEMBL618845,,Intermediate,A,,1,,N,Half life period after 30 mg/kg po dose in Dogs,,,50588,BAO_0000218
6786,,,,1,,In vivo,CHEMBL618846,,Intermediate,A,,1,,N,Half life was measured after oral 2b administration (tested in 6 dogs),,,50588,BAO_0000218
6787,,,,1,,In vivo,CHEMBL618847,,Intermediate,A,,1,,N,Half life was measured in dog after oral 17b administration,,,50588,BAO_0000218
6788,,,,1,,In vivo,CHEMBL618848,,Intermediate,A,,1,,N,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,,50588,BAO_0000218
6789,,,,1,,In vivo,CHEMBL618849,,Intermediate,A,,1,,N,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,,50588,BAO_0000218
6790,,,,1,,In vivo,CHEMBL618850,,Intermediate,A,,1,,N,Tmax value after 15 mg/kg iv dose in Dogs,,,50588,BAO_0000218
6791,,,,1,,In vivo,CHEMBL618851,,Intermediate,A,,1,,N,Tmax value after 30 mg/kg po dose in Dogs,,,50588,BAO_0000218
6792,,,,1,,In vivo,CHEMBL873815,,Intermediate,A,,1,,N,Compound was evaluated for its half life when administered intravenously in dog,,,50588,BAO_0000218
6793,,,1969.0,1,Plasma,In vivo,CHEMBL618852,,Intermediate,A,,1,,N,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,50588,BAO_0000218
6794,,,,1,,,CHEMBL618853,,Intermediate,A,,1,,N,Elimination Half-life of compound was determined in dog,,,50588,BAO_0000218
6795,,,,1,,In vivo,CHEMBL618854,,Intermediate,A,,1,,N,Half life of compound in dog following oral administration,,,50588,BAO_0000218
6796,,,,1,,,CHEMBL618855,,Intermediate,A,,1,,N,Half life of compound was determined in dog,,,50588,BAO_0000218
6797,,,178.0,1,Blood,,CHEMBL618856,,Intermediate,A,,1,,N,Half life of compound was determined in dog blood,,,50588,BAO_0000218
6798,,,,1,,In vivo,CHEMBL875827,,Intermediate,A,,1,,N,Half life after oral and iv dosing in dogs,,,50588,BAO_0000218
6799,,,,1,,,CHEMBL618857,,Intermediate,A,,1,,N,Half life in dogs in hours,,,50588,BAO_0000218
6800,,,,1,,In vivo,CHEMBL618858,,Intermediate,A,,1,,N,Half life on i.v. administration of 2 mg/kg was measured in dog,,,50588,BAO_0000218
6801,,,,1,,In vivo,CHEMBL618859,,Intermediate,A,,1,,N,t1/2 in dog after oral dose (1 mg/kg),,,50588,BAO_0000218
6802,,,,1,,,CHEMBL618860,,Intermediate,A,,1,,N,Half life was evaluated in dog,,,50588,BAO_0000218
6803,,,,1,,In vivo,CHEMBL618861,,Intermediate,A,,1,,N,Half life period of compound was determined after intravenous administration at 2 mg/kg,,,50588,BAO_0000218
6804,,,,1,,In vivo,CHEMBL622539,,Intermediate,A,,1,,N,Half life period of compound was determined after peroral administration at 2 mg/kg,,,50588,BAO_0000218
6805,,,,1,,In vivo,CHEMBL622540,,Intermediate,A,,1,,N,Half life period (10 mg/kg) was determined in dog,,,50588,BAO_0000218
6806,,,,1,,In vivo,CHEMBL873803,,Intermediate,A,,1,,N,Half life period (10 mg/kg) was determined in dog,,,50588,BAO_0000218
6807,,,,1,,In vivo,CHEMBL873804,,Intermediate,A,,1,,N,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,,50588,BAO_0000218
6808,,,,1,,In vivo,CHEMBL624311,,Intermediate,A,,1,,N,Half life period by po administration in dog at a dose of 0.3 mg/kg,,,50588,BAO_0000218
6809,,,,1,,,CHEMBL624312,,Intermediate,A,,1,,N,Half life period in dog,,,50588,BAO_0000218
6810,,,,1,,In vivo,CHEMBL624313,,Intermediate,A,,1,,N,Half life period in dogs after oral administration at 1 mg/kg,,,50588,BAO_0000218
6811,,,,1,,In vivo,CHEMBL624314,,Intermediate,A,,1,,N,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,50588,BAO_0000218
6812,,,,1,,,CHEMBL624315,,Intermediate,A,,1,,N,Half-life of compound was determined in dogs,,,50588,BAO_0000218
6813,,,1969.0,1,Plasma,,CHEMBL624316,,Intermediate,A,,1,,N,Half-life in dog plasma,,,50588,BAO_0000218
6814,,,,1,,,CHEMBL624317,,Intermediate,A,,1,,N,Half-life in mongrel dogs was determined,,,50588,BAO_0000218
6815,,,,1,,In vivo,CHEMBL624318,,Intermediate,A,,1,,N,Half-life in dog upon oral administration,,,50588,BAO_0000218
6816,,,,1,,In vivo,CHEMBL624319,,Intermediate,A,,1,,N,Half-life in dog upon oral administration; Unable to calculate,,,50588,BAO_0000218
6817,,,,1,,,CHEMBL624496,,Intermediate,A,,1,,N,Half-life was measured in dog,,,50588,BAO_0000218
6818,,,,1,,,CHEMBL624497,,Intermediate,A,,1,,N,Half-life was measured in dog,,,50588,BAO_0000218
6819,,,,1,,,CHEMBL624498,,Intermediate,A,,1,,N,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,,50588,BAO_0000218
6820,,,,1,,In vivo,CHEMBL624499,,Intermediate,A,,1,,N,Oral half life was determined,,,50588,BAO_0000218
6821,,,1969.0,1,Plasma,In vivo,CHEMBL624500,,Intermediate,A,,1,,N,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,,50588,BAO_0000218
6822,,,1969.0,1,Plasma,,CHEMBL624501,,Intermediate,A,,1,,N,Plasma half life was evaluated,,,50588,BAO_0000218
6823,,,1969.0,1,Plasma,,CHEMBL623666,,Intermediate,A,,1,,N,Plasma half life was evaluated in Dog,,,50588,BAO_0000218
6824,,,1969.0,1,Plasma,,CHEMBL623667,,Intermediate,A,,1,,N,Plasma half life was evaluated in dog,,,50588,BAO_0000218
6825,,,,1,,In vivo,CHEMBL623668,,Intermediate,A,,1,,N,T1/2 (Half-life) was after oral administration at 5 mg/kg,,,50588,BAO_0000218
6826,,,,1,,,CHEMBL623669,,Intermediate,A,,1,,N,Tested for the half life value in dog,,,50588,BAO_0000218
6827,,,,1,,In vivo,CHEMBL623670,,Intermediate,A,,1,,N,Maximum time at the dose of 2 mg/kg in dog,,,50588,BAO_0000218
6828,,,,1,,In vivo,CHEMBL623671,,Intermediate,A,,1,,N,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,50588,BAO_0000218
6829,,,178.0,1,Blood,In vivo,CHEMBL875945,,Intermediate,A,,1,,N,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,50588,BAO_0000218
6830,,,178.0,1,Blood,In vivo,CHEMBL623672,,Intermediate,A,,1,,N,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,50588,BAO_0000218
6831,,,,1,,In vivo,CHEMBL623673,,Intermediate,A,,1,,N,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,,50588,BAO_0000218
6832,,,,1,,In vivo,CHEMBL623674,,Intermediate,A,,1,,N,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,50588,BAO_0000218
6833,,,,1,,In vivo,CHEMBL623675,,Intermediate,A,,1,,N,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,,50588,BAO_0000218
6834,,,,1,,,CHEMBL872526,,Intermediate,A,,1,,N,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,,50588,BAO_0000218
6835,,,,1,,In vivo,CHEMBL623676,,Intermediate,A,,1,,N,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,,50588,BAO_0000218
6836,,,1969.0,1,Plasma,In vivo,CHEMBL623677,,Intermediate,A,,1,,N,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,50588,BAO_0000218
6837,,,1969.0,1,Plasma,In vivo,CHEMBL623678,,Intermediate,A,,1,,N,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,50588,BAO_0000218
6838,,,1969.0,1,Plasma,,CHEMBL623679,,Intermediate,A,,1,,N,Time taken for maximum plasma concentration in dog,,,50588,BAO_0000218
6839,,,,1,,In vivo,CHEMBL623680,,Intermediate,A,,1,,N,Time to reach Cmax after oral administration to dogs,,,50588,BAO_0000218
6840,,,1969.0,1,Plasma,In vivo,CHEMBL623681,,Intermediate,A,,1,,N,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588,BAO_0000218
6841,,,,1,,In vivo,CHEMBL623682,,Intermediate,A,,1,,N,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,,50588,BAO_0000218
6842,,,,1,,In vivo,CHEMBL623683,,Intermediate,A,,1,,N,Tmax after peroral administration (1 mg/kg) was determined in dog,,,50588,BAO_0000218
6843,,,,1,,In vivo,CHEMBL623684,,Expert,A,,1,,N,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,,50588,BAO_0000218
6844,,,,1,,In vivo,CHEMBL622745,,Intermediate,A,,1,,N,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,,50588,BAO_0000218
6845,,,,1,,In vivo,CHEMBL622746,,Intermediate,A,,1,,N,Tmax after peroral administration in dogs at 2.4 uM/kg,,,50588,BAO_0000218
6846,,,,1,,In vivo,CHEMBL622747,,Intermediate,A,,1,,N,In vivo Cmax in mice at dose of 100 mg/kg,,,50594,BAO_0000218
6847,,,,1,,In vivo,CHEMBL622748,,Intermediate,A,,1,,N,In vivo Cmax in mice at dose of 50 mg/kg,,,50594,BAO_0000218
6848,,,,1,,In vivo,CHEMBL622749,,Intermediate,A,,1,,N,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,,50594,BAO_0000218
6849,,,1969.0,1,Plasma,In vivo,CHEMBL622750,,Intermediate,A,,1,,N,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,50594,BAO_0000218
6850,,,1969.0,1,Plasma,In vivo,CHEMBL623411,,Intermediate,A,,1,,N,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,,50594,BAO_0000218
6851,,,1969.0,1,Plasma,In vivo,CHEMBL875946,,Intermediate,A,,1,,N,Maximum concentration obtained in mouse plasma was determined,,,50594,BAO_0000218
6852,,,1969.0,1,Plasma,In vivo,CHEMBL623412,,Intermediate,A,,1,,N,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,,50594,BAO_0000218
6853,,,1969.0,1,Plasma,In vivo,CHEMBL623413,,Intermediate,A,,1,,N,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594,BAO_0000218
6854,,,1969.0,1,Plasma,In vivo,CHEMBL623414,,Intermediate,A,,1,,N,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,,50594,BAO_0000218
6855,,,1969.0,1,Plasma,In vivo,CHEMBL623415,,Intermediate,A,,1,,N,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,,50594,BAO_0000218
6856,,,1969.0,1,Plasma,In vivo,CHEMBL623416,,Intermediate,A,,1,,N,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,,50594,BAO_0000218
6857,,,1969.0,1,Plasma,In vivo,CHEMBL623417,,Intermediate,A,,1,,N,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,,50594,BAO_0000218
6858,,,1969.0,1,Plasma,In vivo,CHEMBL623418,,Intermediate,A,,1,,N,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,,50594,BAO_0000218
6859,,,1969.0,1,Plasma,In vivo,CHEMBL623419,,Intermediate,A,,1,,N,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,,50594,BAO_0000218
6860,,,,1,,In vivo,CHEMBL622816,,Intermediate,A,,1,,N,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,,50594,BAO_0000218
6861,,,,1,,In vivo,CHEMBL623313,,Intermediate,A,,1,,N,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,,50594,BAO_0000218
6862,,,,1,,In vivo,CHEMBL623314,,Intermediate,A,,1,,N,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,,50594,BAO_0000218
6863,,,,1,,In vivo,CHEMBL876788,,Intermediate,A,,1,,N,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,,50594,BAO_0000218
6864,,,,1,,In vivo,CHEMBL623315,,Intermediate,A,,1,,N,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,,50594,BAO_0000218
6865,,,,1,,In vivo,CHEMBL623316,,Intermediate,A,,1,,N,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,,50594,BAO_0000218
6866,,,,1,,In vivo,CHEMBL623317,,Intermediate,A,,1,,N,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,,50594,BAO_0000218
6868,,,,1,,In vivo,CHEMBL623319,,Intermediate,A,,1,,N,Cmax in male mice after 2 mg/kg oral dose,,,50594,BAO_0000218
6869,,,,1,,In vivo,CHEMBL623320,,Intermediate,A,,1,,N,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,,50594,BAO_0000218
6870,,,,1,,In vivo,CHEMBL623321,,Intermediate,A,,1,,N,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,,50594,BAO_0000218
6871,,,,1,,,CHEMBL623322,,Intermediate,A,,1,,N,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,,50594,BAO_0000218
6872,,,,1,,,CHEMBL623323,,Intermediate,A,,1,,N,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,,50594,BAO_0000218
6873,,,,1,,,CHEMBL623324,,Intermediate,A,,1,,N,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,,50594,BAO_0000218
6874,,,,1,,,CHEMBL623325,,Intermediate,A,,1,,N,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,,50594,BAO_0000218
6875,,,,1,,,CHEMBL623326,,Intermediate,A,,1,,N,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,,50594,BAO_0000218
6876,,,,1,,,CHEMBL623327,,Intermediate,A,,1,,N,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,,50594,BAO_0000218
6877,,,1969.0,1,Plasma,,CHEMBL623328,,Intermediate,A,,1,,N,Maximum concentration in plasma upon oral administration in mouse,,,50594,BAO_0000218
6878,,,1969.0,1,Plasma,,CHEMBL623329,,Intermediate,A,,1,,N,Maximum plasma concentration was evaluated in mice after oral administration,,,50594,BAO_0000218
6879,,,1969.0,1,Plasma,In vivo,CHEMBL623330,,Intermediate,A,,1,,N,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,,50594,BAO_0000218
6880,,,,1,,,CHEMBL876789,,Intermediate,A,,1,,N,Dose at which the compound induced fecal excretion in mice,,,50594,BAO_0000218
6893,164.0,,,1,,,CHEMBL623333,,Expert,F,,1,,N,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,A10,80013,BAO_0000219
6894,164.0,,,1,,,CHEMBL623334,,Expert,F,,1,,N,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,A10,80013,BAO_0000219
6895,164.0,,,1,,,CHEMBL627536,,Expert,F,,1,,N,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,A10,80013,BAO_0000219
6896,164.0,,,1,,,CHEMBL627537,,Expert,F,,1,,N,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,A10,80013,BAO_0000219
6897,164.0,,,1,,,CHEMBL627538,,Intermediate,F,,1,,N,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,A10,80013,BAO_0000219
6898,393.0,,,1,,,CHEMBL884106,,Intermediate,F,,1,,N,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,A121,80655,BAO_0000219
6899,393.0,,,1,,,CHEMBL625294,,Intermediate,F,,1,,N,Anticancer activity against human ovarian carcinoma A121 cells,,A121,80655,BAO_0000219
6900,393.0,,,1,,,CHEMBL625295,,Intermediate,F,,1,,N,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,A121,80655,BAO_0000219
6901,393.0,,,1,,,CHEMBL625296,,Intermediate,F,,1,,N,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,A121,80655,BAO_0000219
6902,393.0,,,1,,,CHEMBL625297,,Expert,F,,1,,N,Growth inhibition of human ovarian carcinoma (A121) cell line,,A121,80655,BAO_0000219
6903,393.0,,,1,,,CHEMBL625298,,Expert,F,,1,,N,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,A121,80655,BAO_0000219
6904,393.0,,,1,,,CHEMBL625960,,Intermediate,F,,1,,N,Cytotoxicity against human A121 ovarian cells,,A121,80655,BAO_0000219
6905,393.0,,,1,,,CHEMBL625961,,Intermediate,F,,1,,N,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,A121,80655,BAO_0000219
6906,393.0,,,1,,,CHEMBL625962,,Intermediate,F,,1,,N,In vitro cytotoxicity against human ovarian carcinoma A21,,A121,80655,BAO_0000219
6907,393.0,,,1,,,CHEMBL624717,,Intermediate,F,,1,,N,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,A121,80655,BAO_0000219
6908,393.0,,,1,,,CHEMBL624718,,Intermediate,F,,1,,N,Inhibitory activity of compound against human A121 ovarian cell line.,,A121,80655,BAO_0000219
6909,393.0,,,1,,,CHEMBL624719,,Intermediate,F,,1,,N,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,A121,80655,BAO_0000219
6910,393.0,,,1,,,CHEMBL624720,,Intermediate,F,,1,,N,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,A121,80655,BAO_0000219
6911,622.0,,,1,,,CHEMBL624721,,Intermediate,F,,1,,N,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,A 172,80012,BAO_0000219
6912,622.0,,,1,,,CHEMBL624722,,Expert,F,,1,,N,In vitro cytotoxicity against A172 human tumor cell lines.,,A 172,80012,BAO_0000219
6913,622.0,,,1,,,CHEMBL877597,,Intermediate,F,,1,,N,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,A 172,80012,BAO_0000219
6914,622.0,,,1,,,CHEMBL624723,,Intermediate,F,,1,,N,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,A 172,80012,BAO_0000219
6915,622.0,,,1,,,CHEMBL624724,,Intermediate,F,,1,,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,A 172,80012,BAO_0000219
6916,,,,4,,,CHEMBL624725,,Autocuration,B,,1,,H,Association constant against A2 adenosine receptor,,,104729,BAO_0000224
6917,1085.0,,,1,,,CHEMBL624726,,Intermediate,F,,1,,N,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,A2,80656,BAO_0000219
6918,,,,5,,,CHEMBL857535,,Autocuration,B,,1,,D,Ratio of Ki for adenosine A2 and A1 receptor binding,,,104713,BAO_0000224
6919,623.0,,,1,,,CHEMBL624727,,Expert,F,,1,,N,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,A204,80014,BAO_0000219
6920,623.0,,,1,,,CHEMBL624728,,Expert,F,,1,,N,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,A204,80014,BAO_0000219
6921,404.0,,,1,,,CHEMBL624729,,Intermediate,F,,1,,N,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,A2058,80015,BAO_0000219
6922,973.0,,,1,,,CHEMBL624730,,Intermediate,F,,1,,N,Growth inhibition against Human squamous cell line(A 253),,A253 cell line,80657,BAO_0000219
6923,973.0,,,1,,,CHEMBL624731,,Intermediate,F,,1,,N,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,A253 cell line,80657,BAO_0000219
6924,973.0,,,1,,,CHEMBL624732,,Intermediate,F,,1,,N,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,A253 cell line,80657,BAO_0000219
6925,973.0,,,1,,,CHEMBL883245,,Intermediate,F,,1,,N,Growth inhibition of A253 cell lines.,,A253 cell line,80657,BAO_0000219
6926,973.0,,,1,,,CHEMBL624733,,Intermediate,F,,1,,N,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,A253 cell line,80657,BAO_0000219
6927,973.0,,,1,,,CHEMBL624734,,Intermediate,F,,1,,N,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,A253 cell line,80657,BAO_0000219
6928,973.0,,,1,,,CHEMBL624735,,Intermediate,F,,1,,N,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,A253 cell line,80657,BAO_0000219
6929,478.0,,,1,,,CHEMBL621780,,Intermediate,F,,1,,N,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,A2780,81034,BAO_0000219
6930,478.0,,,1,,,CHEMBL877598,,Intermediate,F,,1,,N,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,A2780,81034,BAO_0000219
6931,478.0,,,1,,,CHEMBL621781,,Expert,F,,1,,N,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,A2780,81034,BAO_0000219
6932,478.0,,,1,,,CHEMBL621782,,Intermediate,F,,1,,N,Cytotoxicity against human cancer cell lines A2780 (ovarian),,A2780,81034,BAO_0000219
6933,478.0,,,1,,,CHEMBL621783,,Expert,F,,1,,N,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,A2780,81034,BAO_0000219
6934,478.0,,,1,,,CHEMBL621784,,Intermediate,F,,1,,N,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,A2780,81034,BAO_0000219
6935,478.0,,,1,,,CHEMBL621785,,Intermediate,F,,1,,N,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,A2780,81034,BAO_0000219
6936,478.0,,,1,,,CHEMBL621968,,Expert,F,,1,,N,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,A2780,81034,BAO_0000219
6937,478.0,,,1,,,CHEMBL621969,,Expert,F,,1,,N,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,A2780,81034,BAO_0000219
6938,478.0,,,1,,,CHEMBL621970,,Expert,F,,1,,N,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,A2780,81034,BAO_0000219
6939,478.0,,,1,,,CHEMBL621971,,Intermediate,F,,1,,N,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,A2780,81034,BAO_0000219
6940,478.0,,,1,,,CHEMBL621972,,Intermediate,F,,1,,N,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,A2780,81034,BAO_0000219
6941,478.0,,,1,,,CHEMBL884108,,Intermediate,F,,1,,N,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,A2780,81034,BAO_0000219
6942,,,,0,,,CHEMBL623826,,Autocuration,F,,1,,U,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,22224,BAO_0000019
6943,185.0,,,0,,,CHEMBL623827,,Autocuration,A,,1,,U,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,CHO-AA8,22224,BAO_0000219
6944,185.0,,,0,,,CHEMBL623828,,Autocuration,F,,1,,U,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,CHO-AA8,22224,BAO_0000219
6945,185.0,,,0,,,CHEMBL623829,,Autocuration,F,,1,,U,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,CHO-AA8,22224,BAO_0000219
6946,185.0,,,0,,,CHEMBL623830,,Autocuration,F,,1,,U,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,CHO-AA8,22224,BAO_0000219
6947,,,,0,,,CHEMBL623831,,Autocuration,F,,1,,U,Growth inhibition against CHO-derived cell line AA8,,,22224,BAO_0000019
6948,185.0,,,0,,,CHEMBL623832,,Autocuration,F,,1,,U,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,CHO-AA8,22224,BAO_0000219
6949,185.0,,,1,,,CHEMBL623833,,Expert,F,,1,,N,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,CHO-AA8,80089,BAO_0000219
6950,185.0,,,1,,,CHEMBL623834,,Expert,F,,1,,N,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,CHO-AA8,80089,BAO_0000219
6951,185.0,,,0,,,CHEMBL623835,,Autocuration,F,,1,,U,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,CHO-AA8,22224,BAO_0000219
6952,185.0,,,0,,,CHEMBL623836,,Autocuration,F,,1,,U,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,CHO-AA8,22224,BAO_0000219
6953,185.0,,,0,,,CHEMBL623837,,Autocuration,F,,1,,U,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,CHO-AA8,22224,BAO_0000219
6954,185.0,,,1,,,CHEMBL623838,,Expert,F,,1,,N,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,CHO-AA8,80089,BAO_0000219
6955,,,,8,,,CHEMBL623839,,Autocuration,F,,1,,H,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,,12675,BAO_0000019
6956,,,,8,,,CHEMBL623840,,Autocuration,F,,1,,H,Number of binding sites (n) of isolated serum protein AAG,,,12675,BAO_0000019
6957,,,,3,,,CHEMBL623841,,Intermediate,B,,1,,M,Association constant for binding to AATT duplex,,,22222,BAO_0000225
6958,416.0,,,1,,,CHEMBL623842,,Expert,F,,1,,N,Inhibition of ABAE human fibroblast cell proliferation,,ABAE,100090,BAO_0000219
6959,1064.0,,,1,,,CHEMBL623843,,Intermediate,F,,1,,N,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,AC755,80668,BAO_0000218
6960,,,,9,,,CHEMBL618669,,Expert,F,,1,,D,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,,102444,BAO_0000218
6961,,,,9,,In vivo,CHEMBL618670,,Expert,F,,1,,D,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,,102444,BAO_0000218
6962,,,,8,,,CHEMBL618671,,Autocuration,B,,1,,H,Inhibitory activity against angiotensin-converting enzyme (ACE).,,,69,BAO_0000357
6963,,,,8,,,CHEMBL618672,,Autocuration,B,,1,,H,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,,69,BAO_0000357
6964,978.0,,,1,,,CHEMBL618673,,Intermediate,F,,1,,N,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,ACH-2 cell line,80669,BAO_0000219
6965,978.0,,,1,,,CHEMBL618674,,Intermediate,F,,1,,N,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,ACH-2 cell line,80669,BAO_0000219
6966,998.0,,,0,,,CHEMBL618675,,Autocuration,F,,1,,U,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,T cell line,22224,BAO_0000219
6967,998.0,,,0,,,CHEMBL618676,,Autocuration,F,,1,,U,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,T cell line,22224,BAO_0000219
6968,998.0,,,0,,,CHEMBL618677,,Autocuration,F,,1,,U,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,T cell line,22224,BAO_0000219
6969,626.0,,,1,,,CHEMBL618678,,Intermediate,F,,1,,N,Inhibition of growth of renal cancer ACHN cell line,,ACHN,80025,BAO_0000219
6970,626.0,,,1,,,CHEMBL618679,,Intermediate,F,,1,,N,Inhibition of growth of ACHN renal cancer cell line,,ACHN,80025,BAO_0000219
6971,626.0,,,1,,,CHEMBL618680,,Intermediate,F,,1,,N,Inhibitory concentration required against ACHN renal cancer cell line,,ACHN,80025,BAO_0000219
6972,626.0,,,1,,,CHEMBL618681,,Expert,F,,1,,N,Concentration required to inhibit growth of human renal (ACHN) cell line,,ACHN,80025,BAO_0000219
6973,626.0,,,1,,,CHEMBL618682,,Intermediate,F,,1,,N,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,ACHN,80025,BAO_0000219
6974,626.0,,,1,,,CHEMBL618683,,Intermediate,F,,1,,N,Cytotoxic activity against ACHN Renal cancer cell line,,ACHN,80025,BAO_0000219
6975,626.0,,,1,,,CHEMBL618684,,Intermediate,F,,1,,N,Cytotoxicity evaluation against ACHN renal cancer cells,,ACHN,80025,BAO_0000219
6976,626.0,,,1,,,CHEMBL618685,,Intermediate,F,,1,,N,In vitro antitumor activity against human renal ACHN cell line,,ACHN,80025,BAO_0000219
6977,626.0,,,1,,,CHEMBL876499,,Intermediate,F,,1,,N,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,ACHN,80025,BAO_0000219
6978,626.0,,,1,,,CHEMBL618686,,Intermediate,F,,1,,N,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,ACHN,80025,BAO_0000219
6979,626.0,,,1,,,CHEMBL618687,,Intermediate,F,,1,,N,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,ACHN,80025,BAO_0000219
6980,626.0,,,1,,,CHEMBL618688,,Intermediate,F,,1,,N,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,ACHN,80025,BAO_0000219
6981,626.0,,,1,,,CHEMBL618689,,Expert,F,,1,,N,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,ACHN,80025,BAO_0000219
6982,626.0,,,1,,,CHEMBL618690,,Intermediate,F,,1,,N,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,ACHN,80025,BAO_0000219
6983,626.0,,,1,,,CHEMBL618691,,Intermediate,F,,1,,N,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,ACHN,80025,BAO_0000219
6984,626.0,,,1,,,CHEMBL619373,,Intermediate,F,,1,,N,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,ACHN,80025,BAO_0000219
6985,626.0,,,1,,,CHEMBL884008,,Intermediate,F,,1,,N,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,ACHN,80025,BAO_0000219
6986,626.0,,,1,,,CHEMBL619374,,Intermediate,F,,1,,N,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,ACHN,80025,BAO_0000219
6987,626.0,,,1,,,CHEMBL619375,,Intermediate,F,,1,,N,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,ACHN,80025,BAO_0000219
6988,626.0,,,1,,,CHEMBL619376,,Intermediate,F,,1,,N,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,ACHN,80025,BAO_0000219
6989,626.0,,,1,,,CHEMBL619377,,Intermediate,F,,1,,N,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,ACHN,80025,BAO_0000219
6990,626.0,,,1,,,CHEMBL619378,,Intermediate,F,,1,,N,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,ACHN,80025,BAO_0000219
6991,,,,1,,In vivo,CHEMBL872527,,Intermediate,A,,1,,N,Tmax value after administration of 4 mg/Kg oral dose in dog,,,50588,BAO_0000218
6992,,,,1,,,CHEMBL876500,,Intermediate,A,,1,,N,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,,50588,BAO_0000218
6993,,,,1,,,CHEMBL619379,,Intermediate,A,,1,,N,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,50588,BAO_0000218
6994,,,,1,,In vivo,CHEMBL619538,,Intermediate,A,,1,,N,Volume distribution after 15 mg/kg iv dose in Dogs,,,50588,BAO_0000218
6995,,,,1,,In vivo,CHEMBL619539,,Intermediate,A,,1,,N,Volume distribution after 30 mg/kg po dose in Dogs,,,50588,BAO_0000218
6996,,,,1,,In vivo,CHEMBL619540,,Intermediate,A,,1,,N,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,,50588,BAO_0000218
6997,,,,1,,In vivo,CHEMBL619541,,Intermediate,A,,1,,N,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,,50588,BAO_0000218
6998,,,,1,,In vivo,CHEMBL619542,,Intermediate,A,,1,,N,Volume of distribution was evaluated in dog,,,50588,BAO_0000218
6999,,,,1,,In vivo,CHEMBL619543,,Intermediate,A,,1,,N,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,50588,BAO_0000218
7000,,,,1,,,CHEMBL619544,,Expert,A,,1,,N,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,,50588,BAO_0000218
7001,,,,1,,In vivo,CHEMBL619545,,Intermediate,A,,1,,N,The compound was tested for volume of distribution in dog,,,50588,BAO_0000218
7002,,,,1,,In vivo,CHEMBL619546,,Intermediate,A,,1,,N,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,,50588,BAO_0000218
7003,,,,1,,In vivo,CHEMBL619547,,Intermediate,A,,1,,N,Vd (1 mg/kg) was determined in dog (in vivo),,,50588,BAO_0000218
7004,,,,1,,In vivo,CHEMBL619548,,Intermediate,A,,1,,N,Vd in dog,,,50588,BAO_0000218
7005,,,,1,,In vivo,CHEMBL619549,,Intermediate,A,,1,,N,Volume distribution was determined,,,50588,BAO_0000218
7006,,,,1,,In vivo,CHEMBL619550,,Intermediate,A,,1,,N,Volume of distribution in dog,,,50588,BAO_0000218
7007,,,,1,,In vivo,CHEMBL876501,,Intermediate,A,,1,,N,Volume of distribution by as 4 fold increase by iv administration in dogs,,,50588,BAO_0000218
7008,,,,1,,In vivo,CHEMBL619551,,Intermediate,A,,1,,N,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,50588,BAO_0000218
7009,,,,1,,In vivo,CHEMBL619552,,Intermediate,A,,1,,N,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588,BAO_0000218
7010,,,,1,,In vivo,CHEMBL619553,,Intermediate,A,,1,,N,Volume distribution at the dose of 2 mg/kg in dog,,,50588,BAO_0000218
7011,,,,1,,In vivo,CHEMBL618722,,Intermediate,A,,1,,N,Steady state volume of distribution was determined,,,50588,BAO_0000218
7012,,,,1,,In vivo,CHEMBL618723,,Intermediate,A,,1,,N,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,,50588,BAO_0000218
7013,,,,1,,In vivo,CHEMBL618724,,Intermediate,A,,1,,N,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,50588,BAO_0000218
7014,,,,1,,In vivo,CHEMBL618725,,Intermediate,A,,1,,N,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,50588,BAO_0000218
7015,,,,1,,In vivo,CHEMBL618726,,Intermediate,A,,1,,N,Bioavailability in dog (dose 1 mg/kg i.v.),,,50588,BAO_0000218
7016,,,,1,,In vivo,CHEMBL618727,,Intermediate,A,,1,,N,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,50588,BAO_0000218
7017,,,,1,,In vivo,CHEMBL624233,,Intermediate,A,,1,,N,Pharmacokinetic property (vdss) was measured in dog,,,50588,BAO_0000218
7018,,,,1,,In vivo,CHEMBL624234,,Intermediate,A,,1,,N,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,,50588,BAO_0000218
7019,,,,1,,In vivo,CHEMBL624235,,Intermediate,A,,1,,N,Vdss was determined after iv 0.1 mg/kg administration in dog,,,50588,BAO_0000218
7020,,,,1,,In vivo,CHEMBL624236,,Intermediate,A,,1,,N,Volume displacement was calculated in dog,,,50588,BAO_0000218
7021,,,,1,,In vivo,CHEMBL624237,,Intermediate,A,,1,,N,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,50588,BAO_0000218
7022,,,,1,,In vivo,CHEMBL624238,,Intermediate,A,,1,,N,Volume distribution constant was determined,,,50588,BAO_0000218
7023,,,,1,,In vivo,CHEMBL624239,,Intermediate,A,,1,,N,Volume distribution at a dose of 1 uM/kg in dog was determined,,,50588,BAO_0000218
7024,,,,1,,In vivo,CHEMBL875829,,Intermediate,A,,1,,N,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,50588,BAO_0000218
7025,,,,1,,In vivo,CHEMBL624240,,Intermediate,A,,1,,N,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,50588,BAO_0000218
7026,,,,1,,In vivo,CHEMBL624241,,Intermediate,A,,1,,N,Volume distribution (Vdss) was measured in dog,,,50588,BAO_0000218
7027,,,,1,,In vivo,CHEMBL624242,,Intermediate,A,,1,,N,Volume distribution (Vdss) was measured in dog,,,50588,BAO_0000218
7028,,,,1,,In vivo,CHEMBL624243,,Intermediate,A,,1,,N,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50588,BAO_0000218
7029,,,,1,,In vivo,CHEMBL624244,,Intermediate,A,,1,,N,Volume of distribution in steady state was determined in dog,,,50588,BAO_0000218
7030,,,,1,,In vivo,CHEMBL624245,,Intermediate,A,,1,,N,Volume of distribution of compound was determined in dog,,,50588,BAO_0000218
7031,,,,1,,In vivo,CHEMBL624246,,Intermediate,A,,1,,N,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,,50588,BAO_0000218
7032,,,,1,,In vivo,CHEMBL624247,,Intermediate,A,,1,,N,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,50588,BAO_0000218
7033,,,,1,,In vivo,CHEMBL624248,,Intermediate,A,,1,,N,Volume of distribution (Vdss) was measured in dog,,,50588,BAO_0000218
7034,,,,1,,In vivo,CHEMBL624249,,Intermediate,A,,1,,N,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,50588,BAO_0000218
7035,,,,1,,In vivo,CHEMBL624250,,Intermediate,A,,1,,N,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588,BAO_0000218
7036,,,,1,,In vivo,CHEMBL624251,,Intermediate,A,,1,,N,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588,BAO_0000218
7037,,,,1,,,CHEMBL624252,,Intermediate,A,,1,,N,Maximum rate of depolarization of the upstroke of the action potential,,,50588,BAO_0000218
7038,,,,1,,In vivo,CHEMBL624253,,Intermediate,A,,1,,N,Steady state volume distribution in dog,,,50588,BAO_0000218
7039,,,,1,,In vivo,CHEMBL624950,,Intermediate,A,,1,,N,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,,50588,BAO_0000218
7040,,,,1,,In vivo,CHEMBL624951,,Intermediate,A,,1,,N,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,,50588,BAO_0000218
7041,,,,1,,In vivo,CHEMBL875830,,Intermediate,A,,1,,N,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,,50588,BAO_0000218
7042,,,,1,,In vivo,CHEMBL624952,,Intermediate,A,,1,,N,Volume distribution in dog after administration of 1 mg/kg iv,,,50588,BAO_0000218
7043,,,,1,,In vivo,CHEMBL624953,,Intermediate,A,,1,,N,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,,50588,BAO_0000218
7044,,,,1,,In vivo,CHEMBL624954,,Intermediate,A,,1,,N,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,,50588,BAO_0000218
7045,,,,1,,In vivo,CHEMBL624955,,Intermediate,A,,1,,N,Vss on i.v. administration of 2 mg/kg was measured in dog,,,50588,BAO_0000218
7046,,,,1,,,CHEMBL624956,,Intermediate,A,,1,,N,Vss was determined,,,50588,BAO_0000218
7047,,,,1,,,CHEMBL625129,,Intermediate,A,,1,,N,Vss in dog,,,50588,BAO_0000218
7048,,,,1,,In vivo,CHEMBL625130,,Intermediate,A,,1,,N,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,50588,BAO_0000218
7049,,,,1,,In vivo,CHEMBL625131,,Intermediate,A,,1,,N,Volume distribution in dogs,,,50588,BAO_0000218
7050,,,,1,,In vivo,CHEMBL625132,,Intermediate,A,,1,,N,Volume of distribution in dog,,,50588,BAO_0000218
7051,,,,1,,In vivo,CHEMBL872263,,Intermediate,A,,1,,N,Tested for the oral bioavailability in dog,,,50588,BAO_0000218
7060,,,,1,,In vivo,CHEMBL624336,,Intermediate,A,,1,,N,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,,50594,BAO_0000218
7061,,,,1,,In vivo,CHEMBL624337,,Intermediate,A,,1,,N,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,,50594,BAO_0000218
7062,,,,1,,In vivo,CHEMBL624338,,Intermediate,A,,1,,N,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,,50594,BAO_0000218
7063,,,,1,,In vivo,CHEMBL624339,,Intermediate,A,,1,,N,Bioavailability was measured in mouse,,,50594,BAO_0000218
7064,,,,1,,In vivo,CHEMBL624340,,Intermediate,A,,1,,N,Bioavailability in mouse,,,50594,BAO_0000218
7065,,,,1,,In vivo,CHEMBL624341,,Intermediate,A,,1,,N,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594,BAO_0000218
7066,,,,1,,In vivo,CHEMBL624342,,Intermediate,A,,1,,N,Bioavailability in mouse,,,50594,BAO_0000218
7067,,,,1,,In vivo,CHEMBL624343,,Intermediate,A,,1,,N,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,,50594,BAO_0000218
7068,,,,1,,In vivo,CHEMBL624344,,Intermediate,A,,1,,N,Oral bioavailability in mouse,,,50594,BAO_0000218
7069,,,,1,,In vivo,CHEMBL624345,,Intermediate,A,,1,,N,Oral availability at 50 mg/kg po in male mice,,,50594,BAO_0000218
7070,,,,1,,In vivo,CHEMBL624346,,Intermediate,A,,1,,N,Oral bioavailability in mouse (dose 10 mg/kg),,,50594,BAO_0000218
7071,,,,1,,In vivo,CHEMBL624347,,Expert,A,,1,,N,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,,50594,BAO_0000218
7072,,,,1,,In vivo,CHEMBL624348,,Intermediate,A,,1,,N,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,,50594,BAO_0000218
7074,,,,1,,In vivo,CHEMBL622754,,Intermediate,A,,1,,N,Oral bioavailability in mouse,,,50594,BAO_0000218
7075,,,,1,,In vivo,CHEMBL622755,,Intermediate,A,,1,,N,Oral bioavailability in vivo in mice;ND=Not determined,,,50594,BAO_0000218
7076,,,,1,,In vivo,CHEMBL622756,,Intermediate,A,,1,,N,Oral bioavailability in mouse at 10 mg/kg of the compound,,,50594,BAO_0000218
7077,,,,1,,In vivo,CHEMBL622757,,Intermediate,A,,1,,N,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,,50594,BAO_0000218
7078,,,,1,,In vivo,CHEMBL622758,,Intermediate,A,,1,,N,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,,50594,BAO_0000218
7079,,,,1,,In vivo,CHEMBL622759,,Intermediate,A,,1,,N,Tested for bioavailability of the compound,,,50594,BAO_0000218
7080,,,,1,,In vivo,CHEMBL622760,,Intermediate,A,,1,,N,Tested for half life at the dose of 10 mg/kg when administered intravenously,,,50594,BAO_0000218
7081,,,1969.0,1,Plasma,,CHEMBL622761,,Intermediate,A,,1,,N,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,,50594,BAO_0000218
7082,,,1969.0,1,Plasma,,CHEMBL622762,,Intermediate,A,,1,,N,The plasma half life of compound was determined on heparin prepared by human plasma. ,,,50594,BAO_0000218
7083,,,1969.0,1,Plasma,,CHEMBL622763,,Intermediate,A,,1,,N,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,,50594,BAO_0000218
7084,,,1969.0,1,Plasma,,CHEMBL622764,,Intermediate,A,,1,,N,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,,50594,BAO_0000218
7085,,,1969.0,1,Plasma,,CHEMBL622765,,Intermediate,A,,1,,N,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,,50594,BAO_0000218
7086,,,,1,,,CHEMBL622766,,Intermediate,F,,1,,N,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,,50594,BAO_0000218
7087,,,,1,,,CHEMBL622767,,Intermediate,A,,1,,N,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,,50594,BAO_0000218
7088,,,,1,,,CHEMBL622768,,Intermediate,A,,1,,N,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,,50594,BAO_0000218
7089,,,178.0,1,Blood,In vivo,CHEMBL875948,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
7090,,,178.0,1,Blood,In vivo,CHEMBL622769,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594,BAO_0000218
7091,,,178.0,1,Blood,In vivo,CHEMBL622770,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
7092,,,178.0,1,Blood,In vivo,CHEMBL622771,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
7093,,,178.0,1,Blood,In vivo,CHEMBL622772,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
7094,,,178.0,1,Blood,In vivo,CHEMBL622773,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594,BAO_0000218
7095,,,178.0,1,Blood,In vivo,CHEMBL622774,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
7096,,,10000001.0,1,Bone,In vivo,CHEMBL621725,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
7097,,,10000001.0,1,Bone,In vivo,CHEMBL621726,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,50594,BAO_0000218
7098,478.0,,,1,,,CHEMBL621727,,Intermediate,F,,1,,N,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,A2780,81034,BAO_0000219
7099,478.0,,,1,,,CHEMBL622413,,Expert,F,,1,,N,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,A2780,81034,BAO_0000219
7100,478.0,,,1,,,CHEMBL622414,,Intermediate,F,,1,,N,Compound was evaluated for cytotoxicity against A2780 cell line,,A2780,81034,BAO_0000219
7101,478.0,,,1,,,CHEMBL622415,,Expert,F,,1,,N,Inhibition of A2780 cell clonogenic assay,,A2780,81034,BAO_0000219
7102,478.0,,,1,,,CHEMBL884001,,Expert,F,,1,,N,Cytotoxic effect on ovarian cancer cell line (A2780),,A2780,81034,BAO_0000219
7103,478.0,,,1,,,CHEMBL622416,,Intermediate,F,,1,,N,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,A2780,81034,BAO_0000219
7104,478.0,,,1,,,CHEMBL622417,,Intermediate,F,,1,,N,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,A2780,81034,BAO_0000219
7105,478.0,,,1,,,CHEMBL622590,,Expert,F,,1,,N,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,A2780,81034,BAO_0000219
7106,478.0,,,1,,,CHEMBL622591,,Expert,F,,1,,N,Antiproliferative activity against human A2780 cells,,A2780,81034,BAO_0000219
7107,478.0,,,1,,,CHEMBL622592,,Expert,F,,1,,N,Inhibition of human A2780 cell proliferation,,A2780,81034,BAO_0000219
7108,478.0,,,1,,,CHEMBL622593,,Expert,F,,1,,N,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,A2780,81034,BAO_0000219
7109,478.0,,,1,,,CHEMBL622594,,Expert,F,,1,,N,Inhibition of human A2780 cell proliferation (No data),,A2780,81034,BAO_0000219
7110,478.0,,,1,,,CHEMBL622595,,Intermediate,F,,1,,N,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,A2780,81034,BAO_0000219
7111,478.0,,,1,,,CHEMBL622596,,Intermediate,F,,1,,N,Compound was evaluated against human Ovarian carcinoma cell line A2780,,A2780,81034,BAO_0000219
7112,478.0,,,1,,,CHEMBL622597,,Expert,F,,1,,N,Growth inhibition against A2780 wild-type ovarian cell lines,,A2780,81034,BAO_0000219
7113,478.0,,,1,,,CHEMBL622598,,Intermediate,F,,1,,N,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,A2780,81034,BAO_0000219
7114,,,,5,,,CHEMBL622599,,Autocuration,F,,1,,D,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,,104766,BAO_0000019
7115,478.0,,,1,,,CHEMBL622600,,Intermediate,F,,1,,N,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,A2780,81034,BAO_0000219
7116,478.0,,,1,,,CHEMBL622601,,Intermediate,F,,1,,N,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,A2780,81034,BAO_0000219
7117,478.0,,,1,,,CHEMBL622602,,Intermediate,F,,1,,N,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,A2780,81034,BAO_0000219
7118,478.0,,,1,,,CHEMBL622603,,Intermediate,F,,1,,N,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,A2780,81034,BAO_0000219
7119,478.0,,,1,,,CHEMBL622604,,Intermediate,F,,1,,N,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,A2780,81034,BAO_0000219
7120,478.0,,,1,,,CHEMBL622605,,Intermediate,F,,1,,N,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,A2780,81034,BAO_0000219
7121,478.0,,,1,,,CHEMBL622606,,Expert,F,,1,,N,In vitro inhibition of human ovarian cell line A2780,,A2780,81034,BAO_0000219
7122,478.0,,,1,,,CHEMBL619463,,Expert,F,,1,,N,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,A2780,81034,BAO_0000219
7123,478.0,,,1,,,CHEMBL619464,,Intermediate,F,,1,,N,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,A2780,81034,BAO_0000219
7124,478.0,,,1,,,CHEMBL619465,,Expert,F,,1,,N,Concentration required to inhibit A2780-cell growth by 50%,,A2780,81034,BAO_0000219
7125,478.0,,,1,,,CHEMBL619466,,Expert,F,,1,,N,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,A2780,81034,BAO_0000219
7126,478.0,,,1,,,CHEMBL619467,,Expert,F,,1,,N,Cytotoxic effect on human ovarian (A2780) cancer cell line,,A2780,81034,BAO_0000219
7127,478.0,,,1,,,CHEMBL619468,,Intermediate,F,,1,,N,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,A2780,81034,BAO_0000219
7128,478.0,,,1,,,CHEMBL619469,,Expert,F,,1,,N,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,A2780,81034,BAO_0000219
7129,478.0,,,1,,,CHEMBL619470,,Expert,F,,1,,N,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,A2780,81034,BAO_0000219
7130,478.0,,,1,,,CHEMBL619471,,Intermediate,F,,1,,N,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,A2780,81034,BAO_0000219
7131,478.0,,,1,,,CHEMBL619472,,Intermediate,F,,1,,N,Cytotoxicity against human ovarian carcinoma A2780 cell line,,A2780,81034,BAO_0000219
7132,478.0,,,1,,,CHEMBL619473,,Intermediate,F,,1,,N,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,A2780,81034,BAO_0000219
7133,478.0,,,1,,,CHEMBL874368,,Intermediate,F,,1,,N,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,A2780,81034,BAO_0000219
7134,478.0,,,1,,,CHEMBL884003,,Intermediate,F,,1,,N,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,A2780,81034,BAO_0000219
7135,478.0,,,1,,,CHEMBL622690,,Intermediate,F,,1,,N,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,A2780,81034,BAO_0000219
7136,478.0,,,1,,,CHEMBL622691,,Intermediate,F,,1,,N,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,A2780,81034,BAO_0000219
7137,478.0,,,1,,,CHEMBL622692,,Intermediate,F,,1,,N,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,A2780,81034,BAO_0000219
7138,478.0,,,1,,,CHEMBL623406,,Intermediate,F,,1,,N,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,A2780,81034,BAO_0000219
7139,478.0,,,1,,,CHEMBL884004,,Intermediate,F,,1,,N,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,A2780,81034,BAO_0000219
7140,478.0,,,1,,,CHEMBL623407,,Intermediate,F,,1,,N,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,A2780,81034,BAO_0000219
7141,478.0,,,1,,,CHEMBL623408,,Intermediate,F,,1,,N,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,A2780,81034,BAO_0000219
7142,478.0,,,1,,,CHEMBL623409,,Expert,F,,1,,N,In vitro antitumor activity against A2780 cell line.,,A2780,81034,BAO_0000219
7143,478.0,,,1,,,CHEMBL623410,,Intermediate,F,,1,,N,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,A2780,81034,BAO_0000219
7144,478.0,,,1,,,CHEMBL623576,,Expert,F,,1,,N,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,A2780,81034,BAO_0000219
7145,626.0,,,1,,,CHEMBL623577,,Intermediate,F,,1,,N,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,ACHN,80025,BAO_0000219
7146,626.0,,,1,,,CHEMBL623578,,Intermediate,F,,1,,N,The IC50 value was measured on ACHN cell line in renal tumor type.,,ACHN,80025,BAO_0000219
7147,626.0,,,1,,,CHEMBL623579,,Intermediate,F,,1,,N,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,ACHN,80025,BAO_0000219
7148,626.0,,,1,,,CHEMBL623580,,Expert,F,,1,,N,In vitro lethal concentration against most sensitive ACHN cell line,,ACHN,80025,BAO_0000219
7149,626.0,,,1,,,CHEMBL623581,,Intermediate,F,,1,,N,Tested for cytotoxic activity against renal cancer ACHN cell line,,ACHN,80025,BAO_0000219
7150,626.0,,,1,,,CHEMBL857456,,Intermediate,F,,1,,N,Compound tested for growth inhibition of renal cancer cell line ACHN,,ACHN,80025,BAO_0000219
7151,626.0,,,1,,,CHEMBL623582,,Intermediate,F,,1,,N,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,ACHN,80025,BAO_0000219
7152,626.0,,,1,,,CHEMBL623583,,Intermediate,F,,1,,N,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,ACHN,80025,BAO_0000219
7153,626.0,,,1,,,CHEMBL623584,,Intermediate,F,,1,,N,In vitro anticancer activity against ACHN renal cancer cell line,,ACHN,80025,BAO_0000219
7154,626.0,,,1,,,CHEMBL623585,,Intermediate,F,,1,,N,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,ACHN,80025,BAO_0000219
7155,626.0,,,1,,,CHEMBL623586,,Intermediate,F,,1,,N,Percent selectivity was evaluated in renal ACHN cell lines,,ACHN,80025,BAO_0000219
7156,626.0,,,1,,,CHEMBL623587,,Intermediate,F,,1,,N,In vitro inhibitory activity against renal ACHN cancer cell line,,ACHN,80025,BAO_0000219
7157,626.0,,,1,,,CHEMBL875279,,Intermediate,F,,1,,N,Tested for cytotoxicity against ACHN cell lines in renal cancer,,ACHN,80025,BAO_0000219
7158,626.0,,,1,,,CHEMBL623588,,Intermediate,F,,1,,N,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,ACHN,80025,BAO_0000219
7159,626.0,,,1,,,CHEMBL623589,,Intermediate,F,,1,,N,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,ACHN,80025,BAO_0000219
7160,626.0,,,1,,,CHEMBL623590,,Intermediate,F,,1,,N,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,ACHN,80025,BAO_0000219
7161,626.0,,,1,,,CHEMBL623591,,Expert,F,,1,,N,Cytotoxic effect on renal cancer line ACHN,,ACHN,80025,BAO_0000219
7162,626.0,,,1,,,CHEMBL623592,,Intermediate,F,,1,,N,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,ACHN,80025,BAO_0000219
7163,626.0,,,1,,,CHEMBL623593,,Intermediate,F,,1,,N,In vitro inhibition of Renal Cancer ACHN cell lines,,ACHN,80025,BAO_0000219
7164,626.0,,,1,,,CHEMBL623594,,Intermediate,F,,1,,N,Antitumor activity against human renal adenocarcinoma ACHN cells,,ACHN,80025,BAO_0000219
7165,626.0,,,1,,,CHEMBL621833,,Expert,F,,1,,N,Antitumor activity against human renal adenocarcinoma ACHN cells.,,ACHN,80025,BAO_0000219
7166,626.0,,,1,,,CHEMBL621834,,Intermediate,F,,1,,N,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,ACHN,80025,BAO_0000219
7167,626.0,,,1,,,CHEMBL621835,,Intermediate,F,,1,,N,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,ACHN,80025,BAO_0000219
7168,626.0,,,1,,,CHEMBL621836,,Intermediate,F,,1,,N,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,ACHN,80025,BAO_0000219
7169,626.0,,,1,,,CHEMBL621837,,Intermediate,F,,1,,N,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,ACHN,80025,BAO_0000219
7170,626.0,,,1,,,CHEMBL875280,,Intermediate,F,,1,,N,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,ACHN,80025,BAO_0000219
7171,626.0,,,1,,,CHEMBL621838,,Intermediate,F,,1,,N,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,ACHN,80025,BAO_0000219
7172,626.0,,,1,,,CHEMBL621839,,Intermediate,F,,1,,N,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,ACHN,80025,BAO_0000219
7173,,,,0,,,CHEMBL621840,,Autocuration,A,,1,,U,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,22224,BAO_0000019
7174,,,,8,,,CHEMBL621841,,Autocuration,F,,1,,H,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,,10647,BAO_0000019
7175,468.0,,,1,,,CHEMBL622979,,Expert,F,,1,,N,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,HEL,50529,BAO_0000218
7176,,,,1,,,CHEMBL876595,,Intermediate,F,,1,,N,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,,50529,BAO_0000218
7177,,,,8,,,CHEMBL620221,,Autocuration,B,,1,,H,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,,12159,BAO_0000357
7178,,,,8,,,CHEMBL620222,,Autocuration,B,,1,,H,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,,12159,BAO_0000357
7179,979.0,,,1,,,CHEMBL620506,,Intermediate,F,,1,,N,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,ADDP cell line,80670,BAO_0000219
7180,980.0,,,1,,,CHEMBL620507,,Intermediate,F,,1,,N,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,ADJ/PC6,80671,BAO_0000219
7181,980.0,,,1,,,CHEMBL620508,,Intermediate,F,,1,,N,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,ADJ/PC6,80671,BAO_0000219
7182,980.0,,,1,,,CHEMBL620509,,Intermediate,F,,1,,N,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,ADJ/PC6,80671,BAO_0000219
7183,980.0,,,1,,,CHEMBL620510,,Intermediate,F,,1,,N,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,ADJ/PC6,80671,BAO_0000219
7184,980.0,,,1,,,CHEMBL620511,,Intermediate,A,,1,,N,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,ADJ/PC6,80671,BAO_0000219
7185,980.0,,,1,,,CHEMBL620512,,Intermediate,F,,1,,N,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,ADJ/PC6,80671,BAO_0000219
7186,,,,0,,,CHEMBL620513,,Autocuration,F,,1,,U,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,,22224,BAO_0000019
7187,,,,0,,,CHEMBL620514,,Autocuration,F,,1,,U,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,,22224,BAO_0000019
7188,,,,0,,,CHEMBL620515,,Autocuration,F,,1,,U,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,,22224,BAO_0000019
7189,,,,0,,In vivo,CHEMBL620516,,Autocuration,A,,1,,U,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,22224,BAO_0000218
7190,,,1969.0,1,Plasma,,CHEMBL620517,,Intermediate,A,,1,,N,AUC value in dog after IV administration at a dose of 5 mg/kg,,,50588,BAO_0000218
7191,,,1969.0,1,Plasma,,CHEMBL620518,,Intermediate,A,,1,,N,AUC value in dog after oral administration at a dose of 5 mg/kg,,,50588,BAO_0000218
7192,,,,1,,In vivo,CHEMBL620519,,Intermediate,A,,1,,N,Cmax value in dog after oral administration at a dose of 5 mg/kg,,,50588,BAO_0000218
7193,,,,1,,In vivo,CHEMBL621386,,Intermediate,A,,1,,N,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,,50588,BAO_0000218
7194,,,,1,,In vivo,CHEMBL621387,,Intermediate,A,,1,,N,Tmax value in dog after oral administration at a dose of 5 mg/kg,,,50588,BAO_0000218
7195,,,,1,,In vivo,CHEMBL621388,,Intermediate,A,,1,,N,Compound was evaluated for its clearance when administered intravenously in dog,,,50588,BAO_0000218
7196,,,,1,,In vivo,CHEMBL621389,,Intermediate,A,,1,,N,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,50588,BAO_0000218
7197,,,,1,,In vivo,CHEMBL621390,,Intermediate,A,,1,,N,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,50588,BAO_0000218
7198,,,,0,,,CHEMBL621391,,Intermediate,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
7199,,,,1,,,CHEMBL621392,,Intermediate,A,,1,,N,Half life in dog,,,50588,BAO_0000218
7200,,,,1,,,CHEMBL621393,,Intermediate,A,,1,,N,Time taken for EC90 was determined when tested in dog,,,50588,BAO_0000218
7201,,,,1,,,CHEMBL621394,,Intermediate,A,,1,,N,Half life (iv) was determined,,,50588,BAO_0000218
7202,,,2107.0,1,Liver,,CHEMBL621395,,Intermediate,A,,1,,N,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,50588,BAO_0000218
7203,,,,1,,,CHEMBL621396,,Intermediate,A,,1,,N,Area under the curve was calculated in dog after iv administration,,,50588,BAO_0000218
7204,,,,1,,,CHEMBL621397,,Intermediate,A,,1,,N,Area under the curve was calculated in dog after peroral administration,,,50588,BAO_0000218
7205,,,,1,,,CHEMBL621398,,Intermediate,A,,1,,N,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,,50588,BAO_0000218
7206,,,,1,,,CHEMBL618818,,Intermediate,A,,1,,N,pKa was evaluated in dog,,,50588,BAO_0000218
7207,,,,1,,,CHEMBL618819,,Intermediate,A,,1,,N,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,,50588,BAO_0000218
7208,,,,1,,In vivo,CHEMBL618820,,Intermediate,A,,1,,N,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,50588,BAO_0000218
7209,,,,1,,In vivo,CHEMBL873810,,Intermediate,A,,1,,N,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,50588,BAO_0000218
7210,,,,1,,In vivo,CHEMBL876606,,Intermediate,A,,1,,N,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,50588,BAO_0000218
7211,,,,1,,,CHEMBL618821,,Intermediate,A,,1,,N,Compound was evaluated for the half-life (t 1/2) in hours,,,50588,BAO_0000218
7212,,,178.0,1,Blood,In vivo,CHEMBL618822,,Intermediate,A,,1,,N,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,50588,BAO_0000218
7213,,,178.0,1,Blood,In vivo,CHEMBL618823,,Intermediate,A,,1,,N,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,50588,BAO_0000218
7214,,,,1,,In vivo,CHEMBL618824,,Intermediate,A,,1,,N,Half life after intravenous administration of 1 mg/kg in dog,,,50588,BAO_0000218
7215,,,,1,,,CHEMBL618825,,Intermediate,A,,1,,N,Half life was measured in dog,,,50588,BAO_0000218
7216,,,,1,,In vivo,CHEMBL618826,,Intermediate,A,,1,,N,Half life period in dog after 5 mg/kg dose,,,50588,BAO_0000218
7217,,,,1,,,CHEMBL618827,,Intermediate,A,,1,,N,Half life period was evaluated in dog; 4-4.8,,,50588,BAO_0000218
7218,,,,1,,In vivo,CHEMBL618828,,Intermediate,A,,1,,N,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588,BAO_0000218
7219,,,,1,,In vivo,CHEMBL618829,,Intermediate,A,,1,,N,Half-life was determined in dog after a3 mg/kg of iv dose,,,50588,BAO_0000218
7220,,,,1,,,CHEMBL618830,,Intermediate,A,,1,,N,Half-life was determined,,,50588,BAO_0000218
7221,,,,1,,,CHEMBL618831,,Intermediate,A,,1,,N,Half life in dogs,,,50588,BAO_0000218
7222,,,1969.0,1,Plasma,In vivo,CHEMBL619489,,Intermediate,A,,1,,N,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,,50588,BAO_0000218
7223,,,,1,,In vivo,CHEMBL619649,,Intermediate,A,,1,,N,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,,50588,BAO_0000218
7224,,,,1,,In vivo,CHEMBL876607,,Intermediate,A,,1,,N,Compound was evaluated for the half life period after iv administration in Beagle dog.,,,50588,BAO_0000218
7225,,,,1,,In vivo,CHEMBL619650,,Intermediate,A,,1,,N,Compound was evaluated for the half life period after oral administration in conscious dog.,,,50588,BAO_0000218
7226,,,,1,,,CHEMBL619651,,Intermediate,A,,1,,N,Compound was tested for half life in dog,,,50588,BAO_0000218
7227,,,,1,,,CHEMBL619652,,Intermediate,A,,1,,N,Compound was tested for its half life in dog,,,50588,BAO_0000218
7228,,,,1,,In vivo,CHEMBL619653,,Intermediate,A,,1,,N,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,50588,BAO_0000218
7229,,,,1,,,CHEMBL619654,,Intermediate,A,,1,,N,Half life of compound in dog was determined,,,50588,BAO_0000218
7230,,,,1,,In vivo,CHEMBL619655,,Intermediate,A,,1,,N,Half life (iv) was determined,,,50588,BAO_0000218
7231,,,178.0,1,Blood,,CHEMBL619656,,Intermediate,A,,1,,N,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,,50588,BAO_0000218
7232,,,1969.0,1,Plasma,In vivo,CHEMBL873812,,Intermediate,A,,1,,N,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,50588,BAO_0000218
7233,,,1969.0,1,Plasma,In vivo,CHEMBL621365,,Intermediate,F,,1,,N,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,50588,BAO_0000218
7234,,,,1,,,CHEMBL621366,,Intermediate,A,,1,,N,Half life in dog,,,50588,BAO_0000218
7235,,,1969.0,1,Plasma,,CHEMBL621367,,Intermediate,A,,1,,N,Half life in dog plasma,,,50588,BAO_0000218
7236,,,1969.0,1,Plasma,In vivo,CHEMBL621368,,Intermediate,A,,1,,N,Half life in dog plasma after administration of 0.25 mg/kg iv,,,50588,BAO_0000218
7237,,,1969.0,1,Plasma,In vivo,CHEMBL621369,,Intermediate,A,,1,,N,Half life in dog plasma after administration of 1 mg/kg iv,,,50588,BAO_0000218
7238,,,1969.0,1,Plasma,In vivo,CHEMBL621370,,Intermediate,A,,1,,N,Half life in dog plasma was determined at dose 10 mg/kg,,,50588,BAO_0000218
7239,,,,1,,,CHEMBL621371,,Intermediate,A,,1,,N,Half life in dog was determined,,,50588,BAO_0000218
7240,,,,1,,In vivo,CHEMBL621372,,Intermediate,A,,1,,N,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,50588,BAO_0000218
7241,,,1969.0,1,Plasma,,CHEMBL621373,,Intermediate,A,,1,,N,Half life upon exposure to human plasma,,,50588,BAO_0000218
7242,,,,1,,,CHEMBL621374,,Intermediate,A,,1,,N,Half life was calculated in dog,,,50588,BAO_0000218
7243,,,,1,,,CHEMBL621375,,Intermediate,A,,1,,N,Half life was determined,,,50588,BAO_0000218
7244,,,,1,,,CHEMBL621376,,Intermediate,A,,1,,N,Half life was determined,,,50588,BAO_0000218
7245,,,,1,,In vivo,CHEMBL619624,,Intermediate,A,,1,,N,Half life by intravenous administration of 1.2 mg/kg in dog,,,50588,BAO_0000218
7246,,,,1,,,CHEMBL875840,,Intermediate,A,,1,,N,Half life in dog,,,50588,BAO_0000218
7247,,,,1,,,CHEMBL619625,,Intermediate,A,,1,,N,Half life in dog after intra venous administration of the compound,,,50588,BAO_0000218
7248,,,,1,,,CHEMBL619626,,Intermediate,A,,1,,N,Half life in dog after intra venous administration of the compound; ND means Not determined,,,50588,BAO_0000218
7249,,,,1,,In vivo,CHEMBL619627,,Intermediate,A,,1,,N,Half life in dog after po administration of the compound,,,50588,BAO_0000218
7250,,,,1,,In vivo,CHEMBL873817,,Intermediate,A,,1,,N,Half life in dog after po administration of the compound; ND means Not determined,,,50588,BAO_0000218
7251,,,,1,,In vivo,CHEMBL619628,,Intermediate,A,,1,,N,Half life in dog at the single oral dose of 1 mg/kg,,,50588,BAO_0000218
7252,,,,1,,,CHEMBL619629,,Intermediate,A,,1,,N,Half life in dogs,,,50588,BAO_0000218
7253,,,,1,,In vivo,CHEMBL619630,,Intermediate,A,,1,,N,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,,50588,BAO_0000218
7254,,,,1,,,CHEMBL619631,,Intermediate,A,,1,,N,Half life in rat,,,50588,BAO_0000218
7255,,,,1,,In vivo,CHEMBL619632,,Intermediate,A,,1,,N,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,50588,BAO_0000218
7256,,,10000001.0,1,Bone,In vivo,CHEMBL619633,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
7257,,,10000001.0,1,Bone,In vivo,CHEMBL875841,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
7258,,,10000001.0,1,Bone,In vivo,CHEMBL619634,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
7259,,,10000001.0,1,Bone,In vivo,CHEMBL619635,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594,BAO_0000218
7260,,,10000001.0,1,Bone,In vivo,CHEMBL619636,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
7261,,,10000004.0,1,Gut,In vivo,CHEMBL619637,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
7262,,,10000004.0,1,Gut,In vivo,CHEMBL619638,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594,BAO_0000218
7263,,,10000004.0,1,Gut,In vivo,CHEMBL619639,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
7264,,,10000004.0,1,Gut,In vivo,CHEMBL619640,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
7265,,,10000004.0,1,Gut,In vivo,CHEMBL619641,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
7266,,,10000004.0,1,Gut,In vivo,CHEMBL619642,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594,BAO_0000218
7267,,,10000004.0,1,Gut,In vivo,CHEMBL619643,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
7268,,,948.0,1,Heart,In vivo,CHEMBL619644,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
7269,,,948.0,1,Heart,In vivo,CHEMBL621112,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594,BAO_0000218
7270,,,948.0,1,Heart,In vivo,CHEMBL621113,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
7271,,,948.0,1,Heart,In vivo,CHEMBL621114,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
7272,,,948.0,1,Heart,In vivo,CHEMBL621115,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
7273,,,948.0,1,Heart,In vivo,CHEMBL621116,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594,BAO_0000218
7274,,,948.0,1,Heart,In vivo,CHEMBL621117,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
7275,,,2113.0,1,Kidney,In vivo,CHEMBL621118,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
7276,,,2113.0,1,Kidney,In vivo,CHEMBL621119,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,50594,BAO_0000218
7277,,,2113.0,1,Kidney,In vivo,CHEMBL621120,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
7278,,,2113.0,1,Kidney,In vivo,CHEMBL621757,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
7279,,,2113.0,1,Kidney,In vivo,CHEMBL621758,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
7280,,,2113.0,1,Kidney,In vivo,CHEMBL621759,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594,BAO_0000218
7281,,,2113.0,1,Kidney,In vivo,CHEMBL621760,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
7282,,,2107.0,1,Liver,In vivo,CHEMBL621761,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
7283,,,2107.0,1,Liver,In vivo,CHEMBL621762,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594,BAO_0000218
7284,,,2107.0,1,Liver,In vivo,CHEMBL621763,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
7285,,,2107.0,1,Liver,In vivo,CHEMBL624502,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
7286,,,2107.0,1,Liver,In vivo,CHEMBL624503,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
7287,,,2107.0,1,Liver,In vivo,CHEMBL624504,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594,BAO_0000218
7288,,,2107.0,1,Liver,In vivo,CHEMBL624505,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
7289,,,2048.0,1,Lung,In vivo,CHEMBL624506,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
7290,478.0,,,1,,,CHEMBL624507,,Intermediate,F,,1,,N,In vitro cytotoxicity against A2780 (human ovarian cancer),,A2780,81034,BAO_0000219
7291,478.0,,,1,,,CHEMBL624508,,Intermediate,F,,1,,N,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,A2780,81034,BAO_0000219
7292,478.0,,,1,,,CHEMBL624509,,Intermediate,F,,1,,N,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,A2780,81034,BAO_0000219
7293,478.0,,,1,,,CHEMBL624510,,Intermediate,F,,1,,N,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,A2780,81034,BAO_0000219
7294,478.0,,,1,,,CHEMBL875956,,Expert,F,,1,,N,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,A2780,81034,BAO_0000219
7295,478.0,,,1,,,CHEMBL839885,,Expert,F,,1,,N,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,A2780,81034,BAO_0000219
7296,478.0,,,1,,,CHEMBL624511,,Expert,F,,1,,N,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,A2780,81034,BAO_0000219
7297,478.0,,,1,,,CHEMBL624512,,Intermediate,F,,1,,N,In vitro cytotoxicity against A2780 cell line,,A2780,81034,BAO_0000219
7298,478.0,,,1,,,CHEMBL624513,,Intermediate,F,,1,,N,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,A2780,81034,BAO_0000219
7299,478.0,,,1,,,CHEMBL624514,,Intermediate,F,,1,,N,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,A2780,81034,BAO_0000219
7300,478.0,,,1,,,CHEMBL618547,,Intermediate,F,,1,,N,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,A2780,81034,BAO_0000218
7301,478.0,,,1,,,CHEMBL618548,,Intermediate,F,,1,,N,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,A2780,81034,BAO_0000219
7302,478.0,,,1,,,CHEMBL618549,,Intermediate,F,,1,,N,Inhibition of tubulin polymerization in analogy of ca.,,A2780,81034,BAO_0000219
7303,478.0,,,1,,,CHEMBL618550,,Intermediate,F,,1,,N,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,A2780,81034,BAO_0000219
7304,478.0,,,1,,,CHEMBL618551,,Expert,F,,1,,N,Cytotoxic effect in ovarian cancer cell line (A2780),,A2780,81034,BAO_0000219
7305,478.0,,,1,,,CHEMBL618552,,Intermediate,F,,1,,N,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,A2780,81034,BAO_0000219
7306,478.0,,,1,,,CHEMBL618553,,Intermediate,F,,1,,N,Tested for the cytotoxicity in A2780 ovarian cell line,,A2780,81034,BAO_0000219
7307,478.0,,,1,,,CHEMBL618554,,Intermediate,F,,1,,N,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,A2780,81034,BAO_0000219
7308,478.0,,,1,,,CHEMBL618555,,Intermediate,F,,1,,N,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,A2780,81034,BAO_0000219
7309,481.0,,,1,,,CHEMBL618556,,Intermediate,F,,1,,N,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,A2780cisR,80017,BAO_0000219
7310,481.0,,,1,,,CHEMBL618557,,Intermediate,F,,1,,N,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,A2780cisR,80017,BAO_0000219
7311,481.0,,,1,,,CHEMBL618558,,Intermediate,F,,1,,N,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,A2780cisR,80017,BAO_0000219
7312,481.0,,,1,,,CHEMBL618559,,Intermediate,F,,1,,N,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,A2780cisR,80017,BAO_0000219
7313,478.0,,,1,,,CHEMBL618560,,Intermediate,F,,1,,N,In vivo log of cells killed after administration of compound in A2780 cell line,,A2780,81034,BAO_0000218
7314,478.0,,,1,,In vivo,CHEMBL618561,,Intermediate,F,,1,,N,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,A2780,81034,BAO_0000218
7315,478.0,,,1,,,CHEMBL618562,,Intermediate,F,,1,,N,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,A2780,81034,BAO_0000219
7316,478.0,,,1,,,CHEMBL618563,,Intermediate,F,,1,,N,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,A2780,81034,BAO_0000219
7317,478.0,,,1,,,CHEMBL618564,,Intermediate,F,,1,,N,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,A2780,81034,BAO_0000219
7318,478.0,,,1,,,CHEMBL618565,,Intermediate,F,,1,,N,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,A2780,81034,BAO_0000219
7319,478.0,,,1,,,CHEMBL618566,,Intermediate,F,,1,,N,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,A2780,81034,BAO_0000218
7320,478.0,,,1,,,CHEMBL618567,,Intermediate,F,,1,,N,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,A2780,81034,BAO_0000219
7321,478.0,,,1,,,CHEMBL618568,,Expert,F,,1,,N,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,A2780,81034,BAO_0000219
7322,478.0,,,1,,,CHEMBL618569,,Expert,F,,1,,N,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,A2780,81034,BAO_0000219
7323,478.0,,,1,,,CHEMBL621857,,Intermediate,F,,1,,N,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,A2780,81034,BAO_0000219
7324,478.0,,,1,,,CHEMBL621858,,Intermediate,F,,1,,N,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,A2780,81034,BAO_0000219
7325,478.0,,,1,,,CHEMBL621859,,Intermediate,F,,1,,N,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,A2780,81034,BAO_0000219
7326,478.0,,,1,,,CHEMBL621860,,Intermediate,F,,1,,N,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,A2780,81034,BAO_0000219
7327,478.0,,,1,,,CHEMBL621861,,Intermediate,F,,1,,N,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,A2780,81034,BAO_0000219
7328,478.0,,,1,,,CHEMBL621862,,Expert,F,,1,,N,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,A2780,81034,BAO_0000219
7329,478.0,,,1,,,CHEMBL621863,,Intermediate,F,,1,,N,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,A2780,81034,BAO_0000219
7330,478.0,,,1,,,CHEMBL621864,,Intermediate,F,,1,,N,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,A2780,81034,BAO_0000219
7331,478.0,,,1,,,CHEMBL621865,,Intermediate,F,,1,,N,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,A2780,81034,BAO_0000219
7332,478.0,,,1,,,CHEMBL621866,,Intermediate,F,,1,,N,In vitro antiproliferative activity against A2780 cell line,,A2780,81034,BAO_0000219
7333,478.0,,,1,,,CHEMBL621867,,Expert,F,,1,,N,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,A2780,81034,BAO_0000219
7334,478.0,,,1,,,CHEMBL621868,,Intermediate,F,,1,,N,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,A2780,81034,BAO_0000219
7335,478.0,,,1,,,CHEMBL875282,,Intermediate,F,,1,,N,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,A2780,81034,BAO_0000219
7336,,,,1,,,CHEMBL621869,,Intermediate,A,,1,,N,Vc value in dog after IV administration at a dose of 5 mg/kg,,,50588,BAO_0000218
7337,,,,1,,In vivo,CHEMBL621870,,Intermediate,A,,1,,N,Half life period in dog after IV administration at a dose of 5 mg/kg,,,50588,BAO_0000218
7338,,,,0,,,CHEMBL621871,,Autocuration,A,,1,,U,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,22224,BAO_0000019
7339,,,1969.0,0,Plasma,,CHEMBL621243,,Autocuration,A,,1,,U,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
7340,,,1969.0,0,Plasma,,CHEMBL621244,,Autocuration,A,,1,,U,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
7341,,,,0,,In vivo,CHEMBL621245,,Autocuration,A,,1,,U,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,,22224,BAO_0000218
7342,,,,0,,In vivo,CHEMBL621246,,Autocuration,A,,1,,U,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,,22224,BAO_0000218
7343,,,,0,,In vivo,CHEMBL621247,,Autocuration,A,,1,,U,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,,22224,BAO_0000218
7344,,,,0,,In vivo,CHEMBL618386,,Autocuration,A,,1,,U,Oral Bioavailability in rat,,,22224,BAO_0000218
7345,,,,0,,,CHEMBL618387,,Autocuration,A,,1,,U,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,22224,BAO_0000218
7346,,,,0,,,CHEMBL618388,,Autocuration,A,,1,,U,Area under curve value in monkey at a dose of 5 mg/kg,,,22224,BAO_0000218
7347,,,,0,,,CHEMBL618389,,Autocuration,A,,1,,U,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,,22224,BAO_0000218
7348,,,,0,,,CHEMBL618574,,Autocuration,A,,1,,U,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,,22224,BAO_0000019
7349,,,,0,,,CHEMBL618575,,Autocuration,A,,1,,U,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,,22224,BAO_0000019
7350,,,,0,,,CHEMBL618576,,Autocuration,A,,1,,U,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,,22224,BAO_0000019
7351,,,,0,,,CHEMBL618577,,Autocuration,A,,1,,U,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,,22224,BAO_0000218
7352,,,,0,,,CHEMBL876487,,Autocuration,A,,1,,U,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,,22224,BAO_0000218
7353,,,,0,,,CHEMBL618578,,Autocuration,A,,1,,U,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,,22224,BAO_0000218
7354,,,,0,,,CHEMBL618579,,Autocuration,A,,1,,U,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,22224,BAO_0000218
7355,,,,0,,,CHEMBL618580,,Autocuration,A,,1,,U,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,22224,BAO_0000019
7356,,,,0,,,CHEMBL618581,,Autocuration,A,,1,,U,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,,22224,BAO_0000218
7357,,,,0,,,CHEMBL618582,,Autocuration,A,,1,,U,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,,22224,BAO_0000218
7358,,,,0,,,CHEMBL618583,,Autocuration,A,,1,,U,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,,22224,BAO_0000218
7359,,,,0,,,CHEMBL618584,,Autocuration,A,,1,,U,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,,22224,BAO_0000218
7360,,,,0,,In vivo,CHEMBL618585,,Autocuration,A,,1,,U,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,,22224,BAO_0000218
7361,,,,0,,,CHEMBL618586,,Autocuration,A,,1,,U,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,,22224,BAO_0000218
7362,,,,0,,In vivo,CHEMBL618587,,Autocuration,A,,1,,U,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
7363,,,,0,,In vivo,CHEMBL618588,,Autocuration,A,,1,,U,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224,BAO_0000218
7364,,,,0,,,CHEMBL618589,,Autocuration,A,,1,,U,Binding towards monkey plasma protein at 10 uM,,,22224,BAO_0000019
7365,,,,0,,,CHEMBL618590,,Autocuration,A,,1,,U,Binding towards monkey plasma protein at 100 uM,,,22224,BAO_0000019
7366,,,,0,,In vivo,CHEMBL872262,,Autocuration,A,,1,,U,Apparent bioavailability in squirrel monkey was determined,,,22224,BAO_0000218
7367,,,,0,,In vivo,CHEMBL618591,,Autocuration,A,,1,,U,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,22224,BAO_0000218
7368,,,,0,,In vivo,CHEMBL618592,,Autocuration,A,,1,,U,Bioavailability in monkey (dose 2 mg/kg),,,22224,BAO_0000218
7369,,,,0,,In vivo,CHEMBL876488,,Autocuration,A,,1,,U,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,,22224,BAO_0000218
7370,,,,0,,In vivo,CHEMBL618593,,Autocuration,A,,1,,U,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,22224,BAO_0000218
7371,,,,0,,In vivo,CHEMBL618594,,Autocuration,A,,1,,U,Bioavailability in monkey (i.d. dosing),,,22224,BAO_0000218
7372,,,,0,,In vivo,CHEMBL618595,,Autocuration,A,,1,,U,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,,22224,BAO_0000218
7373,,,,0,,,CHEMBL621469,,Autocuration,A,,1,,U,Clearance of the drug was measured in cynomolgus,,,22224,BAO_0000019
7374,,,,0,,In vivo,CHEMBL621470,,Autocuration,A,,1,,U,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,,22224,BAO_0000218
7375,,,,0,,In vivo,CHEMBL621471,,Autocuration,A,,1,,U,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,22224,BAO_0000218
7376,,,1969.0,0,Plasma,In vivo,CHEMBL621472,,Autocuration,A,,1,,U,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,22224,BAO_0000218
7377,,,,0,,In vivo,CHEMBL621473,,Autocuration,A,,1,,U,Plasma clearance in rhesus monkey was determined,,,22224,BAO_0000218
7378,,,,0,,In vivo,CHEMBL621474,,Autocuration,A,,1,,U,Plasma clearance in monkey after administration of 1 mg/kg iv,,,22224,BAO_0000218
7379,,,,0,,In vivo,CHEMBL621475,,Autocuration,A,,1,,U,Plasma clearance in cynomolgus monkey,,,22224,BAO_0000218
7380,,,,0,,In vivo,CHEMBL621476,,Autocuration,A,,1,,U,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,,22224,BAO_0000218
7381,,,,0,,In vivo,CHEMBL624290,,Autocuration,A,,1,,U,Plasma clearance after peroral administration at 10 mpk in Rhesus,,,22224,BAO_0000218
7382,,,,0,,In vivo,CHEMBL624291,,Autocuration,A,,1,,U,The total clearance was determined after intravenous administration in cynomolgus monkeys,,,22224,BAO_0000218
7383,,,,0,,In vivo,CHEMBL624292,,Autocuration,A,,1,,U,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,22224,BAO_0000218
7384,,,,0,,In vivo,CHEMBL624293,,Autocuration,A,,1,,U,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,22224,BAO_0000218
7385,,,,0,,In vivo,CHEMBL624294,,Autocuration,A,,1,,U,Tested for Clearance upon iv administration to african green monkey,,,22224,BAO_0000218
7386,,,,0,,In vivo,CHEMBL624295,,Autocuration,A,,1,,U,Clearance in monkey,,,22224,BAO_0000218
7387,,,,1,,In vivo,CHEMBL624296,,Intermediate,A,,1,,N,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588,BAO_0000218
7388,,,,1,,In vivo,CHEMBL624297,,Intermediate,A,,1,,N,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588,BAO_0000218
7389,,,,1,,In vivo,CHEMBL624298,,Intermediate,A,,1,,N,Half life was evaluated after intravenous administration to dogs,,,50588,BAO_0000218
7390,,,,1,,,CHEMBL624299,,Intermediate,A,,1,,N,Half life was evaluated in dog,,,50588,BAO_0000218
7391,,,,1,,,CHEMBL624300,,Intermediate,A,,1,,N,Half life was evaluated in dog,,,50588,BAO_0000218
7392,,,,1,,In vivo,CHEMBL624301,,Intermediate,A,,1,,N,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,50588,BAO_0000218
7393,,,,1,,In vivo,CHEMBL624302,,Intermediate,A,,1,,N,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,,50588,BAO_0000218
7394,,,,1,,In vivo,CHEMBL876026,,Intermediate,A,,1,,N,Half life period after intravenous administration in dog,,,50588,BAO_0000218
7395,,,,1,,In vivo,CHEMBL624303,,Intermediate,A,,1,,N,Half life period after oral administration (2.5 mg/kg) in dog was determined,,,50588,BAO_0000218
7396,,,,1,,,CHEMBL624304,,Intermediate,A,,1,,N,Half life period at a dose of 1 uM/kg in dog was determined,,,50588,BAO_0000218
7397,,,,1,,In vivo,CHEMBL624305,,Intermediate,A,,1,,N,Half life period was determine after peroral administration at 10 mpk in dog,,,50588,BAO_0000218
7398,,,,1,,In vivo,CHEMBL624306,,Intermediate,A,,1,,N,Half life period was determine after peroral administration at 5 mpk in dog,,,50588,BAO_0000218
7399,,,,1,,,CHEMBL624307,,Intermediate,A,,1,,N,Half life period was determined,,,50588,BAO_0000218
7400,,,,1,,,CHEMBL624308,,Intermediate,A,,1,,N,Half life period was determined,,,50588,BAO_0000218
7401,,,,1,,In vivo,CHEMBL624309,,Intermediate,A,,1,,N,Half life period by iv administration in dog at a dose of 6 mg/kg,,,50588,BAO_0000218
7402,,,,1,,,CHEMBL624310,,Intermediate,A,,1,,N,Half life period was evaluated in dog,,,50588,BAO_0000218
7403,,,,1,,In vivo,CHEMBL625003,,Intermediate,A,,1,,N,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,50588,BAO_0000218
7404,,,,1,,In vivo,CHEMBL625004,,Intermediate,A,,1,,N,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,50588,BAO_0000218
7405,,,,1,,In vivo,CHEMBL625005,,Intermediate,A,,1,,N,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,,50588,BAO_0000218
7406,,,,1,,In vivo,CHEMBL873813,,Intermediate,A,,1,,N,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,,50588,BAO_0000218
7407,,,,1,,In vivo,CHEMBL625006,,Intermediate,A,,1,,N,Half-life after oral dose of compound at 3 mg/kg in dogs,,,50588,BAO_0000218
7408,,,,1,,In vivo,CHEMBL625007,,Intermediate,A,,1,,N,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,,50588,BAO_0000218
7409,,,,1,,In vivo,CHEMBL876027,,Intermediate,A,,1,,N,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,,50588,BAO_0000218
7410,,,,1,,In vivo,CHEMBL625008,,Intermediate,A,,1,,N,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,,50588,BAO_0000218
7411,,,,1,,In vivo,CHEMBL625009,,Intermediate,A,,1,,N,Half-life of compound in dog following p.o. administration of 1 mg/kg,,,50588,BAO_0000218
7412,,,1969.0,1,Plasma,,CHEMBL625010,,Intermediate,A,,1,,N,Half-life of compound in plasma of dog was determined,,,50588,BAO_0000218
7413,,,,1,,,CHEMBL625011,,Intermediate,A,,1,,N,Half-life of compound was determined in dogs,,,50588,BAO_0000218
7414,,,,1,,In vivo,CHEMBL621553,,Intermediate,A,,1,,N,Half-life after administration of 4 mg/Kg oral dose in dog,,,50588,BAO_0000218
7415,,,,1,,In vivo,CHEMBL621554,,Intermediate,A,,1,,N,Half-life after intravenous administration of 1 mg/kg/h in dog,,,50588,BAO_0000218
7416,,,,1,,,CHEMBL621555,,Intermediate,A,,1,,N,Half-life in Dog,,,50588,BAO_0000218
7417,,,,1,,,CHEMBL621556,,Intermediate,A,,1,,N,Half-life in Dog,,,50588,BAO_0000218
7418,,,,1,,,CHEMBL621557,,Intermediate,A,,1,,N,Half-life in dog,,,50588,BAO_0000218
7419,,,,1,,In vivo,CHEMBL621558,,Intermediate,A,,1,,N,Half-life in dog after oral administration at 1 mg/kg,,,50588,BAO_0000218
7420,,,,1,,In vivo,CHEMBL621559,,Intermediate,A,,1,,N,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,,50588,BAO_0000218
7421,,,,1,,,CHEMBL621560,,Intermediate,A,,1,,N,Half-life in dogs,,,50588,BAO_0000218
7422,,,,1,,,CHEMBL876028,,Intermediate,A,,1,,N,Half-life in dogs; ND indicates not determined,,,50588,BAO_0000218
7423,,,1969.0,1,Plasma,,CHEMBL621561,,Intermediate,A,,1,,N,Half-life in plasma of dog,,,50588,BAO_0000218
7424,,,1969.0,1,Plasma,,CHEMBL621562,,Intermediate,A,,1,,N,Half-life in plasma of dog at dose of 3-10 mgkg,,,50588,BAO_0000218
7425,,,,1,,In vivo,CHEMBL621563,,Intermediate,A,,1,,N,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,50588,BAO_0000218
7426,,,,1,,In vivo,CHEMBL621564,,Intermediate,A,,1,,N,Half-life was measured in dog after an iv dose of 1 mg/kg,,,50588,BAO_0000218
7427,,,,1,,In vivo,CHEMBL621565,,Intermediate,A,,1,,N,Half-life was measured in dogs after an oral dose of 10 uM/kg,,,50588,BAO_0000218
7428,,,,1,,In vivo,CHEMBL621566,,Intermediate,A,,1,,N,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,50588,BAO_0000218
7429,,,,1,,In vivo,CHEMBL621567,,Intermediate,A,,1,,N,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,50588,BAO_0000218
7430,,,,1,,In vivo,CHEMBL622978,,Intermediate,A,,1,,N,Half-life of the compound after 0.3 mg/kg po administration in dog,,,50588,BAO_0000218
7431,,,,1,,In vivo,CHEMBL873814,,Intermediate,A,,1,,N,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,,50588,BAO_0000218
7432,,,,1,,In vivo,CHEMBL623219,,Intermediate,A,,1,,N,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,,50588,BAO_0000218
7433,,,,1,,In vivo,CHEMBL624477,,Intermediate,A,,1,,N,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,,50588,BAO_0000218
7434,,,,1,,,CHEMBL624478,,Intermediate,A,,1,,N,t1/2 in dog,,,50588,BAO_0000218
7435,,,,1,,,CHEMBL624479,,Intermediate,A,,1,,N,Half-life period measured in dogs,,,50588,BAO_0000218
7436,,,,1,,In vivo,CHEMBL624480,,Intermediate,A,,1,,N,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,50588,BAO_0000218
7437,,,,1,,In vivo,CHEMBL623595,,Intermediate,A,,1,,N,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,50588,BAO_0000218
7438,,,,1,,In vivo,CHEMBL623596,,Intermediate,A,,1,,N,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50588,BAO_0000218
7439,,,1969.0,1,Plasma,In vitro,CHEMBL623597,,Intermediate,A,,1,,N,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,,50588,BAO_0000218
7440,,,,1,,In vivo,CHEMBL623598,,Intermediate,A,,1,,N,In vivo half life period was calculated at 1 mg/kg in dog,,,50588,BAO_0000218
7441,,,,1,,In vivo,CHEMBL623599,,Intermediate,A,,1,,N,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,,50588,BAO_0000218
7442,,,,1,,In vivo,CHEMBL623600,,Intermediate,A,,1,,N,Longer half-life in dog (i.v.) at 0.5 mpk,,,50588,BAO_0000218
7443,,,,1,,In vivo,CHEMBL623601,,Intermediate,A,,1,,N,Oral bioavailability in dog (dose 5 uM/kg),,,50588,BAO_0000218
7444,,,,1,,In vivo,CHEMBL623602,,Intermediate,A,,1,,N,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,50588,BAO_0000218
7445,,,,1,,In vivo,CHEMBL623603,,Intermediate,A,,1,,N,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,50588,BAO_0000218
7446,,,,1,,In vivo,CHEMBL623604,,Intermediate,A,,1,,N,Bioavailability in dog (dose 1 mg/kg i.v.),,,50588,BAO_0000218
7447,,,2048.0,1,Lung,In vivo,CHEMBL623605,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,50594,BAO_0000218
7448,,,2048.0,1,Lung,In vivo,CHEMBL623606,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
7449,,,2048.0,1,Lung,In vivo,CHEMBL623607,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
7450,,,2048.0,1,Lung,In vivo,CHEMBL623608,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
7451,,,2048.0,1,Lung,In vivo,CHEMBL623609,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594,BAO_0000218
7452,,,2048.0,1,Lung,In vivo,CHEMBL623610,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
7453,,,2385.0,1,Muscle tissue,In vivo,CHEMBL623611,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
7454,,,2385.0,1,Muscle tissue,In vivo,CHEMBL623612,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,50594,BAO_0000218
7455,,,2385.0,1,Muscle tissue,In vivo,CHEMBL623613,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
7456,,,2385.0,1,Muscle tissue,In vivo,CHEMBL623614,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
7457,,,2385.0,1,Muscle tissue,In vivo,CHEMBL623615,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
7458,,,2385.0,1,Muscle tissue,In vivo,CHEMBL623616,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594,BAO_0000218
7459,,,2385.0,1,Muscle tissue,In vivo,CHEMBL623617,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
7460,,,14.0,1,Zone of skin,In vivo,CHEMBL875944,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
7461,,,14.0,1,Zone of skin,In vivo,CHEMBL623618,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594,BAO_0000218
7462,,,14.0,1,Zone of skin,In vivo,CHEMBL623619,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
7463,,,14.0,1,Zone of skin,In vivo,CHEMBL623620,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
7464,,,14.0,1,Zone of skin,In vivo,CHEMBL623621,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
7465,,,14.0,1,Zone of skin,In vivo,CHEMBL623622,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594,BAO_0000218
7466,,,14.0,1,Zone of skin,In vivo,CHEMBL623623,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
7467,,,2106.0,1,Spleen,In vivo,CHEMBL623624,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
7468,,,2106.0,1,Spleen,In vivo,CHEMBL618521,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594,BAO_0000218
7469,,,2106.0,1,Spleen,In vivo,CHEMBL618522,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
7470,,,2106.0,1,Spleen,In vivo,CHEMBL618523,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
7471,,,2106.0,1,Spleen,In vivo,CHEMBL618524,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
7472,,,2106.0,1,Spleen,In vivo,CHEMBL618525,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594,BAO_0000218
7473,,,2106.0,1,Spleen,In vivo,CHEMBL624586,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
7474,,,945.0,1,Stomach,In vivo,CHEMBL624587,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594,BAO_0000218
7475,,,945.0,1,Stomach,In vivo,CHEMBL624588,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594,BAO_0000218
7476,,,945.0,1,Stomach,In vivo,CHEMBL624589,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594,BAO_0000218
7477,,,945.0,1,Stomach,In vivo,CHEMBL624590,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594,BAO_0000218
7478,,,945.0,1,Stomach,In vivo,CHEMBL624591,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594,BAO_0000218
7479,,,945.0,1,Stomach,In vivo,CHEMBL624592,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594,BAO_0000218
7480,,,945.0,1,Stomach,In vivo,CHEMBL624593,,Intermediate,A,,1,,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594,BAO_0000218
7481,,,,1,,In vivo,CHEMBL624594,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
7482,,,,1,,In vivo,CHEMBL624595,,Intermediate,A,,1,,N,Tested for the bioavailability in rat,,,50597,BAO_0000218
7483,,,,1,,In vivo,CHEMBL624596,,Intermediate,A,,1,,N,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,50597,BAO_0000218
7484,,,,1,,In vivo,CHEMBL624597,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
7485,,,,1,,In vivo,CHEMBL624598,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
7486,,,,1,,In vivo,CHEMBL624599,,Intermediate,A,,1,,N,Bioavailability in rat (dose 3-10 mg/kg),,,50597,BAO_0000218
7487,,,,1,,In vivo,CHEMBL875166,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
7488,,,1969.0,1,Plasma,In vivo,CHEMBL624600,,Intermediate,A,,1,,N,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,50597,BAO_0000218
7489,,,1969.0,1,Plasma,In vivo,CHEMBL624601,,Intermediate,A,,1,,N,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,,50597,BAO_0000218
7490,,,,1,,In vivo,CHEMBL624602,,Intermediate,A,,1,,N,Half life after oral administration was determined in rats at 6 mg/kg,,,50597,BAO_0000218
7491,,,,1,,,CHEMBL624603,,Intermediate,A,,1,,N,Half life was determined,,,50597,BAO_0000218
7492,,,,1,,In vivo,CHEMBL624604,,Intermediate,A,,1,,N,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,,50597,BAO_0000218
7493,,,1969.0,1,Plasma,In vivo,CHEMBL624605,,Intermediate,A,,1,,N,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,,50597,BAO_0000218
7494,,,,1,,,CHEMBL624606,,Intermediate,A,,1,,N,Half life in rats,,,50597,BAO_0000218
7495,,,178.0,1,Blood,In vivo,CHEMBL624607,,Intermediate,A,,1,,N,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,,50597,BAO_0000218
7496,,,,1,,,CHEMBL624608,,Intermediate,A,,1,,N,Hill coefficient of the compound,,,50597,BAO_0000218
7497,,,178.0,1,Blood,,CHEMBL624609,,Intermediate,A,,1,,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,,50597,BAO_0000218
7498,,,178.0,1,Blood,,CHEMBL624610,,Intermediate,A,,1,,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,,50597,BAO_0000218
7499,,,178.0,1,Blood,,CHEMBL624611,,Intermediate,A,,1,,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,,50597,BAO_0000218
7500,,,178.0,1,Blood,,CHEMBL624612,,Intermediate,A,,1,,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,,50597,BAO_0000218
7501,,,178.0,1,Blood,,CHEMBL875167,,Intermediate,A,,1,,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,,50597,BAO_0000218
7502,,,178.0,1,Blood,,CHEMBL624613,,Intermediate,A,,1,,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,,50597,BAO_0000218
7503,,,178.0,1,Blood,,CHEMBL624614,,Intermediate,A,,1,,N,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,,50597,BAO_0000218
7504,,,,1,,,CHEMBL624392,,Intermediate,A,,1,,N,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,50597,BAO_0000218
7505,,,955.0,1,Brain,In vivo,CHEMBL624393,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,,50597,BAO_0000218
7506,,,955.0,1,Brain,In vivo,CHEMBL624394,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,,50597,BAO_0000218
7507,,,955.0,1,Brain,In vivo,CHEMBL624395,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,,50597,BAO_0000218
7508,,,955.0,1,Brain,In vivo,CHEMBL624396,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,,50597,BAO_0000218
7509,,,955.0,1,Brain,In vivo,CHEMBL624397,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,,50597,BAO_0000218
7510,,,2046.0,1,Thyroid gland,In vivo,CHEMBL624398,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,,50597,BAO_0000218
7511,,,2046.0,1,Thyroid gland,In vivo,CHEMBL624399,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,,50597,BAO_0000218
7512,,,2046.0,1,Thyroid gland,In vivo,CHEMBL624400,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,,50597,BAO_0000218
7513,,,2046.0,1,Thyroid gland,In vivo,CHEMBL624401,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,,50597,BAO_0000218
7514,,,2046.0,1,Thyroid gland,In vivo,CHEMBL624402,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,,50597,BAO_0000218
7515,,,178.0,1,Blood,In vivo,CHEMBL624403,,Intermediate,A,,1,,N,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,50597,BAO_0000218
7516,,,178.0,1,Blood,In vivo,CHEMBL624404,,Intermediate,A,,1,,N,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,,50597,BAO_0000218
7517,,,178.0,1,Blood,In vivo,CHEMBL624405,,Intermediate,A,,1,,N,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,,50597,BAO_0000218
7518,,,10000001.0,1,Bone,In vivo,CHEMBL624406,,Intermediate,A,,1,,N,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,50597,BAO_0000218
7519,,,10000001.0,1,Bone,In vivo,CHEMBL624407,,Intermediate,A,,1,,N,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,,50597,BAO_0000218
7520,,,10000001.0,1,Bone,In vivo,CHEMBL624408,,Intermediate,A,,1,,N,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,,50597,BAO_0000218
7521,,,948.0,1,Heart,In vivo,CHEMBL618644,,Intermediate,A,,1,,N,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,50597,BAO_0000218
7522,,,948.0,1,Heart,In vivo,CHEMBL618645,,Intermediate,A,,1,,N,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,,50597,BAO_0000218
7523,,,948.0,1,Heart,In vivo,CHEMBL618646,,Intermediate,A,,1,,N,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,,50597,BAO_0000218
7524,,,2113.0,1,Kidney,In vivo,CHEMBL618647,,Intermediate,A,,1,,N,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,50597,BAO_0000218
7525,,,2113.0,1,Kidney,In vivo,CHEMBL618648,,Intermediate,A,,1,,N,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,,,50597,BAO_0000218
7526,,,2113.0,1,Kidney,In vivo,CHEMBL618649,,Intermediate,A,,1,,N,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,,,50597,BAO_0000218
7527,,,2107.0,1,Liver,In vivo,CHEMBL618650,,Intermediate,A,,1,,N,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,50597,BAO_0000218
7528,,,2107.0,1,Liver,In vivo,CHEMBL618651,,Intermediate,A,,1,,N,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,,,50597,BAO_0000218
7529,,,2107.0,1,Liver,In vivo,CHEMBL876497,,Intermediate,A,,1,,N,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,,,50597,BAO_0000218
7530,,,2048.0,1,Lung,In vivo,CHEMBL618652,,Intermediate,A,,1,,N,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,50597,BAO_0000218
7531,,,2048.0,1,Lung,In vivo,CHEMBL618653,,Intermediate,A,,1,,N,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,,,50597,BAO_0000218
7532,,,2048.0,1,Lung,In vivo,CHEMBL618654,,Intermediate,A,,1,,N,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,,,50597,BAO_0000218
7533,,,,1,,,CHEMBL618655,,Intermediate,A,,1,,N,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,,50597,BAO_0000218
7534,,,,1,,,CHEMBL618656,,Intermediate,A,,1,,N,Compound was tested for solubility in water,,,50597,BAO_0000218
7535,,,,0,,,CHEMBL618657,,Intermediate,P,,1,,U,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,,22229,BAO_0000100
7536,,,,1,,,CHEMBL618658,,Intermediate,A,,1,,N,Solubility was determined,,,50597,BAO_0000218
7537,,,,1,,,CHEMBL618659,,Intermediate,A,,1,,N,solubility in water (ug/mL) at 37 degree C.,,,50597,BAO_0000218
7538,,,,1,,,CHEMBL618660,,Intermediate,A,,1,,N,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,,50597,BAO_0000218
7539,,,,1,,,CHEMBL618661,,Intermediate,A,,1,,N,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,,50597,BAO_0000218
7540,,,,1,,,CHEMBL873807,,Intermediate,A,,1,,N,Half life in rats,,,50597,BAO_0000218
7541,,,,1,,,CHEMBL618662,,Intermediate,A,,1,,N,Half life in Dawley rat,,,50597,BAO_0000218
7542,,,,1,,In vivo,CHEMBL618663,,Intermediate,A,,1,,N,Half life period after 3 mg/kg iv administration,,,50597,BAO_0000218
7543,,,,1,,In vivo,CHEMBL618664,,Intermediate,A,,1,,N,Half life period after 3 mg/kg iv administration in rat,,,50597,BAO_0000218
7544,,,,1,,In vivo,CHEMBL618665,,Intermediate,A,,1,,N,Half life period after 3 mg/kg iv administration in the rat,,,50597,BAO_0000218
7545,,,,1,,,CHEMBL876498,,Intermediate,A,,1,,N,Half life period in female Sprague-Dawley rats,,,50597,BAO_0000218
7546,,,,1,,,CHEMBL618666,,Intermediate,A,,1,,N,Half life period in rat,,,50597,BAO_0000218
7547,,,,1,,,CHEMBL620440,,Intermediate,A,,1,,N,Half-life in rats was determined,,,50597,BAO_0000218
7548,,,,1,,,CHEMBL620441,,Intermediate,A,,1,,N,Half-life in rats with metabolic oxidation,,,50597,BAO_0000218
7549,,,,1,,,CHEMBL620442,,Intermediate,A,,1,,N,Half-life in rats,,,50597,BAO_0000218
7550,,,,1,,In vivo,CHEMBL620443,,Intermediate,A,,1,,N,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,50597,BAO_0000218
7551,,,,1,,In vivo,CHEMBL620444,,Intermediate,A,,1,,N,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,50597,BAO_0000218
7552,,,,1,,In vivo,CHEMBL620445,,Intermediate,A,,1,,N,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,50597,BAO_0000218
7553,,,,1,,In vivo,CHEMBL620446,,Intermediate,A,,1,,N,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,50597,BAO_0000218
7554,,,1969.0,1,Plasma,,CHEMBL620447,,Intermediate,A,,1,,N,Biological half-life measured in plasma of rat,,,50597,BAO_0000218
7555,,,1969.0,1,Plasma,,CHEMBL621129,,Intermediate,A,,1,,N,Biological half-life measured in plasma of rat; 22-25,,,50597,BAO_0000218
7556,,,1969.0,1,Plasma,,CHEMBL621130,,Intermediate,A,,1,,N,Biological half-life measured in plasma of rat; 9-16,,,50597,BAO_0000218
7557,,,,1,,In vivo,CHEMBL873808,,Intermediate,A,,1,,N,Compound was evaluated for its half life when administered intravenously in rat,,,50597,BAO_0000218
7558,,,,1,,In vivo,CHEMBL876598,,Intermediate,A,,1,,N,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,,50597,BAO_0000218
7559,,,,1,,In vivo,CHEMBL621131,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,,50597,BAO_0000218
7560,,,,1,,In vivo,CHEMBL621132,,Intermediate,A,,1,,N,Half life (T1/2) after oral administration in rat,,,50597,BAO_0000218
7561,,,,1,,In vivo,CHEMBL621133,,Intermediate,A,,1,,N,Half life of compound after iv administration of 20 mg/kg dose in rat,,,50597,BAO_0000218
7562,,,,1,,In vivo,CHEMBL621312,,Expert,A,,1,,N,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,BAO_0000218
7563,,,,1,,,CHEMBL621313,,Intermediate,A,,1,,N,Half life of compound was determined in rat,,,50597,BAO_0000218
7564,,,178.0,1,Blood,,CHEMBL621314,,Intermediate,A,,1,,N,Half life of compound was determined in rat blood,,,50597,BAO_0000218
7565,,,,1,,In vivo,CHEMBL621315,,Intermediate,A,,1,,N,Half life at 1 mg/kg was determined in rat,,,50597,BAO_0000218
7566,,,,1,,In vivo,CHEMBL621316,,Intermediate,A,,1,,N,Half life at 10 mg/kg was determined in rat,,,50597,BAO_0000218
7567,,,,1,,,CHEMBL621317,,Intermediate,A,,1,,N,Half life in rats,,,50597,BAO_0000218
7568,,,,1,,,CHEMBL621318,,Intermediate,A,,1,,N,Half life in rats in hours,,,50597,BAO_0000218
7569,,,,1,,In vivo,CHEMBL621319,,Intermediate,A,,1,,N,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,,50597,BAO_0000218
7570,,,,1,,In vivo,CHEMBL621377,,Intermediate,A,,1,,N,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,,50597,BAO_0000218
7571,,,,1,,,CHEMBL621378,,Intermediate,A,,1,,N,Half life was determined,,,50597,BAO_0000218
7572,,,,1,,In vivo,CHEMBL876599,,Intermediate,A,,1,,N,Half life after i.v. administration,,,50597,BAO_0000218
7573,,,,1,,In vivo,CHEMBL621379,,Intermediate,A,,1,,N,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,,50597,BAO_0000218
7574,,,1969.0,1,Plasma,,CHEMBL621380,,Intermediate,A,,1,,N,Half life in rat plasma,,,50597,BAO_0000218
7575,,,1969.0,1,Plasma,,CHEMBL621381,,Intermediate,A,,1,,N,Half life in rat plasma; Not detected,,,50597,BAO_0000218
7576,,,,1,,,CHEMBL618515,,Intermediate,A,,1,,N,Half life in rats,,,50597,BAO_0000218
7577,,,,1,,In vivo,CHEMBL618516,,Intermediate,A,,1,,N,Half life period of compound was determined after peroral administration,,,50597,BAO_0000218
7578,,,,1,,In vivo,CHEMBL618517,,Intermediate,A,,1,,N,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,,50597,BAO_0000218
7579,,,,1,,,CHEMBL618518,,Intermediate,A,,1,,N,Half life period in rat,,,50597,BAO_0000218
7580,,,,1,,In vivo,CHEMBL618519,,Intermediate,A,,1,,N,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,,50597,BAO_0000218
7581,,,,1,,In vivo,CHEMBL618698,,Intermediate,A,,1,,N,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,,50597,BAO_0000218
7582,,,,1,,In vivo,CHEMBL618862,,Intermediate,A,,1,,N,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,,50597,BAO_0000218
7583,,,,1,,In vivo,CHEMBL618863,,Intermediate,A,,1,,N,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,50597,BAO_0000218
7584,,,,1,,In vivo,CHEMBL618864,,Intermediate,A,,1,,N,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,,50597,BAO_0000218
7585,,,,1,,In vivo,CHEMBL618865,,Intermediate,A,,1,,N,Half life time in rat the dose of 2 mg/kg,,,50597,BAO_0000218
7586,,,,1,,In vivo,CHEMBL618866,,Intermediate,A,,1,,N,Half-life 24 hr after 10 mg/kg iv administration in rats,,,50597,BAO_0000218
7587,,,,1,,In vivo,CHEMBL618867,,Intermediate,A,,1,,N,Half-life 24 hr after 2 mg/kg iv administration in rats,,,50597,BAO_0000218
7588,,,,1,,,CHEMBL875828,,Intermediate,A,,1,,N,Half-life consistent with the observed metabolic steady state in rats,,,50597,BAO_0000218
7589,,,,1,,In vivo,CHEMBL618868,,Intermediate,A,,1,,N,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,,50597,BAO_0000218
7590,,,,1,,,CHEMBL618869,,Intermediate,A,,1,,N,Half-life for oxidative metabolic stability was determined using male human,,,50597,BAO_0000218
7591,,,,1,,In vivo,CHEMBL618870,,Intermediate,A,,1,,N,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,,50597,BAO_0000218
7592,,,1969.0,1,Plasma,,CHEMBL618871,,Intermediate,A,,1,,N,Half-life in rat plasma,,,50597,BAO_0000218
7593,,,1969.0,1,Plasma,,CHEMBL618872,,Intermediate,A,,1,,N,Half-life in rat plasma was determined,,,50597,BAO_0000218
7594,,,,1,,,CHEMBL873816,,Intermediate,A,,1,,N,Half-life in rats was determined,,,50597,BAO_0000218
7595,,,,0,,,CHEMBL618873,,Autocuration,A,,1,,U,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,,22224,BAO_0000218
7596,,,,0,,,CHEMBL621602,,Autocuration,A,,1,,U,Area under curve after oral dose of 0.1 mg//kg,,,22224,BAO_0000019
7597,,,,0,,,CHEMBL621603,,Autocuration,A,,1,,U,Area under curve after oral dose of 0.3 mg/kg,,,22224,BAO_0000218
7598,,,,0,,,CHEMBL621604,,Autocuration,A,,1,,U,Area under curve after oral dose of 1 mg/kg,,,22224,BAO_0000218
7599,,,,0,,,CHEMBL621605,,Autocuration,A,,1,,U,Area under curve after oral dose of 10 mg/kg,,,22224,BAO_0000218
7600,,,,0,,,CHEMBL621606,,Autocuration,A,,1,,U,Area under curve after oral dose of 23.4 mg/kg,,,22224,BAO_0000218
7601,,,,0,,,CHEMBL621607,,Autocuration,A,,1,,U,Area under curve after oral dose of 3 mg/kg,,,22224,BAO_0000218
7602,,,,0,,,CHEMBL621608,,Autocuration,A,,1,,U,Area under curve after oral dose of 3.87 mg/kg,,,22224,BAO_0000218
7603,,,,0,,,CHEMBL621609,,Autocuration,A,,1,,U,Area under curve was determined,,,22224,BAO_0000019
7604,,,,0,,,CHEMBL621610,,Autocuration,A,,1,,U,Area under curve at a dose of 10 mg/kg,,,22224,BAO_0000218
7605,,,,1,,,CHEMBL621611,,Intermediate,A,,1,,N,Area under curve was determined; ND=No data,,,50597,BAO_0000218
7606,,,,1,,,CHEMBL621612,,Intermediate,A,,1,,N,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,,50597,BAO_0000218
7607,,,,1,,,CHEMBL622308,,Intermediate,A,,1,,N,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,,50597,BAO_0000218
7608,,,,1,,,CHEMBL622309,,Intermediate,A,,1,,N,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,,50597,BAO_0000218
7609,,,,1,,,CHEMBL622310,,Intermediate,A,,1,,N,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,,50597,BAO_0000218
7610,,,,1,,,CHEMBL622311,,Intermediate,A,,1,,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,,50597,BAO_0000218
7611,,,,1,,,CHEMBL622312,,Intermediate,A,,1,,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,,50597,BAO_0000218
7612,,,,1,,,CHEMBL622931,,Intermediate,A,,1,,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,,50597,BAO_0000218
7613,,,,1,,,CHEMBL622932,,Intermediate,A,,1,,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,,50597,BAO_0000218
7614,,,1969.0,1,Plasma,,CHEMBL622736,,Intermediate,A,,1,,N,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,,50597,BAO_0000218
7615,,,1969.0,1,Plasma,,CHEMBL622737,,Intermediate,A,,1,,N,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,,50597,BAO_0000218
7616,,,1969.0,1,Plasma,,CHEMBL622738,,Intermediate,A,,1,,N,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,,50597,BAO_0000218
7617,,,1969.0,1,Plasma,,CHEMBL622739,,Intermediate,A,,1,,N,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,,,50597,BAO_0000218
7618,,,1969.0,1,Plasma,,CHEMBL622740,,Intermediate,A,,1,,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,,50597,BAO_0000218
7619,,,1969.0,1,Plasma,,CHEMBL622741,,Intermediate,A,,1,,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,,,50597,BAO_0000218
7620,,,1969.0,1,Plasma,,CHEMBL622742,,Intermediate,A,,1,,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,,50597,BAO_0000218
7621,,,1969.0,1,Plasma,,CHEMBL622743,,Intermediate,A,,1,,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,,,50597,BAO_0000218
7622,,,1969.0,1,Plasma,,CHEMBL622744,,Intermediate,A,,1,,N,AUC in mice,,,50594,BAO_0000218
7623,,,,0,,,CHEMBL624134,,Autocuration,A,,1,,U,Area under curve was measured from the graph obtained from concentration Vs time,,,22224,BAO_0000019
7624,,,,0,,,CHEMBL624135,,Autocuration,A,,1,,U,Area under curve value of compound per hour after oral administration,,,22224,BAO_0000019
7625,,,,1,,,CHEMBL624136,,Intermediate,A,,1,,N,Area under curve was determined after oral administration in rats,,,50597,BAO_0000218
7626,,,,1,,,CHEMBL624137,,Intermediate,A,,1,,N,Area under curve was determined after oral administration in rats; No data,,,50597,BAO_0000218
7627,,,,1,,,CHEMBL624320,,Intermediate,A,,1,,N,Area under curve was determined after oral administration in rats;No data,,,50597,BAO_0000218
7628,,,,1,,,CHEMBL624321,,Intermediate,A,,1,,N,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,,50588,BAO_0000218
7629,,,,1,,,CHEMBL624322,,Intermediate,A,,1,,N,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,,50597,BAO_0000218
7630,,,,1,,,CHEMBL624323,,Intermediate,A,,1,,N,Area under curve was determined for the compound after iv dose of 5.06 in rats,,,50597,BAO_0000218
7631,,,,1,,,CHEMBL624324,,Intermediate,A,,1,,N,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,,50597,BAO_0000218
7632,,,,1,,,CHEMBL624325,,Intermediate,A,,1,,N,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,,50597,BAO_0000218
7633,,,,1,,,CHEMBL624326,,Intermediate,A,,1,,N,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,,50597,BAO_0000218
7634,,,,1,,,CHEMBL624327,,Intermediate,A,,1,,N,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,,50597,BAO_0000218
7635,,,,1,,,CHEMBL624328,,Intermediate,A,,1,,N,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,,50597,BAO_0000218
7636,,,,1,,,CHEMBL627848,,Intermediate,A,,1,,N,Area under curve was determined in Dogs after peroral administration,,,50588,BAO_0000218
7637,,,,1,,,CHEMBL627849,,Intermediate,A,,1,,N,Area under curve was determined in Rats after peroral administration,,,50597,BAO_0000218
7638,,,,1,,,CHEMBL627850,,Intermediate,A,,1,,N,Area under curve was determined in carotid blood of rat when administered intradermally,,,50597,BAO_0000218
7639,,,,1,,,CHEMBL627851,,Intermediate,A,,1,,N,Area under curve was determined in portal blood of rat when administered intradermally,,,50597,BAO_0000218
7640,,,,1,,,CHEMBL627852,,Intermediate,A,,1,,N,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,50594,BAO_0000218
7641,,,,1,,,CHEMBL627853,,Intermediate,A,,1,,N,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,,50594,BAO_0000218
7642,,,,1,,,CHEMBL627854,,Intermediate,A,,1,,N,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,,50594,BAO_0000218
7643,,,,1,,,CHEMBL627855,,Intermediate,A,,1,,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,50594,BAO_0000218
7644,,,,1,,,CHEMBL627856,,Intermediate,A,,1,,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,,50594,BAO_0000218
7645,,,,1,,,CHEMBL875339,,Intermediate,A,,1,,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,,50594,BAO_0000218
7646,,,,1,,,CHEMBL627857,,Intermediate,A,,1,,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,,50594,BAO_0000218
7647,,,2106.0,1,Spleen,In vivo,CHEMBL627858,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,,,50597,BAO_0000218
7648,,,178.0,1,Blood,,CHEMBL627859,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,,,50597,BAO_0000218
7649,,,955.0,1,Brain,,CHEMBL627860,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,,,50597,BAO_0000218
7650,,,948.0,1,Heart,,CHEMBL627019,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,,,50597,BAO_0000218
7651,,,2107.0,1,Liver,,CHEMBL627020,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,,,50597,BAO_0000218
7652,,,2048.0,1,Lung,,CHEMBL627021,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,,,50597,BAO_0000218
7653,,,2385.0,1,Muscle tissue,,CHEMBL627022,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,,,50597,BAO_0000218
7654,,,,1,,,CHEMBL627023,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,,50597,BAO_0000218
7655,,,2106.0,1,Spleen,,CHEMBL627024,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,,,50597,BAO_0000218
7656,,,2046.0,1,Thyroid gland,,CHEMBL627025,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,,,50597,BAO_0000218
7657,,,2113.0,1,Kidney,,CHEMBL627026,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,,,50597,BAO_0000218
7658,,,178.0,1,Blood,,CHEMBL627027,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,,,50597,BAO_0000218
7659,,,955.0,1,Brain,,CHEMBL627028,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,,,50597,BAO_0000218
7660,,,948.0,1,Heart,,CHEMBL627029,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,,,50597,BAO_0000218
7661,,,2113.0,1,Kidney,,CHEMBL627030,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,,,50597,BAO_0000218
7662,,,2107.0,1,Liver,,CHEMBL627031,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,,,50597,BAO_0000218
7663,,,2048.0,1,Lung,,CHEMBL627032,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,,,50597,BAO_0000218
7664,,,2385.0,1,Muscle tissue,,CHEMBL627033,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,,,50597,BAO_0000218
7665,,,,1,,,CHEMBL627034,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,,50597,BAO_0000218
7666,,,2106.0,1,Spleen,,CHEMBL627035,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,,,50597,BAO_0000218
7667,,,2046.0,1,Thyroid gland,,CHEMBL627036,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,,,50597,BAO_0000218
7668,,,178.0,1,Blood,,CHEMBL875340,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,,,50597,BAO_0000218
7669,,,948.0,1,Heart,,CHEMBL627037,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,,,50597,BAO_0000218
7670,,,2113.0,1,Kidney,,CHEMBL627038,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,,,50597,BAO_0000218
7671,,,2107.0,1,Liver,,CHEMBL627039,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,,,50597,BAO_0000218
7672,,,2385.0,1,Muscle tissue,,CHEMBL627040,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,,,50597,BAO_0000218
7673,,,2106.0,1,Spleen,,CHEMBL624663,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,,,50597,BAO_0000218
7674,,,2046.0,1,Thyroid gland,,CHEMBL625963,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,,,50597,BAO_0000218
7675,,,955.0,1,Brain,,CHEMBL876799,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,,,50597,BAO_0000218
7676,,,2048.0,1,Lung,,CHEMBL626133,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,,,50597,BAO_0000218
7677,,,,1,,,CHEMBL626134,,Intermediate,A,,1,,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,,50597,BAO_0000218
7678,,,,1,,,CHEMBL626135,,Intermediate,A,,1,,N,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,,50597,BAO_0000218
7679,,,,1,,,CHEMBL626136,,Intermediate,A,,1,,N,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,,50597,BAO_0000218
7680,,,,1,,,CHEMBL626137,,Intermediate,A,,1,,N,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,,50597,BAO_0000218
7681,,,,1,,,CHEMBL626138,,Intermediate,A,,1,,N,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,,50597,BAO_0000218
7682,,,,1,,,CHEMBL626139,,Intermediate,A,,1,,N,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,,50597,BAO_0000218
7683,,,,1,,In vivo,CHEMBL626140,,Intermediate,A,,1,,N,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,50597,BAO_0000218
7684,,,,1,,In vivo,CHEMBL626141,,Intermediate,A,,1,,N,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,50597,BAO_0000218
7685,,,,1,,,CHEMBL626142,,Intermediate,A,,1,,N,C24h in rat p.o. at 20 mg/kg concentration,,,50597,BAO_0000218
7686,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627930,,Intermediate,A,,1,,N,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,50597,BAO_0000218
7687,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627931,,Intermediate,A,,1,,N,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,,,50597,BAO_0000218
7688,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627932,,Intermediate,A,,1,,N,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,,,50597,BAO_0000218
7689,,,2106.0,1,Spleen,In vivo,CHEMBL627933,,Intermediate,A,,1,,N,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,50597,BAO_0000218
7690,,,2106.0,1,Spleen,In vivo,CHEMBL627934,,Intermediate,A,,1,,N,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,,,50597,BAO_0000218
7691,,,2106.0,1,Spleen,In vivo,CHEMBL627935,,Intermediate,A,,1,,N,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,,,50597,BAO_0000218
7692,,,178.0,1,Blood,In vivo,CHEMBL627936,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,,,50597,BAO_0000218
7693,,,178.0,1,Blood,In vivo,CHEMBL627937,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,,,50597,BAO_0000218
7694,,,178.0,1,Blood,In vivo,CHEMBL627938,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,,,50597,BAO_0000218
7695,,,178.0,1,Blood,In vivo,CHEMBL627939,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,,,50597,BAO_0000218
7696,,,178.0,1,Blood,In vivo,CHEMBL627940,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,,,50597,BAO_0000218
7697,,,178.0,1,Blood,In vivo,CHEMBL627941,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,,,50597,BAO_0000218
7698,,,178.0,1,Blood,In vivo,CHEMBL876800,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,,50597,BAO_0000218
7699,,,178.0,1,Blood,In vivo,CHEMBL627942,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,,,50597,BAO_0000218
7700,,,178.0,1,Blood,In vivo,CHEMBL627943,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,,,50597,BAO_0000218
7701,,,178.0,1,Blood,In vivo,CHEMBL627944,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,,,50597,BAO_0000218
7702,,,178.0,1,Blood,In vivo,CHEMBL627945,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,,,50597,BAO_0000218
7703,,,178.0,1,Blood,In vivo,CHEMBL628584,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,,,50597,BAO_0000218
7704,,,178.0,1,Blood,In vivo,CHEMBL628585,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA at 15 min,,,50597,BAO_0000218
7705,,,178.0,1,Blood,In vivo,CHEMBL628586,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,,,50597,BAO_0000218
7706,,,178.0,1,Blood,In vivo,CHEMBL628587,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA at 30 min,,,50597,BAO_0000218
7707,,,178.0,1,Blood,In vivo,CHEMBL628588,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,,,50597,BAO_0000218
7708,,,178.0,1,Blood,In vivo,CHEMBL628589,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,,,50597,BAO_0000218
7709,,,178.0,1,Blood,In vivo,CHEMBL625304,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,,,50597,BAO_0000218
7710,,,178.0,1,Blood,In vivo,CHEMBL625305,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,,,50597,BAO_0000218
7711,,,178.0,1,Blood,In vivo,CHEMBL625306,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,,,50597,BAO_0000218
7712,,,178.0,1,Blood,In vivo,CHEMBL625307,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,,,50597,BAO_0000218
7713,,,178.0,1,Blood,In vivo,CHEMBL625308,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,,,50597,BAO_0000218
7714,,,178.0,1,Blood,In vivo,CHEMBL627740,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,,,50597,BAO_0000218
7715,,,178.0,1,Blood,In vivo,CHEMBL627741,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,,,50597,BAO_0000218
7716,,,178.0,1,Blood,In vivo,CHEMBL627742,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,,50597,BAO_0000218
7717,,,178.0,1,Blood,In vivo,CHEMBL627743,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,,,50597,BAO_0000218
7718,,,178.0,1,Blood,In vivo,CHEMBL627744,,Intermediate,A,,1,,N,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,,,50597,BAO_0000218
7719,,,10000001.0,1,Bone,In vivo,CHEMBL627745,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,,,50597,BAO_0000218
7720,,,10000001.0,1,Bone,In vivo,CHEMBL627746,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,,,50597,BAO_0000218
7721,,,10000001.0,1,Bone,In vivo,CHEMBL627747,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,,,50597,BAO_0000218
7722,,,10000001.0,1,Bone,In vivo,CHEMBL876810,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,,,50597,BAO_0000218
7723,,,10000001.0,1,Bone,In vivo,CHEMBL627748,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,,,50597,BAO_0000218
7724,,,10000001.0,1,Bone,In vivo,CHEMBL627749,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,,,50597,BAO_0000218
7725,,,10000001.0,1,Bone,In vivo,CHEMBL627750,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,,50597,BAO_0000218
7726,,,10000001.0,1,Bone,In vivo,CHEMBL618728,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,,,50597,BAO_0000218
7727,,,10000001.0,1,Bone,In vivo,CHEMBL618729,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,,,50597,BAO_0000218
7728,,,10000001.0,1,Bone,In vivo,CHEMBL618730,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA at 15 min,,,50597,BAO_0000218
7729,,,10000001.0,1,Bone,In vivo,CHEMBL618731,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,,,50597,BAO_0000218
7730,,,10000001.0,1,Bone,In vivo,CHEMBL618732,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA at 30 min,,,50597,BAO_0000218
7731,,,10000001.0,1,Bone,In vivo,CHEMBL618733,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,,,50597,BAO_0000218
7732,,,10000001.0,1,Bone,In vivo,CHEMBL618734,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,,,50597,BAO_0000218
7733,,,10000001.0,1,Bone,In vivo,CHEMBL618735,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,,,50597,BAO_0000218
7734,,,10000001.0,1,Bone,In vivo,CHEMBL876602,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,,,50597,BAO_0000218
7735,,,10000001.0,1,Bone,In vivo,CHEMBL618736,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,,,50597,BAO_0000218
7736,,,10000001.0,1,Bone,In vivo,CHEMBL618737,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,,,50597,BAO_0000218
7737,,,10000001.0,1,Bone,In vivo,CHEMBL618738,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,,,50597,BAO_0000218
7738,,,10000001.0,1,Bone,In vivo,CHEMBL618739,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,,,50597,BAO_0000218
7739,,,10000001.0,1,Bone,In vivo,CHEMBL618740,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,,,50597,BAO_0000218
7740,,,10000001.0,1,Bone,In vivo,CHEMBL618741,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,,50597,BAO_0000218
7741,,,10000001.0,1,Bone,In vivo,CHEMBL618742,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,,,50597,BAO_0000218
7742,,,10000001.0,1,Bone,In vivo,CHEMBL618743,,Intermediate,A,,1,,N,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,,,50597,BAO_0000218
7743,,,1969.0,1,Plasma,In vivo,CHEMBL618744,,Intermediate,A,,1,,N,Half-life from rat plasma at a single oral dose of 25 mg/kg,,,50597,BAO_0000218
7744,,,,1,,,CHEMBL618745,,Intermediate,A,,1,,N,Half-life in male rat,,,50597,BAO_0000218
7745,,,,1,,In vivo,CHEMBL620479,,Intermediate,A,,1,,N,Half-life in rat after peroral administration at 10 mg/kg concentration,,,50597,BAO_0000218
7746,,,,1,,In vivo,CHEMBL620480,,Intermediate,A,,1,,N,Half-life in rat after peroral administration at 5 mg/kg concentration,,,50597,BAO_0000218
7747,,,,1,,In vivo,CHEMBL620481,,Intermediate,A,,1,,N,Half-life in rat at a dose of 3 mg/kg,,,50597,BAO_0000218
7748,,,,1,,,CHEMBL620482,,Intermediate,A,,1,,N,Half-life was evaluated in rats,,,50597,BAO_0000218
7749,,,,1,,,CHEMBL876603,,Intermediate,A,,1,,N,Half-life was measured in rat,,,50597,BAO_0000218
7750,,,,1,,In vivo,CHEMBL620483,,Intermediate,A,,1,,N,Half-life period for the compound was determined in rats at 50 mg/kg dose,,,50597,BAO_0000218
7751,,,,1,,In vivo,CHEMBL620484,,Intermediate,A,,1,,N,Half-life period in rats after intravenous administration at 5 mg/kg,,,50597,BAO_0000218
7752,,,,1,,In vivo,CHEMBL620485,,Intermediate,A,,1,,N,Half-life period in rat at 10 mg/kg,,,50597,BAO_0000218
7753,,,,1,,In vivo,CHEMBL620486,,Intermediate,A,,1,,N,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,,50597,BAO_0000218
7754,,,,1,,In vivo,CHEMBL620487,,Intermediate,A,,1,,N,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,,50597,BAO_0000218
7755,,,,1,,In vivo,CHEMBL620488,,Intermediate,A,,1,,N,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,,50597,BAO_0000218
7756,,,,1,,In vivo,CHEMBL620489,,Intermediate,A,,1,,N,Half-life time in rat the dose of 2 mg/kg,,,50597,BAO_0000218
7757,,,,1,,In vivo,CHEMBL620490,,Intermediate,A,,1,,N,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,,50597,BAO_0000218
7758,,,,1,,In vivo,CHEMBL620491,,Intermediate,A,,1,,N,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,,50597,BAO_0000218
7759,,,1969.0,1,Plasma,In vivo,CHEMBL876604,,Intermediate,A,,1,,N,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,,50597,BAO_0000218
7760,,,,1,,In vivo,CHEMBL620492,,Intermediate,A,,1,,N,Oral half life was determined,,,50597,BAO_0000218
7761,,,,1,,In vivo,CHEMBL620493,,Intermediate,A,,1,,N,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,,50597,BAO_0000218
7762,,,,1,,In vivo,CHEMBL620494,,Intermediate,A,,1,,N,Pharmacokinetic property (t1/2) in rat,,,50597,BAO_0000218
7763,,,1969.0,1,Plasma,,CHEMBL620495,,Intermediate,A,,1,,N,Plasma elimination half-life was determined,,,50597,BAO_0000218
7764,,,1969.0,1,Plasma,In vivo,CHEMBL620496,,Intermediate,A,,1,,N,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,,50597,BAO_0000218
7765,,,1969.0,1,Plasma,In vivo,CHEMBL620497,,Intermediate,A,,1,,N,Plasma half life was observed after intravenous administration in rat,,,50597,BAO_0000218
7766,,,1969.0,1,Plasma,,CHEMBL620498,,Intermediate,A,,1,,N,Plasma half-life was determined,,,50597,BAO_0000218
7767,,,1969.0,1,Plasma,In vivo,CHEMBL620499,,Intermediate,A,,1,,N,Plasma half-life following oral administration in Fisher rats,,,50597,BAO_0000218
7768,,,1969.0,1,Plasma,,CHEMBL620500,,Intermediate,A,,1,,N,Plasma half-life in rat,,,50597,BAO_0000218
7769,,,1969.0,1,Plasma,In vivo,CHEMBL873809,,Intermediate,A,,1,,N,Plasmatic Half-life after intravenous administration to rat,,,50597,BAO_0000218
7770,,,,1,,In vivo,CHEMBL620501,,Intermediate,A,,1,,N,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,,50597,BAO_0000218
7771,,,,1,,In vivo,CHEMBL620502,,Intermediate,A,,1,,N,Terminal half life after intravenous administration (1 mg/kg) in rat,,,50597,BAO_0000218
7772,,,,1,,In vivo,CHEMBL620503,,Intermediate,A,,1,,N,Terminal half life in Rat at a oral dose of 5 mg/kg,,,50597,BAO_0000218
7773,,,,1,,In vivo,CHEMBL620504,,Intermediate,A,,1,,N,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,,50597,BAO_0000218
7774,,,,1,,In vivo,CHEMBL876605,,Intermediate,A,,1,,N,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,,50597,BAO_0000218
7775,,,,1,,In vivo,CHEMBL620505,,Intermediate,A,,1,,N,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,,50597,BAO_0000218
7776,,,1969.0,1,Plasma,In vivo,CHEMBL873811,,Intermediate,A,,1,,N,plasma half life was observed after intravenous administration in rat,,,50597,BAO_0000218
7777,,,,1,,In vivo,CHEMBL624016,,Expert,A,,1,,N,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,BAO_0000218
7778,,,,1,,,CHEMBL624017,,Intermediate,A,,1,,N,Half life of compound determined in rat,,,50597,BAO_0000218
7779,,,,1,,,CHEMBL624018,,Intermediate,A,,1,,N,Mean residence time determined in rat,,,50597,BAO_0000218
7780,,,,1,,,CHEMBL624019,,Intermediate,A,,1,,N,Plasma half life determined in rat,,,50597,BAO_0000218
7781,,,955.0,1,Brain,In vivo,CHEMBL624020,,Intermediate,A,,1,,N,Compound was evaluated for Tmax in brain after intravenous administration in male rats,,,50597,BAO_0000218
7782,,,,1,,In vivo,CHEMBL624201,,Intermediate,A,,1,,N,Compound was evaluated for pharmacokinetic parameter maximum time period,,,50597,BAO_0000218
7783,,,,1,,In vivo,CHEMBL872528,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,,50597,BAO_0000218
7784,,,,1,,In vivo,CHEMBL624202,,Intermediate,A,,1,,N,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
7785,,,,1,,In vivo,CHEMBL624203,,Intermediate,A,,1,,N,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
7786,,,,1,,In vivo,CHEMBL624350,,Intermediate,A,,1,,N,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
7787,,,,1,,In vivo,CHEMBL621320,,Intermediate,A,,1,,N,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
7788,,,,1,,In vivo,CHEMBL621321,,Intermediate,A,,1,,N,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,,50597,BAO_0000218
7789,,,,1,,,CHEMBL621322,,Intermediate,A,,1,,N,Maximum time (Tmax) required to reach Cmax in rats,,,50597,BAO_0000218
7790,,,,1,,In vivo,CHEMBL621323,,Intermediate,A,,1,,N,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,,50597,BAO_0000218
7791,,,,1,,In vivo,CHEMBL621324,,Intermediate,A,,1,,N,Maximum time of clearance of compound in rats after peroral administration,,,50597,BAO_0000218
7792,,,,1,,,CHEMBL621325,,Intermediate,A,,1,,N,Maximum time at the dose of 2 mg/kg in rat,,,50597,BAO_0000218
7793,,,1969.0,1,Plasma,In vivo,CHEMBL875837,,Intermediate,A,,1,,N,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,,,50597,BAO_0000218
7794,,,1969.0,1,Plasma,In vivo,CHEMBL621326,,Intermediate,A,,1,,N,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,,,50597,BAO_0000218
7795,,,,1,,In vivo,CHEMBL621327,,Intermediate,A,,1,,N,Tmax in Guinea pig (PO dose),,,50597,BAO_0000218
7796,,,,1,,In vivo,CHEMBL621328,,Intermediate,A,,1,,N,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,,50597,BAO_0000218
7797,,,,1,,In vivo,CHEMBL621329,,Intermediate,A,,1,,N,Pharmacokinetic parameter (Tmax) in rat,,,50597,BAO_0000218
7798,,,,1,,In vivo,CHEMBL621330,,Intermediate,A,,1,,N,Pharmacokinetic parameter (Tmax) was estimated,,,50597,BAO_0000218
7799,,,,1,,In vivo,CHEMBL621331,,Intermediate,A,,1,,N,Pharmacokinetic property (Tmax) in rat,,,50597,BAO_0000218
7800,,,,1,,In vivo,CHEMBL621332,,Intermediate,A,,1,,N,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,,50597,BAO_0000218
7801,,,,1,,In vivo,CHEMBL621333,,Intermediate,A,,1,,N,T max in Rat at a oral dose of 5 mg/kg,,,50597,BAO_0000218
7802,,,,1,,In vivo,CHEMBL621334,,Intermediate,A,,1,,N,T max was determined at 10 mg/kg po dose in rats,,,50597,BAO_0000218
7803,,,,1,,,CHEMBL621335,,Intermediate,A,,1,,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,,50594,BAO_0000218
7804,,,,1,,,CHEMBL621336,,Intermediate,A,,1,,N,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,,50588,BAO_0000218
7805,,,,1,,,CHEMBL621337,,Intermediate,A,,1,,N,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,,50597,BAO_0000218
7806,,,,1,,,CHEMBL621338,,Intermediate,A,,1,,N,Area under curve was measured after i.v. administration into Beagle dog.,,,50588,BAO_0000218
7807,,,,1,,,CHEMBL875838,,Intermediate,A,,1,,N,Area under curve was measured after iv administration into Beagle dog,,,50588,BAO_0000218
7808,,,,1,,,CHEMBL621339,,Intermediate,A,,1,,N,Area under curve was measured after po administration into Beagle dog,,,50588,BAO_0000218
7809,,,,1,,,CHEMBL621340,,Intermediate,A,,1,,N,Area under curve was measured after po administration into Beagle dog.,,,50588,BAO_0000218
7810,,,,0,,,CHEMBL621341,,Autocuration,A,,1,,U,Area under curve was measured at peroral dose of 3 mg/kg,,,22224,BAO_0000218
7811,,,,0,,,CHEMBL621342,,Autocuration,A,,1,,U,Area under curve was measured by using concentration Vs time,,,22224,BAO_0000019
7812,,,,0,,,CHEMBL621343,,Autocuration,A,,1,,U,Area under curve was measured by using concentration Vs time; not tested,,,22224,BAO_0000019
7813,,,,1,,,CHEMBL621344,,Intermediate,A,,1,,N,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,,50594,BAO_0000218
7814,,,,1,,,CHEMBL621345,,Intermediate,A,,1,,N,Area under curve(AUC) was measured in mice after oral administration.,,,50594,BAO_0000218
7815,,,,0,,,CHEMBL621346,,Autocuration,A,,1,,U,Area under curve(AUC) value of the compound,,,22224,BAO_0000019
7816,,,,0,,,CHEMBL621347,,Autocuration,A,,1,,U,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,,22224,BAO_0000218
7817,,,,1,,,CHEMBL621348,,Intermediate,A,,1,,N,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,,50588,BAO_0000218
7818,,,178.0,0,Blood,,CHEMBL621349,,Autocuration,A,,1,,U,Area under curve(carotid artery) was determined by the availability in blood,,,22224,BAO_0000019
7819,,,178.0,0,Blood,,CHEMBL621350,,Autocuration,A,,1,,U,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,,22224,BAO_0000019
7820,,,178.0,0,Blood,,CHEMBL875839,,Autocuration,A,,1,,U,Area under curve(carotid artery) was determined by the availability in blood; No data,,,22224,BAO_0000019
7821,,,178.0,0,Blood,,CHEMBL620211,,Autocuration,A,,1,,U,Area under curve(portal vein) was determined by the availability in blood,,,22224,BAO_0000019
7822,,,178.0,0,Blood,,CHEMBL620212,,Autocuration,A,,1,,U,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,,22224,BAO_0000019
7823,,,178.0,0,Blood,,CHEMBL620213,,Autocuration,A,,1,,U,Area under curve(portal vein) was determined by the availability in blood; No data,,,22224,BAO_0000019
7824,,,1969.0,1,Plasma,,CHEMBL620214,,Intermediate,A,,1,,N,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,,50797,BAO_0000218
7825,,,1969.0,1,Plasma,,CHEMBL620215,,Intermediate,A,,1,,N,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,,50797,BAO_0000218
7826,,,1969.0,1,Plasma,,CHEMBL620216,,Intermediate,A,,1,,N,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,,,50797,BAO_0000218
7827,,,1969.0,1,Plasma,,CHEMBL620888,,Intermediate,A,,1,,N,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",,,50588,BAO_0000218
7828,,,1969.0,1,Plasma,,CHEMBL620889,,Intermediate,A,,1,,N,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",,,50588,BAO_0000218
7829,,,1969.0,0,Plasma,,CHEMBL620890,,Autocuration,A,,1,,U,Area under plasma concentration vs time curve observed in rats for 0-3 h,,,22224,BAO_0000019
7830,,,1969.0,1,Plasma,,CHEMBL620891,,Intermediate,A,,1,,N,Area under plasma time curve determined in male rat,,,50597,BAO_0000218
7831,,,,0,,,CHEMBL620892,,Autocuration,A,,1,,U,Area under the MAP curve measured over 5 min.,,,22224,BAO_0000019
7832,,,,1,,,CHEMBL621079,,Intermediate,A,,1,,N,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,,50594,BAO_0000218
7833,,,,1,,,CHEMBL621080,,Intermediate,A,,1,,N,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,,50594,BAO_0000218
7834,,,,1,,,CHEMBL621081,,Intermediate,A,,1,,N,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,,50588,BAO_0000218
7835,,,,1,,,CHEMBL621082,,Intermediate,A,,1,,N,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,,100712,BAO_0000218
7836,,,,1,,,CHEMBL621083,,Intermediate,A,,1,,N,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,,50597,BAO_0000218
7837,,,,1,,,CHEMBL621084,,Intermediate,A,,1,,N,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,,50588,BAO_0000218
7838,,,,1,,,CHEMBL621085,,Intermediate,A,,1,,N,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,,50588,BAO_0000218
7839,,,,1,,,CHEMBL621086,,Intermediate,A,,1,,N,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,,50588,BAO_0000218
7840,,,,1,,,CHEMBL621087,,Intermediate,A,,1,,N,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,50588,BAO_0000218
7841,,,,1,,,CHEMBL622607,,Intermediate,A,,1,,N,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,,50588,BAO_0000218
7842,,,,1,,,CHEMBL622608,,Intermediate,A,,1,,N,Serum AUC in marmosets (IV dose),,,50588,BAO_0000218
7843,,,,0,,,CHEMBL624481,,Autocuration,A,,1,,U,Area under the curve after intravenous administration at a dose of 10 umol/kg,,,22224,BAO_0000019
7844,,,,0,,,CHEMBL624482,,Autocuration,A,,1,,U,Area under the curve after intravenous administration at a dose of 2 umol/kg,,,22224,BAO_0000019
7845,,,,0,,,CHEMBL624483,,Autocuration,A,,1,,U,Area under the curve after intravenous administration at a dose of 4 umol/kg,,,22224,BAO_0000019
7846,,,,0,,,CHEMBL624484,,Autocuration,A,,1,,U,Area under the curve after intravenous administration at a dose of 40 umol/kg,,,22224,BAO_0000019
7847,,,,0,,,CHEMBL624485,,Autocuration,A,,1,,U,Area under the curve after intravenous administration at a dose of 5 umol/kg,,,22224,BAO_0000019
7848,,,,1,,,CHEMBL624486,,Intermediate,A,,1,,N,Area under the curve for fumarate salt was evaluated in F344 Rats.,,,50597,BAO_0000218
7849,,,,0,,,CHEMBL624487,,Autocuration,A,,1,,U,Area under the curve for the compound was calculated.,,,22224,BAO_0000019
7850,,,,0,,,CHEMBL624488,,Autocuration,A,,1,,U,Area under the curve in concentration/ time,,,22224,BAO_0000019
7851,,,,1,,,CHEMBL624489,,Intermediate,A,,1,,N,Area under the curve administered intraintestinal in rats.,,,50597,BAO_0000218
7852,,,,1,,,CHEMBL625184,,Intermediate,A,,1,,N,Area under the curve administered intravenously in rats.,,,50597,BAO_0000218
7853,,,,0,,,CHEMBL625185,,Autocuration,A,,1,,U,Area under the curve during intravenous administration,,,22224,BAO_0000019
7854,,,,0,,,CHEMBL875954,,Autocuration,A,,1,,U,Area under the curve during intravenous administration; Not determined,,,22224,BAO_0000019
7855,,,,0,,,CHEMBL625186,,Autocuration,A,,1,,U,Area under the curve during systemic administration,,,22224,BAO_0000019
7856,,,,0,,,CHEMBL625187,,Autocuration,A,,1,,U,Area under the curve during systemic administration; Not determined,,,22224,BAO_0000019
7857,,,,0,,,CHEMBL625188,,Autocuration,A,,1,,U,Area under the curve was calculated for the compound.,,,22224,BAO_0000019
7858,,,,1,,,CHEMBL625189,,Intermediate,A,,1,,N,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,,50588,BAO_0000218
7859,,,,1,,,CHEMBL625190,,Intermediate,A,,1,,N,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,,50588,BAO_0000218
7860,,,,1,,,CHEMBL621733,,Intermediate,A,,1,,N,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,,50597,BAO_0000218
7861,,,,1,,,CHEMBL621734,,Intermediate,A,,1,,N,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,,50597,BAO_0000218
7862,,,,1,,,CHEMBL621735,,Intermediate,A,,1,,N,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,,50597,BAO_0000218
7863,,,1969.0,1,Plasma,,CHEMBL621736,,Intermediate,A,,1,,N,Clearance of the drug was measured in the plasma of rat; No data,,,50597,BAO_0000218
7864,,,1969.0,1,Plasma,,CHEMBL621737,,Intermediate,A,,1,,N,The pharmacokinetic parameter plasma clearance in vivo in rats,,,50597,BAO_0000218
7865,,,,1,,,CHEMBL621738,,Intermediate,A,,1,,N,Plasma clearance at the dose of 2 mg/kg in rat,,,50597,BAO_0000218
7866,,,,1,,In vivo,CHEMBL622806,,Intermediate,A,,1,,N,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,50597,BAO_0000218
7867,,,,1,,In vivo,CHEMBL623519,,Intermediate,A,,1,,N,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,50597,BAO_0000218
7868,,,,1,,In vivo,CHEMBL623520,,Intermediate,A,,1,,N,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,50597,BAO_0000218
7869,,,,1,,In vivo,CHEMBL623521,,Intermediate,A,,1,,N,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,50597,BAO_0000218
7870,,,,1,,In vivo,CHEMBL623522,,Intermediate,A,,1,,N,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,50597,BAO_0000218
7871,,,,1,,In vivo,CHEMBL623523,,Intermediate,A,,1,,N,Clearance rate in rat,,,50597,BAO_0000218
7872,,,,1,,In vivo,CHEMBL623690,,Intermediate,A,,1,,N,Clearance rate in rat,,,50597,BAO_0000218
7873,,,,1,,In vivo,CHEMBL623691,,Intermediate,A,,1,,N,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
7874,,,,1,,In vivo,CHEMBL623692,,Intermediate,A,,1,,N,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
7875,,,,1,,In vivo,CHEMBL623693,,Intermediate,A,,1,,N,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
7876,,,,1,,In vivo,CHEMBL623694,,Intermediate,A,,1,,N,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
7877,,,,1,,In vivo,CHEMBL623695,,Intermediate,A,,1,,N,Clearance of compound after iv administration of 20 mg/kg dose in rat,,,50597,BAO_0000218
7878,,,,1,,In vivo,CHEMBL623696,,Intermediate,A,,1,,N,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,,50597,BAO_0000218
7879,,,,1,,In vivo,CHEMBL623697,,Intermediate,A,,1,,N,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,,50597,BAO_0000218
7880,,,1969.0,0,Plasma,In vivo,CHEMBL623698,,Intermediate,A,,1,,U,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,22224,BAO_0000218
7881,,,1969.0,0,Plasma,In vivo,CHEMBL623699,,Intermediate,A,,1,,U,Compound was tested for its plasma clearance rate in Sprague Dawley rats,,,22224,BAO_0000218
7882,,,,1,,In vivo,CHEMBL623700,,Intermediate,A,,1,,N,Mean (%CV) PK parameters for CL(mL/min/kg).,,,50597,BAO_0000218
7883,,,,1,,In vivo,CHEMBL623701,,Intermediate,A,,1,,N,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,,50597,BAO_0000218
7884,,,1969.0,1,Plasma,In vivo,CHEMBL623702,,Intermediate,A,,1,,N,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,,,50597,BAO_0000218
7885,,,,1,,In vivo,CHEMBL623703,,Intermediate,A,,1,,N,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,,50597,BAO_0000218
7886,,,,1,,In vivo,CHEMBL623704,,Intermediate,A,,1,,N,Plasma clearance in rat was determined,,,50597,BAO_0000218
7887,,,,1,,In vivo,CHEMBL623705,,Intermediate,A,,1,,N,Plasma clearance in rat after administration of 2 mg/kg iv,,,50597,BAO_0000218
7888,,,,1,,In vivo,CHEMBL623706,,Intermediate,A,,1,,N,Plasma clearance in rat after administration of 2 mg/kg iv,,,50597,BAO_0000218
7889,,,,1,,In vivo,CHEMBL623707,,Intermediate,A,,1,,N,Plasma clearance was determined,,,50597,BAO_0000218
7890,,,,1,,In vivo,CHEMBL623708,,Intermediate,A,,1,,N,Plasma clearance in rat,,,50597,BAO_0000218
7891,,,,1,,In vivo,CHEMBL623709,,Intermediate,A,,1,,N,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,,50597,BAO_0000218
7892,,,,1,,In vivo,CHEMBL623710,,Intermediate,A,,1,,N,Plasma clearance in rat by iv administration,,,50597,BAO_0000218
7893,,,,1,,In vivo,CHEMBL623711,,Intermediate,A,,1,,N,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,,50597,BAO_0000218
7894,,,,1,,In vivo,CHEMBL623712,,Intermediate,A,,1,,N,Plasma clearance in rat p.o.,,,50597,BAO_0000218
7895,,,,1,,In vivo,CHEMBL623713,,Intermediate,A,,1,,N,Plasma clearance in rats,,,50597,BAO_0000218
7896,,,,1,,In vivo,CHEMBL623714,,Intermediate,A,,1,,N,Plasma clearance was determined; ND denotes no data,,,50597,BAO_0000218
7897,,,,1,,In vivo,CHEMBL623715,,Intermediate,A,,1,,N,Plasma clearance was determined; ND denotes not determined,,,50597,BAO_0000218
7898,,,,1,,In vivo,CHEMBL623716,,Intermediate,A,,1,,N,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,,50597,BAO_0000218
7899,,,,1,,In vivo,CHEMBL622980,,Intermediate,A,,1,,N,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,,50597,BAO_0000218
7900,,,,1,,In vivo,CHEMBL622981,,Intermediate,A,,1,,N,Plasma administration to rats,,,50597,BAO_0000218
7901,,,,1,,In vivo,CHEMBL622982,,Intermediate,A,,1,,N,Plasma clearance of the compound in female Sprague-Dawley rats,,,50597,BAO_0000218
7902,,,,1,,In vivo,CHEMBL622983,,Intermediate,A,,1,,N,Plasma clearance was observed after intravenous administration in rat,,,50597,BAO_0000218
7903,,,,1,,In vivo,CHEMBL622984,,Intermediate,A,,1,,N,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,,50597,BAO_0000218
7904,,,,1,,In vivo,CHEMBL622985,,Intermediate,A,,1,,N,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,,50597,BAO_0000218
7905,,,1969.0,1,Plasma,In vivo,CHEMBL623631,,Intermediate,A,,1,,N,plasma clearance was observed after intravenous administration in rat,,,50597,BAO_0000218
7906,,,,1,,In vivo,CHEMBL623632,,Intermediate,A,,1,,N,In vivo CL/F determined,,,50597,BAO_0000218
7907,,,1969.0,1,Plasma,In vivo,CHEMBL623633,,Intermediate,A,,1,,N,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,,,50597,BAO_0000218
7908,,,1969.0,1,Plasma,In vivo,CHEMBL623634,,Intermediate,A,,1,,N,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,,,50597,BAO_0000218
7909,,,,1,,In vivo,CHEMBL623635,,Intermediate,A,,1,,N,Compound was tested for the lower blood clearance in rat,,,50597,BAO_0000218
7910,,,,1,,In vivo,CHEMBL621195,,Intermediate,A,,1,,N,Evaluated for the low clearance in rat (in vivo),,,50597,BAO_0000218
7911,,,,1,,In vivo,CHEMBL621196,,Intermediate,A,,1,,N,Pharmacokinetic property (CLb)of the compound was determined in rat,,,50597,BAO_0000218
7912,,,,1,,In vivo,CHEMBL875287,,Intermediate,A,,1,,N,Rapid clearance after intravenous administration in rat was determined,,,50597,BAO_0000218
7913,,,,1,,In vivo,CHEMBL621197,,Intermediate,A,,1,,N,Clearance measured in rat,,,50597,BAO_0000218
7914,,,1969.0,1,Plasma,In vivo,CHEMBL621198,,Intermediate,A,,1,,N,Compound was evaluated for plasma clearance in rat,,,50597,BAO_0000218
7915,,,1969.0,1,Plasma,In vivo,CHEMBL621199,,Intermediate,A,,1,,N,Low plasma clearance was calculated in rat,,,50597,BAO_0000218
7916,,,,1,,In vivo,CHEMBL621200,,Intermediate,A,,1,,N,Pharmacokinetic property (Clp) in rat,,,50597,BAO_0000218
7917,,,,1,,In vivo,CHEMBL621201,,Intermediate,A,,1,,N,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,,50597,BAO_0000218
7918,,,,1,,In vivo,CHEMBL621202,,Intermediate,A,,1,,N,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,,50597,BAO_0000218
7919,,,,1,,In vivo,CHEMBL621203,,Intermediate,A,,1,,N,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,,50597,BAO_0000218
7920,,,,1,,In vivo,CHEMBL621204,,Intermediate,A,,1,,N,Plasma clearance after IV dosing at 1 mg/kg in rat,,,50597,BAO_0000218
7921,,,948.0,1,Heart,In vivo,CHEMBL621205,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,,,50597,BAO_0000218
7922,,,948.0,1,Heart,In vivo,CHEMBL621206,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,,,50597,BAO_0000218
7923,,,948.0,1,Heart,In vivo,CHEMBL621207,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,,,50597,BAO_0000218
7924,,,948.0,1,Heart,In vivo,CHEMBL621208,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,,,50597,BAO_0000218
7925,,,948.0,1,Heart,In vivo,CHEMBL621209,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,,,50597,BAO_0000218
7926,,,948.0,1,Heart,In vivo,CHEMBL876484,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,,,50597,BAO_0000218
7927,,,948.0,1,Heart,In vivo,CHEMBL621210,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,,50597,BAO_0000218
7928,,,948.0,1,Heart,In vivo,CHEMBL621211,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,,,50597,BAO_0000218
7929,,,948.0,1,Heart,In vivo,CHEMBL621212,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,,,50597,BAO_0000218
7930,,,948.0,1,Heart,In vivo,CHEMBL621213,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA at 15 min,,,50597,BAO_0000218
7931,,,948.0,1,Heart,In vivo,CHEMBL621214,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,,,50597,BAO_0000218
7932,,,948.0,1,Heart,In vivo,CHEMBL621215,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA at 30 min,,,50597,BAO_0000218
7933,,,948.0,1,Heart,In vivo,CHEMBL621216,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,,,50597,BAO_0000218
7934,,,948.0,1,Heart,In vivo,CHEMBL621217,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,,,50597,BAO_0000218
7935,,,948.0,1,Heart,In vivo,CHEMBL621218,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,,,50597,BAO_0000218
7936,,,948.0,1,Heart,In vivo,CHEMBL621219,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,,,50597,BAO_0000218
7937,,,948.0,1,Heart,In vivo,CHEMBL621220,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,,,50597,BAO_0000218
7938,,,948.0,1,Heart,In vivo,CHEMBL621221,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,,,50597,BAO_0000218
7939,,,948.0,1,Heart,In vivo,CHEMBL621222,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,,,50597,BAO_0000218
7940,,,948.0,1,Heart,In vivo,CHEMBL621223,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,,,50597,BAO_0000218
7941,,,948.0,1,Heart,In vivo,CHEMBL876485,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,,,50597,BAO_0000218
7942,,,948.0,1,Heart,In vivo,CHEMBL621224,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,,50597,BAO_0000218
7943,,,948.0,1,Heart,In vivo,CHEMBL621225,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,,,50597,BAO_0000218
7944,,,948.0,1,Heart,In vivo,CHEMBL621226,,Intermediate,A,,1,,N,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,,,50597,BAO_0000218
7945,,,2113.0,1,Kidney,In vivo,CHEMBL621227,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,,,50597,BAO_0000218
7946,,,2113.0,1,Kidney,In vivo,CHEMBL621228,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,,,50597,BAO_0000218
7947,,,2113.0,1,Kidney,In vivo,CHEMBL621229,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,,,50597,BAO_0000218
7948,,,2113.0,1,Kidney,In vivo,CHEMBL621230,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,,,50597,BAO_0000218
7949,,,2113.0,1,Kidney,In vivo,CHEMBL621231,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,,,50597,BAO_0000218
7950,,,2113.0,1,Kidney,In vivo,CHEMBL621232,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,,,50597,BAO_0000218
7951,,,2113.0,1,Kidney,In vivo,CHEMBL621233,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,,50597,BAO_0000218
7952,,,2113.0,1,Kidney,In vivo,CHEMBL621234,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,,,50597,BAO_0000218
7953,,,2113.0,1,Kidney,In vivo,CHEMBL621235,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,,50597,BAO_0000218
7954,,,2113.0,1,Kidney,In vivo,CHEMBL621236,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,,50597,BAO_0000218
7955,,,2113.0,1,Kidney,In vivo,CHEMBL621237,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,,,50597,BAO_0000218
7956,,,2113.0,1,Kidney,In vivo,CHEMBL876486,,Intermediate,A,,1,,N,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,,,50597,BAO_0000218
7957,,,160.0,1,Intestine,In vivo,CHEMBL622436,,Intermediate,A,,1,,N,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,,,50597,BAO_0000218
7958,,,160.0,1,Intestine,In vivo,CHEMBL622437,,Intermediate,A,,1,,N,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,,,50597,BAO_0000218
7959,,,160.0,1,Intestine,In vivo,CHEMBL622438,,Intermediate,A,,1,,N,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,,,50597,BAO_0000218
7960,,,2107.0,1,Liver,In vivo,CHEMBL622439,,Intermediate,A,,1,,N,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,,,50597,BAO_0000218
7961,,,2107.0,1,Liver,In vivo,CHEMBL622440,,Intermediate,A,,1,,N,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,,,50597,BAO_0000218
7962,,,2107.0,1,Liver,In vivo,CHEMBL622441,,Intermediate,A,,1,,N,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,,,50597,BAO_0000218
7963,,,2107.0,1,Liver,In vivo,CHEMBL622442,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,,,50597,BAO_0000218
7964,,,2107.0,1,Liver,In vivo,CHEMBL622443,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,,,50597,BAO_0000218
7965,,,2107.0,1,Liver,In vivo,CHEMBL622444,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,,,50597,BAO_0000218
7966,,,2107.0,1,Liver,In vivo,CHEMBL622445,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,,,50597,BAO_0000218
7967,,,2107.0,1,Liver,In vivo,CHEMBL622446,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,,,50597,BAO_0000218
7968,,,2107.0,1,Liver,In vivo,CHEMBL622447,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,,50597,BAO_0000218
7969,,,2107.0,1,Liver,In vivo,CHEMBL622448,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,,,50597,BAO_0000218
7970,,,2107.0,1,Liver,In vivo,CHEMBL622449,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,,50597,BAO_0000218
7971,,,2107.0,1,Liver,In vivo,CHEMBL622450,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,,,50597,BAO_0000218
7972,,,2107.0,1,Liver,In vivo,CHEMBL622451,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,,,50597,BAO_0000218
7973,,,2107.0,1,Liver,In vivo,CHEMBL622452,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA at 15 min,,,50597,BAO_0000218
7974,,,2107.0,1,Liver,In vivo,CHEMBL622453,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,,,50597,BAO_0000218
7975,,,2107.0,1,Liver,In vivo,CHEMBL622454,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA at 30 min,,,50597,BAO_0000218
7976,,,2107.0,1,Liver,In vivo,CHEMBL622455,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,,,50597,BAO_0000218
7977,,,2107.0,1,Liver,In vivo,CHEMBL876024,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,,,50597,BAO_0000218
7978,,,,1,,In vivo,CHEMBL622456,,Intermediate,A,,1,,N,T max was determined at 3 mg/kg po dose in rats,,,50597,BAO_0000218
7979,,,,1,,In vivo,CHEMBL622457,,Intermediate,A,,1,,N,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
7980,,,,1,,In vivo,CHEMBL622458,,Intermediate,A,,1,,N,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
7981,,,,1,,,CHEMBL622459,,Intermediate,A,,1,,N,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,,50597,BAO_0000218
7982,,,,1,,,CHEMBL873343,,Intermediate,A,,1,,N,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,,50597,BAO_0000218
7983,,,,1,,,CHEMBL622460,,Intermediate,A,,1,,N,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,,50597,BAO_0000218
7984,,,1969.0,1,Plasma,,CHEMBL622461,,Intermediate,A,,1,,N,Time for maximum plasma concentration determined in rat,,,50597,BAO_0000218
7985,,,1969.0,1,Plasma,In vivo,CHEMBL622462,,Intermediate,A,,1,,N,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,,50597,BAO_0000218
7986,,,,1,,In vivo,CHEMBL622463,,Intermediate,A,,1,,N,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,,50597,BAO_0000218
7987,,,,1,,In vivo,CHEMBL622464,,Intermediate,A,,1,,N,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,,50597,BAO_0000218
7988,,,,1,,In vivo,CHEMBL622465,,Intermediate,A,,1,,N,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,,50597,BAO_0000218
7989,,,,1,,In vivo,CHEMBL622466,,Intermediate,A,,1,,N,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,,50597,BAO_0000218
7990,,,,1,,In vivo,CHEMBL622467,,Intermediate,A,,1,,N,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,,50597,BAO_0000218
7991,,,1969.0,1,Plasma,,CHEMBL622468,,Intermediate,A,,1,,N,Time of maximum plasma concentration in rat,,,50597,BAO_0000218
7992,,,1969.0,1,Plasma,,CHEMBL876025,,Intermediate,A,,1,,N,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,,50597,BAO_0000218
7993,,,1969.0,1,Plasma,,CHEMBL622469,,Intermediate,A,,1,,N,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,,50597,BAO_0000218
7994,,,1969.0,1,Plasma,,CHEMBL622470,,Intermediate,A,,1,,N,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,,50597,BAO_0000218
7995,,,,1,,In vivo,CHEMBL622471,,Intermediate,A,,1,,N,Time required to reach maximum concentration (Cmax) after oral administration in rat,,,50597,BAO_0000218
7996,,,1969.0,1,Plasma,,CHEMBL622472,,Intermediate,A,,1,,N,Time required to reach maximum concentration in rat plasma,,,50597,BAO_0000218
7997,,,1969.0,1,Plasma,In vivo,CHEMBL622473,,Intermediate,A,,1,,N,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,,50597,BAO_0000218
7998,,,1969.0,1,Plasma,In vivo,CHEMBL624282,,Intermediate,A,,1,,N,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,,50597,BAO_0000218
7999,,,1969.0,1,Plasma,In vivo,CHEMBL624283,,Intermediate,A,,1,,N,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,,50597,BAO_0000218
8000,,,1969.0,1,Plasma,In vivo,CHEMBL624284,,Intermediate,A,,1,,N,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,,50597,BAO_0000218
8001,,,1969.0,1,Plasma,In vivo,CHEMBL624285,,Intermediate,A,,1,,N,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,,50597,BAO_0000218
8002,,,,1,,In vivo,CHEMBL624286,,Intermediate,A,,1,,N,Time to reach Cmax after oral administration to rats,,,50597,BAO_0000218
8003,,,,1,,In vivo,CHEMBL624287,,Intermediate,A,,1,,N,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,,50597,BAO_0000218
8004,,,,1,,,CHEMBL624288,,Intermediate,A,,1,,N,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,,50597,BAO_0000218
8005,,,1969.0,1,Plasma,In vivo,CHEMBL624289,,Intermediate,A,,1,,N,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,,,50597,BAO_0000218
8006,,,1969.0,1,Plasma,In vivo,CHEMBL873344,,Intermediate,A,,1,,N,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,,,50597,BAO_0000218
8007,,,,1,,In vivo,CHEMBL619623,,Intermediate,A,,1,,N,Tmax after peroral administration (10 mg/kg) was determined in rat,,,50597,BAO_0000218
8008,,,,1,,In vivo,CHEMBL621399,,Expert,A,,1,,N,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,BAO_0000218
8009,,,,1,,In vivo,CHEMBL621400,,Intermediate,A,,1,,N,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,,50597,BAO_0000218
8010,,,,1,,In vivo,CHEMBL621401,,Intermediate,A,,1,,N,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,,50597,BAO_0000218
8011,,,,1,,,CHEMBL621402,,Intermediate,A,,1,,N,Tmax was determined,,,50597,BAO_0000218
8012,,,,1,,,CHEMBL621403,,Intermediate,A,,1,,N,Tmax was determined,,,50597,BAO_0000218
8013,,,,1,,In vivo,CHEMBL621121,,Intermediate,A,,1,,N,Tmax after oral administration in rat,,,50597,BAO_0000218
8014,,,,1,,In vivo,CHEMBL872525,,Intermediate,A,,1,,N,Tmax after peroral administration in rats at 2.4 uM/kg,,,50597,BAO_0000218
8015,,,,1,,,CHEMBL621122,,Intermediate,A,,1,,N,Tmax in male rat,,,50597,BAO_0000218
8016,,,,1,,In vivo,CHEMBL621123,,Intermediate,A,,1,,N,Tmax in rat at 10 mg/kg,,,50597,BAO_0000218
8017,,,,1,,In vivo,CHEMBL621124,,Intermediate,A,,1,,N,Tmax in rat by po administration at a dose of 40 mg/kg,,,50597,BAO_0000218
8018,,,,1,,,CHEMBL621125,,Intermediate,A,,1,,N,Tmax in rats,,,50597,BAO_0000218
8019,,,,1,,In vivo,CHEMBL621126,,Intermediate,A,,1,,N,Tmax was measured in rats after peroral administration at 5 mg/kg,,,50597,BAO_0000218
8020,,,,1,,In vivo,CHEMBL621127,,Intermediate,A,,1,,N,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,,50597,BAO_0000218
8021,,,,1,,In vivo,CHEMBL621128,,Intermediate,A,,1,,N,Tmax value after administration of 20 mg/Kg oral dose in rat,,,50597,BAO_0000218
8022,,,,1,,In vivo,CHEMBL618263,,Intermediate,A,,1,,N,Tmax value at a dose of 10 mg/kg in male SD rats,,,50597,BAO_0000218
8023,,,,1,,In vivo,CHEMBL618264,,Intermediate,A,,1,,N,Tmax value at a dose of 100 mg/kg in male SD rats,,,50597,BAO_0000218
8024,,,,1,,In vivo,CHEMBL618265,,Intermediate,A,,1,,N,Tmax value at a dose of 50 mg/kg in male SD rats,,,50597,BAO_0000218
8025,,,1969.0,1,Plasma,In vivo,CHEMBL618266,,Intermediate,A,,1,,N,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,50597,BAO_0000218
8026,,,,1,,In vivo,CHEMBL618267,,Intermediate,A,,1,,N,time required to reach maximum concentration (Cmax) after oral administration in rat,,,50597,BAO_0000218
8027,,,1088.0,1,Urine,,CHEMBL618450,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),,,50597,BAO_0000218
8028,,,1088.0,1,Urine,,CHEMBL618451,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),,,50597,BAO_0000218
8029,,,,1,,,CHEMBL618452,,Intermediate,A,,1,,N,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,,50597,BAO_0000218
8030,,,1088.0,1,Urine,,CHEMBL618453,,Intermediate,A,,1,,N,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,,,50597,BAO_0000218
8031,,,1088.0,1,Urine,,CHEMBL618454,,Intermediate,A,,1,,N,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,,,50597,BAO_0000218
8032,,,1088.0,1,Urine,,CHEMBL618455,,Intermediate,A,,1,,N,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,,,50597,BAO_0000218
8033,,,,1,,In vivo,CHEMBL618456,,Intermediate,A,,1,,N,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,,50597,BAO_0000218
8034,,,,1,,In vivo,CHEMBL618457,,Intermediate,A,,1,,N,Compound distribution in rat tissues was determined,,,50597,BAO_0000218
8035,,,,1,,In vivo,CHEMBL618458,,Intermediate,A,,1,,N,Volume of distribution was evaluated in rat,,,50597,BAO_0000218
8036,,,,1,,,CHEMBL618459,,Intermediate,A,,1,,N,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,,50597,BAO_0000218
8037,,,,1,,,CHEMBL876733,,Intermediate,A,,1,,N,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,,50597,BAO_0000218
8038,,,,1,,,CHEMBL618460,,Intermediate,A,,1,,N,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,,50588,BAO_0000218
8039,,,,1,,,CHEMBL618461,,Intermediate,A,,1,,N,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,,50597,BAO_0000218
8040,,,,0,,,CHEMBL618462,,Autocuration,A,,1,,U,Area under the curve was determined after oral administration (300 uM/Kg),,,22224,BAO_0000019
8041,,,,1,,,CHEMBL618463,,Intermediate,A,,1,,N,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,,50597,BAO_0000218
8042,,,,1,,,CHEMBL618464,,Intermediate,A,,1,,N,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,,50597,BAO_0000218
8043,,,,1,,,CHEMBL618465,,Intermediate,A,,1,,N,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,,50597,BAO_0000218
8044,,,,1,,,CHEMBL618466,,Intermediate,A,,1,,N,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,,50597,BAO_0000218
8045,,,,1,,,CHEMBL618467,,Intermediate,A,,1,,N,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,,50597,BAO_0000218
8046,,,,1,,,CHEMBL618468,,Intermediate,A,,1,,N,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,,50597,BAO_0000218
8047,,,1969.0,1,Plasma,,CHEMBL618469,,Intermediate,A,,1,,N,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,,,50588,BAO_0000218
8048,,,1969.0,1,Plasma,,CHEMBL618470,,Intermediate,A,,1,,N,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,,,50588,BAO_0000218
8049,,,,0,,,CHEMBL618471,,Autocuration,A,,1,,U,Plasma drug AUC in rat (PO dose),,,22224,BAO_0000218
8050,,,,1,,,CHEMBL618472,,Intermediate,A,,1,,N,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,,50594,BAO_0000218
8051,,,,0,,,CHEMBL618473,,Autocuration,A,,1,,U,Area under was determined at a dose of 30 mg/kg,,,22224,BAO_0000218
8052,,,,1,,,CHEMBL621699,,Intermediate,A,,1,,N,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,,50506,BAO_0000218
8053,,,,1,,,CHEMBL621700,,Intermediate,A,,1,,N,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,,50597,BAO_0000218
8054,,,,1,,,CHEMBL621701,,Intermediate,A,,1,,N,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,,50597,BAO_0000218
8055,,,,1,,,CHEMBL621702,,Intermediate,A,,1,,N,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,,50506,BAO_0000218
8056,,,,1,,,CHEMBL621703,,Intermediate,A,,1,,N,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,,50588,BAO_0000218
8057,,,,1,,,CHEMBL621704,,Intermediate,A,,1,,N,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,,50588,BAO_0000218
8058,,,,1,,,CHEMBL624259,,Intermediate,A,,1,,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,,50597,BAO_0000218
8059,,,,1,,,CHEMBL624260,,Intermediate,A,,1,,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,,50597,BAO_0000218
8060,,,,1,,,CHEMBL624430,,Intermediate,A,,1,,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,,50597,BAO_0000218
8061,,,,1,,,CHEMBL624431,,Intermediate,A,,1,,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,,50597,BAO_0000218
8062,,,,1,,,CHEMBL624432,,Intermediate,A,,1,,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,,50597,BAO_0000218
8063,,,,1,,,CHEMBL624433,,Intermediate,A,,1,,N,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,,50597,BAO_0000218
8064,,,,1,,,CHEMBL624434,,Intermediate,A,,1,,N,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,,50597,BAO_0000218
8065,,,,1,,,CHEMBL624435,,Intermediate,A,,1,,N,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,,50597,BAO_0000218
8066,,,,1,,,CHEMBL618570,,Intermediate,A,,1,,N,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,,50594,BAO_0000218
8067,,,,1,,,CHEMBL618571,,Intermediate,A,,1,,N,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,50594,BAO_0000218
8068,,,,1,,,CHEMBL618572,,Intermediate,A,,1,,N,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,,50594,BAO_0000218
8069,,,,1,,,CHEMBL618573,,Intermediate,A,,1,,N,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,50594,BAO_0000218
8070,,,,1,,,CHEMBL619267,,Intermediate,A,,1,,N,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,,50594,BAO_0000218
8071,,,,1,,,CHEMBL619431,,Intermediate,A,,1,,N,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,50594,BAO_0000218
8072,,,,1,,,CHEMBL619432,,Intermediate,A,,1,,N,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,,50594,BAO_0000218
8073,,,,1,,,CHEMBL619433,,Intermediate,A,,1,,N,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,50594,BAO_0000218
8074,,,1969.0,0,Plasma,,CHEMBL619434,,Autocuration,A,,1,,U,AUC in mice after oral dose (50 mg/kg),,,22224,BAO_0000218
8075,,,1977.0,1,Serum,,CHEMBL619435,,Intermediate,A,,1,,N,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,,,50594,BAO_0000218
8076,,,1969.0,0,Plasma,,CHEMBL619436,,Autocuration,A,,1,,U,AUC (0-4 hr) ug/ml/h,,,22224,BAO_0000019
8077,,,,1,,,CHEMBL619437,,Intermediate,A,,1,,N,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,,50597,BAO_0000218
8078,,,,0,,,CHEMBL619438,,Autocuration,A,,1,,U,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,,22224,BAO_0000218
8079,,,,1,,,CHEMBL619439,,Intermediate,A,,1,,N,Compound was evaluated for Area under curve in mice,,,50594,BAO_0000218
8080,,,,1,,,CHEMBL619440,,Intermediate,A,,1,,N,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,50597,BAO_0000218
8081,,,,0,,,CHEMBL619441,,Autocuration,F,,1,,U,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,22224,BAO_0000218
8082,,,,1,,,CHEMBL619442,,Intermediate,A,,1,,N,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,,50597,BAO_0000218
8083,,,,0,,,CHEMBL875156,,Autocuration,A,,1,,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,,22224,BAO_0000019
8084,,,,0,,,CHEMBL619443,,Autocuration,A,,1,,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,,22224,BAO_0000019
8085,,,,0,,,CHEMBL619444,,Autocuration,A,,1,,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,,22224,BAO_0000019
8086,,,,0,,,CHEMBL623464,,Autocuration,A,,1,,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,,22224,BAO_0000019
8087,,,,1,,,CHEMBL623465,,Intermediate,A,,1,,N,Compound was evaluated for area under curve when administered through oral route in mouse,,,50594,BAO_0000218
8088,,,,1,,In vivo,CHEMBL623466,,Intermediate,A,,1,,N,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,,50597,BAO_0000218
8089,,,,1,,In vivo,CHEMBL623467,,Intermediate,A,,1,,N,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,,50597,BAO_0000218
8090,,,,1,,In vivo,CHEMBL623468,,Intermediate,A,,1,,N,Plasma clearance in rat,,,50597,BAO_0000218
8091,,,,1,,In vivo,CHEMBL622660,,Intermediate,A,,1,,N,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,,50597,BAO_0000218
8092,,,,1,,In vivo,CHEMBL622661,,Intermediate,A,,1,,N,Plasma clearance rate in Sprague-Dawley rats,,,50597,BAO_0000218
8093,,,,1,,In vivo,CHEMBL622662,,Intermediate,F,,1,,N,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,,50597,BAO_0000218
8094,,,,1,,In vivo,CHEMBL622663,,Intermediate,A,,1,,N,Pharmacokinetic property (total body clearance) in rat,,,50597,BAO_0000218
8095,,,,1,,In vivo,CHEMBL622664,,Intermediate,A,,1,,N,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,,50597,BAO_0000218
8096,,,,1,,,CHEMBL622665,,Intermediate,A,,1,,N,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,,50597,BAO_0000218
8097,,,,1,,,CHEMBL622666,,Intermediate,A,,1,,N,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,,50597,BAO_0000218
8098,,,,1,,In vivo,CHEMBL621615,,Intermediate,A,,1,,N,Cl in rat i.v. at 2 mg/kg concentration,,,50597,BAO_0000218
8099,,,,1,,In vivo,CHEMBL621616,,Intermediate,A,,1,,N,Clearance of compound after intravenous administration in rats at 24 uM/kg,,,50597,BAO_0000218
8100,,,,1,,In vivo,CHEMBL621617,,Intermediate,A,,1,,N,Clearance was determined,,,50597,BAO_0000218
8101,,,,1,,In vivo,CHEMBL621618,,Intermediate,A,,1,,N,Clearance by intravenous administration of 3.4 mg/kg in rat,,,50597,BAO_0000218
8102,,,,1,,In vivo,CHEMBL621619,,Intermediate,A,,1,,N,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,,50597,BAO_0000218
8103,,,,1,,In vivo,CHEMBL621620,,Intermediate,A,,1,,N,Clearance rate after i.v. administration in rats,,,50597,BAO_0000218
8104,,,,1,,In vivo,CHEMBL621786,,Intermediate,A,,1,,N,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,50597,BAO_0000218
8105,,,,1,,In vivo,CHEMBL621787,,Intermediate,A,,1,,N,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,,50597,BAO_0000218
8106,,,,1,,In vivo,CHEMBL621788,,Intermediate,A,,1,,N,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,,50597,BAO_0000218
8107,,,,1,,In vivo,CHEMBL621789,,Intermediate,A,,1,,N,Clearance (Cl) after oral administration in rat,,,50597,BAO_0000218
8108,,,,1,,In vivo,CHEMBL621790,,Intermediate,A,,1,,N,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,,50597,BAO_0000218
8109,,,1969.0,1,Plasma,In vivo,CHEMBL621791,,Intermediate,A,,1,,N,Compound was tested for plasma clearance in rat,,,50597,BAO_0000218
8110,,,,1,,In vitro,CHEMBL621792,,Intermediate,A,,1,Microsomes,N,In vitro microsome metabolism clearance in rat was determined,,,50597,BAO_0000218
8111,,,,1,,In vitro,CHEMBL621793,,Intermediate,A,,1,Microsomes,N,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,,50597,BAO_0000218
8112,,,,1,,In vivo,CHEMBL621794,,Intermediate,A,,1,,N,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
8113,,,1969.0,1,Plasma,In vivo,CHEMBL621795,,Intermediate,A,,1,,N,In vivo plasma clearance was determined,,,50597,BAO_0000218
8114,,,,1,,In vivo,CHEMBL621796,,Intermediate,A,,1,,N,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,,50597,BAO_0000218
8115,401.0,,2107.0,1,Liver,In vivo,CHEMBL621797,,Intermediate,A,,1,,N,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,,Hepatocyte,50597,BAO_0000218
8116,,,,1,,In vivo,CHEMBL621798,,Intermediate,A,,1,,N,Pharmacokinetic property (Plasma clearance) was measured in rat,,,50597,BAO_0000218
8117,,,,1,,In vivo,CHEMBL621799,,Intermediate,A,,1,,N,Pharmacokinetic property (clearance) in rat i.v.,,,50597,BAO_0000218
8118,,,,1,,In vivo,CHEMBL621800,,Intermediate,A,,1,,N,"Plasma Clearance was evaluated in rats, iv",,,50597,BAO_0000218
8119,,,,1,,In vivo,CHEMBL621801,,Intermediate,A,,1,,N,Plasma clearance (in vivo) in rats was determined,,,50597,BAO_0000218
8120,,,,1,,In vivo,CHEMBL621802,,Intermediate,A,,1,,N,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,,50597,BAO_0000218
8121,,,,1,,In vivo,CHEMBL618596,,Intermediate,A,,1,,N,Plasma clearance was determined,,,50597,BAO_0000218
8122,,,,1,,In vivo,CHEMBL618597,,Intermediate,A,,1,,N,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,,50597,BAO_0000218
8123,,,,1,,In vivo,CHEMBL618598,,Intermediate,A,,1,,N,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,,50597,BAO_0000218
8124,,,,1,,In vivo,CHEMBL618599,,Intermediate,A,,1,,N,Plasma clearance in rats,,,50597,BAO_0000218
8125,,,,1,,In vivo,CHEMBL618600,,Intermediate,A,,1,,N,Plasma clearance rate determined in rat,,,50597,BAO_0000218
8126,,,,1,,In vivo,CHEMBL618601,,Intermediate,A,,1,,N,Plasma clearance was determined in rat,,,50597,BAO_0000218
8127,,,,1,,In vivo,CHEMBL618602,,Intermediate,A,,1,,N,Plasma clearance was determined,,,50597,BAO_0000218
8128,,,,1,,In vivo,CHEMBL618603,,Intermediate,A,,1,,N,Plasma clearance value in rat,,,50597,BAO_0000218
8129,,,2107.0,1,Liver,Ex vivo,CHEMBL618604,,Intermediate,A,,1,,N,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,,50597,BAO_0000218
8130,,,,1,,In vivo,CHEMBL618605,,Intermediate,A,,1,,N,Clearance in rat,,,50597,BAO_0000218
8131,,,,1,,In vivo,CHEMBL618606,,Intermediate,A,,1,,N,Total body clearance in rat i.v. at 2 mg/kg concentration,,,50597,BAO_0000218
8132,,,,1,,In vivo,CHEMBL618607,,Intermediate,A,,1,,N,Clearance of compound in rats after intravenous administration,,,50597,BAO_0000218
8133,,,,1,,In vivo,CHEMBL618608,,Intermediate,A,,1,,N,Clearance after iv administration to rats,,,50597,BAO_0000218
8134,,,,1,,In vivo,CHEMBL618609,,Intermediate,A,,1,,N,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,,50597,BAO_0000218
8135,,,,1,,In vivo,CHEMBL618610,,Intermediate,A,,1,,N,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,,50597,BAO_0000218
8136,,,,1,,In vivo,CHEMBL618611,,Intermediate,A,,1,,N,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,,50597,BAO_0000218
8137,,,,1,,In vivo,CHEMBL618612,,Intermediate,A,,1,,N,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,,50597,BAO_0000218
8138,,,,1,,In vivo,CHEMBL618613,,Intermediate,A,,1,,N,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,,50597,BAO_0000218
8139,,,,1,,In vivo,CHEMBL621076,,Intermediate,A,,1,,N,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,,50597,BAO_0000218
8140,,,,1,,In vivo,CHEMBL621077,,Intermediate,A,,1,,N,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,,50597,BAO_0000218
8141,,,,1,,In vivo,CHEMBL621078,,Intermediate,A,,1,,N,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,,50597,BAO_0000218
8142,,,,1,,In vivo,CHEMBL621251,,Intermediate,A,,1,,N,Clearance in rat,,,50597,BAO_0000218
8143,,,,1,,In vivo,CHEMBL621252,,Intermediate,A,,1,,N,Clearance in rat after oral administration at 10 mg/kg,,,50597,BAO_0000218
8144,,,,1,,In vivo,CHEMBL621253,,Intermediate,A,,1,,N,Clearance in rat.,,,50597,BAO_0000218
8145,,,,1,,In vivo,CHEMBL621254,,Intermediate,A,,1,,N,Clearance rate following an oral dose of 20 mg/kg in rats,,,50597,BAO_0000218
8146,,,,1,,In vivo,CHEMBL621255,,Intermediate,A,,1,,N,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,,50597,BAO_0000218
8147,,,1969.0,1,Plasma,In vivo,CHEMBL621256,,Intermediate,A,,1,,N,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,,,50597,BAO_0000218
8148,,,2107.0,1,Liver,In vivo,CHEMBL621257,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,,,50597,BAO_0000218
8149,,,2107.0,1,Liver,In vivo,CHEMBL621258,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,,,50597,BAO_0000218
8150,,,2107.0,1,Liver,In vivo,CHEMBL621259,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,,,50597,BAO_0000218
8151,,,2107.0,1,Liver,In vivo,CHEMBL621260,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,,,50597,BAO_0000218
8152,,,2107.0,1,Liver,In vivo,CHEMBL876494,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,,,50597,BAO_0000218
8153,,,2107.0,1,Liver,In vivo,CHEMBL621261,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,,,50597,BAO_0000218
8154,,,2107.0,1,Liver,In vivo,CHEMBL621262,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,,,50597,BAO_0000218
8155,,,2107.0,1,Liver,In vivo,CHEMBL621263,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,,50597,BAO_0000218
8156,,,2107.0,1,Liver,In vivo,CHEMBL621264,,Intermediate,A,,1,,N,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,,,50597,BAO_0000218
8157,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621265,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,,,50597,BAO_0000218
8158,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621266,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,,,50597,BAO_0000218
8159,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621267,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,,,50597,BAO_0000218
8160,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621268,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,,,50597,BAO_0000218
8161,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621269,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,,,50597,BAO_0000218
8162,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621270,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,,,50597,BAO_0000218
8163,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621271,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,,,50597,BAO_0000218
8164,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621272,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,,,50597,BAO_0000218
8165,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621273,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,,,50597,BAO_0000218
8166,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621274,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,,,50597,BAO_0000218
8167,,,2385.0,1,Muscle tissue,In vivo,CHEMBL876495,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,,,50597,BAO_0000218
8168,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621275,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,,,50597,BAO_0000218
8169,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621276,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,,,50597,BAO_0000218
8170,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621277,,Intermediate,A,,1,,N,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,,,50597,BAO_0000218
8171,,,160.0,1,Intestine,In vivo,CHEMBL621278,,Intermediate,A,,1,,N,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,,,50597,BAO_0000218
8172,,,160.0,1,Intestine,In vivo,CHEMBL621279,,Intermediate,A,,1,,N,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,,,50597,BAO_0000218
8173,,,160.0,1,Intestine,In vivo,CHEMBL621280,,Intermediate,A,,1,,N,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),,,50597,BAO_0000218
8174,,,2106.0,1,Spleen,In vivo,CHEMBL621281,,Intermediate,A,,1,,N,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,,,50597,BAO_0000218
8175,,,2106.0,1,Spleen,In vivo,CHEMBL621282,,Intermediate,A,,1,,N,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,,,50597,BAO_0000218
8176,,,2106.0,1,Spleen,In vivo,CHEMBL621283,,Intermediate,A,,1,,N,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,,,50597,BAO_0000218
8177,,,2106.0,1,Spleen,In vivo,CHEMBL621284,,Intermediate,A,,1,,N,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,,,50597,BAO_0000218
8178,,,2106.0,1,Spleen,In vivo,CHEMBL621285,,Intermediate,A,,1,,N,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,,,50597,BAO_0000218
8179,,,2106.0,1,Spleen,In vivo,CHEMBL621286,,Intermediate,A,,1,,N,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,,,50597,BAO_0000218
8180,,,2106.0,1,Spleen,In vivo,CHEMBL623220,,Intermediate,A,,1,,N,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,,,50597,BAO_0000218
8181,,,2106.0,1,Spleen,In vivo,CHEMBL623221,,Intermediate,A,,1,,N,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,,,50597,BAO_0000218
8182,,,2106.0,1,Spleen,In vivo,CHEMBL876029,,Intermediate,A,,1,,N,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,,,50597,BAO_0000218
8183,,,945.0,1,Stomach,In vivo,CHEMBL623222,,Intermediate,A,,1,,N,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,,,50597,BAO_0000218
8184,,,945.0,1,Stomach,In vivo,CHEMBL623223,,Intermediate,A,,1,,N,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,,,50597,BAO_0000218
8185,,,945.0,1,Stomach,In vivo,CHEMBL621445,,Intermediate,A,,1,,N,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,,,50597,BAO_0000218
8186,,,178.0,1,Blood,In vivo,CHEMBL621446,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8187,,,178.0,1,Blood,In vivo,CHEMBL621447,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8188,,,178.0,1,Blood,In vivo,CHEMBL619681,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8189,,,178.0,1,Blood,In vivo,CHEMBL619682,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8190,,,178.0,1,Blood,In vivo,CHEMBL619683,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8191,,,955.0,1,Brain,In vivo,CHEMBL619684,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8192,,,955.0,1,Brain,In vivo,CHEMBL619685,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8193,,,955.0,1,Brain,In vivo,CHEMBL619686,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8194,,,955.0,1,Brain,In vivo,CHEMBL619687,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8195,,,955.0,1,Brain,In vivo,CHEMBL619688,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8196,,,948.0,1,Heart,In vivo,CHEMBL619689,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8197,,,948.0,1,Heart,In vivo,CHEMBL619690,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8198,,,948.0,1,Heart,In vivo,CHEMBL619691,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8199,,,,1,,In vivo,CHEMBL619692,,Intermediate,A,,1,,N,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,,50597,BAO_0000218
8200,,,,1,,,CHEMBL619693,,Expert,A,,1,,N,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,BAO_0000218
8201,,,,1,,In vivo,CHEMBL619694,,Intermediate,A,,1,,N,Vc value after IV dose at a dose of 5 mg/kg in rats.,,,50597,BAO_0000218
8202,,,,1,,In vivo,CHEMBL619695,,Intermediate,A,,1,,N,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,,50597,BAO_0000218
8203,,,,1,,In vivo,CHEMBL619696,,Intermediate,A,,1,,N,Compound was evaluated for pharmacokinetic parameter volume of distribution,,,50597,BAO_0000218
8204,,,,1,,In vivo,CHEMBL619697,,Intermediate,A,,1,,N,Compound was evaluated for volume of distribution in rat,,,50597,BAO_0000218
8205,,,,1,,In vivo,CHEMBL619698,,Intermediate,A,,1,,N,Steady state volume distribution was determined; steady state(ss),,,50597,BAO_0000218
8206,,,,1,,In vivo,CHEMBL619699,,Intermediate,A,,1,,N,Steady state volume of distribution after iv administration to rats,,,50597,BAO_0000218
8207,,,,1,,In vivo,CHEMBL619700,,Intermediate,A,,1,,N,Steady state volume of distribution dosing at 3 mg/kg iv,,,50597,BAO_0000218
8208,,,,1,,In vivo,CHEMBL619701,,Intermediate,A,,1,,N,The compound was evaluated for volume of distribution in rat,,,50597,BAO_0000218
8209,,,,1,,In vivo,CHEMBL619702,,Intermediate,A,,1,,N,The compound was tested for volume of distribution in rat,,,50597,BAO_0000218
8210,,,,1,,In vivo,CHEMBL620335,,Intermediate,A,,1,,N,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,,50597,BAO_0000218
8211,,,,1,,In vivo,CHEMBL620336,,Intermediate,A,,1,,N,Volume distribution (VD) after oral administration in rat,,,50597,BAO_0000218
8212,,,,1,,In vivo,CHEMBL620337,,Intermediate,A,,1,,N,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,50597,BAO_0000218
8213,,,,1,,In vivo,CHEMBL620520,,Intermediate,A,,1,,N,Volume distribution in rat,,,50597,BAO_0000218
8214,,,,1,,In vivo,CHEMBL620521,,Intermediate,A,,1,,N,Volume distribution in rat,,,50597,BAO_0000218
8215,,,,1,,In vivo,CHEMBL875825,,Intermediate,A,,1,,N,Volume distribution in rat after peroral administration at 10 mg/kg,,,50597,BAO_0000218
8216,,,,1,,In vivo,CHEMBL620522,,Intermediate,A,,1,,N,Volume distribution in rat after peroral administration at 5 mg/kg,,,50597,BAO_0000218
8217,,,,1,,In vivo,CHEMBL620523,,Intermediate,A,,1,,N,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,,50597,BAO_0000218
8218,,,,1,,In vivo,CHEMBL620524,,Intermediate,A,,1,,N,Volume of distribution in rat.,,,50597,BAO_0000218
8219,,,,1,,In vivo,CHEMBL620525,,Intermediate,A,,1,,N,Volume of distribution in rat,,,50597,BAO_0000218
8220,,,,1,,In vivo,CHEMBL620526,,Intermediate,A,,1,,N,Volume of distribution in rat,,,50597,BAO_0000218
8221,,,,1,,In vivo,CHEMBL620527,,Intermediate,A,,1,,N,Volume of distribution in rat by iv administration,,,50597,BAO_0000218
8222,,,,1,,In vivo,CHEMBL620528,,Intermediate,A,,1,,N,Volume of distribution in rats,,,50597,BAO_0000218
8223,,,,1,,In vivo,CHEMBL620529,,Intermediate,A,,1,,N,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,,50597,BAO_0000218
8224,,,,1,,,CHEMBL620530,,Intermediate,A,,1,,N,Volume distribution at the dose of 2 mg/kg in rat,,,50597,BAO_0000218
8225,,,,1,,In vivo,CHEMBL620531,,Intermediate,A,,1,,N,Steady state volume of distribution was determined,,,50597,BAO_0000218
8226,,,,0,,In vivo,CHEMBL620532,,Intermediate,A,,1,,U,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,22224,BAO_0000218
8227,,,,0,,In vivo,CHEMBL620533,,Intermediate,A,,1,,U,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,,22224,BAO_0000218
8228,,,,0,,In vivo,CHEMBL620534,,Intermediate,A,,1,,U,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,,22224,BAO_0000218
8229,,,,1,,In vivo,CHEMBL620535,,Intermediate,A,,1,,N,Mean (%CV) PK parameters for Vdss(mL/kg).,,,50597,BAO_0000218
8230,,,,1,,In vivo,CHEMBL875826,,Intermediate,A,,1,,N,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,,50597,BAO_0000218
8231,,,,1,,In vivo,CHEMBL620536,,Intermediate,A,,1,,N,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,,50597,BAO_0000218
8232,,,,1,,In vivo,CHEMBL620537,,Intermediate,A,,1,,N,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,,50597,BAO_0000218
8233,,,,1,,In vivo,CHEMBL618526,,Intermediate,A,,1,,N,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,,50597,BAO_0000218
8234,,,,1,,In vivo,CHEMBL618527,,Intermediate,A,,1,,N,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,,50597,BAO_0000218
8235,,,,1,,In vivo,CHEMBL618528,,Intermediate,A,,1,,N,Pharmacokinetic property (Vdss) in rat,,,50597,BAO_0000218
8236,,,,1,,In vivo,CHEMBL618529,,Intermediate,A,,1,,N,Pharmacokinetic property (vdss) was measured in rat,,,50597,BAO_0000218
8237,,,,1,,In vivo,CHEMBL618530,,Intermediate,A,,1,,N,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,,50597,BAO_0000218
8238,,,,1,,In vivo,CHEMBL618531,,Intermediate,A,,1,,N,Volume of distribution in rat,,,50597,BAO_0000218
8239,,,,1,,In vivo,CHEMBL618532,,Intermediate,A,,1,,N,The pharmacokinetic parameter volume of distribution in vivo in rats,,,50597,BAO_0000218
8240,,,,1,,In vivo,CHEMBL618533,,Intermediate,F,,1,,N,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,,50597,BAO_0000218
8241,,,,1,,In vivo,CHEMBL618534,,Intermediate,A,,1,,N,Vdss in rat i.v. at 2 mg/kg concentration,,,50597,BAO_0000218
8242,,,,1,,In vivo,CHEMBL618535,,Intermediate,A,,1,,N,Volume distribution after intravenous administration (1 mg/kg) in rat,,,50597,BAO_0000218
8243,,,,1,,In vivo,CHEMBL618536,,Intermediate,A,,1,,N,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,50597,BAO_0000218
8244,,,,1,,In vivo,CHEMBL618537,,Intermediate,A,,1,,N,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,50597,BAO_0000218
8245,,,,1,,In vivo,CHEMBL618538,,Intermediate,A,,1,,N,Volume distribution at a dose of 10 uM/kg in rat was determined,,,50597,BAO_0000218
8246,,,,1,,In vivo,CHEMBL618539,,Intermediate,A,,1,,N,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,50597,BAO_0000218
8247,,,,1,,In vivo,CHEMBL618540,,Intermediate,A,,1,,N,Volume distribution was calculated in rat,,,50597,BAO_0000218
8248,,,,1,,In vivo,CHEMBL618541,,Intermediate,A,,1,,N,Volume distribution was determined,,,50597,BAO_0000218
8249,,,,1,,In vivo,CHEMBL618542,,Intermediate,A,,1,,N,Volume of distribution after intravenous administration was evaluated in rat,,,50597,BAO_0000218
8250,,,,1,,In vivo,CHEMBL622544,,Intermediate,A,,1,,N,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50597,BAO_0000218
8251,,,,1,,In vivo,CHEMBL622545,,Intermediate,A,,1,,N,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,,50597,BAO_0000218
8252,,,,1,,In vivo,CHEMBL622546,,Intermediate,A,,1,,N,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,,50597,BAO_0000218
8253,,,,1,,In vivo,CHEMBL622547,,Intermediate,A,,1,,N,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,,50597,BAO_0000218
8254,,,,1,,In vivo,CHEMBL622548,,Intermediate,A,,1,,N,Volume of distribution in steady state was determined in rat,,,50597,BAO_0000218
8255,,,,1,,In vivo,CHEMBL622549,,Intermediate,A,,1,,N,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,,50597,BAO_0000218
8256,,,,1,,In vivo,CHEMBL622550,,Intermediate,A,,1,,N,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,,50597,BAO_0000218
8257,,,,1,,,CHEMBL622551,,Intermediate,A,,1,,N,Compound was evaluated for area under curve when administered through oral route to mouse,,,50594,BAO_0000218
8258,,,,1,,,CHEMBL622552,,Intermediate,A,,1,,N,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,50597,BAO_0000218
8259,,,,1,,,CHEMBL622553,,Intermediate,A,,1,,N,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,,50597,BAO_0000218
8260,,,,0,,In vivo,CHEMBL622554,,Autocuration,F,,1,,U,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,,22224,BAO_0000218
8261,,,,1,,,CHEMBL622555,,Intermediate,A,,1,,N,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,,50588,BAO_0000218
8262,,,,1,,,CHEMBL622556,,Intermediate,A,,1,,N,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,50594,BAO_0000218
8263,,,,1,,,CHEMBL622557,,Intermediate,A,,1,,N,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,50594,BAO_0000218
8264,,,178.0,1,Blood,,CHEMBL622558,,Intermediate,A,,1,,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,,,50594,BAO_0000218
8265,,,178.0,1,Blood,,CHEMBL622559,,Intermediate,A,,1,,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,,,50594,BAO_0000218
8266,,,,1,,,CHEMBL622560,,Intermediate,A,,1,,N,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,,50588,BAO_0000218
8267,,,,1,,,CHEMBL622561,,Intermediate,A,,1,,N,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,,50597,BAO_0000218
8268,,,,1,,,CHEMBL622562,,Intermediate,A,,1,,N,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,,50597,BAO_0000218
8269,,,,1,,,CHEMBL622563,,Intermediate,A,,1,,N,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,,50597,BAO_0000218
8270,,,,0,,,CHEMBL622564,,Autocuration,A,,1,,U,Concentration of compound in Central nervous system,,,22224,BAO_0000019
8271,,,,0,,,CHEMBL622565,,Autocuration,A,,1,,U,Concentration of compound in Central nervous system; Not detectable,,,22224,BAO_0000019
8272,,,,1,,,CHEMBL622566,,Intermediate,A,,1,,N,"Concentration of diester in the blood, following oral administration in mice",,,50594,BAO_0000218
8273,,,,1,,,CHEMBL624515,,Intermediate,A,,1,,N,"Concentration of monoester in the blood, following oral administration in mice",,,50594,BAO_0000218
8274,,,,1,,,CHEMBL624516,,Intermediate,A,,1,,N,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,,50594,BAO_0000218
8275,,,,0,,,CHEMBL624517,,Autocuration,A,,1,,U,Evaluated for Pharmacokinetic property: Area under the curve,,,22224,BAO_0000019
8276,,,,1,,,CHEMBL624518,,Intermediate,A,,1,,N,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,,50594,BAO_0000218
8277,,,,1,,,CHEMBL624519,,Intermediate,A,,1,,N,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,,100710,BAO_0000218
8278,,,,1,,,CHEMBL624520,,Intermediate,A,,1,,N,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,,100710,BAO_0000218
8279,,,,1,,,CHEMBL624521,,Intermediate,A,,1,,N,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,,100710,BAO_0000218
8280,,,,1,,,CHEMBL624522,,Intermediate,A,,1,,N,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,,100710,BAO_0000218
8281,,,,1,,,CHEMBL624523,,Intermediate,A,,1,,N,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,,100710,BAO_0000218
8282,,,,1,,,CHEMBL624409,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,100710,BAO_0000218
8283,,,,1,,,CHEMBL624410,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,,100710,BAO_0000218
8284,,,,1,,,CHEMBL624411,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,100710,BAO_0000218
8285,,,,1,,,CHEMBL623531,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,,100710,BAO_0000218
8286,,,,1,,,CHEMBL623532,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,,100710,BAO_0000218
8287,,,,1,,,CHEMBL623533,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,,100710,BAO_0000218
8288,,,,1,,,CHEMBL623534,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,100710,BAO_0000218
8289,,,,1,,,CHEMBL623535,,Intermediate,A,,1,,N,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,,50594,BAO_0000218
8290,,,,1,,,CHEMBL623536,,Intermediate,A,,1,,N,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,,50594,BAO_0000218
8291,,,,1,,,CHEMBL623537,,Intermediate,A,,1,,N,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,,50594,BAO_0000218
8292,,,,1,,,CHEMBL623538,,Intermediate,A,,1,,N,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,,50594,BAO_0000218
8293,,,,1,,,CHEMBL623539,,Intermediate,A,,1,,N,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,,50594,BAO_0000218
8294,,,,1,,,CHEMBL623540,,Intermediate,A,,1,,N,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,,50594,BAO_0000218
8295,,,,1,,,CHEMBL623541,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,,50594,BAO_0000218
8296,,,,1,,,CHEMBL623542,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,,50594,BAO_0000218
8297,,,,1,,,CHEMBL623543,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,,50594,BAO_0000218
8298,,,,1,,,CHEMBL623544,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,,50594,BAO_0000218
8299,,,,1,,,CHEMBL623545,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,,50594,BAO_0000218
8300,,,,1,,,CHEMBL623546,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,,50594,BAO_0000218
8301,,,1969.0,1,Plasma,In vivo,CHEMBL623547,,Intermediate,A,,1,,N,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,,,50597,BAO_0000218
8302,,,,1,,In vivo,CHEMBL623548,,Intermediate,A,,1,,N,High i.v. clearance in Dawley rats,,,50597,BAO_0000218
8303,,,2107.0,1,Liver,In vitro,CHEMBL623549,,Intermediate,A,,1,Microsomes,N,In vitro clearance in rat liver microsomes,,,50597,BAO_0000218
8304,,,2107.0,1,Liver,In vitro,CHEMBL623550,,Intermediate,A,,1,Microsomes,N,Intrinsic clearance in rat liver microsomes was determined,,,50597,BAO_0000218
8305,401.0,,2107.0,1,Liver,In vitro,CHEMBL875276,,Intermediate,A,,1,,N,Intrinsic clearance in rat hepatocytes was determined,,Hepatocyte,50597,BAO_0000218
8306,,,,1,,In vivo,CHEMBL621872,,Intermediate,A,,1,,N,Plasma Clearance was determined,,,50597,BAO_0000218
8307,,,,1,,In vivo,CHEMBL621873,,Intermediate,A,,1,,N,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,,50597,BAO_0000218
8308,,,,1,,In vivo,CHEMBL621874,,Intermediate,A,,1,,N,Plasma clearance in rat.,,,50597,BAO_0000218
8309,,,,1,,In vivo,CHEMBL621875,,Intermediate,A,,1,,N,Plasma clearance in rats,,,50597,BAO_0000218
8310,,,,1,,In vivo,CHEMBL621876,,Intermediate,A,,1,,N,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,,50597,BAO_0000218
8311,,,,1,,In vivo,CHEMBL621877,,Intermediate,A,,1,,N,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,,50597,BAO_0000218
8312,,,,1,,In vivo,CHEMBL621878,,Intermediate,A,,1,,N,Plasma clearance was measured in rat,,,50597,BAO_0000218
8313,,,,1,,In vivo,CHEMBL621879,,Intermediate,A,,1,,N,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,,50597,BAO_0000218
8314,,,1969.0,1,Plasma,In vivo,CHEMBL621880,,Intermediate,A,,1,,N,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",,,50597,BAO_0000218
8315,,,,1,,In vivo,CHEMBL621881,,Intermediate,A,,1,,N,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,,50597,BAO_0000218
8316,,,,1,,In vivo,CHEMBL621882,,Intermediate,A,,1,,N,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,50597,BAO_0000218
8317,,,,1,,In vivo,CHEMBL875283,,Intermediate,A,,1,,N,Total clearance at 1 mg/kg was determined in rat,,,50597,BAO_0000218
8318,,,,1,,In vivo,CHEMBL621883,,Intermediate,A,,1,,N,Total clearance at 10 mg/kg was determined in rat,,,50597,BAO_0000218
8319,,,,1,,In vivo,CHEMBL621884,,Intermediate,A,,1,,N,Clearance in rat,,,50597,BAO_0000218
8320,,,,1,,In vivo,CHEMBL621885,,Intermediate,A,,1,,N,Plasma clearance rate determined in rats,,,50597,BAO_0000218
8321,,,,1,,In vivo,CHEMBL621886,,Intermediate,A,,1,,N,Clearance of compound in rat was evaluated,,,50597,BAO_0000218
8322,,,1969.0,1,Plasma,In vivo,CHEMBL621887,,Intermediate,A,,1,,N,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,,50597,BAO_0000218
8323,,,,1,,In vivo,CHEMBL621888,,Intermediate,A,,1,,N,Pharmacokinetic property (blood clearance) in rat,,,50597,BAO_0000218
8324,,,,1,,In vivo,CHEMBL621889,,Intermediate,A,,1,,N,Plasma clearance in rat,,,50597,BAO_0000218
8325,,,,1,,In vivo,CHEMBL621890,,Intermediate,A,,1,,N,Plasma clearance in rats,,,50597,BAO_0000218
8326,,,2107.0,1,Liver,In vitro,CHEMBL621891,,Intermediate,A,,1,Microsomes,N,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,,,50597,BAO_0000218
8327,,,,1,,In vivo,CHEMBL621892,,Intermediate,A,,1,,N,Clearance in Dawley rat,,,50597,BAO_0000218
8328,,,,1,,In vivo,CHEMBL621893,,Intermediate,A,,1,,N,Clearance rat,,,50597,BAO_0000218
8329,,,,1,,In vivo,CHEMBL621894,,Intermediate,A,,1,,N,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,,50597,BAO_0000218
8330,,,,1,,In vivo,CHEMBL621895,,Intermediate,A,,1,,N,Clearance rat; Not determined,,,50597,BAO_0000218
8331,,,,1,,In vivo,CHEMBL875284,,Intermediate,A,,1,,N,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,,50597,BAO_0000218
8332,,,,1,,In vivo,CHEMBL618699,,Intermediate,A,,1,,N,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,,50597,BAO_0000218
8333,,,,1,,In vivo,CHEMBL618700,,Intermediate,A,,1,,N,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,,50597,BAO_0000218
8334,,,,1,,In vivo,CHEMBL618701,,Intermediate,A,,1,,N,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,,50597,BAO_0000218
8335,,,1969.0,1,Plasma,In vivo,CHEMBL876600,,Intermediate,A,,1,,N,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,,50597,BAO_0000218
8336,,,,1,,In vivo,CHEMBL618702,,Intermediate,A,,1,,N,Clearance of compound in rat after 1 mg/kg i.v. administration,,,50597,BAO_0000218
8337,,,,1,,In vivo,CHEMBL618703,,Intermediate,A,,1,,N,Compound was evaluated for Hepatic clearance in rat,,,50597,BAO_0000218
8338,,,,1,,In vivo,CHEMBL618704,,Intermediate,A,,1,,N,In vivo clearance after 5 mg/kg dose,,,50597,BAO_0000218
8339,,,1969.0,1,Plasma,In vivo,CHEMBL618705,,Intermediate,A,,1,,N,Compound was tested for plasma clearance in rats,,,50597,BAO_0000218
8340,,,,1,,In vivo,CHEMBL618706,,Intermediate,A,,1,,N,Hepatic clearance after intravenous administration was evaluated in rat,,,50597,BAO_0000218
8341,,,,1,,In vivo,CHEMBL618707,,Intermediate,A,,1,,N,Lower clearance in rat (i.v.) at 0.5 mpk,,,50597,BAO_0000218
8342,,,1969.0,1,Plasma,In vivo,CHEMBL618708,,Intermediate,A,,1,,N,Pharmacokinetic parameter expressed as plasma clearance in rat,,,50597,BAO_0000218
8343,,,,1,,In vivo,CHEMBL618709,,Intermediate,A,,1,,N,Pharmacokinetic property (Clp) in rat,,,50597,BAO_0000218
8344,,,,1,,In vivo,CHEMBL618710,,Intermediate,A,,1,,N,Plasma clearance in Sprague-Dawley rats,,,50597,BAO_0000218
8345,,,,1,,In vivo,CHEMBL618711,,Intermediate,A,,1,,N,Plasma clearance (Clp) in rat,,,50597,BAO_0000218
8346,,,,1,,In vivo,CHEMBL618712,,Intermediate,A,,1,,N,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,,50597,BAO_0000218
8347,,,,1,,In vivo,CHEMBL618713,,Intermediate,A,,1,,N,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,,50597,BAO_0000218
8348,,,,1,,In vivo,CHEMBL618714,,Intermediate,A,,1,,N,Plasma clearance after intravenous administration of 1 mg/kg in rat,,,50597,BAO_0000218
8349,,,,1,,In vivo,CHEMBL618715,,Intermediate,A,,1,,N,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,50597,BAO_0000218
8350,,,,1,,In vivo,CHEMBL618716,,Intermediate,A,,1,,N,Plasma clearance in rat was determined,,,50597,BAO_0000218
8351,,,,1,,In vivo,CHEMBL876601,,Intermediate,A,,1,,N,Plasma clearance measured in rat,,,50597,BAO_0000218
8352,,,,1,,In vivo,CHEMBL618717,,Intermediate,A,,1,,N,Plasma clearance was calculated in rat,,,50597,BAO_0000218
8353,,,,1,,In vivo,CHEMBL618718,,Intermediate,A,,1,,N,Plasma clearance in rat,,,50597,BAO_0000218
8354,,,,1,,In vivo,CHEMBL618719,,Intermediate,A,,1,,N,Plasma clearance in rat,,,50597,BAO_0000218
8355,,,,1,,In vivo,CHEMBL618720,,Intermediate,A,,1,,N,Plasma clearance in rat,,,50597,BAO_0000218
8356,,,,1,,In vivo,CHEMBL618721,,Intermediate,A,,1,,N,Plasma clearance in rat,,,50597,BAO_0000218
8357,,,,1,,In vivo,CHEMBL621477,,Intermediate,A,,1,,N,Plasma clearance in rats,,,50597,BAO_0000218
8358,,,,1,,In vivo,CHEMBL621478,,Intermediate,A,,1,,N,Plasma clearance in rat,,,50597,BAO_0000218
8359,,,,1,,In vivo,CHEMBL621479,,Intermediate,A,,1,,N,Plasma clearance was evaluated in rat,,,50597,BAO_0000218
8360,,,,1,,In vivo,CHEMBL621480,,Intermediate,A,,1,,N,Plasma clearance was evaluated in rat; Not tested,,,50597,BAO_0000218
8361,,,,1,,In vivo,CHEMBL621481,,Intermediate,A,,1,,N,Plasma clearance rate was determined for the compound in rat,,,50597,BAO_0000218
8362,,,,1,,In vivo,CHEMBL621482,,Intermediate,A,,1,,N,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,,50597,BAO_0000218
8363,,,,1,,In vivo,CHEMBL621483,,Intermediate,A,,1,,N,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,,50597,BAO_0000218
8364,,,,1,,In vivo,CHEMBL621484,,Intermediate,A,,1,,N,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,,50597,BAO_0000218
8365,,,948.0,1,Heart,In vivo,CHEMBL621485,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8366,,,948.0,1,Heart,In vivo,CHEMBL621486,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8367,,,160.0,1,Intestine,In vivo,CHEMBL621487,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8368,,,160.0,1,Intestine,In vivo,CHEMBL621488,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8369,,,160.0,1,Intestine,In vivo,CHEMBL621489,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8370,,,160.0,1,Intestine,In vivo,CHEMBL621490,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8371,,,160.0,1,Intestine,In vivo,CHEMBL621491,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8372,,,2113.0,1,Kidney,In vivo,CHEMBL621492,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8373,,,2113.0,1,Kidney,In vivo,CHEMBL621493,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8374,,,2113.0,1,Kidney,In vivo,CHEMBL621494,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8375,,,2113.0,1,Kidney,In vivo,CHEMBL621495,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8376,,,2113.0,1,Kidney,In vivo,CHEMBL621496,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8377,,,2107.0,1,Liver,In vivo,CHEMBL621497,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8378,,,2107.0,1,Liver,In vivo,CHEMBL621498,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8379,,,2107.0,1,Liver,In vivo,CHEMBL621499,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8380,,,2107.0,1,Liver,In vivo,CHEMBL618634,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8381,,,2107.0,1,Liver,In vivo,CHEMBL618635,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8382,,,2048.0,1,Lung,In vivo,CHEMBL618636,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8383,,,2048.0,1,Lung,In vivo,CHEMBL619737,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8384,,,2048.0,1,Lung,In vivo,CHEMBL619738,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8385,,,2048.0,1,Lung,In vivo,CHEMBL624329,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8386,,,2048.0,1,Lung,In vivo,CHEMBL624330,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8387,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624331,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8388,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624332,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8389,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624333,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8390,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624334,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8391,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624335,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8392,,,2106.0,1,Spleen,In vivo,CHEMBL620016,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8393,,,2106.0,1,Spleen,In vivo,CHEMBL620169,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8394,,,2106.0,1,Spleen,In vivo,CHEMBL620170,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8395,,,2106.0,1,Spleen,In vivo,CHEMBL620171,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8396,,,2106.0,1,Spleen,In vivo,CHEMBL620172,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8397,,,945.0,1,Stomach,In vivo,CHEMBL620173,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8398,,,945.0,1,Stomach,In vivo,CHEMBL620174,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8399,,,945.0,1,Stomach,In vivo,CHEMBL620175,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8400,,,945.0,1,Stomach,In vivo,CHEMBL620176,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8401,,,945.0,1,Stomach,In vivo,CHEMBL620177,,Intermediate,A,,1,,N,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8402,,,2037.0,1,Cerebellum,,CHEMBL620178,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8403,,,2037.0,1,Cerebellum,,CHEMBL620179,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8404,,,,1,,,CHEMBL620180,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8405,,,,1,,In vivo,CHEMBL620181,,Intermediate,A,,1,,N,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,,50597,BAO_0000218
8406,,,,1,,In vivo,CHEMBL620182,,Intermediate,A,,1,,N,Volume of distribution of compound in rats after intravenous administration,,,50597,BAO_0000218
8407,,,,1,,In vivo,CHEMBL620183,,Intermediate,A,,1,,N,Volume of distribution in rat,,,50597,BAO_0000218
8408,,,,1,,In vivo,CHEMBL620184,,Intermediate,A,,1,,N,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,,50597,BAO_0000218
8409,,,,1,,In vivo,CHEMBL620185,,Intermediate,A,,1,,N,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,,50597,BAO_0000218
8410,,,,1,,In vivo,CHEMBL620186,,Intermediate,A,,1,,N,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,,50597,BAO_0000218
8411,,,,1,,In vivo,CHEMBL620187,,Intermediate,A,,1,,N,Volume of distribution was determined in Dawley rat,,,50597,BAO_0000218
8412,,,,1,,In vivo,CHEMBL620188,,Intermediate,A,,1,,N,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,,50597,BAO_0000218
8413,,,,1,,In vivo,CHEMBL620189,,Intermediate,A,,1,,N,Volume of distribution was reported in Sprague-Dawley rat,,,50597,BAO_0000218
8414,,,,1,,In vivo,CHEMBL620190,,Intermediate,A,,1,,N,Volumes of distribution in rat after peroral administration,,,50597,BAO_0000218
8415,,,,1,,In vivo,CHEMBL620191,,Intermediate,A,,1,,N,Volumes of distribution in rat after po administration,,,50597,BAO_0000218
8416,,,,1,,In vivo,CHEMBL620192,,Intermediate,A,,1,,N,Volumes of distribution in rat after po administration; Not determined,,,50597,BAO_0000218
8417,,,,1,,In vivo,CHEMBL620193,,Intermediate,A,,1,,N,Pharmacokinetic property (Volume) in rat i.v.,,,50597,BAO_0000218
8418,,,,1,,In vivo,CHEMBL620194,,Intermediate,A,,1,,N,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,,50597,BAO_0000218
8419,,,,1,,In vivo,CHEMBL876730,,Intermediate,A,,1,,N,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,,50597,BAO_0000218
8420,,,,1,,In vivo,CHEMBL620195,,Intermediate,A,,1,,N,Volume distribution in rat after oral administration at 10 mg/kg,,,50597,BAO_0000218
8421,,,,1,,In vivo,CHEMBL620196,,Intermediate,A,,1,,N,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,,50597,BAO_0000218
8422,,,,1,,In vivo,CHEMBL620197,,Intermediate,A,,1,,N,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,,50597,BAO_0000218
8423,,,,1,,In vivo,CHEMBL620198,,Intermediate,A,,1,,N,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,,50597,BAO_0000218
8424,,,,1,,In vivo,CHEMBL620199,,Intermediate,A,,1,,N,Volume of distribution in rats,,,50597,BAO_0000218
8425,,,,1,,In vivo,CHEMBL620200,,Intermediate,A,,1,,N,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,,50597,BAO_0000218
8426,,,,1,,In vivo,CHEMBL620201,,Intermediate,A,,1,,N,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,,50597,BAO_0000218
8427,,,,1,,In vivo,CHEMBL620202,,Intermediate,A,,1,,N,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
8428,,,,1,,In vivo,CHEMBL620203,,Intermediate,A,,1,,N,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
8429,,,,1,,In vivo,CHEMBL620204,,Intermediate,A,,1,,N,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,,50597,BAO_0000218
8430,,,,1,,In vivo,CHEMBL620205,,Intermediate,A,,1,,N,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
8431,,,,1,,In vivo,CHEMBL624664,,Intermediate,A,,1,,N,Pharmacokinetic parameter (Vss) in rat,,,50597,BAO_0000218
8432,,,,1,,In vivo,CHEMBL624665,,Intermediate,A,,1,,N,Pharmacokinetic property (Volume) in rat i.v.,,,50597,BAO_0000218
8433,,,,1,,,CHEMBL624666,,Intermediate,A,,1,,N,Pharmacokinetic property (Vss) in rat,,,50597,BAO_0000218
8434,,,,1,,In vivo,CHEMBL624667,,Intermediate,A,,1,,N,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,,50597,BAO_0000218
8435,,,,1,,In vivo,CHEMBL624668,,Intermediate,A,,1,,N,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
8436,,,,1,,In vivo,CHEMBL624669,,Intermediate,A,,1,,N,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
8437,,,,1,,In vivo,CHEMBL624670,,Intermediate,A,,1,,N,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
8438,,,,1,,In vivo,CHEMBL624671,,Intermediate,A,,1,,N,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
8439,,,,1,,In vivo,CHEMBL624672,,Intermediate,A,,1,,N,Steady state volume distribution in rat,,,50597,BAO_0000218
8440,,,1969.0,1,Plasma,In vivo,CHEMBL624673,,Intermediate,A,,1,,N,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",,,50597,BAO_0000218
8441,,,,1,,In vivo,CHEMBL624674,,Intermediate,A,,1,,N,Steady state volume of distribution determined in rat,,,50597,BAO_0000218
8442,,,,1,,In vivo,CHEMBL624675,,Intermediate,A,,1,,N,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,50597,BAO_0000218
8443,,,,1,,In vivo,CHEMBL621728,,Intermediate,A,,1,,N,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,,50597,BAO_0000218
8444,,,,1,,,CHEMBL621729,,Intermediate,A,,1,,N,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,,50597,BAO_0000218
8445,,,,1,,,CHEMBL621730,,Intermediate,A,,1,,N,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,,50597,BAO_0000218
8446,,,,1,,In vivo,CHEMBL621731,,Intermediate,A,,1,,N,Volume distribution in rat after administration of 2 mg/kg iv,,,50597,BAO_0000218
8447,,,,1,,In vivo,CHEMBL621732,,Intermediate,A,,1,,N,Volume distribution in rat after administration of 2 mg/kg iv,,,50597,BAO_0000218
8448,,,,1,,In vivo,CHEMBL621908,,Intermediate,A,,1,,N,Volume in steady state distribution value was determined,,,50597,BAO_0000218
8449,,,,1,,In vivo,CHEMBL875347,,Intermediate,A,,1,,N,Volume in steady state distribution value was determined; ND denotes no data,,,50597,BAO_0000218
8450,,,,1,,In vivo,CHEMBL621909,,Intermediate,A,,1,,N,Volume in steady state distribution value was determined; ND denotes not determined,,,50597,BAO_0000218
8451,,,,1,,In vivo,CHEMBL621910,,Intermediate,A,,1,,N,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,50597,BAO_0000218
8452,,,,1,,In vivo,CHEMBL621911,,Intermediate,A,,1,,N,Volume of distribution at steady state was evaluated in rats,,,50597,BAO_0000218
8453,,,,1,,In vivo,CHEMBL621912,,Intermediate,A,,1,,N,Volume of distribution at steady state was observed after intravenous administration in rat,,,50597,BAO_0000218
8454,,,,1,,In vivo,CHEMBL621913,,Intermediate,A,,1,,N,Volume of distribution in steady state was determined in rat,,,50597,BAO_0000218
8455,,,,1,,In vivo,CHEMBL621914,,Intermediate,A,,1,,N,Volume of distribution in steady state was determined in rat,,,50597,BAO_0000218
8456,,,,1,,In vivo,CHEMBL621915,,Intermediate,A,,1,,N,Volume of distribution after i.v. administration,,,50597,BAO_0000218
8457,,,,1,,In vivo,CHEMBL621916,,Intermediate,A,,1,,N,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,,50597,BAO_0000218
8458,,,2107.0,1,Liver,In vivo,CHEMBL621917,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,50594,BAO_0000218
8459,,,2107.0,1,Liver,In vivo,CHEMBL621918,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
8460,,,2106.0,1,Spleen,In vivo,CHEMBL621919,,Intermediate,A,,1,,N,Biodistribution of compound (oxidized form) in spleen tissue,,,50594,BAO_0000218
8461,,,2106.0,1,Spleen,In vivo,CHEMBL621920,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
8462,,,2106.0,1,Spleen,In vivo,CHEMBL621921,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,50594,BAO_0000218
8463,,,2106.0,1,Spleen,In vivo,CHEMBL622401,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
8464,,,2106.0,1,Spleen,In vivo,CHEMBL875348,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594,BAO_0000218
8465,,,2106.0,1,Spleen,In vivo,CHEMBL622402,,Intermediate,A,,1,,N,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,50594,BAO_0000218
8466,,,178.0,1,Blood,In vivo,CHEMBL622403,,Intermediate,A,,1,,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,,,50594,BAO_0000218
8467,,,178.0,1,Blood,In vivo,CHEMBL622404,,Intermediate,A,,1,,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
8468,,,955.0,1,Brain,In vivo,CHEMBL622405,,Intermediate,A,,1,,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,,,50594,BAO_0000218
8469,,,955.0,1,Brain,In vivo,CHEMBL622406,,Intermediate,A,,1,,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,,50594,BAO_0000218
8470,,,955.0,1,Brain,In vivo,CHEMBL622407,,Intermediate,A,,1,,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
8471,,,948.0,1,Heart,In vivo,CHEMBL622408,,Intermediate,A,,1,,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,,,50594,BAO_0000218
8472,,,948.0,1,Heart,In vivo,CHEMBL622409,,Intermediate,A,,1,,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,,50594,BAO_0000218
8473,,,948.0,1,Heart,In vivo,CHEMBL622410,,Intermediate,A,,1,,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
8474,,,2113.0,1,Kidney,In vivo,CHEMBL622411,,Intermediate,A,,1,,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,,,50594,BAO_0000218
8475,,,2113.0,1,Kidney,In vivo,CHEMBL627864,,Intermediate,A,,1,,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",,,50594,BAO_0000218
8476,,,2113.0,1,Kidney,In vivo,CHEMBL627865,,Intermediate,A,,1,,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
8477,,,2107.0,1,Liver,In vivo,CHEMBL627866,,Intermediate,A,,1,,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,,,50594,BAO_0000218
8478,,,2107.0,1,Liver,In vivo,CHEMBL627751,,Intermediate,A,,1,,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
8479,,,2106.0,1,Spleen,In vivo,CHEMBL627752,,Intermediate,A,,1,,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,,,50594,BAO_0000218
8480,,,2106.0,1,Spleen,In vivo,CHEMBL627753,,Intermediate,A,,1,,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",,,50594,BAO_0000218
8481,,,2106.0,1,Spleen,In vivo,CHEMBL627754,,Intermediate,A,,1,,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594,BAO_0000218
8482,,,,1,,,CHEMBL627755,,Intermediate,A,,1,,N,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,,50594,BAO_0000218
8483,,,955.0,1,Brain,In vivo,CHEMBL627756,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8484,,,955.0,1,Brain,In vivo,CHEMBL627757,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8485,,,955.0,1,Brain,In vivo,CHEMBL627758,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8486,,,955.0,1,Brain,In vivo,CHEMBL627759,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8487,,,955.0,1,Brain,In vivo,CHEMBL627760,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8488,,,955.0,1,Brain,In vivo,CHEMBL627761,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8489,,,948.0,1,Heart,In vivo,CHEMBL876811,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8490,,,948.0,1,Heart,In vivo,CHEMBL627762,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8491,,,948.0,1,Heart,In vivo,CHEMBL627763,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8492,,,948.0,1,Heart,In vivo,CHEMBL627764,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8493,,,948.0,1,Heart,In vivo,CHEMBL627765,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8494,,,948.0,1,Heart,In vivo,CHEMBL627766,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8495,,,2113.0,1,Kidney,In vivo,CHEMBL627767,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8496,,,2113.0,1,Kidney,In vivo,CHEMBL627768,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8497,,,2113.0,1,Kidney,In vivo,CHEMBL628422,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8498,,,2113.0,1,Kidney,In vivo,CHEMBL628423,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8499,,,,1,,In vivo,CHEMBL628424,,Intermediate,A,,1,,N,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,,50597,BAO_0000218
8500,,,,1,,In vivo,CHEMBL628425,,Intermediate,A,,1,,N,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,,50597,BAO_0000218
8501,,,,1,,In vivo,CHEMBL628426,,Intermediate,A,,1,,N,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,,50597,BAO_0000218
8502,,,,1,,In vivo,CHEMBL628427,,Intermediate,A,,1,,N,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50597,BAO_0000218
8503,,,,1,,In vivo,CHEMBL626938,,Intermediate,A,,1,,N,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,,50597,BAO_0000218
8504,,,,1,,In vivo,CHEMBL626939,,Intermediate,A,,1,,N,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,,50597,BAO_0000218
8505,,,,1,,In vivo,CHEMBL626940,,Intermediate,A,,1,,N,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,,50597,BAO_0000218
8506,,,,1,,In vivo,CHEMBL626941,,Intermediate,A,,1,,N,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,,50597,BAO_0000218
8507,,,,1,,In vivo,CHEMBL626942,,Intermediate,A,,1,,N,Plasma clearance was reported in Sprague-Dawley rat,,,50597,BAO_0000218
8508,,,,1,,In vivo,CHEMBL876812,,Intermediate,A,,1,,N,Plasma clearance after intravenous administration (1 mg/kg) in rat,,,50597,BAO_0000218
8509,,,,1,,In vivo,CHEMBL626943,,Intermediate,A,,1,,N,Plasma clearance of compound in rats was evaluated,,,50597,BAO_0000218
8510,,,,1,,In vivo,CHEMBL626944,,Intermediate,A,,1,,N,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,,50597,BAO_0000218
8511,,,,1,,In vivo,CHEMBL626945,,Intermediate,A,,1,,N,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,,50597,BAO_0000218
8512,,,,1,,In vivo,CHEMBL626946,,Intermediate,A,,1,,N,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,,50597,BAO_0000218
8513,,,,1,,In vivo,CHEMBL626856,,Intermediate,A,,1,,N,Plasma clearance rate in Sprague-Dawley rats,,,50597,BAO_0000218
8514,,,,1,,In vivo,CHEMBL626857,,Intermediate,A,,1,,N,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,,50597,BAO_0000218
8515,,,1969.0,1,Plasma,In vivo,CHEMBL626858,,Intermediate,A,,1,,N,The compound was evaluated for plasma clearance in rat,,,50597,BAO_0000218
8516,,,1969.0,1,Plasma,In vivo,CHEMBL627018,,Intermediate,A,,1,,N,Total plasma clearance in rat,,,50597,BAO_0000218
8517,,,178.0,1,Blood,In vivo,CHEMBL625331,,Intermediate,A,,1,,N,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,,,50597,BAO_0000218
8518,,,178.0,1,Blood,In vivo,CHEMBL625332,,Intermediate,A,,1,,N,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,,,50597,BAO_0000218
8519,,,,1,,In vivo,CHEMBL877590,,Intermediate,A,,1,,N,C max was determined at 10 mg/kg po dose in rats,,,50597,BAO_0000218
8520,,,,1,,In vivo,CHEMBL625333,,Intermediate,A,,1,,N,C max was determined at 3 mg/kg po dose in rats,,,50597,BAO_0000218
8521,,,,1,,In vivo,CHEMBL625334,,Intermediate,A,,1,,N,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,,50597,BAO_0000218
8522,,,,1,,In vivo,CHEMBL625335,,Intermediate,A,,1,,N,Cmax after single intravenous bolus of 1 mg/kg in rats,,,50597,BAO_0000218
8523,,,,1,,In vivo,CHEMBL625336,,Intermediate,A,,1,,N,Cmax of compound at 5 mg/kg after po administration was determined in rat,,,50597,BAO_0000218
8524,,,,1,,In vivo,CHEMBL625337,,Intermediate,A,,1,,N,Cmax 24 hr after 10 mg/kg oral administration in rats,,,50597,BAO_0000218
8525,,,,1,,In vivo,CHEMBL625338,,Intermediate,A,,1,,N,Cmax 24 hr after 2 mg/kg oral administration in rats,,,50597,BAO_0000218
8526,,,1969.0,1,Plasma,In vivo,CHEMBL625339,,Intermediate,A,,1,,N,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,,,50597,BAO_0000218
8527,,,,1,,In vivo,CHEMBL625340,,Intermediate,A,,1,,N,Cmax in rat after administration of 2 mg/kg iv,,,50597,BAO_0000218
8528,,,,1,,In vivo,CHEMBL625341,,Intermediate,A,,1,,N,Cmax in rat after administration of 2 mg/kg iv,,,50597,BAO_0000218
8529,,,,1,,In vivo,CHEMBL622687,,Intermediate,A,,1,,N,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,,50597,BAO_0000218
8530,,,1969.0,1,Plasma,In vivo,CHEMBL622688,,Intermediate,A,,1,,N,Cmax wa determined in rat plasma at 30 mg/kg after po administration,,,50597,BAO_0000218
8531,,,178.0,1,Blood,In vivo,CHEMBL622689,,Intermediate,A,,1,,N,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,,,50597,BAO_0000218
8532,,,178.0,1,Blood,In vivo,CHEMBL620295,,Intermediate,A,,1,,N,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,,,50597,BAO_0000218
8533,,,,1,,In vivo,CHEMBL620296,,Intermediate,A,,1,,N,Cmax after 10 mg/kg oral administration in rat,,,50597,BAO_0000218
8534,,,,1,,In vivo,CHEMBL620297,,Intermediate,A,,1,,N,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,,50597,BAO_0000218
8535,,,,1,,In vivo,CHEMBL620298,,Intermediate,A,,1,,N,Cmax after IV dosing at 1 mg/kg in rat; no data,,,50597,BAO_0000218
8536,,,,1,,In vivo,CHEMBL620299,,Intermediate,A,,1,,N,Cmax after oral administration at 20 mpk in rats,,,50597,BAO_0000218
8537,,,,1,,In vivo,CHEMBL620300,,Intermediate,A,,1,,N,Cmax after oral administration at 20 mpk in rats; Not performed.,,,50597,BAO_0000218
8538,,,,1,,In vivo,CHEMBL620301,,Intermediate,A,,1,,N,Cmax after oral administration at 20 mpk in rats d; Not performed.,,,50597,BAO_0000218
8539,,,,1,,In vivo,CHEMBL620302,,Intermediate,A,,1,,N,Cmax after oral administration in rat,,,50597,BAO_0000218
8540,,,,1,,In vivo,CHEMBL620303,,Intermediate,A,,1,,N,Cmax after oral administration at a dose of 2 mg/kg in rat,,,50597,BAO_0000218
8541,,,,1,,In vivo,CHEMBL620304,,Intermediate,A,,1,,N,Cmax after oral administration at a dose of 4 mg/kg in rat,,,50597,BAO_0000218
8542,,,,1,,In vivo,CHEMBL620305,,Intermediate,A,,1,,N,Cmax in rats after 20 mg/kg oral dose,,,50597,BAO_0000218
8543,,,,1,,In vivo,CHEMBL620306,,Intermediate,A,,1,,N,Cmax after peroral administration in rats at 2.4 uM/kg,,,50597,BAO_0000218
8544,,,,1,,In vivo,CHEMBL620307,,Intermediate,A,,1,,N,Cmax at the dose of 2 mg/Kg administered perorally in rats,,,50597,BAO_0000218
8545,,,,1,,In vivo,CHEMBL620308,,Intermediate,A,,1,,N,Cmax at the dose of 5 mg/Kg administered perorally in rats,,,50597,BAO_0000218
8546,,,,1,,In vivo,CHEMBL620309,,Intermediate,A,,1,,N,Cmax by administering at 20 mg/kg p.o. in rats,,,50597,BAO_0000218
8547,,,,1,,In vivo,CHEMBL620310,,Intermediate,A,,1,,N,Cmax in male rat,,,50597,BAO_0000218
8548,,,,1,,In vivo,CHEMBL620311,,Intermediate,A,,1,,N,Cmax in rat,,,50597,BAO_0000218
8549,,,,1,,In vivo,CHEMBL620312,,Intermediate,A,,1,,N,Cmax in rat,,,50597,BAO_0000218
8550,,,,1,,In vivo,CHEMBL620313,,Intermediate,A,,1,,N,Cmax in rat,,,50597,BAO_0000218
8551,,,,1,,In vivo,CHEMBL620314,,Intermediate,A,,1,,N,Cmax in rat at 10 mg/kg,,,50597,BAO_0000218
8552,,,,1,,In vivo,CHEMBL620315,,Intermediate,A,,1,,N,Cmax in rat at the dose of 1 mg/kg i.v.,,,50597,BAO_0000218
8553,,,,1,,In vivo,CHEMBL620316,,Intermediate,A,,1,,N,Cmax in rat by po administration at a dose of 40 mg/kg,,,50597,BAO_0000218
8554,,,,1,,In vivo,CHEMBL620317,,Intermediate,A,,1,,N,Cmax in rat p.o. at 20 mg/kg concentration,,,50597,BAO_0000218
8555,,,,1,,In vivo,CHEMBL620318,,Intermediate,A,,1,,N,Cmax in rats,,,50597,BAO_0000218
8556,,,,1,,In vivo,CHEMBL620319,,Intermediate,A,,1,,N,Cmax in rats,,,50597,BAO_0000218
8557,,,,1,,In vivo,CHEMBL620320,,Intermediate,A,,1,,N,Cmax was evaluated after 20 uM/kg of peroral administration,,,50597,BAO_0000218
8558,,,,1,,In vivo,CHEMBL620321,,Intermediate,A,,1,,N,Cmax was measured in rats after peroral administration at 3 mg/kg,,,50597,BAO_0000218
8559,,,,1,,In vivo,CHEMBL620322,,Intermediate,A,,1,,N,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,,50597,BAO_0000218
8560,,,,1,,,CHEMBL620323,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8561,,,1870.0,1,Frontal cortex,,CHEMBL620324,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8562,,,1870.0,1,Frontal cortex,,CHEMBL620325,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8563,,,10000000.0,1,Hippocampus,,CHEMBL620326,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8564,,,10000000.0,1,Hippocampus,,CHEMBL620327,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8565,,,,1,,,CHEMBL620328,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8566,,,,1,,,CHEMBL620329,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8567,,,1891.0,1,Midbrain,,CHEMBL620330,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8568,,,1891.0,1,Midbrain,,CHEMBL875286,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8569,,,,1,,,CHEMBL620331,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8570,,,,1,,,CHEMBL620332,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8571,,,2435.0,1,Striatum,,CHEMBL620333,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8572,,,2435.0,1,Striatum,,CHEMBL620334,,Intermediate,A,,1,,N,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,50597,BAO_0000218
8573,,,178.0,1,Blood,,CHEMBL621015,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
8574,,,178.0,1,Blood,,CHEMBL621016,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,BAO_0000218
8575,,,178.0,1,Blood,,CHEMBL621191,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
8576,,,178.0,1,Blood,,CHEMBL621192,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
8577,,,178.0,1,Blood,,CHEMBL621193,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,BAO_0000218
8578,,,178.0,1,Blood,,CHEMBL621194,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,BAO_0000218
8579,,,178.0,1,Blood,,CHEMBL624204,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,BAO_0000218
8580,,,178.0,1,Blood,,CHEMBL624205,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,50597,BAO_0000218
8581,,,178.0,1,Blood,,CHEMBL624206,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,BAO_0000218
8582,,,178.0,1,Blood,,CHEMBL624207,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,BAO_0000218
8583,,,178.0,1,Blood,,CHEMBL624208,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,BAO_0000218
8584,,,178.0,1,Blood,,CHEMBL624209,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,BAO_0000218
8585,,,178.0,1,Blood,,CHEMBL624210,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,BAO_0000218
8586,,,178.0,1,Blood,,CHEMBL624211,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,BAO_0000218
8587,,,178.0,1,Blood,,CHEMBL624212,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,BAO_0000218
8588,,,178.0,1,Blood,,CHEMBL624213,,Intermediate,A,,1,,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,BAO_0000218
8589,,,178.0,1,Blood,,CHEMBL876611,,Intermediate,A,,1,,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
8590,,,178.0,1,Blood,,CHEMBL624214,,Intermediate,A,,1,,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
8591,,,178.0,1,Blood,,CHEMBL624215,,Intermediate,A,,1,,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
8592,,,178.0,1,Blood,,CHEMBL624216,,Intermediate,A,,1,,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
8593,,,178.0,1,Blood,,CHEMBL624217,,Intermediate,A,,1,,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
8594,,,178.0,1,Blood,,CHEMBL624218,,Intermediate,A,,1,,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
8595,,,178.0,1,Blood,,CHEMBL624219,,Intermediate,A,,1,,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
8596,,,178.0,1,Blood,,CHEMBL624220,,Intermediate,A,,1,,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
8597,,,178.0,1,Blood,,CHEMBL624221,,Intermediate,A,,1,,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
8598,,,,1,,,CHEMBL624222,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
8599,,,,1,,,CHEMBL624223,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,BAO_0000218
8600,,,,1,,,CHEMBL624224,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
8601,,,,1,,,CHEMBL624225,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
8602,,,,1,,In vivo,CHEMBL622420,,Intermediate,A,,1,,N,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,,50597,BAO_0000218
8603,,,,1,,In vivo,CHEMBL622421,,Intermediate,A,,1,,N,Volume of steady state distribution after i.v. administration in rats,,,50597,BAO_0000218
8604,,,,1,,In vivo,CHEMBL622422,,Intermediate,A,,1,,N,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,,50597,BAO_0000218
8605,,,,1,,In vivo,CHEMBL622423,,Intermediate,A,,1,,N,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,50597,BAO_0000218
8606,,,,1,,In vivo,CHEMBL622424,,Intermediate,A,,1,,N,Vss was determined,,,50597,BAO_0000218
8607,,,,1,,In vivo,CHEMBL622425,,Intermediate,A,,1,,N,Vss in rat,,,50597,BAO_0000218
8608,,,,1,,In vivo,CHEMBL876612,,Intermediate,A,,1,,N,Vss was evaluated after 10 uM/kg of intra arterial administration,,,50597,BAO_0000218
8609,,,,1,,In vivo,CHEMBL622426,,Intermediate,A,,1,,N,volume of distribution at steady state was observed after intravenous administration in rat,,,50597,BAO_0000218
8610,,,,1,,In vivo,CHEMBL622427,,Intermediate,A,,1,,N,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,,50597,BAO_0000218
8611,,,,1,,In vivo,CHEMBL622428,,Intermediate,A,,1,,N,Pharmacokinetic (PK) parameter Vz in rat,,,50597,BAO_0000218
8612,,,,1,,In vivo,CHEMBL622429,,Intermediate,A,,1,,N,Volume distribution in rats,,,50597,BAO_0000218
8613,,,,1,,In vivo,CHEMBL622430,,Intermediate,A,,1,,N,Volume of distribution in rat; No data,,,50597,BAO_0000218
8614,,,,1,,In vivo,CHEMBL622431,,Intermediate,A,,1,,N,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,50597,BAO_0000218
8615,,,2116.0,1,Ileum,,CHEMBL622432,,Intermediate,A,,1,,N,% absorption predicted from in vitro rat ileum transport studies,,,50597,BAO_0000218
8616,,,,1,,In vivo,CHEMBL622433,,Intermediate,A,,1,,N,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,,50597,BAO_0000218
8617,,,,1,,In vivo,CHEMBL622434,,Intermediate,A,,1,,N,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,,50597,BAO_0000218
8618,,,,1,,In vivo,CHEMBL622435,,Intermediate,A,,1,,N,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,,50597,BAO_0000218
8619,,,,1,,In vivo,CHEMBL618748,,Intermediate,A,,1,,N,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,,50597,BAO_0000218
8620,,,,1,,In vivo,CHEMBL618749,,Intermediate,A,,1,,N,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,,50597,BAO_0000218
8621,,,,1,,In vivo,CHEMBL618750,,Intermediate,A,,1,,N,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,,50597,BAO_0000218
8622,,,,1,,In vivo,CHEMBL618751,,Intermediate,A,,1,,N,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,,50597,BAO_0000218
8623,,,,1,,In vivo,CHEMBL618752,,Intermediate,A,,1,,N,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,,50597,BAO_0000218
8624,,,,1,,In vivo,CHEMBL618753,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
8625,,,1969.0,1,Plasma,In vivo,CHEMBL618754,,Intermediate,A,,1,,N,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,,,50597,BAO_0000218
8626,,,,1,,In vivo,CHEMBL618755,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
8627,,,,1,,In vivo,CHEMBL618756,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
8628,,,,1,,In vivo,CHEMBL618757,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
8629,,,,1,,In vivo,CHEMBL618758,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
8630,,,,1,,In vivo,CHEMBL621088,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 30 mg/kg),,,50597,BAO_0000218
8631,,,,1,,,CHEMBL621089,,Intermediate,A,,1,,N,Pharmacokinetic property (cLogP) in rat,,,50597,BAO_0000218
8632,,,178.0,1,Blood,,CHEMBL621090,,Intermediate,F,,1,,N,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,,,50597,BAO_0000218
8633,,,178.0,1,Blood,,CHEMBL621091,,Intermediate,F,,1,,N,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,,,50597,BAO_0000218
8634,,,,1,,In vivo,CHEMBL876731,,Intermediate,A,,1,,N,Clearance in rat.,,,50597,BAO_0000218
8635,,,,1,,In vivo,CHEMBL621092,,Intermediate,A,,1,,N,Compound was evaluated for its clearance when administered intravenously in rat,,,50597,BAO_0000218
8636,,,,1,,In vivo,CHEMBL621093,,Intermediate,A,,1,,N,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,50597,BAO_0000218
8637,,,,1,,,CHEMBL621094,,Intermediate,A,,1,,N,Blood: Brain distribution ratio is determined in rat,,,50597,BAO_0000218
8638,,,,1,,,CHEMBL621095,,Intermediate,A,,1,,N,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,,50597,BAO_0000218
8639,,,,1,,,CHEMBL621096,,Intermediate,A,,1,,N,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,,50597,BAO_0000218
8640,,,2113.0,1,Kidney,In vivo,CHEMBL621097,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
8641,,,,1,,,CHEMBL621098,,Intermediate,F,,1,,N,Percent dose excreted in 0-48 hours administered ip to male rat,,,50597,BAO_0000218
8642,,,2037.0,1,Cerebellum,,CHEMBL621099,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8643,,,2037.0,1,Cerebellum,,CHEMBL621100,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8644,,,2037.0,1,Cerebellum,,CHEMBL621101,,Intermediate,A,,1,,N,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
8645,,,2037.0,1,Cerebellum,,CHEMBL621102,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8646,,,2037.0,1,Cerebellum,,CHEMBL876732,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8647,,,,1,,,CHEMBL621103,,Intermediate,A,,1,,N,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8648,,,,1,,,CHEMBL621104,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8649,,,,1,,,CHEMBL621105,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
8650,,,,1,,,CHEMBL621106,,Intermediate,A,,1,,N,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8651,,,,1,,,CHEMBL621107,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8652,,,,1,,,CHEMBL621108,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8653,,,,1,,,CHEMBL621109,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8654,,,2113.0,1,Kidney,In vivo,CHEMBL621110,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8655,,,2113.0,1,Kidney,In vivo,CHEMBL621111,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8656,,,2107.0,1,Liver,In vivo,CHEMBL622541,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8657,,,2107.0,1,Liver,In vivo,CHEMBL622542,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8658,,,2107.0,1,Liver,In vivo,CHEMBL622543,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8659,,,2107.0,1,Liver,In vivo,CHEMBL624412,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8660,,,2107.0,1,Liver,In vivo,CHEMBL624413,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8661,,,2107.0,1,Liver,In vivo,CHEMBL624414,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8662,,,2048.0,1,Lung,In vivo,CHEMBL624415,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8663,,,2048.0,1,Lung,In vivo,CHEMBL624416,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8664,,,2048.0,1,Lung,In vivo,CHEMBL624417,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8665,,,2048.0,1,Lung,In vivo,CHEMBL624418,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8666,,,2048.0,1,Lung,In vivo,CHEMBL624419,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8667,,,2048.0,1,Lung,In vivo,CHEMBL624420,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8668,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624421,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8669,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624422,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8670,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624423,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8671,,,2385.0,1,Muscle tissue,In vivo,CHEMBL625123,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8672,,,2385.0,1,Muscle tissue,In vivo,CHEMBL625124,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8673,,,2385.0,1,Muscle tissue,In vivo,CHEMBL625125,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8674,,,14.0,1,Zone of skin,In vivo,CHEMBL625126,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8675,,,14.0,1,Zone of skin,In vivo,CHEMBL626947,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8676,,,14.0,1,Zone of skin,In vivo,CHEMBL626948,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8677,,,14.0,1,Zone of skin,In vivo,CHEMBL626949,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8678,,,14.0,1,Zone of skin,In vivo,CHEMBL626950,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8679,,,14.0,1,Zone of skin,In vivo,CHEMBL626951,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8680,,,2106.0,1,Spleen,In vivo,CHEMBL626952,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8681,,,2106.0,1,Spleen,In vivo,CHEMBL626953,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8682,,,2106.0,1,Spleen,In vivo,CHEMBL626954,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8683,,,2106.0,1,Spleen,In vivo,CHEMBL626955,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8684,,,2106.0,1,Spleen,In vivo,CHEMBL626956,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8685,,,2106.0,1,Spleen,In vivo,CHEMBL626957,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8686,,,178.0,1,Blood,In vivo,CHEMBL626958,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8687,,,178.0,1,Blood,In vivo,CHEMBL626959,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8688,,,178.0,1,Blood,In vivo,CHEMBL626960,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8689,,,178.0,1,Blood,In vivo,CHEMBL626961,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8690,,,178.0,1,Blood,In vivo,CHEMBL627589,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8691,,,178.0,1,Blood,In vivo,CHEMBL627590,,Intermediate,A,,1,,N,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),,,50594,BAO_0000218
8692,,,,1,,,CHEMBL627591,,Intermediate,A,,1,,N,Time taken for EC90 was determined when tested in mouse,,,50594,BAO_0000218
8693,,,,1,,,CHEMBL627592,,Intermediate,A,,1,,N,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,,50594,BAO_0000218
8694,,,,1,,In vivo,CHEMBL627593,,Intermediate,A,,1,,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,,50594,BAO_0000218
8695,,,,1,,,CHEMBL627594,,Intermediate,A,,1,,N,Half life in mice,,,50594,BAO_0000218
8696,,,,1,,In vivo,CHEMBL876813,,Intermediate,A,,1,,N,Half life period in mouse after 10 mg/Kg dose,,,50594,BAO_0000218
8697,,,,1,,In vivo,CHEMBL627595,,Intermediate,A,,1,,N,Half life period in mouse after 10 mg/kg dose,,,50594,BAO_0000218
8698,,,,1,,In vivo,CHEMBL627596,,Intermediate,A,,1,,N,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594,BAO_0000218
8699,,,,1,,In vivo,CHEMBL627597,,Intermediate,A,,1,,N,Cmax value at 5 mg/kg po was determined in rat,,,50597,BAO_0000218
8700,,,,1,,In vivo,CHEMBL627598,,Intermediate,A,,1,,N,Cmax value evaluated in rat,,,50597,BAO_0000218
8701,,,955.0,1,Brain,In vivo,CHEMBL627599,,Intermediate,A,,1,,N,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,,,50597,BAO_0000218
8702,,,,1,,In vivo,CHEMBL627600,,Intermediate,A,,1,,N,Cmax value after administration of 20 mg/Kg oral dose in rat,,,50597,BAO_0000218
8703,,,,1,,In vivo,CHEMBL627601,,Intermediate,A,,1,,N,Cmax value at 1 mg/kg po in rat,,,50597,BAO_0000218
8704,,,,1,,In vivo,CHEMBL627776,,Intermediate,A,,1,,N,Cmax value at 5 mg/kg po in rat,,,50597,BAO_0000218
8705,,,,1,,In vivo,CHEMBL627777,,Intermediate,A,,1,,N,Cmax value at a dose of 10 mg/kg in male SD rats,,,50597,BAO_0000218
8706,,,,1,,In vivo,CHEMBL627778,,Intermediate,A,,1,,N,Cmax value at a dose of 100 mg/kg in male SD rats,,,50597,BAO_0000218
8707,,,,1,,In vivo,CHEMBL627779,,Intermediate,A,,1,,N,Cmax value at a dose of 50 mg/kg in male SD rats,,,50597,BAO_0000218
8708,,,,1,,In vivo,CHEMBL876814,,Intermediate,A,,1,,N,Cmax value in rats at 10 mg/kg,,,50597,BAO_0000218
8709,,,,1,,In vivo,CHEMBL627780,,Intermediate,A,,1,,N,Cmax value was evaluated in rats at a dose of 20 mg/kg,,,50597,BAO_0000218
8710,,,,1,,In vivo,CHEMBL627781,,Intermediate,A,,1,,N,Cmax value was determined after peroral administration of 20 mg/kg in rat,,,50597,BAO_0000218
8711,,,,1,,In vivo,CHEMBL627782,,Intermediate,A,,1,,N,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,,50597,BAO_0000218
8712,,,1969.0,1,Plasma,In vivo,CHEMBL627783,,Intermediate,A,,1,,N,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,,,50597,BAO_0000218
8713,,,1969.0,1,Plasma,In vivo,CHEMBL627784,,Intermediate,A,,1,,N,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,,,50597,BAO_0000218
8714,,,,1,,In vivo,CHEMBL627785,,Intermediate,A,,1,,N,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,,50597,BAO_0000218
8715,,,,1,,In vivo,CHEMBL627786,,Intermediate,A,,1,,N,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,,50597,BAO_0000218
8716,,,1969.0,1,Plasma,In vivo,CHEMBL627787,,Intermediate,A,,1,,N,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,,,50597,BAO_0000218
8717,,,1969.0,1,Plasma,In vivo,CHEMBL627788,,Intermediate,A,,1,,N,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,,,50597,BAO_0000218
8718,,,1969.0,1,Plasma,In vivo,CHEMBL626579,,Intermediate,A,,1,,N,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,,,50597,BAO_0000218
8719,,,1969.0,1,Plasma,In vivo,CHEMBL626580,,Intermediate,A,,1,,N,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,,,50597,BAO_0000218
8720,,,,1,,In vivo,CHEMBL876815,,Intermediate,A,,1,,N,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,,50597,BAO_0000218
8721,,,1969.0,1,Plasma,In vivo,CHEMBL626581,,Intermediate,A,,1,,N,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,,,50597,BAO_0000218
8722,,,1969.0,1,Plasma,In vivo,CHEMBL626582,,Intermediate,A,,1,,N,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,,,50597,BAO_0000218
8723,,,,1,,In vivo,CHEMBL626583,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,,50597,BAO_0000218
8724,,,,1,,In vivo,CHEMBL626205,,Intermediate,A,,1,,N,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
8725,,,,1,,In vivo,CHEMBL626206,,Intermediate,A,,1,,N,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
8726,,,,1,,In vivo,CHEMBL626207,,Intermediate,A,,1,,N,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
8727,,,,1,,In vivo,CHEMBL623882,,Intermediate,A,,1,,N,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
8728,,,,1,,In vivo,CHEMBL623883,,Intermediate,A,,1,,N,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,,50597,BAO_0000218
8729,,,,1,,In vivo,CHEMBL623884,,Intermediate,A,,1,,N,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,,50597,BAO_0000218
8730,,,1969.0,1,Plasma,In vivo,CHEMBL623885,,Intermediate,A,,1,,N,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,,50597,BAO_0000218
8731,,,1969.0,1,Plasma,In vivo,CHEMBL623886,,Intermediate,A,,1,,N,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,,,50597,BAO_0000218
8732,,,,1,,In vivo,CHEMBL623887,,Intermediate,A,,1,,N,Maximal concentration in rat was determined,,,50597,BAO_0000218
8733,,,,1,,In vivo,CHEMBL623888,,Intermediate,A,,1,,N,Maximal concentration after i.v. administration,,,50597,BAO_0000218
8734,,,1969.0,1,Plasma,In vivo,CHEMBL623889,,Intermediate,A,,1,,N,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,,,50597,BAO_0000218
8735,,,1969.0,1,Plasma,In vivo,CHEMBL623890,,Intermediate,A,,1,,N,Maximal plasma concentration in rat after oral administration at 50 mg/kg,,,50597,BAO_0000218
8736,,,1969.0,1,Plasma,In vivo,CHEMBL623891,,Intermediate,A,,1,,N,Cmax in rat plasma after oral dose (50 mg/Kg),,,50597,BAO_0000218
8737,,,1969.0,1,Plasma,In vivo,CHEMBL623892,,Intermediate,A,,1,,N,Maximal plasma concentration was determined.,,,50597,BAO_0000218
8738,,,1969.0,1,Plasma,In vivo,CHEMBL623893,,Intermediate,A,,1,,N,Maximal plasma drug concentration was determined,,,50597,BAO_0000218
8739,,,,1,,In vivo,CHEMBL877616,,Intermediate,A,,1,,N,Maximal concentration in rats after peroral administration,,,50597,BAO_0000218
8740,,,,1,,In vivo,CHEMBL623894,,Intermediate,A,,1,,N,Maximum concentration in rat after 2 mg/kg peroral administration,,,50597,BAO_0000218
8741,,,1969.0,1,Plasma,In vivo,CHEMBL623895,,Intermediate,A,,1,,N,Maximum concentration in rat plasma after 5 mg/kg oral gavage,,,50597,BAO_0000218
8742,,,,1,,In vivo,CHEMBL623896,,Intermediate,A,,1,,N,Maximum concentration of compound in rat was evaluated.,,,50597,BAO_0000218
8743,,,,1,,In vivo,CHEMBL623897,,Intermediate,A,,1,,N,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,,50597,BAO_0000218
8744,,,,1,,In vivo,CHEMBL623898,,Intermediate,A,,1,,N,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,,50597,BAO_0000218
8745,,,,1,,In vivo,CHEMBL623899,,Intermediate,A,,1,,N,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,,50597,BAO_0000218
8746,,,,1,,In vivo,CHEMBL623900,,Intermediate,A,,1,,N,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,,50597,BAO_0000218
8747,,,,1,,In vivo,CHEMBL623901,,Intermediate,A,,1,,N,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,,50597,BAO_0000218
8748,,,,1,,In vivo,CHEMBL623902,,Intermediate,A,,1,,N,Maximum concentration was evaluated in rats,,,50597,BAO_0000218
8749,,,1359.0,1,Cerebrospinal fluid,In vivo,CHEMBL623903,,Intermediate,A,,1,,N,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,,,50597,BAO_0000218
8750,,,1969.0,1,Plasma,In vivo,CHEMBL623904,,Intermediate,A,,1,,N,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,,,50597,BAO_0000218
8751,,,1969.0,1,Plasma,In vivo,CHEMBL877617,,Intermediate,A,,1,,N,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,,50597,BAO_0000218
8752,,,,1,,In vivo,CHEMBL623905,,Intermediate,A,,1,,N,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,,50597,BAO_0000218
8753,,,,1,,In vivo,CHEMBL623906,,Intermediate,A,,1,,N,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,,50597,BAO_0000218
8754,,,1969.0,1,Plasma,In vivo,CHEMBL623907,,Intermediate,A,,1,,N,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,50597,BAO_0000218
8755,,,,1,,,CHEMBL623908,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,BAO_0000218
8756,,,,1,,,CHEMBL623909,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,,50597,BAO_0000218
8757,,,,1,,,CHEMBL623910,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,BAO_0000218
8758,,,,1,,,CHEMBL623911,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,50597,BAO_0000218
8759,,,,1,,,CHEMBL623912,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,BAO_0000218
8760,,,,1,,,CHEMBL624616,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,BAO_0000218
8761,,,,1,,,CHEMBL624617,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,BAO_0000218
8762,,,,1,,,CHEMBL624618,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,BAO_0000218
8763,,,,1,,,CHEMBL624619,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,BAO_0000218
8764,,,,1,,,CHEMBL624794,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,BAO_0000218
8765,,,,1,,,CHEMBL624795,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,BAO_0000218
8766,,,,1,,,CHEMBL623921,,Intermediate,A,,1,,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,BAO_0000218
8767,,,,1,,,CHEMBL623922,,Intermediate,A,,1,,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
8768,,,,1,,,CHEMBL623923,,Intermediate,A,,1,,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
8769,,,,1,,,CHEMBL623924,,Intermediate,A,,1,,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
8770,,,,1,,,CHEMBL623925,,Intermediate,A,,1,,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
8771,,,,1,,,CHEMBL623926,,Intermediate,A,,1,,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
8772,,,,1,,,CHEMBL623927,,Intermediate,A,,1,,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
8773,,,,1,,,CHEMBL623928,,Intermediate,A,,1,,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
8774,,,,1,,,CHEMBL623929,,Intermediate,A,,1,,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
8775,,,,1,,,CHEMBL623930,,Intermediate,A,,1,,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
8776,,,955.0,1,Brain,,CHEMBL623931,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
8777,,,955.0,1,Brain,,CHEMBL622165,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,BAO_0000218
8778,,,955.0,1,Brain,,CHEMBL621249,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
8779,,,955.0,1,Brain,,CHEMBL621250,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
8780,,,955.0,1,Brain,,CHEMBL621448,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,BAO_0000218
8781,,,955.0,1,Brain,,CHEMBL621449,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,BAO_0000218
8782,,,955.0,1,Brain,,CHEMBL621450,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,BAO_0000218
8783,,,955.0,1,Brain,,CHEMBL621451,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,50597,BAO_0000218
8784,,,955.0,1,Brain,,CHEMBL621452,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,BAO_0000218
8785,,,955.0,1,Brain,,CHEMBL621453,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,BAO_0000218
8786,,,955.0,1,Brain,,CHEMBL621454,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,BAO_0000218
8787,,,955.0,1,Brain,,CHEMBL621455,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,BAO_0000218
8788,,,955.0,1,Brain,,CHEMBL621456,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,BAO_0000218
8789,,,955.0,1,Brain,,CHEMBL625145,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,BAO_0000218
8790,,,955.0,1,Brain,,CHEMBL875847,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,BAO_0000218
8791,,,955.0,1,Brain,,CHEMBL625146,,Intermediate,A,,1,,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,BAO_0000218
8792,,,955.0,1,Brain,,CHEMBL625147,,Intermediate,A,,1,,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
8793,,,955.0,1,Brain,,CHEMBL625148,,Intermediate,A,,1,,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
8794,,,955.0,1,Brain,,CHEMBL625149,,Intermediate,A,,1,,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
8795,,,955.0,1,Brain,,CHEMBL625150,,Intermediate,A,,1,,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
8796,,,955.0,1,Brain,,CHEMBL625151,,Intermediate,A,,1,,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
8797,,,955.0,1,Brain,,CHEMBL625152,,Intermediate,A,,1,,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
8798,,,955.0,1,Brain,,CHEMBL625153,,Intermediate,A,,1,,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
8799,,,955.0,1,Brain,,CHEMBL625154,,Intermediate,A,,1,,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
8800,,,955.0,1,Brain,,CHEMBL625155,,Intermediate,A,,1,,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
8801,,,,1,,,CHEMBL625156,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
8802,,,,1,,,CHEMBL624354,,Intermediate,A,,1,,N,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8803,,,10000000.0,1,Hippocampus,,CHEMBL624355,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8804,,,10000000.0,1,Hippocampus,,CHEMBL624356,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8805,,,10000000.0,1,Hippocampus,,CHEMBL624357,,Intermediate,A,,1,,N,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8806,,,10000000.0,1,Hippocampus,,CHEMBL624358,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8807,,,2435.0,1,Striatum,,CHEMBL624359,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8808,,,2435.0,1,Striatum,,CHEMBL624360,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8809,,,2435.0,1,Striatum,,CHEMBL624361,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
8810,,,2435.0,1,Striatum,,CHEMBL624362,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8811,,,2435.0,1,Striatum,,CHEMBL624363,,Intermediate,A,,1,,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8812,,,178.0,1,Blood,In vivo,CHEMBL624364,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8813,,,178.0,1,Blood,In vivo,CHEMBL624365,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8814,,,178.0,1,Blood,In vivo,CHEMBL624366,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8815,,,178.0,1,Blood,In vivo,CHEMBL624367,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8816,,,955.0,1,Brain,In vivo,CHEMBL624368,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8817,,,955.0,1,Brain,In vivo,CHEMBL624369,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8818,,,955.0,1,Brain,In vivo,CHEMBL624370,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
8819,,,955.0,1,Brain,In vivo,CHEMBL625069,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8820,,,955.0,1,Brain,In vivo,CHEMBL625070,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8821,,,948.0,1,Heart,In vivo,CHEMBL626051,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8822,,,948.0,1,Heart,In vivo,CHEMBL626052,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8823,,,948.0,1,Heart,In vivo,CHEMBL626053,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
8824,,,948.0,1,Heart,In vivo,CHEMBL626054,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8825,,,948.0,1,Heart,In vivo,CHEMBL626055,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8826,,,2113.0,1,Kidney,In vivo,CHEMBL626056,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8827,,,2113.0,1,Kidney,In vivo,CHEMBL626057,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8828,,,2113.0,1,Kidney,In vivo,CHEMBL625193,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8829,,,2113.0,1,Kidney,In vivo,CHEMBL625194,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8830,,,2107.0,1,Liver,In vivo,CHEMBL625195,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8831,,,2107.0,1,Liver,In vivo,CHEMBL625196,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8832,,,2107.0,1,Liver,In vivo,CHEMBL625197,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
8833,,,2107.0,1,Liver,In vivo,CHEMBL625198,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8834,,,2107.0,1,Liver,In vivo,CHEMBL627929,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8835,,,2048.0,1,Lung,In vivo,CHEMBL627074,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8836,,,2048.0,1,Lung,In vivo,CHEMBL627075,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8837,,,2048.0,1,Lung,In vivo,CHEMBL627076,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
8838,,,2048.0,1,Lung,In vivo,CHEMBL627077,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8839,,,2048.0,1,Lung,In vivo,CHEMBL627078,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8840,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627079,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
8841,,,,1,,In vivo,CHEMBL873824,,Intermediate,A,,1,,N,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,50594,BAO_0000218
8842,,,1969.0,1,Plasma,In vivo,CHEMBL627080,,Intermediate,A,,1,,N,Half life in mouse plasma was determined at dose 25 mg/kg,,,50594,BAO_0000218
8843,,,,1,,,CHEMBL627081,,Intermediate,A,,1,,N,Half life was determined,,,50594,BAO_0000218
8844,,,,1,,In vivo,CHEMBL627082,,Intermediate,A,,1,,N,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,,50594,BAO_0000218
8845,,,,1,,In vivo,CHEMBL627083,,Intermediate,A,,1,,N,Half-life in male mice after 1 mg/kg intravenous dose,,,50594,BAO_0000218
8847,,,1969.0,1,Plasma,,CHEMBL627085,,Intermediate,A,,1,,N,Half life in mice plasma,,,50594,BAO_0000218
8848,,,,1,,,CHEMBL627086,,Intermediate,A,,1,,N,Half life in mouse,,,50594,BAO_0000218
8849,,,1969.0,1,Plasma,In vivo,CHEMBL627087,,Intermediate,A,,1,,N,Half life in mouse plasma at dose 25 mg/kg,,,50594,BAO_0000218
8850,,,,1,,In vivo,CHEMBL627088,,Intermediate,A,,1,,N,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,,50594,BAO_0000218
8851,,,,1,,In vivo,CHEMBL627089,,Intermediate,A,,1,,N,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,,50594,BAO_0000218
8852,,,,1,,In vivo,CHEMBL627090,,Intermediate,A,,1,,N,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,,50594,BAO_0000218
8853,,,,1,,In vivo,CHEMBL627091,,Intermediate,A,,1,,N,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,50594,BAO_0000218
8854,,,,1,,In vivo,CHEMBL627092,,Intermediate,A,,1,,N,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,,50594,BAO_0000218
8855,,,,1,,In vivo,CHEMBL876785,,Intermediate,A,,1,,N,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,,50594,BAO_0000218
8856,,,,1,,In vivo,CHEMBL627093,,Intermediate,A,,1,,N,Half-life by iv administration in mouse,,,50594,BAO_0000218
8857,,,,1,,In vivo,CHEMBL627094,,Intermediate,A,,1,,N,Half-life by oral administration in mouse,,,50594,BAO_0000218
8858,,,,1,,,CHEMBL627095,,Intermediate,A,,1,,N,Half-life in mice,,,50594,BAO_0000218
8859,,,955.0,1,Brain,,CHEMBL627096,,Intermediate,A,,1,,N,Half-life using mouse brain homogenate,,,50594,BAO_0000218
8860,,,,1,,,CHEMBL627097,,Intermediate,A,,1,,N,Half-life was measured in mice,,,50594,BAO_0000218
8861,,,,1,,In vivo,CHEMBL627098,,Intermediate,A,,1,,N,Half-life was measured in mouse after an iv dose of 1 mg/kg,,,50594,BAO_0000218
8862,,,178.0,1,Blood,,CHEMBL627099,,Intermediate,A,,1,,N,Half-life period was determined in mouse blood,,,50594,BAO_0000218
8863,,,955.0,1,Brain,,CHEMBL627100,,Intermediate,A,,1,,N,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",,,50594,BAO_0000218
8864,,,1969.0,1,Plasma,,CHEMBL627101,,Intermediate,A,,1,,N,Plasma half life in mouse,,,50594,BAO_0000218
8865,,,,1,,,CHEMBL627102,,Intermediate,A,,1,,N,Stability of the peptide in the presence of mouse serum,,,50594,BAO_0000218
8866,,,,1,,,CHEMBL627103,,Intermediate,A,,1,,N,Terminal half life of compound was determined in mouse,,,50594,BAO_0000218
8867,,,,1,,In vivo,CHEMBL627104,,Intermediate,A,,1,,N,Terminal half life was evaluated in mice after intravenous administration,,,50594,BAO_0000218
8868,,,,1,,In vivo,CHEMBL627105,,Intermediate,A,,1,,N,Terminal half life was evaluated in mice after oral administration,,,50594,BAO_0000218
8869,,,,1,,,CHEMBL876786,,Intermediate,A,,1,,N,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,,50594,BAO_0000218
8870,,,,1,,,CHEMBL873825,,Intermediate,A,,1,,N,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,,50594,BAO_0000218
8871,,,,1,,,CHEMBL627106,,Intermediate,A,,1,,N,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,,50594,BAO_0000218
8872,,,,1,,In vivo,CHEMBL626336,,Intermediate,A,,1,,N,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,,50594,BAO_0000218
8873,,,,1,,In vivo,CHEMBL877462,,Intermediate,A,,1,,N,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,,50594,BAO_0000218
8874,,,,1,,In vivo,CHEMBL626337,,Intermediate,A,,1,,N,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,,50594,BAO_0000218
8875,,,,1,,,CHEMBL626338,,Intermediate,A,,1,,N,Half life after intraperitoneal administration of 100 mg/kg in mice,,,50594,BAO_0000218
8876,,,,1,,In vivo,CHEMBL626339,,Intermediate,A,,1,,N,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,,50594,BAO_0000218
8877,,,,1,,In vivo,CHEMBL626340,,Intermediate,A,,1,,N,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,,50594,BAO_0000218
8878,,,,1,,In vivo,CHEMBL625377,,Intermediate,A,,1,,N,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,,50594,BAO_0000218
8879,,,,1,,In vivo,CHEMBL625378,,Intermediate,A,,1,,N,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,,50594,BAO_0000218
8880,,,,1,,In vivo,CHEMBL625379,,Intermediate,A,,1,,N,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,,50594,BAO_0000218
8881,,,,0,,,CHEMBL625380,,Autocuration,A,,1,Microsomes,U,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,,22224,BAO_0000251
8882,,,,0,,,CHEMBL625381,,Autocuration,A,,1,Microsomes,U,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,,22224,BAO_0000251
8883,,,,0,,,CHEMBL625382,,Autocuration,A,,1,,U,Stability to porcine renal DHP-I,,,22224,BAO_0000019
8884,,,,0,,In vivo,CHEMBL873828,,Autocuration,A,,1,,U,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,,22224,BAO_0000218
8885,,,,0,,In vivo,CHEMBL625383,,Autocuration,A,,1,,U,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,,22224,BAO_0000218
8886,,,,0,,,CHEMBL625384,,Autocuration,A,,1,,U,Half-life of the parent prodrug in porcine esterase solution,,,22224,BAO_0000019
8887,,,,0,,,CHEMBL625385,,Autocuration,A,,1,,U,"First order rate constant, k was determined in in pig liver Esterase",,,22224,BAO_0000019
8888,,,2107.0,0,Liver,,CHEMBL625386,,Autocuration,A,,1,,U,Half life of the in pig liver Esterase,,,22224,BAO_0000221
8889,,,2107.0,0,Liver,,CHEMBL623571,,Autocuration,A,,1,,U,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,,,22224,BAO_0000221
8890,,,2107.0,0,Liver,,CHEMBL623572,,Autocuration,A,,1,,U,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,,,22224,BAO_0000221
8891,,,2107.0,0,Liver,,CHEMBL623573,,Autocuration,A,,1,,U,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,,,22224,BAO_0000221
8892,,,2107.0,0,Liver,,CHEMBL623574,,Autocuration,A,,1,,U,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,,,22224,BAO_0000221
8893,,,2107.0,0,Liver,,CHEMBL623575,,Autocuration,A,,1,,U,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,,,22224,BAO_0000221
8894,,,2107.0,0,Liver,,CHEMBL623749,,Autocuration,A,,1,,U,Half-life in the presence of pig liver esterase(PLE) was evaluated.,,,22224,BAO_0000221
8895,,,2107.0,0,Liver,,CHEMBL623750,,Autocuration,A,,1,,U,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,,,22224,BAO_0000221
8896,,,2107.0,0,Liver,In vitro,CHEMBL623751,,Autocuration,A,,1,,U,Half-life in vitro in pig liver,,,22224,BAO_0000221
8897,,,2107.0,0,Liver,,CHEMBL623752,,Autocuration,A,,1,,U,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,,,22224,BAO_0000221
8898,,,1969.0,1,Plasma,In vivo,CHEMBL623753,,Intermediate,A,,1,,N,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,,50597,BAO_0000218
8899,,,1969.0,1,Plasma,In vivo,CHEMBL623754,,Intermediate,A,,1,,N,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,,50597,BAO_0000218
8900,,,1969.0,1,Plasma,In vivo,CHEMBL623755,,Intermediate,A,,1,,N,Maximum concentration in rat plasma was determined,,,50597,BAO_0000218
8901,,,,1,,In vivo,CHEMBL623756,,Intermediate,A,,1,,N,Maximum concentration in rats,,,50597,BAO_0000218
8902,,,,1,,In vivo,CHEMBL623757,,Intermediate,A,,1,,N,Maximum concentration in rats at 1-2 hours,,,50597,BAO_0000218
8903,,,,1,,In vivo,CHEMBL623758,,Intermediate,A,,1,,N,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,,50597,BAO_0000218
8904,,,955.0,1,Brain,In vivo,CHEMBL623759,,Intermediate,A,,1,,N,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,,,50597,BAO_0000218
8905,,,,1,,In vivo,CHEMBL623760,,Intermediate,A,,1,,N,Maximum concentration at the dose of 2 mg/kg in rat,,,50597,BAO_0000218
8906,,,,1,,In vivo,CHEMBL623761,,Intermediate,A,,1,,N,Maximum concentration was evaluated in rats,,,50597,BAO_0000218
8907,,,1969.0,1,Plasma,In vivo,CHEMBL623762,,Intermediate,A,,1,,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,,,50597,BAO_0000218
8908,,,1969.0,1,Plasma,In vivo,CHEMBL877594,,Intermediate,A,,1,,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,,,50597,BAO_0000218
8909,,,1969.0,1,Plasma,In vivo,CHEMBL623763,,Intermediate,A,,1,,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,,,50597,BAO_0000218
8910,,,1969.0,1,Plasma,In vivo,CHEMBL623764,,Intermediate,A,,1,,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,,,50597,BAO_0000218
8911,,,1969.0,1,Plasma,In vivo,CHEMBL623765,,Intermediate,A,,1,,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,,,50597,BAO_0000218
8912,,,178.0,1,Blood,In vivo,CHEMBL623766,,Intermediate,A,,1,,N,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,,,50597,BAO_0000218
8913,,,178.0,1,Blood,In vivo,CHEMBL623767,,Intermediate,A,,1,,N,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,,,50597,BAO_0000218
8914,,,178.0,1,Blood,In vivo,CHEMBL623768,,Intermediate,A,,1,,N,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,,,50597,BAO_0000218
8915,,,1969.0,1,Plasma,In vivo,CHEMBL623769,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,,,50597,BAO_0000218
8916,,,1969.0,1,Plasma,In vivo,CHEMBL623770,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,,,50597,BAO_0000218
8917,,,1969.0,1,Plasma,In vivo,CHEMBL623771,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,,,50597,BAO_0000218
8918,,,1969.0,1,Plasma,In vivo,CHEMBL623772,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,,,50597,BAO_0000218
8919,,,1969.0,1,Plasma,In vivo,CHEMBL623773,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,,,50597,BAO_0000218
8920,,,1969.0,1,Plasma,In vivo,CHEMBL623774,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,,,50597,BAO_0000218
8921,,,1969.0,1,Plasma,In vivo,CHEMBL623775,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,,,50597,BAO_0000218
8922,,,,1,,In vivo,CHEMBL623776,,Intermediate,A,,1,,N,Cmax in rat (PO dose),,,50597,BAO_0000218
8923,,,1969.0,1,Plasma,In vivo,CHEMBL622191,,Intermediate,A,,1,,N,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
8924,,,1969.0,1,Plasma,In vivo,CHEMBL622192,,Intermediate,A,,1,,N,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
8925,,,1969.0,1,Plasma,In vivo,CHEMBL622193,,Intermediate,A,,1,,N,Maximum plasma concentration determined in rat,,,50597,BAO_0000218
8926,,,1969.0,1,Plasma,In vivo,CHEMBL622194,,Intermediate,A,,1,,N,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,,50597,BAO_0000218
8927,,,1969.0,1,Plasma,In vivo,CHEMBL622195,,Intermediate,A,,1,,N,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,,50597,BAO_0000218
8928,,,1969.0,1,Plasma,In vivo,CHEMBL622196,,Intermediate,A,,1,,N,Maximum plasma concentration in rat,,,50597,BAO_0000218
8929,,,1969.0,1,Plasma,In vivo,CHEMBL622197,,Intermediate,A,,1,,N,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,50597,BAO_0000218
8930,,,1969.0,1,Plasma,In vivo,CHEMBL622198,,Intermediate,A,,1,,N,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,,,50597,BAO_0000218
8931,,,1969.0,1,Plasma,In vivo,CHEMBL622199,,Intermediate,A,,1,,N,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,,,50597,BAO_0000218
8932,,,1969.0,1,Plasma,In vivo,CHEMBL622200,,Intermediate,A,,1,,N,Maximum plasma concentration of compound was measured in rat,,,50597,BAO_0000218
8933,,,1969.0,1,Plasma,In vivo,CHEMBL622201,,Intermediate,A,,1,,N,Maximum plasma concentration after 20 mg/kg oral administration in rat,,,50597,BAO_0000218
8934,,,1969.0,1,Plasma,In vivo,CHEMBL623990,,Intermediate,A,,1,,N,Maximum plasma concentration after oral administration to rats,,,50597,BAO_0000218
8935,,,1969.0,1,Plasma,In vivo,CHEMBL623991,,Intermediate,A,,1,,N,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,50597,BAO_0000218
8936,,,1969.0,1,Plasma,In vivo,CHEMBL623992,,Intermediate,A,,1,,N,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",,,50597,BAO_0000218
8937,,,1969.0,1,Plasma,In vivo,CHEMBL623993,,Intermediate,A,,1,,N,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,50597,BAO_0000218
8938,,,1969.0,1,Plasma,In vivo,CHEMBL623994,,Intermediate,A,,1,,N,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,,,50597,BAO_0000218
8939,,,1969.0,1,Plasma,In vivo,CHEMBL623995,,Intermediate,F,,1,,N,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,,,50597,BAO_0000218
8940,,,1969.0,1,Plasma,In vivo,CHEMBL623996,,Intermediate,F,,1,,N,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,,,50597,BAO_0000218
8941,,,1969.0,1,Plasma,In vivo,CHEMBL623997,,Intermediate,F,,1,,N,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,,,50597,BAO_0000218
8942,,,1969.0,1,Plasma,In vivo,CHEMBL623998,,Intermediate,A,,1,,N,Maximum plasma concentration dosed orally in rats,,,50597,BAO_0000218
8943,,,1969.0,1,Plasma,In vivo,CHEMBL623999,,Intermediate,A,,1,,N,Maximum plasma concentration dosed orally in rats after 6 hours,,,50597,BAO_0000218
8944,,,1969.0,1,Plasma,In vivo,CHEMBL624000,,Intermediate,A,,1,,N,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,,,50597,BAO_0000218
8945,,,1969.0,1,Plasma,In vivo,CHEMBL624001,,Intermediate,A,,1,,N,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,,50597,BAO_0000218
8946,,,1969.0,1,Plasma,In vivo,CHEMBL624002,,Intermediate,A,,1,,N,Maximum plasma concentration in rat after po administration,,,50597,BAO_0000218
8947,,,1969.0,1,Plasma,In vivo,CHEMBL624003,,Intermediate,A,,1,,N,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",,,50597,BAO_0000218
8948,,,1969.0,1,Plasma,In vivo,CHEMBL624004,,Intermediate,A,,1,,N,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",,,50597,BAO_0000218
8949,,,948.0,1,Heart,,CHEMBL624005,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
8950,,,948.0,1,Heart,,CHEMBL624006,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,BAO_0000218
8951,,,948.0,1,Heart,,CHEMBL624007,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
8952,,,948.0,1,Heart,,CHEMBL624008,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
8953,,,948.0,1,Heart,,CHEMBL624009,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,BAO_0000218
8954,,,948.0,1,Heart,,CHEMBL874387,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,BAO_0000218
8955,,,948.0,1,Heart,,CHEMBL624010,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,BAO_0000218
8956,,,948.0,1,Heart,,CHEMBL624011,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,,50597,BAO_0000218
8957,,,948.0,1,Heart,,CHEMBL624012,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,BAO_0000218
8958,,,948.0,1,Heart,,CHEMBL624013,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,BAO_0000218
8959,,,948.0,1,Heart,,CHEMBL624736,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,BAO_0000218
8960,,,948.0,1,Heart,,CHEMBL624737,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,BAO_0000218
8961,,,948.0,1,Heart,,CHEMBL624738,,Intermediate,A,,1,,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
8962,,,948.0,1,Heart,,CHEMBL624739,,Intermediate,A,,1,,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
8963,,,948.0,1,Heart,,CHEMBL624740,,Intermediate,A,,1,,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
8964,,,948.0,1,Heart,,CHEMBL624896,,Intermediate,A,,1,,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
8965,,,948.0,1,Heart,,CHEMBL624897,,Intermediate,A,,1,,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
8966,,,948.0,1,Heart,,CHEMBL624108,,Intermediate,A,,1,,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
8967,,,948.0,1,Heart,,CHEMBL624109,,Intermediate,A,,1,,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
8968,,,948.0,1,Heart,,CHEMBL624110,,Intermediate,A,,1,,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
8969,,,948.0,1,Heart,,CHEMBL624111,,Intermediate,A,,1,,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
8970,,,948.0,1,Heart,,CHEMBL624112,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,BAO_0000218
8971,,,948.0,1,Heart,,CHEMBL624113,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,BAO_0000218
8972,,,948.0,1,Heart,,CHEMBL619709,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,BAO_0000218
8973,,,948.0,1,Heart,,CHEMBL619710,,Intermediate,A,,1,,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,BAO_0000218
8974,,,2113.0,1,Kidney,,CHEMBL619711,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
8975,,,2113.0,1,Kidney,,CHEMBL619712,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,BAO_0000218
8976,,,2113.0,1,Kidney,,CHEMBL619713,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
8977,,,2113.0,1,Kidney,,CHEMBL619714,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
8978,,,2113.0,1,Kidney,,CHEMBL619715,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,BAO_0000218
8979,,,2113.0,1,Kidney,,CHEMBL619716,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,BAO_0000218
8980,,,2113.0,1,Kidney,,CHEMBL619717,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,BAO_0000218
8981,,,2113.0,1,Kidney,,CHEMBL619718,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,50597,BAO_0000218
8982,,,2113.0,1,Kidney,,CHEMBL619719,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,BAO_0000218
8983,,,2113.0,1,Kidney,,CHEMBL875329,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,BAO_0000218
8984,,,2113.0,1,Kidney,,CHEMBL619720,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,BAO_0000218
8985,,,2113.0,1,Kidney,,CHEMBL619721,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,BAO_0000218
8986,,,2113.0,1,Kidney,,CHEMBL619722,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,BAO_0000218
8987,,,2113.0,1,Kidney,,CHEMBL619723,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,BAO_0000218
8988,,,2113.0,1,Kidney,,CHEMBL619724,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,BAO_0000218
8989,,,2113.0,1,Kidney,,CHEMBL619725,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,BAO_0000218
8990,,,2113.0,1,Kidney,,CHEMBL619726,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
8991,,,2113.0,1,Kidney,,CHEMBL619727,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
8992,,,2113.0,1,Kidney,,CHEMBL619728,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
8993,,,2113.0,1,Kidney,,CHEMBL619729,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
8994,,,2385.0,1,Muscle tissue,In vivo,CHEMBL619730,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8995,,,2385.0,1,Muscle tissue,In vivo,CHEMBL619731,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8996,,,2385.0,1,Muscle tissue,In vivo,CHEMBL619732,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
8997,,,2385.0,1,Muscle tissue,In vivo,CHEMBL619733,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8998,,,2385.0,1,Muscle tissue,In vivo,CHEMBL619734,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
8999,,,14.0,1,Zone of skin,In vivo,CHEMBL619735,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9000,,,14.0,1,Zone of skin,In vivo,CHEMBL875330,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9001,,,14.0,1,Zone of skin,In vivo,CHEMBL628465,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
9002,,,14.0,1,Zone of skin,In vivo,CHEMBL628466,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9003,,,14.0,1,Zone of skin,In vivo,CHEMBL628467,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9004,,,2106.0,1,Spleen,In vivo,CHEMBL628468,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9005,,,2106.0,1,Spleen,In vivo,CHEMBL628469,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9006,,,2106.0,1,Spleen,In vivo,CHEMBL628470,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
9007,,,2106.0,1,Spleen,In vivo,CHEMBL628471,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9008,,,2106.0,1,Spleen,In vivo,CHEMBL628472,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9009,,,2046.0,1,Thyroid gland,In vivo,CHEMBL625191,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9010,,,2046.0,1,Thyroid gland,In vivo,CHEMBL625192,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9011,,,2046.0,1,Thyroid gland,In vivo,CHEMBL875337,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,50597,BAO_0000218
9012,,,2046.0,1,Thyroid gland,In vivo,CHEMBL626341,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9013,,,2046.0,1,Thyroid gland,In vivo,CHEMBL626342,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9014,,,2107.0,1,Liver,In vivo,CHEMBL621943,,Intermediate,A,,1,,N,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,50597,BAO_0000218
9015,,,,1,,,CHEMBL621944,,Intermediate,A,,1,,N,Half life in rats,,,50597,BAO_0000218
9016,,,,1,,,CHEMBL621945,,Intermediate,A,,1,,N,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,,50597,BAO_0000218
9017,,,,1,,,CHEMBL621946,,Intermediate,A,,1,,N,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,,50597,BAO_0000218
9018,,,,1,,,CHEMBL621947,,Intermediate,A,,1,,N,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,,50597,BAO_0000218
9019,,,,1,,,CHEMBL621948,,Intermediate,A,,1,,N,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,,50597,BAO_0000218
9020,,,,1,,,CHEMBL621949,,Intermediate,A,,1,,N,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,,50597,BAO_0000218
9021,,,,1,,,CHEMBL621950,,Intermediate,A,,1,,N,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,,50597,BAO_0000218
9022,,,,1,,,CHEMBL621951,,Intermediate,A,,1,,N,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,,50597,BAO_0000218
9023,,,178.0,1,Blood,In vivo,CHEMBL621952,,Intermediate,A,,1,,N,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,,,50597,BAO_0000218
9024,,,2107.0,1,Liver,,CHEMBL621953,,Intermediate,A,,1,,N,Stability (%) in rat liver microsomes,,,50597,BAO_0000218
9025,,,,1,,,CHEMBL621954,,Intermediate,A,,1,,N,Area under curve was calculated after intravenous administration,,,50597,BAO_0000218
9026,,,,1,,,CHEMBL621955,,Intermediate,A,,1,,N,Area under the curve was calculated after iv administration in rat,,,50597,BAO_0000218
9027,,,,1,,,CHEMBL621956,,Intermediate,A,,1,,N,Area under the curve was calculated in rat after peroral administration,,,50597,BAO_0000218
9028,,,,1,,,CHEMBL621957,,Intermediate,A,,1,,N,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,,50597,BAO_0000218
9029,,,,1,,,CHEMBL621958,,Intermediate,A,,1,,N,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,,50597,BAO_0000218
9030,,,,1,,,CHEMBL621959,,Intermediate,A,,1,,N,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,,50597,BAO_0000218
9031,,,,1,,,CHEMBL621960,,Intermediate,A,,1,,N,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,,50597,BAO_0000218
9032,,,,1,,,CHEMBL621961,,Intermediate,A,,1,,N,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,,50597,BAO_0000218
9033,,,,1,,,CHEMBL621962,,Intermediate,A,,1,,N,p value of the compound,,,50597,BAO_0000218
9034,,,,1,,,CHEMBL876787,,Intermediate,F,,1,,N,p value of the compound,,,50597,BAO_0000218
9035,,,,1,,,CHEMBL621963,,Intermediate,A,,1,,N,p value of the compound,,,50597,BAO_0000218
9036,,,945.0,1,Stomach,,CHEMBL622637,,Intermediate,A,,1,,N,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,50597,BAO_0000218
9037,,,945.0,1,Stomach,,CHEMBL622638,,Intermediate,A,,1,,N,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,50597,BAO_0000218
9038,,,945.0,1,Stomach,,CHEMBL626561,,Intermediate,A,,1,,N,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,50597,BAO_0000218
9039,,,,0,,,CHEMBL626562,,Autocuration,F,,1,,U,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,,22224,BAO_0000019
9040,,,,0,,,CHEMBL626563,,Autocuration,A,,1,,U,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,,22224,BAO_0000218
9041,,,,0,,,CHEMBL626564,,Autocuration,A,,1,,U,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,,22224,BAO_0000218
9042,,,,0,,In vivo,CHEMBL626565,,Autocuration,A,,1,,U,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,,22224,BAO_0000218
9043,,,,0,,In vivo,CHEMBL626566,,Autocuration,A,,1,,U,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,,22224,BAO_0000218
9044,,,,0,,In vivo,CHEMBL626567,,Autocuration,A,,1,,U,Clearance rate in rabbits,,,22224,BAO_0000218
9045,,,,0,,In vivo,CHEMBL626568,,Autocuration,A,,1,,U,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,,22224,BAO_0000218
9046,,,,0,,In vivo,CHEMBL626569,,Autocuration,A,,1,,U,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,,22224,BAO_0000218
9047,,,,0,,In vivo,CHEMBL626570,,Autocuration,A,,1,,U,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,,22224,BAO_0000218
9048,,,,0,,In vivo,CHEMBL626571,,Autocuration,A,,1,,U,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,,22224,BAO_0000218
9049,,,,0,,In vivo,CHEMBL626572,,Autocuration,A,,1,,U,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,,22224,BAO_0000218
9050,,,1969.0,0,Plasma,In vivo,CHEMBL626573,,Autocuration,A,,1,,U,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,,22224,BAO_0000218
9051,,,2107.0,0,Liver,,CHEMBL626574,,Autocuration,A,,1,Microsomes,U,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,,,22224,BAO_0000251
9052,,,2107.0,0,Liver,,CHEMBL626575,,Autocuration,A,,1,Microsomes,U,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,,,22224,BAO_0000251
9053,,,,0,,,CHEMBL626576,,Autocuration,A,,1,,U,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,,22224,BAO_0000218
9054,,,,0,,,CHEMBL626577,,Autocuration,A,,1,,U,Dose at which bioavailability of perorally administered compound was tested in rabbit,,,22224,BAO_0000218
9055,,,,0,,In vivo,CHEMBL626578,,Autocuration,A,,1,,U,The compound was tested for its bioavailability in rabbit (by oral dosage).,,,22224,BAO_0000218
9056,,,,0,,In vivo,CHEMBL625263,,Autocuration,A,,1,,U,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,,22224,BAO_0000218
9057,,,,0,,In vivo,CHEMBL625264,,Autocuration,A,,1,,U,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,,22224,BAO_0000218
9058,,,,0,,In vivo,CHEMBL625265,,Autocuration,A,,1,,U,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,,22224,BAO_0000218
9059,,,,0,,,CHEMBL625266,,Autocuration,A,,1,Microsomes,U,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,,22224,BAO_0000251
9060,,,,0,,,CHEMBL876796,,Autocuration,A,,1,Microsomes,U,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,,22224,BAO_0000251
9061,,,,0,,In vivo,CHEMBL625267,,Autocuration,A,,1,,U,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,,22224,BAO_0000218
9062,,,1969.0,0,Plasma,In vivo,CHEMBL625268,,Autocuration,A,,1,,U,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,,22224,BAO_0000218
9063,,,1969.0,0,Plasma,In vivo,CHEMBL625269,,Autocuration,A,,1,,U,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,,22224,BAO_0000218
9064,,,1969.0,0,Plasma,In vivo,CHEMBL624689,,Autocuration,A,,1,,U,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,,22224,BAO_0000218
9065,,,,0,,In vivo,CHEMBL624690,,Autocuration,A,,1,,U,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,,22224,BAO_0000218
9066,,,1088.0,0,Urine,,CHEMBL624691,,Autocuration,A,,1,,U,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),,,22224,BAO_0000218
9067,,,1088.0,0,Urine,,CHEMBL624692,,Autocuration,A,,1,,U,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),,,22224,BAO_0000218
9068,,,,0,,In vivo,CHEMBL624693,,Autocuration,A,,1,,U,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,,22224,BAO_0000218
9069,,,,0,,In vivo,CHEMBL624694,,Autocuration,A,,1,,U,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,,22224,BAO_0000218
9070,,,,0,,In vitro,CHEMBL877596,,Autocuration,A,,1,,U,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,,22224,BAO_0000221
9071,,,,0,,,CHEMBL624695,,Autocuration,A,,1,,U,Time within which only 10% of the drug was degraded,,,22224,BAO_0000019
9072,,,2107.0,0,Liver,,CHEMBL624696,,Autocuration,A,,1,,U,Half life period in rabbit liver homogenate,,,22224,BAO_0000221
9073,,,,0,,,CHEMBL624697,,Autocuration,A,,1,,U,Half life value in rabbits,,,22224,BAO_0000019
9074,,,178.0,0,Blood,In vivo,CHEMBL624698,,Autocuration,A,,1,,U,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,,22224,BAO_0000218
9075,,,178.0,0,Blood,In vivo,CHEMBL624699,,Autocuration,A,,1,,U,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,,22224,BAO_0000218
9076,,,,0,,In vivo,CHEMBL624700,,Autocuration,A,,1,,U,Half-life period in rabbits following intravenous administration at 2 mg/kg,,,22224,BAO_0000218
9077,,,1969.0,1,Plasma,,CHEMBL622903,,Intermediate,A,,1,,N,AUC 0-8 hr value in rats at 10 mg/kg,,,50597,BAO_0000218
9078,,,1969.0,1,Plasma,,CHEMBL622904,,Intermediate,A,,1,,N,AUC after administration at 2000 mg/kg/day in rats,,,50597,BAO_0000218
9079,,,1969.0,1,Plasma,,CHEMBL622905,,Intermediate,A,,1,,N,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,,,50597,BAO_0000218
9080,,,1969.0,1,Plasma,,CHEMBL622906,,Intermediate,A,,1,,N,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,50597,BAO_0000218
9081,,,1969.0,1,Plasma,,CHEMBL622907,,Intermediate,A,,1,,N,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,50597,BAO_0000218
9082,,,1969.0,1,Plasma,,CHEMBL622908,,Intermediate,A,,1,,N,AUC in rat after oral administration at 10.5 mg/kg dose,,,50597,BAO_0000218
9083,,,1969.0,1,Plasma,,CHEMBL622909,,Intermediate,A,,1,,N,AUC in rat after oral administration at 11.2 mg/kg dose,,,50597,BAO_0000218
9084,,,1969.0,1,Plasma,,CHEMBL622910,,Intermediate,A,,1,,N,AUC in rat after oral administration at 9.7 mg/kg dose,,,50597,BAO_0000218
9085,,,955.0,1,Brain,,CHEMBL622911,,Intermediate,A,,1,,N,AUC in rat brain after oral administration at 10 mg/kg,,,50597,BAO_0000218
9086,,,1969.0,1,Plasma,,CHEMBL622912,,Intermediate,A,,1,,N,AUC in rat p.o.,,,50597,BAO_0000218
9087,,,1969.0,1,Plasma,,CHEMBL622913,,Intermediate,A,,1,,N,AUC in rat p.o. at 20 mg/kg concentration,,,50597,BAO_0000218
9088,,,1969.0,1,Plasma,,CHEMBL622914,,Intermediate,A,,1,,N,AUC in rat plasma after oral administration at 10 mg/kg,,,50597,BAO_0000218
9089,,,1969.0,1,Plasma,,CHEMBL622915,,Intermediate,A,,1,,N,AUC in rats,,,50597,BAO_0000218
9090,,,1969.0,1,Plasma,,CHEMBL622916,,Intermediate,A,,1,,N,AUC value after IV dose at a dose of 5 mg/kg in rats.,,,50597,BAO_0000218
9091,,,1969.0,1,Plasma,,CHEMBL622917,,Intermediate,A,,1,,N,AUC value after oral dose at a dose of 10 mg/kg in rats.,,,50597,BAO_0000218
9092,,,1969.0,1,Plasma,In vivo,CHEMBL622918,,Intermediate,A,,1,,N,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,,50597,BAO_0000218
9093,,,1969.0,1,Plasma,In vivo,CHEMBL622919,,Intermediate,A,,1,,N,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,,,50597,BAO_0000218
9094,,,1969.0,1,Plasma,In vivo,CHEMBL622920,,Intermediate,A,,1,,N,Maximum plasma concentration was evaluated in rat,,,50597,BAO_0000218
9095,,,1969.0,1,Plasma,In vivo,CHEMBL622921,,Intermediate,A,,1,,N,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,,50597,BAO_0000218
9096,,,1969.0,1,Plasma,In vivo,CHEMBL622922,,Intermediate,A,,1,,N,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,,50597,BAO_0000218
9097,,,1969.0,1,Plasma,In vivo,CHEMBL622923,,Intermediate,A,,1,,N,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,,50597,BAO_0000218
9098,,,1969.0,1,Plasma,In vivo,CHEMBL877604,,Intermediate,A,,1,,N,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,,50597,BAO_0000218
9099,,,1969.0,1,Plasma,In vivo,CHEMBL622924,,Intermediate,A,,1,,N,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,,,50597,BAO_0000218
9100,,,1969.0,1,Plasma,In vivo,CHEMBL622925,,Intermediate,A,,1,,N,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,,,50597,BAO_0000218
9101,,,1969.0,1,Plasma,In vivo,CHEMBL622926,,Intermediate,A,,1,,N,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,,,50597,BAO_0000218
9102,,,1969.0,1,Plasma,In vivo,CHEMBL623625,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,,,50597,BAO_0000218
9103,,,1969.0,1,Plasma,In vivo,CHEMBL623626,,Expert,A,,1,,N,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,BAO_0000218
9104,,,1969.0,1,Plasma,In vivo,CHEMBL623627,,Intermediate,A,,1,,N,Maximum plasma drug concentration was determined,,,50597,BAO_0000218
9105,,,,1,,In vivo,CHEMBL623628,,Intermediate,A,,1,,N,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,,50597,BAO_0000218
9106,,,1969.0,1,Plasma,In vivo,CHEMBL623629,,Intermediate,A,,1,,N,Mean peak plasma concentration was observed after intravenous administration in rat,,,50597,BAO_0000218
9107,,,1969.0,1,Plasma,In vivo,CHEMBL623630,,Intermediate,A,,1,,N,Mean peak plasma concentration was observed after oral administration in rat,,,50597,BAO_0000218
9108,,,,1,,In vivo,CHEMBL623804,,Intermediate,A,,1,,N,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,,50597,BAO_0000218
9109,,,,1,,In vivo,CHEMBL623805,,Intermediate,A,,1,,N,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,,50597,BAO_0000218
9110,,,1969.0,1,Plasma,In vivo,CHEMBL623806,,Intermediate,A,,1,,N,Peak oral plasma concentration was determined in rats by oral administration,,,50597,BAO_0000218
9111,,,1969.0,1,Plasma,In vivo,CHEMBL623807,,Intermediate,A,,1,,N,Peak plasma concentration (Cmax) was determined,,,50597,BAO_0000218
9112,,,1969.0,1,Plasma,In vivo,CHEMBL623808,,Intermediate,A,,1,,N,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,,,50597,BAO_0000218
9113,,,1969.0,1,Plasma,In vivo,CHEMBL623809,,Intermediate,A,,1,,N,Peak plasma concentration (Cmax) in rats,,,50597,BAO_0000218
9114,,,1969.0,1,Plasma,In vivo,CHEMBL623810,,Intermediate,A,,1,,N,Peak plasma concentration at 1 mg/kg peroral administration,,,50597,BAO_0000218
9115,,,1969.0,1,Plasma,In vivo,CHEMBL623811,,Intermediate,A,,1,,N,Peak plasma concentration in rat,,,50597,BAO_0000218
9116,,,1969.0,1,Plasma,In vivo,CHEMBL623812,,Intermediate,A,,1,,N,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",,,50597,BAO_0000218
9117,,,,1,,In vivo,CHEMBL877605,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,,50597,BAO_0000218
9118,,,,1,,In vivo,CHEMBL623813,,Intermediate,A,,1,,N,Pharmacokinetic property (Cmax) in rat,,,50597,BAO_0000218
9119,,,,1,,In vivo,CHEMBL623814,,Intermediate,A,,1,,N,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,,50597,BAO_0000218
9120,,,,1,,In vivo,CHEMBL623815,,Intermediate,A,,1,,N,Cmax in rat after 3mg/kg oral dose,,,50597,BAO_0000218
9121,,,,1,,In vivo,CHEMBL623816,,Intermediate,A,,1,,N,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,Sprague-Dawley,,50597,BAO_0000218
9122,,,,1,,In vivo,CHEMBL623145,,Intermediate,A,,1,,N,Cmax in rats after 20 mg/kg oral dose,,,50597,BAO_0000218
9123,,,1969.0,1,Plasma,In vivo,CHEMBL623146,,Intermediate,A,,1,,N,Cmax in rat plasma after 30mg/kg oral dose,,,50597,BAO_0000218
9124,,,1969.0,1,Plasma,In vivo,CHEMBL623147,,Intermediate,A,,1,,N,Plasma concentration after oral administration of 100 mg/kg to rats,,,50597,BAO_0000218
9125,,,955.0,1,Brain,In vivo,CHEMBL623042,,Intermediate,A,,1,,N,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,,50597,BAO_0000218
9126,,,,1,,In vivo,CHEMBL623043,,Intermediate,A,,1,,N,Tested for the Cmax in rat at 10 mg/kg per orally,,,50597,BAO_0000218
9127,,,,1,,In vivo,CHEMBL623044,,Intermediate,A,,1,,N,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
9128,,,,1,,In vivo,CHEMBL623045,,Intermediate,A,,1,,N,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
9129,,,,1,,In vivo,CHEMBL623046,,Intermediate,A,,1,,N,Bioavailability as oral Cmax in rats at 30 mins,,,50597,BAO_0000218
9130,,,,1,,In vivo,CHEMBL623226,,Intermediate,A,,1,,N,Bioavailability as oral Cmax in rats at 6hr,,,50597,BAO_0000218
9131,,,,1,,In vivo,CHEMBL623227,,Intermediate,A,,1,,N,The maximum concentration of compound was measured at the dose of 100 umol/kg,,,50597,BAO_0000218
9132,,,,1,,In vivo,CHEMBL623228,,Intermediate,A,,1,,N,The maximum concentration of compound was measured at the dose of 300 umol/kg,,,50597,BAO_0000218
9133,,,,1,,In vivo,CHEMBL623229,,Intermediate,A,,1,,N,The maximum concentration of compound was measured at the dose of 30 umol/kg,,,50597,BAO_0000218
9134,,,1969.0,1,Plasma,In vivo,CHEMBL623230,,Intermediate,A,,1,,N,The maximum plasma levels for the compounds were determined by LC-MS.,,,50597,BAO_0000218
9135,,,1969.0,1,Plasma,In vivo,CHEMBL623231,,Intermediate,A,,1,,N,mean peak plasma concentration was observed after intravenous administration in rat,,,50597,BAO_0000218
9136,,,1969.0,1,Plasma,In vivo,CHEMBL623232,,Intermediate,A,,1,,N,mean peak plasma concentration was observed after oral administration in rat,,,50597,BAO_0000218
9137,,,,1,,,CHEMBL623233,,Intermediate,A,,1,,N,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,,50597,BAO_0000218
9138,,,,1,,,CHEMBL623234,,Intermediate,A,,1,,N,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,,50597,BAO_0000218
9139,,,,1,,,CHEMBL623235,,Intermediate,A,,1,,N,Concentration in plasma (portal) following oral dose in rats at 1 hr,,,50597,BAO_0000218
9140,,,,1,,,CHEMBL623236,,Intermediate,A,,1,,N,Concentration in plasma (portal) following oral dose in rats at 2 hr,,,50597,BAO_0000218
9141,,,,1,,,CHEMBL623237,,Intermediate,A,,1,,N,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,,50597,BAO_0000218
9142,,,,1,,,CHEMBL623238,,Intermediate,A,,1,,N,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,,50597,BAO_0000218
9143,,,,1,,,CHEMBL623239,,Intermediate,A,,1,,N,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,,50597,BAO_0000218
9144,,,1969.0,0,Plasma,In vivo,CHEMBL623240,,Intermediate,A,,1,,U,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,,,22224,BAO_0000218
9145,,,1898.0,1,Hypothalamus,,CHEMBL623241,,Intermediate,A,,1,,N,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",,,50597,BAO_0000218
9146,,,1898.0,1,Hypothalamus,,CHEMBL623242,,Intermediate,A,,1,,N,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",,,50597,BAO_0000218
9147,,,,1,,,CHEMBL874394,,Intermediate,A,,1,,N,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,,50597,BAO_0000218
9148,,,,1,,,CHEMBL623243,,Intermediate,A,,1,,N,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,,50597,BAO_0000218
9149,,,,1,,,CHEMBL623244,,Intermediate,A,,1,,N,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9150,,,2113.0,1,Kidney,,CHEMBL623245,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
9151,,,2113.0,1,Kidney,,CHEMBL623246,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
9152,,,2113.0,1,Kidney,,CHEMBL623247,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
9153,,,2113.0,1,Kidney,,CHEMBL623248,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
9154,,,2113.0,1,Kidney,,CHEMBL623249,,Intermediate,A,,1,,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
9155,,,2107.0,1,Liver,,CHEMBL625072,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
9156,,,2107.0,1,Liver,,CHEMBL625073,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,BAO_0000218
9157,,,2107.0,1,Liver,,CHEMBL625074,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
9158,,,2107.0,1,Liver,,CHEMBL625075,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
9159,,,2107.0,1,Liver,,CHEMBL625076,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,,,50597,BAO_0000218
9160,,,2107.0,1,Liver,,CHEMBL625077,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,BAO_0000218
9161,,,2107.0,1,Liver,,CHEMBL625078,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,BAO_0000218
9162,,,2107.0,1,Liver,,CHEMBL874395,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,50597,BAO_0000218
9163,,,2107.0,1,Liver,,CHEMBL625079,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,BAO_0000218
9164,,,2107.0,1,Liver,,CHEMBL625080,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,BAO_0000218
9165,,,2107.0,1,Liver,,CHEMBL625081,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,BAO_0000218
9166,,,2107.0,1,Liver,,CHEMBL625082,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,BAO_0000218
9167,,,2107.0,1,Liver,,CHEMBL625083,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,BAO_0000218
9168,,,2107.0,1,Liver,,CHEMBL625084,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,BAO_0000218
9169,,,2107.0,1,Liver,,CHEMBL625085,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,BAO_0000218
9170,,,2107.0,1,Liver,,CHEMBL625086,,Intermediate,A,,1,,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,BAO_0000218
9171,,,2107.0,1,Liver,,CHEMBL625087,,Intermediate,A,,1,,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
9172,,,2107.0,1,Liver,,CHEMBL625088,,Intermediate,A,,1,,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
9173,,,2107.0,1,Liver,,CHEMBL622205,,Intermediate,A,,1,,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
9174,,,2107.0,1,Liver,,CHEMBL622206,,Intermediate,A,,1,,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
9175,,,2107.0,1,Liver,,CHEMBL622207,,Intermediate,A,,1,,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
9176,,,2107.0,1,Liver,,CHEMBL622366,,Intermediate,A,,1,,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
9177,,,2107.0,1,Liver,,CHEMBL622367,,Intermediate,A,,1,,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
9178,,,2107.0,1,Liver,,CHEMBL875331,,Intermediate,A,,1,,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
9179,,,2107.0,1,Liver,,CHEMBL622368,,Intermediate,A,,1,,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
9180,,,2048.0,1,Lung,,CHEMBL622369,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
9181,,,2048.0,1,Lung,,CHEMBL622370,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,BAO_0000218
9182,,,2048.0,1,Lung,,CHEMBL622371,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
9183,,,2048.0,1,Lung,,CHEMBL622372,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
9184,,,2048.0,1,Lung,,CHEMBL622373,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,BAO_0000218
9185,,,2048.0,1,Lung,,CHEMBL622374,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,BAO_0000218
9186,,,2048.0,1,Lung,,CHEMBL622375,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,BAO_0000218
9187,,,2048.0,1,Lung,,CHEMBL622376,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,,50597,BAO_0000218
9188,,,2048.0,1,Lung,,CHEMBL622377,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,BAO_0000218
9189,,,2048.0,1,Lung,,CHEMBL622378,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,BAO_0000218
9190,,,2048.0,1,Lung,,CHEMBL622379,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,BAO_0000218
9191,,,2048.0,1,Lung,,CHEMBL622380,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,BAO_0000218
9192,,,2048.0,1,Lung,,CHEMBL622381,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,BAO_0000218
9193,,,2048.0,1,Lung,,CHEMBL622382,,Intermediate,A,,1,,N,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,BAO_0000218
9194,,,2048.0,1,Lung,,CHEMBL622383,,Intermediate,A,,1,,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
9195,,,945.0,1,Stomach,,CHEMBL875332,,Intermediate,A,,1,,N,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,50597,BAO_0000218
9196,,,945.0,1,Stomach,,CHEMBL622384,,Intermediate,A,,1,,N,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,50597,BAO_0000218
9197,,,945.0,1,Stomach,,CHEMBL622385,,Intermediate,A,,1,,N,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,50597,BAO_0000218
9198,,,945.0,1,Stomach,,CHEMBL622386,,Intermediate,A,,1,,N,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,50597,BAO_0000218
9199,,,,1,,,CHEMBL622387,,Intermediate,A,,1,,N,The compound was tested for the plasma binding in rat,,,50597,BAO_0000218
9200,,,,1,,,CHEMBL622388,,Intermediate,A,,1,,N,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,,50597,BAO_0000218
9201,,,,1,,,CHEMBL622389,,Intermediate,A,,1,,N,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,,50597,BAO_0000218
9202,,,,1,,,CHEMBL622390,,Intermediate,A,,1,,N,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,,50597,BAO_0000218
9203,,,,1,,,CHEMBL622391,,Intermediate,A,,1,,N,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,,50597,BAO_0000218
9204,,,,1,,,CHEMBL622392,,Intermediate,A,,1,,N,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,,50597,BAO_0000218
9205,,,,1,,,CHEMBL622393,,Intermediate,A,,1,,N,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,,50597,BAO_0000218
9206,,,,1,,,CHEMBL622394,,Intermediate,A,,1,,N,Plasma level at 2 hr after administration of the compound,,,50597,BAO_0000218
9207,,,,1,,,CHEMBL622395,,Intermediate,A,,1,,N,plasma level at 2 hr after administration of the compound,,,50597,BAO_0000218
9208,,,1977.0,1,Serum,,CHEMBL622396,,Intermediate,A,,1,,N,Stability in rat serum measured as % recovery at 1 min,,,50597,BAO_0000218
9209,,,1977.0,1,Serum,,CHEMBL624894,,Intermediate,A,,1,,N,Stability in rat serum measured as % recovery at 10 min,,,50597,BAO_0000218
9210,,,1977.0,1,Serum,,CHEMBL624895,,Intermediate,A,,1,,N,Stability in rat serum measured as % recovery at 10 mins,,,50597,BAO_0000218
9211,,,1977.0,1,Serum,,CHEMBL624058,,Intermediate,A,,1,,N,Stability in rat serum measured as % recovery at 2 hr,,,50597,BAO_0000218
9212,,,1977.0,1,Serum,,CHEMBL624059,,Intermediate,A,,1,,N,Stability in rat serum measured as % recovery at 3 min,,,50597,BAO_0000218
9213,,,1977.0,1,Serum,,CHEMBL624060,,Intermediate,A,,1,,N,Stability in rat serum measured as % recovery at 3 mins,,,50597,BAO_0000218
9214,,,1977.0,1,Serum,,CHEMBL624061,,Intermediate,A,,1,,N,Stability in rat serum measured as % recovery at 5 min,,,50597,BAO_0000218
9215,,,1977.0,1,Serum,,CHEMBL624062,,Intermediate,A,,1,,N,Stability in rat serum measured as % recovery at 5 mins,,,50597,BAO_0000218
9216,,,,1,,In vivo,CHEMBL624063,,Intermediate,A,,1,,N,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,50597,BAO_0000218
9217,,,,1,,In vivo,CHEMBL624064,,Intermediate,A,,1,,N,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,50597,BAO_0000218
9218,,,1969.0,1,Plasma,,CHEMBL624065,,Intermediate,A,,1,,N,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,,,50597,BAO_0000218
9219,,,1969.0,1,Plasma,,CHEMBL624066,,Intermediate,A,,1,,N,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,,,50597,BAO_0000218
9220,,,,1,,In vivo,CHEMBL877490,,Intermediate,A,,1,,N,Half life tested in mature male rat at a dose of 30 mg/kg,,,50597,BAO_0000218
9221,,,,1,,In vivo,CHEMBL874442,,Intermediate,A,,1,,N,Half life after intravenous administration of 1 mg/kg in rat,,,50597,BAO_0000218
9222,,,,1,,In vivo,CHEMBL626890,,Intermediate,A,,1,,N,Half life period after administration (30 mg/kg) in rat,,,50597,BAO_0000218
9223,,,,1,,In vivo,CHEMBL626891,,Intermediate,A,,1,,N,Half life period in rat after 5 mg/Kg dose,,,50597,BAO_0000218
9224,,,,1,,In vivo,CHEMBL626892,,Intermediate,A,,1,,N,Half life period in rat after 5 mg/kg dose,,,50597,BAO_0000218
9225,,,,1,,,CHEMBL626893,,Intermediate,A,,1,,N,Half life period was determined,,,50597,BAO_0000218
9226,,,,1,,,CHEMBL626894,,Intermediate,A,,1,,N,Half life period was evaluated in rat,,,50597,BAO_0000218
9227,,,,1,,,CHEMBL626895,,Intermediate,A,,1,,N,Half life period was evaluated in rat; 0.5-1.0,,,50597,BAO_0000218
9228,,,,1,,,CHEMBL626896,,Intermediate,A,,1,,N,Half life period was evaluated in rat; 5.9-7.5,,,50597,BAO_0000218
9229,,,1969.0,1,Plasma,,CHEMBL626897,,Intermediate,A,,1,,N,Half-life in rat plasma,,,50597,BAO_0000218
9230,,,,1,,,CHEMBL626898,,Intermediate,A,,1,,N,Half-life time in rat was determined,,,50597,BAO_0000218
9231,,,,1,,In vivo,CHEMBL626899,,Intermediate,A,,1,,N,Terminal half-life after iv administration to rats,,,50597,BAO_0000218
9232,,,,1,,In vivo,CHEMBL626900,,Intermediate,A,,1,,N,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,,50597,BAO_0000218
9233,,,,1,,,CHEMBL626901,,Intermediate,A,,1,,N,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,,50597,BAO_0000218
9234,,,,1,,In vivo,CHEMBL626902,,Intermediate,A,,1,,N,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,,50597,BAO_0000218
9235,,,,1,,In vivo,CHEMBL626903,,Intermediate,A,,1,,N,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,,50597,BAO_0000218
9236,,,,1,,In vivo,CHEMBL874443,,Intermediate,A,,1,,N,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,,50597,BAO_0000218
9237,,,,1,,In vivo,CHEMBL626904,,Intermediate,A,,1,,N,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,,50597,BAO_0000218
9238,,,,1,,,CHEMBL626905,,Intermediate,A,,1,,N,Half life in rats,,,50597,BAO_0000218
9239,,,1969.0,1,Plasma,In vivo,CHEMBL873830,,Intermediate,A,,1,,N,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,,,50597,BAO_0000218
9240,,,,1,,In vivo,CHEMBL626906,,Intermediate,A,,1,,N,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,,50597,BAO_0000218
9241,,,1969.0,1,Plasma,In vivo,CHEMBL631076,,Intermediate,A,,1,,N,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,50597,BAO_0000218
9242,,,1969.0,1,Plasma,,CHEMBL631077,,Intermediate,A,,1,,N,Biological half-life was measured in plasma of rats,,,50597,BAO_0000218
9243,,,,1,,In vivo,CHEMBL631078,,Intermediate,A,,1,,N,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,50597,BAO_0000218
9244,,,,1,,In vivo,CHEMBL631079,,Intermediate,A,,1,,N,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,,50597,BAO_0000218
9245,,,,1,,In vivo,CHEMBL631080,,Intermediate,A,,1,,N,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,,50597,BAO_0000218
9246,,,,1,,In vivo,CHEMBL631081,,Intermediate,A,,1,,N,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,,50597,BAO_0000218
9247,,,,1,,In vivo,CHEMBL631239,,Intermediate,A,,1,,N,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,,50597,BAO_0000218
9248,,,1969.0,1,Plasma,,CHEMBL631240,,Intermediate,A,,1,,N,Compound was evaluated for plasma half life in rat,,,50597,BAO_0000218
9249,,,1969.0,1,Plasma,,CHEMBL631241,,Intermediate,A,,1,,N,AUC value at a dose of 5 mg/kg (p.o.) in rats,,,50597,BAO_0000218
9250,,,1969.0,1,Plasma,,CHEMBL631242,,Intermediate,A,,1,,N,AUC value after administration of 20 mg/Kg oral dose in rat,,,50597,BAO_0000218
9251,,,1969.0,1,Plasma,,CHEMBL631243,,Intermediate,A,,1,,N,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,,,50597,BAO_0000218
9252,,,1969.0,1,Plasma,,CHEMBL874444,,Intermediate,A,,1,,N,AUC0-96 after administration at 50 mg/kg,,,50597,BAO_0000218
9253,,,1969.0,1,Plasma,,CHEMBL631244,,Intermediate,A,,1,,N,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,,,50597,BAO_0000218
9254,,,,1,,,CHEMBL631245,,Intermediate,A,,1,,N,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,,50597,BAO_0000218
9255,,,,1,,,CHEMBL627162,,Intermediate,A,,1,,N,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,,50597,BAO_0000218
9256,,,,1,,,CHEMBL627163,,Intermediate,A,,1,,N,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,,50597,BAO_0000218
9257,,,,1,,,CHEMBL627164,,Intermediate,A,,1,,N,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,,50597,BAO_0000218
9258,,,2113.0,1,Kidney,,CHEMBL627165,,Intermediate,A,,1,,N,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,,,50597,BAO_0000218
9259,,,,1,,,CHEMBL627166,,Intermediate,A,,1,,N,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,,50597,BAO_0000218
9260,,,,1,,,CHEMBL627167,,Intermediate,A,,1,,N,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,,50597,BAO_0000218
9261,,,,1,,,CHEMBL627822,,Intermediate,A,,1,,N,Area under curve (AUC) at a dose of 30 mg/kg in rats,,,50597,BAO_0000218
9262,,,,1,,,CHEMBL627823,,Intermediate,A,,1,,N,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,,50597,BAO_0000218
9263,,,,1,,,CHEMBL627824,,Intermediate,A,,1,,N,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,,50597,BAO_0000218
9264,,,,1,,,CHEMBL627825,,Intermediate,A,,1,,N,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,,50597,BAO_0000218
9265,,,,1,,,CHEMBL627826,,Intermediate,A,,1,,N,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,,50597,BAO_0000218
9266,,,,1,,,CHEMBL627827,,Intermediate,A,,1,,N,Area under curve (Pharmacokinetic property) was determined,,,50597,BAO_0000218
9267,,,,1,,,CHEMBL627828,,Intermediate,A,,1,,N,Area under curve (Pharmacokinetic property) of the compound; Not determined,,,50597,BAO_0000218
9268,,,,1,,,CHEMBL627829,,Intermediate,A,,1,,N,Area under curve after intravenous administration (1 mg/kg) in rat,,,50597,BAO_0000218
9269,,,,1,,,CHEMBL627830,,Intermediate,A,,1,,N,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,,50597,BAO_0000218
9270,,,,1,,,CHEMBL627831,,Intermediate,A,,1,,N,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,,50597,BAO_0000218
9271,,,,1,,,CHEMBL627832,,Intermediate,A,,1,,N,Area under curve in male SD rats was observed after oral administration in rat,,,50597,BAO_0000218
9272,,,,1,,,CHEMBL627833,,Intermediate,A,,1,,N,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,,50597,BAO_0000218
9273,,,,1,,,CHEMBL627834,,Expert,A,,1,,N,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,BAO_0000218
9274,,,,1,,,CHEMBL628004,,Expert,A,,1,,N,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,,50597,BAO_0000218
9275,,,,1,,,CHEMBL628005,,Intermediate,A,,1,,N,Area under curve at 5 mg/kg po was determined in rat,,,50597,BAO_0000218
9276,,,,1,,,CHEMBL628006,,Intermediate,A,,1,,N,Area under curve in Rat at a oral dose of 5 mg/kg,,,50597,BAO_0000218
9277,,,,1,,,CHEMBL628007,,Intermediate,A,,1,,N,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,50597,BAO_0000218
9278,,,,1,,,CHEMBL625676,,Intermediate,A,,1,,N,Area under curve was determined,,,50597,BAO_0000218
9279,,,,1,,,CHEMBL631309,,Intermediate,A,,1,,N,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,,50597,BAO_0000218
9280,,,,1,,,CHEMBL631310,,Intermediate,A,,1,,N,Area under curve after intravenous administration at 3 mg/kg,,,50597,BAO_0000218
9281,,,,1,,,CHEMBL631311,,Intermediate,A,,1,,N,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,,50597,BAO_0000218
9282,,,,1,,,CHEMBL631312,,Intermediate,A,,1,,N,Area under curve at 4 hr in rat,,,50597,BAO_0000218
9283,,,,1,,,CHEMBL631313,,Intermediate,A,,1,,N,Area under curve at a dose of 30 mg/kg,,,50597,BAO_0000218
9284,,,,1,,,CHEMBL631314,,Intermediate,A,,1,,N,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,,50597,BAO_0000218
9285,,,,1,,,CHEMBL631315,,Intermediate,A,,1,,N,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,,50597,BAO_0000218
9286,,,,1,,,CHEMBL631316,,Intermediate,A,,1,,N,Area under curve for a 2-mpk po dose in SD rats,,,50597,BAO_0000218
9287,,,,1,,,CHEMBL631317,,Intermediate,A,,1,,N,Area under curve in SD rats,,,50597,BAO_0000218
9288,,,,1,,,CHEMBL874471,,Intermediate,A,,1,,N,Area under curve in rat after oral administration at 13 mg/kg dose,,,50597,BAO_0000218
9289,,,,1,,,CHEMBL631318,,Intermediate,A,,1,,N,Area under curve in rat by po administration at 0-24 hr,,,50597,BAO_0000218
9290,,,1969.0,1,Plasma,,CHEMBL631319,,Intermediate,A,,1,,N,Area under curve in rat plasma,,,50597,BAO_0000218
9291,,,,1,,,CHEMBL631320,,Intermediate,A,,1,,N,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,,50597,BAO_0000218
9292,,,,1,,,CHEMBL631321,,Intermediate,A,,1,,N,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,,50597,BAO_0000218
9293,,,,1,,,CHEMBL631322,,Intermediate,A,,1,,N,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,,50597,BAO_0000218
9294,,,,1,,,CHEMBL631323,,Intermediate,A,,1,,N,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,,50597,BAO_0000218
9295,,,,1,,,CHEMBL631324,,Intermediate,A,,1,,N,Area under curve value in rat at a dose of 5 mg/kg,,,50597,BAO_0000218
9296,,,,1,,,CHEMBL631325,,Intermediate,A,,1,,N,Area under curve was determined after oral administration in rats,,,50597,BAO_0000218
9297,,,,1,,,CHEMBL631326,,Intermediate,A,,1,,N,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,,50597,BAO_0000218
9298,,,,1,,,CHEMBL631327,,Intermediate,A,,1,,N,Area under curve was determined after peroral administration in rat,,,50597,BAO_0000218
9299,,,,1,,,CHEMBL631328,,Intermediate,A,,1,,N,Area under curve was determined at a dose 30 mpk administered orally.,,,50597,BAO_0000218
9300,,,,1,,,CHEMBL631329,,Intermediate,A,,1,,N,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,,50597,BAO_0000218
9301,,,,1,,,CHEMBL627217,,Intermediate,A,,1,,N,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,,50597,BAO_0000218
9302,,,,1,,,CHEMBL626352,,Intermediate,A,,1,,N,Area under curve was determined in male rat,,,50597,BAO_0000218
9303,,,,1,,,CHEMBL626353,,Intermediate,A,,1,,N,Area under curve was determined in rat after PO administration,,,50597,BAO_0000218
9304,,,,1,,,CHEMBL626354,,Intermediate,A,,1,,N,Area under curve was determined in rat after a 3 mg/kg of oral dose,,,50597,BAO_0000218
9305,,,,1,,,CHEMBL626355,,Intermediate,A,,1,,N,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,,50597,BAO_0000218
9306,,,,1,,,CHEMBL626356,,Intermediate,A,,1,,N,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,,50597,BAO_0000218
9307,,,,1,,,CHEMBL626357,,Intermediate,A,,1,,N,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,,50597,BAO_0000218
9308,,,,1,,,CHEMBL626358,,Intermediate,A,,1,,N,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9309,,,,1,,,CHEMBL626359,,Intermediate,A,,1,,N,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9310,,,1969.0,1,Plasma,,CHEMBL626360,,Intermediate,A,,1,,N,Peak plasma concentration in rat at a dose of 3 mg/kg,,,50597,BAO_0000218
9311,,,,1,,,CHEMBL626361,,Intermediate,A,,1,,N,Plasma concentration at 2 hr in rats was evaluated.,,,50597,BAO_0000218
9312,,,,1,,,CHEMBL626362,,Intermediate,A,,1,,N,Plasma concentration at 2 hr in rats was evaluated; Not available,,,50597,BAO_0000218
9313,,,,1,,,CHEMBL626363,,Intermediate,A,,1,,N,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9314,,,,1,,,CHEMBL626970,,Intermediate,A,,1,,N,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,BAO_0000218
9315,,,,1,,,CHEMBL626971,,Intermediate,A,,1,,N,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,BAO_0000218
9316,,,1969.0,1,Plasma,,CHEMBL626972,,Intermediate,A,,1,,N,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,BAO_0000218
9317,,,1969.0,1,Plasma,,CHEMBL626973,,Intermediate,A,,1,,N,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,BAO_0000218
9318,,,1969.0,1,Plasma,,CHEMBL626974,,Intermediate,A,,1,,N,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,BAO_0000218
9319,,,1969.0,1,Plasma,,CHEMBL874592,,Intermediate,A,,1,,N,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,BAO_0000218
9320,,,,1,,,CHEMBL626975,,Intermediate,A,,1,,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,,50597,BAO_0000218
9321,,,,1,,,CHEMBL626976,,Intermediate,A,,1,,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,,50597,BAO_0000218
9322,,,,1,,,CHEMBL626977,,Intermediate,A,,1,,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,,50597,BAO_0000218
9323,,,,1,,,CHEMBL626978,,Intermediate,A,,1,,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,,50597,BAO_0000218
9324,,,,1,,,CHEMBL626979,,Intermediate,A,,1,,N,PK study was carried to determine the relative absorption ranking in rat.,,,50597,BAO_0000218
9325,,,1969.0,1,Plasma,In vivo,CHEMBL626980,,Intermediate,A,,1,,N,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,,,50597,BAO_0000218
9326,,,178.0,1,Blood,,CHEMBL626981,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",,,50597,BAO_0000218
9327,,,178.0,1,Blood,,CHEMBL626982,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",,,50597,BAO_0000218
9328,,,178.0,1,Blood,,CHEMBL626983,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",,,50597,BAO_0000218
9329,,,178.0,1,Blood,,CHEMBL622522,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",,,50597,BAO_0000218
9330,,,178.0,1,Blood,,CHEMBL622523,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",,,50597,BAO_0000218
9331,,,178.0,1,Blood,,CHEMBL622524,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",,,50597,BAO_0000218
9332,,,955.0,1,Brain,,CHEMBL622525,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",,,50597,BAO_0000218
9333,,,955.0,1,Brain,,CHEMBL622526,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",,,50597,BAO_0000218
9334,,,955.0,1,Brain,,CHEMBL619849,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",,,50597,BAO_0000218
9335,,,955.0,1,Brain,,CHEMBL619850,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",,,50597,BAO_0000218
9336,,,955.0,1,Brain,,CHEMBL623864,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",,,50597,BAO_0000218
9337,,,955.0,1,Brain,,CHEMBL623865,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",,,50597,BAO_0000218
9338,,,948.0,1,Heart,,CHEMBL623866,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",,,50597,BAO_0000218
9339,,,948.0,1,Heart,,CHEMBL623867,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",,,50597,BAO_0000218
9340,,,948.0,1,Heart,,CHEMBL877615,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",,,50597,BAO_0000218
9341,,,948.0,1,Heart,,CHEMBL623868,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",,,50597,BAO_0000218
9342,,,948.0,1,Heart,,CHEMBL623869,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",,,50597,BAO_0000218
9343,,,948.0,1,Heart,,CHEMBL623870,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",,,50597,BAO_0000218
9344,,,2048.0,1,Lung,,CHEMBL623871,,Intermediate,A,,1,,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
9345,,,2048.0,1,Lung,,CHEMBL623872,,Intermediate,A,,1,,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
9346,,,2048.0,1,Lung,,CHEMBL622129,,Intermediate,A,,1,,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
9347,,,2048.0,1,Lung,,CHEMBL622130,,Intermediate,A,,1,,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
9348,,,2048.0,1,Lung,,CHEMBL622131,,Intermediate,A,,1,,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
9349,,,2048.0,1,Lung,,CHEMBL622132,,Intermediate,A,,1,,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
9350,,,2048.0,1,Lung,,CHEMBL622133,,Intermediate,A,,1,,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
9351,,,2048.0,1,Lung,,CHEMBL622134,,Intermediate,A,,1,,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
9352,,,2048.0,1,Lung,,CHEMBL622135,,Intermediate,A,,1,,N,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,BAO_0000218
9353,,,2048.0,1,Lung,,CHEMBL622136,,Intermediate,A,,1,,N,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,BAO_0000218
9354,,,2385.0,1,Muscle tissue,,CHEMBL622137,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
9355,,,2385.0,1,Muscle tissue,,CHEMBL622138,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,BAO_0000218
9356,,,2385.0,1,Muscle tissue,,CHEMBL623017,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
9357,,,2385.0,1,Muscle tissue,,CHEMBL623018,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
9358,,,2385.0,1,Muscle tissue,,CHEMBL623019,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,BAO_0000218
9359,,,2385.0,1,Muscle tissue,,CHEMBL623020,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,BAO_0000218
9360,,,2385.0,1,Muscle tissue,,CHEMBL623021,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,,,50597,BAO_0000218
9361,,,2385.0,1,Muscle tissue,,CHEMBL623022,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,,50597,BAO_0000218
9362,,,2385.0,1,Muscle tissue,,CHEMBL623023,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,BAO_0000218
9363,,,2385.0,1,Muscle tissue,,CHEMBL623024,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,BAO_0000218
9364,,,2385.0,1,Muscle tissue,,CHEMBL623025,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,BAO_0000218
9365,,,2385.0,1,Muscle tissue,,CHEMBL620545,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,BAO_0000218
9366,,,2385.0,1,Muscle tissue,,CHEMBL620546,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,BAO_0000218
9367,,,2385.0,1,Muscle tissue,,CHEMBL620547,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,BAO_0000218
9368,,,2385.0,1,Muscle tissue,,CHEMBL620548,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,BAO_0000218
9369,,,2385.0,1,Muscle tissue,,CHEMBL620549,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,BAO_0000218
9370,,,2385.0,1,Muscle tissue,,CHEMBL620550,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
9371,,,2385.0,1,Muscle tissue,,CHEMBL620551,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
9372,,,2385.0,1,Muscle tissue,,CHEMBL620552,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
9373,,,2385.0,1,Muscle tissue,,CHEMBL620553,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
9374,,,2385.0,1,Muscle tissue,,CHEMBL620554,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
9375,,,2385.0,1,Muscle tissue,,CHEMBL875845,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
9376,,,2385.0,1,Muscle tissue,,CHEMBL620555,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
9377,,,2385.0,1,Muscle tissue,,CHEMBL620556,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
9378,,,2385.0,1,Muscle tissue,,CHEMBL620557,,Intermediate,A,,1,,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
9379,,,,1,,,CHEMBL620558,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
9380,,,,1,,,CHEMBL620559,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,BAO_0000218
9381,,,,1,,,CHEMBL622939,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
9382,,,,1,,,CHEMBL622940,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
9383,,,,1,,,CHEMBL622941,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,BAO_0000218
9384,,,,1,,,CHEMBL622942,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,BAO_0000218
9385,,,,1,,,CHEMBL622943,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,BAO_0000218
9386,,,,1,,,CHEMBL622944,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,50597,BAO_0000218
9387,,,,1,,,CHEMBL622945,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,BAO_0000218
9388,,,,1,,,CHEMBL622946,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,BAO_0000218
9389,,,,1,,,CHEMBL622947,,Intermediate,A,,1,,N,Compound was evaluated for terminal half life in rat,,,50597,BAO_0000218
9390,,,1969.0,1,Plasma,In vivo,CHEMBL622948,,Intermediate,A,,1,,N,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,,,50597,BAO_0000218
9391,,,1969.0,1,Plasma,In vivo,CHEMBL622949,,Intermediate,A,,1,,N,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,,,50597,BAO_0000218
9392,,,,1,,,CHEMBL622950,,Intermediate,A,,1,,N,Compound was tested for its half life in rat,,,50597,BAO_0000218
9393,,,1969.0,0,Plasma,In vivo,CHEMBL622951,,Intermediate,A,,1,,U,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,,22224,BAO_0000218
9394,,,1969.0,0,Plasma,,CHEMBL622952,,Intermediate,A,,1,,U,Compound was tested for its plasma half life in Sprague Dawley rats,,,22224,BAO_0000366
9395,,,1969.0,0,Plasma,,CHEMBL622953,,Intermediate,A,,1,,U,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,,,22224,BAO_0000366
9396,,,1969.0,1,Plasma,,CHEMBL873818,,Intermediate,A,,1,,N,Compound was tested for plasma half-life period in rat,,,50597,BAO_0000218
9397,,,,1,,In vivo,CHEMBL622954,,Intermediate,A,,1,,N,Elimination half life after i.v. administration of compound in rats,,,50597,BAO_0000218
9398,,,,1,,In vivo,CHEMBL622955,,Intermediate,A,,1,,N,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,,50597,BAO_0000218
9399,,,,1,,In vivo,CHEMBL875229,,Intermediate,A,,1,,N,Elimination half-life after IV dosing at 1 mg/kg in rat,,,50597,BAO_0000218
9400,,,,1,,In vivo,CHEMBL622956,,Intermediate,A,,1,,N,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,,50597,BAO_0000218
9401,,,,1,,In vivo,CHEMBL622957,,Intermediate,A,,1,,N,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,,50597,BAO_0000218
9402,,,955.0,1,Brain,In vivo,CHEMBL622958,,Intermediate,A,,1,,N,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,,50597,BAO_0000218
9403,,,1969.0,1,Plasma,In vivo,CHEMBL622959,,Intermediate,A,,1,,N,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,,50597,BAO_0000218
9404,,,955.0,1,Brain,In vivo,CHEMBL622960,,Intermediate,A,,1,,N,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,,50597,BAO_0000218
9405,,,1969.0,1,Plasma,In vivo,CHEMBL622961,,Intermediate,A,,1,,N,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,,50597,BAO_0000218
9406,,,,1,,In vivo,CHEMBL622962,,Intermediate,A,,1,,N,Evaluated for the half life in rat (in vivo),,,50597,BAO_0000218
9407,,,,1,,,CHEMBL622963,,Intermediate,A,,1,,N,Hafl life in rat,,,50597,BAO_0000218
9408,,,,1,,,CHEMBL622964,,Intermediate,A,,1,,N,Hafl life rat,,,50597,BAO_0000218
9409,,,,1,,,CHEMBL622965,,Intermediate,A,,1,,N,Hafl life rat,,,50597,BAO_0000218
9410,,,,1,,,CHEMBL622966,,Intermediate,A,,1,,N,Hafl life rat; Not determined,,,50597,BAO_0000218
9411,,,,1,,,CHEMBL622967,,Intermediate,A,,1,,N,Hafl life rat; Not determined,,,50597,BAO_0000218
9412,,,2113.0,1,Kidney,In vivo,CHEMBL622968,,Intermediate,A,,1,,N,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9413,,,2107.0,1,Liver,In vivo,CHEMBL622969,,Intermediate,A,,1,,N,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9414,,,2048.0,1,Lung,In vivo,CHEMBL875327,,Intermediate,A,,1,,N,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9415,,,,1,,In vivo,CHEMBL628638,,Intermediate,A,,1,,N,Half life in rat after 1 mg/kg i.v. administration,,,50597,BAO_0000218
9416,,,,1,,In vivo,CHEMBL628639,,Intermediate,A,,1,,N,Half life in rat after 2 mg/kg peroral administration,,,50597,BAO_0000218
9417,,,,1,,In vivo,CHEMBL625840,,Intermediate,A,,1,,N,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9418,,,,1,,In vivo,CHEMBL625841,,Intermediate,A,,1,,N,Half life of 10 mg/kg oral dose determined in rats,,,50597,BAO_0000218
9419,,,,1,,In vivo,CHEMBL625842,,Intermediate,A,,1,,N,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
9420,,,,1,,In vivo,CHEMBL625843,,Intermediate,A,,1,,N,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
9421,,,,1,,In vivo,CHEMBL625844,,Intermediate,A,,1,,N,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
9422,,,,1,,In vivo,CHEMBL873822,,Intermediate,A,,1,,N,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
9423,,,,1,,In vivo,CHEMBL625845,,Intermediate,A,,1,,N,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
9424,,,,1,,In vivo,CHEMBL627059,,Intermediate,A,,1,,N,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
9425,,,,1,,In vivo,CHEMBL627060,,Intermediate,A,,1,,N,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
9426,,,,1,,In vivo,CHEMBL627061,,Intermediate,A,,1,,N,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
9427,,,,1,,In vivo,CHEMBL627709,,Intermediate,A,,1,,N,Half life of compound at 5 mg/kg after po administration was determined in rat,,,50597,BAO_0000218
9428,,,,1,,In vivo,CHEMBL627710,,Intermediate,A,,1,,N,Half life of compound determined after intravenous administration to rat,,,50597,BAO_0000218
9429,,,,1,,,CHEMBL627711,,Intermediate,A,,1,,N,Half life of compound was determined in rat,,,50597,BAO_0000218
9430,,,1969.0,1,Plasma,In vivo,CHEMBL627712,,Intermediate,A,,1,,N,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,,50597,BAO_0000218
9431,,,,1,,In vivo,CHEMBL627713,,Intermediate,A,,1,,N,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
9432,,,,1,,In vivo,CHEMBL627714,,Intermediate,A,,1,,N,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
9433,,,,0,,In vivo,CHEMBL627889,,Intermediate,A,,1,,U,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,,22224,BAO_0000218
9434,,,,0,,In vivo,CHEMBL627890,,Intermediate,A,,1,,U,Half life determined in rat by intravenous administration,,,22224,BAO_0000218
9435,,,,1,,In vivo,CHEMBL627891,,Intermediate,A,,1,,N,Half life determined in rats after iv administration,,,50597,BAO_0000218
9436,,,1969.0,1,Plasma,In vivo,CHEMBL627892,,Intermediate,A,,1,,N,Half life in rat plasma after administration of 2 mg/kg iv,,,50597,BAO_0000218
9437,,,1969.0,1,Plasma,In vivo,CHEMBL627893,,Intermediate,A,,1,,N,Half life in rat plasma after administration of 2 mg/kg iv,,,50597,BAO_0000218
9438,,,1969.0,1,Plasma,,CHEMBL627894,,Intermediate,A,,1,,N,Half life in rat plasma was determined,,,50597,BAO_0000218
9439,,,1969.0,1,Plasma,,CHEMBL627895,,Intermediate,A,,1,,N,Half life in rat plasma was determined; NA means not applicable,,,50597,BAO_0000218
9440,,,,1,,,CHEMBL627896,,Intermediate,A,,1,,N,Half life in rat was tested,,,50597,BAO_0000218
9441,,,1969.0,1,Plasma,,CHEMBL627897,,Intermediate,A,,1,,N,Half life measured in rat plasma,,,50597,BAO_0000218
9442,,,,1,,,CHEMBL627898,,Intermediate,A,,1,,N,Half life recorded in rats,,,50597,BAO_0000218
9443,,,,1,,,CHEMBL627899,,Intermediate,A,,1,,N,Half life was calculated,,,50597,BAO_0000218
9444,,,,1,,,CHEMBL873823,,Intermediate,A,,1,,N,Half life was calculated in rat,,,50597,BAO_0000218
9445,,,,1,,,CHEMBL627900,,Intermediate,A,,1,,N,Half life was determined,,,50597,BAO_0000218
9446,,,,1,,In vivo,CHEMBL627901,,Intermediate,A,,1,,N,Half life after 10 mg/kg oral administration in rat,,,50597,BAO_0000218
9447,,,,1,,In vivo,CHEMBL627902,,Intermediate,A,,1,,N,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,,50597,BAO_0000218
9448,,,,1,,In vivo,CHEMBL627903,,Intermediate,A,,1,,N,Half life after administering orally a dose of 30 mg/kg,,,50597,BAO_0000218
9449,,,,1,,,CHEMBL627904,,Intermediate,A,,1,,N,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,,50597,BAO_0000218
9450,,,,1,,,CHEMBL627905,,Intermediate,A,,1,,N,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,,50597,BAO_0000218
9451,,,,1,,,CHEMBL627906,,Intermediate,A,,1,,N,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,,50597,BAO_0000218
9452,,,,1,,,CHEMBL627907,,Intermediate,A,,1,,N,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,,50597,BAO_0000218
9453,,,,1,,,CHEMBL876783,,Intermediate,A,,1,,N,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,,50597,BAO_0000218
9454,,,,1,,,CHEMBL627908,,Intermediate,A,,1,,N,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,,50597,BAO_0000218
9455,,,,1,,,CHEMBL627909,,Intermediate,A,,1,,N,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,50597,BAO_0000218
9456,,,,1,,,CHEMBL627910,,Intermediate,A,,1,,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,,50597,BAO_0000218
9457,,,,1,,,CHEMBL627911,,Intermediate,A,,1,,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,,50597,BAO_0000218
9458,,,,1,,,CHEMBL627912,,Intermediate,A,,1,,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,,50597,BAO_0000218
9459,,,,1,,,CHEMBL627913,,Intermediate,A,,1,,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,,50597,BAO_0000218
9460,,,,1,,,CHEMBL627914,,Intermediate,A,,1,,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,,50597,BAO_0000218
9461,,,,1,,,CHEMBL627915,,Intermediate,A,,1,,N,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,,50597,BAO_0000218
9462,,,,1,,,CHEMBL627916,,Intermediate,A,,1,,N,Area under the curve was evaluated after 20 uM/kg of peroral administration,,,50597,BAO_0000218
9463,,,,1,,,CHEMBL627917,,Intermediate,A,,1,,N,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,,50597,BAO_0000218
9464,,,,1,,,CHEMBL627918,,Intermediate,A,,1,,N,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,,50597,BAO_0000218
9465,,,,1,,,CHEMBL627919,,Intermediate,A,,1,,N,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,,50597,BAO_0000218
9466,,,,1,,,CHEMBL627920,,Intermediate,A,,1,,N,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,,50597,BAO_0000218
9467,,,,1,,,CHEMBL627921,,Intermediate,A,,1,,N,Area under the curve was evaluated at an oral dose of 30 mg/kg,,,50597,BAO_0000218
9468,,,,1,,,CHEMBL627922,,Intermediate,A,,1,,N,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
9469,,,,1,,,CHEMBL876784,,Intermediate,A,,1,,N,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
9470,,,,1,,,CHEMBL627923,,Intermediate,A,,1,,N,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
9471,,,,1,,,CHEMBL626208,,Intermediate,A,,1,,N,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
9472,,,,1,,,CHEMBL626209,,Intermediate,A,,1,,N,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
9473,,,,1,,,CHEMBL626210,,Intermediate,A,,1,,N,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
9474,,,1969.0,1,Plasma,,CHEMBL627994,,Intermediate,A,,1,,N,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,,50597,BAO_0000218
9475,,,,1,,,CHEMBL627995,,Intermediate,A,,1,,N,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,,50597,BAO_0000218
9476,,,,1,,,CHEMBL627996,,Intermediate,A,,1,,N,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,,50597,BAO_0000218
9477,,,,1,,,CHEMBL627997,,Intermediate,A,,1,,N,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,,50597,BAO_0000218
9478,,,,1,,,CHEMBL627998,,Intermediate,A,,1,,N,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,,50597,BAO_0000218
9479,,,,1,,,CHEMBL628640,,Intermediate,A,,1,,N,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,,50597,BAO_0000218
9480,,,,1,,,CHEMBL628641,,Intermediate,A,,1,,N,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,,50597,BAO_0000218
9481,,,,1,,,CHEMBL628642,,Intermediate,A,,1,,N,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,,50597,BAO_0000218
9482,,,,1,,,CHEMBL628643,,Intermediate,A,,1,,N,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,50597,BAO_0000218
9483,,,,1,,,CHEMBL628644,,Intermediate,A,,1,,N,Compound was tested for area under curve in rat,,,50597,BAO_0000218
9484,,,,1,,,CHEMBL628645,,Intermediate,A,,1,,N,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,,50597,BAO_0000218
9485,,,,1,,,CHEMBL628646,,Intermediate,A,,1,,N,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,,50597,BAO_0000218
9486,,,,1,,,CHEMBL628647,,Intermediate,A,,1,,N,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,,50597,BAO_0000218
9487,,,,1,,,CHEMBL628648,,Intermediate,A,,1,,N,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,,50597,BAO_0000218
9488,,,,1,,,CHEMBL625358,,Intermediate,A,,1,,N,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,,50597,BAO_0000218
9489,,,,1,,,CHEMBL625359,,Intermediate,A,,1,,N,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,,50597,BAO_0000218
9490,,,,1,,,CHEMBL625360,,Intermediate,A,,1,,N,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,,50597,BAO_0000218
9491,,,,1,,,CHEMBL625361,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,,50597,BAO_0000218
9492,,,,1,,,CHEMBL625362,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,,50597,BAO_0000218
9493,,,,1,,,CHEMBL625363,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,,50597,BAO_0000218
9494,,,,1,,,CHEMBL625364,,Intermediate,A,,1,,N,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,,50597,BAO_0000218
9495,,,,1,,,CHEMBL625365,,Intermediate,A,,1,,N,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
9496,,,,1,,,CHEMBL625366,,Intermediate,A,,1,,N,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
9497,,,,1,,,CHEMBL625367,,Intermediate,A,,1,,N,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
9498,,,2113.0,1,Kidney,,CHEMBL625368,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",,,50597,BAO_0000218
9499,,,2113.0,1,Kidney,,CHEMBL625369,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",,,50597,BAO_0000218
9500,,,2113.0,1,Kidney,,CHEMBL625370,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",,,50597,BAO_0000218
9501,,,2113.0,1,Kidney,,CHEMBL625371,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",,,50597,BAO_0000218
9502,,,2113.0,1,Kidney,,CHEMBL625372,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",,,50597,BAO_0000218
9503,,,2113.0,1,Kidney,,CHEMBL625373,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",,,50597,BAO_0000218
9504,,,2107.0,1,Liver,,CHEMBL625374,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",,,50597,BAO_0000218
9505,,,2107.0,1,Liver,,CHEMBL877593,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",,,50597,BAO_0000218
9506,,,2107.0,1,Liver,,CHEMBL625375,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",,,50597,BAO_0000218
9507,,,2107.0,1,Liver,,CHEMBL625376,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",,,50597,BAO_0000218
9508,,,2107.0,1,Liver,,CHEMBL621973,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",,,50597,BAO_0000218
9509,,,2107.0,1,Liver,,CHEMBL621974,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",,,50597,BAO_0000218
9510,,,2048.0,1,Lung,,CHEMBL621975,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",,,50597,BAO_0000218
9511,,,2048.0,1,Lung,,CHEMBL622166,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",,,50597,BAO_0000218
9512,,,2048.0,1,Lung,,CHEMBL622167,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",,,50597,BAO_0000218
9513,,,2048.0,1,Lung,,CHEMBL622168,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",,,50597,BAO_0000218
9514,,,2048.0,1,Lung,,CHEMBL622169,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",,,50597,BAO_0000218
9515,,,2048.0,1,Lung,,CHEMBL622170,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",,,50597,BAO_0000218
9516,,,2046.0,1,Thyroid gland,,CHEMBL622171,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",,,50597,BAO_0000218
9517,,,2046.0,1,Thyroid gland,,CHEMBL622172,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",,,50597,BAO_0000218
9518,,,2046.0,1,Thyroid gland,,CHEMBL622173,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",,,50597,BAO_0000218
9519,,,2046.0,1,Thyroid gland,,CHEMBL622174,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",,,50597,BAO_0000218
9520,,,2046.0,1,Thyroid gland,,CHEMBL622175,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",,,50597,BAO_0000218
9521,,,2046.0,1,Thyroid gland,,CHEMBL622176,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",,,50597,BAO_0000218
9522,,,2046.0,1,Thyroid gland,,CHEMBL622177,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",,,50597,BAO_0000218
9523,,,2046.0,1,Thyroid gland,,CHEMBL622178,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",,,50597,BAO_0000218
9524,,,2046.0,1,Thyroid gland,,CHEMBL622179,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",,,50597,BAO_0000218
9525,,,2046.0,1,Thyroid gland,,CHEMBL622180,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",,,50597,BAO_0000218
9526,,,,1,,,CHEMBL622181,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,BAO_0000218
9527,,,,1,,,CHEMBL622182,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,BAO_0000218
9528,,,,1,,,CHEMBL622183,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,BAO_0000218
9529,,,,1,,,CHEMBL622184,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,BAO_0000218
9530,,,,1,,,CHEMBL622185,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,BAO_0000218
9531,,,,1,,,CHEMBL622186,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,BAO_0000218
9532,,,,1,,,CHEMBL622187,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
9533,,,,1,,,CHEMBL625002,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
9534,,,,1,,,CHEMBL622090,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
9535,,,,1,,,CHEMBL622091,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
9536,,,,1,,,CHEMBL622092,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
9537,,,,1,,,CHEMBL622093,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
9538,,,,1,,,CHEMBL622094,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
9539,,,,1,,,CHEMBL622095,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
9540,,,,1,,,CHEMBL622264,,Intermediate,A,,1,,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
9541,,,2106.0,1,Spleen,,CHEMBL622265,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
9542,,,2106.0,1,Spleen,,CHEMBL622266,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,BAO_0000218
9543,,,2106.0,1,Spleen,,CHEMBL622267,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
9544,,,2106.0,1,Spleen,,CHEMBL622268,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
9545,,,2106.0,1,Spleen,,CHEMBL622269,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,BAO_0000218
9546,,,2106.0,1,Spleen,,CHEMBL625071,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,BAO_0000218
9547,,,2106.0,1,Spleen,,CHEMBL621621,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,BAO_0000218
9548,,,2106.0,1,Spleen,,CHEMBL621622,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,50597,BAO_0000218
9549,,,2106.0,1,Spleen,,CHEMBL621623,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,BAO_0000218
9550,,,2106.0,1,Spleen,,CHEMBL621624,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,BAO_0000218
9551,,,2106.0,1,Spleen,,CHEMBL621625,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,BAO_0000218
9552,,,2106.0,1,Spleen,,CHEMBL621626,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,BAO_0000218
9553,,,2106.0,1,Spleen,,CHEMBL621627,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,BAO_0000218
9554,,,2106.0,1,Spleen,,CHEMBL621628,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,BAO_0000218
9555,,,2106.0,1,Spleen,,CHEMBL875328,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,BAO_0000218
9556,,,2106.0,1,Spleen,,CHEMBL621629,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,BAO_0000218
9557,,,2106.0,1,Spleen,,CHEMBL621630,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
9558,,,2106.0,1,Spleen,,CHEMBL621631,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
9559,,,2106.0,1,Spleen,,CHEMBL621632,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
9560,,,2106.0,1,Spleen,,CHEMBL621633,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
9561,,,2106.0,1,Spleen,,CHEMBL621634,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
9562,,,2106.0,1,Spleen,,CHEMBL621635,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
9563,,,2106.0,1,Spleen,,CHEMBL621636,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
9564,,,2106.0,1,Spleen,,CHEMBL621637,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
9565,,,2106.0,1,Spleen,,CHEMBL621638,,Intermediate,A,,1,,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
9566,,,,1,,,CHEMBL618883,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
9567,,,,1,,,CHEMBL618884,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,50597,BAO_0000218
9568,,,,1,,,CHEMBL628627,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
9569,,,,1,,,CHEMBL628628,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
9570,,,,1,,,CHEMBL628629,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,50597,BAO_0000218
9571,,,,1,,In vivo,CHEMBL628630,,Intermediate,A,,1,,N,Half life after administering orally a dose of 3 mg/kg,,,50597,BAO_0000218
9572,,,,1,,In vivo,CHEMBL628631,,Intermediate,A,,1,,N,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,,50597,BAO_0000218
9573,,,,1,,In vivo,CHEMBL628632,,Intermediate,A,,1,,N,Half life after administering intravenously a dose of 1 mg/kg,,,50597,BAO_0000218
9574,,,,1,,In vivo,CHEMBL628633,,Intermediate,A,,1,,N,Half life after oral dosing in rats,,,50597,BAO_0000218
9575,,,,1,,In vivo,CHEMBL628634,,Intermediate,A,,1,,N,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,,50597,BAO_0000218
9576,,,,1,,In vivo,CHEMBL627789,,Intermediate,A,,1,,N,Half life by intravenous administration of 3.4 mg/kg in rat,,,50597,BAO_0000218
9577,,,,1,,,CHEMBL627790,,Intermediate,A,,1,,N,Half life in rat,,,50597,BAO_0000218
9578,,,,1,,,CHEMBL627791,,Intermediate,A,,1,,N,Half life in rat,,,50597,BAO_0000218
9579,,,,1,,,CHEMBL627792,,Intermediate,A,,1,,N,Half life in rat,,,50597,BAO_0000218
9580,,,,1,,In vivo,CHEMBL627793,,Intermediate,A,,1,,N,Half life in rat after intravenous administration of the compound,,,50597,BAO_0000218
9581,,,1969.0,1,Plasma,In vivo,CHEMBL627794,,Intermediate,A,,1,,N,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,,,50597,BAO_0000218
9582,,,,1,,In vivo,CHEMBL627795,,Intermediate,A,,1,,N,Half life in rat after po administration of the compound,,,50597,BAO_0000218
9583,,,,1,,In vivo,CHEMBL627796,,Intermediate,A,,1,,N,Half life in rat after po administration of the compound; ND means Not determined,,,50597,BAO_0000218
9584,,,1969.0,1,Plasma,In vivo,CHEMBL875335,,Intermediate,A,,1,,N,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,,,50597,BAO_0000218
9585,,,1969.0,1,Plasma,In vivo,CHEMBL627797,,Intermediate,A,,1,,N,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,,,50597,BAO_0000218
9586,,,,1,,In vivo,CHEMBL627798,,Intermediate,A,,1,,N,Half life in rat i.v.,,,50597,BAO_0000218
9587,,,,1,,In vivo,CHEMBL627799,,Intermediate,A,,1,,N,Half life in rat i.v. at 2 mg/kg concentration,,,50597,BAO_0000218
9588,,,,1,,,CHEMBL627800,,Intermediate,A,,1,,N,Half life in rats,,,50597,BAO_0000218
9589,,,,1,,In vivo,CHEMBL627801,,Intermediate,A,,1,,N,Half life in rats after intravenous administration,,,50597,BAO_0000218
9590,,,,1,,In vivo,CHEMBL627802,,Intermediate,A,,1,,N,Half life in rats at the dose of 1.0 mpk by i.v. administration,,,50597,BAO_0000218
9591,,,,1,,,CHEMBL627803,,Expert,A,,1,,N,Half life in rat,,,50597,BAO_0000218
9592,,,,1,,In vivo,CHEMBL873820,,Intermediate,A,,1,,N,Half life was evaluated after intravenous administration to rats,,,50597,BAO_0000218
9593,,,,1,,,CHEMBL627804,,Intermediate,A,,1,,N,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,,50597,BAO_0000218
9594,,,,1,,,CHEMBL627805,,Intermediate,A,,1,,N,Half life was evaluated in rat,,,50597,BAO_0000218
9595,,,,1,,,CHEMBL627806,,Intermediate,A,,1,,N,Half life was evaluated in rat,,,50597,BAO_0000218
9596,,,,1,,,CHEMBL627107,,Intermediate,A,,1,,N,Half life was evaluated in rat; Not tested,,,50597,BAO_0000218
9597,,,,1,,In vivo,CHEMBL627108,,Intermediate,A,,1,,N,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,,50597,BAO_0000218
9598,,,,1,,In vivo,CHEMBL627109,,Intermediate,A,,1,,N,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,,50597,BAO_0000218
9599,,,178.0,1,Blood,In vivo,CHEMBL627110,,Intermediate,A,,1,,N,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,,,50597,BAO_0000218
9600,,,,0,,In vivo,CHEMBL627111,,Intermediate,A,,1,,U,Half life was measured in monkey at dose of 10 mg/kg by po administration,,,22224,BAO_0000218
9601,,,,0,,In vivo,CHEMBL627112,,Intermediate,A,,1,,U,Half life was measured in monkey at dose of 10 mg/kg by po administration,,,22224,BAO_0000218
9602,,,,0,,In vivo,CHEMBL627113,,Intermediate,A,,1,,U,Half life was measured in rat at dose of 30 mg/kg by iv administration,,,22224,BAO_0000218
9603,,,,0,,In vivo,CHEMBL627114,,Intermediate,A,,1,,U,Half life was measured in rat at dose of 30 mg/kg by po administration,,,22224,BAO_0000218
9604,,,,1,,,CHEMBL627115,,Intermediate,A,,1,,N,Half life (t1/2) was determined,,,50597,BAO_0000218
9605,,,,1,,,CHEMBL627116,,Intermediate,A,,1,,N,Half life period at a dose of 10 uM/kg in rat was determined,,,50597,BAO_0000218
9606,,,,1,,In vivo,CHEMBL627117,,Intermediate,A,,1,,N,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,,50597,BAO_0000218
9607,,,,1,,,CHEMBL627118,,Intermediate,A,,1,,N,Half life period was determined,,,50597,BAO_0000218
9608,,,,1,,In vivo,CHEMBL627119,,Intermediate,A,,1,,N,Half life period after intravenous administration at 20 mpk in rats,,,50597,BAO_0000218
9609,,,,1,,In vivo,CHEMBL627120,,Intermediate,A,,1,,N,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,,50597,BAO_0000218
9610,,,,1,,In vivo,CHEMBL626922,,Intermediate,A,,1,,N,Half life period after intravenous administration in rat,,,50597,BAO_0000218
9611,,,,1,,In vivo,CHEMBL626923,,Intermediate,A,,1,,N,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,50597,BAO_0000218
9612,,,,1,,In vivo,CHEMBL626924,,Intermediate,A,,1,,N,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,50597,BAO_0000218
9613,,,1969.0,1,Plasma,,CHEMBL626925,,Intermediate,A,,1,,N,Half life period in 80% rat plasma at 37 degree Centigrade,,,50597,BAO_0000218
9614,,,,1,,,CHEMBL626926,,Intermediate,A,,1,,N,Half life period in SD rats,,,50597,BAO_0000218
9615,,,1969.0,1,Plasma,,CHEMBL626927,,Intermediate,A,,1,,N,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),,,50597,BAO_0000218
9616,,,1969.0,1,Plasma,,CHEMBL626928,,Intermediate,A,,1,,N,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),,,50597,BAO_0000218
9617,,,1969.0,1,Plasma,,CHEMBL626929,,Intermediate,A,,1,,N,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,50597,BAO_0000218
9618,,,1969.0,1,Plasma,,CHEMBL626930,,Intermediate,A,,1,,N,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,50597,BAO_0000218
9619,,,,1,,,CHEMBL626931,,Intermediate,A,,1,,N,Half life period in rat,,,50597,BAO_0000218
9620,,,,1,,,CHEMBL626932,,Intermediate,A,,1,,N,Half life period in rat,,,50597,BAO_0000218
9621,,,,1,,,CHEMBL626933,,Intermediate,A,,1,,N,Half life period in rat,,,50597,BAO_0000218
9622,,,,1,,In vivo,CHEMBL873826,,Intermediate,A,,1,,N,Half life period in rat after oral administration at 10.5 mg/kg dose,,,50597,BAO_0000218
9623,,,,1,,In vivo,CHEMBL626934,,Intermediate,A,,1,,N,Half life period in rat after oral administration at 11.2 mg/kg dose,,,50597,BAO_0000218
9624,,,,1,,In vivo,CHEMBL626935,,Intermediate,A,,1,,N,Half life period in rat after oral administration at 13 mg/kg dose,,,50597,BAO_0000218
9625,,,,1,,In vivo,CHEMBL626936,,Intermediate,A,,1,,N,Half life period in rat after oral administration at 9.7 mg/kg dose,,,50597,BAO_0000218
9626,,,,1,,,CHEMBL626937,,Intermediate,A,,1,,N,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
9627,,,,1,,,CHEMBL625906,,Intermediate,A,,1,,N,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,,50597,BAO_0000218
9628,,,,1,,,CHEMBL625907,,Intermediate,A,,1,,N,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,,50597,BAO_0000218
9629,,,,1,,,CHEMBL625908,,Intermediate,A,,1,,N,PK study was carried to determine AUC (area under curve) value in rat,,,50597,BAO_0000218
9630,,,,1,,,CHEMBL625909,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC after intravenous administration to rats,,,50597,BAO_0000218
9631,,,,1,,,CHEMBL625910,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC after oral administration to rats,,,50597,BAO_0000218
9632,,,,1,,,CHEMBL625911,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,,50597,BAO_0000218
9633,,,,1,,,CHEMBL625912,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,,50597,BAO_0000218
9634,,,,1,,,CHEMBL626538,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,,50597,BAO_0000218
9635,,,,1,,,CHEMBL876794,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,,50597,BAO_0000218
9636,,,,1,,,CHEMBL626539,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,,50597,BAO_0000218
9637,,,,1,,,CHEMBL626540,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,,50597,BAO_0000218
9638,,,,1,,,CHEMBL626541,,Intermediate,A,,1,,N,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,,50597,BAO_0000218
9639,,,,1,,,CHEMBL626542,,Intermediate,A,,1,,N,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,,50597,BAO_0000218
9640,,,,1,,,CHEMBL626543,,Intermediate,A,,1,,N,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,,50597,BAO_0000218
9641,,,,1,,,CHEMBL626544,,Intermediate,A,,1,,N,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,,50597,BAO_0000218
9642,,,,1,,,CHEMBL626545,,Intermediate,A,,1,,N,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,,50597,BAO_0000218
9643,,,,1,,,CHEMBL626546,,Intermediate,A,,1,,N,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,,50597,BAO_0000218
9644,,,,1,,,CHEMBL626547,,Intermediate,A,,1,,N,Pharmacokinetic parameter area under curve was reported,,,50597,BAO_0000218
9645,,,,1,,,CHEMBL626548,,Intermediate,A,,1,,N,Pharmacokinetic property (AUC) in rat,,,50597,BAO_0000218
9646,,,,1,,,CHEMBL626549,,Intermediate,A,,1,,N,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,,50597,BAO_0000218
9647,,,,1,,,CHEMBL626550,,Intermediate,A,,1,,N,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,,50597,BAO_0000218
9648,,,,1,,,CHEMBL626551,,Intermediate,A,,1,,N,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,,50597,BAO_0000218
9649,,,,1,,,CHEMBL623777,,Intermediate,A,,1,,N,Pharmacokinetic property was determined,,,50597,BAO_0000218
9650,,,,1,,,CHEMBL623778,,Intermediate,A,,1,,N,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,,50597,BAO_0000218
9651,,,,1,,,CHEMBL623779,,Intermediate,A,,1,,N,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,,50597,BAO_0000218
9652,,,1969.0,1,Plasma,,CHEMBL623780,,Intermediate,A,,1,,N,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,,50597,BAO_0000218
9653,,,1969.0,1,Plasma,,CHEMBL622015,,Intermediate,A,,1,,N,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,,,50597,BAO_0000218
9654,,,1969.0,1,Plasma,,CHEMBL622016,,Intermediate,A,,1,,N,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,,,50597,BAO_0000218
9655,,,,1,,,CHEMBL622017,,Intermediate,A,,1,,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,,50597,BAO_0000218
9656,,,,1,,,CHEMBL622018,,Intermediate,A,,1,,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,,50597,BAO_0000218
9657,,,,1,,,CHEMBL622019,,Intermediate,A,,1,,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,,50597,BAO_0000218
9658,,,,1,,,CHEMBL622020,,Intermediate,A,,1,,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,,50597,BAO_0000218
9659,,,,1,,,CHEMBL622021,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,,50597,BAO_0000218
9660,,,,1,,,CHEMBL622022,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,,50597,BAO_0000218
9661,,,,1,,,CHEMBL622023,,Intermediate,A,,1,,N,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,,50597,BAO_0000218
9662,,,,1,,,CHEMBL622024,,Intermediate,A,,1,,N,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,,50597,BAO_0000218
9663,,,,1,,,CHEMBL622693,,Intermediate,A,,1,,N,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,,50597,BAO_0000218
9664,,,,1,,,CHEMBL622694,,Intermediate,A,,1,,N,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,,50597,BAO_0000218
9665,,,,1,,,CHEMBL622695,,Intermediate,A,,1,,N,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,,50597,BAO_0000218
9666,,,,1,,,CHEMBL622696,,Intermediate,A,,1,,N,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,,50597,BAO_0000218
9667,,,,1,,,CHEMBL622697,,Intermediate,A,,1,,N,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,,50597,BAO_0000218
9668,,,,1,,,CHEMBL622874,,Intermediate,A,,1,,N,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,,50597,BAO_0000218
9669,,,,1,,,CHEMBL622875,,Intermediate,A,,1,,N,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,,50597,BAO_0000218
9670,,,,1,,,CHEMBL622876,,Intermediate,A,,1,,N,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,,50597,BAO_0000218
9671,,,,1,,,CHEMBL622877,,Intermediate,A,,1,,N,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,,50597,BAO_0000218
9672,,,,1,,,CHEMBL622878,,Intermediate,A,,1,,N,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,,50597,BAO_0000218
9673,,,1969.0,1,Plasma,,CHEMBL622879,,Intermediate,A,,1,,N,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,,,50597,BAO_0000218
9674,,,,1,,,CHEMBL877602,,Intermediate,A,,1,,N,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,,50597,BAO_0000218
9675,,,,1,,,CHEMBL622880,,Intermediate,A,,1,,N,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
9676,,,,1,,,CHEMBL622881,,Intermediate,A,,1,,N,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
9677,,,,1,,,CHEMBL622882,,Intermediate,A,,1,,N,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
9678,,,,1,,,CHEMBL622883,,Intermediate,A,,1,,N,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
9679,,,2046.0,1,Thyroid gland,,CHEMBL622884,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",,,50597,BAO_0000218
9680,,,2046.0,1,Thyroid gland,,CHEMBL622885,,Intermediate,A,,1,,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",,,50597,BAO_0000218
9681,,,,1,,,CHEMBL622886,,Intermediate,A,,1,,N,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,50597,BAO_0000218
9682,,,,1,,,CHEMBL622887,,Intermediate,A,,1,,N,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,50597,BAO_0000218
9683,,,1088.0,1,Urine,,CHEMBL622888,,Intermediate,A,,1,,N,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,,50597,BAO_0000218
9684,,,178.0,1,Blood,In vivo,CHEMBL622889,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9685,,,178.0,1,Blood,In vivo,CHEMBL622890,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9686,,,178.0,1,Blood,In vivo,CHEMBL622891,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9687,,,178.0,1,Blood,In vivo,CHEMBL877603,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9688,,,955.0,1,Brain,In vivo,CHEMBL622892,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9689,,,955.0,1,Brain,In vivo,CHEMBL622893,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9690,,,955.0,1,Brain,In vivo,CHEMBL622894,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9691,,,955.0,1,Brain,In vivo,CHEMBL622895,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9692,,,955.0,1,Brain,In vivo,CHEMBL622896,,Intermediate,A,,1,,N,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,,,50597,BAO_0000218
9693,,,948.0,1,Heart,In vivo,CHEMBL622897,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9694,,,948.0,1,Heart,In vivo,CHEMBL622898,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9695,,,948.0,1,Heart,In vivo,CHEMBL622899,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9696,,,2113.0,1,Kidney,In vivo,CHEMBL622900,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9697,,,2113.0,1,Kidney,In vivo,CHEMBL624114,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9698,,,2113.0,1,Kidney,In vivo,CHEMBL624115,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9699,,,2113.0,1,Kidney,In vivo,CHEMBL624116,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9700,,,2107.0,1,Liver,In vivo,CHEMBL624117,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9701,,,2107.0,1,Liver,In vivo,CHEMBL624118,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9702,,,2107.0,1,Liver,In vivo,CHEMBL624119,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9703,,,2107.0,1,Liver,In vivo,CHEMBL624120,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9704,,,2048.0,1,Lung,In vivo,CHEMBL624121,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9705,,,2048.0,1,Lung,In vivo,CHEMBL624122,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9706,,,2048.0,1,Lung,In vivo,CHEMBL624123,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9707,,,2048.0,1,Lung,In vivo,CHEMBL624124,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9708,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624125,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9709,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624126,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9710,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624127,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9711,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624128,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9712,,,14.0,1,Zone of skin,In vivo,CHEMBL624129,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9713,,,14.0,1,Zone of skin,In vivo,CHEMBL624130,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9714,,,14.0,1,Zone of skin,In vivo,CHEMBL622340,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9715,,,14.0,1,Zone of skin,In vivo,CHEMBL622341,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9716,,,160.0,1,Intestine,In vivo,CHEMBL622342,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9717,,,160.0,1,Intestine,In vivo,CHEMBL622343,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9718,,,160.0,1,Intestine,In vivo,CHEMBL622344,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9719,,,160.0,1,Intestine,In vivo,CHEMBL622345,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9720,,,2106.0,1,Spleen,In vivo,CHEMBL622346,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9721,,,2106.0,1,Spleen,In vivo,CHEMBL622347,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9722,,,2106.0,1,Spleen,In vivo,CHEMBL622348,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9723,,,2106.0,1,Spleen,In vivo,CHEMBL622349,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9724,,,,1,,,CHEMBL622350,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,50597,BAO_0000218
9725,,,,1,,,CHEMBL622351,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,50597,BAO_0000218
9726,,,,1,,,CHEMBL622352,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,50597,BAO_0000218
9727,,,,1,,,CHEMBL622353,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,50597,BAO_0000218
9728,,,,1,,,CHEMBL622354,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,50597,BAO_0000218
9729,,,,1,,,CHEMBL622355,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,50597,BAO_0000218
9730,,,,1,,,CHEMBL622356,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,50597,BAO_0000218
9731,,,,1,,,CHEMBL622357,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,50597,BAO_0000218
9732,,,,1,,,CHEMBL622358,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,50597,BAO_0000218
9733,,,,1,,,CHEMBL622359,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,50597,BAO_0000218
9734,,,,1,,,CHEMBL874393,,Intermediate,A,,1,,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,50597,BAO_0000218
9735,,,,1,,,CHEMBL622872,,Intermediate,A,,1,,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
9736,,,,1,,,CHEMBL622873,,Intermediate,A,,1,,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
9737,,,,1,,,CHEMBL623047,,Intermediate,A,,1,,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
9738,,,,1,,,CHEMBL623048,,Intermediate,A,,1,,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
9739,,,,1,,,CHEMBL623049,,Intermediate,A,,1,,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
9740,,,,1,,,CHEMBL623050,,Intermediate,A,,1,,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
9741,,,,1,,,CHEMBL623051,,Intermediate,A,,1,,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
9742,,,,1,,,CHEMBL623052,,Intermediate,A,,1,,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
9743,,,,1,,,CHEMBL626343,,Intermediate,A,,1,,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
9744,,,,1,,,CHEMBL626344,,Intermediate,A,,1,,N,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,50597,BAO_0000218
9745,,,,1,,,CHEMBL626345,,Intermediate,A,,1,,N,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,50597,BAO_0000218
9746,,,,1,,,CHEMBL626346,,Intermediate,A,,1,,N,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,50597,BAO_0000218
9747,,,,1,,,CHEMBL626347,,Intermediate,A,,1,,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,50597,BAO_0000218
9748,,,,1,,,CHEMBL626348,,Intermediate,A,,1,,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,50597,BAO_0000218
9749,,,,1,,,CHEMBL626349,,Intermediate,A,,1,,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,50597,BAO_0000218
9750,,,,1,,,CHEMBL626350,,Intermediate,F,,1,,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,50597,BAO_0000218
9751,,,,1,,,CHEMBL626351,,Intermediate,A,,1,,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,50597,BAO_0000218
9752,,,,1,,,CHEMBL627650,,Intermediate,A,,1,,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,50597,BAO_0000218
9753,,,,1,,,CHEMBL627651,,Intermediate,F,,1,,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,50597,BAO_0000218
9754,,,,1,,,CHEMBL627652,,Intermediate,A,,1,,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,50597,BAO_0000218
9755,,,,1,,,CHEMBL627653,,Intermediate,A,,1,,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,50597,BAO_0000218
9756,,,,1,,,CHEMBL627654,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,,50597,BAO_0000218
9757,,,,1,,,CHEMBL627835,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,,50597,BAO_0000218
9758,,,,1,,,CHEMBL627836,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,,50597,BAO_0000218
9759,,,,1,,,CHEMBL627837,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,,50597,BAO_0000218
9760,,,,1,,,CHEMBL627838,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,,50597,BAO_0000218
9761,,,,1,,,CHEMBL875338,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,,50597,BAO_0000218
9762,,,,1,,,CHEMBL627839,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,,50597,BAO_0000218
9763,,,,1,,,CHEMBL627840,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,,50597,BAO_0000218
9764,,,,1,,,CHEMBL627841,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,,50597,BAO_0000218
9765,,,,1,,,CHEMBL627842,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,,50597,BAO_0000218
9766,,,,1,,,CHEMBL627843,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,,50597,BAO_0000218
9767,,,,1,,,CHEMBL627844,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,,50597,BAO_0000218
9768,,,,1,,,CHEMBL627845,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,,50597,BAO_0000218
9769,,,,1,,In vivo,CHEMBL627846,,Intermediate,A,,1,,N,Half life period in rat by iv administration at a dose of 3 mg/kg,,,50597,BAO_0000218
9770,,,1969.0,1,Plasma,,CHEMBL627847,,Intermediate,A,,1,,N,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),,,50597,BAO_0000218
9771,,,1969.0,1,Plasma,,CHEMBL873821,,Intermediate,A,,1,,N,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),,,50597,BAO_0000218
9772,,,1969.0,1,Plasma,,CHEMBL626079,,Intermediate,A,,1,,N,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,50597,BAO_0000218
9773,,,1969.0,1,Plasma,,CHEMBL626080,,Intermediate,A,,1,,N,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,50597,BAO_0000218
9774,,,1969.0,1,Plasma,,CHEMBL626081,,Intermediate,A,,1,,N,Half life period was evaluated in rat plasma,,,50597,BAO_0000218
9775,,,1969.0,1,Plasma,,CHEMBL875344,,Intermediate,A,,1,,N,Half life period was evaluated in rat plasma; Not tested,,,50597,BAO_0000218
9776,,,,1,,,CHEMBL626082,,Intermediate,A,,1,,N,Half life period was evaluated in rats,,,50597,BAO_0000218
9777,,,,1,,In vivo,CHEMBL626250,,Intermediate,A,,1,,N,"Half life period was evaluated in rats, iv",,,50597,BAO_0000218
9778,,,,1,,In vivo,CHEMBL626251,,Intermediate,A,,1,,N,Half life period after intravenous administration at 5 mg/kg in rat,,,50597,BAO_0000218
9779,,,,1,,In vivo,CHEMBL626252,,Intermediate,A,,1,,N,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,,50597,BAO_0000218
9780,,,,1,,In vivo,CHEMBL626253,,Intermediate,A,,1,,N,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,,50597,BAO_0000218
9781,,,1969.0,1,Plasma,,CHEMBL626254,,Intermediate,A,,1,,N,Half life stability of compound was evaluated in rat plasma,,,50597,BAO_0000218
9782,,,,1,,In vivo,CHEMBL626255,,Intermediate,A,,1,,N,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,,50597,BAO_0000218
9783,,,,1,,In vivo,CHEMBL626256,,Intermediate,A,,1,,N,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,,50597,BAO_0000218
9784,,,,1,,In vivo,CHEMBL626257,,Intermediate,A,,1,,N,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,,50597,BAO_0000218
9785,,,,1,,In vivo,CHEMBL626258,,Intermediate,A,,1,,N,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,,50597,BAO_0000218
9786,,,,1,,In vivo,CHEMBL626259,,Intermediate,A,,1,,N,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,,50597,BAO_0000218
9787,,,,1,,In vivo,CHEMBL626260,,Intermediate,A,,1,,N,Half in rat i.v.,,,50597,BAO_0000218
9788,,,,1,,In vivo,CHEMBL875345,,Intermediate,A,,1,,N,Half period in rat after intravenous administration,,,50597,BAO_0000218
9789,,,,1,,In vivo,CHEMBL626261,,Intermediate,A,,1,,N,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,,50597,BAO_0000218
9790,,,2107.0,1,Liver,In vitro,CHEMBL626262,,Intermediate,A,,1,,N,Half-life measured in in vitro Cathepsin B assay in rat liver,,,50597,BAO_0000218
9791,,,,1,,,CHEMBL626263,,Intermediate,A,,1,,N,Half-life of compound was determined in rats,,,50597,BAO_0000218
9792,,,,1,,In vivo,CHEMBL625270,,Intermediate,A,,1,,N,Half-life at 10 mg/kg in rat upon intravenous administration,,,50597,BAO_0000218
9793,,,,1,,,CHEMBL625271,,Intermediate,A,,1,,N,Half-life determined in rat,,,50597,BAO_0000218
9794,,,,1,,,CHEMBL625272,,Intermediate,A,,1,,N,Half-life determined in rat,,,50597,BAO_0000218
9795,,,955.0,1,Brain,In vivo,CHEMBL625273,,Intermediate,A,,1,,N,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,,,50597,BAO_0000218
9796,,,1969.0,1,Plasma,,CHEMBL625274,,Intermediate,A,,1,,N,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",,,50597,BAO_0000218
9797,,,,1,,In vivo,CHEMBL625275,,Intermediate,A,,1,,N,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,50597,BAO_0000218
9798,,,1969.0,1,Plasma,In vivo,CHEMBL625276,,Intermediate,A,,1,,N,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,,,50597,BAO_0000218
9799,,,1969.0,1,Plasma,,CHEMBL625277,,Intermediate,A,,1,,N,Half-life in rat plasma,,,50597,BAO_0000218
9800,,,1969.0,1,Plasma,,CHEMBL625278,,Intermediate,A,,1,,N,Half-life in rat plasma was determined,,,50597,BAO_0000218
9801,,,1969.0,1,Plasma,,CHEMBL625279,,Intermediate,A,,1,,N,Half-life in rat plasma; Not tested,,,50597,BAO_0000218
9802,,,1977.0,1,Serum,,CHEMBL625280,,Intermediate,A,,1,,N,Half-life in rat serum,,,50597,BAO_0000218
9803,,,1977.0,1,Serum,,CHEMBL876797,,Intermediate,A,,1,,N,Half-life in rat serum; na is not available,,,50597,BAO_0000218
9804,,,,1,,,CHEMBL625281,,Intermediate,A,,1,,N,Half-life was calculated in rat,,,50597,BAO_0000218
9805,,,1969.0,1,Plasma,,CHEMBL873827,,Intermediate,A,,1,,N,Half-life was calculated in rat plasma,,,50597,BAO_0000218
9806,,,,1,,,CHEMBL625282,,Intermediate,A,,1,,N,Half-life was determined,,,50597,BAO_0000218
9807,,,,1,,,CHEMBL625283,,Intermediate,A,,1,,N,Half-life was determined,,,50597,BAO_0000218
9808,,,,1,,In vivo,CHEMBL625284,,Intermediate,A,,1,,N,Half-life after administration of 20 mg/Kg oral dose in rat,,,50597,BAO_0000218
9809,,,,1,,In vivo,CHEMBL625285,,Intermediate,A,,1,,N,Half-life after administration of 3.2 mg/kg intravenously in male rat,,,50597,BAO_0000218
9810,,,,1,,In vivo,CHEMBL625286,,Intermediate,A,,1,,N,Half-life after intravenous administration in female rat,,,50597,BAO_0000218
9811,,,,1,,In vivo,CHEMBL625287,,Intermediate,A,,1,,N,Half-life after intravenous administration in male rat,,,50597,BAO_0000218
9812,,,,1,,In vivo,CHEMBL625288,,Intermediate,A,,1,,N,Half-life after intravenous dose in rat,,,50597,BAO_0000218
9813,,,2107.0,1,Liver,,CHEMBL625289,,Intermediate,A,,1,,N,Half-life in a rat liver homogenate preparation,,,50597,BAO_0000218
9814,,,1969.0,1,Plasma,,CHEMBL625290,,Intermediate,A,,1,,N,Half-life in plasma of rat,,,50597,BAO_0000218
9815,,,1969.0,1,Plasma,,CHEMBL876798,,Intermediate,A,,1,,N,Half-life in plasma of rat at dose of 3-10 mgkg,,,50597,BAO_0000218
9816,,,,1,,,CHEMBL625291,,Intermediate,A,,1,,N,Half-life in rat,,,50597,BAO_0000218
9817,,,,1,,,CHEMBL625292,,Intermediate,A,,1,,N,Half-life in rat,,,50597,BAO_0000218
9818,,,,1,,,CHEMBL625293,,Intermediate,A,,1,,N,Half-life in rat,,,50597,BAO_0000218
9819,,,,1,,,CHEMBL622832,,Intermediate,A,,1,,N,Half-life in rat,,,50597,BAO_0000218
9820,,,,1,,,CHEMBL622833,,Intermediate,A,,1,,N,Half-life in rat,,,50597,BAO_0000218
9821,,,,1,,,CHEMBL622834,,Intermediate,A,,1,,N,Half-life in rat,,,50597,BAO_0000218
9822,,,,1,,In vivo,CHEMBL622835,,Intermediate,A,,1,,N,Half-life in rat after oral administration at 10 mg/kg,,,50597,BAO_0000218
9823,,,,1,,In vivo,CHEMBL622836,,Intermediate,A,,1,,N,Half-life in rat after po administration at a dose of 10 mg/kg,,,50597,BAO_0000218
9824,,,,1,,In vivo,CHEMBL622837,,Intermediate,A,,1,,N,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,,50597,BAO_0000218
9825,,,,1,,In vivo,CHEMBL622838,,Intermediate,A,,1,,N,Half-life in rat at 3 mg/kg dose administered intravenously,,,50597,BAO_0000218
9826,,,955.0,1,Brain,,CHEMBL622839,,Intermediate,A,,1,,N,Half-life in rat brain homogenate,,,50597,BAO_0000218
9827,,,1969.0,1,Plasma,,CHEMBL622840,,Intermediate,A,,1,,N,Half-life in rat plasma,,,50597,BAO_0000218
9828,,,,1,,,CHEMBL622841,,Intermediate,A,,1,,N,Half-life in rats,,,50597,BAO_0000218
9829,,,,1,,,CHEMBL622842,,Intermediate,A,,1,,N,Half-life in Dawley rats,,,50597,BAO_0000218
9830,,,1969.0,1,Plasma,In vitro,CHEMBL622843,,Intermediate,A,,1,,N,Half-life in vitro in rat plasma,,,50597,BAO_0000218
9831,,,1969.0,1,Plasma,In vitro,CHEMBL622844,,Intermediate,A,,1,,N,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,,,50597,BAO_0000218
9832,,,,1,,,CHEMBL622845,,Intermediate,A,,1,,N,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,,50597,BAO_0000218
9833,,,,1,,,CHEMBL622846,,Intermediate,A,,1,,N,The area under the curve of compound was measured at the dose of 100 umol/kg,,,50597,BAO_0000218
9834,,,,1,,,CHEMBL622847,,Intermediate,A,,1,,N,The area under the curve of compound was measured at the dose of 300 umol/kg,,,50597,BAO_0000218
9835,,,,1,,,CHEMBL622848,,Intermediate,A,,1,,N,The area under the curve of compound was measured at the dose of 30 umol/kg,,,50597,BAO_0000218
9836,,,,1,,In vivo,CHEMBL622849,,Intermediate,A,,1,,N,Bioavailability as oral AUC in rats,,,50597,BAO_0000218
9837,,,1969.0,1,Plasma,,CHEMBL622850,,Intermediate,A,,1,,N,The plasma concentration versus time curve (AUC) was determined,,,50597,BAO_0000218
9838,,,,1,,,CHEMBL876807,,Intermediate,A,,1,,N,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9839,,,,1,,,CHEMBL622851,,Intermediate,A,,1,,N,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9840,,,,1,,,CHEMBL622852,,Intermediate,A,,1,,N,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9841,,,,1,,,CHEMBL622853,,Intermediate,A,,1,,N,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,,50597,BAO_0000218
9842,,,,1,,,CHEMBL622854,,Intermediate,A,,1,,N,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,,50597,BAO_0000218
9843,,,,1,,,CHEMBL622855,,Intermediate,A,,1,,N,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,50597,BAO_0000218
9844,,,1969.0,1,Plasma,,CHEMBL622856,,Intermediate,A,,1,,N,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",,,50597,BAO_0000218
9845,,,1969.0,1,Plasma,,CHEMBL622857,,Intermediate,A,,1,,N,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",,,50597,BAO_0000218
9846,,,1969.0,1,Plasma,,CHEMBL622858,,Intermediate,A,,1,,N,AUC in rat after po administration at a dose of 10 mg/kg,,,50597,BAO_0000218
9847,,,1969.0,1,Plasma,,CHEMBL622859,,Intermediate,A,,1,,N,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,,,50597,BAO_0000218
9848,,,,1,,,CHEMBL622860,,Intermediate,A,,1,,N,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,,50597,BAO_0000218
9849,,,,1,,,CHEMBL622861,,Intermediate,A,,1,,N,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,,50597,BAO_0000218
9850,,,,1,,,CHEMBL622862,,Intermediate,A,,1,,N,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,,50597,BAO_0000218
9851,,,,1,,,CHEMBL622863,,Intermediate,A,,1,,N,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,,50597,BAO_0000218
9852,,,,1,,,CHEMBL623817,,Intermediate,A,,1,,N,Area under curve value 6 hr after po administration in rat,,,50597,BAO_0000218
9853,,,,1,,,CHEMBL623818,,Intermediate,A,,1,,N,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,50597,BAO_0000218
9854,,,,1,,,CHEMBL623819,,Intermediate,A,,1,,N,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,,50597,BAO_0000218
9855,,,,1,,,CHEMBL623820,,Intermediate,A,,1,,N,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,50597,BAO_0000218
9856,,,,1,,,CHEMBL623821,,Intermediate,A,,1,,N,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,,50597,BAO_0000218
9857,,,1969.0,1,Plasma,,CHEMBL623822,,Intermediate,A,,1,,N,AUC normalized for dose (AUCN) in rat,,,50597,BAO_0000218
9858,,,,1,,,CHEMBL623823,,Intermediate,A,,1,,N,Area under curve in rat after p.o. administration,,,50597,BAO_0000218
9859,,,,1,,,CHEMBL623824,,Intermediate,A,,1,,N,Area under curve in rat after p.o. administration,,,50597,BAO_0000218
9860,,,,1,,,CHEMBL623825,,Intermediate,A,,1,,N,Area under curve in rat after p.o. administration; Not determined,,,50597,BAO_0000218
9861,,,,1,,,CHEMBL622070,,Intermediate,A,,1,,N,Area under curve in rat after peroral administration,,,50597,BAO_0000218
9862,,,,1,,,CHEMBL622071,,Intermediate,A,,1,,N,Area under curve (carotid artery) value of the compound,,,50597,BAO_0000218
9863,,,,1,,,CHEMBL622072,,Intermediate,A,,1,,N,Bioavailability expressed as the area under curve of rat carotid artery,,,50597,BAO_0000218
9864,,,,1,,,CHEMBL622073,,Intermediate,A,,1,,N,Area under curve in male SD rats was observed after intravenous administration in rat,,,50597,BAO_0000218
9865,,,,1,,,CHEMBL622074,,Intermediate,A,,1,,N,Area under curve of the compound was determined,,,50597,BAO_0000218
9866,,,,1,,,CHEMBL622075,,Intermediate,A,,1,,N,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,,50597,BAO_0000218
9867,,,1969.0,1,Plasma,,CHEMBL622076,,Intermediate,A,,1,,N,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,,,50597,BAO_0000218
9868,,,1969.0,1,Plasma,,CHEMBL622077,,Intermediate,A,,1,,N,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,,,50597,BAO_0000218
9869,,,,1,,,CHEMBL622078,,Intermediate,A,,1,,N,Area under curve (portal vein) value of the compound,,,50597,BAO_0000218
9870,,,,1,,,CHEMBL622079,,Intermediate,A,,1,,N,Bioavailability expressed as the area under curve of rat portal vein,,,50597,BAO_0000218
9871,,,1969.0,1,Plasma,,CHEMBL622080,,Intermediate,A,,1,,N,Area Under plasma concentration time curve in rat upon peroral administration,,,50597,BAO_0000218
9872,,,,1,,,CHEMBL877612,,Intermediate,A,,1,,N,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,,50597,BAO_0000218
9873,,,,1,,,CHEMBL622081,,Intermediate,A,,1,,N,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,,50597,BAO_0000218
9874,,,,1,,,CHEMBL622082,,Intermediate,A,,1,,N,Compound was evaluated for oral bioavailability in rats,,,50597,BAO_0000218
9875,,,,1,,,CHEMBL622083,,Intermediate,A,,1,,N,Compound was evaluated for oral bioavailability in rats after iv administration,,,50597,BAO_0000218
9876,,,,1,,,CHEMBL622084,,Intermediate,A,,1,,N,Compound was evaluated for oral bioavailability in rats; 30-80,,,50597,BAO_0000218
9877,,,,1,,,CHEMBL622085,,Intermediate,A,,1,,N,Compound was evaluated for oral bioavailability in rats; 50-60,,,50597,BAO_0000218
9878,,,,1,,,CHEMBL622086,,Intermediate,A,,1,,N,Compound was evaluated for oral bioavailability in rats; no data,,,50597,BAO_0000218
9879,,,,1,,,CHEMBL622087,,Intermediate,A,,1,,N,Compound was evaluated for oral bioavailability in rats; peptide,,,50597,BAO_0000218
9880,,,178.0,1,Blood,,CHEMBL622088,,Intermediate,A,,1,,N,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",,,50597,BAO_0000218
9881,,,178.0,1,Blood,,CHEMBL622089,,Intermediate,A,,1,,N,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",,,50597,BAO_0000218
9882,,,178.0,1,Blood,,CHEMBL623685,,Intermediate,A,,1,,N,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",,,50597,BAO_0000218
9883,,,178.0,1,Blood,,CHEMBL623686,,Intermediate,A,,1,,N,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",,,50597,BAO_0000218
9884,,,945.0,1,Stomach,In vivo,CHEMBL623687,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9885,,,945.0,1,Stomach,In vivo,CHEMBL623688,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9886,,,945.0,1,Stomach,In vivo,CHEMBL623689,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9887,,,945.0,1,Stomach,In vivo,CHEMBL622485,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9888,,,2046.0,1,Thyroid gland,In vivo,CHEMBL622486,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9889,,,2046.0,1,Thyroid gland,In vivo,CHEMBL877613,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9890,,,2046.0,1,Thyroid gland,In vivo,CHEMBL622487,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9891,,,2046.0,1,Thyroid gland,In vivo,CHEMBL622488,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9892,,,948.0,1,Heart,In vivo,CHEMBL622489,,Intermediate,A,,1,,N,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,50597,BAO_0000218
9893,,,1088.0,1,Urine,,CHEMBL622490,,Intermediate,A,,1,,N,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,,50597,BAO_0000218
9894,,,1088.0,1,Urine,,CHEMBL622491,,Intermediate,A,,1,,N,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,,50597,BAO_0000218
9895,,,2107.0,1,Liver,,CHEMBL622492,,Intermediate,A,,1,,N,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,,,50597,BAO_0000218
9896,,,1088.0,1,Urine,,CHEMBL622493,,Intermediate,A,,1,,N,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,,50597,BAO_0000218
9897,,,1088.0,1,Urine,,CHEMBL622494,,Intermediate,A,,1,,N,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,,50597,BAO_0000218
9898,,,2385.0,1,Muscle tissue,,CHEMBL622495,,Intermediate,A,,1,,N,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,50597,BAO_0000218
9899,,,,1,,,CHEMBL622496,,Intermediate,A,,1,,N,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,,50597,BAO_0000218
9900,,,1088.0,1,Urine,,CHEMBL622497,,Intermediate,A,,1,,N,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,,50597,BAO_0000218
9901,,,,1,,,CHEMBL622498,,Intermediate,A,,1,,N,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,,50597,BAO_0000218
9902,,,1088.0,1,Urine,,CHEMBL624918,,Intermediate,A,,1,,N,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,,,50597,BAO_0000218
9903,,,1088.0,1,Urine,,CHEMBL624919,,Intermediate,A,,1,,N,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,,,50597,BAO_0000218
9904,,,178.0,1,Blood,In vivo,CHEMBL624920,,Intermediate,A,,1,,N,Biodistribution of compound in rat blood after 5 min of administration,,,50597,BAO_0000218
9905,,,178.0,1,Blood,In vivo,CHEMBL624921,,Intermediate,A,,1,,N,Biodistribution of compound in rat blood after 5 min of administration.,,,50597,BAO_0000218
9906,,,955.0,1,Brain,In vivo,CHEMBL624922,,Intermediate,A,,1,,N,Biodistribution of compound in rat brain after 5 min of administration,,,50597,BAO_0000218
9907,,,948.0,1,Heart,In vivo,CHEMBL624923,,Intermediate,A,,1,,N,Biodistribution of compound in rat heart after 5 min of administration,,,50597,BAO_0000218
9908,,,948.0,1,Heart,In vivo,CHEMBL624924,,Intermediate,A,,1,,N,Biodistribution of compound in rat heart after 5 min of administration.,,,50597,BAO_0000218
9909,,,2113.0,1,Kidney,In vivo,CHEMBL624925,,Intermediate,A,,1,,N,Biodistribution of compound in rat kidney after 5 min of administration,,,50597,BAO_0000218
9910,,,2113.0,1,Kidney,In vivo,CHEMBL624926,,Intermediate,A,,1,,N,Biodistribution of compound in rat kidney after 5 min of administration.,,,50597,BAO_0000218
9911,,,2107.0,1,Liver,In vivo,CHEMBL624927,,Intermediate,A,,1,,N,Biodistribution of compound in rat liver after 5 min of administration,,,50597,BAO_0000218
9912,,,2107.0,1,Liver,In vivo,CHEMBL874402,,Intermediate,A,,1,,N,Biodistribution of compound in rat liver after 5 min of administration.,,,50597,BAO_0000218
9913,,,2048.0,1,Lung,In vivo,CHEMBL624928,,Intermediate,A,,1,,N,Biodistribution of compound in rat lung after 5 min of administration,,,50597,BAO_0000218
9914,,,2048.0,1,Lung,In vivo,CHEMBL624929,,Intermediate,A,,1,,N,Biodistribution of compound in rat lung after 5 min of administration.,,,50597,BAO_0000218
9915,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624930,,Intermediate,A,,1,,N,Biodistribution of compound in rat muscle after 5 min of administration,,,50597,BAO_0000218
9916,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624931,,Intermediate,A,,1,,N,Biodistribution of compound in rat muscle after 5 min of administration.,,,50597,BAO_0000218
9917,,,948.0,1,Heart,,CHEMBL624932,,Intermediate,A,,1,,N,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,BAO_0000218
9918,,,948.0,1,Heart,,CHEMBL624933,,Intermediate,A,,1,,N,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,BAO_0000218
9919,,,2107.0,1,Liver,,CHEMBL624934,,Intermediate,A,,1,,N,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,BAO_0000218
9920,,,2107.0,1,Liver,,CHEMBL624935,,Intermediate,A,,1,,N,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,BAO_0000218
9921,,,,1,,,CHEMBL624936,,Intermediate,A,,1,,N,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,BAO_0000218
9922,,,,1,,,CHEMBL624937,,Intermediate,A,,1,,N,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,BAO_0000218
9923,,,2106.0,1,Spleen,,CHEMBL624938,,Intermediate,A,,1,,N,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,BAO_0000218
9924,,,2106.0,1,Spleen,,CHEMBL624939,,Intermediate,A,,1,,N,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,BAO_0000218
9925,,,,1,,,CHEMBL624940,,Intermediate,A,,1,,N,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,BAO_0000218
9926,,,,1,,,CHEMBL874403,,Intermediate,A,,1,,N,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,50597,BAO_0000218
9927,,,,1,,,CHEMBL624941,,Intermediate,A,,1,,N,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,,50597,BAO_0000218
9928,,,1088.0,1,Urine,,CHEMBL624942,,Intermediate,A,,1,,N,Dose required to lower urine osmolality to 300 mOsm/kg in rat,,,50597,BAO_0000218
9929,,,1088.0,1,Urine,,CHEMBL624943,,Intermediate,A,,1,,N,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,,,50597,BAO_0000218
9930,,,,1,,In vivo,CHEMBL624944,,Intermediate,A,,1,,N,% Bioavailability after 1 day of the drug administration in rats,,,50597,BAO_0000218
9931,,,,1,,In vivo,CHEMBL624945,,Intermediate,A,,1,,N,% Bioavailability after 4 day of the drug administration in rats,,,50597,BAO_0000218
9932,,,,1,,In vivo,CHEMBL624946,,Intermediate,A,,1,,N,Absolute bioavailability was evaluated in rat,,,50597,BAO_0000218
9933,,,,1,,,CHEMBL624947,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,,50597,BAO_0000218
9934,,,,1,,,CHEMBL624948,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,,50597,BAO_0000218
9935,,,,1,,,CHEMBL624949,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,,50597,BAO_0000218
9936,,,2113.0,1,Kidney,,CHEMBL622025,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,,,50597,BAO_0000218
9937,,,2113.0,1,Kidney,,CHEMBL622026,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,,,50597,BAO_0000218
9938,,,2113.0,1,Kidney,,CHEMBL622027,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,,,50597,BAO_0000218
9939,,,2113.0,1,Kidney,,CHEMBL622028,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,,,50597,BAO_0000218
9940,,,2107.0,1,Liver,,CHEMBL622029,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,,,50597,BAO_0000218
9941,,,2107.0,1,Liver,,CHEMBL622208,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,,,50597,BAO_0000218
9942,,,2107.0,1,Liver,,CHEMBL622209,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,,,50597,BAO_0000218
9943,,,2107.0,1,Liver,,CHEMBL622210,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,,,50597,BAO_0000218
9944,,,,1,,,CHEMBL622211,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,,50597,BAO_0000218
9945,,,,1,,,CHEMBL622212,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,,50597,BAO_0000218
9946,,,,1,,,CHEMBL622213,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,,50597,BAO_0000218
9947,,,,1,,,CHEMBL874404,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,,50597,BAO_0000218
9948,,,2385.0,1,Muscle tissue,,CHEMBL620452,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,,,50597,BAO_0000218
9949,,,2385.0,1,Muscle tissue,,CHEMBL620453,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,,,50597,BAO_0000218
9950,,,2385.0,1,Muscle tissue,,CHEMBL620454,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,,,50597,BAO_0000218
9951,,,2385.0,1,Muscle tissue,,CHEMBL624067,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,,,50597,BAO_0000218
9952,,,,1,,,CHEMBL624068,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,,50597,BAO_0000218
9953,,,992.0,1,Female gonad,,CHEMBL624069,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,,,50597,BAO_0000218
9954,,,992.0,1,Female gonad,,CHEMBL624070,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,,,50597,BAO_0000218
9955,,,992.0,1,Female gonad,,CHEMBL624071,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,,,50597,BAO_0000218
9956,,,995.0,1,Uterus,,CHEMBL624072,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,,,50597,BAO_0000218
9957,,,995.0,1,Uterus,,CHEMBL624073,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,,,50597,BAO_0000218
9958,,,995.0,1,Uterus,,CHEMBL624788,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,,,50597,BAO_0000218
9959,,,995.0,1,Uterus,,CHEMBL624789,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,,,50597,BAO_0000218
9960,,,,1,,,CHEMBL624790,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,,50597,BAO_0000218
9961,,,,1,,,CHEMBL624791,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,,50597,BAO_0000218
9962,,,,1,,,CHEMBL624792,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,,50597,BAO_0000218
9963,,,,1,,,CHEMBL624793,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,,50597,BAO_0000218
9964,,,2385.0,1,Muscle tissue,,CHEMBL877491,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,,,50597,BAO_0000218
9965,,,2385.0,1,Muscle tissue,,CHEMBL624957,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,,,50597,BAO_0000218
9966,,,2385.0,1,Muscle tissue,,CHEMBL624958,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,,,50597,BAO_0000218
9967,,,2385.0,1,Muscle tissue,,CHEMBL624959,,Intermediate,A,,1,,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,,,50597,BAO_0000218
9968,,,,1,,,CHEMBL624960,,Intermediate,A,,1,,N,Dissociation constant was determined,,,50597,BAO_0000218
9969,,,,1,,,CHEMBL624961,,Intermediate,A,,1,,N,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,,50597,BAO_0000218
9970,,,,1,,,CHEMBL624962,,Intermediate,A,,1,,N,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
9971,,,,1,,,CHEMBL624963,,Intermediate,A,,1,,N,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
9972,,,,1,,,CHEMBL624964,,Intermediate,A,,1,,N,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,,50597,BAO_0000218
9973,,,,1,,,CHEMBL624965,,Intermediate,A,,1,,N,LogP value was evaluated in the in situ rat gut perfusion assay,,,50597,BAO_0000218
9974,,,,1,,In vivo,CHEMBL624966,,Intermediate,A,,1,,N,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,50597,BAO_0000218
9975,,,,1,,In vivo,CHEMBL624967,,Intermediate,A,,1,,N,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,,50597,BAO_0000218
9976,,,,1,,In vivo,CHEMBL624968,,Intermediate,A,,1,,N,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,,50597,BAO_0000218
9977,,,,1,,,CHEMBL624969,,Intermediate,A,,1,,N,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,,50597,BAO_0000218
9978,,,,1,,,CHEMBL624970,,Expert,F,,1,,N,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,,50597,BAO_0000218
9979,,,,1,,,CHEMBL624971,,Intermediate,A,,1,,N,Half-life was evaluated after 10 uM/kg of intra arterial administration,,,50597,BAO_0000218
9980,,,,1,,In vivo,CHEMBL624972,,Intermediate,A,,1,,N,Half-life was evaluated after 20 uM/kg of peroral administration,,,50597,BAO_0000218
9981,,,,1,,In vivo,CHEMBL624973,,Intermediate,A,,1,,N,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,,50597,BAO_0000218
9982,,,1969.0,1,Plasma,,CHEMBL624974,,Intermediate,A,,1,,N,Half-life was evaluated in plasma of rat,,,50597,BAO_0000218
9983,,,,1,,In vivo,CHEMBL624975,,Intermediate,A,,1,,N,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,,50597,BAO_0000218
9984,,,,1,,In vivo,CHEMBL877492,,Intermediate,A,,1,,N,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,,50597,BAO_0000218
9985,,,,1,,In vivo,CHEMBL624976,,Intermediate,A,,1,,N,Half-life was measured in rat after an iv dose of 1 mg/kg,,,50597,BAO_0000218
9986,,,,1,,In vivo,CHEMBL624977,,Intermediate,A,,1,,N,Half-life period of compound in rats after peroral administration,,,50597,BAO_0000218
9987,,,1969.0,1,Plasma,,CHEMBL626848,,Intermediate,A,,1,,N,Half-life period of compound was measured in rat plasma.,,,50597,BAO_0000218
9988,,,1969.0,1,Plasma,,CHEMBL626849,,Intermediate,A,,1,,N,Half-life period of compound was measured in rat plasma; ND is not determined,,,50597,BAO_0000218
9989,,,1969.0,1,Plasma,,CHEMBL626850,,Intermediate,A,,1,,N,Half-life period of compound was measured in rat plasma; not determined,,,50597,BAO_0000218
9990,,,,1,,In vivo,CHEMBL626851,,Intermediate,A,,1,,N,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,50597,BAO_0000218
9991,,,,1,,In vivo,CHEMBL626852,,Intermediate,A,,1,,N,Half-life period in rat by iv administration,,,50597,BAO_0000218
9992,,,,1,,In vivo,CHEMBL626853,,Intermediate,A,,1,,N,Half-life period in rats following intravenous administration at 2 mg/kg,,,50597,BAO_0000218
9993,,,,1,,In vivo,CHEMBL626854,,Intermediate,A,,1,,N,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50597,BAO_0000218
9994,,,,1,,,CHEMBL627486,,Intermediate,A,,1,,N,Half-life period was determined for the compound in rat,,,50597,BAO_0000218
9995,,,,1,,In vivo,CHEMBL627487,,Intermediate,A,,1,,N,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,,50597,BAO_0000218
9996,,,,1,,In vivo,CHEMBL627488,,Intermediate,A,,1,,N,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,,50597,BAO_0000218
9997,,,,1,,In vivo,CHEMBL627489,,Intermediate,A,,1,,N,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,,50597,BAO_0000218
9998,,,,1,,In vivo,CHEMBL627490,,Intermediate,A,,1,,N,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,,50597,BAO_0000218
9999,,,,1,,In vivo,CHEMBL873829,,Intermediate,A,,1,,N,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,,50597,BAO_0000218
10000,,,,1,,In vivo,CHEMBL627655,,Intermediate,A,,1,,N,Half-life was determined in rat at a dose of 1 mpk i.v.,,,50597,BAO_0000218
10001,,,,1,,In vivo,CHEMBL625994,,Intermediate,A,,1,,N,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,,50597,BAO_0000218
10002,,,,1,,In vivo,CHEMBL625995,,Intermediate,A,,1,,N,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,,50597,BAO_0000218
10003,,,,1,,,CHEMBL625996,,Intermediate,A,,1,,N,Half-life in rat,,,50597,BAO_0000218
10004,,,1969.0,1,Plasma,In vitro,CHEMBL625850,,Intermediate,A,,1,,N,In vitro half life in rat plasma,,,50597,BAO_0000218
10005,,,1969.0,1,Plasma,In vitro,CHEMBL625851,,Intermediate,A,,1,,N,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",,,50597,BAO_0000218
10006,,,,1,,In vitro,CHEMBL625852,,Intermediate,A,,1,,N,In vitro half life in rat,,,50597,BAO_0000218
10007,,,,1,,In vivo,CHEMBL625853,,Intermediate,A,,1,,N,In vivo half life period after intravenous administration in rat,,,50597,BAO_0000218
10008,,,,1,,In vivo,CHEMBL625854,,Intermediate,A,,1,,N,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,50597,BAO_0000218
10009,,,,1,,In vivo,CHEMBL874450,,Intermediate,A,,1,,N,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,,50597,BAO_0000218
10010,,,,1,,In vivo,CHEMBL625855,,Intermediate,A,,1,,N,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
10011,,,,1,,In vivo,CHEMBL625856,,Intermediate,A,,1,,N,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
10012,,,,1,,In vivo,CHEMBL625857,,Intermediate,A,,1,,N,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
10013,,,,1,,In vivo,CHEMBL873831,,Intermediate,A,,1,,N,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
10014,,,,1,,In vivo,CHEMBL625858,,Intermediate,A,,1,,N,Longer half-life in rat (i.v.) at 0.5 mpk,,,50597,BAO_0000218
10015,,,,1,,In vivo,CHEMBL625859,,Intermediate,A,,1,,N,Longer half-life in rat (p.o.) at 2.0 mpk,,,50597,BAO_0000218
10016,,,,1,,,CHEMBL625860,,Intermediate,A,,1,,N,Pharmacokinetic property (half life) in rat,,,50597,BAO_0000218
10017,,,,1,,In vivo,CHEMBL625861,,Intermediate,A,,1,,N,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,,50597,BAO_0000218
10018,,,,1,,In vivo,CHEMBL625862,,Intermediate,A,,1,,N,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,,50597,BAO_0000218
10019,,,,1,,In vivo,CHEMBL625863,,Intermediate,A,,1,,N,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,,50597,BAO_0000218
10020,,,,1,,In vivo,CHEMBL625864,,Intermediate,A,,1,,N,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,,50597,BAO_0000218
10021,,,,1,,In vivo,CHEMBL625865,,Intermediate,A,,1,,N,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,,50597,BAO_0000218
10022,,,,1,,In vivo,CHEMBL625866,,Intermediate,A,,1,,N,Pharmacokinetic half time was determined intravenously in rats.,,,50597,BAO_0000218
10023,,,1969.0,1,Plasma,In vivo,CHEMBL625867,,Intermediate,A,,1,,N,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,,,50597,BAO_0000218
10024,,,1969.0,1,Plasma,,CHEMBL625868,,Intermediate,A,,1,,N,Plasma half life of hydrolysis of the compound,,,50597,BAO_0000218
10025,,,1969.0,1,Plasma,In vivo,CHEMBL625869,,Intermediate,A,,1,,N,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,,,50597,BAO_0000218
10026,,,1969.0,1,Plasma,,CHEMBL874451,,Intermediate,A,,1,,N,Plasma half life period was calculated in rat,,,50597,BAO_0000218
10027,,,1969.0,1,Plasma,,CHEMBL625870,,Intermediate,A,,1,,N,Plasma half-life in Sprague-Dawley rats,,,50597,BAO_0000218
10028,,,1969.0,1,Plasma,,CHEMBL625871,,Intermediate,A,,1,,N,Plasma half-life in Sprague-Dawley rats; Not determined,,,50597,BAO_0000218
10029,,,1969.0,1,Plasma,,CHEMBL625872,,Intermediate,A,,1,,N,Plasma half-life in rats,,,50597,BAO_0000218
10030,,,1969.0,1,Plasma,,CHEMBL625873,,Intermediate,A,,1,,N,Plasma half-life in rats; <MQL,,,50597,BAO_0000218
10031,,,1969.0,1,Plasma,,CHEMBL625874,,Intermediate,A,,1,,N,Plasma half-life period (0-8 h) was determined,,,50597,BAO_0000218
10032,,,1969.0,1,Plasma,,CHEMBL625875,,Intermediate,A,,1,,N,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,,,50597,BAO_0000218
10033,,,1969.0,1,Plasma,In vivo,CHEMBL625876,,Intermediate,A,,1,,N,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,,50597,BAO_0000218
10034,,,1969.0,1,Plasma,In vivo,CHEMBL631258,,Intermediate,A,,1,,N,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,,50597,BAO_0000218
10035,,,1969.0,1,Plasma,,CHEMBL631259,,Intermediate,A,,1,,N,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,,,50597,BAO_0000218
10036,,,1969.0,1,Plasma,,CHEMBL631260,,Intermediate,A,,1,,N,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,,,50597,BAO_0000218
10037,,,178.0,1,Blood,,CHEMBL631261,,Intermediate,A,,1,,N,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",,,50597,BAO_0000218
10038,,,178.0,1,Blood,,CHEMBL631262,,Intermediate,A,,1,,N,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",,,50597,BAO_0000218
10039,,,178.0,1,Blood,,CHEMBL631263,,Intermediate,A,,1,,N,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",,,50597,BAO_0000218
10040,,,,1,,,CHEMBL631264,,Intermediate,A,,1,,N,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,,50597,BAO_0000218
10041,,,,1,,,CHEMBL631265,,Intermediate,A,,1,,N,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,,50597,BAO_0000218
10042,,,,1,,,CHEMBL631266,,Intermediate,A,,1,,N,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,,50597,BAO_0000218
10043,,,,1,,,CHEMBL631267,,Intermediate,A,,1,,N,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,,50597,BAO_0000218
10044,,,,1,,,CHEMBL631268,,Intermediate,A,,1,,N,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,,50597,BAO_0000218
10045,,,,1,,,CHEMBL631269,,Intermediate,A,,1,,N,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,,50597,BAO_0000218
10046,,,,1,,,CHEMBL631270,,Intermediate,A,,1,,N,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,,50597,BAO_0000218
10047,,,948.0,1,Heart,,CHEMBL631271,,Intermediate,A,,1,,N,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,,50597,BAO_0000218
10048,,,948.0,1,Heart,,CHEMBL631272,,Intermediate,A,,1,,N,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",,,50597,BAO_0000218
10049,,,948.0,1,Heart,,CHEMBL631273,,Intermediate,A,,1,,N,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",,,50597,BAO_0000218
10050,,,948.0,1,Heart,,CHEMBL631274,,Intermediate,A,,1,,N,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",,,50597,BAO_0000218
10051,,,948.0,1,Heart,,CHEMBL631275,,Intermediate,A,,1,,N,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",,,50597,BAO_0000218
10052,,,948.0,1,Heart,,CHEMBL626984,,Intermediate,A,,1,,N,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",,,50597,BAO_0000218
10053,,,948.0,1,Heart,,CHEMBL626985,,Intermediate,A,,1,,N,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",,,50597,BAO_0000218
10054,,,2107.0,1,Liver,,CHEMBL626986,,Intermediate,A,,1,,N,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,,50597,BAO_0000218
10055,,,2107.0,1,Liver,,CHEMBL626987,,Intermediate,A,,1,,N,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",,,50597,BAO_0000218
10056,,,2107.0,1,Liver,,CHEMBL626988,,Intermediate,A,,1,,N,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",,,50597,BAO_0000218
10057,,,2107.0,1,Liver,,CHEMBL626989,,Intermediate,A,,1,,N,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",,,50597,BAO_0000218
10058,,,2107.0,1,Liver,,CHEMBL626990,,Intermediate,A,,1,,N,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",,,50597,BAO_0000218
10059,,,2107.0,1,Liver,,CHEMBL626991,,Intermediate,A,,1,,N,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",,,50597,BAO_0000218
10060,,,2107.0,1,Liver,,CHEMBL626992,,Intermediate,A,,1,,N,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",,,50597,BAO_0000218
10061,,,2048.0,1,Lung,,CHEMBL626993,,Intermediate,A,,1,,N,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",,,50597,BAO_0000218
10062,,,2048.0,1,Lung,,CHEMBL874593,,Intermediate,A,,1,,N,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",,,50597,BAO_0000218
10063,,,2048.0,1,Lung,,CHEMBL626994,,Intermediate,A,,1,,N,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",,,50597,BAO_0000218
10064,,,2048.0,1,Lung,,CHEMBL626995,,Intermediate,A,,1,,N,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",,,50597,BAO_0000218
10065,,,2048.0,1,Lung,,CHEMBL626190,,Intermediate,A,,1,,N,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",,,50597,BAO_0000218
10066,,,2048.0,1,Lung,,CHEMBL626191,,Intermediate,A,,1,,N,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",,,50597,BAO_0000218
10067,,,2048.0,1,Lung,,CHEMBL626364,,Intermediate,A,,1,,N,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",,,50597,BAO_0000218
10068,,,2046.0,1,Thyroid gland,,CHEMBL626365,,Intermediate,A,,1,,N,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",,,50597,BAO_0000218
10069,,,2046.0,1,Thyroid gland,,CHEMBL626366,,Intermediate,A,,1,,N,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",,,50597,BAO_0000218
10070,,,2046.0,1,Thyroid gland,,CHEMBL626367,,Intermediate,A,,1,,N,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",,,50597,BAO_0000218
10071,,,2046.0,1,Thyroid gland,,CHEMBL626368,,Intermediate,A,,1,,N,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",,,50597,BAO_0000218
10072,,,2046.0,1,Thyroid gland,,CHEMBL626369,,Intermediate,A,,1,,N,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",,,50597,BAO_0000218
10073,,,2046.0,1,Thyroid gland,,CHEMBL626370,,Intermediate,A,,1,,N,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",,,50597,BAO_0000218
10074,,,,1,,In vivo,CHEMBL626371,,Intermediate,A,,1,,N,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,,50597,BAO_0000218
10075,,,,1,,In vivo,CHEMBL626372,,Intermediate,A,,1,,N,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,,50597,BAO_0000218
10076,,,,1,,In vivo,CHEMBL626373,,Intermediate,A,,1,,N,Bioavailability after a dose of 10 mg/kg p.o.,,,50597,BAO_0000218
10077,,,,1,,In vivo,CHEMBL626374,,Intermediate,A,,1,,N,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,,50597,BAO_0000218
10078,,,,1,,In vivo,CHEMBL626375,,Intermediate,A,,1,,N,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,,50597,BAO_0000218
10079,,,,1,,In vivo,CHEMBL626376,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,,50597,BAO_0000218
10080,,,,1,,In vivo,CHEMBL626377,,Intermediate,A,,1,,N,Bioavailability in rat po was determined,,,50597,BAO_0000218
10081,,,,1,,In vivo,CHEMBL626378,,Intermediate,A,,1,,N,Bioavailability of compound at 10 mg/kg in rat after oral administration,,,50597,BAO_0000218
10082,,,,1,,In vivo,CHEMBL626379,,Intermediate,A,,1,,N,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,,50597,BAO_0000218
10083,,,,1,,In vivo,CHEMBL626380,,Intermediate,A,,1,,N,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,50597,BAO_0000218
10084,,,,1,,In vivo,CHEMBL626381,,Intermediate,A,,1,,N,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,50597,BAO_0000218
10085,,,,1,,In vivo,CHEMBL626382,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10086,,,,1,,In vivo,CHEMBL626383,,Intermediate,A,,1,,N,Bioavailability in rat (Sprague-Dawley) (female),,,50597,BAO_0000218
10087,,,,1,,In vivo,CHEMBL874652,,Intermediate,A,,1,,N,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,50597,BAO_0000218
10088,,,,1,,In vivo,CHEMBL626384,,Intermediate,A,,1,,N,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,,50597,BAO_0000218
10089,,,,1,,In vivo,CHEMBL626385,,Intermediate,A,,1,,N,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,,50597,BAO_0000218
10090,,,,1,,In vivo,CHEMBL626386,,Intermediate,A,,1,,N,Bioavailability in rat at an oral dose of 2 mg/kg,,,50597,BAO_0000218
10091,,,,1,,In vivo,CHEMBL626387,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10092,,,,1,,In vivo,CHEMBL626388,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10093,,,,1,,In vivo,CHEMBL626389,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10094,,,,1,,In vivo,CHEMBL626390,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10095,,,,1,,In vivo,CHEMBL626391,,Intermediate,A,,1,,N,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,,50597,BAO_0000218
10096,,,,1,,In vivo,CHEMBL626392,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10097,,,,1,,In vivo,CHEMBL626393,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10098,,,,1,,In vivo,CHEMBL623026,,Intermediate,A,,1,,N,Bioavailability was determined in rat,,,50597,BAO_0000218
10099,,,,1,,In vivo,CHEMBL623027,,Intermediate,A,,1,,N,Bioavailability,,,50597,BAO_0000218
10100,,,,1,,In vivo,CHEMBL623028,,Intermediate,A,,1,,N,Bioavailability,,,50597,BAO_0000218
10101,,,,1,,In vivo,CHEMBL623029,,Intermediate,A,,1,,N,Bioavailability in rat after 1 day dosing,,,50597,BAO_0000218
10102,,,,1,,In vivo,CHEMBL623030,,Intermediate,A,,1,,N,Bioavailability in rat after 4 day dosing,,,50597,BAO_0000218
10103,,,,1,,In vivo,CHEMBL623031,,Intermediate,A,,1,,N,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,,50597,BAO_0000218
10104,,,,1,,In vivo,CHEMBL623032,,Intermediate,A,,1,,N,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,,50597,BAO_0000218
10105,,,,1,,In vivo,CHEMBL623033,,Intermediate,A,,1,,N,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,,50597,BAO_0000218
10106,,,,1,,In vivo,CHEMBL623034,,Intermediate,A,,1,,N,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,,50597,BAO_0000218
10107,,,,1,,In vivo,CHEMBL623035,,Intermediate,A,,1,,N,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,,50597,BAO_0000218
10108,,,,1,,In vivo,CHEMBL623036,,Intermediate,A,,1,,N,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,50597,BAO_0000218
10109,,,,1,,In vivo,CHEMBL623037,,Intermediate,A,,1,,N,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,50597,BAO_0000218
10110,,,,1,,In vivo,CHEMBL623038,,Intermediate,A,,1,,N,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,,50597,BAO_0000218
10111,,,1969.0,1,Plasma,In vivo,CHEMBL874385,,Intermediate,A,,1,,N,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,,,50597,BAO_0000218
10112,,,,1,,In vivo,CHEMBL623039,,Intermediate,A,,1,,N,Bioavailability in rat (Fisher) (fasted),,,50597,BAO_0000218
10113,,,,0,,In vivo,CHEMBL623040,,Intermediate,A,,1,,U,Bioavailability in monkey after po administration of 10 mg/kg dose,,,22224,BAO_0000218
10114,,,,0,,In vivo,CHEMBL623041,,Intermediate,A,,1,,U,Oral bioavailability in monkey (dose 10 mg/kg),,,22224,BAO_0000218
10115,,,,1,,In vivo,CHEMBL623741,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10116,,,,1,,In vivo,CHEMBL623742,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10117,,,,1,,In vivo,CHEMBL623743,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10118,,,,1,,In vivo,CHEMBL623744,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10119,,,,1,,In vivo,CHEMBL623745,,Intermediate,A,,1,,N,Bioavailability in rat (dose 2.0 mg/kg p.o.),,,50597,BAO_0000218
10120,,,,1,,In vivo,CHEMBL623746,,Intermediate,A,,1,,N,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,,50597,BAO_0000218
10121,,,,1,,In vivo,CHEMBL623747,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 5 mg/kg p.o.),,,50597,BAO_0000218
10122,,,,0,,In vivo,CHEMBL623748,,Intermediate,A,,1,,U,Bioavailability in rat after po administration of 30 mg/kg dose,,,22224,BAO_0000218
10123,,,,0,,In vivo,CHEMBL623916,,Intermediate,A,,1,,U,Bioavailability in rat after po administration of 30 mg/kg dose,,,22224,BAO_0000218
10124,,,,1,,In vivo,CHEMBL623917,,Intermediate,A,,1,,N,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,50597,BAO_0000218
10125,,,,1,,In vivo,CHEMBL623918,,Intermediate,A,,1,,N,Bioavailability in rat (dose 2 mg/kg i.v.),,,50597,BAO_0000218
10126,,,,1,,In vivo,CHEMBL874386,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10127,,,1969.0,1,Plasma,In vivo,CHEMBL623919,,Intermediate,A,,1,,N,Bioavailability in rat; Only traces detected in rat plasma,,,50597,BAO_0000218
10128,,,,1,,In vivo,CHEMBL623920,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10129,,,,1,,In vivo,CHEMBL623148,,Intermediate,A,,1,,N,Bioavailability upon oral administration of compound,,,50597,BAO_0000218
10130,,,,1,,In vivo,CHEMBL623149,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,,50597,BAO_0000218
10131,,,,1,,In vivo,CHEMBL623150,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10132,,,,1,,In vivo,CHEMBL623151,,Intermediate,A,,1,,N,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,,50597,BAO_0000218
10133,,,,1,,In vivo,CHEMBL623152,,Intermediate,A,,1,,N,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,,50597,BAO_0000218
10134,,,,1,,,CHEMBL623153,,Expert,F,,1,,N,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,,50597,BAO_0000218
10135,,,,1,,,CHEMBL623154,,Expert,F,,1,,N,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,,50597,BAO_0000218
10136,,,,1,,,CHEMBL623155,,Intermediate,A,,1,,N,In vitro and metabolic stability was determined,,,50597,BAO_0000218
10137,,,,1,,,CHEMBL623156,,Intermediate,A,,1,,N,In vitro metabolic stability in rat hepatocytes,,,50597,BAO_0000218
10138,,,,1,,,CHEMBL623157,,Intermediate,A,,1,,N,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,,50597,BAO_0000218
10139,401.0,,2107.0,1,Liver,In vitro,CHEMBL623158,,Intermediate,A,,1,,N,Metabolic rate for compound was observed in rat hepatocytes,,Hepatocyte,50597,BAO_0000218
10140,,,,1,,,CHEMBL623159,,Intermediate,A,,1,,N,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,,50597,BAO_0000218
10141,,,,1,,,CHEMBL874390,,Intermediate,A,,1,,N,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,,50597,BAO_0000218
10142,,,,1,,,CHEMBL623160,,Intermediate,A,,1,,N,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,,50597,BAO_0000218
10143,,,,1,,,CHEMBL623161,,Intermediate,A,,1,,N,Metabolism of compound in rat S9 microsomes; Trace,,,50597,BAO_0000218
10144,,,,1,,,CHEMBL623162,,Intermediate,A,,1,,N,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,,50597,BAO_0000218
10145,,,,1,,,CHEMBL623163,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,,50597,BAO_0000218
10146,,,,1,,,CHEMBL623164,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,,50597,BAO_0000218
10147,,,,1,,,CHEMBL623165,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,,50597,BAO_0000218
10148,,,,1,,,CHEMBL623166,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,,50597,BAO_0000218
10149,,,,1,,,CHEMBL624983,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,,50597,BAO_0000218
10150,,,,1,,,CHEMBL624984,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,,50597,BAO_0000218
10151,,,,1,,,CHEMBL624985,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,,50597,BAO_0000218
10152,,,,1,,,CHEMBL622970,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,,50597,BAO_0000218
10153,,,,1,,,CHEMBL622971,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,,50597,BAO_0000218
10154,,,,1,,,CHEMBL622972,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,,50597,BAO_0000218
10155,,,,1,,,CHEMBL622973,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,,50597,BAO_0000218
10156,,,,1,,,CHEMBL622974,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,,50597,BAO_0000218
10157,,,,1,,,CHEMBL622975,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,,50597,BAO_0000218
10158,,,,1,,,CHEMBL622976,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,,50597,BAO_0000218
10159,,,,1,,,CHEMBL622977,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,,50597,BAO_0000218
10160,,,,1,,,CHEMBL624351,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,,50597,BAO_0000218
10161,,,,1,,,CHEMBL624352,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,,50597,BAO_0000218
10162,,,,1,,,CHEMBL624353,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,,50597,BAO_0000218
10163,,,,1,,,CHEMBL622397,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,,50597,BAO_0000218
10164,,,,1,,,CHEMBL622398,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,,50597,BAO_0000218
10165,,,,1,,,CHEMBL622399,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,,50597,BAO_0000218
10166,,,,1,,,CHEMBL622400,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,,50597,BAO_0000218
10167,,,,1,,,CHEMBL628428,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,,50597,BAO_0000218
10168,,,,1,,,CHEMBL628590,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,,50597,BAO_0000218
10169,,,,1,,,CHEMBL628591,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,,50597,BAO_0000218
10170,,,,1,,,CHEMBL628592,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,,50597,BAO_0000218
10171,,,,1,,,CHEMBL628593,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,,50597,BAO_0000218
10172,,,,1,,,CHEMBL875333,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,,50597,BAO_0000218
10173,,,,1,,,CHEMBL628594,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,,50597,BAO_0000218
10174,,,1969.0,1,Plasma,,CHEMBL628595,,Intermediate,A,,1,,N,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,,,50597,BAO_0000218
10175,,,1969.0,1,Plasma,,CHEMBL628596,,Intermediate,A,,1,,N,Stability in rat plasma was determined,,,50597,BAO_0000218
10176,,,1969.0,1,Plasma,,CHEMBL628597,,Intermediate,A,,1,,N,Stability in rat plasma was determined; ND= no data,,,50597,BAO_0000218
10177,,,1969.0,1,Plasma,,CHEMBL628598,,Intermediate,A,,1,,N,Tested for plasma half life period in rat (0-8 hr),,,50597,BAO_0000218
10178,,,1969.0,1,Plasma,,CHEMBL628599,,Intermediate,A,,1,,N,Tested for plasma half life period in rat (0-8 hr); Not determined,,,50597,BAO_0000218
10179,,,,1,,In vivo,CHEMBL628600,,Intermediate,A,,1,,N,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,,50597,BAO_0000218
10180,,,,1,,In vivo,CHEMBL628601,,Intermediate,A,,1,,N,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,,50597,BAO_0000218
10181,,,,1,,,CHEMBL628602,,Intermediate,A,,1,,N,Tested for the half life in rat,,,50597,BAO_0000218
10182,,,,1,,In vitro,CHEMBL628603,,Intermediate,A,,1,,N,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,,50597,BAO_0000218
10183,,,,1,,In vitro,CHEMBL628604,,Intermediate,A,,1,,N,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,,50597,BAO_0000218
10184,,,,1,,In vitro,CHEMBL628605,,Intermediate,A,,1,,N,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,,50597,BAO_0000218
10185,,,,1,,In vitro,CHEMBL628606,,Intermediate,A,,1,,N,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,,50597,BAO_0000218
10186,,,,1,,In vitro,CHEMBL628607,,Intermediate,A,,1,,N,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,,50597,BAO_0000218
10187,,,,1,,,CHEMBL628608,,Intermediate,A,,1,,N,The biological half life the compound was measured at the dose of 100 umol/kg,,,50597,BAO_0000218
10188,,,,1,,,CHEMBL628609,,Intermediate,A,,1,,N,The biological half life the compound was measured at the dose of 30 umol/kg,,,50597,BAO_0000218
10189,,,1969.0,1,Plasma,,CHEMBL628610,,Intermediate,A,,1,,N,The compound was evaluated for plasma half life period in rat,,,50597,BAO_0000218
10190,,,,1,,In vivo,CHEMBL873819,,Intermediate,A,,1,,N,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
10191,,,,1,,In vivo,CHEMBL628611,,Intermediate,A,,1,,N,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
10192,,,,1,,In vivo,CHEMBL628612,,Intermediate,A,,1,,N,The pharmacokinetic parameter half-life period in vivo in rats,,,50597,BAO_0000218
10193,,,,1,,In vivo,CHEMBL628613,,Intermediate,A,,1,,N,"The pharmacokinetic property, Half-life was determined",,,50597,BAO_0000218
10194,,,,1,,In vivo,CHEMBL628614,,Intermediate,A,,1,,N,"The pharmacokinetic property, Half-life in rat in vivo",,,50597,BAO_0000218
10195,,,,1,,In vivo,CHEMBL628615,,Intermediate,A,,1,,N,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,,50597,BAO_0000218
10196,,,,1,,In vivo,CHEMBL628616,,Intermediate,A,,1,,N,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,,50597,BAO_0000218
10197,,,1969.0,1,Plasma,,CHEMBL627924,,Intermediate,A,,1,,N,The plasma half life period in rats,,,50597,BAO_0000218
10198,,,2107.0,1,Liver,,CHEMBL627925,,Intermediate,A,,1,,N,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,,,50597,BAO_0000218
10199,,,,1,,In vivo,CHEMBL627926,,Intermediate,A,,1,,N,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,,50597,BAO_0000218
10200,,,,1,,,CHEMBL627927,,Intermediate,A,,1,,N,t1/2 (apparent elimination)of the compound was determined,,,50597,BAO_0000218
10201,,,,1,,,CHEMBL627928,,Intermediate,A,,1,,N,t1/2 value in rat,,,50597,BAO_0000218
10202,,,,1,,,CHEMBL627539,,Intermediate,A,,1,,N,Half life in rat,,,50597,BAO_0000218
10203,,,1969.0,1,Plasma,In vivo,CHEMBL876790,,Intermediate,A,,1,,N,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,,50597,BAO_0000218
10204,,,,1,,In vivo,CHEMBL858186,,Intermediate,A,,1,,N,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,,50597,BAO_0000218
10205,,,,1,,,CHEMBL627540,,Intermediate,A,,1,,N,Half-life period in fasted rats,,,50597,BAO_0000218
10206,,,,1,,In vivo,CHEMBL627541,,Intermediate,A,,1,,N,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,,50597,BAO_0000218
10207,,,,1,,In vivo,CHEMBL627715,,Intermediate,A,,1,,N,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,,50597,BAO_0000218
10208,,,,1,,In vivo,CHEMBL627716,,Intermediate,A,,1,,N,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,,50597,BAO_0000218
10209,,,,1,,,CHEMBL627717,,Intermediate,A,,1,,N,Maximum time required to achieve Cmax was determined in rat,,,50597,BAO_0000218
10210,,,,1,,In vivo,CHEMBL627718,,Intermediate,A,,1,,N,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,50597,BAO_0000218
10211,,,,1,,In vivo,CHEMBL627719,,Intermediate,A,,1,,N,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,50597,BAO_0000218
10212,,,,1,,In vivo,CHEMBL627720,,Intermediate,A,,1,,N,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,,50597,BAO_0000218
10213,,,,1,,In vivo,CHEMBL627721,,Intermediate,A,,1,,N,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,,50597,BAO_0000218
10214,,,,1,,In vivo,CHEMBL627722,,Intermediate,A,,1,,N,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,,50597,BAO_0000218
10215,,,,1,,In vivo,CHEMBL627723,,Intermediate,A,,1,,N,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
10216,,,,1,,In vivo,CHEMBL626058,,Intermediate,A,,1,,N,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
10217,,,,1,,In vivo,CHEMBL626059,,Intermediate,A,,1,,N,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
10218,,,,1,,In vivo,CHEMBL626060,,Intermediate,A,,1,,N,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
10219,,,1969.0,1,Plasma,In vivo,CHEMBL626061,,Intermediate,A,,1,,N,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,,,50597,BAO_0000218
10220,,,,1,,In vivo,CHEMBL876791,,Intermediate,A,,1,,N,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
10221,,,,1,,In vivo,CHEMBL626062,,Intermediate,A,,1,,N,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,50597,BAO_0000218
10222,,,,1,,In vivo,CHEMBL626063,,Intermediate,A,,1,,N,Tmax at the dose of 2 mg/Kg administered perorally in rats,,,50597,BAO_0000218
10223,,,,1,,In vivo,CHEMBL626064,,Intermediate,A,,1,,N,Tmax at the dose of 5 mg/Kg administered perorally in rats,,,50597,BAO_0000218
10224,,,1969.0,1,Plasma,In vivo,CHEMBL626065,,Intermediate,A,,1,,N,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,,,50597,BAO_0000218
10225,,,1969.0,1,Plasma,In vivo,CHEMBL626066,,Intermediate,A,,1,,N,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,,,50597,BAO_0000218
10226,,,,1,,In vivo,CHEMBL626067,,Intermediate,A,,1,,N,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,,50597,BAO_0000218
10227,,,,1,,,CHEMBL626068,,Intermediate,F,,1,,N,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,,50597,BAO_0000218
10228,,,,1,,,CHEMBL626069,,Intermediate,F,,1,,N,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,,50597,BAO_0000218
10229,,,,1,,,CHEMBL626070,,Intermediate,F,,1,,N,Percent total excretion of 3-methoxyacetaminophen glucuronide,,,50597,BAO_0000218
10230,,,,1,,,CHEMBL626071,,Intermediate,F,,1,,N,Percent total excretion of N-methoxyacetaminophen glucuronide,,,50597,BAO_0000218
10231,,,,1,,,CHEMBL626072,,Intermediate,F,,1,,N,Percent total excretion of N-methoxyacetaminophen sulfate,,,50597,BAO_0000218
10232,,,,1,,,CHEMBL626073,,Intermediate,F,,1,,N,Percent total excretion of acetaminophen,,,50597,BAO_0000218
10233,,,2046.0,1,Thyroid gland,,CHEMBL626741,,Intermediate,A,,1,,N,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",,,50597,BAO_0000218
10234,,,,1,,,CHEMBL626742,,Intermediate,A,,1,,N,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,,50597,BAO_0000218
10235,,,,1,,,CHEMBL626743,,Intermediate,A,,1,,N,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,,50597,BAO_0000218
10236,,,,1,,,CHEMBL876792,,Intermediate,A,,1,,N,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,50597,BAO_0000218
10237,,,,1,,,CHEMBL626744,,Intermediate,A,,1,,N,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,,50597,BAO_0000218
10238,,,,1,,,CHEMBL626745,,Intermediate,A,,1,,N,Compound was tested for antidiuretic activity in rats,,,50597,BAO_0000218
10239,,,1969.0,1,Plasma,In vivo,CHEMBL626746,,Intermediate,A,,1,,N,AUC in rat after 3mg/kg oral dose,,,50597,BAO_0000218
10240,,,,1,,,CHEMBL626747,,Intermediate,A,,1,,N,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,,50597,BAO_0000218
10241,,,,1,,,CHEMBL626748,,Intermediate,A,,1,,N,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,,50597,BAO_0000218
10242,,,,1,,,CHEMBL626749,,Intermediate,A,,1,,N,Bioavailability administered orally at a dose of 10 mg/kg to rats,,,50597,BAO_0000218
10243,,,,1,,,CHEMBL626750,,Intermediate,A,,1,,N,Oral Bioavailability was determined,,,50597,BAO_0000218
10244,,,,1,,,CHEMBL626751,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10245,,,,1,,,CHEMBL626913,,Intermediate,A,,1,,N,Oral bioavailability in rat; Not performed.,,,50597,BAO_0000218
10246,,,,1,,,CHEMBL626914,,Intermediate,A,,1,,N,Bioavailability,,,50597,BAO_0000218
10247,,,,1,,,CHEMBL626915,,Intermediate,A,,1,,N,Bioavailability was determined; ND denotes no data,,,50597,BAO_0000218
10248,,,,1,,,CHEMBL626916,,Intermediate,A,,1,,N,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,,50597,BAO_0000218
10249,,,,1,,,CHEMBL626917,,Intermediate,A,,1,,N,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,,50597,BAO_0000218
10250,,,,1,,,CHEMBL626918,,Intermediate,A,,1,,N,Binding towards rat plasma protein at 10 uM,,,50597,BAO_0000218
10251,,,,1,,,CHEMBL626919,,Intermediate,A,,1,,N,Binding towards rat plasma protein at 100 uM,,,50597,BAO_0000218
10252,,,,1,,In vivo,CHEMBL626920,,Intermediate,A,,1,,N,Bioavailability in rat (dose 20 mg/kg p.o.),,,50597,BAO_0000218
10253,,,,1,,In vivo,CHEMBL621976,,Intermediate,A,,1,,N,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,,50597,BAO_0000218
10254,,,,1,,In vivo,CHEMBL877599,,Intermediate,A,,1,,N,Bioavailability in rat after 5 mg/kg oral gavage,,,50597,BAO_0000218
10255,,,,1,,In vivo,CHEMBL621977,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10256,,,,1,,In vivo,CHEMBL621978,,Intermediate,A,,1,,N,Bioavailability in rat (dose 1 mg/kg i.v.),,,50597,BAO_0000218
10257,,,,1,,In vivo,CHEMBL621979,,Intermediate,A,,1,,N,Bioavailability in rat (dose 3 mg/kg p.o.),,,50597,BAO_0000218
10258,,,,1,,In vivo,CHEMBL621980,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10259,,,,1,,In vivo,CHEMBL621981,,Intermediate,A,,1,,N,Bioavailability of the compound in rats after administration of 30 mg/kg,,,50597,BAO_0000218
10260,,,,1,,In vivo,CHEMBL621982,,Intermediate,A,,1,,N,Bioavailability after administration of 10 mg/kg in rats,,,50597,BAO_0000218
10261,,,,1,,In vivo,CHEMBL882953,,Intermediate,A,,1,,N,Bioavailability after administration of 2 mg/kg in rats,,,50597,BAO_0000218
10262,,,,1,,In vivo,CHEMBL621983,,Intermediate,A,,1,,N,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,,50597,BAO_0000218
10263,,,,1,,In vivo,CHEMBL621984,,Intermediate,A,,1,,N,Bioavailability in dogs was determined; high,,,50597,BAO_0000218
10264,,,,1,,In vivo,CHEMBL621985,,Intermediate,A,,1,,N,Bioavailability in monkey after intravenous administration at 1 mpk,,,50597,BAO_0000218
10265,,,,1,,In vivo,CHEMBL621986,,Intermediate,A,,1,,N,Bioavailability in monkey after peroral administration at 10 mpk,,,50597,BAO_0000218
10266,,,,1,,In vivo,CHEMBL621987,,Intermediate,A,,1,,N,Bioavailability in rat after intravenous administration at 1 mpk,,,50597,BAO_0000218
10267,,,,1,,In vivo,CHEMBL877600,,Intermediate,F,,1,,N,Bioavailability in rat after intravenous administration at 2 mpk,,,50597,BAO_0000218
10268,,,,1,,In vivo,CHEMBL621988,,Intermediate,A,,1,,N,Bioavailability in rat after peroral administration at 30 mpk,,,50597,BAO_0000218
10269,,,,1,,In vivo,CHEMBL621989,,Intermediate,F,,1,,N,Bioavailability in rat after peroral administration at at 100 mpk,,,50597,BAO_0000218
10270,,,,1,,In vivo,CHEMBL621990,,Intermediate,A,,1,,N,Bioavailability in rats was evaluated,,,50597,BAO_0000218
10271,,,,1,,In vivo,CHEMBL621991,,Intermediate,A,,1,,N,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,,50597,BAO_0000218
10272,,,,1,,In vivo,CHEMBL621992,,Intermediate,A,,1,,N,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,,50597,BAO_0000218
10273,,,,1,,In vivo,CHEMBL621993,,Intermediate,A,,1,,N,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,,50597,BAO_0000218
10274,,,,1,,In vivo,CHEMBL621994,,Intermediate,A,,1,,N,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,,50597,BAO_0000218
10275,,,,1,,In vivo,CHEMBL621995,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10276,,,,1,,In vivo,CHEMBL621996,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10277,,,,1,,In vivo,CHEMBL621997,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 10 mg/kg),,,50597,BAO_0000218
10278,,,,1,,In vivo,CHEMBL621998,,Intermediate,A,,1,,N,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,,50597,BAO_0000218
10279,,,,1,,In vivo,CHEMBL621999,,Intermediate,A,,1,,N,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,,50597,BAO_0000218
10280,,,,1,,In vivo,CHEMBL622000,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10281,,,,1,,In vivo,CHEMBL622001,,Intermediate,A,,1,,N,Bioavailability was measured in rat after oral administration; 2-4,,,50597,BAO_0000218
10282,,,,1,,In vivo,CHEMBL622002,,Intermediate,A,,1,,N,Bioavailability was measured in rat after oral administration; 3-7,,,50597,BAO_0000218
10283,,,,1,,In vivo,CHEMBL622003,,Intermediate,A,,1,,N,Bioavailability in rat (intraduodenal administration),,,50597,BAO_0000218
10284,,,,1,,In vivo,CHEMBL877601,,Intermediate,A,,1,,N,Bioavailability in rat (intraduodenal administration),,,50597,BAO_0000218
10285,,,,1,,In vivo,CHEMBL624871,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10286,,,,1,,In vivo,CHEMBL622004,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10287,,,,1,,In vivo,CHEMBL882954,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,,50597,BAO_0000218
10288,,,,1,,In vivo,CHEMBL622005,,Intermediate,A,,1,,N,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,,50597,BAO_0000218
10289,,,,1,,In vivo,CHEMBL622006,,Intermediate,A,,1,,N,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,,50597,BAO_0000218
10290,,,,1,,In vivo,CHEMBL622007,,Intermediate,A,,1,,N,Bioavailability was measured in rat,,,50597,BAO_0000218
10291,,,,1,,In vivo,CHEMBL622008,,Intermediate,A,,1,,N,Bioavailability was reported,,,50597,BAO_0000218
10292,,,,1,,In vivo,CHEMBL622009,,Intermediate,A,,1,,N,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,50597,BAO_0000218
10293,,,,1,,In vivo,CHEMBL622010,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,50597,BAO_0000218
10294,,,,1,,In vivo,CHEMBL622011,,Intermediate,A,,1,,N,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,,50597,BAO_0000218
10295,,,,1,,In vivo,CHEMBL622012,,Intermediate,A,,1,,N,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,,50597,BAO_0000218
10296,,,,1,,In vivo,CHEMBL622013,,Intermediate,A,,1,,N,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,,50597,BAO_0000218
10297,,,,1,,In vivo,CHEMBL622014,,Intermediate,A,,1,,N,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,50597,BAO_0000218
10298,,,,1,,In vivo,CHEMBL624749,,Intermediate,A,,1,,N,Bioavailability was determined at 3 mg/kg po dose in rats,,,50597,BAO_0000218
10299,,,,1,,In vivo,CHEMBL624750,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 2 mg/kg),,,50597,BAO_0000218
10300,,,,1,,In vivo,CHEMBL624751,,Intermediate,A,,1,,N,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,,50597,BAO_0000218
10301,,,,1,,In vivo,CHEMBL624752,,Intermediate,A,,1,,N,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,,50597,BAO_0000218
10302,,,,1,,In vivo,CHEMBL624753,,Intermediate,A,,1,,N,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,,50597,BAO_0000218
10303,,,,1,,In vivo,CHEMBL624754,,Intermediate,A,,1,,N,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,,50597,BAO_0000218
10304,,,,1,,In vivo,CHEMBL624755,,Intermediate,A,,1,,N,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,,50597,BAO_0000218
10305,,,,1,,In vivo,CHEMBL624756,,Intermediate,A,,1,,N,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,,50597,BAO_0000218
10306,,,,1,,In vivo,CHEMBL624757,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10307,,,,1,,In vivo,CHEMBL624758,,Intermediate,A,,1,,N,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,,50597,BAO_0000218
10308,,,,1,,In vivo,CHEMBL622270,,Intermediate,A,,1,,N,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,,50597,BAO_0000218
10309,,,,1,,In vivo,CHEMBL622271,,Intermediate,A,,1,,N,Bioavailability in rat (Sprague-Dawley),,,50597,BAO_0000218
10310,,,,1,,In vivo,CHEMBL622272,,Intermediate,A,,1,,N,Bioavailability in rat at the dose of 2 mg/kg,,,50597,BAO_0000218
10311,,,,1,,In vivo,CHEMBL622273,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10312,,,,1,,In vivo,CHEMBL622274,,Intermediate,A,,1,,N,Bioavailability in rat (cannulated) (dose 2 mg/kg),,,50597,BAO_0000218
10313,,,,1,,In vivo,CHEMBL622275,,Intermediate,A,,1,,N,Bioavailability value of compound in rats was determined after peroral administration,,,50597,BAO_0000218
10314,,,,1,,In vivo,CHEMBL622276,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 20 mg/kg),,,50597,BAO_0000218
10315,,,,1,,In vivo,CHEMBL622277,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10316,,,,1,,In vivo,CHEMBL622278,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 5 mg/kg),,,50597,BAO_0000218
10317,,,,1,,In vivo,CHEMBL622279,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10318,,,,1,,In vivo,CHEMBL622280,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10319,,,,1,,In vivo,CHEMBL624083,,Intermediate,A,,1,,N,Compound was evaluated for oral bioavailability in rats; 15-27 %,,,50597,BAO_0000218
10320,,,,1,,In vivo,CHEMBL624084,,Intermediate,A,,1,,N,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,,50597,BAO_0000218
10321,,,,1,,In vivo,CHEMBL624085,,Intermediate,A,,1,,N,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,,50597,BAO_0000218
10322,,,,1,,In vivo,CHEMBL624086,,Intermediate,A,,1,,N,Compound was tested for bioavailability in rats,,,50597,BAO_0000218
10323,,,,1,,In vivo,CHEMBL624087,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10324,,,,1,,In vivo,CHEMBL624088,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10325,,,,0,,In vivo,CHEMBL624089,,Intermediate,A,,1,,U,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,,22224,BAO_0000218
10326,,,,0,,In vivo,CHEMBL624090,,Intermediate,A,,1,,U,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,22224,BAO_0000218
10327,,,,1,,In vivo,CHEMBL624091,,Intermediate,A,,1,,N,Evaluated for the bioavailability in rat (in vivo),,,50597,BAO_0000218
10328,,,,1,,In vivo,CHEMBL624092,,Intermediate,A,,1,,N,F value of compound in rats was determined after peroral administration,,,50597,BAO_0000218
10329,,,,1,,In vivo,CHEMBL624093,,Intermediate,A,,1,,N,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
10330,,,,1,,In vivo,CHEMBL624094,,Intermediate,A,,1,,N,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
10331,,,,1,,In vivo,CHEMBL624095,,Intermediate,A,,1,,N,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
10332,,,,1,,In vivo,CHEMBL624096,,Intermediate,A,,1,,N,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,50597,BAO_0000218
10333,,,,1,,In vivo,CHEMBL624097,,Intermediate,A,,1,,N,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,,50597,BAO_0000218
10334,,,,1,,In vivo,CHEMBL624098,,Intermediate,A,,1,,N,Maximum fall in carotid flow in rat,,,50597,BAO_0000218
10335,,,,1,,In vivo,CHEMBL874392,,Intermediate,A,,1,,N,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,,50597,BAO_0000218
10336,,,,1,,In vivo,CHEMBL624099,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 5 mg/kg),,,50597,BAO_0000218
10337,,,,1,,In vivo,CHEMBL624100,,Intermediate,A,,1,,N,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,50597,BAO_0000218
10338,,,,1,,In vivo,CHEMBL624101,,Intermediate,A,,1,,N,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,50597,BAO_0000218
10339,,,,1,,In vivo,CHEMBL624102,,Intermediate,A,,1,,N,Oral bioavailability in rat (male Wistar),,,50597,BAO_0000218
10340,,,,1,,In vivo,CHEMBL624103,,Intermediate,A,,1,,N,Oral bioavailability after administration (30 mg/kg) in rat; good,,,50597,BAO_0000218
10341,,,,1,,In vivo,CHEMBL624104,,Intermediate,A,,1,,N,Oral bioavailability at the dose of 2 mg/kg in rat,,,50597,BAO_0000218
10342,,,,1,,In vivo,CHEMBL624105,,Intermediate,A,,1,,N,Oral bioavailability determined in rats,,,50597,BAO_0000218
10343,,,,1,,In vivo,CHEMBL624106,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,,50597,BAO_0000218
10344,,,,1,,In vivo,CHEMBL624107,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose single 10 mg/kg),,,50597,BAO_0000218
10345,,,,1,,In vivo,CHEMBL623943,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose single 10 mg/kg),,,50597,BAO_0000218
10346,,,,1,,In vivo,CHEMBL623944,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 5 mg/kg,,,50597,BAO_0000218
10347,,,,1,,,CHEMBL623945,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,,50597,BAO_0000218
10348,,,,1,,,CHEMBL623946,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,,50597,BAO_0000218
10349,,,,1,,,CHEMBL623947,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,,50597,BAO_0000218
10350,,,,1,,,CHEMBL623948,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,,50597,BAO_0000218
10351,,,,1,,,CHEMBL623949,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,,50597,BAO_0000218
10352,,,,1,,,CHEMBL623950,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,,50597,BAO_0000218
10353,,,,1,,,CHEMBL874398,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,,50597,BAO_0000218
10354,,,,1,,,CHEMBL623951,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,,50597,BAO_0000218
10355,,,,1,,,CHEMBL623952,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,,50597,BAO_0000218
10356,,,,1,,,CHEMBL623953,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,,50597,BAO_0000218
10357,,,,1,,,CHEMBL623954,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,,50597,BAO_0000218
10358,,,,1,,,CHEMBL623955,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,,50597,BAO_0000218
10359,,,,1,,,CHEMBL623956,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,,50597,BAO_0000218
10360,,,,1,,,CHEMBL627807,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,,50597,BAO_0000218
10361,,,,1,,,CHEMBL627808,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,,50597,BAO_0000218
10362,,,,1,,,CHEMBL627809,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,,50597,BAO_0000218
10363,,,,1,,,CHEMBL627810,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,,50597,BAO_0000218
10364,,,,1,,,CHEMBL627811,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,,50597,BAO_0000218
10365,,,,1,,,CHEMBL627812,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,,50597,BAO_0000218
10366,,,,1,,,CHEMBL627813,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,,50597,BAO_0000218
10367,,,,1,,,CHEMBL627814,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,,50597,BAO_0000218
10368,,,,1,,,CHEMBL875336,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,,50597,BAO_0000218
10369,,,,1,,,CHEMBL627815,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,,50597,BAO_0000218
10370,,,,1,,,CHEMBL627816,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,,50597,BAO_0000218
10371,,,,1,,,CHEMBL627817,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,,50597,BAO_0000218
10372,,,,1,,,CHEMBL627818,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,,50597,BAO_0000218
10373,,,,1,,,CHEMBL627819,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,,50597,BAO_0000218
10374,,,,1,,,CHEMBL627820,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,,50597,BAO_0000218
10375,,,,1,,,CHEMBL627821,,Intermediate,A,,1,,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,,50597,BAO_0000218
10376,,,,1,,,CHEMBL628464,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,,50597,BAO_0000218
10377,,,,1,,,CHEMBL626239,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,,50597,BAO_0000218
10378,,,,1,,,CHEMBL626240,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,,50597,BAO_0000218
10379,,,,1,,,CHEMBL626241,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,,50597,BAO_0000218
10380,,,,1,,,CHEMBL626242,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,,50597,BAO_0000218
10381,,,,1,,,CHEMBL626243,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,,50597,BAO_0000218
10382,,,,1,,,CHEMBL626244,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,,50597,BAO_0000218
10383,,,,1,,,CHEMBL626907,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,,50597,BAO_0000218
10384,,,,1,,,CHEMBL626908,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,,50597,BAO_0000218
10385,,,,1,,,CHEMBL626909,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,,50597,BAO_0000218
10386,,,,1,,,CHEMBL626910,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,,50597,BAO_0000218
10387,,,,1,,,CHEMBL875342,,Intermediate,F,,1,,N,Percent total excretion of acetaminophen cysteine conjugate,,,50597,BAO_0000218
10388,,,,1,,,CHEMBL626911,,Intermediate,F,,1,,N,Percent total excretion of acetaminophen glucuronide,,,50597,BAO_0000218
10389,,,,1,,,CHEMBL626912,,Intermediate,F,,1,,N,Percent total excretion of acetaminophen sulfate,,,50597,BAO_0000218
10390,,,,1,,,CHEMBL627065,,Intermediate,F,,1,,N,Percent total excretion of acetaminophen-mercapturic acid,,,50597,BAO_0000218
10391,,,1088.0,1,Urine,,CHEMBL627066,,Intermediate,A,,1,,N,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,,,50597,BAO_0000218
10392,,,,1,,In vivo,CHEMBL627067,,Intermediate,A,,1,,N,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,50597,BAO_0000218
10393,,,2385.0,0,Muscle tissue,In vivo,CHEMBL627068,,Autocuration,A,,1,,U,Biodistribution of compound in rat muscle after 5 min of administration,,,22224,BAO_0000218
10394,,,2385.0,0,Muscle tissue,In vivo,CHEMBL627069,,Autocuration,A,,1,,U,Biodistribution of compound in rat muscle after 5 min of administration.,,,22224,BAO_0000218
10395,,,,0,,In vivo,CHEMBL627070,,Autocuration,A,,1,,U,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,,22224,BAO_0000218
10396,,,,0,,In vivo,CHEMBL627071,,Autocuration,A,,1,,U,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,,22224,BAO_0000218
10397,,,,0,,In vivo,CHEMBL627072,,Autocuration,A,,1,,U,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,,22224,BAO_0000218
10398,,,,0,,In vivo,CHEMBL627073,,Autocuration,A,,1,,U,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,,22224,BAO_0000218
10399,,,,0,,In vivo,CHEMBL625387,,Autocuration,A,,1,,U,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,,22224,BAO_0000218
10400,,,,0,,In vivo,CHEMBL625388,,Autocuration,A,,1,,U,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,,22224,BAO_0000218
10401,,,1969.0,0,Plasma,In vivo,CHEMBL625389,,Autocuration,A,,1,,U,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,,22224,BAO_0000218
10402,,,1969.0,0,Plasma,In vivo,CHEMBL875343,,Autocuration,A,,1,,U,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,,22224,BAO_0000218
10403,,,,1,,,CHEMBL876795,,Intermediate,A,,1,,N,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,,50497,BAO_0000218
10404,,,,1,,,CHEMBL626552,,Intermediate,A,,1,,N,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,,50497,BAO_0000218
10405,,,,1,,,CHEMBL626553,,Intermediate,A,,1,,N,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,,50497,BAO_0000218
10406,,,1969.0,0,Plasma,,CHEMBL626554,,Autocuration,A,,1,,U,The human biological plasma half life of the compound,,,22224,BAO_0000366
10407,,,1088.0,1,Urine,,CHEMBL626555,,Intermediate,A,,1,,N,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,,50597,BAO_0000218
10408,,,,1,,,CHEMBL626556,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,,50597,BAO_0000218
10409,,,,1,,,CHEMBL626557,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,,50597,BAO_0000218
10410,,,,1,,,CHEMBL626558,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,,50597,BAO_0000218
10411,,,,1,,,CHEMBL626559,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,,50597,BAO_0000218
10412,,,,1,,,CHEMBL626560,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,,50597,BAO_0000218
10413,,,,1,,,CHEMBL876803,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,,50597,BAO_0000218
10414,,,,1,,,CHEMBL627964,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,,50597,BAO_0000218
10415,,,,1,,,CHEMBL627965,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,,50597,BAO_0000218
10416,,,,1,,,CHEMBL627966,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,,50597,BAO_0000218
10417,,,,1,,,CHEMBL627967,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,,50597,BAO_0000218
10418,,,,1,,,CHEMBL627968,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,,50597,BAO_0000218
10419,,,,1,,,CHEMBL627969,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,,50597,BAO_0000218
10420,,,,1,,,CHEMBL627970,,Intermediate,A,,1,,N,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,,50597,BAO_0000218
10421,,,178.0,1,Blood,,CHEMBL627971,,Intermediate,A,,1,,N,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,,,50597,BAO_0000218
10422,,,178.0,1,Blood,,CHEMBL627972,,Intermediate,A,,1,,N,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,,,50597,BAO_0000218
10423,,,,9,,,CHEMBL856029,,Expert,B,,1,,D,Dissociation constant against binding to human cyclophilin A,,,180,BAO_0000357
10424,,,,8,,,CHEMBL627973,,Expert,B,,1,,H,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,,11591,BAO_0000019
10425,,,,0,,,CHEMBL627974,,Autocuration,A,,1,,U,-Log C was determined by performing the electroshock minimum test,,,22224,BAO_0000019
10426,,,,0,,,CHEMBL627975,,Autocuration,A,,1,,U,-Log C was determined by performing the foot shock test,,,22224,BAO_0000019
10427,,,,0,,,CHEMBL627976,,Autocuration,A,,1,,U,-Log C was determined by performing the incl screen test,,,22224,BAO_0000019
10428,,,,0,,,CHEMBL627977,,Autocuration,A,,1,,U,-Log C was determined by performing the maximum electroshock test,,,22224,BAO_0000019
10429,,,,0,,,CHEMBL627978,,Autocuration,A,,1,,U,-Log C was determined by performing the pentylenetetrazole test,,,22224,BAO_0000019
10430,,,,0,,,CHEMBL627979,,Autocuration,A,,1,,U,Tested for experimental arotinoid inhibitory dose,,,22224,BAO_0000019
10431,,,,0,,,CHEMBL876804,,Autocuration,A,,1,,U,Negative log transformed activity,,,22224,BAO_0000019
10432,,,,0,,,CHEMBL627980,,Autocuration,A,,1,,U,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,,22224,BAO_0000019
10433,,,,1,,,CHEMBL627981,,Intermediate,A,,1,,N,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,,50512,BAO_0000218
10434,,,,1,,,CHEMBL627982,,Intermediate,A,,1,,N,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,,50512,BAO_0000218
10435,,,,1,,,CHEMBL627983,,Intermediate,A,,1,,N,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,,50512,BAO_0000218
10436,,,2116.0,1,Ileum,,CHEMBL627984,,Intermediate,A,,1,,N,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,,,50512,BAO_0000218
10437,,,,0,,,CHEMBL627985,,Autocuration,P,,1,,U,Solubility in water was determined; values expressed as -log,,,22229,BAO_0000100
10438,,,,0,,,CHEMBL627986,,Autocuration,A,,1,,U,Ratio of Kcat to that of Km was determined,,,22224,BAO_0000019
10439,,,,0,,,CHEMBL627987,,Autocuration,A,,1,,U,Observed first order rate constant,,,22224,BAO_0000019
10440,,,,0,,,CHEMBL627988,,Autocuration,A,,1,,U,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,,22224,BAO_0000019
10441,,,,1,,In vivo,CHEMBL627989,,Intermediate,A,,1,,N,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,,50597,BAO_0000218
10442,,,,1,,In vivo,CHEMBL627990,,Intermediate,A,,1,,N,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,,50597,BAO_0000218
10443,,,,1,,In vivo,CHEMBL876805,,Intermediate,A,,1,,N,Oral Bioavailability after administration of 10 mg/kg in male rat,,,50597,BAO_0000218
10444,,,,1,,In vivo,CHEMBL627991,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,,50597,BAO_0000218
10445,,,,1,,In vivo,CHEMBL627992,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10446,,,,1,,In vivo,CHEMBL627993,,Intermediate,A,,1,,N,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,,50597,BAO_0000218
10447,,,,1,,In vivo,CHEMBL622817,,Intermediate,A,,1,,N,Oral bioavailability at 1 mg/kg was determined in rat,,,50597,BAO_0000218
10448,,,,1,,In vivo,CHEMBL622818,,Intermediate,A,,1,,N,Oral bioavailability at 10 mg/kg was determined in rat,,,50597,BAO_0000218
10449,,,,1,,In vivo,CHEMBL622819,,Intermediate,A,,1,,N,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,,50597,BAO_0000218
10450,,,,1,,In vivo,CHEMBL872267,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10451,,,,1,,In vivo,CHEMBL622820,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10452,,,,1,,In vivo,CHEMBL622821,,Intermediate,A,,1,,N,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,,50597,BAO_0000218
10453,,,,1,,In vivo,CHEMBL622822,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10454,,,,1,,In vivo,CHEMBL622823,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10455,,,,1,,In vivo,CHEMBL622824,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10456,,,,1,,In vivo,CHEMBL622825,,Intermediate,A,,1,,N,Oral bioavailability in rat at a dose of 3 mg/kg,,,50597,BAO_0000218
10457,,,,1,,In vivo,CHEMBL622901,,Intermediate,A,,1,,N,Oral bioavailability in rat after oral administration at 10 mg/kg,,,50597,BAO_0000218
10458,,,,1,,In vivo,CHEMBL622902,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10459,,,,1,,In vivo,CHEMBL621844,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10460,,,,1,,In vivo,CHEMBL621845,,Intermediate,A,,1,,N,Oral bioavailability in Dawley rats,,,50597,BAO_0000218
10461,,,,1,,In vivo,CHEMBL621846,,Intermediate,A,,1,,N,Oral bioavailability,,,50597,BAO_0000218
10462,,,,1,,In vivo,CHEMBL621847,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 30 mg/kg),,,50597,BAO_0000218
10463,,,,1,,In vivo,CHEMBL877609,,Intermediate,A,,1,,N,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,,50597,BAO_0000218
10464,,,,1,,In vivo,CHEMBL621848,,Intermediate,A,,1,,N,Bioavailability in rat (dose 3 mg/kg i.v.),,,50597,BAO_0000218
10465,,,,1,,In vivo,CHEMBL621849,,Intermediate,A,,1,,N,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,,50597,BAO_0000218
10466,,,,1,,In vivo,CHEMBL622030,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 60 mg/kg p.o.),,,50597,BAO_0000218
10467,,,,1,,In vivo,CHEMBL622031,,Intermediate,A,,1,,N,Percent oral bioavailability determined in rats,,,50597,BAO_0000218
10468,,,,1,,In vivo,CHEMBL622032,,Intermediate,A,,1,,N,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,,50597,BAO_0000218
10469,,,,1,,In vivo,CHEMBL622033,,Intermediate,A,,1,,N,The compound was evaluated for bioavailability in rats; 32-51,,,50597,BAO_0000218
10470,,,,1,,In vivo,CHEMBL622034,,Intermediate,A,,1,,N,Bioavailability in rat (dose 20 mg/kg p.o.),,,50597,BAO_0000218
10471,,,,1,,In vivo,CHEMBL622035,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10472,,,,1,,In vivo,CHEMBL882966,,Intermediate,A,,1,,N,Bioavailability percent in rat at the dose of 2 mg/kg,,,50597,BAO_0000218
10473,,,,1,,In vivo,CHEMBL622036,,Intermediate,A,,1,,N,Bioavailability was evaluated after 20 uM/kg of peroral administration,,,50597,BAO_0000218
10474,,,,1,,In vivo,CHEMBL622037,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10475,,,,1,,In vivo,CHEMBL622038,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10476,,,,1,,In vivo,CHEMBL622039,,Intermediate,A,,1,,N,Bioavailability in rats,,,50597,BAO_0000218
10477,,,178.0,1,Blood,In vivo,CHEMBL622040,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,,,50597,BAO_0000218
10478,,,178.0,1,Blood,In vivo,CHEMBL622041,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10479,,,178.0,1,Blood,In vivo,CHEMBL622042,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10480,,,178.0,1,Blood,In vivo,CHEMBL622043,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10481,,,178.0,1,Blood,In vivo,CHEMBL622044,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10482,,,10000001.0,1,Bone,In vivo,CHEMBL622045,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10483,,,10000001.0,1,Bone,In vivo,CHEMBL622046,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10484,,,10000001.0,1,Bone,In vivo,CHEMBL622047,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10485,,,10000001.0,1,Bone,In vivo,CHEMBL877610,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10486,,,955.0,1,Brain,In vivo,CHEMBL622048,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10487,,,955.0,1,Brain,In vivo,CHEMBL622049,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10488,,,955.0,1,Brain,In vivo,CHEMBL622050,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10489,,,955.0,1,Brain,In vivo,CHEMBL622051,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10490,,,,1,,In vivo,CHEMBL622052,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10491,,,,1,,In vivo,CHEMBL622053,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10492,,,,1,,In vivo,CHEMBL622054,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10493,,,,1,,In vivo,CHEMBL622055,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10494,,,,1,,In vivo,CHEMBL622056,,Intermediate,A,,1,,N,Oral bioavailability in rats was determined; High,,,50597,BAO_0000218
10495,,,,1,,In vivo,CHEMBL622057,,Intermediate,A,,1,,N,Oral bioavailability in the rat was determined,,,50597,BAO_0000218
10496,,,,1,,In vivo,CHEMBL628008,,Intermediate,A,,1,,N,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,,50597,BAO_0000218
10497,,,,1,,In vivo,CHEMBL622058,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,,50597,BAO_0000218
10498,,,,1,,In vivo,CHEMBL622059,,Intermediate,A,,1,,N,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
10499,,,,1,,In vivo,CHEMBL622060,,Intermediate,A,,1,,N,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
10500,,,,1,,In vivo,CHEMBL622061,,Intermediate,A,,1,,N,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
10501,,,,1,,In vivo,CHEMBL622062,,Intermediate,A,,1,,N,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,,50597,BAO_0000218
10502,,,,1,,In vivo,CHEMBL622063,,Intermediate,A,,1,,N,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,,50597,BAO_0000218
10503,,,,1,,In vivo,CHEMBL877611,,Expert,A,,1,,N,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,,50597,BAO_0000218
10504,,,,1,,In vivo,CHEMBL622064,,Intermediate,A,,1,,N,Oral bioavailability of compound in Sprague Dawley rats,,,50597,BAO_0000218
10505,,,,1,,In vivo,CHEMBL622065,,Intermediate,A,,1,,N,Oral bioavailability of compound in rat,,,50597,BAO_0000218
10506,,,,1,,In vivo,CHEMBL622066,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 2 mg/kg),,,50597,BAO_0000218
10507,,,,1,,In vivo,CHEMBL622067,,Intermediate,A,,1,,N,Oral bioavailability of compound in rat was determined,,,50597,BAO_0000218
10508,,,,1,,In vivo,CHEMBL622068,,Intermediate,A,,1,,N,Oral bioavailability of compound in rats,,,50597,BAO_0000218
10509,,,,1,,In vivo,CHEMBL622069,,Intermediate,A,,1,,N,Oral bioavailability of compound was determined in rats,,,50597,BAO_0000218
10510,,,,1,,In vivo,CHEMBL624796,,Intermediate,A,,1,,N,Oral bioavailability at a dose of 30 mg/kg in rats,,,50597,BAO_0000218
10511,,,,1,,In vivo,CHEMBL624797,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 10 mg/kg),,,50597,BAO_0000218
10512,,,,1,,In vivo,CHEMBL623053,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 10 mg/kg),,,50597,BAO_0000218
10513,,,,1,,In vivo,CHEMBL623054,,Intermediate,A,,1,,N,Oral bioavailability evaluated in rat,,,50597,BAO_0000218
10514,,,,1,,In vivo,CHEMBL623055,,Intermediate,A,,1,,N,Oral bioavailability in fasted rat,,,50597,BAO_0000218
10515,,,,1,,In vivo,CHEMBL623056,,Intermediate,A,,1,,N,Oral bioavailability in fed rat,,,50597,BAO_0000218
10516,,,,1,,In vivo,CHEMBL623057,,Intermediate,A,,1,,N,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,,50597,BAO_0000218
10517,,,,1,,In vivo,CHEMBL623058,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10518,,,,1,,In vivo,CHEMBL623059,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 10 mg/kg p.o.),,,50597,BAO_0000218
10519,,,,1,,In vivo,CHEMBL623060,,Intermediate,A,,1,,N,Oral bioavailability in rat after administration of 10 mg/kg po,,,50597,BAO_0000218
10520,,,,1,,In vivo,CHEMBL623061,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10521,,,,1,,In vivo,CHEMBL623062,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10522,,,,1,,In vivo,CHEMBL623063,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10523,,,,1,,In vivo,CHEMBL623064,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10524,,,,1,,In vivo,CHEMBL623065,,Intermediate,A,,1,,N,Oral bioavailability in ratrs,,,50597,BAO_0000218
10525,,,,1,,In vivo,CHEMBL623066,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10526,,,,1,,In vivo,CHEMBL623067,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10527,,,,1,,In vivo,CHEMBL623068,,Intermediate,A,,1,,N,Oral bioavailability in rats was determined; High,,,50597,BAO_0000218
10528,,,,1,,In vivo,CHEMBL623069,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10529,,,,1,,In vivo,CHEMBL623070,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10530,,,,1,,In vivo,CHEMBL623071,,Intermediate,A,,1,,N,Oral bioavailability was calculated in rat,,,50597,BAO_0000218
10531,,,,1,,In vivo,CHEMBL623072,,Intermediate,A,,1,,N,Oral bioavailability,,,50597,BAO_0000218
10532,,,,1,,In vivo,CHEMBL623073,,Intermediate,A,,1,,N,Oral bioavailability,,,50597,BAO_0000218
10533,,,,1,,In vivo,CHEMBL623074,,Intermediate,A,,1,,N,Oral bioavailability,,,50597,BAO_0000218
10534,,,,1,,In vivo,CHEMBL623075,,Intermediate,A,,1,,N,Oral bioavailability,,,50597,BAO_0000218
10535,,,,1,,In vivo,CHEMBL623076,,Intermediate,A,,1,,N,Oral bioavailability after i.v. administration,,,50597,BAO_0000218
10536,,,,1,,In vivo,CHEMBL623077,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,50597,BAO_0000218
10537,,,,1,,In vivo,CHEMBL623078,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley),,,50597,BAO_0000218
10538,,,,1,,In vivo,CHEMBL623079,,Intermediate,A,,1,,N,Oral bioavailability in Sprague-Dawley rats,,,50597,BAO_0000218
10539,,,,1,,In vivo,CHEMBL623080,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,50597,BAO_0000218
10540,,,,1,,In vivo,CHEMBL623081,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,50597,BAO_0000218
10541,,,,1,,In vivo,CHEMBL623082,,Intermediate,A,,1,,N,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,,50597,BAO_0000218
10542,,,,1,,In vivo,CHEMBL874400,,Intermediate,A,,1,,N,Oral bioavailability in fasted rat,,,50597,BAO_0000218
10543,,,,1,,In vivo,CHEMBL623083,,Intermediate,A,,1,,N,Oral bioavailability in fed rat,,,50597,BAO_0000218
10544,,,,1,,In vivo,CHEMBL623084,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10545,,,,1,,In vivo,CHEMBL623085,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10546,,,,1,,In vivo,CHEMBL623086,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10547,,,,1,,In vivo,CHEMBL623087,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10548,,,,1,,In vivo,CHEMBL623088,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10549,,,,1,,In vivo,CHEMBL623089,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10550,,,,1,,In vivo,CHEMBL623090,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10551,,,,1,,In vivo,CHEMBL623091,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10552,,,,1,,In vivo,CHEMBL623092,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10553,,,,1,,In vivo,CHEMBL623093,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10554,,,,1,,In vivo,CHEMBL874401,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10555,,,,1,,In vivo,CHEMBL623094,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10556,,,,1,,In vivo,CHEMBL623095,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10557,,,,1,,In vivo,CHEMBL623096,,Intermediate,A,,1,,N,Oral bioavailability in rat after peroral administration at 10 mg/kg,,,50597,BAO_0000218
10558,,,,1,,In vivo,CHEMBL624913,,Intermediate,A,,1,,N,Oral bioavailability in rat after peroral administration at 5 mg/kg,,,50597,BAO_0000218
10559,,,,1,,In vivo,CHEMBL624914,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,,50597,BAO_0000218
10560,,,,1,,In vivo,CHEMBL624915,,Intermediate,A,,1,,N,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,,50597,BAO_0000218
10561,,,,1,,In vivo,CHEMBL624916,,Intermediate,A,,1,,N,Oral bioavailability in rat; Not measured,,,50597,BAO_0000218
10562,,,,1,,In vivo,CHEMBL624917,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10563,,,,1,,,CHEMBL625157,,Intermediate,A,,1,,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,,50597,BAO_0000218
10564,,,2107.0,1,Liver,,CHEMBL625158,,Intermediate,A,,1,,N,In vitro metabolic potential in rat liver microsomes,,,50597,BAO_0000218
10565,,,,1,,In vivo,CHEMBL625159,,Intermediate,A,,1,,N,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,,50597,BAO_0000218
10566,,,,1,,In vivo,CHEMBL625160,,Intermediate,A,,1,,N,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,,50597,BAO_0000218
10567,,,,1,,In vivo,CHEMBL625161,,Intermediate,A,,1,,N,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,,50597,BAO_0000218
10568,,,,1,,In vivo,CHEMBL625162,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10569,,,,1,,In vivo,CHEMBL625163,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10570,,,,1,,In vivo,CHEMBL625164,,Intermediate,A,,1,,N,Oral bioavailability in rats at 10 mg/kg,,,50597,BAO_0000218
10571,,,,1,,In vivo,CHEMBL625165,,Intermediate,A,,1,,N,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50597,BAO_0000218
10572,,,,1,,In vivo,CHEMBL625166,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10573,,,,1,,,CHEMBL625167,,Intermediate,A,,1,,N,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,,50597,BAO_0000218
10574,,,,1,,,CHEMBL625168,,Intermediate,A,,1,,N,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,,50597,BAO_0000218
10575,,,,1,,In vivo,CHEMBL625169,,Intermediate,A,,1,,N,Plasma clearance of the compound,,,50597,BAO_0000218
10576,,,,1,,In vivo,CHEMBL626264,,Intermediate,A,,1,,N,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,,50597,BAO_0000218
10577,,,,1,,In vivo,CHEMBL626265,,Intermediate,A,,1,,N,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,,50597,BAO_0000218
10578,,,1969.0,1,Plasma,In vivo,CHEMBL626266,,Intermediate,A,,1,,N,The compound was tested for plasma clearance in rat,,,50597,BAO_0000218
10579,,,1969.0,1,Plasma,In vivo,CHEMBL626267,,Intermediate,A,,1,,N,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,,,50597,BAO_0000218
10580,,,,1,,,CHEMBL626268,,Intermediate,A,,1,,N,Plasma concentration upon oral administration of 1 mg/Kg in rats,,,50597,BAO_0000218
10581,,,,1,,,CHEMBL626269,,Intermediate,A,,1,,N,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,,50597,BAO_0000218
10582,,,,1,,,CHEMBL626270,,Intermediate,A,,1,,N,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,,50597,BAO_0000218
10583,,,,1,,,CHEMBL626271,,Intermediate,A,,1,,N,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,,50597,BAO_0000218
10584,,,,1,,,CHEMBL626272,,Intermediate,A,,1,,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,,50597,BAO_0000218
10585,,,,1,,,CHEMBL626273,,Intermediate,A,,1,,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,,50597,BAO_0000218
10586,,,,1,,,CHEMBL875346,,Intermediate,A,,1,,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,,50597,BAO_0000218
10587,,,,1,,,CHEMBL626274,,Intermediate,A,,1,,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,,50597,BAO_0000218
10588,,,,1,,,CHEMBL626275,,Intermediate,A,,1,,N,Compound was tested for protein binding in rat plasma,,,50597,BAO_0000218
10589,,,,1,,,CHEMBL624646,,Intermediate,A,,1,,N,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,,50597,BAO_0000218
10590,,,,1,,,CHEMBL624647,,Intermediate,A,,1,,N,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,,50597,BAO_0000218
10591,,,2107.0,1,Liver,,CHEMBL624648,,Intermediate,A,,1,,N,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,,,50597,BAO_0000218
10592,,,,1,,,CHEMBL624649,,Intermediate,A,,1,,N,Area under curve ratio was determined (po/iv) in rat,,,50597,BAO_0000218
10593,,,,1,,,CHEMBL624650,,Intermediate,A,,1,,N,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,,50597,BAO_0000218
10594,,,,1,,,CHEMBL624651,,Intermediate,A,,1,,N,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,,50597,BAO_0000218
10595,,,,1,,,CHEMBL624652,,Intermediate,A,,1,,N,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,,50597,BAO_0000218
10596,,,,1,,,CHEMBL624653,,Intermediate,A,,1,,N,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,,50597,BAO_0000218
10597,,,,1,,,CHEMBL624654,,Intermediate,A,,1,,N,Ratio of AUCbrain to AUCplasma,,,50597,BAO_0000218
10598,,,,1,,,CHEMBL624655,,Intermediate,A,,1,,N,Ratio of brain to plasma,,,50597,BAO_0000218
10599,,,,1,,,CHEMBL624656,,Intermediate,A,,1,,N,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,,50597,BAO_0000218
10600,,,,1,,,CHEMBL624657,,Intermediate,A,,1,,N,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,,50597,BAO_0000218
10601,,,,1,,,CHEMBL624658,,Intermediate,A,,1,,N,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,,50597,BAO_0000218
10602,,,,1,,,CHEMBL624659,,Intermediate,A,,1,,N,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,,50597,BAO_0000218
10603,,,,1,,,CHEMBL624660,,Intermediate,A,,1,,N,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,,50597,BAO_0000218
10604,,,,1,,,CHEMBL624661,,Intermediate,A,,1,,N,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,,50597,BAO_0000218
10605,,,,1,,,CHEMBL624662,,Intermediate,A,,1,,N,Steady state brain :blood ratio was determined,,,50597,BAO_0000218
10606,,,,1,,,CHEMBL625199,,Intermediate,A,,1,,N,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,BAO_0000218
10607,,,,1,,,CHEMBL625200,,Intermediate,A,,1,,N,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,,50597,BAO_0000218
10608,,,,1,,,CHEMBL625201,,Intermediate,A,,1,,N,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,50597,BAO_0000218
10609,,,,1,,,CHEMBL625202,,Intermediate,A,,1,,N,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,,50597,BAO_0000218
10610,,,,1,,,CHEMBL625203,,Intermediate,A,,1,,N,Percentage recovery after 3h incubation with rat hapatocytes was determined,,,50597,BAO_0000218
10611,,,,1,,,CHEMBL625204,,Intermediate,A,,1,,N,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,,50597,BAO_0000218
10612,,,,1,,,CHEMBL625205,,Intermediate,A,,1,,N,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,,50597,BAO_0000218
10613,,,,1,,,CHEMBL625206,,Intermediate,A,,1,,N,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,,50597,BAO_0000218
10614,,,,0,,,CHEMBL625207,,Autocuration,A,,1,,U,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,,22224,BAO_0000019
10615,,,,0,,,CHEMBL625208,,Autocuration,A,,1,,U,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,,22224,BAO_0000019
10616,495.0,,,1,,,CHEMBL625209,,Intermediate,A,,1,,N,In vivo absorption in Caco-2 cell line monolayers was determined,,Caco-2,50587,BAO_0000218
10617,,,,0,,,CHEMBL625210,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
10618,,,,1,,,CHEMBL625211,,Intermediate,A,,1,,N,Area under curve was determine after peroral administration at 10 mpk in Rat,,,50597,BAO_0000218
10619,,,,1,,,CHEMBL625212,,Intermediate,A,,1,,N,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,50797,BAO_0000218
10620,,,,1,,,CHEMBL625213,,Intermediate,A,,1,,N,Area under curve was determine after peroral administration at 160 mpk in Rat,,,50597,BAO_0000218
10621,,,,1,,,CHEMBL625214,,Intermediate,A,,1,,N,Area under curve was determine after peroral administration at 20 mpk in Rat,,,50597,BAO_0000218
10622,,,,1,,,CHEMBL874542,,Intermediate,A,,1,,N,Area under curve was determine after peroral administration at 50 mpk in Rat,,,50597,BAO_0000218
10623,,,,0,,,CHEMBL625215,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP) (AlogP),,,22229,BAO_0000100
10624,,,,0,,,CHEMBL625216,,Autocuration,A,,1,,U,Activated partial thromboplastin time measured,,,22224,BAO_0000019
10625,,,,0,,,CHEMBL625217,,Autocuration,P,,1,,U,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,,22224,BAO_0000100
10626,,,,0,,,CHEMBL625218,,Autocuration,P,,1,,U,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,,22224,BAO_0000100
10627,,,1969.0,1,Plasma,,CHEMBL622864,,Intermediate,A,,1,,N,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,,,50588,BAO_0000218
10628,,,1969.0,1,Plasma,,CHEMBL622865,,Intermediate,A,,1,,N,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,,,50597,BAO_0000218
10629,,,1969.0,1,Plasma,,CHEMBL622866,,Intermediate,A,,1,,N,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,,,50597,BAO_0000218
10630,,,1969.0,1,Plasma,,CHEMBL622867,,Intermediate,A,,1,,N,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,,,50588,BAO_0000218
10631,,,1969.0,1,Plasma,,CHEMBL876808,,Intermediate,A,,1,,N,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,,,50512,BAO_0000218
10632,,,955.0,0,Brain,,CHEMBL627725,,Autocuration,A,,1,,U,AUC in brain,,,22224,BAO_0000019
10633,,,1977.0,0,Serum,,CHEMBL627726,,Autocuration,A,,1,,U,AUC in serum,,,22224,BAO_0000019
10634,,,1969.0,0,Plasma,,CHEMBL627727,,Autocuration,A,,1,,U,AUC was determined,,,22224,BAO_0000019
10635,,,1969.0,0,Plasma,,CHEMBL627728,,Autocuration,A,,1,,U,AUC of the compound.,,,22224,BAO_0000019
10636,,,1969.0,0,Plasma,,CHEMBL627729,,Autocuration,A,,1,,U,AUC value (0-4 hr),,,22224,BAO_0000019
10637,,,1969.0,0,Plasma,,CHEMBL627730,,Autocuration,A,,1,,U,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,,22224,BAO_0000019
10638,,,1969.0,0,Plasma,,CHEMBL627731,,Autocuration,A,,1,,U,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,,22224,BAO_0000019
10639,,,1969.0,0,Plasma,,CHEMBL627732,,Autocuration,A,,1,,U,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,,22224,BAO_0000019
10640,,,1969.0,0,Plasma,,CHEMBL627733,,Autocuration,A,,1,,U,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,,22224,BAO_0000019
10641,,,1969.0,1,Plasma,,CHEMBL627734,,Intermediate,A,,1,,N,AUC(area under curve) was determined after intravenous administration in rats,,,50597,BAO_0000218
10642,,,1969.0,1,Plasma,,CHEMBL627735,,Intermediate,A,,1,,N,AUC(area under curve) was determined after oral administration in rats,,,50597,BAO_0000218
10643,,,1969.0,1,Plasma,,CHEMBL627736,,Intermediate,A,,1,,N,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,,,50512,BAO_0000218
10644,,,1969.0,1,Plasma,,CHEMBL876809,,Intermediate,A,,1,,N,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,,,50597,BAO_0000218
10645,,,,0,,,CHEMBL627737,,Autocuration,A,,1,,U,Area Under Curve after oral dosing of 100 uM/Kg,,,22224,BAO_0000019
10646,,,,0,,,CHEMBL627738,,Autocuration,A,,1,,U,Area Under Curve after oral dosing of 30 uM/Kg,,,22224,BAO_0000019
10647,,,,0,,,CHEMBL627739,,Autocuration,A,,1,,U,Area Under Curve was measured by ploting the graph between concentration verses time,,,22224,BAO_0000019
10648,,,,1,,,CHEMBL626143,,Intermediate,A,,1,,N,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,,50588,BAO_0000218
10649,,,,0,,,CHEMBL626144,,Autocuration,A,,1,,U,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,,22224,BAO_0000218
10650,,,,1,,,CHEMBL626145,,Intermediate,A,,1,,N,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,,50592,BAO_0000218
10651,,,,1,,,CHEMBL626146,,Intermediate,A,,1,,N,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,,50597,BAO_0000218
10652,,,178.0,1,Blood,,CHEMBL626147,,Intermediate,A,,1,,N,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,,,50597,BAO_0000218
10653,,,,0,,,CHEMBL626148,,Autocuration,A,,1,,U,Area under curve (AUC) was determined,,,22224,BAO_0000019
10654,,,,0,,,CHEMBL626149,,Autocuration,A,,1,,U,Area under curve (AUC) following ip administration at 1 mg/kg,,,22224,BAO_0000218
10655,,,,0,,,CHEMBL626150,,Autocuration,A,,1,,U,Area under curve (AUC) was determined; ND is Not determined,,,22224,BAO_0000019
10656,,,,1,,,CHEMBL626151,,Intermediate,A,,1,,N,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,,50588,BAO_0000218
10657,,,,1,,,CHEMBL626152,,Intermediate,A,,1,,N,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,,50588,BAO_0000218
10658,,,,1,,,CHEMBL626153,,Intermediate,A,,1,,N,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,,50588,BAO_0000218
10659,,,,0,,,CHEMBL626154,,Autocuration,A,,1,,U,Area under curve (AUR) was determined,,,22224,BAO_0000019
10660,,,,0,,,CHEMBL626155,,Autocuration,A,,1,,U,Area under curve at 1 uM/dg administered intravenously,,,22224,BAO_0000019
10661,,,,0,,,CHEMBL626156,,Autocuration,A,,1,,U,Area under curve at 10 uM/dg administered perorally,,,22224,BAO_0000019
10662,,,,0,,,CHEMBL626157,,Autocuration,A,,1,,U,Area under curve at 2 uM/dg administered intravenously,,,22224,BAO_0000019
10663,,,,0,,,CHEMBL626158,,Autocuration,A,,1,,U,Area under curve at 20 uM/dg administered perorally,,,22224,BAO_0000019
10664,,,,1,,,CHEMBL626159,,Intermediate,A,,1,,N,Area under curve at a peroral dose of 3 mg/kg in dog,,,50588,BAO_0000218
10665,,,,1,,,CHEMBL626160,,Intermediate,A,,1,,N,Area under curve at a peroral dose of 3 mg/kg in rat,,,50597,BAO_0000218
10666,,,,1,,,CHEMBL626161,,Intermediate,A,,1,,N,Area under curve at an iv dose of 1 mg/kg in dog,,,50588,BAO_0000218
10667,,,,1,,,CHEMBL626162,,Intermediate,A,,1,,N,Area under curve at an iv dose of 1 mg/kg in rat,,,50597,BAO_0000218
10668,,,,0,,,CHEMBL626163,,Autocuration,A,,1,,U,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,,22224,BAO_0000019
10669,,,,0,,,CHEMBL626164,,Autocuration,A,,1,,U,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,,22224,BAO_0000019
10670,,,,1,,,CHEMBL626165,,Intermediate,A,,1,,N,Area under curve measured as conc vs time after intravenous administration to mice.,,,50594,BAO_0000218
10671,,,,1,,,CHEMBL626166,,Intermediate,A,,1,,N,Area under curve measured as conc vs time after peroral administration to mice.,,,50594,BAO_0000218
10672,,,,1,,,CHEMBL626167,,Intermediate,A,,1,,N,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,,50588,BAO_0000218
10673,,,,1,,,CHEMBL626168,,Intermediate,A,,1,,N,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,,50588,BAO_0000218
10674,,,,1,,,CHEMBL877463,,Intermediate,A,,1,,N,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,,50588,BAO_0000218
10675,,,,1,,,CHEMBL626169,,Intermediate,A,,1,,N,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,,50588,BAO_0000218
10676,,,948.0,1,Heart,In vivo,CHEMBL626170,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10677,,,948.0,1,Heart,In vivo,CHEMBL626171,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10678,,,948.0,1,Heart,In vivo,CHEMBL626172,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10679,,,948.0,1,Heart,In vivo,CHEMBL626173,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10680,,,2113.0,1,Kidney,In vivo,CHEMBL626174,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,,,50597,BAO_0000218
10681,,,2113.0,1,Kidney,In vivo,CHEMBL626175,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10682,,,2113.0,1,Kidney,In vivo,CHEMBL626176,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10683,,,2113.0,1,Kidney,In vivo,CHEMBL626177,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10684,,,2113.0,1,Kidney,In vivo,CHEMBL622499,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10685,,,2107.0,1,Liver,In vivo,CHEMBL622500,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,,,50597,BAO_0000218
10686,,,2107.0,1,Liver,In vivo,CHEMBL622501,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10687,,,2107.0,1,Liver,In vivo,CHEMBL622502,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10688,,,2107.0,1,Liver,In vivo,CHEMBL622503,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10689,,,2107.0,1,Liver,In vivo,CHEMBL877614,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10690,,,2048.0,1,Lung,In vivo,CHEMBL624839,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10691,,,2048.0,1,Lung,In vivo,CHEMBL624840,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10692,,,2048.0,1,Lung,In vivo,CHEMBL624841,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10693,,,2048.0,1,Lung,In vivo,CHEMBL624842,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10694,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624843,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10695,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624844,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,,,50597,BAO_0000218
10696,,,2385.0,1,Muscle tissue,In vivo,CHEMBL624845,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10697,,,2385.0,1,Muscle tissue,In vivo,CHEMBL621904,,Intermediate,A,,1,,N,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,,,50597,BAO_0000218
10698,,,178.0,1,Blood,In vivo,CHEMBL621905,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,,,50597,BAO_0000218
10699,,,178.0,1,Blood,In vivo,CHEMBL874382,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,,,50597,BAO_0000218
10700,,,178.0,1,Blood,In vivo,CHEMBL621906,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,,,50597,BAO_0000218
10701,,,955.0,1,Brain,In vivo,CHEMBL621907,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,,,50597,BAO_0000218
10702,,,955.0,1,Brain,In vivo,CHEMBL622096,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,,,50597,BAO_0000218
10703,,,955.0,1,Brain,In vivo,CHEMBL622097,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,,,50597,BAO_0000218
10704,,,948.0,1,Heart,In vivo,CHEMBL622098,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,,,50597,BAO_0000218
10705,,,948.0,1,Heart,In vivo,CHEMBL622099,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,,,50597,BAO_0000218
10706,,,948.0,1,Heart,In vivo,CHEMBL622100,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,,,50597,BAO_0000218
10707,,,2113.0,1,Kidney,In vivo,CHEMBL622101,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,,,50597,BAO_0000218
10708,,,2113.0,1,Kidney,In vivo,CHEMBL622102,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,,,50597,BAO_0000218
10709,,,2113.0,1,Kidney,In vivo,CHEMBL622103,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,,,50597,BAO_0000218
10710,,,2107.0,1,Liver,In vivo,CHEMBL622104,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,,,50597,BAO_0000218
10711,,,2107.0,1,Liver,In vivo,CHEMBL622105,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,,,50597,BAO_0000218
10712,,,2107.0,1,Liver,In vivo,CHEMBL622106,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,,,50597,BAO_0000218
10713,,,2048.0,1,Lung,In vivo,CHEMBL622107,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,,,50597,BAO_0000218
10714,,,2048.0,1,Lung,In vivo,CHEMBL622108,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,,,50597,BAO_0000218
10715,,,2048.0,1,Lung,In vivo,CHEMBL622109,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,,,50597,BAO_0000218
10716,,,2385.0,1,Muscle tissue,In vivo,CHEMBL622110,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,,,50597,BAO_0000218
10717,,,2385.0,1,Muscle tissue,In vivo,CHEMBL622111,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,,,50597,BAO_0000218
10718,,,2385.0,1,Muscle tissue,In vivo,CHEMBL874383,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,,,50597,BAO_0000218
10719,,,14.0,1,Zone of skin,In vivo,CHEMBL622112,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,,,50597,BAO_0000218
10720,,,14.0,1,Zone of skin,In vivo,CHEMBL622113,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,,,50597,BAO_0000218
10721,,,14.0,1,Zone of skin,In vivo,CHEMBL622114,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,,,50597,BAO_0000218
10722,,,2106.0,1,Spleen,In vivo,CHEMBL622115,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,,,50597,BAO_0000218
10723,,,2106.0,1,Spleen,In vivo,CHEMBL622116,,Intermediate,A,,1,,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,,,50597,BAO_0000218
10724,,,,1,,In vivo,CHEMBL622117,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10725,,,,1,,In vivo,CHEMBL622118,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10726,,,,1,,In vivo,CHEMBL622119,,Intermediate,A,,1,,N,Oral bioavailability in rats at 6 mg/kg,,,50597,BAO_0000218
10727,,,,1,,In vivo,CHEMBL622120,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 6 mg/kg),,,50597,BAO_0000218
10728,,,,1,,In vivo,CHEMBL622121,,Intermediate,A,,1,,N,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,,50597,BAO_0000218
10729,,,,1,,In vivo,CHEMBL622122,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10730,,,,1,,In vivo,CHEMBL622123,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10731,,,,1,,In vivo,CHEMBL622124,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10732,,,,1,,In vivo,CHEMBL622125,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10733,,,,1,,In vivo,CHEMBL622126,,Intermediate,A,,1,,N,Oral bioavailability,,,50597,BAO_0000218
10734,,,,1,,In vivo,CHEMBL620455,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,50597,BAO_0000218
10735,,,,1,,In vivo,CHEMBL620456,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10736,,,,1,,In vivo,CHEMBL620457,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10737,,,,1,,In vivo,CHEMBL620458,,Intermediate,A,,1,,N,Oral bioavailability was evaluated; Not tested,,,50597,BAO_0000218
10738,,,,1,,In vivo,CHEMBL620459,,Intermediate,A,,1,,N,Oral bioavailability,,,50597,BAO_0000218
10739,,,,1,,In vivo,CHEMBL620460,,Intermediate,A,,1,,N,Oral bioavailability in rat by oral dosing,,,50597,BAO_0000218
10740,,,,1,,In vivo,CHEMBL620461,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 10 mg/kg p.o.),,,50597,BAO_0000218
10741,,,,1,,In vivo,CHEMBL620462,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley),,,50597,BAO_0000218
10742,,,,1,,In vivo,CHEMBL620463,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,50597,BAO_0000218
10743,,,,1,,In vivo,CHEMBL620464,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,50597,BAO_0000218
10744,,,,1,,In vivo,CHEMBL620465,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,50597,BAO_0000218
10745,,,,1,,In vivo,CHEMBL620466,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,,50597,BAO_0000218
10746,,,,1,,In vivo,CHEMBL620467,,Intermediate,A,,1,,N,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,,50597,BAO_0000218
10747,,,,1,,In vivo,CHEMBL620468,,Intermediate,A,,1,,N,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,,50597,BAO_0000218
10748,,,,1,,In vivo,CHEMBL620469,,Intermediate,A,,1,,N,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,,50597,BAO_0000218
10749,,,,1,,In vivo,CHEMBL620470,,Intermediate,A,,1,,N,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,,50597,BAO_0000218
10750,,,,1,,In vivo,CHEMBL620471,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10751,,,,1,,In vivo,CHEMBL620472,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10752,,,,1,,In vivo,CHEMBL620473,,Intermediate,A,,1,,N,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,,50597,BAO_0000218
10753,,,,1,,In vivo,CHEMBL620474,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10754,,,,1,,In vivo,CHEMBL620475,,Intermediate,A,,1,,N,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,,50597,BAO_0000218
10755,,,,1,,In vivo,CHEMBL620476,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10756,,,,1,,In vivo,CHEMBL620477,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10757,,,,1,,In vivo,CHEMBL620478,,Intermediate,A,,1,,N,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,,50597,BAO_0000218
10758,,,,1,,In vivo,CHEMBL618768,,Intermediate,A,,1,,N,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,,50597,BAO_0000218
10759,,,,1,,In vivo,CHEMBL618769,,Intermediate,A,,1,,N,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,,50597,BAO_0000218
10760,,,,1,,In vivo,CHEMBL618770,,Intermediate,A,,1,,N,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,,50597,BAO_0000218
10761,,,,1,,In vivo,CHEMBL618771,,Intermediate,A,,1,,N,Oral bioavailability (dose 20 mg/kg p.o.),,,50597,BAO_0000218
10762,,,,1,,In vivo,CHEMBL618772,,Intermediate,A,,1,,N,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,,50597,BAO_0000218
10763,,,,1,,In vivo,CHEMBL618773,,Intermediate,A,,1,,N,Oral bioavailability in rat at 10 mg/kg of the compound,,,50597,BAO_0000218
10764,,,,1,,In vivo,CHEMBL875842,,Intermediate,A,,1,,N,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,,50597,BAO_0000218
10765,,,,1,,In vivo,CHEMBL618774,,Intermediate,A,,1,,N,Bioavailability in rat (dose 3 mg/kg i.v.),,,50597,BAO_0000218
10766,,,,1,,In vivo,CHEMBL618775,,Intermediate,A,,1,,N,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,,50597,BAO_0000218
10767,,,,1,,In vivo,CHEMBL618776,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 60 mg/kg p.o.),,,50597,BAO_0000218
10768,,,,1,,In vivo,CHEMBL618777,,Intermediate,A,,1,,N,Percent bioavailability (F) in rats after iv administration,,,50597,BAO_0000218
10769,,,,1,,In vivo,CHEMBL618778,,Intermediate,A,,1,,N,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,,50597,BAO_0000218
10770,,,,1,,In vivo,CHEMBL618779,,Intermediate,A,,1,,N,Bioavailability in rat (dose 5 uM/kg p.o.),,,50597,BAO_0000218
10771,,,,1,,In vivo,CHEMBL618780,,Intermediate,A,,1,,N,Oral bioavailability,,,50597,BAO_0000218
10772,,,,1,,In vivo,CHEMBL618781,,Intermediate,A,,1,,N,Bioavailability in rat (dose 2 mg/kg p.o.),,,50597,BAO_0000218
10773,,,,1,,In vivo,CHEMBL618782,,Intermediate,A,,1,,N,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,,50597,BAO_0000218
10774,,,,1,,In vivo,CHEMBL618783,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 20 mg/kg),,,50597,BAO_0000218
10775,,,,1,,In vivo,CHEMBL618784,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10776,,,,1,,In vivo,CHEMBL618785,,Intermediate,A,,1,,N,Percent oral bioavailability evaluated in rat,,,50597,BAO_0000218
10777,,,,1,,In vivo,CHEMBL618786,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10778,,,,1,,In vivo,CHEMBL618787,,Intermediate,A,,1,,N,Percent oral bioavailability in rat; Not determined,,,50597,BAO_0000218
10779,,,,1,,In vivo,CHEMBL618788,,Intermediate,A,,1,,N,Oral bioavailability in rat,,,50597,BAO_0000218
10780,,,,1,,In vivo,CHEMBL618789,,Intermediate,A,,1,,N,Bioavailability in rat,,,50597,BAO_0000218
10781,,,,1,,In vivo,CHEMBL618790,,Intermediate,A,,1,,N,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,,50597,BAO_0000218
10782,,,,1,,In vivo,CHEMBL618791,,Intermediate,A,,1,,N,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,,50597,BAO_0000218
10783,,,,1,,In vivo,CHEMBL875843,,Intermediate,A,,1,,N,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,,50597,BAO_0000218
10784,,,,1,,In vivo,CHEMBL618792,,Intermediate,A,,1,,N,Oral bioavailability in rat (dose 20 mg/kg p.o.),,,50597,BAO_0000218
10785,,,,1,,In vivo,CHEMBL623395,,Intermediate,A,,1,,N,Cmax at a dose of 30 mg/kg in rat,,,50597,BAO_0000218
10786,,,,0,,In vivo,CHEMBL623396,,Autocuration,A,,1,,U,Cmax in monkeys at a dose of 1 mg/kg,,,22224,BAO_0000218
10787,,,,1,,In vivo,CHEMBL623397,,Intermediate,A,,1,,N,Cmax in rat,,,50597,BAO_0000218
10788,,,,1,,In vivo,CHEMBL623398,,Intermediate,A,,1,,N,Cmax in rats at a dose of 1 mg/kg,,,50597,BAO_0000218
10789,,,,1,,In vivo,CHEMBL623399,,Intermediate,A,,1,,N,Cmax was measured in mice after an oral dose of 50 mg/kg.,,,50594,BAO_0000218
10790,,,,0,,In vivo,CHEMBL623400,,Autocuration,A,,1,,U,"Cmax value at a dose of 12.7 uM/kg, po",,,22224,BAO_0000218
10791,,,,0,,In vivo,CHEMBL623401,,Autocuration,A,,1,,U,"Cmax value at a dose of 6.3 uM/kg, iv",,,22224,BAO_0000218
10792,,,,0,,In vivo,CHEMBL623402,,Autocuration,A,,1,,U,"Cmax value at a dose of 7.1 uM/kg, iv",,,22224,BAO_0000218
10793,,,,0,,In vivo,CHEMBL623403,,Autocuration,A,,1,,U,Cmax value of compound was determined after 1 hr,,,22224,BAO_0000218
10794,,,,0,,In vivo,CHEMBL623404,,Autocuration,A,,1,,U,Cmax value of the compound,,,22224,BAO_0000218
10795,,,,1,,In vivo,CHEMBL625997,,Intermediate,A,,1,,N,Cmax value administered intraintestinal in rats.,,,50597,BAO_0000218
10796,,,,1,,In vivo,CHEMBL625998,,Intermediate,A,,1,,N,Cmax value administered perorally was determined in rat; Not determined,,,50597,BAO_0000218
10797,,,,0,,In vivo,CHEMBL625999,,Autocuration,A,,1,,U,Cmax value at the dose of 2.3 mg/kg,,,22224,BAO_0000218
10798,,,,0,,In vivo,CHEMBL626000,,Autocuration,A,,1,,U,Cmax value at the dose of 5 mg/kg,,,22224,BAO_0000218
10799,,,,0,,In vivo,CHEMBL626001,,Autocuration,A,,1,,U,Cmax value in the period of 8 hr after dosing. ,,,22224,BAO_0000218
10800,,,,0,,In vivo,CHEMBL626002,,Autocuration,A,,1,,U,Cmax value at a oral dose of 20 mg/kg; Not tested,,,22224,BAO_0000218
10801,,,,0,,In vivo,CHEMBL626003,,Autocuration,A,,1,,U,Cmax value at a oral dose of 20 mg/kg,,,22224,BAO_0000218
10802,,,,1,,In vivo,CHEMBL626004,,Intermediate,A,,1,,N,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,,50597,BAO_0000218
10803,,,,1,,In vivo,CHEMBL626005,,Intermediate,A,,1,,N,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,,50512,BAO_0000218
10804,,,,1,,In vivo,CHEMBL626006,,Intermediate,A,,1,,N,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,,50597,BAO_0000218
10805,,,1969.0,1,Plasma,In vivo,CHEMBL626007,,Intermediate,A,,1,,N,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,,,50597,BAO_0000218
10806,,,1969.0,1,Plasma,In vivo,CHEMBL626008,,Intermediate,A,,1,,N,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,,50594,BAO_0000218
10807,,,2107.0,1,Liver,In vivo,CHEMBL626009,,Intermediate,A,,1,,N,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,,,50588,BAO_0000218
10808,,,,1,,In vivo,CHEMBL626010,,Intermediate,A,,1,,N,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,,50588,BAO_0000218
10809,,,178.0,1,Blood,In vivo,CHEMBL626011,,Intermediate,A,,1,,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,,,50594,BAO_0000218
10810,,,178.0,1,Blood,In vivo,CHEMBL626012,,Intermediate,A,,1,,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,,,50594,BAO_0000218
10811,,,178.0,1,Blood,In vivo,CHEMBL626013,,Intermediate,A,,1,,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,,,50594,BAO_0000218
10812,,,178.0,1,Blood,In vivo,CHEMBL626014,,Intermediate,A,,1,,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,,,50594,BAO_0000218
10813,,,178.0,1,Blood,In vivo,CHEMBL877496,,Intermediate,A,,1,,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,,,50594,BAO_0000218
10814,,,,1,,In vivo,CHEMBL626015,,Intermediate,F,,1,,N,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,,50588,BAO_0000218
10815,,,,1,,In vivo,CHEMBL626016,,Intermediate,F,,1,,N,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,,50588,BAO_0000218
10816,,,,1,,In vivo,CHEMBL626017,,Intermediate,F,,1,,N,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,,50588,BAO_0000218
10817,,,1969.0,1,Plasma,In vivo,CHEMBL626018,,Intermediate,A,,1,,N,Bioavailability as maximal plasma concentration in dogs,,,50588,BAO_0000218
10818,,,1969.0,1,Plasma,In vivo,CHEMBL626692,,Intermediate,A,,1,,N,Bioavailability as maximal plasma concentration in dogs,,,50588,BAO_0000218
10819,,,1969.0,1,Plasma,In vivo,CHEMBL626693,,Intermediate,A,,1,,N,Bioavailability as maximal plasma concentration in rats,,,50597,BAO_0000218
10820,,,1969.0,0,Plasma,In vivo,CHEMBL626694,,Autocuration,A,,1,,U,Bioavailability as maximal plasma concentration in rats,,,22224,BAO_0000218
10821,,,178.0,1,Blood,In vivo,CHEMBL626695,,Intermediate,A,,1,,N,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,,50588,BAO_0000218
10822,,,178.0,1,Blood,In vivo,CHEMBL626696,,Intermediate,A,,1,,N,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,,50588,BAO_0000218
10823,,,178.0,1,Blood,In vivo,CHEMBL626697,,Intermediate,A,,1,,N,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,,50588,BAO_0000218
10824,,,178.0,1,Blood,In vivo,CHEMBL626859,,Intermediate,A,,1,,N,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,,,50588,BAO_0000218
10825,,,178.0,1,Blood,In vivo,CHEMBL626860,,Intermediate,A,,1,,N,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,,50588,BAO_0000218
10826,,,178.0,1,Blood,In vivo,CHEMBL626861,,Intermediate,A,,1,,N,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,,50588,BAO_0000218
10827,,,,1,,In vivo,CHEMBL626296,,Intermediate,A,,1,,N,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,,50597,BAO_0000218
10828,,,,0,,In vivo,CHEMBL626297,,Autocuration,A,,1,,U,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,,22224,BAO_0000218
10829,,,1969.0,0,Plasma,In vivo,CHEMBL626298,,Autocuration,A,,1,,U,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,,,22224,BAO_0000218
10830,,,1969.0,1,Plasma,In vivo,CHEMBL626299,,Intermediate,A,,1,,N,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",,,50597,BAO_0000218
10831,,,1969.0,1,Plasma,In vivo,CHEMBL626300,,Intermediate,A,,1,,N,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,,,50597,BAO_0000218
10832,,,1969.0,1,Plasma,In vivo,CHEMBL626301,,Intermediate,A,,1,,N,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,,,50597,BAO_0000218
10833,,,1969.0,1,Plasma,In vivo,CHEMBL626962,,Intermediate,A,,1,,N,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,,,50597,BAO_0000218
10834,,,1969.0,1,Plasma,In vivo,CHEMBL626963,,Intermediate,A,,1,,N,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,,,50597,BAO_0000218
10835,,,1969.0,1,Plasma,In vivo,CHEMBL626964,,Intermediate,A,,1,,N,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,,,50597,BAO_0000218
10836,,,1969.0,1,Plasma,In vivo,CHEMBL626965,,Intermediate,A,,1,,N,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,,,100710,BAO_0000218
10837,,,1969.0,1,Plasma,In vivo,CHEMBL626966,,Intermediate,A,,1,,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,50594,BAO_0000218
10838,,,1969.0,1,Plasma,In vivo,CHEMBL626967,,Intermediate,A,,1,,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,50594,BAO_0000218
10839,,,1969.0,1,Plasma,In vivo,CHEMBL626968,,Intermediate,A,,1,,N,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,,,100710,BAO_0000218
10840,,,948.0,1,Heart,,CHEMBL626969,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,,,50597,BAO_0000218
10841,,,948.0,1,Heart,,CHEMBL627126,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,,,50597,BAO_0000218
10842,,,948.0,1,Heart,,CHEMBL631276,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,,,50597,BAO_0000218
10843,,,948.0,1,Heart,,CHEMBL631277,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,,,50597,BAO_0000218
10844,,,948.0,1,Heart,,CHEMBL631278,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,,,50597,BAO_0000218
10845,,,948.0,1,Heart,,CHEMBL874457,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,,,50597,BAO_0000218
10846,,,948.0,1,Heart,,CHEMBL631279,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,,,50597,BAO_0000218
10847,,,948.0,1,Heart,,CHEMBL631280,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,,,50597,BAO_0000218
10848,,,948.0,1,Heart,,CHEMBL631281,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,,,50597,BAO_0000218
10849,,,948.0,1,Heart,,CHEMBL631968,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,,,50597,BAO_0000218
10850,,,948.0,1,Heart,,CHEMBL631969,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,,,50597,BAO_0000218
10851,,,948.0,1,Heart,,CHEMBL631970,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,,,50597,BAO_0000218
10852,,,948.0,1,Heart,,CHEMBL631971,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,,,50597,BAO_0000218
10853,,,948.0,1,Heart,,CHEMBL631972,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,,,50597,BAO_0000218
10854,,,948.0,1,Heart,,CHEMBL630435,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,,,50597,BAO_0000218
10855,,,948.0,1,Heart,,CHEMBL630436,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,,,50597,BAO_0000218
10856,,,948.0,1,Heart,,CHEMBL630437,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,,,50597,BAO_0000218
10857,,,948.0,1,Heart,,CHEMBL630438,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,,,50597,BAO_0000218
10858,,,948.0,1,Heart,,CHEMBL630439,,Intermediate,A,,1,,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,,,50597,BAO_0000218
10859,,,2113.0,1,Kidney,,CHEMBL630440,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,,,50597,BAO_0000218
10860,,,2113.0,1,Kidney,,CHEMBL630441,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,,,50597,BAO_0000218
10861,,,2113.0,1,Kidney,,CHEMBL630442,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,,,50597,BAO_0000218
10862,,,2113.0,1,Kidney,,CHEMBL625234,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,,,50597,BAO_0000218
10863,,,2113.0,1,Kidney,,CHEMBL625235,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,,,50597,BAO_0000218
10864,,,2113.0,1,Kidney,,CHEMBL625236,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,,,50597,BAO_0000218
10865,,,2113.0,1,Kidney,,CHEMBL625237,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,,,50597,BAO_0000218
10866,,,2113.0,1,Kidney,,CHEMBL626125,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,,,50597,BAO_0000218
10867,,,2113.0,1,Kidney,,CHEMBL626126,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,,,50597,BAO_0000218
10868,,,2113.0,1,Kidney,,CHEMBL626127,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,,,50597,BAO_0000218
10869,,,2113.0,1,Kidney,,CHEMBL626128,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,,,50597,BAO_0000218
10870,,,2113.0,1,Kidney,,CHEMBL626129,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,,,50597,BAO_0000218
10871,,,2113.0,1,Kidney,,CHEMBL626130,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,,,50597,BAO_0000218
10872,,,2113.0,1,Kidney,,CHEMBL626131,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,,,50597,BAO_0000218
10873,,,2113.0,1,Kidney,,CHEMBL626132,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,,,50597,BAO_0000218
10874,,,2113.0,1,Kidney,,CHEMBL626752,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,,,50597,BAO_0000218
10875,,,2113.0,1,Kidney,,CHEMBL626753,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,,,50597,BAO_0000218
10876,,,2113.0,1,Kidney,,CHEMBL626754,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,,,50597,BAO_0000218
10877,,,2113.0,1,Kidney,,CHEMBL626755,,Intermediate,A,,1,,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,,,50597,BAO_0000218
10878,,,2107.0,1,Liver,,CHEMBL626756,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,,,50597,BAO_0000218
10879,,,2107.0,1,Liver,,CHEMBL626757,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,,,50597,BAO_0000218
10880,,,2107.0,1,Liver,,CHEMBL626758,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,,,50597,BAO_0000218
10881,,,2107.0,1,Liver,,CHEMBL626759,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,,,50597,BAO_0000218
10882,,,2107.0,1,Liver,,CHEMBL626760,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,,,50597,BAO_0000218
10883,,,,1,,,CHEMBL626394,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
10884,,,,1,,,CHEMBL626395,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,,50588,BAO_0000218
10885,,,,1,,,CHEMBL626396,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
10886,,,,1,,,CHEMBL626397,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,50588,BAO_0000218
10887,,,,1,,,CHEMBL626398,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,50588,BAO_0000218
10888,,,,1,,,CHEMBL626399,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
10889,,,,1,,,CHEMBL874653,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,,50597,BAO_0000218
10890,,,,1,,,CHEMBL626400,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
10891,,,,1,,,CHEMBL626401,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
10892,,,,1,,,CHEMBL626402,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,50597,BAO_0000218
10893,,,,1,,,CHEMBL626403,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
10894,,,,1,,,CHEMBL626404,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
10895,,,,1,,,CHEMBL626405,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,,50597,BAO_0000218
10896,,,,1,,,CHEMBL625529,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
10897,,,,1,,,CHEMBL625530,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
10898,,,,1,,,CHEMBL625531,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,50597,BAO_0000218
10899,,,,1,,,CHEMBL625532,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
10900,,,,1,,,CHEMBL625533,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
10901,,,,1,,,CHEMBL875474,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,,50597,BAO_0000218
10902,,,,1,,,CHEMBL625534,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
10903,,,,1,,,CHEMBL625535,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
10904,,,,1,,,CHEMBL625536,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,,50597,BAO_0000218
10905,,,,1,,,CHEMBL625537,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
10906,,,,1,,,CHEMBL625538,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
10907,,,,1,,,CHEMBL625539,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,,50597,BAO_0000218
10908,,,,1,,,CHEMBL625540,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
10909,,,,1,,,CHEMBL625541,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
10910,,,,1,,,CHEMBL625542,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,50597,BAO_0000218
10911,,,,1,,,CHEMBL625543,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
10912,,,,1,,,CHEMBL625544,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
10913,,,,1,,,CHEMBL625545,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,,50588,BAO_0000218
10914,,,,1,,,CHEMBL625546,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
10915,,,,1,,,CHEMBL625547,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,,50588,BAO_0000218
10916,,,,1,,,CHEMBL625548,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
10917,,,,1,,,CHEMBL625549,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
10918,,,,1,,,CHEMBL625550,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
10919,,,,1,,,CHEMBL625551,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
10920,,,,1,,,CHEMBL875475,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
10921,,,,1,,,CHEMBL625552,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
10922,,,,1,,,CHEMBL625553,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
10923,,,,1,,,CHEMBL625554,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,50588,BAO_0000218
10924,,,,1,,,CHEMBL625555,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,50588,BAO_0000218
10925,,,,1,,,CHEMBL625556,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
10926,,,,1,,,CHEMBL624986,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,,50588,BAO_0000218
10927,,,,1,,,CHEMBL624987,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
10928,,,,1,,,CHEMBL624988,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,50588,BAO_0000218
10929,,,1637.0,1,Artery,In vivo,CHEMBL624989,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,,,50588,BAO_0000218
10930,,,1637.0,1,Artery,In vivo,CHEMBL624990,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,,,50588,BAO_0000218
10931,,,1637.0,1,Artery,In vivo,CHEMBL874391,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,,,50588,BAO_0000218
10932,,,1637.0,1,Artery,In vivo,CHEMBL624991,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,,,50588,BAO_0000218
10933,,,1637.0,1,Artery,In vivo,CHEMBL624992,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,,,50588,BAO_0000218
10934,,,1637.0,1,Artery,In vivo,CHEMBL624993,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,,,50588,BAO_0000218
10935,,,1637.0,1,Artery,In vivo,CHEMBL624994,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,,,50588,BAO_0000218
10936,,,1637.0,1,Artery,In vivo,CHEMBL624995,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,,,50588,BAO_0000218
10937,,,1637.0,1,Artery,In vivo,CHEMBL624996,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,,,50588,BAO_0000218
10938,,,1637.0,1,Artery,In vivo,CHEMBL624997,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,,,50588,BAO_0000218
10939,,,1637.0,1,Artery,In vivo,CHEMBL624998,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,,,50588,BAO_0000218
10940,,,1637.0,1,Artery,In vivo,CHEMBL624999,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,,,50588,BAO_0000218
10941,,,1637.0,1,Artery,In vivo,CHEMBL882955,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,,,50588,BAO_0000218
10942,,,1637.0,1,Artery,In vivo,CHEMBL625000,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,,,50588,BAO_0000218
10943,,,1637.0,1,Artery,In vivo,CHEMBL625001,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,,,50588,BAO_0000218
10944,,,1637.0,1,Artery,In vivo,CHEMBL625089,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,,,50588,BAO_0000218
10945,,,1637.0,1,Artery,In vivo,CHEMBL625090,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,,,50588,BAO_0000218
10946,,,1637.0,1,Artery,In vivo,CHEMBL625091,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,,,50588,BAO_0000218
10947,,,1637.0,1,Artery,In vivo,CHEMBL625092,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,,,50588,BAO_0000218
10948,,,1637.0,1,Artery,In vivo,CHEMBL625093,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,,,50588,BAO_0000218
10949,,,1637.0,1,Artery,In vivo,CHEMBL625094,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,,,50588,BAO_0000218
10950,,,1637.0,1,Artery,In vivo,CHEMBL625095,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,,,50588,BAO_0000218
10951,,,,1,,In vivo,CHEMBL625096,,Intermediate,A,,1,,N,Compound was evaluated for its bioavailability in the dogs,,,50588,BAO_0000218
10952,,,,1,,In vivo,CHEMBL625097,,Intermediate,A,,1,,N,Compound was evaluated for its bioavailability in the rats,,,50597,BAO_0000218
10953,,,,0,,In vivo,CHEMBL882956,,Autocuration,A,,1,,U,Compound was evaluated for oral bioavailability,,,22224,BAO_0000218
10954,,,,1,,In vivo,CHEMBL625098,,Intermediate,A,,1,,N,Compound was evaluated for percentage of Oral bioavailability in rats,,,50597,BAO_0000218
10955,,,,0,,In vivo,CHEMBL625099,,Autocuration,A,,1,,U,Bioavailability in guinea pig,,,22224,BAO_0000218
10956,,,,1,,In vivo,CHEMBL625100,,Intermediate,A,,1,,N,Compound was evaluated for the oral bioavailability in rat,,,50597,BAO_0000218
10957,,,,1,,In vivo,CHEMBL625101,,Intermediate,A,,1,,N,Compound was evaluated for the oral bioavailability in dog,,,50588,BAO_0000218
10958,,,,1,,In vivo,CHEMBL874396,,Intermediate,A,,1,,N,Compound was evaluated for the oral bioavailability in rat,,,50597,BAO_0000218
10959,,,,0,,In vivo,CHEMBL625102,,Autocuration,F,,1,,U,Bioavailability in dog (dosed i.v.),,,22224,BAO_0000218
10960,,,,1,,In vivo,CHEMBL625103,,Intermediate,A,,1,,N,Compound was tested for in vivo bioavailability in dog,,,50588,BAO_0000218
10961,,,,1,,In vivo,CHEMBL625104,,Intermediate,A,,1,,N,Compound was tested for in vivo bioavailability in hamsters,,,100712,BAO_0000218
10962,,,,0,,In vivo,CHEMBL625105,,Autocuration,A,,1,,U,Compound was tested for in vivo bioavailability in monkey,,,22224,BAO_0000218
10963,,,,1,,In vivo,CHEMBL625106,,Intermediate,A,,1,,N,Compound was tested for in vivo bioavailability in rat,,,50597,BAO_0000218
10964,,,,0,,In vivo,CHEMBL625107,,Autocuration,A,,1,,U,Oral bioavailability in mouse,,,22224,BAO_0000218
10965,,,,1,,In vivo,CHEMBL625108,,Intermediate,A,,1,,N,Compound was tested for percent of oral bioavailability in mice; 56-74,,,50594,BAO_0000218
10966,,,,0,,In vivo,CHEMBL625109,,Autocuration,A,,1,,U,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,,22224,BAO_0000218
10967,,,,0,,In vivo,CHEMBL625110,,Autocuration,A,,1,,U,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,,22224,BAO_0000218
10968,,,,0,,In vivo,CHEMBL625111,,Autocuration,A,,1,,U,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,,22224,BAO_0000218
10969,,,,1,,In vivo,CHEMBL625112,,Intermediate,A,,1,,N,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,,50594,BAO_0000218
10970,,,,1,,In vivo,CHEMBL875334,,Intermediate,A,,1,,N,Oral bioavailability in nude mice,,,50594,BAO_0000218
10971,,,,0,,In vivo,CHEMBL628617,,Autocuration,A,,1,,U,Bioavailability in monkey (i.d. dosing),,,22224,BAO_0000218
10972,,,,0,,In vivo,CHEMBL628618,,Autocuration,A,,1,,U,Bioavailability in rat,,,22224,BAO_0000218
10973,,,,0,,In vivo,CHEMBL628619,,Autocuration,A,,1,,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,,22224,BAO_0000218
10974,,,,0,,In vivo,CHEMBL628620,,Autocuration,A,,1,,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,,22224,BAO_0000218
10975,,,,1,,In vivo,CHEMBL628621,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,,100710,BAO_0000218
10976,,,,1,,In vivo,CHEMBL628622,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,,100710,BAO_0000218
10977,,,,1,,In vivo,CHEMBL628623,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,,100710,BAO_0000218
10978,,,1969.0,1,Plasma,In vivo,CHEMBL628624,,Intermediate,A,,1,,N,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,,,100710,BAO_0000218
10979,,,1969.0,1,Plasma,In vivo,CHEMBL628625,,Intermediate,A,,1,,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,50594,BAO_0000218
10980,,,1969.0,1,Plasma,In vivo,CHEMBL628626,,Intermediate,A,,1,,N,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,,,100710,BAO_0000218
10981,,,1969.0,1,Plasma,In vivo,CHEMBL627041,,Intermediate,A,,1,,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,50594,BAO_0000218
10982,,,1969.0,1,Plasma,In vivo,CHEMBL627042,,Intermediate,A,,1,,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,50594,BAO_0000218
10983,,,1969.0,1,Plasma,In vivo,CHEMBL627043,,Intermediate,A,,1,,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,50594,BAO_0000218
10984,,,1969.0,0,Plasma,In vivo,CHEMBL627044,,Autocuration,A,,1,,U,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,,,22224,BAO_0000218
10985,,,1969.0,1,Plasma,In vivo,CHEMBL627045,,Intermediate,A,,1,,N,Cmax in mouse plasma,,,50594,BAO_0000218
10986,,,1969.0,0,Plasma,In vivo,CHEMBL627046,,Autocuration,A,,1,,U,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,,,22224,BAO_0000218
10987,,,1969.0,1,Plasma,In vivo,CHEMBL627047,,Intermediate,A,,1,,N,Maximal plasma concentration in rat,,,50597,BAO_0000218
10988,,,1969.0,1,Plasma,In vivo,CHEMBL627048,,Intermediate,A,,1,,N,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,,,50597,BAO_0000218
10989,,,,1,,In vivo,CHEMBL627049,,Intermediate,A,,1,,N,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,,50597,BAO_0000218
10990,,,,1,,In vivo,CHEMBL627050,,Intermediate,A,,1,,N,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,,50597,BAO_0000218
10991,,,,1,,In vivo,CHEMBL627051,,Intermediate,A,,1,,N,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,,50597,BAO_0000218
10992,,,,1,,In vivo,CHEMBL627052,,Intermediate,A,,1,,N,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,,50597,BAO_0000218
10993,,,,1,,In vivo,CHEMBL627053,,Intermediate,A,,1,,N,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,,50597,BAO_0000218
10994,,,,1,,In vivo,CHEMBL627054,,Intermediate,A,,1,,N,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,,50597,BAO_0000218
10995,,,,1,,In vivo,CHEMBL627055,,Intermediate,A,,1,,N,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,50594,BAO_0000218
10996,,,,1,,In vivo,CHEMBL627056,,Intermediate,A,,1,,N,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,,50594,BAO_0000218
10997,,,,1,,In vivo,CHEMBL627057,,Intermediate,A,,1,,N,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,,50594,BAO_0000218
10998,,,,1,,In vivo,CHEMBL627058,,Intermediate,A,,1,,N,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,50594,BAO_0000218
10999,,,,1,,In vivo,CHEMBL626211,,Intermediate,A,,1,,N,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,,50594,BAO_0000218
11000,,,,0,,In vivo,CHEMBL626212,,Autocuration,A,,1,,U,Maximum Concentration of the compound.,,,22224,BAO_0000218
11001,,,,1,,In vivo,CHEMBL626213,,Intermediate,A,,1,,N,Maximum Concentration was measured after iv administration into Beagle dog,,,50588,BAO_0000218
11002,,,,1,,In vivo,CHEMBL626214,,Intermediate,A,,1,,N,Maximum Concentration was measured after iv administration into Beagle dog.,,,50588,BAO_0000218
11003,,,,1,,In vivo,CHEMBL626215,,Intermediate,A,,1,,N,Maximum Concentration was measured after po administration into Beagle dog,,,50588,BAO_0000218
11004,,,,1,,In vivo,CHEMBL626216,,Intermediate,A,,1,,N,Maximum Concentration was measured after po administration into Beagle dog.,,,50588,BAO_0000218
11005,,,178.0,0,Blood,In vivo,CHEMBL626217,,Autocuration,A,,1,,U,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,,,22224,BAO_0000218
11006,,,178.0,0,Blood,In vivo,CHEMBL626218,,Autocuration,A,,1,,U,Maximum blood level reached after an iv dose of 12.2 uM/kg,,,22224,BAO_0000218
11007,,,178.0,0,Blood,In vivo,CHEMBL626219,,Autocuration,A,,1,,U,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,,,22224,BAO_0000218
11008,,,178.0,0,Blood,In vivo,CHEMBL626220,,Autocuration,A,,1,,U,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,,,22224,BAO_0000218
11009,,,178.0,0,Blood,In vivo,CHEMBL626221,,Autocuration,A,,1,,U,Maximum blood level reached after an oral dose of 5.0 mg/kg,,,22224,BAO_0000218
11010,,,178.0,0,Blood,In vivo,CHEMBL626222,,Autocuration,A,,1,,U,Maximum blood level reached at dose of 10.6 uM/kg orally,,,22224,BAO_0000218
11011,,,,1,,In vivo,CHEMBL626223,,Intermediate,A,,1,,N,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,,50512,BAO_0000218
11012,,,,1,,In vivo,CHEMBL626224,,Intermediate,A,,1,,N,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,,50512,BAO_0000218
11013,,,955.0,1,Brain,In vivo,CHEMBL626225,,Intermediate,A,,1,,N,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,,,50597,BAO_0000218
11014,,,955.0,1,Brain,In vivo,CHEMBL626226,,Intermediate,A,,1,,N,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,,,50597,BAO_0000218
11015,,,955.0,1,Brain,In vivo,CHEMBL626227,,Intermediate,A,,1,,N,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,,,50597,BAO_0000218
11016,,,955.0,1,Brain,In vivo,CHEMBL626228,,Intermediate,A,,1,,N,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,,,50597,BAO_0000218
11017,,,,1,,In vivo,CHEMBL626229,,Intermediate,A,,1,,N,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,,50597,BAO_0000218
11018,,,,1,,In vivo,CHEMBL626921,,Intermediate,A,,1,,N,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,,50597,BAO_0000218
11019,,,,1,,In vivo,CHEMBL876793,,Intermediate,A,,1,,N,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,,50597,BAO_0000218
11020,,,,1,,In vivo,CHEMBL625309,,Intermediate,A,,1,,N,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,,50597,BAO_0000218
11021,,,,1,,In vivo,CHEMBL625310,,Intermediate,A,,1,,N,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,50278,BAO_0000218
11022,,,,0,,In vivo,CHEMBL625311,,Autocuration,A,,1,,U,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,,22224,BAO_0000218
11023,,,,1,,In vivo,CHEMBL625312,,Intermediate,A,,1,,N,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,,50597,BAO_0000218
11024,,,,0,,In vivo,CHEMBL625313,,Autocuration,A,,1,,U,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,,22224,BAO_0000218
11025,,,,1,,In vivo,CHEMBL625314,,Intermediate,A,,1,,N,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,,50594,BAO_0000218
11026,,,,1,,In vivo,CHEMBL625315,,Intermediate,A,,1,,N,Maximum concentration in male rats after iv administration of 20 mg/kg,,,50597,BAO_0000218
11027,,,2107.0,1,Liver,,CHEMBL625316,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,,,50597,BAO_0000218
11028,,,2107.0,1,Liver,,CHEMBL625317,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,,,50597,BAO_0000218
11029,,,2107.0,1,Liver,,CHEMBL625318,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,,,50597,BAO_0000218
11030,,,2107.0,1,Liver,,CHEMBL625319,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,,,50597,BAO_0000218
11031,,,2107.0,1,Liver,,CHEMBL625320,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,,,50597,BAO_0000218
11032,,,2107.0,1,Liver,,CHEMBL625321,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,,,50597,BAO_0000218
11033,,,2107.0,1,Liver,,CHEMBL625322,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,,,50597,BAO_0000218
11034,,,2107.0,1,Liver,,CHEMBL876801,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,,,50597,BAO_0000218
11035,,,2107.0,1,Liver,,CHEMBL625323,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,,,50597,BAO_0000218
11036,,,2107.0,1,Liver,,CHEMBL625324,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,,,50597,BAO_0000218
11037,,,2107.0,1,Liver,,CHEMBL625325,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,,,50597,BAO_0000218
11038,,,2107.0,1,Liver,,CHEMBL625326,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,,,50597,BAO_0000218
11039,,,2107.0,1,Liver,,CHEMBL625327,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,,,50597,BAO_0000218
11040,,,2107.0,1,Liver,,CHEMBL625328,,Intermediate,A,,1,,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,,,50597,BAO_0000218
11041,,,2048.0,1,Lung,,CHEMBL625329,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,,,50597,BAO_0000218
11042,,,2048.0,1,Lung,,CHEMBL625330,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,,,50597,BAO_0000218
11043,,,2048.0,1,Lung,,CHEMBL627774,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,,,50597,BAO_0000218
11044,,,2048.0,1,Lung,,CHEMBL627775,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,,,50597,BAO_0000218
11045,,,2048.0,1,Lung,,CHEMBL627949,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,,,50597,BAO_0000218
11046,,,2048.0,1,Lung,,CHEMBL627950,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,,,50597,BAO_0000218
11047,,,2048.0,1,Lung,,CHEMBL627951,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,,,50597,BAO_0000218
11048,,,2048.0,1,Lung,,CHEMBL627952,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,,,50597,BAO_0000218
11049,,,2048.0,1,Lung,,CHEMBL627953,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,,,50597,BAO_0000218
11050,,,2048.0,1,Lung,,CHEMBL627954,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,,,50597,BAO_0000218
11051,,,2048.0,1,Lung,,CHEMBL627955,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,,,50597,BAO_0000218
11052,,,2048.0,1,Lung,,CHEMBL627956,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,,,50597,BAO_0000218
11053,,,2048.0,1,Lung,,CHEMBL876802,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,,,50597,BAO_0000218
11054,,,2048.0,1,Lung,,CHEMBL627957,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,,,50597,BAO_0000218
11055,,,2048.0,1,Lung,,CHEMBL627958,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,,,50597,BAO_0000218
11056,,,2048.0,1,Lung,,CHEMBL627959,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,,,50597,BAO_0000218
11057,,,2048.0,1,Lung,,CHEMBL627960,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,,,50597,BAO_0000218
11058,,,2048.0,1,Lung,,CHEMBL627961,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,,,50597,BAO_0000218
11059,,,2048.0,1,Lung,,CHEMBL627962,,Intermediate,A,,1,,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,,,50597,BAO_0000218
11060,,,,1,,,CHEMBL627963,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,50597,BAO_0000218
11061,,,,1,,,CHEMBL624759,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11062,,,,1,,,CHEMBL624760,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11063,,,,1,,,CHEMBL624761,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11064,,,,1,,,CHEMBL877607,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11065,,,2107.0,1,Liver,,CHEMBL624762,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,50597,BAO_0000218
11066,,,2107.0,1,Liver,,CHEMBL624763,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11067,,,2107.0,1,Liver,,CHEMBL624764,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11068,,,2107.0,1,Liver,,CHEMBL624765,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11069,,,2107.0,1,Liver,,CHEMBL624766,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11070,,,,1,,,CHEMBL624767,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
11071,,,,1,,,CHEMBL624768,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,,50588,BAO_0000218
11072,,,,1,,,CHEMBL624769,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
11073,,,,1,,,CHEMBL624770,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,50588,BAO_0000218
11074,,,,1,,,CHEMBL624771,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,50588,BAO_0000218
11075,,,,1,,,CHEMBL624772,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
11076,,,,1,,,CHEMBL624773,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,,50597,BAO_0000218
11077,,,,1,,,CHEMBL624774,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
11078,,,,1,,,CHEMBL624775,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
11079,,,,1,,,CHEMBL624776,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,50597,BAO_0000218
11080,,,,1,,,CHEMBL624777,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
11081,,,,1,,,CHEMBL624778,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
11082,,,,1,,,CHEMBL624779,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,,50597,BAO_0000218
11083,,,,1,,,CHEMBL624780,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,50597,BAO_0000218
11084,,,,1,,,CHEMBL624781,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
11085,,,,1,,,CHEMBL877608,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
11086,,,,1,,,CHEMBL624782,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
11087,,,,1,,,CHEMBL624783,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
11088,,,,1,,,CHEMBL624784,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,,50597,BAO_0000218
11089,,,,1,,,CHEMBL624785,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
11090,,,,1,,,CHEMBL624786,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
11091,,,,1,,,CHEMBL624787,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
11092,,,,1,,,CHEMBL628676,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
11093,,,,1,,,CHEMBL621842,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,,50597,BAO_0000218
11094,,,,1,,,CHEMBL621843,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
11095,,,,1,,,CHEMBL623873,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
11096,,,,1,,,CHEMBL623874,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,50597,BAO_0000218
11097,,,,1,,,CHEMBL623875,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
11098,,,,1,,,CHEMBL623876,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
11099,,,,1,,,CHEMBL623877,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,,50588,BAO_0000218
11100,,,,1,,,CHEMBL623878,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
11101,,,,1,,,CHEMBL623879,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,,50588,BAO_0000218
11102,,,,1,,,CHEMBL623880,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
11103,,,,1,,,CHEMBL623881,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
11104,,,,1,,,CHEMBL623957,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
11105,,,,1,,,CHEMBL623958,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
11106,,,,1,,,CHEMBL623959,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
11107,,,,1,,,CHEMBL623960,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
11108,,,,1,,,CHEMBL623961,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
11109,,,,1,,,CHEMBL623962,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,50588,BAO_0000218
11110,,,,1,,,CHEMBL624676,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,50588,BAO_0000218
11111,,,,1,,,CHEMBL624677,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
11112,,,,1,,,CHEMBL624678,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,,50588,BAO_0000218
11113,,,,1,,,CHEMBL624679,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
11114,,,,1,,,CHEMBL624680,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,50588,BAO_0000218
11115,,,,0,,In vivo,CHEMBL624849,,Autocuration,A,,1,,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,,22224,BAO_0000218
11116,,,,0,,In vivo,CHEMBL624850,,Autocuration,A,,1,,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,,22224,BAO_0000218
11117,,,,0,,In vivo,CHEMBL874399,,Autocuration,A,,1,,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,,22224,BAO_0000218
11118,,,,0,,In vivo,CHEMBL624851,,Autocuration,A,,1,,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,,22224,BAO_0000218
11119,,,,0,,In vivo,CHEMBL624852,,Autocuration,A,,1,,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,,22224,BAO_0000218
11120,,,,0,,In vivo,CHEMBL624853,,Autocuration,A,,1,,U,Oral bioavailability in rat (dose 10 mg/kg),,,22224,BAO_0000218
11121,,,,0,,In vivo,CHEMBL624854,,Autocuration,A,,1,,U,Oral bioavailability in rat (Sprague-Dawley),,,22224,BAO_0000218
11122,,,,0,,In vivo,CHEMBL624855,,Autocuration,A,,1,,U,Oral bioavailability in rat,,,22224,BAO_0000218
11123,,,,0,,In vivo,CHEMBL624856,,Autocuration,A,,1,,U,Oral bioavailability in rats was determined in vivo,,,22224,BAO_0000218
11124,,,,0,,In vivo,CHEMBL882957,,Autocuration,A,,1,,U,Oral bioavailability in dog,,,22224,BAO_0000218
11125,,,,0,,In vivo,CHEMBL624857,,Autocuration,A,,1,,U,Oral bioavailability of compound in monkey,,,22224,BAO_0000218
11126,,,,1,,In vivo,CHEMBL622202,,Intermediate,A,,1,,N,Oral bioavailability of compound in rat,,,50597,BAO_0000218
11127,,,,0,,In vivo,CHEMBL622203,,Autocuration,A,,1,,U,Bioavailability in rat of PMEA prodrug,,,22224,BAO_0000218
11128,,,,1,,In vivo,CHEMBL625522,,Intermediate,A,,1,,N,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,,50597,BAO_0000218
11129,,,,0,,In vivo,CHEMBL622868,,Autocuration,A,,1,,U,Serum conc at 3 hours following 25 mg/kg dose,,,22224,BAO_0000218
11130,,,1088.0,0,Urine,In vivo,CHEMBL622869,,Autocuration,A,,1,,U,Urine conc 0-5 hours following 25 mg/kg dose,,,22224,BAO_0000218
11131,,,1088.0,0,Urine,In vivo,CHEMBL622870,,Autocuration,A,,1,,U,Urine conc 0-24 hours following 25 mg/kg dose,,,22224,BAO_0000218
11132,,,,0,,In vivo,CHEMBL622871,,Autocuration,A,,1,,U,Oral bioavailability in African green monkeys; 20-25,,,22224,BAO_0000218
11133,,,,1,,In vivo,CHEMBL620560,,Intermediate,A,,1,,N,Oral bioavailability in cynomolgus monkey.,,,100710,BAO_0000218
11134,,,,0,,In vivo,CHEMBL620561,,Autocuration,A,,1,,U,Oral bioavailability in dog,,,22224,BAO_0000218
11135,,,,1,,In vivo,CHEMBL620562,,Intermediate,A,,1,,N,Oral bioavailability in dog at 10 mg/kg oral dose,,,50588,BAO_0000218
11136,,,,1,,In vivo,CHEMBL620563,,Intermediate,A,,1,,N,Oral bioavailability in hamster at 10 mg/kg oral dose,,,100712,BAO_0000218
11137,,,,1,,In vivo,CHEMBL620564,,Intermediate,A,,1,,N,Oral bioavailability in rat at 10 mg/kg oral dose,,,50597,BAO_0000218
11138,,,,0,,In vivo,CHEMBL872265,,Autocuration,A,,1,,U,Oral bioavailability in rat,,,22224,BAO_0000218
11139,,,,0,,In vivo,CHEMBL620565,,Autocuration,A,,1,,U,Oral bioavailability in rat,,,22224,BAO_0000218
11140,,,,0,,In vivo,CHEMBL620566,,Autocuration,A,,1,,U,Oral bioavailability,,,22224,BAO_0000218
11141,,,,0,,In vivo,CHEMBL620567,,Autocuration,A,,1,,U,Oral bioavailability was determined; range 49-102%,,,22224,BAO_0000218
11142,,,,1,,In vivo,CHEMBL620568,,Intermediate,A,,1,,N,Oral bioavailability was determined in dogs,,,50588,BAO_0000218
11143,,,,0,,In vivo,CHEMBL620569,,Autocuration,A,,1,,U,Oral bioavailability in rat,,,22224,BAO_0000218
11144,,,,0,,In vivo,CHEMBL620570,,Autocuration,A,,1,,U,Oral bioavailability,,,22224,BAO_0000218
11145,,,,0,,In vivo,CHEMBL620571,,Autocuration,A,,1,,U,Oral bioavailability was determined; Not orally available,,,22224,BAO_0000218
11146,,,,1,,In vivo,CHEMBL620572,,Intermediate,A,,1,,N,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,,50594,BAO_0000218
11147,,,,0,,In vivo,CHEMBL620573,,Autocuration,A,,1,,U,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,,22224,BAO_0000218
11148,,,,0,,In vivo,CHEMBL620574,,Autocuration,A,,1,,U,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,,22224,BAO_0000218
11149,,,,0,,In vivo,CHEMBL620575,,Autocuration,A,,1,,U,Oral bioavailability in Rhesus monkey,,,22224,BAO_0000218
11150,,,,0,,In vivo,CHEMBL620576,,Autocuration,A,,1,,U,Oral bioavailability in dog (female mongrel),,,22224,BAO_0000218
11151,,,,0,,In vivo,CHEMBL875846,,Autocuration,A,,1,,U,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,,22224,BAO_0000218
11152,,,,0,,In vivo,CHEMBL620577,,Autocuration,A,,1,,U,Oral bioavailability in dog,,,22224,BAO_0000218
11153,,,,0,,In vivo,CHEMBL620578,,Autocuration,A,,1,,U,Percentage Bioavailability was evaluated.,,,22224,BAO_0000218
11154,,,,0,,In vivo,CHEMBL620579,,Autocuration,A,,1,,U,Bioavailability in rat administered i.d.,,,22224,BAO_0000218
11155,,,,0,,In vivo,CHEMBL621248,,Autocuration,A,,1,,U,Bioavailability,,,22224,BAO_0000218
11156,,,,0,,In vivo,CHEMBL625390,,Autocuration,A,,1,,U,Bioavailability in dog (male Beagle) i.v. administration,,,22224,BAO_0000218
11157,,,,0,,In vivo,CHEMBL625391,,Autocuration,A,,1,,U,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,,22224,BAO_0000218
11158,,,,0,,In vivo,CHEMBL872266,,Autocuration,A,,1,,U,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,,22224,BAO_0000218
11159,,,,0,,In vivo,CHEMBL625392,,Autocuration,A,,1,,U,Oral bioavailability in rat (Sprague-Dawley) (male),,,22224,BAO_0000218
11160,,,,1,,In vivo,CHEMBL625393,,Intermediate,A,,1,,N,The oral bioavailability was measured on rats after oral administration,,,50597,BAO_0000218
11161,,,,1,,In vivo,CHEMBL625394,,Intermediate,A,,1,,N,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,,50597,BAO_0000218
11162,,,,1,,In vivo,CHEMBL625395,,Intermediate,A,,1,,N,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,,50797,BAO_0000218
11163,,,,0,,In vivo,CHEMBL625396,,Autocuration,A,,1,,U,Bioavailability in rat (dose 10 mg/kg i.d.),,,22224,BAO_0000218
11164,,,,0,,In vivo,CHEMBL625397,,Autocuration,A,,1,,U,Bioavailability in dog (male Beagle) i.v. administration,,,22224,BAO_0000218
11165,,,,1,,In vivo,CHEMBL625398,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11166,,,178.0,1,Blood,In vivo,CHEMBL625399,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11167,,,2037.0,1,Cerebellum,In vivo,CHEMBL626074,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11168,,,,1,,In vivo,CHEMBL626075,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11169,,,1969.0,1,Plasma,In vivo,CHEMBL626076,,Intermediate,A,,1,,N,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,,50597,BAO_0000218
11170,,,1969.0,1,Plasma,In vivo,CHEMBL626077,,Intermediate,A,,1,,N,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,,50797,BAO_0000218
11171,,,178.0,1,Blood,In vivo,CHEMBL626078,,Intermediate,A,,1,,N,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),,,50597,BAO_0000218
11172,,,178.0,0,Blood,In vivo,CHEMBL625846,,Autocuration,A,,1,,U,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),,,22224,BAO_0000218
11173,,,178.0,0,Blood,In vivo,CHEMBL625847,,Autocuration,A,,1,,U,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),,,22224,BAO_0000218
11174,,,,1,,In vivo,CHEMBL625848,,Expert,A,,1,,N,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,,50597,BAO_0000218
11175,,,1969.0,1,Plasma,In vivo,CHEMBL625849,,Intermediate,A,,1,,N,Maximum concentration of compound in plasma administered orally to rats,,,50597,BAO_0000218
11176,,,1969.0,1,Plasma,In vivo,CHEMBL626023,,Intermediate,A,,1,,N,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",,,50588,BAO_0000218
11177,,,1969.0,1,Plasma,In vivo,CHEMBL626024,,Intermediate,A,,1,,N,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",,,50588,BAO_0000218
11178,,,1969.0,1,Plasma,In vivo,CHEMBL626025,,Intermediate,A,,1,,N,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",,,50588,BAO_0000218
11179,,,,0,,In vivo,CHEMBL626026,,Autocuration,A,,1,,U,Maximum concentration after 10 mg/kg by oral administration,,,22224,BAO_0000218
11180,,,,0,,In vivo,CHEMBL626027,,Autocuration,A,,1,,U,Maximum concentration at a dose of 1.5 mg/kg,,,22224,BAO_0000218
11181,,,,0,,In vivo,CHEMBL626028,,Autocuration,A,,1,,U,Maximum concentration at a dose of 2.0 mg/kg,,,22224,BAO_0000218
11182,,,1969.0,1,Plasma,In vivo,CHEMBL626029,,Intermediate,A,,1,,N,Maximum concentration in dog plasma,,,50588,BAO_0000218
11183,,,1969.0,0,Plasma,In vivo,CHEMBL626030,,Autocuration,A,,1,,U,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,,,22224,BAO_0000218
11184,,,1969.0,0,Plasma,In vivo,CHEMBL626031,,Autocuration,A,,1,,U,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,,,22224,BAO_0000218
11185,,,1969.0,0,Plasma,In vivo,CHEMBL626032,,Autocuration,A,,1,,U,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,,,22224,BAO_0000218
11186,,,1969.0,0,Plasma,In vivo,CHEMBL626033,,Autocuration,A,,1,,U,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,,,22224,BAO_0000218
11187,,,1969.0,0,Plasma,In vivo,CHEMBL626034,,Autocuration,A,,1,,U,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,,,22224,BAO_0000218
11188,,,1969.0,1,Plasma,In vivo,CHEMBL626035,,Intermediate,A,,1,,N,Maximum concentration in plasma after oral administration in dog (25 mg/kg),,,50588,BAO_0000218
11189,,,1969.0,0,Plasma,In vivo,CHEMBL626036,,Autocuration,A,,1,,U,Maximum concentration in plasma at Tmax,,,22224,BAO_0000218
11190,,,1969.0,1,Plasma,In vivo,CHEMBL626037,,Expert,A,,1,,N,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,,,50588,BAO_0000218
11191,,,1969.0,1,Plasma,In vivo,CHEMBL626038,,Intermediate,A,,1,,N,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,,,100712,BAO_0000218
11192,,,1969.0,1,Plasma,In vivo,CHEMBL626039,,Intermediate,A,,1,,N,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,,,50597,BAO_0000218
11193,,,1969.0,1,Plasma,In vivo,CHEMBL626040,,Intermediate,A,,1,,N,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,,,50597,BAO_0000218
11194,,,1969.0,1,Plasma,In vivo,CHEMBL626041,,Intermediate,A,,1,,N,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,,,50592,BAO_0000218
11195,,,,0,,In vivo,CHEMBL626042,,Autocuration,A,,1,,U,Maximum concentration was calculated,,,22224,BAO_0000218
11196,,,,0,,In vivo,CHEMBL626043,,Autocuration,A,,1,,U,Maximum concentration was calculated.,,,22224,BAO_0000218
11197,,,,0,,In vivo,CHEMBL626044,,Autocuration,A,,1,,U,Maximum concentration at a peroral dose of 10 mg/kg,,,22224,BAO_0000218
11198,,,,0,,In vivo,CHEMBL626045,,Autocuration,A,,1,,U,Maximum concentration of the drug at 10 uM/dg administered perorally,,,22224,BAO_0000218
11199,,,,0,,In vivo,CHEMBL626046,,Autocuration,A,,1,,U,Maximum concentration of the drug at 2 uM/dg administered intravenously,,,22224,BAO_0000218
11200,,,1969.0,1,Plasma,In vivo,CHEMBL626047,,Intermediate,A,,1,,N,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",,,50588,BAO_0000218
11201,,,1969.0,1,Plasma,In vivo,CHEMBL626048,,Intermediate,A,,1,,N,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",,,100712,BAO_0000218
11202,,,1969.0,1,Plasma,In vivo,CHEMBL626049,,Intermediate,A,,1,,N,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",,,50597,BAO_0000218
11203,,,1969.0,1,Plasma,In vivo,CHEMBL626050,,Intermediate,A,,1,,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,,,50597,BAO_0000218
11204,,,1969.0,1,Plasma,In vivo,CHEMBL874541,,Intermediate,A,,1,,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,,,50588,BAO_0000218
11205,,,1969.0,1,Plasma,In vivo,CHEMBL622826,,Intermediate,A,,1,,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,,,100712,BAO_0000218
11206,,,1969.0,1,Plasma,In vivo,CHEMBL622827,,Intermediate,A,,1,,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,,,100712,BAO_0000218
11207,,,1969.0,1,Plasma,In vivo,CHEMBL622828,,Intermediate,A,,1,,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,,,50597,BAO_0000218
11208,,,1969.0,1,Plasma,In vivo,CHEMBL622829,,Intermediate,A,,1,,N,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,,,50597,BAO_0000218
11209,,,,1,,In vivo,CHEMBL876806,,Intermediate,A,,1,,N,Maximum concentration reached following intravenous administration in male rat,,,50597,BAO_0000218
11210,,,,1,,In vivo,CHEMBL622830,,Intermediate,A,,1,,N,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,,50588,BAO_0000218
11211,,,,1,,In vivo,CHEMBL622831,,Intermediate,A,,1,,N,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,,50597,BAO_0000218
11212,,,,1,,In vivo,CHEMBL626794,,Intermediate,A,,1,,N,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,,50588,BAO_0000218
11213,,,,1,,In vivo,CHEMBL626795,,Intermediate,A,,1,,N,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,,50597,BAO_0000218
11214,,,,1,,In vivo,CHEMBL626796,,Intermediate,A,,1,,N,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,,50597,BAO_0000218
11215,,,,1,,In vivo,CHEMBL626797,,Intermediate,A,,1,,N,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,,50597,BAO_0000218
11216,,,,1,,In vivo,CHEMBL626798,,Intermediate,A,,1,,N,Maximum drug concentration is determined after oral dosing in rats.,,,50597,BAO_0000218
11217,,,,1,,In vivo,CHEMBL626799,,Intermediate,A,,1,,N,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,,50588,BAO_0000218
11218,,,,1,,In vivo,CHEMBL626800,,Intermediate,A,,1,,N,Maximum observed concentration in oral (5 mg/kg) fed dogs,,,50588,BAO_0000218
11219,,,1969.0,0,Plasma,In vivo,CHEMBL626801,,Autocuration,A,,1,,U,Maximum plasma concentration,,,22224,BAO_0000218
11220,,,1969.0,1,Plasma,In vivo,CHEMBL876816,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,,,50597,BAO_0000218
11221,,,1969.0,1,Plasma,In vivo,CHEMBL626802,,Intermediate,A,,1,,N,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,,,50597,BAO_0000218
11222,,,1969.0,1,Plasma,In vivo,CHEMBL626803,,Intermediate,A,,1,,N,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,,,50588,BAO_0000218
11223,,,1969.0,0,Plasma,In vivo,CHEMBL626804,,Autocuration,A,,1,,U,Maximum plasma concentration following oral administration of 30 umol/kg,,,22224,BAO_0000218
11224,,,1969.0,1,Plasma,,CHEMBL626805,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,,,50597,BAO_0000218
11225,,,1969.0,1,Plasma,,CHEMBL626309,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,50597,BAO_0000218
11226,,,1969.0,1,Plasma,,CHEMBL626310,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11227,,,1969.0,1,Plasma,,CHEMBL626311,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11228,,,1969.0,1,Plasma,,CHEMBL626312,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11229,,,995.0,1,Uterus,,CHEMBL626313,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11230,,,995.0,1,Uterus,,CHEMBL626314,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,50597,BAO_0000218
11231,,,995.0,1,Uterus,,CHEMBL626315,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11232,,,995.0,1,Uterus,,CHEMBL626316,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11233,,,995.0,1,Uterus,,CHEMBL626317,,Intermediate,A,,1,,N,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,50597,BAO_0000218
11234,,,,1,,,CHEMBL626318,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,BAO_0000218
11235,,,,1,,,CHEMBL626319,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,BAO_0000218
11236,,,,1,,,CHEMBL626320,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,BAO_0000218
11237,,,,1,,,CHEMBL875053,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,BAO_0000218
11238,,,,1,,,CHEMBL626321,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,BAO_0000218
11239,,,,1,,,CHEMBL626322,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,BAO_0000218
11240,,,,1,,,CHEMBL626323,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,BAO_0000218
11241,,,,1,,,CHEMBL626324,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,BAO_0000218
11242,,,,1,,,CHEMBL626325,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,BAO_0000218
11243,,,,1,,,CHEMBL626326,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,BAO_0000218
11244,,,,1,,,CHEMBL626327,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,,50597,BAO_0000218
11245,,,,1,,,CHEMBL626328,,Intermediate,A,,1,,N,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,,50597,BAO_0000218
11246,,,178.0,1,Blood,,CHEMBL626329,,Intermediate,A,,1,,N,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11247,,,178.0,1,Blood,,CHEMBL626330,,Intermediate,A,,1,,N,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11248,,,178.0,1,Blood,,CHEMBL626331,,Intermediate,A,,1,,N,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11249,,,178.0,1,Blood,,CHEMBL626332,,Intermediate,A,,1,,N,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11250,,,178.0,1,Blood,,CHEMBL626333,,Intermediate,A,,1,,N,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11251,,,178.0,1,Blood,,CHEMBL626334,,Intermediate,A,,1,,N,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11252,,,178.0,1,Blood,,CHEMBL626335,,Intermediate,A,,1,,N,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11253,,,178.0,1,Blood,,CHEMBL624798,,Intermediate,A,,1,,N,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11254,,,955.0,1,Brain,,CHEMBL624799,,Intermediate,A,,1,,N,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",,,50597,BAO_0000218
11255,,,955.0,1,Brain,,CHEMBL624800,,Intermediate,A,,1,,N,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",,,50597,BAO_0000218
11256,,,955.0,1,Brain,,CHEMBL624801,,Intermediate,A,,1,,N,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",,,50597,BAO_0000218
11257,,,955.0,1,Brain,,CHEMBL624802,,Intermediate,A,,1,,N,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",,,50597,BAO_0000218
11258,,,955.0,1,Brain,,CHEMBL624803,,Intermediate,A,,1,,N,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",,,50597,BAO_0000218
11259,,,955.0,1,Brain,,CHEMBL624804,,Intermediate,A,,1,,N,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",,,50597,BAO_0000218
11260,,,955.0,1,Brain,,CHEMBL624805,,Intermediate,A,,1,,N,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",,,50597,BAO_0000218
11261,,,955.0,1,Brain,,CHEMBL624806,,Intermediate,A,,1,,N,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",,,50597,BAO_0000218
11262,,,,1,,,CHEMBL624807,,Intermediate,A,,1,,N,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11263,,,,1,,,CHEMBL624808,,Intermediate,A,,1,,N,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11264,,,,1,,,CHEMBL624809,,Intermediate,A,,1,,N,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11265,,,,1,,,CHEMBL624810,,Intermediate,A,,1,,N,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11266,,,,1,,,CHEMBL877618,,Intermediate,A,,1,,N,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11267,,,,1,,,CHEMBL624811,,Intermediate,A,,1,,N,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11268,,,,1,,,CHEMBL624812,,Intermediate,A,,1,,N,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11269,,,,1,,,CHEMBL624813,,Intermediate,A,,1,,N,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11270,,,,1,,,CHEMBL624814,,Intermediate,A,,1,,N,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11271,,,,1,,,CHEMBL624815,,Intermediate,A,,1,,N,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11272,,,,1,,,CHEMBL624816,,Intermediate,A,,1,,N,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11273,,,,1,,,CHEMBL624817,,Intermediate,A,,1,,N,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11274,,,,1,,,CHEMBL624818,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
11275,,,,1,,,CHEMBL624819,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,,50588,BAO_0000218
11276,,,,1,,,CHEMBL624820,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
11277,,,,1,,,CHEMBL624821,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,50588,BAO_0000218
11278,,,,1,,,CHEMBL624822,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,50588,BAO_0000218
11279,,,,1,,,CHEMBL624823,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
11280,,,,1,,,CHEMBL624824,,Intermediate,A,,1,,N,Observed diffusion coefficient in organic solvent for Escherichia coli,,,50212,BAO_0000218
11281,,,178.0,1,Blood,,CHEMBL624825,,Intermediate,A,,1,,N,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,50597,BAO_0000218
11282,,,178.0,1,Blood,,CHEMBL624826,,Intermediate,A,,1,,N,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,50597,BAO_0000218
11283,,,2081.0,1,Cardiac atrium,,CHEMBL876817,,Intermediate,A,,1,,N,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,50597,BAO_0000218
11284,,,2081.0,1,Cardiac atrium,,CHEMBL624827,,Intermediate,A,,1,,N,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,50597,BAO_0000218
11285,,,,1,,,CHEMBL624828,,Intermediate,A,,1,,N,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,50597,BAO_0000218
11286,,,,1,,,CHEMBL624829,,Intermediate,A,,1,,N,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,50597,BAO_0000218
11287,,,2107.0,1,Liver,,CHEMBL624830,,Intermediate,A,,1,,N,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,50597,BAO_0000218
11288,,,2107.0,1,Liver,,CHEMBL624831,,Intermediate,A,,1,,N,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,50597,BAO_0000218
11289,,,2081.0,1,Cardiac atrium,,CHEMBL624832,,Intermediate,A,,1,,N,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,50597,BAO_0000218
11290,,,2081.0,1,Cardiac atrium,,CHEMBL624833,,Intermediate,A,,1,,N,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,50597,BAO_0000218
11291,,,,1,,,CHEMBL624834,,Intermediate,A,,1,,N,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,50597,BAO_0000218
11292,,,,1,,,CHEMBL624835,,Intermediate,A,,1,,N,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,50597,BAO_0000218
11293,,,2106.0,1,Spleen,,CHEMBL624836,,Intermediate,A,,1,,N,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,50597,BAO_0000218
11294,,,2106.0,1,Spleen,,CHEMBL624837,,Intermediate,A,,1,,N,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,50597,BAO_0000218
11295,,,178.0,1,Blood,,CHEMBL624838,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,,,50597,BAO_0000218
11296,,,178.0,1,Blood,,CHEMBL622188,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,,,50597,BAO_0000218
11297,,,948.0,1,Heart,,CHEMBL622189,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,,,50597,BAO_0000218
11298,,,948.0,1,Heart,,CHEMBL622190,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,,,50597,BAO_0000218
11299,,,948.0,1,Heart,,CHEMBL625170,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,,,50597,BAO_0000218
11300,,,2113.0,1,Kidney,,CHEMBL625171,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,,50597,BAO_0000218
11301,,,2113.0,1,Kidney,,CHEMBL625172,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,,50597,BAO_0000218
11302,,,2113.0,1,Kidney,,CHEMBL625173,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,,,50597,BAO_0000218
11303,,,2107.0,1,Liver,,CHEMBL625174,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,,,50597,BAO_0000218
11304,,,2107.0,1,Liver,,CHEMBL625175,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,,,50597,BAO_0000218
11305,,,2107.0,1,Liver,,CHEMBL625176,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,,,50597,BAO_0000218
11306,,,2048.0,1,Lung,,CHEMBL625177,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,,50597,BAO_0000218
11307,,,2048.0,1,Lung,,CHEMBL625178,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,,,50597,BAO_0000218
11308,,,2048.0,1,Lung,,CHEMBL625179,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,,,50597,BAO_0000218
11309,,,2048.0,1,Lung,,CHEMBL625180,,Intermediate,A,,1,,N,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,,50597,BAO_0000218
11310,,,,0,,,CHEMBL625181,,Autocuration,A,,1,,U,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,,22224,BAO_0000218
11311,,,1088.0,1,Urine,,CHEMBL625182,,Intermediate,A,,1,,N,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,,,50594,BAO_0000218
11312,,,,1,,,CHEMBL625183,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11313,,,,1,,,CHEMBL875848,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,,50597,BAO_0000218
11314,,,,1,,,CHEMBL622260,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11315,,,,1,,,CHEMBL622261,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,,50597,BAO_0000218
11316,,,,1,,,CHEMBL622262,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11317,,,2113.0,1,Kidney,,CHEMBL622263,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,50597,BAO_0000218
11318,,,2113.0,1,Kidney,,CHEMBL622418,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11319,,,2107.0,1,Liver,,CHEMBL622419,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,,50597,BAO_0000218
11320,,,,1,,In vivo,CHEMBL623388,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11321,,,2107.0,1,Liver,In vivo,CHEMBL623389,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11322,,,,1,,In vivo,CHEMBL623390,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11323,,,,1,,In vivo,CHEMBL623391,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11324,,,178.0,1,Blood,In vivo,CHEMBL623392,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11325,,,2037.0,1,Cerebellum,In vivo,CHEMBL623393,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11326,,,,1,,In vivo,CHEMBL623394,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11327,,,,1,,In vivo,CHEMBL618885,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11328,,,2107.0,1,Liver,In vivo,CHEMBL618886,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11329,,,,1,,In vivo,CHEMBL618887,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11330,,,,1,,In vivo,CHEMBL619535,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11331,,,178.0,1,Blood,In vivo,CHEMBL619536,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11332,,,2037.0,1,Cerebellum,In vivo,CHEMBL619537,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11333,,,,1,,In vivo,CHEMBL619705,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11334,,,,1,,In vivo,CHEMBL619706,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11335,,,2107.0,1,Liver,In vivo,CHEMBL619707,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11336,,,,1,,In vivo,CHEMBL619708,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11337,,,,1,,In vivo,CHEMBL625219,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11338,,,178.0,1,Blood,In vivo,CHEMBL625220,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11339,,,2037.0,1,Cerebellum,In vivo,CHEMBL625221,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11340,,,,1,,In vivo,CHEMBL625222,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11341,,,,1,,In vivo,CHEMBL625223,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11342,,,2107.0,1,Liver,In vivo,CHEMBL625224,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11343,,,,1,,In vivo,CHEMBL625225,,Intermediate,A,,1,,N,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,,50594,BAO_0000218
11344,,,178.0,1,Blood,In vivo,CHEMBL625226,,Intermediate,A,,1,,N,Biodistribution in Rat blood after 24 hours of iv administration,,,50597,BAO_0000218
11345,,,178.0,1,Blood,In vivo,CHEMBL625227,,Intermediate,A,,1,,N,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,,,50597,BAO_0000218
11346,,,178.0,1,Blood,In vivo,CHEMBL625228,,Intermediate,A,,1,,N,Biodistribution in Rat blood after 30 minutes of iv administration,,,50597,BAO_0000218
11347,,,178.0,1,Blood,In vivo,CHEMBL875354,,Intermediate,A,,1,,N,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,,,50597,BAO_0000218
11348,,,178.0,1,Blood,In vivo,CHEMBL625229,,Intermediate,A,,1,,N,Biodistribution in Rat blood after 5 minutes of iv administration,,,50597,BAO_0000218
11349,,,178.0,1,Blood,In vivo,CHEMBL625230,,Intermediate,A,,1,,N,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,,,50597,BAO_0000218
11350,,,948.0,1,Heart,In vivo,CHEMBL625231,,Intermediate,A,,1,,N,Biodistribution in Rat heart after 24 hours of iv administration,,,50597,BAO_0000218
11351,,,948.0,1,Heart,In vivo,CHEMBL625900,,Intermediate,A,,1,,N,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,,,50597,BAO_0000218
11352,,,948.0,1,Heart,In vivo,CHEMBL625901,,Intermediate,A,,1,,N,Biodistribution in Rat heart after 30 minutes of iv administration,,,50597,BAO_0000218
11353,,,948.0,1,Heart,In vivo,CHEMBL625902,,Intermediate,A,,1,,N,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,,,50597,BAO_0000218
11354,,,948.0,1,Heart,In vivo,CHEMBL625903,,Intermediate,A,,1,,N,Biodistribution in Rat heart after 5 minutes of iv administration,,,50597,BAO_0000218
11355,,,948.0,1,Heart,In vivo,CHEMBL625904,,Intermediate,A,,1,,N,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,,,50597,BAO_0000218
11356,,,2107.0,1,Liver,In vivo,CHEMBL625905,,Intermediate,A,,1,,N,Biodistribution in Rat liver after 24 hours of iv administration,,,50597,BAO_0000218
11357,,,2107.0,1,Liver,In vivo,CHEMBL627861,,Intermediate,A,,1,,N,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,,,50597,BAO_0000218
11358,,,2107.0,1,Liver,In vivo,CHEMBL627862,,Intermediate,A,,1,,N,Biodistribution in Rat liver after 30 minutes of iv administration,,,50597,BAO_0000218
11359,,,2107.0,1,Liver,In vivo,CHEMBL627863,,Intermediate,A,,1,,N,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,,50597,BAO_0000218
11360,,,2107.0,1,Liver,In vivo,CHEMBL627769,,Intermediate,A,,1,,N,Biodistribution in Rat liver after 30 minutes of iv administration,,,50597,BAO_0000218
11361,,,1969.0,1,Plasma,In vivo,CHEMBL627770,,Intermediate,A,,1,,N,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,,50588,BAO_0000218
11362,,,,1,,In vivo,CHEMBL627771,,Intermediate,A,,1,,N,Cmax in cynomolgus monkey (PO dose),,,100710,BAO_0000218
11363,,,,1,,In vivo,CHEMBL627772,,Intermediate,A,,1,,N,Cmax in rat (PO dose),,,50597,BAO_0000218
11364,,,,1,,In vivo,CHEMBL627773,,Intermediate,A,,1,,N,Cmax in rat (PO dose),,,50597,BAO_0000218
11365,,,1969.0,1,Plasma,In vivo,CHEMBL621922,,Intermediate,A,,1,,N,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,,,50597,BAO_0000218
11366,,,1969.0,1,Plasma,In vivo,CHEMBL621923,,Intermediate,A,,1,,N,Cmax in rat plasma after oral dose (10 mg/kg),,,50597,BAO_0000218
11367,,,1969.0,0,Plasma,In vivo,CHEMBL621924,,Autocuration,A,,1,,U,Cmax in plasma after oral dose (10 mg/kg),,,22224,BAO_0000218
11368,,,1969.0,1,Plasma,In vivo,CHEMBL621925,,Intermediate,A,,1,,N,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,,,50588,BAO_0000218
11369,,,1969.0,0,Plasma,In vivo,CHEMBL621926,,Autocuration,A,,1,,U,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,,,22224,BAO_0000218
11370,,,1969.0,1,Plasma,In vivo,CHEMBL621927,,Intermediate,A,,1,,N,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,,,50592,BAO_0000218
11371,,,1969.0,1,Plasma,In vivo,CHEMBL621928,,Intermediate,A,,1,,N,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,,,50597,BAO_0000218
11372,,,1969.0,1,Plasma,In vivo,CHEMBL621929,,Intermediate,A,,1,,N,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,,,50597,BAO_0000218
11373,,,1969.0,1,Plasma,In vivo,CHEMBL621930,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,,,50594,BAO_0000218
11374,,,1969.0,1,Plasma,In vivo,CHEMBL621931,,Intermediate,A,,1,,N,Maximum plasma concentration after oral dosing in rat,,,50597,BAO_0000218
11375,,,1969.0,0,Plasma,In vivo,CHEMBL621932,,Autocuration,A,,1,,U,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11376,,,1969.0,0,Plasma,In vivo,CHEMBL621933,,Autocuration,A,,1,,U,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11377,,,1969.0,1,Plasma,In vivo,CHEMBL621934,,Intermediate,A,,1,,N,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,,,50588,BAO_0000218
11378,,,1969.0,1,Plasma,In vivo,CHEMBL621935,,Intermediate,A,,1,,N,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,,,50588,BAO_0000218
11379,,,1969.0,1,Plasma,In vivo,CHEMBL621936,,Intermediate,A,,1,,N,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,,,50597,BAO_0000218
11380,,,1969.0,0,Plasma,In vivo,CHEMBL621937,,Autocuration,A,,1,,U,Maximum plasma concentration was determined,,,22224,BAO_0000218
11381,,,1969.0,0,Plasma,In vivo,CHEMBL621938,,Autocuration,A,,1,,U,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11382,,,1969.0,0,Plasma,In vivo,CHEMBL621939,,Autocuration,A,,1,,U,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11383,,,1969.0,0,Plasma,In vivo,CHEMBL621940,,Autocuration,A,,1,,U,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11384,,,1969.0,0,Plasma,In vivo,CHEMBL621941,,Autocuration,A,,1,,U,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11385,,,1969.0,0,Plasma,In vivo,CHEMBL621942,,Autocuration,A,,1,,U,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11386,,,1969.0,0,Plasma,In vivo,CHEMBL626178,,Autocuration,A,,1,,U,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11387,,,1969.0,0,Plasma,In vivo,CHEMBL626179,,Autocuration,A,,1,,U,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11388,,,1969.0,0,Plasma,In vivo,CHEMBL626180,,Autocuration,A,,1,,U,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11389,,,1969.0,1,Plasma,In vivo,CHEMBL626181,,Intermediate,A,,1,,N,Plasma Cmax in rat (PO dose),,,50597,BAO_0000218
11390,,,,1,,In vivo,CHEMBL626182,,Intermediate,A,,1,,N,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,,50597,BAO_0000218
11391,,,,1,,In vivo,CHEMBL626183,,Intermediate,A,,1,,N,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,,50597,BAO_0000218
11392,,,,1,,In vivo,CHEMBL626184,,Intermediate,A,,1,,N,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,,50597,BAO_0000218
11393,,,,1,,In vivo,CHEMBL626185,,Intermediate,A,,1,,N,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,,50597,BAO_0000218
11394,,,1969.0,1,Plasma,In vivo,CHEMBL626186,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,,,50588,BAO_0000218
11395,,,1969.0,1,Plasma,In vivo,CHEMBL877589,,Intermediate,A,,1,,N,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,,,50588,BAO_0000218
11396,,,,0,,In vivo,CHEMBL626187,,Autocuration,A,,1,,U,Maximum concentration of the drug at 1 uM/dg administered intravenously,,,22224,BAO_0000218
11397,,,,0,,In vivo,CHEMBL626188,,Autocuration,A,,1,,U,Maximum concentration of the drug at 20 uM/dg administered perorally,,,22224,BAO_0000218
11398,,,,0,,In vivo,CHEMBL626189,,Autocuration,A,,1,,U,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,,22224,BAO_0000218
11399,,,178.0,0,Blood,In vivo,CHEMBL626855,,Autocuration,A,,1,,U,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,,22224,BAO_0000218
11400,,,178.0,0,Blood,In vivo,CHEMBL623781,,Autocuration,A,,1,,U,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,,22224,BAO_0000218
11401,,,178.0,0,Blood,In vivo,CHEMBL623782,,Autocuration,A,,1,,U,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,,22224,BAO_0000218
11402,,,1969.0,1,Plasma,In vivo,CHEMBL623783,,Intermediate,A,,1,,N,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,,,50597,BAO_0000218
11403,,,1969.0,1,Plasma,In vivo,CHEMBL623784,,Intermediate,A,,1,,N,Cmax in dog plasma after 1mg/kg oral dose,,,50588,BAO_0000218
11404,,,1969.0,1,Plasma,In vivo,CHEMBL623785,,Intermediate,A,,1,,N,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,,,50588,BAO_0000218
11405,,,1969.0,1,Plasma,In vivo,CHEMBL623786,,Intermediate,A,,1,,N,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,,,50597,BAO_0000218
11406,,,,1,,In vivo,CHEMBL623787,,Intermediate,A,,1,,N,Oral maximum concentration in rat,,,50597,BAO_0000218
11407,,,,1,,In vivo,CHEMBL623788,,Intermediate,A,,1,,N,Oral maximum concentration in rat,,,50597,BAO_0000218
11408,,,1969.0,1,Plasma,In vivo,CHEMBL623789,,Intermediate,A,,1,,N,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,,,50594,BAO_0000218
11409,,,178.0,1,Blood,In vivo,CHEMBL623790,,Intermediate,A,,1,,N,Peak concentration in blood after intravenous administration to mice,,,50594,BAO_0000218
11410,,,178.0,1,Blood,In vivo,CHEMBL623791,,Intermediate,A,,1,,N,Peak concentration in blood after peroral administration to mice,,,50594,BAO_0000218
11411,,,1969.0,1,Plasma,In vivo,CHEMBL623792,,Intermediate,A,,1,,N,Peak concentration in rat plasma was determined,,,50597,BAO_0000218
11412,,,1969.0,0,Plasma,In vivo,CHEMBL623793,,Autocuration,A,,1,,U,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,,,22224,BAO_0000218
11413,,,1969.0,1,Plasma,In vivo,CHEMBL623794,,Intermediate,A,,1,,N,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,,,50594,BAO_0000218
11414,,,1969.0,1,Plasma,In vivo,CHEMBL623795,,Intermediate,A,,1,,N,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,,,50597,BAO_0000218
11415,,,,1,,,CHEMBL623796,,Intermediate,A,,1,,N,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11416,,,,1,,,CHEMBL623797,,Intermediate,A,,1,,N,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11417,,,,1,,,CHEMBL623798,,Intermediate,A,,1,,N,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11418,,,,1,,,CHEMBL623799,,Intermediate,A,,1,,N,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11419,,,160.0,1,Intestine,,CHEMBL624490,,Intermediate,A,,1,,N,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11420,,,160.0,1,Intestine,,CHEMBL624491,,Intermediate,A,,1,,N,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11421,,,160.0,1,Intestine,,CHEMBL624492,,Intermediate,A,,1,,N,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11422,,,160.0,1,Intestine,,CHEMBL624493,,Intermediate,A,,1,,N,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11423,,,160.0,1,Intestine,,CHEMBL877595,,Intermediate,A,,1,,N,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11424,,,160.0,1,Intestine,,CHEMBL624494,,Intermediate,A,,1,,N,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11425,,,160.0,1,Intestine,,CHEMBL624495,,Intermediate,A,,1,,N,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11426,,,160.0,1,Intestine,,CHEMBL624681,,Intermediate,A,,1,,N,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11427,,,,1,,,CHEMBL624682,,Intermediate,A,,1,,N,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11428,,,,1,,,CHEMBL624683,,Intermediate,A,,1,,N,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11429,,,,1,,,CHEMBL624684,,Intermediate,A,,1,,N,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11430,,,,1,,,CHEMBL624685,,Intermediate,A,,1,,N,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11431,,,,1,,,CHEMBL624686,,Intermediate,A,,1,,N,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11432,,,,1,,,CHEMBL624687,,Intermediate,A,,1,,N,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11433,,,,1,,,CHEMBL624688,,Intermediate,A,,1,,N,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11434,,,,1,,,CHEMBL627161,,Intermediate,A,,1,,N,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11435,,,,1,,,CHEMBL622127,,Intermediate,A,,1,,N,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11436,,,,1,,,CHEMBL622128,,Intermediate,A,,1,,N,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11437,,,,1,,,CHEMBL874384,,Intermediate,A,,1,,N,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11438,,,,1,,,CHEMBL624898,,Intermediate,A,,1,,N,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11439,,,,1,,,CHEMBL624899,,Intermediate,A,,1,,N,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11440,,,,1,,,CHEMBL624900,,Intermediate,A,,1,,N,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11441,,,,1,,,CHEMBL624901,,Intermediate,A,,1,,N,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11442,,,,1,,,CHEMBL624902,,Intermediate,A,,1,,N,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11443,,,,1,,,CHEMBL624903,,Intermediate,A,,1,,N,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11444,,,,1,,,CHEMBL624904,,Intermediate,A,,1,,N,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11445,,,,1,,,CHEMBL624905,,Intermediate,A,,1,,N,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11446,,,,1,,,CHEMBL624906,,Intermediate,A,,1,,N,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11447,,,,1,,,CHEMBL624907,,Intermediate,A,,1,,N,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11448,,,,1,,,CHEMBL624908,,Intermediate,A,,1,,N,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11449,,,,1,,,CHEMBL624909,,Intermediate,A,,1,,N,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11450,,,,1,,,CHEMBL624910,,Intermediate,A,,1,,N,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11451,,,2385.0,1,Muscle tissue,,CHEMBL624911,,Intermediate,A,,1,,N,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11452,,,2385.0,1,Muscle tissue,,CHEMBL874388,,Intermediate,A,,1,,N,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11453,,,2385.0,1,Muscle tissue,,CHEMBL624912,,Intermediate,A,,1,,N,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11454,,,2385.0,1,Muscle tissue,,CHEMBL622930,,Intermediate,A,,1,,N,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11455,,,2385.0,1,Muscle tissue,,CHEMBL623121,,Intermediate,A,,1,,N,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11456,,,2385.0,1,Muscle tissue,,CHEMBL623122,,Intermediate,A,,1,,N,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11457,,,2385.0,1,Muscle tissue,,CHEMBL623123,,Intermediate,A,,1,,N,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11458,,,2385.0,1,Muscle tissue,,CHEMBL623124,,Intermediate,A,,1,,N,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11459,,,,1,,,CHEMBL623125,,Intermediate,A,,1,,N,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11460,,,,1,,,CHEMBL623126,,Intermediate,A,,1,,N,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11461,,,,1,,,CHEMBL623127,,Intermediate,A,,1,,N,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11462,,,,1,,,CHEMBL623128,,Intermediate,A,,1,,N,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11463,,,,1,,,CHEMBL623129,,Intermediate,A,,1,,N,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11464,,,,1,,,CHEMBL623130,,Intermediate,A,,1,,N,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11465,,,,1,,,CHEMBL623131,,Intermediate,A,,1,,N,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11466,,,,1,,,CHEMBL623132,,Intermediate,A,,1,,N,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11467,,,2107.0,1,Liver,,CHEMBL623133,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11468,,,,1,,,CHEMBL623134,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11469,,,,1,,,CHEMBL874389,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11470,,,,1,,,CHEMBL623135,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,,50597,BAO_0000218
11471,,,,1,,,CHEMBL623136,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11472,,,,1,,,CHEMBL623137,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,,50597,BAO_0000218
11473,,,,1,,,CHEMBL623138,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11474,,,2113.0,1,Kidney,,CHEMBL623139,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,50597,BAO_0000218
11475,,,2113.0,1,Kidney,,CHEMBL623140,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11476,,,2107.0,1,Liver,,CHEMBL623141,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,,50597,BAO_0000218
11477,,,2107.0,1,Liver,,CHEMBL623142,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11478,,,,1,,,CHEMBL623143,,Intermediate,A,,1,,N,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11479,,,1088.0,1,Urine,,CHEMBL623144,,Intermediate,A,,1,,N,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,,,50594,BAO_0000218
11480,,,1088.0,1,Urine,,CHEMBL623405,,Intermediate,A,,1,,N,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,,,50597,BAO_0000218
11481,,,,1,,,CHEMBL624074,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11482,,,,1,,,CHEMBL624075,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,,50597,BAO_0000218
11483,,,,1,,,CHEMBL624076,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11484,,,,1,,,CHEMBL624077,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,,50597,BAO_0000218
11485,,,,1,,,CHEMBL624078,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11486,,,2113.0,1,Kidney,,CHEMBL624079,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,50597,BAO_0000218
11487,,,2113.0,1,Kidney,,CHEMBL624261,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11488,,,,1,,,CHEMBL624262,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,,50597,BAO_0000218
11489,,,,1,,,CHEMBL624263,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11490,,,,1,,,CHEMBL624264,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11491,,,,1,,,CHEMBL624265,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11492,,,,1,,,CHEMBL624266,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,,50597,BAO_0000218
11493,,,,1,,,CHEMBL624267,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11494,,,,1,,,CHEMBL624268,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,,50597,BAO_0000218
11495,,,,1,,,CHEMBL875227,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11496,,,2113.0,1,Kidney,,CHEMBL624269,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,50597,BAO_0000218
11497,,,2113.0,1,Kidney,,CHEMBL624270,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11498,,,,1,,,CHEMBL624271,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,,50597,BAO_0000218
11499,,,,1,,,CHEMBL624272,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11500,,,,1,,,CHEMBL624273,,Intermediate,A,,1,,N,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,50597,BAO_0000218
11501,,,1088.0,1,Urine,,CHEMBL624274,,Intermediate,A,,1,,N,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,,,50597,BAO_0000218
11502,,,1088.0,1,Urine,,CHEMBL624275,,Intermediate,A,,1,,N,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,,,50597,BAO_0000218
11503,,,1088.0,1,Urine,,CHEMBL624276,,Intermediate,A,,1,,N,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,,,50597,BAO_0000218
11504,,,1088.0,1,Urine,,CHEMBL624277,,Intermediate,A,,1,,N,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,,,50597,BAO_0000218
11505,,,,0,,,CHEMBL624278,,Autocuration,A,,1,,U,% dose converted to 2-amino-5-chlorophenyl sulfate,,,22224,BAO_0000019
11506,,,,0,,,CHEMBL624279,,Autocuration,A,,1,,U,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,,22224,BAO_0000019
11507,,,1988.0,1,Feces,,CHEMBL624280,,Intermediate,A,,1,,N,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,,50597,BAO_0000218
11508,,,1988.0,1,Feces,,CHEMBL624281,,Intermediate,A,,1,,N,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,,50597,BAO_0000218
11509,,,1988.0,1,Feces,,CHEMBL622933,,Intermediate,A,,1,,N,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,,50597,BAO_0000218
11510,,,1988.0,1,Feces,,CHEMBL622934,,Intermediate,A,,1,,N,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,,50597,BAO_0000218
11511,,,2107.0,1,Liver,In vivo,CHEMBL622935,,Intermediate,A,,1,,N,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,,50597,BAO_0000218
11512,,,2107.0,1,Liver,In vivo,CHEMBL622936,,Intermediate,A,,1,,N,Biodistribution in Rat liver after 5 minutes of iv administration,,,50597,BAO_0000218
11513,,,2107.0,1,Liver,In vivo,CHEMBL875228,,Intermediate,A,,1,,N,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,,,50597,BAO_0000218
11514,,,2048.0,1,Lung,In vivo,CHEMBL622937,,Intermediate,A,,1,,N,Biodistribution in Rat lung after 24 hours of iv administration,,,50597,BAO_0000218
11515,,,2048.0,1,Lung,In vivo,CHEMBL622938,,Intermediate,A,,1,,N,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,,,50597,BAO_0000218
11516,,,2048.0,1,Lung,In vivo,CHEMBL619736,,Intermediate,A,,1,,N,Biodistribution in Rat lung after 30 minutes of iv administration,,,50597,BAO_0000218
11517,,,2048.0,1,Lung,In vivo,CHEMBL625117,,Intermediate,A,,1,,N,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,,,50597,BAO_0000218
11518,,,2048.0,1,Lung,In vivo,CHEMBL625118,,Intermediate,A,,1,,N,Biodistribution in Rat lung after 5 minutes of iv administration,,,50597,BAO_0000218
11519,,,2048.0,1,Lung,In vivo,CHEMBL625119,,Intermediate,A,,1,,N,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,,,50597,BAO_0000218
11520,,,2037.0,1,Cerebellum,In vivo,CHEMBL625120,,Intermediate,A,,1,,N,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",,,50597,BAO_0000218
11521,,,,1,,In vivo,CHEMBL625121,,Intermediate,A,,1,,N,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,,50597,BAO_0000218
11522,,,10000006.0,1,Thalamus,In vivo,CHEMBL625122,,Intermediate,A,,1,,N,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",,,50597,BAO_0000218
11523,,,178.0,1,Blood,In vivo,CHEMBL622204,,Intermediate,A,,1,,N,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11524,,,178.0,1,Blood,In vivo,CHEMBL877503,,Intermediate,A,,1,,N,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11525,,,178.0,1,Blood,In vivo,CHEMBL627127,,Intermediate,A,,1,,N,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11526,,,10000000.0,0,Hippocampus,In vivo,CHEMBL627128,,Autocuration,A,,1,,U,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,22224,BAO_0000218
11527,,,10000000.0,0,Hippocampus,In vivo,CHEMBL627129,,Autocuration,A,,1,,U,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,22224,BAO_0000218
11528,,,10000000.0,0,Hippocampus,In vivo,CHEMBL627130,,Autocuration,A,,1,,U,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,22224,BAO_0000218
11529,,,955.0,1,Brain,In vivo,CHEMBL627131,,Intermediate,A,,1,,N,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11530,,,955.0,1,Brain,In vivo,CHEMBL627132,,Intermediate,A,,1,,N,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11531,,,955.0,1,Brain,In vivo,CHEMBL627133,,Intermediate,A,,1,,N,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11532,,,2037.0,1,Cerebellum,In vivo,CHEMBL627134,,Intermediate,A,,1,,N,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11533,,,2037.0,1,Cerebellum,In vivo,CHEMBL627135,,Intermediate,A,,1,,N,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11534,,,2037.0,1,Cerebellum,In vivo,CHEMBL627136,,Intermediate,A,,1,,N,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11535,,,,1,,In vivo,CHEMBL628435,,Intermediate,A,,1,,N,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11536,,,,1,,In vivo,CHEMBL628436,,Intermediate,A,,1,,N,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11537,,,,1,,In vivo,CHEMBL628437,,Intermediate,A,,1,,N,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11538,,,948.0,1,Heart,In vivo,CHEMBL628438,,Intermediate,A,,1,,N,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11539,,,948.0,1,Heart,In vivo,CHEMBL628439,,Intermediate,A,,1,,N,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11540,,,948.0,1,Heart,In vivo,CHEMBL628440,,Intermediate,A,,1,,N,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11541,,,10000000.0,1,Hippocampus,In vivo,CHEMBL628441,,Intermediate,A,,1,,N,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11542,,,10000000.0,1,Hippocampus,In vivo,CHEMBL628442,,Intermediate,A,,1,,N,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11543,,,10000000.0,1,Hippocampus,In vivo,CHEMBL628443,,Intermediate,A,,1,,N,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11544,,,2113.0,1,Kidney,In vivo,CHEMBL628444,,Intermediate,A,,1,,N,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11545,,,2113.0,1,Kidney,In vivo,CHEMBL628445,,Intermediate,A,,1,,N,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11546,,,2113.0,1,Kidney,In vivo,CHEMBL877504,,Intermediate,A,,1,,N,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11547,,,2107.0,1,Liver,In vivo,CHEMBL628446,,Intermediate,A,,1,,N,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11548,,,2107.0,1,Liver,In vivo,CHEMBL626874,,Intermediate,A,,1,,N,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11549,,,2107.0,1,Liver,In vivo,CHEMBL626875,,Intermediate,A,,1,,N,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11550,,,2048.0,1,Lung,In vivo,CHEMBL626876,,Intermediate,A,,1,,N,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11551,,,2048.0,1,Lung,In vivo,CHEMBL626877,,Intermediate,A,,1,,N,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11552,,,2048.0,1,Lung,In vivo,CHEMBL626878,,Intermediate,A,,1,,N,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11553,,,2385.0,1,Muscle tissue,In vivo,CHEMBL626879,,Intermediate,A,,1,,N,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11554,,,1969.0,0,Plasma,In vivo,CHEMBL626880,,Autocuration,A,,1,,U,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,,,22224,BAO_0000218
11555,,,1969.0,1,Plasma,In vivo,CHEMBL626881,,Intermediate,A,,1,,N,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,,,50594,BAO_0000218
11556,,,1969.0,1,Plasma,In vivo,CHEMBL626882,,Intermediate,A,,1,,N,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,,,50597,BAO_0000218
11557,,,1969.0,1,Plasma,In vivo,CHEMBL626883,,Intermediate,A,,1,,N,Peak plasma concentration was measured in dogs,,,50588,BAO_0000218
11558,,,,1,,In vivo,CHEMBL626884,,Intermediate,A,,1,,N,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,BAO_0000218
11559,,,,1,,In vivo,CHEMBL626885,,Intermediate,A,,1,,N,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,,50597,BAO_0000218
11560,,,,1,,In vivo,CHEMBL626886,,Intermediate,A,,1,,N,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,,50597,BAO_0000218
11561,,,,1,,In vivo,CHEMBL626887,,Intermediate,A,,1,,N,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,,50597,BAO_0000218
11562,,,,1,,In vivo,CHEMBL626888,,Intermediate,A,,1,,N,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,BAO_0000218
11563,,,,1,,In vivo,CHEMBL626889,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,,50588,BAO_0000218
11564,,,,0,,In vivo,CHEMBL626761,,Autocuration,A,,1,,U,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,,22224,BAO_0000218
11565,,,,1,,In vivo,CHEMBL626762,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,,50588,BAO_0000218
11566,,,,1,,In vivo,CHEMBL626763,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,,50588,BAO_0000218
11567,,,,1,,In vivo,CHEMBL626764,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,,50597,BAO_0000218
11568,,,,1,,In vivo,CHEMBL626765,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,,50597,BAO_0000218
11569,,,,1,,In vivo,CHEMBL626766,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,,50588,BAO_0000218
11570,,,,1,,In vivo,CHEMBL626767,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,,50597,BAO_0000218
11571,,,,1,,In vivo,CHEMBL626768,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,,50597,BAO_0000218
11572,,,,1,,In vivo,CHEMBL626769,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,,50588,BAO_0000218
11573,,,,1,,In vivo,CHEMBL874463,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,,50588,BAO_0000218
11574,,,,0,,In vivo,CHEMBL626770,,Autocuration,A,,1,,U,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,,22224,BAO_0000218
11575,,,,0,,In vivo,CHEMBL626771,,Autocuration,A,,1,,U,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,,22224,BAO_0000218
11576,,,,1,,In vivo,CHEMBL626772,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,,50597,BAO_0000218
11577,,,,1,,In vivo,CHEMBL626773,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,,100710,BAO_0000218
11578,,,,1,,In vivo,CHEMBL626774,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,,50594,BAO_0000218
11579,,,,1,,In vivo,CHEMBL626775,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,,50588,BAO_0000218
11580,,,,1,,In vivo,CHEMBL626776,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,,50588,BAO_0000218
11581,,,,1,,In vivo,CHEMBL626777,,Intermediate,A,,1,,N,Maximum concentration (Cmax) in rat when administered orally,,,50597,BAO_0000218
11582,,,1969.0,0,Plasma,In vivo,CHEMBL626778,,Autocuration,A,,1,,U,Maximal concentration in monkey plasma after 25 mg/kg oral dose,,,22224,BAO_0000218
11583,,,,0,,In vivo,CHEMBL626779,,Autocuration,A,,1,,U,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,,22224,BAO_0000218
11584,,,,0,,In vivo,CHEMBL626780,,Autocuration,A,,1,,U,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,,22224,BAO_0000218
11585,,,1969.0,0,Plasma,In vivo,CHEMBL626781,,Autocuration,A,,1,,U,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,,,22224,BAO_0000218
11586,,,,1,,In vivo,CHEMBL632164,,Intermediate,A,,1,,N,Pharmacokinetic profile Cmax was evaluated in rats,,,50597,BAO_0000218
11587,,,,1,,In vivo,CHEMBL632165,,Intermediate,A,,1,,N,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,,50588,BAO_0000218
11588,,,,1,,In vivo,CHEMBL632166,,Intermediate,A,,1,,N,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,,50594,BAO_0000218
11589,,,,1,,In vivo,CHEMBL632167,,Intermediate,A,,1,,N,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,,50588,BAO_0000218
11590,,,,1,,In vivo,CHEMBL632168,,Intermediate,A,,1,,N,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,,50594,BAO_0000218
11591,,,1969.0,0,Plasma,In vivo,CHEMBL632169,,Autocuration,A,,1,,U,Cmax in rat plasma,,,22224,BAO_0000218
11592,,,1969.0,1,Plasma,In vivo,CHEMBL632170,,Intermediate,A,,1,,N,Cmax in dog plasma after 30mg/kg oral dose,,,50588,BAO_0000218
11593,,,1969.0,1,Plasma,In vivo,CHEMBL632171,,Intermediate,A,,1,,N,Cmax in rat plasma after 30mg/kg oral dose,,,50597,BAO_0000218
11594,,,1969.0,1,Plasma,In vivo,CHEMBL632172,,Intermediate,A,,1,,N,Plasma level in rats at 30 mg/kg,,,50597,BAO_0000218
11595,,,1969.0,1,Plasma,In vivo,CHEMBL632173,,Intermediate,A,,1,,N,Tested for maximum plasma concentration in mice,,,50594,BAO_0000218
11596,,,,1,,In vivo,CHEMBL632174,,Intermediate,A,,1,,N,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
11597,,,,1,,In vivo,CHEMBL632175,,Intermediate,A,,1,,N,The Cmax values in female wistar rats.,,,50597,BAO_0000218
11598,,,1969.0,1,Plasma,In vivo,CHEMBL632176,,Intermediate,A,,1,,N,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,,,50588,BAO_0000218
11599,,,1969.0,1,Plasma,In vivo,CHEMBL632177,,Intermediate,A,,1,,N,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,,,50597,BAO_0000218
11600,,,1969.0,1,Plasma,In vivo,CHEMBL632178,,Intermediate,A,,1,,N,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,,,50597,BAO_0000218
11601,,,,1,,In vivo,CHEMBL632179,,Intermediate,A,,1,,N,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,,50597,BAO_0000218
11602,,,178.0,1,Blood,In vivo,CHEMBL632180,,Intermediate,A,,1,,N,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,,,50597,BAO_0000218
11603,,,178.0,1,Blood,In vivo,CHEMBL632181,,Intermediate,A,,1,,N,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,,,50597,BAO_0000218
11604,,,178.0,1,Blood,In vivo,CHEMBL632182,,Intermediate,A,,1,,N,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,,,50597,BAO_0000218
11605,,,178.0,0,Blood,In vivo,CHEMBL632183,,Autocuration,A,,1,,U,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,,,22224,BAO_0000218
11606,,,,1,,In vivo,CHEMBL632184,,Intermediate,A,,1,,N,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,,50588,BAO_0000218
11607,,,,1,,In vivo,CHEMBL874470,,Intermediate,A,,1,,N,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,,50597,BAO_0000218
11608,,,,1,,,CHEMBL631302,,Intermediate,A,,1,,N,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11609,,,,1,,,CHEMBL631303,,Intermediate,A,,1,,N,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11610,,,,1,,,CHEMBL631304,,Intermediate,A,,1,,N,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11611,,,,1,,,CHEMBL631305,,Intermediate,A,,1,,N,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11612,,,,1,,,CHEMBL631306,,Intermediate,A,,1,,N,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11613,,,,1,,,CHEMBL631307,,Intermediate,A,,1,,N,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11614,,,,1,,,CHEMBL631308,,Intermediate,A,,1,,N,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11615,,,,1,,,CHEMBL625557,,Intermediate,A,,1,,N,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11616,,,2106.0,1,Spleen,,CHEMBL625558,,Intermediate,A,,1,,N,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11617,,,2106.0,1,Spleen,,CHEMBL625559,,Intermediate,A,,1,,N,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11618,,,2106.0,1,Spleen,,CHEMBL625560,,Intermediate,A,,1,,N,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11619,,,2106.0,1,Spleen,,CHEMBL625561,,Intermediate,A,,1,,N,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11620,,,2106.0,1,Spleen,,CHEMBL625562,,Intermediate,A,,1,,N,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11621,,,2106.0,1,Spleen,,CHEMBL875320,,Intermediate,A,,1,,N,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11622,,,2106.0,1,Spleen,,CHEMBL625563,,Intermediate,A,,1,,N,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11623,,,2106.0,1,Spleen,,CHEMBL625564,,Intermediate,A,,1,,N,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11624,,,995.0,1,Uterus,,CHEMBL625565,,Intermediate,A,,1,,N,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11625,,,995.0,1,Uterus,,CHEMBL625566,,Intermediate,A,,1,,N,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11626,,,995.0,1,Uterus,,CHEMBL625567,,Intermediate,A,,1,,N,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11627,,,995.0,1,Uterus,,CHEMBL625568,,Intermediate,A,,1,,N,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11628,,,995.0,1,Uterus,,CHEMBL628217,,Intermediate,A,,1,,N,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11629,,,995.0,1,Uterus,,CHEMBL628218,,Intermediate,A,,1,,N,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11630,,,995.0,1,Uterus,,CHEMBL628219,,Intermediate,A,,1,,N,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11631,,,995.0,1,Uterus,,CHEMBL628220,,Intermediate,A,,1,,N,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",,,50597,BAO_0000218
11632,,,,0,,,CHEMBL628221,,Autocuration,A,,1,,U,Distribution in the blood after 120 min of intravenous administration,,,22224,BAO_0000019
11633,,,,0,,,CHEMBL628222,,Autocuration,A,,1,,U,Distribution in the blood after 15 min of intravenous administration,,,22224,BAO_0000019
11634,,,,0,,,CHEMBL628223,,Autocuration,A,,1,,U,Distribution in the blood after 30 min of intravenous administration,,,22224,BAO_0000019
11635,,,,0,,,CHEMBL628224,,Autocuration,A,,1,,U,Distribution in the blood after 5 min of intravenous administration,,,22224,BAO_0000019
11636,,,,0,,,CHEMBL628225,,Autocuration,A,,1,,U,Distribution in the blood after 60 min of intravenous administration,,,22224,BAO_0000019
11637,,,,0,,,CHEMBL628226,,Autocuration,A,,1,,U,Distribution in the blood after 90 min of intravenous administration,,,22224,BAO_0000019
11638,,,,0,,,CHEMBL628227,,Autocuration,A,,1,,U,Distribution in the bone after 120 min of intravenous administration,,,22224,BAO_0000019
11639,,,,0,,,CHEMBL875481,,Autocuration,A,,1,,U,Distribution in the bone after 15 min of intravenous administration,,,22224,BAO_0000019
11640,,,,0,,,CHEMBL628228,,Autocuration,A,,1,,U,Distribution in the bone after 30 min of intravenous administration,,,22224,BAO_0000019
11641,,,,0,,,CHEMBL628229,,Autocuration,A,,1,,U,Distribution in the bone after 5 min of intravenous administration,,,22224,BAO_0000019
11642,,,,0,,,CHEMBL628230,,Autocuration,A,,1,,U,Distribution in the bone after 60 min of intravenous administration,,,22224,BAO_0000019
11643,,,,0,,,CHEMBL628231,,Autocuration,A,,1,,U,Distribution in the bone after 90 min of intravenous administration,,,22224,BAO_0000019
11644,,,,0,,,CHEMBL628232,,Autocuration,A,,1,,U,Distribution in the heart after 120 min of intravenous administration,,,22224,BAO_0000019
11645,,,,0,,,CHEMBL628233,,Autocuration,A,,1,,U,Distribution in the heart after 15 min of intravenous administration,,,22224,BAO_0000019
11646,,,,0,,,CHEMBL628234,,Autocuration,A,,1,,U,Distribution in the heart after 30 min of intravenous administration,,,22224,BAO_0000019
11647,,,,0,,,CHEMBL628235,,Autocuration,A,,1,,U,Distribution in the heart after 5 min of intravenous administration,,,22224,BAO_0000019
11648,,,,0,,,CHEMBL628236,,Autocuration,A,,1,,U,Distribution in the heart after 60 min of intravenous administration,,,22224,BAO_0000019
11649,,,,0,,,CHEMBL628237,,Autocuration,A,,1,,U,Distribution in the heart after 90 min of intravenous administration,,,22224,BAO_0000019
11650,,,,0,,,CHEMBL628238,,Autocuration,A,,1,,U,Distribution in the kidneys after 120 min of intravenous administration,,,22224,BAO_0000019
11651,,,,0,,,CHEMBL628239,,Autocuration,A,,1,,U,Distribution in the kidneys after 15 min of intravenous administration,,,22224,BAO_0000019
11652,,,,0,,,CHEMBL628240,,Autocuration,A,,1,,U,Distribution in the kidneys after 30 min of intravenous administration,,,22224,BAO_0000019
11653,,,,0,,,CHEMBL628241,,Autocuration,A,,1,,U,Distribution in the kidneys after 5 min of intravenous administration,,,22224,BAO_0000019
11654,,,,0,,,CHEMBL628242,,Autocuration,A,,1,,U,Distribution in the kidneys after 60 min of intravenous administration,,,22224,BAO_0000019
11655,,,,0,,,CHEMBL875482,,Autocuration,A,,1,,U,Distribution in the kidneys after 90 min of intravenous administration,,,22224,BAO_0000019
11656,,,,0,,,CHEMBL628243,,Autocuration,A,,1,,U,Distribution in the liver after 120 min of intravenous administration,,,22224,BAO_0000019
11657,,,,0,,,CHEMBL628244,,Autocuration,A,,1,,U,Distribution in the liver after 15 min of intravenous administration,,,22224,BAO_0000019
11658,,,,0,,,CHEMBL628245,,Autocuration,A,,1,,U,Distribution in the liver after 30 min of intravenous administration,,,22224,BAO_0000019
11659,,,,0,,,CHEMBL628246,,Autocuration,A,,1,,U,Distribution in the liver after 5 min of intravenous administration,,,22224,BAO_0000019
11660,,,,0,,,CHEMBL628247,,Autocuration,A,,1,,U,Distribution in the liver after 60 min of intravenous administration,,,22224,BAO_0000019
11661,,,,0,,,CHEMBL628248,,Autocuration,A,,1,,U,Distribution in the liver after 90 min of intravenous administration,,,22224,BAO_0000019
11662,,,,0,,,CHEMBL628249,,Autocuration,A,,1,,U,Distribution in the lung after 120 min of intravenous administration,,,22224,BAO_0000019
11663,,,,1,,,CHEMBL625452,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,,50594,BAO_0000218
11664,,,,1,,,CHEMBL625453,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,,50594,BAO_0000218
11665,,,,1,,,CHEMBL625454,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,,50594,BAO_0000218
11666,,,,1,,,CHEMBL623844,,Intermediate,A,,1,,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,,50594,BAO_0000218
11667,,,,1,,,CHEMBL623845,,Intermediate,A,,1,,N,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,,50597,BAO_0000218
11668,,,,1,,,CHEMBL623846,,Intermediate,A,,1,,N,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,,50597,BAO_0000218
11669,,,,0,,,CHEMBL623847,,Autocuration,A,,1,,U,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,,22224,BAO_0000218
11670,,,,1,,,CHEMBL623848,,Intermediate,A,,1,,N,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,100710,BAO_0000218
11671,,,,1,,,CHEMBL623849,,Intermediate,A,,1,,N,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,100710,BAO_0000218
11672,,,,1,,,CHEMBL623850,,Intermediate,A,,1,,N,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,100710,BAO_0000218
11673,,,,1,,,CHEMBL623851,,Intermediate,A,,1,,N,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,100710,BAO_0000218
11674,,,,0,,,CHEMBL623852,,Autocuration,A,,1,,U,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,,22224,BAO_0000218
11675,,,,1,,,CHEMBL624551,,Intermediate,A,,1,,N,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,,50506,BAO_0000218
11676,,,,1,,,CHEMBL624552,,Intermediate,A,,1,,N,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,,50506,BAO_0000218
11677,,,,0,,,CHEMBL624553,,Autocuration,A,,1,,U,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,,22224,BAO_0000218
11678,,,,0,,,CHEMBL624554,,Autocuration,A,,1,,U,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,,22224,BAO_0000218
11679,,,,1,,,CHEMBL624555,,Intermediate,A,,1,,N,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,,50597,BAO_0000218
11680,,,,1,,,CHEMBL624741,,Intermediate,A,,1,,N,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,,50597,BAO_0000218
11681,,,,1,,,CHEMBL624742,,Intermediate,A,,1,,N,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,,50588,BAO_0000218
11682,,,,1,,,CHEMBL624743,,Intermediate,A,,1,,N,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,,100712,BAO_0000218
11683,,,,1,,,CHEMBL877606,,Intermediate,A,,1,,N,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,,50597,BAO_0000218
11684,,,,0,,,CHEMBL624744,,Autocuration,A,,1,,U,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,,22224,BAO_0000218
11685,,,178.0,0,Blood,,CHEMBL624745,,Autocuration,A,,1,,U,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,,22224,BAO_0000218
11686,,,178.0,0,Blood,,CHEMBL624746,,Autocuration,A,,1,,U,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,,22224,BAO_0000218
11687,,,178.0,0,Blood,,CHEMBL624747,,Autocuration,A,,1,,U,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,,22224,BAO_0000218
11688,,,,0,,,CHEMBL624748,,Autocuration,A,,1,,U,Oral absorption expressed as Area under curve was determined,,,22224,BAO_0000019
11689,,,,1,,,CHEMBL622504,,Intermediate,A,,1,,N,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,,50588,BAO_0000218
11690,,,,1,,,CHEMBL622505,,Intermediate,A,,1,,N,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,,50588,BAO_0000218
11691,,,,1,,,CHEMBL622506,,Intermediate,A,,1,,N,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,,100712,BAO_0000218
11692,,,,1,,,CHEMBL622507,,Intermediate,A,,1,,N,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,,100712,BAO_0000218
11693,,,,1,,,CHEMBL622508,,Intermediate,A,,1,,N,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,,50597,BAO_0000218
11694,,,,0,,,CHEMBL622509,,Autocuration,A,,1,,U,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,,22224,BAO_0000019
11695,,,,1,,,CHEMBL622510,,Intermediate,A,,1,,N,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,BAO_0000218
11696,,,,1,,,CHEMBL622511,,Intermediate,A,,1,,N,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,,50597,BAO_0000218
11697,,,,1,,,CHEMBL622512,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,,100710,BAO_0000218
11698,,,,1,,,CHEMBL622513,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,,100710,BAO_0000218
11699,,,,1,,,CHEMBL622514,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,,100710,BAO_0000218
11700,,,,1,,,CHEMBL622515,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,,50588,BAO_0000218
11701,,,,1,,,CHEMBL622516,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,,50588,BAO_0000218
11702,,,,1,,,CHEMBL622517,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,,50597,BAO_0000218
11703,,,,1,,,CHEMBL622518,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,,50597,BAO_0000218
11704,,,,1,,,CHEMBL622519,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,,50597,BAO_0000218
11705,,,2385.0,1,Muscle tissue,In vivo,CHEMBL622520,,Intermediate,A,,1,,N,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11706,,,2385.0,1,Muscle tissue,In vivo,CHEMBL622521,,Intermediate,A,,1,,N,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11707,,,14.0,1,Zone of skin,In vivo,CHEMBL625113,,Intermediate,A,,1,,N,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50594,BAO_0000218
11708,,,14.0,1,Zone of skin,In vivo,CHEMBL625114,,Intermediate,A,,1,,N,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11709,,,14.0,1,Zone of skin,In vivo,CHEMBL874397,,Intermediate,A,,1,,N,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11710,,,2106.0,1,Spleen,In vivo,CHEMBL625115,,Intermediate,A,,1,,N,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11711,,,2106.0,1,Spleen,In vivo,CHEMBL625116,,Intermediate,A,,1,,N,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11712,,,2106.0,1,Spleen,In vivo,CHEMBL623932,,Intermediate,A,,1,,N,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11713,,,2435.0,1,Striatum,In vivo,CHEMBL623933,,Intermediate,A,,1,,N,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11714,,,2435.0,1,Striatum,In vivo,CHEMBL623934,,Intermediate,A,,1,,N,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11715,,,2435.0,1,Striatum,In vivo,CHEMBL623935,,Intermediate,A,,1,,N,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11716,,,2046.0,1,Thyroid gland,In vivo,CHEMBL623936,,Intermediate,A,,1,,N,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,50597,BAO_0000218
11717,,,2046.0,1,Thyroid gland,In vivo,CHEMBL623937,,Intermediate,A,,1,,N,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,50597,BAO_0000218
11718,,,2046.0,1,Thyroid gland,In vivo,CHEMBL623938,,Intermediate,A,,1,,N,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,50597,BAO_0000218
11719,,,,1,,,CHEMBL623939,,Intermediate,A,,1,,N,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,50594,BAO_0000218
11720,,,,1,,,CHEMBL623940,,Intermediate,A,,1,,N,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,50594,BAO_0000218
11721,,,,1,,,CHEMBL623941,,Intermediate,A,,1,,N,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,50594,BAO_0000218
11722,,,,1,,,CHEMBL627216,,Intermediate,A,,1,,N,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,BAO_0000218
11723,,,,1,,,CHEMBL623942,,Intermediate,A,,1,,N,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,BAO_0000218
11724,,,955.0,1,Brain,,CHEMBL618793,,Intermediate,A,,1,,N,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,50594,BAO_0000218
11725,,,955.0,1,Brain,,CHEMBL618794,,Intermediate,A,,1,,N,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,BAO_0000218
11726,,,955.0,1,Brain,,CHEMBL618795,,Intermediate,A,,1,,N,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,BAO_0000218
11727,,,,1,,,CHEMBL618796,,Intermediate,A,,1,,N,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,BAO_0000218
11728,,,,1,,,CHEMBL618797,,Intermediate,A,,1,,N,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,BAO_0000218
11729,,,2113.0,1,Kidney,,CHEMBL618798,,Intermediate,A,,1,,N,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,,50594,BAO_0000218
11730,,,2113.0,1,Kidney,,CHEMBL618799,,Intermediate,A,,1,,N,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,50594,BAO_0000218
11731,,,2113.0,1,Kidney,,CHEMBL618800,,Intermediate,A,,1,,N,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,50594,BAO_0000218
11732,,,2113.0,1,Kidney,,CHEMBL618801,,Intermediate,A,,1,,N,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,50594,BAO_0000218
11733,,,2113.0,1,Kidney,,CHEMBL618802,,Intermediate,A,,1,,N,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,BAO_0000218
11734,,,2113.0,1,Kidney,,CHEMBL618803,,Intermediate,A,,1,,N,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,BAO_0000218
11735,,,2107.0,1,Liver,,CHEMBL618804,,Intermediate,A,,1,,N,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,,50594,BAO_0000218
11736,,,2107.0,1,Liver,,CHEMBL618805,,Intermediate,A,,1,,N,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,50594,BAO_0000218
11737,,,2107.0,1,Liver,,CHEMBL618806,,Intermediate,A,,1,,N,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,50594,BAO_0000218
11738,,,2107.0,1,Liver,,CHEMBL618807,,Intermediate,A,,1,,N,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,50594,BAO_0000218
11739,,,2107.0,1,Liver,,CHEMBL618808,,Intermediate,A,,1,,N,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,BAO_0000218
11740,,,2107.0,1,Liver,,CHEMBL618809,,Intermediate,A,,1,,N,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,BAO_0000218
11741,,,2385.0,1,Muscle tissue,,CHEMBL618810,,Intermediate,A,,1,,N,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,50594,BAO_0000218
11742,,,2385.0,1,Muscle tissue,,CHEMBL618811,,Intermediate,A,,1,,N,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,50594,BAO_0000218
11743,,,2385.0,1,Muscle tissue,,CHEMBL875844,,Intermediate,A,,1,,N,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,50594,BAO_0000218
11744,,,2385.0,1,Muscle tissue,,CHEMBL618812,,Intermediate,A,,1,,N,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,BAO_0000218
11745,,,2385.0,1,Muscle tissue,,CHEMBL618813,,Intermediate,A,,1,,N,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,BAO_0000218
11746,,,,1,,,CHEMBL618814,,Intermediate,A,,1,,N,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,50594,BAO_0000218
11747,,,,1,,,CHEMBL618815,,Intermediate,A,,1,,N,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,BAO_0000218
11748,,,,1,,,CHEMBL618816,,Intermediate,A,,1,,N,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,BAO_0000218
11749,,,,1,,,CHEMBL618817,,Intermediate,A,,1,,N,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,BAO_0000218
11750,,,,1,,,CHEMBL620544,,Intermediate,A,,1,,N,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,BAO_0000218
11751,,,,1,,In vivo,CHEMBL626230,,Intermediate,A,,1,,N,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,,50597,BAO_0000218
11752,,,,1,,In vivo,CHEMBL626231,,Intermediate,A,,1,,N,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,,50597,BAO_0000218
11753,,,,1,,In vivo,CHEMBL626232,,Intermediate,A,,1,,N,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,,50597,BAO_0000218
11754,,,1969.0,1,Plasma,In vivo,CHEMBL626233,,Intermediate,A,,1,,N,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,,,50588,BAO_0000218
11755,,,1969.0,1,Plasma,In vivo,CHEMBL626234,,Intermediate,A,,1,,N,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,,,50597,BAO_0000218
11756,,,1969.0,1,Plasma,In vivo,CHEMBL875341,,Intermediate,A,,1,,N,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,,,50597,BAO_0000218
11757,,,1969.0,1,Plasma,In vivo,CHEMBL626235,,Intermediate,A,,1,,N,The maximum plasma concentration (100 mg/kg) administered orally in human,,,50587,BAO_0000218
11758,,,1969.0,0,Plasma,In vivo,CHEMBL626236,,Autocuration,A,,1,,U,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,,,22224,BAO_0000218
11759,,,1969.0,0,Plasma,In vivo,CHEMBL626237,,Autocuration,A,,1,,U,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,,,22224,BAO_0000218
11760,,,1969.0,1,Plasma,In vivo,CHEMBL626238,,Intermediate,A,,1,,N,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,,,50588,BAO_0000218
11761,,,1969.0,1,Plasma,In vivo,CHEMBL622412,,Intermediate,A,,1,,N,The maximum plasma concentration (200 mg/kg) administered orally in human,,,50587,BAO_0000218
11762,,,1969.0,1,Plasma,In vivo,CHEMBL623114,,Intermediate,A,,1,,N,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,,,50597,BAO_0000218
11763,,,1969.0,0,Plasma,In vivo,CHEMBL623115,,Autocuration,A,,1,,U,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,,,22224,BAO_0000218
11764,,,1969.0,0,Plasma,In vivo,CHEMBL623116,,Autocuration,A,,1,,U,The maximum plasma concentration (25 mg/kg) administered orally in monkey,,,22224,BAO_0000218
11765,,,1969.0,0,Plasma,In vivo,CHEMBL623117,,Autocuration,A,,1,,U,The maximum plasma concentration (30 mg/kg) administered orally in dog,,,22224,BAO_0000218
11766,,,1969.0,1,Plasma,In vivo,CHEMBL623118,,Intermediate,A,,1,,N,The maximum plasma concentration (400 mg/kg) administered orally in human,,,50587,BAO_0000218
11767,,,1969.0,1,Plasma,In vivo,CHEMBL623119,,Intermediate,A,,1,,N,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,,,50597,BAO_0000218
11768,,,1969.0,1,Plasma,In vivo,CHEMBL623120,,Intermediate,A,,1,,N,The maximum plasma concentration (50 mg/kg) administered orally in rat,,,50597,BAO_0000218
11769,,,1969.0,1,Plasma,In vivo,CHEMBL623286,,Intermediate,A,,1,,N,The maximum plasma concentration (800 mg/kg) administered orally in human,,,50587,BAO_0000218
11770,,,1969.0,1,Plasma,In vivo,CHEMBL623287,,Intermediate,A,,1,,N,The maximum plasma concentration was measured on rats,,,50597,BAO_0000218
11771,,,1969.0,1,Plasma,In vivo,CHEMBL623288,,Intermediate,A,,1,,N,The maximum plasma concentration was measured on rats after oral administration,,,50597,BAO_0000218
11772,,,1969.0,1,Plasma,In vivo,CHEMBL623289,,Intermediate,A,,1,,N,Plasma drug Cmax in rat (PO dose),,,50597,BAO_0000218
11773,,,,0,,In vivo,CHEMBL623290,,Autocuration,A,,1,,U,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,,22224,BAO_0000218
11774,,,1969.0,1,Plasma,In vivo,CHEMBL623291,,Intermediate,A,,1,,N,maximum Plasma concentration in Dog was determined after Peroral administration,,,50588,BAO_0000218
11775,,,1969.0,1,Plasma,In vivo,CHEMBL623292,,Intermediate,A,,1,,N,maximum Plasma concentration in Rats was determined after Peroral administration,,,50597,BAO_0000218
11776,,,1969.0,1,Plasma,In vivo,CHEMBL623293,,Intermediate,A,,1,,N,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,,50588,BAO_0000218
11777,,,1969.0,0,Plasma,In vivo,CHEMBL623294,,Autocuration,A,,1,,U,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,,22224,BAO_0000218
11778,,,1969.0,1,Plasma,In vivo,CHEMBL623295,,Intermediate,A,,1,,N,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,,50597,BAO_0000218
11779,,,,1,,In vivo,CHEMBL623296,,Intermediate,A,,1,,N,maximum concentration was measured when administered through oral route in mice,,,50594,BAO_0000218
11780,,,,1,,,CHEMBL875349,,Intermediate,A,,1,,N,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,,50594,BAO_0000218
11781,,,,0,,,CHEMBL623297,,Autocuration,A,,1,,U,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,,22224,BAO_0000019
11782,,,,0,,,CHEMBL623298,,Autocuration,A,,1,,U,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,,22224,BAO_0000019
11783,,,,0,,,CHEMBL623299,,Autocuration,A,,1,,U,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,,22224,BAO_0000019
11784,,,,1,,,CHEMBL623300,,Intermediate,A,,1,,N,Pharmacokinetic parameter was evaluated in rats,,,50597,BAO_0000218
11785,,,,1,,,CHEMBL623301,,Intermediate,A,,1,,N,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,,50594,BAO_0000218
11786,,,,1,,,CHEMBL623302,,Intermediate,A,,1,,N,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,,50594,BAO_0000218
11787,,,,1,,,CHEMBL623303,,Intermediate,A,,1,,N,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,,50594,BAO_0000218
11788,,,,1,,,CHEMBL623304,,Intermediate,A,,1,,N,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,,50594,BAO_0000218
11789,,,,1,,,CHEMBL623305,,Intermediate,A,,1,,N,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,,50594,BAO_0000218
11790,,,1969.0,1,Plasma,,CHEMBL623306,,Intermediate,A,,1,,N,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,,,50597,BAO_0000218
11791,,,1969.0,1,Plasma,,CHEMBL623307,,Intermediate,A,,1,,N,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,,,50597,BAO_0000218
11792,,,1969.0,1,Plasma,,CHEMBL623308,,Intermediate,A,,1,,N,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,,,50597,BAO_0000218
11793,,,1969.0,1,Plasma,,CHEMBL623309,,Intermediate,A,,1,,N,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,,,50594,BAO_0000218
11794,,,,1,,,CHEMBL623310,,Intermediate,A,,1,,N,Plasma Concentration after 120 min of oral administration to mice,,,50594,BAO_0000218
11795,,,,1,,,CHEMBL623311,,Intermediate,A,,1,,N,Plasma Concentration after 30 min of oral administration to mice,,,50594,BAO_0000218
11796,,,,1,,,CHEMBL623312,,Intermediate,A,,1,,N,Plasma Concentration after 60 min of oral administration to mice,,,100710,BAO_0000218
11797,,,,1,,,CHEMBL875350,,Intermediate,A,,1,,N,Plasma Concentration after 60 min of oral administration to mice; Not determined,,,50594,BAO_0000218
11798,,,,1,,,CHEMBL628635,,Intermediate,A,,1,,N,Plasma Concentration after 90 min of oral administration to mice,,,50594,BAO_0000218
11799,,,,1,,,CHEMBL628636,,Intermediate,A,,1,,N,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,,50597,BAO_0000218
11800,,,,1,,,CHEMBL628637,,Intermediate,A,,1,,N,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,,50597,BAO_0000218
11801,,,,1,,,CHEMBL628058,,Intermediate,A,,1,,N,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,,50597,BAO_0000218
11802,,,,1,,,CHEMBL628059,,Intermediate,A,,1,,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,,50597,BAO_0000218
11803,,,,1,,,CHEMBL628060,,Intermediate,A,,1,,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,,50597,BAO_0000218
11804,,,,0,,,CHEMBL628061,,Autocuration,A,,1,,U,Distribution in the lung after 15 min of intravenous administration,,,22224,BAO_0000019
11805,,,,0,,,CHEMBL628062,,Autocuration,A,,1,,U,Distribution in the lung after 30 min of intravenous administration,,,22224,BAO_0000019
11806,,,,0,,,CHEMBL628063,,Autocuration,A,,1,,U,Distribution in the lung after 5 min of intravenous administration,,,22224,BAO_0000019
11807,,,,0,,,CHEMBL628064,,Autocuration,A,,1,,U,Distribution in the lung after 60 min of intravenous administration,,,22224,BAO_0000019
11808,,,,0,,,CHEMBL628065,,Autocuration,A,,1,,U,Distribution in the lung after 90 min of intravenous administration,,,22224,BAO_0000019
11809,,,2385.0,0,Muscle tissue,,CHEMBL628066,,Autocuration,A,,1,,U,Distribution in the muscle after 120 min of intravenous administration,,,22224,BAO_0000019
11810,,,2385.0,0,Muscle tissue,,CHEMBL628067,,Autocuration,A,,1,,U,Distribution in the muscle after 15 min of intravenous administration,,,22224,BAO_0000019
11811,,,2385.0,1,Muscle tissue,,CHEMBL874646,,Intermediate,A,,1,,N,Distribution in the muscle after 30 min of intravenous administration,,,50594,BAO_0000218
11812,,,2385.0,0,Muscle tissue,,CHEMBL628068,,Autocuration,A,,1,,U,Distribution in the muscle after 5 min of intravenous administration,,,22224,BAO_0000019
11813,,,2385.0,0,Muscle tissue,,CHEMBL628069,,Autocuration,A,,1,,U,Distribution in the muscle after 60 min of intravenous administration,,,22224,BAO_0000019
11814,,,2385.0,0,Muscle tissue,,CHEMBL628070,,Autocuration,A,,1,,U,Distribution in the muscle after 90 min of intravenous administration,,,22224,BAO_0000019
11815,,,2106.0,0,Spleen,,CHEMBL628071,,Autocuration,A,,1,,U,Distribution in the spleen after 120 min of intravenous administration,,,22224,BAO_0000019
11816,,,2106.0,0,Spleen,,CHEMBL628072,,Autocuration,A,,1,,U,Distribution in the spleen after 15 min of intravenous administration,,,22224,BAO_0000019
11817,,,2106.0,0,Spleen,,CHEMBL628073,,Autocuration,A,,1,,U,Distribution in the spleen after 30 min of intravenous administration,,,22224,BAO_0000019
11818,,,2106.0,0,Spleen,,CHEMBL628074,,Autocuration,A,,1,,U,Distribution in the spleen after 5 min of intravenous administration,,,22224,BAO_0000019
11819,,,2106.0,0,Spleen,,CHEMBL628075,,Autocuration,A,,1,,U,Distribution in the spleen after 60 min of intravenous administration,,,22224,BAO_0000019
11820,,,2106.0,0,Spleen,,CHEMBL628076,,Autocuration,A,,1,,U,Distribution in the spleen after 90 min of intravenous administration,,,22224,BAO_0000019
11821,,,1235.0,1,Adrenal cortex,,CHEMBL628077,,Intermediate,A,,1,,N,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,,,50597,BAO_0000218
11822,,,178.0,1,Blood,,CHEMBL628078,,Intermediate,A,,1,,N,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,,,50597,BAO_0000218
11823,,,2107.0,1,Liver,,CHEMBL628079,,Intermediate,A,,1,,N,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,,,50597,BAO_0000218
11824,,,992.0,1,Female gonad,,CHEMBL628080,,Intermediate,A,,1,,N,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,,,50597,BAO_0000218
11825,,,2046.0,1,Thyroid gland,,CHEMBL628081,,Intermediate,A,,1,,N,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,,,50597,BAO_0000218
11826,,,1235.0,1,Adrenal cortex,,CHEMBL628082,,Intermediate,A,,1,,N,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,,,50597,BAO_0000218
11827,,,178.0,1,Blood,,CHEMBL874647,,Intermediate,A,,1,,N,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,,,50597,BAO_0000218
11828,,,2107.0,1,Liver,,CHEMBL626406,,Intermediate,A,,1,,N,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,,,50597,BAO_0000218
11829,,,992.0,1,Female gonad,,CHEMBL626407,,Intermediate,A,,1,,N,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,,,50597,BAO_0000218
11830,,,2046.0,1,Thyroid gland,,CHEMBL626408,,Intermediate,A,,1,,N,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,,,50597,BAO_0000218
11831,,,178.0,1,Blood,,CHEMBL626409,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",,,50597,BAO_0000218
11832,,,178.0,1,Blood,,CHEMBL626410,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",,,50597,BAO_0000218
11833,,,178.0,1,Blood,,CHEMBL626411,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",,,50597,BAO_0000218
11834,,,178.0,1,Blood,,CHEMBL626412,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",,,50597,BAO_0000218
11835,,,178.0,1,Blood,,CHEMBL626413,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",,,50597,BAO_0000218
11836,,,178.0,1,Blood,,CHEMBL626414,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",,,50597,BAO_0000218
11837,,,178.0,1,Blood,,CHEMBL626415,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",,,50597,BAO_0000218
11838,,,178.0,1,Blood,,CHEMBL626416,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",,,50597,BAO_0000218
11839,,,178.0,1,Blood,,CHEMBL627062,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",,,50597,BAO_0000218
11840,,,178.0,1,Blood,,CHEMBL627063,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",,,50597,BAO_0000218
11841,,,178.0,1,Blood,,CHEMBL627064,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",,,50597,BAO_0000218
11842,,,178.0,1,Blood,,CHEMBL627227,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",,,50597,BAO_0000218
11843,,,178.0,1,Blood,,CHEMBL627228,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",,,50597,BAO_0000218
11844,,,178.0,1,Blood,,CHEMBL627229,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",,,50597,BAO_0000218
11845,,,178.0,1,Blood,,CHEMBL625792,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",,,50597,BAO_0000218
11846,,,178.0,1,Blood,,CHEMBL625793,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",,,50597,BAO_0000218
11847,,,178.0,1,Blood,,CHEMBL625794,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",,,50597,BAO_0000218
11848,,,178.0,1,Blood,,CHEMBL625795,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",,,50597,BAO_0000218
11849,,,,1,,,CHEMBL625796,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,,50594,BAO_0000218
11850,,,,1,,,CHEMBL625797,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,,50588,BAO_0000218
11851,,,,1,,,CHEMBL625798,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,,50588,BAO_0000218
11852,,,,0,,,CHEMBL875613,,Autocuration,A,,1,,U,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11853,,,,0,,,CHEMBL625799,,Autocuration,A,,1,,U,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11854,,,,0,,,CHEMBL625800,,Autocuration,A,,1,,U,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11855,,,,0,,,CHEMBL625801,,Autocuration,A,,1,,U,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11856,,,,0,,,CHEMBL625802,,Autocuration,A,,1,,U,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11857,,,,0,,,CHEMBL625803,,Autocuration,A,,1,,U,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11858,,,,0,,,CHEMBL625804,,Autocuration,A,,1,,U,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,,22224,BAO_0000019
11859,,,,0,,,CHEMBL622530,,Autocuration,A,,1,,U,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,,22224,BAO_0000218
11860,,,,1,,,CHEMBL622531,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,,50594,BAO_0000218
11861,,,,1,,,CHEMBL622532,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,50594,BAO_0000218
11862,,,,1,,,CHEMBL623176,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,50594,BAO_0000218
11863,,,,1,,,CHEMBL623177,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,,50594,BAO_0000218
11864,,,,1,,,CHEMBL623178,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,50594,BAO_0000218
11865,,,,1,,,CHEMBL623179,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,,50594,BAO_0000218
11866,,,,1,,,CHEMBL623180,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,,50594,BAO_0000218
11867,,,,1,,,CHEMBL623181,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,50594,BAO_0000218
11868,,,,1,,,CHEMBL624131,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,50594,BAO_0000218
11869,,,,1,,,CHEMBL624132,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,,50594,BAO_0000218
11870,,,,1,,,CHEMBL624133,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,,50594,BAO_0000218
11871,,,,1,,,CHEMBL624846,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,,50594,BAO_0000218
11872,,,,1,,,CHEMBL624847,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,,50594,BAO_0000218
11873,,,,1,,,CHEMBL624848,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,50594,BAO_0000218
11874,,,,1,,,CHEMBL625012,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,50594,BAO_0000218
11875,,,,1,,,CHEMBL625013,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,50594,BAO_0000218
11876,,,,1,,,CHEMBL625014,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,,50594,BAO_0000218
11877,,,,1,,,CHEMBL625015,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,,50594,BAO_0000218
11878,,,,1,,,CHEMBL625016,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,,50594,BAO_0000218
11879,,,,1,,,CHEMBL625017,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,,50594,BAO_0000218
11880,,,,1,,,CHEMBL625018,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,50594,BAO_0000218
11881,,,,1,,,CHEMBL625019,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,,50594,BAO_0000218
11882,,,,1,,,CHEMBL625020,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,,50594,BAO_0000218
11883,,,,1,,,CHEMBL625021,,Intermediate,A,,1,,N,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,,50594,BAO_0000218
11884,,,,1,,,CHEMBL625022,,Intermediate,A,,1,,N,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,BAO_0000218
11885,,,,1,,,CHEMBL625023,,Intermediate,A,,1,,N,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,,50594,BAO_0000218
11886,,,,1,,,CHEMBL625024,,Intermediate,A,,1,,N,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,,100710,BAO_0000218
11887,,,,1,,,CHEMBL627626,,Intermediate,A,,1,,N,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,,100710,BAO_0000218
11888,,,955.0,0,Brain,,CHEMBL627627,,Autocuration,A,,1,,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,,22224,BAO_0000218
11889,,,1977.0,0,Serum,,CHEMBL627628,,Autocuration,A,,1,,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,,,22224,BAO_0000218
11890,,,955.0,0,Brain,,CHEMBL627629,,Autocuration,A,,1,,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,,22224,BAO_0000218
11891,,,1977.0,0,Serum,,CHEMBL627630,,Autocuration,A,,1,,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,,,22224,BAO_0000218
11892,,,,0,,,CHEMBL627631,,Autocuration,A,,1,,U,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,,22224,BAO_0000019
11893,,,,0,,,CHEMBL629515,,Autocuration,A,,1,,U,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,,22224,BAO_0000218
11894,,,2106.0,1,Spleen,,CHEMBL629516,,Intermediate,A,,1,,N,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,50594,BAO_0000218
11895,,,2106.0,1,Spleen,,CHEMBL629517,,Intermediate,A,,1,,N,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,BAO_0000218
11896,,,2106.0,1,Spleen,,CHEMBL629518,,Intermediate,A,,1,,N,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,BAO_0000218
11897,,,,1,,,CHEMBL877499,,Intermediate,A,,1,,N,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,50594,BAO_0000218
11898,,,,1,,,CHEMBL629519,,Intermediate,A,,1,,N,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,50594,BAO_0000218
11899,,,,1,,,CHEMBL629520,,Intermediate,A,,1,,N,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,50594,BAO_0000218
11900,,,,1,,,CHEMBL629521,,Intermediate,A,,1,,N,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,50594,BAO_0000218
11901,,,,1,,,CHEMBL629522,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,,50594,BAO_0000218
11902,,,,1,,,CHEMBL629523,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,,50594,BAO_0000218
11903,,,,1,,,CHEMBL629524,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,,50594,BAO_0000218
11904,,,,1,,,CHEMBL629525,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,,50594,BAO_0000218
11905,,,,1,,,CHEMBL629526,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,,50594,BAO_0000218
11906,,,,1,,,CHEMBL629527,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,,50594,BAO_0000218
11907,,,,1,,,CHEMBL629528,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,,50594,BAO_0000218
11908,,,,1,,,CHEMBL629529,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,,50594,BAO_0000218
11909,,,,1,,,CHEMBL629530,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,,50594,BAO_0000218
11910,,,,1,,,CHEMBL629531,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,,50594,BAO_0000218
11911,,,,1,,,CHEMBL628656,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,,50594,BAO_0000218
11912,,,,1,,,CHEMBL628657,,Intermediate,A,,1,,N,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,,50594,BAO_0000218
11913,,,,1,,In vivo,CHEMBL628658,,Intermediate,A,,1,,N,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
11914,,,,1,,In vivo,CHEMBL628659,,Intermediate,A,,1,,N,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,BAO_0000218
11915,,,,1,,In vivo,CHEMBL877500,,Intermediate,A,,1,,N,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,50597,BAO_0000218
11916,,,,1,,In vivo,CHEMBL628660,,Intermediate,A,,1,,N,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,BAO_0000218
11917,,,,1,,In vivo,CHEMBL628661,,Intermediate,A,,1,,N,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,BAO_0000218
11918,,,,1,,In vivo,CHEMBL628662,,Intermediate,A,,1,,N,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
11919,,,,1,,In vivo,CHEMBL628663,,Intermediate,A,,1,,N,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,50597,BAO_0000218
11920,,,,1,,In vivo,CHEMBL628664,,Intermediate,A,,1,,N,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,50597,BAO_0000218
11921,,,178.0,1,Blood,In vivo,CHEMBL628665,,Intermediate,A,,1,,N,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,BAO_0000218
11922,,,178.0,1,Blood,In vivo,CHEMBL628666,,Intermediate,A,,1,,N,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,50597,BAO_0000218
11923,,,178.0,1,Blood,In vivo,CHEMBL628667,,Intermediate,A,,1,,N,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,BAO_0000218
11924,,,178.0,1,Blood,In vivo,CHEMBL628668,,Intermediate,A,,1,,N,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,BAO_0000218
11925,,,178.0,1,Blood,In vivo,CHEMBL628669,,Intermediate,A,,1,,N,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
11926,,,178.0,1,Blood,In vivo,CHEMBL628670,,Intermediate,A,,1,,N,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,50597,BAO_0000218
11927,,,178.0,1,Blood,In vivo,CHEMBL628671,,Intermediate,A,,1,,N,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,50597,BAO_0000218
11928,,,10000001.0,1,Bone,In vivo,CHEMBL628672,,Intermediate,A,,1,,N,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,BAO_0000218
11929,,,10000001.0,1,Bone,In vivo,CHEMBL630300,,Intermediate,A,,1,,N,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,BAO_0000218
11930,,,10000001.0,1,Bone,In vivo,CHEMBL629787,,Intermediate,A,,1,,N,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,BAO_0000218
11931,,,10000001.0,1,Bone,In vivo,CHEMBL629788,,Intermediate,A,,1,,N,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
11932,,,955.0,1,Brain,In vivo,CHEMBL629789,,Intermediate,A,,1,,N,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,BAO_0000218
11933,,,955.0,1,Brain,In vivo,CHEMBL629790,,Intermediate,A,,1,,N,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,50597,BAO_0000218
11934,,,955.0,1,Brain,In vivo,CHEMBL629791,,Intermediate,A,,1,,N,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,BAO_0000218
11935,,,955.0,1,Brain,In vivo,CHEMBL629792,,Intermediate,A,,1,,N,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,BAO_0000218
11936,,,955.0,1,Brain,In vivo,CHEMBL629793,,Intermediate,A,,1,,N,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
11937,,,955.0,1,Brain,In vivo,CHEMBL629794,,Intermediate,A,,1,,N,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,50597,BAO_0000218
11938,,,,1,,,CHEMBL874459,,Intermediate,A,,1,,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,,50597,BAO_0000218
11939,,,,1,,,CHEMBL629795,,Intermediate,A,,1,,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,,50597,BAO_0000218
11940,,,,1,,,CHEMBL629796,,Intermediate,A,,1,,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,,50597,BAO_0000218
11941,,,,1,,,CHEMBL629797,,Intermediate,A,,1,,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,,50597,BAO_0000218
11942,,,,1,,,CHEMBL629798,,Intermediate,A,,1,,N,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,,50597,BAO_0000218
11943,,,2369.0,1,Adrenal gland,In vivo,CHEMBL629799,,Intermediate,A,,1,,N,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11944,,,2369.0,1,Adrenal gland,In vivo,CHEMBL629800,,Intermediate,A,,1,,N,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11945,,,2369.0,1,Adrenal gland,In vivo,CHEMBL629801,,Intermediate,A,,1,,N,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11946,,,2369.0,1,Adrenal gland,In vivo,CHEMBL629802,,Intermediate,A,,1,,N,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,,,50597,BAO_0000218
11947,,,2369.0,1,Adrenal gland,In vivo,CHEMBL629803,,Intermediate,A,,1,,N,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11948,,,178.0,1,Blood,In vivo,CHEMBL629804,,Intermediate,A,,1,,N,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11949,,,178.0,1,Blood,In vivo,CHEMBL629805,,Intermediate,A,,1,,N,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11950,,,178.0,1,Blood,In vivo,CHEMBL629806,,Intermediate,A,,1,,N,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11951,,,178.0,1,Blood,In vivo,CHEMBL629807,,Intermediate,A,,1,,N,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11952,,,178.0,1,Blood,In vivo,CHEMBL629808,,Intermediate,A,,1,,N,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11953,,,955.0,1,Brain,In vivo,CHEMBL629809,,Intermediate,A,,1,,N,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11954,,,955.0,1,Brain,In vivo,CHEMBL629810,,Intermediate,A,,1,,N,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11955,,,955.0,1,Brain,In vivo,CHEMBL629811,,Intermediate,A,,1,,N,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11956,,,955.0,1,Brain,In vivo,CHEMBL629812,,Intermediate,A,,1,,N,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11957,,,955.0,1,Brain,In vivo,CHEMBL629813,,Intermediate,A,,1,,N,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11958,,,955.0,1,Brain,In vivo,CHEMBL874460,,Intermediate,A,,1,,N,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11959,,,,1,,In vivo,CHEMBL629814,,Intermediate,A,,1,,N,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11960,,,,1,,In vivo,CHEMBL629815,,Intermediate,A,,1,,N,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11961,,,,1,,In vivo,CHEMBL629816,,Intermediate,A,,1,,N,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11962,,,,1,,In vivo,CHEMBL629817,,Intermediate,A,,1,,N,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11963,,,2113.0,1,Kidney,In vivo,CHEMBL626643,,Intermediate,A,,1,,N,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11964,,,2113.0,1,Kidney,In vivo,CHEMBL626644,,Intermediate,A,,1,,N,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11965,,,2113.0,1,Kidney,In vivo,CHEMBL626806,,Intermediate,A,,1,,N,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11966,,,2113.0,1,Kidney,In vivo,CHEMBL626807,,Intermediate,A,,1,,N,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11967,,,2107.0,1,Liver,In vivo,CHEMBL627261,,Intermediate,A,,1,,N,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11968,,,2107.0,1,Liver,In vivo,CHEMBL627262,,Intermediate,A,,1,,N,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11969,,,2107.0,1,Liver,In vivo,CHEMBL627263,,Intermediate,A,,1,,N,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11970,,,2107.0,1,Liver,In vivo,CHEMBL627264,,Intermediate,A,,1,,N,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11971,,,2048.0,1,Lung,In vivo,CHEMBL627265,,Intermediate,A,,1,,N,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11972,,,2048.0,1,Lung,In vivo,CHEMBL627266,,Intermediate,A,,1,,N,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11973,,,2048.0,1,Lung,In vivo,CHEMBL627267,,Intermediate,A,,1,,N,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11974,,,2048.0,1,Lung,In vivo,CHEMBL627268,,Intermediate,A,,1,,N,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11975,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627269,,Intermediate,A,,1,,N,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11976,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627270,,Intermediate,A,,1,,N,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
11977,,,,1,,,CHEMBL627271,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,,50597,BAO_0000218
11978,,,,1,,,CHEMBL627946,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,,50597,BAO_0000218
11979,,,,1,,,CHEMBL875472,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,,50597,BAO_0000218
11980,,,,1,,,CHEMBL627947,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,,50597,BAO_0000218
11981,,,,1,,,CHEMBL627948,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,,50597,BAO_0000218
11982,,,,1,,,CHEMBL628113,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,,50597,BAO_0000218
11983,,,,1,,,CHEMBL628114,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,,50597,BAO_0000218
11984,,,,1,,,CHEMBL628115,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,,50597,BAO_0000218
11985,,,,1,,,CHEMBL628116,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,,50597,BAO_0000218
11986,,,,1,,,CHEMBL628117,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,,50597,BAO_0000218
11987,,,,1,,,CHEMBL628118,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,,50597,BAO_0000218
11988,,,,1,,,CHEMBL628119,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,,50597,BAO_0000218
11989,,,,1,,,CHEMBL628120,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,,50597,BAO_0000218
11990,,,,1,,,CHEMBL628121,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,,50597,BAO_0000218
11991,,,,1,,,CHEMBL628122,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,,50597,BAO_0000218
11992,,,,1,,,CHEMBL627297,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,,50597,BAO_0000218
11993,,,,1,,,CHEMBL627298,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,,50597,BAO_0000218
11994,,,,1,,,CHEMBL627299,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,,50597,BAO_0000218
11995,,,,1,,,CHEMBL627300,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,,50597,BAO_0000218
11996,,,,1,,,CHEMBL627301,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,,50597,BAO_0000218
11997,,,,1,,,CHEMBL627302,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,,50597,BAO_0000218
11998,,,,1,,,CHEMBL627303,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,,50597,BAO_0000218
11999,,,,1,,,CHEMBL627304,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,,50597,BAO_0000218
12000,,,,1,,,CHEMBL627305,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,,50597,BAO_0000218
12001,,,,1,,,CHEMBL627306,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,,50597,BAO_0000218
12002,,,,1,,,CHEMBL623982,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,,50597,BAO_0000218
12003,,,,1,,,CHEMBL623983,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,,50597,BAO_0000218
12004,,,,1,,,CHEMBL623984,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,,50597,BAO_0000218
12005,,,,1,,,CHEMBL623985,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,,50597,BAO_0000218
12006,,,,1,,,CHEMBL623986,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,,50597,BAO_0000218
12007,,,,1,,,CHEMBL623987,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,,50597,BAO_0000218
12008,,,,1,,,CHEMBL623988,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,,50597,BAO_0000218
12009,,,,1,,,CHEMBL623989,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,,50597,BAO_0000218
12010,,,,1,,,CHEMBL622215,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,,50597,BAO_0000218
12011,,,,1,,,CHEMBL622216,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,,50597,BAO_0000218
12012,,,,1,,,CHEMBL877481,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,,50597,BAO_0000218
12013,,,,0,,,CHEMBL622217,,Autocuration,A,,1,,U,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,,22224,BAO_0000218
12014,,,,1,,,CHEMBL622218,,Intermediate,A,,1,,N,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,,50594,BAO_0000218
12015,,,,1,,,CHEMBL622219,,Intermediate,A,,1,,N,Pharmacokinetic profile AUC was evaluated in rats,,,50597,BAO_0000218
12016,,,,0,,,CHEMBL622220,,Autocuration,A,,1,,U,Pharmacokinetic property (Area under curve),,,22224,BAO_0000019
12017,,,,1,,,CHEMBL622221,,Intermediate,A,,1,,N,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,,50588,BAO_0000218
12018,,,,1,,,CHEMBL622222,,Intermediate,A,,1,,N,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,,50594,BAO_0000218
12019,,,,1,,,CHEMBL622223,,Intermediate,A,,1,,N,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,,50588,BAO_0000218
12020,,,,1,,,CHEMBL622224,,Intermediate,A,,1,,N,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,,50594,BAO_0000218
12021,,,,0,,,CHEMBL622225,,Autocuration,A,,1,,U,Plasma concentration (AUC) was determined,,,22224,BAO_0000019
12022,,,,0,,,CHEMBL622226,,Autocuration,A,,1,,U,Plasma concentration (AUC) was determined; Not detectable,,,22224,BAO_0000019
12023,,,,1,,,CHEMBL624154,,Intermediate,A,,1,,N,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,,50512,BAO_0000218
12024,,,,1,,,CHEMBL624155,,Intermediate,A,,1,,N,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,,50597,BAO_0000218
12025,,,,1,,,CHEMBL624156,,Intermediate,A,,1,,N,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,,50597,BAO_0000218
12026,,,,1,,,CHEMBL624157,,Intermediate,A,,1,,N,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,,50597,BAO_0000218
12027,,,,1,,,CHEMBL624158,,Intermediate,A,,1,,N,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,,50597,BAO_0000218
12028,,,,1,,,CHEMBL624159,,Intermediate,A,,1,,N,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,,50597,BAO_0000218
12029,,,,1,,,CHEMBL624160,,Intermediate,A,,1,,N,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,,50597,BAO_0000218
12030,,,,1,,,CHEMBL624161,,Intermediate,A,,1,,N,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,,50597,BAO_0000218
12031,,,,1,,,CHEMBL624162,,Intermediate,A,,1,,N,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,,50597,BAO_0000218
12032,,,,1,,,CHEMBL624163,,Intermediate,A,,1,,N,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,,50588,BAO_0000218
12033,,,,1,,,CHEMBL624164,,Intermediate,A,,1,,N,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
12034,,,,1,,,CHEMBL624165,,Intermediate,A,,1,,N,The AUC(0-infinity) values in female wistar rats.,,,50597,BAO_0000218
12035,,,,1,,,CHEMBL624166,,Intermediate,A,,1,,N,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
12036,,,,1,,,CHEMBL624167,,Intermediate,A,,1,,N,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,,50597,BAO_0000218
12037,,,,1,,,CHEMBL624168,,Intermediate,A,,1,,N,The AUC(0-t)values in female wistar rats.,,,50597,BAO_0000218
12038,,,,1,,,CHEMBL624169,,Intermediate,A,,1,,N,The Area under the concentration time curve of compound was measured on rats,,,50597,BAO_0000218
12039,,,,1,,,CHEMBL624170,,Intermediate,A,,1,,N,The area under curve (100 mg/kg) administered orally in humans,,,50587,BAO_0000218
12040,,,,0,,,CHEMBL624171,,Autocuration,A,,1,,U,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,,22224,BAO_0000218
12041,,,,0,,,CHEMBL624172,,Autocuration,A,,1,,U,The area under curve (12.5 mg/kg) administered intravenously in monkey,,,22224,BAO_0000218
12042,,,,1,,,CHEMBL624173,,Intermediate,A,,1,,N,The area under curve (15 mg/kg) administered intravenously in dog,,,50588,BAO_0000218
12043,,,,1,,,CHEMBL877488,,Intermediate,A,,1,,N,The area under curve (200 mg/kg) administered orally in humans,,,50587,BAO_0000218
12044,,,,1,,,CHEMBL624174,,Intermediate,A,,1,,N,The area under curve (25 mg/kg) administered intravenously in rat,,,50597,BAO_0000218
12045,,,,0,,,CHEMBL624175,,Autocuration,A,,1,,U,The area under curve (25 mg/kg) administered orally in marmoset,,,22224,BAO_0000218
12046,,,,0,,,CHEMBL624176,,Autocuration,A,,1,,U,The area under curve (25 mg/kg) administered orally in monkey,,,22224,BAO_0000218
12047,,,,1,,,CHEMBL624177,,Intermediate,A,,1,,N,The area under curve (30 mg/kg) administered orally in dog,,,50588,BAO_0000218
12048,,,,1,,,CHEMBL624178,,Intermediate,A,,1,,N,The area under curve (400 mg/kg) administered orally in humans,,,50587,BAO_0000218
12049,,,,1,,,CHEMBL624179,,Intermediate,A,,1,,N,The area under curve (50 mg/kg) administered orally in fasted rat,,,50597,BAO_0000218
12050,,,,1,,,CHEMBL627689,,Intermediate,A,,1,,N,The area under curve (50 mg/kg) administered orally in rat,,,50597,BAO_0000218
12051,,,,1,,,CHEMBL627690,,Intermediate,A,,1,,N,The area under curve (800 mg/kg) administered orally in humans,,,50587,BAO_0000218
12052,,,,0,,,CHEMBL627691,,Autocuration,A,,1,,U,The compound was evaluated for area under the curve,,,22224,BAO_0000019
12053,,,,0,,,CHEMBL627692,,Autocuration,A,,1,,U,The compound was evaluated for area under the curve in marmosets,,,22224,BAO_0000019
12054,,,,0,,,CHEMBL627693,,Autocuration,A,,1,,U,The compound was evaluated for area under the curve in marmosets,,,22224,BAO_0000019
12055,,,,1,,,CHEMBL627694,,Intermediate,A,,1,,N,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,50597,BAO_0000218
12056,,,,1,,,CHEMBL627695,,Intermediate,A,,1,,N,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,,50597,BAO_0000218
12057,,,,0,,,CHEMBL627696,,Autocuration,A,,1,,U,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,,22224,BAO_0000218
12058,,,,1,,,CHEMBL627697,,Intermediate,A,,1,,N,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,50597,BAO_0000218
12059,,,,1,,,CHEMBL627698,,Intermediate,A,,1,,N,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,50597,BAO_0000218
12060,,,,1,,,CHEMBL627699,,Intermediate,A,,1,,N,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,,50597,BAO_0000218
12061,,,,1,,,CHEMBL627700,,Intermediate,A,,1,,N,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,,50597,BAO_0000218
12062,,,,1,,,CHEMBL627701,,Intermediate,A,,1,,N,Total drug exposure is determined after oral dosing in rats.,,,50597,BAO_0000218
12063,,,,0,,,CHEMBL627702,,Autocuration,A,,1,,U,Total drug exposure (5 mg/kg) when administered intravenously,,,22224,BAO_0000218
12064,,,,0,,,CHEMBL627703,,Autocuration,A,,1,,U,Total drug exposure (5 mg/kg) when administered orally,,,22224,BAO_0000218
12065,,,,0,,,CHEMBL626873,,Autocuration,A,,1,,U,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,,22224,BAO_0000218
12066,,,,1,,,CHEMBL629583,,Intermediate,A,,1,,N,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,,50597,BAO_0000218
12067,,,,1,,,CHEMBL629584,,Intermediate,A,,1,,N,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,,50588,BAO_0000218
12068,,,,1,,,CHEMBL629585,,Intermediate,A,,1,,N,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,,50588,BAO_0000218
12069,,,955.0,1,Brain,In vivo,CHEMBL629586,,Intermediate,A,,1,,N,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,50597,BAO_0000218
12070,,,955.0,1,Brain,In vivo,CHEMBL629587,,Intermediate,A,,1,,N,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
12071,,,,1,,In vivo,CHEMBL629588,,Intermediate,A,,1,,N,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,BAO_0000218
12072,,,,1,,In vivo,CHEMBL629589,,Intermediate,A,,1,,N,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,50597,BAO_0000218
12073,,,,1,,In vivo,CHEMBL629590,,Intermediate,A,,1,,N,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,BAO_0000218
12074,,,,1,,In vivo,CHEMBL629591,,Intermediate,A,,1,,N,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,BAO_0000218
12075,,,,1,,In vivo,CHEMBL629592,,Intermediate,A,,1,,N,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
12076,,,,1,,In vivo,CHEMBL629593,,Intermediate,A,,1,,N,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,50597,BAO_0000218
12077,,,,1,,In vivo,CHEMBL629594,,Intermediate,A,,1,,N,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,50597,BAO_0000218
12078,,,948.0,1,Heart,In vivo,CHEMBL629595,,Intermediate,A,,1,,N,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,BAO_0000218
12079,,,948.0,1,Heart,In vivo,CHEMBL630290,,Intermediate,A,,1,,N,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,50597,BAO_0000218
12080,,,948.0,1,Heart,In vivo,CHEMBL627137,,Intermediate,A,,1,,N,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,BAO_0000218
12081,,,948.0,1,Heart,In vivo,CHEMBL627138,,Intermediate,A,,1,,N,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,BAO_0000218
12082,,,948.0,1,Heart,In vivo,CHEMBL627139,,Intermediate,A,,1,,N,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
12083,,,948.0,1,Heart,In vivo,CHEMBL627140,,Intermediate,A,,1,,N,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,50597,BAO_0000218
12084,,,948.0,1,Heart,In vivo,CHEMBL627141,,Intermediate,A,,1,,N,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,50597,BAO_0000218
12085,,,2113.0,1,Kidney,In vivo,CHEMBL627142,,Intermediate,A,,1,,N,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,BAO_0000218
12086,,,2113.0,1,Kidney,In vivo,CHEMBL627143,,Intermediate,A,,1,,N,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,50597,BAO_0000218
12087,,,2113.0,1,Kidney,In vivo,CHEMBL874449,,Intermediate,A,,1,,N,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,BAO_0000218
12088,,,2113.0,1,Kidney,In vivo,CHEMBL627144,,Intermediate,A,,1,,N,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,BAO_0000218
12089,,,2113.0,1,Kidney,In vivo,CHEMBL627145,,Intermediate,A,,1,,N,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
12090,,,2113.0,1,Kidney,In vivo,CHEMBL627146,,Intermediate,A,,1,,N,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,50597,BAO_0000218
12091,,,2113.0,1,Kidney,In vivo,CHEMBL627147,,Intermediate,A,,1,,N,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,50597,BAO_0000218
12092,,,2107.0,1,Liver,In vivo,CHEMBL627148,,Intermediate,A,,1,,N,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,BAO_0000218
12093,,,2048.0,1,Lung,In vivo,CHEMBL627149,,Intermediate,A,,1,,N,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,BAO_0000218
12094,,,2048.0,1,Lung,In vivo,CHEMBL632160,,Intermediate,A,,1,,N,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,50597,BAO_0000218
12095,,,2048.0,1,Lung,In vivo,CHEMBL632161,,Intermediate,A,,1,,N,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,BAO_0000218
12096,,,2048.0,1,Lung,In vivo,CHEMBL632162,,Intermediate,A,,1,,N,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,BAO_0000218
12097,,,2048.0,1,Lung,In vivo,CHEMBL632163,,Intermediate,A,,1,,N,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
12098,,,2048.0,1,Lung,In vivo,CHEMBL874469,,Intermediate,A,,1,,N,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,50597,BAO_0000218
12099,,,2048.0,1,Lung,In vivo,CHEMBL627182,,Intermediate,A,,1,,N,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,50597,BAO_0000218
12100,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627183,,Intermediate,A,,1,,N,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,50597,BAO_0000218
12101,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627184,,Intermediate,A,,1,,N,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,50597,BAO_0000218
12102,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627185,,Intermediate,A,,1,,N,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,BAO_0000218
12103,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627186,,Intermediate,A,,1,,N,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,BAO_0000218
12104,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627187,,Intermediate,A,,1,,N,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
12105,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627188,,Intermediate,A,,1,,N,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,50597,BAO_0000218
12106,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627189,,Intermediate,A,,1,,N,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,50597,BAO_0000218
12107,,,,1,,In vivo,CHEMBL627190,,Intermediate,A,,1,,N,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
12108,,,2107.0,1,Liver,In vivo,CHEMBL627191,,Intermediate,A,,1,,N,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,50597,BAO_0000218
12109,,,2107.0,1,Liver,In vivo,CHEMBL627192,,Intermediate,A,,1,,N,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,50597,BAO_0000218
12110,,,2107.0,1,Liver,In vivo,CHEMBL627193,,Intermediate,A,,1,,N,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,50597,BAO_0000218
12111,,,2385.0,1,Muscle tissue,In vivo,CHEMBL874590,,Intermediate,A,,1,,N,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12112,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627194,,Intermediate,A,,1,,N,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12113,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627195,,Intermediate,A,,1,,N,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12114,,,992.0,1,Female gonad,In vivo,CHEMBL627196,,Intermediate,A,,1,,N,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12115,,,992.0,1,Female gonad,In vivo,CHEMBL627197,,Intermediate,A,,1,,N,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12116,,,992.0,1,Female gonad,In vivo,CHEMBL627198,,Intermediate,A,,1,,N,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12117,,,992.0,1,Female gonad,In vivo,CHEMBL627199,,Intermediate,A,,1,,N,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,,,50597,BAO_0000218
12118,,,992.0,1,Female gonad,In vivo,CHEMBL627200,,Intermediate,A,,1,,N,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12119,,,1969.0,1,Plasma,In vivo,CHEMBL627201,,Intermediate,A,,1,,N,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12120,,,1969.0,1,Plasma,In vivo,CHEMBL627202,,Intermediate,A,,1,,N,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12121,,,1969.0,1,Plasma,In vivo,CHEMBL627203,,Intermediate,A,,1,,N,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12122,,,1969.0,1,Plasma,In vivo,CHEMBL627204,,Intermediate,A,,1,,N,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12123,,,2106.0,1,Spleen,In vivo,CHEMBL627205,,Intermediate,A,,1,,N,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12124,,,2106.0,1,Spleen,In vivo,CHEMBL627206,,Intermediate,A,,1,,N,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12125,,,2106.0,1,Spleen,In vivo,CHEMBL627207,,Intermediate,A,,1,,N,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12126,,,2106.0,1,Spleen,In vivo,CHEMBL627208,,Intermediate,A,,1,,N,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12127,,,2046.0,1,Thyroid gland,In vivo,CHEMBL627209,,Intermediate,A,,1,,N,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12128,,,2046.0,1,Thyroid gland,In vivo,CHEMBL627210,,Intermediate,A,,1,,N,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12129,,,2046.0,1,Thyroid gland,In vivo,CHEMBL627211,,Intermediate,A,,1,,N,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12130,,,2046.0,1,Thyroid gland,In vivo,CHEMBL627212,,Intermediate,A,,1,,N,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12131,,,995.0,1,Uterus,In vivo,CHEMBL627213,,Intermediate,A,,1,,N,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12132,,,995.0,1,Uterus,In vivo,CHEMBL626599,,Intermediate,A,,1,,N,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12133,,,995.0,1,Uterus,In vivo,CHEMBL626600,,Intermediate,A,,1,,N,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12134,,,995.0,1,Uterus,In vivo,CHEMBL626601,,Intermediate,A,,1,,N,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,50597,BAO_0000218
12135,,,,0,,,CHEMBL627484,,Autocuration,A,,1,,U,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,,22224,BAO_0000019
12136,,,1969.0,1,Plasma,,CHEMBL627485,,Intermediate,A,,1,,N,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),,,100710,BAO_0000218
12137,,,1969.0,1,Plasma,,CHEMBL628147,,Intermediate,A,,1,,N,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,,,100710,BAO_0000218
12138,,,1969.0,1,Plasma,,CHEMBL628148,,Intermediate,A,,1,,N,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,,,100710,BAO_0000218
12139,,,1969.0,1,Plasma,,CHEMBL628149,,Intermediate,A,,1,,N,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),,,50588,BAO_0000218
12140,,,1969.0,1,Plasma,,CHEMBL628150,,Intermediate,A,,1,,N,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,,,50588,BAO_0000218
12141,,,1969.0,1,Plasma,,CHEMBL628318,,Intermediate,A,,1,,N,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,,,50588,BAO_0000218
12142,,,1969.0,1,Plasma,,CHEMBL628319,,Intermediate,A,,1,,N,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,,,50588,BAO_0000218
12143,,,,1,,,CHEMBL875609,,Intermediate,A,,1,,N,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,,50588,BAO_0000218
12144,,,,0,,,CHEMBL628320,,Autocuration,A,,1,,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,,22224,BAO_0000019
12145,,,,0,,,CHEMBL628321,,Autocuration,A,,1,,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,,22224,BAO_0000019
12146,,,,0,,,CHEMBL628322,,Autocuration,A,,1,,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,,22224,BAO_0000019
12147,,,,0,,,CHEMBL628323,,Autocuration,A,,1,,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,,22224,BAO_0000019
12148,,,,0,,,CHEMBL628324,,Autocuration,A,,1,,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,,22224,BAO_0000019
12149,,,,0,,,CHEMBL628325,,Autocuration,A,,1,,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,,22224,BAO_0000019
12150,,,,0,,,CHEMBL628326,,Autocuration,A,,1,,U,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,,22224,BAO_0000019
12151,,,1236.0,1,Adrenal medulla,,CHEMBL628327,,Intermediate,A,,1,,N,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",,,50588,BAO_0000218
12152,,,1236.0,1,Adrenal medulla,,CHEMBL628328,,Intermediate,A,,1,,N,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",,,50588,BAO_0000218
12153,,,178.0,1,Blood,,CHEMBL628329,,Intermediate,A,,1,,N,"Concentration of compound in blood of dog 1, after administering intravenously",,,50588,BAO_0000218
12154,,,2107.0,1,Liver,,CHEMBL628330,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",,,50597,BAO_0000218
12155,,,2107.0,1,Liver,,CHEMBL628331,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",,,50597,BAO_0000218
12156,,,2107.0,1,Liver,,CHEMBL628332,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",,,50597,BAO_0000218
12157,,,2107.0,1,Liver,,CHEMBL628333,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",,,50597,BAO_0000218
12158,,,2107.0,1,Liver,,CHEMBL628334,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",,,50597,BAO_0000218
12159,,,2107.0,1,Liver,,CHEMBL628335,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",,,50597,BAO_0000218
12160,,,2107.0,1,Liver,,CHEMBL628336,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",,,50597,BAO_0000218
12161,,,2107.0,1,Liver,,CHEMBL628337,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,,50597,BAO_0000218
12162,,,2107.0,1,Liver,,CHEMBL628338,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",,,50597,BAO_0000218
12163,,,2107.0,1,Liver,,CHEMBL875610,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",,,50597,BAO_0000218
12164,,,2107.0,1,Liver,,CHEMBL628339,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",,,50597,BAO_0000218
12165,,,2107.0,1,Liver,,CHEMBL628340,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",,,50597,BAO_0000218
12166,,,2107.0,1,Liver,,CHEMBL628341,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",,,50597,BAO_0000218
12167,,,2107.0,1,Liver,,CHEMBL622214,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",,,50597,BAO_0000218
12168,,,2107.0,1,Liver,,CHEMBL623167,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",,,50597,BAO_0000218
12169,,,2107.0,1,Liver,,CHEMBL623168,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",,,50597,BAO_0000218
12170,,,2107.0,1,Liver,,CHEMBL623169,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",,,50597,BAO_0000218
12171,,,2107.0,1,Liver,,CHEMBL623170,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",,,50597,BAO_0000218
12172,,,2048.0,1,Lung,,CHEMBL627224,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",,,50597,BAO_0000218
12173,,,2048.0,1,Lung,,CHEMBL875634,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",,,50597,BAO_0000218
12174,,,2048.0,1,Lung,,CHEMBL627225,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",,,50597,BAO_0000218
12175,,,2048.0,1,Lung,,CHEMBL627226,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",,,50597,BAO_0000218
12176,,,2048.0,1,Lung,,CHEMBL626083,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",,,50597,BAO_0000218
12177,,,2048.0,1,Lung,,CHEMBL626084,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",,,50597,BAO_0000218
12178,,,2048.0,1,Lung,,CHEMBL626085,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",,,50597,BAO_0000218
12179,,,2048.0,1,Lung,,CHEMBL626086,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",,,50597,BAO_0000218
12180,,,2048.0,1,Lung,,CHEMBL626087,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",,,50597,BAO_0000218
12181,,,2048.0,1,Lung,,CHEMBL626088,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",,,50597,BAO_0000218
12182,,,2048.0,1,Lung,,CHEMBL626089,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",,,50597,BAO_0000218
12183,,,2048.0,1,Lung,,CHEMBL626090,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",,,50597,BAO_0000218
12184,,,2048.0,1,Lung,,CHEMBL626091,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",,,50597,BAO_0000218
12185,,,2048.0,1,Lung,,CHEMBL626092,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",,,50597,BAO_0000218
12186,,,2048.0,1,Lung,,CHEMBL626093,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",,,50597,BAO_0000218
12187,,,2048.0,1,Lung,,CHEMBL626094,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",,,50597,BAO_0000218
12188,,,2048.0,1,Lung,,CHEMBL626095,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",,,50597,BAO_0000218
12189,,,2048.0,1,Lung,,CHEMBL626096,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",,,50597,BAO_0000218
12190,,,,0,,,CHEMBL626097,,Autocuration,A,,1,,U,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,,22224,BAO_0000218
12191,,,,1,,,CHEMBL626098,,Intermediate,A,,1,,N,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,,50597,BAO_0000218
12192,,,1969.0,0,Plasma,,CHEMBL626099,,Autocuration,A,,1,,U,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,,,22224,BAO_0000218
12193,,,1969.0,0,Plasma,,CHEMBL626100,,Autocuration,A,,1,,U,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,,,22224,BAO_0000218
12194,,,1969.0,1,Plasma,,CHEMBL626101,,Intermediate,A,,1,,N,AUC 0-inf in dog,,,50588,BAO_0000218
12195,,,1969.0,1,Plasma,,CHEMBL626102,,Intermediate,A,,1,,N,AUC 0-inf in guinea pig,,,50512,BAO_0000218
12196,,,1969.0,1,Plasma,,CHEMBL626103,,Intermediate,A,,1,,N,AUC 0-t in dog,,,50588,BAO_0000218
12197,,,1969.0,1,Plasma,,CHEMBL628391,,Intermediate,A,,1,,N,AUC 0-t in guinea pig,,,50512,BAO_0000218
12198,,,,1,,,CHEMBL628392,,Intermediate,A,,1,,N,The compound was tested for brain to plasma partition in rat,,,50597,BAO_0000218
12199,,,,1,,,CHEMBL628393,,Intermediate,A,,1,,N,The compound was tested for brain to plasma partition in rat.,,,50597,BAO_0000218
12200,,,178.0,0,Blood,,CHEMBL628394,,Autocuration,A,,1,,U,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,,,22224,BAO_0000019
12201,,,,1,,,CHEMBL628395,,Intermediate,A,,1,,N,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,,50588,BAO_0000218
12202,,,,0,,,CHEMBL628396,,Autocuration,A,,1,,U,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,,22224,BAO_0000218
12203,,,,1,,,CHEMBL628397,,Intermediate,A,,1,,N,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,,50592,BAO_0000218
12204,,,,1,,,CHEMBL628398,,Intermediate,A,,1,,N,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,,50597,BAO_0000218
12205,,,,1,,,CHEMBL628399,,Intermediate,A,,1,,N,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,,50797,BAO_0000218
12206,,,,1,,,CHEMBL628400,,Intermediate,A,,1,,N,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,,50588,BAO_0000218
12207,,,,1,,,CHEMBL874907,,Intermediate,A,,1,,N,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,,50597,BAO_0000218
12208,,,,0,,,CHEMBL628401,,Autocuration,A,,1,,U,Area under curve of the compound was determined,,,22224,BAO_0000019
12209,,,1969.0,0,Plasma,,CHEMBL628402,,Autocuration,A,,1,,U,AUC in monkeys at a dose of 1 mg/kg,,,22224,BAO_0000218
12210,,,1969.0,1,Plasma,,CHEMBL628403,,Intermediate,A,,1,,N,AUC in rats at a dose of 1 mg/kg,,,50597,BAO_0000218
12211,,,,0,,,CHEMBL628404,,Autocuration,A,,1,,U,Compound was evaluated for the overall absorbance loss at pH of 2,,,22224,BAO_0000019
12212,,,,0,,,CHEMBL628405,,Autocuration,A,,1,,U,Compound was evaluated for the overall absorbance loss at pH of 4,,,22224,BAO_0000019
12213,,,,0,,,CHEMBL628406,,Autocuration,A,,1,,U,Compound was evaluated for the overall absorbance loss at pH of 7,,,22224,BAO_0000019
12214,,,,1,,,CHEMBL628407,,Intermediate,A,,1,,N,Compound was evaluated for its absorption in the rats,,,50597,BAO_0000218
12215,,,1088.0,1,Urine,,CHEMBL628408,,Intermediate,A,,1,,N,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,,50597,BAO_0000218
12216,,,1088.0,1,Urine,,CHEMBL629171,,Intermediate,A,,1,,N,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,,,50597,BAO_0000218
12217,,,1088.0,1,Urine,,CHEMBL629172,,Intermediate,A,,1,,N,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,,50597,BAO_0000218
12218,,,1088.0,1,Urine,,CHEMBL629173,,Intermediate,A,,1,,N,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,,,50597,BAO_0000218
12219,,,,1,,,CHEMBL629174,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum,,,50597,BAO_0000218
12220,,,,1,,,CHEMBL629175,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 10-17,,,50597,BAO_0000218
12221,,,,1,,,CHEMBL629176,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 10-18,,,50597,BAO_0000218
12222,,,,1,,,CHEMBL629177,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 10-19,,,50597,BAO_0000218
12223,,,,1,,,CHEMBL629178,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 12-15,,,50597,BAO_0000218
12224,,,,1,,,CHEMBL631869,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 13-19,,,50597,BAO_0000218
12225,,,,1,,,CHEMBL631870,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 14-17,,,50597,BAO_0000218
12226,,,,1,,,CHEMBL631871,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 15-18,,,50597,BAO_0000218
12227,,,,1,,,CHEMBL631872,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 2-5,,,50597,BAO_0000218
12228,,,2116.0,0,Ileum,,CHEMBL875775,,Autocuration,A,,1,,U,In vitro percent permeability into rat ileum; Range is 23-42,,,22224,BAO_0000221
12229,,,,1,,,CHEMBL631873,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 28-36,,,50597,BAO_0000218
12230,,,,1,,,CHEMBL631874,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 29-35,,,50597,BAO_0000218
12231,,,,1,,,CHEMBL631875,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 46-66,,,50597,BAO_0000218
12232,,,,1,,,CHEMBL631876,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 50-68,,,50597,BAO_0000218
12233,,,,1,,,CHEMBL631877,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; Range is 78-81,,,50597,BAO_0000218
12234,,,,1,,,CHEMBL631878,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,,50597,BAO_0000218
12235,,,,1,,,CHEMBL631879,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; nd indicates not detected,,,50597,BAO_0000218
12236,,,,1,,,CHEMBL631880,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; nt indicates not detected,,,50597,BAO_0000218
12237,,,,1,,,CHEMBL631881,,Intermediate,A,,1,,N,In vitro percent permeability into rat ileum; nt indicates not tested,,,50597,BAO_0000218
12238,,,,1,,,CHEMBL631882,,Intermediate,A,,1,,N,Compound was tested for oral absorption in bile-duct cannulated rats,,,50597,BAO_0000218
12239,,,,1,,,CHEMBL630749,,Intermediate,A,,1,,N,Compound was tested for oral absorption in bile-duct cannulated rats.,,,50597,BAO_0000218
12240,,,,1,,,CHEMBL630750,,Intermediate,A,,1,,N,Oral absorption using Caco-2 cell monolayers.,,,50587,BAO_0000218
12241,,,,1,,,CHEMBL630253,,Intermediate,A,,1,,N,Percent of the drug absorbed after administration to humans was determined,,,50587,BAO_0000218
12242,,,1969.0,1,Plasma,,CHEMBL630254,,Intermediate,A,,1,,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,,50597,BAO_0000218
12243,,,1969.0,1,Plasma,,CHEMBL630255,,Intermediate,A,,1,,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,,50597,BAO_0000218
12244,,,1969.0,1,Plasma,,CHEMBL630256,,Intermediate,A,,1,,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,,50597,BAO_0000218
12245,,,2107.0,1,Liver,In vivo,CHEMBL875781,,Intermediate,A,,1,,N,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,50597,BAO_0000218
12246,,,2107.0,1,Liver,In vivo,CHEMBL630257,,Intermediate,A,,1,,N,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,50597,BAO_0000218
12247,,,2107.0,1,Liver,In vivo,CHEMBL630258,,Intermediate,A,,1,,N,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,50597,BAO_0000218
12248,,,,1,,,CHEMBL630259,,Intermediate,A,,1,,N,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,,50597,BAO_0000218
12249,,,2435.0,1,Striatum,,CHEMBL630260,,Intermediate,A,,1,,N,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",,,50597,BAO_0000218
12250,,,2435.0,1,Striatum,,CHEMBL630261,,Intermediate,A,,1,,N,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",,,50597,BAO_0000218
12251,,,,1,,,CHEMBL630262,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,,50597,BAO_0000218
12252,,,,1,,,CHEMBL630263,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,,50597,BAO_0000218
12253,,,,1,,,CHEMBL630264,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,,50597,BAO_0000218
12254,,,,1,,,CHEMBL630265,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,,50597,BAO_0000218
12255,,,,1,,,CHEMBL630266,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,,50597,BAO_0000218
12256,,,2113.0,1,Kidney,,CHEMBL630267,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,,,50597,BAO_0000218
12257,,,2113.0,1,Kidney,,CHEMBL630268,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,,,50597,BAO_0000218
12258,,,,1,,,CHEMBL630269,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,,50597,BAO_0000218
12259,,,,1,,,CHEMBL630270,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,,50597,BAO_0000218
12260,,,2048.0,1,Lung,,CHEMBL630141,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,,,50597,BAO_0000218
12261,,,2048.0,1,Lung,,CHEMBL630142,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,,,50597,BAO_0000218
12262,,,2385.0,1,Muscle tissue,,CHEMBL630143,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,,,50597,BAO_0000218
12263,,,2385.0,1,Muscle tissue,,CHEMBL630144,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,,,50597,BAO_0000218
12264,,,2367.0,1,Prostate gland,,CHEMBL630145,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,,,50597,BAO_0000218
12265,,,2367.0,1,Prostate gland,,CHEMBL630146,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,,,50597,BAO_0000218
12266,,,,1,,,CHEMBL630147,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,,50597,BAO_0000218
12267,,,,1,,,CHEMBL630148,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,,50597,BAO_0000218
12268,,,,1,,,CHEMBL630149,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,,50597,BAO_0000218
12269,,,2106.0,1,Spleen,,CHEMBL630150,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,,,50597,BAO_0000218
12270,,,2106.0,1,Spleen,,CHEMBL630151,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,,,50597,BAO_0000218
12271,,,2046.0,1,Thyroid gland,,CHEMBL632031,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,,,50597,BAO_0000218
12272,,,2046.0,1,Thyroid gland,,CHEMBL632032,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,,,50597,BAO_0000218
12273,,,,1,,,CHEMBL632033,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,,50597,BAO_0000218
12274,,,,1,,,CHEMBL632034,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,,50597,BAO_0000218
12275,,,2385.0,1,Muscle tissue,,CHEMBL632035,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,,,50597,BAO_0000218
12276,,,,1,,,CHEMBL632036,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,,50597,BAO_0000218
12277,,,2046.0,1,Thyroid gland,,CHEMBL632037,,Intermediate,A,,1,,N,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,,,50597,BAO_0000218
12278,,,178.0,1,Blood,,CHEMBL632038,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,,50597,BAO_0000218
12279,,,178.0,1,Blood,,CHEMBL632039,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,,50597,BAO_0000218
12280,,,178.0,1,Blood,,CHEMBL632040,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,,50597,BAO_0000218
12281,,,178.0,1,Blood,,CHEMBL632041,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,,50597,BAO_0000218
12282,,,178.0,1,Blood,,CHEMBL632042,,Intermediate,A,,1,,N,"Concentration of compound in blood of dog 2, after administering intravenously",,,50588,BAO_0000218
12283,,,,1,,,CHEMBL632043,,Intermediate,A,,1,,N,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,,50588,BAO_0000218
12284,,,,1,,,CHEMBL632044,,Intermediate,A,,1,,N,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,,50588,BAO_0000218
12285,,,2107.0,1,Liver,,CHEMBL632045,,Intermediate,A,,1,,N,"Concentration of compound in liver of dog 1, after administering intravenously",,,50588,BAO_0000218
12286,,,2107.0,1,Liver,,CHEMBL632046,,Intermediate,A,,1,,N,"Concentration of compound in liver of dog 2, after administering intravenously",,,50588,BAO_0000218
12287,,,2048.0,1,Lung,,CHEMBL632047,,Intermediate,A,,1,,N,"Concentration of compound in lung of dog 1, after administering intravenously",,,50588,BAO_0000218
12288,,,2048.0,1,Lung,,CHEMBL632048,,Intermediate,A,,1,,N,"Concentration of compound in lung of dog 2, after administering intravenously",,,50588,BAO_0000218
12289,,,2385.0,1,Muscle tissue,,CHEMBL632049,,Intermediate,A,,1,,N,"Concentration of compound in muscle of dog 1, after administering intravenously",,,50588,BAO_0000218
12290,,,2385.0,1,Muscle tissue,,CHEMBL876418,,Intermediate,A,,1,,N,"Concentration of compound in muscle of dog 2, after administering intravenously",,,50588,BAO_0000218
12291,,,2106.0,1,Spleen,,CHEMBL632050,,Intermediate,A,,1,,N,"Concentration of compound in spleen of dog 1,after administering intravenously",,,50588,BAO_0000218
12292,,,2106.0,1,Spleen,,CHEMBL632051,,Intermediate,A,,1,,N,"Concentration of compound in spleen of dog 2, after administering intravenously",,,50588,BAO_0000218
12293,,,,0,,,CHEMBL632052,,Autocuration,F,,1,,U,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,,22224,BAO_0000218
12294,,,,0,,,CHEMBL632053,,Autocuration,F,,1,,U,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,,22224,BAO_0000218
12295,,,,0,,,CHEMBL632054,,Autocuration,A,,1,,U,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,22224,BAO_0000218
12296,,,,0,,,CHEMBL632055,,Autocuration,F,,1,,U,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,22224,BAO_0000218
12297,,,,0,,,CHEMBL631181,,Autocuration,F,,1,,U,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,,22224,BAO_0000218
12298,,,,0,,,CHEMBL631182,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,,22224,BAO_0000218
12299,,,,0,,,CHEMBL631183,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,22224,BAO_0000218
12300,,,,0,,,CHEMBL631184,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,22224,BAO_0000218
12301,,,,0,,,CHEMBL629774,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,22224,BAO_0000218
12302,,,,0,,,CHEMBL629775,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,22224,BAO_0000218
12303,,,,0,,,CHEMBL876549,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,22224,BAO_0000218
12304,,,,0,,,CHEMBL628172,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,22224,BAO_0000218
12305,,,,0,,,CHEMBL628173,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,22224,BAO_0000218
12306,,,,0,,,CHEMBL628174,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,,22224,BAO_0000218
12307,,,,0,,,CHEMBL628175,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,,22224,BAO_0000218
12308,,,,0,,,CHEMBL628176,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,22224,BAO_0000218
12309,,,,0,,,CHEMBL628177,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,22224,BAO_0000218
12310,,,,0,,,CHEMBL628178,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,22224,BAO_0000218
12311,,,,0,,,CHEMBL628179,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,22224,BAO_0000218
12312,,,,0,,,CHEMBL628180,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,22224,BAO_0000218
12313,,,,0,,,CHEMBL628181,,Autocuration,A,,1,,U,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,,22224,BAO_0000218
12314,,,,0,,,CHEMBL628182,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,22224,BAO_0000218
12315,,,,0,,,CHEMBL628183,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,22224,BAO_0000218
12316,,,,0,,,CHEMBL628184,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,,22224,BAO_0000218
12317,,,,0,,,CHEMBL628185,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,22224,BAO_0000218
12318,,,,0,,,CHEMBL875617,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,22224,BAO_0000218
12319,,,,0,,,CHEMBL628186,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,22224,BAO_0000218
12320,,,,0,,,CHEMBL628187,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,22224,BAO_0000218
12321,,,,0,,,CHEMBL628188,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,22224,BAO_0000218
12322,,,,0,,,CHEMBL628189,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,22224,BAO_0000218
12323,,,,0,,,CHEMBL628190,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,,22224,BAO_0000218
12324,,,,0,,,CHEMBL628191,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,22224,BAO_0000218
12325,,,,0,,,CHEMBL626513,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,,22224,BAO_0000218
12326,,,2046.0,1,Thyroid gland,,CHEMBL626514,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",,,50597,BAO_0000218
12327,,,2046.0,1,Thyroid gland,,CHEMBL626515,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",,,50597,BAO_0000218
12328,,,2046.0,1,Thyroid gland,,CHEMBL626516,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",,,50597,BAO_0000218
12329,,,2046.0,1,Thyroid gland,,CHEMBL626517,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",,,50597,BAO_0000218
12330,,,2046.0,1,Thyroid gland,,CHEMBL626518,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",,,50597,BAO_0000218
12331,,,2046.0,1,Thyroid gland,,CHEMBL626519,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",,,50597,BAO_0000218
12332,,,2046.0,1,Thyroid gland,,CHEMBL626520,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",,,50597,BAO_0000218
12333,,,2046.0,1,Thyroid gland,,CHEMBL626521,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",,,50597,BAO_0000218
12334,,,2046.0,1,Thyroid gland,,CHEMBL626522,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",,,50597,BAO_0000218
12335,,,2046.0,1,Thyroid gland,,CHEMBL626523,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",,,50597,BAO_0000218
12336,,,2046.0,1,Thyroid gland,,CHEMBL626524,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",,,50597,BAO_0000218
12337,,,2046.0,1,Thyroid gland,,CHEMBL626688,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",,,50597,BAO_0000218
12338,,,2046.0,1,Thyroid gland,,CHEMBL626689,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",,,50597,BAO_0000218
12339,,,2046.0,1,Thyroid gland,,CHEMBL626690,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",,,50597,BAO_0000218
12340,,,2046.0,1,Thyroid gland,,CHEMBL626691,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",,,50597,BAO_0000218
12341,,,2046.0,1,Thyroid gland,,CHEMBL627319,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",,,50597,BAO_0000218
12342,,,2046.0,1,Thyroid gland,,CHEMBL624052,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",,,50597,BAO_0000218
12343,,,2046.0,1,Thyroid gland,,CHEMBL624053,,Intermediate,A,,1,,N,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",,,50597,BAO_0000218
12344,,,,1,,,CHEMBL624054,,Intermediate,A,,1,,N,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,BAO_0000218
12345,,,,1,,,CHEMBL624055,,Intermediate,A,,1,,N,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,BAO_0000218
12346,,,,1,,,CHEMBL624056,,Intermediate,A,,1,,N,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,BAO_0000218
12347,,,995.0,1,Uterus,,CHEMBL624057,,Intermediate,A,,1,,N,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,BAO_0000218
12348,,,995.0,1,Uterus,,CHEMBL622281,,Intermediate,A,,1,,N,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,BAO_0000218
12349,,,995.0,1,Uterus,,CHEMBL622282,,Intermediate,A,,1,,N,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,BAO_0000218
12350,,,995.0,1,Uterus,,CHEMBL622283,,Intermediate,A,,1,,N,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,BAO_0000218
12351,,,995.0,1,Uterus,,CHEMBL622284,,Intermediate,A,,1,,N,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,BAO_0000218
12352,,,995.0,1,Uterus,,CHEMBL622285,,Intermediate,A,,1,,N,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,BAO_0000218
12353,,,995.0,1,Uterus,,CHEMBL622286,,Intermediate,A,,1,,N,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,50597,BAO_0000218
12354,,,,0,,,CHEMBL622287,,Autocuration,P,,1,,U,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,,22224,BAO_0000100
12355,,,,1,,,CHEMBL622288,,Intermediate,A,,1,,N,Partition coefficient (logD7.4),,,50594,BAO_0000218
12356,,,,1,,,CHEMBL622289,,Intermediate,A,,1,,N,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,,50594,BAO_0000218
12357,,,955.0,1,Brain,,CHEMBL622290,,Intermediate,A,,1,,N,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,,50594,BAO_0000218
12358,,,,1,,,CHEMBL622291,,Intermediate,A,,1,,N,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,,50594,BAO_0000218
12359,,,955.0,1,Brain,,CHEMBL622292,,Intermediate,A,,1,,N,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,,50594,BAO_0000218
12360,,,,1,,,CHEMBL622293,,Intermediate,A,,1,,N,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,,50594,BAO_0000218
12361,,,955.0,1,Brain,,CHEMBL622294,,Intermediate,A,,1,,N,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,,50594,BAO_0000218
12362,,,,1,,,CHEMBL622295,,Intermediate,A,,1,,N,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,,50594,BAO_0000218
12363,,,955.0,1,Brain,,CHEMBL622296,,Intermediate,A,,1,,N,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,,50597,BAO_0000218
12364,,,1969.0,1,Plasma,,CHEMBL874409,,Intermediate,A,,1,,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,,,50597,BAO_0000218
12365,,,1969.0,1,Plasma,,CHEMBL622297,,Intermediate,A,,1,,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,,50597,BAO_0000218
12366,,,1969.0,1,Plasma,,CHEMBL622298,,Intermediate,A,,1,,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,,50597,BAO_0000218
12367,,,1969.0,1,Plasma,,CHEMBL622299,,Intermediate,A,,1,,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,,50597,BAO_0000218
12368,,,1969.0,1,Plasma,,CHEMBL622300,,Intermediate,A,,1,,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,,50597,BAO_0000218
12369,,,1969.0,1,Plasma,,CHEMBL622301,,Intermediate,A,,1,,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,,50597,BAO_0000218
12370,,,1969.0,1,Plasma,,CHEMBL622302,,Intermediate,A,,1,,N,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,,50597,BAO_0000218
12371,,,1969.0,1,Plasma,,CHEMBL622303,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,,50597,BAO_0000218
12372,,,1969.0,1,Plasma,,CHEMBL622304,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,,50597,BAO_0000218
12373,,,1969.0,1,Plasma,,CHEMBL622305,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,,,50597,BAO_0000218
12374,,,1969.0,1,Plasma,,CHEMBL622306,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,,50597,BAO_0000218
12375,,,1969.0,1,Plasma,,CHEMBL626864,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,,,50597,BAO_0000218
12376,,,1969.0,1,Plasma,,CHEMBL626865,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,,50597,BAO_0000218
12377,,,1969.0,1,Plasma,,CHEMBL626866,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,,,50597,BAO_0000218
12378,,,1969.0,1,Plasma,,CHEMBL626867,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,,50597,BAO_0000218
12379,,,1969.0,1,Plasma,,CHEMBL626868,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,,50597,BAO_0000218
12380,,,1969.0,1,Plasma,,CHEMBL626869,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,,,50597,BAO_0000218
12381,,,1969.0,1,Plasma,,CHEMBL626870,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,,50597,BAO_0000218
12382,,,1969.0,1,Plasma,,CHEMBL626871,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,,,50597,BAO_0000218
12383,,,1969.0,1,Plasma,,CHEMBL626872,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,,50597,BAO_0000218
12384,,,1969.0,1,Plasma,,CHEMBL632185,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,,50597,BAO_0000218
12385,,,1969.0,1,Plasma,,CHEMBL632186,,Intermediate,A,,1,,N,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,,,50597,BAO_0000218
12386,,,,0,,,CHEMBL629310,,Autocuration,A,,1,,U,Amount of acetic acid produced by the compound,,,22224,BAO_0000019
12387,,,,0,,,CHEMBL629311,,Autocuration,A,,1,,U,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,,22224,BAO_0000019
12388,,,,1,,,CHEMBL629312,,Intermediate,A,,1,,N,Log of (Cbrain/Cblood) in rats,,,50597,BAO_0000218
12389,,,,0,,,CHEMBL629313,,Autocuration,A,,1,,U,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,22224,BAO_0000221
12390,,,,0,,,CHEMBL629314,,Autocuration,A,,1,,U,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,22224,BAO_0000221
12391,,,,0,,,CHEMBL629315,,Autocuration,A,,1,,U,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,22224,BAO_0000221
12392,,,,0,,,CHEMBL629316,,Autocuration,B,,1,,U,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,,22224,BAO_0000219
12393,,,,0,,,CHEMBL629317,,Autocuration,A,,1,,U,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,22224,BAO_0000221
12394,,,,0,,,CHEMBL629318,,Autocuration,A,,1,,U,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,22224,BAO_0000019
12395,,,,0,,,CHEMBL877497,,Autocuration,A,,1,,U,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,,22224,BAO_0000019
12396,,,,0,,,CHEMBL629319,,Autocuration,A,,1,,U,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,,22224,BAO_0000019
12397,,,,0,,,CHEMBL629320,,Autocuration,A,,1,,U,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,22224,BAO_0000019
12398,,,,0,,,CHEMBL629496,,Autocuration,A,,1,,U,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,,22224,BAO_0000019
12399,,,,0,,,CHEMBL629497,,Autocuration,A,,1,,U,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,,22224,BAO_0000019
12400,,,,0,,,CHEMBL629498,,Autocuration,A,,1,,U,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,,22224,BAO_0000019
12401,,,,0,,,CHEMBL629499,,Autocuration,A,,1,,U,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,,22224,BAO_0000019
12402,,,,0,,,CHEMBL629500,,Autocuration,A,,1,,U,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,22224,BAO_0000019
12403,,,,0,,,CHEMBL629501,,Autocuration,A,,1,,U,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,,22224,BAO_0000019
12404,,,,0,,,CHEMBL629502,,Autocuration,A,,1,,U,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,,22224,BAO_0000019
12405,,,,0,,In vivo,CHEMBL629503,,Autocuration,F,,1,,U,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,,22224,BAO_0000218
12406,,,,1,,,CHEMBL629504,,Intermediate,A,,1,,N,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,,50588,BAO_0000218
12407,,,,0,,,CHEMBL629505,,Autocuration,A,,1,,U,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,,22224,BAO_0000019
12408,,,,0,,,CHEMBL629506,,Autocuration,A,,1,,U,Compound was evaluated for total body clearance,,,22224,BAO_0000019
12409,,,,0,,,CHEMBL629507,,Autocuration,A,,1,,U,Compound was evaluated for volume of distribution at steady state,,,22224,BAO_0000019
12410,,,,0,,,CHEMBL877498,,Autocuration,A,,1,,U,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,,22224,BAO_0000019
12411,,,,0,,,CHEMBL629508,,Autocuration,A,,1,,U,Percentage of the diamine which is monoprotonated at pH 7.4,,,22224,BAO_0000019
12412,,,,0,,,CHEMBL629509,,Autocuration,A,,1,,U,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,,22224,BAO_0000019
12413,,,178.0,1,Blood,,CHEMBL629510,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,,50597,BAO_0000218
12414,,,178.0,1,Blood,,CHEMBL629511,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,,50597,BAO_0000218
12415,,,178.0,1,Blood,,CHEMBL629512,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,50597,BAO_0000218
12416,,,178.0,1,Blood,,CHEMBL629513,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,50597,BAO_0000218
12417,,,178.0,1,Blood,,CHEMBL629514,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,,50597,BAO_0000218
12418,,,178.0,1,Blood,,CHEMBL628447,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,50597,BAO_0000218
12419,,,178.0,1,Blood,,CHEMBL628448,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,,50597,BAO_0000218
12420,,,178.0,1,Blood,,CHEMBL628449,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,,50597,BAO_0000218
12421,,,178.0,1,Blood,,CHEMBL631119,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,,50597,BAO_0000218
12422,,,178.0,1,Blood,,CHEMBL631120,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,,50597,BAO_0000218
12423,,,178.0,1,Blood,,CHEMBL631121,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,,50597,BAO_0000218
12424,,,178.0,1,Blood,,CHEMBL874458,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,,,50597,BAO_0000218
12425,,,178.0,1,Blood,,CHEMBL631122,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,50597,BAO_0000218
12426,,,178.0,1,Blood,,CHEMBL631123,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,50597,BAO_0000218
12427,,,178.0,1,Blood,,CHEMBL631124,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,50597,BAO_0000218
12428,,,178.0,1,Blood,,CHEMBL631125,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,,50597,BAO_0000218
12429,,,178.0,1,Blood,,CHEMBL631290,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,50597,BAO_0000218
12430,,,178.0,1,Blood,,CHEMBL631291,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,50597,BAO_0000218
12431,,,178.0,1,Blood,,CHEMBL631292,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,50597,BAO_0000218
12432,,,178.0,1,Blood,,CHEMBL631293,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,,50597,BAO_0000218
12433,,,178.0,1,Blood,,CHEMBL631294,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,50597,BAO_0000218
12434,,,178.0,1,Blood,,CHEMBL631295,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,50597,BAO_0000218
12435,,,178.0,1,Blood,,CHEMBL631296,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,,50597,BAO_0000218
12436,,,178.0,1,Blood,,CHEMBL631297,,Intermediate,A,,1,,N,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,50597,BAO_0000218
12437,,,,0,,,CHEMBL631298,,Autocuration,A,,1,,U,Maximum biodistribution (Bmax) was determined.,,,22224,BAO_0000218
12438,,,,1,,,CHEMBL631299,,Intermediate,A,,1,,N,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,,50594,BAO_0000218
12439,,,,1,,,CHEMBL631300,,Intermediate,A,,1,,N,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,,50594,BAO_0000218
12440,,,,1,,,CHEMBL631301,,Intermediate,A,,1,,N,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,,50594,BAO_0000218
12441,,,,1,,,CHEMBL630291,,Intermediate,A,,1,,N,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,,50594,BAO_0000218
12442,,,,0,,,CHEMBL630292,,Autocuration,A,,1,,U,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,,22224,BAO_0000218
12443,,,,0,,,CHEMBL630293,,Autocuration,A,,1,,U,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,,22224,BAO_0000218
12444,,,,0,,,CHEMBL630294,,Autocuration,A,,1,,U,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,,22224,BAO_0000218
12445,,,,0,,,CHEMBL630295,,Autocuration,A,,1,,U,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,,22224,BAO_0000218
12446,,,,0,,,CHEMBL630296,,Autocuration,A,,1,,U,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,,22224,BAO_0000218
12447,,,,0,,,CHEMBL626782,,Autocuration,A,,1,,U,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,,22224,BAO_0000218
12448,,,,0,,,CHEMBL626783,,Autocuration,A,,1,,U,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,,22224,BAO_0000218
12449,,,,0,,,CHEMBL626784,,Autocuration,A,,1,,U,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,,22224,BAO_0000218
12450,,,,0,,,CHEMBL626785,,Autocuration,A,,1,,U,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,,22224,BAO_0000218
12451,,,,0,,,CHEMBL626786,,Autocuration,A,,1,,U,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,,22224,BAO_0000218
12452,,,,0,,,CHEMBL626787,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,22224,BAO_0000218
12453,,,,0,,,CHEMBL626788,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,22224,BAO_0000218
12454,,,,0,,,CHEMBL625927,,Autocuration,A,,1,,U,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,22224,BAO_0000218
12455,,,178.0,1,Blood,,CHEMBL625928,,Intermediate,A,,1,,N,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12456,,,178.0,1,Blood,,CHEMBL625929,,Intermediate,A,,1,,N,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,50597,BAO_0000218
12457,,,178.0,1,Blood,,CHEMBL625930,,Intermediate,A,,1,,N,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,,50597,BAO_0000218
12458,,,178.0,1,Blood,,CHEMBL625931,,Intermediate,A,,1,,N,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",,,50597,BAO_0000218
12459,,,178.0,1,Blood,,CHEMBL627230,,Intermediate,A,,1,,N,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,,,50597,BAO_0000218
12460,,,178.0,1,Blood,,CHEMBL627231,,Intermediate,A,,1,,N,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12461,,,178.0,1,Blood,,CHEMBL627232,,Intermediate,A,,1,,N,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,50597,BAO_0000218
12462,,,178.0,1,Blood,,CHEMBL627233,,Intermediate,A,,1,,N,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,,50597,BAO_0000218
12463,,,178.0,1,Blood,,CHEMBL875470,,Intermediate,A,,1,,N,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12464,,,178.0,1,Blood,,CHEMBL627234,,Intermediate,A,,1,,N,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12465,,,178.0,1,Blood,,CHEMBL627235,,Intermediate,A,,1,,N,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12466,,,178.0,1,Blood,,CHEMBL627236,,Intermediate,A,,1,,N,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12467,,,178.0,1,Blood,,CHEMBL627237,,Intermediate,A,,1,,N,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12468,,,178.0,1,Blood,,CHEMBL627238,,Intermediate,A,,1,,N,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12469,,,178.0,1,Blood,,CHEMBL627239,,Intermediate,A,,1,,N,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12470,,,178.0,1,Blood,,CHEMBL627240,,Intermediate,A,,1,,N,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12471,,,178.0,1,Blood,,CHEMBL627241,,Intermediate,A,,1,,N,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12472,,,178.0,1,Blood,,CHEMBL627242,,Intermediate,A,,1,,N,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12473,,,178.0,1,Blood,,CHEMBL627243,,Intermediate,A,,1,,N,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,,,50597,BAO_0000218
12474,,,178.0,1,Blood,,CHEMBL627244,,Intermediate,A,,1,,N,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,50597,BAO_0000218
12475,,,178.0,1,Blood,,CHEMBL627245,,Intermediate,A,,1,,N,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12476,,,178.0,1,Blood,,CHEMBL627246,,Intermediate,A,,1,,N,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12477,,,178.0,1,Blood,,CHEMBL627247,,Intermediate,A,,1,,N,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12478,,,178.0,1,Blood,,CHEMBL627248,,Intermediate,A,,1,,N,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12479,,,178.0,1,Blood,,CHEMBL627249,,Intermediate,A,,1,,N,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12480,,,178.0,1,Blood,,CHEMBL625569,,Intermediate,A,,1,,N,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12481,,,178.0,1,Blood,,CHEMBL625570,,Intermediate,A,,1,,N,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12482,,,178.0,1,Blood,,CHEMBL625571,,Intermediate,A,,1,,N,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12483,,,178.0,1,Blood,,CHEMBL625572,,Intermediate,A,,1,,N,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,50597,BAO_0000218
12484,,,178.0,1,Blood,,CHEMBL625573,,Intermediate,A,,1,,N,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,50597,BAO_0000218
12485,,,178.0,1,Blood,,CHEMBL625574,,Intermediate,A,,1,,N,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,,,50597,BAO_0000218
12486,,,178.0,1,Blood,,CHEMBL626245,,Intermediate,A,,1,,N,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,50597,BAO_0000218
12487,,,178.0,1,Blood,,CHEMBL626246,,Intermediate,A,,1,,N,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12488,,,,0,,,CHEMBL626247,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,22224,BAO_0000218
12489,,,,0,,,CHEMBL626248,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,22224,BAO_0000218
12490,,,,0,,,CHEMBL626249,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,22224,BAO_0000218
12491,,,,0,,,CHEMBL626420,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,22224,BAO_0000218
12492,,,,0,,,CHEMBL626421,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,22224,BAO_0000218
12493,,,,0,,,CHEMBL626422,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,22224,BAO_0000218
12494,,,,0,,,CHEMBL626423,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,22224,BAO_0000218
12495,,,,0,,,CHEMBL626424,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,22224,BAO_0000218
12496,,,,1,,,CHEMBL626425,,Intermediate,A,,1,,N,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,,50588,BAO_0000218
12497,,,,1,,,CHEMBL875476,,Intermediate,A,,1,,N,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,,50597,BAO_0000218
12498,,,,1,,,CHEMBL626426,,Intermediate,A,,1,,N,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,,100710,BAO_0000218
12499,,,,0,,,CHEMBL626427,,Autocuration,P,,1,,U,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,,22224,BAO_0000100
12500,,,,0,,,CHEMBL626428,,Autocuration,P,,1,,U,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,,22224,BAO_0000100
12501,,,,0,,,CHEMBL626429,,Autocuration,A,,1,,U,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,,22224,BAO_0000019
12502,,,1088.0,0,Urine,,CHEMBL625025,,Autocuration,A,,1,,U,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,,,22224,BAO_0000019
12503,,,178.0,1,Blood,,CHEMBL625026,,Intermediate,A,,1,,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12504,,,178.0,1,Blood,,CHEMBL625027,,Intermediate,A,,1,,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12505,,,178.0,1,Blood,,CHEMBL874410,,Intermediate,A,,1,,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12506,,,178.0,1,Blood,,CHEMBL625028,,Intermediate,A,,1,,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,50597,BAO_0000218
12507,,,178.0,1,Blood,,CHEMBL625029,,Intermediate,A,,1,,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,50597,BAO_0000218
12508,,,178.0,1,Blood,,CHEMBL625030,,Intermediate,A,,1,,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12509,,,178.0,1,Blood,,CHEMBL625031,,Intermediate,A,,1,,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12510,,,178.0,1,Blood,,CHEMBL625032,,Intermediate,A,,1,,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12511,,,178.0,1,Blood,,CHEMBL625033,,Intermediate,A,,1,,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12512,,,178.0,1,Blood,,CHEMBL625034,,Intermediate,A,,1,,N,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12513,,,948.0,1,Heart,,CHEMBL624872,,Intermediate,A,,1,,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12514,,,948.0,1,Heart,,CHEMBL624873,,Intermediate,A,,1,,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12515,,,948.0,1,Heart,,CHEMBL624874,,Intermediate,A,,1,,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12516,,,948.0,1,Heart,,CHEMBL624875,,Intermediate,A,,1,,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,50597,BAO_0000218
12517,,,948.0,1,Heart,,CHEMBL624876,,Intermediate,A,,1,,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,50597,BAO_0000218
12518,,,948.0,1,Heart,,CHEMBL624877,,Intermediate,A,,1,,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12519,,,948.0,1,Heart,,CHEMBL624878,,Intermediate,A,,1,,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12520,,,948.0,1,Heart,,CHEMBL624879,,Intermediate,A,,1,,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12521,,,948.0,1,Heart,,CHEMBL624880,,Intermediate,A,,1,,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12522,,,948.0,1,Heart,,CHEMBL624881,,Intermediate,A,,1,,N,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,,,50597,BAO_0000218
12523,,,948.0,1,Heart,,CHEMBL624882,,Intermediate,A,,1,,N,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",,,50597,BAO_0000218
12524,,,2113.0,1,Kidney,,CHEMBL624883,,Intermediate,A,,1,,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12525,,,2113.0,1,Kidney,,CHEMBL624884,,Intermediate,A,,1,,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12526,,,2113.0,1,Kidney,,CHEMBL624885,,Intermediate,A,,1,,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12527,,,2113.0,1,Kidney,,CHEMBL624886,,Intermediate,A,,1,,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,50597,BAO_0000218
12528,,,2113.0,1,Kidney,,CHEMBL624887,,Intermediate,A,,1,,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,50597,BAO_0000218
12529,,,2113.0,1,Kidney,,CHEMBL624888,,Intermediate,A,,1,,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12530,,,2113.0,1,Kidney,,CHEMBL624889,,Intermediate,A,,1,,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12531,,,2113.0,1,Kidney,,CHEMBL624890,,Intermediate,A,,1,,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12532,,,2113.0,1,Kidney,,CHEMBL621964,,Intermediate,A,,1,,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12533,,,2113.0,1,Kidney,,CHEMBL621965,,Intermediate,A,,1,,N,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12534,,,2107.0,1,Liver,,CHEMBL621966,,Intermediate,A,,1,,N,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12535,,,2107.0,1,Liver,,CHEMBL621967,,Intermediate,A,,1,,N,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12536,,,2107.0,1,Liver,,CHEMBL622164,,Intermediate,A,,1,,N,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12537,,,,0,,,CHEMBL623097,,Autocuration,A,,1,,U,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,,22224,BAO_0000019
12538,,,,0,,,CHEMBL623098,,Autocuration,A,,1,,U,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,,22224,BAO_0000019
12539,,,,0,,,CHEMBL623099,,Autocuration,A,,1,,U,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,,22224,BAO_0000019
12540,,,,0,,,CHEMBL623100,,Autocuration,A,,1,,U,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,,22224,BAO_0000019
12541,,,,1,,,CHEMBL628673,,Intermediate,A,,1,,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,,50597,BAO_0000218
12542,,,,1,,,CHEMBL628674,,Intermediate,A,,1,,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,,50597,BAO_0000218
12543,,,,1,,,CHEMBL628675,,Intermediate,A,,1,,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,,50597,BAO_0000218
12544,,,,1,,,CHEMBL627644,,Intermediate,A,,1,,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,,50597,BAO_0000218
12545,,,,1,,,CHEMBL627645,,Intermediate,A,,1,,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,,50597,BAO_0000218
12546,,,,1,,,CHEMBL627646,,Intermediate,A,,1,,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,,50597,BAO_0000218
12547,,,,1,,,CHEMBL627647,,Intermediate,A,,1,,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,,50597,BAO_0000218
12548,,,,1,,,CHEMBL627648,,Intermediate,A,,1,,N,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,,50597,BAO_0000218
12549,,,,1,,,CHEMBL627649,,Intermediate,A,,1,,N,Free level in rat plasma,,,50597,BAO_0000218
12550,,,,0,,,CHEMBL628313,,Autocuration,A,,1,,U,Level reaching in blood plasma of rat or human was determined,,,22224,BAO_0000019
12551,,,,1,,,CHEMBL628314,,Intermediate,A,,1,,N,Log (Cbrain/Cblood) in rats,,,50597,BAO_0000218
12552,,,,0,,,CHEMBL628315,,Autocuration,A,,1,,U,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,,22224,BAO_0000019
12553,,,,0,,,CHEMBL628316,,Autocuration,A,,1,,U,Mean percentage of compound transport through membrane; expressed as membrane transport,,,22224,BAO_0000019
12554,,,,0,,,CHEMBL628317,,Autocuration,A,,1,,U,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,,22224,BAO_0000218
12555,,,,0,,,CHEMBL628473,,Autocuration,A,,1,,U,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,,22224,BAO_0000019
12556,,,,0,,,CHEMBL628474,,Autocuration,A,,1,,U,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,,22224,BAO_0000019
12557,,,,0,,,CHEMBL628475,,Autocuration,A,,1,,U,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,,22224,BAO_0000019
12558,,,,0,,,CHEMBL628476,,Autocuration,A,,1,,U,Net water uptake by a carrier mediated transport (%cm) mechanism,,,22224,BAO_0000019
12559,,,,0,,,CHEMBL628477,,Autocuration,A,,1,,U,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,,22224,BAO_0000218
12560,,,,1,,,CHEMBL628478,,Intermediate,A,,1,,N,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,,50506,BAO_0000218
12561,,,,1,,,CHEMBL628479,,Intermediate,A,,1,,N,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,,50506,BAO_0000218
12562,,,,0,,,CHEMBL628480,,Autocuration,A,,1,,U,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,,22224,BAO_0000218
12563,,,,0,,,CHEMBL628481,,Autocuration,A,,1,,U,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,,22224,BAO_0000218
12564,,,,1,,,CHEMBL628482,,Intermediate,A,,1,,N,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,,50597,BAO_0000218
12565,,,,1,,,CHEMBL628483,,Intermediate,A,,1,,N,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,,50597,BAO_0000218
12566,,,1969.0,1,Plasma,,CHEMBL628484,,Intermediate,A,,1,,N,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,,50597,BAO_0000218
12567,,,1969.0,1,Plasma,,CHEMBL628485,,Intermediate,A,,1,,N,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,,50597,BAO_0000218
12568,,,1969.0,1,Plasma,,CHEMBL628486,,Intermediate,A,,1,,N,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",,,100710,BAO_0000218
12569,,,1969.0,1,Plasma,,CHEMBL628487,,Intermediate,A,,1,,N,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",,,50587,BAO_0000218
12570,,,1969.0,1,Plasma,,CHEMBL628488,,Intermediate,A,,1,,N,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,,50597,BAO_0000218
12571,,,1969.0,1,Plasma,,CHEMBL628489,,Intermediate,A,,1,,N,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,,50597,BAO_0000218
12572,,,1969.0,1,Plasma,,CHEMBL628490,,Intermediate,A,,1,,N,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,,50597,BAO_0000218
12573,,,,1,,,CHEMBL628491,,Intermediate,A,,1,,N,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,100710,BAO_0000218
12574,,,,1,,,CHEMBL877507,,Intermediate,A,,1,,N,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,100710,BAO_0000218
12575,,,,0,,,CHEMBL628492,,Autocuration,A,,1,,U,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,22224,BAO_0000218
12576,,,,0,,,CHEMBL628493,,Autocuration,A,,1,,U,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,,22224,BAO_0000019
12577,,,,0,,,CHEMBL628494,,Autocuration,A,,1,,U,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,,22224,BAO_0000019
12578,,,,0,,,CHEMBL628495,,Autocuration,A,,1,,U,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,,22224,BAO_0000019
12579,,,,1,,,CHEMBL628496,,Intermediate,A,,1,,N,Permeability in Caco-2 assay at 10E-6,,,50587,BAO_0000218
12580,,,955.0,0,Brain,,CHEMBL628497,,Autocuration,A,,1,,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,,22224,BAO_0000218
12581,,,955.0,0,Brain,,CHEMBL628498,,Autocuration,A,,1,,U,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,,22224,BAO_0000218
12582,,,,0,,,CHEMBL628499,,Autocuration,A,,1,,U,Plasma protein binding was determined,,,22224,BAO_0000019
12583,,,,0,,,CHEMBL627656,,Autocuration,A,,1,,U,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,,22224,BAO_0000218
12584,,,,0,,,CHEMBL627657,,Autocuration,A,,1,,U,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,,22224,BAO_0000218
12585,,,,0,,,CHEMBL626808,,Autocuration,A,,1,,U,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,,22224,BAO_0000218
12586,,,,0,,,CHEMBL626809,,Autocuration,A,,1,,U,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,,22224,BAO_0000218
12587,,,,0,,,CHEMBL626810,,Autocuration,A,,1,,U,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,,22224,BAO_0000218
12588,,,,0,,,CHEMBL626811,,Autocuration,A,,1,,U,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,,22224,BAO_0000218
12589,,,,0,,,CHEMBL874465,,Autocuration,A,,1,,U,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,,22224,BAO_0000218
12590,,,,0,,,CHEMBL626812,,Autocuration,A,,1,,U,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,,22224,BAO_0000218
12591,,,,0,,,CHEMBL626813,,Autocuration,A,,1,,U,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,,22224,BAO_0000218
12592,,,,0,,,CHEMBL626814,,Autocuration,A,,1,,U,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,,22224,BAO_0000218
12593,,,,0,,,CHEMBL626815,,Autocuration,A,,1,,U,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,,22224,BAO_0000019
12594,,,,0,,,CHEMBL628566,,Autocuration,A,,1,,U,Partition coefficient (logP),,,22224,BAO_0000019
12595,,,,0,,,CHEMBL628567,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,22229,BAO_0000100
12596,,,,0,,,CHEMBL628568,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12597,,,,1,,In vivo,CHEMBL628569,,Intermediate,A,,1,,N,C max in dog,,,50588,BAO_0000218
12598,,,,1,,In vivo,CHEMBL628570,,Intermediate,A,,1,,N,C max in guinea pig,,,50512,BAO_0000218
12599,,,,0,,In vivo,CHEMBL628571,,Autocuration,A,,1,,U,C max value was evaluated,,,22224,BAO_0000218
12600,,,,0,,In vivo,CHEMBL628572,,Autocuration,A,,1,,U,Cmax value after oral dose of 0.1 mg//kg,,,22224,BAO_0000218
12601,,,,0,,In vivo,CHEMBL628573,,Autocuration,A,,1,,U,Cmax value after oral dose of 0.3 mg/kg,,,22224,BAO_0000218
12602,,,,0,,In vivo,CHEMBL628574,,Autocuration,A,,1,,U,Cmax value after oral dose of 1 mg/kg,,,22224,BAO_0000218
12603,,,,0,,In vivo,CHEMBL628575,,Autocuration,A,,1,,U,Cmax value after oral dose of 10 mg/kg,,,22224,BAO_0000218
12604,,,,0,,In vivo,CHEMBL628576,,Autocuration,A,,1,,U,Cmax value after oral dose of 23.4 mg/kg,,,22224,BAO_0000218
12605,,,,0,,In vivo,CHEMBL628577,,Autocuration,A,,1,,U,Cmax value after oral dose of 3 mg/kg,,,22224,BAO_0000218
12606,,,,0,,In vivo,CHEMBL628578,,Autocuration,A,,1,,U,Cmax value after oral dose of 3.87 mg/kg,,,22224,BAO_0000218
12607,,,,1,,In vivo,CHEMBL874466,,Intermediate,A,,1,,N,Cmax value in female Beagle dogs,,,50588,BAO_0000218
12608,,,,1,,In vivo,CHEMBL628579,,Intermediate,A,,1,,N,Cmax value in male rats,,,50597,BAO_0000218
12609,,,1969.0,1,Plasma,In vivo,CHEMBL628580,,Intermediate,A,,1,,N,Cmax value in rat plasma when administered 20 mg/kg perorally,,,50597,BAO_0000218
12610,,,1969.0,1,Plasma,In vivo,CHEMBL628581,,Intermediate,A,,1,,N,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,,50588,BAO_0000218
12611,,,1969.0,1,Plasma,In vivo,CHEMBL628582,,Intermediate,A,,1,,N,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,,50588,BAO_0000218
12612,,,,1,,,CHEMBL628583,,Intermediate,A,,1,,N,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,,50588,BAO_0000218
12613,,,,0,,,CHEMBL625782,,Autocuration,A,,1,,U,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,,22224,BAO_0000218
12614,,,,1,,,CHEMBL625783,,Intermediate,A,,1,,N,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,,50592,BAO_0000218
12615,,,,1,,,CHEMBL625784,,Intermediate,A,,1,,N,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,,50597,BAO_0000218
12616,,,1969.0,1,Plasma,,CHEMBL625785,,Intermediate,A,,1,,N,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,,,50797,BAO_0000218
12617,,,,1,,,CHEMBL625786,,Intermediate,A,,1,,N,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,,50597,BAO_0000218
12618,,,,0,,,CHEMBL874467,,Autocuration,A,,1,,U,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,,22224,BAO_0000019
12619,,,,1,,,CHEMBL625787,,Intermediate,A,,1,,N,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,,50588,BAO_0000218
12620,,,,1,,,CHEMBL625964,,Intermediate,A,,1,,N,cytotoxicity against HIV protease enzyme.,,,50677,BAO_0000218
12621,,,,1,,,CHEMBL625965,,Intermediate,A,,1,,N,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,,50594,BAO_0000218
12622,,,,1,,,CHEMBL625966,,Intermediate,A,,1,,N,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,,50594,BAO_0000218
12623,,,1969.0,1,Plasma,In vivo,CHEMBL625967,,Intermediate,A,,1,,N,The plasma clearance in dog.,,,50588,BAO_0000218
12624,,,1969.0,1,Plasma,In vivo,CHEMBL625968,,Intermediate,A,,1,,N,The plasma clearance in rat.,,,50597,BAO_0000218
12625,,,1969.0,1,Plasma,In vivo,CHEMBL625969,,Intermediate,A,,1,,N,Clearance from plasma in male Sprague-Dawley rats,,,50597,BAO_0000218
12626,,,1969.0,1,Plasma,In vivo,CHEMBL625970,,Intermediate,A,,1,,N,Clearance from plasma in male cynomolgus monkeys,,,100710,BAO_0000218
12627,,,1969.0,1,Plasma,In vivo,CHEMBL625971,,Intermediate,A,,1,,N,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",,,50588,BAO_0000218
12628,,,1969.0,1,Plasma,In vivo,CHEMBL625972,,Intermediate,A,,1,,N,Clearance of compound in dog plasma,,,50588,BAO_0000218
12629,,,1969.0,1,Plasma,In vivo,CHEMBL625973,,Intermediate,A,,1,,N,Clearance of compound in human plasma,,,50587,BAO_0000218
12630,,,,1,,In vivo,CHEMBL625974,,Intermediate,A,,1,,N,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,,50588,BAO_0000218
12631,,,,1,,In vivo,CHEMBL625975,,Intermediate,A,,1,,N,Clearance of compound when administered intravenously as an individual dose to a single dog.,,,50588,BAO_0000218
12632,,,1969.0,1,Plasma,In vivo,CHEMBL625976,,Intermediate,A,,1,,N,"Clearance (10 mg/kg, intravenously) in dog plasma",,,50588,BAO_0000218
12633,,,,1,,In vivo,CHEMBL625977,,Intermediate,A,,1,,N,Clearance value in dog,,,50588,BAO_0000218
12634,,,,1,,In vivo,CHEMBL625978,,Intermediate,A,,1,,N,Clearance value in guinea pig,,,50512,BAO_0000218
12635,,,,1,,In vivo,CHEMBL874468,,Intermediate,A,,1,,N,Clearance values in rats after iv administration.,,,50597,BAO_0000218
12636,,,1969.0,0,Plasma,In vivo,CHEMBL625421,,Autocuration,A,,1,,U,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,,,22224,BAO_0000218
12637,,,,1,,In vivo,CHEMBL625422,,Intermediate,A,,1,,N,In vivo clearance (5 mg/kg) was determined in rabbits,,,50592,BAO_0000218
12638,,,,1,,In vivo,CHEMBL625423,,Intermediate,A,,1,,N,Plasma Clearance rate was determined for the compound in rats,,,50597,BAO_0000218
12639,,,,0,,In vivo,CHEMBL625424,,Autocuration,A,,1,,U,Plasma Clearance rate was determined for the compound in squirrel monkeys,,,22224,BAO_0000218
12640,,,,1,,In vivo,CHEMBL625425,,Intermediate,A,,1,,N,Plasma clearance in rat,,,50597,BAO_0000218
12641,,,,0,,In vivo,CHEMBL625426,,Autocuration,A,,1,,U,Plasma clearance of the compound,,,22224,BAO_0000218
12642,,,,1,,In vivo,CHEMBL625427,,Intermediate,A,,1,,N,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,,50512,BAO_0000218
12643,,,,1,,In vivo,CHEMBL625428,,Intermediate,A,,1,,N,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,,50512,BAO_0000218
12644,,,,0,,In vivo,CHEMBL625429,,Autocuration,A,,1,,U,Plasma clearance was determined,,,22224,BAO_0000218
12645,,,,1,,In vivo,CHEMBL625430,,Intermediate,A,,1,,N,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,,50588,BAO_0000218
12646,,,,1,,In vivo,CHEMBL625431,,Intermediate,A,,1,,N,Plasma clearance rate was determined for the compound in rats,,,50597,BAO_0000218
12647,,,,0,,In vivo,CHEMBL627307,,Autocuration,A,,1,,U,Plasma clearance rate was determined for the compound in squirrel monkeys,,,22224,BAO_0000218
12648,,,,0,,In vivo,CHEMBL627308,,Autocuration,A,,1,,U,Slow clearance (CL) was determined,,,22224,BAO_0000218
12649,,,,0,,,CHEMBL627309,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,22224,BAO_0000218
12650,,,,0,,,CHEMBL627310,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,22224,BAO_0000218
12651,,,,0,,,CHEMBL627311,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,22224,BAO_0000218
12652,,,,0,,,CHEMBL627312,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,22224,BAO_0000218
12653,,,,0,,,CHEMBL627313,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,22224,BAO_0000218
12654,,,,0,,,CHEMBL627314,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,22224,BAO_0000218
12655,,,,0,,,CHEMBL627315,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,22224,BAO_0000218
12656,,,,0,,,CHEMBL627316,,Autocuration,A,,1,,U,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,22224,BAO_0000218
12657,,,,0,,,CHEMBL627317,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,22224,BAO_0000218
12658,,,,0,,,CHEMBL627318,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,22224,BAO_0000218
12659,,,,0,,,CHEMBL627999,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,22224,BAO_0000218
12660,,,,0,,,CHEMBL628000,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,22224,BAO_0000218
12661,,,,0,,,CHEMBL628001,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,22224,BAO_0000218
12662,,,,0,,,CHEMBL628002,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,22224,BAO_0000218
12663,,,,0,,,CHEMBL625610,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,22224,BAO_0000218
12664,,,,0,,,CHEMBL625611,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,22224,BAO_0000218
12665,,,,0,,,CHEMBL625612,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,22224,BAO_0000218
12666,,,,0,,,CHEMBL625613,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,22224,BAO_0000218
12667,,,,0,,,CHEMBL875479,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,22224,BAO_0000218
12668,,,,0,,,CHEMBL625614,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,22224,BAO_0000218
12669,,,,0,,,CHEMBL625615,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,22224,BAO_0000218
12670,,,,0,,,CHEMBL626302,,Autocuration,A,,1,,U,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,22224,BAO_0000218
12671,,,178.0,1,Blood,,CHEMBL626303,,Intermediate,A,,1,,N,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12672,,,178.0,1,Blood,,CHEMBL627420,,Intermediate,A,,1,,N,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,50597,BAO_0000218
12673,,,,1,,,CHEMBL627421,,Intermediate,A,,1,,N,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,,50597,BAO_0000218
12674,,,,1,,,CHEMBL625695,,Intermediate,A,,1,,N,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,,50597,BAO_0000218
12675,,,,1,,,CHEMBL625696,,Intermediate,A,,1,,N,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,,50597,BAO_0000218
12676,,,955.0,1,Brain,,CHEMBL875606,,Intermediate,A,,1,,N,Distribution of compound in mice brain was measured after 1 hr,,,50594,BAO_0000218
12677,,,955.0,1,Brain,,CHEMBL625697,,Intermediate,A,,1,,N,Distribution of compound in mice brain was measured after 24 hr r,,,50594,BAO_0000218
12678,,,955.0,1,Brain,,CHEMBL625698,,Intermediate,A,,1,,N,Distribution of compound in mice brain was measured after 2 hr,,,50594,BAO_0000218
12679,,,955.0,1,Brain,,CHEMBL625699,,Intermediate,A,,1,,N,Distribution of compound in mice brain was measured after 3 hr,,,50594,BAO_0000218
12680,,,955.0,1,Brain,,CHEMBL625700,,Intermediate,A,,1,,N,Distribution of compound in mice brain was measured after 6 hr,,,50594,BAO_0000218
12681,,,,1,,,CHEMBL625701,,Intermediate,A,,1,,N,Distribution of compound in mice liver was measured after 1 hr,,,50594,BAO_0000218
12682,,,,1,,,CHEMBL625702,,Intermediate,A,,1,,N,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,,50594,BAO_0000218
12683,,,,1,,,CHEMBL625703,,Intermediate,A,,1,,N,Distribution of compound in mice liver was measured after 2 hr,,,50594,BAO_0000218
12684,,,,1,,,CHEMBL625704,,Intermediate,A,,1,,N,Distribution of compound in mice liver was measured after 3 hr,,,50594,BAO_0000218
12685,,,,1,,,CHEMBL625705,,Intermediate,A,,1,,N,Distribution of compound in mice liver was measured after 6 hr,,,50594,BAO_0000218
12686,,,1236.0,1,Adrenal medulla,,CHEMBL625706,,Intermediate,A,,1,,N,Distribution in dog adrenal medulla 30 min after administration.,,,50588,BAO_0000218
12687,,,1236.0,1,Adrenal medulla,,CHEMBL625707,,Intermediate,A,,1,,N,Distribution in dog adrenal medulla 72 hours after administration.,,,50588,BAO_0000218
12688,,,,1,,,CHEMBL625708,,Intermediate,A,,1,,N,Distribution in female dog Ovary 24 hours after administration.,,,50588,BAO_0000218
12689,,,,1,,,CHEMBL625709,,Intermediate,A,,1,,N,Distribution in female dog Ovary 72 hours after administration.,,,50588,BAO_0000218
12690,,,,1,,,CHEMBL624180,,Intermediate,A,,1,,N,Distribution in female dog adipose 24 hours after administration.,,,50588,BAO_0000218
12691,,,,1,,,CHEMBL624181,,Intermediate,A,,1,,N,Distribution in female dog adipose 72 hours after administration.,,,50588,BAO_0000218
12692,,,1235.0,1,Adrenal cortex,,CHEMBL624182,,Intermediate,A,,1,,N,Distribution in female dog adrenal cortex 72 hours after administration.,,,50588,BAO_0000218
12693,,,1235.0,1,Adrenal cortex,,CHEMBL624183,,Intermediate,A,,1,,N,Distribution in female dog adrenal cortex 72 hours after administration.,,,50588,BAO_0000218
12694,,,2107.0,1,Liver,,CHEMBL624184,,Intermediate,A,,1,,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,50597,BAO_0000218
12695,,,2107.0,1,Liver,,CHEMBL877489,,Intermediate,A,,1,,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,50597,BAO_0000218
12696,,,2107.0,1,Liver,,CHEMBL624185,,Intermediate,A,,1,,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12697,,,2107.0,1,Liver,,CHEMBL624186,,Intermediate,A,,1,,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12698,,,2107.0,1,Liver,,CHEMBL624187,,Intermediate,A,,1,,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12699,,,2107.0,1,Liver,,CHEMBL624188,,Intermediate,A,,1,,N,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12700,,,2048.0,1,Lung,,CHEMBL624189,,Intermediate,A,,1,,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12701,,,2048.0,1,Lung,,CHEMBL624190,,Intermediate,A,,1,,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12702,,,2048.0,1,Lung,,CHEMBL624191,,Intermediate,A,,1,,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12703,,,2048.0,1,Lung,,CHEMBL624192,,Intermediate,A,,1,,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12704,,,2048.0,1,Lung,,CHEMBL624193,,Intermediate,A,,1,,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,50597,BAO_0000218
12705,,,2048.0,1,Lung,,CHEMBL624194,,Intermediate,A,,1,,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,50597,BAO_0000218
12706,,,2048.0,1,Lung,,CHEMBL624891,,Intermediate,A,,1,,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12707,,,2048.0,1,Lung,,CHEMBL624892,,Intermediate,A,,1,,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12708,,,2048.0,1,Lung,,CHEMBL624893,,Intermediate,A,,1,,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12709,,,2048.0,1,Lung,,CHEMBL627632,,Intermediate,A,,1,,N,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12710,,,,1,,,CHEMBL627633,,Intermediate,A,,1,,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12711,,,,1,,,CHEMBL627634,,Intermediate,A,,1,,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12712,,,,1,,,CHEMBL627635,,Intermediate,A,,1,,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12713,,,,1,,,CHEMBL627636,,Intermediate,A,,1,,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12714,,,,1,,,CHEMBL626816,,Intermediate,A,,1,,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,50597,BAO_0000218
12715,,,,1,,,CHEMBL626817,,Intermediate,A,,1,,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,50597,BAO_0000218
12716,,,,1,,,CHEMBL626818,,Intermediate,A,,1,,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12717,,,,1,,,CHEMBL626819,,Intermediate,A,,1,,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12718,,,,1,,,CHEMBL626820,,Intermediate,A,,1,,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12719,,,,1,,,CHEMBL626821,,Intermediate,A,,1,,N,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12720,,,2046.0,1,Thyroid gland,,CHEMBL626822,,Intermediate,A,,1,,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12721,,,2046.0,1,Thyroid gland,,CHEMBL626823,,Intermediate,A,,1,,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12722,,,2046.0,1,Thyroid gland,,CHEMBL626824,,Intermediate,A,,1,,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12723,,,2046.0,1,Thyroid gland,,CHEMBL626825,,Intermediate,A,,1,,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12724,,,2046.0,1,Thyroid gland,,CHEMBL626826,,Intermediate,A,,1,,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,50597,BAO_0000218
12725,,,2046.0,1,Thyroid gland,,CHEMBL626827,,Intermediate,A,,1,,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,50597,BAO_0000218
12726,,,2046.0,1,Thyroid gland,,CHEMBL626828,,Intermediate,A,,1,,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12727,,,2046.0,1,Thyroid gland,,CHEMBL626829,,Intermediate,A,,1,,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12728,,,2046.0,1,Thyroid gland,,CHEMBL626830,,Intermediate,A,,1,,N,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12729,,,,1,,,CHEMBL627150,,Intermediate,A,,1,,N,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12730,,,,1,,,CHEMBL627151,,Intermediate,A,,1,,N,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12731,,,,1,,,CHEMBL627152,,Intermediate,A,,1,,N,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,50597,BAO_0000218
12732,,,,1,,,CHEMBL627153,,Intermediate,A,,1,,N,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,50597,BAO_0000218
12733,,,,0,,,CHEMBL627154,,Autocuration,A,,1,,U,Rate of acetate production by the compound was determined,,,22224,BAO_0000019
12734,,,,0,,,CHEMBL627155,,Autocuration,A,,1,,U,Rate of acetate production by the compound was determined; Not determined,,,22224,BAO_0000019
12735,,,,0,,,CHEMBL627156,,Autocuration,A,,1,,U,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,,22224,BAO_0000019
12736,,,,0,,,CHEMBL627157,,Autocuration,A,,1,,U,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,,22224,BAO_0000019
12737,,,,1,,,CHEMBL627158,,Intermediate,A,,1,,N,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,,50592,BAO_0000218
12738,,,1969.0,1,Plasma,,CHEMBL627159,,Intermediate,A,,1,,N,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,,50592,BAO_0000218
12739,,,,1,,,CHEMBL627160,,Intermediate,A,,1,,N,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,,50594,BAO_0000218
12740,,,,1,,,CHEMBL628540,,Intermediate,A,,1,,N,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,,50597,BAO_0000218
12741,,,1969.0,1,Plasma,,CHEMBL628541,,Intermediate,A,,1,,N,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,,50597,BAO_0000218
12742,,,1969.0,1,Plasma,,CHEMBL628542,,Intermediate,A,,1,,N,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,,50597,BAO_0000218
12743,,,,0,,,CHEMBL628543,,Autocuration,P,,1,,U,Solubility after at a pH 1.2,,,22229,BAO_0000100
12744,,,,0,,,CHEMBL628544,,Autocuration,P,,1,,U,Solubility after at pH 1.2,,,22229,BAO_0000100
12745,,,,0,,,CHEMBL628545,,Autocuration,P,,1,,U,Solubility after injection of water,,,22229,BAO_0000100
12746,,,,0,,,CHEMBL628546,,Autocuration,A,,1,,U,Statistical significance of IC 50 values; Expressed as R value,,,22224,BAO_0000019
12747,,,,0,,,CHEMBL874455,,Autocuration,A,,1,,U,Systemic availability with respect to methyldopa was determined,,,22224,BAO_0000019
12748,,,,1,,,CHEMBL628547,,Intermediate,A,,1,,N,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,,50597,BAO_0000218
12749,,,1969.0,1,Plasma,,CHEMBL628548,,Intermediate,A,,1,,N,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,,,50597,BAO_0000218
12750,,,1988.0,1,Feces,,CHEMBL628549,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",,,50592,BAO_0000218
12751,,,1988.0,1,Feces,,CHEMBL628550,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",,,50592,BAO_0000218
12752,,,1988.0,1,Feces,,CHEMBL628551,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",,,50592,BAO_0000218
12753,,,1088.0,1,Urine,,CHEMBL628552,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",,,50592,BAO_0000218
12754,,,1088.0,1,Urine,,CHEMBL628553,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",,,50592,BAO_0000218
12755,,,1088.0,1,Urine,,CHEMBL628554,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",,,50592,BAO_0000218
12756,,,1088.0,1,Urine,,CHEMBL628555,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",,,50592,BAO_0000218
12757,,,1088.0,1,Urine,,CHEMBL628556,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",,,50592,BAO_0000218
12758,,,2113.0,1,Kidney,,CHEMBL628557,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",,,50592,BAO_0000218
12759,,,1988.0,1,Feces,,CHEMBL628558,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",,,50592,BAO_0000218
12760,,,1988.0,1,Feces,,CHEMBL628559,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",,,50592,BAO_0000218
12761,,,1988.0,1,Feces,,CHEMBL628560,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",,,50592,BAO_0000218
12762,,,1088.0,1,Urine,,CHEMBL874456,,Intermediate,A,,1,,N,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",,,50592,BAO_0000218
12763,,,1988.0,1,Feces,,CHEMBL628561,,Intermediate,A,,1,,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",,,50592,BAO_0000218
12764,,,1988.0,1,Feces,,CHEMBL628562,,Intermediate,A,,1,,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",,,50592,BAO_0000218
12765,,,1088.0,1,Urine,,CHEMBL628563,,Intermediate,A,,1,,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",,,50592,BAO_0000218
12766,,,1088.0,1,Urine,,CHEMBL628564,,Intermediate,A,,1,,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",,,50592,BAO_0000218
12767,,,1088.0,1,Urine,,CHEMBL628565,,Intermediate,A,,1,,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",,,50592,BAO_0000218
12768,,,1088.0,1,Urine,,CHEMBL631248,,Intermediate,A,,1,,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",,,50592,BAO_0000218
12769,,,1088.0,1,Urine,,CHEMBL631249,,Intermediate,A,,1,,N,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",,,50592,BAO_0000218
12770,,,2113.0,1,Kidney,,CHEMBL627214,,Intermediate,A,,1,,N,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",,,50592,BAO_0000218
12771,,,1988.0,1,Feces,,CHEMBL874591,,Intermediate,A,,1,,N,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",,,50592,BAO_0000218
12772,,,1988.0,1,Feces,,CHEMBL627215,,Intermediate,A,,1,,N,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",,,50592,BAO_0000218
12773,,,1988.0,1,Feces,,CHEMBL625471,,Intermediate,A,,1,,N,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,,,50592,BAO_0000218
12774,,,,1,,,CHEMBL625472,,Intermediate,A,,1,,N,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,,50592,BAO_0000218
12775,,,,1,,,CHEMBL625473,,Intermediate,A,,1,,N,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,,50592,BAO_0000218
12776,,,,1,,In vivo,CHEMBL625474,,Intermediate,A,,1,,N,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,,50588,BAO_0000218
12777,,,,1,,In vivo,CHEMBL625475,,Intermediate,A,,1,,N,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,,50588,BAO_0000218
12778,,,,1,,In vivo,CHEMBL625476,,Intermediate,A,,1,,N,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,,50597,BAO_0000218
12779,,,,1,,In vivo,CHEMBL625477,,Intermediate,A,,1,,N,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,,50597,BAO_0000218
12780,,,,1,,In vivo,CHEMBL625478,,Intermediate,A,,1,,N,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,,50597,BAO_0000218
12781,,,,1,esophageal tunica muscularis mucosae,In vitro,CHEMBL625479,,Intermediate,A,,1,,N,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,,50597,BAO_0000218
12782,,,,1,esophageal tunica muscularis mucosae,In vitro,CHEMBL625480,,Intermediate,A,,1,,N,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,,50597,BAO_0000218
12783,,,1969.0,1,Plasma,In vivo,CHEMBL625481,,Intermediate,A,,1,,N,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,,,50597,BAO_0000218
12784,,,,1,,In vivo,CHEMBL625482,,Intermediate,A,,1,,N,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,,50597,BAO_0000218
12785,,,,1,,In vivo,CHEMBL625483,,Intermediate,A,,1,,N,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,,50597,BAO_0000218
12786,,,,1,,In vivo,CHEMBL625484,,Intermediate,A,,1,,N,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,,50597,BAO_0000218
12787,,,,1,,In vivo,CHEMBL625485,,Intermediate,A,,1,,N,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,,50597,BAO_0000218
12788,,,1969.0,1,Plasma,In vivo,CHEMBL625486,,Intermediate,A,,1,,N,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,,,50588,BAO_0000218
12789,,,1969.0,1,Plasma,In vivo,CHEMBL625487,,Intermediate,A,,1,,N,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,,,50597,BAO_0000218
12790,,,1969.0,1,Plasma,In vivo,CHEMBL625488,,Intermediate,A,,1,,N,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,,,50597,BAO_0000218
12791,,,1969.0,1,Plasma,In vivo,CHEMBL625489,,Intermediate,A,,1,,N,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,,,50597,BAO_0000218
12792,,,1969.0,1,Plasma,In vivo,CHEMBL625490,,Intermediate,A,,1,,N,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,,,50597,BAO_0000218
12793,,,1969.0,1,Plasma,In vivo,CHEMBL625491,,Intermediate,A,,1,,N,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,,,50588,BAO_0000218
12794,,,1969.0,1,Plasma,In vivo,CHEMBL625492,,Intermediate,A,,1,,N,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,,,50597,BAO_0000218
12795,,,1969.0,1,Plasma,In vivo,CHEMBL625493,,Intermediate,A,,1,,N,plasma clearance in human,,,50587,BAO_0000218
12796,,,,1,,In vivo,CHEMBL625494,,Intermediate,A,,1,,N,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,,50597,BAO_0000218
12797,,,,1,,In vivo,CHEMBL625495,,Intermediate,A,,1,,N,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,,50597,BAO_0000218
12798,,,,1,,In vivo,CHEMBL625496,,Intermediate,A,,1,,N,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,,50597,BAO_0000218
12799,,,,0,,,CHEMBL625497,,Autocuration,P,,1,,U,1-Octanol/water partition coefficient measured at 7.4,,,22229,BAO_0000100
12800,,,,0,,,CHEMBL625498,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12801,,,,0,,,CHEMBL625499,,Autocuration,A,,1,,U,Partition coefficient (logP),,,22224,BAO_0000019
12802,,,,0,,,CHEMBL625500,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12803,,,,0,,,CHEMBL625501,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12804,,,,0,,,CHEMBL625502,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12805,,,,0,,,CHEMBL625503,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP) (relative to BAY K 8644),,,22229,BAO_0000100
12806,,,,0,,,CHEMBL625504,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12807,,,,0,,,CHEMBL625505,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12808,,,,0,,,CHEMBL625506,,Autocuration,P,,1,,U,Calculated partition coefficient of the compound,,,22229,BAO_0000100
12809,,,,0,,,CHEMBL625507,,Autocuration,A,,1,,U,Partition coefficient (logP),,,22224,BAO_0000019
12810,,,,0,,,CHEMBL625508,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12811,,,,0,,,CHEMBL625509,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12812,,,,0,,,CHEMBL625510,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12813,,,,0,,,CHEMBL883125,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12814,,,,0,,,CHEMBL625511,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12815,,,,0,,,CHEMBL874650,,Autocuration,A,,1,,U,Partition coefficient of the compound,,,22224,BAO_0000019
12816,,,,0,,,CHEMBL625512,,Autocuration,A,,1,,U,Partition coefficient of the compound,,,22224,BAO_0000019
12817,,,,0,,,CHEMBL625513,,Autocuration,A,,1,,U,Partition coefficient of compound was determined,,,22224,BAO_0000019
12818,,,,0,,,CHEMBL625514,,Autocuration,A,,1,,U,Partition coefficient was determined,,,22224,BAO_0000019
12819,,,,0,,,CHEMBL625515,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12820,,,,0,,,CHEMBL625516,,Autocuration,P,,1,,U,partition coefficient of compound was determined,,,22229,BAO_0000100
12821,,,,1,,In vivo,CHEMBL625517,,Intermediate,A,,1,,N,The total body administered intravenously in dog,,,50588,BAO_0000218
12822,,,,1,,In vivo,CHEMBL625518,,Intermediate,A,,1,,N,The total body administered intravenously in rats,,,50597,BAO_0000218
12823,,,,1,,,CHEMBL625519,,Intermediate,A,,1,,N,Time taken for the administration to female NIH mice weighing 25-30 g.,,,50594,BAO_0000218
12824,,,,0,,,CHEMBL625520,,Autocuration,A,,1,,U,Time taken for the administration,,,22224,BAO_0000019
12825,,,,1,,In vivo,CHEMBL874651,,Intermediate,A,,1,,N,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,,50588,BAO_0000218
12826,,,,0,,In vivo,CHEMBL625521,,Autocuration,A,,1,,U,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,,22224,BAO_0000218
12827,,,,1,,In vivo,CHEMBL623171,,Intermediate,A,,1,,N,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,,50592,BAO_0000218
12828,,,,1,,In vivo,CHEMBL623853,,Intermediate,A,,1,,N,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,,50597,BAO_0000218
12829,,,,0,,,CHEMBL623854,,Autocuration,A,,1,,U,Plasma clearance for the compound was determined.,,,22224,BAO_0000019
12830,,,,0,,,CHEMBL874405,,Autocuration,P,,1,,U,CLog P value of the compound,,,22224,BAO_0000100
12831,,,,0,,,CHEMBL623855,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12832,,,,0,,,CHEMBL623856,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12833,,,,0,,,CHEMBL623857,,Autocuration,P,,1,,U,ClogP value of the compound; nd ='no data',,,22224,BAO_0000100
12834,,,,0,,,CHEMBL623858,,Autocuration,P,,1,,U,ClogP value of the compound; nd ='not determined',,,22224,BAO_0000100
12835,,,,0,,,CHEMBL623859,,Autocuration,P,,1,,U,CLog P was determined,,,22224,BAO_0000100
12836,,,,0,,,CHEMBL839829,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12837,,,,0,,,CHEMBL623860,,Autocuration,A,,1,,U,CLogP was calculated,,,22224,BAO_0000019
12838,,,,0,,,CHEMBL623861,,Autocuration,A,,1,,U,CLogP value was determined,,,22224,BAO_0000019
12839,,,,0,,,CHEMBL623862,,Autocuration,A,,1,,U,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,,22224,BAO_0000019
12840,,,,0,,,CHEMBL874406,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12841,,,,0,,,CHEMBL623863,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12842,,,,0,,,CHEMBL624021,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12843,,,1236.0,1,Adrenal medulla,,CHEMBL624022,,Intermediate,A,,1,,N,Distribution in female dog adrenal medulla 24 hours after administration.,,,50588,BAO_0000218
12844,,,1236.0,1,Adrenal medulla,,CHEMBL624023,,Intermediate,A,,1,,N,Distribution in female dog adrenal medulla 72 hours after administration.,,,50588,BAO_0000218
12845,,,,1,,,CHEMBL624024,,Intermediate,A,,1,,N,Distribution in female dog bile 24 hours after administration.,,,50588,BAO_0000218
12846,,,,1,,,CHEMBL624025,,Intermediate,A,,1,,N,Distribution in female dog bile 72 hr after administration.,,,50588,BAO_0000218
12847,,,,1,,,CHEMBL624026,,Intermediate,A,,1,,N,Distribution in female dog blood 24 hours after administration.,,,50588,BAO_0000218
12848,,,,1,,,CHEMBL624027,,Intermediate,A,,1,,N,Distribution in female dog blood 72 hours after administration.,,,50588,BAO_0000218
12849,,,,1,,,CHEMBL624028,,Intermediate,A,,1,,N,Distribution in female dog heart 24 hours after administration.,,,50588,BAO_0000218
12850,,,,1,,,CHEMBL624029,,Intermediate,A,,1,,N,Distribution in female dog heart 72 hours after administration.,,,50588,BAO_0000218
12851,,,,1,,,CHEMBL624030,,Intermediate,A,,1,,N,Distribution in female dog kidney 24 hours after administration.,,,50588,BAO_0000218
12852,,,,1,,,CHEMBL624031,,Intermediate,A,,1,,N,Distribution in female dog kidney 72 hours after administration.,,,50588,BAO_0000218
12853,,,160.0,1,Intestine,,CHEMBL624032,,Intermediate,A,,1,,N,Distribution in female dog large intestine 24 hours after administration.,,,50588,BAO_0000218
12854,,,160.0,1,Intestine,,CHEMBL874407,,Intermediate,A,,1,,N,Distribution in female dog large intestine 72 hours after administration.,,,50588,BAO_0000218
12855,,,,1,,,CHEMBL624033,,Intermediate,A,,1,,N,Distribution in female dog liver 24 hours after administration.,,,50588,BAO_0000218
12856,,,,1,,,CHEMBL624034,,Intermediate,A,,1,,N,Distribution in female dog liver 72 hours after administration.,,,50588,BAO_0000218
12857,,,,1,,,CHEMBL624035,,Intermediate,A,,1,,N,Distribution in female dog lung 24 hours after administration.,,,50588,BAO_0000218
12858,,,,1,,,CHEMBL624036,,Intermediate,A,,1,,N,Distribution in female dog lung 72 hours after administration.,,,50588,BAO_0000218
12859,,,2385.0,1,Muscle tissue,,CHEMBL624037,,Intermediate,A,,1,,N,Distribution in female dog muscle 24 hours after administration.,,,50588,BAO_0000218
12860,,,2385.0,1,Muscle tissue,,CHEMBL624038,,Intermediate,A,,1,,N,Distribution in female dog muscle 72 hours after administration.,,,50588,BAO_0000218
12861,,,,1,,,CHEMBL624039,,Intermediate,A,,1,,N,Distribution in female dog pancreas 24 hours after administration.,,,50588,BAO_0000218
12862,,,,1,,,CHEMBL624040,,Intermediate,A,,1,,N,Distribution in female dog pancreas 72 hours after administration.,,,50588,BAO_0000218
12863,,,160.0,1,Intestine,,CHEMBL624041,,Intermediate,A,,1,,N,Distribution in female dog small intestine 24 hours after administration.,,,50588,BAO_0000218
12864,,,160.0,1,Intestine,,CHEMBL624042,,Intermediate,A,,1,,N,Distribution in female dog small intestine 72 hours after administration.,,,50588,BAO_0000218
12865,,,2106.0,1,Spleen,,CHEMBL624043,,Intermediate,A,,1,,N,Distribution in female dog spleen 24 hours after administration.,,,50588,BAO_0000218
12866,,,2106.0,1,Spleen,,CHEMBL624044,,Intermediate,A,,1,,N,Distribution in female dog spleen 72 hours after administration.,,,50588,BAO_0000218
12867,,,945.0,1,Stomach,,CHEMBL624045,,Intermediate,A,,1,,N,Distribution in female dog stomach 24 hours after administration.,,,50588,BAO_0000218
12868,,,945.0,1,Stomach,,CHEMBL624046,,Intermediate,A,,1,,N,Distribution in female dog stomach 72 hours after administration.,,,50588,BAO_0000218
12869,,,2046.0,1,Thyroid gland,,CHEMBL624047,,Intermediate,A,,1,,N,Distribution in female dog thyroid 24 hours after administration.,,,50588,BAO_0000218
12870,,,2046.0,1,Thyroid gland,,CHEMBL624048,,Intermediate,A,,1,,N,Distribution in female dog thyroid 72 hours after administration.,,,50588,BAO_0000218
12871,,,1088.0,1,Urine,,CHEMBL874408,,Intermediate,A,,1,,N,Distribution in female dog urine 24 hours after administration.,,,50588,BAO_0000218
12872,,,1088.0,1,Urine,,CHEMBL624049,,Intermediate,A,,1,,N,Distribution in female dog urine 72 hr after administration.,,,50588,BAO_0000218
12873,,,1969.0,0,Plasma,,CHEMBL624050,,Autocuration,A,,1,,U,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,,,22224,BAO_0000218
12874,,,,0,,,CHEMBL624051,,Autocuration,A,,1,,U,Plasma concentration at 7 hr after intravenous dosing,,,22224,BAO_0000019
12875,,,,1,,,CHEMBL623278,,Intermediate,A,,1,,N,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,,50597,BAO_0000218
12876,,,,1,,,CHEMBL623279,,Intermediate,A,,1,,N,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,,50597,BAO_0000218
12877,,,,1,,,CHEMBL623280,,Intermediate,A,,1,,N,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,,50597,BAO_0000218
12878,,,,1,,,CHEMBL623963,,Intermediate,A,,1,,N,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,,50597,BAO_0000218
12879,,,,1,,,CHEMBL623964,,Intermediate,A,,1,,N,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,,50597,BAO_0000218
12880,,,,1,,,CHEMBL623965,,Intermediate,A,,1,,N,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,,50597,BAO_0000218
12881,,,,1,,,CHEMBL623966,,Intermediate,A,,1,,N,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,,50597,BAO_0000218
12882,,,,1,,,CHEMBL874415,,Intermediate,A,,1,,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,,50597,BAO_0000218
12883,,,,1,,,CHEMBL623967,,Intermediate,A,,1,,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,,50597,BAO_0000218
12884,,,,1,,,CHEMBL623968,,Intermediate,A,,1,,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,,50597,BAO_0000218
12885,,,,1,,,CHEMBL623969,,Intermediate,A,,1,,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,,50597,BAO_0000218
12886,,,,1,,,CHEMBL628409,,Intermediate,A,,1,,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,,50597,BAO_0000218
12887,,,,1,,,CHEMBL628410,,Intermediate,A,,1,,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,,50597,BAO_0000218
12888,,,,1,,,CHEMBL628411,,Intermediate,A,,1,,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,,50597,BAO_0000218
12889,,,,1,,,CHEMBL628412,,Intermediate,A,,1,,N,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,,50597,BAO_0000218
12890,,,,0,,,CHEMBL628413,,Autocuration,A,,1,,U,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,,22224,BAO_0000019
12891,,,1969.0,0,Plasma,,CHEMBL628414,,Autocuration,A,,1,,U,The concentration in plasmat; Not determined,,,22224,BAO_0000019
12892,,,,1,,,CHEMBL628415,,Intermediate,A,,1,,N,Tissue level at 10 mg/kg/po in wistar rats in blood,,,50597,BAO_0000218
12893,,,,1,,,CHEMBL628416,,Intermediate,A,,1,,N,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,,50597,BAO_0000218
12894,,,,1,,,CHEMBL628417,,Intermediate,A,,1,,N,Tissue level at 10 mg/kg/po in wistar rats in heart,,,50597,BAO_0000218
12895,,,2107.0,1,Liver,,CHEMBL874908,,Intermediate,A,,1,,N,Tissue level at 10 mg/kg/po in wistar rats in liver,,,50597,BAO_0000218
12896,,,,1,,,CHEMBL628418,,Intermediate,A,,1,,N,Tissue level at 10 mg/kg/po in wistar rats in plasma,,,50597,BAO_0000218
12897,,,2385.0,1,Muscle tissue,,CHEMBL628419,,Intermediate,A,,1,,N,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,,,50597,BAO_0000218
12898,,,,1,,,CHEMBL628420,,Intermediate,A,,1,,N,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,,50597,BAO_0000218
12899,,,,0,,,CHEMBL628421,,Autocuration,A,,1,,U,Water solubility at 37 degree C.,,,22224,BAO_0000019
12900,,,,0,,,CHEMBL626726,,Autocuration,P,,1,,U,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,22229,BAO_0000100
12901,,,,0,,,CHEMBL626727,,Autocuration,P,,1,,U,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,22229,BAO_0000100
12902,,,178.0,1,Blood,,CHEMBL626728,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12903,,,178.0,1,Blood,,CHEMBL626729,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12904,,,178.0,1,Blood,,CHEMBL626730,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12905,,,178.0,1,Blood,,CHEMBL626731,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12906,,,178.0,1,Blood,,CHEMBL626732,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12907,,,948.0,1,Heart,,CHEMBL626733,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12908,,,948.0,1,Heart,,CHEMBL626734,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12909,,,948.0,1,Heart,,CHEMBL626735,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12910,,,948.0,1,Heart,,CHEMBL874909,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12911,,,948.0,1,Heart,,CHEMBL626736,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12912,,,2113.0,1,Kidney,,CHEMBL626737,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12913,,,2113.0,1,Kidney,,CHEMBL630999,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12914,,,2113.0,1,Kidney,,CHEMBL631000,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12915,,,2113.0,1,Kidney,,CHEMBL631001,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12916,,,2113.0,1,Kidney,,CHEMBL631002,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12917,,,2107.0,1,Liver,,CHEMBL631003,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12918,,,2107.0,1,Liver,,CHEMBL631004,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12919,,,2107.0,1,Liver,,CHEMBL631005,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12920,,,2107.0,1,Liver,,CHEMBL631006,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12921,,,2107.0,1,Liver,,CHEMBL631007,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12922,,,2048.0,1,Lung,,CHEMBL631008,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12923,,,2048.0,1,Lung,,CHEMBL631009,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12924,,,2048.0,1,Lung,,CHEMBL631010,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12925,,,2048.0,1,Lung,,CHEMBL631011,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12926,,,2048.0,1,Lung,,CHEMBL631012,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12927,,,2046.0,1,Thyroid gland,,CHEMBL630271,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12928,,,2046.0,1,Thyroid gland,,CHEMBL630272,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12929,,,2046.0,1,Thyroid gland,,CHEMBL630273,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12930,,,2046.0,1,Thyroid gland,,CHEMBL630274,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12931,,,2046.0,1,Thyroid gland,,CHEMBL630275,,Intermediate,A,,1,,N,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12932,,,,1,,,CHEMBL875782,,Intermediate,A,,1,,N,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12933,,,,1,,,CHEMBL630276,,Intermediate,A,,1,,N,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12934,,,,1,,,CHEMBL630277,,Intermediate,A,,1,,N,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12935,,,,1,,,CHEMBL630278,,Intermediate,A,,1,,N,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12936,,,,1,,,CHEMBL630279,,Intermediate,A,,1,,N,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,,50597,BAO_0000218
12937,,,,0,,,CHEMBL630280,,Autocuration,A,,1,,U,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,,22224,BAO_0000019
12938,,,,0,,,CHEMBL630281,,Autocuration,A,,1,,U,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,22224,BAO_0000019
12939,,,,1,,,CHEMBL630282,,Intermediate,A,,1,,N,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,,50592,BAO_0000218
12940,,,,1,,,CHEMBL630283,,Intermediate,A,,1,,N,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,,50592,BAO_0000218
12941,,,,0,,,CHEMBL630284,,Autocuration,A,,1,,U,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,,22224,BAO_0000019
12942,,,,0,,,CHEMBL630285,,Autocuration,A,,1,,U,Alkylating activity was determined,,,22224,BAO_0000019
12943,,,,0,,,CHEMBL630286,,Autocuration,A,,1,Microsomes,U,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,,22224,BAO_0000251
12944,,,,1,,,CHEMBL630069,,Intermediate,A,,1,,N,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,,50592,BAO_0000218
12945,,,,1,,,CHEMBL630070,,Intermediate,A,,1,,N,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,,50592,BAO_0000218
12946,,,,1,,,CHEMBL630071,,Intermediate,A,,1,,N,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,,50592,BAO_0000218
12947,,,,1,,,CHEMBL630072,,Intermediate,A,,1,,N,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,,50592,BAO_0000218
12948,,,,1,,,CHEMBL875110,,Intermediate,A,,1,,N,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,,50592,BAO_0000218
12949,,,,1,,,CHEMBL630073,,Intermediate,A,,1,,N,Compound was tested for antidiuretic activity in rats,,,50597,BAO_0000218
12950,,,,0,,,CHEMBL630074,,Autocuration,A,,1,,U,Compound was tested for inactivation kinetic values,,,22224,BAO_0000019
12951,,,,0,,In vivo,CHEMBL630075,,Autocuration,A,,1,,U,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,,22224,BAO_0000218
12952,,,,0,,,CHEMBL630076,,Autocuration,A,,1,,U,Dissociation rate calculated from the first-order equation using the t1/2 value,,,22224,BAO_0000019
12953,,,,0,,,CHEMBL630077,,Autocuration,P,,1,,U,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,,22229,BAO_0000100
12954,,,,0,,,CHEMBL630078,,Autocuration,P,,1,,U,Aqueous solubility was measured,,,22229,BAO_0000100
12955,,,,0,,,CHEMBL630079,,Autocuration,P,,1,,U,Aqueous solubility was measured at a pH 4,,,22229,BAO_0000100
12956,,,,0,,,CHEMBL630080,,Autocuration,P,,1,,U,Aqueous solubility (pH 7),,,22229,BAO_0000100
12957,,,,0,,,CHEMBL630081,,Autocuration,P,,1,,U,Aqueous solubility was measured at a pH 9,,,22229,BAO_0000100
12958,,,,0,,,CHEMBL630082,,Autocuration,A,,1,,U,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,,22224,BAO_0000019
12959,,,,0,,,CHEMBL630083,,Autocuration,A,,1,,U,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,22224,BAO_0000019
12960,,,,0,,,CHEMBL630084,,Autocuration,A,,1,,U,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,22224,BAO_0000019
12961,,,,0,,,CHEMBL629198,,Autocuration,P,,1,,U,Aqueous solubility of the compound,,,22229,BAO_0000100
12962,,,,0,,,CHEMBL629199,,Autocuration,P,,1,,U,Aqueous solubility at 37 degree Celsius at pH 7.38,,,22229,BAO_0000100
12963,,,,0,,,CHEMBL629200,,Autocuration,P,,1,,U,Aqueous solubility in pH 7.4 phosphate buffer,,,22229,BAO_0000100
12964,,,,1,,,CHEMBL629201,,Intermediate,A,,1,,N,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,,50588,BAO_0000218
12965,,,,1,,,CHEMBL629202,,Intermediate,A,,1,,N,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,,50588,BAO_0000218
12966,,,,1,,,CHEMBL875111,,Intermediate,A,,1,,N,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,,50587,BAO_0000218
12967,,,,1,,,CHEMBL629203,,Intermediate,A,,1,,N,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,,50587,BAO_0000218
12968,,,,1,,,CHEMBL629204,,Intermediate,A,,1,,N,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,,50587,BAO_0000218
12969,,,,1,,,CHEMBL629205,,Intermediate,A,,1,,N,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,,50587,BAO_0000218
12970,,,,1,,,CHEMBL629206,,Intermediate,A,,1,,N,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,,50587,BAO_0000218
12971,,,,0,,,CHEMBL631185,,Autocuration,A,,1,,U,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,,22224,BAO_0000019
12972,,,,1,,,CHEMBL631186,,Intermediate,A,,1,,N,Compound was evaluated for the average bile flow rat in rats,,,50597,BAO_0000218
12973,,,,1,,,CHEMBL631187,,Intermediate,A,,1,,N,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,,50592,BAO_0000218
12974,,,,1,,,CHEMBL631188,,Intermediate,A,,1,,N,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,,50592,BAO_0000218
12975,,,,0,,,CHEMBL876419,,Autocuration,A,,1,,U,Average half life period was determined,,,22224,BAO_0000019
12976,,,,0,,,CHEMBL631189,,Autocuration,A,,1,,U,Average half life period was determined,,,22224,BAO_0000019
12977,,,,1,,,CHEMBL631190,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,,50602,BAO_0000218
12978,,,,1,,,CHEMBL631191,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,,50602,BAO_0000218
12979,,,,1,,,CHEMBL631192,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,,50602,BAO_0000218
12980,,,,1,,,CHEMBL632400,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,,50602,BAO_0000218
12981,,,,1,,,CHEMBL630564,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,,50602,BAO_0000218
12982,,,,1,,,CHEMBL630565,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,,50602,BAO_0000218
12983,,,,1,,,CHEMBL630566,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,,50602,BAO_0000218
12984,,,,1,,,CHEMBL631229,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,,50602,BAO_0000218
12985,,,,1,,,CHEMBL631230,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,,50602,BAO_0000218
12986,,,,0,,,CHEMBL876428,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12987,,,,0,,,CHEMBL631231,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12988,,,,0,,,CHEMBL631232,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP) (MacLogP),,,22229,BAO_0000100
12989,,,,0,,,CHEMBL631233,,Autocuration,A,,1,,U,Hydrophilicity was determined,,,22224,BAO_0000019
12990,,,,0,,,CHEMBL631234,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12991,,,,0,,,CHEMBL883126,,Autocuration,A,,1,,U,Increased absorption was determined,,,22224,BAO_0000019
12992,,,,0,,,CHEMBL631235,,Autocuration,P,,1,,U,Lipophilicity value was evaluated,,,22224,BAO_0000100
12993,,,,0,,,CHEMBL631236,,Autocuration,P,,1,,U,Log P value of the compound.,,,22224,BAO_0000100
12994,,,,0,,,CHEMBL631237,,Autocuration,A,,1,,U,Partition coefficient of compound was determined,,,22224,BAO_0000019
12995,,,,0,,,CHEMBL631238,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12996,,,,0,,,CHEMBL876429,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
12997,,,,0,,,CHEMBL631414,,Autocuration,A,,1,,U,Partition coefficient was measured by medchem software; Not calculated,,,22224,BAO_0000019
12998,,,,0,,,CHEMBL631415,,Autocuration,P,,1,,U,Partition coefficient was measured by octanol-water using standard shake-flask method,,,22224,BAO_0000100
12999,,,,0,,,CHEMBL631416,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13000,,,,0,,,CHEMBL631417,,Autocuration,A,,1,,U,Partition coefficient (logP),,,22224,BAO_0000019
13001,,,,0,,,CHEMBL631418,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13002,,,,0,,,CHEMBL631419,,Autocuration,P,,1,,U,The Octanol/Water partition coefficient CLogP,,,22229,BAO_0000100
13003,,,,0,,,CHEMBL631420,,Autocuration,A,,1,,U,The pharmacokinetic parameter C Log p was reported,,,22224,BAO_0000019
13004,,,,0,,,CHEMBL631421,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13005,,,,0,,,CHEMBL631422,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13006,,,,0,,,CHEMBL631423,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13007,,,1969.0,1,Plasma,In vivo,CHEMBL876430,,Intermediate,A,,1,,N,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,,50597,BAO_0000218
13008,,,1969.0,1,Plasma,In vivo,CHEMBL631424,,Intermediate,A,,1,,N,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,,,50597,BAO_0000218
13009,,,1969.0,1,Plasma,In vivo,CHEMBL631425,,Intermediate,A,,1,,N,Compound was administered intravenously in dog to evaluate plasma clearance values,,,50588,BAO_0000218
13010,,,1969.0,0,Plasma,In vivo,CHEMBL631426,,Autocuration,A,,1,,U,Compound was administered intravenously in monkey to evaluate plasma clearance values,,,22224,BAO_0000218
13011,,,1969.0,1,Plasma,In vivo,CHEMBL631427,,Intermediate,A,,1,,N,Compound was administered intravenously in mouse to evaluate plasma clearance values,,,50594,BAO_0000218
13012,,,1969.0,1,Plasma,In vivo,CHEMBL631428,,Intermediate,A,,1,,N,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,,,50588,BAO_0000218
13013,,,2107.0,1,Liver,In vitro,CHEMBL631429,,Intermediate,A,,1,Microsomes,N,Intrinsic clearance in Rhesus liver microsome,,,50797,BAO_0000218
13014,,,2107.0,1,Liver,In vitro,CHEMBL631430,,Intermediate,A,,1,Microsomes,N,Intrinsic clearance in dog liver microsome,,,50588,BAO_0000218
13015,,,2107.0,1,Liver,In vitro,CHEMBL631431,,Intermediate,A,,1,Microsomes,N,Intrinsic clearance in rat liver microsome,,,50597,BAO_0000218
13016,,,1969.0,1,Plasma,In vivo,CHEMBL631432,,Intermediate,A,,1,,N,Low plasma clearance was calculated in rhesus monkey,,,50797,BAO_0000218
13017,,,,1,,In vivo,CHEMBL631433,,Intermediate,A,,1,,N,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,50588,BAO_0000218
13018,,,,0,,In vivo,CHEMBL631434,,Autocuration,A,,1,,U,Plasma clearance after intravenous dose of 0.3 mg/kg,,,22224,BAO_0000218
13019,,,,0,,In vivo,CHEMBL631435,,Autocuration,A,,1,,U,Plasma clearance after intravenous dose of 1 mg/kg,,,22224,BAO_0000218
13020,,,,0,,In vivo,CHEMBL631436,,Autocuration,A,,1,,U,Plasma clearance after intravenous dose of 3 mg/kg,,,22224,BAO_0000218
13021,,,,0,,In vivo,CHEMBL631437,,Autocuration,A,,1,,U,Plasma clearance after intravenous dose of 3.87 mg/kg,,,22224,BAO_0000218
13022,,,,1,,In vivo,CHEMBL631438,,Intermediate,A,,1,,N,Plasma clearance after peroral administration at 10 mpk in Rat,,,50597,BAO_0000218
13023,,,,1,,In vivo,CHEMBL876431,,Intermediate,A,,1,,N,Plasma clearance after peroral administration at 10 mpk in Rhesus,,,50797,BAO_0000218
13024,,,,1,,In vivo,CHEMBL631439,,Intermediate,A,,1,,N,Plasma clearance after peroral administration at 10 mpk in dog,,,50588,BAO_0000218
13025,,,,1,,In vivo,CHEMBL631440,,Intermediate,A,,1,,N,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,,50597,BAO_0000218
13026,,,,0,,,CHEMBL631441,,Autocuration,A,,1,,U,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,,22224,BAO_0000019
13027,,,,0,,,CHEMBL631442,,Autocuration,A,,1,,U,Critical Micellar concentration was determined,,,22224,BAO_0000019
13028,,,,0,,,CHEMBL626525,,Autocuration,A,,1,,U,Critical Micellar concentration of the compound. was determined,,,22224,BAO_0000019
13029,,,,0,,,CHEMBL627168,,Autocuration,A,,1,,U,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,,22224,BAO_0000019
13030,,,,0,,,CHEMBL875618,,Autocuration,A,,1,,U,Critical micellar concentration was measured in water by the dye solubilization method,,,22224,BAO_0000019
13031,,,,0,,,CHEMBL626612,,Autocuration,B,,1,,U,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,,22224,BAO_0000019
13032,,,,0,,,CHEMBL626613,,Autocuration,A,,1,,U,CMR value (relative to BAY K 8644),,,22224,BAO_0000019
13033,,,,0,,,CHEMBL626614,,Autocuration,A,,1,,U,Carbamoylating activity was determined,,,22224,BAO_0000019
13034,,,,0,,,CHEMBL626615,,Autocuration,A,,1,,U,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,,22224,BAO_0000218
13035,,,,0,,,CHEMBL626616,,Autocuration,A,,1,,U,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,,22224,BAO_0000019
13036,,,,0,,,CHEMBL626617,,Autocuration,A,,1,,U,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,,22224,BAO_0000019
13037,,,1969.0,1,Plasma,In vivo,CHEMBL626618,,Intermediate,A,,1,,N,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,,,50588,BAO_0000218
13038,,,1969.0,1,Plasma,In vivo,CHEMBL626619,,Intermediate,A,,1,,N,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,,,50597,BAO_0000218
13039,,,,1,,In vivo,CHEMBL626620,,Intermediate,A,,1,,N,"Clearance rate at 0.46 mg/kg, iv, in dogs",,,50588,BAO_0000218
13040,,,,1,,In vivo,CHEMBL626621,,Intermediate,A,,1,,N,"Clearance rate at 5.5 mg/kg, iv, in rat",,,50597,BAO_0000218
13041,,,,1,,In vivo,CHEMBL626622,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,,100710,BAO_0000218
13042,,,,1,,In vivo,CHEMBL626623,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,,100710,BAO_0000218
13043,,,,1,,In vivo,CHEMBL626624,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,,50588,BAO_0000218
13044,,,,1,,In vivo,CHEMBL626625,,Intermediate,A,,1,,N,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,,50597,BAO_0000218
13045,,,2107.0,1,Liver,Ex vivo,CHEMBL626626,,Intermediate,A,,1,,N,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,,50597,BAO_0000218
13046,,,,0,,In vivo,CHEMBL626627,,Autocuration,A,,1,,U,Tested for the total clearance of the compound,,,22224,BAO_0000218
13047,,,,1,,In vivo,CHEMBL626628,,Intermediate,A,,1,,N,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,,50588,BAO_0000218
13048,,,,0,,In vivo,CHEMBL626629,,Autocuration,A,,1,,U,Total body clearance was determined,,,22224,BAO_0000218
13049,,,,1,,,CHEMBL626630,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,50597,BAO_0000218
13050,,,,1,,,CHEMBL626631,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,50597,BAO_0000218
13051,,,,0,,,CHEMBL626632,,Autocuration,P,,1,,U,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,22229,BAO_0000100
13052,,,,0,,,CHEMBL626633,,Autocuration,P,,1,,U,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,22229,BAO_0000100
13053,,,,0,,,CHEMBL626634,,Autocuration,P,,1,,U,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,,22229,BAO_0000100
13054,,,,0,,,CHEMBL626635,,Autocuration,P,,1,,U,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,22229,BAO_0000100
13055,,,,0,,,CHEMBL626636,,Autocuration,P,,1,,U,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,22229,BAO_0000100
13056,,,,0,,,CHEMBL626637,,Autocuration,P,,1,,U,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,22229,BAO_0000100
13057,,,,1,,,CHEMBL626638,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,,50339,BAO_0000218
13058,,,,1,,,CHEMBL626639,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,,50339,BAO_0000218
13059,,,,1,,,CHEMBL626640,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,,50339,BAO_0000218
13060,,,,1,,,CHEMBL626641,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,,50339,BAO_0000218
13061,,,,1,,,CHEMBL627272,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,,50339,BAO_0000218
13062,,,,1,,,CHEMBL627273,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,,50339,BAO_0000218
13063,,,,1,,,CHEMBL627441,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,,50339,BAO_0000218
13064,,,,1,,,CHEMBL628355,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,,50339,BAO_0000218
13065,,,,1,,,CHEMBL628356,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,,50339,BAO_0000218
13066,,,,1,,,CHEMBL628357,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,,50339,BAO_0000218
13067,,,,1,,,CHEMBL628358,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,,50339,BAO_0000218
13068,,,,1,,,CHEMBL622307,,Intermediate,A,,1,,N,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,,50339,BAO_0000218
13069,,,,0,,,CHEMBL622527,,Autocuration,A,,1,,U,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,,22224,BAO_0000019
13070,,,,0,,,CHEMBL622528,,Autocuration,A,,1,,U,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,,22224,BAO_0000019
13071,,,,0,,,CHEMBL622529,,Autocuration,A,,1,,U,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,,22224,BAO_0000019
13072,,,,0,,,CHEMBL622992,,Autocuration,A,,1,,U,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,,22224,BAO_0000019
13073,,,,0,,,CHEMBL622993,,Autocuration,A,,1,,U,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,,22224,BAO_0000019
13074,,,,0,,,CHEMBL622994,,Autocuration,A,,1,,U,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,,22224,BAO_0000019
13075,,,,1,,,CHEMBL622995,,Intermediate,A,,1,,N,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,,50597,BAO_0000218
13076,,,,1,,,CHEMBL622996,,Intermediate,A,,1,,N,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,,50597,BAO_0000218
13077,,,,1,,,CHEMBL622997,,Intermediate,A,,1,,N,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,,50597,BAO_0000218
13078,,,,1,,,CHEMBL622998,,Intermediate,A,,1,,N,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,,50597,BAO_0000218
13079,,,,0,,,CHEMBL622999,,Autocuration,A,,1,,U,Cp max following ip administration at 1 mg/kg,,,22224,BAO_0000218
13080,,,1969.0,0,Plasma,In vivo,CHEMBL623000,,Autocuration,A,,1,,U,Maximum concentration in plasma was reported at 0.5 hour,,,22224,BAO_0000218
13081,,,1969.0,0,Plasma,In vivo,CHEMBL623001,,Autocuration,A,,1,,U,Maximum concentration in plasma was reported at 2 hour,,,22224,BAO_0000218
13082,,,,1,,,CHEMBL623002,,Intermediate,A,,1,,N,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,,50594,BAO_0000218
13083,,,,0,,,CHEMBL623003,,Autocuration,P,,1,,U,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,,22229,BAO_0000100
13084,,,,0,,,CHEMBL623004,,Autocuration,A,,1,,U,Steady state concentration was evaluated,,,22224,BAO_0000019
13085,,,,0,,,CHEMBL623005,,Autocuration,A,,1,,U,Partition coefficient (logP),,,22224,BAO_0000019
13086,,,,0,,,CHEMBL623006,,Autocuration,A,,1,,U,Partition coefficient (logD7.4),,,22224,BAO_0000019
13087,,,2107.0,1,Liver,In vivo,CHEMBL623007,,Intermediate,A,,1,,N,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,,,50597,BAO_0000218
13088,,,10000001.0,1,Bone,In vivo,CHEMBL623008,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,,,50597,BAO_0000218
13089,,,2037.0,1,Cerebellum,In vivo,CHEMBL876654,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,,,50597,BAO_0000218
13090,,,,1,,In vivo,CHEMBL623009,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,,50597,BAO_0000218
13091,,,,1,,In vivo,CHEMBL623010,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,,50597,BAO_0000218
13092,,,948.0,1,Heart,In vivo,CHEMBL623011,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,,,50597,BAO_0000218
13093,,,160.0,1,Intestine,In vivo,CHEMBL623012,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,,,50597,BAO_0000218
13094,,,,0,,,CHEMBL623013,,Autocuration,A,,1,,U,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,,22224,BAO_0000019
13095,,,,0,,,CHEMBL623014,,Autocuration,A,,1,,U,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,22224,BAO_0000019
13096,,,1088.0,0,Urine,,CHEMBL623015,,Autocuration,A,,1,,U,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,,,22224,BAO_0000019
13097,,,1088.0,0,Urine,,CHEMBL623016,,Autocuration,A,,1,,U,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,,22224,BAO_0000019
13098,,,1088.0,0,Urine,,CHEMBL624858,,Autocuration,A,,1,,U,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,,,22224,BAO_0000019
13099,,,,1,,,CHEMBL624859,,Intermediate,A,,1,,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,,50597,BAO_0000218
13100,,,,1,,,CHEMBL624860,,Intermediate,A,,1,,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,50597,BAO_0000218
13101,,,,1,,,CHEMBL624861,,Intermediate,A,,1,,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,50597,BAO_0000218
13102,,,,1,,,CHEMBL624862,,Intermediate,A,,1,,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,,50597,BAO_0000218
13103,,,,1,,,CHEMBL624863,,Intermediate,A,,1,,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,,50597,BAO_0000218
13104,,,,1,,,CHEMBL876655,,Intermediate,A,,1,,N,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,50597,BAO_0000218
13105,,,,1,,,CHEMBL624864,,Intermediate,A,,1,,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,,50588,BAO_0000218
13106,,,,1,,,CHEMBL624865,,Intermediate,A,,1,,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,,50588,BAO_0000218
13107,,,,1,,,CHEMBL624866,,Intermediate,A,,1,,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,50588,BAO_0000218
13108,,,,1,,,CHEMBL624867,,Expert,F,,1,,N,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,,50588,BAO_0000218
13109,,,,1,,,CHEMBL624868,,Intermediate,A,,1,,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,,50588,BAO_0000218
13110,,,,1,,,CHEMBL628450,,Intermediate,A,,1,,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,,50588,BAO_0000218
13111,,,,1,,,CHEMBL628451,,Intermediate,A,,1,,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,,50588,BAO_0000218
13112,,,,1,,,CHEMBL628452,,Intermediate,A,,1,,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,,50588,BAO_0000218
13113,,,,1,,,CHEMBL628453,,Intermediate,A,,1,,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,50588,BAO_0000218
13114,,,,1,,,CHEMBL628454,,Intermediate,A,,1,,N,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,,50588,BAO_0000218
13115,,,,1,,,CHEMBL628455,,Intermediate,A,,1,,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,,50588,BAO_0000218
13116,,,,1,,,CHEMBL628456,,Intermediate,A,,1,,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,,50588,BAO_0000218
13117,,,,1,,,CHEMBL628457,,Intermediate,A,,1,,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,50588,BAO_0000218
13118,,,,1,,,CHEMBL877505,,Intermediate,A,,1,,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,,50588,BAO_0000218
13119,,,,1,,,CHEMBL628458,,Intermediate,A,,1,,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,,50588,BAO_0000218
13120,,,,1,,,CHEMBL628459,,Intermediate,A,,1,,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,,50588,BAO_0000218
13121,,,,1,,,CHEMBL628460,,Intermediate,A,,1,,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,,50588,BAO_0000218
13122,,,,1,,,CHEMBL628461,,Intermediate,A,,1,,N,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,,50588,BAO_0000218
13123,,,,0,,,CHEMBL628462,,Autocuration,B,,1,,U,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,,22224,BAO_0000218
13124,,,,1,,,CHEMBL628463,,Intermediate,A,,1,,N,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,50588,BAO_0000218
13125,,,,1,,,CHEMBL625666,,Expert,F,,1,,N,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,,50597,BAO_0000218
13126,,,,0,,,CHEMBL625667,,Autocuration,B,,1,,U,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,22224,BAO_0000218
13127,,,,1,,,CHEMBL625668,,Expert,A,,1,,N,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,50597,BAO_0000218
13128,,,,1,,,CHEMBL625669,,Intermediate,A,,1,,N,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,50597,BAO_0000218
13129,,,,0,,,CHEMBL625670,,Autocuration,A,,1,,U,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,,22224,BAO_0000019
13130,,,,1,,,CHEMBL625671,,Intermediate,A,,1,,N,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,,50597,BAO_0000218
13131,,,,1,,,CHEMBL625672,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,,50602,BAO_0000218
13132,,,,1,,,CHEMBL625673,,Intermediate,A,,1,,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,,50602,BAO_0000218
13133,,,,1,,,CHEMBL625674,,Intermediate,A,,1,,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,,50602,BAO_0000218
13134,,,,1,,,CHEMBL625675,,Intermediate,A,,1,,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,,50602,BAO_0000218
13135,,,,1,,,CHEMBL627637,,Intermediate,A,,1,,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,,50602,BAO_0000218
13136,,,,1,,,CHEMBL627638,,Intermediate,A,,1,,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,,50602,BAO_0000218
13137,,,,1,,,CHEMBL627639,,Intermediate,A,,1,,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,,50602,BAO_0000218
13138,,,,1,,,CHEMBL627640,,Intermediate,A,,1,,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,,50602,BAO_0000218
13139,,,,1,,,CHEMBL627641,,Intermediate,A,,1,,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,,50602,BAO_0000218
13140,,,,1,,,CHEMBL627642,,Intermediate,A,,1,,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,,50602,BAO_0000218
13141,,,,1,,,CHEMBL877506,,Intermediate,A,,1,,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,,50602,BAO_0000218
13142,,,,1,,,CHEMBL627275,,Intermediate,A,,1,,N,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,,50594,BAO_0000218
13143,,,,1,,,CHEMBL627643,,Intermediate,A,,1,,N,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,,50506,BAO_0000218
13144,,,,1,,,CHEMBL631246,,Intermediate,A,,1,,N,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,,50506,BAO_0000218
13145,,,,1,,,CHEMBL631247,,Intermediate,A,,1,,N,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,,50506,BAO_0000218
13146,,,,1,,,CHEMBL629532,,Intermediate,A,,1,,N,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,,50506,BAO_0000218
13147,,,,1,,,CHEMBL629533,,Intermediate,A,,1,,N,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,,50506,BAO_0000218
13148,,,,1,,,CHEMBL629534,,Intermediate,A,,1,,N,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,,50506,BAO_0000218
13149,,,,1,,,CHEMBL629535,,Intermediate,A,,1,,N,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,,50506,BAO_0000218
13150,,,,0,,,CHEMBL625932,,Autocuration,A,,1,,U,Pharmacokinetic parameter :drug bound to plasma was reported,,,22224,BAO_0000019
13151,,,,0,,,CHEMBL625933,,Autocuration,A,,1,,U,compound was evaluated for drug bound in plasma,,,22224,BAO_0000019
13152,,,,1,,,CHEMBL625934,,Intermediate,A,,1,,N,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,,50597,BAO_0000218
13153,,,,0,,,CHEMBL625935,,Autocuration,A,,1,,U,Bioavailability,,,22224,BAO_0000218
13154,,,,1,,,CHEMBL625936,,Intermediate,A,,1,,N,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,,50597,BAO_0000218
13155,,,,1,,,CHEMBL625937,,Intermediate,A,,1,,N,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,,50597,BAO_0000218
13156,,,,1,,,CHEMBL625938,,Intermediate,A,,1,,N,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,,50588,BAO_0000218
13157,,,1970.0,1,Bile,,CHEMBL625939,,Intermediate,A,,1,,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,,,50597,BAO_0000218
13158,,,1970.0,1,Bile,,CHEMBL625940,,Intermediate,A,,1,,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,,,50597,BAO_0000218
13159,,,1970.0,1,Bile,,CHEMBL874464,,Intermediate,A,,1,,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,,,50597,BAO_0000218
13160,,,1970.0,1,Bile,,CHEMBL625941,,Intermediate,A,,1,,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,,,50597,BAO_0000218
13161,,,1970.0,1,Bile,,CHEMBL625942,,Intermediate,A,,1,,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,,,50597,BAO_0000218
13162,,,1970.0,1,Bile,,CHEMBL625943,,Intermediate,A,,1,,N,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,,,50597,BAO_0000218
13163,,,1977.0,1,Serum,,CHEMBL625944,,Intermediate,A,,1,,N,In vitro protein binding in human serum at 5 ug/ml,,,50587,BAO_0000218
13164,,,,0,,,CHEMBL625945,,Autocuration,A,,1,,U,Serum protein binding ability was measured,,,22224,BAO_0000019
13165,,,,0,,,CHEMBL625946,,Autocuration,A,,1,,U,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,22224,BAO_0000019
13166,,,,0,,In vivo,CHEMBL625947,,Autocuration,A,,1,,U,Oral bioavailability in dog,,,22224,BAO_0000218
13167,,,,1,,In vivo,CHEMBL625948,,Intermediate,A,,1,,N,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,,50597,BAO_0000218
13168,,,,0,,In vivo,CHEMBL625949,,Autocuration,A,,1,,U,Absolute oral bioavailability at an iv dose of 14 mg/kg,,,22224,BAO_0000218
13169,,,,0,,In vivo,CHEMBL625950,,Autocuration,A,,1,,U,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,,22224,BAO_0000218
13170,,,,0,,In vivo,CHEMBL625951,,Autocuration,A,,1,,U,Oral bioavailability (dose 15 mg/kg i.v.),,,22224,BAO_0000218
13171,,,,0,,In vivo,CHEMBL625952,,Autocuration,A,,1,,U,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,,22224,BAO_0000218
13172,,,,0,,In vivo,CHEMBL625953,,Autocuration,A,,1,,U,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,,22224,BAO_0000218
13173,,,,0,,In vivo,CHEMBL625954,,Autocuration,A,,1,,U,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,,22224,BAO_0000218
13174,,,,0,,In vivo,CHEMBL882959,,Autocuration,A,,1,,U,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,,22224,BAO_0000218
13175,,,,1,,In vivo,CHEMBL625955,,Intermediate,A,,1,,N,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,,50588,BAO_0000218
13176,,,,0,,In vivo,CHEMBL625956,,Autocuration,A,,1,,U,Bioavailability in ferret,,,22224,BAO_0000218
13177,,,,1,,In vivo,CHEMBL625957,,Intermediate,A,,1,,N,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,,100710,BAO_0000218
13178,,,,1,,,CHEMBL625958,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,50597,BAO_0000218
13179,,,,1,,,CHEMBL625959,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,50597,BAO_0000218
13180,,,,1,,,CHEMBL626642,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,50597,BAO_0000218
13181,,,,1,,,CHEMBL631330,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,50597,BAO_0000218
13182,,,,1,,,CHEMBL631331,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,50597,BAO_0000218
13183,,,,1,,,CHEMBL631332,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,50597,BAO_0000218
13184,,,,1,,,CHEMBL631333,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,50597,BAO_0000218
13185,,,,1,,,CHEMBL632018,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,50597,BAO_0000218
13186,,,,1,,,CHEMBL632019,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,50597,BAO_0000218
13187,,,,1,,,CHEMBL632020,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,50597,BAO_0000218
13188,,,,1,,,CHEMBL632021,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,50597,BAO_0000218
13189,,,,1,,,CHEMBL632022,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,50597,BAO_0000218
13190,,,,1,,,CHEMBL632023,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,50597,BAO_0000218
13191,,,,1,,,CHEMBL632024,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,50597,BAO_0000218
13192,,,,1,,,CHEMBL874472,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,50597,BAO_0000218
13193,,,,1,,,CHEMBL632025,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,50597,BAO_0000218
13194,,,,1,,,CHEMBL632026,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,50597,BAO_0000218
13195,,,,1,,,CHEMBL632027,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,50597,BAO_0000218
13196,,,,1,,,CHEMBL632028,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,50597,BAO_0000218
13197,,,,1,,,CHEMBL626430,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,50597,BAO_0000218
13198,,,,1,,,CHEMBL626431,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,50597,BAO_0000218
13199,,,,1,,,CHEMBL626432,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,50597,BAO_0000218
13200,,,,1,,,CHEMBL626433,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,50597,BAO_0000218
13201,,,,1,,,CHEMBL626434,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,50597,BAO_0000218
13202,,,,1,,,CHEMBL627280,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,50597,BAO_0000218
13203,,,,1,,,CHEMBL627281,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,50597,BAO_0000218
13204,,,,1,,,CHEMBL627282,,Intermediate,A,,1,,N,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,50597,BAO_0000218
13205,,,,0,,,CHEMBL627283,,Autocuration,A,,1,,U,Total body clearance was measured at given dose,,,22224,BAO_0000019
13206,,,,0,,,CHEMBL627284,,Autocuration,A,,1,,U,Total body clearance was measured at given dose.,,,22224,BAO_0000218
13207,,,,1,,,CHEMBL627285,,Intermediate,A,,1,,N,Metabolic clearance from the body in rat,,,50597,BAO_0000218
13208,,,,0,,In vivo,CHEMBL627286,,Autocuration,A,,1,,U,Renal clearance from the body,,,22224,BAO_0000218
13209,,,,1,,In vivo,CHEMBL875477,,Intermediate,A,,1,,N,Renal clearance from the body in rat,,,50597,BAO_0000218
13210,,,,1,,In vivo,CHEMBL627287,,Intermediate,A,,1,,N,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,,50597,BAO_0000218
13211,,,,1,,In vivo,CHEMBL627288,,Intermediate,A,,1,,N,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,,50588,BAO_0000218
13212,,,,1,,,CHEMBL627289,,Intermediate,A,,1,,N,Total clearance from the body in rat,,,50597,BAO_0000218
13213,,,1969.0,1,Plasma,In vivo,CHEMBL627290,,Intermediate,A,,1,,N,Clearance into cortex from rat plasma or PBS,,,50597,BAO_0000218
13214,,,,0,,In vivo,CHEMBL627291,,Autocuration,A,,1,,U,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,,22224,BAO_0000218
13215,,,,0,,In vivo,CHEMBL627292,,Autocuration,A,,1,,U,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,,22224,BAO_0000218
13216,,,,0,,In vivo,CHEMBL627293,,Autocuration,A,,1,,U,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,,22224,BAO_0000218
13217,,,,0,,In vivo,CHEMBL627294,,Autocuration,A,,1,,U,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,,22224,BAO_0000218
13218,,,,0,,In vivo,CHEMBL875478,,Autocuration,A,,1,,U,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,,22224,BAO_0000218
13219,,,,0,,In vivo,CHEMBL627295,,Autocuration,A,,1,,U,Clearance was determined,,,22224,BAO_0000218
13220,,,,1,,In vivo,CHEMBL627296,,Intermediate,A,,1,,N,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,,50594,BAO_0000218
13221,,,,1,,In vivo,CHEMBL626119,,Intermediate,A,,1,,N,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,,50592,BAO_0000218
13222,,,,1,,In vivo,CHEMBL626120,,Intermediate,A,,1,,N,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,,50597,BAO_0000218
13223,,,,1,,In vivo,CHEMBL626121,,Intermediate,A,,1,,N,Clearance in rat after iv dose (100 ug/kg),,,50597,BAO_0000218
13224,,,,0,,In vivo,CHEMBL626122,,Autocuration,A,,1,,U,Clearance in guinea pig,,,22224,BAO_0000218
13225,,,,1,,In vivo,CHEMBL626123,,Intermediate,A,,1,,N,Compound was evaluated for clearance in rat,,,50597,BAO_0000218
13226,,,,1,,In vivo,CHEMBL623456,,Intermediate,A,,1,,N,Compound was evaluated for the clearance in dog,,,50588,BAO_0000218
13227,,,,1,,In vivo,CHEMBL623457,,Intermediate,A,,1,,N,Compound was evaluated for the clearance in rat,,,50597,BAO_0000218
13228,,,,1,,In vivo,CHEMBL623458,,Intermediate,A,,1,,N,Compound was tested in vivo for clearance after iv administration in the rat,,,50597,BAO_0000218
13229,,,,0,,In vivo,CHEMBL623459,,Autocuration,A,,1,,U,IV clearance determined at an iv dose of 14 mg/kg,,,22224,BAO_0000218
13230,,,,0,,In vivo,CHEMBL875484,,Autocuration,A,,1,,U,IV clearance determined at an iv dose of 15.2 mg/kg,,,22224,BAO_0000218
13231,,,,0,,In vivo,CHEMBL623460,,Autocuration,A,,1,,U,IV clearance determined at an iv dose of 15 mg/kg,,,22224,BAO_0000218
13232,,,,0,,In vivo,CHEMBL623461,,Autocuration,A,,1,,U,IV clearance determined at an peroral dose of 30 mg/kg.,,,22224,BAO_0000218
13233,,,,0,,In vivo,CHEMBL623462,,Autocuration,A,,1,,U,IV clearance determined at an peroral dose of 30.2 mg/kg.,,,22224,BAO_0000218
13234,,,,0,,In vivo,CHEMBL627386,,Autocuration,A,,1,,U,IV clearance determined at an peroral dose of 30.3 mg/kg.,,,22224,BAO_0000218
13235,,,2113.0,1,Kidney,In vivo,CHEMBL627387,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,,,50597,BAO_0000218
13236,,,2107.0,1,Liver,In vivo,CHEMBL627388,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,,,50597,BAO_0000218
13237,,,2048.0,1,Lung,In vivo,CHEMBL627389,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,,,50597,BAO_0000218
13238,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627390,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,,,50597,BAO_0000218
13239,,,1969.0,1,Plasma,In vivo,CHEMBL627391,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,,,50597,BAO_0000218
13240,,,,1,,In vivo,CHEMBL627392,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,,50597,BAO_0000218
13241,,,2106.0,1,Spleen,In vivo,CHEMBL627393,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,,,50597,BAO_0000218
13242,,,3126.0,1,Trachea,In vivo,CHEMBL627394,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,,,50597,BAO_0000218
13243,,,10000001.0,1,Bone,In vivo,CHEMBL627395,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,,,50597,BAO_0000218
13244,,,2037.0,1,Cerebellum,In vivo,CHEMBL875485,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,,,50597,BAO_0000218
13245,,,,1,,In vivo,CHEMBL627396,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,,50597,BAO_0000218
13246,,,,1,,In vivo,CHEMBL627397,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,,50597,BAO_0000218
13247,,,948.0,1,Heart,In vivo,CHEMBL627398,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,,,50597,BAO_0000218
13248,,,10000001.0,1,Bone,In vivo,CHEMBL627399,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,,,50597,BAO_0000218
13249,,,2113.0,1,Kidney,In vivo,CHEMBL627400,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,,,50597,BAO_0000218
13250,,,2107.0,1,Liver,In vivo,CHEMBL627401,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,,,50597,BAO_0000218
13251,,,2048.0,1,Lung,In vivo,CHEMBL627402,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,,,50597,BAO_0000218
13252,,,2385.0,1,Muscle tissue,In vivo,CHEMBL627403,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,,,50597,BAO_0000218
13253,,,1969.0,1,Plasma,In vivo,CHEMBL627404,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,,,50597,BAO_0000218
13254,,,,1,,In vivo,CHEMBL623101,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,,50597,BAO_0000218
13255,,,2106.0,1,Spleen,In vivo,CHEMBL877480,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,,,50597,BAO_0000218
13256,,,3126.0,1,Trachea,In vivo,CHEMBL623102,,Intermediate,A,,1,,N,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,,,50597,BAO_0000218
13257,,,10000001.0,1,Bone,In vivo,CHEMBL623103,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,,,50597,BAO_0000218
13258,,,2037.0,1,Cerebellum,In vivo,CHEMBL623104,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,,,50597,BAO_0000218
13259,,,,1,,In vivo,CHEMBL623105,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,,50597,BAO_0000218
13260,,,,1,,In vivo,CHEMBL623106,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,,50597,BAO_0000218
13261,,,948.0,1,Heart,In vivo,CHEMBL623107,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,,,50597,BAO_0000218
13262,,,160.0,1,Intestine,In vivo,CHEMBL623108,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,,,50597,BAO_0000218
13263,,,2113.0,1,Kidney,In vivo,CHEMBL623109,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,,,50597,BAO_0000218
13264,,,2107.0,1,Liver,In vivo,CHEMBL623110,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,,,50597,BAO_0000218
13265,,,2048.0,1,Lung,In vivo,CHEMBL623111,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,,,50597,BAO_0000218
13266,,,2385.0,1,Muscle tissue,In vivo,CHEMBL625060,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,,,50597,BAO_0000218
13267,,,1969.0,1,Plasma,In vivo,CHEMBL625061,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,,,50597,BAO_0000218
13268,,,,1,,In vivo,CHEMBL625062,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,,50597,BAO_0000218
13269,,,2106.0,1,Spleen,In vivo,CHEMBL625063,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,,,50597,BAO_0000218
13270,,,3126.0,1,Trachea,In vivo,CHEMBL625064,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,,,50597,BAO_0000218
13271,,,10000001.0,1,Bone,In vivo,CHEMBL625065,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,,,50597,BAO_0000218
13272,,,2037.0,1,Cerebellum,In vivo,CHEMBL625066,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,,,50597,BAO_0000218
13273,,,,1,,In vivo,CHEMBL625067,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,,50597,BAO_0000218
13274,,,,1,,In vivo,CHEMBL625068,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,,50597,BAO_0000218
13275,,,948.0,1,Heart,In vivo,CHEMBL622159,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,,,50597,BAO_0000218
13276,,,160.0,1,Intestine,In vivo,CHEMBL622160,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,,,50597,BAO_0000218
13277,,,2113.0,1,Kidney,In vivo,CHEMBL622161,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,,,50597,BAO_0000218
13278,,,2048.0,1,Lung,In vivo,CHEMBL622162,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,,,50597,BAO_0000218
13279,,,2385.0,1,Muscle tissue,In vivo,CHEMBL622163,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,,,50597,BAO_0000218
13280,,,1969.0,1,Plasma,In vivo,CHEMBL622313,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,,,50597,BAO_0000218
13281,,,,1,,In vivo,CHEMBL622314,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,,50597,BAO_0000218
13282,,,2106.0,1,Spleen,In vivo,CHEMBL622315,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,,,50597,BAO_0000218
13283,,,3126.0,1,Trachea,In vivo,CHEMBL622316,,Intermediate,A,,1,,N,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,,,50597,BAO_0000218
13284,,,,1,,,CHEMBL877486,,Intermediate,A,,1,,N,Normal diffusion coefficient in water for Escherichia coli,,,50212,BAO_0000218
13285,,,,0,,,CHEMBL622317,,Autocuration,A,,1,,U,Average max percent decrease in RVR (renal vascular resistance) was determined,,,22224,BAO_0000019
13286,,,,0,,,CHEMBL622318,,Autocuration,A,,1,,U,Average max percent decrease in RVR (renal vascular resistance) was determined.,,,22224,BAO_0000019
13287,,,,0,,,CHEMBL622319,,Autocuration,A,,1,,U,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,,22224,BAO_0000019
13288,,,,0,,,CHEMBL622320,,Autocuration,A,,1,,U,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,,22224,BAO_0000019
13289,,,,0,,,CHEMBL622321,,Autocuration,A,,1,,U,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,,22224,BAO_0000019
13290,,,,0,,,CHEMBL622322,,Autocuration,A,,1,,U,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,,22224,BAO_0000019
13291,,,,0,,,CHEMBL622323,,Autocuration,A,,1,,U,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,,22224,BAO_0000019
13292,,,,1,,,CHEMBL622324,,Intermediate,A,,1,,N,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,,50597,BAO_0000218
13293,,,1088.0,1,Urine,,CHEMBL622325,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,,50588,BAO_0000218
13294,,,1088.0,1,Urine,,CHEMBL622326,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,,50588,BAO_0000218
13295,,,1088.0,1,Urine,,CHEMBL877487,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",,,50588,BAO_0000218
13296,,,1088.0,1,Urine,,CHEMBL622327,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,,50588,BAO_0000218
13297,,,1088.0,1,Urine,,CHEMBL622328,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",,,50588,BAO_0000218
13298,,,1088.0,1,Urine,,CHEMBL622329,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,,50588,BAO_0000218
13299,,,1088.0,1,Urine,,CHEMBL622330,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,,50588,BAO_0000218
13300,,,1088.0,1,Urine,,CHEMBL622331,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,,50588,BAO_0000218
13301,,,1088.0,1,Urine,,CHEMBL622332,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,,50588,BAO_0000218
13302,,,1088.0,1,Urine,,CHEMBL622333,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",,,50588,BAO_0000218
13303,,,1088.0,0,Urine,,CHEMBL627658,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,,22224,BAO_0000218
13304,,,1088.0,0,Urine,,CHEMBL630428,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",,,22224,BAO_0000218
13305,,,1088.0,0,Urine,,CHEMBL630429,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,,22224,BAO_0000218
13306,,,1088.0,0,Urine,,CHEMBL630430,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",,,22224,BAO_0000218
13307,,,1088.0,0,Urine,,CHEMBL630431,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",,,22224,BAO_0000218
13308,,,1088.0,1,Urine,,CHEMBL630432,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,,50597,BAO_0000218
13309,,,1088.0,1,Urine,,CHEMBL630433,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,,50597,BAO_0000218
13310,,,1088.0,1,Urine,,CHEMBL630434,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,,50597,BAO_0000218
13311,,,1088.0,1,Urine,,CHEMBL629372,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,,50597,BAO_0000218
13312,,,1088.0,1,Urine,,CHEMBL629553,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",,,50597,BAO_0000218
13313,,,1088.0,1,Urine,,CHEMBL629554,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,,50597,BAO_0000218
13314,,,1088.0,1,Urine,,CHEMBL874447,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,,50597,BAO_0000218
13315,,,1088.0,1,Urine,,CHEMBL629555,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,,50597,BAO_0000218
13316,,,1088.0,1,Urine,,CHEMBL629556,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,,50597,BAO_0000218
13317,,,1088.0,1,Urine,,CHEMBL629557,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",,,50597,BAO_0000218
13318,,,1088.0,1,Urine,,CHEMBL629558,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,,50597,BAO_0000218
13319,,,1088.0,1,Urine,,CHEMBL629559,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,,50597,BAO_0000218
13320,,,1088.0,1,Urine,,CHEMBL629560,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,,50597,BAO_0000218
13321,,,1088.0,1,Urine,,CHEMBL629561,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,,50588,BAO_0000218
13322,,,1088.0,1,Urine,,CHEMBL629562,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,,50588,BAO_0000218
13323,,,1088.0,1,Urine,,CHEMBL629563,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,,50588,BAO_0000218
13324,,,1088.0,1,Urine,,CHEMBL629564,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,,50588,BAO_0000218
13325,,,1088.0,1,Urine,,CHEMBL629565,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,,50588,BAO_0000218
13326,,,1088.0,1,Urine,,CHEMBL629566,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,,50588,BAO_0000218
13327,,,1088.0,1,Urine,,CHEMBL629567,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",,,50588,BAO_0000218
13328,,,1088.0,1,Urine,,CHEMBL629568,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,,50588,BAO_0000218
13329,,,1088.0,1,Urine,,CHEMBL629569,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",,,50588,BAO_0000218
13330,,,1088.0,1,Urine,,CHEMBL629570,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,,50588,BAO_0000218
13331,,,1088.0,0,Urine,,CHEMBL629571,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,,22224,BAO_0000218
13332,,,,0,,In vivo,CHEMBL629572,,Autocuration,A,,1,,U,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,,22224,BAO_0000218
13333,,,,0,,In vivo,CHEMBL629573,,Autocuration,A,,1,,U,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,,22224,BAO_0000218
13334,,,,0,,In vivo,CHEMBL629574,,Autocuration,A,,1,,U,Bioavailability (dose 20 mg/kg),,,22224,BAO_0000218
13335,,,,0,,In vivo,CHEMBL629575,,Autocuration,A,,1,,U,Bioavailability in dog,,,22224,BAO_0000218
13336,,,,0,,In vivo,CHEMBL874448,,Autocuration,A,,1,,U,Bioavailability in rat (Sprague-Dawley) (male),,,22224,BAO_0000218
13337,,,,0,,In vivo,CHEMBL629576,,Autocuration,A,,1,,U,Bioavailability in monkey (dose 10 mg/kg i.d.),,,22224,BAO_0000218
13338,,,,0,,In vivo,CHEMBL629577,,Autocuration,A,,1,,U,Bioavailability in rat,,,22224,BAO_0000218
13339,,,,0,,In vivo,CHEMBL629578,,Autocuration,A,,1,,U,Bioavailability in rat,,,22224,BAO_0000218
13340,,,,0,,In vivo,CHEMBL629579,,Autocuration,A,,1,,U,Bioavailability in dog (dose 3.0 mg/kg p.o.),,,22224,BAO_0000218
13341,,,,0,,In vivo,CHEMBL882958,,Autocuration,A,,1,,U,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,,22224,BAO_0000218
13342,,,,1,,In vivo,CHEMBL629580,,Intermediate,A,,1,,N,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,,50505,BAO_0000218
13343,,,,0,,In vivo,CHEMBL629581,,Autocuration,A,,1,,U,Bioavailability,,,22224,BAO_0000218
13344,,,,0,,In vivo,CHEMBL629582,,Autocuration,A,,1,,U,Bioavailability in squirrel monkey,,,22224,BAO_0000218
13345,,,,1,,In vivo,CHEMBL628522,,Intermediate,A,,1,,N,Bioavailability was evaluated in dog,,,50588,BAO_0000218
13346,,,,1,,In vivo,CHEMBL625432,,Intermediate,A,,1,,N,Bioavailability was evaluated in hamster,,,100712,BAO_0000218
13347,,,,0,,In vivo,CHEMBL625433,,Autocuration,A,,1,,U,Bioavailability in rat,,,22224,BAO_0000218
13348,,,1969.0,1,Plasma,In vivo,CHEMBL625434,,Intermediate,A,,1,,N,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,,50597,BAO_0000218
13349,,,1969.0,1,Plasma,In vivo,CHEMBL625435,,Intermediate,A,,1,,N,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,,,50597,BAO_0000218
13350,,,,0,,In vivo,CHEMBL625436,,Autocuration,A,,1,,U,Bioavailability in rat (dose 10 mg/kg p.o.),,,22224,BAO_0000218
13351,,,,1,,In vivo,CHEMBL874588,,Intermediate,A,,1,,N,Bioavailability was measured in cynomolgus monkeys.,,,100710,BAO_0000218
13352,,,,1,,In vivo,CHEMBL625437,,Intermediate,A,,1,,N,Bioavailability was measured in nude mice.,,,50594,BAO_0000218
13353,,,,0,,In vivo,CHEMBL625438,,Autocuration,A,,1,,U,Bioavailability in ferret (dose 10 mg/kg i.d.),,,22224,BAO_0000218
13354,,,,0,,In vivo,CHEMBL625439,,Autocuration,A,,1,,U,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,,22224,BAO_0000218
13355,,,,0,,In vivo,CHEMBL625440,,Autocuration,A,,1,,U,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,,22224,BAO_0000218
13356,,,,0,,In vivo,CHEMBL625441,,Autocuration,A,,1,,U,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,,22224,BAO_0000218
13357,,,,0,,In vivo,CHEMBL625442,,Autocuration,A,,1,,U,Bioavailability in rat (dose 10 mg/kg i.d.),,,22224,BAO_0000218
13358,,,,1,,In vivo,CHEMBL625443,,Intermediate,A,,1,,N,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,,50597,BAO_0000218
13359,,,,0,,In vivo,CHEMBL625444,,Autocuration,A,,1,,U,Bioavailability was determined; extremely poor,,,22224,BAO_0000218
13360,,,,1,,In vivo,CHEMBL625445,,Intermediate,A,,1,,N,% bioavailability in mice after oral administration of prodrug,,,50594,BAO_0000218
13361,,,,1,,In vivo,CHEMBL625446,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,,50588,BAO_0000218
13362,,,,1,,In vivo,CHEMBL882960,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,,50588,BAO_0000218
13363,,,,1,,In vivo,CHEMBL625447,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,,50588,BAO_0000218
13364,,,,1,,In vivo,CHEMBL625448,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,,50588,BAO_0000218
13365,,,,1,,In vivo,CHEMBL625449,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,,50588,BAO_0000218
13366,,,,1,,In vivo,CHEMBL874589,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,,50588,BAO_0000218
13367,,,,1,,In vivo,CHEMBL625450,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,,50588,BAO_0000218
13368,,,,1,,In vivo,CHEMBL625451,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,,50588,BAO_0000218
13369,,,,1,,In vivo,CHEMBL626584,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,,50588,BAO_0000218
13370,,,,1,,In vivo,CHEMBL626585,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,,50588,BAO_0000218
13371,,,,1,,In vivo,CHEMBL626586,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,,50588,BAO_0000218
13372,,,,1,,In vivo,CHEMBL626587,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,,50588,BAO_0000218
13373,,,,1,,In vivo,CHEMBL626588,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,,50588,BAO_0000218
13374,,,,1,,In vivo,CHEMBL626589,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,,50588,BAO_0000218
13375,,,,1,,In vivo,CHEMBL626590,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,,50588,BAO_0000218
13376,,,,1,,In vivo,CHEMBL626591,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,,50588,BAO_0000218
13377,,,,1,,In vivo,CHEMBL627181,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,,50588,BAO_0000218
13378,,,,1,,In vivo,CHEMBL628083,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,,50588,BAO_0000218
13379,,,,0,,In vivo,CHEMBL628084,,Autocuration,A,,1,,U,IV clearance determined at an peroral dose of 15 mg/kg.,,,22224,BAO_0000218
13380,,,,1,,In vivo,CHEMBL628085,,Expert,F,,1,,N,Mouse oral clearance was measured against Hymenolepiasis nana.,,,50064,BAO_0000218
13381,,,,1,,In vivo,CHEMBL628086,,Expert,F,,1,,N,Mouse oral clearance was measured against Nematospiroides dubius,,,50545,BAO_0000218
13382,,,,0,,In vivo,CHEMBL628087,,Autocuration,F,,1,,U,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,,22224,BAO_0000218
13383,,,,1,,In vivo,CHEMBL628088,,Intermediate,A,,1,,N,Mouse oral clearance was measured against N. nana; NT is Not Tested,,,50594,BAO_0000218
13384,,,,0,,In vivo,CHEMBL628089,,Autocuration,B,,1,,U,Mouse oral clearance was measured against N. nana; NT is Not Tested,,,22224,BAO_0000218
13385,,,,0,,In vivo,CHEMBL628090,,Autocuration,A,,1,,U,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,,22224,BAO_0000218
13386,,,,0,,In vivo,CHEMBL628091,,Autocuration,A,,1,,U,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,,22224,BAO_0000218
13387,,,,0,,In vivo,CHEMBL628092,,Autocuration,A,,1,,U,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,,22224,BAO_0000218
13388,,,,0,,In vivo,CHEMBL628093,,Autocuration,A,,1,,U,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,,22224,BAO_0000218
13389,,,,0,,In vivo,CHEMBL875607,,Autocuration,A,,1,,U,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,,22224,BAO_0000218
13390,,,,0,,In vivo,CHEMBL625710,,Autocuration,A,,1,,U,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,,22224,BAO_0000218
13391,,,,0,,In vivo,CHEMBL625711,,Autocuration,A,,1,,U,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,,22224,BAO_0000218
13392,,,,0,,In vivo,CHEMBL625712,,Autocuration,A,,1,,U,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,,22224,BAO_0000218
13393,,,,0,,In vivo,CHEMBL625713,,Autocuration,A,,1,,U,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,,22224,BAO_0000218
13394,,,,1,,In vivo,CHEMBL625714,,Intermediate,A,,1,,N,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,,50588,BAO_0000218
13395,,,,1,,In vivo,CHEMBL625715,,Intermediate,A,,1,,N,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,,50797,BAO_0000218
13396,,,,1,,In vivo,CHEMBL625716,,Intermediate,A,,1,,N,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,,50597,BAO_0000218
13397,,,,1,,In vivo,CHEMBL625717,,Intermediate,A,,1,,N,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,,50597,BAO_0000218
13398,,,,1,,In vivo,CHEMBL625718,,Intermediate,A,,1,,N,Plasma clearance was determined for the compound in rats,,,50597,BAO_0000218
13399,,,,1,,In vivo,CHEMBL625719,,Intermediate,A,,1,,N,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,,50597,BAO_0000218
13400,,,,1,,In vivo,CHEMBL625720,,Intermediate,A,,1,,N,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,,50597,BAO_0000218
13401,,,,1,,In vivo,CHEMBL625721,,Intermediate,A,,1,,N,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,,50597,BAO_0000218
13402,,,,1,,In vivo,CHEMBL625722,,Intermediate,A,,1,,N,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,,50597,BAO_0000218
13403,,,,1,,In vivo,CHEMBL625723,,Intermediate,A,,1,,N,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,,50597,BAO_0000218
13404,,,,1,,In vivo,CHEMBL625724,,Intermediate,A,,1,,N,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,,50545,BAO_0000218
13405,,,,1,,In vivo,CHEMBL625725,,Intermediate,A,,1,,N,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,,50545,BAO_0000218
13406,,,,1,,In vivo,CHEMBL625726,,Intermediate,A,,1,,N,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,,50545,BAO_0000218
13407,,,,1,,In vivo,CHEMBL875608,,Intermediate,A,,1,,N,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,,50545,BAO_0000218
13408,,,,1,,In vivo,CHEMBL625727,,Intermediate,A,,1,,N,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,,50545,BAO_0000218
13409,,,1088.0,0,Urine,In vivo,CHEMBL625728,,Autocuration,A,,1,,U,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,,,22224,BAO_0000218
13410,,,,0,,In vivo,CHEMBL625729,,Autocuration,A,,1,,U,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,,22224,BAO_0000218
13411,,,,0,,In vivo,CHEMBL625730,,Autocuration,A,,1,,U,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,,22224,BAO_0000218
13412,,,1088.0,0,Urine,In vivo,CHEMBL625731,,Autocuration,A,,1,,U,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,,22224,BAO_0000218
13413,,,1088.0,0,Urine,In vivo,CHEMBL626417,,Autocuration,A,,1,,U,Urinary clearance was determined in rat at 25 mg/kg os dosage,,,22224,BAO_0000218
13414,,,1088.0,1,Urine,In vivo,CHEMBL626418,,Intermediate,A,,1,,N,Urinary clearance was determined at 100 mg/kg oral dosage in human,,,50587,BAO_0000218
13415,,,1088.0,1,Urine,In vivo,CHEMBL626419,,Intermediate,A,,1,,N,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,,,50588,BAO_0000218
13416,,,1969.0,1,Plasma,In vivo,CHEMBL626592,,Intermediate,A,,1,,N,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,,50588,BAO_0000218
13417,,,1969.0,1,Plasma,In vivo,CHEMBL626593,,Intermediate,A,,1,,N,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,,50597,BAO_0000218
13418,,,,1,,In vivo,CHEMBL626594,,Intermediate,A,,1,,N,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,,50597,BAO_0000218
13419,,,,1,,In vivo,CHEMBL625035,,Intermediate,A,,1,,N,Clearance rate in dogs,,,50588,BAO_0000218
13420,,,,0,,In vitro,CHEMBL625036,,Autocuration,A,,1,,U,Compound was measured for intrinsic clearance,,,22224,BAO_0000019
13421,,,,0,,,CHEMBL625037,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13422,,,,0,,,CHEMBL625038,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13423,,,,0,,,CHEMBL625039,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13424,,,,0,,,CHEMBL625040,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13425,,,,0,,,CHEMBL625041,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13426,,,,0,,,CHEMBL625042,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13427,,,,0,,,CHEMBL874411,,Autocuration,A,,1,,U,Partition coefficient of the compound,,,22224,BAO_0000019
13428,,,,0,,,CHEMBL625043,,Autocuration,A,,1,,U,Permeability,,,22224,BAO_0000019
13429,,,,0,,,CHEMBL625044,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13430,,,,0,,,CHEMBL625045,,Autocuration,A,,1,,U,Partition coefficient (logD),,,22224,BAO_0000019
13431,,,,0,,,CHEMBL625046,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,22229,BAO_0000100
13432,,,,0,,,CHEMBL625047,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,22229,BAO_0000100
13433,,,,0,,,CHEMBL625048,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13434,,,,0,,,CHEMBL625049,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13435,,,,0,,,CHEMBL625050,,Autocuration,P,,1,,U,Calculated logarithm of partition coefficient (P) was determined,,,22229,BAO_0000100
13436,,,,0,,,CHEMBL625051,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13437,,,,0,,,CHEMBL874412,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13438,,,,0,,,CHEMBL625052,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13439,,,,0,,,CHEMBL625053,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13440,,,,0,,,CHEMBL623250,,Autocuration,A,,1,,U,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,,22224,BAO_0000019
13441,,,,0,,,CHEMBL623251,,Autocuration,A,,1,,U,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,,22224,BAO_0000019
13442,,,,0,,,CHEMBL623252,,Autocuration,A,,1,,U,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,,22224,BAO_0000019
13443,,,,0,,,CHEMBL623253,,Autocuration,A,,1,,U,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,,22224,BAO_0000019
13444,,,,0,,,CHEMBL623254,,Autocuration,A,,1,,U,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,,22224,BAO_0000019
13445,,,,0,,,CHEMBL623255,,Autocuration,A,,1,,U,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,,22224,BAO_0000019
13446,,,,0,,,CHEMBL626831,,Autocuration,A,,1,,U,Percent degradation of compound at a pH of 1 over a 18 hr period,,,22224,BAO_0000019
13447,,,,0,,,CHEMBL877494,,Autocuration,A,,1,,U,Percent degradation of compound at pH of 1 over an 18 hr period,,,22224,BAO_0000019
13448,,,,0,,,CHEMBL626832,,Autocuration,A,,1,,U,Delta Logarithm of Partition Coefficient value was determined.,,,22224,BAO_0000019
13449,,,,0,,,CHEMBL626833,,Autocuration,A,,1,,U,Delta logPoct-cyc,,,22224,BAO_0000019
13450,,,,0,,,CHEMBL626834,,Autocuration,P,,1,,U,Lipophilicity estimated on reversed phase TLC,,,22224,BAO_0000100
13451,,,,0,,,CHEMBL626835,,Autocuration,A,,1,,U,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,,22224,BAO_0000019
13452,,,,0,,,CHEMBL626836,,Autocuration,A,,1,,U,Delta logPoct-cyc,,,22224,BAO_0000019
13453,,,,0,,,CHEMBL626837,,Autocuration,P,,1,,U,Change in logarithm of partition coefficient of the compound,,,22229,BAO_0000100
13454,,,,0,,,CHEMBL626838,,Autocuration,A,,1,,U,Delta logD (pH 6.5),,,22224,BAO_0000019
13455,,,,0,,,CHEMBL626839,,Autocuration,P,,1,,U,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,,22224,BAO_0000100
13456,,,,0,,,CHEMBL626840,,Autocuration,A,,1,,U,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,,22224,BAO_0000019
13457,,,,0,,,CHEMBL626841,,Autocuration,A,,1,,U,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,,22224,BAO_0000019
13458,,,,0,,,CHEMBL626842,,Autocuration,A,,1,,U,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,,22224,BAO_0000219
13459,,,,0,,,CHEMBL626843,,Autocuration,A,,1,,U,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,,22224,BAO_0000219
13460,,,,1,,,CHEMBL626844,,Intermediate,A,,1,,N,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,,50597,BAO_0000218
13461,,,,1,,,CHEMBL877495,,Intermediate,A,,1,,N,Amount of deuterium retained was reported after normal workup in rats,,,50597,BAO_0000218
13462,,,,1,,,CHEMBL626845,,Intermediate,A,,1,,N,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,,50597,BAO_0000218
13463,,,,1,,,CHEMBL626846,,Intermediate,A,,1,,N,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,,50597,BAO_0000218
13464,,,,1,,,CHEMBL626847,,Intermediate,A,,1,,N,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,,50597,BAO_0000218
13465,,,,1,,,CHEMBL628677,,Intermediate,A,,1,,N,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,,50597,BAO_0000218
13466,,,,1,,,CHEMBL628678,,Intermediate,A,,1,,N,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,,50597,BAO_0000218
13467,,,,0,,,CHEMBL628679,,Autocuration,A,,1,,U,Compound was subjected to electrochemical oxidation,,,22224,BAO_0000019
13468,,,,0,,,CHEMBL628680,,Autocuration,A,,1,,U,Compound was subjected to photochemical oxidation,,,22224,BAO_0000019
13469,,,,0,,,CHEMBL628681,,Autocuration,A,,1,,U,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,,22224,BAO_0000019
13470,,,,0,,,CHEMBL628682,,Autocuration,A,,1,,U,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,,22224,BAO_0000019
13471,,,,0,,,CHEMBL628683,,Autocuration,A,,1,,U,Oxidation of compound by methemoglobin in presence of hydroperoxide,,,22224,BAO_0000019
13472,,,,1,,,CHEMBL628684,,Intermediate,A,,1,,N,Percent diffusion through fuzzy rat skin after 48 h of incubation,,,50597,BAO_0000218
13473,,,,0,,,CHEMBL877501,,Autocuration,P,,1,,U,Dissociation constant (pKa),,,22229,BAO_0000100
13474,,,,0,,,CHEMBL628685,,Autocuration,P,,1,,U,Dissociation constant value of the compound; ND means not determined.,,,22224,BAO_0000100
13475,,,178.0,1,Blood,,CHEMBL628686,,Intermediate,A,,1,,N,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,,,50597,BAO_0000218
13476,,,178.0,1,Blood,,CHEMBL628687,,Intermediate,A,,1,,N,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,50597,BAO_0000218
13477,,,,1,,,CHEMBL628688,,Intermediate,A,,1,,N,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,,50597,BAO_0000218
13478,,,,1,,,CHEMBL628689,,Intermediate,A,,1,,N,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,50597,BAO_0000218
13479,,,2107.0,1,Liver,,CHEMBL628690,,Intermediate,A,,1,,N,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,,,50597,BAO_0000218
13480,,,2107.0,1,Liver,,CHEMBL629363,,Intermediate,A,,1,,N,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,,50597,BAO_0000218
13481,,,2106.0,1,Spleen,,CHEMBL629364,,Intermediate,A,,1,,N,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,,,50597,BAO_0000218
13482,,,2106.0,1,Spleen,,CHEMBL629365,,Intermediate,A,,1,,N,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,50597,BAO_0000218
13483,,,,1,,,CHEMBL629366,,Intermediate,A,,1,,N,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,,50597,BAO_0000218
13484,,,1088.0,1,Urine,,CHEMBL629367,,Intermediate,A,,1,,N,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,,,50597,BAO_0000218
13485,,,1988.0,1,Feces,,CHEMBL629368,,Intermediate,A,,1,,N,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,50597,BAO_0000218
13486,,,1088.0,1,Urine,,CHEMBL877502,,Intermediate,A,,1,,N,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,,50597,BAO_0000218
13487,,,2037.0,1,Cerebellum,,CHEMBL629369,,Intermediate,A,,1,,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,,,50594,BAO_0000218
13488,,,955.0,1,Brain,,CHEMBL629370,,Intermediate,A,,1,,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,,,50594,BAO_0000218
13489,,,1088.0,0,Urine,,CHEMBL629371,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",,,22224,BAO_0000218
13490,,,1088.0,0,Urine,,CHEMBL626276,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,,22224,BAO_0000218
13491,,,1088.0,0,Urine,,CHEMBL626277,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,,22224,BAO_0000218
13492,,,1088.0,0,Urine,,CHEMBL631250,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,,22224,BAO_0000218
13493,,,1088.0,1,Urine,,CHEMBL631251,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,,50597,BAO_0000218
13494,,,1088.0,1,Urine,,CHEMBL631252,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,,50597,BAO_0000218
13495,,,1088.0,1,Urine,,CHEMBL631253,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",,,50597,BAO_0000218
13496,,,1088.0,1,Urine,,CHEMBL631254,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,,50597,BAO_0000218
13497,,,1088.0,1,Urine,,CHEMBL631255,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,,50597,BAO_0000218
13498,,,1088.0,1,Urine,,CHEMBL631256,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,,50597,BAO_0000218
13499,,,1088.0,1,Urine,,CHEMBL631257,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,,50597,BAO_0000218
13500,,,1088.0,1,Urine,,CHEMBL628009,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",,,50597,BAO_0000218
13501,,,1088.0,1,Urine,,CHEMBL628010,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,,50597,BAO_0000218
13502,,,1088.0,1,Urine,,CHEMBL628011,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,,50597,BAO_0000218
13503,,,1088.0,1,Urine,,CHEMBL628012,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",,,50597,BAO_0000218
13504,,,1088.0,1,Urine,,CHEMBL628013,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,,50597,BAO_0000218
13505,,,1088.0,1,Urine,,CHEMBL628014,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,,50597,BAO_0000218
13506,,,1088.0,1,Urine,,CHEMBL628015,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",,,50588,BAO_0000218
13507,,,1088.0,1,Urine,,CHEMBL628016,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,,50588,BAO_0000218
13508,,,1088.0,1,Urine,,CHEMBL874461,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",,,50588,BAO_0000218
13509,,,1088.0,1,Urine,,CHEMBL628017,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,,50588,BAO_0000218
13510,,,1088.0,1,Urine,,CHEMBL628018,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,,50588,BAO_0000218
13511,,,1088.0,1,Urine,,CHEMBL628019,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,,50588,BAO_0000218
13512,,,1088.0,1,Urine,,CHEMBL628020,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,,50588,BAO_0000218
13513,,,1088.0,1,Urine,,CHEMBL628021,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,,50588,BAO_0000218
13514,,,1088.0,1,Urine,,CHEMBL628022,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,,50588,BAO_0000218
13515,,,1088.0,1,Urine,,CHEMBL628023,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,,50588,BAO_0000218
13516,,,1088.0,0,Urine,,CHEMBL628024,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,,22224,BAO_0000218
13517,,,1088.0,0,Urine,,CHEMBL628025,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",,,22224,BAO_0000218
13518,,,1088.0,0,Urine,,CHEMBL628026,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,,22224,BAO_0000218
13519,,,1088.0,0,Urine,,CHEMBL628027,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,,22224,BAO_0000218
13520,,,1088.0,0,Urine,,CHEMBL628028,,Autocuration,A,,1,,U,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,,22224,BAO_0000218
13521,,,1088.0,1,Urine,,CHEMBL628029,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,,50597,BAO_0000218
13522,,,1088.0,1,Urine,,CHEMBL628030,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",,,50597,BAO_0000218
13523,,,1088.0,1,Urine,,CHEMBL628031,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,,50597,BAO_0000218
13524,,,1088.0,1,Urine,,CHEMBL628032,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",,,50597,BAO_0000218
13525,,,1088.0,1,Urine,,CHEMBL628033,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,,50597,BAO_0000218
13526,,,1088.0,1,Urine,,CHEMBL628034,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",,,50597,BAO_0000218
13527,,,1088.0,1,Urine,,CHEMBL628035,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,,50597,BAO_0000218
13528,,,1088.0,1,Urine,,CHEMBL628036,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",,,50597,BAO_0000218
13529,,,1088.0,1,Urine,,CHEMBL874462,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,,50597,BAO_0000218
13530,,,,1,,In vivo,CHEMBL628037,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,,50588,BAO_0000218
13531,,,,1,,In vivo,CHEMBL628123,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,,50588,BAO_0000218
13532,,,,1,,In vivo,CHEMBL628124,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,,50588,BAO_0000218
13533,,,,1,,In vivo,CHEMBL628125,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,,50588,BAO_0000218
13534,,,,1,,In vivo,CHEMBL628126,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,,50588,BAO_0000218
13535,,,,1,,In vivo,CHEMBL628127,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,,50588,BAO_0000218
13536,,,,1,,In vivo,CHEMBL628128,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,,50588,BAO_0000218
13537,,,,1,,In vivo,CHEMBL628129,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,,50588,BAO_0000218
13538,,,,1,,In vivo,CHEMBL628130,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,,50588,BAO_0000218
13539,,,,1,,In vivo,CHEMBL628131,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,,50588,BAO_0000218
13540,,,,1,,In vivo,CHEMBL628132,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,,50588,BAO_0000218
13541,,,,1,,In vivo,CHEMBL628133,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,,50588,BAO_0000218
13542,,,,1,,In vivo,CHEMBL628134,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,,50588,BAO_0000218
13543,,,,1,,In vivo,CHEMBL628135,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,,50588,BAO_0000218
13544,,,,1,,In vivo,CHEMBL628136,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,,50588,BAO_0000218
13545,,,,1,,In vivo,CHEMBL628137,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,,50588,BAO_0000218
13546,,,,1,,In vivo,CHEMBL628138,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,,50588,BAO_0000218
13547,,,,1,,In vivo,CHEMBL628139,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,,50588,BAO_0000218
13548,,,,1,,In vivo,CHEMBL628140,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,,50588,BAO_0000218
13549,,,,1,,In vivo,CHEMBL628141,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,,50588,BAO_0000218
13550,,,,1,,In vivo,CHEMBL628142,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,,50588,BAO_0000218
13551,,,,1,,In vivo,CHEMBL628143,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,,50588,BAO_0000218
13552,,,,1,,In vivo,CHEMBL628144,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,,50588,BAO_0000218
13553,,,,1,,In vivo,CHEMBL628145,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,,50588,BAO_0000218
13554,,,,1,,In vivo,CHEMBL628146,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,,50588,BAO_0000218
13555,,,,1,,In vivo,CHEMBL625355,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,,50588,BAO_0000218
13556,,,,1,,In vivo,CHEMBL625356,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,,50588,BAO_0000218
13557,,,,1,,In vivo,CHEMBL625357,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,,50588,BAO_0000218
13558,,,,1,,In vivo,CHEMBL625527,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,,50588,BAO_0000218
13559,,,,1,,In vivo,CHEMBL875473,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,,50588,BAO_0000218
13560,,,,1,,In vivo,CHEMBL625528,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,,50588,BAO_0000218
13561,,,,1,,In vivo,CHEMBL626304,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,,50597,BAO_0000218
13562,,,1637.0,1,Artery,In vivo,CHEMBL624138,,Intermediate,A,,1,,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,,,50588,BAO_0000218
13563,,,,0,,,CHEMBL624139,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13564,,,,0,,,CHEMBL624140,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13565,,,,0,,,CHEMBL624141,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13566,,,,0,,,CHEMBL624142,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13567,,,,0,,,CHEMBL624143,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13568,,,,0,,,CHEMBL624144,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13569,,,,0,,,CHEMBL624145,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13570,,,,0,,,CHEMBL624146,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13571,,,,0,,,CHEMBL624147,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13572,,,,0,,,CHEMBL883123,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP) (MacLogP),,,22229,BAO_0000100
13573,,,,0,,,CHEMBL624148,,Autocuration,A,,1,,U,Partition coefficient (logP),,,22224,BAO_0000019
13574,,,,0,,,CHEMBL874416,,Autocuration,A,,1,,U,Kinetic parameter was determined,,,22224,BAO_0000019
13575,,,,0,,,CHEMBL624149,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13576,,,,0,,,CHEMBL624150,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13577,,,,0,,,CHEMBL624151,,Autocuration,P,,1,,U,Lipophilicity was determined,,,22224,BAO_0000100
13578,,,,0,,,CHEMBL624152,,Autocuration,P,,1,,U,Lipophilicity was determined,,,22224,BAO_0000100
13579,,,,0,,,CHEMBL622139,,Autocuration,P,,1,,U,Lipophilicity was determined,,,22224,BAO_0000100
13580,,,,0,,,CHEMBL622140,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13581,,,,0,,,CHEMBL622141,,Autocuration,P,,1,,U,Lipophilicity was determined,,,22224,BAO_0000100
13582,,,,0,,,CHEMBL622142,,Autocuration,P,,1,,U,Lipophilicity in octanol-water,,,22224,BAO_0000100
13583,,,,0,,,CHEMBL622143,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13584,,,,0,,,CHEMBL622144,,Autocuration,P,,1,,U,Octanol-water partition coefficient was determined,,,22229,BAO_0000100
13585,,,,0,,,CHEMBL877473,,Autocuration,A,,1,,U,Partition coefficient (logP),,,22224,BAO_0000019
13586,,,,0,,,CHEMBL622145,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13587,,,,0,,,CHEMBL622146,,Autocuration,A,,1,,U,Partition coefficient was determined; ND means not determined,,,22224,BAO_0000019
13588,,,,0,,,CHEMBL622147,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP),,,22229,BAO_0000100
13589,,,,0,,,CHEMBL622148,,Autocuration,A,,1,,U,Partition coefficient of the compound,,,22224,BAO_0000019
13590,,,,0,,,CHEMBL883124,,Autocuration,A,,1,,U,Permeability was determined,,,22224,BAO_0000019
13591,,,,0,,,CHEMBL622149,,Autocuration,P,,1,,U,The compound was evaluated for the partition coefficient,,,22229,BAO_0000100
13592,,,,0,,,CHEMBL622150,,Autocuration,A,,1,,U,Partition coefficient (logP),,,22224,BAO_0000019
13593,,,,0,,,CHEMBL622151,,Autocuration,P,,1,,U,The lipophilicity was reported,,,22224,BAO_0000100
13594,,,,0,,,CHEMBL622152,,Autocuration,P,,1,,U,logarithm of the octanol-water partition coefficient for the compound,,,22229,BAO_0000100
13595,,,,0,,,CHEMBL622153,,Autocuration,A,,1,,U,Clogp value was determined,,,22224,BAO_0000019
13596,,,,0,,In vivo,CHEMBL877474,,Autocuration,A,,1,,U,Clp at a dose of 1.5 mg/kg,,,22224,BAO_0000218
13597,,,,0,,In vivo,CHEMBL622154,,Autocuration,A,,1,,U,Clp at a dose of 2.0 mg/kg,,,22224,BAO_0000218
13598,,,1969.0,0,Plasma,In vivo,CHEMBL622155,,Autocuration,A,,1,,U,"Clp, plasma clearance at a dose of 10 mg/kg",,,22224,BAO_0000218
13599,,,1969.0,0,Plasma,In vivo,CHEMBL622156,,Autocuration,A,,1,,U,"Clp, plasma clearance at a dose of 50 mg/kg",,,22224,BAO_0000218
13600,,,1969.0,1,Plasma,In vivo,CHEMBL622157,,Intermediate,A,,1,,N,Compound was tested for plasma clearance in rat,,,50597,BAO_0000218
13601,,,1969.0,1,Plasma,In vivo,CHEMBL622158,,Intermediate,A,,1,,N,Compound was tested for plasma clearance in rat; Not determined,,,50597,BAO_0000218
13602,,,,1,,In vivo,CHEMBL622807,,Intermediate,A,,1,,N,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,,50597,BAO_0000218
13603,,,,1,,In vivo,CHEMBL622808,,Intermediate,A,,1,,N,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,,50797,BAO_0000218
13604,,,,0,,In vivo,CHEMBL622809,,Autocuration,A,,1,,U,Plasma clearance by iv administration at a dose 0.003 ug/mL,,,22224,BAO_0000218
13605,,,,0,,In vivo,CHEMBL622810,,Autocuration,A,,1,,U,Plasma clearance determined,,,22224,BAO_0000218
13606,,,,1,,In vivo,CHEMBL876653,,Intermediate,A,,1,,N,Plasma clearance after iv administration at 3 mg/kg in hamster,,,100712,BAO_0000218
13607,,,,1,,In vivo,CHEMBL622811,,Intermediate,A,,1,,N,Plasma clearance after iv administration at 4 mg/kg in hamster,,,100712,BAO_0000218
13608,,,,1,,In vivo,CHEMBL622986,,Intermediate,A,,1,,N,Rate of clearance in rat was determined,,,50597,BAO_0000218
13609,,,1969.0,1,Plasma,In vivo,CHEMBL622987,,Intermediate,A,,1,,N,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,,,50597,BAO_0000218
13610,,,1969.0,1,Plasma,In vivo,CHEMBL622988,,Intermediate,A,,1,,N,Total plasma clearance after iv dose of 5.10 mg/kg in rats,,,50597,BAO_0000218
13611,,,1969.0,1,Plasma,In vivo,CHEMBL622989,,Intermediate,A,,1,,N,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,,,50597,BAO_0000218
13612,,,1969.0,1,Plasma,In vivo,CHEMBL622990,,Intermediate,A,,1,,N,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,,,50597,BAO_0000218
13613,,,1969.0,0,Plasma,In vivo,CHEMBL622991,,Autocuration,A,,1,,U,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,,22224,BAO_0000218
13614,,,1969.0,1,Plasma,In vivo,CHEMBL622227,,Intermediate,A,,1,,N,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,,50597,BAO_0000218
13615,,,1969.0,1,Plasma,In vivo,CHEMBL622228,,Intermediate,A,,1,,N,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,,50588,BAO_0000218
13616,,,,1,,In vivo,CHEMBL622229,,Intermediate,A,,1,,N,Clpl value in rat,,,50597,BAO_0000218
13617,,,,1,,In vivo,CHEMBL622230,,Intermediate,A,,1,,N,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,,50512,BAO_0000218
13618,,,,1,,In vivo,CHEMBL622231,,Intermediate,A,,1,,N,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,,50597,BAO_0000218
13619,,,,1,,In vivo,CHEMBL622232,,Intermediate,A,,1,,N,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,,100710,BAO_0000218
13620,,,,0,,In vivo,CHEMBL622233,,Autocuration,A,,1,,U,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,,22224,BAO_0000218
13621,,,,0,,In vivo,CHEMBL622234,,Autocuration,A,,1,,U,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,,22224,BAO_0000218
13622,,,,0,,In vivo,CHEMBL622235,,Autocuration,A,,1,,U,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,,22224,BAO_0000218
13623,,,,0,,In vivo,CHEMBL622236,,Autocuration,A,,1,,U,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,,22224,BAO_0000218
13624,,,,0,,In vivo,CHEMBL622237,,Autocuration,A,,1,,U,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,,22224,BAO_0000218
13625,,,,0,,In vivo,CHEMBL877482,,Autocuration,A,,1,,U,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,,22224,BAO_0000218
13626,,,,0,,In vivo,CHEMBL622238,,Autocuration,A,,1,,U,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,,22224,BAO_0000218
13627,,,,0,,In vivo,CHEMBL622239,,Autocuration,A,,1,,U,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,,22224,BAO_0000218
13628,,,178.0,0,Blood,In vivo,CHEMBL622240,,Autocuration,A,,1,,U,Cmax was calculated as maximum concentration reached in the blood,,,22224,BAO_0000218
13629,,,178.0,0,Blood,In vivo,CHEMBL622241,,Autocuration,A,,1,,U,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,,,22224,BAO_0000218
13630,,,,1,,In vivo,CHEMBL631013,,Intermediate,A,,1,,N,Cmax was determine after peroral administration at 10 mpk in Rat,,,50597,BAO_0000218
13631,,,,1,,In vivo,CHEMBL631014,,Intermediate,A,,1,,N,Cmax was determine after peroral administration at 10 mpk in Rhesus,,,50797,BAO_0000218
13632,,,,1,,In vivo,CHEMBL631015,,Intermediate,A,,1,,N,Cmax was determine after peroral administration at 10 mpk in dog,,,50588,BAO_0000218
13633,,,,1,,In vivo,CHEMBL631016,,Intermediate,A,,1,,N,Cmax was determine after peroral administration at 160 mpk in Rat,,,50597,BAO_0000218
13634,,,,1,,In vivo,CHEMBL631017,,Intermediate,A,,1,,N,Cmax was determine after peroral administration at 20 mpk in Rat,,,50597,BAO_0000218
13635,,,,1,,In vivo,CHEMBL631018,,Intermediate,A,,1,,N,Cmax was determine after peroral administration at 50 mpk in Rat,,,50597,BAO_0000218
13636,,,,0,,In vivo,CHEMBL631019,,Autocuration,A,,1,,U,Cmax was determined,,,22224,BAO_0000218
13637,,,955.0,1,Brain,,CHEMBL875761,,Intermediate,A,,1,,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,,,50594,BAO_0000218
13638,,,955.0,1,Brain,,CHEMBL631020,,Intermediate,A,,1,,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,,,50594,BAO_0000218
13639,,,955.0,1,Brain,,CHEMBL631669,,Intermediate,A,,1,,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,,,50594,BAO_0000218
13640,,,955.0,1,Brain,,CHEMBL631670,,Intermediate,A,,1,,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,,,50594,BAO_0000218
13641,,,2435.0,1,Striatum,,CHEMBL631671,,Intermediate,A,,1,,N,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,,,50594,BAO_0000218
13642,,,178.0,1,Blood,,CHEMBL631672,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,,,50597,BAO_0000218
13643,,,178.0,1,Blood,,CHEMBL631673,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,,,50597,BAO_0000218
13644,,,178.0,1,Blood,,CHEMBL631856,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,,,50597,BAO_0000218
13645,,,178.0,1,Blood,,CHEMBL631857,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,,,50597,BAO_0000218
13646,,,178.0,1,Blood,,CHEMBL631858,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,,,50597,BAO_0000218
13647,,,178.0,1,Blood,,CHEMBL631859,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,,,50597,BAO_0000218
13648,,,178.0,1,Blood,,CHEMBL631860,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,,,50597,BAO_0000218
13649,,,178.0,1,Blood,,CHEMBL631861,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,,,50597,BAO_0000218
13650,,,178.0,1,Blood,,CHEMBL631862,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,,,50597,BAO_0000218
13651,,,178.0,1,Blood,,CHEMBL631863,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,,,50597,BAO_0000218
13652,,,178.0,1,Blood,,CHEMBL631864,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,,,50597,BAO_0000218
13653,,,178.0,1,Blood,,CHEMBL631865,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,,,50597,BAO_0000218
13654,,,178.0,1,Blood,,CHEMBL631866,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,,,50597,BAO_0000218
13655,,,178.0,1,Blood,,CHEMBL629360,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,,,50597,BAO_0000218
13656,,,178.0,1,Blood,,CHEMBL629361,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,,,50597,BAO_0000218
13657,,,178.0,1,Blood,,CHEMBL629362,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,,,50597,BAO_0000218
13658,,,178.0,1,Blood,,CHEMBL630740,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,,,50597,BAO_0000218
13659,,,178.0,1,Blood,,CHEMBL630741,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,,,50597,BAO_0000218
13660,,,178.0,1,Blood,,CHEMBL630742,,Intermediate,A,,1,,N,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,,,50597,BAO_0000218
13661,,,,1,,,CHEMBL630743,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,,50597,BAO_0000218
13662,,,,1,,,CHEMBL630744,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,,50597,BAO_0000218
13663,,,,1,,,CHEMBL630745,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,,50597,BAO_0000218
13664,,,,1,,,CHEMBL630746,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,,50597,BAO_0000218
13665,,,,1,,,CHEMBL630747,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,,50597,BAO_0000218
13666,,,,1,,,CHEMBL630748,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,,50597,BAO_0000218
13667,,,,1,,,CHEMBL632056,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,,50597,BAO_0000218
13668,,,,1,,,CHEMBL632057,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,,50597,BAO_0000218
13669,,,,1,,,CHEMBL632058,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,,50597,BAO_0000218
13670,,,,1,,,CHEMBL632059,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,,50597,BAO_0000218
13671,,,,1,,,CHEMBL632060,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,,50597,BAO_0000218
13672,,,,1,,,CHEMBL632061,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,,50597,BAO_0000218
13673,,,,1,,,CHEMBL629207,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,,50597,BAO_0000218
13674,,,,1,,,CHEMBL629208,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,,50597,BAO_0000218
13675,,,,1,,,CHEMBL629209,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,,50597,BAO_0000218
13676,,,,1,,,CHEMBL629210,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,,50597,BAO_0000218
13677,,,,1,,,CHEMBL629211,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,,50597,BAO_0000218
13678,,,,1,,,CHEMBL629212,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,,50597,BAO_0000218
13679,,,,1,,,CHEMBL629213,,Intermediate,A,,1,,N,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,,50597,BAO_0000218
13680,,,1088.0,1,Urine,,CHEMBL629214,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,,50597,BAO_0000218
13681,,,1088.0,1,Urine,,CHEMBL629215,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",,,50597,BAO_0000218
13682,,,1088.0,1,Urine,,CHEMBL635154,,Intermediate,A,,1,,N,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",,,50597,BAO_0000218
13683,,,,1,,,CHEMBL629216,,Intermediate,A,,1,,N,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
13684,,,,1,,,CHEMBL629217,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,,50597,BAO_0000218
13685,,,,1,,,CHEMBL629218,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
13686,,,,1,,,CHEMBL629219,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
13687,,,,1,,,CHEMBL629220,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,50597,BAO_0000218
13688,,,,1,,,CHEMBL629221,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
13689,,,,1,,,CHEMBL631127,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
13690,,,,1,,,CHEMBL631128,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,,50597,BAO_0000218
13691,,,,1,,,CHEMBL631129,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
13692,,,,1,,,CHEMBL631130,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
13693,,,,1,,,CHEMBL631131,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,50597,BAO_0000218
13694,,,,1,,,CHEMBL631132,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
13695,,,,1,,,CHEMBL631133,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
13696,,,,1,,,CHEMBL631134,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,,50597,BAO_0000218
13697,,,,1,,,CHEMBL875120,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
13698,,,,1,,,CHEMBL631135,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
13699,,,,1,,,CHEMBL631136,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,,50597,BAO_0000218
13700,,,,1,,,CHEMBL631137,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
13701,,,,1,,,CHEMBL631138,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
13702,,,,1,,,CHEMBL631139,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,,50597,BAO_0000218
13703,,,,1,,,CHEMBL631140,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
13704,,,,1,,,CHEMBL631141,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,50597,BAO_0000218
13705,,,,1,,,CHEMBL631142,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,50597,BAO_0000218
13706,,,,1,,,CHEMBL631143,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,50597,BAO_0000218
13707,,,,1,,,CHEMBL631144,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,50597,BAO_0000218
13708,,,,1,,,CHEMBL631145,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,,50588,BAO_0000218
13709,,,,1,,,CHEMBL631146,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
13710,,,,1,,,CHEMBL631147,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,,50588,BAO_0000218
13711,,,,1,,,CHEMBL631148,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
13712,,,,1,,,CHEMBL631149,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
13713,,,,1,,,CHEMBL631150,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
13714,,,,1,,,CHEMBL631151,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
13715,,,,1,,,CHEMBL631152,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
13716,,,,1,,,CHEMBL631443,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
13717,,,,1,,,CHEMBL631444,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
13718,,,,1,,,CHEMBL631445,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,50588,BAO_0000218
13719,,,,1,,,CHEMBL631446,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,50588,BAO_0000218
13720,,,,1,,,CHEMBL631447,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,,50588,BAO_0000218
13721,,,,1,,,CHEMBL631448,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,50588,BAO_0000218
13722,,,,1,,,CHEMBL631449,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,,50588,BAO_0000218
13723,,,,1,,,CHEMBL631450,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,50588,BAO_0000218
13724,,,,1,,,CHEMBL629724,,Intermediate,A,,1,,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,50588,BAO_0000218
13725,,,14.0,1,Zone of skin,In vivo,CHEMBL629725,,Intermediate,A,,1,,N,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13726,,,14.0,1,Zone of skin,In vivo,CHEMBL629726,,Intermediate,A,,1,,N,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13727,,,2106.0,1,Spleen,In vivo,CHEMBL629727,,Intermediate,A,,1,,N,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13728,,,2106.0,1,Spleen,In vivo,CHEMBL630404,,Intermediate,A,,1,,N,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13729,,,2106.0,1,Spleen,In vivo,CHEMBL630405,,Intermediate,A,,1,,N,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13730,,,2106.0,1,Spleen,In vivo,CHEMBL630406,,Intermediate,A,,1,,N,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13731,,,945.0,1,Stomach,In vivo,CHEMBL630407,,Intermediate,A,,1,,N,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13732,,,945.0,1,Stomach,In vivo,CHEMBL630573,,Intermediate,A,,1,,N,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13733,,,945.0,1,Stomach,In vivo,CHEMBL630574,,Intermediate,A,,1,,N,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13734,,,945.0,1,Stomach,In vivo,CHEMBL630575,,Intermediate,A,,1,,N,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13735,,,,1,,In vivo,CHEMBL630576,,Intermediate,A,,1,,N,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13736,,,,1,,In vivo,CHEMBL630577,,Intermediate,A,,1,,N,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13737,,,,1,,In vivo,CHEMBL630578,,Intermediate,A,,1,,N,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13738,,,,1,,In vivo,CHEMBL630579,,Intermediate,A,,1,,N,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,50594,BAO_0000218
13739,,,2113.0,1,Kidney,,CHEMBL630580,,Intermediate,A,,1,,N,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),,,50594,BAO_0000218
13740,,,2113.0,1,Kidney,,CHEMBL630581,,Intermediate,A,,1,,N,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,,,50594,BAO_0000218
13741,,,2113.0,1,Kidney,,CHEMBL630582,,Intermediate,A,,1,,N,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),,,50594,BAO_0000218
13742,,,,1,,,CHEMBL630583,,Intermediate,A,,1,,N,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,,50594,BAO_0000218
13743,,,,1,,,CHEMBL630584,,Intermediate,A,,1,,N,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,,50594,BAO_0000218
13744,,,,1,,,CHEMBL630585,,Intermediate,A,,1,,N,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,,50594,BAO_0000218
13745,,,,1,,,CHEMBL630586,,Intermediate,A,,1,,N,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,,50594,BAO_0000218
13746,,,,1,,,CHEMBL630587,,Intermediate,A,,1,,N,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,,50594,BAO_0000218
13747,,,,1,,,CHEMBL630588,,Intermediate,A,,1,,N,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,,50594,BAO_0000218
13748,,,,1,,,CHEMBL630589,,Intermediate,A,,1,,N,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,,50594,BAO_0000218
13749,,,,1,,,CHEMBL630590,,Intermediate,A,,1,,N,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,,50594,BAO_0000218
13750,,,1988.0,0,Feces,,CHEMBL630591,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in feces at 24 h,,,22224,BAO_0000019
13751,,,1988.0,0,Feces,,CHEMBL630592,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),,,22224,BAO_0000019
13752,,,,0,,,CHEMBL630593,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,,22224,BAO_0000019
13753,,,,0,,,CHEMBL630594,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,,22224,BAO_0000019
13754,,,1088.0,0,Urine,,CHEMBL630595,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),,,22224,BAO_0000019
13755,,,1088.0,0,Urine,,CHEMBL630596,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),,,22224,BAO_0000019
13756,,,1088.0,0,Urine,,CHEMBL630597,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in urine after 0-24 h,,,22224,BAO_0000019
13757,,,1088.0,0,Urine,,CHEMBL630598,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),,,22224,BAO_0000019
13758,,,1088.0,0,Urine,,CHEMBL630599,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in urine after 0-4 h,,,22224,BAO_0000019
13759,,,1088.0,0,Urine,,CHEMBL630600,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),,,22224,BAO_0000019
13760,,,1088.0,0,Urine,,CHEMBL630601,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in urine after 4-24 h,,,22224,BAO_0000019
13761,,,1088.0,0,Urine,,CHEMBL630602,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),,,22224,BAO_0000019
13762,,,1088.0,0,Urine,,CHEMBL630603,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),,,22224,BAO_0000019
13763,,,1088.0,0,Urine,,CHEMBL630604,,Autocuration,A,,1,,U,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),,,22224,BAO_0000019
13764,,,178.0,1,Blood,In vivo,CHEMBL624869,,Intermediate,A,,1,,N,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13765,,,178.0,1,Blood,In vivo,CHEMBL624870,,Intermediate,A,,1,,N,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13766,,,178.0,1,Blood,In vivo,CHEMBL623189,,Intermediate,A,,1,,N,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
13767,,,178.0,1,Blood,In vivo,CHEMBL623190,,Intermediate,A,,1,,N,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13768,,,178.0,1,Blood,In vivo,CHEMBL623191,,Intermediate,A,,1,,N,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13769,,,,1,,In vivo,CHEMBL623192,,Intermediate,A,,1,,N,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13770,,,,1,,In vivo,CHEMBL623193,,Intermediate,A,,1,,N,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13771,,,,1,,In vivo,CHEMBL623194,,Intermediate,A,,1,,N,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
13772,,,,1,,In vivo,CHEMBL623195,,Intermediate,A,,1,,N,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13773,,,,1,,In vivo,CHEMBL623196,,Intermediate,A,,1,,N,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13774,,,,1,,,CHEMBL623197,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,,50597,BAO_0000218
13775,,,,1,,,CHEMBL623198,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,,50597,BAO_0000218
13776,,,,1,,,CHEMBL623199,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,,50597,BAO_0000218
13777,,,2385.0,1,Muscle tissue,,CHEMBL623200,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,,,50597,BAO_0000218
13778,,,2385.0,1,Muscle tissue,,CHEMBL623201,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,,,50597,BAO_0000218
13779,,,2385.0,1,Muscle tissue,,CHEMBL623202,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,,,50597,BAO_0000218
13780,,,2385.0,1,Muscle tissue,,CHEMBL623203,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,,,50597,BAO_0000218
13781,,,2385.0,1,Muscle tissue,,CHEMBL623204,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,,,50597,BAO_0000218
13782,,,2385.0,1,Muscle tissue,,CHEMBL623205,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,,,50597,BAO_0000218
13783,,,2385.0,1,Muscle tissue,,CHEMBL623206,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,,50597,BAO_0000218
13784,,,2385.0,1,Muscle tissue,,CHEMBL623207,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,,,50597,BAO_0000218
13785,,,2385.0,1,Muscle tissue,,CHEMBL623208,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,,,50597,BAO_0000218
13786,,,2385.0,1,Muscle tissue,,CHEMBL623209,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,,50597,BAO_0000218
13787,,,2385.0,1,Muscle tissue,,CHEMBL623210,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,,50597,BAO_0000218
13788,,,,1,,,CHEMBL623211,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,,50597,BAO_0000218
13789,,,995.0,1,Uterus,,CHEMBL623212,,Intermediate,A,,1,,N,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,,50597,BAO_0000218
13790,,,,0,,,CHEMBL623213,,Autocuration,A,,1,,U,Tested in vitro for intrinsic activity relative to quinpirole,,,22224,BAO_0000019
13791,,,,0,,,CHEMBL623214,,Autocuration,A,,1,,U,"Relative ion enhancement, determined in pulsed ultrafiltration",,,22224,BAO_0000019
13792,,,,0,,,CHEMBL623215,,Autocuration,A,,1,,U,% ionization at the pH 7.4 at 37 degree Centigrade,,,22224,BAO_0000019
13793,,,,0,,,CHEMBL623216,,Autocuration,A,,1,,U,Percentage ionization was measured,,,22224,BAO_0000019
13794,,,,1,,,CHEMBL623217,,Intermediate,A,,1,,N,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,,50591,BAO_0000218
13795,,,,0,,,CHEMBL623218,,Autocuration,A,,1,,U,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,,22224,BAO_0000019
13796,,,,0,,,CHEMBL623913,,Autocuration,A,,1,,U,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,,22224,BAO_0000019
13797,,,,0,,,CHEMBL623914,,Autocuration,A,,1,,U,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,,22224,BAO_0000019
13798,,,,0,,,CHEMBL623915,,Autocuration,P,,1,,U,Compound was evaluated for the partition coefficient in octanol/water,,,22229,BAO_0000100
13799,,,,0,,,CHEMBL624080,,Autocuration,P,,1,,U,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,,22229,BAO_0000100
13800,,,,0,,,CHEMBL624081,,Autocuration,A,,1,,U,Equilibrium constant measured by the pulse radiolysis at pH 7,,,22224,BAO_0000019
13801,,,,1,,,CHEMBL624082,,Intermediate,A,,1,,N,In vitro hydrolytic rate constant determined in human blood,,,50587,BAO_0000218
13802,,,,1,,,CHEMBL625054,,Intermediate,A,,1,,N,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,,50587,BAO_0000218
13803,,,,0,,,CHEMBL877485,,Autocuration,A,,1,,U,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,,22224,BAO_0000019
13804,,,,1,,,CHEMBL625055,,Intermediate,A,,1,,N,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,,50594,BAO_0000218
13805,,,,1,,,CHEMBL625056,,Intermediate,A,,1,,N,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,,50594,BAO_0000218
13806,,,,1,,,CHEMBL625057,,Intermediate,A,,1,,N,In vitro oxidation of compound in presence of human plasma,,,50587,BAO_0000218
13807,,,,0,,,CHEMBL625058,,Autocuration,A,,1,,U,In vitro oxidation of compound in presence of hydrogen peroxide,,,22224,BAO_0000019
13808,,,,1,,,CHEMBL625059,,Intermediate,A,,1,,N,In vitro oxidation of compound in presence of mouse brain homogenate,,,50594,BAO_0000218
13809,,,,1,,,CHEMBL629536,,Intermediate,A,,1,,N,In vitro oxidation of compound in presence of mouse liver homogenate,,,50594,BAO_0000218
13810,,,,1,,,CHEMBL629537,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,50597,BAO_0000218
13811,,,,1,,,CHEMBL629538,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,50597,BAO_0000218
13812,,,,1,,,CHEMBL629539,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,50597,BAO_0000218
13813,,,,1,,,CHEMBL874445,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,50597,BAO_0000218
13814,,,,1,,,CHEMBL629540,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,50597,BAO_0000218
13815,,,,1,,,CHEMBL629541,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,50597,BAO_0000218
13816,,,,1,,,CHEMBL629542,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,50597,BAO_0000218
13817,,,,1,,,CHEMBL630243,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,50597,BAO_0000218
13818,,,,1,,,CHEMBL630244,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,50597,BAO_0000218
13819,,,,1,,,CHEMBL630245,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,50597,BAO_0000218
13820,,,,1,,,CHEMBL630246,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,50597,BAO_0000218
13821,,,,1,,,CHEMBL630247,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,50597,BAO_0000218
13822,,,,1,,,CHEMBL630248,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,50597,BAO_0000218
13823,,,178.0,1,Blood,In vivo,CHEMBL630249,,Intermediate,A,,1,,N,Biodistribution in rat blood at 240 minutes after dose administration.,,,50597,BAO_0000218
13824,,,178.0,1,Blood,In vivo,CHEMBL630250,,Intermediate,A,,1,,N,Biodistribution in rat blood at 30 minutes after dose administration.,,,50597,BAO_0000218
13825,,,178.0,1,Blood,In vivo,CHEMBL630251,,Intermediate,A,,1,,N,Biodistribution in rat blood at 360 minutes after dose administration.,,,50597,BAO_0000218
13826,,,178.0,1,Blood,In vivo,CHEMBL630252,,Intermediate,A,,1,,N,Biodistribution in rat blood at 3 hr after dose administration.,,,50597,BAO_0000218
13827,,,178.0,1,Blood,In vivo,CHEMBL630408,,Intermediate,A,,1,,N,Biodistribution in rat blood at 60 minutes after dose administration.,,,50597,BAO_0000218
13828,,,2037.0,1,Cerebellum,In vivo,CHEMBL630409,,Intermediate,A,,1,,N,Biodistribution in rat cerebellum at 120 minutes after dose administration.,,,50597,BAO_0000218
13829,,,2037.0,1,Cerebellum,In vivo,CHEMBL874446,,Intermediate,A,,1,,N,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,,,50597,BAO_0000218
13830,,,2037.0,1,Cerebellum,In vivo,CHEMBL630410,,Intermediate,A,,1,,N,Biodistribution in rat cerebellum at 15 minutes after dose administration.,,,50597,BAO_0000218
13831,,,2037.0,1,Cerebellum,In vivo,CHEMBL630411,,Intermediate,A,,1,,N,Biodistribution in rat cerebellum at 240 minutes after dose administration.,,,50597,BAO_0000218
13832,,,2037.0,1,Cerebellum,In vivo,CHEMBL630412,,Intermediate,A,,1,,N,Biodistribution in rat cerebellum at 30 minutes after dose administration.,,,50597,BAO_0000218
13833,,,2037.0,1,Cerebellum,In vivo,CHEMBL630413,,Intermediate,A,,1,,N,Biodistribution in rat cerebellum at 360 minutes after dose administration.,,,50597,BAO_0000218
13834,,,2037.0,1,Cerebellum,In vivo,CHEMBL630414,,Intermediate,A,,1,,N,Biodistribution in rat cerebellum at 3 hr after dose administration.,,,50597,BAO_0000218
13835,,,2037.0,1,Cerebellum,In vivo,CHEMBL630415,,Intermediate,A,,1,,N,Biodistribution in rat cerebellum at 60 minutes after dose administration.,,,50597,BAO_0000218
13836,,,,1,,In vivo,CHEMBL630416,,Intermediate,A,,1,,N,Biodistribution in rat cortex at 120 minutes after dose administration.,,,50597,BAO_0000218
13837,,,,1,,In vivo,CHEMBL630417,,Intermediate,A,,1,,N,Biodistribution in rat cortex at 1440 minutes after dose administration.,,,50597,BAO_0000218
13838,,,,1,,In vivo,CHEMBL630418,,Intermediate,A,,1,,N,Biodistribution in rat cortex at 15 minutes after dose administration.,,,50597,BAO_0000218
13839,,,,1,,In vivo,CHEMBL630419,,Intermediate,A,,1,,N,Biodistribution in rat cortex at 240 minutes after dose administration.,,,50597,BAO_0000218
13840,,,,1,,In vivo,CHEMBL630420,,Intermediate,A,,1,,N,Biodistribution in rat cortex at 30 minutes after dose administration.,,,50597,BAO_0000218
13841,,,,1,,In vivo,CHEMBL630421,,Intermediate,A,,1,,N,Biodistribution in rat cortex at 360 minutes after dose administration.,,,50597,BAO_0000218
13842,,,,1,,In vivo,CHEMBL630422,,Intermediate,A,,1,,N,Biodistribution in rat cortex at 3 hr after dose administration.,,,50597,BAO_0000218
13843,,,,1,,In vivo,CHEMBL630423,,Intermediate,A,,1,,N,Biodistribution in rat cortex at 60 minutes after dose administration.,,,50597,BAO_0000218
13844,,,948.0,1,Heart,In vivo,CHEMBL630424,,Intermediate,A,,1,,N,Biodistribution in rat heart at 120 minutes after dose administration.,,,50597,BAO_0000218
13845,,,948.0,1,Heart,In vivo,CHEMBL630425,,Intermediate,A,,1,,N,Biodistribution in rat heart at 15 minutes after dose administration.,,,50597,BAO_0000218
13846,,,948.0,1,Heart,In vivo,CHEMBL629462,,Intermediate,A,,1,,N,Biodistribution in rat heart at 240 minutes after dose administration.,,,50597,BAO_0000218
13847,,,948.0,1,Heart,In vivo,CHEMBL630426,,Intermediate,A,,1,,N,Biodistribution in rat heart at 30 minutes after dose administration.,,,50597,BAO_0000218
13848,,,948.0,1,Heart,In vivo,CHEMBL630427,,Intermediate,A,,1,,N,Biodistribution in rat heart at 360 minutes after dose administration.,,,50597,BAO_0000218
13849,,,948.0,1,Heart,In vivo,CHEMBL625877,,Intermediate,A,,1,,N,Biodistribution in rat heart at 3 hr after dose administration.,,,50597,BAO_0000218
13850,,,948.0,1,Heart,In vivo,CHEMBL625878,,Intermediate,A,,1,,N,Biodistribution in rat heart at 60 minutes after dose administration.,,,50597,BAO_0000218
13851,,,10000000.0,1,Hippocampus,In vivo,CHEMBL625879,,Intermediate,A,,1,,N,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,,,50597,BAO_0000218
13852,,,10000000.0,1,Hippocampus,In vivo,CHEMBL625880,,Intermediate,A,,1,,N,Biodistribution in rat hippocampus at 240 minutes after dose administration.,,,50597,BAO_0000218
13853,,,10000000.0,1,Hippocampus,In vivo,CHEMBL625881,,Intermediate,A,,1,,N,Biodistribution in rat hippocampus at 30 minutes after dose administration.,,,50597,BAO_0000218
13854,,,10000000.0,1,Hippocampus,In vivo,CHEMBL625882,,Intermediate,A,,1,,N,Biodistribution in rat hippocampus at 360 minutes after dose administration.,,,50597,BAO_0000218
13855,,,10000000.0,1,Hippocampus,In vivo,CHEMBL625883,,Intermediate,A,,1,,N,Biodistribution in rat hippocampus at 15 minutes after dose administration.,,,50597,BAO_0000218
13856,,,2113.0,1,Kidney,In vivo,CHEMBL625884,,Intermediate,A,,1,,N,Biodistribution in rat kidney at 120 minutes after dose administration.,,,50597,BAO_0000218
13857,,,2113.0,1,Kidney,In vivo,CHEMBL625885,,Intermediate,A,,1,,N,Biodistribution in rat kidney at 1440 minutes after dose administration.,,,50597,BAO_0000218
13858,,,2113.0,1,Kidney,In vivo,CHEMBL628649,,Intermediate,A,,1,,N,Biodistribution in rat kidney at 15 minutes after dose administration.,,,50597,BAO_0000218
13859,,,2113.0,1,Kidney,In vivo,CHEMBL628650,,Intermediate,A,,1,,N,Biodistribution in rat kidney at 240 minutes after dose administration.,,,50597,BAO_0000218
13860,,,2113.0,1,Kidney,In vivo,CHEMBL628651,,Intermediate,A,,1,,N,Biodistribution in rat kidney at 30 minutes after dose administration.,,,50597,BAO_0000218
13861,,,2113.0,1,Kidney,In vivo,CHEMBL628652,,Intermediate,A,,1,,N,Biodistribution in rat kidney at 360 minutes after dose administration.,,,50597,BAO_0000218
13862,,,2113.0,1,Kidney,In vivo,CHEMBL628653,,Intermediate,A,,1,,N,Biodistribution in rat kidney at 60 minutes after dose administration.,,,50597,BAO_0000218
13863,,,2107.0,1,Liver,In vivo,CHEMBL628654,,Intermediate,A,,1,,N,Biodistribution in rat liver at 120 minutes after dose administration.,,,50597,BAO_0000218
13864,,,2107.0,1,Liver,In vivo,CHEMBL628655,,Intermediate,A,,1,,N,Biodistribution in rat liver at 1440 minutes after dose administration.,,,50597,BAO_0000218
13865,,,2107.0,1,Liver,In vivo,CHEMBL625238,,Intermediate,A,,1,,N,Biodistribution in rat liver at 15 minutes after dose administration.,,,50597,BAO_0000218
13866,,,2107.0,1,Liver,In vivo,CHEMBL625239,,Intermediate,A,,1,,N,Biodistribution in rat liver at 240 minutes after dose administration.,,,50597,BAO_0000218
13867,,,2107.0,1,Liver,In vivo,CHEMBL625240,,Intermediate,A,,1,,N,Biodistribution in rat liver at 30 minutes after dose administration.,,,50597,BAO_0000218
13868,,,2107.0,1,Liver,In vivo,CHEMBL625241,,Intermediate,A,,1,,N,Biodistribution in rat liver at 360 minutes after dose administration.,,,50597,BAO_0000218
13869,,,2107.0,1,Liver,In vivo,CHEMBL625242,,Intermediate,A,,1,,N,Biodistribution in rat liver at 60 minutes after dose administration.,,,50597,BAO_0000218
13870,,,2048.0,1,Lung,In vivo,CHEMBL874587,,Intermediate,A,,1,,N,Biodistribution in rat lung at 120 minutes after dose administration.,,,50597,BAO_0000218
13871,,,2048.0,1,Lung,In vivo,CHEMBL625405,,Intermediate,A,,1,,N,Biodistribution in rat lung at 1440 minutes after dose administration.,,,50597,BAO_0000218
13872,,,2048.0,1,Lung,In vivo,CHEMBL625406,,Intermediate,A,,1,,N,Biodistribution in rat lung at 15 minutes after dose administration.,,,50597,BAO_0000218
13873,,,2048.0,1,Lung,In vivo,CHEMBL625407,,Intermediate,A,,1,,N,Biodistribution in rat lung at 240 minutes after dose administration.,,,50597,BAO_0000218
13874,,,2048.0,1,Lung,In vivo,CHEMBL625408,,Intermediate,A,,1,,N,Biodistribution in rat lung at 30 minutes after dose administration.,,,50597,BAO_0000218
13875,,,2048.0,1,Lung,In vivo,CHEMBL625409,,Intermediate,A,,1,,N,Biodistribution in rat lung at 360 minutes after dose administration.,,,50597,BAO_0000218
13876,,,1515.0,1,Thoracic aorta,,CHEMBL625410,,Intermediate,A,,1,,N,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,,,50597,BAO_0000218
13877,,,1515.0,1,Thoracic aorta,,CHEMBL625411,,Intermediate,A,,1,,N,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,,,50597,BAO_0000218
13878,,,1515.0,1,Thoracic aorta,,CHEMBL625412,,Intermediate,A,,1,,N,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,,,50597,BAO_0000218
13879,,,1515.0,1,Thoracic aorta,,CHEMBL625413,,Intermediate,A,,1,,N,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,,,50597,BAO_0000218
13880,,,1515.0,1,Thoracic aorta,,CHEMBL625414,,Intermediate,A,,1,,N,Percent of maximal contractile response to compound in rat thoracic aorta strips v,,,50597,BAO_0000218
13881,,,1515.0,1,Thoracic aorta,,CHEMBL625415,,Intermediate,A,,1,,N,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,,,50597,BAO_0000218
13882,,,1515.0,1,Thoracic aorta,,CHEMBL625416,,Intermediate,A,,1,,N,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,,,50597,BAO_0000218
13883,,,1088.0,1,Urine,,CHEMBL625417,,Intermediate,A,,1,,N,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,,,50597,BAO_0000218
13884,,,1988.0,1,Feces,,CHEMBL625418,,Intermediate,A,,1,,N,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,,,50597,BAO_0000218
13885,,,1088.0,1,Urine,,CHEMBL625419,,Intermediate,A,,1,,N,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,,,50597,BAO_0000218
13886,,,,1,,,CHEMBL625420,,Intermediate,A,,1,,N,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,,50597,BAO_0000218
13887,,,,1,,,CHEMBL626996,,Intermediate,A,,1,,N,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,,50597,BAO_0000218
13888,,,1988.0,1,Feces,,CHEMBL626997,,Intermediate,A,,1,,N,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",,,50597,BAO_0000218
13889,,,1088.0,1,Urine,,CHEMBL626998,,Intermediate,A,,1,,N,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",,,50597,BAO_0000218
13890,,,,1,,,CHEMBL626999,,Intermediate,A,,1,,N,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,,50597,BAO_0000218
13891,,,,1,,,CHEMBL627000,,Intermediate,A,,1,,N,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,,50594,BAO_0000218
13892,,,,1,,,CHEMBL627001,,Intermediate,A,,1,,N,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,,50594,BAO_0000218
13893,,,,1,,,CHEMBL627002,,Intermediate,A,,1,,N,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,,50594,BAO_0000218
13894,,,,1,,,CHEMBL627003,,Intermediate,A,,1,,N,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,,50594,BAO_0000218
13895,,,1088.0,1,Urine,,CHEMBL627004,,Intermediate,A,,1,,N,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,,,50594,BAO_0000218
13896,,,1088.0,1,Urine,,CHEMBL627005,,Intermediate,A,,1,,N,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,,,50594,BAO_0000218
13897,,,1088.0,1,Urine,,CHEMBL874594,,Intermediate,A,,1,,N,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,,,50594,BAO_0000218
13898,,,1088.0,1,Urine,,CHEMBL627006,,Intermediate,A,,1,,N,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,,,50594,BAO_0000218
13899,,,1088.0,1,Urine,,CHEMBL627007,,Intermediate,A,,1,,N,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,,,50594,BAO_0000218
13900,,,1088.0,1,Urine,,CHEMBL627884,,Intermediate,A,,1,,N,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,,,50594,BAO_0000218
13901,,,1088.0,1,Urine,,CHEMBL627885,,Intermediate,A,,1,,N,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,,,50594,BAO_0000218
13902,,,1088.0,1,Urine,,CHEMBL627886,,Intermediate,A,,1,,N,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,,,50594,BAO_0000218
13903,,,1088.0,1,Urine,,CHEMBL627887,,Intermediate,A,,1,,N,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,,,50594,BAO_0000218
13904,,,1088.0,1,Urine,,CHEMBL627888,,Intermediate,A,,1,,N,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,,,50594,BAO_0000218
13905,,,1088.0,1,Urine,,CHEMBL628057,,Intermediate,A,,1,,N,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,,,50594,BAO_0000218
13906,,,1088.0,1,Urine,,CHEMBL627405,,Intermediate,A,,1,,N,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,,,50594,BAO_0000218
13907,,,1088.0,1,Urine,,CHEMBL627406,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,,50588,BAO_0000218
13908,,,1088.0,1,Urine,,CHEMBL627407,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,,50588,BAO_0000218
13909,,,1088.0,1,Urine,,CHEMBL627408,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,,50588,BAO_0000218
13910,,,1088.0,1,Urine,,CHEMBL627409,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,,50588,BAO_0000218
13911,,,1088.0,1,Urine,,CHEMBL875486,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,,50588,BAO_0000218
13912,,,1088.0,1,Urine,,CHEMBL627410,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,,50588,BAO_0000218
13913,,,1088.0,1,Urine,,CHEMBL627411,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,,50588,BAO_0000218
13914,,,1088.0,1,Urine,,CHEMBL627412,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,,50588,BAO_0000218
13915,,,1088.0,1,Urine,,CHEMBL627413,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,,50588,BAO_0000218
13916,,,1088.0,1,Urine,,CHEMBL627414,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,,50588,BAO_0000218
13917,,,1088.0,1,Urine,,CHEMBL627415,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,,50588,BAO_0000218
13918,,,1088.0,1,Urine,,CHEMBL627416,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,,,50588,BAO_0000218
13919,,,1088.0,1,Urine,,CHEMBL627417,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,,50588,BAO_0000218
13920,,,1088.0,1,Urine,,CHEMBL627418,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,,50588,BAO_0000218
13921,,,1088.0,1,Urine,,CHEMBL627419,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,,50588,BAO_0000218
13922,,,1088.0,1,Urine,,CHEMBL627320,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,,50588,BAO_0000218
13923,,,1088.0,1,Urine,,CHEMBL627321,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,,50588,BAO_0000218
13924,,,2113.0,1,Kidney,In vivo,CHEMBL627322,,Intermediate,A,,1,,N,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13925,,,2113.0,1,Kidney,In vivo,CHEMBL627323,,Intermediate,A,,1,,N,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13926,,,2113.0,1,Kidney,In vivo,CHEMBL627491,,Intermediate,A,,1,,N,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
13927,,,2113.0,1,Kidney,In vivo,CHEMBL627492,,Intermediate,A,,1,,N,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13928,,,2113.0,1,Kidney,In vivo,CHEMBL627493,,Intermediate,A,,1,,N,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13929,,,2107.0,1,Liver,In vivo,CHEMBL627494,,Intermediate,A,,1,,N,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13930,,,2107.0,1,Liver,In vivo,CHEMBL627495,,Intermediate,A,,1,,N,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13931,,,2107.0,1,Liver,In vivo,CHEMBL627496,,Intermediate,A,,1,,N,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
13932,,,2107.0,1,Liver,In vivo,CHEMBL627497,,Intermediate,A,,1,,N,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13933,,,2107.0,1,Liver,In vivo,CHEMBL627498,,Intermediate,A,,1,,N,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13934,,,2048.0,1,Lung,In vivo,CHEMBL627499,,Intermediate,A,,1,,N,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13935,,,2048.0,1,Lung,In vivo,CHEMBL627500,,Intermediate,A,,1,,N,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13936,,,2048.0,1,Lung,In vivo,CHEMBL627501,,Intermediate,A,,1,,N,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
13937,,,2048.0,1,Lung,In vivo,CHEMBL625616,,Intermediate,A,,1,,N,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13938,,,2048.0,1,Lung,In vivo,CHEMBL625617,,Intermediate,A,,1,,N,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13939,,,2385.0,1,Muscle tissue,In vivo,CHEMBL625618,,Intermediate,A,,1,,N,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13940,,,2385.0,1,Muscle tissue,In vivo,CHEMBL625619,,Intermediate,A,,1,,N,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13941,,,2385.0,1,Muscle tissue,In vivo,CHEMBL625620,,Intermediate,A,,1,,N,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
13942,,,2385.0,1,Muscle tissue,In vivo,CHEMBL625621,,Intermediate,A,,1,,N,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13943,,,2385.0,1,Muscle tissue,In vivo,CHEMBL625622,,Intermediate,A,,1,,N,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13944,,,2106.0,1,Spleen,In vivo,CHEMBL625788,,Intermediate,A,,1,,N,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13945,,,2106.0,1,Spleen,In vivo,CHEMBL625789,,Intermediate,A,,1,,N,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13946,,,2106.0,1,Spleen,In vivo,CHEMBL625790,,Intermediate,A,,1,,N,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
13947,,,2106.0,1,Spleen,In vivo,CHEMBL625791,,Intermediate,A,,1,,N,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13948,,,2106.0,1,Spleen,In vivo,CHEMBL622334,,Intermediate,A,,1,,N,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13949,,,2046.0,1,Thyroid gland,In vivo,CHEMBL622335,,Intermediate,A,,1,,N,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13950,,,2046.0,1,Thyroid gland,In vivo,CHEMBL622336,,Intermediate,A,,1,,N,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13951,,,2046.0,1,Thyroid gland,In vivo,CHEMBL622337,,Intermediate,A,,1,,N,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
13952,,,2046.0,1,Thyroid gland,In vivo,CHEMBL622338,,Intermediate,A,,1,,N,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13953,,,2046.0,1,Thyroid gland,In vivo,CHEMBL622339,,Intermediate,A,,1,,N,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13954,,,,1,,In vivo,CHEMBL624153,,Intermediate,A,,1,,N,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13955,,,,1,,In vivo,CHEMBL628430,,Intermediate,A,,1,,N,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13956,,,,1,,In vivo,CHEMBL628431,,Intermediate,A,,1,,N,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
13957,,,,1,,In vivo,CHEMBL628432,,Intermediate,A,,1,,N,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13958,,,,1,,In vivo,CHEMBL628433,,Intermediate,A,,1,,N,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
13959,,,2106.0,1,Spleen,In vivo,CHEMBL628434,,Intermediate,A,,1,,N,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,50597,BAO_0000218
13960,,,2106.0,1,Spleen,In vivo,CHEMBL626789,,Intermediate,A,,1,,N,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,50597,BAO_0000218
13961,,,2106.0,1,Spleen,In vivo,CHEMBL626790,,Intermediate,A,,1,,N,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",,,50597,BAO_0000218
13962,,,2106.0,1,Spleen,In vivo,CHEMBL626791,,Intermediate,A,,1,,N,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,50597,BAO_0000218
13963,,,2106.0,1,Spleen,In vivo,CHEMBL626792,,Intermediate,A,,1,,N,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,50597,BAO_0000218
13964,,,2106.0,1,Spleen,In vivo,CHEMBL626793,,Intermediate,A,,1,,N,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,50597,BAO_0000218
13965,,,,1,,,CHEMBL627436,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,50597,BAO_0000218
13966,,,,1,,,CHEMBL627437,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,50597,BAO_0000218
13967,,,,1,,,CHEMBL627438,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,50597,BAO_0000218
13968,,,,1,,,CHEMBL627439,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,50597,BAO_0000218
13969,,,,1,,,CHEMBL627440,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,50597,BAO_0000218
13970,,,,1,,,CHEMBL627602,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,50597,BAO_0000218
13971,,,,1,,,CHEMBL627603,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,50597,BAO_0000218
13972,,,,1,,,CHEMBL627604,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,50597,BAO_0000218
13973,,,,1,,,CHEMBL627605,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,50597,BAO_0000218
13974,,,,1,,,CHEMBL627606,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,50597,BAO_0000218
13975,,,,1,,,CHEMBL627607,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,50597,BAO_0000218
13976,,,,1,,,CHEMBL627608,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,50597,BAO_0000218
13977,,,,1,,,CHEMBL627609,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,50597,BAO_0000218
13978,,,,1,,,CHEMBL627610,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,50597,BAO_0000218
13979,,,,1,,,CHEMBL627611,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,50597,BAO_0000218
13980,,,,1,,,CHEMBL627612,,Intermediate,A,,1,,N,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,50597,BAO_0000218
13981,,,,0,,,CHEMBL627613,,Autocuration,P,,1,,U,Octanol:water partition coefficient is evaluated,,,22229,BAO_0000100
13982,,,,0,,,CHEMBL627614,,Autocuration,P,,1,,U,Partition coefficient in 1-octanol/water system,,,22224,BAO_0000100
13983,,,,0,,,CHEMBL627615,,Autocuration,P,,1,,U,Partition coefficient in 1-octanol/water system measured using radio active compounds,,,22224,BAO_0000100
13984,,,,0,,,CHEMBL627616,,Autocuration,P,,1,,U,Partition coefficient in octanol/water system was determined,,,22224,BAO_0000100
13985,,,,0,,,CHEMBL627617,,Autocuration,P,,1,,U,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,,22224,BAO_0000100
13986,,,,0,,,CHEMBL627618,,Autocuration,A,,1,,U,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,,22224,BAO_0000019
13987,,,,0,,,CHEMBL627619,,Autocuration,A,,1,,U,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,,22224,BAO_0000019
13988,,,,0,,,CHEMBL627620,,Autocuration,A,,1,,U,Pseudo-first-order rate constant of the compound,,,22224,BAO_0000019
13989,,,,0,,,CHEMBL627621,,Autocuration,A,,1,,U,Pseudo-first-order rate constant with 1-min time point,,,22224,BAO_0000019
13990,,,,0,,,CHEMBL627622,,Autocuration,A,,1,,U,Pseudo-first-order rate constant without 1-min time point,,,22224,BAO_0000019
13991,,,,0,,,CHEMBL627623,,Autocuration,A,,1,,U,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,,22224,BAO_0000019
13992,,,,0,,,CHEMBL627624,,Autocuration,A,,1,,U,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,,22224,BAO_0000019
13993,,,,0,,,CHEMBL627625,,Autocuration,A,,1,,U,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,,22224,BAO_0000019
13994,,,,0,,,CHEMBL628523,,Autocuration,A,,1,,U,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,,22224,BAO_0000019
13995,,,,0,,,CHEMBL628524,,Autocuration,A,,1,,U,The alkaline hydrolysis second order rate constant(K OH) of the compound,,,22224,BAO_0000019
13996,,,,0,,,CHEMBL628525,,Autocuration,A,,1,,U,The efflux rate constant of the compound,,,22224,BAO_0000019
13997,,,,0,,,CHEMBL625732,,Autocuration,A,,1,,U,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,22224,BAO_0000019
13998,,,,0,,,CHEMBL625733,,Autocuration,A,,1,,U,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,22224,BAO_0000019
13999,,,,0,,,CHEMBL625734,,Autocuration,F,,1,,U,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,22224,BAO_0000019
14000,,,,0,,,CHEMBL625913,,Autocuration,A,,1,,U,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,,22224,BAO_0000019
14001,,,,0,,,CHEMBL625914,,Autocuration,A,,1,,U,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,,22224,BAO_0000019
14002,,,,0,,,CHEMBL625915,,Autocuration,A,,1,,U,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,,22224,BAO_0000019
14003,,,,0,,,CHEMBL625916,,Autocuration,A,,1,,U,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,,22224,BAO_0000019
14004,,,,0,,,CHEMBL625917,,Autocuration,A,,1,,U,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,,22224,BAO_0000019
14005,,,,0,,,CHEMBL625918,,Autocuration,A,,1,,U,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
14006,,,,0,,,CHEMBL625919,,Autocuration,A,,1,,U,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
14007,,,,0,,,CHEMBL625920,,Autocuration,A,,1,,U,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
14008,,,,0,,,CHEMBL874453,,Autocuration,A,,1,,U,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
14009,,,,0,,,CHEMBL625921,,Autocuration,A,,1,,U,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
14010,,,,0,,,CHEMBL625922,,Autocuration,A,,1,,U,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,,22224,BAO_0000019
14011,,,,0,,,CHEMBL625923,,Autocuration,A,,1,,U,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
14012,,,,0,,,CHEMBL625924,,Autocuration,A,,1,,U,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
14013,,,,0,,,CHEMBL625925,,Autocuration,A,,1,,U,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
14014,,,,0,,,CHEMBL625926,,Autocuration,A,,1,,U,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
14015,,,2048.0,1,Lung,In vivo,CHEMBL627704,,Intermediate,A,,1,,N,Biodistribution in rat lung at 60 minutes after dose administration.,,,50597,BAO_0000218
14016,,,,1,,In vivo,CHEMBL627705,,Intermediate,A,,1,,N,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,,50597,BAO_0000218
14017,,,,1,,In vivo,CHEMBL627706,,Intermediate,A,,1,,N,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,,50597,BAO_0000218
14018,,,,1,,In vivo,CHEMBL627707,,Intermediate,A,,1,,N,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,,50597,BAO_0000218
14019,,,,1,,In vivo,CHEMBL627708,,Intermediate,A,,1,,N,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,,50597,BAO_0000218
14020,,,,1,,In vivo,CHEMBL628361,,Intermediate,A,,1,,N,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,,50597,BAO_0000218
14021,,,,1,,In vivo,CHEMBL628362,,Intermediate,A,,1,,N,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,,50597,BAO_0000218
14022,,,2435.0,1,Striatum,In vivo,CHEMBL628363,,Intermediate,A,,1,,N,Biodistribution in rat striatum at 120 minutes after dose administration.,,,50597,BAO_0000218
14023,,,2435.0,1,Striatum,In vivo,CHEMBL628364,,Intermediate,A,,1,,N,Biodistribution in rat striatum at 1440 minutes after dose administration.,,,50597,BAO_0000218
14024,,,2435.0,1,Striatum,In vivo,CHEMBL628365,,Intermediate,A,,1,,N,Biodistribution in rat striatum at 15 minutes after dose administration.,,,50597,BAO_0000218
14025,,,2435.0,1,Striatum,In vivo,CHEMBL874454,,Intermediate,A,,1,,N,Biodistribution in rat striatum at 240 minutes after dose administration.,,,50597,BAO_0000218
14026,,,2435.0,1,Striatum,In vivo,CHEMBL628531,,Intermediate,A,,1,,N,Biodistribution in rat striatum at 30 minutes after dose administration.,,,50597,BAO_0000218
14027,,,2435.0,1,Striatum,In vivo,CHEMBL628532,,Intermediate,A,,1,,N,Biodistribution in rat striatum at 360 minutes after dose administration.,,,50597,BAO_0000218
14028,,,2435.0,1,Striatum,In vivo,CHEMBL628533,,Intermediate,A,,1,,N,Biodistribution in rat striatum at 3 hr after dose administration.,,,50597,BAO_0000218
14029,,,2435.0,1,Striatum,In vivo,CHEMBL628534,,Intermediate,A,,1,,N,Biodistribution in rat striatum at 60 minutes after dose administration.,,,50597,BAO_0000218
14030,,,2046.0,1,Thyroid gland,In vivo,CHEMBL628535,,Intermediate,A,,1,,N,Biodistribution in rat thyroid at 120 minutes after dose administration.,,,50597,BAO_0000218
14031,,,2046.0,1,Thyroid gland,In vivo,CHEMBL628536,,Intermediate,A,,1,,N,Biodistribution in rat thyroid at 1440 minutes after dose administration.,,,50597,BAO_0000218
14032,,,2046.0,1,Thyroid gland,In vivo,CHEMBL628537,,Intermediate,A,,1,,N,Biodistribution in rat thyroid at 15 minutes after dose administration.,,,50597,BAO_0000218
14033,,,2046.0,1,Thyroid gland,In vivo,CHEMBL628538,,Intermediate,A,,1,,N,Biodistribution in rat thyroid at 240 minutes after dose administration.,,,50597,BAO_0000218
14034,,,2046.0,1,Thyroid gland,In vivo,CHEMBL628539,,Intermediate,A,,1,,N,Biodistribution in rat thyroid at 30 minutes after dose administration.,,,50597,BAO_0000218
14035,,,2046.0,1,Thyroid gland,In vivo,CHEMBL630297,,Intermediate,A,,1,,N,Biodistribution in rat thyroid at 360 minutes after dose administration.,,,50597,BAO_0000218
14036,,,2046.0,1,Thyroid gland,In vivo,CHEMBL630298,,Intermediate,A,,1,,N,Biodistribution in rat thyroid at 60 minutes after dose administration.,,,50597,BAO_0000218
14037,,,955.0,1,Brain,In vivo,CHEMBL630299,,Intermediate,A,,1,,N,Biodistribution in rest of brain of rat 120 minutes after dose administration.,,,50597,BAO_0000218
14038,,,955.0,1,Brain,In vivo,CHEMBL628094,,Intermediate,A,,1,,N,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,,,50597,BAO_0000218
14039,,,955.0,1,Brain,In vivo,CHEMBL628095,,Intermediate,A,,1,,N,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,,,50597,BAO_0000218
14040,,,955.0,1,Brain,In vivo,CHEMBL874648,,Intermediate,A,,1,,N,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,,,50597,BAO_0000218
14041,,,955.0,1,Brain,In vivo,CHEMBL628096,,Intermediate,A,,1,,N,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,,,50597,BAO_0000218
14042,,,955.0,1,Brain,In vivo,CHEMBL628097,,Intermediate,A,,1,,N,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,,,50597,BAO_0000218
14043,,,955.0,1,Brain,In vivo,CHEMBL628098,,Intermediate,A,,1,,N,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,,,50597,BAO_0000218
14044,,,,0,,,CHEMBL628099,,Autocuration,A,,1,,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,,22224,BAO_0000019
14045,,,,0,,,CHEMBL628100,,Autocuration,A,,1,,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,22224,BAO_0000019
14046,,,,0,,,CHEMBL628101,,Autocuration,A,,1,,U,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,,22224,BAO_0000019
14047,,,,0,,,CHEMBL628102,,Autocuration,A,,1,,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,,22224,BAO_0000019
14048,,,,0,,,CHEMBL628103,,Autocuration,A,,1,,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,,22224,BAO_0000019
14049,,,,0,,,CHEMBL628104,,Autocuration,A,,1,,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,22224,BAO_0000019
14050,,,,0,,,CHEMBL628105,,Autocuration,A,,1,,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,,22224,BAO_0000019
14051,,,,0,,,CHEMBL628106,,Autocuration,A,,1,,U,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,,22224,BAO_0000019
14052,,,1088.0,1,Urine,,CHEMBL628107,,Intermediate,A,,1,,N,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,,50597,BAO_0000218
14053,,,1088.0,0,Urine,,CHEMBL628108,,Autocuration,F,,1,,U,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,,22224,BAO_0000218
14054,,,1088.0,1,Urine,,CHEMBL628109,,Intermediate,A,,1,,N,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,,50597,BAO_0000218
14055,,,1088.0,0,Urine,,CHEMBL625299,,Autocuration,F,,1,,U,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,,22224,BAO_0000218
14056,,,1088.0,1,Urine,,CHEMBL625300,,Intermediate,A,,1,,N,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,,,50597,BAO_0000218
14057,,,1088.0,1,Urine,,CHEMBL625301,,Intermediate,A,,1,,N,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,,,50597,BAO_0000218
14058,,,1088.0,1,Urine,,CHEMBL625302,,Intermediate,A,,1,,N,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,,,50597,BAO_0000218
14059,,,1088.0,1,Urine,,CHEMBL874649,,Intermediate,A,,1,,N,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,,,50597,BAO_0000218
14060,,,,1,,,CHEMBL625303,,Intermediate,A,,1,,N,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,,50597,BAO_0000218
14061,,,,1,,,CHEMBL625463,,Intermediate,A,,1,,N,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,,50597,BAO_0000218
14062,,,2107.0,1,Liver,,CHEMBL625464,,Intermediate,A,,1,,N,In vitro metabolism in human liver microsomes,,,50587,BAO_0000218
14063,,,,1,,,CHEMBL625465,,Intermediate,A,,1,,N,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,,50587,BAO_0000218
14064,,,1088.0,1,Urine,,CHEMBL625466,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,,50588,BAO_0000218
14065,,,1088.0,1,Urine,,CHEMBL625467,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,,50588,BAO_0000218
14066,,,1088.0,1,Urine,,CHEMBL625468,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,,50597,BAO_0000218
14067,,,1088.0,1,Urine,,CHEMBL625469,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,,,50597,BAO_0000218
14068,,,1088.0,1,Urine,,CHEMBL625470,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,,,50597,BAO_0000218
14069,,,1088.0,1,Urine,,CHEMBL632418,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,,,50597,BAO_0000218
14070,,,1088.0,1,Urine,,CHEMBL627250,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,,,50597,BAO_0000218
14071,,,1088.0,1,Urine,,CHEMBL627251,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,,,50597,BAO_0000218
14072,,,1088.0,1,Urine,,CHEMBL627252,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,,,50597,BAO_0000218
14073,,,1088.0,1,Urine,,CHEMBL627253,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,,,50597,BAO_0000218
14074,,,1088.0,1,Urine,,CHEMBL627254,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,,,50597,BAO_0000218
14075,,,1088.0,1,Urine,,CHEMBL875471,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,,,50597,BAO_0000218
14076,,,1088.0,1,Urine,,CHEMBL627255,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,,,50597,BAO_0000218
14077,,,1088.0,1,Urine,,CHEMBL627256,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,,,50597,BAO_0000218
14078,,,1088.0,1,Urine,,CHEMBL627257,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,,,50597,BAO_0000218
14079,,,1088.0,1,Urine,,CHEMBL627258,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,,,50597,BAO_0000218
14080,,,1088.0,1,Urine,,CHEMBL627259,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,,,50597,BAO_0000218
14081,,,1088.0,1,Urine,,CHEMBL627260,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,,,50597,BAO_0000218
14082,,,1088.0,1,Urine,,CHEMBL623256,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,,,50597,BAO_0000218
14083,,,1088.0,1,Urine,,CHEMBL874413,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,,,50597,BAO_0000218
14084,,,1088.0,1,Urine,,CHEMBL623257,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,,,50597,BAO_0000218
14085,,,1088.0,1,Urine,,CHEMBL623258,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,,,50597,BAO_0000218
14086,,,1088.0,1,Urine,,CHEMBL623259,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,,,50597,BAO_0000218
14087,,,1088.0,1,Urine,,CHEMBL623260,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,,,50597,BAO_0000218
14088,,,1088.0,1,Urine,,CHEMBL623261,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,,,50597,BAO_0000218
14089,,,1088.0,1,Urine,,CHEMBL623262,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,,,50597,BAO_0000218
14090,,,1088.0,1,Urine,,CHEMBL623263,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,,,50597,BAO_0000218
14091,,,1088.0,1,Urine,,CHEMBL623264,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,,,50597,BAO_0000218
14092,,,1088.0,1,Urine,,CHEMBL623265,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,,,50597,BAO_0000218
14093,,,1088.0,1,Urine,,CHEMBL623266,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,,,50597,BAO_0000218
14094,,,1088.0,1,Urine,,CHEMBL623267,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,,,50597,BAO_0000218
14095,,,1088.0,1,Urine,,CHEMBL623268,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,,,50597,BAO_0000218
14096,,,1088.0,1,Urine,,CHEMBL623269,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,,,50597,BAO_0000218
14097,,,1088.0,1,Urine,,CHEMBL623270,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,,,50597,BAO_0000218
14098,,,1088.0,1,Urine,,CHEMBL623271,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,,,50597,BAO_0000218
14099,,,1088.0,1,Urine,,CHEMBL623272,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,,,50597,BAO_0000218
14100,,,1088.0,1,Urine,,CHEMBL623273,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,,,50597,BAO_0000218
14101,,,1088.0,1,Urine,,CHEMBL623274,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,,,50597,BAO_0000218
14102,,,1088.0,1,Urine,,CHEMBL874414,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,,,50597,BAO_0000218
14103,,,1088.0,1,Urine,,CHEMBL623275,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,,,50597,BAO_0000218
14104,,,1088.0,1,Urine,,CHEMBL629150,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,,,50597,BAO_0000218
14105,,,1088.0,1,Urine,,CHEMBL623276,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,,,50597,BAO_0000218
14106,,,1088.0,1,Urine,,CHEMBL623277,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,,,50597,BAO_0000218
14107,,,1088.0,1,Urine,,CHEMBL623112,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,,,50597,BAO_0000218
14108,,,1088.0,1,Urine,,CHEMBL623113,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,,,50597,BAO_0000218
14109,,,1088.0,1,Urine,,CHEMBL623800,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,,,50597,BAO_0000218
14110,,,1088.0,1,Urine,,CHEMBL623801,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,,,50597,BAO_0000218
14111,,,2106.0,1,Spleen,In vivo,CHEMBL623802,,Intermediate,A,,1,,N,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,50597,BAO_0000218
14112,,,995.0,1,Uterus,In vivo,CHEMBL623803,,Intermediate,A,,1,,N,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14113,,,995.0,1,Uterus,In vivo,CHEMBL623970,,Intermediate,A,,1,,N,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14114,,,995.0,1,Uterus,In vivo,CHEMBL623971,,Intermediate,A,,1,,N,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14115,,,178.0,1,Blood,In vivo,CHEMBL623972,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),,,50597,BAO_0000218
14116,,,178.0,1,Blood,In vivo,CHEMBL623973,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),,,50597,BAO_0000218
14117,,,178.0,1,Blood,In vivo,CHEMBL623974,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),,,50597,BAO_0000218
14118,,,178.0,1,Blood,In vivo,CHEMBL623975,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),,,50597,BAO_0000218
14119,,,955.0,1,Brain,In vivo,CHEMBL623976,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),,,50597,BAO_0000218
14120,,,955.0,1,Brain,In vivo,CHEMBL623977,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),,,50597,BAO_0000218
14121,,,955.0,1,Brain,In vivo,CHEMBL623978,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),,,50597,BAO_0000218
14122,,,955.0,1,Brain,In vivo,CHEMBL623979,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),,,50597,BAO_0000218
14123,,,,1,,In vivo,CHEMBL623980,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,,50597,BAO_0000218
14124,,,,1,,In vivo,CHEMBL623981,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,,50597,BAO_0000218
14125,,,,1,,In vivo,CHEMBL626278,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,,50597,BAO_0000218
14126,,,,1,,In vivo,CHEMBL626279,,Intermediate,A,,1,,N,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,,50597,BAO_0000218
14127,,,,1,,In vivo,CHEMBL626280,,Intermediate,A,,1,,N,Biodistribution in mice bladder plus excreted urine was determined,,,50594,BAO_0000218
14128,,,,1,,,CHEMBL626281,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse blood, 10 minutes post injection",,,50594,BAO_0000218
14129,,,,1,,,CHEMBL626282,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse blood, 30 minutes post injection",,,50594,BAO_0000218
14130,,,,1,,,CHEMBL626283,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse blood, 5 minutes post injection",,,50594,BAO_0000218
14131,,,,1,,,CHEMBL626284,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse blood, 60 minutes post injection",,,50594,BAO_0000218
14132,,,955.0,1,Brain,,CHEMBL626285,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse brain, 10 minutes post injection",,,50594,BAO_0000218
14133,,,955.0,1,Brain,,CHEMBL626286,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse brain, 30 minutes post injection",,,50594,BAO_0000218
14134,,,955.0,1,Brain,,CHEMBL626287,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse brain, 5 minutes post injection",,,50594,BAO_0000218
14135,,,955.0,1,Brain,,CHEMBL626288,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse brain, 60 minutes post injection",,,50594,BAO_0000218
14136,,,,1,,,CHEMBL626289,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse heart, 10 minutes post injection",,,50594,BAO_0000218
14137,,,,1,,,CHEMBL626290,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse heart, 30 minutes post injection",,,50594,BAO_0000218
14138,,,,1,,,CHEMBL626291,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse heart, 5 minutes post injection",,,50594,BAO_0000218
14139,,,,1,,,CHEMBL839888,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse heart, 60 minutes post injection",,,50594,BAO_0000218
14140,,,160.0,1,Intestine,,CHEMBL626292,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse intestine, 10 minutes post injection",,,50594,BAO_0000218
14141,,,160.0,1,Intestine,,CHEMBL626293,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse intestine, 30 minutes post injection",,,50594,BAO_0000218
14142,,,160.0,1,Intestine,,CHEMBL626294,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse intestine, 5 minutes post injection",,,50594,BAO_0000218
14143,,,160.0,1,Intestine,,CHEMBL626295,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse intestine, 60 minutes post injection",,,50594,BAO_0000218
14144,,,2107.0,1,Liver,,CHEMBL627659,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse liver, 10 minutes post injection",,,50594,BAO_0000218
14145,,,2107.0,1,Liver,,CHEMBL627660,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse liver, 30 minutes of post injection",,,50594,BAO_0000218
14146,,,2107.0,1,Liver,,CHEMBL627661,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse liver, 5 minutes post injection",,,50594,BAO_0000218
14147,,,2107.0,1,Liver,In vivo,CHEMBL627662,,Intermediate,A,,1,,N,Biodistribution in mice liver at 60 minutes of post injection,,,50594,BAO_0000218
14148,,,2048.0,1,Lung,In vivo,CHEMBL627663,,Intermediate,A,,1,,N,Biodistribution in mice lungs at 10 min of post injection,,,50594,BAO_0000218
14149,,,,1,,,CHEMBL627664,,Intermediate,A,,1,,N,"Percentage biodistribution in mouse lung, 30 minutes post injection",,,50594,BAO_0000218
14150,,,,1,,,CHEMBL627665,,Intermediate,A,,1,,N,"Percentage biodistribution in mousee lung, 5 minutes post injection",,,50594,BAO_0000218
14151,,,2048.0,1,Lung,In vivo,CHEMBL627666,,Intermediate,A,,1,,N,Biodistribution in mice lungs at 60 min of post injection,,,50594,BAO_0000218
14152,,,2106.0,1,Spleen,,CHEMBL627667,,Intermediate,A,,1,,N,Percentage biodistribution in mouse spleen,,,50594,BAO_0000218
14153,,,945.0,1,Stomach,,CHEMBL627668,,Intermediate,A,,1,,N,Percentage biodistribution in mouse stomach,,,50594,BAO_0000218
14154,,,1088.0,1,Urine,,CHEMBL627669,,Intermediate,A,,1,,N,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,,,50594,BAO_0000218
14155,,,1255.0,0,Urinary bladder,In vivo,CHEMBL627670,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,,,22224,BAO_0000218
14156,,,178.0,0,Blood,In vivo,CHEMBL627671,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,,,22224,BAO_0000218
14157,,,1474.0,0,Bone element,In vivo,CHEMBL627672,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,,,22224,BAO_0000218
14158,,,,0,,In vivo,CHEMBL627673,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,,22224,BAO_0000218
14159,,,2113.0,0,Kidney,In vivo,CHEMBL627674,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,,,22224,BAO_0000218
14160,,,2107.0,0,Liver,In vivo,CHEMBL627675,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,,,22224,BAO_0000218
14161,,,2048.0,0,Lung,In vivo,CHEMBL627676,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,,,22224,BAO_0000218
14162,,,2385.0,0,Muscle tissue,In vivo,CHEMBL627677,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,,,22224,BAO_0000218
14163,,,,0,,,CHEMBL627678,,Autocuration,A,,1,,U,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
14164,,,1977.0,1,Serum,,CHEMBL627679,,Intermediate,A,,1,,N,Affinity for protein binding expressed as association constant in fresh rat serum,,,50597,BAO_0000218
14165,,,,0,,,CHEMBL627680,,Autocuration,A,,1,,U,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,22224,BAO_0000019
14166,,,,0,,,CHEMBL627681,,Autocuration,A,,1,,U,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,22224,BAO_0000019
14167,,,,0,,,CHEMBL627682,,Autocuration,A,,1,,U,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,22224,BAO_0000019
14168,,,,0,,,CHEMBL627683,,Autocuration,A,,1,,U,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,22224,BAO_0000019
14169,,,,0,,,CHEMBL627684,,Autocuration,A,,1,,U,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,,22224,BAO_0000019
14170,,,,0,,,CHEMBL874441,,Autocuration,A,,1,,U,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,22224,BAO_0000019
14171,,,,0,,,CHEMBL627685,,Autocuration,A,,1,,U,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,,22224,BAO_0000019
14172,,,,0,,,CHEMBL627686,,Autocuration,A,,1,,U,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,22224,BAO_0000019
14173,,,,0,,,CHEMBL627687,,Autocuration,A,,1,,U,Apparent rate constant Koff for inactivation of dTMP synthase.,,,22224,BAO_0000019
14174,,,,0,,,CHEMBL627688,,Autocuration,A,,1,,U,The irreversible inhibitor activity by second order rate equation.,,,22224,BAO_0000019
14175,,,,1,,,CHEMBL628038,,Intermediate,A,,1,,N,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,,50597,BAO_0000218
14176,,,,1,,,CHEMBL628039,,Intermediate,A,,1,,N,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,,50597,BAO_0000218
14177,,,,1,,,CHEMBL628040,,Intermediate,A,,1,,N,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,,50597,BAO_0000218
14178,,,,0,,,CHEMBL628041,,Autocuration,A,,1,,U,Dissociation rate calculated from the first-order equation using t1/2 value,,,22224,BAO_0000019
14179,,,,0,,,CHEMBL630226,,Autocuration,A,,1,,U,The compound was tested for Binding constant against DNA,,,22224,BAO_0000019
14180,,,,0,,,CHEMBL628042,,Autocuration,A,,1,,U,First order rate constant for cyclization of the compound,,,22224,BAO_0000019
14181,,,,0,,,CHEMBL625232,,Autocuration,A,,1,,U,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,22224,BAO_0000019
14182,,,,0,,,CHEMBL625233,,Autocuration,A,,1,,U,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,22224,BAO_0000019
14183,,,,0,,,CHEMBL625979,,Autocuration,A,,1,,U,Hydrolysis rate constant was determined,,,22224,BAO_0000019
14184,,,,0,,,CHEMBL625980,,Autocuration,A,,1,,U,Observed first order rate constant,,,22224,BAO_0000019
14185,,,,0,,,CHEMBL625981,,Autocuration,A,,1,,U,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,22224,BAO_0000019
14186,,,,0,,,CHEMBL625982,,Autocuration,A,,1,,U,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,22224,BAO_0000019
14187,,,,0,,,CHEMBL625983,,Autocuration,A,,1,,U,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,,22224,BAO_0000019
14188,,,,0,,,CHEMBL625984,,Autocuration,A,,1,,U,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14189,,,,0,,,CHEMBL625985,,Autocuration,A,,1,,U,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14190,,,,0,,,CHEMBL625986,,Autocuration,A,,1,,U,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14191,,,,0,,,CHEMBL625987,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14192,,,,0,,,CHEMBL625988,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14193,,,,0,,,CHEMBL625989,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14194,,,,0,,,CHEMBL625990,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14195,,,,0,,,CHEMBL625991,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14196,,,,0,,,CHEMBL625992,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14197,,,,0,,,CHEMBL625993,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14198,,,,0,,,CHEMBL631973,,Autocuration,A,,1,,U,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14199,,,,0,,,CHEMBL632143,,Autocuration,A,,1,,U,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14200,,,,0,,,CHEMBL632144,,Autocuration,A,,1,,U,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14201,,,,0,,,CHEMBL632145,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14202,,,,0,,,CHEMBL632146,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14203,,,,0,,,CHEMBL632147,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14204,,,,0,,,CHEMBL632148,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14205,,,,0,,,CHEMBL632149,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14206,,,,0,,,CHEMBL632150,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14207,,,,0,,,CHEMBL632151,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14208,,,,1,,,CHEMBL632152,,Intermediate,A,,1,,N,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,,50587,BAO_0000218
14209,,,,1,,,CHEMBL632153,,Intermediate,A,,1,,N,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,,50587,BAO_0000218
14210,,,,1,,,CHEMBL632154,,Intermediate,A,,1,,N,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,,50587,BAO_0000218
14211,,,,1,,,CHEMBL632155,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,,50602,BAO_0000218
14212,,,,1,,,CHEMBL632156,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,,50602,BAO_0000218
14213,,,,1,,,CHEMBL632157,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,,50602,BAO_0000218
14214,,,,1,,,CHEMBL632158,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,,50602,BAO_0000218
14215,,,,1,,,CHEMBL632159,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,,50602,BAO_0000218
14216,,,,1,,,CHEMBL626305,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,,50602,BAO_0000218
14217,,,,1,,,CHEMBL626306,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,,50602,BAO_0000218
14218,,,,1,,,CHEMBL626307,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,,50602,BAO_0000218
14219,,,,1,,,CHEMBL626308,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,,50602,BAO_0000218
14220,,,,1,,,CHEMBL626479,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,,50602,BAO_0000218
14221,,,,1,,,CHEMBL626480,,Intermediate,A,,1,,N,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,,50602,BAO_0000218
14222,,,,0,,,CHEMBL626481,,Autocuration,P,,1,,U,Calculated partition coefficient (clogP) (MlogP),,,22229,BAO_0000100
14223,,,,0,,,CHEMBL626482,,Autocuration,A,,1,,U,Equipotent potent ratio relative to carbachol (nicotinic activity),,,22224,BAO_0000019
14224,,,,1,,,CHEMBL626483,,Intermediate,A,,1,,N,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,,50588,BAO_0000218
14225,,,,1,,,CHEMBL626484,,Intermediate,A,,1,,N,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,,50588,BAO_0000218
14226,,,,0,,,CHEMBL626485,,Autocuration,P,,1,,U,Solubility at pH 7.4 in micro g/mL;NA denotes available,,,22229,BAO_0000100
14227,,,,0,,,CHEMBL626486,,Autocuration,P,,1,,U,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,,22229,BAO_0000100
14228,,,,0,,,CHEMBL626487,,Autocuration,P,,1,,U,Solubility at pH 7.4 in ug/mL;NA denotes not available,,,22229,BAO_0000100
14229,,,1969.0,1,Plasma,In vivo,CHEMBL626488,,Intermediate,A,,1,,N,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,,50588,BAO_0000218
14230,,,1977.0,1,Serum,,CHEMBL626489,,Intermediate,A,,1,,N,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,,,50597,BAO_0000218
14231,,,,0,,,CHEMBL626490,,Autocuration,A,,1,,U,Area under the MAP curve measured over 5 min; ND means Not determined,,,22224,BAO_0000019
14232,,,,0,,,CHEMBL626491,,Autocuration,P,,1,,U,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,,22224,BAO_0000100
14233,,,,0,,,CHEMBL626492,,Autocuration,P,,1,,U,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,,22229,BAO_0000100
14234,,,,0,,,CHEMBL626493,,Autocuration,A,,1,,U,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,,22224,BAO_0000019
14235,,,,1,,In vivo,CHEMBL626494,,Intermediate,A,,1,,N,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,,50597,BAO_0000218
14236,,,,0,,In vivo,CHEMBL626495,,Autocuration,A,,1,,U,Half life after oral tested,,,22224,BAO_0000218
14237,,,1969.0,1,Plasma,,CHEMBL626496,,Intermediate,A,,1,,N,Half life was determined in plasma of rat; NT indicates not tested,,,50597,BAO_0000218
14238,,,,1,,In vivo,CHEMBL626497,,Intermediate,A,,1,,N,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,,50597,BAO_0000218
14239,,,,0,,In vivo,CHEMBL626498,,Autocuration,A,,1,,U,Oral bioavailability after oral tested,,,22224,BAO_0000218
14240,,,,1,,,CHEMBL626499,,Intermediate,A,,1,,N,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,,50597,BAO_0000218
14241,,,,1,,,CHEMBL626500,,Intermediate,A,,1,,N,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,,50597,BAO_0000218
14242,,,1969.0,1,Plasma,,CHEMBL626501,,Intermediate,A,,1,,N,half life was determined in plasma of rat; NT indicates not tested,,,50597,BAO_0000218
14243,,,1969.0,1,Plasma,,CHEMBL626502,,Intermediate,A,,1,,N,half life was determined in plasma of rat; NT means not tested,,,50597,BAO_0000218
14244,,,,1,,,CHEMBL626503,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,,50597,BAO_0000218
14245,,,,1,,,CHEMBL626504,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,,50597,BAO_0000218
14246,,,,1,,,CHEMBL626505,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,,50597,BAO_0000218
14247,,,,1,,,CHEMBL626506,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,,50597,BAO_0000218
14248,,,,1,,,CHEMBL626507,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,,50597,BAO_0000218
14249,,,,1,,,CHEMBL626508,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,,50597,BAO_0000218
14250,,,,1,,,CHEMBL626509,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,,50597,BAO_0000218
14251,,,,1,,,CHEMBL875480,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,,50597,BAO_0000218
14252,,,,1,,,CHEMBL626510,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,,50597,BAO_0000218
14253,,,,1,,,CHEMBL626511,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,,50597,BAO_0000218
14254,,,,1,,,CHEMBL626512,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,,50597,BAO_0000218
14255,,,,1,,,CHEMBL628208,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,,50597,BAO_0000218
14256,,,,1,,,CHEMBL628209,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,,50597,BAO_0000218
14257,,,,1,,,CHEMBL628210,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,,50597,BAO_0000218
14258,,,,1,,,CHEMBL628211,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,,50597,BAO_0000218
14259,,,,1,,,CHEMBL628212,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,,50597,BAO_0000218
14260,,,,1,,,CHEMBL628213,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,,50597,BAO_0000218
14261,,,1088.0,1,Urine,,CHEMBL628214,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,,,50597,BAO_0000218
14262,,,1088.0,1,Urine,,CHEMBL628215,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,,,50597,BAO_0000218
14263,,,1088.0,1,Urine,,CHEMBL628216,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,,,50597,BAO_0000218
14264,,,1088.0,1,Urine,,CHEMBL626595,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,,,50597,BAO_0000218
14265,,,1088.0,1,Urine,,CHEMBL626596,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,,,50597,BAO_0000218
14266,,,1088.0,1,Urine,,CHEMBL626597,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,,,50597,BAO_0000218
14267,,,1088.0,1,Urine,,CHEMBL626598,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,,,50597,BAO_0000218
14268,,,1088.0,1,Urine,,CHEMBL622242,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,,,50597,BAO_0000218
14269,,,1088.0,1,Urine,,CHEMBL622243,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,,,50597,BAO_0000218
14270,,,1088.0,1,Urine,,CHEMBL622244,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,,,50597,BAO_0000218
14271,,,1088.0,1,Urine,,CHEMBL622245,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,,,50597,BAO_0000218
14272,,,1088.0,1,Urine,,CHEMBL622246,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,,,50597,BAO_0000218
14273,,,1088.0,1,Urine,,CHEMBL622247,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,,,50597,BAO_0000218
14274,,,1088.0,1,Urine,,CHEMBL622248,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,,,50597,BAO_0000218
14275,,,1088.0,1,Urine,,CHEMBL877483,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,,,50597,BAO_0000218
14276,,,1088.0,1,Urine,,CHEMBL622249,,Intermediate,A,,1,,N,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,,,50597,BAO_0000218
14277,,,1088.0,1,Urine,,CHEMBL622250,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,,50588,BAO_0000218
14278,,,1088.0,1,Urine,,CHEMBL622251,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,,50588,BAO_0000218
14279,,,1088.0,1,Urine,,CHEMBL622252,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,,50588,BAO_0000218
14280,,,1088.0,1,Urine,,CHEMBL622253,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,,50588,BAO_0000218
14281,,,1088.0,1,Urine,,CHEMBL622254,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,,50588,BAO_0000218
14282,,,1088.0,1,Urine,,CHEMBL622255,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,,50588,BAO_0000218
14283,,,1088.0,1,Urine,,CHEMBL622256,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,,50588,BAO_0000218
14284,,,1088.0,1,Urine,,CHEMBL622257,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,,50588,BAO_0000218
14285,,,1088.0,1,Urine,,CHEMBL622258,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,,50588,BAO_0000218
14286,,,1088.0,1,Urine,,CHEMBL622259,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,,50588,BAO_0000218
14287,,,1088.0,1,Urine,,CHEMBL622927,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,,50588,BAO_0000218
14288,,,1088.0,1,Urine,,CHEMBL622928,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,,50588,BAO_0000218
14289,,,1088.0,1,Urine,,CHEMBL622929,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,,50588,BAO_0000218
14290,,,1088.0,1,Urine,,CHEMBL623182,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,,50588,BAO_0000218
14291,,,1088.0,1,Urine,,CHEMBL623183,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,,50588,BAO_0000218
14292,,,1088.0,1,Urine,,CHEMBL623184,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,,,50597,BAO_0000218
14293,,,1088.0,1,Urine,,CHEMBL623185,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,,50597,BAO_0000218
14294,,,1088.0,1,Urine,,CHEMBL877484,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,,50597,BAO_0000218
14295,,,1088.0,1,Urine,,CHEMBL627274,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,,50597,BAO_0000218
14296,,,1088.0,1,Urine,,CHEMBL623186,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,,,50597,BAO_0000218
14297,,,1088.0,1,Urine,,CHEMBL623187,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,,,50597,BAO_0000218
14298,,,1088.0,1,Urine,,CHEMBL623188,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,,50597,BAO_0000218
14299,,,1088.0,1,Urine,,CHEMBL628055,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,,,50597,BAO_0000218
14300,,,1088.0,1,Urine,,CHEMBL628056,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,,50597,BAO_0000218
14301,,,1088.0,1,Urine,,CHEMBL628200,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,,,50597,BAO_0000218
14302,,,1088.0,1,Urine,,CHEMBL628201,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,,50597,BAO_0000218
14303,,,1088.0,1,Urine,,CHEMBL628202,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,,,50597,BAO_0000218
14304,,,1088.0,1,Urine,,CHEMBL628203,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,,50597,BAO_0000218
14305,,,1088.0,1,Urine,,CHEMBL628204,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,,,50597,BAO_0000218
14306,,,1088.0,1,Urine,,CHEMBL628205,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,,50597,BAO_0000218
14307,,,1088.0,1,Urine,,CHEMBL628206,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,,,50597,BAO_0000218
14308,,,2367.0,0,Prostate gland,In vivo,CHEMBL628207,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),,,22224,BAO_0000218
14309,,,2367.0,0,Prostate gland,In vivo,CHEMBL627220,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,,,22224,BAO_0000218
14310,,,2385.0,0,Muscle tissue,In vivo,CHEMBL627221,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,,,22224,BAO_0000218
14311,,,2367.0,0,Prostate gland,In vivo,CHEMBL627222,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),,,22224,BAO_0000218
14312,,,,0,,In vivo,CHEMBL627223,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,,22224,BAO_0000218
14313,,,2385.0,0,Muscle tissue,In vivo,CHEMBL632062,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,,,22224,BAO_0000218
14314,,,2106.0,0,Spleen,In vivo,CHEMBL632063,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,,,22224,BAO_0000218
14315,,,1255.0,0,Urinary bladder,In vivo,CHEMBL632064,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,,,22224,BAO_0000218
14316,,,178.0,0,Blood,In vivo,CHEMBL632065,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,,,22224,BAO_0000218
14317,,,1474.0,0,Bone element,In vivo,CHEMBL632066,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,,,22224,BAO_0000218
14318,,,,0,,In vivo,CHEMBL632067,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,,22224,BAO_0000218
14319,,,2113.0,0,Kidney,In vivo,CHEMBL629188,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,,,22224,BAO_0000218
14320,,,2107.0,0,Liver,In vivo,CHEMBL629189,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,,,22224,BAO_0000218
14321,,,2048.0,0,Lung,In vivo,CHEMBL629190,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,,,22224,BAO_0000218
14322,,,2385.0,0,Muscle tissue,In vivo,CHEMBL629191,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,,,22224,BAO_0000218
14323,,,2367.0,0,Prostate gland,In vivo,CHEMBL629192,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),,,22224,BAO_0000218
14324,,,2385.0,0,Muscle tissue,In vivo,CHEMBL629193,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,,,22224,BAO_0000218
14325,,,2367.0,0,Prostate gland,In vivo,CHEMBL629194,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),,,22224,BAO_0000218
14326,,,,0,,In vivo,CHEMBL629195,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,,22224,BAO_0000218
14327,,,2385.0,0,Muscle tissue,In vivo,CHEMBL629373,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,,,22224,BAO_0000218
14328,,,2106.0,0,Spleen,In vivo,CHEMBL629374,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,,,22224,BAO_0000218
14329,,,2367.0,0,Prostate gland,In vivo,CHEMBL629375,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,,,22224,BAO_0000218
14330,,,1255.0,0,Urinary bladder,In vivo,CHEMBL629376,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,,,22224,BAO_0000218
14331,,,178.0,0,Blood,In vivo,CHEMBL629377,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,,,22224,BAO_0000218
14332,,,1474.0,0,Bone element,In vivo,CHEMBL629378,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,,,22224,BAO_0000218
14333,,,,0,,In vivo,CHEMBL629379,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,,22224,BAO_0000218
14334,,,2113.0,0,Kidney,In vivo,CHEMBL629151,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,,,22224,BAO_0000218
14335,,,2107.0,0,Liver,In vivo,CHEMBL629152,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,,,22224,BAO_0000218
14336,,,2048.0,0,Lung,In vivo,CHEMBL629153,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,,,22224,BAO_0000218
14337,,,2385.0,0,Muscle tissue,In vivo,CHEMBL629154,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,,,22224,BAO_0000218
14338,,,2367.0,0,Prostate gland,In vivo,CHEMBL629155,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),,,22224,BAO_0000218
14339,,,2367.0,0,Prostate gland,In vivo,CHEMBL629156,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,,,22224,BAO_0000218
14340,,,2385.0,0,Muscle tissue,In vivo,CHEMBL629157,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,,,22224,BAO_0000218
14341,,,2367.0,0,Prostate gland,In vivo,CHEMBL629158,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),,,22224,BAO_0000218
14342,,,,0,,In vivo,CHEMBL629159,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,,22224,BAO_0000218
14343,,,2385.0,0,Muscle tissue,In vivo,CHEMBL629160,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,,,22224,BAO_0000218
14344,,,2106.0,0,Spleen,In vivo,CHEMBL629161,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,,,22224,BAO_0000218
14345,,,1255.0,0,Urinary bladder,In vivo,CHEMBL629162,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,,,22224,BAO_0000218
14346,,,178.0,0,Blood,In vivo,CHEMBL629163,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,,,22224,BAO_0000218
14347,,,1474.0,0,Bone element,In vivo,CHEMBL629164,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,,,22224,BAO_0000218
14348,,,,0,,In vivo,CHEMBL629165,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,,22224,BAO_0000218
14349,,,2107.0,0,Liver,In vivo,CHEMBL629166,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,,,22224,BAO_0000218
14350,,,2048.0,0,Lung,In vivo,CHEMBL629167,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,,,22224,BAO_0000218
14351,,,2385.0,0,Muscle tissue,In vivo,CHEMBL629168,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,,,22224,BAO_0000218
14352,,,,0,,,CHEMBL629169,,Autocuration,A,,1,,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,,22224,BAO_0000019
14353,,,,0,,,CHEMBL629170,,Autocuration,A,,1,,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,,22224,BAO_0000019
14354,,,,0,,,CHEMBL631153,,Autocuration,A,,1,,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,,22224,BAO_0000019
14355,,,,0,,,CHEMBL875121,,Autocuration,A,,1,,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,,22224,BAO_0000019
14356,,,,0,,,CHEMBL631154,,Autocuration,A,,1,,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,,22224,BAO_0000019
14357,,,,0,,,CHEMBL631155,,Autocuration,A,,1,,U,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,,22224,BAO_0000019
14358,,,,0,,,CHEMBL631156,,Autocuration,A,,1,,U,Hydrolysis rate constant was determined,,,22224,BAO_0000019
14359,,,,0,,,CHEMBL631157,,Autocuration,A,,1,,U,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,,22224,BAO_0000019
14360,,,,0,,,CHEMBL631158,,Autocuration,A,,1,,U,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,22224,BAO_0000019
14361,,,,0,,,CHEMBL631159,,Autocuration,A,,1,,U,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,22224,BAO_0000019
14362,,,,0,,,CHEMBL631160,,Autocuration,A,,1,,U,Observed second order rate constant,,,22224,BAO_0000019
14363,,,,0,,,CHEMBL631161,,Autocuration,A,,1,,U,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,22224,BAO_0000019
14364,,,,0,,,CHEMBL631162,,Autocuration,A,,1,,U,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,22224,BAO_0000019
14365,,,,0,,,CHEMBL630313,,Autocuration,A,,1,,U,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,22224,BAO_0000019
14366,,,,0,,,CHEMBL630314,,Autocuration,A,,1,,U,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,22224,BAO_0000019
14367,,,,0,,,CHEMBL630315,,Autocuration,A,,1,,U,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,22224,BAO_0000019
14368,,,,0,,,CHEMBL630316,,Autocuration,A,,1,,U,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14369,,,,0,,,CHEMBL630986,,Autocuration,A,,1,,U,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14370,,,,0,,,CHEMBL630987,,Autocuration,A,,1,,U,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14371,,,,0,,,CHEMBL630988,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14372,,,,0,,,CHEMBL630989,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14373,,,,0,,,CHEMBL630990,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14374,,,,0,,,CHEMBL630991,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14375,,,,0,,,CHEMBL630992,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14376,,,,0,,,CHEMBL630993,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14377,,,,0,,,CHEMBL630994,,Autocuration,A,,1,,U,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,22224,BAO_0000019
14378,,,,1,,,CHEMBL630995,,Intermediate,A,,1,,N,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,,50597,BAO_0000218
14379,,,,0,,,CHEMBL629252,,Autocuration,A,,1,,U,Association constant for compound at 31 degree C was determined,,,22224,BAO_0000019
14380,,,,0,,,CHEMBL629253,,Autocuration,A,,1,,U,Calculated antagonist equilibrium dissociation constant of the compound,,,22224,BAO_0000019
14381,,,,0,,,CHEMBL629944,,Autocuration,A,,1,,U,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,,22224,BAO_0000019
14382,,,3126.0,1,Trachea,,CHEMBL629945,,Intermediate,A,,1,,N,Dissociation constants vs LTE4 on guinea pig trachea,,,50512,BAO_0000218
14383,,,,0,,,CHEMBL629946,,Autocuration,A,,1,,U,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,,22224,BAO_0000019
14384,,,,0,,,CHEMBL629947,,Autocuration,A,,1,,U,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,,22224,BAO_0000019
14385,,,,0,,,CHEMBL629948,,Autocuration,A,,1,,U,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,,22224,BAO_0000019
14386,,,,0,,,CHEMBL856024,,Autocuration,A,,1,,U,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,,22224,BAO_0000019
14387,,,,0,,,CHEMBL629949,,Autocuration,A,,1,,U,Affinity constant KD value was derived from TMP,,,22224,BAO_0000019
14388,,,,0,,,CHEMBL629950,,Autocuration,A,,1,,U,Apparent dissociation (binding) rate constant was evaluated,,,22224,BAO_0000019
14389,,,,0,,,CHEMBL630127,,Autocuration,P,,1,,U,Dissociation constant (KD) of the compound,,,22224,BAO_0000100
14390,,,,0,,,CHEMBL630128,,Autocuration,P,,1,,U,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,,22224,BAO_0000100
14391,,,,0,,,CHEMBL630129,,Autocuration,P,,1,,U,Dissociation constant from ESR titration experiments,,,22224,BAO_0000100
14392,,,,0,,,CHEMBL630130,,Autocuration,,,1,,U,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,22224,BAO_0000019
14393,,,,0,,,CHEMBL875234,,Autocuration,P,,1,,U,Dissociation constant was evaluated.,,,22224,BAO_0000100
14394,,,,0,,,CHEMBL630131,,Autocuration,P,,1,,U,Dissociation constant was reported,,,22224,BAO_0000100
14395,,,,1,,,CHEMBL630132,,Intermediate,A,,1,,N,Dissociation constant was determined in rat pituitary cells.,,,50597,BAO_0000218
14396,,,,0,,,CHEMBL630133,,Autocuration,A,,1,,U,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,,22224,BAO_0000019
14397,,,,0,,,CHEMBL630134,,Autocuration,A,,1,,U,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,,22224,BAO_0000019
14398,,,,0,,,CHEMBL630135,,Autocuration,A,,1,,U,Equilibrium dissociation constant of the compound,,,22224,BAO_0000019
14399,,,,0,,,CHEMBL630136,,Autocuration,A,,1,,U,Equilibrium dissociation constant was determined,,,22224,BAO_0000019
14400,,,,0,,,CHEMBL630137,,Autocuration,A,,1,,U,Kinetic constant KD was evaluated,,,22224,BAO_0000019
14401,,,,0,,,CHEMBL630138,,Autocuration,A,,1,,U,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,,22224,BAO_0000019
14402,,,,0,,,CHEMBL630139,,Autocuration,A,,1,,U,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,,22224,BAO_0000019
14403,,,,0,,,CHEMBL630140,,Autocuration,A,,1,,U,Rate constant for hydrolysis in aqueous acetone.,,,22224,BAO_0000019
14404,,,,0,,,CHEMBL875235,,Autocuration,A,,1,,U,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,,22224,BAO_0000019
14405,,,,1,,,CHEMBL876439,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,,50597,BAO_0000218
14406,,,,1,,,CHEMBL630605,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,,50597,BAO_0000218
14407,,,,1,,,CHEMBL630606,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,,50597,BAO_0000218
14408,,,,1,,,CHEMBL630607,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,,50597,BAO_0000218
14409,,,,1,,,CHEMBL630608,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,,50597,BAO_0000218
14410,,,,1,,,CHEMBL630609,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,,50597,BAO_0000218
14411,,,,1,,,CHEMBL630610,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,,50597,BAO_0000218
14412,,,,1,,,CHEMBL630611,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,,50597,BAO_0000218
14413,,,,1,,,CHEMBL629552,,Intermediate,A,,1,,N,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,,50597,BAO_0000218
14414,,,,1,,,CHEMBL629733,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,50597,BAO_0000218
14415,,,,1,,,CHEMBL629734,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,50597,BAO_0000218
14416,,,,1,,,CHEMBL629735,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,50597,BAO_0000218
14417,,,,1,,,CHEMBL629736,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,50597,BAO_0000218
14418,,,,1,,,CHEMBL629737,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,50597,BAO_0000218
14419,,,,1,,,CHEMBL629738,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,50597,BAO_0000218
14420,,,,1,,,CHEMBL629739,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,50597,BAO_0000218
14421,,,,1,,,CHEMBL629740,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,50597,BAO_0000218
14422,,,,1,,,CHEMBL629741,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,50597,BAO_0000218
14423,,,,1,,,CHEMBL629742,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,50597,BAO_0000218
14424,,,,1,,,CHEMBL629743,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,50597,BAO_0000218
14425,,,,1,,,CHEMBL629744,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,50597,BAO_0000218
14426,,,,1,,,CHEMBL629745,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,50597,BAO_0000218
14427,,,,1,,,CHEMBL629746,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,50597,BAO_0000218
14428,,,,1,,,CHEMBL629747,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,50597,BAO_0000218
14429,,,,1,,,CHEMBL629748,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,50597,BAO_0000218
14430,,,,1,,,CHEMBL629749,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,50597,BAO_0000218
14431,,,,1,,,CHEMBL629750,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,50597,BAO_0000218
14432,,,,1,,,CHEMBL629751,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,50597,BAO_0000218
14433,,,,1,,,CHEMBL629752,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,50597,BAO_0000218
14434,,,,1,,,CHEMBL629753,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,50597,BAO_0000218
14435,,,,1,,,CHEMBL629754,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,50597,BAO_0000218
14436,,,,1,,,CHEMBL629755,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,50597,BAO_0000218
14437,,,,1,,,CHEMBL629756,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,50597,BAO_0000218
14438,,,,1,,,CHEMBL629757,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,50597,BAO_0000218
14439,,,,1,,,CHEMBL629758,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,50597,BAO_0000218
14440,,,,1,,,CHEMBL629759,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,50597,BAO_0000218
14441,,,,1,,,CHEMBL629760,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,50597,BAO_0000218
14442,,,,1,,,CHEMBL876443,,Intermediate,A,,1,,N,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,50597,BAO_0000218
14443,,,,1,,,CHEMBL629761,,Intermediate,A,,1,,N,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,,50588,BAO_0000218
14444,,,,1,,,CHEMBL629762,,Intermediate,A,,1,,N,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,,50588,BAO_0000218
14445,,,,1,,,CHEMBL629763,,Intermediate,A,,1,,N,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,50594,BAO_0000218
14446,,,,1,,,CHEMBL629764,,Intermediate,A,,1,,N,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,50594,BAO_0000218
14447,,,,1,,,CHEMBL629765,,Intermediate,A,,1,,N,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,50594,BAO_0000218
14448,,,,1,,,CHEMBL629766,,Intermediate,A,,1,,N,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,,50594,BAO_0000218
14449,,,,1,,,CHEMBL629767,,Intermediate,A,,1,,N,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,50594,BAO_0000218
14450,,,,1,,,CHEMBL629768,,Intermediate,A,,1,,N,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,,50588,BAO_0000218
14451,,,,1,,,CHEMBL629769,,Intermediate,A,,1,,N,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,,50594,BAO_0000218
14452,,,,1,,,CHEMBL629770,,Intermediate,A,,1,,N,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,,50588,BAO_0000218
14453,,,,1,,,CHEMBL629771,,Intermediate,A,,1,,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,,50588,BAO_0000218
14454,,,,1,,,CHEMBL629772,,Intermediate,A,,1,,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,50594,BAO_0000218
14455,,,,1,,,CHEMBL629773,,Intermediate,A,,1,,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,50594,BAO_0000218
14456,,,,1,,,CHEMBL625455,,Intermediate,A,,1,,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,50594,BAO_0000218
14457,,,,1,,,CHEMBL625456,,Intermediate,A,,1,,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,,50594,BAO_0000218
14458,,,,1,,,CHEMBL625457,,Intermediate,A,,1,,N,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,,50594,BAO_0000218
14459,,,1088.0,1,Urine,,CHEMBL625458,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,,50597,BAO_0000218
14460,,,1088.0,1,Urine,,CHEMBL625459,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,,,50597,BAO_0000218
14461,,,1088.0,1,Urine,,CHEMBL875483,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,,50597,BAO_0000218
14462,,,1088.0,1,Urine,,CHEMBL634779,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,,,50597,BAO_0000218
14463,,,1088.0,1,Urine,,CHEMBL625460,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,,,50597,BAO_0000218
14464,,,1088.0,1,Urine,,CHEMBL626117,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,,50597,BAO_0000218
14465,,,1088.0,1,Urine,,CHEMBL626118,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,,,50597,BAO_0000218
14466,,,1088.0,1,Urine,,CHEMBL628342,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,,,50597,BAO_0000218
14467,,,1088.0,1,Urine,,CHEMBL628343,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,,50597,BAO_0000218
14468,,,1088.0,1,Urine,,CHEMBL628344,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,,,50597,BAO_0000218
14469,,,1088.0,1,Urine,,CHEMBL628345,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,,50597,BAO_0000218
14470,,,1088.0,1,Urine,,CHEMBL628346,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,,,50597,BAO_0000218
14471,,,1088.0,1,Urine,,CHEMBL628347,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,,,50597,BAO_0000218
14472,,,1088.0,1,Urine,,CHEMBL628348,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,,50597,BAO_0000218
14473,,,1088.0,1,Urine,,CHEMBL628349,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,,50597,BAO_0000218
14474,,,1088.0,1,Urine,,CHEMBL875611,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,,,50597,BAO_0000218
14475,,,1088.0,1,Urine,,CHEMBL628350,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,,,50597,BAO_0000218
14476,,,1088.0,1,Urine,,CHEMBL628351,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,,50597,BAO_0000218
14477,,,1088.0,1,Urine,,CHEMBL628352,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,,,50597,BAO_0000218
14478,,,1088.0,1,Urine,,CHEMBL628353,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,,50597,BAO_0000218
14479,,,1088.0,1,Urine,,CHEMBL628354,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,,,50597,BAO_0000218
14480,,,1088.0,1,Urine,,CHEMBL626667,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,,50597,BAO_0000218
14481,,,1088.0,1,Urine,,CHEMBL626668,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,,50597,BAO_0000218
14482,,,1088.0,1,Urine,,CHEMBL626669,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,,50597,BAO_0000218
14483,,,1088.0,1,Urine,,CHEMBL626670,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,,,50597,BAO_0000218
14484,,,1088.0,1,Urine,,CHEMBL626671,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,,,50597,BAO_0000218
14485,,,1088.0,1,Urine,,CHEMBL626672,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,,50597,BAO_0000218
14486,,,1088.0,1,Urine,,CHEMBL626673,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,,,50597,BAO_0000218
14487,,,1088.0,1,Urine,,CHEMBL626674,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,,50597,BAO_0000218
14488,,,1088.0,1,Urine,,CHEMBL626675,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,,50597,BAO_0000218
14489,,,1088.0,1,Urine,,CHEMBL626676,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,,,50597,BAO_0000218
14490,,,1088.0,1,Urine,,CHEMBL626677,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,,,50597,BAO_0000218
14491,,,1088.0,1,Urine,,CHEMBL626678,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,,50597,BAO_0000218
14492,,,1088.0,1,Urine,,CHEMBL626679,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,,50597,BAO_0000218
14493,,,1088.0,1,Urine,,CHEMBL875612,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,,50597,BAO_0000218
14494,,,1088.0,1,Urine,,CHEMBL626680,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,,50597,BAO_0000218
14495,,,1088.0,1,Urine,,CHEMBL626681,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,,50597,BAO_0000218
14496,,,1088.0,1,Urine,,CHEMBL626682,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,,50597,BAO_0000218
14497,,,1088.0,1,Urine,,CHEMBL626683,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,,50597,BAO_0000218
14498,,,1088.0,1,Urine,,CHEMBL626684,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,,50597,BAO_0000218
14499,,,1088.0,1,Urine,,CHEMBL626685,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,,50597,BAO_0000218
14500,,,1088.0,1,Urine,,CHEMBL626686,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,,50597,BAO_0000218
14501,,,1088.0,1,Urine,,CHEMBL626687,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,,50597,BAO_0000218
14502,,,1088.0,1,Urine,,CHEMBL624978,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,,50597,BAO_0000218
14503,,,1088.0,1,Urine,,CHEMBL624979,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,,50597,BAO_0000218
14504,,,1088.0,1,Urine,,CHEMBL624980,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,,50597,BAO_0000218
14505,,,1088.0,1,Urine,,CHEMBL624981,,Intermediate,A,,1,,N,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,,50597,BAO_0000218
14506,,,1088.0,1,Urine,,CHEMBL624982,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,,50588,BAO_0000218
14507,,,2367.0,0,Prostate gland,In vivo,CHEMBL627564,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),,,22224,BAO_0000218
14508,,,2367.0,0,Prostate gland,In vivo,CHEMBL627565,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),,,22224,BAO_0000218
14509,,,,0,,In vivo,CHEMBL627566,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,,22224,BAO_0000218
14510,,,2385.0,0,Muscle tissue,In vivo,CHEMBL627567,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,,,22224,BAO_0000218
14511,,,2106.0,0,Spleen,In vivo,CHEMBL627568,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,,,22224,BAO_0000218
14512,,,2113.0,0,Kidney,In vivo,CHEMBL627569,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,,,22224,BAO_0000218
14513,,,1255.0,0,Urinary bladder,In vivo,CHEMBL627570,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,,,22224,BAO_0000218
14514,,,178.0,0,Blood,In vivo,CHEMBL627571,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,,,22224,BAO_0000218
14515,,,1474.0,0,Bone element,In vivo,CHEMBL627572,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,,,22224,BAO_0000218
14516,,,,0,,In vivo,CHEMBL627573,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,,22224,BAO_0000218
14517,,,2113.0,0,Kidney,In vivo,CHEMBL627574,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,,,22224,BAO_0000218
14518,,,2107.0,0,Liver,In vivo,CHEMBL627575,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,,,22224,BAO_0000218
14519,,,2048.0,0,Lung,In vivo,CHEMBL627576,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,,,22224,BAO_0000218
14520,,,2385.0,0,Muscle tissue,In vivo,CHEMBL627577,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,,,22224,BAO_0000218
14521,,,2367.0,0,Prostate gland,In vivo,CHEMBL627578,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),,,22224,BAO_0000218
14522,,,2367.0,0,Prostate gland,In vivo,CHEMBL627579,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,,,22224,BAO_0000218
14523,,,2385.0,0,Muscle tissue,In vivo,CHEMBL627580,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,,,22224,BAO_0000218
14524,,,2367.0,0,Prostate gland,In vivo,CHEMBL627581,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),,,22224,BAO_0000218
14525,,,,0,,In vivo,CHEMBL627582,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,,22224,BAO_0000218
14526,,,2385.0,0,Muscle tissue,In vivo,CHEMBL627583,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,,,22224,BAO_0000218
14527,,,2106.0,0,Spleen,In vivo,CHEMBL627584,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,,,22224,BAO_0000218
14528,,,2367.0,0,Prostate gland,In vivo,CHEMBL627585,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,,,22224,BAO_0000218
14529,,,2385.0,0,Muscle tissue,In vivo,CHEMBL627586,,Autocuration,A,,1,,U,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,,,22224,BAO_0000218
14530,,,,1,,In vivo,CHEMBL627587,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,,50597,BAO_0000218
14531,,,,1,,In vivo,CHEMBL627588,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,,50597,BAO_0000218
14532,,,,1,,In vivo,CHEMBL628250,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,,50597,BAO_0000218
14533,,,,1,,In vivo,CHEMBL628251,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,,50597,BAO_0000218
14534,,,10000000.0,1,Hippocampus,In vivo,CHEMBL628252,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,,,50597,BAO_0000218
14535,,,10000000.0,1,Hippocampus,In vivo,CHEMBL628253,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,,50597,BAO_0000218
14536,,,1898.0,1,Hypothalamus,In vivo,CHEMBL628254,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,,,50597,BAO_0000218
14537,,,1898.0,1,Hypothalamus,In vivo,CHEMBL877493,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,,50597,BAO_0000218
14538,,,,1,,In vivo,CHEMBL628255,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,,50597,BAO_0000218
14539,,,,1,,In vivo,CHEMBL628256,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,,50597,BAO_0000218
14540,,,10000000.0,1,Hippocampus,In vivo,CHEMBL628257,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,,50597,BAO_0000218
14541,,,1898.0,1,Hypothalamus,In vivo,CHEMBL628258,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,,50597,BAO_0000218
14542,,,,1,,In vivo,CHEMBL628259,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,,50597,BAO_0000218
14543,,,,1,,In vivo,CHEMBL628429,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,,50597,BAO_0000218
14544,,,10000000.0,1,Hippocampus,In vivo,CHEMBL626862,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,,50597,BAO_0000218
14545,,,1898.0,1,Hypothalamus,In vivo,CHEMBL626863,,Intermediate,A,,1,,N,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,,,50597,BAO_0000218
14546,,,2037.0,1,Cerebellum,In vivo,CHEMBL625886,,Intermediate,A,,1,,N,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,,,50597,BAO_0000218
14547,,,2037.0,1,Cerebellum,In vivo,CHEMBL625887,,Intermediate,A,,1,,N,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,,,50597,BAO_0000218
14548,,,,1,,In vivo,CHEMBL625888,,Intermediate,A,,1,,N,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,,50597,BAO_0000218
14549,,,,1,,In vivo,CHEMBL625889,,Intermediate,A,,1,,N,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,,50597,BAO_0000218
14550,,,10000000.0,1,Hippocampus,In vivo,CHEMBL625890,,Intermediate,A,,1,,N,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,,,50597,BAO_0000218
14551,,,10000000.0,1,Hippocampus,In vivo,CHEMBL625891,,Intermediate,A,,1,,N,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,,,50597,BAO_0000218
14552,,,1898.0,1,Hypothalamus,In vivo,CHEMBL625892,,Intermediate,A,,1,,N,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,,,50597,BAO_0000218
14553,,,1898.0,1,Hypothalamus,In vivo,CHEMBL625893,,Intermediate,A,,1,,N,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,,,50597,BAO_0000218
14554,,,2037.0,1,Cerebellum,In vivo,CHEMBL625894,,Intermediate,A,,1,,N,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,,,50597,BAO_0000218
14555,,,,1,,In vivo,CHEMBL625895,,Intermediate,A,,1,,N,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,,50597,BAO_0000218
14556,,,,0,,,CHEMBL625896,,Autocuration,A,,1,,U,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,22224,BAO_0000019
14557,,,,0,,,CHEMBL625897,,Autocuration,A,,1,,U,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,,22224,BAO_0000019
14558,,,,0,,,CHEMBL625898,,Autocuration,A,,1,,U,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,22224,BAO_0000019
14559,,,,0,,,CHEMBL625899,,Autocuration,A,,1,,U,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,22224,BAO_0000019
14560,,,,0,,,CHEMBL626124,,Autocuration,A,,1,,U,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,22224,BAO_0000019
14561,,,,1,,,CHEMBL628500,,Intermediate,A,,1,,N,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,,50212,BAO_0000218
14562,,,,1,,,CHEMBL857856,,Intermediate,A,,1,,N,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,,50597,BAO_0000218
14563,,,,1,,,CHEMBL628501,,Intermediate,A,,1,,N,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,,50597,BAO_0000218
14564,,,,0,,,CHEMBL628502,,Autocuration,A,,1,,U,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,,22224,BAO_0000019
14565,,,,0,,,CHEMBL628503,,Autocuration,A,,1,,U,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,,22224,BAO_0000019
14566,,,,0,,,CHEMBL628504,,Autocuration,A,,1,,U,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,,22224,BAO_0000019
14567,,,,0,,,CHEMBL628505,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,22224,BAO_0000019
14568,,,,0,,,CHEMBL874452,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,,22224,BAO_0000019
14569,,,,0,,,CHEMBL628506,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,,22224,BAO_0000019
14570,,,,0,,,CHEMBL628507,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,22224,BAO_0000019
14571,,,,0,,,CHEMBL628508,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,,22224,BAO_0000019
14572,,,,0,,,CHEMBL628509,,Autocuration,A,,1,,U,Michaelis constant (KM) was evaluated,,,22224,BAO_0000019
14573,,,,0,,,CHEMBL628510,,Autocuration,A,,1,,U,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,22224,BAO_0000019
14574,,,,0,,,CHEMBL628511,,Autocuration,B,,1,,U,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,,22224,BAO_0000019
14575,,,,0,,,CHEMBL628512,,Autocuration,B,,1,,U,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,,22224,BAO_0000019
14576,,,,0,,,CHEMBL628513,,Autocuration,B,,1,,U,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,,22224,BAO_0000019
14577,,,,0,,,CHEMBL628514,,Autocuration,B,,1,,U,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,,22224,BAO_0000019
14578,,,,0,,,CHEMBL628515,,Autocuration,A,,1,,U,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,,22224,BAO_0000019
14579,,,,0,,,CHEMBL628516,,Autocuration,A,,1,,U,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,,22224,BAO_0000019
14580,,,,0,,,CHEMBL628517,,Autocuration,A,,1,,U,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,22224,BAO_0000019
14581,,,,0,,,CHEMBL628518,,Autocuration,A,,1,,U,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,22224,BAO_0000019
14582,,,,0,,,CHEMBL628519,,Autocuration,A,,1,,U,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,,22224,BAO_0000019
14583,,,,0,,,CHEMBL628520,,Autocuration,A,,1,,U,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,,22224,BAO_0000019
14584,,,,0,,,CHEMBL628521,,Autocuration,A,,1,,U,Binding constant was determined,,,22224,BAO_0000019
14585,,,,0,,,CHEMBL630443,,Autocuration,A,,1,,U,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,,22224,BAO_0000019
14586,,,,0,,,CHEMBL630444,,Autocuration,A,,1,,U,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,,22224,BAO_0000019
14587,,,,0,,,CHEMBL857732,,Autocuration,A,,1,,U,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,,22224,BAO_0000019
14588,,,,0,,,CHEMBL630445,,Autocuration,P,,1,,U,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,,22224,BAO_0000100
14589,,,,0,,,CHEMBL630446,,Autocuration,A,,1,,U,Catalytic rate constant of the compound,,,22224,BAO_0000019
14590,,,,0,,,CHEMBL630447,,Autocuration,B,,1,,U,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,,22224,BAO_0000019
14591,,,,0,,,CHEMBL630448,,Autocuration,A,,1,,U,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,,22224,BAO_0000019
14592,,,,0,,,CHEMBL630449,,Autocuration,A,,1,,U,Catalytic rate constant against phospholipase A2 was determined,,,22224,BAO_0000019
14593,,,,0,,,CHEMBL630450,,Autocuration,A,,1,,U,"Compound was evaluated for catalytic constant, Kcat",,,22224,BAO_0000019
14594,,,,0,,,CHEMBL630451,,Autocuration,A,,1,,U,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,,22224,BAO_0000019
14595,,,,0,,,CHEMBL630452,,Autocuration,A,,1,,U,Kcat calculated from 0.693/T1/2,,,22224,BAO_0000019
14596,,,,0,,,CHEMBL630453,,Autocuration,A,,1,,U,Kcat was determined,,,22224,BAO_0000019
14597,,,,0,,,CHEMBL630454,,Autocuration,A,,1,,U,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,,22224,BAO_0000019
14598,,,,0,,,CHEMBL630455,,Autocuration,A,,1,,U,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,,22224,BAO_0000019
14599,,,,0,,,CHEMBL631487,,Autocuration,A,,1,,U,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,,22224,BAO_0000019
14600,,,,0,,,CHEMBL631488,,Autocuration,A,,1,,U,Kcat value was determined,,,22224,BAO_0000019
14601,,,,0,,,CHEMBL876440,,Autocuration,A,,1,,U,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,,22224,BAO_0000019
14602,,,,0,,,CHEMBL631489,,Autocuration,A,,1,,U,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,,22224,BAO_0000019
14603,,,,0,,,CHEMBL857742,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,22224,BAO_0000019
14604,,,,0,,,CHEMBL631490,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,22224,BAO_0000019
14605,,,,0,,,CHEMBL631491,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,,22224,BAO_0000019
14606,,,,0,,,CHEMBL631492,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,22224,BAO_0000019
14607,,,,0,,,CHEMBL631493,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,22224,BAO_0000019
14608,,,,0,,,CHEMBL631494,,Autocuration,A,,1,,U,Kinetic parameter for rate of conversion to PABA was determined,,,22224,BAO_0000019
14609,,,,0,,,CHEMBL631495,,Autocuration,A,,1,,U,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,22224,BAO_0000019
14610,,,1988.0,1,Feces,,CHEMBL631496,,Intermediate,A,,1,,N,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,,50597,BAO_0000218
14611,,,1088.0,1,Urine,,CHEMBL631497,,Intermediate,A,,1,,N,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,,50597,BAO_0000218
14612,,,1088.0,1,Urine,,CHEMBL631498,,Intermediate,A,,1,,N,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,,50597,BAO_0000218
14613,,,1088.0,1,Urine,,CHEMBL629776,,Intermediate,A,,1,,N,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,,50597,BAO_0000218
14614,,,1088.0,1,Urine,,CHEMBL629777,,Intermediate,A,,1,,N,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,,50597,BAO_0000218
14615,,,1088.0,1,Urine,,CHEMBL629778,,Intermediate,A,,1,,N,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,,50597,BAO_0000218
14616,,,,1,,,CHEMBL630456,,Intermediate,A,,1,,N,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,,50597,BAO_0000218
14617,,,,1,,,CHEMBL630457,,Intermediate,A,,1,,N,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,,50597,BAO_0000218
14618,,,,1,,,CHEMBL630458,,Intermediate,A,,1,,N,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,,50597,BAO_0000218
14619,,,,1,,,CHEMBL630459,,Intermediate,A,,1,,N,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,,50597,BAO_0000218
14620,,,,1,,,CHEMBL630460,,Intermediate,A,,1,,N,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,,50597,BAO_0000218
14621,,,,1,,,CHEMBL876550,,Intermediate,A,,1,,N,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,,50597,BAO_0000218
14622,,,,1,,,CHEMBL630461,,Intermediate,A,,1,,N,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,,50597,BAO_0000218
14623,,,,1,,,CHEMBL630462,,Intermediate,A,,1,,N,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,,50597,BAO_0000218
14624,,,,1,,,CHEMBL630463,,Intermediate,A,,1,,N,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,,50597,BAO_0000218
14625,,,,1,,,CHEMBL630464,,Intermediate,A,,1,,N,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,,50597,BAO_0000218
14626,,,,1,,,CHEMBL630465,,Intermediate,A,,1,,N,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,,50597,BAO_0000218
14627,,,,1,,,CHEMBL630466,,Intermediate,A,,1,,N,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,,50597,BAO_0000218
14628,,,,1,,,CHEMBL630467,,Intermediate,A,,1,,N,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,,50597,BAO_0000218
14629,,,,1,,,CHEMBL630633,,Intermediate,A,,1,,N,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,,50597,BAO_0000218
14630,,,,1,,,CHEMBL630634,,Intermediate,A,,1,,N,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,,50597,BAO_0000218
14631,,,,1,,,CHEMBL630635,,Intermediate,A,,1,,N,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,,50597,BAO_0000218
14632,,,,1,,,CHEMBL630636,,Intermediate,A,,1,,N,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,,50597,BAO_0000218
14633,,,,1,,,CHEMBL630637,,Intermediate,A,,1,,N,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,,50597,BAO_0000218
14634,,,1988.0,1,Feces,,CHEMBL630638,,Intermediate,A,,1,,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,,50592,BAO_0000218
14635,,,1988.0,1,Feces,,CHEMBL630639,,Intermediate,A,,1,,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,,50592,BAO_0000218
14636,,,1988.0,1,Feces,,CHEMBL630640,,Intermediate,A,,1,,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,,50592,BAO_0000218
14637,,,1988.0,1,Feces,,CHEMBL876551,,Intermediate,A,,1,,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,,50592,BAO_0000218
14638,,,1088.0,1,Urine,,CHEMBL630641,,Intermediate,A,,1,,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",,,50592,BAO_0000218
14639,,,1088.0,1,Urine,,CHEMBL630642,,Intermediate,A,,1,,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,,50592,BAO_0000218
14640,,,1088.0,1,Urine,,CHEMBL630643,,Intermediate,A,,1,,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,,50592,BAO_0000218
14641,,,1088.0,1,Urine,,CHEMBL630644,,Intermediate,A,,1,,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,,50592,BAO_0000218
14642,,,1088.0,1,Urine,,CHEMBL630645,,Intermediate,A,,1,,N,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,,50592,BAO_0000218
14643,,,1988.0,1,Feces,,CHEMBL625599,,Intermediate,A,,1,,N,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,,50592,BAO_0000218
14644,,,1988.0,1,Feces,,CHEMBL625600,,Intermediate,A,,1,,N,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,,50592,BAO_0000218
14645,,,1988.0,1,Feces,,CHEMBL625601,,Intermediate,A,,1,,N,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,,50592,BAO_0000218
14646,,,1988.0,1,Feces,,CHEMBL625602,,Intermediate,A,,1,,N,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,,50592,BAO_0000218
14647,,,1088.0,1,Urine,,CHEMBL627470,,Intermediate,A,,1,,N,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",,,50592,BAO_0000218
14648,,,1088.0,1,Urine,,CHEMBL627471,,Intermediate,A,,1,,N,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,,50592,BAO_0000218
14649,,,1088.0,1,Urine,,CHEMBL627472,,Intermediate,A,,1,,N,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,,50592,BAO_0000218
14650,,,1088.0,1,Urine,,CHEMBL627473,,Intermediate,A,,1,,N,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,,50592,BAO_0000218
14651,,,1088.0,1,Urine,,CHEMBL627474,,Intermediate,A,,1,,N,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,,50592,BAO_0000218
14652,,,178.0,1,Blood,In vivo,CHEMBL627475,,Intermediate,A,,1,,N,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14653,,,178.0,1,Blood,In vivo,CHEMBL627476,,Intermediate,A,,1,,N,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14654,,,1088.0,1,Urine,,CHEMBL627477,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,,50588,BAO_0000218
14655,,,1088.0,1,Urine,,CHEMBL627478,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,,50588,BAO_0000218
14656,,,1088.0,1,Urine,,CHEMBL627479,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,,50588,BAO_0000218
14657,,,1088.0,1,Urine,,CHEMBL627480,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,,50588,BAO_0000218
14658,,,1088.0,1,Urine,,CHEMBL627481,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,,50588,BAO_0000218
14659,,,1088.0,1,Urine,,CHEMBL627482,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,,50588,BAO_0000218
14660,,,1088.0,1,Urine,,CHEMBL627483,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,,50588,BAO_0000218
14661,,,1088.0,1,Urine,,CHEMBL875636,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,,50588,BAO_0000218
14662,,,1088.0,1,Urine,,CHEMBL625764,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,,50588,BAO_0000218
14663,,,1088.0,1,Urine,,CHEMBL625765,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,,50588,BAO_0000218
14664,,,1088.0,1,Urine,,CHEMBL625766,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,,,50588,BAO_0000218
14665,,,1088.0,1,Urine,,CHEMBL625767,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,,50588,BAO_0000218
14666,,,1088.0,1,Urine,,CHEMBL625768,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,,50588,BAO_0000218
14667,,,1088.0,1,Urine,,CHEMBL625769,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,,50588,BAO_0000218
14668,,,1088.0,1,Urine,,CHEMBL625770,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,,50588,BAO_0000218
14669,,,1088.0,1,Urine,,CHEMBL625771,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,,50588,BAO_0000218
14670,,,1088.0,1,Urine,,CHEMBL625772,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,,,50588,BAO_0000218
14671,,,1088.0,1,Urine,,CHEMBL625773,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,,50588,BAO_0000218
14672,,,1088.0,1,Urine,,CHEMBL625774,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,,50597,BAO_0000218
14673,,,1088.0,1,Urine,,CHEMBL625775,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,,,50597,BAO_0000218
14674,,,1088.0,1,Urine,,CHEMBL625776,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,,50597,BAO_0000218
14675,,,1088.0,1,Urine,,CHEMBL625777,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,,50597,BAO_0000218
14676,,,1088.0,1,Urine,,CHEMBL625778,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,,50597,BAO_0000218
14677,,,1088.0,1,Urine,,CHEMBL625779,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,,,50597,BAO_0000218
14678,,,1088.0,1,Urine,,CHEMBL625780,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,,,50597,BAO_0000218
14679,,,1088.0,1,Urine,,CHEMBL625781,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,,50597,BAO_0000218
14680,,,1088.0,1,Urine,,CHEMBL875637,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,,,50597,BAO_0000218
14681,,,1088.0,1,Urine,,CHEMBL626473,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,,50597,BAO_0000218
14682,,,1088.0,1,Urine,,CHEMBL626474,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,,,50597,BAO_0000218
14683,,,1088.0,1,Urine,,CHEMBL626475,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,,50597,BAO_0000218
14684,,,1088.0,1,Urine,,CHEMBL626476,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,,,50597,BAO_0000218
14685,,,1088.0,1,Urine,,CHEMBL634397,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,,50597,BAO_0000218
14686,,,1088.0,1,Urine,,CHEMBL626477,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,,,50597,BAO_0000218
14687,,,1088.0,1,Urine,,CHEMBL631069,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,,50597,BAO_0000218
14688,,,1088.0,1,Urine,,CHEMBL631070,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,,,50597,BAO_0000218
14689,,,1088.0,1,Urine,,CHEMBL631071,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,,50597,BAO_0000218
14690,,,1088.0,1,Urine,,CHEMBL631072,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,,,50597,BAO_0000218
14691,,,1088.0,1,Urine,,CHEMBL631073,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,,50597,BAO_0000218
14692,,,1088.0,1,Urine,,CHEMBL631074,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,,,50597,BAO_0000218
14693,,,1088.0,1,Urine,,CHEMBL631075,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,,,50597,BAO_0000218
14694,,,1088.0,1,Urine,,CHEMBL631725,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,,50597,BAO_0000218
14695,,,1088.0,1,Urine,,CHEMBL631726,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,,,50597,BAO_0000218
14696,,,1088.0,1,Urine,,CHEMBL631727,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,,,50597,BAO_0000218
14697,,,1088.0,1,Urine,,CHEMBL631728,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,,50597,BAO_0000218
14698,,,1088.0,1,Urine,,CHEMBL631729,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,,50597,BAO_0000218
14699,,,1088.0,1,Urine,,CHEMBL631730,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,,,50597,BAO_0000218
14700,,,1088.0,1,Urine,,CHEMBL631731,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,,,50597,BAO_0000218
14701,,,1088.0,1,Urine,,CHEMBL631910,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,,50597,BAO_0000218
14702,,,10000000.0,1,Hippocampus,In vivo,CHEMBL631911,,Intermediate,A,,1,,N,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,,,50597,BAO_0000218
14703,,,1898.0,1,Hypothalamus,In vivo,CHEMBL631912,,Intermediate,A,,1,,N,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,,,50597,BAO_0000218
14704,,,1898.0,1,Hypothalamus,In vivo,CHEMBL631913,,Intermediate,A,,1,,N,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,,,50597,BAO_0000218
14705,,,178.0,1,Blood,In vivo,CHEMBL631914,,Intermediate,A,,1,,N,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14706,,,178.0,1,Blood,In vivo,CHEMBL631915,,Intermediate,A,,1,,N,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14707,,,178.0,1,Blood,In vivo,CHEMBL875778,,Intermediate,A,,1,,N,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14708,,,178.0,1,Blood,In vivo,CHEMBL631916,,Intermediate,A,,1,,N,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14709,,,178.0,1,Blood,In vivo,CHEMBL631917,,Intermediate,A,,1,,N,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14710,,,178.0,1,Blood,In vivo,CHEMBL631918,,Intermediate,A,,1,,N,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14711,,,178.0,1,Blood,In vivo,CHEMBL631919,,Intermediate,A,,1,,N,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14712,,,178.0,1,Blood,In vivo,CHEMBL631920,,Intermediate,A,,1,,N,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14713,,,178.0,1,Blood,In vivo,CHEMBL631921,,Intermediate,A,,1,,N,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14714,,,178.0,1,Blood,In vivo,CHEMBL631922,,Intermediate,A,,1,,N,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14715,,,178.0,1,Blood,In vivo,CHEMBL631923,,Intermediate,A,,1,,N,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14716,,,,1,,In vivo,CHEMBL631924,,Intermediate,A,,1,,N,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14717,,,,1,,In vivo,CHEMBL630234,,Intermediate,A,,1,,N,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14718,,,,1,,In vivo,CHEMBL630235,,Intermediate,A,,1,,N,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14719,,,,1,,In vivo,CHEMBL630236,,Intermediate,A,,1,,N,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14720,,,,1,,In vivo,CHEMBL630237,,Intermediate,A,,1,,N,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14721,,,,1,,In vivo,CHEMBL630238,,Intermediate,A,,1,,N,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14722,,,,1,,In vivo,CHEMBL630239,,Intermediate,A,,1,,N,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14723,,,,1,,In vivo,CHEMBL630303,,Intermediate,A,,1,,N,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14724,,,,1,,In vivo,CHEMBL630304,,Intermediate,A,,1,,N,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14725,,,,1,,In vivo,CHEMBL630305,,Intermediate,A,,1,,N,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14726,,,2113.0,1,Kidney,In vivo,CHEMBL630306,,Intermediate,A,,1,,N,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14727,,,2113.0,1,Kidney,In vivo,CHEMBL630307,,Intermediate,A,,1,,N,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14728,,,2113.0,1,Kidney,In vivo,CHEMBL630308,,Intermediate,A,,1,,N,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14729,,,2113.0,1,Kidney,In vivo,CHEMBL630309,,Intermediate,A,,1,,N,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14730,,,2113.0,1,Kidney,In vivo,CHEMBL629309,,Intermediate,A,,1,,N,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14731,,,2113.0,1,Kidney,In vivo,CHEMBL629993,,Intermediate,A,,1,,N,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14732,,,2113.0,1,Kidney,In vivo,CHEMBL629994,,Intermediate,A,,1,,N,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14733,,,2113.0,1,Kidney,In vivo,CHEMBL629995,,Intermediate,A,,1,,N,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14734,,,2113.0,1,Kidney,In vivo,CHEMBL631993,,Intermediate,A,,1,,N,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14735,,,2113.0,1,Kidney,In vivo,CHEMBL631994,,Intermediate,A,,1,,N,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14736,,,2113.0,1,Kidney,In vivo,CHEMBL631995,,Intermediate,A,,1,,N,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14737,,,2107.0,1,Liver,In vivo,CHEMBL631996,,Intermediate,A,,1,,N,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14738,,,2107.0,1,Liver,In vivo,CHEMBL631997,,Intermediate,A,,1,,N,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14739,,,2107.0,1,Liver,In vivo,CHEMBL631998,,Intermediate,A,,1,,N,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14740,,,2107.0,1,Liver,In vivo,CHEMBL631999,,Intermediate,A,,1,,N,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14741,,,2107.0,1,Liver,In vivo,CHEMBL632000,,Intermediate,A,,1,,N,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14742,,,2107.0,1,Liver,In vivo,CHEMBL632001,,Intermediate,A,,1,,N,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14743,,,2107.0,1,Liver,In vivo,CHEMBL874424,,Intermediate,A,,1,,N,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14744,,,2107.0,1,Liver,In vivo,CHEMBL632002,,Intermediate,A,,1,,N,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14745,,,2107.0,1,Liver,In vivo,CHEMBL632003,,Intermediate,A,,1,,N,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14746,,,,0,,,CHEMBL632004,,Autocuration,A,,1,,U,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,22224,BAO_0000019
14747,,,,0,,,CHEMBL632005,,Autocuration,A,,1,,U,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,,22224,BAO_0000019
14748,,,,0,,,CHEMBL632006,,Autocuration,A,,1,,U,Compound was tested for amidase rate in the presence of N62C screen enzyme,,,22224,BAO_0000019
14749,,,,0,,,CHEMBL632007,,Autocuration,A,,1,,U,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,,22224,BAO_0000019
14750,,,,0,,,CHEMBL632008,,Autocuration,A,,1,,U,Compound was tested for amidase rate in the presence of S166C screen enzyme,,,22224,BAO_0000019
14751,,,,0,,,CHEMBL632009,,Autocuration,A,,1,,U,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,,22224,BAO_0000019
14752,,,,0,,,CHEMBL632010,,Autocuration,A,,1,,U,Compound was tested for esterase rate in the presence of N62C screen enzyme,,,22224,BAO_0000019
14753,,,,0,,,CHEMBL857750,,Autocuration,A,,1,,U,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,,22224,BAO_0000019
14754,,,,0,,,CHEMBL632011,,Autocuration,A,,1,,U,Compound was tested for esterase rate in the presence of S166C screen enzyme,,,22224,BAO_0000019
14755,,,,0,,,CHEMBL632012,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,22224,BAO_0000019
14756,,,,0,,,CHEMBL632013,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,22224,BAO_0000019
14757,,,,0,,,CHEMBL632014,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,,22224,BAO_0000019
14758,,,,0,,,CHEMBL629622,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,22224,BAO_0000019
14759,,,,0,,,CHEMBL629623,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,22224,BAO_0000019
14760,,,,0,,,CHEMBL629624,,Autocuration,A,,1,,U,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,,22224,BAO_0000019
14761,,,,0,,,CHEMBL629625,,Autocuration,A,,1,,U,Ratio of Kcat to that of Km was determined,,,22224,BAO_0000019
14762,,,,0,,,CHEMBL629626,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,22224,BAO_0000019
14763,,,,0,,,CHEMBL629627,,Autocuration,A,,1,,U,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,22224,BAO_0000019
14764,,,,0,,,CHEMBL629628,,Autocuration,A,,1,,U,"Compound was evaluated for constant, Kd",,,22224,BAO_0000019
14765,,,,0,,,CHEMBL629629,,Autocuration,A,,1,,U,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,,22224,BAO_0000019
14766,,,,0,,,CHEMBL629630,,Autocuration,A,,1,,U,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,,22224,BAO_0000019
14767,,,,0,,,CHEMBL856030,,Autocuration,A,,1,,U,Dissociation Constant of compound determined,,,22224,BAO_0000019
14768,,,,0,,,CHEMBL629631,,Autocuration,B,,1,,U,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,,22224,BAO_0000019
14769,,,,0,,,CHEMBL629632,,Autocuration,B,,1,,U,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,,22224,BAO_0000019
14770,,,,0,,,CHEMBL629633,,Autocuration,P,,1,,U,Dissociation constant of compound with Fructose was determined,,,22224,BAO_0000100
14771,,,,0,,,CHEMBL629634,,Autocuration,P,,1,,U,Dissociation constant of compound with Fructose was determined; Not determined,,,22224,BAO_0000100
14772,,,,0,,,CHEMBL629635,,Autocuration,P,,1,,U,Dissociation constant of compound with Lactulose was determined,,,22224,BAO_0000100
14773,,,,0,,,CHEMBL629636,,Autocuration,P,,1,,U,Dissociation constant of compound with Lactulose was determined; Not determined,,,22224,BAO_0000100
14774,,,,0,,,CHEMBL629637,,Autocuration,P,,1,,U,Dissociation constant of the Compound,,,22224,BAO_0000100
14775,,,,0,,,CHEMBL629638,,Autocuration,P,,1,,U,Dissociation constant by non-linear regression analysis,,,22224,BAO_0000100
14776,,,,0,,,CHEMBL629639,,Autocuration,P,,1,,U,Dissociation constant was determined,,,22224,BAO_0000100
14777,,,,0,,,CHEMBL629640,,Autocuration,P,,1,,U,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,,22224,BAO_0000100
14778,,,,0,,,CHEMBL629641,,Autocuration,P,,1,,U,Dissociation constant was determined,,,22224,BAO_0000100
14779,,,,0,,,CHEMBL631344,,Autocuration,P,,1,,U,Dissociation constant was determined,,,22224,BAO_0000100
14780,,,2385.0,1,Muscle tissue,,CHEMBL631345,,Intermediate,A,,1,,N,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,,,50597,BAO_0000218
14781,,,,0,,,CHEMBL631346,,Autocuration,A,,1,,U,The dissociation constant determined by fluorescence displacement assay,,,22224,BAO_0000019
14782,,,,0,,,CHEMBL631524,,Autocuration,A,,1,,U,kd value surface plasmon resonance (SPR) method,,,22224,BAO_0000019
14783,,,2385.0,1,Muscle tissue,,CHEMBL631525,,Intermediate,A,,1,,N,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,,,50597,BAO_0000218
14784,,,,0,,,CHEMBL631526,,Autocuration,F,,1,,U,First dissociation constant of the binding of compound to V30M TTR,,,22224,BAO_0000019
14785,,,,0,,,CHEMBL631527,,Autocuration,F,,1,,U,Second dissociation constant of the binding of compound to V30M TTR,,,22224,BAO_0000019
14786,,,,0,,,CHEMBL631528,,Autocuration,A,,1,,U,"Compound was evaluated for equilibrium constant, Ke",,,22224,BAO_0000019
14787,,,1898.0,0,Hypothalamus,,CHEMBL631529,,Autocuration,A,,1,,U,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,,,22224,BAO_0000019
14788,,,1898.0,0,Hypothalamus,,CHEMBL631530,,Autocuration,A,,1,,U,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,,,22224,BAO_0000019
14789,,,,0,,,CHEMBL631531,,Autocuration,A,,1,,U,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,,22224,BAO_0000019
14790,,,,0,,,CHEMBL631532,,Autocuration,A,,1,,U,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,22224,BAO_0000019
14791,,,,0,,,CHEMBL631533,,Autocuration,A,,1,,U,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,,22224,BAO_0000019
14792,,,,1,,,CHEMBL876552,,Intermediate,A,,1,,N,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,50594,BAO_0000218
14793,,,,1,,,CHEMBL631534,,Intermediate,A,,1,,N,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,,50594,BAO_0000218
14794,,,,1,,,CHEMBL631535,,Intermediate,A,,1,,N,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,50594,BAO_0000218
14795,,,,1,,,CHEMBL631536,,Intermediate,A,,1,,N,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,50594,BAO_0000218
14796,,,,1,,,CHEMBL631537,,Intermediate,A,,1,,N,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,,50594,BAO_0000218
14797,,,,1,,,CHEMBL631538,,Intermediate,A,,1,,N,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,,50594,BAO_0000218
14798,,,,1,,,CHEMBL631539,,Intermediate,A,,1,,N,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,,50594,BAO_0000218
14799,,,,1,,,CHEMBL631540,,Intermediate,A,,1,,N,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,50594,BAO_0000218
14800,,,,1,,,CHEMBL625637,,Intermediate,A,,1,,N,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,BAO_0000218
14801,,,,1,,,CHEMBL625638,,Intermediate,A,,1,,N,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,50597,BAO_0000218
14802,,,,1,,,CHEMBL625639,,Intermediate,A,,1,,N,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,,50597,BAO_0000218
14803,,,955.0,1,Brain,In vivo,CHEMBL625640,,Intermediate,A,,1,,N,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14804,,,955.0,1,Brain,In vivo,CHEMBL625641,,Intermediate,A,,1,,N,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14805,,,948.0,1,Heart,In vivo,CHEMBL625642,,Intermediate,A,,1,,N,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14806,,,948.0,1,Heart,In vivo,CHEMBL625643,,Intermediate,A,,1,,N,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14807,,,2113.0,1,Kidney,In vivo,CHEMBL625644,,Intermediate,A,,1,,N,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14808,,,2113.0,1,Kidney,In vivo,CHEMBL625645,,Intermediate,A,,1,,N,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14809,,,2107.0,1,Liver,In vivo,CHEMBL625646,,Intermediate,A,,1,,N,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14810,,,2107.0,1,Liver,In vivo,CHEMBL625647,,Intermediate,A,,1,,N,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14811,,,2048.0,1,Lung,In vivo,CHEMBL625648,,Intermediate,A,,1,,N,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14812,,,2048.0,1,Lung,In vivo,CHEMBL625649,,Intermediate,A,,1,,N,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14813,,,2385.0,1,Muscle tissue,In vivo,CHEMBL625650,,Intermediate,A,,1,,N,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14814,,,2385.0,1,Muscle tissue,In vivo,CHEMBL625651,,Intermediate,A,,1,,N,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14815,,,14.0,1,Zone of skin,In vivo,CHEMBL625652,,Intermediate,A,,1,,N,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14816,,,14.0,1,Zone of skin,In vivo,CHEMBL625653,,Intermediate,A,,1,,N,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14817,,,2106.0,1,Spleen,In vivo,CHEMBL625654,,Intermediate,A,,1,,N,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14818,,,2106.0,1,Spleen,In vivo,CHEMBL625655,,Intermediate,A,,1,,N,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,50597,BAO_0000218
14819,,,178.0,1,Blood,In vivo,CHEMBL625656,,Intermediate,A,,1,,N,Biodistribution of Compound in rat blood after 15 minutes of administration,,,50597,BAO_0000218
14820,,,178.0,1,Blood,In vivo,CHEMBL625657,,Intermediate,A,,1,,N,Biodistribution of Compound in rat blood after 2 minutes of administration,,,50597,BAO_0000218
14821,,,955.0,1,Brain,In vivo,CHEMBL625658,,Intermediate,A,,1,,N,Biodistribution of Compound in rat brain after 15 minutes of administration,,,50597,BAO_0000218
14822,,,955.0,1,Brain,In vivo,CHEMBL625659,,Intermediate,A,,1,,N,Biodistribution of Compound in rat brain after 2 minutes of administration,,,50597,BAO_0000218
14823,,,948.0,1,Heart,In vivo,CHEMBL625660,,Intermediate,A,,1,,N,Biodistribution of Compound in rat heart after 15 minutes of administration,,,50597,BAO_0000218
14824,,,948.0,1,Heart,In vivo,CHEMBL625661,,Intermediate,A,,1,,N,Biodistribution of Compound in rat heart after 2 minutes of administration,,,50597,BAO_0000218
14825,,,2107.0,1,Liver,In vivo,CHEMBL625662,,Intermediate,A,,1,,N,Biodistribution of Compound in rat liver after 15 minutes of administration,,,50597,BAO_0000218
14826,,,2107.0,1,Liver,In vivo,CHEMBL625663,,Intermediate,A,,1,,N,Biodistribution of Compound in rat liver after 2 minutes of administration,,,50597,BAO_0000218
14827,,,2048.0,1,Lung,In vivo,CHEMBL875621,,Intermediate,A,,1,,N,Biodistribution of Compound in rat lung after 15 minutes of administration,,,50597,BAO_0000218
14828,,,2048.0,1,Lung,In vivo,CHEMBL628382,,Intermediate,A,,1,,N,Biodistribution of Compound in rat lung after 2 minutes of administration,,,50597,BAO_0000218
14829,,,2385.0,1,Muscle tissue,In vivo,CHEMBL628383,,Intermediate,A,,1,,N,Biodistribution of Compound in rat muscle after 15 minutes of administration,,,50597,BAO_0000218
14830,,,2385.0,1,Muscle tissue,In vivo,CHEMBL628384,,Intermediate,A,,1,,N,Biodistribution of Compound in rat muscle after 2 minutes of administration,,,50597,BAO_0000218
14831,,,,1,,,CHEMBL628385,,Intermediate,A,,1,,N,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,,50597,BAO_0000218
14832,,,,1,,,CHEMBL875753,,Intermediate,A,,1,,N,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,,50597,BAO_0000218
14833,,,,1,,,CHEMBL628386,,Intermediate,A,,1,,N,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,,50597,BAO_0000218
14834,,,,1,,,CHEMBL628387,,Intermediate,A,,1,,N,Organ distribution in rat blood 2 minutes after intravenous injection,,,50597,BAO_0000218
14835,,,,1,,,CHEMBL628388,,Intermediate,A,,1,,N,Organ distribution in rat blood 2 hr after intravenous injection,,,50597,BAO_0000218
14836,,,,1,,,CHEMBL628389,,Intermediate,A,,1,,N,Organ distribution in rat blood 30 minutes after intravenous injection,,,50597,BAO_0000218
14837,,,,1,,,CHEMBL632756,,Intermediate,A,,1,,N,Organ distribution in rat blood 30 min after intravenous injection,,,50597,BAO_0000218
14838,,,,1,,,CHEMBL628390,,Intermediate,A,,1,,N,Organ distribution in rat brain 2 minutes after intravenous injection,,,50597,BAO_0000218
14839,,,,1,,,CHEMBL631811,,Intermediate,A,,1,,N,Organ distribution in rat brain 2 hr after intravenous injection,,,50597,BAO_0000218
14840,,,,1,,,CHEMBL631812,,Intermediate,A,,1,,N,Organ distribution in rat brain 30 minutes after intravenous injection,,,50597,BAO_0000218
14841,,,,1,,,CHEMBL631813,,Intermediate,A,,1,,N,Organ distribution in rat heart 2 minutes after intravenous injection,,,50597,BAO_0000218
14842,,,,1,,,CHEMBL631814,,Intermediate,A,,1,,N,Organ distribution in rat heart 2 hr after intravenous injection,,,50597,BAO_0000218
14843,,,,1,,,CHEMBL631815,,Intermediate,A,,1,,N,Organ distribution in rat heart 30 minutes after intravenous injection,,,50597,BAO_0000218
14844,,,,1,,,CHEMBL631816,,Intermediate,A,,1,,N,Organ distribution in rat kidney 2 minutes after intravenous injection,,,50597,BAO_0000218
14845,,,,1,,,CHEMBL875758,,Intermediate,A,,1,,N,Organ distribution in rat kidney 2 hr after intravenous injection,,,50597,BAO_0000218
14846,,,,1,,,CHEMBL631817,,Intermediate,A,,1,,N,Organ distribution in rat kidney 30 minutes after intravenous injection,,,50597,BAO_0000218
14847,,,2107.0,1,Liver,,CHEMBL631818,,Intermediate,A,,1,,N,Organ distribution in rat liver 2 minutes after intravenous injection,,,50597,BAO_0000218
14848,,,2107.0,1,Liver,,CHEMBL631819,,Intermediate,A,,1,,N,Organ distribution in rat liver 2 hr after intravenous injection,,,50597,BAO_0000218
14849,,,2107.0,1,Liver,,CHEMBL631820,,Intermediate,A,,1,,N,Organ distribution in rat liver 30 minutes after intravenous injection,,,50597,BAO_0000218
14850,,,,1,,,CHEMBL631821,,Intermediate,A,,1,,N,Organ distribution in rat lung 2 minutes after intravenous injection,,,50597,BAO_0000218
14851,,,,1,,,CHEMBL631822,,Intermediate,A,,1,,N,Organ distribution in rat lung 2 hr after intravenous injection,,,50597,BAO_0000218
14852,,,,1,,,CHEMBL631823,,Intermediate,A,,1,,N,Organ distribution in rat lung 30 minutes after intravenous injection,,,50597,BAO_0000218
14853,,,2385.0,1,Muscle tissue,,CHEMBL631824,,Intermediate,A,,1,,N,Organ distribution in rat muscle 2 minutes after intravenous injection,,,50597,BAO_0000218
14854,,,2385.0,1,Muscle tissue,,CHEMBL631825,,Intermediate,A,,1,,N,Organ distribution in rat muscle 2 hr after intravenous injection,,,50597,BAO_0000218
14855,,,2385.0,1,Muscle tissue,,CHEMBL631826,,Intermediate,A,,1,,N,Organ distribution in rat muscle 30 minutes after intravenous injection,,,50597,BAO_0000218
14856,,,,1,,In vivo,CHEMBL631827,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,,50594,BAO_0000218
14857,,,,1,,In vivo,CHEMBL631828,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,,50594,BAO_0000218
14858,,,,1,,In vivo,CHEMBL631829,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,,50594,BAO_0000218
14859,,,1088.0,1,Urine,,CHEMBL875759,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,,50597,BAO_0000218
14860,,,1088.0,1,Urine,,CHEMBL631830,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,,,50597,BAO_0000218
14861,,,1088.0,1,Urine,,CHEMBL631831,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,,,50597,BAO_0000218
14862,,,1088.0,1,Urine,,CHEMBL631832,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,,50597,BAO_0000218
14863,,,1088.0,1,Urine,,CHEMBL631833,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,,,50597,BAO_0000218
14864,,,1088.0,1,Urine,,CHEMBL631834,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,,50597,BAO_0000218
14865,,,1088.0,1,Urine,,CHEMBL631835,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,,,50597,BAO_0000218
14866,,,1088.0,1,Urine,,CHEMBL631836,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,,50597,BAO_0000218
14867,,,1088.0,1,Urine,,CHEMBL631837,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,,50597,BAO_0000218
14868,,,1088.0,1,Urine,,CHEMBL631838,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,,50597,BAO_0000218
14869,,,1088.0,1,Urine,,CHEMBL631839,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,,,50597,BAO_0000218
14870,,,1088.0,1,Urine,,CHEMBL631840,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,,,50597,BAO_0000218
14871,,,1088.0,1,Urine,,CHEMBL631841,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,,50597,BAO_0000218
14872,,,1088.0,1,Urine,,CHEMBL631842,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,,50597,BAO_0000218
14873,,,1088.0,1,Urine,,CHEMBL631843,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,,50597,BAO_0000218
14874,,,1088.0,1,Urine,,CHEMBL631844,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,,50597,BAO_0000218
14875,,,1088.0,1,Urine,,CHEMBL631845,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,,50597,BAO_0000218
14876,,,1088.0,1,Urine,,CHEMBL631846,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,,50597,BAO_0000218
14877,,,1088.0,1,Urine,,CHEMBL875760,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,,50597,BAO_0000218
14878,,,1088.0,1,Urine,,CHEMBL632199,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,,50597,BAO_0000218
14879,,,1088.0,1,Urine,,CHEMBL631847,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,,50597,BAO_0000218
14880,,,1088.0,1,Urine,,CHEMBL631848,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,,50597,BAO_0000218
14881,,,1088.0,1,Urine,,CHEMBL628707,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,,50597,BAO_0000218
14882,,,1088.0,1,Urine,,CHEMBL628708,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,,50597,BAO_0000218
14883,,,1088.0,1,Urine,,CHEMBL628709,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,,50597,BAO_0000218
14884,,,1088.0,1,Urine,,CHEMBL628710,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,,50597,BAO_0000218
14885,,,1088.0,1,Urine,,CHEMBL628711,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,,50597,BAO_0000218
14886,,,1088.0,1,Urine,,CHEMBL628712,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,,50597,BAO_0000218
14887,,,1088.0,1,Urine,,CHEMBL628713,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,,50597,BAO_0000218
14888,,,1088.0,1,Urine,,CHEMBL628714,,Intermediate,A,,1,,N,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,,50597,BAO_0000218
14889,,,,1,,,CHEMBL628715,,Intermediate,A,,1,,N,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,,50597,BAO_0000218
14890,,,,0,,,CHEMBL629179,,Autocuration,A,,1,,U,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,,22224,BAO_0000019
14891,,,,0,,,CHEMBL629180,,Autocuration,A,,1,,U,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,,22224,BAO_0000019
14892,,,,0,,,CHEMBL875108,,Autocuration,A,,1,,U,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,,22224,BAO_0000019
14893,,,1235.0,0,Adrenal cortex,,CHEMBL629181,,Autocuration,A,,1,,U,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,,22224,BAO_0000019
14894,,,1235.0,0,Adrenal cortex,,CHEMBL629182,,Autocuration,A,,1,,U,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,,22224,BAO_0000019
14895,,,,0,,,CHEMBL629183,,Autocuration,A,,1,,U,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,,22224,BAO_0000019
14896,,,,0,,,CHEMBL629184,,Autocuration,A,,1,,U,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,22224,BAO_0000019
14897,,,1235.0,0,Adrenal cortex,,CHEMBL629185,,Autocuration,A,,1,,U,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,,22224,BAO_0000019
14898,,,1235.0,0,Adrenal cortex,,CHEMBL629186,,Autocuration,A,,1,,U,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,,,22224,BAO_0000019
14899,,,,0,,,CHEMBL629187,,Autocuration,A,,1,,U,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,,22224,BAO_0000019
14900,,,,0,,,CHEMBL629887,,Autocuration,A,,1,,U,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,,22224,BAO_0000019
14901,,,,0,,,CHEMBL629888,,Autocuration,A,,1,,U,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,,22224,BAO_0000019
14902,,,,0,,,CHEMBL629889,,Autocuration,A,,1,,U,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,,22224,BAO_0000019
14903,,,1235.0,0,Adrenal cortex,,CHEMBL629890,,Autocuration,A,,1,,U,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,,,22224,BAO_0000019
14904,,,,0,,,CHEMBL629891,,Autocuration,A,,1,,U,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,22224,BAO_0000019
14905,,,,0,,,CHEMBL629892,,Autocuration,A,,1,,U,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,,22224,BAO_0000019
14906,,,1235.0,0,Adrenal cortex,,CHEMBL629893,,Autocuration,A,,1,,U,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,,22224,BAO_0000019
14907,,,,0,,,CHEMBL629894,,Autocuration,A,,1,,U,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,,22224,BAO_0000019
14908,,,,0,,,CHEMBL629895,,Autocuration,A,,1,,U,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,,22224,BAO_0000019
14909,,,,0,,In vivo,CHEMBL875109,,Autocuration,A,,1,,U,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,,22224,BAO_0000218
14910,,,,0,,In vivo,CHEMBL629896,,Autocuration,A,,1,,U,Absolute bioavailability in male cynomolgus monkeys,,,22224,BAO_0000218
14911,,,,0,,In vivo,CHEMBL629897,,Autocuration,A,,1,,U,Absolute bioavailability in maleSprague-Dawley rats,,,22224,BAO_0000218
14912,,,2107.0,1,Liver,In vivo,CHEMBL629898,,Intermediate,A,,1,,N,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14913,,,2107.0,1,Liver,In vivo,CHEMBL630057,,Intermediate,A,,1,,N,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14914,,,2107.0,1,Liver,In vivo,CHEMBL630058,,Intermediate,A,,1,,N,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14915,,,2048.0,1,Lung,In vivo,CHEMBL630059,,Intermediate,A,,1,,N,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14916,,,2048.0,1,Lung,In vivo,CHEMBL630060,,Intermediate,A,,1,,N,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14917,,,2048.0,1,Lung,In vivo,CHEMBL630061,,Intermediate,A,,1,,N,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14918,,,2048.0,1,Lung,In vivo,CHEMBL630062,,Intermediate,A,,1,,N,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14919,,,2048.0,1,Lung,In vivo,CHEMBL630063,,Intermediate,A,,1,,N,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14920,,,2048.0,1,Lung,In vivo,CHEMBL630064,,Intermediate,A,,1,,N,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14921,,,2048.0,1,Lung,In vivo,CHEMBL630065,,Intermediate,A,,1,,N,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14922,,,2048.0,1,Lung,In vivo,CHEMBL630066,,Intermediate,A,,1,,N,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14923,,,2048.0,1,Lung,In vivo,CHEMBL630067,,Intermediate,A,,1,,N,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14924,,,2048.0,1,Lung,In vivo,CHEMBL630068,,Intermediate,A,,1,,N,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14925,,,2385.0,1,Muscle tissue,In vivo,CHEMBL631113,,Intermediate,A,,1,,N,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14926,,,2385.0,1,Muscle tissue,In vivo,CHEMBL631114,,Intermediate,A,,1,,N,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14927,,,2385.0,1,Muscle tissue,In vivo,CHEMBL631115,,Intermediate,A,,1,,N,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14928,,,2385.0,1,Muscle tissue,In vivo,CHEMBL631116,,Intermediate,A,,1,,N,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14929,,,2385.0,1,Muscle tissue,In vivo,CHEMBL630528,,Intermediate,A,,1,,N,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14930,,,2385.0,1,Muscle tissue,In vivo,CHEMBL630529,,Intermediate,A,,1,,N,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14931,,,2385.0,1,Muscle tissue,In vivo,CHEMBL630530,,Intermediate,A,,1,,N,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14932,,,2385.0,1,Muscle tissue,In vivo,CHEMBL630531,,Intermediate,A,,1,,N,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14933,,,2385.0,1,Muscle tissue,In vivo,CHEMBL630532,,Intermediate,A,,1,,N,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14934,,,2385.0,1,Muscle tissue,In vivo,CHEMBL630533,,Intermediate,A,,1,,N,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14935,,,178.0,1,Blood,In vivo,CHEMBL630534,,Intermediate,A,,1,,N,Biodistribution in normal mice blood after 120 hr,,,50594,BAO_0000218
14936,,,178.0,1,Blood,In vivo,CHEMBL630535,,Intermediate,A,,1,,N,Biodistribution in normal mice blood after 24 hr,,,50594,BAO_0000218
14937,,,178.0,1,Blood,In vivo,CHEMBL630536,,Intermediate,A,,1,,N,Biodistribution in normal mice blood after 4 hr,,,50594,BAO_0000218
14938,,,10000001.0,1,Bone,In vivo,CHEMBL630537,,Intermediate,A,,1,,N,Biodistribution in normal mice bone after 120 hr,,,50594,BAO_0000218
14939,,,10000001.0,1,Bone,In vivo,CHEMBL630538,,Intermediate,A,,1,,N,Biodistribution in normal mice bone after 24 hr,,,50594,BAO_0000218
14940,,,10000001.0,1,Bone,In vivo,CHEMBL630539,,Intermediate,A,,1,,N,Biodistribution in normal mice bone after 4 hr,,,50594,BAO_0000218
14941,,,948.0,1,Heart,In vivo,CHEMBL630540,,Intermediate,A,,1,,N,Biodistribution in normal mice heart after 120 hr,,,50594,BAO_0000218
14942,,,948.0,1,Heart,In vivo,CHEMBL630541,,Intermediate,A,,1,,N,Biodistribution in normal mice heart after 24 hr,,,50594,BAO_0000218
14943,,,948.0,1,Heart,In vivo,CHEMBL630542,,Intermediate,A,,1,,N,Biodistribution in normal mice heart after 4 hr,,,50594,BAO_0000218
14944,,,2113.0,1,Kidney,In vivo,CHEMBL630543,,Intermediate,A,,1,,N,Biodistribution in normal mice kidney after 120 hr,,,50594,BAO_0000218
14945,,,2113.0,1,Kidney,In vivo,CHEMBL630544,,Intermediate,A,,1,,N,Biodistribution in normal mice kidney after 24 hr,,,50594,BAO_0000218
14946,,,2113.0,1,Kidney,In vivo,CHEMBL630545,,Intermediate,A,,1,,N,Biodistribution in normal mice kidney after 4 hr,,,50594,BAO_0000218
14947,,,2107.0,1,Liver,In vivo,CHEMBL630546,,Intermediate,A,,1,,N,Biodistribution in normal mice liver after 120 hr,,,50594,BAO_0000218
14948,,,2107.0,1,Liver,In vivo,CHEMBL630547,,Intermediate,A,,1,,N,Biodistribution in normal mice liver after 24 hr,,,50594,BAO_0000218
14949,,,2107.0,1,Liver,In vivo,CHEMBL630548,,Intermediate,A,,1,,N,Biodistribution in normal mice liver after 4 hr,,,50594,BAO_0000218
14950,,,2106.0,1,Spleen,In vivo,CHEMBL630549,,Intermediate,A,,1,,N,Biodistribution in normal mice spleen after 120 hr,,,50594,BAO_0000218
14951,,,2106.0,1,Spleen,In vivo,CHEMBL630550,,Intermediate,A,,1,,N,Biodistribution in normal mice spleen after 24 hr,,,50594,BAO_0000218
14952,,,2106.0,1,Spleen,In vivo,CHEMBL876426,,Intermediate,A,,1,,N,Biodistribution in normal mice spleen after 4 hr,,,50594,BAO_0000218
14953,,,2106.0,1,Spleen,In vivo,CHEMBL630551,,Intermediate,A,,1,,N,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14954,,,2106.0,1,Spleen,In vivo,CHEMBL630552,,Intermediate,A,,1,,N,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14955,,,2106.0,1,Spleen,In vivo,CHEMBL630553,,Intermediate,A,,1,,N,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14956,,,2106.0,1,Spleen,In vivo,CHEMBL630554,,Intermediate,A,,1,,N,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14957,,,2106.0,1,Spleen,In vivo,CHEMBL630555,,Intermediate,A,,1,,N,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14958,,,2106.0,1,Spleen,In vivo,CHEMBL630556,,Intermediate,A,,1,,N,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14959,,,2106.0,1,Spleen,In vivo,CHEMBL630557,,Intermediate,A,,1,,N,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14960,,,2106.0,1,Spleen,In vivo,CHEMBL630558,,Intermediate,A,,1,,N,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,50597,BAO_0000218
14961,,,2106.0,1,Spleen,In vivo,CHEMBL630559,,Intermediate,A,,1,,N,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14962,,,2106.0,1,Spleen,In vivo,CHEMBL630560,,Intermediate,A,,1,,N,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14963,,,2046.0,1,Thyroid gland,In vivo,CHEMBL876427,,Intermediate,A,,1,,N,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,50597,BAO_0000218
14964,,,,1,,,CHEMBL630561,,Intermediate,A,,1,,N,The Kel values in female wistar rats.,,,50597,BAO_0000218
14965,,,,0,,,CHEMBL630562,,Autocuration,A,,1,,U,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,,22224,BAO_0000019
14966,,,,0,,,CHEMBL630563,,Autocuration,A,,1,,U,Hydrolysis rate constant of the compound,,,22224,BAO_0000019
14967,,,,0,,,CHEMBL629673,,Autocuration,P,,1,,U,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,,22229,BAO_0000100
14968,,,,0,,,CHEMBL629674,,Autocuration,A,,1,,U,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,,22224,BAO_0000019
14969,,,,0,,,CHEMBL629675,,Autocuration,A,,1,,U,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,,22224,BAO_0000019
14970,,,,0,,,CHEMBL629676,,Autocuration,A,,1,,U,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,,22224,BAO_0000019
14971,,,,0,,,CHEMBL629677,,Autocuration,A,,1,,U,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,,22224,BAO_0000019
14972,,,,0,,,CHEMBL629678,,Autocuration,A,,1,,U,Apparent inactivation rate constant was evaluated,,,22224,BAO_0000019
14973,,,,0,,,CHEMBL629679,,Autocuration,A,,1,,U,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,,22224,BAO_0000019
14974,,,,0,,,CHEMBL629680,,Autocuration,A,,1,,U,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,,22224,BAO_0000019
14975,,,,0,,,CHEMBL629681,,Autocuration,A,,1,,U,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,,22224,BAO_0000019
14976,,,,0,,,CHEMBL629682,,Autocuration,A,,1,,U,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,,22224,BAO_0000019
14977,,,,0,,,CHEMBL629683,,Autocuration,A,,1,,U,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,,22224,BAO_0000019
14978,,,,0,,,CHEMBL629684,,Autocuration,F,,1,,U,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,,22224,BAO_0000019
14979,,,,0,,,CHEMBL629685,,Autocuration,P,,1,,U,Dissociation constant was determined,,,22224,BAO_0000100
14980,,,,0,,,CHEMBL629686,,Autocuration,P,,1,,U,Dissociation constant was determined,,,22224,BAO_0000100
14981,,,,0,,,CHEMBL872932,,Autocuration,P,,1,,U,Dissociation constant at pH 7.4,,,22224,BAO_0000100
14982,,,,0,,,CHEMBL629687,,Autocuration,P,,1,,U,Dissociation constant in presence of 1 mM dithiothreitol,,,22224,BAO_0000100
14983,,,,0,,,CHEMBL872931,,Autocuration,A,,1,,U,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,22224,BAO_0000019
14984,,,,0,,,CHEMBL628151,,Autocuration,A,,1,,U,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,22224,BAO_0000019
14985,,,,0,,,CHEMBL628152,,Autocuration,A,,1,,U,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,22224,BAO_0000019
14986,,,,0,,,CHEMBL628153,,Autocuration,A,,1,,U,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,22224,BAO_0000019
14987,,,,0,,,CHEMBL628154,,Autocuration,A,,1,,U,Kinetic constant for aromatization of androstenedione,,,22224,BAO_0000019
14988,,,,0,,,CHEMBL628155,,Autocuration,A,,1,,U,Kinetic constant for aromatization of testosterone,,,22224,BAO_0000019
14989,,,,0,,,CHEMBL628156,,Autocuration,A,,1,,U,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,,22224,BAO_0000019
14990,,,,0,,,CHEMBL628157,,Autocuration,A,,1,,U,Local inhibition constant was determined,,,22224,BAO_0000019
14991,,,,1,,,CHEMBL857533,,Intermediate,A,,1,,N,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,,50347,BAO_0000218
14992,,,,0,,,CHEMBL628158,,Autocuration,P,,1,,U,Dissociation constant value of the compound,,,22224,BAO_0000100
14993,,,964.0,0,Cornea,,CHEMBL628159,,Autocuration,A,,1,,U,In vitro permeability through cornea without epithelium,,,22224,BAO_0000019
14994,,,964.0,0,Cornea,,CHEMBL875616,,Autocuration,A,,1,,U,In vitro permeability through intact cornea,,,22224,BAO_0000019
14995,,,964.0,1,Cornea,,CHEMBL628160,,Intermediate,A,,1,,N,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,,,50592,BAO_0000218
14996,,,,0,,,CHEMBL628161,,Autocuration,A,,1,,U,Rate of enzyme inactivation for the compound was determined,,,22224,BAO_0000019
14997,,,964.0,0,Cornea,,CHEMBL628162,,Autocuration,A,,1,,U,In vitro permeability through cornea without epithelium,,,22224,BAO_0000019
14998,,,964.0,0,Cornea,,CHEMBL628163,,Autocuration,A,,1,,U,In vitro permeability through intact cornea,,,22224,BAO_0000019
14999,,,,0,,,CHEMBL628164,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15000,,,,0,,,CHEMBL628165,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15001,,,,0,,,CHEMBL628166,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15002,,,,0,,,CHEMBL628167,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15003,,,,0,,,CHEMBL628168,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15004,,,,0,,,CHEMBL628169,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15005,,,,0,,,CHEMBL628170,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15006,,,,0,,,CHEMBL628171,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15007,,,,0,,,CHEMBL627434,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15008,,,,0,,,CHEMBL627435,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15009,,,,0,,,CHEMBL628110,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15010,,,,0,,,CHEMBL628111,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15011,,,,0,,,CHEMBL628112,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15012,,,,0,,,CHEMBL628260,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15013,,,,0,,,CHEMBL628261,,Autocuration,A,,1,,U,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,22224,BAO_0000019
15014,,,,1,,In vivo,CHEMBL628262,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,,50594,BAO_0000218
15015,,,,1,,In vivo,CHEMBL628263,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,,50587,BAO_0000218
15016,,,,1,,In vivo,CHEMBL628264,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,,50594,BAO_0000218
15017,,,,1,,In vivo,CHEMBL628265,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,,50594,BAO_0000218
15018,,,,1,,In vivo,CHEMBL628266,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,,50594,BAO_0000218
15019,,,,1,,In vivo,CHEMBL628267,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,,50594,BAO_0000218
15020,,,,1,,In vivo,CHEMBL628268,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,,50594,BAO_0000218
15021,,,,1,,In vivo,CHEMBL628269,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,,50594,BAO_0000218
15022,,,,1,,In vivo,CHEMBL628270,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,,50594,BAO_0000218
15023,,,,1,,In vivo,CHEMBL628271,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,,50594,BAO_0000218
15024,,,,1,,In vivo,CHEMBL628272,,Intermediate,A,,1,,N,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,,50594,BAO_0000218
